
<html lang="en"     class="pb-page"  data-request-id="dc48ea3d-89d1-41ee-8e1d-76b3ae542169"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;article:article:10.1021/acs.jmedchem.9b00446;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;issue:issue:10.1021/jmcmar.2019.62.issue-24;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Drug Discovery Targeting Anaplastic Lymphoma Kinase (ALK)" /></meta><meta name="dc.Creator" content="Xiaotian  Kong" /></meta><meta name="dc.Creator" content="Peichen  Pan" /></meta><meta name="dc.Creator" content="Huiyong  Sun" /></meta><meta name="dc.Creator" content="Hongguang  Xia" /></meta><meta name="dc.Creator" content="Xuwen  Wang" /></meta><meta name="dc.Creator" content="Youyong  Li" /></meta><meta name="dc.Creator" content="Tingjun  Hou" /></meta><meta name="dc.Description" content="As a receptor tyrosine kinase of insulin receptor (IR) subfamily, anaplastic lymphoma kinase (ALK) has been validated to play important roles in various cancers, especially anaplastic large cell ly..." /></meta><meta name="Description" content="As a receptor tyrosine kinase of insulin receptor (IR) subfamily, anaplastic lymphoma kinase (ALK) has been validated to play important roles in various cancers, especially anaplastic large cell ly..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="August 16, 2019" /></meta><meta name="dc.Type" content="review-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.9b00446" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2019 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b00446" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.9b00446" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b00446" /></link>
        
    
    

<title>Drug Discovery Targeting Anaplastic Lymphoma Kinase (ALK) | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.9b00446" /></meta><meta property="og:title" content="Drug Discovery Targeting Anaplastic Lymphoma Kinase (ALK)" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00446/20191219/images/large/jm9b00446_0028.jpeg" /></meta><meta property="og:description" content="As a receptor tyrosine kinase of insulin receptor (IR) subfamily, anaplastic lymphoma kinase (ALK) has been validated to play important roles in various cancers, especially anaplastic large cell lymphoma (ALCL), nonsmall cell lung cancer (NSCLC), and neuroblastomas. Currently, five small-molecule inhibitors of ALK, including Crizotinib, Ceritinib, Alectinib, Brigatinib, and Lorlatinib, have been approved by the U.S. Food and Drug Administration (FDA) against ALK-positive NSCLCs. Novel type-I1/2 and type-II ALK inhibitors with improved kinase selectivity and enhanced capability to combat drug resistance have also been reported. Moreover, the “proteolysis targeting chimera” (PROTAC) technique has been successfully applied in developing ALK degraders, which opened a new avenue for targeted ALK therapies. This review provides an overview of the physiological and biological functions of ALK, the discovery and development of drugs targeting ALK by focusing on their chemotypes, activity, selectivity, and resistance as well as potential therapeutic strategies to overcome drug resistance." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.9b00446"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b00446">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-14/achre4.2021.54.issue-14/20210720/achre4.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-29/aamick.2021.13.issue-29/20210728/aamick.2021.13.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-14/acncdm.2021.12.issue-14/20210721/acncdm.2021.12.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-7/amlcef.2021.3.issue-7/20210705/amlcef.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-29/acsodf.2021.6.issue-29/20210727/acsodf.2021.6.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-29/ascecg.2021.9.issue-29/20210726/ascecg.2021.9.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-29/ancham.2021.93.issue-29/20210727/ancham.2021.93.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-29/bichaw.2021.60.issue-29/20210727/bichaw.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-27/cgeabj.2021.99.issue-27/20210726-01/cgeabj.2021.99.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-7/cgdefu.2021.21.issue-7/20210707/cgdefu.2021.21.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-14/esthag.2021.55.issue-14/20210720/esthag.2021.55.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-29/iecred.2021.60.issue-29/20210728/iecred.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-14/inocaj.2021.60.issue-14/20210719/inocaj.2021.60.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-29/jafcau.2021.69.issue-29/20210728/jafcau.2021.69.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-29/jacsat.2021.143.issue-29/20210728/jacsat.2021.143.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-7/jamsef.2021.32.issue-7/20210707/jamsef.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-29/langd5.2021.37.issue-29/20210727/langd5.2021.37.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-7/mpohbp.2021.18.issue-7/20210705/mpohbp.2021.18.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.9b00446&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.9b00446&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.9b00446&amp;href=/doi/10.1021/acs.jmedchem.9b00446" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2019</span><span class="cit-fg-volume">, 62</span><span class="cit-fg-issue">, 24</span><span class="cit-fg-pageRange">, 10927-10954</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/62/24" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><span class="content-navigation__contentType">Perspective</span><a href="/doi/10.1021/acs.jmedchem.9b00875" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Drug Discovery Targeting Anaplastic Lymphoma Kinase (ALK)</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Xiaotian Kong</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Xiaotian Kong</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Hangzhou Institute of Innovative Medicine, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, Zhejiang 310058, China</div><div class="loa-info-affiliations-info">Institute of Functional Nano and Soft Materials (FUNSOM), Soochow University, Suzhou, Jiangsu 215123, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Xiaotian++Kong">Xiaotian Kong</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath1">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Peichen Pan</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Peichen Pan</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Hangzhou Institute of Innovative Medicine, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, Zhejiang 310058, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Peichen++Pan">Peichen Pan</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath2">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Huiyong Sun</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Huiyong Sun</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Hangzhou Institute of Innovative Medicine, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, Zhejiang 310058, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Huiyong++Sun">Huiyong Sun</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath3">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-7107-7481" title="Orcid link">http://orcid.org/0000-0002-7107-7481</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Hongguang Xia</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Hongguang Xia</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Biochemistry & Research Center of Clinical Pharmacy of the First Affiliated Hospital, Zhejiang University, Hangzhou 310058, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Hongguang++Xia">Hongguang Xia</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath4">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Xuwen Wang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Xuwen Wang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Hangzhou Institute of Innovative Medicine, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, Zhejiang 310058, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Xuwen++Wang">Xuwen Wang</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath5">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Youyong Li</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Youyong Li</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Institute of Functional Nano and Soft Materials (FUNSOM), Soochow University, Suzhou, Jiangsu 215123, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Youyong++Li">Youyong Li</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath6">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-5248-2756" title="Orcid link">http://orcid.org/0000-0002-5248-2756</a></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Tingjun Hou</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Tingjun Hou</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Hangzhou Institute of Innovative Medicine, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, Zhejiang 310058, China</div></div><span class="conrtib-corresp"><strong>*</strong>Phone: +86-517-88208412. E-mail: <a href="/cdn-cgi/l/email-protection#691d00070e031c0701061c2913031c470c0d1c470a07"><span class="__cf_email__" data-cfemail="c7b3aea9a0adb2a9afa8b287bdadb2e9a2a3b2e9a4a9">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Tingjun++Hou">Tingjun Hou</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath7">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-7227-2580" title="Orcid link">http://orcid.org/0000-0001-7227-2580</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b00446&amp;href=/doi/10.1021%2Facs.jmedchem.9b00446" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2019</span></span><span class="cit-volume">, 62</span><span class="cit-issue">, 24</span><span class="cit-pageRange">, 10927–10954</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">August 16, 2019</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>14 March 2019</li><li><span class="item_label"><b>Published</b> online</span>16 August 2019</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 26 December 2019</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.9b00446" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00446</a></div><div class="article_header-article-copyright"><strong>Copyright © 2019 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D10927%26pageCount%3D28%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DXiaotian%2BKong%252C%2BPeichen%2BPan%252C%2BHuiyong%2BSun%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D62%26issueNum%3D24%26contentID%3Dacs.jmedchem.9b00446%26title%3DDrug%2BDiscovery%2BTargeting%2BAnaplastic%2BLymphoma%2BKinase%2B%2528ALK%2529%26numPages%3D28%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D10954%26publicationDate%3DDecember%2B2019">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.9b00446"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">6817</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">22</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.9b00446" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Drug Discovery Targeting Anaplastic Lymphoma Kinase (ALK)&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Xiaotian&quot;,&quot;last_name&quot;:&quot;Kong&quot;},{&quot;first_name&quot;:&quot;Peichen&quot;,&quot;last_name&quot;:&quot;Pan&quot;},{&quot;first_name&quot;:&quot;Huiyong&quot;,&quot;last_name&quot;:&quot;Sun&quot;},{&quot;first_name&quot;:&quot;Hongguang&quot;,&quot;last_name&quot;:&quot;Xia&quot;},{&quot;first_name&quot;:&quot;Xuwen&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Youyong&quot;,&quot;last_name&quot;:&quot;Li&quot;},{&quot;first_name&quot;:&quot;Tingjun&quot;,&quot;last_name&quot;:&quot;Hou&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2019&quot;,&quot;month&quot;:&quot;08&quot;,&quot;day&quot;:&quot;16&quot;,&quot;issue&quot;:&quot;24&quot;,&quot;volume&quot;:&quot;62&quot;,&quot;pages&quot;:&quot;10927-10954&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.9b00446&quot;},&quot;abstract&quot;:&quot;As a receptor tyrosine kinase of insulin receptor (IR) subfamily, anaplastic lymphoma kinase (ALK) has been validated to play important roles in various cancers, especially anaplastic large cell lymphoma (ALCL), nonsmall cell lung cancer (NSCLC), and neuroblastomas. Currently, five small-molecule inhibitors of ALK, including Crizotinib, Ceritinib, Alectinib, Brigatinib, and Lorlatinib, have been approved by the U.S. Food and Drug Administration (FDA) against ALK-positive NSCLCs. Novel type-I1/2 and type-II ALK inhibitors with improved kinase selectivity and enhanced capability to combat drug resistance have also been reported. Moreover, the “proteolysis targeting chimera” (PROTAC) technique has been successfully applied in developing ALK degraders, which opened a new avenue for targeted ALK therapies. This review provides an overview of the physiological and biological functions of ALK, the discovery and development of drugs targeting ALK by focusing on their chemotypes, activity, selectivity, and resistance &quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b00446&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b00446" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b00446&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b00446" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b00446&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b00446" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b00446&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b00446&amp;href=/doi/10.1021/acs.jmedchem.9b00446" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.9b00446" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.9b00446" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (5 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00446&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.9b00446%26sid%3Dliteratum%253Aachs%26pmid%3D31419130%26genre%3Darticle%26aulast%3DKong%26date%3D2019%26atitle%3DDrug%2BDiscovery%2BTargeting%2BAnaplastic%2BLymphoma%2BKinase%2B%2528ALK%2529%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D62%26issue%3D24%26spage%3D10927%26epage%3D10954%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292258" title="Cancer">Cancer</a>,</li><li><a href="/action/doSearch?ConceptID=292227" title="Drug resistance">Drug resistance</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=291439" title="Genetics">Genetics</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/62/24" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/jmcmar.2019.62.issue-24/20191226/jmcmar.2019.62.issue-24.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00446/20191219/images/medium/jm9b00446_0028.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00446/20191219/images/large/jm9b00446_0028.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00446&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">As a receptor tyrosine kinase of insulin receptor (IR) subfamily, anaplastic lymphoma kinase (ALK) has been validated to play important roles in various cancers, especially anaplastic large cell lymphoma (ALCL), nonsmall cell lung cancer (NSCLC), and neuroblastomas. Currently, five small-molecule inhibitors of ALK, including Crizotinib, Ceritinib, Alectinib, Brigatinib, and Lorlatinib, have been approved by the U.S. Food and Drug Administration (FDA) against ALK-positive NSCLCs. Novel type-I<sup>1</sup>/<sub>2</sub> and type-II ALK inhibitors with improved kinase selectivity and enhanced capability to combat drug resistance have also been reported. Moreover, the “proteolysis targeting chimera” (PROTAC) technique has been successfully applied in developing ALK degraders, which opened a new avenue for targeted ALK therapies. This review provides an overview of the physiological and biological functions of ALK, the discovery and development of drugs targeting ALK by focusing on their chemotypes, activity, selectivity, and resistance as well as potential therapeutic strategies to overcome drug resistance.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">1.  Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_40773" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_40773" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Anaplastic lymphoma kinase (ALK), a member of the insulin receptor (IR) protein–tyrosine kinase superfamily, was originally identified as a nucleophosmin (NPM)-ALK fusion form in an anaplastic large cell lymphoma (ALCL) cell line with a t(2;5) chromosomal rearrangement.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> The physiological functions of ALK have not been fully elucidated, but some evidence have validated the regulatory roles of ALK in the normal development and function of central and peripheral nervous systems.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> As shown in <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figures <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a> and <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>, chromosomal rearrangements, as the most prevalent genetic aberrations of ALK, result in the generation of a wide variety of ALK fusions, in which the kinase domain and the N-terminal portion of protein partners are fused.<a onclick="showRef(event, 'ref3 ref4 ref5 ref6 ref7'); return false;" href="javascript:void(0);" class="ref ref3 ref4 ref5 ref6 ref7">(3−7)</a> Different ALK fusion proteins, such as CARS-ALK in inflammatory myofibroblastic tumor (IMT),<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> CLTC-ALK in diffuse large B-cell lymphoma (DLBCL),<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> and EML4-ALK in nonsmall-cell lung cancer (NSCLC),<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> can mediate different signaling cascades and enhance oncogenic potential of ALK by promoting dimerization/oligomerization of ALK fusion proteins.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> Other tumorigenic forms of ALK, such as the acquisition of activating point mutations and gene amplification in the full-length ALK (shown in <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>), have also been reported in neuroblastoma, anaplastic thyroid cancer (ATC), rhabdomyosarcoma, ovarian cancer, etc. (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>).<a onclick="showRef(event, 'ref12 ref13 ref14 ref15'); return false;" href="javascript:void(0);" class="ref ref12 ref13 ref14 ref15">(12−15)</a> Over the past decade, great efforts have been made to develop targeted therapies against ALK in both pharmaceutical industry and academia. Crizotinib/PF2341066 (<b>1</b>, 2011, Pfizer)<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> is the first FDA-approved drug for the treatment of ALK-positive NSCLC (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>). Unfortunately, ALK-positive NSCLC patients rapidly developed resistance to <b>1</b>, which led to the development of more effective drugs (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>),<a onclick="showRef(event, 'ref17 ref18'); return false;" href="javascript:void(0);" class="ref ref17 ref18">(17,18)</a> including Ceritinib/LDK-378 (<b>3</b>, 2014, Novartis),<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> Alectinib/CH5424802 (<b>4</b>, 2015, Roche),<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> Brigatinib/AP26113 (<b>5</b>, 2017, Ariad),<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> and Lorlatinib/PF-0646392 (<b>11</b>, 2018, Pfizer).<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> Moreover, a number of other ALK inhibitors, such as Belizatinib/TSR-011 (<b>6</b>),<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> CEP-37440 (<b>7</b>),<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> ASP3026 (<b>8</b>),<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> Entrectinib/RXDX-101 (<b>9</b>),<a onclick="showRef(event, 'ref26 ref27'); return false;" href="javascript:void(0);" class="ref ref26 ref27">(26,27)</a> Ensartinib/X-396 (<b>10</b>),<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> and Repotrectinib/TPX-0005 (<b>12</b>),<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> are currently being evaluated in different stages of clinical trials (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>). In spite of the great efforts that have been made in the past decade, drug resistance still remains a crucial problem. As shown in <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>, acquired secondary mutations, and gene amplification and/or increased copy number account for about one-third of drug resistance cases.<a onclick="showRef(event, 'ref18 ref30 ref31'); return false;" href="javascript:void(0);" class="ref ref18 ref30 ref31">(18,30,31)</a> In addition, the activation of alternative signaling pathways and epithelial–mesenchymal transition (EMT) can also compromise therapeutic efficacy.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> To overcome drug resistance and improve kinase selectivity, novel type-I<sup>1</sup>/<sub>2</sub> and type-II inhibitors of ALK that can probe the extended hydrophobic pocket were developed.<a onclick="showRef(event, 'ref33 ref34 ref35'); return false;" href="javascript:void(0);" class="ref ref33 ref34 ref35">(33−35)</a> Particularly, inspired by the success of the “proteolysis targeting chimera” (PROTAC) technique in drug discovery, several ALK PROTACs have already been developed.<a onclick="showRef(event, 'ref36 ref37 ref38'); return false;" href="javascript:void(0);" class="ref ref36 ref37 ref38">(36−38)</a> This review provides a general outline of the structure, biological functions, and aberrations of ALK, the discovery and development of ALK drugs, structural rationales for drug resistance, and potential anti-resistance therapeutic strategies.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00446/20191219/images/medium/jm9b00446_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00446/20191219/images/large/jm9b00446_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Schematic summary of different categories of ALK alterations (gene amplification, mutations, and rearrangement) and corresponding cancers.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00446/20191219/images/large/jm9b00446_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00446&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00446/20191219/images/medium/jm9b00446_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00446/20191219/images/large/jm9b00446_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. (A) Overview of the native human anaplastic lymphoma kinase (ALK). The extracellular segment of ALK (residues 19–1038) contains an LDLa domain (453–471) sandwiched between the two MAM domains (264–427 and 480–626) along with a glycine-rich component (UniprotKB <a href="https://Q9UM73" class="ext-link">Q9UM73</a>). Architectures of (B) the anaplastic large cell lymphoma kinase (ALCL) NPM-ALK fusion protein, and (C) nonsmall cell lung cancer (NSCLC) EML4-ALK fusion protein (variant 1).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00446/20191219/images/large/jm9b00446_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00446&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00446/20191219/images/medium/jm9b00446_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00446/20191219/images/large/jm9b00446_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Mechanisms of acquired resistance to ALK inhibitor therapy in ALK-positive cancers, including acquired secondary mutations of ALK and/or fused ALK, gene amplification, bypass signaling pathway activation, and other mechanisms.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00446/20191219/images/large/jm9b00446_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00446&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00446/20191219/images/medium/jm9b00446_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00446/20191219/images/large/jm9b00446_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Representative ALK inhibitors in clinical and preclinical stages.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00446/20191219/images/large/jm9b00446_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00446&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">2.  Structure and Downstream Signaling Pathways of ALK</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_57400" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_57400" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4">2.1.  Structural Biology of ALK</h3><div class="NLM_p">As shown in <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>A, human ALK consists of a signal peptide (1–18), an extracellular ligand-binding domain (19–1038), a transmembrane domain (1039–1059), and an intracellular tyrosine kinase domain (1060–1620). Rearrangements on the 2p23 chromosomal segment can result in the fusion of ALK to various partner genes,<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> as exemplified by NPM-ALK and EML4-ALK (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>B,C). As shown in <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>, the kinase domain of ALK comprises a small amino-terminal lobe (N-lobe) and a large carboxyl-terminal lobe (C-lobe) that are connected by a flexible hinge region. A cleft that serves as the binding pocket for ATP is formed between the two lobes. The small N-lobe is mainly composed of five-stranded β-sheets (β1−β5) and an important regulatory α-helix called the αC-helix.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> The N-lobe also contains a glycine-rich loop (G-loop) between the β1- and β2-strands, which participates in the coordination of the β- and γ- phosphates of ATP.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> The large C-lobe contains six conserved α-helices (αD−αI) and two short conserved β-strands (β7−β8) located between the αE- and αF-helices.<a onclick="showRef(event, 'ref39 ref40'); return false;" href="javascript:void(0);" class="ref ref39 ref40">(39,40)</a> In <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>A, the unphosphorylated ALK kinase domain contains an additional helix (αEF) within the activation loop (A-loop) that follows the β8 strand. In addition, ALK contains two conserved hydrophobic noncontiguous motifs, termed the regulatory spine (R-spine) and catalytic spine (C-spine), which span both the N- and C-lobes (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>A). Assembly of the R-spine is the hallmark of the insulin receptor activation, and structural changes in the A-loop and αC-helix by disassembling the R-spines regulates the activation/in-activation cycles of ALK.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> As shown in <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>B, Lys1150, Glu1167, Asp1249, and Asp1270 (K/E/D/D signature) in the ATP binding region are critical residues involved in the catalytic activity of ALK.<a onclick="showRef(event, 'ref39 ref40'); return false;" href="javascript:void(0);" class="ref ref39 ref40">(39,40)</a> Biochemical data suggests that autophosphorylation of the Y′RAS′YY motif in the A-loop affects both substrate binding and catalytic efficiency of ALK.<a onclick="showRef(event, 'ref39 ref40'); return false;" href="javascript:void(0);" class="ref ref39 ref40">(39,40)</a> Phosphorylation of Tyr1278 in the Y′RAS′YY motif may activate ALK by relaxing ALK from inactive conformational constraints.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a></div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00446/20191219/images/medium/jm9b00446_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00446/20191219/images/large/jm9b00446_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. (A) Crystal structure of the ALK domain (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4Z55">4Z55</a>), and (B) 2D diagram of the inferred interactions between the human ALK catalytic core residue, ATP, and a protein substrate.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00446/20191219/images/large/jm9b00446_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00446&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5">2.2.  Downstream Signaling Pathways of ALK</h3><div class="NLM_p">ALK is a membrane-bound receptor, which normally receives and transfers extracellular signals by activating multiple intracellular signaling pathways. Different ALK aberrations cause diverse pathogenic signaling anomalies<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> such as SRC/RAS/MEK/ERK1/2, JAK/STAT, PI3K/AKT/mTOR, and PLC-γ/DAG/PKC pathways.<a onclick="showRef(event, 'ref31 ref41'); return false;" href="javascript:void(0);" class="ref ref31 ref41">(31,41)</a> The PLC-γ/DAG/PKC and SRC/RAS/ERK1/2 pathways affect cell growth and proliferation, while the JAKs/STAT and PI3K/AKT/mTOR pathways regulate cell survival.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> However, the full picture of ALK signaling has not been illuminated. The critical pathways involved in ALK downstream signaling events can be activated by the fusion proteins such as NPM-ALK and EML4-ALK.<a onclick="showRef(event, 'ref31 ref41'); return false;" href="javascript:void(0);" class="ref ref31 ref41">(31,41)</a> As shown in <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>, ERK1/2, PI3K/AKT/mTOR, and STAT3 could be activated by the NPM-ALK fusion protein, while the transforming potential of NPM-ALK in ALCL is mainly mediated by STAT3.<a onclick="showRef(event, 'ref43 ref44'); return false;" href="javascript:void(0);" class="ref ref43 ref44">(43,44)</a> In cellular models of NSCLC harboring EML4-ALK rearrangement, the PI3K/AKT and RAS/MAPK pathways are strongly activated.<a onclick="showRef(event, 'ref6 ref41'); return false;" href="javascript:void(0);" class="ref ref6 ref41">(6,41)</a> In recent years, extensive efforts have been dedicated to study the ALK-dependent signaling events in neuroblastoma characterized by point mutations/amplification in the full-length ALK, and the results illustrate that the activated ALK acts synergistically with the overexpressed MYCN to drive neuroblastoma development.<a onclick="showRef(event, 'ref45 ref46 ref47'); return false;" href="javascript:void(0);" class="ref ref45 ref46 ref47">(45−47)</a> Besides, activation of adaptor proteins and other cellular proteins, such as NF-κB, SRC, SHC-GRB2, IRS-1, and JUN/AP1, has been proved to play important roles in ALK signaling transduction, suggesting potential “bypass” signaling pathways.<a onclick="showRef(event, 'ref6 ref41'); return false;" href="javascript:void(0);" class="ref ref6 ref41">(6,41)</a></div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00446/20191219/images/medium/jm9b00446_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00446/20191219/images/large/jm9b00446_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. ALK signaling pathways and the important downstream targets of ALK. ALK, as a membrane receptor, receives and transfers extracellular signals by activating multiple intracellular signaling pathways. The PLC-γ/DAG/PKC and SRC/RAS/ERK1/2 pathways affect cell growth and proliferation, while the JAKs/STAT and PI3K/AKT/mTOR pathways regulate cell survival.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00446/20191219/images/large/jm9b00446_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00446&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i6">3.  Pathological Roles of ALK in Related Diseases</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_51732" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_51732" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7">3.1.  ALK Translocations</h3><div class="NLM_p">At present, nearly 30 fusion proteins of ALK have been identified as oncogenic drivers in many types of cancers (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>), among which EML4-ALK and NPM-ALK are the two most common variants. Parts B and C of <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a> illustrate that the translocations lead to the fusion of the normally expressed NPM and EML4 proteins to the ALK kinase domain.</div><div class="NLM_p">EML4-ALK is the most common fusion type in ALK-positive NSCLC patients, and about 3–7% of all NSCLC cases worldwide contain an EML4-ALK rearrangement.<a onclick="showRef(event, 'ref48 ref49'); return false;" href="javascript:void(0);" class="ref ref48 ref49">(48,49)</a> EML4-ALK rearranged NSCLC often occurs in young and lifelong nonsmoking adenocarcinoma patients.<a onclick="showRef(event, 'ref10 ref50'); return false;" href="javascript:void(0);" class="ref ref10 ref50">(10,50)</a> Notably, the oncogenic EML4-ALK fusion gene exclusively exists in NSCLC cases without epidermal growth factor receptor (EGFR) or Kirsten rat sarcoma virus (KRAS) mutation, which makes EML4-ALK an essential target for NSCLC.<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> Additionally, some less frequent ALK fusions have also been identified in NSCLC, including PTPN3-ALK, TFG-ALK, HIP1-ALK, KIF5B-ALK, KLC1-ALK, STRN-ALK, and TPR-ALK.<a onclick="showRef(event, 'ref17 ref31 ref52 ref53'); return false;" href="javascript:void(0);" class="ref ref17 ref31 ref52 ref53">(17,31,52,53)</a></div><div class="NLM_p">NPM-ALK has been detected in nearly 75–80% of ALK-positive ALCL patients,<a onclick="showRef(event, 'ref1 ref43'); return false;" href="javascript:void(0);" class="ref ref1 ref43">(1,43)</a> and about 15% of ALK-positive ALCLs have TPM3/4-ALK translocations.<a onclick="showRef(event, 'ref31 ref41'); return false;" href="javascript:void(0);" class="ref ref31 ref41">(31,41)</a> Besides, the other fusion proteins occur at much lower frequency (<2%), including RNF213-ALK,<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a> TFG-ALK, MSN-ALK, ATIC-ALK, MYH9-ALK, CLTC-ALK, and TRAF1-ALK.<a onclick="showRef(event, 'ref31 ref41'); return false;" href="javascript:void(0);" class="ref ref31 ref41">(31,41)</a></div><div class="NLM_p">ALK-positive IMT is a kind of solid tumor, typically occurring in soft tissues of young patients.<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a> TPM3/4-ALK fusion proteins were detected in up to 50% of IMTs.<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> The expressions of the other ALK fusion partners in IMTs, such as CLTC, CARS, ATIC, SEC31A, RRBP1, RANBP2, and ETV6, were found at much lower level (<5%).<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a></div><div class="NLM_p">DLBCL is an aggressive type of non-Hodgkin lymphoma in adults<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> and shows poor response to conventional therapies. The majority of ALK-positive DLBCL possess the t(2;17)(p23;q23) chromosomal translocation, producing the CLTC-ALK fusion protein.<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a> NPM-ALK and other fusion proteins (SQSTM1-ALK and SEC31A-ALK) are less expressed in DLBCL.<a onclick="showRef(event, 'ref60 ref61'); return false;" href="javascript:void(0);" class="ref ref60 ref61">(60,61)</a> Studies show that ALK-rearranged DLBCL could benefit from individually tailored therapy by targeting ALK.<a onclick="showRef(event, 'ref62 ref63'); return false;" href="javascript:void(0);" class="ref ref62 ref63">(62,63)</a></div><div class="NLM_p last">Besides, ALK translocations are also involved in the occurrence of esophageal squamous cell carcinoma (TPM4-ALK),<a onclick="showRef(event, 'ref64'); return false;" href="javascript:void(0);" class="ref ref64">(64)</a> renal cell carcinoma (VCL-ALK, TPM3-ALK, and EML4-ALK),<a onclick="showRef(event, 'ref65 ref66 ref67'); return false;" href="javascript:void(0);" class="ref ref65 ref66 ref67">(65−67)</a> colorectal cancer (C2orf44-ALK),<a onclick="showRef(event, 'ref68'); return false;" href="javascript:void(0);" class="ref ref68">(68)</a> breast cancer (EML4-ALK),<a onclick="showRef(event, 'ref69'); return false;" href="javascript:void(0);" class="ref ref69">(69)</a> papillary thyroid cancer (EML4-ALK, GFPT1-ALK, TFG-ALK, and STRN-ALK),<a onclick="showRef(event, 'ref70 ref71 ref72'); return false;" href="javascript:void(0);" class="ref ref70 ref71 ref72">(70−72)</a> spitz tumors (DCTN1-ALK and TPM3-ALK),<a onclick="showRef(event, 'ref73'); return false;" href="javascript:void(0);" class="ref ref73">(73)</a> etc. Recently, a novel fibronectin 1 (FN1)-ALK fusion was identified in serous ovarian carcinoma (SOC) and IMTs.<a onclick="showRef(event, 'ref74'); return false;" href="javascript:void(0);" class="ref ref74">(74)</a></div></div><div id="sec3_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8">3.2.  Gene Mutations or Amplification of ALK</h3><div class="NLM_p last">About 7% of neuroblastoma are ALK-positive at diagnosis, and recent data indicate that ALK mutations occur in 20–25% of patients with relapsed neuroblastoma regardless of initial ALK status.<a onclick="showRef(event, 'ref75'); return false;" href="javascript:void(0);" class="ref ref75">(75)</a> Cancer-associated ALK mutations can be roughly divided into three groups: ligand-independent mutations (such as F1174I/S/L and R1275Q), ligand-dependent mutations (such as D1091N, T1151M, and A1234T), and a kinase-dead mutation (I1250T).<a onclick="showRef(event, 'ref76'); return false;" href="javascript:void(0);" class="ref ref76">(76)</a> In <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>, F1174L/S/I/C/V, R1245L/Q, and R1275Q/L in the kinase domain are three hotspot mutations observed in neuroblastoma and occur in ∼85% of all mutated cases.<a onclick="showRef(event, 'ref4 ref76 ref77'); return false;" href="javascript:void(0);" class="ref ref4 ref76 ref77">(4,76,77)</a> The synergy of the F1174L mutation and MYCN overexpression aggressively potentiates the oncogenic activity of MYCN and drives the formation of neuroblastoma with enhanced lethality.<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> Moreover, gain-of-function mutations, such as L1198F and G1201E, have been reported in ATC.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> Collectively, ALK mutations can induce the occurrence of various types of cancers, including neuroblastoma, esophageal cancer, colorectal cancer, inflammatory breast cancer, rhabdomyosarcoma, and NSCLC. However, the mechanisms involving cancer initiation and progression remain to be elucidated. Of note, neuroblastomas harboring both ALK mutations and amplified MYCN oncogene are more aggressive than the other cases.<a onclick="showRef(event, 'ref78'); return false;" href="javascript:void(0);" class="ref ref78">(78)</a></div></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i9">4.  Development of ALK Inhibitors and Their Therapeutic Implications</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_23568" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_23568" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10">4.1.  Approved Drugs Targeting ALK</h3><div class="NLM_p">Blockading of the aberrant ALK signaling pathways by small-molecule inhibitors has been validated as an effective way to inhibit the growth of ALK-positive cancer cells. Over the past decade, intensive efforts have thus been made to develop ALK inhibitors with different chemotypes.<a onclick="showRef(event, 'ref18 ref31 ref79'); return false;" href="javascript:void(0);" class="ref ref18 ref31 ref79">(18,31,79)</a> At present, five ALK inhibitors, including <b>1</b>, <b>2</b>, <b>4</b>, <b>5</b> and <b>11</b>, have been approved by the FDA for the treatment of ALK-positive NSCLCs.<a onclick="showRef(event, 'ref18 ref30 ref31 ref79'); return false;" href="javascript:void(0);" class="ref ref18 ref30 ref31 ref79">(18,30,31,79)</a></div><div class="NLM_p">Compound <b>1</b>, the first FDA-approved ALK inhibitor, was initially designed for the c-Met kinase by Pfizer using an integrated drug discovery strategy.<a onclick="showRef(event, 'ref16 ref80'); return false;" href="javascript:void(0);" class="ref ref16 ref80">(16,80)</a> As shown in <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>, Pfizer’s researchers first identified a 3-substituted indoline-2-ones derivative, SU-11274 (<b>13</b>), and then optimized it to a potent inhibitor of c-Met, PHA-665752 (<b>14</b>). Because of its poor physicochemical properties, they redesigned the core skeleton to a novel 5-aryl-3-benzyloxy-2-aminopyridine core by structure-based drug design (SBDD).<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> Further optimization based on the core structure of <b>15</b> led to the discovery of <b>1</b> as an effective dual inhibitor against c-Met and ALK. As a type-I inhibitor, compound <b>1</b> occupies the front ATP binding pocket in the active “DFG-in” conformation and forms two H-bonds with Glu1197 and Met1199 (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>A). The biochemical and cellular assays illustrate that <b>1</b> is nearly 20-fold more selective for c-Met and ALK over a panel of >120 kinases from different families.<a onclick="showRef(event, 'ref80'); return false;" href="javascript:void(0);" class="ref ref80">(80)</a> Compound <b>1</b> can effectively suppress NPM-ALK phosphorylation in Karpas-299 and SU-DHL-1 ALCL cell lines with IC<sub>50</sub> values of 32 and 43 nM, respectively.<a onclick="showRef(event, 'ref80'); return false;" href="javascript:void(0);" class="ref ref80">(80)</a> A series of clinical response data, including PROFILE 1001 (phase I, 2008), PROFILE 1005 (phase I/II, 2011), PROFILE 1007 (phase III, 2012), and PROFILE 1014 (phase III, 2014), confirmed that <b>1</b> is superior to the standard chemotherapy (pemetrexed or docetaxel) in the treatment of advanced or metastatic EML4-ALK NSCLCs,<a onclick="showRef(event, 'ref81 ref82 ref83'); return false;" href="javascript:void(0);" class="ref ref81 ref82 ref83">(81−83)</a> which led to the approval of <b>1</b> for the treatment of ALK-positive NSCLC in 2011. In addition, compound <b>1</b> also shows excellent efficacy in ALK-positive IMTs and Kelly neuroblastomas induced by gene amplification and/or mutations.<a onclick="showRef(event, 'ref84 ref85'); return false;" href="javascript:void(0);" class="ref ref84 ref85">(84,85)</a> Unfortunately, the success of <b>1</b> was overshadowed by the rapid emergence of drug resistance.<a onclick="showRef(event, 'ref30 ref86'); return false;" href="javascript:void(0);" class="ref ref30 ref86">(30,86)</a> The most frequently acquired mutations are L1196M, C1156Y, G1202, and G1269A/S (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>B). Moreover, the 1151Tins, L1152R, I1171T/N/S, F1174 V/L/C, G1202R, D1203N, S1206Y, and V1180L mutations were also reported to be able to confer resistance to <b>1</b> (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>A). The emergence of drug resistance and increasing need for better drugs led to the development and approval of the second- and third-generation ALK inhibitors (<a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figures <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>, <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a>, <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a>, and <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a>), including <b>3</b>, <b>4</b>, <b>5</b>, and <b>11</b>.<a onclick="showRef(event, 'ref28 ref30 ref41 ref87 ref88'); return false;" href="javascript:void(0);" class="ref ref28 ref30 ref41 ref87 ref88">(28,30,41,87,88)</a></div><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00446/20191219/images/medium/jm9b00446_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00446/20191219/images/large/jm9b00446_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Discovery and design procedure of the dual c-Met/ALK inhibitor, Crizotinib, by combing SBDD strategy and medicinal chemistry. The procedure started from a moderate c-Met inhibitor (compound <b>13</b>, SU-11274) and optimized it to a potent inhibitor for c-Met (PHA-665752) and then generated compounds <b>15</b>, <b>16</b>, <b>17</b>, and Crizotinib after a series of optimizations.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00446/20191219/images/large/jm9b00446_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00446&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00446/20191219/images/medium/jm9b00446_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00446/20191219/images/large/jm9b00446_0008.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Binding modes of the selected representative ALK inhibitors: (A) Crizotinib (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2XP2">2XP2</a>), (B) Ceritinib (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4MKE">4MKE</a>), (C) Alectinib (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3AOX">3AOX</a>), (D) Brigatinib (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5J7H">5J7H</a>), (E) Entrectinib (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5FTO">5FTO</a>), and (F) Lorlatinib (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4CLI">4CLI</a>). The key residues involved in the interactions between ALK kinase and ALK inhibitors, such as Leu1122, Glu1167, Ile1171, Phe1174, Glu1197, Met1199, and Phe1271.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00446/20191219/images/large/jm9b00446_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00446&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00446/20191219/images/medium/jm9b00446_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00446/20191219/images/large/jm9b00446_0009.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. (A) Reported Crizotinib resistant mutations in the ALK kinase domain (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2XP2">2XP2</a>), and (B) the frequency (reported cases) of each mutation detected directly from the Crizotinib-resistant patients.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00446/20191219/images/large/jm9b00446_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00446&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00446/20191219/images/medium/jm9b00446_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00446/20191219/images/large/jm9b00446_0010.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Evolution of Ceritinib (<b>3</b>) from the initial hit TAE684 (<b>2</b>) due to its toxicity as a result of oxidative metabolism.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00446/20191219/images/large/jm9b00446_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00446&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00446/20191219/images/medium/jm9b00446_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00446/20191219/images/large/jm9b00446_0011.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Design strategy used from the initial hit <b>18</b> to the FDA-approved Alectinib (<b>4</b>) through a series of optimizations (compounds <b>19</b>–<b>21</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00446/20191219/images/large/jm9b00446_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00446&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig12" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00446/20191219/images/medium/jm9b00446_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00446/20191219/images/large/jm9b00446_0012.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Design and optimization strategy used to develop Brigatinib (<b>5</b>) and ALK-IN-1 (<b>27</b>) and key Brigatinib analogues during the discovery process (compounds <b>25</b>, <b>26</b>, and <b>28</b>–<b>32</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00446/20191219/images/large/jm9b00446_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00446&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig13" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00446/20191219/images/medium/jm9b00446_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00446/20191219/images/large/jm9b00446_0013.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. Macrocyclic ALK inhibitor TPX-0005 (<b>12</b>) and the design procedure of Loratinib (<b>11</b>) by the cyclization (compounds <b>33</b>–<b>35</b>) and optimization (compound <b>36</b>) of Crizotinib.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00446/20191219/images/large/jm9b00446_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00446&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In 2013, Marsilje and colleagues from Novartis reported the discovery of <b>3</b> with a 2,4-diaminopyrimidine core scaffold, which was optimized based on the structure of compound <b>2</b> from high-throughput screening (HTS).<a onclick="showRef(event, 'ref19 ref79'); return false;" href="javascript:void(0);" class="ref ref19 ref79">(19,79)</a> TAE684 exhibited strong potency against Ba/F3 harboring NPM-ALK and two NSCLC cell lines (NCI-H2228 and NCI-H3122) harboring EML4-ALK.<a onclick="showRef(event, 'ref89'); return false;" href="javascript:void(0);" class="ref ref89">(89)</a> However, as shown in <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>, compound <b>2</b> did not enter clinical trials due to its potential toxic effects as a result of oxidative metabolism.<a onclick="showRef(event, 'ref79 ref89'); return false;" href="javascript:void(0);" class="ref ref79 ref89">(79,89)</a> Structure–activity relationship (SAR) analysis further confirmed that generation of the reactive metabolite was primarily attributed to the solubilizing group linked by the nitrogen atom on the central aniline moiety (<a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>). Further modifications were performed to improve kinase selectivity and to obstruct the formation of reactive metabolites and ultimately yielded <b>3</b>.<a onclick="showRef(event, 'ref90'); return false;" href="javascript:void(0);" class="ref ref90">(90)</a> In <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>B, compound <b>3</b> forms two H-bonds with the hinge region residue Met1199, and the reversed piperidine ring is engaged in a salt bridge with Glu1210. The isopropoxy group can form favorable interactions with Arg1120, Glu1132, and the Leu1198–Ala1200–Gly1201–Gly1202 hinge segment, which may improve the selectivity and potency of <b>3</b>. As expected, compound <b>3</b> retained high potency against ALK with an IC<sub>50</sub> value of 0.2 nM and showed potent antiproliferative activity for Karpass-299 and Ba/F3 cell lines carrying the NPM-ALK fusion gene with IC<sub>50</sub> values of 22.8 and 26.0 nM, respectively.<a onclick="showRef(event, 'ref88'); return false;" href="javascript:void(0);" class="ref ref88">(88)</a> Moreover, compound <b>3</b> could induce complete tumor regression in H2228 rat xenograft model and partially suppress tumor progression in a Karpass-299 xenograft model.<a onclick="showRef(event, 'ref79 ref88'); return false;" href="javascript:void(0);" class="ref ref79 ref88">(79,88)</a> Three multicenter phase I/II trials (<a href="http://ClinicalTrials.gov" class="extLink">ClinicalTrials.gov</a> identifiers: ASCEND-1, -2, and -3) and two randomized phase III clinical trials (<a href="http://ClinicalTrials.gov" class="extLink">ClinicalTrials.gov</a> identifiers: ASCEND-4 and -5) showed that <b>3</b> exhibited favorable efficacy in patients with ALK-rearranged and Crizotinib-naïve and -resistant NSCLCs.<a onclick="showRef(event, 'ref88 ref91 ref92 ref93 ref94'); return false;" href="javascript:void(0);" class="ref ref88 ref91 ref92 ref93 ref94">(88,91−94)</a> In patients with advanced NSCLC harboring ALK rearrangements, compound <b>3</b> achieved an overall response rate (ORR) of 58% and a median progression free survival (PFS) of 8.2 months (<a href="http://ClinicalTrials.gov" class="extLink">ClinicalTrials.gov</a> identifiers: ASCEND-1).<a onclick="showRef(event, 'ref91'); return false;" href="javascript:void(0);" class="ref ref91">(91)</a> Compound <b>3</b> bearing a unique benzo[<i>b</i>]carbazole scaffold is a potent and selective ALK inhibitor modified from the initial screening hit <b>18</b> (<a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>).<a onclick="showRef(event, 'ref20 ref91 ref95'); return false;" href="javascript:void(0);" class="ref ref20 ref91 ref95">(20,91,95)</a> In the cocrystal structure of ALK bound to <b>4</b>, the tetracylic benzo[<i>b</i>]carbazolone scaffold adopts a planar conformation where the carbonyl and cyano groups form favorable H-bonds interactions with Met1199 and Lys1150 (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>C). In in vitro testing, compound <b>4</b> displayed strong inhibitory activity against different ALK-driven cell lines, especially NCI-H2228 and Karpas-299.<a onclick="showRef(event, 'ref96 ref97'); return false;" href="javascript:void(0);" class="ref ref96 ref97">(96,97)</a> Of note, compound <b>4</b> is more effective than <b>1</b> against tumors with brain metastasis (BM),<a onclick="showRef(event, 'ref95'); return false;" href="javascript:void(0);" class="ref ref95">(95)</a> which can be explained by the higher penetration rate of <b>4</b> across the blood–brain barrier (BBB).<a onclick="showRef(event, 'ref98'); return false;" href="javascript:void(0);" class="ref ref98">(98)</a> In two multicenter phase II studies (<a href="http://ClinicalTrials.gov" class="extLink">ClinicalTrials.gov</a> identifiers: NP28761 and NP28673),<a onclick="showRef(event, 'ref99 ref100 ref101'); return false;" href="javascript:void(0);" class="ref ref99 ref100 ref101">(99−101)</a> the excellent efficacy and good tolerance of <b>4</b> were confirmed in patients with advanced crizotinib-refractory ALK-positive NSCLC,<a onclick="showRef(event, 'ref102'); return false;" href="javascript:void(0);" class="ref ref102">(102)</a> which accelerated its approval by the FDA in 2015. In 2016, Huang and colleagues at Ariad Pharmaceuticals reported a series of dimethylphosphine oxide (DMPO)-containing 2-aminopyrimidine-based ALK inhibitors with improved activity and selectivity compared with the unsubstituted analogue (<b>23</b>, <b>24</b> vs <b>22</b>).<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> As shown in <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>, compounds <b>5</b> and <b>25</b>–<b>27</b> (ALK-IN-1) show favorable selectivity over InsR and IGF1R. Moreover, Huang et al. explored the SAR at the C2 position of the pyrimidine core,<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> and they found that seven-membered homopiperazine or five-membered pyrrolidine analogues were less active than the corresponding six-membered inhibitors (<b>28</b> vs <b>27</b>, <b>30</b> vs <b>29</b>, and <b>32</b> vs <b>31</b>).<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> The improved potency of <b>5</b> and its analogues may be largely due to the enhanced interactions of the methoxy group with Leu1198, the C5-chlorine atom with Leu1196, and the dimethylphosphine oxide (DMPO) moiety with the DFG motif (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>D). Besides, the unique DMPO acts as a H-bond acceptor, effectively fostering the intramolecular interactions and stabilizing its U-shaped conformation. In both enzyme-based and cellular assays, compound <b>5</b> exhibited low nanomolar IC<sub>50</sub> against WT ALK/ROS1/EGFR and a broad panel of drug-resistant mutants of ALK<a onclick="showRef(event, 'ref18 ref30 ref31 ref103 ref104'); return false;" href="javascript:void(0);" class="ref ref18 ref30 ref31 ref103 ref104">(18,30,31,103,104)</a> (shown in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). In addition, compound <b>5</b> demonstrated remarkable efficacy in multiple mouse models of NSCLCs without significant side effects.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> In 2016, a phase II, multicenter, randomized study (<a href="http://ClinicalTrials.gov" class="extLink">ClinicalTrials.gov</a> identifier: ALTA) demonstrated that the disease control rate (DCR) of <b>5</b> could reach 86% in patients with advanced or metastatic ALK-positive NSCLC resistant to crizotinib.<a onclick="showRef(event, 'ref105'); return false;" href="javascript:void(0);" class="ref ref105">(105)</a> Compound <b>5</b> also yielded substantial whole-body (ORR: 54%) and intracranial responses (ORR: 67%) with robust PFS up to 12.9 months.<a onclick="showRef(event, 'ref105'); return false;" href="javascript:void(0);" class="ref ref105">(105)</a> Compound <b>5</b> was approved by the FDA in 2017 due to its favorable potency, selectivity, and ADME (absorption, distribution, metabolism, and excretion) profiles.<a onclick="showRef(event, 'ref106'); return false;" href="javascript:void(0);" class="ref ref106">(106)</a></div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Acquired Secondary Mutations Conferring Resistance to ALK Inhibitors</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">drugs</th><th class="colsep0 rowsep0" align="center">tumor type</th><th class="colsep0 rowsep0" align="center">activity against L1196M</th><th class="colsep0 rowsep0" align="center">activity against C1156Y</th><th class="colsep0 rowsep0" align="center">activity against G1202R</th><th class="colsep0 rowsep0" align="center">other Crizotinib resistant mutations (sensitive)</th><th class="colsep0 rowsep0" align="center">resistant mutations</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Crizotinib</td><td class="colsep0 rowsep0" align="center">NSCLC IMT neuroblastoma</td><td class="colsep0 rowsep0" align="center">no</td><td class="colsep0 rowsep0" align="center">no</td><td class="colsep0 rowsep0" align="center">no</td><td class="colsep0 rowsep0" align="center">L1198F</td><td class="colsep0 rowsep0" align="center">1151insT, L1152R, F1174V, S1206Y, G1269A, D1203N</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="7" align="left">     </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Ceritinib</td><td class="colsep0 rowsep0" align="center">NSCLC thyroid</td><td class="colsep0 rowsep0" align="center">yes</td><td class="colsep0 rowsep0" align="center">no</td><td class="colsep0 rowsep0" align="center">no</td><td class="colsep0 rowsep0" align="center">G1269A, I1171T/N/S, S1206Y, V1180L</td><td class="colsep0 rowsep0" align="center">EML4-ALK/1151Tins</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center">EML4-ALK/L1152R</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center">EML4-ALK/C1156Y</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center">EML4-ALK/F1174C</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="7" align="left">     </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Alectinib</td><td class="colsep0 rowsep0" align="center">neuroblastoma NSCLC</td><td class="colsep0 rowsep0" align="center">yes</td><td class="colsep0 rowsep0" align="center">yes</td><td class="colsep0 rowsep0" align="center">no</td><td class="colsep0 rowsep0" align="center">G1269A, S1206Y, L1152R, F1174L, 1151T-ins</td><td class="colsep0 rowsep0" align="center">EML4-ALK/I1171Tins</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center">EML4-ALK/V1180L</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="7" align="left">     </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Brigatinib</td><td class="colsep0 rowsep0" align="center">NSCLC</td><td class="colsep0 rowsep0" align="center">yes</td><td class="colsep0 rowsep0" align="center">yes</td><td class="colsep0 rowsep0" align="center">no</td><td class="colsep0 rowsep0" align="center">G1269A, A1206Y, 1151T-ins, F1174C, I1171T, D1203N, E1210K, F1245C</td><td class="colsep0 rowsep0" align="center">NA</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="7" align="left">     </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Entrectinib</td><td class="colsep0 rowsep0" align="center">colorectal</td><td class="colsep0 rowsep0" align="center">yes</td><td class="colsep0 rowsep0" align="center">yes</td><td class="colsep0 rowsep0" align="center">NA</td><td class="colsep0 rowsep0" align="center">NA</td><td class="colsep0 rowsep0" align="center">NA</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="7" align="left">     </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">X-396</td><td class="colsep0 rowsep0" align="center">lung neuroblastoma</td><td class="colsep0 rowsep0" align="center">yes</td><td class="colsep0 rowsep0" align="center">yes</td><td class="colsep0 rowsep0" align="center">NA</td><td class="colsep0 rowsep0" align="center">F1174L, R1275Q</td><td class="colsep0 rowsep0" align="center">NA</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="7" align="left">     </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ASP3026</td><td class="colsep0 rowsep0" align="center">ALCL NSCLC</td><td class="colsep0 rowsep0" align="center">yes</td><td class="colsep0 rowsep0" align="center">NA</td><td class="colsep0 rowsep0" align="center">NA</td><td class="colsep0 rowsep0" align="center">F1174L</td><td class="colsep0 rowsep0" align="center">NA</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="7" align="left">     </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Lorlatinib</td><td class="colsep0 rowsep0" align="center">ALCL neuroblastoma</td><td class="colsep0 rowsep0" align="center">yes</td><td class="colsep0 rowsep0" align="center">yes</td><td class="colsep0 rowsep0" align="center">yes</td><td class="colsep0 rowsep0" align="center">G1269A, F1174L, S1206Y, I1171T, E1210K, L1152R, 1151Tins, V1180L, D1203N</td><td class="colsep0 rowsep0" align="center">L1198F</td></tr></tbody></table></div></div><div class="NLM_p">Although compounds <b>3</b>–<b>5</b> were active in inhibiting several crizotinib-resistant mutants of ALK, they were not able to cover the broad range of drug-resistant cases.<a onclick="showRef(event, 'ref18 ref30 ref31 ref79'); return false;" href="javascript:void(0);" class="ref ref18 ref30 ref31 ref79">(18,30,31,79)</a> In ALK-positive Ba/F3 models, compound <b>3</b> is highly active against L1196M, G1269A, S1206Y, and I1171T EML4-ALK mutants but less active against C1156Y, G1202R, 1151Tins, L1152P, and F1174C mutants.<a onclick="showRef(event, 'ref107 ref108'); return false;" href="javascript:void(0);" class="ref ref107 ref108">(107,108)</a> Patients with V1180L and I1171T/N/S mutations are sensitive to <b>3</b> but are insensitive to compound <b>4</b>.<a onclick="showRef(event, 'ref109'); return false;" href="javascript:void(0);" class="ref ref109">(109)</a> Even through <b>5</b> exhibited higher potency against ALK<sup>G1202R</sup> than <b>3</b> and <b>4</b>, its potency in Ba/F3 cells harboring the G1202R mutation was unfavorable.<a onclick="showRef(event, 'ref110'); return false;" href="javascript:void(0);" class="ref ref110">(110)</a> The ALK<sup>E1210K/S1206C</sup> and ALK<sup>E1210K/D1203N</sup> mutants were successively detected in excisional biopsies of recurrent left axillary disease after treating with <b>5</b>.<a onclick="showRef(event, 'ref109'); return false;" href="javascript:void(0);" class="ref ref109">(109)</a> The ALK<sup>G1202<i>R</i>/1196M</sup> double mutants conferred resistance to all first- and second-generation inhibitors of ALK.<a onclick="showRef(event, 'ref110'); return false;" href="javascript:void(0);" class="ref ref110">(110)</a> Obviously, G1202R is a common high-level resistance mutation to <b>1</b> and <b>3</b>–<b>5</b>.<a onclick="showRef(event, 'ref18 ref30 ref98'); return false;" href="javascript:void(0);" class="ref ref18 ref30 ref98">(18,30,98)</a> Besides, “bypass” drug resistance mechanism also affects drug efficacy. An MAP2K1 K57N-activating mutation was identified in <b>3</b>- and <b>4</b>-resistant cases.<a onclick="showRef(event, 'ref103'); return false;" href="javascript:void(0);" class="ref ref103">(103)</a> Activation of the hepatocyte growth factor (HGF)/Met pathway was also potentially responsible for the resistance to <b>4</b>, and the NRG1–HER3–EGFR axis was proposed to mediate the resistance to both <b>3</b> and <b>4</b>.<a onclick="showRef(event, 'ref18 ref30'); return false;" href="javascript:void(0);" class="ref ref18 ref30">(18,30)</a></div><div class="NLM_p last">All FDA-approved ALK drugs are ATP-competitive inhibitors that contain an ATP-adenine equivalent kinase hinge binder and an extra motif extending to the solvent area. Inevitably, these compounds are vulnerable to the solvent-front mutations (SFMs) such as ALK<sup>G1202R</sup>. Fortunately, in 2014, Johnson et al. reported the discovery of an effective ALK inhibitor with an amido-linked 12-membered macrocycles, compound <b>11</b>, using a structure guided approach.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> In their work, the design campaign of <b>11</b> was initiated by comparing the crystal structures of apo ALK with ALK/<b>1</b>. As shown in <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>, the final successful generation of the macrocyclic <b>11</b> is credited to a series of efforts made to improve the potency, selectivity, CNS ADME, and lipophilic efficiency (<b>33</b>–<b>36</b>). In <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>F, the rigid macrocycle in <b>11</b> is precisely anchored in the adenine binding site with a bioactive binding posture predefined to avoid the entropy penalty. Besides, compound <b>11</b> can form two stable H-bonds with Glu1197 and Met1199 and favorable contact with DGF-Asp1270 via van der Waals interaction. As expected, compound <b>11</b> is a potent dual ALK/ROS1 inhibitor with <i>K</i><sub>i</sub> values of <0.02, <0.07, and 0.7 nM for ROS1, ALK, and L1196M mutated ALK, respectively, and shows favorable inhibitory activity against Ba/F3 cells expressing ALK<sup>G1202R</sup> with the IC<sub>50</sub> value of 77 nM.<a onclick="showRef(event, 'ref111'); return false;" href="javascript:void(0);" class="ref ref111">(111)</a> Besides, compound <b>11</b> exhibits remarkable in vivo efficacy against H3122 EML4-ALK<sup>WT</sup>, H3122 EML4-ALK<sup>L1196M</sup>, H3122 EML4-ALK<sup>G1269A</sup>, and H3122 EML4-ALK<sup>G1202R</sup> tumors in mice.<a onclick="showRef(event, 'ref112'); return false;" href="javascript:void(0);" class="ref ref112">(112)</a> Moreover, compound <b>11</b> has been reported as an effective agent against neuroblastoma carrying ALK resistant mutations (F1174L, F1245C, and R1275L), especially the aggressive cases caused by the co-overexpression of ALK and MYCN.<a onclick="showRef(event, 'ref75'); return false;" href="javascript:void(0);" class="ref ref75">(75)</a> Of note, as a substrate of the ATP binding cassette subfamily B member 1 (ABCB1), compound <b>11</b> can effectively cross the BBB and penetrate into the central nerve system (CNS).<a onclick="showRef(event, 'ref113 ref114'); return false;" href="javascript:void(0);" class="ref ref113 ref114">(113,114)</a> According to the phase I/II clinical trials launched by Pfizer (<a href="http://ClinicalTrials.gov" class="extLink">ClinicalTrials.gov</a> identifiers: NCT01970865, NCT02584634, and NCT02927340), compound <b>11</b> showed promising systemic and intracranial activity in patients with ALK- or ROS1-positive NSCLC.<a onclick="showRef(event, 'ref7 ref115 ref116'); return false;" href="javascript:void(0);" class="ref ref7 ref115 ref116">(7,115,116)</a> The results from the phase I/II trials promoted <b>11</b>’s first approval in Japan on September 2018 for the treatment of drug-resistant ALK fusion-positive advanced and/or recurrent NSCLC as the third-generation inhibitors, followed by its approval in the USA on November 2018 against ALK-positive metastatic NSCLC resistant to <b>1</b>, <b>3</b>, or <b>4</b>.<a onclick="showRef(event, 'ref117 ref118'); return false;" href="javascript:void(0);" class="ref ref117 ref118">(117,118)</a> Currently, a multinational phase III trial (<a href="http://ClinicalTrials.gov" class="extLink">ClinicalTrials.gov</a> identifier: NCT03052608) has been initiated to compare <b>11</b> and <b>1</b> as first-line monotherapy against ALK-positive NSCLC.<a onclick="showRef(event, 'ref118'); return false;" href="javascript:void(0);" class="ref ref118">(118)</a> Besides, clinical trials of <b>11</b> are still ongoing in order to explore the efficacy in lymphoma (phase II, NCT03505554) and neuroblastoma (phase I, NCT03107988).<a onclick="showRef(event, 'ref118'); return false;" href="javascript:void(0);" class="ref ref118">(118)</a> In a preclinical study reported by Shaw et al., the L1198F mutation conferred resistance to <b>11</b> through unfavorable steric interference with drug binding, but it could enhance the binding of <b>1</b> and negate the unfavorable effect of C1156Y.<a onclick="showRef(event, 'ref119'); return false;" href="javascript:void(0);" class="ref ref119">(119)</a></div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12">4.2.  ALK Inhibitors in Clinical and Preclinical Trials</h3><div class="NLM_p">Currently, numerous ALK inhibitors are under clinical and/or preclinical studies, which are expected to outperform the FDA-approved drugs. On the basis of the core scaffolds, the reported ALK inhibitors can be classified into several series, including 2,4-aminopyrimidine,<a onclick="showRef(event, 'ref21 ref24 ref79 ref89 ref120 ref121 ref122'); return false;" href="javascript:void(0);" class="ref ref21 ref24 ref79 ref89 ref120 ref121 ref122">(21,24,79,89,120−122)</a> 1,3,5-triazine,<a onclick="showRef(event, 'ref123'); return false;" href="javascript:void(0);" class="ref ref123">(123)</a> 3-aminoindazole,<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> aminopyrazine,<a onclick="showRef(event, 'ref124'); return false;" href="javascript:void(0);" class="ref ref124">(124)</a> acyliminobenzimidazoles, 1<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine,<a onclick="showRef(event, 'ref125'); return false;" href="javascript:void(0);" class="ref ref125">(125)</a> 3-benzyloxyaminopyridine,<a onclick="showRef(event, 'ref126'); return false;" href="javascript:void(0);" class="ref ref126">(126)</a> benzo[<i>b</i>]carbazole derivative,<a onclick="showRef(event, 'ref127'); return false;" href="javascript:void(0);" class="ref ref127">(127)</a> 1<i>H</i>-pyrazol-5-yl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine derivatives,<a onclick="showRef(event, 'ref128'); return false;" href="javascript:void(0);" class="ref ref128">(128)</a> as well as the recently identified macrocyclic ALK inhibitors.<a onclick="showRef(event, 'ref29 ref129'); return false;" href="javascript:void(0);" class="ref ref29 ref129">(29,129)</a></div><div id="sec4_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i13" class="anchor-spacer"></div><h4 class="article-section__title" id="_i13">4.2.1.  2,4-Diaminopyrimidine</h4><div class="NLM_p">Over the years, Teva Pharmaceuticals made great efforts to develop effective ALK inhibitors based on the 2-aminopyrimidine core scaffold. As shown in <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a></a>, Gingrich and colleagues from Teva identified compound <b>37</b> with the bicyclo[2.2.1]hept-5-ene ring, which could achieve the balance between ALK potency and global kinase selectivity.<a onclick="showRef(event, 'ref24 ref120 ref130'); return false;" href="javascript:void(0);" class="ref ref24 ref120 ref130">(24,120,130)</a> However, the moderate IR/ALK selectivity (>100) prompted further optimization of this diaminopyrimidine analogue. In their work, the medicinal chemistry efforts by combining <b>37</b> and 2,3,4,5-tetrahydro-1<i>H</i>-benzo[<i>d</i>]azepine fragment of the diaminopyrimidine analogue <b>38</b> yielded <b>39</b> (CEP-28122), which exhibited enhanced ALK inhibitory activity and improved IR selectivity (>600-fold).<a onclick="showRef(event, 'ref120'); return false;" href="javascript:void(0);" class="ref ref120">(120)</a> However, the development of <b>39</b> was unfortunately terminated because of the severe lung toxicity in monkey models, which advanced the generation of a novel dual ALK/FAK inhibitor <b>7</b> by several rounds of optimizations (<b>40</b> and <b>41</b>).<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> Of particular note, compound <b>7</b> showed high potency against multiple ALK mutants, including 1151Tins ALK (<i>K</i><sub>d</sub> = 2.6 nM), C1156Y ALK (<i>K</i><sub>d</sub> = 1.6 nM), F1174L ALK (<i>K</i><sub>d</sub> = 1.1 nM), and L1196 M ALK (<i>K</i><sub>d</sub> = 3.3 nM).<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> Compound <b>7</b> could induce complete tumor regression without toxicity in both Sup-M2 and Karpas-299 mouse xenograft models.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> Moreover, compared with <b>39</b>, compound <b>7</b> possessed superior solubility and metabolic stability, improved oral bioavailability, lower clearance and toxicity, and favorable brain penetration.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> At present, the completed phase I clinical trials showed the striking inhibitory activity of <b>7</b> in patients with advanced or metastatic solid tumor such as inflammatory breast cancer and NSCLC.<a onclick="showRef(event, 'ref131'); return false;" href="javascript:void(0);" class="ref ref131">(131)</a></div><figure id="fig14" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00446/20191219/images/medium/jm9b00446_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00446/20191219/images/large/jm9b00446_0014.jpeg" id="gr14" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. Development strategy for CEP-28122 (39) and CEP-37440. The combination of compound <b>37</b> and the 2,3,4,5-tetrahydro-1<i>H</i>-benzo[<i>d</i>]azepine fragment of the diaminopyrimidine analogue <b>38</b> yielded CEP-28122. The toxicity of CEP-28122 advanced the generation of CEP-37440 by optimizations (compounds <b>40</b> and <b>41</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00446/20191219/images/large/jm9b00446_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00446&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">AZD3463 (<b>42</b>, <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a></a>), a preclinical ALK/IGF1R inhibitor designed by AstraZeneca in 2013, showed good activity against multiple crizotinib-resistant mutations (L1196M and T115Ins) and inhibited ALK autophosphorylation in tumor cell lines containing ALK fusions, such as DEL (ALCL NPM-ALK), H3122 (NSCLC EML4-ALK), and H2228 (NSCLC EML4-ALK).<a onclick="showRef(event, 'ref132'); return false;" href="javascript:void(0);" class="ref ref132">(132)</a> In 2016, Wang et al. reported that <b>42</b> could effectively suppress the proliferation of neuroblastoma cell lines with the WT ALK and ALK activating mutations (F1174L and D1091N) by blocking the ALK-mediated PI3K/AKT/mTOR pathway.<a onclick="showRef(event, 'ref133'); return false;" href="javascript:void(0);" class="ref ref133">(133)</a></div><div class="NLM_p">In 2014, Liu et al. identified a series of 2,4-diarylaminopyrimidine analogues (DAAPalogues) by repurposing a typical dopamine D1/D5 receptor agonist motif (<b>43</b> and <b>44</b>), <i>C</i>1-substituted-<i>N</i>3-benzazepine (A) or benzazecine (B), into the C2 position of the DAAP skeleton, which led to the generation of a 1-methyl/aryl-<i>N</i>3-benzazepine framework.<a onclick="showRef(event, 'ref121'); return false;" href="javascript:void(0);" class="ref ref121">(121)</a> As shown in <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a></a>, compound <b>45</b> bearing a C1-methyl substituted N3-benzazepine motif showed high potency against both the c-Met and ALK, with IC<sub>50</sub> values of 6.0 and 9.0 nM, respectively. Compound <b>46</b> bearing a larger ring system has an IC<sub>50</sub> value of 17 nM against ALK and is 40-fold more potent than that against c-Met. In BF3 EML4-ALK xenograft mice model, compound <b>45</b> displayed significant antitumor efficacy with an inhibitory rate of 60.6% at the dose of 1 mg/kg, higher than that of <b>1</b> at the dose of 50 mg/kg. However, compound <b>45</b> needs further optimization due to its moderate inhibitory activity toward L1196M and C1156Y ALK mutants. By opening the azepanone ring of <b>47</b> (<a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">16</a></a>), a series of novel DAAP analogues bearing a flexible amino acid side chain were synthesized by Song et al.<a onclick="showRef(event, 'ref122'); return false;" href="javascript:void(0);" class="ref ref122">(122)</a> Compound <b>49</b> optimized from <b>48</b> was identified a potent and selective ALK inhibitor possessing IC<sub>50</sub> values of 2.7 and 15.3 nM against the WT and L1196 mutated ALK, respectively. Compound <b>49</b> bearing a primary amino group showed an IC<sub>50</sub> value of 15.3 nM against SUPM2 cell line and was found to inhibit several resistant tumors with the L1196M, L1174M, or/and R1275Q mutated ALK.</div><figure id="fig15" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00446/20191219/images/medium/jm9b00446_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00446/20191219/images/large/jm9b00446_0015.jpeg" id="gr15" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 15. Design of new 2,4-diarylaminopyrimidine analogues (DAAPalogues) by repurposing a typical dopamine D1/D5 (compounds <b>43</b> and <b>44</b>), which led to the generation of compounds <b>45</b> and <b>46</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00446/20191219/images/large/jm9b00446_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00446&amp;id=fig15"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig16" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 16</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00446/20191219/images/medium/jm9b00446_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00446/20191219/images/large/jm9b00446_0016.jpeg" id="gr16" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 16. Development strategy for the new DAAPalogues with a flexible amino acid side chain by ring opening (compound <b>48</b>) and SBDD (compound <b>49</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00446/20191219/images/large/jm9b00446_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00446&amp;id=fig16"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">By adopting a bioisosteric strategy, Zhang et al. developed a new series of potent ALK inhibitors with a unique amino pyrazole side chain in DAAPs scaffold, in which the N atom in morpholine was removed to avoid the metabolic liability.<a onclick="showRef(event, 'ref134'); return false;" href="javascript:void(0);" class="ref ref134">(134)</a> The SAR exploration of the scaffold delivered several potential compounds (<b>50</b>–<b>54</b>) with nanomolar IC<sub>50</sub> values against the WT and L1196M ALK and favorable antiproliferative activity toward Karpass-299 and H2228 cell lines (<a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">17</a></a>). Among them, compound <b>52</b> showed good pharmacokinetic properties in rats and dogs and dose-dependent antitumor efficacy in H2228 xenograft model.<a onclick="showRef(event, 'ref134'); return false;" href="javascript:void(0);" class="ref ref134">(134)</a></div><figure id="fig17" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Figure 17</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00446/20191219/images/medium/jm9b00446_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00446/20191219/images/large/jm9b00446_0017.jpeg" id="gr17" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 17. Representative ALK inhibitors (compounds <b>50</b>–<b>54</b>) with the DAAPs scaffold by adopting a bioisosteric strategy.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00446/20191219/images/large/jm9b00446_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00446&amp;id=fig17"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec4_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i14" class="anchor-spacer"></div><h4 class="article-section__title" id="_i14">4.2.2.  1,3,5-Triazine</h4><div class="NLM_p last">Compound <b>8</b>, developed by Astellas, is an analogue of <b>2</b> from Novartis. The only difference is the structure that binds in the hinge-binding motif (1,3,5-triazine vs 5-chloropyrimidine).<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> In xenograft model of H2228, <b>8</b> could be well absorbed by tumor tissue via oral administration, where the concentration was 10-fold higher than that in plasma and could induce tumor regression with a wide therapeutic window.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> Besides, compound <b>8</b> exhibited potent antitumor activity against cells expressing the <b>1</b>-resistant L1196M and <b>4</b>-resistant V1180L mutants.<a onclick="showRef(event, 'ref135 ref136'); return false;" href="javascript:void(0);" class="ref ref135 ref136">(135,136)</a> According to the two completed phase I clinical trials (<a href="http://ClinicalTrials.gov" class="extLink">ClinicalTrials.gov</a> identifiers: NCT01401504 and NCT01284192), compound <b>8</b> also showed efficacy in patients with solid tumors and B-cell lymphoma.<a onclick="showRef(event, 'ref137 ref138'); return false;" href="javascript:void(0);" class="ref ref137 ref138">(137,138)</a></div></div><div id="sec4_2_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i15" class="anchor-spacer"></div><h4 class="article-section__title" id="_i15">4.2.3.  3-Aminoindazole</h4><div class="NLM_p">In 2016, Maria et al. screened a promising 3-amino-5-substituted indazole compound (<b>55</b>), which showed a good biochemical potency (IC<sub>50</sub> = 73 nM) against ALK and moderate antiproliferative activity against ALK-positive Karpass-299 cell line (IC<sub>50</sub> = 253 nM).<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> Further optimization of the substituent of ring A led to the discovery of <b>9</b> (<a data-tab="pane-pcw-Figures" href="#fig18" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig18" id="" class=" internalNav">18</a></a>). The cocrystal structure of ALK in complex with <b>9</b> (<a data-tab="pane-pcw-Figures" href="#fig18" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig18" id="" class=" internalNav">18</a></a>E) indicated that the 4-aminotetrahydropyranyl moiety added to ring A optimally occupies the hydrophobic space underneath G-loop and adopts a roughly orthogonal orientation with respect to the scaffold, which can explain the improved biochemical potency with IC<sub>50</sub> of 12 and 31 nM against ALK and Karpass-299 cell lines.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> Besides, compound <b>9</b> is sensitive to crizotinib-resistant mutations such as L1196M and C1156Y. Of note, compound <b>9</b> could efficiently cross the BBB and thus could be used in the treatment of NSCLCs with brain metastasis.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> In addition to stable regression in ALK-dependent ALCL and NSCLC, the novel CAD-ALK dependent colorectal cancer could also be well suppressed by <b>9</b>.<a onclick="showRef(event, 'ref139'); return false;" href="javascript:void(0);" class="ref ref139">(139)</a> In the ongoing phase I/II trials launched by Ignyta, durable objective responses (DOR) were observed in patients with solid tumors harboring TRKA/B/C, ROS1, or ALK gene fusion such as neuroblastoma (ALKA-372-001 and STARTRK-1).<a onclick="showRef(event, 'ref140 ref141'); return false;" href="javascript:void(0);" class="ref ref140 ref141">(140,141)</a></div><figure id="fig18" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Figure 18</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00446/20191219/images/medium/jm9b00446_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00446/20191219/images/large/jm9b00446_0018.jpeg" id="gr18" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 18. Optimization of the substituent of ring A in hit <b>55</b> led to the discovery of Entrectinib (<b>9</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00446/20191219/images/large/jm9b00446_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00446&amp;id=fig18"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec4_2_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i16" class="anchor-spacer"></div><h4 class="article-section__title" id="_i16">4.2.4.  Aminopyrazine</h4><div class="NLM_p">Compound <b>10</b> was synthesized based on <b>1</b> according to the procedure published in WO 2009/154769.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> As shown in <a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">19</a></a>, compounds <b>10</b> and <b>1</b> share the same hydrophobic 2,6-dichloro-3-fluoro-phenylethoxy groups and similar kinase hinge binding groups, but the side chains are significantly different. The cellular activity of <b>10</b> against H3122 was 10-fold higher than that of <b>1</b>,<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> and <b>10</b> exhibited improved inhibitory activity against L1196M and C1156Y mutants.<a onclick="showRef(event, 'ref124'); return false;" href="javascript:void(0);" class="ref ref124">(124)</a> In a phase I/II, multicenter “Xalt2” study of <b>10</b>, 10 out of 17 (59%) ALK-rearranged NSCLC patients achieved partial responses, and 7 out of 13 patients resistant to <b>1</b> responded to <b>10</b> due to its favorable penetration into the brain.<a onclick="showRef(event, 'ref142'); return false;" href="javascript:void(0);" class="ref ref142">(142)</a> Currently, a phase III study (eXalt3) is in progress to compare the efficacy and safety of <b>10</b> with <b>1</b> in patients with ALK-positive NSCLCs.<a onclick="showRef(event, 'ref143'); return false;" href="javascript:void(0);" class="ref ref143">(143)</a></div><figure id="fig19" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Figure 19</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00446/20191219/images/medium/jm9b00446_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00446/20191219/images/large/jm9b00446_0019.jpeg" id="gr19" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 19. X-396 was generated by optimizing the side chain of Crizotinib.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00446/20191219/images/large/jm9b00446_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00446&amp;id=fig19"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec4_2_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i17" class="anchor-spacer"></div><h4 class="article-section__title" id="_i17">4.2.5.  Acyliminobenzimidazoles</h4><div class="NLM_p">Compound <b>56</b>, a 2-acyliminobenzimidazole derivative, was discovered via HTS from the Amgen compound library and used as a starting structure. A series of optimization on <b>56</b> finally led to the discovery of the 3,5-difluoro analogues <b>59</b> (Belizatinib) and <b>61</b> with improved potency and selectivity toward ALK (<a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">20</a></a>). Both compounds had acceptable PK distribution and high selectivity over JAK2, SRC, and IGF1R and could also effectively inhibit R1275Q and L1196M mutants.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> In particular, compound <b>61</b> achieved dose-dependent regression in an NPM-ALK driven tumor xenograft model.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> A completed phase I/II study of <b>59</b> (<a href="http://ClinicalTrials.gov" class="extLink">ClinicalTrials.gov</a> identifier: NCT02048488) showed that <b>59</b> is a well-tolerated agent against ALK-dependent and crizotinib-refractory NSCLCs.<a onclick="showRef(event, 'ref144 ref145'); return false;" href="javascript:void(0);" class="ref ref144 ref145">(144,145)</a></div><figure id="fig20" data-index="20" class="article__inlineFigure"><h2 class="fig-label">Figure 20</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00446/20191219/images/medium/jm9b00446_0020.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00446/20191219/images/large/jm9b00446_0020.jpeg" id="gr20" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 20. Representative ALK inhibitors with the acyliminobenzimidazole scaffold. The optimizations of the HTS hit <b>56</b> led to the generation of the 3,5-difluoro analogues <b>59</b> (Belizatinib) and <b>61</b> with improved potency and selectivity toward ALK.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00446/20191219/images/large/jm9b00446_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00446&amp;id=fig20"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec4_2_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i18" class="anchor-spacer"></div><h4 class="article-section__title" id="_i18">4.2.6.  Benzo[<i>b</i>]carbazoles</h4><div class="NLM_p">Inspired by the structural insights of <b>4</b> bound to ALK (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3AOX">3AOX</a>), JH-VIII-157–02 (<b>63</b>) was developed with the expectation to overcome resistance caused by G1202R mutations<a onclick="showRef(event, 'ref127'); return false;" href="javascript:void(0);" class="ref ref127">(127)</a> (<a data-tab="pane-pcw-Figures" href="#fig21" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig21" id="" class=" internalNav">21</a></a>). In addition to the extremely potent inhibitory activity against the G1202R mutant, <b>63</b> exhibited improved potency against ALK-positive neuroblastoma cell lines (Kelly, SH-SY5Y (F1174L) and LAN-5 (R1275Q)) and NSCLC cell lines (H3122, DFC176 (L1152R), and DFCI114 (G1269)).<a onclick="showRef(event, 'ref146 ref147'); return false;" href="javascript:void(0);" class="ref ref146 ref147">(146,147)</a></div><figure id="fig21" data-index="21" class="article__inlineFigure"><h2 class="fig-label">Figure 21</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00446/20191219/images/medium/jm9b00446_0021.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00446/20191219/images/large/jm9b00446_0021.jpeg" id="gr21" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 21. Optimization process (compound <b>62</b>) of Alectinib leading to the development of JH-VII-157-02 (<b>63</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00446/20191219/images/large/jm9b00446_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00446&amp;id=fig21"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec4_2_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i19" class="anchor-spacer"></div><h4 class="article-section__title" id="_i19">4.2.7.  1<i>H</i>-Pyrrolo[2,3-<i>d</i>]pyrimidine</h4><div class="NLM_p">GSK1838705A (<b>64</b>), a derivative of 1<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine, was first identified as a IGF-IR inhibitor.<a onclick="showRef(event, 'ref125'); return false;" href="javascript:void(0);" class="ref ref125">(125)</a> Later on, it was found to inhibit ALK with an IC<sub>50</sub> of 0.5 nM (<a data-tab="pane-pcw-Figures" href="#fig22" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig22" id="" class=" internalNav">22</a></a>). Compound <b>64</b> could repress the growth of ALCL and NSCLC cell lines containing ALK fusion genes in vitro and induce complete regression of NPM-ALK dependent tumors in vivo.<a onclick="showRef(event, 'ref148 ref149'); return false;" href="javascript:void(0);" class="ref ref148 ref149">(148,149)</a></div><figure id="fig22" data-index="22" class="article__inlineFigure"><h2 class="fig-label">Figure 22</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00446/20191219/images/medium/jm9b00446_0022.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00446/20191219/images/large/jm9b00446_0022.jpeg" id="gr22" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 22. Compound <b>65</b> was generated by the optimization of the 2,6-dichloro-3-fluorophenyl head and pyrazolopiperidine tail groups in Crizotinib (<b>1</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00446/20191219/images/large/jm9b00446_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00446&amp;id=fig22"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec4_2_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i20" class="anchor-spacer"></div><h4 class="article-section__title" id="_i20">4.2.8.  3-Benzyloxyaminopyridine</h4><div class="NLM_p last">Compound <b>65</b> shown in <a data-tab="pane-pcw-Figures" href="#fig22" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig22" id="" class=" internalNav">22</a></a> was generated by modifying the 2,6-dichloro-3-fluorophenyl head and pyrazolopiperidine tail groups in <b>1</b>.<a onclick="showRef(event, 'ref126'); return false;" href="javascript:void(0);" class="ref ref126">(126)</a> The in vitro activity of <b>65</b> was significantly improved against both WT and resistant mutants of ALK (L1196M, G1269A, S1206Y, C1156Y, F1174L, L1152R, and 1151Tins) compared with that of <b>1</b>. In cellular assays, the activity of <b>65</b> was also improved in both the WT cell lines (H3122, H2228, and Karpas299) or engineered mutant lines (H3122-L1196M and H3122-G1269A).</div></div><div id="sec4_2_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i21" class="anchor-spacer"></div><h4 class="article-section__title" id="_i21">4.2.9.  1<i>H</i>-Pyrazol-5-yl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine Derivatives</h4><div class="NLM_p">Most recently, Fushimi et al. reported the discovery of a 1<i>H</i>-pyrazol-5-yl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine derivative <b>68</b> as a highly selective, potent, and brain-penetrant ALK inhibitor.<a onclick="showRef(event, 'ref128'); return false;" href="javascript:void(0);" class="ref ref128">(128)</a><a data-tab="pane-pcw-Figures" href="#fig23" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig23" id="" class=" internalNav">23</a></a> shows that the discovery process started from a HTS hit <b>66</b>, followed by scaffold hopping and SBDD-driven lead optimization.<a onclick="showRef(event, 'ref128'); return false;" href="javascript:void(0);" class="ref ref128">(128)</a> Then, compound <b>68</b> was proved to have good pharmacokinetic and BBB profiles and could significantly decrease the phosphorylated-ALK levels in hippocampus after intraperitoneal administration.<a onclick="showRef(event, 'ref128'); return false;" href="javascript:void(0);" class="ref ref128">(128)</a> These results suggest that <b>68</b> can serve as a useful in vivo tool to explore the mechanism of ALK-mediated CNS disorders.</div><figure id="fig23" data-index="23" class="article__inlineFigure"><h2 class="fig-label">Figure 23</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00446/20191219/images/medium/jm9b00446_0023.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00446/20191219/images/large/jm9b00446_0023.jpeg" id="gr23" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 23. Discovery of a 1<i>H</i>-pyrazol-5-yl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine derivative <b>68</b> as a highly selective, potent, and brain-penetrant ALK inhibitor. The discovery process started from a HTS hit <b>66</b>, followed by scaffold hopping and SBDD-driven lead optimization.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00446/20191219/images/large/jm9b00446_0023.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00446&amp;id=fig23"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec4_2_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i22" class="anchor-spacer"></div><h4 class="article-section__title" id="_i22">4.2.10.  Macrocyclic ALK Inhibitors</h4><div class="NLM_p last">The great success of newly FDA-approved drug <b>11</b> intrigued the researchers’ enthusiasm to design macrocyclic ALK inhibitors, and most recently, TP Therapeutics developed another macrocyclic compound, the fourth-generation ALK inhibitor <b>12</b> (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>), which showed excellent efficacy for WT ALK and SRC (IC<sub>50</sub> = 1.01 and 5.3 nM) as well as a broad spectrum of acquired resistant mutants, especially G1202R (IC<sub>50</sub> = 1.26 nM) and L1196M (IC<sub>50</sub> = 1.08 nM).<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> Structural modeling predicted that <b>12</b> could accommodate the bulky and positively charged arginine side chain in the solvent front without any steric clashes.<a onclick="showRef(event, 'ref129'); return false;" href="javascript:void(0);" class="ref ref129">(129)</a> Additionally, compound <b>12</b> effectively suppressed the phosphorylation of EML4-ALK and SRC substrate paxillin with IC<sub>50</sub> values of 13 and 107 nM, respectively.<a onclick="showRef(event, 'ref129'); return false;" href="javascript:void(0);" class="ref ref129">(129)</a> Moreover, compound <b>12</b> also could inactivate multiple downstream targets, such as ERK, AKT, and STAT3, which indicated its potential ability to overcome ALK resistance due to “bypass” signaling activation.<a onclick="showRef(event, 'ref150 ref151'); return false;" href="javascript:void(0);" class="ref ref150 ref151">(150,151)</a> At present, a phase I/II, open-label, and multicenter clinical trial of <b>12</b> has been initiated to evaluate its safety, tolerability, pharmacokinetics, and antitumor activity in patients with advanced solid tumors expressing ALK/ROS1/TRK(A/B/C) rearrangements (<a href="http://ClinicalTrials.gov" class="extLink">ClinicalTrials.gov</a> identifier: TRIDENT-1).<a onclick="showRef(event, 'ref129'); return false;" href="javascript:void(0);" class="ref ref129">(129)</a></div></div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23">4.3.  Type-I<sup>1</sup>/<sub>2</sub> and Type-II Inhibitors of ALK</h3><div class="NLM_p">In 2013, Bryan and colleagues first reported a novel type-I<sup>1</sup>/<sub>2</sub> ALK inhibitor,<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> piperidine carboxamide <b>69</b>, which occupies both the ATP active site and the less conserved back cleft in a “DFG-in” conformation (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4CDE">4CDE</a>) shown in <a data-tab="pane-pcw-Figures" href="#fig24" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig24" id="" class=" internalNav">24</a></a>B,C. A series of analogues with improved activity, such as <b>70</b>–<b>72</b>, were subsequently synthesized by a modular and parallel-synthesis approach. As expected, these type-I<sup>1</sup>/<sub>2</sub> compounds exhibited selectivity over the other kinase family members, such as insulin-like growth factor-1 (IGF1R), because of the further extension into the less conserved hydrophobic back pocket (<a data-tab="pane-pcw-Figures" href="#fig24" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig24" id="" class=" internalNav">24</a></a>A). However, the binding affinities of these piperidine carboxamide derivatives were relatively weak compared to type-I ALK inhibitors in clinic. In 2017, by tethering a rigid conjugate structure, pyrrole pyrimidine, to the piperidine carboxamide structure, our group designed a scaffold containing hydrogen bond donors and/or acceptors and hydrophobic moieties and finally synthesized 32 type-I<sup>1</sup>/<sub>2</sub> ALK inhibitors after several rounds of optimizations (<a data-tab="pane-pcw-Figures" href="#fig25" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig25" id="" class=" internalNav">25</a></a>B,C).<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> In enzyme-based assay, five compounds (<b>73</b>–<b>77</b>) exhibited extremely potent inhibitory activity against ALK (<a data-tab="pane-pcw-Figures" href="#fig25" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig25" id="" class=" internalNav">25</a></a>A). The most potent analogue <b>77</b> is >37-fold (IC<sub>50</sub> = 0.27 nM) more active than piperidine carboxamide <b>70</b> (IC<sub>50</sub> = 10 nM) and more potent than <b>1</b> (IC<sub>50</sub> = 4.66 nM) and <b>3</b> (IC<sub>50</sub> = 3.94 nM).<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> Besides, compound <b>77</b> displayed superior sensitivity over the FDA-approved ALK inhibitors, <b>1</b> and <b>3</b>, against L1196M, C1156Y, R1275Q, and F1174L ALK mutants with IC<sub>50</sub> of 7.51, 4.71, 2.69, and 9.81 nM, respectively.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> Moreover, compound <b>77</b> showed excellent antiproliferation activity against NSCLC cell line NCI-H2228 and ALCL cell line Karpass-299 with the inhibition rates of 71.67% and 70.99%, respectively, at the concentration of 8 ng/mL.</div><figure id="fig24" data-index="24" class="article__inlineFigure"><h2 class="fig-label">Figure 24</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00446/20191219/images/medium/jm9b00446_0024.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00446/20191219/images/large/jm9b00446_0024.jpeg" id="gr24" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 24. (A) Representative type-I1/2 ALK inhibitors with the piperidine carboxamide scaffold (compounds <b>69</b>–<b>72</b>), (B) cocrystal structure of compound <b>69</b> in complex with the ALK kinase, and (C) the pharmacophore modeling of compound <b>69</b> in the ALK kinase.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00446/20191219/images/large/jm9b00446_0024.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00446&amp;id=fig24"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig25" data-index="25" class="article__inlineFigure"><h2 class="fig-label">Figure 25</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00446/20191219/images/medium/jm9b00446_0025.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00446/20191219/images/large/jm9b00446_0025.jpeg" id="gr25" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 25. (A) Representative type-I1/2 ALK inhibitors with the 1-purine-3-piperidinecarboxamide scaffold (compounds <b>73</b>–<b>77</b>), (B) cocrystal structure of compound <b>77</b> in complex with the ALK kinase, and (C) the pharmacophore modeling of compound <b>77</b> in the ALK kinase.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00446/20191219/images/large/jm9b00446_0025.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00446&amp;id=fig25"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In 2016, a 3-phenyl-1<i>H</i>-5-pyrazolylamine-based compound bearing a urea substituent (<b>79</b>) was identified as a type-II ALK inhibitor with an IC<sub>50</sub> value of 177 nM from an in-house screening.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> Chih Hsiang et al. revealed that <b>79</b> induced the reallocation of the activation loop, αC-helix, and juxtamembrane domain (<a data-tab="pane-pcw-Figures" href="#fig26" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig26" id="" class=" internalNav">26</a></a>B,C), which affected the autoinhibition of ALK and the downstream signaling pathways.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> Comparison of the cocrystal structures of the ALK/<b>78</b> and ALK/<b>79</b> complexes indicated that the substituted-urea tail moiety regulated the switch between the type-I and type-II binding modes by inducing dramatic conformational changes of the A-loop, αC-helix, and JM domain (<a data-tab="pane-pcw-Figures" href="#fig26" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig26" id="" class=" internalNav">26</a></a>). This work is the first structural biology study to explore how the structure changes of a small molecule regulate the switch between the “DFG-in” and “DFG-out” conformations, which provides valuable guidance to the development of novel type-II inhibitors for ALK or other kinases.</div><figure id="fig26" data-index="26" class="article__inlineFigure"><h2 class="fig-label">Figure 26</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00446/20191219/images/medium/jm9b00446_0026.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00446/20191219/images/large/jm9b00446_0026.jpeg" id="gr26" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 26. (A) Transition from type-I (compound <b>78</b>) to type-II (compound <b>79</b>) ALK inhibitors, (B) cocrystal structure of compound <b>79</b> in complex with the ALK kinase, and (C) the pharmacophore modeling of compound <b>79</b> in the ALK kinase.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00446/20191219/images/large/jm9b00446_0026.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00446&amp;id=fig26"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">In summary, the improved kinase selectivity and enhanced capability to combat drug resistance of these type-I<sup>1</sup>/<sub>2</sub> and/or type-II inhibitors against ALK can be explained by the conformational changes of the back hydrophobic cavity, such as Arg1275 and Leu1174, which is supported by the crystallographic evidence reported by Epstein et al.<a onclick="showRef(event, 'ref152'); return false;" href="javascript:void(0);" class="ref ref152">(152)</a> Two molecular modeling studies published in 2015 and 2018 by our group indicated that the hydrophobic interactions between type-I<sup>1</sup>/<sub>2</sub> inhibitors and residues surrounding the extended pocket determined the binding strength of these inhibitors.<a onclick="showRef(event, 'ref153 ref154'); return false;" href="javascript:void(0);" class="ref ref153 ref154">(153,154)</a> And the umbrella sampling (US) simulations suggested type-I<sup>1</sup>/<sub>2</sub> and type-II inhibitors may exhibit decreased dissociation rate (<i>k</i><sub>off</sub>) with prolonged residence time, which is consistent with the results of other studies on these types of inhibitors.<a onclick="showRef(event, 'ref155 ref156 ref157 ref158'); return false;" href="javascript:void(0);" class="ref ref155 ref156 ref157 ref158">(155−158)</a> However, these types of inhibitors may also encounter several problems due to relatively high molecular weight and lipophilicity, such as limited solubility and poor pharmacokinetic (PK) properties,<a onclick="showRef(event, 'ref159'); return false;" href="javascript:void(0);" class="ref ref159">(159)</a> suggesting rational modifications need to be made on these types of drugs.</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24">4.4.  Proteolysis Targeting Chimeras (PROTACs) of ALK</h3><div class="NLM_p">Currently, “proteolysis targeting chimera” (PROTAC) technique has been widely used in the field of drug discovery.<a onclick="showRef(event, 'ref160 ref161'); return false;" href="javascript:void(0);" class="ref ref160 ref161">(160,161)</a> Inspired by the success of this approach in degradation of multiple protein targets, several ALK PROTACs have been developed (<a data-tab="pane-pcw-Figures" href="#fig27" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig27" id="" class=" internalNav">27</a></a>). In 2018, Powell et al. developed two ALK PROTACs, <b>80</b> (TL13-12) and <b>81</b> (TL13-112), by conjugating pyrimidine-based ALK inhibitors <b>2</b> and <b>3</b> to the CRBN ligand Pomalidomide.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> These bivalent small molecules led to the ubiquitination and degradation of ALK in NSCLC cells harboring EML4-ALK, ALCL cells harboring NPM-ALK, and NB cells expressing F1174L/R1275Q ALK, meanwhile sustaining the inhibition of downstream ALK signaling. In the same year, Zhang et al. reported other two ALK PROTACs, <b>82</b> (MS4077) and <b>83</b> (MS4078), by connecting <b>3</b> and Pomalidomide using two distinct linkers.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> In addition to the degradation of NPM-ALK and EML4-ALK, <b>82</b> and <b>83</b> could inhibit the phosphorylation of ALK and STAT3 in a concentration- and time-dependent manner in both SU-DHL-1 cells and NCI-H2228 cells. Subsequently, Kang and colleagues reported new ALK PROTAC, <b>84</b> (TD-004), that showed excellent efficacy in cellular level and in vivo xenograft mouse model.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> Even if the efficacy of ALK degraders needs further exploration, ALK PROPACs undoubtedly opened a new window for targeted ALK therapies.</div><figure id="fig27" data-index="27" class="article__inlineFigure"><h2 class="fig-label">Figure 27</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00446/20191219/images/medium/jm9b00446_0027.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00446/20191219/images/large/jm9b00446_0027.jpeg" id="gr27" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 27. Structures of the reported ALK PROTACs and the degradation process of ALK by PROTACs.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00446/20191219/images/large/jm9b00446_0027.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00446&amp;id=fig27"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i25">5.  Structural Analyses of Drug-Resistant Mutants of ALK</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_25516" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_25516" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Crizotinib-resistant mutations, such as L1196M, G1269A, G1202R, and S1206Y, may hamper drug binding and induce drug resistance of ALK (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). For instance, L1196M is a typical “gate keeper” mutation, which locates just in the ATP binding pocket of ALK and can directly hinder crizotinib binding.<a onclick="showRef(event, 'ref162'); return false;" href="javascript:void(0);" class="ref ref162">(162)</a> MD simulations executed by Nagasundaram et al. suggested that L1196M and G1269A had significant impact on the dynamics and flexibility of ALK.<a onclick="showRef(event, 'ref163'); return false;" href="javascript:void(0);" class="ref ref163">(163)</a> Although the C1156Y and L1152R mutations locate a bit far from the ATP binding pocket of ALK (∼15 Å), they conferred drug resistance either by continuously activating the protein or by affecting the conformation of the binding pocket, which could attenuate the binding affinity of <b>1</b> to ALK indirectly.<a onclick="showRef(event, 'ref164'); return false;" href="javascript:void(0);" class="ref ref164">(164)</a> Our theoretical studies showed that the L1152R and C1156Y mutations could affect the conformation of the G-rich loop (also known as P-loop) in ALK, which is flexible and susceptible to be regulated by both drugs and mutations around it.<a onclick="showRef(event, 'ref165 ref166'); return false;" href="javascript:void(0);" class="ref ref165 ref166">(165,166)</a> Moreover, Kumar et al. pointed out that the F1174L mutation enhanced the flexibility and dynamics of ALK and affected the formation of intermolecular interactions, especially H-bonding interaction, which led to the resistance to <b>1</b>.<a onclick="showRef(event, 'ref166'); return false;" href="javascript:void(0);" class="ref ref166">(166)</a> Notably, both Gly1202 and Ser1206 are solvent-front residues located at the entrance of the ATP binding pocket and can form direct contacts with drugs such as <b>1</b>, <b>3</b>, and <b>4</b> (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>A–C). Unfortunately, these residues inevitably mutate (such as G1202R and S1206Y) and confer resistance to several FDA-approved ALK drugs, where G1202R is a very harmful mutation and can confer resistance to many ALK drugs (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). Mutations located at the same position as G1202R are also found in other kinases, such as G2032R in ROS1 and G595R in TRK1,<a onclick="showRef(event, 'ref167'); return false;" href="javascript:void(0);" class="ref ref167">(167)</a> which all confer resistance to ALK inhibitors, suggesting that it is urgent to uncover the drug-resistance mechanisms for designing new inhibitors to overcome the resistance induced by the solvent-front mutations for various kinases. To reach the goal, our group has also done several theoretical works to reveal the drug resistance mechanisms induced by the solvent-front mutations.<a onclick="showRef(event, 'ref168 ref169'); return false;" href="javascript:void(0);" class="ref ref168 ref169">(168,169)</a> Taking crizotinib as an example, these solvent-front mutations (G1202R and S1206Y) can hinder drug binding to the “binding channel” outside the ATP binding pocket and thus directly attenuate the binding of crizotinib to ALK.<a onclick="showRef(event, 'ref168'); return false;" href="javascript:void(0);" class="ref ref168">(168)</a></div><div class="NLM_p last">To overcome the G1202R-induced drug resistance, macrocyclic inhibitors, such as <b>11</b>, have been designed, and they almost bind into the center of the pocket and do not form direct interaction with G1202. Thus, macrocyclic inhibitors are not quite sensitive to the G1202R mutation. Unfortunately, in 2016, the L1198F mutation was found to confer resistance in <b>11</b>-resistant patients.<a onclick="showRef(event, 'ref119'); return false;" href="javascript:void(0);" class="ref ref119">(119)</a> As shown in <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>F, the L1198F mutation may force <b>11</b> to rotate away from Phe1271 and attenuates its interaction with the hinge region. However, as to <b>1</b>, the distance between Phe1271 and <b>1</b> in the L1198F mutant is smaller than that in the WT complex, thus possibly enhancing the interactions between <b>1</b> and ALK (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>A). These findings coincide with the experimental observation that the L1198F mutation confers resistance to <b>11</b> but not <b>1</b><a onclick="showRef(event, 'ref119'); return false;" href="javascript:void(0);" class="ref ref119">(119)</a> and also suggest that drug combination is needed to overcome drug resistance in ALK.</div></div><div id="sec6" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i26">6.  Potential Therapeutic Strategies to Overcome Drug Resistance</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_44388" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_44388" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec6_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27">6.1.  Sequential Dosing of Multiple ALK TKIs</h3><div class="NLM_p last">According to the accumulated basic knowledge, different ALK inhibitors have their own advantages and defects and exhibit specific target profiles in various ALK mutants, suggesting a potential therapeutic strategy that the patients could be treated sequentially with multiple ALK TKIs. For example, patients harboring the C1156Y mutation, which occurred after the <b>1</b> treatment, were resistant to <b>1</b> but sensitive to <b>11</b>.<a onclick="showRef(event, 'ref119'); return false;" href="javascript:void(0);" class="ref ref119">(119)</a> In some cases, the secondary acquired resistance to <b>11</b>, such as L1198F, could be overcome again by <b>1</b>.<a onclick="showRef(event, 'ref119'); return false;" href="javascript:void(0);" class="ref ref119">(119)</a> Activation of the HGF/Met pathway and/or c-Met amplification was a validated factor inducing resistance to <b>4</b>, while <b>1</b> could strongly inhibit the activity of the Met tyrosine kinase in both in vitro and in vivo assays.<a onclick="showRef(event, 'ref170'); return false;" href="javascript:void(0);" class="ref ref170">(170)</a> Thus, compound <b>1</b> might demonstrate favorable efficacy in patients with <b>4</b>-refractory NSCLC harboring EML4-ALK and MET activation. Two randomized clinical trials (<a href="http://ClinicalTrials.gov" class="extLink">ClinicalTrials.gov</a> identifiers: J-ALEX and ALEX) are currently ongoing in order to compare the performance of <b>4</b> versus <b>1</b> in participants with treatment-naïve ALK-positive advanced NSCLC.<a onclick="showRef(event, 'ref101 ref171'); return false;" href="javascript:void(0);" class="ref ref101 ref171">(101,171)</a> In view of this, clinicians should have a precise and deep insight into ALK kinase aberration and/or its signaling transduction to put forward a tailored and personalized ALK TKI therapies.</div></div><div id="sec6_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28">6.2.  Combinational Therapy</h3><div class="NLM_p last">The effectiveness of combined inhibition of both ALK and another related kinase (IGF1R, MEK, cKIT, EGFR, VEGF, mTOR, or SRC) is still under preclinical/clinical investigations (<a href="http://ClinicalTrials.gov" class="extLink">ClinicalTrials.gov</a> identifiers: NCT02321501, NCT0252105, etc.), which might overcome drug resistance mediated by alternative “bypass” pathways.<a onclick="showRef(event, 'ref18 ref30 ref31 ref103 ref104'); return false;" href="javascript:void(0);" class="ref ref18 ref30 ref31 ref103 ref104">(18,30,31,103,104)</a> For instance, compound <b>4</b> was combined with a EGFR inhibitor Erlotinib, and <b>1</b> was administrated together with a pan-Her inhibitor PF-0299804 for the treatment of NSCLC patients.<a onclick="showRef(event, 'ref172'); return false;" href="javascript:void(0);" class="ref ref172">(172)</a> The combination of <b>11</b> and PI3K pathway inhibitors exhibited good efficacy in overcoming ALK resistance.<a onclick="showRef(event, 'ref117'); return false;" href="javascript:void(0);" class="ref ref117">(117)</a> Two clinical trials for the combination of the nonkinase Hsp90 inhibitor AUY922 and <b>3</b> as well as the Hsp90 inhibitor Onalespib and <b>1</b> are also underway (<a href="http://ClinicalTrials.gov" class="extLink">ClinicalTrials.gov</a> identifiers: NCT01772797 and NCT01712217).<a onclick="showRef(event, 'ref173'); return false;" href="javascript:void(0);" class="ref ref173">(173)</a> Recent preclinical data indicated that the combinational therapies of checkpoint (PD-1/PD-L1 and CTLA-4) inhibitors with ALK inhibitors might improve the therapeutic effects in ALK-positive NSCLC patients, which were illustrated in several clinical trials, including <b>3</b> with Nivolumab (<a href="http://ClinicalTrials.gov" class="extLink">ClinicalTrials.gov</a> identifier: NCT02393625),<a onclick="showRef(event, 'ref174'); return false;" href="javascript:void(0);" class="ref ref174">(174)</a><b>1</b> or <b>11</b> with Avelumab (<a href="http://ClinicalTrials.gov" class="extLink">ClinicalTrials.gov</a> identifier: NCT02584634),<a onclick="showRef(event, 'ref175'); return false;" href="javascript:void(0);" class="ref ref175">(175)</a><b>1</b> with Ipilimumab or Nivolumab (<a href="http://ClinicalTrials.gov" class="extLink">ClinicalTrials.gov</a> identifier: NCT01998126).<a onclick="showRef(event, 'ref176'); return false;" href="javascript:void(0);" class="ref ref176">(176)</a> In addition, combination with conventional chemotherapy also remains an option for patients with ALK translocations (<a href="http://ClinicalTrials.gov" class="extLink">ClinicalTrials.gov</a> identifier: NCT02134912).<a onclick="showRef(event, 'ref177 ref178'); return false;" href="javascript:void(0);" class="ref ref177 ref178">(177,178)</a> Collectively, the selection of appropriate combination strategy should be individualized according to the mechanisms of acquired resistance and the signal transduction of ALK.</div></div></div><div id="sec7" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i29">7.  Concluding Remarks and Future Perspectives</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_87834" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_87834" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">Oncogenic ALK acts as a driver in a set of cancer types, such as NSCLC, ALCL, IMT, and neuroblastoma, which could be suppressed by small molecule inhibitors of ALK. The emergence of drug resistance led to the development of the first-, second-, third-, and fourth-generation ALK inhibitors. Besides, novel type-I<sup>1</sup>/<sub>2</sub> and type-II inhibitors of ALK that could occupy both the ATP active site and the extended less-conserved hydrophobic pocket were developed. This kind of inhibitors is expected to improve kinase selectivity and enhance capability to combat drug resistance. Particularly, the PROTAC technique was also applied in the development of ALK drugs, and several potential ALK PROTACs have already been reported, which opened a new window for targeted ALK therapies. Dual blockade of both ALK and other kinases has been proved to be a potential antiresistant therapeutic strategy. In addition, combination of ALK inhibitors with chemotherapy or immunotherapy is also being evaluated in both preclinical and clinical trials, but special attention should be paid to avoiding additional toxicity. Because of the heterogeneity of tumors and the constantly acquired drug resistance, the pathogenesis and signal transductions of ALK in different tumors exhibit distinct features, which brings more challenge to successful therapy. Nowadays, more sophisticated detection techniques, such as fluorescence in situ hybridization (FISH), next-generation sequencing (NGS) of tumor tissue, and sequencing of circulating tumor cells (CTCs), serve as alternative or complementary strategies to optimize drug treatment. Besides, computational modeling methods also benefit to discovering and developing novel ALK drugs as well as exploring the binding features and resistance mechanisms of the drugs. Together, in-depth understanding the roles of ALK in cancer biology and more precise techniques to detect ALK aberrations are of vital significance to improve the therapeutic outcomes in clinic. Besides, attempts to discover novel ALK drugs and alternative targeted ALK therapies are in urgent need to combat drug resistance.</div></div><div class="NLM_back"><div class="article_supporting-info" id=""></div><div class="testing" data-doi="10.1021/acs.jmedchem.9b00446" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_08480" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_08480" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Tingjun Hou</span> - <span class="hlFld-Affiliation affiliation">Hangzhou
Institute of Innovative Medicine, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, Zhejiang 310058, China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-7227-2580" title="Orcid link">http://orcid.org/0000-0001-7227-2580</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#7c0815121b1609121413093c06160952191809521f12"><span class="__cf_email__" data-cfemail="d3a7babdb4b9a6bdbbbca693a9b9a6fdb6b7a6fdb0bd">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xiaotian Kong</span> - <span class="hlFld-Affiliation affiliation">Hangzhou
Institute of Innovative Medicine, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, Zhejiang 310058, China</span>; 
    <span class="hlFld-Affiliation affiliation">Institute
of Functional Nano and Soft Materials (FUNSOM), Soochow University, Suzhou, Jiangsu 215123, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Peichen Pan</span> - <span class="hlFld-Affiliation affiliation">Hangzhou
Institute of Innovative Medicine, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, Zhejiang 310058, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Huiyong Sun</span> - <span class="hlFld-Affiliation affiliation">Hangzhou
Institute of Innovative Medicine, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, Zhejiang 310058, China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-7107-7481" title="Orcid link">http://orcid.org/0000-0002-7107-7481</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hongguang Xia</span> - <span class="hlFld-Affiliation affiliation">Department
of Biochemistry & Research Center of Clinical Pharmacy of the
First Affiliated Hospital, Zhejiang University, Hangzhou 310058, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xuwen Wang</span> - <span class="hlFld-Affiliation affiliation">Hangzhou
Institute of Innovative Medicine, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, Zhejiang 310058, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Youyong Li</span> - <span class="hlFld-Affiliation affiliation">Institute
of Functional Nano and Soft Materials (FUNSOM), Soochow University, Suzhou, Jiangsu 215123, China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-5248-2756" title="Orcid link">http://orcid.org/0000-0002-5248-2756</a></span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>X.K and P.P. contributed equally.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="bio" rid="ath1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="biographies">Biographies</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_11563" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_11563" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><figure id="ath1" data-index="28" class="article__inlineFigure"><h2 class="fig-label">Xiaotian Kong</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00446&amp;id=BIO-d7e3115-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Xiaotian Kong</b> received her Ph.D. degree in Chemistry in 2018 under the supervision of Prof. Tingjun Hou at Zhejiang University and Prof. Youyong Li at Soochow University. Currently, she is a postdoctoral fellow in College of Pharmacy at The Ohio State University. She focuses on design and discovery of novel small molecules targeting cancer-related proteins, such as ALK.</p></figure></div><div class="bio" rid="ath2"><figure id="ath2" data-index="29" class="article__inlineFigure"><h2 class="fig-label">Peichen Pan</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00446&amp;id=BIO-d7e3120-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Peichen Pan</b> is a Ph.D candidate in the College of Pharmaceutical Sciences at Zhejiang University. His research mainly focuses on screening and optimization of small-molecule inhibitors targeting ALK.</p></figure></div><div class="bio" rid="ath3"><figure id="ath3" data-index="30" class="article__inlineFigure"><h2 class="fig-label">Huiyong Sun</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00446&amp;id=BIO-d7e3125-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Huiyong Sun</b> received his Ph.D. from the Institute of Functional Nano & Soft Materials (FUNSOM) at Soochow University (2012–2015). Currently, he is an associated professor in School of Pharmacy at China Pharmaceutical University. His research interest is in computer-aided drug design (CADD). To date, he has coauthored more than 50 peer-reviewed articles.</p></figure></div><div class="bio" rid="ath4"><figure id="ath4" data-index="31" class="article__inlineFigure"><h2 class="fig-label">Hongguang Xia</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00446&amp;id=BIO-d7e3130-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Hongguang Xia</b> received his Ph.D. from Shanghai Institute of Organic Chemistry. He did his postdoctoral program in Junying Yuan’s lab at Harvard Medical School. Currently, he is a professor and deputy director of the Molecular Medicine Center in the School of Medicine at Zhejiang University. Prof. Xia has published over 30 peer-reviewed articles in top journals, and he is one of the main inventors for a novel antitumor drug which is now in phase I clinical trials.</p></figure></div><div class="bio" rid="ath5"><figure id="ath5" data-index="32" class="article__inlineFigure"><h2 class="fig-label">Xuwen Wang</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00446&amp;id=BIO-d7e3135-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Xuwen Wang</b> is a Ph.D candidate in the College of Pharmaceutical Sciences at Zhejiang University in China. His research focuses on design and discovery of novel leading compounds towards key targets relevant to cancers.</p></figure></div><div class="bio" rid="ath6"><figure id="ath6" data-index="33" class="article__inlineFigure"><h2 class="fig-label">Youyong Li</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00446&amp;id=BIO-d7e3140-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Youyong Li</b> received his B.Sc. from Peking University and Ph.D. from the California Institute of Technology. He is currently a full professor of the Institute of Functional Nano & Soft Materials at Soochow University. His main research interest is the development of multiscale simulation methods and their applications for different functional materials. Dr. Li has published over 200 articles.</p></figure></div><div class="bio" rid="ath7"><figure id="ath7" data-index="34" class="article__inlineFigure"><h2 class="fig-label">Tingjun Hou</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00446&amp;id=BIO-d7e3145-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Tingjun Hou</b> received his Ph.D. in Computational Chemistry from Peking University in 2002. His current research focuses on molecular modeling and computer-aided drug design (CADD), including development of structure-based virtual screening methodologies, theoretical predictions of ADMET and drug-likeness, discovery of small molecular inhibitors towards important drug targets, and multiscale simulations of target-ligand recognition. Currently, he is a full professor in College of Pharmaceutical Sciences at Zhejiang University. He is also the director of Drug Informatics and Computational Biology Center in Hangzhou Institute of Innovative Medicine at Zhejiang University. Prof. Hou has coauthored more than 320 publications in peer-reviewed journals with a h-index of 52, 4 book chapters and 1 multimedia courseware.</p></figure></div><div class="ack" id="ACK-d7e3150-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i38">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_23742" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_23742" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">This study was supported by National Science & Technology Major Project of China “Key New Drug Creation and Manufacturing Program” (2018ZX09711002-007), National Science Foundation of China (21575128, 81603031), and Zhejiang Provincial Natural Science Foundation of China (LZ19H300001).</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">ABCB1</td><td class="NLM_def"><p class="first last">ATP binding cassette subfamily B member 1</p></td></tr><tr><td class="NLM_term">AKT</td><td class="NLM_def"><p class="first last">protein kinase B (PKB)</p></td></tr><tr><td class="NLM_term">ALCL</td><td class="NLM_def"><p class="first last">anaplastic large cell lymphoma</p></td></tr><tr><td class="NLM_term">ALK</td><td class="NLM_def"><p class="first last">anaplastic lymphoma kinase</p></td></tr><tr><td class="NLM_term">ATC</td><td class="NLM_def"><p class="first last">anaplastic thyroid cancer</p></td></tr><tr><td class="NLM_term">ATIC</td><td class="NLM_def"><p class="first last">bifunctional purine biosynthesis protein PURH</p></td></tr><tr><td class="NLM_term">BBB</td><td class="NLM_def"><p class="first last">blood–brain barrier</p></td></tr><tr><td class="NLM_term">BM</td><td class="NLM_def"><p class="first last">brain metastasis</p></td></tr><tr><td class="NLM_term">C2orf44</td><td class="NLM_def"><p class="first last">chromosome 2 open reading frame 44</p></td></tr><tr><td class="NLM_term">CAD</td><td class="NLM_def"><p class="first last">carbamoyl-phosphate synthetase 2, aspartate transcarbamylase, and dihydroorotase</p></td></tr><tr><td class="NLM_term">CARS</td><td class="NLM_def"><p class="first last">cysteinyl-tRNA synthetase</p></td></tr><tr><td class="NLM_term">cKIT</td><td class="NLM_def"><p class="first last">KIT proto-oncogene</p></td></tr><tr><td class="NLM_term">CLTC</td><td class="NLM_def"><p class="first last">clathrin heavy chain</p></td></tr><tr><td class="NLM_term">c-Met</td><td class="NLM_def"><p class="first last">tyrosine-protein kinase Met or hepatocyte growth factor receptor</p></td></tr><tr><td class="NLM_term">CNS</td><td class="NLM_def"><p class="first last">central nerve system</p></td></tr><tr><td class="NLM_term">C-spine</td><td class="NLM_def"><p class="first last">catalytic spine</p></td></tr><tr><td class="NLM_term">CTCs</td><td class="NLM_def"><p class="first last">sequencing of circulating tumor cells</p></td></tr><tr><td class="NLM_term">CTLA</td><td class="NLM_def"><p class="first last">cytotoxic T-lymphocyte associated protein 4</p></td></tr><tr><td class="NLM_term">DAG</td><td class="NLM_def"><p class="first last">dystroglycan</p></td></tr><tr><td class="NLM_term">DCR</td><td class="NLM_def"><p class="first last">disease control rate</p></td></tr><tr><td class="NLM_term">DCTN1</td><td class="NLM_def"><p class="first last">dynactin subunit 1</p></td></tr><tr><td class="NLM_term">DFG</td><td class="NLM_def"><p class="first last">Asp-Phe- Gly</p></td></tr><tr><td class="NLM_term">DLBCL</td><td class="NLM_def"><p class="first last">diffuse large B-cell lymphoma</p></td></tr><tr><td class="NLM_term">DMPO</td><td class="NLM_def"><p class="first last">dimethylphosphine oxide</p></td></tr><tr><td class="NLM_term">DOR</td><td class="NLM_def"><p class="first last">durable objective responses</p></td></tr><tr><td class="NLM_term">EGFR</td><td class="NLM_def"><p class="first last">epidermal growth factor receptor</p></td></tr><tr><td class="NLM_term">EML4</td><td class="NLM_def"><p class="first last">echinoderm microtubule associated protein-like 4</p></td></tr><tr><td class="NLM_term">EMT</td><td class="NLM_def"><p class="first last">epithelial–mesenchymal transition</p></td></tr><tr><td class="NLM_term">ERK1/2</td><td class="NLM_def"><p class="first last">mitogen-activated protein (MAP) kinase 3/1</p></td></tr><tr><td class="NLM_term">ETV6</td><td class="NLM_def"><p class="first last">transcription factor Etv6</p></td></tr><tr><td class="NLM_term">FDA</td><td class="NLM_def"><p class="first last">Food and Drug Administration</p></td></tr><tr><td class="NLM_term">FISH</td><td class="NLM_def"><p class="first last">fluorescence in situ hybridization</p></td></tr><tr><td class="NLM_term">FN1</td><td class="NLM_def"><p class="first last">fibronectin 1</p></td></tr><tr><td class="NLM_term">GFPT1</td><td class="NLM_def"><p class="first last">glucosamine efructose 6 phosphate aminotransferase isomerizing 1</p></td></tr><tr><td class="NLM_term">GRB2</td><td class="NLM_def"><p class="first last">growth factor receptor bound protein 2</p></td></tr><tr><td class="NLM_term">HER3</td><td class="NLM_def"><p class="first last">human epidermal growth factor receptor 3</p></td></tr><tr><td class="NLM_term">HGF</td><td class="NLM_def"><p class="first last">hepatocyte growth factor</p></td></tr><tr><td class="NLM_term">HIP1</td><td class="NLM_def"><p class="first last">huntingtin-interacting protein 1</p></td></tr><tr><td class="NLM_term">IGF1R</td><td class="NLM_def"><p class="first last">insulin-like growth factor 1 receptor</p></td></tr><tr><td class="NLM_term">IMT</td><td class="NLM_def"><p class="first last">inflammatory myofibroblastic tumor</p></td></tr><tr><td class="NLM_term">IR</td><td class="NLM_def"><p class="first last">insulin receptor</p></td></tr><tr><td class="NLM_term">IRS-1</td><td class="NLM_def"><p class="first last">insulin receptor substrate 1</p></td></tr><tr><td class="NLM_term">JAK</td><td class="NLM_def"><p class="first last">Janus kinase</p></td></tr><tr><td class="NLM_term">Jun/AP1</td><td class="NLM_def"><p class="first last">Jun proto-oncogene/activating protein-1</p></td></tr><tr><td class="NLM_term">KIF5B</td><td class="NLM_def"><p class="first last">kinesin family member 5B</p></td></tr><tr><td class="NLM_term">KLC1</td><td class="NLM_def"><p class="first last">kinesin light chain 1</p></td></tr><tr><td class="NLM_term">KRAS</td><td class="NLM_def"><p class="first last">Kirsten rat sarcoma virus</p></td></tr><tr><td class="NLM_term">MAP2K1</td><td class="NLM_def"><p class="first last">mitogen-activated protein kinase kinase 1</p></td></tr><tr><td class="NLM_term">MAPK</td><td class="NLM_def"><p class="first last">mitogen activated kinase-like protein</p></td></tr><tr><td class="NLM_term">MEK</td><td class="NLM_def"><p class="first last">mitogen-activated protein kinase kinase</p></td></tr><tr><td class="NLM_term">MSN</td><td class="NLM_def"><p class="first last">moesin</p></td></tr><tr><td class="NLM_term">mTOR</td><td class="NLM_def"><p class="first last">serine/threonine-protein kinase mTOR</p></td></tr><tr><td class="NLM_term">MYCN</td><td class="NLM_def"><p class="first last">N-myc proto-oncogene protein</p></td></tr><tr><td class="NLM_term">MYH9</td><td class="NLM_def"><p class="first last">myosin heavy chain 9</p></td></tr><tr><td class="NLM_term">NF-κB</td><td class="NLM_def"><p class="first last">nuclear factor kappa-light-chain-enhancer of activated B cells</p></td></tr><tr><td class="NLM_term">NGS</td><td class="NLM_def"><p class="first last">next-generation sequencing</p></td></tr><tr><td class="NLM_term">NPM</td><td class="NLM_def"><p class="first last">nucleophosmin</p></td></tr><tr><td class="NLM_term">NRG1</td><td class="NLM_def"><p class="first last">neuregulin 1</p></td></tr><tr><td class="NLM_term">NSCLC</td><td class="NLM_def"><p class="first last">nonsmall cell lung cancer</p></td></tr><tr><td class="NLM_term">ORR</td><td class="NLM_def"><p class="first last">overall response rate</p></td></tr><tr><td class="NLM_term">PD-1/PD-L1</td><td class="NLM_def"><p class="first last">programmed cell death protein 1/programmed death-ligand 1</p></td></tr><tr><td class="NLM_term">PI3K</td><td class="NLM_def"><p class="first last">phosphoinositide 3-kinases</p></td></tr><tr><td class="NLM_term">PKC</td><td class="NLM_def"><p class="first last">protein kinase C</p></td></tr><tr><td class="NLM_term">PLC-γ</td><td class="NLM_def"><p class="first last">phosphoinositide phospholipase C-γ</p></td></tr><tr><td class="NLM_term">PROTAC</td><td class="NLM_def"><p class="first last">proteolysis targeting chimera</p></td></tr><tr><td class="NLM_term">PTPN3</td><td class="NLM_def"><p class="first last">tyrosine-protein phosphatase nonreceptor type 3</p></td></tr><tr><td class="NLM_term">RANBP2</td><td class="NLM_def"><p class="first last">E3 SUMO-protein ligase RanBP2</p></td></tr><tr><td class="NLM_term">RNF213 E3</td><td class="NLM_def"><p class="first last">ubiquitin–protein ligase RNF213</p></td></tr><tr><td class="NLM_term">ROS1</td><td class="NLM_def"><p class="first last">ROS proto-oncogene 1</p></td></tr><tr><td class="NLM_term">RRBP1</td><td class="NLM_def"><p class="first last">ribosome binding protein 1</p></td></tr><tr><td class="NLM_term">R-spine</td><td class="NLM_def"><p class="first last">regulatory spine</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structure–activity relationship</p></td></tr><tr><td class="NLM_term">SBDD</td><td class="NLM_def"><p class="first last">structure-based drug design</p></td></tr><tr><td class="NLM_term">SEC31A</td><td class="NLM_def"><p class="first last">protein transport protein Sec31A</p></td></tr><tr><td class="NLM_term">SFMs</td><td class="NLM_def"><p class="first last">solvent-front mutations</p></td></tr><tr><td class="NLM_term">SHC</td><td class="NLM_def"><p class="first last">SHC-adaptor protein</p></td></tr><tr><td class="NLM_term">SOC</td><td class="NLM_def"><p class="first last">ovarian carcinoma</p></td></tr><tr><td class="NLM_term">SQSTM1</td><td class="NLM_def"><p class="first last">sequestosome 1</p></td></tr><tr><td class="NLM_term">SRC</td><td class="NLM_def"><p class="first last">SRC proto-oncogene</p></td></tr><tr><td class="NLM_term">STAT</td><td class="NLM_def"><p class="first last">signal transducer and activator of transcription</p></td></tr><tr><td class="NLM_term">STRN</td><td class="NLM_def"><p class="first last">striatin</p></td></tr><tr><td class="NLM_term">TFG</td><td class="NLM_def"><p class="first last">protein TFG</p></td></tr><tr><td class="NLM_term">TPM3/4</td><td class="NLM_def"><p class="first last">tropomyosin 3/4</p></td></tr><tr><td class="NLM_term">TPR</td><td class="NLM_def"><p class="first last">translocated promoter region</p></td></tr><tr><td class="NLM_term">TRAF1</td><td class="NLM_def"><p class="first last">TNF receptor associated factor 1</p></td></tr><tr><td class="NLM_term">TRKA/B/C</td><td class="NLM_def"><p class="first last">tropomyosin receptor kinase A/B/C</p></td></tr><tr><td class="NLM_term">VCL</td><td class="NLM_def"><p class="first last">vinculin</p></td></tr><tr><td class="NLM_term">VEGF</td><td class="NLM_def"><p class="first last">vascular endothelial growth factor A</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i40">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_04464" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_04464" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 178 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morris, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirstein, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valentine, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dittmer, K. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shapiro, D. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saltman, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Look, A. T. J. S.</span></span> <span> </span><span class="NLM_article-title">Fusion of a Kinase Gene, ALK, to a Nucleolar Protein Gene, NPM, in Non-Hodgkin’s Lymphoma</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>263</i></span>,  <span class="NLM_fpage">1281</span>– <span class="NLM_lpage">1284</span>, <span class="refDoi"> DOI: 10.1126/science.8122112</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1126%2Fscience.8122112" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=8122112" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADyaK2cXis1aks7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=263&publication_year=1994&pages=1281-1284&author=S.+W.+Morrisauthor=M.+N.+Kirsteinauthor=M.+B.+Valentineauthor=K.+G.+Dittmerauthor=D.+N.+Shapiroauthor=D.+L.+Saltmanauthor=A.+T.+J.+S.+Look&title=Fusion+of+a+Kinase+Gene%2C+ALK%2C+to+a+Nucleolar+Protein+Gene%2C+NPM%2C+in+Non-Hodgkin%E2%80%99s+Lymphoma&doi=10.1126%2Fscience.8122112"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma</span></div><div class="casAuthors">Morris, Stephan, W.; Kirstein, Mark, N.; Valentine, Marcus B.; Dittmer, Kristopher G.; Shapiro, David N.; Saltman, David L.; Look, A. Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">263</span>
        (<span class="NLM_cas:issue">5151</span>),
    <span class="NLM_cas:pages">1281-4</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    </div><div class="casAbstract">The 2;5 chromosomal translocation occurs in most anaplastic large-cell non-Hodgkin's lymphomas arising from activated T lymphocytes.  This rearrangement was shown to fuse the NPM nucleolar phosphoprotein gene on chromosome 5q35 to a previously unidentified protein tyrosine kinase gene, ALK, on chromosome 2p23.  In the predicted hybrid protein, the amino terminus of nucleophosmin (NPM) is linked to the catalytic domain of anaplastic lymphoma kinase (ALK).  Expressed in the small intestine, testis, and brain but not in normal lymphoid cells, ALK shows greatest sequence similarity to the insulin receptor subfamily of kinases.  Unscheduled expression of the truncated ALK may contribute to malignant transformation in these lymphomas.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGox3KZnxLYaerVg90H21EOLACvtfcHk0lgQa4gvWkZ8YQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXis1aks7Y%253D&md5=219ee9615e613be456a05f8f1ded6066</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1126%2Fscience.8122112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.8122112%26sid%3Dliteratum%253Aachs%26aulast%3DMorris%26aufirst%3DS.%2BW.%26aulast%3DKirstein%26aufirst%3DM.%2BN.%26aulast%3DValentine%26aufirst%3DM.%2BB.%26aulast%3DDittmer%26aufirst%3DK.%2BG.%26aulast%3DShapiro%26aufirst%3DD.%2BN.%26aulast%3DSaltman%26aufirst%3DD.%2BL.%26aulast%3DLook%26aufirst%3DA.%2BT.%2BJ.%2BS.%26atitle%3DFusion%2520of%2520a%2520Kinase%2520Gene%252C%2520ALK%252C%2520to%2520a%2520Nucleolar%2520Protein%2520Gene%252C%2520NPM%252C%2520in%2520Non-Hodgkin%25E2%2580%2599s%2520Lymphoma%26jtitle%3DScience%26date%3D1994%26volume%3D263%26spage%3D1281%26epage%3D1284%26doi%3D10.1126%2Fscience.8122112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Iwahara, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujimoto, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cupples, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bucay, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arakawa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mori, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ratzkin, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, T. J. O.</span></span> <span> </span><span class="NLM_article-title">Molecular Characterization of ALK, a Receptor Tyrosine Kinase Expressed Specifically in the Nervous System</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">439</span>– <span class="NLM_lpage">449</span>, <span class="refDoi"> DOI: 10.1038/sj.onc.1200849</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1038%2Fsj.onc.1200849" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=9053841" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADyaK2sXht1ensbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=1997&pages=439-449&author=T.+Iwaharaauthor=J.+Fujimotoauthor=D.+Wenauthor=R.+Cupplesauthor=N.+Bucayauthor=T.+Arakawaauthor=S.+Moriauthor=B.+Ratzkinauthor=T.+J.+O.+Yamamoto&title=Molecular+Characterization+of+ALK%2C+a+Receptor+Tyrosine+Kinase+Expressed+Specifically+in+the+Nervous+System&doi=10.1038%2Fsj.onc.1200849"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system</span></div><div class="casAuthors">Iwahara, Toshinori; Fujimoto, Jiro; Wen, Duanzhi; Cupples, Rod; Bucay, Nathan; Arakawa, Tsutomu; Mori, Shigeo; Ratzkin, Barry; Yamamoto, Tadashi</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">439-449</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Stockton</span>)
        </div><div class="casAbstract">The 2;5 chromosomal translocation is frequently assocd. with anaplastic large cell lymphomas (ALCLs).  The translocation creates a fusion gene consisting of the alk (anaplastic lymphoma kinase) gene and the nucelophosmin (npm) gene: the 3' half of alk derived from chromosome 2 is fused to the 5' portion of npm from chromosome 5.  A recent study shows that the product of the npm-alk fusion gene is oncogenic.  To help understand how the npm-alk oncogene transform cells, it is important to investigate the normal biol. function of the alk gene product, ALK.  Here, we show mol. cloning of cDNAs for both the human and mouse ALK proteins.  The deduced amino acid sequences reveal that ALK is a novel receptor protein-tyrosine kinase having a putative transmembrane domain and an extracellular domain.  These sequences are absent in the product of the transforming npm-alk gene.  ALK shows the greatest sequence similarity to LTK (leukocyte tyrosine kinase) whose biol. function is presently unknown.  RNA blot hybridization anal. of various tissues reveals that the alk mRNA is dominantly detected in the brain and spinal cord.  Immunoblotting with anti-ALK antibody shows that ALK is highly expressed in the neonatal brain.  Furthermore, RNA in situ hybridization anal. shows that the alk mRNA is dominantly expressed in neurons in specific regions of the nervous system such as the thalamus, mid-brain, olfactory bulb, and ganglia of embryonic and neonatal mice.  These data suggest that ALK plays an important role(s) in the development of the brain and exerts its effects on specific neurons in the nervous system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-hGYy9uKgGbVg90H21EOLACvtfcHk0lj37CRyqhVpCg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXht1ensbs%253D&md5=7143e0a25247dd354bbf564cfd1702b6</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1200849&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1200849%26sid%3Dliteratum%253Aachs%26aulast%3DIwahara%26aufirst%3DT.%26aulast%3DFujimoto%26aufirst%3DJ.%26aulast%3DWen%26aufirst%3DD.%26aulast%3DCupples%26aufirst%3DR.%26aulast%3DBucay%26aufirst%3DN.%26aulast%3DArakawa%26aufirst%3DT.%26aulast%3DMori%26aufirst%3DS.%26aulast%3DRatzkin%26aufirst%3DB.%26aulast%3DYamamoto%26aufirst%3DT.%2BJ.%2BO.%26atitle%3DMolecular%2520Characterization%2520of%2520ALK%252C%2520a%2520Receptor%2520Tyrosine%2520Kinase%2520Expressed%2520Specifically%2520in%2520the%2520Nervous%2520System%26jtitle%3DOncogene%26date%3D1997%26volume%3D14%26spage%3D439%26epage%3D449%26doi%3D10.1038%2Fsj.onc.1200849" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cools, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wlodarska, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Somers, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mentens, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pedeutour, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maes, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Wolf-Peeters, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pauwels, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hagemeijer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marynen, P.</span></span> <span> </span><span class="NLM_article-title">Identification of Novel Fusion Partners of ALK, the Anaplastic Lymphoma Kinase, in Anaplastic Large-cell Lymphoma and Inflammatory Myofibroblastic Tumor</span>. <i>Genes, Chromosomes Cancer</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">354</span>– <span class="NLM_lpage">362</span>, <span class="refDoi"> DOI: 10.1002/gcc.10033</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1002%2Fgcc.10033" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=12112524" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BD38XlslyrtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2002&pages=354-362&author=J.+Coolsauthor=I.+Wlodarskaauthor=R.+Somersauthor=N.+Mentensauthor=F.+Pedeutourauthor=B.+Maesauthor=C.+De+Wolf-Peetersauthor=P.+Pauwelsauthor=A.+Hagemeijerauthor=P.+Marynen&title=Identification+of+Novel+Fusion+Partners+of+ALK%2C+the+Anaplastic+Lymphoma+Kinase%2C+in+Anaplastic+Large-cell+Lymphoma+and+Inflammatory+Myofibroblastic+Tumor&doi=10.1002%2Fgcc.10033"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of novel fusion partners of ALK, the anaplastic lymphoma kinase, in anaplastic large-cell lymphoma and inflammatory myofibroblastic tumor</span></div><div class="casAuthors">Cools, Jan; Wlodarska, Iwona; Somers, Riet; Mentens, Nicole; Pedeutour, Florence; Maes, Brigitte; De Wolf-Peeters, Christiane; Pauwels, Patrick; Hagemeijer, Anne; Marynen, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Genes, Chromosomes & Cancer</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">354-362</span>CODEN:
                <span class="NLM_cas:coden">GCCAES</span>;
        ISSN:<span class="NLM_cas:issn">1045-2257</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">ALK-pos. anaplastic large-cell lymphoma (ALCL) has been recognized as a distinct type of lymphoma in the heterogeneous group of T/Null-ALCL.  While most of the ALK-pos. ALCL (ALKomas) are characterized by the presence of the NPM-ALK fusion protein, the product of the t(2;5)(p23;q35), 10-20% of ALKomas contain variant ALK fusions, including ATIC-ALK, TFG-ALK, CLTC-ALK (previously designated CLTCL-ALK), TMP3-ALK, and MSN-ALK.  TMP3-ALK and TMP4-ALK fusions also have been detected in inflammatory myofibroblastic tumors (IMTs), making clear that aberrations of the ALK gene are not assocd. exclusively with the pathogenesis of ALK-pos. ALCL.  Here the authors report results of mol. studies on two lymphoma cases and one IMT case with variant rearrangements of ALK.  The authors' study led to the detection of the CLTC-ALK fusion in an ALCL case and to the identification of two novel fusion partners of ALK: ALO17 (KIAA 1618), a gene with unknown function, which was fused to ALK in an ALCL case with a t(2;17)(p23;q25), and CARS, encoding the cysteinyl-tRNA synthetase, which was fused to ALK in an IMT case with a t(2;11;2)(p23;p15;q31).  These results confirm the recurrent involvement of ALK in IMT and further demonstrate the diversity of ALK fusion partners, with the ability to homodimerize as a common characteristic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXRK_iZnUkNrVg90H21EOLACvtfcHk0lj37CRyqhVpCg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XlslyrtL8%253D&md5=5e15ec7d207444665354c7f08d2620fc</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1002%2Fgcc.10033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fgcc.10033%26sid%3Dliteratum%253Aachs%26aulast%3DCools%26aufirst%3DJ.%26aulast%3DWlodarska%26aufirst%3DI.%26aulast%3DSomers%26aufirst%3DR.%26aulast%3DMentens%26aufirst%3DN.%26aulast%3DPedeutour%26aufirst%3DF.%26aulast%3DMaes%26aufirst%3DB.%26aulast%3DDe%2BWolf-Peeters%26aufirst%3DC.%26aulast%3DPauwels%26aufirst%3DP.%26aulast%3DHagemeijer%26aufirst%3DA.%26aulast%3DMarynen%26aufirst%3DP.%26atitle%3DIdentification%2520of%2520Novel%2520Fusion%2520Partners%2520of%2520ALK%252C%2520the%2520Anaplastic%2520Lymphoma%2520Kinase%252C%2520in%2520Anaplastic%2520Large-cell%2520Lymphoma%2520and%2520Inflammatory%2520Myofibroblastic%2520Tumor%26jtitle%3DGenes%252C%2520Chromosomes%2520Cancer%26date%3D2002%26volume%3D34%26spage%3D354%26epage%3D362%26doi%3D10.1002%2Fgcc.10033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Carén, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abel, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kogner, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinsson, T. J. B. J.</span></span> <span> </span><span class="NLM_article-title">High Incidence of DNA Mutations and Gene Amplifications of the ALK Gene in Advanced Sporadic Neuroblastoma Tumours</span>. <i>Biochem. J.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>416</i></span>,  <span class="NLM_fpage">153</span>– <span class="NLM_lpage">159</span>, <span class="refDoi"> DOI: 10.1042/BJ20081834</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1042%2FBJ20081834" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=18990089" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtlGls7bO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=416&publication_year=2008&pages=153-159&author=H.+Car%C3%A9nauthor=F.+Abelauthor=P.+Kognerauthor=T.+J.+B.+J.+Martinsson&title=High+Incidence+of+DNA+Mutations+and+Gene+Amplifications+of+the+ALK+Gene+in+Advanced+Sporadic+Neuroblastoma+Tumours&doi=10.1042%2FBJ20081834"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">High incidence of DNA mutations and gene amplifications of the ALK gene in advanced sporadic neuroblastoma tumors</span></div><div class="casAuthors">Caren, Helena; Abel, Frida; Kogner, Per; Martinsson, Tommy</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Journal</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">416</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">153-159</span>CODEN:
                <span class="NLM_cas:coden">BIJOAK</span>;
        ISSN:<span class="NLM_cas:issn">0264-6021</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">ALK (anaplastic lymphoma kinase) is oncogenic in several tumors and has recently been identified as a predisposition gene for familial NB (neuroblastoma) harboring mutations in the TKD (tyrosine kinase domain).  We have analyzed a large set of sporadic human NB primary tumors of all clin. stages for chromosomal re-arrangements using a CGH (comparative genomic hybridization) array (n = 108) and mutations of the ALK gene (n = 90), and expression of ALK and related genes (n = 19).  ALK amplification or in-gene re-arrangements were found in 5% of NB tumors and mutations were found in 11%, including two novel not previously published mutations in the TKD, c.3733T > A and c.3735C > A.  DNA mutations in the TKD and gene amplifications were only found in advanced large primary tumors or metastatic tumors, and correlated with the expression levels of ALK and downstream genes as well as other unfavorable features, and poor outcome.  The results of the present study support that the ALK protein contributes to NB oncogenesis providing a highly interesting putative therapeutic target in a subset of unfavorable NB tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_-7KLmFXGrbVg90H21EOLACvtfcHk0lj37CRyqhVpCg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtlGls7bO&md5=b01f1d1181d189dd6db6c58590b8da9c</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1042%2FBJ20081834&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FBJ20081834%26sid%3Dliteratum%253Aachs%26aulast%3DCar%25C3%25A9n%26aufirst%3DH.%26aulast%3DAbel%26aufirst%3DF.%26aulast%3DKogner%26aufirst%3DP.%26aulast%3DMartinsson%26aufirst%3DT.%2BJ.%2BB.%2BJ.%26atitle%3DHigh%2520Incidence%2520of%2520DNA%2520Mutations%2520and%2520Gene%2520Amplifications%2520of%2520the%2520ALK%2520Gene%2520in%2520Advanced%2520Sporadic%2520Neuroblastoma%2520Tumours%26jtitle%3DBiochem.%2520J.%26date%3D2008%26volume%3D416%26spage%3D153%26epage%3D159%26doi%3D10.1042%2FBJ20081834" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Solomon, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varella-Garcia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camidge, D. R.</span></span> <span> </span><span class="NLM_article-title">ALK Gene Rearrangements: a New Therapeutic Target in a Molecularly Defined Subset of Non-small Cell Lung Cancer</span>. <i>J. Thorac. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">1450</span>– <span class="NLM_lpage">1454</span>, <span class="refDoi"> DOI: 10.1097/JTO.0b013e3181c4dedb</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1097%2FJTO.0b013e3181c4dedb" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=20009909" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A280%3ADC%252BD1MfisFGkuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2009&pages=1450-1454&author=B.+Solomonauthor=M.+Varella-Garciaauthor=D.+R.+Camidge&title=ALK+Gene+Rearrangements%3A+a+New+Therapeutic+Target+in+a+Molecularly+Defined+Subset+of+Non-small+Cell+Lung+Cancer&doi=10.1097%2FJTO.0b013e3181c4dedb"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">ALK gene rearrangements: a new therapeutic target in a molecularly defined subset of non-small cell lung cancer</span></div><div class="casAuthors">Solomon Benjamin; Varella-Garcia Marileila; Camidge D Ross</div><div class="citationInfo"><span class="NLM_cas:title">Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1450-4</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Transforming rearrangements of the ALK (anaplastic lymphoma kinase) gene have recently been described in non-small cell lung cancer (NSCLC).  The most common rearrangement arises from an inversion in the short arm of chromosome 2 that creates a fusion between the 5' portion of the EML4 (echinoderm microtubule-associated protein-like 4) gene and the 3' portion of the ALK gene.  At least seven ALK gene rearrangement variants have been described involving different EML4-ALK breakpoints or rarely other non-EML4 fusion partners.  ALK rearrangements may be readily identified in tumor tissue by reverse transcription-polymerase chain reaction or fluorescent in situ hybridization.  Although ALK gene rearrangements affect only about 4% of all lung cancers, they are more frequent in adenocarcinomas, in never or light smokers, and seem almost mutually exclusive with activating EGFR or KRAS mutations.  Promising results seen in patients with NSCLC containing fluorescent in situ hybridization-detected ALK rearrangements treated on a phase I study with PF02341066, an oral ALK inhibitor, indicate that ALK represents a new therapeutic target in this molecularly defined subset of NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcToajfqAoubLEEgZCMqtRBifW6udTcc2eY1KUfZF5bhdrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1MfisFGkuw%253D%253D&md5=f9cba2d2339e725ed625f629f66ba6a6</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1097%2FJTO.0b013e3181c4dedb&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FJTO.0b013e3181c4dedb%26sid%3Dliteratum%253Aachs%26aulast%3DSolomon%26aufirst%3DB.%26aulast%3DVarella-Garcia%26aufirst%3DM.%26aulast%3DCamidge%26aufirst%3DD.%2BR.%26atitle%3DALK%2520Gene%2520Rearrangements%253A%2520a%2520New%2520Therapeutic%2520Target%2520in%2520a%2520Molecularly%2520Defined%2520Subset%2520of%2520Non-small%2520Cell%2520Lung%2520Cancer%26jtitle%3DJ.%2520Thorac.%2520Oncol.%26date%3D2009%26volume%3D4%26spage%3D1450%26epage%3D1454%26doi%3D10.1097%2FJTO.0b013e3181c4dedb" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hallberg, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmer, R. H.</span></span> <span> </span><span class="NLM_article-title">Mechanistic Insight into ALK Receptor Tyrosine Kinase in Human Cancer Biology</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">685</span>– <span class="NLM_lpage">700</span>, <span class="refDoi"> DOI: 10.1038/nrc3580</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1038%2Fnrc3580" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=24060861" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsV2jtrbP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2013&pages=685-700&author=B.+Hallbergauthor=R.+H.+Palmer&title=Mechanistic+Insight+into+ALK+Receptor+Tyrosine+Kinase+in+Human+Cancer+Biology&doi=10.1038%2Fnrc3580"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology</span></div><div class="casAuthors">Hallberg, Bengt; Palmer, Ruth H.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">685-700</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The burgeoning field of anaplastic lymphoma kinase (ALK) in cancer encompasses many cancer types, from very rare cancers to the more prevalent non-small-cell lung cancer (NSCLC).  The common activation of ALK has led to the use of the ALK tyrosine kinase inhibitor (TKI) crizotinib in a range of patient populations and to the rapid development of second-generation drugs targeting ALK.  In this review, we discuss our current understanding of ALK function in human cancer and the implications for tumor treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrADI-N0ZBEr7Vg90H21EOLACvtfcHk0liFSLnFRXKfvQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsV2jtrbP&md5=fab66b12114ca01348df4ca08d3b3e4e</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1038%2Fnrc3580&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc3580%26sid%3Dliteratum%253Aachs%26aulast%3DHallberg%26aufirst%3DB.%26aulast%3DPalmer%26aufirst%3DR.%2BH.%26atitle%3DMechanistic%2520Insight%2520into%2520ALK%2520Receptor%2520Tyrosine%2520Kinase%2520in%2520Human%2520Cancer%2520Biology%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2013%26volume%3D13%26spage%3D685%26epage%3D700%26doi%3D10.1038%2Fnrc3580" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Solomon, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ou, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Besse, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felip, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soo, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bearz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clancy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abbattista, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thurm, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peltz, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masters, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martini, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seto, T.</span></span> <span> </span><span class="NLM_article-title">Oa 05.06 Phase 2 Study of Lorlatinib in Patients with Advanced ALK+/ROS1+ Non-small-cell Lung Cancer</span>. <i>J. Thorac. Oncol..</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">S1756</span>, <span class="refDoi"> DOI: 10.1016/j.jtho.2017.09.351</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1016%2Fj.jtho.2017.09.351" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2017&pages=S1756&author=B.+Solomonauthor=A.+Shawauthor=S.+Ouauthor=B.+Besseauthor=E.+Felipauthor=T.+Bauerauthor=R.+Sooauthor=A.+Bearzauthor=C.+Linauthor=J.+Clancyauthor=A.+Abbattistaauthor=H.+Thurmauthor=G.+Peltzauthor=E.+Mastersauthor=J.+Martiniauthor=L.+Jamesauthor=T.+Seto&title=Oa+05.06+Phase+2+Study+of+Lorlatinib+in+Patients+with+Advanced+ALK%2B%2FROS1%2B+Non-small-cell+Lung+Cancer&doi=10.1016%2Fj.jtho.2017.09.351"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2Fj.jtho.2017.09.351&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jtho.2017.09.351%26sid%3Dliteratum%253Aachs%26aulast%3DSolomon%26aufirst%3DB.%26aulast%3DShaw%26aufirst%3DA.%26aulast%3DOu%26aufirst%3DS.%26aulast%3DBesse%26aufirst%3DB.%26aulast%3DFelip%26aufirst%3DE.%26aulast%3DBauer%26aufirst%3DT.%26aulast%3DSoo%26aufirst%3DR.%26aulast%3DBearz%26aufirst%3DA.%26aulast%3DLin%26aufirst%3DC.%26aulast%3DClancy%26aufirst%3DJ.%26aulast%3DAbbattista%26aufirst%3DA.%26aulast%3DThurm%26aufirst%3DH.%26aulast%3DPeltz%26aufirst%3DG.%26aulast%3DMasters%26aufirst%3DE.%26aulast%3DMartini%26aufirst%3DJ.%26aulast%3DJames%26aufirst%3DL.%26aulast%3DSeto%26aufirst%3DT.%26atitle%3DOa%252005.06%2520Phase%25202%2520Study%2520of%2520Lorlatinib%2520in%2520Patients%2520with%2520Advanced%2520ALK%252B%252FROS1%252B%2520Non-small-cell%2520Lung%2520Cancer%26jtitle%3DJ.%2520Thorac.%2520Oncol..%26date%3D2017%26volume%3D12%26spage%3DS1756%26doi%3D10.1016%2Fj.jtho.2017.09.351" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Debelenko, L. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arthur, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pack, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Helman, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schrump, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsokos, M.</span></span> <span> </span><span class="NLM_article-title">Identification of CARS-ALK Fusion in Primary and Metastatic Lesions of an Inflammatory Myofibroblastic Tumor</span>. <i>Lab. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>83</i></span>,  <span class="NLM_fpage">1255</span>– <span class="NLM_lpage">1265</span>, <span class="refDoi"> DOI: 10.1097/01.LAB.0000088856.49388.EA</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1097%2F01.LAB.0000088856.49388.EA" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=13679433" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BD3sXntFSlu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=83&publication_year=2003&pages=1255-1265&author=L.+V.+Debelenkoauthor=D.+C.+Arthurauthor=S.+D.+Packauthor=L.+J.+Helmanauthor=D.+S.+Schrumpauthor=M.+Tsokos&title=Identification+of+CARS-ALK+Fusion+in+Primary+and+Metastatic+Lesions+of+an+Inflammatory+Myofibroblastic+Tumor&doi=10.1097%2F01.LAB.0000088856.49388.EA"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of CARS-ALK Fusion in Primary and Metastatic Lesions of an Inflammatory Myofibroblastic Tumor</span></div><div class="casAuthors">Debelenko, Larisa V.; Arthur, Diane C.; Pack, Svetlana D.; Helman, Lee J.; Schrump, David S.; Tsokos, Maria</div><div class="citationInfo"><span class="NLM_cas:title">Laboratory Investigation</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">83</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1255-1265</span>CODEN:
                <span class="NLM_cas:coden">LAINAW</span>;
        ISSN:<span class="NLM_cas:issn">0023-6837</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Inflammatory myofibroblastic tumor (IMT) is a rare childhood neoplasm.  The natural history of this disease is poorly understood.  Recently chromosomal rearrangements involving the anaplastic lymphoma kinase (ALK) gene have been implicated in this tumor.  We have studied a case of ALK-pos. soft tissue IMT showing clin. and morphol. features of malignancy.  Interphase fluorescence in situ hybridization demonstrated ALK rearrangements in both primary and metastatic lesions.  Rapid amplification of cDNA ends (5'RACE) identified cysteinyl-tRNA synthetase (CARS) gene fused to ALK, which predicts an in-frame chimeric protein with the preserved functional catalytic domain of ALK at the C terminus.  Amplification and sequencing of tumor DNA confirmed the breakpoint at the genomic level.  Restriction anal. of DNA from primary soft tissue and recurrent lung tumors showed identical patterns, indicating the same clonal origin of both lesions.  Western blot anal. with C-terminus ALK antibody showed expression of an aberrantly sized chimeric protein of approx. 130 kd in tumor tissue.  This is the second case of IMT demonstrating CARS as the ALK fusion partner, which confirms the recurring involvement of ALK in IMT by a common genetic mechanism.  Moreover, identical clonality of sep. lesions involving different sites supports metastasis in IMT.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrllwxoK_YWV7Vg90H21EOLACvtfcHk0lgRnLdjMBXB3w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXntFSlu7o%253D&md5=4ac7cbe6b8cad0692c784c48fe62250b</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1097%2F01.LAB.0000088856.49388.EA&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F01.LAB.0000088856.49388.EA%26sid%3Dliteratum%253Aachs%26aulast%3DDebelenko%26aufirst%3DL.%2BV.%26aulast%3DArthur%26aufirst%3DD.%2BC.%26aulast%3DPack%26aufirst%3DS.%2BD.%26aulast%3DHelman%26aufirst%3DL.%2BJ.%26aulast%3DSchrump%26aufirst%3DD.%2BS.%26aulast%3DTsokos%26aufirst%3DM.%26atitle%3DIdentification%2520of%2520CARS-ALK%2520Fusion%2520in%2520Primary%2520and%2520Metastatic%2520Lesions%2520of%2520an%2520Inflammatory%2520Myofibroblastic%2520Tumor%26jtitle%3DLab.%2520Invest.%26date%3D2003%26volume%3D83%26spage%3D1255%26epage%3D1265%26doi%3D10.1097%2F01.LAB.0000088856.49388.EA" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gascoyne, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamant, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin-Subero, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lestou, V. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, N. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller-Hermelink, H.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seymour, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horsman, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Auvigne, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Espinos, E.</span></span> <span> </span><span class="NLM_article-title">ALK-positive Diffuse Large B-cell Lymphoma is Associated with Clathrin-ALK Rearrangements: report of 6 cases</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>102</i></span>,  <span class="NLM_fpage">2568</span>– <span class="NLM_lpage">2573</span>, <span class="refDoi"> DOI: 10.1182/blood-2003-03-0786</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1182%2Fblood-2003-03-0786" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=12763927" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BD3sXnslykurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2003&pages=2568-2573&author=R.+D.+Gascoyneauthor=L.+Lamantauthor=J.+I.+Martin-Suberoauthor=V.+S.+Lestouauthor=N.+L.+Harrisauthor=H.-K.+M%C3%BCller-Hermelinkauthor=J.+F.+Seymourauthor=L.+J.+Campbellauthor=D.+E.+Horsmanauthor=I.+Auvigneauthor=E.+Espinos&title=ALK-positive+Diffuse+Large+B-cell+Lymphoma+is+Associated+with+Clathrin-ALK+Rearrangements%3A+report+of+6+cases&doi=10.1182%2Fblood-2003-03-0786"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">ALK-positive diffuse large B-cell lymphoma is associated with clathrin-ALK rearrangements: Report of 6 cases</span></div><div class="casAuthors">Gascoyne, Randy D.; Lamant, Laurence; Martin-Subero, Jose I.; Lestou, Valia S.; Harris, Nancy Lee; Mueller-Hermelink, Hans-Konrad; Seymour, John F.; Campbell, Lynda J.; Horsman, Douglas E.; Auvigne, Isabelle; Espinos, Estelle; Siebert, Reiner; Delsol, Georges</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2568-2573</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Expression of ALK protein by lymphoid cells and the description of variant anaplastic lymphoma kinase (ALK) translocations have typically been restricted to cases of T-cell and null anaplastic large-cell lymphoma (ALCL).  All such cases result from a novel fusion created by the ALK gene on chromosome 2p23 and NPM on 5q35 or other variant translocation partners.  A rare variant of diffuse large B-cell lymphoma (DLBCL), originally described in 1997, was thought to overexpress full-length ALK in contrast to a chimeric protein characteristic of ALCL.  However, full-length ALK protein lacks tyrosine kinase activity and thus the mechanism of oncogenesis has remained elusive.  We describe 6 cases of ALK+ DLBCL characterized by a simple or complex t(2;17)(p23;q23) involving the clathrin gene (CLTC) at chromosome band 17q23 and the ALK gene at chromosome band 2p23.  All cases were studied using fluorescence in situ hybridization (FISH), complemented in one case with std. cytogenetic anal., multicolor karyotyping (M-FISH), and reverse transcriptase-polymerase chain reaction.  These results clearly demonstrate that most cases of ALK+ DLBCL share the same mechanism of deregulated ALK expression.  Moreover, these results demonstrate the presence of CLTC-ALK fusions in these tumors and extend the list of diseases assocd. with this genetic abnormality to include classical T-cell or null ALCL, ALK+ DLBCL, and inflammatory myofibroblastic tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3UcmsuahiXLVg90H21EOLACvtfcHk0lgRnLdjMBXB3w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXnslykurw%253D&md5=9eedc8c22c580dbadee982b4d3da35a8</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1182%2Fblood-2003-03-0786&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2003-03-0786%26sid%3Dliteratum%253Aachs%26aulast%3DGascoyne%26aufirst%3DR.%2BD.%26aulast%3DLamant%26aufirst%3DL.%26aulast%3DMartin-Subero%26aufirst%3DJ.%2BI.%26aulast%3DLestou%26aufirst%3DV.%2BS.%26aulast%3DHarris%26aufirst%3DN.%2BL.%26aulast%3DM%25C3%25BCller-Hermelink%26aufirst%3DH.-K.%26aulast%3DSeymour%26aufirst%3DJ.%2BF.%26aulast%3DCampbell%26aufirst%3DL.%2BJ.%26aulast%3DHorsman%26aufirst%3DD.%2BE.%26aulast%3DAuvigne%26aufirst%3DI.%26aulast%3DEspinos%26aufirst%3DE.%26atitle%3DALK-positive%2520Diffuse%2520Large%2520B-cell%2520Lymphoma%2520is%2520Associated%2520with%2520Clathrin-ALK%2520Rearrangements%253A%2520report%2520of%25206%2520cases%26jtitle%3DBlood%26date%3D2003%26volume%3D102%26spage%3D2568%26epage%3D2573%26doi%3D10.1182%2Fblood-2003-03-0786" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Soda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Enomoto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takada, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamashita, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishikawa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujiwara, S. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurashina, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hatanaka, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bando, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohno, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishikawa, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aburatani, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sohara, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugiyama, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Man, H.</span></span> <span> </span><span class="NLM_article-title">Identification of the Transforming EML4–ALK Fusion Gene in Non-small-cell Lung Cancer</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>448</i></span>,  <span class="NLM_fpage">561</span>– <span class="NLM_lpage">566</span>, <span class="refDoi"> DOI: 10.1038/nature05945</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1038%2Fnature05945" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=17625570" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BD2sXosVSrtrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=448&publication_year=2007&pages=561-566&author=M.+Sodaauthor=Y.+L.+Choiauthor=M.+Enomotoauthor=S.+Takadaauthor=Y.+Yamashitaauthor=S.+Ishikawaauthor=S.+I.+Fujiwaraauthor=H.+Watanabeauthor=K.+Kurashinaauthor=H.+Hatanakaauthor=M.+Bandoauthor=S.+Ohnoauthor=Y.+Ishikawaauthor=H.+Aburataniauthor=T.+Nikiauthor=Y.+Soharaauthor=Y.+Sugiyamaauthor=H.+Man&title=Identification+of+the+Transforming+EML4%E2%80%93ALK+Fusion+Gene+in+Non-small-cell+Lung+Cancer&doi=10.1038%2Fnature05945"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer</span></div><div class="casAuthors">Soda, Manabu; Choi, Young Lim; Enomoto, Munehiro; Takada, Shuji; Yamashita, Yoshihiro; Ishikawa, Shunpei; Fujiwara, Shin-ichiro; Watanabe, Hideki; Kurashina, Kentaro; Hatanaka, Hisashi; Bando, Masashi; Ohno, Shoji; Ishikawa, Yuichi; Aburatani, Hiroyuki; Niki, Toshiro; Sohara, Yasunori; Sugiyama, Yukihiko; Mano, Hiroyuki</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">448</span>
        (<span class="NLM_cas:issue">7153</span>),
    <span class="NLM_cas:pages">561-566</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Improvement in the clin. outcome of lung cancer is likely to be achieved by identification of the mol. events that underlie its pathogenesis.  Here we show that a small inversion within chromosome 2p results in the formation of a fusion gene comprising portions of the echinoderm microtubule-assocd. protein-like 4 (EML4) gene and the anaplastic lymphoma kinase (ALK) gene in non-small-cell lung cancer (NSCLC) cells.  Mouse 3T3 fibroblasts forced to express this human fusion tyrosine kinase generated transformed foci in culture and s.c. tumors in nude mice.  The EML4-ALK fusion transcript was detected in 6.7% (5 out of 75) of NSCLC patients examd.; these individuals were distinct from those harboring mutations in the epidermal growth factor receptor gene.  Our data demonstrate that a subset of NSCLC patients may express a transforming fusion kinase that is a promising candidate for a therapeutic target as well as for a diagnostic mol. marker in NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomhAXuLtrJ6rVg90H21EOLACvtfcHk0lgRnLdjMBXB3w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXosVSrtrs%253D&md5=7f567e80814b9ccc87e5bceeebb467a7</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1038%2Fnature05945&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature05945%26sid%3Dliteratum%253Aachs%26aulast%3DSoda%26aufirst%3DM.%26aulast%3DChoi%26aufirst%3DY.%2BL.%26aulast%3DEnomoto%26aufirst%3DM.%26aulast%3DTakada%26aufirst%3DS.%26aulast%3DYamashita%26aufirst%3DY.%26aulast%3DIshikawa%26aufirst%3DS.%26aulast%3DFujiwara%26aufirst%3DS.%2BI.%26aulast%3DWatanabe%26aufirst%3DH.%26aulast%3DKurashina%26aufirst%3DK.%26aulast%3DHatanaka%26aufirst%3DH.%26aulast%3DBando%26aufirst%3DM.%26aulast%3DOhno%26aufirst%3DS.%26aulast%3DIshikawa%26aufirst%3DY.%26aulast%3DAburatani%26aufirst%3DH.%26aulast%3DNiki%26aufirst%3DT.%26aulast%3DSohara%26aufirst%3DY.%26aulast%3DSugiyama%26aufirst%3DY.%26aulast%3DMan%26aufirst%3DH.%26atitle%3DIdentification%2520of%2520the%2520Transforming%2520EML4%25E2%2580%2593ALK%2520Fusion%2520Gene%2520in%2520Non-small-cell%2520Lung%2520Cancer%26jtitle%3DNature%26date%3D2007%26volume%3D448%26spage%3D561%26epage%3D566%26doi%3D10.1038%2Fnature05945" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chiarle, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voena, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ambrogio, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piva, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inghirami, G.</span></span> <span> </span><span class="NLM_article-title">The Anaplastic Lymphoma Kinase in the Pathogenesis of Cancer</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">11</span>– <span class="NLM_lpage">23</span>, <span class="refDoi"> DOI: 10.1038/nrc2291</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1038%2Fnrc2291" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=18097461" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhsVKku73P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2008&pages=11-23&author=R.+Chiarleauthor=C.+Voenaauthor=C.+Ambrogioauthor=R.+Pivaauthor=G.+Inghirami&title=The+Anaplastic+Lymphoma+Kinase+in+the+Pathogenesis+of+Cancer&doi=10.1038%2Fnrc2291"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">The anaplastic lymphoma kinase in the pathogenesis of cancer</span></div><div class="casAuthors">Chiarle, Roberto; Voena, Claudia; Ambrogio, Chiara; Piva, Roberto; Inghirami, Giorgio</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">11-23</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The receptor tyrosine kinase anaplastic lymphoma kinase (ALK) was first identified as part of a chromosomal translocation assocd. with some anaplastic large cell lymphomas (ALCLs).  Now data are emerging that indicate that ALK might be a valid therapeutic target in ALCL and that it could also be involved in other cancers.  Tyrosine kinases are involved in the pathogenesis of most cancers.  However, few tyrosine kinases have been shown to have a well-defined pathogenetic role in lymphomas.  The anaplastic lymphoma kinase (ALK) is the oncogene of most anaplastic large cell lymphomas (ALCL), driving transformation through many mol. mechanisms.  In this review, we will analyze how translocations or deregulated expression of ALK contribute to oncogenesis and how recent genetic or pharmacol. tools, aimed at neutralizing its activity, can represent the basis for the design of powerful combination therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5HoaZPQUiUrVg90H21EOLACvtfcHk0lgDUV0gZwaDYQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhsVKku73P&md5=a57d7ab61be51664ca9f5b804c3e2910</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1038%2Fnrc2291&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2291%26sid%3Dliteratum%253Aachs%26aulast%3DChiarle%26aufirst%3DR.%26aulast%3DVoena%26aufirst%3DC.%26aulast%3DAmbrogio%26aufirst%3DC.%26aulast%3DPiva%26aufirst%3DR.%26aulast%3DInghirami%26aufirst%3DG.%26atitle%3DThe%2520Anaplastic%2520Lymphoma%2520Kinase%2520in%2520the%2520Pathogenesis%2520of%2520Cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2008%26volume%3D8%26spage%3D11%26epage%3D23%26doi%3D10.1038%2Fnrc2291" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pillay, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Govender, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chetty, R.</span></span> <span> </span><span class="NLM_article-title">ALK Protein Expression in Rhabdomyosarcomas</span>. <i>Histopathol.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">461</span>– <span class="NLM_lpage">467</span>, <span class="refDoi"> DOI: 10.1046/j.1365-2559.2002.01534.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1046%2Fj.1365-2559.2002.01534.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=12405914" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A280%3ADC%252BD38nkslWqtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2002&pages=461-467&author=K.+Pillayauthor=D.+Govenderauthor=R.+Chetty&title=ALK+Protein+Expression+in+Rhabdomyosarcomas&doi=10.1046%2Fj.1365-2559.2002.01534.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">ALK protein expression in rhabdomyosarcomas</span></div><div class="casAuthors">Pillay K; Govender D; Chetty R</div><div class="citationInfo"><span class="NLM_cas:title">Histopathology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">461-7</span>
        ISSN:<span class="NLM_cas:issn">0309-0167</span>.
    </div><div class="casAbstract">AIMS:  The ALK p80 chimeric protein is thought to be up-regulated as a result of the t(2;5) as classically seen in anaplastic large cell lymphoma.  However, rhabdomyosarcomas (in particular, the alveolar subtype) have also been noted to show expression of this protein.  This study set out to examine ALK expression in a large number of rhabdomyosarcomas.  METHODS AND RESULTS:  Eighty-three cases of rhabdomyosarcomas and 16 cases of malignant mixed mullerian tumours with a rhabdomyosarcomatous component were retrieved from the archives of the Department of Anatomical Pathology for the period 1983-2001.  The sections were stained with polyclonal ALK antibody.  There were 52 male and 30 female patients.  In one case, the gender of the patient was not indicated.  The ages ranged from 1 week to 77 years.  The most common site was the head and neck region, followed by the pelvis and extremities.  Thirty-one cases were of the alveolar subtype while 40 cases were embryonal.  There were four mixed embryonal/alveolar, six pleomorphic and two unclassifiable rhabdomyosarcomas.  Fourteen of the 31 (45%) alveolar rhabdomyosarcomas stained positively for the ALK protein, while only six of the 40 embryonal (15%) cases showed positivity.  One case each of the mixed embryonal/alveolar, pleomorphic and unclassified cases was also immunopositive.  The rhabdomyosarcomatous component in the malignant mixed mullerian tumours was positive in four of the 16 cases.  CONCLUSION:  We conclude that a proportion of alveolar rhabdomyosarcomas (in particular) exhibit ALK protein expression.  However, ALK expression is not restricted to this subtype.  An extension of this study is to determine if this over-expression is as a result of the t(2;5) translocation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSUup51yhOB7-kdrW1FkXG-fW6udTcc2eb3vv4psUB3FLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD38nkslWqtA%253D%253D&md5=1996dd2820ce0f74bbd8031cab29e1a9</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1046%2Fj.1365-2559.2002.01534.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1046%252Fj.1365-2559.2002.01534.x%26sid%3Dliteratum%253Aachs%26aulast%3DPillay%26aufirst%3DK.%26aulast%3DGovender%26aufirst%3DD.%26aulast%3DChetty%26aufirst%3DR.%26atitle%3DALK%2520Protein%2520Expression%2520in%2520Rhabdomyosarcomas%26jtitle%3DHistopathol.%26date%3D2002%26volume%3D41%26spage%3D461%26epage%3D467%26doi%3D10.1046%2Fj.1365-2559.2002.01534.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mosse, Y. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laudenslager, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Longo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cole, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Attiyeh, E. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laquaglia, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sennett, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lynch, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perri, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laureys, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Speleman, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hakonarson, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torkamani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schork, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brodeur, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tonini, G. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rappaport, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Devoto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maris, J. M.</span></span> <span> </span><span class="NLM_article-title">Identification of ALK as a Major Familial Neuroblastoma Predisposition Gene</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>455</i></span>,  <span class="NLM_fpage">930</span>– <span class="NLM_lpage">935</span>, <span class="refDoi"> DOI: 10.1038/nature07261</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1038%2Fnature07261" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=18724359" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht1Ggur%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=455&publication_year=2008&pages=930-935&author=Y.+P.+Mosseauthor=M.+Laudenslagerauthor=L.+Longoauthor=K.+A.+Coleauthor=A.+Woodauthor=E.+F.+Attiyehauthor=M.+J.+Laquagliaauthor=R.+Sennettauthor=J.+E.+Lynchauthor=P.+Perriauthor=G.+Laureysauthor=F.+Spelemanauthor=C.+Kimauthor=C.+Houauthor=H.+Hakonarsonauthor=A.+Torkamaniauthor=N.+J.+Schorkauthor=G.+M.+Brodeurauthor=G.+P.+Toniniauthor=E.+Rappaportauthor=M.+Devotoauthor=J.+M.+Maris&title=Identification+of+ALK+as+a+Major+Familial+Neuroblastoma+Predisposition+Gene&doi=10.1038%2Fnature07261"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of ALK as a major familial neuroblastoma predisposition gene</span></div><div class="casAuthors">Mosse, Yael P.; Laudenslager, Marci; Longo, Luca; Cole, Kristina A.; Wood, Andrew; Attiyeh, Edward F.; Laquaglia, Michael J.; Sennett, Rachel; Lynch, Jill E.; Perri, Patrizia; Laureys, Genevieve; Speleman, Frank; Kim, Cecilia; Hou, Cuiping; Hakonarson, Hakon; Torkamani, Ali; Schork, Nicholas J.; Brodeur, Garrett M.; Tonini, Gian P.; Rappaport, Eric; Devoto, Marcella; Maris, John M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">455</span>
        (<span class="NLM_cas:issue">7215</span>),
    <span class="NLM_cas:pages">930-935</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Neuroblastoma is a childhood cancer that can be inherited, but the genetic etiol. is largely unknown.  Here we show that germline mutations in the anaplastic lymphoma kinase (ALK) gene explain most hereditary neuroblastomas, and that activating mutations can also be somatically acquired.  We first identified a significant linkage signal at chromosome bands 2p23-24 using a whole-genome scan in neuroblastoma pedigrees.  Re-sequencing of regional candidate genes identified three sep. germline missense mutations in the tyrosine kinase domain of ALK that segregated with the disease in eight sep. families.  Re-sequencing in 194 high-risk neuroblastoma samples showed somatically acquired mutations in the tyrosine kinase domain in 12.4% of samples.  Nine of the ten mutations map to crit. regions of the kinase domain and were predicted, with high probability, to be oncogenic drivers.  Mutations resulted in constitutive phosphorylation, and targeted knockdown of ALK mRNA resulted in profound inhibition of growth in all cell lines harboring mutant or amplified ALK, as well as in two out of six wild-type cell lines for ALK.  Our results demonstrate that heritable mutations of ALK are the main cause of familial neuroblastoma, and that germline or acquired activation of this cell-surface kinase is a tractable therapeutic target for this lethal pediatric malignancy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMNOcIFf5xjbVg90H21EOLACvtfcHk0lgbbHsiehvz5Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht1Ggur%252FP&md5=bb998ef8f6bfbd85f928263e13954ce4</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1038%2Fnature07261&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature07261%26sid%3Dliteratum%253Aachs%26aulast%3DMosse%26aufirst%3DY.%2BP.%26aulast%3DLaudenslager%26aufirst%3DM.%26aulast%3DLongo%26aufirst%3DL.%26aulast%3DCole%26aufirst%3DK.%2BA.%26aulast%3DWood%26aufirst%3DA.%26aulast%3DAttiyeh%26aufirst%3DE.%2BF.%26aulast%3DLaquaglia%26aufirst%3DM.%2BJ.%26aulast%3DSennett%26aufirst%3DR.%26aulast%3DLynch%26aufirst%3DJ.%2BE.%26aulast%3DPerri%26aufirst%3DP.%26aulast%3DLaureys%26aufirst%3DG.%26aulast%3DSpeleman%26aufirst%3DF.%26aulast%3DKim%26aufirst%3DC.%26aulast%3DHou%26aufirst%3DC.%26aulast%3DHakonarson%26aufirst%3DH.%26aulast%3DTorkamani%26aufirst%3DA.%26aulast%3DSchork%26aufirst%3DN.%2BJ.%26aulast%3DBrodeur%26aufirst%3DG.%2BM.%26aulast%3DTonini%26aufirst%3DG.%2BP.%26aulast%3DRappaport%26aufirst%3DE.%26aulast%3DDevoto%26aufirst%3DM.%26aulast%3DMaris%26aufirst%3DJ.%2BM.%26atitle%3DIdentification%2520of%2520ALK%2520as%2520a%2520Major%2520Familial%2520Neuroblastoma%2520Predisposition%2520Gene%26jtitle%3DNature%26date%3D2008%26volume%3D455%26spage%3D930%26epage%3D935%26doi%3D10.1038%2Fnature07261" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Murugan, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xing, M.</span></span> <span> </span><span class="NLM_article-title">Anaplastic Thyroid Cancers Harbor Novel Oncogenic Mutations of the ALK Gene</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">4403</span>– <span class="NLM_lpage">4411</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-10-4041</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1158%2F0008-5472.CAN-10-4041" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=21596819" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC3MXotlersb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2011&pages=4403-4411&author=A.+K.+Muruganauthor=M.+Xing&title=Anaplastic+Thyroid+Cancers+Harbor+Novel+Oncogenic+Mutations+of+the+ALK+Gene&doi=10.1158%2F0008-5472.CAN-10-4041"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Anaplastic Thyroid Cancers Harbor Novel Oncogenic Mutations of the ALK Gene</span></div><div class="casAuthors">Murugan, Avaniyapuram Kannan; Xing, Mingzhao</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">4403-4411</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Thyroid cancer is the most common endocrine cancer, and targeted approaches to treat it pose considerable interest.  In this study, the authors report the discovery of ALK gene mutations in thyroid cancer that may rationalize clin. evaluation of anaplastic lymphoma kinase (ALK) inhibitors in this setting.  In undifferentiated anaplastic thyroid cancer (ATC), the authors identified 2 novel point mutations, C3592T and G3602A, in exon 23 of the ALK gene, with a prevalence of 11.11%, but found no mutations in the matched normal tissues or in well-differentiated thyroid cancers.  These 2 mutations, resulting in L1198F and G1201E amino acid changes, resp., both reside within the ALK tyrosine kinase domain where they dramatically increased tyrosine kinase activities.  Similarly, these mutations heightened the ability of ALK to activate the phosphatidylinositol 3-kinase (PI3K)/Akt and mitogen-activated protein (MAP) kinase pathways in established mouse cells.  Further investigations showed that these 2 ALK mutants strongly promoted cell focus formation, anchorage-independent growth, and cell invasion.  Similar oncogenic properties were obsd. in the neuroblastoma-assocd. ALK mutants K1062M and F1174L but not in wild-type ALK.  Overall, the authors' results reveal 2 novel gain-of-function mutations of ALK in certain ATCs, and they suggest efforts to clin. evaluate the use of ALK kinase inhibitors to treat patients who harbor ATCs with these mutations.  Cancer Res; 71(13); 4403-11.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLyuBgJ52gn7Vg90H21EOLACvtfcHk0lgbbHsiehvz5Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXotlersb4%253D&md5=0316be9945baab3a8d08b6c75e2cd90f</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-10-4041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-10-4041%26sid%3Dliteratum%253Aachs%26aulast%3DMurugan%26aufirst%3DA.%2BK.%26aulast%3DXing%26aufirst%3DM.%26atitle%3DAnaplastic%2520Thyroid%2520Cancers%2520Harbor%2520Novel%2520Oncogenic%2520Mutations%2520of%2520the%2520ALK%2520Gene%26jtitle%3DCancer%2520Res.%26date%3D2011%26volume%3D71%26spage%3D4403%26epage%3D4411%26doi%3D10.1158%2F0008-5472.CAN-10-4041" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ren, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, Z.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crosby, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haack, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, J.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beausoleil, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moritz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Innocenti, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rush, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, X.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, T.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Comb, M. J.</span></span> <span> </span><span class="NLM_article-title">Identification of Anaplastic Lymphoma Kinase as a Potential Therapeutic Target in Ovarian Cancer</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>72</i></span>,  <span class="NLM_fpage">3312</span>– <span class="NLM_lpage">3323</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-11-3931</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1158%2F0008-5472.CAN-11-3931" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=22570254" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC38XpsFKku7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2012&pages=3312-3323&author=H.+Renauthor=Z.-P.+Tanauthor=X.+Zhuauthor=K.+Crosbyauthor=H.+Haackauthor=J.-M.+Renauthor=S.+Beausoleilauthor=A.+Moritzauthor=G.+Innocentiauthor=J.+Rushauthor=Y.+Zhangauthor=X.-M.+Zhouauthor=T.-L.+Guauthor=Y.-F.+Yangauthor=M.+J.+Comb&title=Identification+of+Anaplastic+Lymphoma+Kinase+as+a+Potential+Therapeutic+Target+in+Ovarian+Cancer&doi=10.1158%2F0008-5472.CAN-11-3931"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of Anaplastic Lymphoma Kinase as a Potential Therapeutic Target in Ovarian Cancer</span></div><div class="casAuthors">Ren, Hong; Tan, Zhi-Ping; Zhu, Xin; Crosby, Katherine; Haack, Herbert; Ren, Jian-Min; Beausoleil, Sean; Moritz, Albrecht; Innocenti, Gregory; Rush, John; Zhang, Yi; Zhou, Xin-Min; Gu, Ting-Lei; Yang, Yi-Feng; Comb, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3312-3323</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Findings suggest the use of ALK kinase inhibitors now in clin. development as potential agents for treatment of some patients with serous ovarian carcinoma or stromal sarcoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoi924EZXGeJ7Vg90H21EOLACvtfcHk0lgbbHsiehvz5Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XpsFKku7w%253D&md5=a263a135244b307b864c098769d10a7a</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-11-3931&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-11-3931%26sid%3Dliteratum%253Aachs%26aulast%3DRen%26aufirst%3DH.%26aulast%3DTan%26aufirst%3DZ.-P.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DCrosby%26aufirst%3DK.%26aulast%3DHaack%26aufirst%3DH.%26aulast%3DRen%26aufirst%3DJ.-M.%26aulast%3DBeausoleil%26aufirst%3DS.%26aulast%3DMoritz%26aufirst%3DA.%26aulast%3DInnocenti%26aufirst%3DG.%26aulast%3DRush%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DX.-M.%26aulast%3DGu%26aufirst%3DT.-L.%26aulast%3DYang%26aufirst%3DY.-F.%26aulast%3DComb%26aufirst%3DM.%2BJ.%26atitle%3DIdentification%2520of%2520Anaplastic%2520Lymphoma%2520Kinase%2520as%2520a%2520Potential%2520Therapeutic%2520Target%2520in%2520Ovarian%2520Cancer%26jtitle%3DCancer%2520Res.%26date%3D2012%26volume%3D72%26spage%3D3312%26epage%3D3323%26doi%3D10.1158%2F0008-5472.CAN-11-3931" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cui, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tran-Dube, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nambu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kung, P.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pairish, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Funk, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Botrous, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McTigue, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grodsky, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Padrique, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alton, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timofeevski, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamazaki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christensen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mroczkowski, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bender, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kania, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, M. P.</span></span> <span> </span><span class="NLM_article-title">Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective dual Inhibitor of Mesenchymal–Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">6342</span>– <span class="NLM_lpage">6363</span>, <span class="refDoi"> DOI: 10.1021/jm2007613</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm2007613" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtVegtLrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=6342-6363&author=J.+J.+Cuiauthor=M.+Tran-Dubeauthor=H.+Shenauthor=M.+Nambuauthor=P.-P.+Kungauthor=M.+Pairishauthor=L.+Jiaauthor=J.+Mengauthor=L.+Funkauthor=I.+Botrousauthor=M.+McTigueauthor=N.+Grodskyauthor=K.+Ryanauthor=E.+Padriqueauthor=G.+Altonauthor=S.+Timofeevskiauthor=S.+Yamazakiauthor=Q.+Liauthor=H.+Zouauthor=J.+Christensenauthor=B.+Mroczkowskiauthor=S.+Benderauthor=R.+S.+Kaniaauthor=M.+P.+Edwards&title=Structure+Based+Drug+Design+of+Crizotinib+%28PF-02341066%29%2C+a+Potent+and+Selective+dual+Inhibitor+of+Mesenchymal%E2%80%93Epithelial+Transition+Factor+%28c-MET%29+Kinase+and+Anaplastic+Lymphoma+Kinase+%28ALK%29&doi=10.1021%2Fjm2007613"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal-Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)</span></div><div class="casAuthors">Cui, J. Jean; Tran-Dube, Michelle; Shen, Hong; Nambu, Mitchell; Kung, Pei-Pei; Pairish, Mason; Jia, Lei; Meng, Jerry; Funk, Lee; Botrous, Iriny; McTigue, Michele; Grodsky, Neil; Ryan, Kevin; Padrique, Ellen; Alton, Gordon; Timofeevski, Sergei; Yamazaki, Shinji; Li, Qiuhua; Zou, Helen; Christensen, James; Mroczkowski, Barbara; Bender, Steve; Kania, Robert S.; Edwards, Martin P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">6342-6363</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Because of the crit. roles of aberrant signaling in cancer, both c-MET and ALK receptor tyrosine kinases are attractive oncol. targets for therapeutic intervention.  The cocrystal structure of 3 (PHA-665752), bound to c-MET kinase domain, revealed a novel ATP site environment, which served as the target to guide parallel, multiattribute drug design.  A novel 2-amino-5-aryl-3-benzyloxypyridine series was created to more effectively make the key interactions achieved with 3.  In the novel series, the 2-aminopyridine core allowed a 3-benzyloxy group to reach into the same pocket as the 2,6-dichlorophenyl group of 3 via a more direct vector and thus with a better ligand efficiency (LE).  Further optimization of the lead series generated the clin. candidate crizotinib (PF-02341066), which demonstrated potent in vitro and in vivo c-MET kinase and ALK inhibition, effective tumor growth inhibition, and good pharmaceutical properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHs_cKJ-U3t7Vg90H21EOLACvtfcHk0lhZD3PDIpzyeA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtVegtLrN&md5=dbab4c1b3e7c76180dbad04be2b6a474</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Fjm2007613&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm2007613%26sid%3Dliteratum%253Aachs%26aulast%3DCui%26aufirst%3DJ.%2BJ.%26aulast%3DTran-Dube%26aufirst%3DM.%26aulast%3DShen%26aufirst%3DH.%26aulast%3DNambu%26aufirst%3DM.%26aulast%3DKung%26aufirst%3DP.-P.%26aulast%3DPairish%26aufirst%3DM.%26aulast%3DJia%26aufirst%3DL.%26aulast%3DMeng%26aufirst%3DJ.%26aulast%3DFunk%26aufirst%3DL.%26aulast%3DBotrous%26aufirst%3DI.%26aulast%3DMcTigue%26aufirst%3DM.%26aulast%3DGrodsky%26aufirst%3DN.%26aulast%3DRyan%26aufirst%3DK.%26aulast%3DPadrique%26aufirst%3DE.%26aulast%3DAlton%26aufirst%3DG.%26aulast%3DTimofeevski%26aufirst%3DS.%26aulast%3DYamazaki%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DZou%26aufirst%3DH.%26aulast%3DChristensen%26aufirst%3DJ.%26aulast%3DMroczkowski%26aufirst%3DB.%26aulast%3DBender%26aufirst%3DS.%26aulast%3DKania%26aufirst%3DR.%2BS.%26aulast%3DEdwards%26aufirst%3DM.%2BP.%26atitle%3DStructure%2520Based%2520Drug%2520Design%2520of%2520Crizotinib%2520%2528PF-02341066%2529%252C%2520a%2520Potent%2520and%2520Selective%2520dual%2520Inhibitor%2520of%2520Mesenchymal%25E2%2580%2593Epithelial%2520Transition%2520Factor%2520%2528c-MET%2529%2520Kinase%2520and%2520Anaplastic%2520Lymphoma%2520Kinase%2520%2528ALK%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D6342%26epage%3D6363%26doi%3D10.1021%2Fjm2007613" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Krause, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Etten, R. A.</span></span> <span> </span><span class="NLM_article-title">Tyrosine Kinases as Targets for Cancer Therapy</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>353</i></span>,  <span class="NLM_fpage">172</span>– <span class="NLM_lpage">187</span>, <span class="refDoi"> DOI: 10.1056/NEJMra044389</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1056%2FNEJMra044389" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=16014887" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BD2MXmtFClsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=353&publication_year=2005&pages=172-187&author=D.+S.+Krauseauthor=R.+A.+Van+Etten&title=Tyrosine+Kinases+as+Targets+for+Cancer+Therapy&doi=10.1056%2FNEJMra044389"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Tyrosine kinases as targets for cancer therapy</span></div><div class="casAuthors">Krause, Daniela S.; Van Etten, Richard A.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">353</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">172-187</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">A review discusses the mechanisms of aberrant tyrosine kinase signaling and strategies to inhibit TKs in cancer.  It also summarizes the status of TK-directed cancer therapies, and discusses challenges and prospects for the future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq89QOl9E0UMLVg90H21EOLACvtfcHk0liZ2OzKK9Erpg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXmtFClsbs%253D&md5=0a98c8840a983300f6b0743673cf480c</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1056%2FNEJMra044389&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMra044389%26sid%3Dliteratum%253Aachs%26aulast%3DKrause%26aufirst%3DD.%2BS.%26aulast%3DVan%2BEtten%26aufirst%3DR.%2BA.%26atitle%3DTyrosine%2520Kinases%2520as%2520Targets%2520for%2520Cancer%2520Therapy%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2005%26volume%3D353%26spage%3D172%26epage%3D187%26doi%3D10.1056%2FNEJMra044389" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roskoski, R.,  Jr</span></span> <span> </span><span class="NLM_article-title">Anaplastic Lymphoma Kinase (ALK) Inhibitors in the Treatment of ALK-driven Lung Cancers</span>. <i>Pharmacol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>117</i></span>,  <span class="NLM_fpage">343</span>– <span class="NLM_lpage">356</span>, <span class="refDoi"> DOI: 10.1016/j.phrs.2017.01.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1016%2Fj.phrs.2017.01.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=28077299" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlaktbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=117&publication_year=2017&pages=343-356&author=R.+Roskoski&title=Anaplastic+Lymphoma+Kinase+%28ALK%29+Inhibitors+in+the+Treatment+of+ALK-driven+Lung+Cancers&doi=10.1016%2Fj.phrs.2017.01.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Anaplastic lymphoma kinase (ALK) inhibitors in the treatment of ALK-driven lung cancers</span></div><div class="casAuthors">Roskoski, Robert, Jr.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">117</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">343-356</span>CODEN:
                <span class="NLM_cas:coden">PHMREP</span>;
        ISSN:<span class="NLM_cas:issn">1043-6618</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Anaplastic lymphoma kinase is expressed in two-thirds of the anaplastic large-cell lymphomas as an NPM-ALK fusion protein.  Physiol. ALK is a receptor protein-tyrosine kinase within the insulin receptor superfamily of proteins that participates in nervous system development.  The EML4-ALK fusion protein and four other ALK-fusion proteins play a fundamental role in the development in about 5% of non-small cell lung cancers.  The amino-terminal portions of the ALK fusion proteins result in dimerization and subsequent activation of the ALK protein kinase domain that plays a key role in the pathogenesis of various tumors.  Downstream signaling from the ALK fusion protein leads to the activation of the Ras/Raf/MEK/ERK1/2 cell proliferation module and the JAK/STAT cell survival pathways.  Moreover, nearly two dozen ALK activating mutations are involved in the pathogenesis of childhood neuroblastomas.  The occurrence of oncogenic ALK-fusion proteins, particularly in non-small cell lung cancer, has fostered considerable interest in the development of ALK inhibitors.  Crizotinib was the first such inhibitor approved by the US Food and Drug Administration for the treatment of ALK-pos. non-small cell lung cancer in 2011.  The median time for the emergence of crizotinib drug resistance is 10.5 mo after the initiation of therapy.  Such resistance prompted the development of second-generation drugs including ceritinib and alectinib, which are approved for the treatment of non-small cell lung cancer.  Unlike the single gatekeeper mutation that occurs in drug-resistant epidermal growth factor receptor in lung cancer, nearly a dozen different mutations in the catalytic domain of ALK fusion proteins have been discovered that result in crizotinib resistance.  Crizotinib, ceritinib, and alectinib form a complex within the front cleft between the small and large lobes of an inactive ALK protein-kinase domain with a compact activation segment.  These drugs are classified as type I1/2 B inhibitors because they bind to an inactive enzyme and they do not extend past the gatekeeper into the back pocket of the drug binding site.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoq0rrYNRqutrVg90H21EOLACvtfcHk0lgswANJEoK_pA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlaktbo%253D&md5=49200353921714b975e564df79631578</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.phrs.2017.01.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.phrs.2017.01.007%26sid%3Dliteratum%253Aachs%26aulast%3DRoskoski%26aufirst%3DR.%26atitle%3DAnaplastic%2520Lymphoma%2520Kinase%2520%2528ALK%2529%2520Inhibitors%2520in%2520the%2520Treatment%2520of%2520ALK-driven%2520Lung%2520Cancers%26jtitle%3DPharmacol.%2520Res.%26date%3D2017%26volume%3D117%26spage%3D343%26epage%3D356%26doi%3D10.1016%2Fj.phrs.2017.01.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marsilje, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pei, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uno, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warmuth, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarkisova, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steffy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pferdekamper, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joseph, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuntland, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steensma, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chopiuk, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, W. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richmond, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groessl, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, Y.-Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phimister, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aycinena, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bursulaya, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karanewsky, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seidel, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michellys, P.-Y.</span></span> <span> </span><span class="NLM_article-title">Synthesis, Structure–activity Relationships, and in Vivo Efficacy of the Novel Potent and Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor 5-Chloro-N 2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl) phenyl)-N 4-(2-(isopropylsulfonyl) phenyl) Pyrimidine-2, 4-diamine (LDK378) Currently in Phase 1 and Phase 2 Clinical Trials</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">5675</span>– <span class="NLM_lpage">5690</span>, <span class="refDoi"> DOI: 10.1021/jm400402q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400402q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC3sXptVWjs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=5675-5690&author=T.+H.+Marsiljeauthor=W.+Peiauthor=B.+Chenauthor=W.+Luauthor=T.+Unoauthor=Y.+Jinauthor=T.+Jiangauthor=S.+Kimauthor=N.+Liauthor=M.+Warmuthauthor=Y.+Sarkisovaauthor=F.+Sunauthor=A.+Steffyauthor=A.+C.+Pferdekamperauthor=A.+G.+Liauthor=S.+B.+Josephauthor=Y.+Kimauthor=B.+Liuauthor=T.+Tuntlandauthor=X.+Cuiauthor=N.+S.+Grayauthor=R.+Steensmaauthor=Y.+Wanauthor=J.+Jiangauthor=G.+Chopiukauthor=J.+Liauthor=W.+P.+Gordonauthor=W.+Richmondauthor=K.+Johnsonauthor=J.+Changauthor=T.+Groesslauthor=Y.-Q.+Heauthor=A.+Phimisterauthor=A.+Aycinenaauthor=C.+C.+Leeauthor=B.+Bursulayaauthor=D.+S.+Karanewskyauthor=H.+M.+Seidelauthor=J.+L.+Harrisauthor=P.-Y.+Michellys&title=Synthesis%2C+Structure%E2%80%93activity+Relationships%2C+and+in+Vivo+Efficacy+of+the+Novel+Potent+and+Selective+Anaplastic+Lymphoma+Kinase+%28ALK%29+Inhibitor+5-Chloro-N+2-%282-isopropoxy-5-methyl-4-%28piperidin-4-yl%29+phenyl%29-N+4-%282-%28isopropylsulfonyl%29+phenyl%29+Pyrimidine-2%2C+4-diamine+%28LDK378%29+Currently+in+Phase+1+and+Phase+2+Clinical+Trials&doi=10.1021%2Fjm400402q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis, Structure-Activity Relationships, and in Vivo Efficacy of the Novel Potent and Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor 5-Chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) Currently in Phase 1 and Phase 2 Clinical Trials</span></div><div class="casAuthors">Marsilje, Thomas H.; Pei, Wei; Chen, Bei; Lu, Wenshuo; Uno, Tetsuo; Jin, Yunho; Jiang, Tao; Kim, Sungjoon; Li, Nanxin; Warmuth, Markus; Sarkisova, Yelena; Sun, Frank; Steffy, Auzon; Pferdekamper, AnneMarie C.; Li, Allen G.; Joseph, Sean B.; Kim, Young; Liu, Bo; Tuntland, Tove; Cui, Xiaoming; Gray, Nathanael S.; Steensma, Ruo; Wan, Yongqin; Jiang, Jiqing; Chopiuk, Greg; Li, Jie; Gordon, W. Perry; Richmond, Wendy; Johnson, Kevin; Chang, Jonathan; Groessl, Todd; He, You-Qun; Phimister, Andrew; Aycinena, Alex; Lee, Christian C.; Bursulaya, Badry; Karanewsky, Donald S.; Seidel, H. Martin; Harris, Jennifer L.; Michellys, Pierre-Yves</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">5675-5690</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The synthesis, preclin. profile, and in vivo efficacy in rat xenograft models of the novel and selective anaplastic lymphoma kinase inhibitor (I; LDK378) are described.  In this initial report, preliminary structure-activity relationships (SARs) are described as well as the rational design strategy employed to overcome the development deficiencies of the first generation ALK inhibitor (II; TAE684).  Compd. I is currently in phase 1 and phase 2 clin. trials with substantial antitumor activity being obsd. in ALK-pos. cancer patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZ-y7ZuX2XLLVg90H21EOLACvtfcHk0lgswANJEoK_pA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXptVWjs7g%253D&md5=4b8f66e4acb27efe814956d7d0016068</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Fjm400402q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400402q%26sid%3Dliteratum%253Aachs%26aulast%3DMarsilje%26aufirst%3DT.%2BH.%26aulast%3DPei%26aufirst%3DW.%26aulast%3DChen%26aufirst%3DB.%26aulast%3DLu%26aufirst%3DW.%26aulast%3DUno%26aufirst%3DT.%26aulast%3DJin%26aufirst%3DY.%26aulast%3DJiang%26aufirst%3DT.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DN.%26aulast%3DWarmuth%26aufirst%3DM.%26aulast%3DSarkisova%26aufirst%3DY.%26aulast%3DSun%26aufirst%3DF.%26aulast%3DSteffy%26aufirst%3DA.%26aulast%3DPferdekamper%26aufirst%3DA.%2BC.%26aulast%3DLi%26aufirst%3DA.%2BG.%26aulast%3DJoseph%26aufirst%3DS.%2BB.%26aulast%3DKim%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DB.%26aulast%3DTuntland%26aufirst%3DT.%26aulast%3DCui%26aufirst%3DX.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DSteensma%26aufirst%3DR.%26aulast%3DWan%26aufirst%3DY.%26aulast%3DJiang%26aufirst%3DJ.%26aulast%3DChopiuk%26aufirst%3DG.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DGordon%26aufirst%3DW.%2BP.%26aulast%3DRichmond%26aufirst%3DW.%26aulast%3DJohnson%26aufirst%3DK.%26aulast%3DChang%26aufirst%3DJ.%26aulast%3DGroessl%26aufirst%3DT.%26aulast%3DHe%26aufirst%3DY.-Q.%26aulast%3DPhimister%26aufirst%3DA.%26aulast%3DAycinena%26aufirst%3DA.%26aulast%3DLee%26aufirst%3DC.%2BC.%26aulast%3DBursulaya%26aufirst%3DB.%26aulast%3DKaranewsky%26aufirst%3DD.%2BS.%26aulast%3DSeidel%26aufirst%3DH.%2BM.%26aulast%3DHarris%26aufirst%3DJ.%2BL.%26aulast%3DMichellys%26aufirst%3DP.-Y.%26atitle%3DSynthesis%252C%2520Structure%25E2%2580%2593activity%2520Relationships%252C%2520and%2520in%2520Vivo%2520Efficacy%2520of%2520the%2520Novel%2520Potent%2520and%2520Selective%2520Anaplastic%2520Lymphoma%2520Kinase%2520%2528ALK%2529%2520Inhibitor%25205-Chloro-N%25202-%25282-isopropoxy-5-methyl-4-%2528piperidin-4-yl%2529%2520phenyl%2529-N%25204-%25282-%2528isopropylsulfonyl%2529%2520phenyl%2529%2520Pyrimidine-2%252C%25204-diamine%2520%2528LDK378%2529%2520Currently%2520in%2520Phase%25201%2520and%2520Phase%25202%2520Clinical%2520Trials%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D5675%26epage%3D5690%26doi%3D10.1021%2Fjm400402q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kinoshita, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobayashi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asoh, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furuichi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawada, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hara, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohwada, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hattori, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyagi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, W.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, M.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takanashi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsukaguchi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakamoto, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsukuda, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oikawa, N.</span></span> <span> </span><span class="NLM_article-title">9-substituted 6, 6-dimethyl-11-oxo-6, 11-dihydro-5 H-benzo [b] carbazoles as Highly Selective and Potent Anaplastic Lymphoma Kinase Inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">6286</span>– <span class="NLM_lpage">6294</span>, <span class="refDoi"> DOI: 10.1021/jm200652u</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm200652u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtVOns7vP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=6286-6294&author=K.+Kinoshitaauthor=T.+Kobayashiauthor=K.+Asohauthor=N.+Furuichiauthor=T.+Itoauthor=H.+Kawadaauthor=S.+Haraauthor=J.+Ohwadaauthor=K.+Hattoriauthor=T.+Miyagiauthor=W.-S.+Hongauthor=M.-J.+Parkauthor=K.+Takanashiauthor=T.+Tsukaguchiauthor=H.+Sakamotoauthor=T.+Tsukudaauthor=N.+Oikawa&title=9-substituted+6%2C+6-dimethyl-11-oxo-6%2C+11-dihydro-5+H-benzo+%5Bb%5D+carbazoles+as+Highly+Selective+and+Potent+Anaplastic+Lymphoma+Kinase+Inhibitors&doi=10.1021%2Fjm200652u"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">9-Substituted 6,6-Dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazoles as Highly Selective and Potent Anaplastic Lymphoma Kinase Inhibitors</span></div><div class="casAuthors">Kinoshita, Kazutomo; Kobayashi, Takamitsu; Asoh, Kohsuke; Furuichi, Noriyuki; Ito, Toshiya; Kawada, Hatsuo; Hara, Sousuke; Ohwada, Jun; Hattori, Kazuo; Miyagi, Takuho; Hong, Woo-Sang; Park, Min-Jeong; Takanashi, Kenji; Tsukaguchi, Toshiyuki; Sakamoto, Hiroshi; Tsukuda, Takuo; Oikawa, Nobuhiro</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">6286-6294</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">9-Substituted 6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazoles were discovered as highly selective and potent anaplastic lymphoma kinase (ALK) inhibitors by structure-based drug design.  The high target selectivity was achieved by introducing a substituent close to the E0 region of the ATP binding site, which has a unique amino acid sequence.  Among the identified inhibitors, compd. 13d (I) showed highly selective and potent inhibitory activity against ALK with an IC50 value of 2.9 nM and strong antiproliferative activity against KARPAS-299 with an IC50 value of 12.8 nM.  The compd. also displayed significant antitumor efficacy in an established ALK fusion gene-pos. anaplastic large-cell lymphoma (ALCL) xenograft model in mice without body wt. loss.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrfpJsdIdDvO7Vg90H21EOLACvtfcHk0ljI8Lx2yJzZPw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtVOns7vP&md5=6293368243c840e12beefc8c8d6bb69a</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Fjm200652u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200652u%26sid%3Dliteratum%253Aachs%26aulast%3DKinoshita%26aufirst%3DK.%26aulast%3DKobayashi%26aufirst%3DT.%26aulast%3DAsoh%26aufirst%3DK.%26aulast%3DFuruichi%26aufirst%3DN.%26aulast%3DIto%26aufirst%3DT.%26aulast%3DKawada%26aufirst%3DH.%26aulast%3DHara%26aufirst%3DS.%26aulast%3DOhwada%26aufirst%3DJ.%26aulast%3DHattori%26aufirst%3DK.%26aulast%3DMiyagi%26aufirst%3DT.%26aulast%3DHong%26aufirst%3DW.-S.%26aulast%3DPark%26aufirst%3DM.-J.%26aulast%3DTakanashi%26aufirst%3DK.%26aulast%3DTsukaguchi%26aufirst%3DT.%26aulast%3DSakamoto%26aufirst%3DH.%26aulast%3DTsukuda%26aufirst%3DT.%26aulast%3DOikawa%26aufirst%3DN.%26atitle%3D9-substituted%25206%252C%25206-dimethyl-11-oxo-6%252C%252011-dihydro-5%2520H-benzo%2520%255Bb%255D%2520carbazoles%2520as%2520Highly%2520Selective%2520and%2520Potent%2520Anaplastic%2520Lymphoma%2520Kinase%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D6286%26epage%3D6294%26doi%3D10.1021%2Fjm200652u" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, W.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romero, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohlmann, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dwight, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dodd, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toms, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parillon, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anjum, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keats, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wardwell, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ning, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moran, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohemmad, Q. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jang, H. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clackson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narasimhan, N. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivera, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalgarno, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shakespeare, W. C.</span></span> <span> </span><span class="NLM_article-title">Discovery of Brigatinib (AP26113), a Phosphine Oxide-containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma Kinase</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">4948</span>– <span class="NLM_lpage">4964</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00306</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00306" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC28XntlCgur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=4948-4964&author=W.-S.+Huangauthor=S.+Liuauthor=D.+Zouauthor=M.+Thomasauthor=Y.+Wangauthor=T.+Zhouauthor=J.+Romeroauthor=A.+Kohlmannauthor=F.+Liauthor=J.+Qiauthor=L.+Caiauthor=T.+A.+Dwightauthor=Y.+Xuauthor=R.+Xuauthor=R.+Doddauthor=A.+Tomsauthor=L.+Parillonauthor=X.+Luauthor=R.+Anjumauthor=S.+Zhangauthor=F.+Wangauthor=J.+Keatsauthor=S.+D.+Wardwellauthor=Y.+Ningauthor=Q.+Xuauthor=L.+E.+Moranauthor=Q.+K.+Mohemmadauthor=H.+G.+Jangauthor=T.+Clacksonauthor=N.+I.+Narasimhanauthor=V.+M.+Riveraauthor=X.+Zhuauthor=D.+Dalgarnoauthor=W.+C.+Shakespeare&title=Discovery+of+Brigatinib+%28AP26113%29%2C+a+Phosphine+Oxide-containing%2C+Potent%2C+Orally+Active+Inhibitor+of+Anaplastic+Lymphoma+Kinase&doi=10.1021%2Facs.jmedchem.6b00306"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma Kinase</span></div><div class="casAuthors">Huang, Wei-Sheng; Liu, Shuangying; Zou, Dong; Thomas, Mathew; Wang, Yihan; Zhou, Tianjun; Romero, Jan; Kohlmann, Anna; Li, Feng; Qi, Jiwei; Cai, Lisi; Dwight, Timothy A.; Xu, Yongjin; Xu, Rongsong; Dodd, Rory; Toms, Angela; Parillon, Lois; Lu, Xiaohui; Anjum, Rana; Zhang, Sen; Wang, Frank; Keats, Jeffrey; Wardwell, Scott D.; Ning, Yaoyu; Xu, Qihong; Moran, Lauren E.; Mohemmad, Qurish K.; Jang, Hyun Gyung; Clackson, Tim; Narasimhan, Narayana I.; Rivera, Victor M.; Zhu, Xiaotian; Dalgarno, David; Shakespeare, William C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4948-4964</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In the treatment of echinoderm microtubule-assocd. protein-like 4 (EML4)-anaplastic lymphoma kinase pos. (ALK+) non-small-cell lung cancer (NSCLC), secondary mutations within the ALK kinase domain have emerged as a major resistance mechanism to both first- and second-generation ALK inhibitors.  This report describes the design and synthesis of a series of 2,4-diarylaminopyrimidine-based potent and selective ALK inhibitors culminating in identification of the investigational clin. candidate brigatinib.  A unique structural feature of brigatinib is a phosphine oxide, an overlooked but novel hydrogen-bond acceptor that drives potency and selectivity in addn. to favorable ADME properties.  Brigatinib displayed low nanomolar IC50s against native ALK and all tested clin. relevant ALK mutants in both enzyme-based biochem. and cell-based viability assays and demonstrated efficacy in multiple ALK+ xenografts in mice, including Karpas-299 (anaplastic large-cell lymphomas [ALCL]) and H3122 (NSCLC).  Brigatinib represents the most clin. advanced phosphine oxide-contg. drug candidate to date and is currently being evaluated in a global phase 2 registration trial.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5_iqprSA4QbVg90H21EOLACvtfcHk0ljI8Lx2yJzZPw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XntlCgur8%253D&md5=4cb93ff587579c97fda8aff0c7d43317</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00306%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DW.-S.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DZou%26aufirst%3DD.%26aulast%3DThomas%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DT.%26aulast%3DRomero%26aufirst%3DJ.%26aulast%3DKohlmann%26aufirst%3DA.%26aulast%3DLi%26aufirst%3DF.%26aulast%3DQi%26aufirst%3DJ.%26aulast%3DCai%26aufirst%3DL.%26aulast%3DDwight%26aufirst%3DT.%2BA.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DR.%26aulast%3DDodd%26aufirst%3DR.%26aulast%3DToms%26aufirst%3DA.%26aulast%3DParillon%26aufirst%3DL.%26aulast%3DLu%26aufirst%3DX.%26aulast%3DAnjum%26aufirst%3DR.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DKeats%26aufirst%3DJ.%26aulast%3DWardwell%26aufirst%3DS.%2BD.%26aulast%3DNing%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DQ.%26aulast%3DMoran%26aufirst%3DL.%2BE.%26aulast%3DMohemmad%26aufirst%3DQ.%2BK.%26aulast%3DJang%26aufirst%3DH.%2BG.%26aulast%3DClackson%26aufirst%3DT.%26aulast%3DNarasimhan%26aufirst%3DN.%2BI.%26aulast%3DRivera%26aufirst%3DV.%2BM.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DDalgarno%26aufirst%3DD.%26aulast%3DShakespeare%26aufirst%3DW.%2BC.%26atitle%3DDiscovery%2520of%2520Brigatinib%2520%2528AP26113%2529%252C%2520a%2520Phosphine%2520Oxide-containing%252C%2520Potent%252C%2520Orally%2520Active%2520Inhibitor%2520of%2520Anaplastic%2520Lymphoma%2520Kinase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D4948%26epage%3D4964%26doi%3D10.1021%2Facs.jmedchem.6b00306" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, P. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brooun, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deal, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, Y.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dinh, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engstrom, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kania, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kath, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lingardo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McTigue, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmer, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sach, N. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smeal, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timofeevski, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, M. P.</span></span> <span> </span><span class="NLM_article-title">Discovery of (10 R)-7-Amino-12-fluoro-2, 10, 16-trimethyl-15-oxo-10, 15, 16, 17-tetrahydro-2H-8, 4-(metheno) pyrazolo [4, 3-h][2, 5, 11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a Macrocyclic Inhibitor of Anaplastic Lymphoma Kinase (ALK) and c-ROS Oncogene 1 (ROS1) with Preclinical Brain Exposure and Broad-spectrum Potency against ALK-resistant mutations</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">4720</span>– <span class="NLM_lpage">4744</span>, <span class="refDoi"> DOI: 10.1021/jm500261q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500261q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC2cXnvVSgtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=4720-4744&author=T.+W.+Johnsonauthor=P.+F.+Richardsonauthor=S.+Baileyauthor=A.+Broounauthor=B.+J.+Burkeauthor=M.+R.+Collinsauthor=J.+J.+Cuiauthor=J.+G.+Dealauthor=Y.-L.+Dengauthor=D.+Dinhauthor=L.+D.+Engstromauthor=M.+Heauthor=J.+Hoffmanauthor=R.+L.+Hoffmanauthor=Q.+Huangauthor=R.+S.+Kaniaauthor=J.+C.+Kathauthor=H.+Lamauthor=J.+L.+Lamauthor=P.+T.+Leauthor=L.+Lingardoauthor=W.+Liuauthor=M.+McTigueauthor=C.+L.+Palmerauthor=N.+W.+Sachauthor=T.+Smealauthor=G.+L.+Smithauthor=A.+E.+Stewartauthor=S.+Timofeevskiauthor=H.+Zhuauthor=J.+Zhuauthor=H.+Y.+Zouauthor=M.+P.+Edwards&title=Discovery+of+%2810+R%29-7-Amino-12-fluoro-2%2C+10%2C+16-trimethyl-15-oxo-10%2C+15%2C+16%2C+17-tetrahydro-2H-8%2C+4-%28metheno%29+pyrazolo+%5B4%2C+3-h%5D%5B2%2C+5%2C+11%5D-benzoxadiazacyclotetradecine-3-carbonitrile+%28PF-06463922%29%2C+a+Macrocyclic+Inhibitor+of+Anaplastic+Lymphoma+Kinase+%28ALK%29+and+c-ROS+Oncogene+1+%28ROS1%29+with+Preclinical+Brain+Exposure+and+Broad-spectrum+Potency+against+ALK-resistant+mutations&doi=10.1021%2Fjm500261q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of (10R)-7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a Macrocyclic Inhibitor of Anaplastic Lymphoma Kinase (ALK) and c-ros Oncogene 1 (ROS1) with Preclinical Brain Exposure and Broad-Spectrum Potency against ALK-Resistant Mutations</span></div><div class="casAuthors">Johnson, Ted W.; Richardson, Paul F.; Bailey, Simon; Brooun, Alexei; Burke, Benjamin J.; Collins, Michael R.; Cui, J. Jean; Deal, Judith G.; Deng, Ya-Li; Dinh, Dac; Engstrom, Lars D.; He, Mingying; Hoffman, Jacqui; Hoffman, Robert L.; Huang, Qinhua; Kania, Robert S.; Kath, John C.; Lam, Hieu; Lam, Justine L.; Le, Phuong T.; Lingardo, Laura; Liu, Wei; McTigue, Michele; Palmer, Cynthia L.; Sach, Neal W.; Smeal, Tod; Smith, Graham L.; Stewart, Albert E.; Timofeevski, Sergei; Zhu, Huichun; Zhu, Jinjiang; Zou, Helen Y.; Edwards, Martin P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4720-4744</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Although crizotinib demonstrates robust efficacy in anaplastic lymphoma kinase (ALK)-pos. non-small-cell lung carcinoma patients, progression during treatment eventually develops.  Resistant patient samples revealed a variety of point mutations in the kinase domain of ALK, including the L1196M gatekeeper mutation.  In addn., some patients progress due to cancer metastasis in the brain.  Using structure-based drug design, lipophilic efficiency, and phys.-property-based optimization, highly potent macrocyclic ALK inhibitors were prepd. with good absorption, distribution, metab., and excretion (ADME), low propensity for p-glycoprotein 1-mediated efflux, and good passive permeability.  These structurally unusual macrocyclic inhibitors were potent against wild-type ALK and clin. reported ALK kinase domain mutations.  Significant synthetic challenges were overcome, utilizing novel transformations to enable the use of these macrocycles in drug discovery paradigms.  This work led to the discovery of 8k (PF-06463922), combining broad-spectrum potency, central nervous system ADME, and a high degree of kinase selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqXkb49ad31bVg90H21EOLACvtfcHk0ljOJXeuHFwzZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXnvVSgtL4%253D&md5=db21844f8e9a2f9ca5953bca56ad7b1c</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Fjm500261q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500261q%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DT.%2BW.%26aulast%3DRichardson%26aufirst%3DP.%2BF.%26aulast%3DBailey%26aufirst%3DS.%26aulast%3DBrooun%26aufirst%3DA.%26aulast%3DBurke%26aufirst%3DB.%2BJ.%26aulast%3DCollins%26aufirst%3DM.%2BR.%26aulast%3DCui%26aufirst%3DJ.%2BJ.%26aulast%3DDeal%26aufirst%3DJ.%2BG.%26aulast%3DDeng%26aufirst%3DY.-L.%26aulast%3DDinh%26aufirst%3DD.%26aulast%3DEngstrom%26aufirst%3DL.%2BD.%26aulast%3DHe%26aufirst%3DM.%26aulast%3DHoffman%26aufirst%3DJ.%26aulast%3DHoffman%26aufirst%3DR.%2BL.%26aulast%3DHuang%26aufirst%3DQ.%26aulast%3DKania%26aufirst%3DR.%2BS.%26aulast%3DKath%26aufirst%3DJ.%2BC.%26aulast%3DLam%26aufirst%3DH.%26aulast%3DLam%26aufirst%3DJ.%2BL.%26aulast%3DLe%26aufirst%3DP.%2BT.%26aulast%3DLingardo%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DMcTigue%26aufirst%3DM.%26aulast%3DPalmer%26aufirst%3DC.%2BL.%26aulast%3DSach%26aufirst%3DN.%2BW.%26aulast%3DSmeal%26aufirst%3DT.%26aulast%3DSmith%26aufirst%3DG.%2BL.%26aulast%3DStewart%26aufirst%3DA.%2BE.%26aulast%3DTimofeevski%26aufirst%3DS.%26aulast%3DZhu%26aufirst%3DH.%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DZou%26aufirst%3DH.%2BY.%26aulast%3DEdwards%26aufirst%3DM.%2BP.%26atitle%3DDiscovery%2520of%2520%252810%2520R%2529-7-Amino-12-fluoro-2%252C%252010%252C%252016-trimethyl-15-oxo-10%252C%252015%252C%252016%252C%252017-tetrahydro-2H-8%252C%25204-%2528metheno%2529%2520pyrazolo%2520%255B4%252C%25203-h%255D%255B2%252C%25205%252C%252011%255D-benzoxadiazacyclotetradecine-3-carbonitrile%2520%2528PF-06463922%2529%252C%2520a%2520Macrocyclic%2520Inhibitor%2520of%2520Anaplastic%2520Lymphoma%2520Kinase%2520%2528ALK%2529%2520and%2520c-ROS%2520Oncogene%25201%2520%2528ROS1%2529%2520with%2520Preclinical%2520Brain%2520Exposure%2520and%2520Broad-spectrum%2520Potency%2520against%2520ALK-resistant%2520mutations%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D4720%26epage%3D4744%26doi%3D10.1021%2Fjm500261q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bode, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choquette, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potashman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romero, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stellwagen, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teffera, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whittington, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Epstein, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emkey, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, V. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saffran, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drew, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merkel, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szilvassy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brake, R. L.</span></span> <span> </span><span class="NLM_article-title">The Discovery and Optimization of a Novel Class of Potent, Selective, and Orally Bioavailable Anaplastic Lymphoma Kinase (ALK) Inhibitors with Potential Utility for the Treatment of Cancer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">6523</span>– <span class="NLM_lpage">6540</span>, <span class="refDoi"> DOI: 10.1021/jm3005866</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm3005866" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC38XptF2hsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=6523-6540&author=R.+T.+Lewisauthor=C.+M.+Bodeauthor=D.+M.+Choquetteauthor=M.+Potashmanauthor=K.+Romeroauthor=J.+C.+Stellwagenauthor=Y.+Tefferaauthor=E.+Mooreauthor=D.+A.+Whittingtonauthor=H.+Chenauthor=L.+F.+Epsteinauthor=R.+Emkeyauthor=P.+S.+Andrewsauthor=V.+L.+Yuauthor=D.+C.+Saffranauthor=M.+Xuauthor=A.+Drewauthor=P.+Merkelauthor=S.+Szilvassyauthor=R.+L.+Brake&title=The+Discovery+and+Optimization+of+a+Novel+Class+of+Potent%2C+Selective%2C+and+Orally+Bioavailable+Anaplastic+Lymphoma+Kinase+%28ALK%29+Inhibitors+with+Potential+Utility+for+the+Treatment+of+Cancer&doi=10.1021%2Fjm3005866"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">The Discovery and Optimization of a Novel Class of Potent, Selective, and Orally Bioavailable Anaplastic Lymphoma Kinase (ALK) Inhibitors with Potential Utility for the Treatment of Cancer</span></div><div class="casAuthors">Lewis, Richard T.; Bode, Christiane M.; Choquette, Deborah M.; Potashman, Michele; Romero, Karina; Stellwagen, John C.; Teffera, Yohannes; Moore, Earl; Whittington, Douglas A.; Chen, Hao; Epstein, Linda F.; Emkey, Renee; Andrews, Paul S.; Yu, Violeta L.; Saffran, Douglas C.; Xu, Man; Drew, Allison; Merkel, Patricia; Szilvassy, Steven; Brake, Rachael L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">6523-6540</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A class of 2-acyliminobenzimidazoles has been developed as potent and selective inhibitors of anaplastic lymphoma kinase (ALK).  Structure based design facilitated the rapid development of structure-activity relationships (SAR) and the optimization of kinase selectivity.  Introduction of an optimally placed polar substituent was key to solving issues of metabolic stability and led to the development of potent, selective, orally bioavailable ALK inhibitors.  Compd. I [Ar = 3,5-F2Ph] achieved substantial tumor regression in an NPM-ALK driven murine tumor xenograft model when dosed qd.  Compd. I [Ar = 3,5-F2Ph, 4-FPh] show favorable potency and PK characteristics in preclin. species indicative of suitability for further development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDAwmBMVhyL7Vg90H21EOLACvtfcHk0ljOJXeuHFwzZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XptF2hsbo%253D&md5=a3c2f9e8dbf7d73319657e456bd45076</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Fjm3005866&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm3005866%26sid%3Dliteratum%253Aachs%26aulast%3DLewis%26aufirst%3DR.%2BT.%26aulast%3DBode%26aufirst%3DC.%2BM.%26aulast%3DChoquette%26aufirst%3DD.%2BM.%26aulast%3DPotashman%26aufirst%3DM.%26aulast%3DRomero%26aufirst%3DK.%26aulast%3DStellwagen%26aufirst%3DJ.%2BC.%26aulast%3DTeffera%26aufirst%3DY.%26aulast%3DMoore%26aufirst%3DE.%26aulast%3DWhittington%26aufirst%3DD.%2BA.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DEpstein%26aufirst%3DL.%2BF.%26aulast%3DEmkey%26aufirst%3DR.%26aulast%3DAndrews%26aufirst%3DP.%2BS.%26aulast%3DYu%26aufirst%3DV.%2BL.%26aulast%3DSaffran%26aufirst%3DD.%2BC.%26aulast%3DXu%26aufirst%3DM.%26aulast%3DDrew%26aufirst%3DA.%26aulast%3DMerkel%26aufirst%3DP.%26aulast%3DSzilvassy%26aufirst%3DS.%26aulast%3DBrake%26aufirst%3DR.%2BL.%26atitle%3DThe%2520Discovery%2520and%2520Optimization%2520of%2520a%2520Novel%2520Class%2520of%2520Potent%252C%2520Selective%252C%2520and%2520Orally%2520Bioavailable%2520Anaplastic%2520Lymphoma%2520Kinase%2520%2528ALK%2529%2520Inhibitors%2520with%2520Potential%2520Utility%2520for%2520the%2520Treatment%2520of%2520Cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D6523%26epage%3D6540%26doi%3D10.1021%2Fjm3005866" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ott, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Learn, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gingrich, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lisko, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curry, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mesaros, E. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghose, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quail, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dobrzanski, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albom, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angeles, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wells-Knecht, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aimone, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruckheimer, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandez, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ator, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruggeri, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dorsey, B. D.</span></span> <span> </span><span class="NLM_article-title">Discovery of Clinical Candidate CEP-37440, a Selective Inhibitor of Focal Adhesion Kinase (FAK) and Anaplastic Lymphoma Kinase (ALK)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">7478</span>– <span class="NLM_lpage">7496</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00487</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00487" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhtlaru77P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=7478-7496&author=G.+R.+Ottauthor=M.+Chengauthor=K.+S.+Learnauthor=J.+Wagnerauthor=D.+E.+Gingrichauthor=J.+G.+Liskoauthor=M.+Curryauthor=E.+F.+Mesarosauthor=A.+K.+Ghoseauthor=M.+R.+Quailauthor=W.+Wanauthor=L.+Luauthor=P.+Dobrzanskiauthor=M.+S.+Albomauthor=T.+S.+Angelesauthor=K.+Wells-Knechtauthor=Z.+Huangauthor=L.+D.+Aimoneauthor=E.+Bruckheimerauthor=N.+Andersonauthor=J.+Friedmanauthor=S.+V.+Fernandezauthor=M.+A.+Atorauthor=B.+A.+Ruggeriauthor=B.+D.+Dorsey&title=Discovery+of+Clinical+Candidate+CEP-37440%2C+a+Selective+Inhibitor+of+Focal+Adhesion+Kinase+%28FAK%29+and+Anaplastic+Lymphoma+Kinase+%28ALK%29&doi=10.1021%2Facs.jmedchem.6b00487"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Clinical Candidate CEP-37440, a Selective Inhibitor of Focal Adhesion Kinase (FAK) and Anaplastic Lymphoma Kinase (ALK)</span></div><div class="casAuthors">Ott, Gregory R.; Cheng, Mangeng; Learn, Keith S.; Wagner, Jason; Gingrich, Diane E.; Lisko, Joseph G.; Curry, Matthew; Mesaros, Eugen F.; Ghose, Arup K.; Quail, Matthew R.; Wan, Weihua; Lu, Lihui; Dobrzanski, Pawel; Albom, Mark S.; Angeles, Thelma S.; Wells-Knecht, Kevin; Huang, Zeqi; Aimone, Lisa D.; Bruckheimer, Elizabeth; Anderson, Nathan; Friedman, Jay; Fernandez, Sandra V.; Ator, Mark A.; Ruggeri, Bruce A.; Dorsey, Bruce D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">7478-7496</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Analogs structurally related to anaplastic lymphoma kinase (ALK) inhibitor (CEP-28122) were optimized for metabolic stability.  The results from this endeavor not only led to improved metabolic stability, pharmacokinetic parameters, and in vitro activity against clin. derived resistance mutations but also led to the incorporation of activity for focal adhesion kinase (FAK).  FAK activation, via amplification and/or overexpression, is characteristic of multiple invasive solid tumors and metastasis.  The discovery of the clin. stage, dual FAK/ALK inhibitor 27b (CEP-37440), including details surrounding SAR, in vitro/in vivo pharmacol., and pharmacokinetics, is reported herein.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9Ojryum63_LVg90H21EOLACvtfcHk0lgbVHFggT5v4w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhtlaru77P&md5=3fcd1342d901b2379d0efbd118d3049f</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00487&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00487%26sid%3Dliteratum%253Aachs%26aulast%3DOtt%26aufirst%3DG.%2BR.%26aulast%3DCheng%26aufirst%3DM.%26aulast%3DLearn%26aufirst%3DK.%2BS.%26aulast%3DWagner%26aufirst%3DJ.%26aulast%3DGingrich%26aufirst%3DD.%2BE.%26aulast%3DLisko%26aufirst%3DJ.%2BG.%26aulast%3DCurry%26aufirst%3DM.%26aulast%3DMesaros%26aufirst%3DE.%2BF.%26aulast%3DGhose%26aufirst%3DA.%2BK.%26aulast%3DQuail%26aufirst%3DM.%2BR.%26aulast%3DWan%26aufirst%3DW.%26aulast%3DLu%26aufirst%3DL.%26aulast%3DDobrzanski%26aufirst%3DP.%26aulast%3DAlbom%26aufirst%3DM.%2BS.%26aulast%3DAngeles%26aufirst%3DT.%2BS.%26aulast%3DWells-Knecht%26aufirst%3DK.%26aulast%3DHuang%26aufirst%3DZ.%26aulast%3DAimone%26aufirst%3DL.%2BD.%26aulast%3DBruckheimer%26aufirst%3DE.%26aulast%3DAnderson%26aufirst%3DN.%26aulast%3DFriedman%26aufirst%3DJ.%26aulast%3DFernandez%26aufirst%3DS.%2BV.%26aulast%3DAtor%26aufirst%3DM.%2BA.%26aulast%3DRuggeri%26aufirst%3DB.%2BA.%26aulast%3DDorsey%26aufirst%3DB.%2BD.%26atitle%3DDiscovery%2520of%2520Clinical%2520Candidate%2520CEP-37440%252C%2520a%2520Selective%2520Inhibitor%2520of%2520Focal%2520Adhesion%2520Kinase%2520%2528FAK%2529%2520and%2520Anaplastic%2520Lymphoma%2520Kinase%2520%2528ALK%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D7478%26epage%3D7496%26doi%3D10.1021%2Facs.jmedchem.6b00487" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mori, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ueno, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konagai, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fushiki, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimada, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kondoh, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saito, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mori, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shindou, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soga, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakagami, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furutani, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doihara, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kudoh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuromitsu, S.</span></span> <span> </span><span class="NLM_article-title">The Selective Anaplastic Lymphoma Receptor Tyrosine Kinase Inhibitor ASP3026 Induces Tumor Regression and Prolongs Survival in Non-small Cell Lung Cancer Model Mice</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">329</span>– <span class="NLM_lpage">340</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-13-0395</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1158%2F1535-7163.MCT-13-0395" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=24419060" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFWmsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=329-340&author=M.+Moriauthor=Y.+Uenoauthor=S.+Konagaiauthor=H.+Fushikiauthor=I.+Shimadaauthor=Y.+Kondohauthor=R.+Saitoauthor=K.+Moriauthor=N.+Shindouauthor=T.+Sogaauthor=H.+Sakagamiauthor=T.+Furutaniauthor=H.+Doiharaauthor=M.+Kudohauthor=S.+Kuromitsu&title=The+Selective+Anaplastic+Lymphoma+Receptor+Tyrosine+Kinase+Inhibitor+ASP3026+Induces+Tumor+Regression+and+Prolongs+Survival+in+Non-small+Cell+Lung+Cancer+Model+Mice&doi=10.1158%2F1535-7163.MCT-13-0395"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">The Selective Anaplastic Lymphoma Receptor Tyrosine Kinase Inhibitor ASP3026 Induces Tumor Regression and Prolongs Survival in Non-Small Cell Lung Cancer Model Mice</span></div><div class="casAuthors">Mori, Masamichi; Ueno, Yoko; Konagai, Satoshi; Fushiki, Hiroshi; Shimada, Itsuro; Kondoh, Yutaka; Saito, Rika; Mori, Kenichi; Shindou, Nobuaki; Soga, Takatoshi; Sakagami, Hideki; Furutani, Takashi; Doihara, Hitoshi; Kudoh, Masafumi; Kuromitsu, Sadao</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">329-340</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Activation of anaplastic lymphoma receptor tyrosine kinase (ALK) is involved in the pathogenesis of several carcinomas, including non-small cell lung cancer (NSCLC).  Echinoderm microtubule-assocd. protein like 4 (EML4)-ALK, which is derived from the rearrangement of ALK and EML4 genes, has been validated as a therapeutic target in a subset of patients with NSCLC.  Here, we investigated the effects of ASP3026, a novel small-mol. ALK inhibitor, against ALK-driven NSCLC.  ASP3026 inhibited ALK activity in an ATP-competitive manner and had an inhibitory spectrum that differed from that of crizotinib, a dual ALK/MET inhibitor.  In mice xenografted with NCI-H2228 cells expressing EML4-ALK, orally administered ASP3026 was well absorbed in tumor tissues, reaching concns. >10-fold higher than those in plasma, and induced tumor regression with a wide therapeutic margin between efficacious and toxic doses.  In the same mouse model, ASP3026 enhanced the antitumor activities of paclitaxel and pemetrexed without affecting body wt.  ASP3026 also showed potent antitumor activities, including tumor shrinkage to a nondetectable level, in hEML4-ALK transgenic mice and prolonged survival in mice with intrapleural NCI-H2228 xenografts.  In an intrahepatic xenograft model using NCI-H2228 cells, ASP3026 induced continuous tumor regression, whereas mice treated with crizotinib showed tumor relapse after an initial response.  Finally, ASP3026 exhibited potent antitumor activity against cells expressing EML4-ALK with a mutation in the gatekeeper position (L1196M) that confers crizotinib resistance.  Taken together, these findings indicate that ASP3026 has potential efficacy for NSCLC and is expected to improve the therapeutic outcomes of patients with cancer with ALK abnormality.  Mol Cancer Ther; 13(2); 329-40. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpU-kqfwbUJrLVg90H21EOLACvtfcHk0lgbVHFggT5v4w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFWmsb8%253D&md5=4d8de3814f3f8fa198f2d3acb5d3860a</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-13-0395&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-13-0395%26sid%3Dliteratum%253Aachs%26aulast%3DMori%26aufirst%3DM.%26aulast%3DUeno%26aufirst%3DY.%26aulast%3DKonagai%26aufirst%3DS.%26aulast%3DFushiki%26aufirst%3DH.%26aulast%3DShimada%26aufirst%3DI.%26aulast%3DKondoh%26aufirst%3DY.%26aulast%3DSaito%26aufirst%3DR.%26aulast%3DMori%26aufirst%3DK.%26aulast%3DShindou%26aufirst%3DN.%26aulast%3DSoga%26aufirst%3DT.%26aulast%3DSakagami%26aufirst%3DH.%26aulast%3DFurutani%26aufirst%3DT.%26aulast%3DDoihara%26aufirst%3DH.%26aulast%3DKudoh%26aufirst%3DM.%26aulast%3DKuromitsu%26aufirst%3DS.%26atitle%3DThe%2520Selective%2520Anaplastic%2520Lymphoma%2520Receptor%2520Tyrosine%2520Kinase%2520Inhibitor%2520ASP3026%2520Induces%2520Tumor%2520Regression%2520and%2520Prolongs%2520Survival%2520in%2520Non-small%2520Cell%2520Lung%2520Cancer%2520Model%2520Mice%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2014%26volume%3D13%26spage%3D329%26epage%3D340%26doi%3D10.1158%2F1535-7163.MCT-13-0395" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ardini, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menichincheri, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banfi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bosotti, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Ponti, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pulci, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballinari, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciomei, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Texido, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Degrassi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avanzi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amboldi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saccardo, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casero, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orsini, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bandiera, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mologni, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vernier, J.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felder, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donati, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isacchi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pesenti, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magnaghi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galvani, A.</span></span> <span> </span><span class="NLM_article-title">Entrectinib, a Pan-TRK, ROS1 and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">628</span>– <span class="NLM_lpage">639</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-15-0758</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1158%2F1535-7163.MCT-15-0758" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=26939704" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC28XlsVSqtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2016&pages=628-639&author=E.+Ardiniauthor=M.+Menichincheriauthor=P.+Banfiauthor=R.+Bosottiauthor=C.+De+Pontiauthor=R.+Pulciauthor=D.+Ballinariauthor=M.+Ciomeiauthor=G.+Texidoauthor=A.+Degrassiauthor=N.+Avanziauthor=N.+Amboldiauthor=M.+B.+Saccardoauthor=D.+Caseroauthor=P.+Orsiniauthor=T.+Bandieraauthor=L.+Mologniauthor=D.+Andersonauthor=G.+Weiauthor=J.+Harrisauthor=J.-M.+Vernierauthor=G.+Liauthor=E.+Felderauthor=D.+Donatiauthor=A.+Isacchiauthor=E.+Pesentiauthor=P.+Magnaghiauthor=A.+Galvani&title=Entrectinib%2C+a+Pan-TRK%2C+ROS1+and+ALK+Inhibitor+with+Activity+in+Multiple+Molecularly+Defined+Cancer+Indications&doi=10.1158%2F1535-7163.MCT-15-0758"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications</span></div><div class="casAuthors">Ardini, Elena; Menichincheri, Maria; Banfi, Patrizia; Bosotti, Roberta; De Ponti, Cristina; Pulci, Romana; Ballinari, Dario; Ciomei, Marina; Texido, Gemma; Degrassi, Anna; Avanzi, Nilla; Amboldi, Nadia; Saccardo, Maria Beatrice; Casero, Daniele; Orsini, Paolo; Bandiera, Tiziano; Mologni, Luca; Anderson, David; Wei, Ge; Harris, Jason; Vernier, Jean-Michel; Li, Gang; Felder, Eduard; Donati, Daniele; Isacchi, Antonella; Pesenti, Enrico; Magnaghi, Paola; Galvani, Arturo</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">628-639</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Activated ALK and ROS1 tyrosine kinases, resulting from chromosomal rearrangements, occur in a subset of non-small cell lung cancers (NSCLC) as well as other tumor types and their oncogenic relevance as actionable targets has been demonstrated by the efficacy of selective kinase inhibitors such as crizotinib, ceritinib, and alectinib.  More recently, low-frequency rearrangements of TRK kinases have been described in NSCLC, colorectal carcinoma, glioblastoma, and Spitzoid melanoma.  Entrectinib, whose discovery and preclin. characterization are reported herein, is a novel, potent inhibitor of ALK, ROS1, and, importantly, of TRK family kinases, which shows promise for therapy of tumors bearing oncogenic forms of these proteins.  Proliferation profiling against over 200 human tumor cell lines revealed that entrectinib is exquisitely potent in vitro against lines that are dependent on the drug's pharmacol. targets.  Oral administration of entrectinib to tumor-bearing mice induced regression in relevant human xenograft tumors, including the TRKA-dependent colorectal carcinoma KM12, ROS1-driven tumors, and several ALK-dependent models of different tissue origins, including a model of brain-localized lung cancer metastasis.  Entrectinib is currently showing great promise in phase I/II clin. trials, including the first documented objective responses to a TRK inhibitor in colorectal carcinoma and in NSCLC.  The drug is, thus, potentially suited to the therapy of several molecularly defined cancer settings, esp. that of TRK-dependent tumors, for which no approved drugs are currently available.  Mol Cancer Ther; 15(4); 628-39. ©2016 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOaNX-kFz2qbVg90H21EOLACvtfcHk0lhYtp6Jf6kqxQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XlsVSqtL4%253D&md5=dd75115cb344f0e3a6d299781043d7d6</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-15-0758&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-15-0758%26sid%3Dliteratum%253Aachs%26aulast%3DArdini%26aufirst%3DE.%26aulast%3DMenichincheri%26aufirst%3DM.%26aulast%3DBanfi%26aufirst%3DP.%26aulast%3DBosotti%26aufirst%3DR.%26aulast%3DDe%2BPonti%26aufirst%3DC.%26aulast%3DPulci%26aufirst%3DR.%26aulast%3DBallinari%26aufirst%3DD.%26aulast%3DCiomei%26aufirst%3DM.%26aulast%3DTexido%26aufirst%3DG.%26aulast%3DDegrassi%26aufirst%3DA.%26aulast%3DAvanzi%26aufirst%3DN.%26aulast%3DAmboldi%26aufirst%3DN.%26aulast%3DSaccardo%26aufirst%3DM.%2BB.%26aulast%3DCasero%26aufirst%3DD.%26aulast%3DOrsini%26aufirst%3DP.%26aulast%3DBandiera%26aufirst%3DT.%26aulast%3DMologni%26aufirst%3DL.%26aulast%3DAnderson%26aufirst%3DD.%26aulast%3DWei%26aufirst%3DG.%26aulast%3DHarris%26aufirst%3DJ.%26aulast%3DVernier%26aufirst%3DJ.-M.%26aulast%3DLi%26aufirst%3DG.%26aulast%3DFelder%26aufirst%3DE.%26aulast%3DDonati%26aufirst%3DD.%26aulast%3DIsacchi%26aufirst%3DA.%26aulast%3DPesenti%26aufirst%3DE.%26aulast%3DMagnaghi%26aufirst%3DP.%26aulast%3DGalvani%26aufirst%3DA.%26atitle%3DEntrectinib%252C%2520a%2520Pan-TRK%252C%2520ROS1%2520and%2520ALK%2520Inhibitor%2520with%2520Activity%2520in%2520Multiple%2520Molecularly%2520Defined%2520Cancer%2520Indications%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2016%26volume%3D15%26spage%3D628%26epage%3D639%26doi%3D10.1158%2F1535-7163.MCT-15-0758" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Menichincheri, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ardini, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magnaghi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avanzi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banfi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bossi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buffa, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Canevari, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ceriani, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colombo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corti, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donati, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fasolini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felder, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiorelli, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiorentini, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galvani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isacchi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borgia, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marchionni, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nesi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orrenius, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panzeri, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pesenti, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rusconi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saccardo, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanotti, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perrone, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orsini, P.</span></span> <span> </span><span class="NLM_article-title">Discovery of Entrectinib: a New 3-aminoindazole as a Potent Anaplastic Lymphoma Kinase (ALK), c-ros Oncogene 1 Kinase (ROS1), and Pan-tropomyosin Receptor Kinases (Pan-TRKs) Inhibitor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">3392</span>– <span class="NLM_lpage">3408</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00064</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00064" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC28Xks1eitL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=3392-3408&author=M.+Menichincheriauthor=E.+Ardiniauthor=P.+Magnaghiauthor=N.+Avanziauthor=P.+Banfiauthor=R.+Bossiauthor=L.+Buffaauthor=G.+Canevariauthor=L.+Cerianiauthor=M.+Colomboauthor=L.+Cortiauthor=D.+Donatiauthor=M.+Fasoliniauthor=E.+Felderauthor=C.+Fiorelliauthor=F.+Fiorentiniauthor=A.+Galvaniauthor=A.+Isacchiauthor=A.+L.+Borgiaauthor=C.+Marchionniauthor=M.+Nesiauthor=C.+Orreniusauthor=A.+Panzeriauthor=E.+Pesentiauthor=L.+Rusconiauthor=M.+B.+Saccardoauthor=E.+Vanottiauthor=E.+Perroneauthor=P.+Orsini&title=Discovery+of+Entrectinib%3A+a+New+3-aminoindazole+as+a+Potent+Anaplastic+Lymphoma+Kinase+%28ALK%29%2C+c-ros+Oncogene+1+Kinase+%28ROS1%29%2C+and+Pan-tropomyosin+Receptor+Kinases+%28Pan-TRKs%29+Inhibitor&doi=10.1021%2Facs.jmedchem.6b00064"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Entrectinib: A New 3-Aminoindazole As a Potent Anaplastic Lymphoma Kinase (ALK), c-ros Oncogene 1 Kinase (ROS1), and Pan-Tropomyosin Receptor Kinases (Pan-TRKs) inhibitor</span></div><div class="casAuthors">Menichincheri, Maria; Ardini, Elena; Magnaghi, Paola; Avanzi, Nilla; Banfi, Patrizia; Bossi, Roberto; Buffa, Laura; Canevari, Giulia; Ceriani, Lucio; Colombo, Maristella; Corti, Luca; Donati, Daniele; Fasolini, Marina; Felder, Eduard; Fiorelli, Claudio; Fiorentini, Francesco; Galvani, Arturo; Isacchi, Antonella; Borgia, Andrea Lombardi; Marchionni, Chiara; Nesi, Marcella; Orrenius, Christian; Panzeri, Achille; Pesenti, Enrico; Rusconi, Luisa; Saccardo, Maria Beatrice; Vanotti, Ermes; Perrone, Ettore; Orsini, Paolo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3392-3408</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase responsible for the development of different tumor types.  Despite the remarkable clin. activity of crizotinib (Xalkori), the first ALK inhibitor approved in 2011, the emergence of resistance mutations and of brain metastases frequently causes relapse in patients.  Within the ALK drug discovery program, the authors identified compd. I, a novel 3-aminoindazole active on ALK in biochem. and in cellular assays.  Its optimization led to compd. II (entrectinib), a potent orally available ALK inhibitor active on ALK-dependent cell lines, efficiently penetrant the blood-brain barrier (BBB) in different animal species and highly efficacious in in vivo xenograft models.  Moreover, entrectinib resulted to be strictly potent on the closely related tyrosine kinases ROS1 and TRKs recently found constitutively activated in several tumor types.  Entrectinib is currently undergoing phase I/II clin. trial for the treatment of patients affected by ALK-, ROS1-, and TRK-pos. tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpU_xyLC5-GabVg90H21EOLACvtfcHk0lhYtp6Jf6kqxQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xks1eitL8%253D&md5=140217fba2ac81d71600f7344f2d8a3e</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00064%26sid%3Dliteratum%253Aachs%26aulast%3DMenichincheri%26aufirst%3DM.%26aulast%3DArdini%26aufirst%3DE.%26aulast%3DMagnaghi%26aufirst%3DP.%26aulast%3DAvanzi%26aufirst%3DN.%26aulast%3DBanfi%26aufirst%3DP.%26aulast%3DBossi%26aufirst%3DR.%26aulast%3DBuffa%26aufirst%3DL.%26aulast%3DCanevari%26aufirst%3DG.%26aulast%3DCeriani%26aufirst%3DL.%26aulast%3DColombo%26aufirst%3DM.%26aulast%3DCorti%26aufirst%3DL.%26aulast%3DDonati%26aufirst%3DD.%26aulast%3DFasolini%26aufirst%3DM.%26aulast%3DFelder%26aufirst%3DE.%26aulast%3DFiorelli%26aufirst%3DC.%26aulast%3DFiorentini%26aufirst%3DF.%26aulast%3DGalvani%26aufirst%3DA.%26aulast%3DIsacchi%26aufirst%3DA.%26aulast%3DBorgia%26aufirst%3DA.%2BL.%26aulast%3DMarchionni%26aufirst%3DC.%26aulast%3DNesi%26aufirst%3DM.%26aulast%3DOrrenius%26aufirst%3DC.%26aulast%3DPanzeri%26aufirst%3DA.%26aulast%3DPesenti%26aufirst%3DE.%26aulast%3DRusconi%26aufirst%3DL.%26aulast%3DSaccardo%26aufirst%3DM.%2BB.%26aulast%3DVanotti%26aufirst%3DE.%26aulast%3DPerrone%26aufirst%3DE.%26aulast%3DOrsini%26aufirst%3DP.%26atitle%3DDiscovery%2520of%2520Entrectinib%253A%2520a%2520New%25203-aminoindazole%2520as%2520a%2520Potent%2520Anaplastic%2520Lymphoma%2520Kinase%2520%2528ALK%2529%252C%2520c-ros%2520Oncogene%25201%2520Kinase%2520%2528ROS1%2529%252C%2520and%2520Pan-tropomyosin%2520Receptor%2520Kinases%2520%2528Pan-TRKs%2529%2520Inhibitor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D3392%26epage%3D3408%26doi%3D10.1021%2Facs.jmedchem.6b00064" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lovly, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heuckmann, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Stanchina, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pao, W.</span></span> <span> </span><span class="NLM_article-title">Insights into ALK-driven Cancers Revealed through Development of Novel ALK Tyrosine Kinase Inhibitors</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">4920</span>– <span class="NLM_lpage">4931</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-10-3879</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1158%2F0008-5472.CAN-10-3879" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=21613408" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC3MXovFartro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2011&pages=4920-4931&author=C.+M.+Lovlyauthor=J.+M.+Heuckmannauthor=E.+de+Stanchinaauthor=H.+Chenauthor=R.+K.+Thomasauthor=C.+Liangauthor=W.+Pao&title=Insights+into+ALK-driven+Cancers+Revealed+through+Development+of+Novel+ALK+Tyrosine+Kinase+Inhibitors&doi=10.1158%2F0008-5472.CAN-10-3879"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Insights into ALK-Driven Cancers Revealed through Development of Novel ALK Tyrosine Kinase Inhibitors</span></div><div class="casAuthors">Lovly, Christine M.; Heuckmann, Johannes M.; de Stanchina, Elisa; Chen, Heidi; Thomas, Roman K.; Liang, Chris; Pao, William</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">4920-4931</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Aberrant forms of the anaplastic lymphoma kinase (ALK) have been implicated in the pathogenesis of multiple human cancers, where ALK represents a rational therapeutic target in these settings.  In this study, we report the identification and biol. characterization of X-376 and X-396, two potent and highly specific ALK small mol. tyrosine kinase inhibitors (TKIs).  In Ambit kinome screens, cell growth inhibition studies, and surrogate kinase assays, X-376 and X-396 were more potent inhibitors of ALK but less potent inhibitors of MET compared to PF-02341066 (PF-1066), an ALK/MET dual TKI currently in clin. trials.  Both X-376 and X-396 displayed potent antitumor activity in vivo with favorable pharmacokinetic and toxicity profiles.  Similar levels of drug sensitivity were displayed by the three most common ALK fusion proteins in lung cancer (EML4-ALK variants E13;A20, E20;A20, and E6b;A20) as well as a KIF5B-ALK fusion protein.  Moreover, X-396 could potently inhibit ALK kinases engineered with two point mutations assocd. with acquired resistance to PF-1066, L1196M, and C1156Y, when engineered into an E13;A20 fusion variant.  Finally, X-396 displayed synergistic growth inhibitory activity when combined with the mTOR inhibitor rapamycin.  Our findings offer preclin. proof-of-concept for use of these novel agents to improve therapeutic outcomes of patients with mutant ALK-driven malignancies.  Cancer Res; 71(14); 4920-31.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmCEJra8njI7Vg90H21EOLACvtfcHk0ljAP3uCynnInw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXovFartro%253D&md5=000cbd1295c9d9fa6a43027f08c31247</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-10-3879&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-10-3879%26sid%3Dliteratum%253Aachs%26aulast%3DLovly%26aufirst%3DC.%2BM.%26aulast%3DHeuckmann%26aufirst%3DJ.%2BM.%26aulast%3Dde%2BStanchina%26aufirst%3DE.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DThomas%26aufirst%3DR.%2BK.%26aulast%3DLiang%26aufirst%3DC.%26aulast%3DPao%26aufirst%3DW.%26atitle%3DInsights%2520into%2520ALK-driven%2520Cancers%2520Revealed%2520through%2520Development%2520of%2520Novel%2520ALK%2520Tyrosine%2520Kinase%2520Inhibitors%26jtitle%3DCancer%2520Res.%26date%3D2011%26volume%3D71%26spage%3D4920%26epage%3D4931%26doi%3D10.1158%2F0008-5472.CAN-10-3879" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cui, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhai, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogers, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitten, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span> <span> </span><span class="NLM_article-title">TPX-0005, a Novel ALK/ROS1/TRK inhibitor, Effectively Inhibited a Broad Spectrum of mMutations Including Solvent front ALK G1202R, ROS1 G2032R and TRKA G595R Mutants</span>. <i>Eur. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>69</i></span>,  <span class="NLM_fpage">S32</span>, <span class="refDoi"> DOI: 10.1016/S0959-8049(16)32675-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1016%2FS0959-8049%2816%2932675-2" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2016&pages=S32&author=J.+Cuiauthor=D.+Zhaiauthor=W.+Dengauthor=E.+Rogersauthor=Z.+Huangauthor=J.+Whittenauthor=Y.+Li&title=TPX-0005%2C+a+Novel+ALK%2FROS1%2FTRK+inhibitor%2C+Effectively+Inhibited+a+Broad+Spectrum+of+mMutations+Including+Solvent+front+ALK+G1202R%2C+ROS1+G2032R+and+TRKA+G595R+Mutants&doi=10.1016%2FS0959-8049%2816%2932675-2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1016%2FS0959-8049%2816%2932675-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0959-8049%252816%252932675-2%26sid%3Dliteratum%253Aachs%26aulast%3DCui%26aufirst%3DJ.%26aulast%3DZhai%26aufirst%3DD.%26aulast%3DDeng%26aufirst%3DW.%26aulast%3DRogers%26aufirst%3DE.%26aulast%3DHuang%26aufirst%3DZ.%26aulast%3DWhitten%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DY.%26atitle%3DTPX-0005%252C%2520a%2520Novel%2520ALK%252FROS1%252FTRK%2520inhibitor%252C%2520Effectively%2520Inhibited%2520a%2520Broad%2520Spectrum%2520of%2520mMutations%2520Including%2520Solvent%2520front%2520ALK%2520G1202R%252C%2520ROS1%2520G2032R%2520and%2520TRKA%2520G595R%2520Mutants%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D2016%26volume%3D69%26spage%3DS32%26doi%3D10.1016%2FS0959-8049%2816%2932675-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hatcher, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span> <span> </span><span class="NLM_article-title">Small Molecule Inhibitors of ALK</span>. <i>Top. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">435</span>– <span class="NLM_lpage">467</span>, <span class="refDoi"> DOI: 10.1007/7355_2017_18</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1007%2F7355_2017_18" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2017&pages=435-467&author=J.+M.+Hatcherauthor=N.+S.+Gray&title=Small+Molecule+Inhibitors+of+ALK&doi=10.1007%2F7355_2017_18"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1007%2F7355_2017_18&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F7355_2017_18%26sid%3Dliteratum%253Aachs%26aulast%3DHatcher%26aufirst%3DJ.%2BM.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DSmall%2520Molecule%2520Inhibitors%2520of%2520ALK%26jtitle%3DTop.%2520Med.%2520Chem.%26date%3D2017%26volume%3D28%26spage%3D435%26epage%3D467%26doi%3D10.1007%2F7355_2017_18" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Holla, V. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elamin, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Litzenburger, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khotskaya, Y. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shufean, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mendelsohn, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mills, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meric-Bernstam, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simon, G. R.</span></span> <span> </span><span class="NLM_article-title">ALK: a Tyrosine Kinase Target for Cancer Therapy</span>. <i>Cold Spring Harbor Mol. Case. Stud.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">a001115</span>, <span class="refDoi"> DOI: 10.1101/mcs.a001115</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1101%2Fmcs.a001115" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=28050598" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC1cXotlajtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2017&pages=a001115&author=V.+R.+Hollaauthor=Y.+Y.+Elaminauthor=A.+M.+Baileyauthor=A.+M.+Johnsonauthor=B.+C.+Litzenburgerauthor=Y.+B.+Khotskayaauthor=N.+S.+Sanchezauthor=J.+Zengauthor=M.+A.+Shufeanauthor=K.+R.+Shawauthor=J.+Mendelsohnauthor=G.+B.+Millsauthor=F.+Meric-Bernstamauthor=G.+R.+Simon&title=ALK%3A+a+Tyrosine+Kinase+Target+for+Cancer+Therapy&doi=10.1101%2Fmcs.a001115"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">ALK: a tyrosine kinase target for cancer therapy</span></div><div class="casAuthors">Holla, Vijaykumar R.; Elamin, Yasir Y.; Bailey, Ann Marie; Johnson, Amber M.; Litzenburger, Beate C.; Khotskaya, Yekaterina B.; Sanchez, Nora S.; Zeng, Jia; Abu Shufean, Md .; Shaw, Kenna R.; Mendelsohn, John; Mills, Gordon B.; Meric-Bernstam, Funda; Simon, George R.</div><div class="citationInfo"><span class="NLM_cas:title">Cold Spring Harbor Molecular Case Studies</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">a001115/1-a001115/21</span>CODEN:
                <span class="NLM_cas:coden">CSHMCJ</span>;
        ISSN:<span class="NLM_cas:issn">2373-2873</span>.
    
            (<span class="NLM_cas:orgname">Cold Spring Harbor Laboratory Press</span>)
        </div><div class="casAbstract">The anaplastic lymphoma kinase (ALK) gene plays an important physiol. role in the development of the brain and can be oncogenically altered in several malignancies, including non-small-cell lung cancer (NSCLC) and anaplastic large cell lymphomas (ALCL).  Most prevalent ALK alterations are chromosomal rearrangements resulting in fusion genes, as seen in ALCL and NSCLC.  In other tumors, ALK copy-no. gains and activating ALK mutations have been described.  Dramatic and often prolonged responses are seen in patients with ALK alterations when treated with ALK inhibitors.  Three of these-crizotinib, ceritinib, and alectinib-are now FDA approved for the treatment of metastatic NSCLC pos. for ALK fusions.  However, the emergence of resistance is universal.  Newer ALK inhibitors and other targeting strategies are being developed to counteract the newly emergent mechanism(s) of ALK inhibitor resistance.  This review outlines the recent developments in our understanding and treatment of tumors with ALK alterations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_NbgGW-_iP7Vg90H21EOLACvtfcHk0ljLlDrwuBWX0Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXotlajtbk%253D&md5=ab377ffa836af0e0a8380977c1c1cdb7</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1101%2Fmcs.a001115&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252Fmcs.a001115%26sid%3Dliteratum%253Aachs%26aulast%3DHolla%26aufirst%3DV.%2BR.%26aulast%3DElamin%26aufirst%3DY.%2BY.%26aulast%3DBailey%26aufirst%3DA.%2BM.%26aulast%3DJohnson%26aufirst%3DA.%2BM.%26aulast%3DLitzenburger%26aufirst%3DB.%2BC.%26aulast%3DKhotskaya%26aufirst%3DY.%2BB.%26aulast%3DSanchez%26aufirst%3DN.%2BS.%26aulast%3DZeng%26aufirst%3DJ.%26aulast%3DShufean%26aufirst%3DM.%2BA.%26aulast%3DShaw%26aufirst%3DK.%2BR.%26aulast%3DMendelsohn%26aufirst%3DJ.%26aulast%3DMills%26aufirst%3DG.%2BB.%26aulast%3DMeric-Bernstam%26aufirst%3DF.%26aulast%3DSimon%26aufirst%3DG.%2BR.%26atitle%3DALK%253A%2520a%2520Tyrosine%2520Kinase%2520Target%2520for%2520Cancer%2520Therapy%26jtitle%3DCold%2520Spring%2520Harbor%2520Mol.%2520Case.%2520Stud.%26date%3D2017%26volume%3D3%26spage%3Da001115%26doi%3D10.1101%2Fmcs.a001115" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Katayama, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lovly, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, A. T.</span></span> <span> </span><span class="NLM_article-title">Therapeutic Targeting of Anaplastic Lymphoma Kinase in Lung Cancer: a Paradigm for Precision Cancer Medicine</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">2227</span>– <span class="NLM_lpage">2235</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-14-2791</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1158%2F1078-0432.CCR-14-2791" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=25979929" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC2MXoslOktbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=2227-2235&author=R.+Katayamaauthor=C.+M.+Lovlyauthor=A.+T.+Shaw&title=Therapeutic+Targeting+of+Anaplastic+Lymphoma+Kinase+in+Lung+Cancer%3A+a+Paradigm+for+Precision+Cancer+Medicine&doi=10.1158%2F1078-0432.CCR-14-2791"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic Targeting of Anaplastic Lymphoma Kinase in Lung Cancer: A Paradigm for Precision Cancer Medicine</span></div><div class="casAuthors">Katayama, Ryohei; Lovly, Christine M.; Shaw, Alice T.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2227-2235</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  The anaplastic lymphoma kinase (ALK) receptor tyrosine kinase was initially discovered as a component of the fusion protein nucleophosmin (NPM)-ALK in anaplastic large-cell lymphoma (ALCL).  Genomic alterations in ALK, including rearrangements, point mutations, and genomic amplification, have now been identified in several malignancies, including lymphoma, non-small cell lung cancer (NSCLC), neuroblastoma, inflammatory myofibroblastic tumor, and others.  Importantly, ALK serves as a validated therapeutic target in these diseases.  Several ALK tyrosine kinase inhibitors (TKI), including crizotinib, ceritinib, and alectinib, have been developed, and some of them have already been approved for clin. use.  These ALK inhibitors have all shown remarkable clin. outcomes in ALK-rearranged NSCLC.  Unfortunately, as is the case for other kinase inhibitors in clin. use, sensitive tumors inevitably relapse due to acquired resistance.  This review focuses on the discovery, function, and therapeutic targeting of ALK, with a particular focus on ALK-rearranged NSCLC.  Clin Cancer Res; 21(10); 2227-35. cpr2015 AACR.  See all articles in this section, "Progress in Lung Cancer".</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr00cDhFZSKBrVg90H21EOLACvtfcHk0ljLlDrwuBWX0Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXoslOktbw%253D&md5=80994c4611159b7f7d007fd16e4f8472</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-14-2791&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-14-2791%26sid%3Dliteratum%253Aachs%26aulast%3DKatayama%26aufirst%3DR.%26aulast%3DLovly%26aufirst%3DC.%2BM.%26aulast%3DShaw%26aufirst%3DA.%2BT.%26atitle%3DTherapeutic%2520Targeting%2520of%2520Anaplastic%2520Lymphoma%2520Kinase%2520in%2520Lung%2520Cancer%253A%2520a%2520Paradigm%2520for%2520Precision%2520Cancer%2520Medicine%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2015%26volume%3D21%26spage%3D2227%26epage%3D2235%26doi%3D10.1158%2F1078-0432.CCR-14-2791" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bryan, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whittington, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doherty, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Falsey, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emkey, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brake, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, R. T.</span></span> <span> </span><span class="NLM_article-title">Rapid Development of Piperidine Carboxamides as Potent and Selective Anaplastic Lymphoma Kinase Inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">1698</span>– <span class="NLM_lpage">1705</span>, <span class="refDoi"> DOI: 10.1021/jm201565s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm201565s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVymsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=1698-1705&author=M.+C.+Bryanauthor=D.+A.+Whittingtonauthor=E.+M.+Dohertyauthor=J.+R.+Falseyauthor=A.+C.+Chengauthor=R.+Emkeyauthor=R.+L.+Brakeauthor=R.+T.+Lewis&title=Rapid+Development+of+Piperidine+Carboxamides+as+Potent+and+Selective+Anaplastic+Lymphoma+Kinase+Inhibitors&doi=10.1021%2Fjm201565s"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Rapid Development of Piperidine Carboxamides as Potent and Selective Anaplastic Lymphoma Kinase Inhibitors</span></div><div class="casAuthors">Bryan, Marian C.; Whittington, Douglas A.; Doherty, Elizabeth M.; Falsey, James R.; Cheng, Alan C.; Emkey, Renee; Brake, Rachael L.; Lewis, Richard T.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1698-1705</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Piperidine carboxamide I was identified as a novel inhibitor of anaplastic lymphoma kinase (ALK enzyme assay IC50 = 0.174 μM) during high throughput screening, with selectivity over the related kinase insulin-like growth factor-1 (IGF1R).  The X-ray cocrystal structure of 1 with the ALK kinase domain revealed an unusual DFG-shifted conformation, allowing access to an extended hydrophobic pocket.  Structure-activity relationship (SAR) studies were focused on the rapid parallel optimization of both the right- and left-hand side of the mol., culminating in mols. with improved potency and selectivity over IGF1R.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-7cIB41ZJN7Vg90H21EOLACvtfcHk0ljLlDrwuBWX0Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVymsbs%253D&md5=04d47fd0f0a5b8b85c7add9787fe736e</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Fjm201565s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm201565s%26sid%3Dliteratum%253Aachs%26aulast%3DBryan%26aufirst%3DM.%2BC.%26aulast%3DWhittington%26aufirst%3DD.%2BA.%26aulast%3DDoherty%26aufirst%3DE.%2BM.%26aulast%3DFalsey%26aufirst%3DJ.%2BR.%26aulast%3DCheng%26aufirst%3DA.%2BC.%26aulast%3DEmkey%26aufirst%3DR.%26aulast%3DBrake%26aufirst%3DR.%2BL.%26aulast%3DLewis%26aufirst%3DR.%2BT.%26atitle%3DRapid%2520Development%2520of%2520Piperidine%2520Carboxamides%2520as%2520Potent%2520and%2520Selective%2520Anaplastic%2520Lymphoma%2520Kinase%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D1698%26epage%3D1705%26doi%3D10.1021%2Fjm201565s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tu, C.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, W.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, Y.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, C.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyu, P.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shih, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiaang, W. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, S. Y.</span></span> <span> </span><span class="NLM_article-title">Pyrazolylamine Derivatives Reveal the Conformational Switching between Type I and Type II Binding Modes of Anaplastic Lymphoma Kinase (ALK)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">3906</span>– <span class="NLM_lpage">3919</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00106</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00106" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC28Xlt1GjsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=3906-3919&author=C.-H.+Tuauthor=W.-H.+Linauthor=Y.-H.+Pengauthor=T.+Hsuauthor=J.-S.+Wuauthor=C.-Y.+Changauthor=C.-T.+Luauthor=P.-C.+Lyuauthor=C.+Shihauthor=W.+T.+Jiaangauthor=S.+Y.+Wu&title=Pyrazolylamine+Derivatives+Reveal+the+Conformational+Switching+between+Type+I+and+Type+II+Binding+Modes+of+Anaplastic+Lymphoma+Kinase+%28ALK%29&doi=10.1021%2Facs.jmedchem.6b00106"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Pyrazolylamine Derivatives Reveal the Conformational Switching between Type I and Type II Binding Modes of Anaplastic Lymphoma Kinase (ALK)</span></div><div class="casAuthors">Tu, Chih-Hsiang; Lin, Wen-Hsing; Peng, Yi-Hui; Hsu, Tsu; Wu, Jian-Sung; Chang, Chun-Yu; Lu, Cheng-Tai; Lyu, Ping-Chiang; Shih, Chuan; Jiaang, Weir-Torn; Wu, Su-Ying</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3906-3919</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Most anaplastic lymphoma kinase (ALK) inhibitors adopt a type I binding mode, but only limited type II ALK structural studies are available.  Herein, the authors present the structure of ALK in complex with N1-(3-4-[([5-(tert-butyl)-3-isoxazolyl]aminocarbonyl)amino]-3-methylphenyl-1H-5-pyrazolyl)-4-[(4-methylpiperazino)methyl]benzamide (5a), a novel ALK inhibitor adopting a type II binding mode.  It revealed binding of 5a resulted in the conformational change and reposition of the activation loop, αC-helix, and juxtamembrane domain, which are all important domains for the autoinhibition mechanism and downstream signal pathway regulation of ALK.  A structure-activity relationship study revealed that modifications to the structure of 5a led to significant differences in the ALK potency and altered the protein structure of ALK.  To the best of the authors' knowledge, this is the first structural biol. study to directly observe how changes in the structure of a small mol. can regulate the switch between the type I and type II binding modes and induce dramatic conformational changes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpX2IoqRzkgK7Vg90H21EOLACvtfcHk0lg6o4qZVjKzVQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xlt1GjsLk%253D&md5=732cbe2ef77a84f50de49aeef838895d</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00106%26sid%3Dliteratum%253Aachs%26aulast%3DTu%26aufirst%3DC.-H.%26aulast%3DLin%26aufirst%3DW.-H.%26aulast%3DPeng%26aufirst%3DY.-H.%26aulast%3DHsu%26aufirst%3DT.%26aulast%3DWu%26aufirst%3DJ.-S.%26aulast%3DChang%26aufirst%3DC.-Y.%26aulast%3DLu%26aufirst%3DC.-T.%26aulast%3DLyu%26aufirst%3DP.-C.%26aulast%3DShih%26aufirst%3DC.%26aulast%3DJiaang%26aufirst%3DW.%2BT.%26aulast%3DWu%26aufirst%3DS.%2BY.%26atitle%3DPyrazolylamine%2520Derivatives%2520Reveal%2520the%2520Conformational%2520Switching%2520between%2520Type%2520I%2520and%2520Type%2520II%2520Binding%2520Modes%2520of%2520Anaplastic%2520Lymphoma%2520Kinase%2520%2528ALK%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D3906%26epage%3D3919%26doi%3D10.1021%2Facs.jmedchem.6b00106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, T.</span></span> <span> </span><span class="NLM_article-title">Combating Drug-Resistant Mutants of Anaplastic Lymphoma Kinase with Potent and Selective Type-I1/2 Inhibitors by Stabilizing Unique DFG-Shifted Loop Conformation</span>. <i>ACS Central Sci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">1208</span>– <span class="NLM_lpage">1220</span>, <span class="refDoi"> DOI: 10.1021/acscentsci.7b00419</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acscentsci.7b00419" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhslGgs77I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2017&pages=1208-1220&author=P.+Panauthor=H.+Yuauthor=Q.+Liuauthor=X.+Kongauthor=H.+Chenauthor=J.+Chenauthor=Q.+Liuauthor=D.+Liauthor=Y.+Kangauthor=H.+Sunauthor=W.+Zhouauthor=S.+Tianauthor=S.+Cuiauthor=F.+Zhuauthor=Y.+Liauthor=Y.+Huangauthor=T.+Hou&title=Combating+Drug-Resistant+Mutants+of+Anaplastic+Lymphoma+Kinase+with+Potent+and+Selective+Type-I1%2F2+Inhibitors+by+Stabilizing+Unique+DFG-Shifted+Loop+Conformation&doi=10.1021%2Facscentsci.7b00419"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Combating Drug-Resistant Mutants of Anaplastic Lymphoma Kinase with Potent and Selective Type-I1/2 Inhibitors by Stabilizing Unique DFG-Shifted Loop Conformation</span></div><div class="casAuthors">Pan, Peichen; Yu, Huidong; Liu, Qinglan; Kong, Xiaotian; Chen, Hu; Chen, Jiean; Liu, Qi; Li, Dan; Kang, Yu; Sun, Huiyong; Zhou, Wenfang; Tian, Sheng; Cui, Sunliang; Zhu, Feng; Li, Youyong; Huang, Yong; Hou, Tingjun</div><div class="citationInfo"><span class="NLM_cas:title">ACS Central Science</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1208-1220</span>CODEN:
                <span class="NLM_cas:coden">ACSCII</span>;
        ISSN:<span class="NLM_cas:issn">2374-7951</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Targeted inhibition of anaplastic lymphoma kinase (ALK) dramatically improved therapeutic outcomes in the treatment of ALK-pos. cancers, but unfortunately patients invariably progressed due to acquired resistance mutations in ALK.  Currently available drugs are all type-I inhibitors bound to the ATP-binding pocket and are most likely to be resistant in patients harboring genetic mutations surrounding the ATP pocket.  To overcome drug resistance, the authors rationally designed a novel kind of "bridge" inhibitor, which specially bind into an extended hydrophobic back pocket adjacent to the ATP-binding site of ALK.  The novel type-I1/2 inhibitors display excellent antiproliferation activity against ALK-pos. cancer cells and appear superior to two clin. used drugs, crizotinib and ceritinib.  Structural and mol. modeling analyses indicate that the inhibitor induces dramatic conformational transition and stabilizes unique DFG-shifted loop conformation, enabling persistent sensitivity to different genetic mutations in ALK.  These data highlight a rationale for further development of next-generation ALK inhibitors to combat drug resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUNJfWr_d0k7Vg90H21EOLACvtfcHk0lg6o4qZVjKzVQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhslGgs77I&md5=9e0517648f375fe4fb7b9a3d622d5a8d</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1021%2Facscentsci.7b00419&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facscentsci.7b00419%26sid%3Dliteratum%253Aachs%26aulast%3DPan%26aufirst%3DP.%26aulast%3DYu%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DKong%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DKang%26aufirst%3DY.%26aulast%3DSun%26aufirst%3DH.%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DTian%26aufirst%3DS.%26aulast%3DCui%26aufirst%3DS.%26aulast%3DZhu%26aufirst%3DF.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DHou%26aufirst%3DT.%26atitle%3DCombating%2520Drug-Resistant%2520Mutants%2520of%2520Anaplastic%2520Lymphoma%2520Kinase%2520with%2520Potent%2520and%2520Selective%2520Type-I1%252F2%2520Inhibitors%2520by%2520Stabilizing%2520Unique%2520DFG-Shifted%2520Loop%2520Conformation%26jtitle%3DACS%2520Central%2520Sci.%26date%3D2017%26volume%3D3%26spage%3D1208%26epage%3D1220%26doi%3D10.1021%2Facscentsci.7b00419" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kang, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du Ha, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hwang, J. Y.</span></span> <span> </span><span class="NLM_article-title">Induced Protein Degradation of Anaplastic Lymphoma Kinase (ALK) by Proteolysis Targeting Chimera (PROTAC)</span>. <i>Biochem. Biophys. Res. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>505</i></span>,  <span class="NLM_fpage">542</span>– <span class="NLM_lpage">547</span>, <span class="refDoi"> DOI: 10.1016/j.bbrc.2018.09.169</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1016%2Fj.bbrc.2018.09.169" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=30274779" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvVejs7fE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=505&publication_year=2018&pages=542-547&author=C.+H.+Kangauthor=D.+H.+Leeauthor=C.+O.+Leeauthor=J.+Du+Haauthor=C.+H.+Parkauthor=J.+Y.+Hwang&title=Induced+Protein+Degradation+of+Anaplastic+Lymphoma+Kinase+%28ALK%29+by+Proteolysis+Targeting+Chimera+%28PROTAC%29&doi=10.1016%2Fj.bbrc.2018.09.169"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Induced protein degradation of anaplastic lymphoma kinase (ALK) by proteolysis targeting chimera (PROTAC)</span></div><div class="casAuthors">Kang, Chung Hyo; Lee, Dong Ho; Lee, Chong Ock; Du Ha, Jae; Park, Chi Hoon; Hwang, Jong Yeon</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical and Biophysical Research Communications</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">505</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">542-547</span>CODEN:
                <span class="NLM_cas:coden">BBRCA9</span>;
        ISSN:<span class="NLM_cas:issn">0006-291X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Recently, proteolysis targeting chimera (PROTAC) technol. is highlighted in drug discovery area as a new therapeutic approach.  PROTAC as a heterobifunctional mol. is comprised of two ligands, which recruit target protein and E3 ligase, resp.  To degrade the anaplastic lymphoma kinase (ALK) fusion protein, such as NPM-ALK or EML4-ALK, we generated several ALK-PROTAC mols. consisted of ceritinib, one of the ALK inhibitors, and ligand of von Hippel-Lindau (VHL) E3 ligase.  Among these mols., TD-004 effectively induced ALK degrdn. and inhibited the growth of ALK fusion pos. cell lines, SU-DHL-1 and H3122.  We also confirmed that TD-004 significantly reduced the tumor growth in H3122 xenograft model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8JUOZ5fYNW7Vg90H21EOLACvtfcHk0ljnlW8eS5LnKg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvVejs7fE&md5=cac9252fca98ebec4ad8e5aeed7b7550</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1016%2Fj.bbrc.2018.09.169&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbrc.2018.09.169%26sid%3Dliteratum%253Aachs%26aulast%3DKang%26aufirst%3DC.%2BH.%26aulast%3DLee%26aufirst%3DD.%2BH.%26aulast%3DLee%26aufirst%3DC.%2BO.%26aulast%3DDu%2BHa%26aufirst%3DJ.%26aulast%3DPark%26aufirst%3DC.%2BH.%26aulast%3DHwang%26aufirst%3DJ.%2BY.%26atitle%3DInduced%2520Protein%2520Degradation%2520of%2520Anaplastic%2520Lymphoma%2520Kinase%2520%2528ALK%2529%2520by%2520Proteolysis%2520Targeting%2520Chimera%2520%2528PROTAC%2529%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D2018%26volume%3D505%26spage%3D542%26epage%3D547%26doi%3D10.1016%2Fj.bbrc.2018.09.169" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Powell, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donovan, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nowak, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loehr, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bahcall, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janne, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">George, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span> <span> </span><span class="NLM_article-title">Chemically Induced Degradation of Anaplastic Lymphoma Kinase (ALK)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">4249</span>– <span class="NLM_lpage">4255</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01655</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01655" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC1cXns1OitrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=4249-4255&author=C.+E.+Powellauthor=Y.+Gaoauthor=L.+Tanauthor=K.+A.+Donovanauthor=R.+P.+Nowakauthor=A.+Loehrauthor=M.+Bahcallauthor=E.+S.+Fischerauthor=P.+A.+Janneauthor=R.+E.+Georgeauthor=N.+S.+Gray&title=Chemically+Induced+Degradation+of+Anaplastic+Lymphoma+Kinase+%28ALK%29&doi=10.1021%2Facs.jmedchem.7b01655"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Chemically Induced Degradation of Anaplastic Lymphoma Kinase (ALK)</span></div><div class="casAuthors">Powell, Chelsea E.; Gao, Yang; Tan, Li; Donovan, Katherine A.; Nowak, Radoslaw P.; Loehr, Amanda; Bahcall, Magda; Fischer, Eric S.; Janne, Pasi A.; George, Rani E.; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4249-4255</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We present the development of the first small mol. degraders that can induce anaplastic lymphoma kinase (ALK) degrdn., including in non-small-cell lung cancer (NSCLC), anaplastic large-cell lymphoma (ALCL), and neuroblastoma (NB) cell lines.  These degraders were developed through conjugation of known pyrimidine-based ALK inhibitors, TAE684 or LDK378, and the cereblon ligand pomalidomide.  We demonstrate that in some cell types degrader potency is compromised by expression of drug transporter ABCB1.  In addn., proteomic profiling demonstrated that these compds. also promote the degrdn. of addnl. kinases including PTK2 (FAK), Aurora A, FER, and RPS6KA1 (RSK1).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7mDH7Sj8EqbVg90H21EOLACvtfcHk0ljnlW8eS5LnKg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXns1OitrY%253D&md5=486db11b3fbc2283700f38b09cc39bd7</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01655&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01655%26sid%3Dliteratum%253Aachs%26aulast%3DPowell%26aufirst%3DC.%2BE.%26aulast%3DGao%26aufirst%3DY.%26aulast%3DTan%26aufirst%3DL.%26aulast%3DDonovan%26aufirst%3DK.%2BA.%26aulast%3DNowak%26aufirst%3DR.%2BP.%26aulast%3DLoehr%26aufirst%3DA.%26aulast%3DBahcall%26aufirst%3DM.%26aulast%3DFischer%26aufirst%3DE.%2BS.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26aulast%3DGeorge%26aufirst%3DR.%2BE.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DChemically%2520Induced%2520Degradation%2520of%2520Anaplastic%2520Lymphoma%2520Kinase%2520%2528ALK%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D4249%26epage%3D4255%26doi%3D10.1021%2Facs.jmedchem.7b01655" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, X.-R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, J.</span></span> <span> </span><span class="NLM_article-title">Proteolysis Targeting Chimeras (PROTACs) of Anaplastic Lymphoma Kinase (ALK)</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>151</i></span>,  <span class="NLM_fpage">304</span>– <span class="NLM_lpage">314</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2018.03.071</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1016%2Fj.ejmech.2018.03.071" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=29627725" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC1cXnt1ejs7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=151&publication_year=2018&pages=304-314&author=C.+Zhangauthor=X.-R.+Hanauthor=X.+Yangauthor=B.+Jiangauthor=J.+Liuauthor=Y.+Xiongauthor=J.+Jin&title=Proteolysis+Targeting+Chimeras+%28PROTACs%29+of+Anaplastic+Lymphoma+Kinase+%28ALK%29&doi=10.1016%2Fj.ejmech.2018.03.071"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Proteolysis Targeting Chimeras (PROTACs) of Anaplastic Lymphoma Kinase (ALK)</span></div><div class="casAuthors">Zhang, Chengwei; Han, Xiao-Ran; Yang, Xiaobao; Jiang, Biao; Liu, Jing; Xiong, Yue; Jin, Jian</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">151</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">304-314</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Anaplastic lymphoma kinase (ALK) activation has been assocd. with many types of human cancer.  Significant efforts have been devoted to the development of ALK inhibitors to antagonize the kinase activity of ALK.  Four ALK inhibitors have been approved by the FDA to date for treating patients with ALK-pos. nonsmall cell lung cancers (NSCLC).  However, drug resistance has been obsd. in the majority of patients treated with these inhibitors.  New therapeutic strategies (e.g., compds. with novel mechanisms of action) are needed to overcome the drug resistance issue.  The emerging PROTAC (Proteolysis Targeting Chimera) technol. has been successfully applied to selective degrdn. of multiple protein targets, but not ALK.  Since ALK protein levels are not important for viability in mammals, ALK PROTACs could lead to novel therapeutics with minimal toxicity.  Here the authors report the design, synthesis and biol. evaluation of novel PROTACs (degraders) of ALK.  MS4077 (I) and MS4078 (II) potently decreased cellular levels of oncogenic active ALK fusion proteins in a concn.- and time-dependent manner in SU-DHL-1 lymphoma and NCI-H2228 lung cancer cells.  The ALK protein degrdn. induced by compds. I and II was cereblon and proteasome dependent.  In addn., compds. I and II potently inhibited proliferation of SU-DHL-1 cells.  Furthermore, compd. II displayed good plasma exposure in a mouse pharmacokinetic study, thus is suitable for in vivo efficacy studies.  The authors also developed MS4748 and MS4740 , very close analogs of I and II resp., which are incapable to degrade the ALK fusion proteins, as neg. controls.  All 4 compds. are valuable chem. tools for investigating effects of ALK pharmacol. degrdn.  The study paved the way for developing the next generation of ALK PROTACs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPGM3aAZZ6h7Vg90H21EOLACvtfcHk0liqxXtL82WbWg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXnt1ejs7Y%253D&md5=804324b95034f38b46e45f89e18e55be</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.03.071&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.03.071%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DHan%26aufirst%3DX.-R.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DJiang%26aufirst%3DB.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DXiong%26aufirst%3DY.%26aulast%3DJin%26aufirst%3DJ.%26atitle%3DProteolysis%2520Targeting%2520Chimeras%2520%2528PROTACs%2529%2520of%2520Anaplastic%2520Lymphoma%2520Kinase%2520%2528ALK%2529%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D151%26spage%3D304%26epage%3D314%26doi%3D10.1016%2Fj.ejmech.2018.03.071" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bossi, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saccardo, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ardini, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menichincheri, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rusconi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magnaghi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orsini, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avanzi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borgia, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nesi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bandiera, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fogliatto, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertrand, J. A.</span></span> <span> </span><span class="NLM_article-title">Crystal Structures of Anaplastic Lymphoma Kinase in Complex with ATP Competitive Inhibitors</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">6813</span>– <span class="NLM_lpage">6825</span>, <span class="refDoi"> DOI: 10.1021/bi1005514</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi1005514" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpt1Clsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2010&pages=6813-6825&author=R.+T.+Bossiauthor=M.+B.+Saccardoauthor=E.+Ardiniauthor=M.+Menichincheriauthor=L.+Rusconiauthor=P.+Magnaghiauthor=P.+Orsiniauthor=N.+Avanziauthor=A.+L.+Borgiaauthor=M.+Nesiauthor=T.+Bandieraauthor=G.+Fogliattoauthor=J.+A.+Bertrand&title=Crystal+Structures+of+Anaplastic+Lymphoma+Kinase+in+Complex+with+ATP+Competitive+Inhibitors&doi=10.1021%2Fbi1005514"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal Structures of Anaplastic Lymphoma Kinase in Complex with ATP Competitive Inhibitors</span></div><div class="casAuthors">Bossi, Roberto T.; Saccardo, M. Beatrice; Ardini, Elena; Menichincheri, Maria; Rusconi, Luisa; Magnaghi, Paola; Orsini, Paolo; Avanzi, Nilla; Borgia, Andrea Lombardi; Nesi, Marcella; Bandiera, Tiziano; Fogliatto, Gianpaolo; Bertrand, Jay A.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">32</span>),
    <span class="NLM_cas:pages">6813-6825</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase involved in the development of several human cancers and, as a result, is a recognized target for the development of small-mol. inhibitors for the treatment of ALK-pos. malignancies.  Here, the crystal structures of the unphosphorylated human ALK kinase domain in complex with the ATP competitive ligands PHA-E429 and NVP-TAE684 are presented.  Anal. of these structures provides valuable information concerning the specific characteristics of the ALK active site as well as giving indications about how to obtain selective ALK inhibitors.  In addn., the ALK-KD-PHA-E429 structure led to the identification of a potential regulatory mechanism involving a link made between a short helical segment immediately following the DFG motif and an N-terminal two-stranded β-sheet.  Finally, mapping of the activating mutations assocd. with neuroblastoma onto the structures may explain the roles these residues have in the activation process.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2b8yuzTuAYbVg90H21EOLACvtfcHk0liqxXtL82WbWg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpt1Clsbs%253D&md5=e8e9e3fde63a196a15c874300c995342</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1021%2Fbi1005514&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi1005514%26sid%3Dliteratum%253Aachs%26aulast%3DBossi%26aufirst%3DR.%2BT.%26aulast%3DSaccardo%26aufirst%3DM.%2BB.%26aulast%3DArdini%26aufirst%3DE.%26aulast%3DMenichincheri%26aufirst%3DM.%26aulast%3DRusconi%26aufirst%3DL.%26aulast%3DMagnaghi%26aufirst%3DP.%26aulast%3DOrsini%26aufirst%3DP.%26aulast%3DAvanzi%26aufirst%3DN.%26aulast%3DBorgia%26aufirst%3DA.%2BL.%26aulast%3DNesi%26aufirst%3DM.%26aulast%3DBandiera%26aufirst%3DT.%26aulast%3DFogliatto%26aufirst%3DG.%26aulast%3DBertrand%26aufirst%3DJ.%2BA.%26atitle%3DCrystal%2520Structures%2520of%2520Anaplastic%2520Lymphoma%2520Kinase%2520in%2520Complex%2520with%2520ATP%2520Competitive%2520Inhibitors%26jtitle%3DBiochemistry%26date%3D2010%26volume%3D49%26spage%3D6813%26epage%3D6825%26doi%3D10.1021%2Fbi1005514" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ng, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ambing, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, M.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hua, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michellys, P.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lesley, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spraggon, G.</span></span> <span> </span><span class="NLM_article-title">Crystal Structure of the ALK (Anaplastic Lymphoma Kinase) Catalytic Domain</span>. <i>Biochem. J.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>430</i></span>,  <span class="NLM_fpage">425</span>– <span class="NLM_lpage">437</span>, <span class="refDoi"> DOI: 10.1042/BJ20100609</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1042%2FBJ20100609" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=20632993" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVyrtbzF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=430&publication_year=2010&pages=425-437&author=C.+C.+Leeauthor=Y.+Jiaauthor=N.+Liauthor=X.+Sunauthor=K.+Ngauthor=E.+Ambingauthor=M.-Y.+Gaoauthor=S.+Huaauthor=C.+Chenauthor=S.+Kimauthor=P.-Y.+Michellysauthor=S.+A.+Lesleyauthor=J.+L.+Harrisauthor=G.+Spraggon&title=Crystal+Structure+of+the+ALK+%28Anaplastic+Lymphoma+Kinase%29+Catalytic+Domain&doi=10.1042%2FBJ20100609"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structure of the ALK (anaplastic lymphoma kinase) catalytic domain</span></div><div class="casAuthors">Lee, Christian C.; Jia, Yong; Li, Nanxin; Sun, Xiuying; Ng, Kenneth; Ambing, Eileen; Gao, Mu-Yun; Hua, Su; Chen, Connie; Kim, Sungjoon; Michellys, Pierre-Yves; Lesley, Scott A.; Harris, Jennifer L.; Spraggon, Glen</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Journal</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">430</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">425-437</span>CODEN:
                <span class="NLM_cas:coden">BIJOAK</span>;
        ISSN:<span class="NLM_cas:issn">0264-6021</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">ALK (anaplastic lymphoma kinase) is an RTK (receptor tyrosine kinase) of the IRK (insulin receptor kinase) superfamily, which share an YXXXYY autophosphorylation motif within their A-loops (activation loops).  A common activation and regulatory mechanism is believed to exist for members of this superfamily typified by IRK and IGF1RK (insulin-like growth factor receptor kinase-1).  Chromosomal translocations involving ALK were first identified in anaplastic large-cell lymphoma, a subtype of non-Hodgkin's lymphoma, where aberrant fusion of the ALK kinase domain with the NPM (nucleophosmin) dimerization domain results in autophosphosphorylation and ligand-independent activation.  Activating mutations within the full-length ALK kinase domain, most commonly R1275Q and F1174L, which play a major role in neuroblastoma, were recently identified.  To provide a structural framework for understanding these mutations and to guide structure-assisted drug discovery efforts, the X-ray crystal structure of the unphosphorylated ALK catalytic domain was detd. in the apo, ADP-, and staurosporine-bound forms.  The structures reveal a partially inactive protein kinase conformation distinct from, and lacking, many of the neg. regulatory features obsd. in inactive IGF1RK/IRK structures in their unphosphorylated forms.  The A-loop adopts an inhibitory pose where a short proximal A-loop helix (αAL) packs against the αC helix and a novel N-terminal β-turn motif, whereas the distal portion obstructs part of the predicted peptide-binding region.  The structure helps explain the reported unique peptide substrate specificity and the importance of phosphorylation of the first A-loop Tyr1278 for kinase activity and NPM-ALK transforming potential.  A single amino acid difference in the ALK substrate peptide binding P-1 site (where the P-site is the phosphoacceptor site) was identified such that in conjunction with A-loop sequence variation including the RAS (Arg-Ala-Ser)-motif, rationalizes the difference in the A-loop tyrosine autophosphorylation preference between ALK and IGF1RK/IRK.  Enzymic anal. of recombinant R1275Q and F1174L ALK mutant catalytic domains confirms the enhanced activity and transforming potential of these mutants.  The transforming ability of the full-length ALK mutants in soft agar colony growth assays corroborates these findings.  The availability of a three-dimensional structure for ALK will facilitate future structure-function and rational drug design efforts targeting this receptor tyrosine kinase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWD8K_u619kbVg90H21EOLACvtfcHk0lgvOEPM0yTmbA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVyrtbzF&md5=e9e4f5bc0b22e3e2289eecfa10309c16</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1042%2FBJ20100609&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FBJ20100609%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DC.%2BC.%26aulast%3DJia%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DN.%26aulast%3DSun%26aufirst%3DX.%26aulast%3DNg%26aufirst%3DK.%26aulast%3DAmbing%26aufirst%3DE.%26aulast%3DGao%26aufirst%3DM.-Y.%26aulast%3DHua%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DMichellys%26aufirst%3DP.-Y.%26aulast%3DLesley%26aufirst%3DS.%2BA.%26aulast%3DHarris%26aufirst%3DJ.%2BL.%26aulast%3DSpraggon%26aufirst%3DG.%26atitle%3DCrystal%2520Structure%2520of%2520the%2520ALK%2520%2528Anaplastic%2520Lymphoma%2520Kinase%2529%2520Catalytic%2520Domain%26jtitle%3DBiochem.%2520J.%26date%3D2010%26volume%3D430%26spage%3D425%26epage%3D437%26doi%3D10.1042%2FBJ20100609" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hallberg, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmer, R. H.</span></span> <span> </span><span class="NLM_article-title">The Role of the ALK Receptor in Cancer Biology</span>. <i>Ann. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">iii4</span>– <span class="NLM_lpage">iii15</span>, <span class="refDoi"> DOI: 10.1093/annonc/mdw301</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1093%2Fannonc%2Fmdw301" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=27573755" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2016&pages=iii4-iii15&author=B.+Hallbergauthor=R.+H.+Palmer&title=The+Role+of+the+ALK+Receptor+in+Cancer+Biology&doi=10.1093%2Fannonc%2Fmdw301"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdw301&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdw301%26sid%3Dliteratum%253Aachs%26aulast%3DHallberg%26aufirst%3DB.%26aulast%3DPalmer%26aufirst%3DR.%2BH.%26atitle%3DThe%2520Role%2520of%2520the%2520ALK%2520Receptor%2520in%2520Cancer%2520Biology%26jtitle%3DAnn.%2520Oncol.%26date%3D2016%26volume%3D27%26spage%3Diii4%26epage%3Diii15%26doi%3D10.1093%2Fannonc%2Fmdw301" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tartari, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunby, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coluccia, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sottocornola, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cimbro, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scapozza, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donella-Deana, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinna, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gambacorti-Passerini, C.</span></span> <span> </span><span class="NLM_article-title">Characterization of Some Molecular Mechanisms Governing Autoactivation of the Catalytic Domain of the Anaplastic Lymphoma Kinase</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>283</i></span>,  <span class="NLM_fpage">3743</span>– <span class="NLM_lpage">3750</span>, <span class="refDoi"> DOI: 10.1074/jbc.M706067200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1074%2Fjbc.M706067200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=18070884" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhs1WgsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=283&publication_year=2008&pages=3743-3750&author=C.+J.+Tartariauthor=R.+H.+Gunbyauthor=A.+M.+Colucciaauthor=R.+Sottocornolaauthor=B.+Cimbroauthor=L.+Scapozzaauthor=A.+Donella-Deanaauthor=L.+A.+Pinnaauthor=C.+Gambacorti-Passerini&title=Characterization+of+Some+Molecular+Mechanisms+Governing+Autoactivation+of+the+Catalytic+Domain+of+the+Anaplastic+Lymphoma+Kinase&doi=10.1074%2Fjbc.M706067200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of Some Molecular Mechanisms Governing Autoactivation of the Catalytic Domain of the Anaplastic Lymphoma Kinase</span></div><div class="casAuthors">Tartari, Carmen J.; Gunby, Rosalind H.; Coluccia, Addolorata M. L.; Sottocornola, Roberta; Cimbro, Barbara; Scapozza, Leonardo; Donella-Deana, Arianna; Pinna, Lorenzo A.; Gambacorti-Passerini, Carlo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">283</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3743-3750</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">NPM/ALK is an oncogenic fusion protein expressed in ∼50% of anaplastic large cell lymphoma cases.  It derives from the t(2;5)(p23;q35) chromosomal translocation that fuses the catalytic domain of the tyrosine kinase, anaplastic lymphoma kinase (ALK), with the dimerization domain of the ubiquitously expressed nucleophosmin (NPM) protein.  Dimerization of the ALK kinase domain leads to its autophosphorylation and constitutive activation.  Activated NPM/ALK stimulates downstream survival and proliferation signaling pathways leading to malignant transformation.  Herein, we investigated the mol. mechanisms of autoactivation of the catalytic domain of ALK.  Because kinases are typically regulated by autophosphorylation of their activation loops, we systematically mutated (Tyr Phe) three potential autophosphorylation sites contained in the "YXXXYY" motif of the ALK activation loop, and detd. the effect of these mutations on the catalytic activity and biol. function of NPM/ALK.  We obsd. that mutation of both the second and third tyrosine residues (YFF mutant) did not affect the kinase activity or transforming ability of NPM/ALK.  In contrast, mutation of the first and second (FFY), first and third (FYF), or all three (FFF) tyrosine residues impaired both kinase activity and transforming ability of NPM/ALK.  Furthermore, a DFF mutant, in which the aspartic residue introduces a neg. charge similar to a phosphorylated tyrosine, possessed catalytic activity similar to the YFF mutant.  Together, our findings indicate that phosphorylation of the first tyrosine of the YXXXYY motif is necessary for the autoactivation of the ALK kinase domain and the transforming activity of NPM/ALK.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGop38yy8tqZ5LVg90H21EOLACvtfcHk0lg5powLGDoTLQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhs1WgsL8%253D&md5=b6089571580540b97253db0b916e6ed3</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M706067200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M706067200%26sid%3Dliteratum%253Aachs%26aulast%3DTartari%26aufirst%3DC.%2BJ.%26aulast%3DGunby%26aufirst%3DR.%2BH.%26aulast%3DColuccia%26aufirst%3DA.%2BM.%26aulast%3DSottocornola%26aufirst%3DR.%26aulast%3DCimbro%26aufirst%3DB.%26aulast%3DScapozza%26aufirst%3DL.%26aulast%3DDonella-Deana%26aufirst%3DA.%26aulast%3DPinna%26aufirst%3DL.%2BA.%26aulast%3DGambacorti-Passerini%26aufirst%3DC.%26atitle%3DCharacterization%2520of%2520Some%2520Molecular%2520Mechanisms%2520Governing%2520Autoactivation%2520of%2520the%2520Catalytic%2520Domain%2520of%2520the%2520Anaplastic%2520Lymphoma%2520Kinase%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2008%26volume%3D283%26spage%3D3743%26epage%3D3750%26doi%3D10.1074%2Fjbc.M706067200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bai, R.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ouyang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miething, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morris, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peschel, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duyster, J.</span></span> <span> </span><span class="NLM_article-title">Nucleophosmin–anaplastic Lymphoma Kinase Associated with Anaplastic Large-cell Lymphoma Activates the Phosphatidylinositol 3-kinase/Akt antiapoptotic Signaling Pathway</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>96</i></span>,  <span class="NLM_fpage">4319</span>– <span class="NLM_lpage">4327</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1182%2Fblood.V96.13.4319" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=11110708" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BD3cXosl2htLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=2000&pages=4319-4327&author=R.-Y.+Baiauthor=T.+Ouyangauthor=C.+Miethingauthor=S.+W.+Morrisauthor=C.+Peschelauthor=J.+Duyster&title=Nucleophosmin%E2%80%93anaplastic+Lymphoma+Kinase+Associated+with+Anaplastic+Large-cell+Lymphoma+Activates+the+Phosphatidylinositol+3-kinase%2FAkt+antiapoptotic+Signaling+Pathway"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Nucleophosmin-anaplastic lymphoma kinase associated with anaplastic large-cell lymphoma activates the phosphatidylinositol 3-kinase/Akt antiapoptotic signaling pathway</span></div><div class="casAuthors">Bai, Ren-Yuan; Ouyang, Tao; Miething, Cornelius; Morris, Stephan W.; Peschel, Christian; Duyster, Justus</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">96</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">4319-4327</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">More than half of anaplastic large-cell lymphomas (ALCLs) have a chromosomal translocation t(2;5) that leads to the expression of a hybrid protein composed of the nucleolar phosphoprotein nucleophosmin (NPM) and the anaplastic lymphoma kinase (ALK) that exhibits an unregulated tyrosine kinase activity.  We have previously identified PLC-γ as a crucial downstream signaling mol. of NPM-ALK that contributes to its mitogenic potential.  Here, we show that NPM-ALK recruits the C-terminal SH2 domain of the phosphatidylinositol 3-kinase (PI 3-kinase) p85 subunit.  PI 3-kinase assays revealed that the kinase is activated by NPM-ALK in vivo, in turn activating PKB/Akt in NPM-ALK-expressing cells.  The use of 2 specific PI 3-kinase inhibitors, wortmannin and LY294002, demonstrated the requirement of PI 3-kinase for the growth of NPM-ALK-transformed cell lines, as well as a cell line established from a patient with ALCL.  Primary murine bone marrow retrovirally transduced with NPM-ALK showed a transformed phenotype that was reversible on treatment with PI 3-kinase inhibitors.  Flow cytometric anal. revealed that wortmannin-treated NPM-ALK-transformed cell lines underwent apoptosis.  Furthermore, apoptosis induced by overexpression of the proapoptotic mol. Bad could be partially blocked by the overexpression of NPM-ALK.  Thus, NPM-ALK activates the antiapoptotic PI 3-kinase/Akt pathway, which likely contributes to the mol. pathogenesis of ALCL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkqKB28Z-9f7Vg90H21EOLACvtfcHk0lhy_tGsyFQkag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXosl2htLg%253D&md5=cc7077b113a3ab10d76f9915aad6592d</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1182%2Fblood.V96.13.4319&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood.V96.13.4319%26sid%3Dliteratum%253Aachs%26aulast%3DBai%26aufirst%3DR.-Y.%26aulast%3DOuyang%26aufirst%3DT.%26aulast%3DMiething%26aufirst%3DC.%26aulast%3DMorris%26aufirst%3DS.%2BW.%26aulast%3DPeschel%26aufirst%3DC.%26aulast%3DDuyster%26aufirst%3DJ.%26atitle%3DNucleophosmin%25E2%2580%2593anaplastic%2520Lymphoma%2520Kinase%2520Associated%2520with%2520Anaplastic%2520Large-cell%2520Lymphoma%2520Activates%2520the%2520Phosphatidylinositol%25203-kinase%252FAkt%2520antiapoptotic%2520Signaling%2520Pathway%26jtitle%3DBlood%26date%3D2000%26volume%3D96%26spage%3D4319%26epage%3D4327" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ruchatz, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coluccia, A. M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stano, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marchesi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gambacorti-Passerini, C.</span></span> <span> </span><span class="NLM_article-title">Constitutive Activation of Jak2 Contributes to Proliferation and Resistance to Apoptosis in NPM/ALK-transformed Cells</span>. <i>Exp. Hematol.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">309</span>– <span class="NLM_lpage">315</span>, <span class="refDoi"> DOI: 10.1016/S0301-472X(03)00007-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1016%2FS0301-472X%2803%2900007-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=12691918" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BD3sXislChtrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2003&pages=309-315&author=H.+Ruchatzauthor=A.+M.+L.+Colucciaauthor=P.+Stanoauthor=E.+Marchesiauthor=C.+Gambacorti-Passerini&title=Constitutive+Activation+of+Jak2+Contributes+to+Proliferation+and+Resistance+to+Apoptosis+in+NPM%2FALK-transformed+Cells&doi=10.1016%2FS0301-472X%2803%2900007-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Constitutive activation of Jak2 contributes to proliferation and resistance to apoptosis in NPM/ALK-transformed cells</span></div><div class="casAuthors">Ruchatz, Holger; Coluccia, Addolorata Maria Luce; Stano, Paola; Marchesi, Edoardo; Gambacorti-Passerini, Carlo</div><div class="citationInfo"><span class="NLM_cas:title">Experimental Hematology (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">309-315</span>CODEN:
                <span class="NLM_cas:coden">EXHMA6</span>;
        ISSN:<span class="NLM_cas:issn">0301-472X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Inc.</span>)
        </div><div class="casAbstract">The t(2;5) translocation results in a 80-kDa oncogenic fusion protein consisting of NPM and the kinase domain of the tyrosine kinase ALK and is present in over half the cases of anaplastic large cell lymphoma (ALCL).  NPM/ALK exerts its transforming potential via activation of multiple signaling pathways promoting growth factor independence and protection from apoptosis.  Jak/Stat signaling is aberrantly activated in several human hematopoietic malignancies.  We investigated the role of Jak2 in the context of NPM/ALK-mediated oncogenesis.  Constitutive tyrosine phosphorylation of Jak2 was analyzed by Jak2 immunopptn. and subsequent anti-phosphotyrosine Western blotting.  NPM/ALK-transformed cells were treated with the Jak2 inhibitor AG490 or transfected with wild-type or dominant-neg. Jak2 expression constructs to measure [3H]-thymidine incorporation.  Apoptosis was assessed by flow cytometric anal. of annexin V-stained cells.  The effect of Jak2 on Stat5-dependent transcriptional activity was measured by β-casein promoter-dependent luciferase expression.  Jak2 was found to be constitutively tyrosine phosphorylated in ALCL cells and in NPM/ALK-transformed hematopoietic cells.  Also, NPM/ALK was present in immunoppts. of Jak2.  Inhibition of Jak2 led to a redn. of NPM/ALK-mediated proliferation and induced apoptosis.  Stat5-dependent transcriptional activity was inhibited by transfection of NPM/ALK-transformed cells with a dominant-neg. Jak2 expression construct or treatment with AG490.  Constitutive activation of Jak2 constitutes a pro-proliferative, anti-apoptotic signaling pathway in NPM/ALK-transformed hematopoietic cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9lWibjrvvMLVg90H21EOLACvtfcHk0lhy_tGsyFQkag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXislChtrg%253D&md5=4bd66278ccee9af218d0c2d133515e6a</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1016%2FS0301-472X%2803%2900007-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0301-472X%252803%252900007-9%26sid%3Dliteratum%253Aachs%26aulast%3DRuchatz%26aufirst%3DH.%26aulast%3DColuccia%26aufirst%3DA.%2BM.%2BL.%26aulast%3DStano%26aufirst%3DP.%26aulast%3DMarchesi%26aufirst%3DE.%26aulast%3DGambacorti-Passerini%26aufirst%3DC.%26atitle%3DConstitutive%2520Activation%2520of%2520Jak2%2520Contributes%2520to%2520Proliferation%2520and%2520Resistance%2520to%2520Apoptosis%2520in%2520NPM%252FALK-transformed%2520Cells%26jtitle%3DExp.%2520Hematol.%26date%3D2003%26volume%3D31%26spage%3D309%26epage%3D315%26doi%3D10.1016%2FS0301-472X%2803%2900007-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Berry, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luther, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhatnagar, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jamin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poon, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanda, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pei, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vetharoy, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hallsworth, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmad, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barker, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreau, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webber, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez-Atayde, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodig, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheung, N.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raynaud, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hallberg, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pearson, A. D.J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eccles, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chesler, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">George, R. E.</span></span> <span> </span><span class="NLM_article-title">The ALKF1174L Mutation Potentiates the Oncogenic Activity of MYCN in Neuroblastoma</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">117</span>– <span class="NLM_lpage">130</span>, <span class="refDoi"> DOI: 10.1016/j.ccr.2012.06.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1016%2Fj.ccr.2012.06.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=22789543" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVSltLzJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=117-130&author=T.+Berryauthor=W.+Lutherauthor=N.+Bhatnagarauthor=Y.+Jaminauthor=E.+Poonauthor=T.+Sandaauthor=D.+Peiauthor=B.+Sharmaauthor=W.+R.+Vetharoyauthor=A.+Hallsworthauthor=Z.+Ahmadauthor=K.+Barkerauthor=L.+Moreauauthor=H.+Webberauthor=W.+Wangauthor=Q.+Liuauthor=A.+Perez-Ataydeauthor=S.+Rodigauthor=N.-K.+Cheungauthor=F.+Raynaudauthor=B.+Hallbergauthor=S.+P.+Robinsonauthor=N.+S.+Grayauthor=A.+D.J.+Pearsonauthor=S.+A.+Ecclesauthor=L.+Cheslerauthor=R.+E.+George&title=The+ALKF1174L+Mutation+Potentiates+the+Oncogenic+Activity+of+MYCN+in+Neuroblastoma&doi=10.1016%2Fj.ccr.2012.06.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">The ALKF1174L Mutation Potentiates the Oncogenic Activity of MYCN in Neuroblastoma</span></div><div class="casAuthors">Berry, Teeara; Luther, William; Bhatnagar, Namrata; Jamin, Yann; Poon, Evon; Sanda, Takaomi; Pei, Desheng; Sharma, Bandana; Vetharoy, Winston R.; Hallsworth, Albert; Ahmad, Zai; Barker, Karen; Moreau, Lisa; Webber, Hannah; Wang, Wenchao; Liu, Qingsong; Perez-Atayde, Antonio; Rodig, Scott; Cheung, Nai-Kong; Raynaud, Florence; Hallberg, Bengt; Robinson, Simon P.; Gray, Nathanael S.; Pearson, Andrew D. J.; Eccles, Suzanne A.; Chesler, Louis; George, Rani E.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">117-130</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">The ALKF1174L mutation is assocd. with intrinsic and acquired resistance to crizotinib and cosegregates with MYCN in neuroblastoma.  In this study, we generated a mouse model overexpressing ALKF1174L in the neural crest.  Compared to ALKF1174L and MYCN alone, co-expression of these two oncogenes led to the development of neuroblastomas with earlier onset, higher penetrance, and enhanced lethality.  ALKF1174L/MYCN tumors exhibited increased MYCN dosage due to ALKF1174L-induced activation of the PI3K/AKT/mTOR and MAPK pathways, coupled with suppression of MYCN pro-apoptotic effects.  Combined treatment with the ATP-competitive mTOR inhibitor Torin2 overcame the resistance of ALKF1174L/MYCN tumors to crizotinib.  Our findings demonstrate a pathogenic role for ALKF1174L in neuroblastomas overexpressing MYCN and suggest a strategy for improving targeted therapy for ALK-pos. neuroblastoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQvwCqpbNJsbVg90H21EOLACvtfcHk0lhIub7BjuKM4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVSltLzJ&md5=17eaed93b440461999c4f8f099f57723</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2012.06.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2012.06.001%26sid%3Dliteratum%253Aachs%26aulast%3DBerry%26aufirst%3DT.%26aulast%3DLuther%26aufirst%3DW.%26aulast%3DBhatnagar%26aufirst%3DN.%26aulast%3DJamin%26aufirst%3DY.%26aulast%3DPoon%26aufirst%3DE.%26aulast%3DSanda%26aufirst%3DT.%26aulast%3DPei%26aufirst%3DD.%26aulast%3DSharma%26aufirst%3DB.%26aulast%3DVetharoy%26aufirst%3DW.%2BR.%26aulast%3DHallsworth%26aufirst%3DA.%26aulast%3DAhmad%26aufirst%3DZ.%26aulast%3DBarker%26aufirst%3DK.%26aulast%3DMoreau%26aufirst%3DL.%26aulast%3DWebber%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DPerez-Atayde%26aufirst%3DA.%26aulast%3DRodig%26aufirst%3DS.%26aulast%3DCheung%26aufirst%3DN.-K.%26aulast%3DRaynaud%26aufirst%3DF.%26aulast%3DHallberg%26aufirst%3DB.%26aulast%3DRobinson%26aufirst%3DS.%2BP.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DPearson%26aufirst%3DA.%2BD.J.%26aulast%3DEccles%26aufirst%3DS.%2BA.%26aulast%3DChesler%26aufirst%3DL.%26aulast%3DGeorge%26aufirst%3DR.%2BE.%26atitle%3DThe%2520ALKF1174L%2520Mutation%2520Potentiates%2520the%2520Oncogenic%2520Activity%2520of%2520MYCN%2520in%2520Neuroblastoma%26jtitle%3DCancer%2520Cell%26date%3D2012%26volume%3D22%26spage%3D117%26epage%3D130%26doi%3D10.1016%2Fj.ccr.2012.06.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schönherr, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruuth, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamaraj, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Combaret, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Djos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinsson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christensen, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmer, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hallberg, B.</span></span> <span> </span><span class="NLM_article-title">Anaplastic Lymphoma Kinase (ALK) Regulates Initiation of Transcription of MYCN in Neuroblastoma cells</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">5193</span>– <span class="NLM_lpage">5200</span>, <span class="refDoi"> DOI: 10.1038/onc.2012.12</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1038%2Fonc.2012.12" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=22286764" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A280%3ADC%252BC38vhsVGktg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2012&pages=5193-5200&author=C.+Sch%C3%B6nherrauthor=K.+Ruuthauthor=S.+Kamarajauthor=C.-L.+Wangauthor=H.-L.+Yangauthor=V.+Combaretauthor=A.+Djosauthor=T.+Martinssonauthor=J.+G.+Christensenauthor=R.+H.+Palmerauthor=B.+Hallberg&title=Anaplastic+Lymphoma+Kinase+%28ALK%29+Regulates+Initiation+of+Transcription+of+MYCN+in+Neuroblastoma+cells&doi=10.1038%2Fonc.2012.12"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Anaplastic Lymphoma Kinase (ALK) regulates initiation of transcription of MYCN in neuroblastoma cells</span></div><div class="casAuthors">Schonherr C; Ruuth K; Kamaraj S; Wang C-L; Yang H-L; Combaret V; Djos A; Martinsson T; Christensen J G; Palmer R H; Hallberg B</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">50</span>),
    <span class="NLM_cas:pages">5193-200</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Neuroblastoma is a neural crest-derived embryonal tumour of the postganglionic sympathetic nervous system and a disease with several different chromosomal gains and losses, which include MYCN-amplified neuroblastoma on chromosome 2, deletions of parts of the chromosomes 1p and 11q, gain of parts of 17q and triploidy.  Recently, activating mutations of the ALK (Anaplastic Lymphoma Kinase) RTK (Receptor Tyrosine Kinase) gene have been described in neuroblastoma.  A meta-analysis of neuroblastoma cases revealed that ALK mutations (49 of 709 cases) in relation to genomic subtype were most frequently observed in MYCN amplified tumours (8.9%), correlating with a poor clinical outcome.  MYCN proteins target proliferation and apoptotic pathways, and have an important role in the progression of neuroblastoma.  Here, we show that both wild-type and gain-of-function mutants in ALK are able to stimulate transcription at the MYCN promoter and initiate mRNA transcription of the MYCN gene in both neuronal and neuroblastoma cell lines.  Further, this stimulation of MYCN gene transcription and de novo MYCN protein expression is abrogated by specific ALK inhibitors, such as crizotinib (PF-2341066), NVP-TAE684, and by small interfering RNA to ALK resulting in a decrease in proliferation rate.  Finally, co-transfection of ALK gain-of-function mutations together with MYCN leads to an increase in transformation potential.  Taken together, our results indicate that ALK signalling regulates initiation of transcription of the MYCN gene providing a possible explanation for the poor clinical outcome observed when MYCN is amplified together with activated ALK.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQD76YHu5cthoqdXsLcGTEUfW6udTcc2eayFiSr-nK-D7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38vhsVGktg%253D%253D&md5=e74e929dc9a43ba57fabd85e44e659d3</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1038%2Fonc.2012.12&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fonc.2012.12%26sid%3Dliteratum%253Aachs%26aulast%3DSch%25C3%25B6nherr%26aufirst%3DC.%26aulast%3DRuuth%26aufirst%3DK.%26aulast%3DKamaraj%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DC.-L.%26aulast%3DYang%26aufirst%3DH.-L.%26aulast%3DCombaret%26aufirst%3DV.%26aulast%3DDjos%26aufirst%3DA.%26aulast%3DMartinsson%26aufirst%3DT.%26aulast%3DChristensen%26aufirst%3DJ.%2BG.%26aulast%3DPalmer%26aufirst%3DR.%2BH.%26aulast%3DHallberg%26aufirst%3DB.%26atitle%3DAnaplastic%2520Lymphoma%2520Kinase%2520%2528ALK%2529%2520Regulates%2520Initiation%2520of%2520Transcription%2520of%2520MYCN%2520in%2520Neuroblastoma%2520cells%26jtitle%3DOncogene%26date%3D2012%26volume%3D31%26spage%3D5193%26epage%3D5200%26doi%3D10.1038%2Fonc.2012.12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez-Atayde, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kutok, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodig, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neuberg, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Helman, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">George, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanki, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Look, A. T.</span></span> <span> </span><span class="NLM_article-title">Activated ALK Collaborates with MYCN in Neuroblastoma Pathogenesis</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">362</span>– <span class="NLM_lpage">373</span>, <span class="refDoi"> DOI: 10.1016/j.ccr.2012.02.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1016%2Fj.ccr.2012.02.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=22439933" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC38Xkt1ymur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2012&pages=362-373&author=S.+Zhuauthor=J.-S.+Leeauthor=F.+Guoauthor=J.+Shinauthor=A.+R.+Perez-Ataydeauthor=J.+L.+Kutokauthor=S.+J.+Rodigauthor=D.+S.+Neubergauthor=D.+Helmanauthor=H.+Fengauthor=R.+A.+Stewartauthor=W.+Wangauthor=R.+E.+Georgeauthor=J.+P.+Kankiauthor=A.+T.+Look&title=Activated+ALK+Collaborates+with+MYCN+in+Neuroblastoma+Pathogenesis&doi=10.1016%2Fj.ccr.2012.02.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Activated ALK Collaborates with MYCN in Neuroblastoma Pathogenesis</span></div><div class="casAuthors">Zhu, Shizhen; Lee, Jeong-Soo; Guo, Feng; Shin, Jimann; Perez-Atayde, Antonio R.; Kutok, Jeffery L.; Rodig, Scott J.; Neuberg, Donna S.; Helman, Daniel; Feng, Hui; Stewart, Rodney A.; Wang, Wenchao; George, Rani E.; Kanki, John P.; Look, A. Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">362-373</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Amplification of the MYCN oncogene in childhood neuroblastoma is often accompanied by mutational activation of ALK (anaplastic lymphoma kinase), suggesting their pathogenic cooperation.  We generated a transgenic zebrafish model of neuroblastoma in which MYCN-induced tumors arise from a subpopulation of neuroblasts that migrate into the adrenal medulla analog following organogenesis.  Coexpression of activated ALK with MYCN in this model triples the disease penetrance and markedly accelerates tumor onset.  MYCN overexpression induces adrenal sympathetic neuroblast hyperplasia, blocks chromaffin cell differentiation, and ultimately triggers a developmentally-timed apoptotic response in the hyperplastic sympathoadrenal cells.  Coexpression of activated ALK with MYCN provides prosurvival signals that block this apoptotic response and allow continued expansion and oncogenic transformation of hyperplastic neuroblasts, thus promoting progression to neuroblastoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqsKEhBF_umXbVg90H21EOLACvtfcHk0lg3wpm1xIW5EQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xkt1ymur8%253D&md5=2ba0ffaa43656604d6269ff8a3e9052d</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2012.02.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2012.02.010%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DS.%26aulast%3DLee%26aufirst%3DJ.-S.%26aulast%3DGuo%26aufirst%3DF.%26aulast%3DShin%26aufirst%3DJ.%26aulast%3DPerez-Atayde%26aufirst%3DA.%2BR.%26aulast%3DKutok%26aufirst%3DJ.%2BL.%26aulast%3DRodig%26aufirst%3DS.%2BJ.%26aulast%3DNeuberg%26aufirst%3DD.%2BS.%26aulast%3DHelman%26aufirst%3DD.%26aulast%3DFeng%26aufirst%3DH.%26aulast%3DStewart%26aufirst%3DR.%2BA.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DGeorge%26aufirst%3DR.%2BE.%26aulast%3DKanki%26aufirst%3DJ.%2BP.%26aulast%3DLook%26aufirst%3DA.%2BT.%26atitle%3DActivated%2520ALK%2520Collaborates%2520with%2520MYCN%2520in%2520Neuroblastoma%2520Pathogenesis%26jtitle%3DCancer%2520Cell%26date%3D2012%26volume%3D21%26spage%3D362%26epage%3D373%26doi%3D10.1016%2Fj.ccr.2012.02.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Martelli, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sozzi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hernandez, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pettirossi, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Navarro, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conte, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gasparini, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perrone, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Modena, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pastorino, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carbone, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fabbri, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sidoni, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakamura, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gambacorta, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandez, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramirez, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, J. K.C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grigioni, W. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campo, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pileri, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Falini, B.</span></span> <span> </span><span class="NLM_article-title">EML4-ALK Rearrangement in Non-small Cell Lung Cancer and Non-tumor Lung Tissues</span>. <i>Am. J. Pathol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>174</i></span>,  <span class="NLM_fpage">661</span>– <span class="NLM_lpage">670</span>, <span class="refDoi"> DOI: 10.2353/ajpath.2009.080755</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.2353%2Fajpath.2009.080755" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=19147828" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BD1MXivVWntLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=174&publication_year=2009&pages=661-670&author=M.+P.+Martelliauthor=G.+Sozziauthor=L.+Hernandezauthor=V.+Pettirossiauthor=A.+Navarroauthor=D.+Conteauthor=P.+Gaspariniauthor=F.+Perroneauthor=P.+Modenaauthor=U.+Pastorinoauthor=A.+Carboneauthor=A.+Fabbriauthor=A.+Sidoniauthor=S.+Nakamuraauthor=M.+Gambacortaauthor=P.+L.+Fernandezauthor=J.+Ramirezauthor=J.+K.C.+Chanauthor=W.+F.+Grigioniauthor=E.+Campoauthor=S.+A.+Pileriauthor=B.+Falini&title=EML4-ALK+Rearrangement+in+Non-small+Cell+Lung+Cancer+and+Non-tumor+Lung+Tissues&doi=10.2353%2Fajpath.2009.080755"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">EML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissues</span></div><div class="casAuthors">Martelli, Maria Paola; Sozzi, Gabriella; Hernandez, Luis; Pettirossi, Valentina; Navarro, Alba; Conte, Davide; Gasparini, Patrizia; Perrone, Federica; Modena, Piergiorgio; Pastorino, Ugo; Carbone, Antonino; Fabbri, Alessandra; Sidoni, Angelo; Nakamura, Shigeo; Gambacorta, Marcello; Fernandez, Pedro Luis; Ramirez, Jose; Chan, John K. C.; Grigioni, Walter Franco; Campo, Elias; Pileri, Stefano A.; Falini, Brunangelo</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Pathology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">174</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">661-670</span>CODEN:
                <span class="NLM_cas:coden">AJPAA4</span>;
        ISSN:<span class="NLM_cas:issn">0002-9440</span>.
    
            (<span class="NLM_cas:orgname">American Society for Investigative Pathology</span>)
        </div><div class="casAbstract">A fusion gene, echinoderm microtubule assocd. protein like 4 - anaplastic lymphoma kinase (EML4-ALK), with transforming activity has recently been identified in a subset of non-small cell lung cancer (NSCLC), but its pathogenetic, diagnostic, and therapeutic roles remain unclear.  Both frequency and type of EML4-ALK transcripts were investigated by reverse transcription PCR in 120 frozen NSCLC specimens from Italy and Spain; non-neoplastic lung tissues taken far from the tumor were used as controls.  In cases carrying the fusion transcript, we detd. EML4-ALK gene and protein levels using fluorescence in situ hybridization, Western blotting, and immunopptn.  We also analyzed ALK protein levels in paraffin samples from 662 NSCLC specimens, including the 120 cases investigated in the mol. studies.  EML4-ALK transcripts (variants 1 and 3) were detected in 9 of 120 NSCLC samples but were not specific for NSCLC since they were also found in non-cancerous lung tissues taken far from the tumor.  Notably, no transcripts were detected in matching tumor samples from these patients.  Fluorescence in situ hybridization anal. of cases expressing EML4-ALK transcripts showed that only a minority of cells harbored the EML4-ALK gene.  None of these cases was found to express the EML4-ALK protein as examd. by immunohistochem., Western blotting, and immunopptn.  The EML4-ALK transcript cannot be regarded as a specific diagnostic tool for NSCLC.  Our results show therefore that the causal role and value of EML4-ALK as a therapeutic target remain to be defined.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYd62xRrWU0LVg90H21EOLACvtfcHk0lg3wpm1xIW5EQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXivVWntLo%253D&md5=de2ae3f7a31558e1d6ad18c2c9b7dcc5</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.2353%2Fajpath.2009.080755&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2353%252Fajpath.2009.080755%26sid%3Dliteratum%253Aachs%26aulast%3DMartelli%26aufirst%3DM.%2BP.%26aulast%3DSozzi%26aufirst%3DG.%26aulast%3DHernandez%26aufirst%3DL.%26aulast%3DPettirossi%26aufirst%3DV.%26aulast%3DNavarro%26aufirst%3DA.%26aulast%3DConte%26aufirst%3DD.%26aulast%3DGasparini%26aufirst%3DP.%26aulast%3DPerrone%26aufirst%3DF.%26aulast%3DModena%26aufirst%3DP.%26aulast%3DPastorino%26aufirst%3DU.%26aulast%3DCarbone%26aufirst%3DA.%26aulast%3DFabbri%26aufirst%3DA.%26aulast%3DSidoni%26aufirst%3DA.%26aulast%3DNakamura%26aufirst%3DS.%26aulast%3DGambacorta%26aufirst%3DM.%26aulast%3DFernandez%26aufirst%3DP.%2BL.%26aulast%3DRamirez%26aufirst%3DJ.%26aulast%3DChan%26aufirst%3DJ.%2BK.C.%26aulast%3DGrigioni%26aufirst%3DW.%2BF.%26aulast%3DCampo%26aufirst%3DE.%26aulast%3DPileri%26aufirst%3DS.%2BA.%26aulast%3DFalini%26aufirst%3DB.%26atitle%3DEML4-ALK%2520Rearrangement%2520in%2520Non-small%2520Cell%2520Lung%2520Cancer%2520and%2520Non-tumor%2520Lung%2520Tissues%26jtitle%3DAm.%2520J.%2520Pathol.%26date%3D2009%26volume%3D174%26spage%3D661%26epage%3D670%26doi%3D10.2353%2Fajpath.2009.080755" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jin, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeon, H.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, H.-G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoo, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cha, S. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, T. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jheon, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, J. Y.</span></span> <span> </span><span class="NLM_article-title">EML4-ALK Fusion Gene in Korean Non-small Cell Lung Cancer</span>. <i>J. Korean Med. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">228</span>– <span class="NLM_lpage">230</span>, <span class="refDoi"> DOI: 10.3346/jkms.2012.27.2.228</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.3346%2Fjkms.2012.27.2.228" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=22323876" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC38Xks1Sis7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2012&pages=228-230&author=G.+Jinauthor=H.-S.+Jeonauthor=E.+B.+Leeauthor=H.-G.+Kangauthor=S.+S.+Yooauthor=S.+Y.+Leeauthor=J.+H.+Leeauthor=S.+I.+Chaauthor=T.+I.+Parkauthor=C.+H.+Kimauthor=S.+H.+Jheonauthor=J.+Y.+Park&title=EML4-ALK+Fusion+Gene+in+Korean+Non-small+Cell+Lung+Cancer&doi=10.3346%2Fjkms.2012.27.2.228"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">EML4-ALK fusion gene in Korean non-small cell lung cancer</span></div><div class="casAuthors">Jin, Guang; Jeon, Hyo-Sung; Lee, Eung Bae; Kang, Hyo-Gyoung; Yoo, Seung Soo; Lee, Shin Yup; Lee, Jae Hee; Cha, Sung Ick; Park, Tae In; Kim, Chang Ho; Jheon, Sang Hoon; Park, Jae Yong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Korean Medical Science</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">228-230</span>CODEN:
                <span class="NLM_cas:coden">JKMSEH</span>;
        ISSN:<span class="NLM_cas:issn">1011-8934</span>.
    
            (<span class="NLM_cas:orgname">Korean Academy of Medical Sciences</span>)
        </div><div class="casAbstract">A fusion gene between echinoderm microtubule-assocd. protein-like 4 (EML4) and the anaplastic lymphoma kinase (ALK) has been identified in non-small cell lung cancers (NSCLCs).  Although a few studies have evaluated EML4-ALK fusion genes in Korean NSCLCs, the prevalence of different EML4-ALK fusion variants has yet to be clearly assessed.  Herein, we have examd. the profiles of EML4-ALK fusion gene variants in Korean patients of NSCLCs.  EML4-ALK fusion genes have been detected in 10 (6.0%) of 167 patients of NSCLCs and in 9 (7.4%) of 121 patients of adenocarcinoma.  Of the 10 patients with fusion genes identified, 8 (80%) were E13;A20 (variant 1) and 2 (20%) were E6;A20, with an addnl. 33-bp sequence derived from intron 6 of EML4 (variant 3b).  These results indicate that the profiles of EML4-ALK fusion gene variants in Korean patients of NSCLC may differ from those in other ethnic populations.  Herein, we describe for the first time the profiles of EML4-ALK fusion variants of Korean patients with NSCLCs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkiLBeFQgaVLVg90H21EOLACvtfcHk0lh9bJAZAfLccA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xks1Sis7s%253D&md5=170cc1d4a768ed0f3aba204044bbc56a</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.3346%2Fjkms.2012.27.2.228&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3346%252Fjkms.2012.27.2.228%26sid%3Dliteratum%253Aachs%26aulast%3DJin%26aufirst%3DG.%26aulast%3DJeon%26aufirst%3DH.-S.%26aulast%3DLee%26aufirst%3DE.%2BB.%26aulast%3DKang%26aufirst%3DH.-G.%26aulast%3DYoo%26aufirst%3DS.%2BS.%26aulast%3DLee%26aufirst%3DS.%2BY.%26aulast%3DLee%26aufirst%3DJ.%2BH.%26aulast%3DCha%26aufirst%3DS.%2BI.%26aulast%3DPark%26aufirst%3DT.%2BI.%26aulast%3DKim%26aufirst%3DC.%2BH.%26aulast%3DJheon%26aufirst%3DS.%2BH.%26aulast%3DPark%26aufirst%3DJ.%2BY.%26atitle%3DEML4-ALK%2520Fusion%2520Gene%2520in%2520Korean%2520Non-small%2520Cell%2520Lung%2520Cancer%26jtitle%3DJ.%2520Korean%2520Med.%2520Sci.%26date%3D2012%26volume%3D27%26spage%3D228%26epage%3D230%26doi%3D10.3346%2Fjkms.2012.27.2.228" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Koivunen, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mermel, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zejnullahu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lifshits, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holmes, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, H. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richards, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugarbaker, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ducko, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindeman, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marcoux, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engelman, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyerson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janne, P. A.</span></span> <span> </span><span class="NLM_article-title">EML4-ALK Fusion Gene and Efficacy of an ALK Kinase Inhibitor in Lung Cancer</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">4275</span>– <span class="NLM_lpage">4283</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-08-0168</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1158%2F1078-0432.CCR-08-0168" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=18594010" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BD1cXnvFyks7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2008&pages=4275-4283&author=J.+P.+Koivunenauthor=C.+Mermelauthor=K.+Zejnullahuauthor=C.+Murphyauthor=E.+Lifshitsauthor=A.+J.+Holmesauthor=H.+G.+Choiauthor=J.+Kimauthor=D.+Chiangauthor=R.+Thomasauthor=J.+Leeauthor=W.+G.+Richardsauthor=D.+J.+Sugarbakerauthor=C.+Duckoauthor=N.+Lindemanauthor=J.+P.+Marcouxauthor=J.+A.+Engelmanauthor=N.+S.+Grayauthor=C.+Leeauthor=M.+Meyersonauthor=P.+A.+Janne&title=EML4-ALK+Fusion+Gene+and+Efficacy+of+an+ALK+Kinase+Inhibitor+in+Lung+Cancer&doi=10.1158%2F1078-0432.CCR-08-0168"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">EML4-ALK Fusion Gene and Efficacy of an ALK Kinase Inhibitor in Lung Cancer</span></div><div class="casAuthors">Koivunen, Jussi P.; Mermel, Craig; Zejnullahu, Kreshnik; Murphy, Carly; Lifshits, Eugene; Holmes, Alison J.; Choi, Hwan Geun; Kim, Jhingook; Chiang, Derek; Thomas, Roman; Lee, Jinseon; Richards, William G.; Sugarbaker, David J.; Ducko, Christopher; Lindeman, Neal; Marcoux, J. Paul; Engelman, Jeffrey A.; Gray, Nathanael S.; Lee, Charles; Meyerson, Matthew; Jaenne, Pasi A.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">4275-4283</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The EML4-ALK fusion gene has been detected in ∼7% of Japanese non-small cell lung cancers (NSCLC).  We detd. the frequency of EML4-ALK in Caucasian NSCLC and in NSCLC cell lines.  We also detd. whether TAE684, a specific ALK kinase inhibitor, would inhibit the growth of EML4-ALK-contg. cell lines in vitro and in vivo.  We screened 305 primary NSCLC [both U.S. (n = 138) and Korean (n = 167) patients] and 83 NSCLC cell lines using reverse transcription-PCR and by exon array analyses.  We evaluated the efficacy of TAE684 against NSCLC cell lines in vitro and in vivo.  We detected four different variants, including two novel variants, of EML4-ALK using reverse transcription-PCR in 8 of 305 tumors (3%) and 3 of 83 (3.6%) NSCLC cell lines.  All EML4-ALK-contg. tumors and cell lines were adenocarcinomas.  EML4-ALK was detected more frequently in NSCLC patients who were never or light (<10 pack-years) cigarette smokers compared with current/former smokers (6% vs. 1%; P = 0.049).  TAE684 inhibited the growth of one of three (H3122) EML4-ALK-contg. cell lines in vitro and in vivo, inhibited Akt phosphorylation, and caused apoptosis.  In another EML4-ALK cell line, DFCI032, TAE684 was ineffective due to coactivation of epidermal growth factor receptor and ERBB2.  The combination of TAE684 and CL-387,785 (epidermal growth factor receptor/ERBB2 kinase inhibitor) inhibited growth and Akt phosphorylation and led to apoptosis in the DFCI032 cell line.  EML4-ALK is found in the minority of NSCLC.  ALK kinase inhibitors alone or in combination may nevertheless be clin. effective treatments for NSCLC patients whose tumors contain EML4-ALK.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOXKywqERg6rVg90H21EOLACvtfcHk0lh9bJAZAfLccA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXnvFyks7s%253D&md5=6e29703c783e6a29cf77e3c4b93fc15f</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-08-0168&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-08-0168%26sid%3Dliteratum%253Aachs%26aulast%3DKoivunen%26aufirst%3DJ.%2BP.%26aulast%3DMermel%26aufirst%3DC.%26aulast%3DZejnullahu%26aufirst%3DK.%26aulast%3DMurphy%26aufirst%3DC.%26aulast%3DLifshits%26aufirst%3DE.%26aulast%3DHolmes%26aufirst%3DA.%2BJ.%26aulast%3DChoi%26aufirst%3DH.%2BG.%26aulast%3DKim%26aufirst%3DJ.%26aulast%3DChiang%26aufirst%3DD.%26aulast%3DThomas%26aufirst%3DR.%26aulast%3DLee%26aufirst%3DJ.%26aulast%3DRichards%26aufirst%3DW.%2BG.%26aulast%3DSugarbaker%26aufirst%3DD.%2BJ.%26aulast%3DDucko%26aufirst%3DC.%26aulast%3DLindeman%26aufirst%3DN.%26aulast%3DMarcoux%26aufirst%3DJ.%2BP.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DLee%26aufirst%3DC.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26atitle%3DEML4-ALK%2520Fusion%2520Gene%2520and%2520Efficacy%2520of%2520an%2520ALK%2520Kinase%2520Inhibitor%2520in%2520Lung%2520Cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2008%26volume%3D14%26spage%3D4275%26epage%3D4283%26doi%3D10.1158%2F1078-0432.CCR-08-0168" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gainor, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varghese, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ou, S.-H. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kabraji, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Awad, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katayama, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pawlak, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mino-Kenudson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeap, B. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riely, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iafrate, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arcila, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ladanyi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engelman, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dias-Santagata, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, A. T.</span></span> <span> </span><span class="NLM_article-title">ALK Rearrangements are Mutually Exclusive with Mutations in EGFR or KRAS: an Analysis of 1,683 Patients with Non–small Cell Lung Cancer</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">4273</span>– <span class="NLM_lpage">4281</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-13-0318</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1158%2F1078-0432.CCR-13-0318" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=23729361" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1amt7zI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=4273-4281&author=J.+F.+Gainorauthor=A.+M.+Vargheseauthor=S.-H.+I.+Ouauthor=S.+Kabrajiauthor=M.+M.+Awadauthor=R.+Katayamaauthor=A.+Pawlakauthor=M.+Mino-Kenudsonauthor=B.+Y.+Yeapauthor=G.+J.+Rielyauthor=A.+J.+Iafrateauthor=M.+E.+Arcilaauthor=M.+Ladanyiauthor=J.+A.+Engelmanauthor=D.+Dias-Santagataauthor=A.+T.+Shaw&title=ALK+Rearrangements+are+Mutually+Exclusive+with+Mutations+in+EGFR+or+KRAS%3A+an+Analysis+of+1%2C683+Patients+with+Non%E2%80%93small+Cell+Lung+Cancer&doi=10.1158%2F1078-0432.CCR-13-0318"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">ALK Rearrangements Are Mutually Exclusive with Mutations in EGFR or KRAS: An Analysis of 1,683 Patients with Non-Small Cell Lung Cancer</span></div><div class="casAuthors">Gainor, Justin F.; Varghese, Anna M.; Ou, Sai-Hong Ignatius; Kabraji, Sheheryar; Awad, Mark M.; Katayama, Ryohei; Pawlak, Amanda; Mino-Kenudson, Mari; Yeap, Beow Y.; Riely, Gregory J.; Iafrate, A. John; Arcila, Maria E.; Ladanyi, Marc; Engelman, Jeffrey A.; Dias-Santagata, Dora; Shaw, Alice T.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4273-4281</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Anaplastic lymphoma kinase (ALK) gene rearrangements define a distinct mol. subset of non-small cell lung cancer (NSCLC).  Recently, several case reports and small series have reported that ALK rearrangements can overlap with other oncogenic drivers in NSCLC in crizotinib-naive and crizotinib-resistant cancers.  Exptl. Design: We reviewed clin. genotyping data from 1,683 patients with NSCLC and investigated the prevalence of concomitant EGFR or KRAS mutations among patients with ALK-pos. NSCLC.  We also examd. biopsy specimens from 34 patients with ALK-pos. NSCLC after the development of resistance to crizotinib.  Results: Screening identified 301 (17.8%) EGFR mutations, 465 (27.6%) KRAS mutations, and 75 (4.4%) ALK rearrangements.  EGFR mutations and ALK rearrangements were mutually exclusive.  Four patients with KRAS mutations were found to have abnormal ALK FISH patterns, most commonly involving isolated 5' green probes.  Sufficient tissue was available for confirmatory ALK immunohistochem. in 3 cases, all of which were neg. for ALK expression.  Among patients with ALK-pos. NSCLC who acquired resistance to crizotinib, repeat biopsy specimens were ALK FISH pos. in 29 of 29 (100%) cases.  Secondary mutations in the ALK kinase domain and ALK gene amplification were obsd. in 7 of 34 (20.6%) and 3 of 29 (10.3%) cases, resp.  No EGFR or KRAS mutations were identified among any of the 25 crizotinib-resistant, ALK-pos. patients with sufficient tissue for testing.  Conclusions: Functional ALK rearrangements were mutually exclusive with EGFR and KRAS mutations in a large Western patient population.  This lack of overlap was also obsd. in ALK-pos. cancers with acquired resistance to crizotinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnuDecyNaYQrVg90H21EOLACvtfcHk0lh9bJAZAfLccA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1amt7zI&md5=6355f3f634ef5b7ba06a497d0bf71a1a</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-13-0318&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-13-0318%26sid%3Dliteratum%253Aachs%26aulast%3DGainor%26aufirst%3DJ.%2BF.%26aulast%3DVarghese%26aufirst%3DA.%2BM.%26aulast%3DOu%26aufirst%3DS.-H.%2BI.%26aulast%3DKabraji%26aufirst%3DS.%26aulast%3DAwad%26aufirst%3DM.%2BM.%26aulast%3DKatayama%26aufirst%3DR.%26aulast%3DPawlak%26aufirst%3DA.%26aulast%3DMino-Kenudson%26aufirst%3DM.%26aulast%3DYeap%26aufirst%3DB.%2BY.%26aulast%3DRiely%26aufirst%3DG.%2BJ.%26aulast%3DIafrate%26aufirst%3DA.%2BJ.%26aulast%3DArcila%26aufirst%3DM.%2BE.%26aulast%3DLadanyi%26aufirst%3DM.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26aulast%3DDias-Santagata%26aufirst%3DD.%26aulast%3DShaw%26aufirst%3DA.%2BT.%26atitle%3DALK%2520Rearrangements%2520are%2520Mutually%2520Exclusive%2520with%2520Mutations%2520in%2520EGFR%2520or%2520KRAS%253A%2520an%2520Analysis%2520of%25201%252C683%2520Patients%2520with%2520Non%25E2%2580%2593small%2520Cell%2520Lung%2520Cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2013%26volume%3D19%26spage%3D4273%26epage%3D4281%26doi%3D10.1158%2F1078-0432.CCR-13-0318" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Takeuchi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Togashi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hatano, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inamura, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takada, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ueno, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamashita, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Satoh, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okumura, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakagawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishikawa, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mano, H.</span></span> <span> </span><span class="NLM_article-title">KIF5B-ALK, a Novel Fusion Oncokinase Identified by an Immunohistochemistry-based Diagnostic System for ALK-positive Lung Cancer</span>. <i>Clin, Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">3143</span>– <span class="NLM_lpage">3149</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-08-3248</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1158%2F1078-0432.CCR-08-3248" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=19383809" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BD1MXltFOrtbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2009&pages=3143-3149&author=K.+Takeuchiauthor=Y.+L.+Choiauthor=Y.+Togashiauthor=M.+Sodaauthor=S.+Hatanoauthor=K.+Inamuraauthor=S.+Takadaauthor=T.+Uenoauthor=Y.+Yamashitaauthor=Y.+Satohauthor=S.+Okumuraauthor=K.+Nakagawaauthor=Y.+Ishikawaauthor=H.+Mano&title=KIF5B-ALK%2C+a+Novel+Fusion+Oncokinase+Identified+by+an+Immunohistochemistry-based+Diagnostic+System+for+ALK-positive+Lung+Cancer&doi=10.1158%2F1078-0432.CCR-08-3248"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">KIF5B-ALK, a Novel Fusion Oncokinase Identified by an Immunohistochemistry-based Diagnostic System for ALK-positive Lung Cancer</span></div><div class="casAuthors">Takeuchi, Kengo; Choi, Young Lim; Togashi, Yuki; Soda, Manabu; Hatano, Satoko; Inamura, Kentaro; Takada, Shuji; Ueno, Toshihide; Yamashita, Yoshihiro; Satoh, Yukitoshi; Okumura, Sakae; Nakagawa, Ken; Ishikawa, Yuichi; Mano, Hiroyuki</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3143-3149</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">EML4-ALK is a transforming fusion tyrosine kinase, several isoforms of which have been identified in lung cancer.  Immunohistochem. detection of EML4-ALK has proved difficult, however, likely as a result of low transcriptional activity conferred by the promoter-enhancer region of EML4.  The sensitivity of EML4-ALK detection by immunohistochem. should be increased adequately.  We developed an intercalated antibody-enhanced polymer (iAEP) method that incorporates an intercalating antibody between the primary antibody to ALK and the dextran polymer-based detection reagents.  Our iAEP method discriminated between tumors pos. or neg. for EML4-ALK in a test set of specimens.  Four tumors were also found to be pos. for ALK in an archive of lung adenocarcinoma (n = 130) and another 4 among fresh cases analyzed in a diagnostic lab.  These 8 tumors were found to include 1 with EML4-ALK variant 1, 1 with variant 2, 3 with variant 3, and 2 with previously unidentified variants (designated variants 6 and 7).  Inverse reverse transcription-PCR anal. revealed that the remaining tumor harbored a novel fusion in which intron 24 of KIF5B was ligated to intron 19 of ALK.  Multiplex reverse transcription-PCR anal. of addnl. archival tumor specimens identified another case of lung adenocarcinoma pos. for KIF5B-ALK.  The iAEP method should prove suitable for immunohistochem. screening of tumors pos. for ALK or ALK fusion proteins among pathol. archives.  Coupling of PCR-based detection to the iAEP method should further facilitate the rapid identification of novel ALK fusion genes such as KIF5B-ALK.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzRVhmhcxYtrVg90H21EOLACvtfcHk0lhchGnf_uhCKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXltFOrtbY%253D&md5=50abc7202077715519e1d41c024e4624</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-08-3248&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-08-3248%26sid%3Dliteratum%253Aachs%26aulast%3DTakeuchi%26aufirst%3DK.%26aulast%3DChoi%26aufirst%3DY.%2BL.%26aulast%3DTogashi%26aufirst%3DY.%26aulast%3DSoda%26aufirst%3DM.%26aulast%3DHatano%26aufirst%3DS.%26aulast%3DInamura%26aufirst%3DK.%26aulast%3DTakada%26aufirst%3DS.%26aulast%3DUeno%26aufirst%3DT.%26aulast%3DYamashita%26aufirst%3DY.%26aulast%3DSatoh%26aufirst%3DY.%26aulast%3DOkumura%26aufirst%3DS.%26aulast%3DNakagawa%26aufirst%3DK.%26aulast%3DIshikawa%26aufirst%3DY.%26aulast%3DMano%26aufirst%3DH.%26atitle%3DKIF5B-ALK%252C%2520a%2520Novel%2520Fusion%2520Oncokinase%2520Identified%2520by%2520an%2520Immunohistochemistry-based%2520Diagnostic%2520System%2520for%2520ALK-positive%2520Lung%2520Cancer%26jtitle%3DClin%252C%2520Cancer%2520Res.%26date%3D2009%26volume%3D15%26spage%3D3143%26epage%3D3149%26doi%3D10.1158%2F1078-0432.CCR-08-3248" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Takeuchi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Togashi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakata, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hatano, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asaka, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamanaka, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ninomiya, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uehara, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim Choi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Satoh, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okumura, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakagawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mano, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishikawa, Y.</span></span> <span> </span><span class="NLM_article-title">RET, ROS1 and ALK Fusions in Lung Cancer</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">378</span>– <span class="NLM_lpage">381</span>, <span class="refDoi"> DOI: 10.1038/nm.2658</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1038%2Fnm.2658" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=22327623" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC38XitFaks7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=378-381&author=K.+Takeuchiauthor=M.+Sodaauthor=Y.+Togashiauthor=R.+Suzukiauthor=S.+Sakataauthor=S.+Hatanoauthor=R.+Asakaauthor=W.+Hamanakaauthor=H.+Ninomiyaauthor=H.+Ueharaauthor=Y.+Lim+Choiauthor=Y.+Satohauthor=S.+Okumuraauthor=K.+Nakagawaauthor=H.+Manoauthor=Y.+Ishikawa&title=RET%2C+ROS1+and+ALK+Fusions+in+Lung+Cancer&doi=10.1038%2Fnm.2658"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">RET, ROS1 and ALK fusions in lung cancer</span></div><div class="casAuthors">Takeuchi, Kengo; Soda, Manabu; Togashi, Yuki; Suzuki, Ritsuro; Sakata, Seiji; Hatano, Satoko; Asaka, Reimi; Hamanaka, Wakako; Ninomiya, Hironori; Uehara, Hirofumi; Lim Choi, Young; Satoh, Yukitoshi; Okumura, Sakae; Nakagawa, Ken; Mano, Hiroyuki; Ishikawa, Yuichi</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">378-381</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Through an integrated mol.- and histopathol.-based screening system, we performed a screening for fusions of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1, receptor tyrosine kinase (ROS1) in 1,529 lung cancers and identified 44 ALK-fusion-pos. and 13 ROS1-fusion-pos. adenocarcinomas, including for unidentified fusion partners for ROS1.  In addn., we discovered previously unidentified kinase fusions that may be promising for mol.-targeted therapy, kinesin family member 5B (KIF5B)-ret proto-oncogene (RET) and coiled-coil domain contg. 6 (CCDC6)-RET, in 14 adenocarcinomas.  A multivariate anal. of 1,116 adenocarcinomas contg. these 71 kinase-fusion-pos. adenocarcinomas identified four independent factors that are indicators of poor prognosis: age ≥50 years, male sex, high pathol. stage and neg. kinase-fusion status.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhJr0BIAnHWLVg90H21EOLACvtfcHk0lhchGnf_uhCKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XitFaks7s%253D&md5=986c7eba0992b29950756e129a395d60</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1038%2Fnm.2658&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.2658%26sid%3Dliteratum%253Aachs%26aulast%3DTakeuchi%26aufirst%3DK.%26aulast%3DSoda%26aufirst%3DM.%26aulast%3DTogashi%26aufirst%3DY.%26aulast%3DSuzuki%26aufirst%3DR.%26aulast%3DSakata%26aufirst%3DS.%26aulast%3DHatano%26aufirst%3DS.%26aulast%3DAsaka%26aufirst%3DR.%26aulast%3DHamanaka%26aufirst%3DW.%26aulast%3DNinomiya%26aufirst%3DH.%26aulast%3DUehara%26aufirst%3DH.%26aulast%3DLim%2BChoi%26aufirst%3DY.%26aulast%3DSatoh%26aufirst%3DY.%26aulast%3DOkumura%26aufirst%3DS.%26aulast%3DNakagawa%26aufirst%3DK.%26aulast%3DMano%26aufirst%3DH.%26aulast%3DIshikawa%26aufirst%3DY.%26atitle%3DRET%252C%2520ROS1%2520and%2520ALK%2520Fusions%2520in%2520Lung%2520Cancer%26jtitle%3DNat.%2520Med.%26date%3D2012%26volume%3D18%26spage%3D378%26epage%3D381%26doi%3D10.1038%2Fnm.2658" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">van
der Krogt, J.-A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bempt, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferreiro, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mentens, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobs, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pluys, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doms, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geerdens, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uyttebroeck, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pierre, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michaux, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Devos, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vandenberghe, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tousseyn, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cools, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wlodarska, I.</span></span> <span> </span><span class="NLM_article-title">ALK-positive Anaplastic Large Cell Lymphoma with the Variant RNF213-, ATIC-and TPM3-ALK Fusions is Characterized by Copy Number Gain of the Rearranged ALK gene</span>. <i>Haematologica</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>102</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">1605</span>– <span class="NLM_lpage">1616</span>, <span class="refDoi"> DOI: 10.3324/haematol.2016.146571</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.3324%2Fhaematol.2016.146571" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=28659337" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitV2jsrfI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2017&pages=1605-1616&issue=9&author=J.-A.+van%0Ader+Krogtauthor=M.+V.+Bemptauthor=J.+F.+Ferreiroauthor=N.+Mentensauthor=K.+Jacobsauthor=U.+Pluysauthor=K.+Domsauthor=E.+Geerdensauthor=A.+Uyttebroeckauthor=P.+Pierreauthor=L.+Michauxauthor=T.+Devosauthor=P.+Vandenbergheauthor=T.+Tousseynauthor=J.+Coolsauthor=I.+Wlodarska&title=ALK-positive+Anaplastic+Large+Cell+Lymphoma+with+the+Variant+RNF213-%2C+ATIC-and+TPM3-ALK+Fusions+is+Characterized+by+Copy+Number+Gain+of+the+Rearranged+ALK+gene&doi=10.3324%2Fhaematol.2016.146571"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Anaplastic lymphoma kinase-positive anaplastic large cell lymphoma with the variant RNF213-, ATIC- and TPM3-ALK fusions is characterized by copy number gain of the rearranged ALK gene</span></div><div class="casAuthors">van der Krogt, Jo-Anne; Bempt, Marlies Vanden; Ferreiro, Julio Finalet; Mentens, Nicole; Jacobs, Kris; Pluys, Ursula; Doms, Kathleen; Geerdens, Ellen; Uyttebroeck, Anne; Pierre, Pascal; Michaux, Lucienne; Devos, Timothy; Vandenberghe, Peter; Tousseyn, Thomas; Cools, Jan; Wlodarska, Iwona</div><div class="citationInfo"><span class="NLM_cas:title">Haematologica</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1605-1616</span>CODEN:
                <span class="NLM_cas:coden">HAEMAX</span>;
        ISSN:<span class="NLM_cas:issn">1592-8721</span>.
    
            (<span class="NLM_cas:orgname">Ferrata Storti Foundation</span>)
        </div><div class="casAbstract">Anaplastic lymphoma kinase (ALK)-pos. anaplastic large cell lymphoma is characterized by 2p23/ALK aberrations, including the classic t(2;5)(p23;q35)/NPM1-ALK rearrangement present in ∼80% of cases and several variant t(2p23/ALK) occurring in the remaining cases.  The ALK fusion partners play a key role in the constitutive activation of the chimeric protein and its subcellular localization.  Using various mol. technologies, we have characterized ALK fusions in eight recently diagnosed anaplastic large cell lymphoma cases with cytoplasmic- only ALK expression.  The identified partner genes included EEF1G (one case), RNF213/ALO17 (one case), ATIC (four cases) and TPM3 (two cases).  Notably, all cases showed copy no. gain of the rearranged ALK gene, which is never obsd. in NPM1-ALK-pos. lymphomas.  We hypothesized that this could be due to lower expression levels and/or lower oncogenic potential of the variant ALK fusions.  Indeed, all partner genes, except EEF1G, showed lower expression in normal and malignant T cells, in comparison with NPM1.  In addn., we investigated the transformation potential of endogenous Npm1-Alk and Atic-Alk fusions generated by clustered regularly interspaced short palindromic repeats/Cas9 genome editing in Ba/F3 cells.  We found that Npm1-Alk has a stronger transformation potential than Atic-Alk, and we obsd. a subclonal gain of Atic-Alk after a longer culture period, which was not obsd. for Npm1-Alk.  Taken together, our data illustrate that lymphomas driven by the variant ATIC-ALK fusion (and likely by RNF213- ALK and TPM3-ALK), but not the classic NPM1-ALK, require an increased dosage of the ALK hybrid gene to compensate for the relatively low and insufficient expression and signaling properties of the chimeric gene.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopa0QUpQo5y7Vg90H21EOLACvtfcHk0lgzHqiHct8O-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitV2jsrfI&md5=69b0f94368167ddaad61fa7e0b617c09</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.3324%2Fhaematol.2016.146571&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3324%252Fhaematol.2016.146571%26sid%3Dliteratum%253Aachs%26aulast%3Dvan%2Bder%2BKrogt%26aufirst%3DJ.-A.%26aulast%3DBempt%26aufirst%3DM.%2BV.%26aulast%3DFerreiro%26aufirst%3DJ.%2BF.%26aulast%3DMentens%26aufirst%3DN.%26aulast%3DJacobs%26aufirst%3DK.%26aulast%3DPluys%26aufirst%3DU.%26aulast%3DDoms%26aufirst%3DK.%26aulast%3DGeerdens%26aufirst%3DE.%26aulast%3DUyttebroeck%26aufirst%3DA.%26aulast%3DPierre%26aufirst%3DP.%26aulast%3DMichaux%26aufirst%3DL.%26aulast%3DDevos%26aufirst%3DT.%26aulast%3DVandenberghe%26aufirst%3DP.%26aulast%3DTousseyn%26aufirst%3DT.%26aulast%3DCools%26aufirst%3DJ.%26aulast%3DWlodarska%26aufirst%3DI.%26atitle%3DALK-positive%2520Anaplastic%2520Large%2520Cell%2520Lymphoma%2520with%2520the%2520Variant%2520RNF213-%252C%2520ATIC-and%2520TPM3-ALK%2520Fusions%2520is%2520Characterized%2520by%2520Copy%2520Number%2520Gain%2520of%2520the%2520Rearranged%2520ALK%2520gene%26jtitle%3DHaematologica%26date%3D2017%26volume%3D102%26issue%3D9%26spage%3D1605%26epage%3D1616%26doi%3D10.3324%2Fhaematol.2016.146571" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kovach, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katzman, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salloum, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ettinghausen, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madeb, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koniaris, L. G.</span></span> <span> </span><span class="NLM_article-title">Inflammatory Myofibroblastic Tumors</span>. <i>J. Surg. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>94</i></span>,  <span class="NLM_fpage">385</span>– <span class="NLM_lpage">391</span>, <span class="refDoi"> DOI: 10.1002/jso.20516</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1002%2Fjso.20516" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=16967468" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A280%3ADC%252BD28rlsVygtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=2006&pages=385-391&author=S.+J.+Kovachauthor=A.+C.+Fischerauthor=P.+J.+Katzmanauthor=R.+M.+Salloumauthor=S.+E.+Ettinghausenauthor=R.+Madebauthor=L.+G.+Koniaris&title=Inflammatory+Myofibroblastic+Tumors&doi=10.1002%2Fjso.20516"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Inflammatory myofibroblastic tumors</span></div><div class="casAuthors">Kovach Stephen J; Fischer Anne C; Katzman Philip J; Salloum Rabih M; Ettinghausen Stephen E; Madeb Ralph; Koniaris Leonidas G</div><div class="citationInfo"><span class="NLM_cas:title">Journal of surgical oncology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">94</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">385-91</span>
        ISSN:<span class="NLM_cas:issn">0022-4790</span>.
    </div><div class="casAbstract">INTRODUCTION:  Inflammatory myofibroblastic tumors (IMT) while uncommon may arise within numerous organs.  Historically, the literature regarding IMT has been confined to small one organ case series, with few reviews encompassing multiple anatomic sites, and little data regarding adjuvant treatment.  METHODS:  A review of patients with IMT treated at two large academic medical centers over a 15-year period was undertaken.  Patient demographics, pathologic diagnoses, and pertinent clinical data were obtained.  RESULTS:  Forty-four cases of pathologically confirmed IMT were identified.  Tumor locations included multiple anatomic sites.  Therapies included complete resection, incomplete resection, observation, or chemotherapy, and/or radiation.  Five patients underwent adjuvant chemotherapy and/or radiation therapy following surgery (14%) for local aggressiveness of the tumor, invasion, positive margins, or location of tumor that was not amenable to surgical resection.  A second, concomitant, histologically distinct, neoplasm was identified in five cases.  Of the patients who underwent treatment three local recurrences were noted (8%) and occurred in patients with partial resection without adjuvant chemo- or radiotherapy.  CONCLUSIONS:  Inflammatory myofibroblastic tumors may be a locally aggressive and destructive neoplasm.  Tumor recurrence is unusual following complete surgical resection or organ-preserving combined modality therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTNcHU--PsRpzAyhZbj3lKdfW6udTcc2eZ650p6t0ZUZrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD28rlsVygtA%253D%253D&md5=de1262010b27e35365b3f666b26d3a37</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1002%2Fjso.20516&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjso.20516%26sid%3Dliteratum%253Aachs%26aulast%3DKovach%26aufirst%3DS.%2BJ.%26aulast%3DFischer%26aufirst%3DA.%2BC.%26aulast%3DKatzman%26aufirst%3DP.%2BJ.%26aulast%3DSalloum%26aufirst%3DR.%2BM.%26aulast%3DEttinghausen%26aufirst%3DS.%2BE.%26aulast%3DMadeb%26aufirst%3DR.%26aulast%3DKoniaris%26aufirst%3DL.%2BG.%26atitle%3DInflammatory%2520Myofibroblastic%2520Tumors%26jtitle%3DJ.%2520Surg.%2520Oncol.%26date%3D2006%26volume%3D94%26spage%3D385%26epage%3D391%26doi%3D10.1002%2Fjso.20516" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hawkins, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dvorak, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henkle, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellingham, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perlman, E. J.</span></span> <span> </span><span class="NLM_article-title">Recurrent Involvement of 2p23 in Inflammatory Myofibroblastic Tumors</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">2776</span>– <span class="NLM_lpage">2780</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10383129" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADyaK1MXktVOktbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=1999&pages=2776-2780&author=C.+A.+Griffinauthor=A.+L.+Hawkinsauthor=C.+Dvorakauthor=C.+Henkleauthor=T.+Ellinghamauthor=E.+J.+Perlman&title=Recurrent+Involvement+of+2p23+in+Inflammatory+Myofibroblastic+Tumors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Recurrent involvement of 2p23 in inflammatory myofibroblastic tumors</span></div><div class="casAuthors">Griffin, Constance A.; Hawkins, Anita L.; Dvorak, Cecily; Henkle, Carol; Ellingham, Tara; Perlman, Elizabeth J.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2776-2780</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">AACR Subscription Office</span>)
        </div><div class="casAbstract">Inflammatory myofibroblastic tumor (IMT) is a relatively rare soft tissue tumor.  The reactive vs. neoplastic pathogenesis of this tumor is unresolved.  We found clonal chromosome aberrations involving 2p23 upon metaphase anal. of two IMTs.  Fluorescence in situ hybridization with a probe flanking the ALK gene at 2p23 demonstrated rearrangement of the probe in both of these cases and in a third case, and immunohistochem. revealed ALK expression in all three cases.  A 2p22-24 involvement has been reported previously in four addnl. cases of IMT.  We suggest that chromosomal rearrangements involving 2p23 near or within ALK are recurrent alterations in IMT and that ALK may have a novel role outside its previously recognized realm of lymphoid neoplasms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocvXV2ukz3crVg90H21EOLACvtfcHk0lgzHqiHct8O-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXktVOktbk%253D&md5=8054eeaaf0cb85ee85afff461797c84c</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGriffin%26aufirst%3DC.%2BA.%26aulast%3DHawkins%26aufirst%3DA.%2BL.%26aulast%3DDvorak%26aufirst%3DC.%26aulast%3DHenkle%26aufirst%3DC.%26aulast%3DEllingham%26aufirst%3DT.%26aulast%3DPerlman%26aufirst%3DE.%2BJ.%26atitle%3DRecurrent%2520Involvement%2520of%25202p23%2520in%2520Inflammatory%2520Myofibroblastic%2520Tumors%26jtitle%3DCancer%2520Res.%26date%3D1999%26volume%3D59%26spage%3D2776%26epage%3D2780" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lovly, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lipson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otto, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brennan, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borinstein, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stephens, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, V. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coffin, C. M.</span></span> <span> </span><span class="NLM_article-title">Inflammatory Myofibroblastic Tumors Harbor Multiple Potentially Actionable Kinase Fusions</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">889</span>– <span class="NLM_lpage">895</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-14-0377</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1158%2F2159-8290.CD-14-0377" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=24875859" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtlSrtbzP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2014&pages=889-895&author=C.+M.+Lovlyauthor=A.+Guptaauthor=D.+Lipsonauthor=G.+Ottoauthor=T.+Brennanauthor=C.+T.+Chungauthor=S.+C.+Borinsteinauthor=J.+S.+Rossauthor=P.+J.+Stephensauthor=V.+A.+Millerauthor=C.+M.+Coffin&title=Inflammatory+Myofibroblastic+Tumors+Harbor+Multiple+Potentially+Actionable+Kinase+Fusions&doi=10.1158%2F2159-8290.CD-14-0377"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Inflammatory Myofibroblastic Tumors Harbor Multiple Potentially Actionable Kinase Fusions</span></div><div class="casAuthors">Lovly, Christine M.; Gupta, Abha; Lipson, Doron; Otto, Geoff; Brennan, Tina; Chung, Catherine T.; Borinstein, Scott C.; Ross, Jeffrey S.; Stephens, Philip J.; Miller, Vincent A.; Coffin, Cheryl M.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">889-895</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Inflammatory myofibroblastic tumor (IMT) is a neoplasm that typically occurs in 1 children.  The genetic landscape of this tumor is incompletely understood and therapeutic options are limited.  Although 50% of IMTs harbor anaplastic lymphoma kinase (ALK) rearrangements, no therapeutic targets have been identified in ALK-neg. tumors.  We report for the first time 1 that IMTs harbor other actionable targets, including ROS1 and PDGFRβ fusions.  We detail the case of an 8-yr-old boy with treatment-refractory ALK-neg. IMT.  Mol. tumor profiling revealed a ROS1 fusion, and he had a dramatic response to the ROS1 inhibitor crizotinib.  This case prompted assessment of a larger series of IMTs.  Next-generation sequencing revealed that 85% of cases evaluated harbored kinase fusions involving ALK1R0S1, or PDGFRp.  Our study represents the most comprehensive genetic anal. of IMTs to date and also provides a rationale for routine mol. profiling of these tumors to detect therapeutically actionable kinase fusions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr63dmuwBRGZLVg90H21EOLACvtfcHk0lgb9wz7s4OrjA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtlSrtbzP&md5=a61b1ddd3f6eac36782b33601d1beb3a</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-14-0377&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-14-0377%26sid%3Dliteratum%253Aachs%26aulast%3DLovly%26aufirst%3DC.%2BM.%26aulast%3DGupta%26aufirst%3DA.%26aulast%3DLipson%26aufirst%3DD.%26aulast%3DOtto%26aufirst%3DG.%26aulast%3DBrennan%26aufirst%3DT.%26aulast%3DChung%26aufirst%3DC.%2BT.%26aulast%3DBorinstein%26aufirst%3DS.%2BC.%26aulast%3DRoss%26aufirst%3DJ.%2BS.%26aulast%3DStephens%26aufirst%3DP.%2BJ.%26aulast%3DMiller%26aufirst%3DV.%2BA.%26aulast%3DCoffin%26aufirst%3DC.%2BM.%26atitle%3DInflammatory%2520Myofibroblastic%2520Tumors%2520Harbor%2520Multiple%2520Potentially%2520Actionable%2520Kinase%2520Fusions%26jtitle%3DCancer%2520Discovery%26date%3D2014%26volume%3D4%26spage%3D889%26epage%3D895%26doi%3D10.1158%2F2159-8290.CD-14-0377" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lenz, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staudt, L. M.</span></span> <span> </span><span class="NLM_article-title">Aggressive lymphomas</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>362</i></span>,  <span class="NLM_fpage">1417</span>– <span class="NLM_lpage">1429</span>, <span class="refDoi"> DOI: 10.1056/NEJMra0807082</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1056%2FNEJMra0807082" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=20393178" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC3cXkslajtbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=362&publication_year=2010&pages=1417-1429&author=G.+Lenzauthor=L.+M.+Staudt&title=Aggressive+lymphomas&doi=10.1056%2FNEJMra0807082"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Aggressive lymphomas</span></div><div class="casAuthors">Lenz, Georg; Staudt, Louis M.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">362</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">1417-1429</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">A review.  Given the emergence of many new therapeutic agents that affect essential regulatory pathways in lymphomas, the challenge is to identify rational combinations that kill lymphoma cells synergistically.  This effort requires both preclin. evaluation and the development of clin.-trial strategies that include mol. profiling.  Gene expression profiling could be used to det. the lymphoma subtype and to est. the risk assocd. with std. therapy.  Cancer gene resequencing could be used to identify tumors that are likely to be dependent on a particular signaling pathway and to det. which step in the pathway to inhibit.  Finally, the activity of the targeted pathways before and during therapy could be used to assess the efficacy of the treatment.  We expect that this "divide-and-conquer" approach will provide increasingly effective and nontoxic therapies for patients with lymphomas.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpAtbs8gSY6hrVg90H21EOLACvtfcHk0lg4n4TVkAwp7w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXkslajtbY%253D&md5=005333ef8156a770b418a07aae2f19d8</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1056%2FNEJMra0807082&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMra0807082%26sid%3Dliteratum%253Aachs%26aulast%3DLenz%26aufirst%3DG.%26aulast%3DStaudt%26aufirst%3DL.%2BM.%26atitle%3DAggressive%2520lymphomas%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2010%26volume%3D362%26spage%3D1417%26epage%3D1429%26doi%3D10.1056%2FNEJMra0807082" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chikatsu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kojima, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzukawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shinagawa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagasawa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ozawa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamashita, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mori, N.</span></span> <span> </span><span class="NLM_article-title">ALK+, CD30–, CD20– large B-cell Lymphoma Containing Anaplastic Lymphoma Kinase (ALK) Fused to Clathrin Heavy Chain Gene (CLTC)</span>. <i>Mod. Pathol.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">828</span>– <span class="NLM_lpage">832</span>, <span class="refDoi"> DOI: 10.1097/01.MP.0000081729.40230.1F</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1097%2F01.MP.0000081729.40230.1F" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=12920229" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A280%3ADC%252BD3szotl2gtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2003&pages=828-832&author=N.+Chikatsuauthor=H.+Kojimaauthor=K.+Suzukawaauthor=A.+Shinagawaauthor=T.+Nagasawaauthor=H.+Ozawaauthor=Y.+Yamashitaauthor=N.+Mori&title=ALK%2B%2C+CD30%E2%80%93%2C+CD20%E2%80%93+large+B-cell+Lymphoma+Containing+Anaplastic+Lymphoma+Kinase+%28ALK%29+Fused+to+Clathrin+Heavy+Chain+Gene+%28CLTC%29&doi=10.1097%2F01.MP.0000081729.40230.1F"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">ALK+, CD30-, CD20- large B-cell lymphoma containing anaplastic lymphoma kinase (ALK) fused to clathrin heavy chain gene (CLTC)</span></div><div class="casAuthors">Chikatsu Norio; Kojima Hiroshi; Suzukawa Kazumi; Shinagawa Atsushi; Nagasawa Toshiro; Ozawa Hiroaki; Yamashita Yoriko; Mori Naoyoshi</div><div class="citationInfo"><span class="NLM_cas:title">Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">828-32</span>
        ISSN:<span class="NLM_cas:issn">0893-3952</span>.
    </div><div class="casAbstract">Pathological features and genomic basis of a rare case of ALK(+), CD30(-), CD20(-) large B-cell lymphoma were analyzed.  A 36-year-old Japanese female was admitted because of lumbago and constitutional symptoms.  Physical examination and laboratory tests showed anemia (hemoglobin, 7.5 g/dL), mild hepatosplenomegaly, and immunoglobin G (IgG) lambda-type monoclonal gammopathy (IgG, 2782 mg/dL).  The lymphoma spread exclusively in extranodal sites such as bone marrow, liver, spleen, ovary, and muscle.  Biopsy specimens obtained from the ovary showed monomorphic proliferation of large immunoblastic cells with basophilic cytoplasm, round-shaped nuclei with a high nuclear to cytoplasmic ratio, and prominent single nucleolus.  Immunostaining with anti-anaplastic lymphoma kinase (ALK) antibody, ALK1, showed finely granular cytoplasmic staining pattern.  These cells were also positive for epithelial membrane antigen, CD4, CD19, CD38, CD138, cytoplasmic IgG, and lambda chain, but negative for CD30 (Ber-H2), CD56, CD57, and other T- and B-cell markers.  Southern blot analyses revealed that Ig heavy and lambda light chain genes, but not T-cell receptor (TCR) beta gene, were clonally rearranged.  Chromosomal analyses by conventional G-banding, spectral karyotyping, and fluorescence in situ hybridization showed complex abnormality involving 2p23, and chromosome 2 was translocated to chromosome 17.  As 2;17 translocation resulting in the fusion of clathrin heavy chain (CLTC) gene with ALK was previously reported in inflammatory myofibroblastic tumor, we performed reverse transcriptase-polymerase chain reaction and demonstrated that the lymphoma cells contained CLTC-ALK fusion transcript.  Under the diagnosis of ALK(+), CD30(-), CD20(-) large B-cell lymphoma, she was treated with conventional combination chemotherapies.  However, the lymphoma was primarily chemotherapy resistant, and the patient died 11 months after admission.  We consider that this case confirms the existence of ALK(+), CD30(-), CD20(-) large B-cell lymphomas proposed by Delsol et al. (16) and further provides relevant information regarding their clinicopathological features and cytogenetics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRjvhATsCXEtwaK-_ZudimnfW6udTcc2eZVWCsF8XmmD7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3szotl2gtQ%253D%253D&md5=79464c7972c0383f24b2a4c287aa10e3</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1097%2F01.MP.0000081729.40230.1F&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F01.MP.0000081729.40230.1F%26sid%3Dliteratum%253Aachs%26aulast%3DChikatsu%26aufirst%3DN.%26aulast%3DKojima%26aufirst%3DH.%26aulast%3DSuzukawa%26aufirst%3DK.%26aulast%3DShinagawa%26aufirst%3DA.%26aulast%3DNagasawa%26aufirst%3DT.%26aulast%3DOzawa%26aufirst%3DH.%26aulast%3DYamashita%26aufirst%3DY.%26aulast%3DMori%26aufirst%3DN.%26atitle%3DALK%252B%252C%2520CD30%25E2%2580%2593%252C%2520CD20%25E2%2580%2593%2520large%2520B-cell%2520Lymphoma%2520Containing%2520Anaplastic%2520Lymphoma%2520Kinase%2520%2528ALK%2529%2520Fused%2520to%2520Clathrin%2520Heavy%2520Chain%2520Gene%2520%2528CLTC%2529%26jtitle%3DMod.%2520Pathol.%26date%3D2003%26volume%3D16%26spage%3D828%26epage%3D832%26doi%3D10.1097%2F01.MP.0000081729.40230.1F" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Van
Roosbroeck, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cools, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dierickx, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vandenberghe, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stul, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delabie, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Wolf-Peeters, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marynen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wlodarska, I.</span></span> <span> </span><span class="NLM_article-title">ALK-positive Large B-cell Lymphomas with Cryptic SEC31A-ALK and NPM1-ALK Fusions</span>. <i>Haematologica</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>95</i></span>,  <span class="NLM_fpage">509</span>– <span class="NLM_lpage">513</span>, <span class="refDoi"> DOI: 10.3324/haematol.2009.014761</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.3324%2Fhaematol.2009.014761" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=20207848" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht12msLvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=2010&pages=509-513&author=K.+Van%0ARoosbroeckauthor=J.+Coolsauthor=D.+Dierickxauthor=J.+Thomasauthor=P.+Vandenbergheauthor=M.+Stulauthor=J.+Delabieauthor=C.+De+Wolf-Peetersauthor=P.+Marynenauthor=I.+Wlodarska&title=ALK-positive+Large+B-cell+Lymphomas+with+Cryptic+SEC31A-ALK+and+NPM1-ALK+Fusions&doi=10.3324%2Fhaematol.2009.014761"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">ALK-positive large B-cell lymphomas with cryptic SEC31A-ALK and NPM1-ALK fusions</span></div><div class="casAuthors">Van Roosbroeck, Katrien; Cools, Jan; Dierickx, Daan; Thomas, Jose; Vandenberghe, Peter; Stul, Michel; Delabie, Jan; De Wolf-Peeters, Chris; Marynen, Peter; Wlodarska, Iwona</div><div class="citationInfo"><span class="NLM_cas:title">Haematologica</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">95</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">509-513</span>CODEN:
                <span class="NLM_cas:coden">HAEMAX</span>;
        ISSN:<span class="NLM_cas:issn">0390-6078</span>.
    
            (<span class="NLM_cas:orgname">Ferrata Storti Foundation</span>)
        </div><div class="casAbstract">We report 2 ALK-pos. large B-cell lymphoma cases showing granular cytoplasmic and cytoplasmic/nuclear ALK immunostaining in which cryptic ALK rearrangements were identified by fluorescent in situ hybridization and mol. anal.  In the first case, the ALK-involving t(2;3)(p23;q27) masked the cryptic SEC31A-ALK fusion generated by an insertion of the 5' end of SEC31A (4q21) upstream of the 3' end of ALK.  This rearrangement was assocd. with loss of the 5' end of ALK and duplication of SEC31A-ALK on der(20).  In the second case with complex rearrangements of both chromosomes 2, a submicroscopic NPM1-ALK fusion created by insertion of the 3' end of ALK into the NPM1 locus was evidenced.  Further studies of SEC31A-ALK showed that this variant fusion transforms IL3-dependent Ba/F3 cells to growth factor independence, and that the ALK inhibitor TAE-684 reduces cell proliferation and kinase activity of SEC31A-ALK and its downstream effectors ERK1/2, AKT, STAT3 and STAT5.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfOGiY_6QU4LVg90H21EOLACvtfcHk0lg4n4TVkAwp7w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht12msLvN&md5=f9a7c32c4b6cc160d6866fe58ca0bb57</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.3324%2Fhaematol.2009.014761&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3324%252Fhaematol.2009.014761%26sid%3Dliteratum%253Aachs%26aulast%3DVan%2BRoosbroeck%26aufirst%3DK.%26aulast%3DCools%26aufirst%3DJ.%26aulast%3DDierickx%26aufirst%3DD.%26aulast%3DThomas%26aufirst%3DJ.%26aulast%3DVandenberghe%26aufirst%3DP.%26aulast%3DStul%26aufirst%3DM.%26aulast%3DDelabie%26aufirst%3DJ.%26aulast%3DDe%2BWolf-Peeters%26aufirst%3DC.%26aulast%3DMarynen%26aufirst%3DP.%26aulast%3DWlodarska%26aufirst%3DI.%26atitle%3DALK-positive%2520Large%2520B-cell%2520Lymphomas%2520with%2520Cryptic%2520SEC31A-ALK%2520and%2520NPM1-ALK%2520Fusions%26jtitle%3DHaematologica%26date%3D2010%26volume%3D95%26spage%3D509%26epage%3D513%26doi%3D10.3324%2Fhaematol.2009.014761" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Takeuchi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Togashi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ota, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sekiguchi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hatano, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asaka, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noguchi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mano, H.</span></span> <span> </span><span class="NLM_article-title">Identification of a Novel Fusion, SQSTM1-ALK, in ALK-positive Large B-cell Lymphoma</span>. <i>Haematologica</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>96</i></span>,  <span class="NLM_fpage">464</span>– <span class="NLM_lpage">467</span>, <span class="refDoi"> DOI: 10.3324/haematol.2010.033514</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.3324%2Fhaematol.2010.033514" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=21134980" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1WnsLfO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=2011&pages=464-467&author=K.+Takeuchiauthor=M.+Sodaauthor=Y.+Togashiauthor=Y.+Otaauthor=Y.+Sekiguchiauthor=S.+Hatanoauthor=R.+Asakaauthor=M.+Noguchiauthor=H.+Mano&title=Identification+of+a+Novel+Fusion%2C+SQSTM1-ALK%2C+in+ALK-positive+Large+B-cell+Lymphoma&doi=10.3324%2Fhaematol.2010.033514"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of a novel fusion, SQSTM1-ALK, in ALK-positive large B-cell lymphoma</span></div><div class="casAuthors">Takeuchi, Kengo; Soda, Manabu; Togashi, Yuki; Ota, Yasunori; Sekiguchi, Yasunobu; Hatano, Satoko; Asaka, Reimi; Noguchi, Masaaki; Mano, Hiroyuki</div><div class="citationInfo"><span class="NLM_cas:title">Haematologica</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">96</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">464-467</span>CODEN:
                <span class="NLM_cas:coden">HAEMAX</span>;
        ISSN:<span class="NLM_cas:issn">0390-6078</span>.
    
            (<span class="NLM_cas:orgname">Ferrata Storti Foundation</span>)
        </div><div class="casAbstract">ALK-pos. large B-cell lymphoma is a rare subtype of lymphoma, and most cases follow an aggressive clin. course with a poor prognosis.  We examd. an ALK-pos. large B-cell lymphoma case showing an anti-ALK immunohistochem. pattern distinct from those of 2 known ALK fusions, CLTC-ALK and NPM-ALK, for the presence of a novel ALK fusion; this led to the identification of SQSTM1-ALK.  SQSTM1 is an ubiquitin binding protein that is assocd. with oxidative stress, cell signaling, and autophagy.  We showed transforming activities of SQSTM1-ALK with a focus formation assay and an in vivo tumorigenicity assay using 3T3 fibroblasts infected with a recombinant retrovirus encoding SQSTM1-ALK.  ALK-inhibitor therapies are promising for treating ALK-pos. large B-cell lymphoma, esp. for refractory cases.  SQSTM1-ALK may be a rare fusion, but our data provide novel biol. insights and serve as a key for the accurate diagnosis of this rare lymphoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpJvBjSH8V87Vg90H21EOLACvtfcHk0lghoKFL11aqpg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1WnsLfO&md5=0d760599f0a3559f50a962a1d5aad22c</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.3324%2Fhaematol.2010.033514&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3324%252Fhaematol.2010.033514%26sid%3Dliteratum%253Aachs%26aulast%3DTakeuchi%26aufirst%3DK.%26aulast%3DSoda%26aufirst%3DM.%26aulast%3DTogashi%26aufirst%3DY.%26aulast%3DOta%26aufirst%3DY.%26aulast%3DSekiguchi%26aufirst%3DY.%26aulast%3DHatano%26aufirst%3DS.%26aulast%3DAsaka%26aufirst%3DR.%26aulast%3DNoguchi%26aufirst%3DM.%26aulast%3DMano%26aufirst%3DH.%26atitle%3DIdentification%2520of%2520a%2520Novel%2520Fusion%252C%2520SQSTM1-ALK%252C%2520in%2520ALK-positive%2520Large%2520B-cell%2520Lymphoma%26jtitle%3DHaematologica%26date%3D2011%26volume%3D96%26spage%3D464%26epage%3D467%26doi%3D10.3324%2Fhaematol.2010.033514" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ouyang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span> <span> </span><span class="NLM_article-title">Promising Response of Anaplastic Lymphoma Kinase-positive Large B-cell Lymphoma to Crizotinib Salvage Treatment: Case Report and Review of Literature</span>. <i>Int. J. Clin. Exp. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">6977</span>– <span class="NLM_lpage">6985</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=26221234" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVWgtLzN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2015&pages=6977-6985&author=J.+Liauthor=J.+Ouyangauthor=R.+Zhouauthor=B.+Chenauthor=Y.+Xu&title=Promising+Response+of+Anaplastic+Lymphoma+Kinase-positive+Large+B-cell+Lymphoma+to+Crizotinib+Salvage+Treatment%3A+Case+Report+and+Review+of+Literature"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Promising response of anaplastic lymphoma kinase-positive large B-cell lymphoma to crizotinib salvage treatment: case report and review of literature</span></div><div class="casAuthors">Li, Jian; Ouyang, Jian; Zhou, Rongfu; Chen, Bing; Xu, Yong</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Clinical and Experimental Medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">6977-6985</span>CODEN:
                <span class="NLM_cas:coden">IJCEFA</span>;
        ISSN:<span class="NLM_cas:issn">1940-5901</span>.
    
            (<span class="NLM_cas:orgname">e-Century Publishing Corp.</span>)
        </div><div class="casAbstract">Anaplastic lymphoma kinase (ALK)-pos. diffuse large B-cell lymphoma (ALK + DLBCL) is a rare and poorly characterized subtype of lymphoma.  Reports suggest that this type of tumor responds poorly to std. regimens for non-Hodgkin's lymphoma, with rituximab playing no therapeutic role due to the absence of CD20 expression.  In view of the expression of ALK in this disease, it is plausible that the ALK inhibitor crizotinib may be an effective treatment.  We report a case of a 21-yr-old male ALK + DLBCL patient.  He initially received five cycles of CHOP-21 (vincristine, pirarubicin, cyclophosphamide and prednisone) and achieved a partial remission (PR) but soon deteriorated.  He was subsequently treated with five courses of the salvage chemotherapy regimen ICE (ifosfamide, carboplatin and etoposide) and achieved PR again.  He refused to accept an autologous stem-cell transplantation, after which the disease progressed rapidly.  We administered two courses of an alternative salvage chemotherapy regimen contg. GEMOX and dexamethasone with the addn. of the ALK inhibitor crizotinib.  His symptoms alleviated for a short time but soon worsened and the patient died of massive progressive disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrD7dTikl9df7Vg90H21EOLACvtfcHk0lghoKFL11aqpg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVWgtLzN&md5=6814dafe3466a245e0be2f7d1ca6bb9f</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DOuyang%26aufirst%3DJ.%26aulast%3DZhou%26aufirst%3DR.%26aulast%3DChen%26aufirst%3DB.%26aulast%3DXu%26aufirst%3DY.%26atitle%3DPromising%2520Response%2520of%2520Anaplastic%2520Lymphoma%2520Kinase-positive%2520Large%2520B-cell%2520Lymphoma%2520to%2520Crizotinib%2520Salvage%2520Treatment%253A%2520Case%2520Report%2520and%2520Review%2520of%2520Literature%26jtitle%3DInt.%2520J.%2520Clin.%2520Exp.%2520Med.%26date%3D2015%26volume%3D8%26spage%3D6977%26epage%3D6985" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Philip, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Specialities, M.</span></span> <span> </span><span class="NLM_article-title">ALK Positive DLBCL-A Report of Two Cases and Review of Literature</span>. <i>Univ. J. Med. Med. Special.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">2455</span>– <span class="NLM_lpage">2460</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2016&pages=2455-2460&author=A.+Philipauthor=M.+Specialities&title=ALK+Positive+DLBCL-A+Report+of+Two+Cases+and+Review+of+Literature"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPhilip%26aufirst%3DA.%26aulast%3DSpecialities%26aufirst%3DM.%26atitle%3DALK%2520Positive%2520DLBCL-A%2520Report%2520of%2520Two%2520Cases%2520and%2520Review%2520of%2520Literature%26jtitle%3DUniv.%2520J.%2520Med.%2520Med.%2520Special.%26date%3D2016%26volume%3D2%26spage%3D2455%26epage%3D2460" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Röttgers, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gombert, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teigler-Schlegel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Busch, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gamerdinger, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slany, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harbott, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borkhardt, A.</span></span> <span> </span><span class="NLM_article-title">ALK Fusion Genes in Children with Atypical Myeloproliferative Leukemia</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">1197</span>– <span class="NLM_lpage">1200</span>, <span class="refDoi"> DOI: 10.1038/leu.2010.18</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1038%2Fleu.2010.18" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=20428197" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A280%3ADC%252BC3cvotlGqsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2010&pages=1197-1200&author=S.+R%C3%B6ttgersauthor=M.+Gombertauthor=A.+Teigler-Schlegelauthor=K.+Buschauthor=U.+Gamerdingerauthor=R.+Slanyauthor=J.+Harbottauthor=A.+Borkhardt&title=ALK+Fusion+Genes+in+Children+with+Atypical+Myeloproliferative+Leukemia&doi=10.1038%2Fleu.2010.18"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">ALK fusion genes in children with atypical myeloproliferative leukemia</span></div><div class="casAuthors">Rottgers S; Gombert M; Teigler-Schlegel A; Busch K; Gamerdinger U; Slany R; Harbott J; Borkhardt A</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1197-200</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRTs975Eq7vfLP3FVUi_gf8fW6udTcc2ebTK_ph35p2Brntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3cvotlGqsA%253D%253D&md5=f80cacdded9c4f6b1b9ffebc639f204e</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1038%2Fleu.2010.18&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2010.18%26sid%3Dliteratum%253Aachs%26aulast%3DR%25C3%25B6ttgers%26aufirst%3DS.%26aulast%3DGombert%26aufirst%3DM.%26aulast%3DTeigler-Schlegel%26aufirst%3DA.%26aulast%3DBusch%26aufirst%3DK.%26aulast%3DGamerdinger%26aufirst%3DU.%26aulast%3DSlany%26aufirst%3DR.%26aulast%3DHarbott%26aufirst%3DJ.%26aulast%3DBorkhardt%26aufirst%3DA.%26atitle%3DALK%2520Fusion%2520Genes%2520in%2520Children%2520with%2520Atypical%2520Myeloproliferative%2520Leukemia%26jtitle%3DLeukemia%26date%3D2010%26volume%3D24%26spage%3D1197%26epage%3D1200%26doi%3D10.1038%2Fleu.2010.18" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shinmura, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kageyama, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bunai, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamo, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takamochi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanahashi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niwa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogawa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugimura, H.</span></span> <span> </span><span class="NLM_article-title">EML4-ALK Fusion Transcripts, but no NPM-, TPM3-, CLTC-, ATIC-, or TFG-ALK Fusion Transcripts, in Non-small Cell Lung Carcinomas</span>. <i>Lung Cancer</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">163</span>– <span class="NLM_lpage">169</span>, <span class="refDoi"> DOI: 10.1016/j.lungcan.2007.12.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1016%2Fj.lungcan.2007.12.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=18242762" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A280%3ADC%252BD1cvns1ShtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2008&pages=163-169&author=K.+Shinmuraauthor=S.+Kageyamaauthor=H.+Taoauthor=T.+Bunaiauthor=M.+Suzukiauthor=T.+Kamoauthor=K.+Takamochiauthor=K.+Suzukiauthor=M.+Tanahashiauthor=H.+Niwaauthor=H.+Ogawaauthor=H.+Sugimura&title=EML4-ALK+Fusion+Transcripts%2C+but+no+NPM-%2C+TPM3-%2C+CLTC-%2C+ATIC-%2C+or+TFG-ALK+Fusion+Transcripts%2C+in+Non-small+Cell+Lung+Carcinomas&doi=10.1016%2Fj.lungcan.2007.12.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">EML4-ALK fusion transcripts, but no NPM-, TPM3-, CLTC-, ATIC-, or TFG-ALK fusion transcripts, in non-small cell lung carcinomas</span></div><div class="casAuthors">Shinmura Kazuya; Kageyama Shinji; Tao Hong; Bunai Tomoyasu; Suzuki Masaya; Kamo Takaharu; Takamochi Kazuya; Suzuki Kazuya; Tanahashi Masayuki; Niwa Hiroshi; Ogawa Hiroshi; Sugimura Haruhiko</div><div class="citationInfo"><span class="NLM_cas:title">Lung cancer (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">163-9</span>
        ISSN:<span class="NLM_cas:issn">0169-5002</span>.
    </div><div class="casAbstract">EML4-ALK gene fusions have recently been discovered in a subset of human lung carcinomas, and fusions of the ALK tyrosine kinase gene with the NPM, TPM3, CLTC, ATIC, and TFG genes have been found in hematological malignancies.  To elucidate the role of fusions between ALK and other genes in pulmonary carcinogenesis, we examined 77 non-small cell lung carcinomas (NSCLCs) for EML4-, NPM-, TPM3-, CLTC-, ATIC-, and TFG-ALK fusion transcripts by RT-PCR and subsequent sequencing analysis.  Although no expression of NPM-, TPM3-, CLTC-, ATIC-, or TFG-ALK fusion transcripts were detected in any of the cases, expression of EML4-ALK fusion transcripts was detected in two (2.6%) of the 77 NSCLCs.  In one of the two NSCLCs there was fusion between exon 13 of EML4 and exon 20 of ALK, i.e., variant 1, and in the other there was fusion between exon 20 of EML4 and exon 20 of ALK, i.e., variant 2.  Both patients had a history of smoking, and histologically the carcinomas were adenocarcinoma.  No somatic mutations were detected in the mutation cluster regions of the EGFR, K-RAS, and PIK3CA genes in these two carcinomas, however, a Pro177Ser mutation of the p53 gene was detected in the carcinoma that contained the variant 1 EML4-ALK fusion transcripts.  In situ PCR of a paraffin block section showed that the carcinoma with expression of the variant 1 actually contained an EML4-ALK fusion gene.  These results suggested that the EML4-ALK fusion gene product is involved in the carcinogenesis of a subset of NSCLCs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ7jmhu7h4ah3O4gDb7JggCfW6udTcc2ebaqzDhJJhkVLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1cvns1ShtQ%253D%253D&md5=22dc66a7d0dc1d7451e55a22fb4675bd</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1016%2Fj.lungcan.2007.12.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.lungcan.2007.12.013%26sid%3Dliteratum%253Aachs%26aulast%3DShinmura%26aufirst%3DK.%26aulast%3DKageyama%26aufirst%3DS.%26aulast%3DTao%26aufirst%3DH.%26aulast%3DBunai%26aufirst%3DT.%26aulast%3DSuzuki%26aufirst%3DM.%26aulast%3DKamo%26aufirst%3DT.%26aulast%3DTakamochi%26aufirst%3DK.%26aulast%3DSuzuki%26aufirst%3DK.%26aulast%3DTanahashi%26aufirst%3DM.%26aulast%3DNiwa%26aufirst%3DH.%26aulast%3DOgawa%26aufirst%3DH.%26aulast%3DSugimura%26aufirst%3DH.%26atitle%3DEML4-ALK%2520Fusion%2520Transcripts%252C%2520but%2520no%2520NPM-%252C%2520TPM3-%252C%2520CLTC-%252C%2520ATIC-%252C%2520or%2520TFG-ALK%2520Fusion%2520Transcripts%252C%2520in%2520Non-small%2520Cell%2520Lung%2520Carcinomas%26jtitle%3DLung%2520Cancer%26date%3D2008%26volume%3D61%26spage%3D163%26epage%3D169%26doi%3D10.1016%2Fj.lungcan.2007.12.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Debelenko, L. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raimondi, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daw, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shivakumar, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bridge, J. A.</span></span> <span> </span><span class="NLM_article-title">Renal Cell Carcinoma with Novel VCL–ALK Fusion: New Representative of ALK-associated Tumor Spectrum</span>. <i>Mod. Pathol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">430</span>– <span class="NLM_lpage">442</span>, <span class="refDoi"> DOI: 10.1038/modpathol.2010.213</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1038%2Fmodpathol.2010.213" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=21076462" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC3MXisFartLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2011&pages=430-442&author=L.+V.+Debelenkoauthor=S.+C.+Raimondiauthor=N.+Dawauthor=B.+R.+Shivakumarauthor=D.+Huangauthor=M.+Nelsonauthor=J.+A.+Bridge&title=Renal+Cell+Carcinoma+with+Novel+VCL%E2%80%93ALK+Fusion%3A+New+Representative+of+ALK-associated+Tumor+Spectrum&doi=10.1038%2Fmodpathol.2010.213"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Renal cell carcinoma with novel VCL-ALK fusion: new representative of ALK-associated tumor spectrum</span></div><div class="casAuthors">Debelenko, Larisa V.; Raimondi, Susana C.; Daw, Najat; Shivakumar, Bangalore R.; Huang, Dali; Nelson, Marilu; Bridge, Julia A.</div><div class="citationInfo"><span class="NLM_cas:title">Modern Pathology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">430-442</span>CODEN:
                <span class="NLM_cas:coden">MODPEO</span>;
        ISSN:<span class="NLM_cas:issn">0893-3952</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Renal cell carcinoma represents a model for contemporary classification of solid tumors; however, unusual and unclassifiable cases exist and are not rare in children and young adults.  The anaplastic lymphoma kinase (ALK) gene has recently been implicated in subsets of pulmonary, esophageal, breast, and colon cancers.  These findings strengthen the importance of mol. classification of carcinomas across different organ sites, esp. considering the evolving targeted anticancer therapies with ALK inhibitors.  In the current study of six pediatric renal cell carcinomas, two cases exhibited structural karyotypic abnormalities involving the ALK locus on chromosomal band 2p23.  Fluorescence in situ hybridization (FISH) studies were pos. for an ALK rearrangement in one case, and subsequent 5' rapid amplification of cDNA ends anal. of this tumor revealed that the 3' portion of the ALK transcript encoding for the kinase domain was fused in frame to the 5' portion of vinculin.  The new fusion gene is predicted to have an open reading frame of 4122 bp encoding for a 1374-aa oncoprotein; its expression was shown by immunoblotting with anti-VCL and anti-ALK antibodies in tumor tissue lysates.  Immunohistochem. with the same antibodies demonstrated cytoplasmic and subplasmalemmal localization of the oncoprotein detd. by its N-terminal VCL portion.  FISH with a custom-designed VCL-ALK dual-fusion probe set confirmed the presence of the fusion in neoplastic cells and demonstrated the potential clin. utility of this approach for detecting VCL-ALK in routinely processed tissue.  The five remaining pediatric renal cell carcinomas did not show ALK rearrangement by FISH or ALK expression by immunohistochem.  The data identify the kidney as a new organ site for ALK-assocd. carcinomas and VCL as a novel ALK fusion partner.  The results should prompt further studies to advance the mol. classification of renal cell carcinoma and help to select patients who would benefit from appropriate targeted therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGph2N9DB-4oJ7Vg90H21EOLACvtfcHk0lgJzK2Xfw1wfg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXisFartLY%253D&md5=9b228dba96ec3e98598c82963d851002</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1038%2Fmodpathol.2010.213&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fmodpathol.2010.213%26sid%3Dliteratum%253Aachs%26aulast%3DDebelenko%26aufirst%3DL.%2BV.%26aulast%3DRaimondi%26aufirst%3DS.%2BC.%26aulast%3DDaw%26aufirst%3DN.%26aulast%3DShivakumar%26aufirst%3DB.%2BR.%26aulast%3DHuang%26aufirst%3DD.%26aulast%3DNelson%26aufirst%3DM.%26aulast%3DBridge%26aufirst%3DJ.%2BA.%26atitle%3DRenal%2520Cell%2520Carcinoma%2520with%2520Novel%2520VCL%25E2%2580%2593ALK%2520Fusion%253A%2520New%2520Representative%2520of%2520ALK-associated%2520Tumor%2520Spectrum%26jtitle%3DMod.%2520Pathol.%26date%3D2011%26volume%3D24%26spage%3D430%26epage%3D442%26doi%3D10.1038%2Fmodpathol.2010.213" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thorner, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shago, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marrano, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaikh, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Somers, G. R.</span></span> <span> </span><span class="NLM_article-title">TFE3-positive Renal Cell Carcinomas are not always Xp11 Translocation Carcinomas: Report of a Case with a TPM3-ALK Translocation</span>. <i>Pathol., Res. Pract.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>212</i></span>,  <span class="NLM_fpage">937</span>– <span class="NLM_lpage">942</span>, <span class="refDoi"> DOI: 10.1016/j.prp.2016.07.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1016%2Fj.prp.2016.07.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=27450657" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1aitrjE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=212&publication_year=2016&pages=937-942&author=P.+S.+Thornerauthor=M.+Shagoauthor=P.+Marranoauthor=F.+Shaikhauthor=G.+R.+Somers&title=TFE3-positive+Renal+Cell+Carcinomas+are+not+always+Xp11+Translocation+Carcinomas%3A+Report+of+a+Case+with+a+TPM3-ALK+Translocation&doi=10.1016%2Fj.prp.2016.07.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">TFE3-positive renal cell carcinomas are not always Xp11 translocation carcinomas: Report of a case with a TPM3-ALK translocation</span></div><div class="casAuthors">Thorner, Paul Scott; Shago, Mary; Marrano, Paula; Shaikh, Furqan; Somers, Gino R.</div><div class="citationInfo"><span class="NLM_cas:title">Pathology, Research and Practice</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">212</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">937-942</span>CODEN:
                <span class="NLM_cas:coden">PARPDS</span>;
        ISSN:<span class="NLM_cas:issn">0344-0338</span>.
    
            (<span class="NLM_cas:orgname">Elsevier GmbH</span>)
        </div><div class="casAbstract">Translocation-assocd. renal cell carcinoma (RCC) is a distinct subtype of RCC with gene rearrangements of the TFE3 or TFEB loci.  The TFE3 gene is located at Xp11 and can fuse to a no. of translocation partners, resulting in high nuclear expression of TFE3 protein.  TFE3 immunostaining is often used as a surrogate marker for a TFE3 translocation.  We report a case of an RCC that expressed TFE3 but showed only gain of TFE3 rather than a translocation.  Moreover, this case had a t(1;2) translocation fusing ALK and TMP3, identical to that seen in inflammatory myofibroblastic tumor.  There was resulting overexpression of ALK protein in a cytoplasmic and membranous pattern.  The patient was not treated with chemotherapy but following regional nodal recurrence, an ALK inhibitor was added and the patient remains alive one year later.  There are only rare reports of RCC with an ALK-TMP3 fusion, and these tumors can express TFE3 on some unknown basis not related to a TFE3 translocation.  Any RCC pos. for TFE3 and lacking a translocation should be tested for ALK expression and translocation.  Recognition of this subtype of RCC will allow ALK inhibitor therapy to be added, in the hope of improving patient outcome.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrdVKPjHxvuf7Vg90H21EOLACvtfcHk0lgJzK2Xfw1wfg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1aitrjE&md5=94e5a2ef64c27431a3d1e5373a4a5116</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1016%2Fj.prp.2016.07.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.prp.2016.07.004%26sid%3Dliteratum%253Aachs%26aulast%3DThorner%26aufirst%3DP.%2BS.%26aulast%3DShago%26aufirst%3DM.%26aulast%3DMarrano%26aufirst%3DP.%26aulast%3DShaikh%26aufirst%3DF.%26aulast%3DSomers%26aufirst%3DG.%2BR.%26atitle%3DTFE3-positive%2520Renal%2520Cell%2520Carcinomas%2520are%2520not%2520always%2520Xp11%2520Translocation%2520Carcinomas%253A%2520Report%2520of%2520a%2520Case%2520with%2520a%2520TPM3-ALK%2520Translocation%26jtitle%3DPathol.%252C%2520Res.%2520Pract.%26date%3D2016%26volume%3D212%26spage%3D937%26epage%3D942%26doi%3D10.1016%2Fj.prp.2016.07.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pietrantonio, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maggi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Bartolomeo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Facciorusso, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perrone, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Testi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iacovelli, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miceli, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bossi, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leone, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milione, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pelosi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Braud, F.</span></span> <span> </span><span class="NLM_article-title">Gain of ALK Gene Copy Number may Predict Lack of Benefit from Anti-EGFR Treatment in Patients with Advanced Colorectal Cancer and RAS-RAF-PI3KCA Wild-type Status</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">e92147</span>, <span class="refDoi"> DOI: 10.1371/journal.pone.0092147</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1371%2Fjournal.pone.0092147" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=24691006" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1aqtr3K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=e92147&issue=4&author=F.+Pietrantonioauthor=C.+Maggiauthor=M.+Di+Bartolomeoauthor=M.+G.+Facciorussoauthor=F.+Perroneauthor=A.+Testiauthor=R.+Iacovelliauthor=R.+Miceliauthor=I.+Bossiauthor=G.+Leoneauthor=M.+Milioneauthor=G.+Pelosiauthor=F.+de+Braud&title=Gain+of+ALK+Gene+Copy+Number+may+Predict+Lack+of+Benefit+from+Anti-EGFR+Treatment+in+Patients+with+Advanced+Colorectal+Cancer+and+RAS-RAF-PI3KCA+Wild-type+Status&doi=10.1371%2Fjournal.pone.0092147"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Gain of ALK gene copy number may predict lack of benefit from anti-EGFR treatment in patients with advanced colorectal cancer and RAS-RAF-PI3KCA wild-type status</span></div><div class="casAuthors">Pietrantonio, Filippo; Maggi, Claudia; Di Bartolomeo, Maria; Facciorusso, Maria Grazia; Perrone, Federica; Testi, Adele; Iacovelli, Roberto; Miceli, Rosalba; Bossi, Ilaria; Leone, Giorgia; Milione, Massimo; Pelosi, Giuseppe; de Braud, Filippo</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">e92147/1-e92147/6, 6 pp.</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Introduction: Although cetuximab and panitumumab show an increased efficacy for patients with KRAS-NRAS-BRAF and PI3KCA wild-type metastatic colorectal cancer, primary resistance occurs in a relevant subset of molecularly enriched populations.  Patients and Methods: We evaluated the outcome of 68 patients with advanced colorectal cancer and RAS, BRAF and PI3KCA status according to ALK gene status (disomic vs. gain of ALK gene copy no. - defined as mean of 3 to 5 fusion signals in ≥10% of cells).  All consecutive patients received cetuximab and irinotecan or panitumumab alone for chemorefractory disease.  Results: No ALK translocations or amplifications were detected.  ALK gene copy no. gain was found in 25 (37%) tumors.  Response rate was significantly higher in patients with disomic ALK as compared to those with gain of gene copy no. (70% vs. 32%; p = 0.0048).  Similarly, progression-free survival was significantly different when comparing the two groups (6.7 vs. 5.3 mo; p = 0.045).  A trend was obsd. also for overall survival (18.5 vs. 15.6 mo; p = 0.885).  Conclusion: Gain of ALK gene copy no. might represent a neg. prognostic factor in mCRC and may have a role in resistance to anti-EGFR therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1XkXZJKSCNLVg90H21EOLACvtfcHk0liQfLOV0yeZpw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1aqtr3K&md5=4ad6f527567c2fabec7fbda64dcd1b84</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0092147&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0092147%26sid%3Dliteratum%253Aachs%26aulast%3DPietrantonio%26aufirst%3DF.%26aulast%3DMaggi%26aufirst%3DC.%26aulast%3DDi%2BBartolomeo%26aufirst%3DM.%26aulast%3DFacciorusso%26aufirst%3DM.%2BG.%26aulast%3DPerrone%26aufirst%3DF.%26aulast%3DTesti%26aufirst%3DA.%26aulast%3DIacovelli%26aufirst%3DR.%26aulast%3DMiceli%26aufirst%3DR.%26aulast%3DBossi%26aufirst%3DI.%26aulast%3DLeone%26aufirst%3DG.%26aulast%3DMilione%26aufirst%3DM.%26aulast%3DPelosi%26aufirst%3DG.%26aulast%3Dde%2BBraud%26aufirst%3DF.%26atitle%3DGain%2520of%2520ALK%2520Gene%2520Copy%2520Number%2520may%2520Predict%2520Lack%2520of%2520Benefit%2520from%2520Anti-EGFR%2520Treatment%2520in%2520Patients%2520with%2520Advanced%2520Colorectal%2520Cancer%2520and%2520RAS-RAF-PI3KCA%2520Wild-type%2520Status%26jtitle%3DPLoS%2520One%26date%3D2014%26volume%3D9%26issue%3D4%26spage%3De92147%26doi%3D10.1371%2Fjournal.pone.0092147" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref69"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref69'); return false;" data-citation="" class="refNumLink">69</a></strong><div class="NLM_citation" id="cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lin, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soriano, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivers, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pandita, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Modrusan, Z.</span></span> <span> </span><span class="NLM_article-title">Exon Array Profiling Detects EML4-ALK Fusion in Breast, Colorectal, and Non–small Cell Lung Cancers</span>. <i>Mol. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">1466</span>– <span class="NLM_lpage">1476</span>, <span class="refDoi"> DOI: 10.1158/1541-7786.MCR-08-0522</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1158%2F1541-7786.MCR-08-0522" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=19737969" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtFCjtbvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2009&pages=1466-1476&author=E.+Linauthor=L.+Liauthor=Y.+Guanauthor=R.+Sorianoauthor=C.+S.+Riversauthor=S.+Mohanauthor=A.+Panditaauthor=J.+Tangauthor=Z.+Modrusan&title=Exon+Array+Profiling+Detects+EML4-ALK+Fusion+in+Breast%2C+Colorectal%2C+and+Non%E2%80%93small+Cell+Lung+Cancers&doi=10.1158%2F1541-7786.MCR-08-0522"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Exon Array Profiling Detects EML4-ALK Fusion in Breast, Colorectal, and Non-Small Cell Lung Cancers</span></div><div class="casAuthors">Lin, Eva; Li, Li; Guan, Yinghui; Soriano, Robert; Rivers, Celina Sanchez; Mohan, Sankar; Pandita, Ajay; Tang, Jerry; Modrusan, Zora</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1466-1476</span>CODEN:
                <span class="NLM_cas:coden">MCROC5</span>;
        ISSN:<span class="NLM_cas:issn">1541-7786</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The echinoderm microtubule-assocd. protein-like 4-anaplastic lymphoma kinase (EML4-ALK) fusion gene has been identified as an oncogene in a subset of non-small cell lung cancers (NSCLC).  We used profiling of cancer genomes on an exon array to develop a novel computational method for the global search of gene rearrangements.  This approach led to the detection of EML4-ALK fusion in breast and colorectal carcinomas in addn. to NSCLC.  Screening of a large collection of patient tumor samples showed the presence of EML4-ALK fusion in 2.4% of breast (5 of 209), 2.4% of colorectal (2 of 83), and in 11.3% of NSCLC (12 of 106).  Besides previously known EML4-ALK variants 1 (E13; A20) and 2 (E20; A20), a novel variant E21; A20 was found in colorectal carcinoma.  The presence of an EML-ALK rearrangement was verified by identifying genomic fusion points in tumor samples representative of breast, colon, and NSCLC.  EML4-ALK translocation was also confirmed by fluorescence in situ hybridization assay, which revealed its substantial heterogeneity in both primary tumors and tumor-derived cell lines.  To elucidate the functional significance of EML4-ALK, we examd. the growth of cell lines harboring the fusion following EML4 and ALK silencing by small interfering RNA.  Significant growth inhibition was obsd. in some but not all cell lines, suggesting their variable dependence on ALK-mediated cell survival signaling.  Collectively, these findings show the recurrence of EML4-ALK fusion in multiple solid tumors and further substantiate its role in tumorigenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpeB-bLrMJbCbVg90H21EOLACvtfcHk0liQfLOV0yeZpw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtFCjtbvN&md5=4723927a63f9621cc3714ec080b37ae8</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1158%2F1541-7786.MCR-08-0522&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1541-7786.MCR-08-0522%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DE.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DGuan%26aufirst%3DY.%26aulast%3DSoriano%26aufirst%3DR.%26aulast%3DRivers%26aufirst%3DC.%2BS.%26aulast%3DMohan%26aufirst%3DS.%26aulast%3DPandita%26aufirst%3DA.%26aulast%3DTang%26aufirst%3DJ.%26aulast%3DModrusan%26aufirst%3DZ.%26atitle%3DExon%2520Array%2520Profiling%2520Detects%2520EML4-ALK%2520Fusion%2520in%2520Breast%252C%2520Colorectal%252C%2520and%2520Non%25E2%2580%2593small%2520Cell%2520Lung%2520Cancers%26jtitle%3DMol.%2520Cancer%2520Res.%26date%3D2009%26volume%3D7%26spage%3D1466%26epage%3D1476%26doi%3D10.1158%2F1541-7786.MCR-08-0522" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref70"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref70'); return false;" data-citation="" class="refNumLink">70</a></strong><div class="NLM_citation" id="cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Demeure, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aziz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenberg, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gurley, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bussey, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carpten, J. D.</span></span> <span> </span><span class="NLM_article-title">Whole-genome Sequencing of an Aggressive BRAF Wild-type Papillary Thyroid Cancer Identified EML4–ALK Translocation as a Therapeutic Target</span>. <i>World J. Surg.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">1296</span>– <span class="NLM_lpage">1305</span>, <span class="refDoi"> DOI: 10.1007/s00268-014-2485-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1007%2Fs00268-014-2485-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=24633422" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A280%3ADC%252BC2crktFyhsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2014&pages=1296-1305&author=M.+J.+Demeureauthor=M.+Azizauthor=R.+Rosenbergauthor=S.+D.+Gurleyauthor=K.+J.+Busseyauthor=J.+D.+Carpten&title=Whole-genome+Sequencing+of+an+Aggressive+BRAF+Wild-type+Papillary+Thyroid+Cancer+Identified+EML4%E2%80%93ALK+Translocation+as+a+Therapeutic+Target&doi=10.1007%2Fs00268-014-2485-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Whole-genome sequencing of an aggressive BRAF wild-type papillary thyroid cancer identified EML4-ALK translocation as a therapeutic target</span></div><div class="casAuthors">Demeure Michael J; Aziz Meraj; Rosenberg Richard; Gurley Steven D; Bussey Kimberly J; Carpten John D</div><div class="citationInfo"><span class="NLM_cas:title">World journal of surgery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1296-305</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Recent advances in the treatment of cancer have focused on targeting genomic aberrations with selective therapeutic agents.  In radioiodine resistant aggressive papillary thyroid cancers, there remain few effective therapeutic options.  A 62-year-old man who underwent multiple operations for papillary thyroid cancer and whose metastases progressed despite standard treatments provided tumor tissue.  METHODS:  We analyzed tumor and whole blood DNA by whole genome sequencing, achieving 80× or greater coverage over 94 % of the exome and 90 % of the genome.  We determined somatic mutations and structural alterations.  RESULTS:  We found a total of 57 somatic mutations in 55 genes of the cancer genome.  There was notably a lack of mutations in NRAS and BRAF, and no RET/PTC rearrangement.  There was a mutation in the TRAPP oncogene and a loss of heterozygosity of the p16, p18, and RB1 tumor suppressor genes.  The oncogenic driver for this tumor is a translocation involving the genes for anaplastic lymphoma receptor tyrosine kinase (ALK) and echinoderm microtubule associated protein like 4 (EML4).  The EML4-ALK translocation has been reported in approximately 5 % of lung cancers, as well as in pediatric neuroblastoma, and is a therapeutic target for crizotinib.  CONCLUSIONS:  This is the first report of the whole genomic sequencing of a papillary thyroid cancer in which we identified an EML4-ALK translocation of a TRAPP oncogene mutation.  These findings suggest that this tumor has a more distinct oncogenesis than BRAF mutant papillary thyroid cancer.  Whole genome sequencing can elucidate an oncogenic context and expose potential therapeutic vulnerabilities in rare cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRIV4GB44ay0I2y4bB4mnvYfW6udTcc2eZEDLO5du1iz7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2crktFyhsg%253D%253D&md5=706f7ff0576d59301ba6af47e1853dbd</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1007%2Fs00268-014-2485-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00268-014-2485-3%26sid%3Dliteratum%253Aachs%26aulast%3DDemeure%26aufirst%3DM.%2BJ.%26aulast%3DAziz%26aufirst%3DM.%26aulast%3DRosenberg%26aufirst%3DR.%26aulast%3DGurley%26aufirst%3DS.%2BD.%26aulast%3DBussey%26aufirst%3DK.%2BJ.%26aulast%3DCarpten%26aufirst%3DJ.%2BD.%26atitle%3DWhole-genome%2520Sequencing%2520of%2520an%2520Aggressive%2520BRAF%2520Wild-type%2520Papillary%2520Thyroid%2520Cancer%2520Identified%2520EML4%25E2%2580%2593ALK%2520Translocation%2520as%2520a%2520Therapeutic%2520Target%26jtitle%3DWorld%2520J.%2520Surg.%26date%3D2014%26volume%3D38%26spage%3D1296%26epage%3D1305%26doi%3D10.1007%2Fs00268-014-2485-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref71"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref71'); return false;" data-citation="" class="refNumLink">71</a></strong><div class="NLM_citation" id="cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barila, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evdokimova, V. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trivedi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panebianco, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gandhi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carty, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodak, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dacic, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Y. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nikiforova, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferris, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altschuler, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nikiforov, Y. E.</span></span> <span> </span><span class="NLM_article-title">Identification of the Transforming STRN-ALK Fusion as a Potential Therapeutic Target in the Aggressive Forms of Thyroid Cancer</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>111</i></span>,  <span class="NLM_fpage">4233</span>– <span class="NLM_lpage">4238</span>, <span class="refDoi"> DOI: 10.1073/pnas.1321937111</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1073%2Fpnas.1321937111" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=24613930" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjtlyntr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2014&pages=4233-4238&author=L.+M.+Kellyauthor=G.+Barilaauthor=P.+Liuauthor=V.+N.+Evdokimovaauthor=S.+Trivediauthor=F.+Panebiancoauthor=M.+Gandhiauthor=S.+E.+Cartyauthor=S.+P.+Hodakauthor=J.+Luoauthor=S.+Dacicauthor=Y.+P.+Yuauthor=M.+N.+Nikiforovaauthor=R.+L.+Ferrisauthor=D.+L.+Altschulerauthor=Y.+E.+Nikiforov&title=Identification+of+the+Transforming+STRN-ALK+Fusion+as+a+Potential+Therapeutic+Target+in+the+Aggressive+Forms+of+Thyroid+Cancer&doi=10.1073%2Fpnas.1321937111"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of the transforming STRN-ALK fusion as a potential therapeutic target in the aggressive forms of thyroid cancer</span></div><div class="casAuthors">Kelly, Lindsey M.; Barila, Guillermo; Liu, Pengyuan; Evdokimova, Viktoria N.; Trivedi, Sumita; Panebianco, Federica; Gandhi, Manoj; Carty, Sally E.; Hodak, Steven P.; Luo, Jianhua; Dacic, Sanja; Yu, Yan P.; Nikiforova, Marina N.; Ferris, Robert L.; Altschuler, Daniel L.; Nikiforov, Yuri E.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4233-4238</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Thyroid cancer is a common endocrine malignancy that encompasses well-differentiated as well as dedifferentiated cancer types.  The latter tumors have high mortality and lack effective therapies.  Using a paired-end RNA-sequencing approach, we report the discovery of rearrangements involving the anaplastic lymphoma kinase (ALK) gene in thyroid cancer.  The most common of these involves a fusion between ALK and the striatin (STRN) gene, which is the result of a complex rearrangement involving the short arm of chromosome 2.  STRN-ALK leads to constitutive activation of ALK kinase via dimerization mediated by the coiled-coil domain of STRN and to a kinase-dependent, TSH-independent proliferation of thyroid cells.  Moreover, expression of STRN-ALK transforms cells in vitro and induces tumor formation in nude mice.  The kinase activity of STRN-ALK and the ALK-induced cell growth can be blocked by the ALK inhibitors crizotinib and TAE684.  In addn. to well-differentiated papillary cancer, STRN-ALK was found with a higher prevalence in poorly differentiated and anaplastic thyroid cancers, and it did not overlap with other known driver mutations in these tumors.  Our data demonstrate that STRN-ALK fusion occurs in a subset of patients with highly aggressive types of thyroid cancer and provide initial evidence suggesting that it may represent a therapeutic target for these patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvFujoadOIy7Vg90H21EOLACvtfcHk0li6UQLNr6fkRw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjtlyntr8%253D&md5=f2698ba003f5fcf98b05f82122c94f15</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1321937111&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1321937111%26sid%3Dliteratum%253Aachs%26aulast%3DKelly%26aufirst%3DL.%2BM.%26aulast%3DBarila%26aufirst%3DG.%26aulast%3DLiu%26aufirst%3DP.%26aulast%3DEvdokimova%26aufirst%3DV.%2BN.%26aulast%3DTrivedi%26aufirst%3DS.%26aulast%3DPanebianco%26aufirst%3DF.%26aulast%3DGandhi%26aufirst%3DM.%26aulast%3DCarty%26aufirst%3DS.%2BE.%26aulast%3DHodak%26aufirst%3DS.%2BP.%26aulast%3DLuo%26aufirst%3DJ.%26aulast%3DDacic%26aufirst%3DS.%26aulast%3DYu%26aufirst%3DY.%2BP.%26aulast%3DNikiforova%26aufirst%3DM.%2BN.%26aulast%3DFerris%26aufirst%3DR.%2BL.%26aulast%3DAltschuler%26aufirst%3DD.%2BL.%26aulast%3DNikiforov%26aufirst%3DY.%2BE.%26atitle%3DIdentification%2520of%2520the%2520Transforming%2520STRN-ALK%2520Fusion%2520as%2520a%2520Potential%2520Therapeutic%2520Target%2520in%2520the%2520Aggressive%2520Forms%2520of%2520Thyroid%2520Cancer%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2014%26volume%3D111%26spage%3D4233%26epage%3D4238%26doi%3D10.1073%2Fpnas.1321937111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref72"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref72'); return false;" data-citation="" class="refNumLink">72</a></strong><div class="NLM_citation" id="cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ji, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oh, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yun, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, W.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, H.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, M.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, J.-M.</span></span> <span> </span><span class="NLM_article-title">Identification of Driving ALK Fusion Genes and Genomic Landscape of Medullary Thyroid Cancer</span>. <i>PLoS Genet.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">e1005467</span>, <span class="refDoi"> DOI: 10.1371/journal.pgen.1005467</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1371%2Fjournal.pgen.1005467" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=26295973" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC28Xls1Wisbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2015&pages=e1005467&author=J.+H.+Jiauthor=Y.+L.+Ohauthor=M.+Hongauthor=J.+W.+Yunauthor=H.-W.+Leeauthor=D.+Kimauthor=Y.+Jiauthor=D.-H.+Kimauthor=W.-Y.+Parkauthor=H.-T.+Shinauthor=K.-M.+Kimauthor=M.-J.+Ahnauthor=K.+Parkauthor=J.-M.+Sun&title=Identification+of+Driving+ALK+Fusion+Genes+and+Genomic+Landscape+of+Medullary+Thyroid+Cancer&doi=10.1371%2Fjournal.pgen.1005467"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of Driving ALK fusion genes and genomic landscape of medullary thyroid cancer</span></div><div class="casAuthors">Ho, Ji Jun; Oh, Young Lyun; Hong, Mineui; Yun, Jae Won; Lee, Hyun-Woo; Kim, Deok-Geun; Ji, Yongick; Kim, Duk-Hwan; Park, Woong-Yang; Shin, Hyun-Tae; Kim, Kyoung-Mee; Ahn, Myung-Ju; Park, Keunchil; Sun, Jong-Mu</div><div class="citationInfo"><span class="NLM_cas:title">PLoS Genetics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">e1005467/1-e1005467/12</span>CODEN:
                <span class="NLM_cas:coden">PGLEB5</span>;
        ISSN:<span class="NLM_cas:issn">1553-7404</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">The genetic landscape of medullary thyroid cancer (MTC) is not yet fully understood, although some oncogenic mutations have been identified.  To explore genetic profiles of MTCs, formalin-fixed, paraffin-embedded tumor tissues from MTC patients were assayed on the Ion AmpliSeq Cancer Panel v2.  Eighty-four sporadic MTC samples and 36 paired normal thyroid tissues were successfully sequenced.  We discovered 101 hotspot mutations in 18 genes in the 84 MTC tissue samples.  The most common mutation was in the ret proto-oncogene, which occurred in 47 cases followed by mutations in genes encoding Harvey rat sarcoma viral oncogene homolog (N = 14), serine/threonine kinase 11 (N = 11), v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog (N = 6), mutL homolog 1 (N = 4), Kiesten rat sarcoma viral oncogene homolog (N = 3) and MET protooncogene (N = 3).  We also evaluated anaplastic lymphoma kinase (ALK) rearrangement by immunohistochem. and break-apart fluorescence in situ hybridization (FISH).  Two of 98 screened cases were pos. for ALK FISH.  To identify the genomic breakpoint and 5' fusion partner of ALK, customized targeted cancer panel sequencing was performed using DNA from tumor samples of the two patients.  Glutamine: fructose-6-phosphate transaminase 1 (GFPT1)-ALK and echinoderm microtubule-assocd. protein-like 4 (EML4)-ALK fusions were identified.  Addnl. PCR anal., followed by Sanger sequencing, confirmed the GFPT1 ALK fusion, indicating that the fusion is a result of intra-chromosomal translocation or deletion.  Notably, a metastatic MTC case harboring the EML4-ALK fusion showed a dramatic response to an ALK inhibitor, crizotinib.  In conclusion, we found several genetic mutations in MTC and are the first to identify ALK fusions in MTC.  Our results suggest that the EML4-ALK fusion in MTC may be a potential driver mutation and a valid target of ALK inhibitors.  Furthermore, the GFPT1-ALK fusion may be a potential candidate for mol. target therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXTAvKjl0oerVg90H21EOLACvtfcHk0lgGeYiDYyZybg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xls1Wisbw%253D&md5=89569abca7307a746aab80ef3823ee21</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pgen.1005467&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pgen.1005467%26sid%3Dliteratum%253Aachs%26aulast%3DJi%26aufirst%3DJ.%2BH.%26aulast%3DOh%26aufirst%3DY.%2BL.%26aulast%3DHong%26aufirst%3DM.%26aulast%3DYun%26aufirst%3DJ.%2BW.%26aulast%3DLee%26aufirst%3DH.-W.%26aulast%3DKim%26aufirst%3DD.%26aulast%3DJi%26aufirst%3DY.%26aulast%3DKim%26aufirst%3DD.-H.%26aulast%3DPark%26aufirst%3DW.-Y.%26aulast%3DShin%26aufirst%3DH.-T.%26aulast%3DKim%26aufirst%3DK.-M.%26aulast%3DAhn%26aufirst%3DM.-J.%26aulast%3DPark%26aufirst%3DK.%26aulast%3DSun%26aufirst%3DJ.-M.%26atitle%3DIdentification%2520of%2520Driving%2520ALK%2520Fusion%2520Genes%2520and%2520Genomic%2520Landscape%2520of%2520Medullary%2520Thyroid%2520Cancer%26jtitle%3DPLoS%2520Genet.%26date%3D2015%26volume%3D11%26spage%3De1005467%26doi%3D10.1371%2Fjournal.pgen.1005467" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref73"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref73'); return false;" data-citation="" class="refNumLink">73</a></strong><div class="NLM_citation" id="cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Busam, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kutzner, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cerroni, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiesner, T.</span></span> <span> </span><span class="NLM_article-title">Clinical and Pathologic Findings of Spitz Nevi and Atypical Spitz Tumors with ALK Fusions</span>. <i>Am. J. Surg. Pathol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">925</span>– <span class="NLM_lpage">933</span>, <span class="refDoi"> DOI: 10.1097/PAS.0000000000000187</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1097%2FPAS.0000000000000187" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=24698967" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A280%3ADC%252BC2cngsFGlsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2014&pages=925-933&author=K.+J.+Busamauthor=H.+Kutznerauthor=L.+Cerroniauthor=T.+Wiesner&title=Clinical+and+Pathologic+Findings+of+Spitz+Nevi+and+Atypical+Spitz+Tumors+with+ALK+Fusions&doi=10.1097%2FPAS.0000000000000187"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical and pathologic findings of Spitz nevi and atypical Spitz tumors with ALK fusions</span></div><div class="casAuthors">Busam Klaus J; Kutzner Heinz; Cerroni Lorenzo; Wiesner Thomas</div><div class="citationInfo"><span class="NLM_cas:title">The American journal of surgical pathology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">925-33</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Spitz tumors represent a group of melanocytic neoplasms that typically affect young individuals.  Microscopically, the lesions are composed of cytologically distinct spindle and epithelioid melanocytes, with a range in the architectural display or the cells, their nuclear features, and secondary epidermal or stromal changes.  Recently, kinase fusions have been documented in a subset of Spitz tumors, but there is limited information on the clinical and pathologic features associated with those lesions.  Here, we report a series of 17 patients (9 male, 8 female) with spitzoid neoplasms showing ALK fusions (5 Spitz nevi and 12 atypical Spitz tumors).  The patients' ages ranged from 2 years to 35 years (mean=17 y; median=16 y).  Most lesions were located on the lower extremities and presented clinically as polypoid nodules.  All tumors were compound melanocytic proliferations with a predominant intradermal growth.  Tumor thickness ranged from 1.1 to 6 mm (mean=2.9 mm; median=2.5 mm).  The most characteristic histopathologic feature of the tumors (seen in all but 2 lesions) was a plexiform dermal growth of intersecting fascicles of fusiform melanocytes.  All but 2 tumors were amelanotic.  All tumors were strongly immunoreactive for ALK.  The ALK rearrangements were confirmed in all cases by fluorescence in situ hybridization (FISH), and the fusion partner was determined by quantitative polymerase chain reaction as TPM3 (tropomyosin 3) in 11 cases and DCTN1 (dynactin 1) in 6 cases.  None of the 8 tumors that were analyzed by FISH for copy number changes of 6p, 6q, 9p, or 11q met criteria for melanoma.  Two patients underwent a sentinel lymph node biopsy, and in both cases melanocyte nests were found in the subcapsular sinus of the node.  Array comparative genomic hybridization of these 2 tumors revealed no chromosomal gains or losses.  In conclusion, our study revealed that Spitz nevi/tumors with ALK rearrangement show a characteristic plexiform morphology and that ALK immunohistochemistry and FISH enable the accurate identification of this morphologic and genetic distinct subset of spitzoid neoplasms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSyswsOXNcjAiXXDYhVZBdlfW6udTcc2ebHMNVoLGQiQLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cngsFGlsw%253D%253D&md5=a01efaff0c91475ecc621cbcad020a61</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1097%2FPAS.0000000000000187&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FPAS.0000000000000187%26sid%3Dliteratum%253Aachs%26aulast%3DBusam%26aufirst%3DK.%2BJ.%26aulast%3DKutzner%26aufirst%3DH.%26aulast%3DCerroni%26aufirst%3DL.%26aulast%3DWiesner%26aufirst%3DT.%26atitle%3DClinical%2520and%2520Pathologic%2520Findings%2520of%2520Spitz%2520Nevi%2520and%2520Atypical%2520Spitz%2520Tumors%2520with%2520ALK%2520Fusions%26jtitle%3DAm.%2520J.%2520Surg.%2520Pathol.%26date%3D2014%26volume%3D38%26spage%3D925%26epage%3D933%26doi%3D10.1097%2FPAS.0000000000000187" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref74"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref74'); return false;" data-citation="" class="refNumLink">74</a></strong><div class="NLM_citation" id="cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ouchi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyachi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuma, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuchiya, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iehara, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konishi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yanagisawa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hosoi, H.</span></span> <span> </span><span class="NLM_article-title">FN1: a Novel Fusion Partner of ALK in an Inflammatory Myofibroblastic Tumor</span>. <i>Pediatr. Blood Cancer</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">909</span>– <span class="NLM_lpage">911</span>, <span class="refDoi"> DOI: 10.1002/pbc.25424</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1002%2Fpbc.25424" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=25682942" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A280%3ADC%252BC2Mrls1Glug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2015&pages=909-911&author=K.+Ouchiauthor=M.+Miyachiauthor=Y.+Tsumaauthor=K.+Tsuchiyaauthor=T.+Ieharaauthor=E.+Konishiauthor=A.+Yanagisawaauthor=H.+Hosoi&title=FN1%3A+a+Novel+Fusion+Partner+of+ALK+in+an+Inflammatory+Myofibroblastic+Tumor&doi=10.1002%2Fpbc.25424"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">FN1: a novel fusion partner of ALK in an inflammatory myofibroblastic tumor</span></div><div class="casAuthors">Ouchi Kazutaka; Miyachi Mitsuru; Tsuma Yusuke; Tsuchiya Kunihiko; Iehara Tomoko; Konishi Eiichi; Yanagisawa Akio; Hosoi Hajime</div><div class="citationInfo"><span class="NLM_cas:title">Pediatric blood & cancer</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">909-11</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Inflammatory myofibroblastic tumors (IMTs) are rare tumors characterized as low-to-intermediate grade sarcomas.  Rearrangements of the anaplastic lymphoma kinase (ALK) gene have been reported in IMT.  Here, we describe a novel fusion gene in an IMT tumor specimen.  A 12-year-old male was admitted to our hospital with a bladder tumor.  We identified the fibronectin 1 gene (FN1) as a fusion partner of ALK using 5'RACE.  This novel fusion, FN1-ALK, resulted in ALK overexpression in the IMT.  This finding should clarify the causes of IMT and facilitate development of novel therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRjaaAYd2aD2OWhZTslLrfffW6udTcc2ebHMNVoLGQiQLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2Mrls1Glug%253D%253D&md5=41480048a531d203fbb98429634242b2</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1002%2Fpbc.25424&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpbc.25424%26sid%3Dliteratum%253Aachs%26aulast%3DOuchi%26aufirst%3DK.%26aulast%3DMiyachi%26aufirst%3DM.%26aulast%3DTsuma%26aufirst%3DY.%26aulast%3DTsuchiya%26aufirst%3DK.%26aulast%3DIehara%26aufirst%3DT.%26aulast%3DKonishi%26aufirst%3DE.%26aulast%3DYanagisawa%26aufirst%3DA.%26aulast%3DHosoi%26aufirst%3DH.%26atitle%3DFN1%253A%2520a%2520Novel%2520Fusion%2520Partner%2520of%2520ALK%2520in%2520an%2520Inflammatory%2520Myofibroblastic%2520Tumor%26jtitle%3DPediatr.%2520Blood%2520Cancer%26date%3D2015%26volume%3D62%26spage%3D909%26epage%3D911%26doi%3D10.1002%2Fpbc.25424" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref75"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref75'); return false;" data-citation="" class="refNumLink">75</a></strong><div class="NLM_citation" id="cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tucker, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chand, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Danielson, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruuth, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El Wakil, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witek, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jamin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Umapathy, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smeal, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinsson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chesler, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmer, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hallberg, B.</span></span> <span> </span><span class="NLM_article-title">The ALK Inhibitor PF-06463922 is Effective as a Single Agent in Neuroblastoma Driven by Expression of ALK and MYCN</span>. <i>Dis. Models &amp; Mech.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">941</span>– <span class="NLM_lpage">952</span>, <span class="refDoi"> DOI: 10.1242/dmm.024448</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1242%2Fdmm.024448" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=27483357" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2016&pages=941-952&author=J.+Guanauthor=E.+R.+Tuckerauthor=H.+Wanauthor=D.+Chandauthor=L.+S.+Danielsonauthor=K.+Ruuthauthor=A.+El+Wakilauthor=B.+Witekauthor=Y.+Jaminauthor=G.+Umapathyauthor=S.+P.+Robinsonauthor=T.+W.+Johnsonauthor=T.+Smealauthor=T.+Martinssonauthor=L.+Cheslerauthor=R.+H.+Palmerauthor=B.+Hallberg&title=The+ALK+Inhibitor+PF-06463922+is+Effective+as+a+Single+Agent+in+Neuroblastoma+Driven+by+Expression+of+ALK+and+MYCN&doi=10.1242%2Fdmm.024448"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1242%2Fdmm.024448&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1242%252Fdmm.024448%26sid%3Dliteratum%253Aachs%26aulast%3DGuan%26aufirst%3DJ.%26aulast%3DTucker%26aufirst%3DE.%2BR.%26aulast%3DWan%26aufirst%3DH.%26aulast%3DChand%26aufirst%3DD.%26aulast%3DDanielson%26aufirst%3DL.%2BS.%26aulast%3DRuuth%26aufirst%3DK.%26aulast%3DEl%2BWakil%26aufirst%3DA.%26aulast%3DWitek%26aufirst%3DB.%26aulast%3DJamin%26aufirst%3DY.%26aulast%3DUmapathy%26aufirst%3DG.%26aulast%3DRobinson%26aufirst%3DS.%2BP.%26aulast%3DJohnson%26aufirst%3DT.%2BW.%26aulast%3DSmeal%26aufirst%3DT.%26aulast%3DMartinsson%26aufirst%3DT.%26aulast%3DChesler%26aufirst%3DL.%26aulast%3DPalmer%26aufirst%3DR.%2BH.%26aulast%3DHallberg%26aufirst%3DB.%26atitle%3DThe%2520ALK%2520Inhibitor%2520PF-06463922%2520is%2520Effective%2520as%2520a%2520Single%2520Agent%2520in%2520Neuroblastoma%2520Driven%2520by%2520Expression%2520of%2520ALK%2520and%2520MYCN%26jtitle%3DDis.%2520Models%2520%2526amp%253B%2520Mech.%26date%3D2016%26volume%3D9%26spage%3D941%26epage%3D952%26doi%3D10.1242%2Fdmm.024448" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref76"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref76'); return false;" data-citation="" class="refNumLink">76</a></strong><div class="NLM_citation" id="cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chand, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamazaki, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruuth, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schonherr, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinsson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kogner, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Attiyeh, E. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maris, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morozova, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marra, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohira, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakagawara, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sandstrom, P.-E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmer, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hallberg, B.</span></span> <span> </span><span class="NLM_article-title">Cell Culture and Drosophila Model Systems Define Three Classes of Anaplastic Lymphoma Kinase Mutations in Neuroblastoma</span>. <i>Dis. Models &amp; Mech.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">373</span>– <span class="NLM_lpage">382</span>, <span class="refDoi"> DOI: 10.1242/dmm.010348</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1242%2Fdmm.010348" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=23104988" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2013&pages=373-382&author=D.+Chandauthor=Y.+Yamazakiauthor=K.+Ruuthauthor=C.+Schonherrauthor=T.+Martinssonauthor=P.+Kognerauthor=E.+F.+Attiyehauthor=J.+Marisauthor=O.+Morozovaauthor=M.+A.+Marraauthor=M.+Ohiraauthor=A.+Nakagawaraauthor=P.-E.+Sandstromauthor=R.+H.+Palmerauthor=B.+Hallberg&title=Cell+Culture+and+Drosophila+Model+Systems+Define+Three+Classes+of+Anaplastic+Lymphoma+Kinase+Mutations+in+Neuroblastoma&doi=10.1242%2Fdmm.010348"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1242%2Fdmm.010348&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1242%252Fdmm.010348%26sid%3Dliteratum%253Aachs%26aulast%3DChand%26aufirst%3DD.%26aulast%3DYamazaki%26aufirst%3DY.%26aulast%3DRuuth%26aufirst%3DK.%26aulast%3DSchonherr%26aufirst%3DC.%26aulast%3DMartinsson%26aufirst%3DT.%26aulast%3DKogner%26aufirst%3DP.%26aulast%3DAttiyeh%26aufirst%3DE.%2BF.%26aulast%3DMaris%26aufirst%3DJ.%26aulast%3DMorozova%26aufirst%3DO.%26aulast%3DMarra%26aufirst%3DM.%2BA.%26aulast%3DOhira%26aufirst%3DM.%26aulast%3DNakagawara%26aufirst%3DA.%26aulast%3DSandstrom%26aufirst%3DP.-E.%26aulast%3DPalmer%26aufirst%3DR.%2BH.%26aulast%3DHallberg%26aufirst%3DB.%26atitle%3DCell%2520Culture%2520and%2520Drosophila%2520Model%2520Systems%2520Define%2520Three%2520Classes%2520of%2520Anaplastic%2520Lymphoma%2520Kinase%2520Mutations%2520in%2520Neuroblastoma%26jtitle%3DDis.%2520Models%2520%2526amp%253B%2520Mech.%26date%3D2013%26volume%3D6%26spage%3D373%26epage%3D382%26doi%3D10.1242%2Fdmm.010348" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref77"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref77'); return false;" data-citation="" class="refNumLink">77</a></strong><div class="NLM_citation" id="cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Janoueix-Lerosey, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lequin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brugieres, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ribeiro, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Pontual, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Combaret, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raynal, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puisieux, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schleiermacher, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pierron, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valteau-Couanet, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frebourg, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyonnet, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amiel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delattre, O.</span></span> <span> </span><span class="NLM_article-title">Somatic and Germline Activating Mutations of the ALK Kinase Receptor in Neuroblastoma</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>455</i></span>,  <span class="NLM_fpage">967</span>, <span class="refDoi"> DOI: 10.1038/nature07398</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1038%2Fnature07398" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=18923523" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht1GgurrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=455&publication_year=2008&pages=967&author=I.+Janoueix-Leroseyauthor=D.+Lequinauthor=L.+Brugieresauthor=A.+Ribeiroauthor=L.+de+Pontualauthor=V.+Combaretauthor=V.+Raynalauthor=A.+Puisieuxauthor=G.+Schleiermacherauthor=G.+Pierronauthor=D.+Valteau-Couanetauthor=T.+Frebourgauthor=J.+Michonauthor=S.+Lyonnetauthor=J.+Amielauthor=O.+Delattre&title=Somatic+and+Germline+Activating+Mutations+of+the+ALK+Kinase+Receptor+in+Neuroblastoma&doi=10.1038%2Fnature07398"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma</span></div><div class="casAuthors">Janoueix-Lerosey, Isabelle; Lequin, Delphine; Brugieres, Laurence; Ribeiro, Agnes; de Pontual, Loic; Combaret, Valerie; Raynal, Virginie; Puisieux, Alain; Schleiermacher, Gudrun; Pierron, Gaelle; Valteau-Couanet, Dominique; Frebourg, Thierry; Michon, Jean; Lyonnet, Stanislas; Amiel, Jeanne; Delattre, Olivier</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">455</span>
        (<span class="NLM_cas:issue">7215</span>),
    <span class="NLM_cas:pages">967-970</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Neuroblastoma, a tumor derived from the peripheral sympathetic nervous system, is one of the most frequent solid tumors in childhood.  It usually occurs sporadically but familial cases are obsd., with a subset of cases occurring in assocn. with congenital malformations of the neural crest being linked to germline mutations of the PHOX2B gene.  Here the authors conducted genome-wide comparative genomic hybridization anal. on a large series of neuroblastomas.  Copy no. increase at the locus encoding the anaplastic lymphoma kinase (ALK) tyrosine kinase receptor was obsd. recurrently.  One particularly informative case presented a high-level gene amplification that was strictly limited to ALK, indicating that this gene may contribute on its own to neuroblastoma development.  Through subsequent direct sequencing of cell lines and primary tumor DNAs the authors identified somatic mutations of the ALK kinase domain that mainly clustered in two hotspots.  Germline mutations were obsd. in two neuroblastoma families, indicating that ALK is a neuroblastoma predisposition gene.  Mutated ALK proteins were overexpressed, hyperphosphorylated and showed constitutive kinase activity.  The knockdown of ALK expression in ALK-mutated cells, but also in cell lines overexpressing a wild-type ALK, led to a marked decrease of cell proliferation.  Altogether, these data identify ALK as a crit. player in neuroblastoma development that may hence represent a very attractive therapeutic target in this disease that is still frequently fatal with current treatments.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrr_O_BMCZk7rVg90H21EOLACvtfcHk0lilhJgzPp_NDQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht1GgurrI&md5=7321fe0dc6408f9b5b3c53b8d83478ce</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1038%2Fnature07398&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature07398%26sid%3Dliteratum%253Aachs%26aulast%3DJanoueix-Lerosey%26aufirst%3DI.%26aulast%3DLequin%26aufirst%3DD.%26aulast%3DBrugieres%26aufirst%3DL.%26aulast%3DRibeiro%26aufirst%3DA.%26aulast%3Dde%2BPontual%26aufirst%3DL.%26aulast%3DCombaret%26aufirst%3DV.%26aulast%3DRaynal%26aufirst%3DV.%26aulast%3DPuisieux%26aufirst%3DA.%26aulast%3DSchleiermacher%26aufirst%3DG.%26aulast%3DPierron%26aufirst%3DG.%26aulast%3DValteau-Couanet%26aufirst%3DD.%26aulast%3DFrebourg%26aufirst%3DT.%26aulast%3DMichon%26aufirst%3DJ.%26aulast%3DLyonnet%26aufirst%3DS.%26aulast%3DAmiel%26aufirst%3DJ.%26aulast%3DDelattre%26aufirst%3DO.%26atitle%3DSomatic%2520and%2520Germline%2520Activating%2520Mutations%2520of%2520the%2520ALK%2520Kinase%2520Receptor%2520in%2520Neuroblastoma%26jtitle%3DNature%26date%3D2008%26volume%3D455%26spage%3D967%26doi%3D10.1038%2Fnature07398" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref78"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref78'); return false;" data-citation="" class="refNumLink">78</a></strong><div class="NLM_citation" id="cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Javanmardi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fransson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Djos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sjöberg, R.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nilsson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Truvé, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kogner, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinsson, T.</span></span> <span> </span><span class="NLM_article-title">Low Frequency ALK Hotspots Mutations in Neuroblastoma Tumours Detected by Ultra-deep Sequencing: Implications for ALK Inhibitor Treatment</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">2199</span>, <span class="refDoi"> DOI: 10.1038/s41598-018-37240-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1038%2Fs41598-018-37240-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=30778092" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A280%3ADC%252BB3cfkvVKjsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2019&pages=2199&author=N.+Javanmardiauthor=S.+Franssonauthor=A.+Djosauthor=R.-M.+Sj%C3%B6bergauthor=S.+Nilssonauthor=K.+Truv%C3%A9author=P.+Kognerauthor=T.+Martinsson&title=Low+Frequency+ALK+Hotspots+Mutations+in+Neuroblastoma+Tumours+Detected+by+Ultra-deep+Sequencing%3A+Implications+for+ALK+Inhibitor+Treatment&doi=10.1038%2Fs41598-018-37240-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Low Frequency ALK Hotspots Mutations In Neuroblastoma Tumours Detected By Ultra-deep Sequencing: Implications For ALK Inhibitor Treatment</span></div><div class="casAuthors">Javanmardi Niloufar; Fransson Susanne; Djos Anna; Sjoberg Rose-Marie; Nilsson Staffan; Martinsson Tommy; Truve Katarina; Kogner Per</div><div class="citationInfo"><span class="NLM_cas:title">Scientific reports</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">2199</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The ALK tyrosine kinase receptor is oncogenically activated in neuroblastoma.  Whereas numerous ALK fusion genes have been reported in different malignancies, in neuroblastoma ALK is mainly activated through point mutations.  Three hotspot residues (F1174, F1245, and R1275) account for 85% of mutant ALK seen in neuroblastoma.  In a cohort of 105 Swedish neuroblastoma cases of all stages, these hotspot regions were re-sequenced (>5000X).  ALK mutations were detected in 16 of 105 patients (range of variant allele fraction: 2.7-60%).  Mutations at the F1174 and F1245 hotspot were observed in eleven and three cases respectively.  ALK mutations were also detected at the I1171 and L1240 codons in one tumor each.  No mutations were detected at R1275.  Sanger sequencing could confirm ALK status for all mutated samples with variant allele fraction above 15%.  Four of the samples with subclonal ALK mutation fraction below this would have gone undetected relying on Sanger sequencing only.  No distinct mutation spectrum in relation to neuroblastoma tumours genomic subtypes could be detected although there was a paucity of ALK mutations among 11q-deleted tumors.  As ALK mutations status opens up an excellent opportunity for application of small molecule inhibitors targeting ALK, early and sensitive detection of ALK alterations is clinically important considering its potential role in tumour progression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQXJxcEA9wkeY3yKPtYViAGfW6udTcc2eabey2fLMC8fbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cfkvVKjsw%253D%253D&md5=8afd0c50192683e770638326e3042e64</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1038%2Fs41598-018-37240-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41598-018-37240-z%26sid%3Dliteratum%253Aachs%26aulast%3DJavanmardi%26aufirst%3DN.%26aulast%3DFransson%26aufirst%3DS.%26aulast%3DDjos%26aufirst%3DA.%26aulast%3DSj%25C3%25B6berg%26aufirst%3DR.-M.%26aulast%3DNilsson%26aufirst%3DS.%26aulast%3DTruv%25C3%25A9%26aufirst%3DK.%26aulast%3DKogner%26aufirst%3DP.%26aulast%3DMartinsson%26aufirst%3DT.%26atitle%3DLow%2520Frequency%2520ALK%2520Hotspots%2520Mutations%2520in%2520Neuroblastoma%2520Tumours%2520Detected%2520by%2520Ultra-deep%2520Sequencing%253A%2520Implications%2520for%2520ALK%2520Inhibitor%2520Treatment%26jtitle%3DSci.%2520Rep.%26date%3D2019%26volume%3D9%26spage%3D2199%26doi%3D10.1038%2Fs41598-018-37240-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref79"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref79'); return false;" data-citation="" class="refNumLink">79</a></strong><div class="NLM_citation" id="cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Karachaliou, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santarpia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez Cao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teixido, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sosa, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berenguer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez Capote, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altavilla, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosell, R.</span></span> <span> </span><span class="NLM_article-title">Anaplastic lymphoma Kinase Inhibitors in Phase I and Phase II Clinical Trials for Non-small Cell Lung Cancer</span>. <i>Expert Opin. Invest. Drugs</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">713</span>– <span class="NLM_lpage">722</span>, <span class="refDoi"> DOI: 10.1080/13543784.2017.1324572</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1080%2F13543784.2017.1324572" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=28463570" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC2sXot1Shu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2017&pages=713-722&author=N.+Karachaliouauthor=M.+Santarpiaauthor=M.+Gonzalez+Caoauthor=C.+Teixidoauthor=A.+E.+Sosaauthor=J.+Berenguerauthor=A.+Rodriguez+Capoteauthor=G.+Altavillaauthor=R.+Rosell&title=Anaplastic+lymphoma+Kinase+Inhibitors+in+Phase+I+and+Phase+II+Clinical+Trials+for+Non-small+Cell+Lung+Cancer&doi=10.1080%2F13543784.2017.1324572"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">Anaplastic lymphoma kinase inhibitors in phase I and phase II clinical trials for non-small cell lung cancer</span></div><div class="casAuthors">Karachaliou, Niki; Santarpia, Mariacarmela; Gonzalez Cao, Maria; Teixido, Cristina; Sosa, Aaron E.; Berenguer, Jordi; Rodriguez Capote, Alejandra; Altavilla, Giuseppe; Rosell, Rafael</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Investigational Drugs</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">713-722</span>CODEN:
                <span class="NLM_cas:coden">EOIDER</span>;
        ISSN:<span class="NLM_cas:issn">1354-3784</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Crizotinib is a first-in-class ALK tyrosine kinase inhibitor (TKI), which has proven its superiority over std. platinum-based chemotherapy for the first-line therapy of ALK-rearranged non-small cell lung cancer (NSCLC) patients.  The development of acquired resistance to crizotinib represents an ongoing challenge with the central nervous system being one of the most common sites of relapse.  Ceritinib and alectinib are approved second-generation ALK TKIs.  Several novel ALK inhibitors, more potent and with different selectivity compared to crizotinib, are currently in development.  This review will focus on new ALK inhibitors, currently in phase 1 or 2 clin. studies.  We will also comment on the mechanisms of resistance to ALK inhibition and the strategies to delay or overcome resistance.  The therapeutic management of ALK-rearranged NSCLC has been greatly improved.  Next-generation ALK inhibitors have shown differential potency against ALK rearrangements and ALK resistance mutations.  The mol. profile of the tumor at the time of disease progression to crizotinib is crucial for the sequencing of novel ALK TKIs.  Ongoing clin. studies will address key issues, including the optimal therapeutic algorithm and whether combinational approaches are more effective than single ALK inhibition for the outcome of ALK-rearranged NSCLC patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFDGNGYI_s2rVg90H21EOLACvtfcHk0ljK_qdEKqGnoA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXot1Shu7k%253D&md5=ebf670719201fd89280b1ae88c162dd5</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1080%2F13543784.2017.1324572&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F13543784.2017.1324572%26sid%3Dliteratum%253Aachs%26aulast%3DKarachaliou%26aufirst%3DN.%26aulast%3DSantarpia%26aufirst%3DM.%26aulast%3DGonzalez%2BCao%26aufirst%3DM.%26aulast%3DTeixido%26aufirst%3DC.%26aulast%3DSosa%26aufirst%3DA.%2BE.%26aulast%3DBerenguer%26aufirst%3DJ.%26aulast%3DRodriguez%2BCapote%26aufirst%3DA.%26aulast%3DAltavilla%26aufirst%3DG.%26aulast%3DRosell%26aufirst%3DR.%26atitle%3DAnaplastic%2520lymphoma%2520Kinase%2520Inhibitors%2520in%2520Phase%2520I%2520and%2520Phase%2520II%2520Clinical%2520Trials%2520for%2520Non-small%2520Cell%2520Lung%2520Cancer%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2017%26volume%3D26%26spage%3D713%26epage%3D722%26doi%3D10.1080%2F13543784.2017.1324572" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref80"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref80'); return false;" data-citation="" class="refNumLink">80</a></strong><div class="NLM_citation" id="cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Christensen, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arango, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonnell, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamazaki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alton, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mroczkowski, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Los, G.</span></span> <span> </span><span class="NLM_article-title">Cytoreductive Antitumor Activity of PF-2341066, a Novel Inhibitor of Anaplastic Lymphoma Kinase and c-Met, in Experimental Models of Anaplastic Large-cell Lymphoma</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">3314</span>– <span class="NLM_lpage">3322</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-07-0365</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1158%2F1535-7163.MCT-07-0365" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=18089725" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhsVCjsrrL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=3314-3322&author=J.+G.+Christensenauthor=H.+Y.+Zouauthor=M.+E.+Arangoauthor=Q.+Liauthor=J.+H.+Leeauthor=S.+R.+McDonnellauthor=S.+Yamazakiauthor=G.+R.+Altonauthor=B.+Mroczkowskiauthor=G.+Los&title=Cytoreductive+Antitumor+Activity+of+PF-2341066%2C+a+Novel+Inhibitor+of+Anaplastic+Lymphoma+Kinase+and+c-Met%2C+in+Experimental+Models+of+Anaplastic+Large-cell+Lymphoma&doi=10.1158%2F1535-7163.MCT-07-0365"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma</span></div><div class="casAuthors">Christensen, James G.; Zou, Helen Y.; Arango, Maria E.; Li, Qiuhua; Lee, Joseph H.; McDonnell, Scott R.; Yamazaki, Shinji; Alton, Gordon R.; Mroczkowski, Barbara; Los, Gerrit</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">12, Pt. 1</span>),
    <span class="NLM_cas:pages">3314-3322</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A t(2;5) chromosomal translocation resulting in expression of an oncogenic kinase fusion protein known as nucleophosmin-anaplastic lymphoma kinase (NPM-ALK) has been implicated in the pathogenesis of anaplastic large-cell lymphoma (ALCL).  PF-2341066 was recently identified as a p.o. bioavailable, small-mol. inhibitor of the catalytic activity of c-Met kinase and the NPM-ALK fusion protein.  PF-2341066 also potently inhibited NPM-ALK phosphorylation in Karpas299 or SU-DHL-1 ALCL cells (mean IC50 value, 24 nmol/L).  In biochem. and cellular screens, PF-2341066 was shown to be selective for c-Met and ALK at pharmacol. relevant concns. across a panel of >120 diverse kinases.  PF-2341066 potently inhibited cell proliferation, which was assocd. with G1-S-phase cell cycle arrest and induction of apoptosis in ALK-pos. ALCL cells (IC50 values, ∼30 nmol/L) but not ALK-neg. lymphoma cells.  The induction of apoptosis was confirmed using terminal deoxyribonucleotide transferase-mediated nick-end labeling and Annexin V staining (IC50 values, 25-50 nmol/L).  P.o. administration of PF-2341066 to severe combined immunodeficient-Beige mice bearing Karpas299 ALCL tumor xenografts resulted in dose-dependent antitumor efficacy with complete regression of all tumors at the 100 mg/kg/d dose within 15 days of initial compd. administration.  A strong correlation was obsd. between antitumor response and inhibition of NPM-ALK phosphorylation and induction of apoptosis in tumor tissue.  In addn., inhibition of key NPM-ALK signaling mediators, including phospholipase C-γ, signal transducers and activators of transcription 3, extracellular signal-regulated kinases, and Akt by PF-2341066 were obsd. at concns. or dose levels, which correlated with inhibition of NPM-ALK phosphorylation and function.  Collectively, these data illustrate the potential clin. utility of inhibitors of NPM-ALK in treatment of patients with ALK-pos. ALCL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGptqY0tUwGnurVg90H21EOLACvtfcHk0ljK_qdEKqGnoA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhsVCjsrrL&md5=04fbbaf43ca527408bde8cabcd38e1fd</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-07-0365&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-07-0365%26sid%3Dliteratum%253Aachs%26aulast%3DChristensen%26aufirst%3DJ.%2BG.%26aulast%3DZou%26aufirst%3DH.%2BY.%26aulast%3DArango%26aufirst%3DM.%2BE.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DLee%26aufirst%3DJ.%2BH.%26aulast%3DMcDonnell%26aufirst%3DS.%2BR.%26aulast%3DYamazaki%26aufirst%3DS.%26aulast%3DAlton%26aufirst%3DG.%2BR.%26aulast%3DMroczkowski%26aufirst%3DB.%26aulast%3DLos%26aufirst%3DG.%26atitle%3DCytoreductive%2520Antitumor%2520Activity%2520of%2520PF-2341066%252C%2520a%2520Novel%2520Inhibitor%2520of%2520Anaplastic%2520Lymphoma%2520Kinase%2520and%2520c-Met%252C%2520in%2520Experimental%2520Models%2520of%2520Anaplastic%2520Large-cell%2520Lymphoma%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2007%26volume%3D6%26spage%3D3314%26epage%3D3322%26doi%3D10.1158%2F1535-7163.MCT-07-0365" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref81"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref81'); return false;" data-citation="" class="refNumLink">81</a></strong><div class="NLM_citation" id="cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Camidge, D R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bang, Y.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwak, E. L</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iafrate, A J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varella-Garcia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fox, S. B</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riely, G. J</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solomon, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ou, S.-H. I</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salgia, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fidias, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engelman, J. A</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gandhi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janne, P. A</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costa, D. B</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shapiro, G. I</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LoRusso, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruffner, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stephenson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilner, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, J. W</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, A. T</span></span> <span> </span><span class="NLM_article-title">Activity and Safety of Crizotinib in Patients with ALK-positive Non-small Cell Lung Cancer: Updated Results from a Phase 1 Study</span>. <i>Lancet Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">1011</span>– <span class="NLM_lpage">1019</span>, <span class="refDoi"> DOI: 10.1016/S1470-2045(12)70344-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1016%2FS1470-2045%2812%2970344-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=22954507" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsVCjsb3E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2012&pages=1011-1019&author=D+R.+Camidgeauthor=Y.-J.+Bangauthor=E.+L+Kwakauthor=A+J.+Iafrateauthor=M.+Varella-Garciaauthor=S.+B+Foxauthor=G.+J+Rielyauthor=B.+Solomonauthor=S.-H.+I+Ouauthor=D.-W.+Kimauthor=R.+Salgiaauthor=P.+Fidiasauthor=J.+A+Engelmanauthor=L.+Gandhiauthor=P.+A+Janneauthor=D.+B+Costaauthor=G.+I+Shapiroauthor=P.+LoRussoauthor=K.+Ruffnerauthor=P.+Stephensonauthor=Y.+Tangauthor=K.+Wilnerauthor=J.+W+Clarkauthor=A.+T+Shaw&title=Activity+and+Safety+of+Crizotinib+in+Patients+with+ALK-positive+Non-small+Cell+Lung+Cancer%3A+Updated+Results+from+a+Phase+1+Study&doi=10.1016%2FS1470-2045%2812%2970344-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study</span></div><div class="casAuthors">Camidge, D. Ross; Bang, Yung-Jue; Kwak, Eunice L.; Iafrate, A. John; Varella-Garcia, Marileila; Fox, Stephen B.; Riely, Gregory J.; Solomon, Benjamin; Ou, Sai-Hong I.; Kim, Dong-Wan; Salgia, Ravi; Fidias, Panagiotis; Engelman, Jeffrey A.; Gandhi, Leena; Jaenne, Pasi A.; Costa, Daniel B.; Shapiro, Geoffrey I.; LoRusso, Patricia; Ruffner, Katherine; Stephenson, Patricia; Tang, Yiyun; Wilner, Keith; Clark, Jeffrey W.; Shaw, Alice T.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1011-1019</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Summary: Background: ALK fusion genes occur in a subset of non-small-cell lung cancers (NSCLCs).  We assessed the tolerability and activity of crizotinib in patients with NSCLC who were prospectively identified to have an ALK fusion within the first-in-man phase 1 crizotinib study.  Methods: In this phase 1 study, patients with ALK-pos. stage III or IV NSCLC received oral crizotinib 250 mg twice daily in 28-day cycles.  Endpoints included tumor responses, duration of response, time to tumor response, progression-free survival (PFS), overall survival at 6 and 12 mo, and detn. of the safety and tolerability and characterization of the plasma pharmacokinetic profile of crizotinib after oral administration.  Responses were analyzed in evaluable patients and PFS and safety were analyzed in all patients.  This study is registered with ClinicalTrials.gov, no. NCT00585195.  Findings: Between Aug 27, 2008, and June 1, 2011, 149 ALK-pos. patients were enrolled, 143 of whom were included in the response-evaluable population. 87 of 143 patients had an objective response (60·8%, 95% CI 52·3-68·9), including three complete responses and 84 partial responses.  Median time to first documented objective response was 7·9 wk (range 2·1-39·6) and median duration of response was 49·1 wk (95% CI 39·3-75·4).  The response rate seemed to be largely independent of age, sex, performance status, or line of treatment.  Median PFS was 9·7 mo (95% CI 7·7-12·8).  Median overall survival data are not yet mature, but estd. overall survival at 6 and 12 mo was 87·9% (95% CI 81·3-92·3) and 74·8% (66·4-81·5), resp. 39 patients continued to receive crizotinib for more than 2 wk after progression because of perceived ongoing clin. benefit from the drug (12 for at least 6 mo from the time of their initial investigator-defined disease progression).  Overall, 144 (97%) of 149 patients experienced treatment-related adverse events, which were mostly grade 1 or 2.  The most common adverse events were visual effects, nausea, diarrhoea, constipation, vomiting, and peripheral edema.  The most common treatment-related grade 3 or 4 adverse events were neutropenia (n=9), raised alanine aminotransferase (n=6), hypophosphatemia (n=6), and lymphopenia (n=6).  Interpretation: Crizotinib is well tolerated with rapid, durable responses in patients with ALK-pos. NSCLC.  There seems to be potential for ongoing benefit after initial disease progression in this population, but a more formal definition of ongoing benefit in this context is needed.  Funding: Pfizer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNr3aI1rrjmbVg90H21EOLACvtfcHk0lh6V41ewqyliQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsVCjsb3E&md5=bd3aec44b197ee2f4c9d49ea540a672f</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2812%2970344-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252812%252970344-3%26sid%3Dliteratum%253Aachs%26aulast%3DCamidge%26aufirst%3DD%2BR.%26aulast%3DBang%26aufirst%3DY.-J.%26aulast%3DKwak%26aufirst%3DE.%2BL%26aulast%3DIafrate%26aufirst%3DA%2BJ.%26aulast%3DVarella-Garcia%26aufirst%3DM.%26aulast%3DFox%26aufirst%3DS.%2BB%26aulast%3DRiely%26aufirst%3DG.%2BJ%26aulast%3DSolomon%26aufirst%3DB.%26aulast%3DOu%26aufirst%3DS.-H.%2BI%26aulast%3DKim%26aufirst%3DD.-W.%26aulast%3DSalgia%26aufirst%3DR.%26aulast%3DFidias%26aufirst%3DP.%26aulast%3DEngelman%26aufirst%3DJ.%2BA%26aulast%3DGandhi%26aufirst%3DL.%26aulast%3DJanne%26aufirst%3DP.%2BA%26aulast%3DCosta%26aufirst%3DD.%2BB%26aulast%3DShapiro%26aufirst%3DG.%2BI%26aulast%3DLoRusso%26aufirst%3DP.%26aulast%3DRuffner%26aufirst%3DK.%26aulast%3DStephenson%26aufirst%3DP.%26aulast%3DTang%26aufirst%3DY.%26aulast%3DWilner%26aufirst%3DK.%26aulast%3DClark%26aufirst%3DJ.%2BW%26aulast%3DShaw%26aufirst%3DA.%2BT%26atitle%3DActivity%2520and%2520Safety%2520of%2520Crizotinib%2520in%2520Patients%2520with%2520ALK-positive%2520Non-small%2520Cell%2520Lung%2520Cancer%253A%2520Updated%2520Results%2520from%2520a%2520Phase%25201%2520Study%26jtitle%3DLancet%2520Oncol.%26date%3D2012%26volume%3D13%26spage%3D1011%26epage%3D1019%26doi%3D10.1016%2FS1470-2045%2812%2970344-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref82"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref82'); return false;" data-citation="" class="refNumLink">82</a></strong><div class="NLM_citation" id="cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakagawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crino, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, M.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Pas, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Besse, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solomon, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blackhall, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O'Byrne, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moro-Sibilot, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camidge, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mok, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirsh, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riely, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iyer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tassell, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilner, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janne, P. A.</span></span> <span> </span><span class="NLM_article-title">Crizotinib versus Chemotherapy in Advanced ALK-positive Lung Cancer</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>368</i></span>,  <span class="NLM_fpage">2385</span>– <span class="NLM_lpage">2394</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1214886</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1056%2FNEJMoa1214886" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=23724913" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtVSnu7%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=368&publication_year=2013&pages=2385-2394&author=A.+T.+Shawauthor=D.-W.+Kimauthor=K.+Nakagawaauthor=T.+Setoauthor=L.+Crinoauthor=M.-J.+Ahnauthor=T.+De+Pasauthor=B.+Besseauthor=B.+J.+Solomonauthor=F.+Blackhallauthor=Y.-L.+Wuauthor=M.+Thomasauthor=K.+J.+O%27Byrneauthor=D.+Moro-Sibilotauthor=D.+R.+Camidgeauthor=T.+Mokauthor=V.+Hirshauthor=G.+J.+Rielyauthor=S.+Iyerauthor=V.+Tassellauthor=A.+Polliauthor=K.+D.+Wilnerauthor=P.+A.+Janne&title=Crizotinib+versus+Chemotherapy+in+Advanced+ALK-positive+Lung+Cancer&doi=10.1056%2FNEJMoa1214886"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">Crizotinib versus chemotherapy in advanced ALK-positive lung cancer</span></div><div class="casAuthors">Shaw, Alice T.; Kim, Dong-Wan; Nakagawa, Kazuhiko; Seto, Takashi; Crino, Lucio; Ahn, Myung-Ju; De Pas, Tommaso; Besse, Benjamin; Solomon, Benjamin J.; Blackhall, Fiona; Wu, Yi-Long; Thomas, Michael; O'Byrne, Kenneth J.; Moro-Sibilot, Denis; Camidge, D. Ross; Mok, Tony; Hirsh, Vera; Riely, Gregory J.; Iyer, Shrividya; Tassell, Vanessa; Polli, Anna; Wilner, Keith D.; Janne, Pasi A.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">368</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">2385-2394</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">In single-group studies, chromosomal rearrangements of the anaplastic lymphoma kinase gene (ALK) have been assocd. with marked clin. responses to crizotinib, an oral tyrosine kinase inhibitor targeting ALK.  Whether crizotinib is superior to std. chemotherapy with respect to efficacy is unknown.  We conducted a phase 3, open-label trial comparing crizotinib with chemotherapy in 347 patients with locally advanced or metastatic ALK-pos. lung cancer who had received one prior platinum-based regimen.  Patients were randomly assigned to receive oral treatment with crizotinib (250 mg) twice daily or i.v. chemotherapy with either pemetrexed (500 mg per square meter of body-surface area) or docetaxel (75 mg per square meter) every 3 wk.  Patients in the chemotherapy group who had disease progression were permitted to cross over to crizotinib as part of a sep. study.  The primary end point was progression-free survival.  The median progression-free survival was 7.7 mo in the crizotinib group and 3.0 mo in the chemotherapy group (hazard ratio for progression or death with crizotinib, 0.49; 95% confidence interval [CI], 0.37 to 0.64; P<0.001).  The response rates were 65% (95% CI, 58 to 72) with crizotinib, as compared with 20% (95% CI, 14 to 26) with chemotherapy (P<0.001).  An interim anal. of overall survival showed no significant improvement with crizotinib as compared with chemotherapy (hazard ratio for death in the crizotinib group, 1.02; 95% CI, 0.68 to 1.54; P = 0.54).  Common adverse events assocd. with crizotinib were visual disorder, gastrointestinal side effects, and elevated liver aminotransferase levels, whereas common adverse events with chemotherapy were fatigue, alopecia, and dyspnea.  Patients reported greater redns. in symptoms of lung cancer and greater improvement in global quality of life with crizotinib than with chemotherapy.  Crizotinib is superior to std. chemotherapy in patients with previously treated, advanced non-small-cell lung cancer with ALK rearrangement.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrk62MsVCiljLVg90H21EOLACvtfcHk0lh6V41ewqyliQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtVSnu7%252FM&md5=8c6f1a73472f87fa9a19ceac6fdbb132</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1214886&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1214886%26sid%3Dliteratum%253Aachs%26aulast%3DShaw%26aufirst%3DA.%2BT.%26aulast%3DKim%26aufirst%3DD.-W.%26aulast%3DNakagawa%26aufirst%3DK.%26aulast%3DSeto%26aufirst%3DT.%26aulast%3DCrino%26aufirst%3DL.%26aulast%3DAhn%26aufirst%3DM.-J.%26aulast%3DDe%2BPas%26aufirst%3DT.%26aulast%3DBesse%26aufirst%3DB.%26aulast%3DSolomon%26aufirst%3DB.%2BJ.%26aulast%3DBlackhall%26aufirst%3DF.%26aulast%3DWu%26aufirst%3DY.-L.%26aulast%3DThomas%26aufirst%3DM.%26aulast%3DO%2527Byrne%26aufirst%3DK.%2BJ.%26aulast%3DMoro-Sibilot%26aufirst%3DD.%26aulast%3DCamidge%26aufirst%3DD.%2BR.%26aulast%3DMok%26aufirst%3DT.%26aulast%3DHirsh%26aufirst%3DV.%26aulast%3DRiely%26aufirst%3DG.%2BJ.%26aulast%3DIyer%26aufirst%3DS.%26aulast%3DTassell%26aufirst%3DV.%26aulast%3DPolli%26aufirst%3DA.%26aulast%3DWilner%26aufirst%3DK.%2BD.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26atitle%3DCrizotinib%2520versus%2520Chemotherapy%2520in%2520Advanced%2520ALK-positive%2520Lung%2520Cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2013%26volume%3D368%26spage%3D2385%26epage%3D2394%26doi%3D10.1056%2FNEJMoa1214886" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref83"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref83'); return false;" data-citation="" class="refNumLink">83</a></strong><div class="NLM_citation" id="cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yoneda, K. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scranton, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cadogan, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tassell, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nadanaciva, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilner, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stollenwerk, N. S.</span></span> <span> </span><span class="NLM_article-title">Interstitial Lung Disease Associated with Crizotinib in Patients with Advanced Non–small Cell Lung Cancer: Independent Review of Four PROFILE Trials</span>. <i>Clin. Lung Cancer</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">472</span>– <span class="NLM_lpage">479</span>, <span class="refDoi"> DOI: 10.1016/j.cllc.2017.03.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1016%2Fj.cllc.2017.03.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=28373069" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC2sXltVWqs70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2017&pages=472-479&author=K.+Y.+Yonedaauthor=J.+R.+Scrantonauthor=M.+A.+Cadoganauthor=V.+Tassellauthor=S.+Nadanacivaauthor=K.+D.+Wilnerauthor=N.+S.+Stollenwerk&title=Interstitial+Lung+Disease+Associated+with+Crizotinib+in+Patients+with+Advanced+Non%E2%80%93small+Cell+Lung+Cancer%3A+Independent+Review+of+Four+PROFILE+Trials&doi=10.1016%2Fj.cllc.2017.03.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Interstitial Lung Disease Associated With Crizotinib in Patients With Advanced Non-Small Cell Lung Cancer: Independent Review of Four PROFILE Trials</span></div><div class="casAuthors">Yoneda, Ken Y.; Scranton, Judith R.; Cadogan, Michael A.; Tassell, Vanessa; Nadanaciva, Sashi; Wilner, Keith D.; Stollenwerk, Nicholas S.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Lung Cancer</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">472-479</span>CODEN:
                <span class="NLM_cas:coden">CLCLCA</span>;
        ISSN:<span class="NLM_cas:issn">1525-7304</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Interstitial lung disease (ILD) is a rare, but potentially serious, side effect assocd. with crizotinib, a tyrosine kinase inhibitor for anaplastic lymphoma kinase-pos. (ALK+) advanced non-small cell lung cancer.  Our objective was to det. the incidence and nature of ILD assocd. with crizotinib in 4 PROFILE trials (ClinicalTrials.gov identifiers, NCT00585195, NCT00932451, NCT00932893, and NCT01154140).Grade ≥ 3 respiratory adverse events (AEs) and serious AEs (SAEs) and any grade AEs/SAEs reported as pneumonitis, ILD, or radiation pneumonitis in trials PROFILE 1001, PROFILE 1005, PROFILE 1007, and PROFILE 1014 were evaluated by an expert independent review committee that included a pulmonologist, medical oncologist, and radiologist.  Events were designated as disease progression, de novo ILD possibly or probably related to crizotinib, exacerbation or recurrence of pre-existing ILD, concurrent illness, other toxicity not thought to be related to ILD, or inconclusive.The independent review committee evaluated 446 events (in 368 of 1669 patients who had received crizotinib therapy).  They classified these events as follows: progressive disease, 77; de novo ILD, 20; pre-existing ILD, 3; concurrent illness, 9; other toxicities, 310; and inconclusive, 27.  The incidence of de novo ILD was 1.2% overall, 1.3% in whites, and 1.2% overall in Asians, but greater at 3.7% in Japanese patients.  The median onset of ILD from the initiation of crizotinib therapy was 23 days (range, 3-763 days).  The mortality rate due to ILD was 50%.  Survival was improved if crizotinib was discontinued on presentation of ILD (9 of 14 patients) compared with discontinued later or continued (1 of 6 patients).ILD assocd. with crizotinib, although rare, can occur at any time and requires close monitoring.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMBcvulNV2H7Vg90H21EOLACvtfcHk0lhI3bF_5A7ZBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXltVWqs70%253D&md5=2d20be1a1b9d34bb53530139a5894543</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1016%2Fj.cllc.2017.03.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cllc.2017.03.004%26sid%3Dliteratum%253Aachs%26aulast%3DYoneda%26aufirst%3DK.%2BY.%26aulast%3DScranton%26aufirst%3DJ.%2BR.%26aulast%3DCadogan%26aufirst%3DM.%2BA.%26aulast%3DTassell%26aufirst%3DV.%26aulast%3DNadanaciva%26aufirst%3DS.%26aulast%3DWilner%26aufirst%3DK.%2BD.%26aulast%3DStollenwerk%26aufirst%3DN.%2BS.%26atitle%3DInterstitial%2520Lung%2520Disease%2520Associated%2520with%2520Crizotinib%2520in%2520Patients%2520with%2520Advanced%2520Non%25E2%2580%2593small%2520Cell%2520Lung%2520Cancer%253A%2520Independent%2520Review%2520of%2520Four%2520PROFILE%2520Trials%26jtitle%3DClin.%2520Lung%2520Cancer%26date%3D2017%26volume%3D18%26spage%3D472%26epage%3D479%26doi%3D10.1016%2Fj.cllc.2017.03.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref84"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref84'); return false;" data-citation="" class="refNumLink">84</a></strong><div class="NLM_citation" id="cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wood, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laudenslager, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haglund, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Attiyeh, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pawel, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Courtright, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plegaria, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christensen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maris, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mosse, Y.</span></span> <span> </span><span class="NLM_article-title">Inhibition of ALK Mutated Neuroblastomas by the Selective Inhibitor PF-02341066</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>27</i></span> (<span class="NLM_issue">Suppl 15</span>),  <span class="NLM_fpage">10008b</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2009&pages=10008b&issue=Suppl+15&author=A.+Woodauthor=M.+Laudenslagerauthor=E.+Haglundauthor=E.+Attiyehauthor=B.+Pawelauthor=J.+Courtrightauthor=J.+Plegariaauthor=J.+Christensenauthor=J.+Marisauthor=Y.+Mosse&title=Inhibition+of+ALK+Mutated+Neuroblastomas+by+the+Selective+Inhibitor+PF-02341066"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWood%26aufirst%3DA.%26aulast%3DLaudenslager%26aufirst%3DM.%26aulast%3DHaglund%26aufirst%3DE.%26aulast%3DAttiyeh%26aufirst%3DE.%26aulast%3DPawel%26aufirst%3DB.%26aulast%3DCourtright%26aufirst%3DJ.%26aulast%3DPlegaria%26aufirst%3DJ.%26aulast%3DChristensen%26aufirst%3DJ.%26aulast%3DMaris%26aufirst%3DJ.%26aulast%3DMosse%26aufirst%3DY.%26atitle%3DInhibition%2520of%2520ALK%2520Mutated%2520Neuroblastomas%2520by%2520the%2520Selective%2520Inhibitor%2520PF-02341066%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2009%26volume%3D27%26issue%3DSuppl%252015%26spage%3D10008b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref85"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref85'); return false;" data-citation="" class="refNumLink">85</a></strong><div class="NLM_citation" id="cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mossé, Y. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voss, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rolland, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minard, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fox, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adamson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilner, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blaney, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weigel, B. J.</span></span> <span> </span><span class="NLM_article-title">Targeting ALK with Crizotinib in Pediatric Anaplastic Large Cell Lymphoma and Inflammatory Myofibroblastic Tumor: A Children’s Oncology Group Study</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">3215</span>– <span class="NLM_lpage">3221</span>, <span class="refDoi"> DOI: 10.1200/JCO.2017.73.4830</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1200%2FJCO.2017.73.4830" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=28787259" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitVemu7vM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2017&pages=3215-3221&author=Y.+P.+Moss%C3%A9author=S.+D.+Vossauthor=M.+S.+Limauthor=D.+Rollandauthor=C.+G.+Minardauthor=E.+Foxauthor=P.+Adamsonauthor=K.+Wilnerauthor=S.+M.+Blaneyauthor=B.+J.+Weigel&title=Targeting+ALK+with+Crizotinib+in+Pediatric+Anaplastic+Large+Cell+Lymphoma+and+Inflammatory+Myofibroblastic+Tumor%3A+A+Children%E2%80%99s+Oncology+Group+Study&doi=10.1200%2FJCO.2017.73.4830"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting ALK with crizotinib in pediatric anaplastic large cell lymphoma and inflammatory myofibroblastic tumor: a children's oncology group study</span></div><div class="casAuthors">Mosse, Yael P.; Voss, Stephan D.; Lim, Megan S.; Rolland, Delphine; Minard, Charles G.; Fox, Elizabeth; Adamson, Peter; Wilner, Keith; Blaney, Susan M.; Weigel, Brenda J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">28</span>),
    <span class="NLM_cas:pages">3215-3221</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">1527-7755</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose Fusions involving the ALK gene are the predominant genetic lesion underlying pediatric anaplastic large cell lymphomas (ALCL) and inflammatory myofibroblastic tumors (IMTs).  We assessed the activity of the ALK inhibitor crizotinib in patients who had no known curative treatment options at diagnosis or with relapsed/recurrent disease.  Methods In this study, 26 patients with relapsed/refractory ALK-pos. ALCL and 14 patients with metastatic or inoperable ALK-pos. IMT received crizotinib orally twice daily.  Study objectives were measurement of efficacy and safety.  Correlative studies evaluated the serial detection of NPM-ALK fusion transcripts in patients with ALCL.  Results The overall response rates for patients with ALCL treated at doses of 165 (ALCL165) and 280 (ALCL280) mg/m2 were 83% and 90%, resp.  The overall response rate for patients with IMT (treated at 100, 165, and 280 mg/m2/dose) was 86%.  A complete response was obsd. in 83% (five of six) of ALCL165, 80% (16 of 20) of ALCL280, and 36% (five of 14) of patients with IMT.  Partial response rates were 0% (none of six), 10% (two of 20), and 50% (seven of 14), resp.  The median duration of therapy was 2.79, 0.4, and 1.63 years, resp., with 12 patients ceasing protocol therapy to proceed to transplantation.  The most common drug-related adverse event was decrease in neutrophil count in 33% and 70% of the ALCL165 and ALCL280 groups, resp., and in 43% of patients with IMT.  Levels of NPM-ALK decreased during therapy in most patients with ALCL.  Conclusion The robust and sustained clin. responses to crizotinib therapy in patients with relapsed ALCL and metastatic or unresectable IMT highlight the importance of the ALK pathway in these diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGTozo3kOHTrVg90H21EOLACvtfcHk0lhI3bF_5A7ZBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitVemu7vM&md5=82b4c6382025c935271554cfe71189bd</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1200%2FJCO.2017.73.4830&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2017.73.4830%26sid%3Dliteratum%253Aachs%26aulast%3DMoss%25C3%25A9%26aufirst%3DY.%2BP.%26aulast%3DVoss%26aufirst%3DS.%2BD.%26aulast%3DLim%26aufirst%3DM.%2BS.%26aulast%3DRolland%26aufirst%3DD.%26aulast%3DMinard%26aufirst%3DC.%2BG.%26aulast%3DFox%26aufirst%3DE.%26aulast%3DAdamson%26aufirst%3DP.%26aulast%3DWilner%26aufirst%3DK.%26aulast%3DBlaney%26aufirst%3DS.%2BM.%26aulast%3DWeigel%26aufirst%3DB.%2BJ.%26atitle%3DTargeting%2520ALK%2520with%2520Crizotinib%2520in%2520Pediatric%2520Anaplastic%2520Large%2520Cell%2520Lymphoma%2520and%2520Inflammatory%2520Myofibroblastic%2520Tumor%253A%2520A%2520Children%25E2%2580%2599s%2520Oncology%2520Group%2520Study%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2017%26volume%3D35%26spage%3D3215%26epage%3D3221%26doi%3D10.1200%2FJCO.2017.73.4830" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref86"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref86'); return false;" data-citation="" class="refNumLink">86</a></strong><div class="NLM_citation" id="cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sullivan, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Planchard, D.</span></span> <span> </span><span class="NLM_article-title">ALK Inhibitors in Non-small Cell Lung Cancer: the Latest Evidence and Developments</span>. <i>Ther. Adv. Med. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">32</span>– <span class="NLM_lpage">47</span>, <span class="refDoi"> DOI: 10.1177/1758834015617355</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1177%2F1758834015617355" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=26753004" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVSns7jE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2016&pages=32-47&author=I.+Sullivanauthor=D.+Planchard&title=ALK+Inhibitors+in+Non-small+Cell+Lung+Cancer%3A+the+Latest+Evidence+and+Developments&doi=10.1177%2F1758834015617355"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">ALK inhibitors in non-small cell lung cancer: the latest evidence and developments</span></div><div class="casAuthors">Sullivan, Ivana; Planchard, David</div><div class="citationInfo"><span class="NLM_cas:title">Therapeutic Advances in Medical Oncology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">32-47</span>CODEN:
                <span class="NLM_cas:coden">TAMOB8</span>;
        ISSN:<span class="NLM_cas:issn">1758-8340</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications Ltd.</span>)
        </div><div class="casAbstract">The treatment of patients with advanced non-small cell lung cancer (NSCLC) harbouring chromosomal rearrangements of ALK (anaplastic lymphoma kinase) was revolutionized by crizotinib, a small mol. inhibitor of ALK, ROS1 and MET.  Unfortunately, the disease progressed within the first 12 mo in most of the patients because of the development of crizotinib resistance in the majority of patients and the emergence of acquired resistance mutations in most of them.  Many of them had been reported even before its approval leading to the rapid development of second-generation ALK inhibitors for crizotinibresistant NSCLC.  In the last few years, novel potent ALK inhibitors with promising results and a good toxicity profile have become available: ceritinib (LDK378), alectinib (RG7853/ AF-802/RO5424802/CH5424802), brigatinib (AP26113), entrectinib (RXDX-101, NMS-E628), PF-06463922, ASP3026, TSR-011, X-376/X-396 and CEP-28122/CEP-37440.  Moreover, HSP90 (90 kDa heat shock protein) inhibitors have demonstrated clin. activity in patients with ALK+ NSCLC.  This review focuses on the mol. and clin. properties of this new generation of ALK inhibitors under development in the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDmT62DyyrILVg90H21EOLACvtfcHk0lhI3bF_5A7ZBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVSns7jE&md5=9266542af3ea2ad9aadde47361105372</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1177%2F1758834015617355&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1758834015617355%26sid%3Dliteratum%253Aachs%26aulast%3DSullivan%26aufirst%3DI.%26aulast%3DPlanchard%26aufirst%3DD.%26atitle%3DALK%2520Inhibitors%2520in%2520Non-small%2520Cell%2520Lung%2520Cancer%253A%2520the%2520Latest%2520Evidence%2520and%2520Developments%26jtitle%3DTher.%2520Adv.%2520Med.%2520Oncol.%26date%3D2016%26volume%3D8%26spage%3D32%26epage%3D47%26doi%3D10.1177%2F1758834015617355" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref87"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref87'); return false;" data-citation="" class="refNumLink">87</a></strong><div class="NLM_citation" id="cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gainor, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sherman, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willoughby, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Logan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kennedy, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brastianos, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chi, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, A. T.</span></span> <span> </span><span class="NLM_article-title">Alectinib Salvages CNS Relapses in ALK-positive Lung Cancer Patients Previously Treated with Crizotinib and Ceritinib</span>. <i>J. Thorac. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">232</span>– <span class="NLM_lpage">236</span>, <span class="refDoi"> DOI: 10.1097/JTO.0000000000000455</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1097%2FJTO.0000000000000455" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=25526238" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvVentLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=232-236&author=J.+F.+Gainorauthor=C.+A.+Shermanauthor=K.+Willoughbyauthor=J.+Loganauthor=E.+Kennedyauthor=P.+K.+Brastianosauthor=A.+S.+Chiauthor=A.+T.+Shaw&title=Alectinib+Salvages+CNS+Relapses+in+ALK-positive+Lung+Cancer+Patients+Previously+Treated+with+Crizotinib+and+Ceritinib&doi=10.1097%2FJTO.0000000000000455"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">Alectinib Salvages CNS Relapses in ALK-Positive Lung Cancer Patients Previously Treated with Crizotinib and Ceritinib</span></div><div class="casAuthors">Gainor, Justin F.; Sherman, Carol A.; Willoughby, Kathryn; Logan, Jennifer; Kennedy, Elizabeth; Brastianos, Priscilla K.; Chi, Andrew S.; Shaw, Alice T.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Thoracic Oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">232-236</span>CODEN:
                <span class="NLM_cas:coden">JTOOB7</span>;
        ISSN:<span class="NLM_cas:issn">1556-0864</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Background: Leptomeningeal metastases (LM) are an increasingly frequent and devastating complication of anaplastic lymphoma kinase (ALK)-rearranged non-small-cell lung cancer (NSCLC).  Currently, the optimal management of LM in ALK-pos. patients remains poorly understood as these patients have been routinely excluded from clin. trials.  Methods: We describe four ALK-pos. patients with LM who were treated with the next-generation ALK inhibitor alectinib through single-patient, compassionate use protocols at two institutions.  All patients had previously been treated with both FDA-approved ALK inhibitors-crizotinib and ceritinib.  Patients received alectinib at a starting dose of 600 mg twice daily.  Results: Four ALK-pos. NSCLC patients with symptomatic leptomeningeal disease were identified.  Three of four patients experienced significant clin. and radiog. improvements in LM upon treatment with alectinib.  A fourth patient had stable intracranial disease for 4 mo before eventual systemic disease progression.  Overall, alectinib was well tolerated.  One patient required dose redn. due to grade 2 hyperbilirubinemia.  Conclusions: Alectinib is active in ALK-rearranged NSCLC patients with LM, including in patients previously treated with crizotinib and ceritinib.  Addnl. prospective studies of alectinib in ALK-pos. patients with LM are warranted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmmZ6TOOMXVrVg90H21EOLACvtfcHk0lhxW4SHO30FXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvVentLY%253D&md5=02a74597e914c4472f8d4d7edc128ba1</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1097%2FJTO.0000000000000455&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FJTO.0000000000000455%26sid%3Dliteratum%253Aachs%26aulast%3DGainor%26aufirst%3DJ.%2BF.%26aulast%3DSherman%26aufirst%3DC.%2BA.%26aulast%3DWilloughby%26aufirst%3DK.%26aulast%3DLogan%26aufirst%3DJ.%26aulast%3DKennedy%26aufirst%3DE.%26aulast%3DBrastianos%26aufirst%3DP.%2BK.%26aulast%3DChi%26aufirst%3DA.%2BS.%26aulast%3DShaw%26aufirst%3DA.%2BT.%26atitle%3DAlectinib%2520Salvages%2520CNS%2520Relapses%2520in%2520ALK-positive%2520Lung%2520Cancer%2520Patients%2520Previously%2520Treated%2520with%2520Crizotinib%2520and%2520Ceritinib%26jtitle%3DJ.%2520Thorac.%2520Oncol.%26date%3D2015%26volume%3D10%26spage%3D232%26epage%3D236%26doi%3D10.1097%2FJTO.0000000000000455" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref88"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref88'); return false;" data-citation="" class="refNumLink">88</a></strong><div class="NLM_citation" id="cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Deeks, E. D.</span></span> <span> </span><span class="NLM_article-title">Ceritinib: a Review in ALK-positive Advanced NSCLC</span>. <i>Target. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">693</span>– <span class="NLM_lpage">700</span>, <span class="refDoi"> DOI: 10.1007/s11523-016-0460-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1007%2Fs11523-016-0460-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=27699584" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A280%3ADC%252BC2svmsVCruw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=693-700&author=E.+D.+Deeks&title=Ceritinib%3A+a+Review+in+ALK-positive+Advanced+NSCLC&doi=10.1007%2Fs11523-016-0460-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">Ceritinib: a Review in ALK-Positive Advanced NSCLC</span></div><div class="casAuthors">Deeks Emma D</div><div class="citationInfo"><span class="NLM_cas:title">Targeted oncology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">693-700</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Ceritinib (Zykadia®) is an oral, selective inhibitor of the anaplastic lymphoma kinase (ALK), a receptor tyrosine kinase which, after genetic rearrangement, acts as an oncogenic driver in a proportion of non-small cell lung cancers (NSCLCs).  The drug is approved in several countries worldwide for the treatment of patients with ALK-positive, advanced NSCLC who have previously received the first-generation ALK inhibitor crizotinib (indication details may vary by country).  Approval was based on its clinical benefit in this setting in the phase I and II trials known as ASCEND-1 and -2.  Across these noncomparative studies, 36-56 % of patients achieved a response with ceritinib (at the recommended dosage of 750 mg once daily) and the responses were durable, lasting up to a median of 10 months.  Patients survived free from progression for a median of up to 7 months and had a median overall survival of up to 17 months.  Moreover, efficacy outcomes in patients with brain metastases were generally consistent with those of the overall study populations.  Ceritinib has an acceptable tolerability profile, with gastrointestinal issues, fatigue and liver test abnormalities being the most common adverse reactions.  Thus, ceritinib is a valuable treatment option for patients with ALK-positive advanced NSCLC who have already received crizotinib therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRKOyGNG4eqHGmbXvSEQle5fW6udTcc2eaxSgiJ5AgtLrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2svmsVCruw%253D%253D&md5=27514a024616dc2b02e8fbcd5c7bbd70</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1007%2Fs11523-016-0460-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11523-016-0460-7%26sid%3Dliteratum%253Aachs%26aulast%3DDeeks%26aufirst%3DE.%2BD.%26atitle%3DCeritinib%253A%2520a%2520Review%2520in%2520ALK-positive%2520Advanced%2520NSCLC%26jtitle%3DTarget.%2520Oncol.%26date%3D2016%26volume%3D11%26spage%3D693%26epage%3D700%26doi%3D10.1007%2Fs11523-016-0460-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref89"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref89'); return false;" data-citation="" class="refNumLink">89</a></strong><div class="NLM_citation" id="cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Galkin, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melnick, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hood, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xia, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steensma, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chopiuk, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schultz, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warmuth, M.</span></span> <span> </span><span class="NLM_article-title">Identification of NVP-TAE684, a Potent, Selective, and Efficacious Inhibitor of NPM-ALK</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>104</i></span>,  <span class="NLM_fpage">270</span>– <span class="NLM_lpage">275</span>, <span class="refDoi"> DOI: 10.1073/pnas.0609412103</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1073%2Fpnas.0609412103" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=17185414" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjt12jsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2007&pages=270-275&author=A.+V.+Galkinauthor=J.+S.+Melnickauthor=S.+Kimauthor=T.+L.+Hoodauthor=N.+Liauthor=L.+Liauthor=G.+Xiaauthor=R.+Steensmaauthor=G.+Chopiukauthor=J.+Jiangauthor=Y.+Wanauthor=P.+Dingauthor=Y.+Liuauthor=F.+Sunauthor=P.+G.+Schultzauthor=N.+S.+Grayauthor=M.+Warmuth&title=Identification+of+NVP-TAE684%2C+a+Potent%2C+Selective%2C+and+Efficacious+Inhibitor+of+NPM-ALK&doi=10.1073%2Fpnas.0609412103"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK</span></div><div class="casAuthors">Galkin, Anna V.; Melnick, Jonathon S.; Kim, Sunjoon; Hood, Tami L.; Li, Nanxin; Li, Lintong; Xia, Gang; Steensma, Ruo; Chopiuk, Greg; Wan, Yongqin; Ding, Peter; Liu, Yi; Sun, Fangxian; Schultz, Peter G.; Gray, Nathanael S.; Warmuth, Markus</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">104</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">270-275</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Constitutive overexpression and activation of NPM-ALK fusion protein [t(2:5)(p23;q35)] is a key oncogenic event that drives the survival and proliferation of anaplastic large cell lymphomas (ALCLs).  We have identified a highly potent and selective small-mol. ALK inhibitor, NVP-TAE684, which blocked the growth of ALCL-derived and ALK-dependent cell lines with IC50 values between 2 and 10 nM.  NVP-TAE684 treatment resulted in a rapid and sustained inhibition of phosphorylation of NPM-ALK and its downstream effectors and subsequent induction of apoptosis and cell cycle arrest.  In vivo, NVP-TAE684 suppressed lymphomagenesis in two independent models of ALK-pos. ALCL and induced regression of established Karpas-299 lymphomas.  NVP-TAE684 also induced down-regulation of CD30 expression, suggesting that CD30 may be used as a biomarker of therapeutic NPM-ALK kinase activity inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLbZwqZzPX-bVg90H21EOLACvtfcHk0lhxW4SHO30FXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjt12jsQ%253D%253D&md5=4a3441ee637a67dc496c80730bd0e184</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0609412103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0609412103%26sid%3Dliteratum%253Aachs%26aulast%3DGalkin%26aufirst%3DA.%2BV.%26aulast%3DMelnick%26aufirst%3DJ.%2BS.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DHood%26aufirst%3DT.%2BL.%26aulast%3DLi%26aufirst%3DN.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DXia%26aufirst%3DG.%26aulast%3DSteensma%26aufirst%3DR.%26aulast%3DChopiuk%26aufirst%3DG.%26aulast%3DJiang%26aufirst%3DJ.%26aulast%3DWan%26aufirst%3DY.%26aulast%3DDing%26aufirst%3DP.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DSun%26aufirst%3DF.%26aulast%3DSchultz%26aufirst%3DP.%2BG.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DWarmuth%26aufirst%3DM.%26atitle%3DIdentification%2520of%2520NVP-TAE684%252C%2520a%2520Potent%252C%2520Selective%252C%2520and%2520Efficacious%2520Inhibitor%2520of%2520NPM-ALK%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2007%26volume%3D104%26spage%3D270%26epage%3D275%26doi%3D10.1073%2Fpnas.0609412103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref90"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref90'); return false;" data-citation="" class="refNumLink">90</a></strong><div class="NLM_citation" id="cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Khozin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blumenthal, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brower, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fox, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Helms, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leong, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al Hakim, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boyd, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keegan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Justice, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pazdur, R.</span></span> <span> </span><span class="NLM_article-title">FDA Approval: Ceritinib for the Treatment of Metastatic Anaplastic Lymphoma Kinase–positive Non–small Cell Lung Cancer</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">2436</span>– <span class="NLM_lpage">2439</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-14-3157</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1158%2F1078-0432.CCR-14-3157" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=25754348" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC2MXps1aktLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=2436-2439&author=S.+Khozinauthor=G.+M.+Blumenthalauthor=L.+Zhangauthor=S.+Tangauthor=M.+Browerauthor=E.+Foxauthor=W.+Helmsauthor=R.+Leongauthor=P.+Songauthor=Y.+Panauthor=Q.+Liuauthor=P.+Zhaoauthor=H.+Zhaoauthor=D.+Luauthor=Z.+Tangauthor=A.+Al+Hakimauthor=K.+Boydauthor=P.+Keeganauthor=R.+Justiceauthor=R.+Pazdur&title=FDA+Approval%3A+Ceritinib+for+the+Treatment+of+Metastatic+Anaplastic+Lymphoma+Kinase%E2%80%93positive+Non%E2%80%93small+Cell+Lung+Cancer&doi=10.1158%2F1078-0432.CCR-14-3157"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">FDA Approval: Ceritinib for the Treatment of Metastatic Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer</span></div><div class="casAuthors">Khozin, Sean; Blumenthal, Gideon M.; Zhang, Lijun; Tang, Shenghui; Brower, Margaret; Fox, Emily; Helms, Whitney; Leong, Ruby; Song, Pengfei; Pan, Yuzhuo; Liu, Qi; Zhao, Ping; Zhao, Hong; Lu, Donghao; Tang, Zhe; Al Hakim, Ali; Boyd, Karen; Keegan, Patricia; Justice, Robert; Pazdur, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2436-2439</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">On Apr. 29, 2014, the FDA granted accelerated approval to ceritinib (ZYKADIA; Novartis Pharmaceuticals Corporation), a breakthrough therapy-designated drug, for the treatment of patients with anaplastic lymphoma kinase (ALK)-pos., metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib.  The approval was based on a single-arm multicenter trial enrolling 163 patients with metastatic ALK-pos. NSCLC who had disease progression on (91%) or intolerance to crizotinib.  Patients received ceritinib at a starting dose of 750 mg orally once daily.  The objective response rate (ORR) by a blinded independent review committee was 44% (95% CI, 36-52), and the median duration of response (DOR) was 7.1 mo.  The ORR by investigator assessment was similar.  Safety was evaluated in 255 patients.  The most common adverse reactions and lab. abnormalities included diarrhea (86%), nausea (80%), increased alanine transaminase (80%), increased aspartate transaminase (75%), vomiting (60%), increased glucose (49%), and increased lipase (28%).  Although 74% of patients required at least one dose redn. or interruption due to adverse reactions, the discontinuation rate due to adverse reactions was low (10%).  With this safety profile, the benefit-risk anal. was considered favorable because of the clin. meaningful ORR and DOR.  Clin Cancer Res; 21(11); 2436-9. ©2015 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoopHbie8F3MLVg90H21EOLACvtfcHk0lgMU-RqgEsMOA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXps1aktLY%253D&md5=0b83c696c11bdc5281cdae60a8b0bf50</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-14-3157&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-14-3157%26sid%3Dliteratum%253Aachs%26aulast%3DKhozin%26aufirst%3DS.%26aulast%3DBlumenthal%26aufirst%3DG.%2BM.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DTang%26aufirst%3DS.%26aulast%3DBrower%26aufirst%3DM.%26aulast%3DFox%26aufirst%3DE.%26aulast%3DHelms%26aufirst%3DW.%26aulast%3DLeong%26aufirst%3DR.%26aulast%3DSong%26aufirst%3DP.%26aulast%3DPan%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DZhao%26aufirst%3DP.%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DLu%26aufirst%3DD.%26aulast%3DTang%26aufirst%3DZ.%26aulast%3DAl%2BHakim%26aufirst%3DA.%26aulast%3DBoyd%26aufirst%3DK.%26aulast%3DKeegan%26aufirst%3DP.%26aulast%3DJustice%26aufirst%3DR.%26aulast%3DPazdur%26aufirst%3DR.%26atitle%3DFDA%2520Approval%253A%2520Ceritinib%2520for%2520the%2520Treatment%2520of%2520Metastatic%2520Anaplastic%2520Lymphoma%2520Kinase%25E2%2580%2593positive%2520Non%25E2%2580%2593small%2520Cell%2520Lung%2520Cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2015%26volume%3D21%26spage%3D2436%26epage%3D2439%26doi%3D10.1158%2F1078-0432.CCR-14-3157" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref91"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref91'); return false;" data-citation="" class="refNumLink">91</a></strong><div class="NLM_citation" id="cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dhillon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, M.</span></span> <span> </span><span class="NLM_article-title">Ceritinib: First Global Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>74</i></span>,  <span class="NLM_fpage">1285</span>– <span class="NLM_lpage">1291</span>, <span class="refDoi"> DOI: 10.1007/s40265-014-0251-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1007%2Fs40265-014-0251-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=24980964" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVOisbbK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2014&pages=1285-1291&author=S.+Dhillonauthor=M.+Clark&title=Ceritinib%3A+First+Global+Approval&doi=10.1007%2Fs40265-014-0251-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">Ceritinib: First Global Approval</span></div><div class="casAuthors">Dhillon, Sohita; Clark, Madeleine</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1285-1291</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  Ceritinib is an oral anaplastic lymphoma kinase (ALK) inhibitor developed by Novartis for the treatment of tumors characterised by genetic abnormalities in ALK.  ALK is a member of the insulin receptor family of tyrosine kinases that can become oncogenic when fused to other proteins.  Ceritinib has been approved in the US under 'Breakthrough Therapy' designation for the second-line treatment of ALK-pos. non-small cell lung cancer (NSCLC).  Regulatory submissions have also been made in the EU and other countries.  Phase III development is ongoing worldwide to evaluate ceritinib both as a first- and second-line therapy for ALK-pos. NSCLC.  This article summarizes the milestones in the development of ceritinib leading to this first approval for the treatment of patients with ALK-pos. metastatic NSCLC who have progressed on or are intolerant to crizotinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGot1rTUW_DPL7Vg90H21EOLACvtfcHk0lgMU-RqgEsMOA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVOisbbK&md5=ec44e05bf8556567826c3eb7f5dbd5dc</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1007%2Fs40265-014-0251-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-014-0251-3%26sid%3Dliteratum%253Aachs%26aulast%3DDhillon%26aufirst%3DS.%26aulast%3DClark%26aufirst%3DM.%26atitle%3DCeritinib%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2014%26volume%3D74%26spage%3D1285%26epage%3D1291%26doi%3D10.1007%2Fs40265-014-0251-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref92"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref92'); return false;" data-citation="" class="refNumLink">92</a></strong><div class="NLM_citation" id="cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Felip, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orlov, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, C.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, C.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishio, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cobo Dols, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKeage, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, W.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mok, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scagliotti, G. V.</span></span> <span> </span><span class="NLM_article-title">ASCEND-3: A Single-arm, Open-label, Multicenter Phase II Study of Ceritinib in ALKi-naïve Adult Patients (pts) with ALK-rearranged (ALK+) Non-small Cell Lung Cancer (NSCLC)</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>33</i></span> (<span class="NLM_issue">Suppl 15</span>),  <span class="NLM_fpage">8060</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1200%2Fjco.2015.33.15_suppl.8060" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2015&pages=8060&issue=Suppl+15&author=E.+Felipauthor=S.+Orlovauthor=K.+Parkauthor=C.-J.+Yuauthor=C.-M.+Tsaiauthor=M.+Nishioauthor=M.+Cobo+Dolsauthor=M.+J.+McKeageauthor=W.-C.+Suauthor=T.+Mokauthor=G.+V.+Scagliotti&title=ASCEND-3%3A+A+Single-arm%2C+Open-label%2C+Multicenter+Phase+II+Study+of+Ceritinib+in+ALKi-na%C3%AFve+Adult+Patients+%28pts%29+with+ALK-rearranged+%28ALK%2B%29+Non-small+Cell+Lung+Cancer+%28NSCLC%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1200%2Fjco.2015.33.15_suppl.8060&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252Fjco.2015.33.15_suppl.8060%26sid%3Dliteratum%253Aachs%26aulast%3DFelip%26aufirst%3DE.%26aulast%3DOrlov%26aufirst%3DS.%26aulast%3DPark%26aufirst%3DK.%26aulast%3DYu%26aufirst%3DC.-J.%26aulast%3DTsai%26aufirst%3DC.-M.%26aulast%3DNishio%26aufirst%3DM.%26aulast%3DCobo%2BDols%26aufirst%3DM.%26aulast%3DMcKeage%26aufirst%3DM.%2BJ.%26aulast%3DSu%26aufirst%3DW.-C.%26aulast%3DMok%26aufirst%3DT.%26aulast%3DScagliotti%26aufirst%3DG.%2BV.%26atitle%3DASCEND-3%253A%2520A%2520Single-arm%252C%2520Open-label%252C%2520Multicenter%2520Phase%2520II%2520Study%2520of%2520Ceritinib%2520in%2520ALKi-na%25C3%25AFve%2520Adult%2520Patients%2520%2528pts%2529%2520with%2520ALK-rearranged%2520%2528ALK%252B%2529%2520Non-small%2520Cell%2520Lung%2520Cancer%2520%2528NSCLC%2529%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2015%26volume%3D33%26issue%3DSuppl%252015%26spage%3D8060" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref93"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref93'); return false;" data-citation="" class="refNumLink">93</a></strong><div class="NLM_citation" id="cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, A. T</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crino, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gridelli, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiura, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novello, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bearz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gautschi, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mok, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishio, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scagliotti, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spigel, D. R</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deudon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pantano, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urban, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Massacesi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viraswami-Appanna, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felip, E.</span></span> <span> </span><span class="NLM_article-title">Ceritinib versus Chemotherapy in Patients with ALK-rearranged Non-small-cell Lung Cancer Previously Given Chemotherapy and Crizotinib (ASCEND-5): a Randomised, Controlled, Open-label, Phase 3 Trial</span>. <i>Lancet Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">874</span>– <span class="NLM_lpage">886</span>, <span class="refDoi"> DOI: 10.1016/S1470-2045(17)30339-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1016%2FS1470-2045%2817%2930339-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=28602779" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC2sXpvVWhsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2017&pages=874-886&author=A.+T+Shawauthor=T.+M.+Kimauthor=L.+Crinoauthor=C.+Gridelliauthor=K.+Kiuraauthor=G.+Liuauthor=S.+Novelloauthor=A.+Bearzauthor=O.+Gautschiauthor=T.+Mokauthor=M.+Nishioauthor=G.+Scagliottiauthor=D.+R+Spigelauthor=S.+Deudonauthor=C.+Zhengauthor=S.+Pantanoauthor=P.+Urbanauthor=C.+Massacesiauthor=K.+Viraswami-Appannaauthor=E.+Felip&title=Ceritinib+versus+Chemotherapy+in+Patients+with+ALK-rearranged+Non-small-cell+Lung+Cancer+Previously+Given+Chemotherapy+and+Crizotinib+%28ASCEND-5%29%3A+a+Randomised%2C+Controlled%2C+Open-label%2C+Phase+3+Trial&doi=10.1016%2FS1470-2045%2817%2930339-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial</span></div><div class="casAuthors">Shaw, Alice T.; Kim, Tae Min; Crino, Lucio; Gridelli, Cesare; Kiura, Katsuyuki; Liu, Geoffrey; Novello, Silvia; Bearz, Alessandra; Gautschi, Oliver; Mok, Tony; Nishio, Makoto; Scagliotti, Giorgio; Spigel, David R.; Deudon, Stephanie; Zheng, Cheng; Pantano, Serafino; Urban, Patrick; Massacesi, Cristian; Viraswami-Appanna, Kalyanee; Felip, Enriqueta</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">874-886</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Ceritinib is a next-generation anaplastic lymphoma kinase (ALK) inhibitor, which has shown robust anti-tumor efficacy, along with intracranial activity, in patients with ALK-rearranged non-small-cell lung cancer.  In phase 1 and 2 studies, ceritinib has been shown to be highly active in both ALK inhibitor-naive and ALK inhibitor-pretreated patients who had progressed after chemotherapy (mostly multiple lines).  In this study, we compared the efficacy and safety of ceritinib vs. single-agent chemotherapy in patients with advanced ALK-rearranged non-small-cell lung cancer who had previously progressed following crizotinib and platinum-based doublet chemotherapy.  In this randomized, controlled, open-label, phase 3 trial, we recruited patients aged at least 18 years with ALK-rearranged stage IIIB or IV non-small-cell lung cancer (with at least one measurable lesion) who had received previous chemotherapy (one or two lines, including a platinum doublet) and crizotinib and had subsequent disease progression, from 99 centers across 20 countries.  Other inclusion criteria were a WHO performance status of 0-2, adequate organ function and lab. test results, a life expectancy of at least 12 wk, and having recovered from previous anticancer treatment-related toxicities.  We randomly allocated patients (1:1; with blocking [block size of four]; stratified by WHO performance status [0 vs 1-2] and presence or absence of brain metastases) to oral ceritinib 750 mg per day fasted (in 21 day treatment cycles) or chemotherapy (i.v. pemetrexed 500 mg/m2 or docetaxel 75 mg/m2 [investigator choice], every 21 days).  Patients who discontinued chemotherapy because of progressive disease could cross over to the ceritinib group.  The primary endpoint was progression-free survival, assessed by a masked independent review committee using Response Evaluation Criteria in Solid Tumors 1.1 in the intention-to-treat population, assessed every 6 wk until month 18 and every 9 wk thereafter.  This trial is registered with ClinicalTrials.gov, no. NCT01828112, and is ongoing but no longer recruiting patients.  Between June 28, 2013, and Nov 2, 2015, we randomly allocated 231 patients; 115 (50%) to ceritinib and 116 (50%) to chemotherapy (40 [34%] to pemetrexed, 73 [63%] to docetaxel, and three [3%] discontinued before receiving treatment).  Median follow-up was 16·5 mo (IQR 11·5-21·4).  Ceritinib showed a significant improvement in median progression-free survival compared with chemotherapy (5·4 mo [95% CI 4·1-6·9] for ceritinib vs 1·6 mo [1·4-2·8] for chemotherapy; hazard ratio 0·49 [0·36-0·67]; p<0·0001).  Serious adverse events were reported in 49 (43%) of 115 patients in the ceritinib group and 36 (32%) of 113 in the chemotherapy group.  Treatment-related serious adverse events were similar between groups (13 [11%] in the ceritinib group vs 12 [11%] in the chemotherapy group).  The most frequent grade 3-4 adverse events in the ceritinib group were increased alanine aminotransferase concn. (24 [21%] of 115 vs two [2%] of 113 in the chemotherapy group), increased γ glutamyltransferase concn. (24 [21%] vs one [1%]), and increased aspartate aminotransferase concn. (16 [14%] vs one [1%] in the chemotherapy group).  Six (5%) of 115 patients in the ceritinib group discontinued because of adverse events compared with eight (7%) of 116 in the chemotherapy group. 15 (13%) of 115 patients in the ceritinib group and five (4%) of 113 in the chemotherapy group died during the treatment period (from the day of the first dose of study treatment to 30 days after the final dose). 13 (87%) of the 15 patients who died in the ceritinib group died because of disease progression and two (13%) died because of an adverse event (one [7%] cerebrovascular accident and one [7%] respiratory failure); neither of these deaths were considered by the investigator to be treatment related.  The five (4%) deaths in the chemotherapy group were all due to disease progression.  These findings show that patients derive significant clin. benefit from a more potent ALK inhibitor after failure of crizotinib, and establish ceritinib as a more efficacious treatment option compared with chemotherapy in this patient population.  Novartis Pharmaceuticals Corporation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpMT91wojAiELVg90H21EOLACvtfcHk0lix8n_XYQPJjA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXpvVWhsLc%253D&md5=b75ab3a89c51975715ba614a1780d433</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2817%2930339-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252817%252930339-X%26sid%3Dliteratum%253Aachs%26aulast%3DShaw%26aufirst%3DA.%2BT%26aulast%3DKim%26aufirst%3DT.%2BM.%26aulast%3DCrino%26aufirst%3DL.%26aulast%3DGridelli%26aufirst%3DC.%26aulast%3DKiura%26aufirst%3DK.%26aulast%3DLiu%26aufirst%3DG.%26aulast%3DNovello%26aufirst%3DS.%26aulast%3DBearz%26aufirst%3DA.%26aulast%3DGautschi%26aufirst%3DO.%26aulast%3DMok%26aufirst%3DT.%26aulast%3DNishio%26aufirst%3DM.%26aulast%3DScagliotti%26aufirst%3DG.%26aulast%3DSpigel%26aufirst%3DD.%2BR%26aulast%3DDeudon%26aufirst%3DS.%26aulast%3DZheng%26aufirst%3DC.%26aulast%3DPantano%26aufirst%3DS.%26aulast%3DUrban%26aufirst%3DP.%26aulast%3DMassacesi%26aufirst%3DC.%26aulast%3DViraswami-Appanna%26aufirst%3DK.%26aulast%3DFelip%26aufirst%3DE.%26atitle%3DCeritinib%2520versus%2520Chemotherapy%2520in%2520Patients%2520with%2520ALK-rearranged%2520Non-small-cell%2520Lung%2520Cancer%2520Previously%2520Given%2520Chemotherapy%2520and%2520Crizotinib%2520%2528ASCEND-5%2529%253A%2520a%2520Randomised%252C%2520Controlled%252C%2520Open-label%252C%2520Phase%25203%2520Trial%26jtitle%3DLancet%2520Oncol.%26date%3D2017%26volume%3D18%26spage%3D874%26epage%3D886%26doi%3D10.1016%2FS1470-2045%2817%2930339-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref94"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref94'); return false;" data-citation="" class="refNumLink">94</a></strong><div class="NLM_citation" id="cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Soria, J.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, D. S W</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiari, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paz-Ares, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolf, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geater, S. L</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orlov, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortinovis, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, C.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hochmair, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortot, A. B</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, C.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moro-Sibilot, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campelo, R. G</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCulloch, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dugan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pantano, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Branle, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Massacesi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Castro, G.</span></span> <span> </span><span class="NLM_article-title">First-line Ceritinib versus Platinum-based Chemotherapy in Advanced ALK-rearranged Non-small Cell Lung Cancer (ASCEND-4): a Randomised, Open-label, Phase 3 Study</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>389</i></span>,  <span class="NLM_fpage">917</span>– <span class="NLM_lpage">929</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(17)30123-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1016%2FS0140-6736%2817%2930123-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=28126333" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFGku7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=389&publication_year=2017&pages=917-929&author=J.-C.+Soriaauthor=D.+S+W+Tanauthor=R.+Chiariauthor=Y.-L.+Wuauthor=L.+Paz-Aresauthor=J.+Wolfauthor=S.+L+Geaterauthor=S.+Orlovauthor=D.+Cortinovisauthor=C.-J.+Yuauthor=M.+Hochmairauthor=A.+B+Cortotauthor=C.-M.+Tsaiauthor=D.+Moro-Sibilotauthor=R.+G+Campeloauthor=T.+McCullochauthor=P.+Senauthor=M.+Duganauthor=S.+Pantanoauthor=F.+Branleauthor=C.+Massacesiauthor=G.+de+Castro&title=First-line+Ceritinib+versus+Platinum-based+Chemotherapy+in+Advanced+ALK-rearranged+Non-small+Cell+Lung+Cancer+%28ASCEND-4%29%3A+a+Randomised%2C+Open-label%2C+Phase+3+Study&doi=10.1016%2FS0140-6736%2817%2930123-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study</span></div><div class="casAuthors">Soria, Jean-Charles; Tan, Daniel S. W.; Chiari, Rita; Wu, Yi-Long; Paz-Ares, Luis; Wolf, Juergen; Geater, Sarayut L.; Orlov, Sergey; Cortinovis, Diego; Yu, Chong-Jen; Hochmair, Maximillian; Cortot, Alexis B.; Tsai, Chun-Ming; Moro-Sibilot, Denis; Campelo, Rosario G.; McCulloch, Tracey; Sen, Paramita; Dugan, Margaret; Pantano, Serafino; Branle, Fabrice; Massacesi, Cristian; de Castro, Gilberto, Jr.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">389</span>
        (<span class="NLM_cas:issue">10072</span>),
    <span class="NLM_cas:pages">917-929</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The efficacy of ceritinib in patients with untreated anaplastic lymphoma kinase (ALK)-rearranged non-small-cell lung cancer (NSCLC) is not known.  We assessed the efficacy and safety of ceritinib vs. platinum-based chemotherapy in these patients.  This randomised, open-label, phase 3 study in untreated patients with stage IIIB/IV ALK-rearranged non-squamous NSCLC was done in 134 centers across 28 countries.  Eligible patients were assigned via interactive response technol. to oral ceritinib 750 mg/day or platinum-based chemotherapy ([cisplatin 75 mg/m2 or carboplatin AUC 5-6 plus pemetrexed 500 mg/m2] every 3 wk for four cycles followed by maintenance pemetrexed); randomization was stratified by World Health Organization performance status (0 vs 1-2), previous neoadjuvant or adjuvant chemotherapy, and presence of brain metastases as per investigator's assessment at screening.  Investigators and patients were not masked to treatment assignment.  The primary endpoint was blinded independent review committee assessed progression-free survival, based on all randomly assigned patients (the full anal. set).  Efficacy analyses were done based on the full anal. set.  All safety analyses were done based on the safety set, which included all patients who received at least one dose of study drug.  This trial is registered with ClinicalTrials.gov, no. NCT01828099.  Between Aug 19, 2013, and May 11, 2015, 376 patients were randomly assigned to ceritinib (n=189) or chemotherapy (n=187).  Median progression-free survival (as assessed by blinded independent review committee) was 16·6 mo (95% CI 12·6-27·2) in the ceritinib group and 8·1 mo (5·8-11·1) in the chemotherapy group (hazard ratio 0·55 [95% CI 0·42-0·73]; p<0·00001).  The most common adverse events were diarrhoea (in 160 [85%] of 189 patients), nausea (130 [69%]), vomiting (125 [66%]), and an increase in alanine aminotransferase (114 [60%]) in the ceritinib group and nausea (in 97 [55%] of 175 patients), vomiting (63 [36%]), and anemia (62 [35%]) in the chemotherapy group.  First-line ceritinib showed a statistically significant and clin. meaningful improvement in progression-free survival vs. chemotherapy in patients with advanced ALK-rearranged NSCLC.  Novartis Pharmaceuticals Corporation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdGKYa204H9rVg90H21EOLACvtfcHk0lix8n_XYQPJjA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFGku7Y%253D&md5=a51029d59399ff42f840ffc1b2b5caf7</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2817%2930123-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252817%252930123-X%26sid%3Dliteratum%253Aachs%26aulast%3DSoria%26aufirst%3DJ.-C.%26aulast%3DTan%26aufirst%3DD.%2BS%2BW%26aulast%3DChiari%26aufirst%3DR.%26aulast%3DWu%26aufirst%3DY.-L.%26aulast%3DPaz-Ares%26aufirst%3DL.%26aulast%3DWolf%26aufirst%3DJ.%26aulast%3DGeater%26aufirst%3DS.%2BL%26aulast%3DOrlov%26aufirst%3DS.%26aulast%3DCortinovis%26aufirst%3DD.%26aulast%3DYu%26aufirst%3DC.-J.%26aulast%3DHochmair%26aufirst%3DM.%26aulast%3DCortot%26aufirst%3DA.%2BB%26aulast%3DTsai%26aufirst%3DC.-M.%26aulast%3DMoro-Sibilot%26aufirst%3DD.%26aulast%3DCampelo%26aufirst%3DR.%2BG%26aulast%3DMcCulloch%26aufirst%3DT.%26aulast%3DSen%26aufirst%3DP.%26aulast%3DDugan%26aufirst%3DM.%26aulast%3DPantano%26aufirst%3DS.%26aulast%3DBranle%26aufirst%3DF.%26aulast%3DMassacesi%26aufirst%3DC.%26aulast%3Dde%2BCastro%26aufirst%3DG.%26atitle%3DFirst-line%2520Ceritinib%2520versus%2520Platinum-based%2520Chemotherapy%2520in%2520Advanced%2520ALK-rearranged%2520Non-small%2520Cell%2520Lung%2520Cancer%2520%2528ASCEND-4%2529%253A%2520a%2520Randomised%252C%2520Open-label%252C%2520Phase%25203%2520Study%26jtitle%3DLancet%26date%3D2017%26volume%3D389%26spage%3D917%26epage%3D929%26doi%3D10.1016%2FS0140-6736%2817%2930123-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref95"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref95'); return false;" data-citation="" class="refNumLink">95</a></strong><div class="NLM_citation" id="cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sakamoto, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsukaguchi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hiroshima, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kodama, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobayashi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukami, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oikawa, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsukuda, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishii, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aoki, Y.</span></span> <span> </span><span class="NLM_article-title">CH5424802, a Selective ALK Inhibitor Capable of Blocking the Resistant Gatekeeper Mutant</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">679</span>– <span class="NLM_lpage">690</span>, <span class="refDoi"> DOI: 10.1016/j.ccr.2011.04.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1016%2Fj.ccr.2011.04.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=21575866" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmtFGlsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2011&pages=679-690&author=H.+Sakamotoauthor=T.+Tsukaguchiauthor=S.+Hiroshimaauthor=T.+Kodamaauthor=T.+Kobayashiauthor=T.+A.+Fukamiauthor=N.+Oikawaauthor=T.+Tsukudaauthor=N.+Ishiiauthor=Y.+Aoki&title=CH5424802%2C+a+Selective+ALK+Inhibitor+Capable+of+Blocking+the+Resistant+Gatekeeper+Mutant&doi=10.1016%2Fj.ccr.2011.04.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">CH5424802, a Selective ALK Inhibitor Capable of Blocking the Resistant Gatekeeper Mutant</span></div><div class="casAuthors">Sakamoto, Hiroshi; Tsukaguchi, Toshiyuki; Hiroshima, Sayuri; Kodama, Tatsushi; Kobayashi, Takamitsu; Fukami, Takaaki A.; Oikawa, Nobuhiro; Tsukuda, Takuo; Ishii, Nobuya; Aoki, Yuko</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">679-690</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Anaplastic lymphoma kinase (ALK) is a tyrosine kinase that is constitutively activated in certain cancers, following gene alterations such as chromosomal translocation, amplification, or point mutation.  Here, the authors identified CH5424802, a potent, selective, and orally available ALK inhibitor with a unique chem. scaffold, showing preferential antitumor activity against cancers with gene alterations of ALK, such as non-small cell lung cancer (NSCLC) cells expressing EML4-ALK fusion and anaplastic large-cell lymphoma (ALCL) cells expressing NPM-ALK fusion in vitro and in vivo.  CH5424802 inhibited ALK L1196M, which corresponds to the gatekeeper mutation conferring common resistance to kinase inhibitors, and blocked EML4-ALK L1196M-driven cell growth.  The authors' results support the potential for clin. evaluation of CH5424802 for the treatment of patients with ALK-driven tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrk3zvzF9p67Vg90H21EOLACvtfcHk0lix8n_XYQPJjA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmtFGlsL8%253D&md5=cae32f3a3647926ba835293b68e776f8</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2011.04.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2011.04.004%26sid%3Dliteratum%253Aachs%26aulast%3DSakamoto%26aufirst%3DH.%26aulast%3DTsukaguchi%26aufirst%3DT.%26aulast%3DHiroshima%26aufirst%3DS.%26aulast%3DKodama%26aufirst%3DT.%26aulast%3DKobayashi%26aufirst%3DT.%26aulast%3DFukami%26aufirst%3DT.%2BA.%26aulast%3DOikawa%26aufirst%3DN.%26aulast%3DTsukuda%26aufirst%3DT.%26aulast%3DIshii%26aufirst%3DN.%26aulast%3DAoki%26aufirst%3DY.%26atitle%3DCH5424802%252C%2520a%2520Selective%2520ALK%2520Inhibitor%2520Capable%2520of%2520Blocking%2520the%2520Resistant%2520Gatekeeper%2520Mutant%26jtitle%3DCancer%2520Cell%26date%3D2011%26volume%3D19%26spage%3D679%26epage%3D690%26doi%3D10.1016%2Fj.ccr.2011.04.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref96"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref96'); return false;" data-citation="" class="refNumLink">96</a></strong><div class="NLM_citation" id="cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McKeage, K.</span></span> <span> </span><span class="NLM_article-title">Alectinib: a Review of its Use in Advanced ALK-rearranged Non-small Cell Lung Cancer</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>75</i></span>,  <span class="NLM_fpage">75</span>– <span class="NLM_lpage">82</span>, <span class="refDoi"> DOI: 10.1007/s40265-014-0329-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1007%2Fs40265-014-0329-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=25428710" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvF2hu73P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2015&pages=75-82&author=K.+McKeage&title=Alectinib%3A+a+Review+of+its+Use+in+Advanced+ALK-rearranged+Non-small+Cell+Lung+Cancer&doi=10.1007%2Fs40265-014-0329-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">Alectinib: A Review of Its Use in Advanced ALK-Rearranged Non-Small Cell Lung Cancer</span></div><div class="casAuthors">McKeage, Kate</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">75-82</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  Alectinib (Alecensa) is a second-generation, orally active, potent and highly selective inhibitor of anaplastic lymphoma kinase (ALK).  Alectinib is approved for the treatment of ALK fusion-gene pos., unresectable, advanced or recurrent non-small cell lung cancer (NSCLC) in Japan, where it has been given orphan drug designation.  Approval was based on a phase 1-2 study in ALK inhibitor-naive patients with ALK-rearranged advanced NSCLC who received twice-daily alectinib 300 mg.  In the phase 2 portion, 93.5 % of patients achieved an objective response.  Treatment response was rapid, with a partial response achieved in two-thirds of patients within 3 wk (cycle 1).  Patient follow-up is ongoing, and after approx. 2 years, 19.6 % of patients had achieved a complete response, and the 2-yr progression-free survival rate is 76 %.  During treatment with alectinib (median follow-up approx. 8 mo), there was no progression of CNS lesions among patients with known CNS metastases at baseline (although prior radiation therapy may have confounded results).  In preclin. models, alectinib was active against most ALK fusion-gene mutations related to crizotinib resistance, and preliminary results from clin. trials indicate efficacy in crizotinib-refractory NSCLC.  Alectinib was generally well tolerated in clin. trials, and there were no treatment-related grade 4 adverse events or deaths.  The most common grade 3 treatment-related adverse events were decreased neutrophil counts and increased creatinine phosphokinase.  While more data are needed to confirm the efficacy of alectinib and to evaluate its activity in crizotinib-resistant disease, the drug provides a very promising option for the treatment of ALK-rearranged advanced NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq38gxDn8-OqbVg90H21EOLACvtfcHk0ljnhyx3TrfkEg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvF2hu73P&md5=17517e7ce95efd8be1b5c5300b404c8a</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1007%2Fs40265-014-0329-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-014-0329-y%26sid%3Dliteratum%253Aachs%26aulast%3DMcKeage%26aufirst%3DK.%26atitle%3DAlectinib%253A%2520a%2520Review%2520of%2520its%2520Use%2520in%2520Advanced%2520ALK-rearranged%2520Non-small%2520Cell%2520Lung%2520Cancer%26jtitle%3DDrugs%26date%3D2015%26volume%3D75%26spage%3D75%26epage%3D82%26doi%3D10.1007%2Fs40265-014-0329-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref97"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref97'); return false;" data-citation="" class="refNumLink">97</a></strong><div class="NLM_citation" id="cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Song, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, A.</span></span> <span> </span><span class="NLM_article-title">Alectinib: a Novel Second Generation Anaplastic Lymphoma Kinase (ALK) Inhibitor for Overcoming Clinically-acquired Resistance</span>. <i>Acta Pharm. Sin. B</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">34</span>– <span class="NLM_lpage">37</span>, <span class="refDoi"> DOI: 10.1016/j.apsb.2014.12.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1016%2Fj.apsb.2014.12.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=26579422" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A280%3ADC%252BC28rgtlOnsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2015&pages=34-37&author=Z.+Songauthor=M.+Wangauthor=A.+Zhang&title=Alectinib%3A+a+Novel+Second+Generation+Anaplastic+Lymphoma+Kinase+%28ALK%29+Inhibitor+for+Overcoming+Clinically-acquired+Resistance&doi=10.1016%2Fj.apsb.2014.12.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">Alectinib: a novel second generation anaplastic lymphoma kinase (ALK) inhibitor for overcoming clinically-acquired resistance</span></div><div class="casAuthors">Song Zilan; Wang Meining; Zhang Ao</div><div class="citationInfo"><span class="NLM_cas:title">Acta pharmaceutica Sinica. B</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">34-7</span>
        ISSN:<span class="NLM_cas:issn">2211-3835</span>.
    </div><div class="casAbstract">The development of inhibitors for the tyrosine anaplastic lymphoma kinase (ALK) has advanced rapidly, driven by biology and medicinal chemistry.  The first generation ALK inhibitor crizotinib was granted US FDA approval with only four years of preclinical and clinical testing.  Although this drug offers significant clinical benefit to the ALK-positive patients, resistance has been developed through a variety of mechanisms.  In addition to ceritinib, alectinib is another second-generation ALK inhibitor launched in 2014 in Japan.  This drug has a unique chemical structure bearing a 5H-benzo[b]carbazol-11(6H)-one structural scaffold with an IC50 value of 1.9 nmol/L, and is highly potent against ALK bearing the gatekeeper mutation L1196M with an IC50 of 1.56 nmol/L.  In the clinic, alectinib is highly efficacious in treatment of ALK-positive non-small cell lung cancer (NSCLC), and retains potency to combat crizotinib-resistant ALK mutations L1196M, F1174L, R1275Q and C1156Y.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ-qtzzXrDFl0loaUqgkFHkfW6udTcc2eb0FV4iKQuy1bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28rgtlOnsQ%253D%253D&md5=897904214b032d104d09280ebe1b95ca</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1016%2Fj.apsb.2014.12.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.apsb.2014.12.007%26sid%3Dliteratum%253Aachs%26aulast%3DSong%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DA.%26atitle%3DAlectinib%253A%2520a%2520Novel%2520Second%2520Generation%2520Anaplastic%2520Lymphoma%2520Kinase%2520%2528ALK%2529%2520Inhibitor%2520for%2520Overcoming%2520Clinically-acquired%2520Resistance%26jtitle%3DActa%2520Pharm.%2520Sin.%2520B%26date%3D2015%26volume%3D5%26spage%3D34%26epage%3D37%26doi%3D10.1016%2Fj.apsb.2014.12.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref98"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref98'); return false;" data-citation="" class="refNumLink">98</a></strong><div class="NLM_citation" id="cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kodama, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hasegawa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takanashi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakurai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kondoh, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakamoto, H.</span></span> <span> </span><span class="NLM_article-title">Antitumor Activity of the Selective ALK Inhibitor Alectinib in Models of Intracranial Metastases</span>. <i>Cancer Chemother. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>74</i></span>,  <span class="NLM_fpage">1023</span>– <span class="NLM_lpage">1028</span>, <span class="refDoi"> DOI: 10.1007/s00280-014-2578-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1007%2Fs00280-014-2578-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=25205428" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFeju7%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2014&pages=1023-1028&author=T.+Kodamaauthor=M.+Hasegawaauthor=K.+Takanashiauthor=Y.+Sakuraiauthor=O.+Kondohauthor=H.+Sakamoto&title=Antitumor+Activity+of+the+Selective+ALK+Inhibitor+Alectinib+in+Models+of+Intracranial+Metastases&doi=10.1007%2Fs00280-014-2578-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">Antitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastases</span></div><div class="casAuthors">Kodama, Tatsushi; Hasegawa, Masami; Takanashi, Kenji; Sakurai, Yuji; Kondoh, Osamu; Sakamoto, Hiroshi</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Chemotherapy and Pharmacology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1023-1028</span>CODEN:
                <span class="NLM_cas:coden">CCPHDZ</span>;
        ISSN:<span class="NLM_cas:issn">0344-5704</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Purpose: The clin. efficacy of the anaplastic lymphoma kinase (ALK) inhibitor crizotinib has been demonstrated in ALK fusion-pos. non-small cell lung cancer (NSCLC); however, brain metastases are frequent sites of initial failure in patients due to poor penetration of the central nervous system by crizotinib.  Here, we examd. the efficacy of a selective ALK inhibitor alectinib/CH5424802 in preclin. models of intracranial tumors.  Methods: We established intracranial tumor implantation mouse models of EML4-ALK-pos. NSCLC NCI-H2228 and examd. the antitumor activity of alectinib in this model.  Plasma distribution and brain distribution of alectinib were examd. by quant. whole-body autoradiog. administrating a single oral dose of 14C-labeled alectinib to rats.  The drug permeability of alectinib was evaluated in Caco-2 cell.  Results: Alectinib resulted in regression of NCI-H2228 tumor in mouse brain and provided a survival benefit.  In a pharmacokinetic study using rats, alectinib showed a high brain-to-plasma ratio, and in an in vitro drug permeability study using Caco-2 cells, alectinib was not transported by P-glycoprotein efflux transporter that is a key factor in blood-brain barrier penetration.  Conclusions: We established intracranial tumor implantation models of EML4-ALK-pos. NSCLC.  Alectinib showed potent efficacy against intracranial EML4-ALK-pos. tumor.  These results demonstrated that alectinib might provide therapeutic opportunities for crizotinib-treated patients with brain metastases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCY4brINPNC7Vg90H21EOLACvtfcHk0ljnhyx3TrfkEg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFeju7%252FK&md5=19b3fa282fb58bf492714d39207edac6</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1007%2Fs00280-014-2578-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00280-014-2578-6%26sid%3Dliteratum%253Aachs%26aulast%3DKodama%26aufirst%3DT.%26aulast%3DHasegawa%26aufirst%3DM.%26aulast%3DTakanashi%26aufirst%3DK.%26aulast%3DSakurai%26aufirst%3DY.%26aulast%3DKondoh%26aufirst%3DO.%26aulast%3DSakamoto%26aufirst%3DH.%26atitle%3DAntitumor%2520Activity%2520of%2520the%2520Selective%2520ALK%2520Inhibitor%2520Alectinib%2520in%2520Models%2520of%2520Intracranial%2520Metastases%26jtitle%3DCancer%2520Chemother.%2520Pharmacol.%26date%3D2014%26volume%3D74%26spage%3D1023%26epage%3D1028%26doi%3D10.1007%2Fs00280-014-2578-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref99"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref99'); return false;" data-citation="" class="refNumLink">99</a></strong><div class="NLM_citation" id="cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ou, S.-H. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Petris, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Govindan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J. C.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lena, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moro-Sibilot, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bearz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramirez, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mekhail, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spira, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bordogna, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balas, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morcos, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monnet, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeaiter, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D.-W.</span></span> <span> </span><span class="NLM_article-title">Alectinib in Crizotinib-refractory ALK-rearranged Non-small Cell Lung Cancer: a Phase II Global Study</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">661</span>– <span class="NLM_lpage">668</span>, <span class="refDoi"> DOI: 10.1200/JCO.2015.63.9443</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1200%2FJCO.2015.63.9443" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=26598747" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC28Xpt1Oqsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2016&pages=661-668&author=S.-H.+I.+Ouauthor=J.+S.+Ahnauthor=L.+De+Petrisauthor=R.+Govindanauthor=J.+C.-H.+Yangauthor=B.+Hughesauthor=H.+Lenaauthor=D.+Moro-Sibilotauthor=A.+Bearzauthor=S.+V.+Ramirezauthor=T.+Mekhailauthor=A.+Spiraauthor=W.+Bordognaauthor=B.+Balasauthor=P.+N.+Morcosauthor=A.+Monnetauthor=A.+Zeaiterauthor=D.-W.+Kim&title=Alectinib+in+Crizotinib-refractory+ALK-rearranged+Non-small+Cell+Lung+Cancer%3A+a+Phase+II+Global+Study&doi=10.1200%2FJCO.2015.63.9443"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">Alectinib in crizotinib-refractory ALK-rearranged non-small-cell lung cancer: a phase II global study</span></div><div class="casAuthors">Ou, Sai-Hong Ignatius; Ahn, Jin Seok; De Petris, Luigi; Govindan, Ramaswamy; Yang, James Chih-Hsin; Hughes, Brett; Lena, Herve; Moro-Sibilot, Denis; Bearz, Alessandra; Ramirez, Santiago Viteri; Mekhail, Tarek; Spira, Alexander; Bordogna, Walter; Balas, Bogdana; Morcos, Peter N.; Monnet, Annabelle; Zeaiter, Ali; Kim, Dong-Wan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">661-668</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose Crizotinib confers improved progression-free survival compared with chemotherapy in anaplastic lymphoma kinase (ALK)-rearranged non-small-cell lung cancer (NSCLC), but progression invariably occurs.  We investigated the efficacy and safety of alectinib, a potent and selective ALK inhibitor with excellent CNS penetration, in patients with crizotinib-refractory ALK-pos. NSCLC.  Patients and Methods Alectinib 600 mg was administered orally twice daily.  The primary end point was objective response rate (ORR) by central independent review committee (IRC).  Results Of the 138 patients treated, 84 patients (61%) had CNS metastases at baseline, and 122 were response evaluable (RE) by IRC.  ORR by IRC was 50% (95% CI, 41% to 59%), and the median duration of response (DOR) was 11.2 mo (95% CI, 9.6 mo to not reached).  In 96 patients (79%) previously treated with chemotherapy, the ORR was 45% (95% CI, 35% to 55%).  Median IRC-assessed progression-free survival for all 138 patients was 8.9 mo (95% CI, 5.6 to 11.3 mo).  CNS disease control rate was 83% (95% CI, 74% to 91%), and the median CNS DOR was 10.3 mo (95% CI, 7.6 to 11.2 mo).  CNS ORR in 35 patients with baseline measurable CNS lesions was 57% (95% CI, 39% to 74%).  Of the 23 patients with baseline CNS metastases (measurable or nonmeasurable) and no prior radiation, 10 (43%) had a complete CNS response.  At 12 mo, the cumulative CNS progression rate (24.8%) was lower than the cumulative non-CNS progression rate (33.2%) for all patients.  Common adverse events were constipation (33%), fatigue (26%), and peripheral edema (25%); most were grade 1 to 2.  Conclusion Alectinib is highly active and well tolerated in patients with advanced, crizotinib-refractory ALK-pos. NSCLC, including those with CNS metastases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxXslEhXXl2bVg90H21EOLACvtfcHk0lgAfoOHCDznyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xpt1Oqsb8%253D&md5=d5ff375edc945f1a930564e3fb2a42aa</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1200%2FJCO.2015.63.9443&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2015.63.9443%26sid%3Dliteratum%253Aachs%26aulast%3DOu%26aufirst%3DS.-H.%2BI.%26aulast%3DAhn%26aufirst%3DJ.%2BS.%26aulast%3DDe%2BPetris%26aufirst%3DL.%26aulast%3DGovindan%26aufirst%3DR.%26aulast%3DYang%26aufirst%3DJ.%2BC.-H.%26aulast%3DHughes%26aufirst%3DB.%26aulast%3DLena%26aufirst%3DH.%26aulast%3DMoro-Sibilot%26aufirst%3DD.%26aulast%3DBearz%26aufirst%3DA.%26aulast%3DRamirez%26aufirst%3DS.%2BV.%26aulast%3DMekhail%26aufirst%3DT.%26aulast%3DSpira%26aufirst%3DA.%26aulast%3DBordogna%26aufirst%3DW.%26aulast%3DBalas%26aufirst%3DB.%26aulast%3DMorcos%26aufirst%3DP.%2BN.%26aulast%3DMonnet%26aufirst%3DA.%26aulast%3DZeaiter%26aufirst%3DA.%26aulast%3DKim%26aufirst%3DD.-W.%26atitle%3DAlectinib%2520in%2520Crizotinib-refractory%2520ALK-rearranged%2520Non-small%2520Cell%2520Lung%2520Cancer%253A%2520a%2520Phase%2520II%2520Global%2520Study%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2016%26volume%3D34%26spage%3D661%26epage%3D668%26doi%3D10.1200%2FJCO.2015.63.9443" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref100"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref100'); return false;" data-citation="" class="refNumLink">100</a></strong><div class="NLM_citation" id="cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, A. T</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gandhi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gadgeel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riely, G. J</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cetnar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">West, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camidge, D R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Socinski, M. A</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiappori, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mekhail, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chao, B. H</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borghaei, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gold, K. A</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeaiter, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bordogna, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balas, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puig, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henschel, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ou, S.-H. I.</span></span> <span> </span><span class="NLM_article-title">Alectinib in ALK-positive, Crizotinib-resistant, Non-small cell Lung Cancer: a Single-group, Multicentre, Phase 2 Trial</span>. <i>Lancet Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">234</span>– <span class="NLM_lpage">242</span>, <span class="refDoi"> DOI: 10.1016/S1470-2045(15)00488-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1016%2FS1470-2045%2815%2900488-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=26708155" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitVGrtLzL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2016&pages=234-242&author=A.+T+Shawauthor=L.+Gandhiauthor=S.+Gadgeelauthor=G.+J+Rielyauthor=J.+Cetnarauthor=H.+Westauthor=D+R.+Camidgeauthor=M.+A+Socinskiauthor=A.+Chiapporiauthor=T.+Mekhailauthor=B.+H+Chaoauthor=H.+Borghaeiauthor=K.+A+Goldauthor=A.+Zeaiterauthor=W.+Bordognaauthor=B.+Balasauthor=O.+Puigauthor=V.+Henschelauthor=S.-H.+I.+Ou&title=Alectinib+in+ALK-positive%2C+Crizotinib-resistant%2C+Non-small+cell+Lung+Cancer%3A+a+Single-group%2C+Multicentre%2C+Phase+2+Trial&doi=10.1016%2FS1470-2045%2815%2900488-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial</span></div><div class="casAuthors">Shaw, Alice T.; Gandhi, Leena; Gadgeel, Shirish; Riely, Gregory J.; Cetnar, Jeremy; West, Howard; Camidge, D. Ross; Socinski, Mark A.; Chiappori, Alberto; Mekhail, Tarek; Chao, Bo H.; Borghaei, Hossein; Gold, Kathryn A.; Zeaiter, Ali; Bordogna, Walter; Balas, Bogdana; Puig, Oscar; Henschel, Volkmar; Ou, Sai-Hong Ignatius</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">234-242</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Alectinib-a highly selective, CNS-active, ALK inhibitor-showed promising clin. activity in crizotinib-naive and crizotinib-resistant patients with ALK-rearranged (ALK-pos.) non-small-cell lung cancer (NSCLC).  We aimed to assess the safety and efficacy of alectinib in patients with ALK-pos. NSCLC who progressed on previous crizotinib.  We did a phase 2 study at 27 centers in the USA and Canada.  We enrolled patients aged 18 years or older with stage IIIB-IV, ALK-pos. NSCLC who had progressed after crizotinib.  Patients were treated with oral alectinib 600 mg twice daily until progression, death, or withdrawal.  The primary endpoint was the proportion of patients achieving an objective response by an independent review committee using Response Evaluation Criteria in Solid Tumors, version 1.1.  Response endpoints were assessed in the response-evaluable population (ie, patients with measurable disease at baseline who received at least one dose of study drug), and efficacy and safety analyses were done in the intention-to-treat population (all enrolled patients).  This study is registered with ClinicalTrials.gov, no. NCT01871805.  The study is ongoing and patients are still receiving treatment.  Between Sept 4, 2013, and Aug 4, 2014, 87 patients were enrolled into the study (intention-to-treat population).  At the time of the primary anal. (median follow-up 4·8 mo [IQR 3·3-7·1]), 33 of 69 patients with measurable disease at baseline had a confirmed partial response; thus, the proportion of patients achieving an objective response by the independent review committee was 48% (95% CI 36-60).  Adverse events were predominantly grade 1 or 2, most commonly constipation (31 [36%]), fatigue (29 [33%]), myalgia (21 [24%]), and peripheral edema (20 [23%]).  The most common grade 3 and 4 adverse events were changes in lab. values, including increased blood creatine phosphokinase (seven [8%]), increased alanine aminotransferase (five [6%]), and increased aspartate aminotransferase (four [5%]).  Two patients died: one had a hemorrhage (judged related to study treatment), and one had disease progression and a history of stroke (judged unrelated to treatment).  Alectinib showed clin. activity and was well tolerated in patients with ALK-pos. NSCLC who had progressed on crizotinib.  Therefore, alectinib could be a suitable treatment for patients with ALK-pos. disease who have progressed on crizotinib.F Hoffmann-La Roche.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoG8mULfydoWbVg90H21EOLACvtfcHk0lgAfoOHCDznyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitVGrtLzL&md5=5d1fb42c02d26aa8b99c29442a36e2ed</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2815%2900488-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252815%252900488-X%26sid%3Dliteratum%253Aachs%26aulast%3DShaw%26aufirst%3DA.%2BT%26aulast%3DGandhi%26aufirst%3DL.%26aulast%3DGadgeel%26aufirst%3DS.%26aulast%3DRiely%26aufirst%3DG.%2BJ%26aulast%3DCetnar%26aufirst%3DJ.%26aulast%3DWest%26aufirst%3DH.%26aulast%3DCamidge%26aufirst%3DD%2BR.%26aulast%3DSocinski%26aufirst%3DM.%2BA%26aulast%3DChiappori%26aufirst%3DA.%26aulast%3DMekhail%26aufirst%3DT.%26aulast%3DChao%26aufirst%3DB.%2BH%26aulast%3DBorghaei%26aufirst%3DH.%26aulast%3DGold%26aufirst%3DK.%2BA%26aulast%3DZeaiter%26aufirst%3DA.%26aulast%3DBordogna%26aufirst%3DW.%26aulast%3DBalas%26aufirst%3DB.%26aulast%3DPuig%26aufirst%3DO.%26aulast%3DHenschel%26aufirst%3DV.%26aulast%3DOu%26aufirst%3DS.-H.%2BI.%26atitle%3DAlectinib%2520in%2520ALK-positive%252C%2520Crizotinib-resistant%252C%2520Non-small%2520cell%2520Lung%2520Cancer%253A%2520a%2520Single-group%252C%2520Multicentre%252C%2520Phase%25202%2520Trial%26jtitle%3DLancet%2520Oncol.%26date%3D2016%26volume%3D17%26spage%3D234%26epage%3D242%26doi%3D10.1016%2FS1470-2045%2815%2900488-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref101"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref101'); return false;" data-citation="" class="refNumLink">101</a></strong><div class="NLM_citation" id="cit101"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hida, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nokihara, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kondo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Azuma, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takiguchi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishio, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshioka, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imamura, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hotta, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goto, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Satouchi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozuki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shukuya, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakagawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitsudomi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asakawa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asabe, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamura, T.</span></span> <span> </span><span class="NLM_article-title">Alectinib versus Crizotinib in Patients with ALK-positive Non-small-cell Lung Cancer (J-ALEX): an Open-label, Randomised Phase 3 trial</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>390</i></span>,  <span class="NLM_fpage">29</span>– <span class="NLM_lpage">39</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(17)30565-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1016%2FS0140-6736%2817%2930565-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=28501140" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC2sXns1yhsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=390&publication_year=2017&pages=29-39&author=T.+Hidaauthor=H.+Nokiharaauthor=M.+Kondoauthor=Y.+H.+Kimauthor=K.+Azumaauthor=T.+Setoauthor=Y.+Takiguchiauthor=M.+Nishioauthor=H.+Yoshiokaauthor=F.+Imamuraauthor=K.+Hottaauthor=S.+Watanabeauthor=K.+Gotoauthor=M.+Satouchiauthor=T.+Kozukiauthor=T.+Shukuyaauthor=K.+Nakagawaauthor=T.+Mitsudomiauthor=N.+Yamamotoauthor=T.+Asakawaauthor=R.+Asabeauthor=T.+Tanakaauthor=T.+Tamura&title=Alectinib+versus+Crizotinib+in+Patients+with+ALK-positive+Non-small-cell+Lung+Cancer+%28J-ALEX%29%3A+an+Open-label%2C+Randomised+Phase+3+trial&doi=10.1016%2FS0140-6736%2817%2930565-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial</span></div><div class="casAuthors">Hida, Toyoaki; Nokihara, Hiroshi; Kondo, Masashi; Kim, Young Hak; Azuma, Koichi; Seto, Takashi; Takiguchi, Yuichi; Nishio, Makoto; Yoshioka, Hiroshige; Imamura, Fumio; Hotta, Katsuyuki; Watanabe, Satoshi; Goto, Koichi; Satouchi, Miyako; Kozuki, Toshiyuki; Shukuya, Takehito; Nakagawa, Kazuhiko; Mitsudomi, Tetsuya; Yamamoto, Nobuyuki; Asakawa, Takashi; Asabe, Ryoichi; Tanaka, Tomohiro; Tamura, Tomohide</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">390</span>
        (<span class="NLM_cas:issue">10089</span>),
    <span class="NLM_cas:pages">29-39</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Alectinib, a potent, highly selective, CNS-active inhibitor of anaplastic lymphoma kinase (ALK), showed promising efficacy and tolerability in the single-arm phase 1/2 AF-001JP trial in Japanese patients with ALK-pos. non-small-cell lung cancer.  Given those promising results, we did a phase 3 trial to directly compare the efficacy and safety of alectinib and crizotinib.  J-ALEX was a randomized, open-label, phase 3 trial that recruited ALK inhibitor-naive Japanese patients with ALK-pos. non-small-cell lung cancer, who were chemotherapy-naive or had received one previous chemotherapy regimen, from 41 study sites in Japan.  Patients were randomly assigned (1:1) via an interactive web response system using a permuted-block method stratified by Eastern Cooperative Oncol. Group performance status, treatment line, and disease stage to receive oral alectinib 300 mg twice daily or crizotinib 250 mg twice daily until progressive disease, unacceptable toxicity, death, or withdrawal.  The primary endpoint was progression-free survival assessed by an independent review facility.  The efficacy anal. was done in the intention-to-treat population, and safety analyses were done in all patients who received at least one dose of the study drug.  The study is ongoing and patient recruitment is closed.  This study is registered with the Japan Pharmaceutical Information Center (no. JapicCTI-132316).  Between Nov 18, 2013, and Aug 4, 2015, 207 patients were recruited and assigned to the alectinib (n=103) or crizotinib (n=104) groups.  At data cutoff for the second interim anal., 24 patients in the alectinib group had discontinued treatment compared with 61 in the crizotinib group, mostly due to lack of efficacy or adverse events.  At the second interim anal. (data cutoff date Dec 3, 2015), an independent data monitoring committee detd. that the primary endpoint of the study had been met (hazard ratio 0·34 [99·7% CI 0·17-0·71], stratified log-rank p<0·0001) and recommended an immediate release of the data.  Median progression-free survival had not yet been reached with alectinib (95% CI 20·3-not estd.) and was 10·2 mo (8·2-12·0) with crizotinib.  Grade 3 or 4 adverse events occurred at a greater frequency with crizotinib (54 [52%] of 104) than alectinib (27 [26%] of 103).  Dose interruptions due to adverse events were also more prevalent with crizotinib (77 [74%] of 104) than with alectinib (30 [29%] of 103), and more patients receiving crizotinib (21 [20%]) than alectinib (nine [9%]) discontinued the study drug because of an adverse event.  No adverse events with a fatal outcome occurred in either treatment group.  These results provide the first head-to-head comparison of alectinib and crizotinib and have the potential to change the std. of care for the first-line treatment of ALK-pos. non-small-cell lung cancer.  The dose of alectinib (300 mg twice daily) used in this study is lower than the approved dose in countries other than Japan; however, this limitation is being addressed in the ongoing ALEX study.Chugai Pharmaceutical Co, Ltd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoyh_vdatHGGrVg90H21EOLACvtfcHk0lgAfoOHCDznyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXns1yhsb8%253D&md5=aabae96d2acd1e4f9e4a5a1041fe04c6</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2817%2930565-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252817%252930565-2%26sid%3Dliteratum%253Aachs%26aulast%3DHida%26aufirst%3DT.%26aulast%3DNokihara%26aufirst%3DH.%26aulast%3DKondo%26aufirst%3DM.%26aulast%3DKim%26aufirst%3DY.%2BH.%26aulast%3DAzuma%26aufirst%3DK.%26aulast%3DSeto%26aufirst%3DT.%26aulast%3DTakiguchi%26aufirst%3DY.%26aulast%3DNishio%26aufirst%3DM.%26aulast%3DYoshioka%26aufirst%3DH.%26aulast%3DImamura%26aufirst%3DF.%26aulast%3DHotta%26aufirst%3DK.%26aulast%3DWatanabe%26aufirst%3DS.%26aulast%3DGoto%26aufirst%3DK.%26aulast%3DSatouchi%26aufirst%3DM.%26aulast%3DKozuki%26aufirst%3DT.%26aulast%3DShukuya%26aufirst%3DT.%26aulast%3DNakagawa%26aufirst%3DK.%26aulast%3DMitsudomi%26aufirst%3DT.%26aulast%3DYamamoto%26aufirst%3DN.%26aulast%3DAsakawa%26aufirst%3DT.%26aulast%3DAsabe%26aufirst%3DR.%26aulast%3DTanaka%26aufirst%3DT.%26aulast%3DTamura%26aufirst%3DT.%26atitle%3DAlectinib%2520versus%2520Crizotinib%2520in%2520Patients%2520with%2520ALK-positive%2520Non-small-cell%2520Lung%2520Cancer%2520%2528J-ALEX%2529%253A%2520an%2520Open-label%252C%2520Randomised%2520Phase%25203%2520trial%26jtitle%3DLancet%26date%3D2017%26volume%3D390%26spage%3D29%26epage%3D39%26doi%3D10.1016%2FS0140-6736%2817%2930565-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref102"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref102'); return false;" data-citation="" class="refNumLink">102</a></strong><div class="NLM_citation" id="cit102"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J. C.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ou, S.-H. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Petris, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gadgeel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gandhi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barlesi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Govindan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dingemans, A.-M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crino, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lena, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Popat, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dansin, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golding, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bordogna, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balas, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morcos, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeaiter, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, A. T.</span></span> <span> </span><span class="NLM_article-title">Pooled Systemic Efficacy and Safety Data from the Pivotal Phase II Studies (NP28673 and NP28761) of Alectinib in ALK-positive Non-small Cell Lung Cancer</span>. <i>J. Thorac. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">1552</span>– <span class="NLM_lpage">1560</span>, <span class="refDoi"> DOI: 10.1016/j.jtho.2017.06.070</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1016%2Fj.jtho.2017.06.070" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=28689043" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A280%3ADC%252BC1cjlslSnug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2017&pages=1552-1560&author=J.+C.-H.+Yangauthor=S.-H.+I.+Ouauthor=L.+De+Petrisauthor=S.+Gadgeelauthor=L.+Gandhiauthor=D.-W.+Kimauthor=F.+Barlesiauthor=R.+Govindanauthor=A.-M.+C.+Dingemansauthor=L.+Crinoauthor=H.+Lenaauthor=S.+Popatauthor=J.+S.+Ahnauthor=E.+Dansinauthor=S.+Goldingauthor=W.+Bordognaauthor=B.+Balasauthor=P.+N.+Morcosauthor=A.+Zeaiterauthor=A.+T.+Shaw&title=Pooled+Systemic+Efficacy+and+Safety+Data+from+the+Pivotal+Phase+II+Studies+%28NP28673+and+NP28761%29+of+Alectinib+in+ALK-positive+Non-small+Cell+Lung+Cancer&doi=10.1016%2Fj.jtho.2017.06.070"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit102R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">Pooled Systemic Efficacy and Safety Data from the Pivotal Phase II Studies (NP28673 and NP28761) of Alectinib in ALK-positive Non-Small Cell Lung Cancer</span></div><div class="casAuthors">Yang James Chih-Hsin; Ou Sai-Hong Ignatius; De Petris Luigi; Gadgeel Shirish; Gandhi Leena; Kim Dong-Wan; Barlesi Fabrice; Govindan Ramaswamy; Dingemans Anne-Marie C; Crino Lucio; Lena Herve; Popat Sanjay; Ahn Jin Seok; Dansin Eric; Golding Sophie; Bordogna Walter; Balas Bogdana; Zeaiter Ali; Morcos Peter N; Shaw Alice T</div><div class="citationInfo"><span class="NLM_cas:title">Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1552-1560</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">INTRODUCTION:  Alectinib demonstrated clinical efficacy and an acceptable safety profile in two phase II studies (NP28761 and NP28673).  Here we report the pooled efficacy and safety data after 15 and 18 months more follow-up than in the respective primary analyses.  METHODS:  Enrolled patients had ALK receptor tyrosine kinase gene (ALK)-positive NSCLC and had progressed while taking, or could not tolerate, crizotinib.  Patients received oral alectinib, 600 mg twice daily.  The primary end point in both studies was objective response rate assessed by an independent review committee (IRC) using the Response Evaluation Criteria in Solid Tumors, version 1.1.  Secondary end points included disease control rate, duration of response, progression-free survival, overall survival, and safety.  RESULTS:  The pooled data set included 225 patients (n = 138 in NP28673 and n = 87 in NP28761).  The response-evaluable population included 189 patients (84% [n = 122 in NP28673 and n = 67 in NP28761]).  In the response-evaluable population, objective response rate as assessed by the IRC was 51.3% (95% confidence interval [CI]: 44.0-58.6 [all PRs]), the disease control rate was 78.8% (95% CI: 72.3-84.4), and the median duration of response was 14.9 months (95% CI: 11.1-20.4) after 58% of events.  Median progression-free survival as assessed by the IRC was 8.3 months (95% CI: 7.0-11.3) and median overall survival was 26.0 months (95% CI: 21.4-not estimable).  Grade 3 or higher adverse events (AEs) occurred in 40% of patients, 6% of patients had treatment withdrawn on account of AEs, and 33% had AEs leading to dose interruptions/modification.  CONCLUSIONS:  This pooled data analysis confirmed the robust systemic efficacy of alectinib in ALK-positive NSCLC with a durable response rate.  Alectinib also had an acceptable safety profile with a longer duration of follow-up.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSKYNXogQ0TxJHZzFRCXxVKfW6udTcc2eYihFS8fS_M3Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cjlslSnug%253D%253D&md5=6e811162d59e5c66ce21ceef64479b02</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1016%2Fj.jtho.2017.06.070&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jtho.2017.06.070%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DJ.%2BC.-H.%26aulast%3DOu%26aufirst%3DS.-H.%2BI.%26aulast%3DDe%2BPetris%26aufirst%3DL.%26aulast%3DGadgeel%26aufirst%3DS.%26aulast%3DGandhi%26aufirst%3DL.%26aulast%3DKim%26aufirst%3DD.-W.%26aulast%3DBarlesi%26aufirst%3DF.%26aulast%3DGovindan%26aufirst%3DR.%26aulast%3DDingemans%26aufirst%3DA.-M.%2BC.%26aulast%3DCrino%26aufirst%3DL.%26aulast%3DLena%26aufirst%3DH.%26aulast%3DPopat%26aufirst%3DS.%26aulast%3DAhn%26aufirst%3DJ.%2BS.%26aulast%3DDansin%26aufirst%3DE.%26aulast%3DGolding%26aufirst%3DS.%26aulast%3DBordogna%26aufirst%3DW.%26aulast%3DBalas%26aufirst%3DB.%26aulast%3DMorcos%26aufirst%3DP.%2BN.%26aulast%3DZeaiter%26aufirst%3DA.%26aulast%3DShaw%26aufirst%3DA.%2BT.%26atitle%3DPooled%2520Systemic%2520Efficacy%2520and%2520Safety%2520Data%2520from%2520the%2520Pivotal%2520Phase%2520II%2520Studies%2520%2528NP28673%2520and%2520NP28761%2529%2520of%2520Alectinib%2520in%2520ALK-positive%2520Non-small%2520Cell%2520Lung%2520Cancer%26jtitle%3DJ.%2520Thorac.%2520Oncol.%26date%3D2017%26volume%3D12%26spage%3D1552%26epage%3D1560%26doi%3D10.1016%2Fj.jtho.2017.06.070" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref103"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref103'); return false;" data-citation="" class="refNumLink">103</a></strong><div class="NLM_citation" id="cit103"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riely, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, A. T.</span></span> <span> </span><span class="NLM_article-title">Targeting ALK: Precision Medicine Takes on Drug Resistance</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">137</span>– <span class="NLM_lpage">155</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-16-1123</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1158%2F2159-8290.CD-16-1123" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=28122866" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC2sXitVCjs7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&pages=137-155&author=J.+J.+Linauthor=G.+J.+Rielyauthor=A.+T.+Shaw&title=Targeting+ALK%3A+Precision+Medicine+Takes+on+Drug+Resistance&doi=10.1158%2F2159-8290.CD-16-1123"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting ALK: Precision Medicine Takes on Drug Resistance</span></div><div class="casAuthors">Lin, Jessica J.; Riely, Gregory J.; Shaw, Alice T.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">137-155</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Anaplastic lymphoma kinase (ALK) is a validated mol. target in several ALK-rearranged malignancies, including non-small cell lung cancer.  However, the clin. benefit of targeting ALK using tyrosine kinase inhibitors (TKI) is almost universally limited by the emergence of drug resistance.  Diverse mechanisms of resistance to ALK TKIs have now been discovered, and these basic mechanisms are informing the development of novel therapeutic strategies to overcome resistance in the clinic.  In this review, we summarize the current successes and challenges of targeting ALK.  Significance: Effective long-term treatment of ALK-rearranged cancers requires a mechanistic understanding of resistance to ALK TKIs so that rational therapies can be selected to combat resistance.  This review underscores the importance of serial biopsies in capturing the dynamic therapeutic vulnerabilities within a patient's tumor and offers a perspective into the complexity of on-target and off-target ALK TKI resistance mechanisms.  Therapeutic strategies that can successfully overcome, and potentially prevent, these resistance mechanisms will have the greatest impact on patient outcome.  Cancer Discov; 7(2); 137-55. ©2017 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLmMz7s4fYu7Vg90H21EOLACvtfcHk0ljvJMfdYluT_w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXitVCjs7c%253D&md5=6f7d5358d13c75b215b0d1e6ce8ac8ff</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-16-1123&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-16-1123%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DJ.%2BJ.%26aulast%3DRiely%26aufirst%3DG.%2BJ.%26aulast%3DShaw%26aufirst%3DA.%2BT.%26atitle%3DTargeting%2520ALK%253A%2520Precision%2520Medicine%2520Takes%2520on%2520Drug%2520Resistance%26jtitle%3DCancer%2520Discovery%26date%3D2017%26volume%3D7%26spage%3D137%26epage%3D155%26doi%3D10.1158%2F2159-8290.CD-16-1123" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref104"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref104'); return false;" data-citation="" class="refNumLink">104</a></strong><div class="NLM_citation" id="cit104"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Qian, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liebman, M.</span></span> <span> </span><span class="NLM_article-title">Drug Resistance in ALK-positive Non-small Cell Lung Cancer Patients</span>. <i>Semin. Cell Dev. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">150</span>– <span class="NLM_lpage">157</span>, <span class="refDoi"> DOI: 10.1016/j.semcdb.2016.09.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1016%2Fj.semcdb.2016.09.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=27693505" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhs1Cgu7%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2017&pages=150-157&author=M.+Qianauthor=B.+Zhuauthor=X.+Wangauthor=M.+Liebman&title=Drug+Resistance+in+ALK-positive+Non-small+Cell+Lung+Cancer+Patients&doi=10.1016%2Fj.semcdb.2016.09.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit104R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">Drug resistance in ALK-positive Non-small cell lung cancer patients</span></div><div class="casAuthors">Qian, Mengjia; Zhu, Bijun; Wang, Xiangdong; Liebman, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Seminars in Cell & Developmental Biology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">150-157</span>CODEN:
                <span class="NLM_cas:coden">SCDBFX</span>;
        ISSN:<span class="NLM_cas:issn">1084-9521</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Patients are diagnosed as anaplastic lymphoma kinase (ALK) pos., i.e. exhibiting the ALK rearrangement, and comprise 3-7% of non-small-cell lung cancer (NSCLC) cases.  Three generations of ALK inhibitors have been developed and used in targeted therapy, although there are still improving spaces of drug resistance at the initiation of each treatment.  The current review discusses the pathophysiol. of ALK-pos. NSCLC and the role of three generations of ALK target inhibitors including crizotinib, ceritinib, alectinib and lorlatinib, as well as the mechanisms of the secondary resistance.  We mainly focused on the point mutations that are the most important resistance-producing mechanism and most common form caused by each inhibitor.  In addn., we examine the three-dimensional structure of ALK to understand the functional impact of these mutations and analyze the underlying mol. mechanisms of the resistance to each generation of ALK inhibitor to benefit the selection decision of the most rational therapy and improve therapeutic effects to the disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOXTnzPNyv8rVg90H21EOLACvtfcHk0lhXqdx4Oya0Ig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhs1Cgu7%252FN&md5=6e8f364568b5fa51ea521b30a2d654f6</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1016%2Fj.semcdb.2016.09.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.semcdb.2016.09.016%26sid%3Dliteratum%253Aachs%26aulast%3DQian%26aufirst%3DM.%26aulast%3DZhu%26aufirst%3DB.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DLiebman%26aufirst%3DM.%26atitle%3DDrug%2520Resistance%2520in%2520ALK-positive%2520Non-small%2520Cell%2520Lung%2520Cancer%2520Patients%26jtitle%3DSemin.%2520Cell%2520Dev.%2520Biol.%26date%3D2017%26volume%3D64%26spage%3D150%26epage%3D157%26doi%3D10.1016%2Fj.semcdb.2016.09.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref105"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref105'); return false;" data-citation="" class="refNumLink">105</a></strong><div class="NLM_citation" id="cit105"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tiseo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, M.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reckamp, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansen, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huber, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">West, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groen, H. J.M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hochmair, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leighl, N. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gettinger, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langer, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paz-Ares Rodriguez, L. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smit, E. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reichmann, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haluska, F. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kerstein, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camidge, D. R.</span></span> <span> </span><span class="NLM_article-title">Brigatinib in Patients with Crizotinib-refractory Anaplastic Lymphoma Kinase-positive Non-small-cell Lung Cancer: a Randomized, Multicenter Phase II Trial</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">2490</span>– <span class="NLM_lpage">2498</span>, <span class="refDoi"> DOI: 10.1200/JCO.2016.71.5904</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1200%2FJCO.2016.71.5904" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=28475456" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitVSqsbfK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2017&pages=2490-2498&author=D.-W.+Kimauthor=M.+Tiseoauthor=M.-J.+Ahnauthor=K.+L.+Reckampauthor=K.+H.+Hansenauthor=S.-W.+Kimauthor=R.+M.+Huberauthor=H.+L.+Westauthor=H.+J.M.+Groenauthor=M.+J.+Hochmairauthor=N.+B.+Leighlauthor=S.+N.+Gettingerauthor=C.+J.+Langerauthor=L.+G.+Paz-Ares+Rodriguezauthor=E.+F.+Smitauthor=E.+S.+Kimauthor=W.+Reichmannauthor=F.+G.+Haluskaauthor=D.+Kersteinauthor=D.+R.+Camidge&title=Brigatinib+in+Patients+with+Crizotinib-refractory+Anaplastic+Lymphoma+Kinase-positive+Non-small-cell+Lung+Cancer%3A+a+Randomized%2C+Multicenter+Phase+II+Trial&doi=10.1200%2FJCO.2016.71.5904"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit105R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">Brigatinib in patients with crizotinib-refractory anaplastic lymphoma kinase-positive non-small-cell lung cancer: a randomized, multicenter phase II trial</span></div><div class="casAuthors">Kim, Dong-Wan; Tiseo, Marcello; Ahn, Myung-Ju; Reckamp, Karen L.; Hansen, Karin Holmskov; Kim, Sang-We; Huber, Rudolf M.; West, Howard L.; Groen, Harry J. M.; Hochmair, Maximilian J.; Leighl, Natasha B.; Gettinger, Scott N.; Langer, Corey J.; Rodr'iguez, Luis G. Paz-Ares; Smit, Egbert F.; Kim, Edward S.; Reichmann, William; Haluska, Frank G.; Kerstein, David; Camidge, D. Ross</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">2490-2500</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">1527-7755</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: Most crizotinib-treated patients with anaplastic lymphoma kinase gene (ALK)-rearranged non-smallcell lung cancer (ALK-pos. NSCLC) eventually experience disease progression.  We evaluated two regimens of brigatinib, an investigational next-generation ALK inhibitor, in crizotinib-refractory ALK-pos. NSCLC.  Patients and Methods Patients were stratified by brain metastases and best response to crizotinib.  They were randomly assigned (1:1) to oral brigatinib 90 mg once daily (arm A) or 180 mg once daily with a 7-day lead-in at 90 mg (180 mg once daily [with lead-in]; arm B).  Investigator-assessed confirmed objective response rate (ORR) was the primary end point.  Results Of 222 patients enrolled (arm A: n = 112, 109 treated; arm B: n = 110, 110 treated), 154 (69%) had baseline brain metastases and 164 of 222 (74%) had received prior chemotherapy.  With 8.0-mo median follow-up, investigator-assessed confirmed ORR was 45% (97.5% CI, 34% to 56%) in arm A and 54% (97.5% CI, 43% to 65%) in arm B.  Investigator-assessed median progression-free survival was 9.2 mo (95% CI, 7.4 to 15.6) and 12.9 mo (95% CI, 11.1 to not reached) in arms A and B, resp.  Independent review committee-assessed intracranial ORR in patients with measurable brain metastases at baseline was 42% (11 of 26 patients) in arm A and 67% (12 of 18 patients) in arm B.  Common treatment-emergent adverse events were nausea (arm A/B, 33%/ 40%), diarrhea (arm A/B, 19%/38%), headache (arm A/B, 28%/27%), and cough (arm A/B, 18%/ 34%), and were mainly grades 1 to 2.  A subset of pulmonary adverse events with early onset (median onset: day 2) occurred in 14 of 219 treated patients (all grades, 6%; grade $ 3, 3%); none occurred after escalation to 180 mg in arm B.  Seven of 14 patients were successfully retreated with brigatinib.  Conclusion Brigatinib yielded substantial whole-body and intracranial responses as well as robust progressionfree survival; 180 mg (with lead-in) showed consistently better efficacy than 90 mg, with acceptable safety.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4RtdJwkNkyLVg90H21EOLACvtfcHk0lhXqdx4Oya0Ig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitVSqsbfK&md5=efe68d35d297c3d9e70023f887c23a2c</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1200%2FJCO.2016.71.5904&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2016.71.5904%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DD.-W.%26aulast%3DTiseo%26aufirst%3DM.%26aulast%3DAhn%26aufirst%3DM.-J.%26aulast%3DReckamp%26aufirst%3DK.%2BL.%26aulast%3DHansen%26aufirst%3DK.%2BH.%26aulast%3DKim%26aufirst%3DS.-W.%26aulast%3DHuber%26aufirst%3DR.%2BM.%26aulast%3DWest%26aufirst%3DH.%2BL.%26aulast%3DGroen%26aufirst%3DH.%2BJ.M.%26aulast%3DHochmair%26aufirst%3DM.%2BJ.%26aulast%3DLeighl%26aufirst%3DN.%2BB.%26aulast%3DGettinger%26aufirst%3DS.%2BN.%26aulast%3DLanger%26aufirst%3DC.%2BJ.%26aulast%3DPaz-Ares%2BRodriguez%26aufirst%3DL.%2BG.%26aulast%3DSmit%26aufirst%3DE.%2BF.%26aulast%3DKim%26aufirst%3DE.%2BS.%26aulast%3DReichmann%26aufirst%3DW.%26aulast%3DHaluska%26aufirst%3DF.%2BG.%26aulast%3DKerstein%26aufirst%3DD.%26aulast%3DCamidge%26aufirst%3DD.%2BR.%26atitle%3DBrigatinib%2520in%2520Patients%2520with%2520Crizotinib-refractory%2520Anaplastic%2520Lymphoma%2520Kinase-positive%2520Non-small-cell%2520Lung%2520Cancer%253A%2520a%2520Randomized%252C%2520Multicenter%2520Phase%2520II%2520Trial%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2017%26volume%3D35%26spage%3D2490%26epage%3D2498%26doi%3D10.1200%2FJCO.2016.71.5904" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref106"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref106'); return false;" data-citation="" class="refNumLink">106</a></strong><div class="NLM_citation" id="cit106"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Markham, A.</span></span> <span> </span><span class="NLM_article-title">Brigatinib: First Global Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>77</i></span>,  <span class="NLM_fpage">1131</span>– <span class="NLM_lpage">1135</span>, <span class="refDoi"> DOI: 10.1007/s40265-017-0776-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1007%2Fs40265-017-0776-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=28597393" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtVOjsrzL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2017&pages=1131-1135&author=A.+Markham&title=Brigatinib%3A+First+Global+Approval&doi=10.1007%2Fs40265-017-0776-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">Brigatinib: First Global Approval</span></div><div class="casAuthors">Markham, Anthony</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1131-1135</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Brigatinib (ALUNBRIG) is a small mol. antineoplastic anaplastic lymphoma kinase (ALK) inhibitor being developed by ARIAD Pharmaceuticals (a wholly-owned subsidiary of Takeda Pharmaceutical Company).  In Apr. 2017 brigatinib received accelerated approval in the USA for the treatment of patients with ALK-pos. metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib.  The development of resistance to crizotinib is a therapeutic challenge that has led to the development of second-generation ALK-inhibitors such as brigatinib, which have activity against treatment-resistant ALK mutants.  This article summarizes the milestones in the development of brigatinib leading to this first global approval for the treatment of patients with ALK-pos. metastatic NSCLC who have progressed on or are intolerant to crizotinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmmCYwTukZCLVg90H21EOLACvtfcHk0lhXqdx4Oya0Ig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtVOjsrzL&md5=c03f9d61e8e8fd4187d47ee207452f31</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1007%2Fs40265-017-0776-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-017-0776-3%26sid%3Dliteratum%253Aachs%26aulast%3DMarkham%26aufirst%3DA.%26atitle%3DBrigatinib%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2017%26volume%3D77%26spage%3D1131%26epage%3D1135%26doi%3D10.1007%2Fs40265-017-0776-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref107"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref107'); return false;" data-citation="" class="refNumLink">107</a></strong><div class="NLM_citation" id="cit107"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Friboulet, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katayama, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gainor, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crystal, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michellys, P.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Awad, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yanagitani, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pferdekamper, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kasibhatla, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hua, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNamara, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahmood, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lockerman, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujita, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishio, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engelman, J. A.</span></span> <span> </span><span class="NLM_article-title">The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non–small Cell Lung Cancer</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">662</span>– <span class="NLM_lpage">673</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-13-0846</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1158%2F2159-8290.CD-13-0846" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=24675041" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC2cXpsVGgs78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2014&pages=662-673&author=L.+Fribouletauthor=N.+Liauthor=R.+Katayamaauthor=C.+C.+Leeauthor=J.+F.+Gainorauthor=A.+S.+Crystalauthor=P.-Y.+Michellysauthor=M.+M.+Awadauthor=N.+Yanagitaniauthor=S.+Kimauthor=A.+C.+Pferdekamperauthor=J.+Liauthor=S.+Kasibhatlaauthor=F.+Sunauthor=X.+Sunauthor=S.+Huaauthor=P.+McNamaraauthor=S.+Mahmoodauthor=E.+L.+Lockermanauthor=N.+Fujitaauthor=M.+Nishioauthor=J.+L.+Harrisauthor=A.+T.+Shawauthor=J.+A.+Engelman&title=The+ALK+Inhibitor+Ceritinib+Overcomes+Crizotinib+Resistance+in+Non%E2%80%93small+Cell+Lung+Cancer&doi=10.1158%2F2159-8290.CD-13-0846"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit107R"><div class="casContent"><span class="casTitleNuber">107</span><div class="casTitle"><span class="NLM_cas:atitle">The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non-Small Cell Lung Cancer</span></div><div class="casAuthors">Friboulet, Luc; Li, Nanxin; Katayama, Ryohei; Lee, Christian C.; Gainor, Justin F.; Crystal, Adam S.; Michellys, Pierre-Yves; Awad, Mark M.; Yanagitani, Noriko; Kim, Sungjoon; Pferdekamper, AnneMarie C.; Li, Jie; Kasibhatla, Shailaja; Sun, Frank; Sun, Xiuying; Hua, Su; McNamara, Peter; Mahmood, Sidra; Lockerman, Elizabeth L.; Fujita, Naoya; Nishio, Makoto; Harris, Jennifer L.; Shaw, Alice T.; Engelman, Jeffrey A.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">662-673</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Non-small cell lung cancers (NSCLC) harboring anaplastic lymphoma kinase (ALK) gene rearrangements invariably develop resistance to the ALK tyrosine kinase inhibitor (TKI) crizotinib.  Herein, we report the first preclin. evaluation of the next-generation ALK TKI, ceritinib (LDKB78), in the setting of crizotinib resistance.  An interrogation of in vitro and in vivo models of acquired resistance to crizotinib, including cell lines established from biopsies of patients with crizotinib-resistant NSCLC, revealed that ceritinib potently overcomes crizotinib-resistant mutations.  In particular, ceritinib effectively inhibits ALK harboring L1196M, G1269A, 11171T1 and S1206Y mutations, and a cocrystal structure of ceritinib bound to ALK provides structural bases for this increased potency.  However, we obsd. that ceritinib did not overcome two crizotinib-resistant ALK mutations, G1202R and F1174C, and one of these mutations was identified in 5 of 11 biopsies from patients with acquired resistance to ceritinib.  Altogether, our results demonstrate that ceritinib can overcome crizotinib resistance, consistent with clin. data showing marked efficacy of ceritinib in patients with crizotinib-resistant disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrRf8PgZpJ60bVg90H21EOLACvtfcHk0ljizYIfg0SB7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXpsVGgs78%253D&md5=f60c45d0debfa6e86ff10c758c95da8d</span></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-13-0846&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-13-0846%26sid%3Dliteratum%253Aachs%26aulast%3DFriboulet%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DN.%26aulast%3DKatayama%26aufirst%3DR.%26aulast%3DLee%26aufirst%3DC.%2BC.%26aulast%3DGainor%26aufirst%3DJ.%2BF.%26aulast%3DCrystal%26aufirst%3DA.%2BS.%26aulast%3DMichellys%26aufirst%3DP.-Y.%26aulast%3DAwad%26aufirst%3DM.%2BM.%26aulast%3DYanagitani%26aufirst%3DN.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DPferdekamper%26aufirst%3DA.%2BC.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DKasibhatla%26aufirst%3DS.%26aulast%3DSun%26aufirst%3DF.%26aulast%3DSun%26aufirst%3DX.%26aulast%3DHua%26aufirst%3DS.%26aulast%3DMcNamara%26aufirst%3DP.%26aulast%3DMahmood%26aufirst%3DS.%26aulast%3DLockerman%26aufirst%3DE.%2BL.%26aulast%3DFujita%26aufirst%3DN.%26aulast%3DNishio%26aufirst%3DM.%26aulast%3DHarris%26aufirst%3DJ.%2BL.%26aulast%3DShaw%26aufirst%3DA.%2BT.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26atitle%3DThe%2520ALK%2520Inhibitor%2520Ceritinib%2520Overcomes%2520Crizotinib%2520Resistance%2520in%2520Non%25E2%2580%2593small%2520Cell%2520Lung%2520Cancer%26jtitle%3DCancer%2520Discovery%26date%3D2014%26volume%3D4%26spage%3D662%26epage%3D673%26doi%3D10.1158%2F2159-8290.CD-13-0846" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref108"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref108'); return false;" data-citation="" class="refNumLink">108</a></strong><div class="NLM_citation" id="cit108"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, C.</span></span> <span> </span><span class="NLM_article-title">Ceritinib (LDK378): A Potent Alternative to Crizotinib for ALK-rearranged Non–small-cell Lung Cancer</span>. <i>Clin. Lung Cancer</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">86</span>– <span class="NLM_lpage">91</span>, <span class="refDoi"> DOI: 10.1016/j.cllc.2014.09.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1016%2Fj.cllc.2014.09.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=25458559" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVGksrzE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2015&pages=86-91&author=S.+Liauthor=X.+Qiauthor=Y.+Huangauthor=D.+Liuauthor=F.+Zhouauthor=C.+Zhou&title=Ceritinib+%28LDK378%29%3A+A+Potent+Alternative+to+Crizotinib+for+ALK-rearranged+Non%E2%80%93small-cell+Lung+Cancer&doi=10.1016%2Fj.cllc.2014.09.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit108R"><div class="casContent"><span class="casTitleNuber">108</span><div class="casTitle"><span class="NLM_cas:atitle">Ceritinib (LDK378): A Potent Alternative to Crizotinib for ALK-Rearranged Non-Small-Cell Lung Cancer</span></div><div class="casAuthors">Li, Sen; Qi, Xiaolong; Huang, Yufeng; Liu, Dingfeng; Zhou, Fangyu; Zhou, Caicun</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Lung Cancer</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">86-91</span>CODEN:
                <span class="NLM_cas:coden">CLCLCA</span>;
        ISSN:<span class="NLM_cas:issn">1525-7304</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  The success in identifying the chromosomal rearrangements involving the anaplastic lymphoma kinase (ALK) as an oncogenic driver has thoroughly changed the treatment of non-small-cell lung cancer.  In the past decade, targeted drugs have emerged as an efficient personalized strategy for ALK-rearranged non-small-cell lung cancer.  The accelerated approval of potent ALK inhibitors, such as crizotinib and more recently ceritinib (LDK378), based on the well designed phase I/II trials has been a landmark success in clin. cancer research and contributes a new era of oncogenic targeted therapy characterized by elegant clin. trial design.  In this review, the authors aim to present the current knowledge on acquired resistance of crizotinib known as a first-in-class ALK inhibitor and potential solns. to improve the cost-effectiveness, and to review the difference between ceritinib and crizotinib; preclin. data and results of the elegant early clin. trial of ceritinib which promoted its accelerated approval, pharmacokinetics, safety profile, and tolerability, the updated results (eg, efficacy on brain metastases), and robust design of ongoing phase II/III trials, and future directions of ceritinib to be a potent alternative to crizotinib for ALK-rearranged non-small-cell lung cancer are also presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGorcQKb4SrB8bVg90H21EOLACvtfcHk0ljizYIfg0SB7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVGksrzE&md5=aa7cc0221ecea1ce5dc9bb3b87a77c67</span></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1016%2Fj.cllc.2014.09.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cllc.2014.09.011%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DS.%26aulast%3DQi%26aufirst%3DX.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DD.%26aulast%3DZhou%26aufirst%3DF.%26aulast%3DZhou%26aufirst%3DC.%26atitle%3DCeritinib%2520%2528LDK378%2529%253A%2520A%2520Potent%2520Alternative%2520to%2520Crizotinib%2520for%2520ALK-rearranged%2520Non%25E2%2580%2593small-cell%2520Lung%2520Cancer%26jtitle%3DClin.%2520Lung%2520Cancer%26date%3D2015%26volume%3D16%26spage%3D86%26epage%3D91%26doi%3D10.1016%2Fj.cllc.2014.09.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref109"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref109'); return false;" data-citation="" class="refNumLink">109</a></strong><div class="NLM_citation" id="cit109"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gainor, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dardaei, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friboulet, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leshchiner, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katayama, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dagogo-Jack, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gadgeel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schultz, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chin, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parks, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiCecca, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lockerman, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huynh, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Logan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ritterhouse, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le, L. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muniappan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Digumarthy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Channick, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keyes, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Getz, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dias-Santagata, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heist, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lennerz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sequist, L. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benes, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iafrate, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mino-Kenudson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engelman, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, A. T.</span></span> <span> </span><span class="NLM_article-title">Molecular Mechanisms of Resistance to First-and Second-generation ALK Inhibitors in ALK-rearranged Lung Cancer</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">1118</span>– <span class="NLM_lpage">1133</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-16-0596</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1158%2F2159-8290.CD-16-0596" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=27432227" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhs1OhurrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2016&pages=1118-1133&author=J.+F.+Gainorauthor=L.+Dardaeiauthor=S.+Yodaauthor=L.+Fribouletauthor=I.+Leshchinerauthor=R.+Katayamaauthor=I.+Dagogo-Jackauthor=S.+Gadgeelauthor=K.+Schultzauthor=M.+Singhauthor=E.+Chinauthor=M.+Parksauthor=D.+Leeauthor=R.+H.+DiCeccaauthor=E.+Lockermanauthor=T.+Huynhauthor=J.+Loganauthor=L.+L.+Ritterhouseauthor=L.+P.+Leauthor=A.+Muniappanauthor=S.+Digumarthyauthor=C.+Channickauthor=C.+Keyesauthor=G.+Getzauthor=D.+Dias-Santagataauthor=R.+S.+Heistauthor=J.+Lennerzauthor=L.+V.+Sequistauthor=C.+H.+Benesauthor=A.+J.+Iafrateauthor=M.+Mino-Kenudsonauthor=J.+A.+Engelmanauthor=A.+T.+Shaw&title=Molecular+Mechanisms+of+Resistance+to+First-and+Second-generation+ALK+Inhibitors+in+ALK-rearranged+Lung+Cancer&doi=10.1158%2F2159-8290.CD-16-0596"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit109R"><div class="casContent"><span class="casTitleNuber">109</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer</span></div><div class="casAuthors">Gainor, Justin F.; Dardaei, Leila; Yoda, Satoshi; Friboulet, Luc; Leshchiner, Ignaty; Katayama, Ryohei; Dagogo-Jack, Ibiayi; Gadgeel, Shirish; Schultz, Katherine; Singh, Manrose; Chin, Emily; Parks, Melissa; Lee, Dana; DiCecca, Richard H.; Lockerman, Elizabeth; Huynh, Tiffany; Logan, Jennifer; Ritterhouse, Lauren L.; Le, Long P.; Muniappan, Ashok; Digumarthy, Subba; Channick, Colleen; Keyes, Colleen; Getz, Gad; Dias-Santagata, Dora; Heist, Rebecca S.; Lennerz, Jochen; Sequist, Lecia V.; Benes, Cyril H.; Iafrate, A. John; Mino-Kenudson, Mari; Engelman, Jeffrey A.; Shaw, Alice T.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1118-1133</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Advanced, anaplastic lymphoma kinase (ALK)-pos. lung cancer is currently treated with the first-generation ALK inhibitor crizotinib followed by more potent, second-generation ALK inhibitors (e.g., ceritinib and alectinib) upon progression.  Second-generation inhibitors are generally effective even in the absence of crizotinib-resistant ALK mutations, likely reflecting incomplete inhibition of ALK by crizotinib in many cases.  Herein, we analyzed 103 repeat biopsies from ALK-pos. patients progressing on various ALK inhibitors.  We find that each ALK inhibitor is assocd. with a distinct spectrum of ALK resistance mutations and that the frequency of one mutation, ALKG1202R, increases significantly after treatment with second-generation agents.  To investigate strategies to overcome resistance to second-generation ALK inhibitors, we examine the activity of the third-generation ALK inhibitor lorlatinib in a series of ceritinib-resistant, patient-derived cell lines, and observe that the presence of ALK resistance mutations is highly predictive for sensitivity to lorlatinib, whereas those cell lines without ALK mutations are resistant.  Significance: Secondary ALK mutations are a common resistance mechanism to second-generation ALK inhibitors and predict for sensitivity to the third-generation ALK inhibitor lorlatinib.  These findings highlight the importance of repeat biopsies and genotyping following disease progression on targeted therapies, particularly second-generation ALK inhibitors.  Cancer Discov; 6(10); 1118-33. ©2016 AACR.  See related commentary by Qiao and Lovly, p. 1084.  This article is highlighted in the In This Issue feature, p.  1069.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqg_wNC_RoH0LVg90H21EOLACvtfcHk0ljizYIfg0SB7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhs1OhurrJ&md5=e68f42dbce3f4f4de0c6d9c64f6b7b82</span></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-16-0596&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-16-0596%26sid%3Dliteratum%253Aachs%26aulast%3DGainor%26aufirst%3DJ.%2BF.%26aulast%3DDardaei%26aufirst%3DL.%26aulast%3DYoda%26aufirst%3DS.%26aulast%3DFriboulet%26aufirst%3DL.%26aulast%3DLeshchiner%26aufirst%3DI.%26aulast%3DKatayama%26aufirst%3DR.%26aulast%3DDagogo-Jack%26aufirst%3DI.%26aulast%3DGadgeel%26aufirst%3DS.%26aulast%3DSchultz%26aufirst%3DK.%26aulast%3DSingh%26aufirst%3DM.%26aulast%3DChin%26aufirst%3DE.%26aulast%3DParks%26aufirst%3DM.%26aulast%3DLee%26aufirst%3DD.%26aulast%3DDiCecca%26aufirst%3DR.%2BH.%26aulast%3DLockerman%26aufirst%3DE.%26aulast%3DHuynh%26aufirst%3DT.%26aulast%3DLogan%26aufirst%3DJ.%26aulast%3DRitterhouse%26aufirst%3DL.%2BL.%26aulast%3DLe%26aufirst%3DL.%2BP.%26aulast%3DMuniappan%26aufirst%3DA.%26aulast%3DDigumarthy%26aufirst%3DS.%26aulast%3DChannick%26aufirst%3DC.%26aulast%3DKeyes%26aufirst%3DC.%26aulast%3DGetz%26aufirst%3DG.%26aulast%3DDias-Santagata%26aufirst%3DD.%26aulast%3DHeist%26aufirst%3DR.%2BS.%26aulast%3DLennerz%26aufirst%3DJ.%26aulast%3DSequist%26aufirst%3DL.%2BV.%26aulast%3DBenes%26aufirst%3DC.%2BH.%26aulast%3DIafrate%26aufirst%3DA.%2BJ.%26aulast%3DMino-Kenudson%26aufirst%3DM.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26aulast%3DShaw%26aufirst%3DA.%2BT.%26atitle%3DMolecular%2520Mechanisms%2520of%2520Resistance%2520to%2520First-and%2520Second-generation%2520ALK%2520Inhibitors%2520in%2520ALK-rearranged%2520Lung%2520Cancer%26jtitle%3DCancer%2520Discovery%26date%3D2016%26volume%3D6%26spage%3D1118%26epage%3D1133%26doi%3D10.1158%2F2159-8290.CD-16-0596" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref110"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref110'); return false;" data-citation="" class="refNumLink">110</a></strong><div class="NLM_citation" id="cit110"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yoda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawrence, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friboulet, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langenbucher, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dardaei, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prutisto-Chang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dagogo-Jack, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timofeevski, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hubbeling, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gainor, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferris, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riley, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kattermann, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timonina, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heist, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iafrate, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benes, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lennerz, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mino-Kenudson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engelman, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hata, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, A. T.</span></span> <span> </span><span class="NLM_article-title">Sequential ALK Inhibitors can Select for Lorlatinib-resistant Compound ALK Mutations in ALK-positive Lung Cancer</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">714</span>– <span class="NLM_lpage">729</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-17-1256</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1158%2F2159-8290.CD-17-1256" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=29650534" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVKjs7nL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2018&pages=714-729&author=S.+Yodaauthor=J.+J.+Linauthor=M.+S.+Lawrenceauthor=B.+J.+Burkeauthor=L.+Fribouletauthor=A.+Langenbucherauthor=L.+Dardaeiauthor=K.+Prutisto-Changauthor=I.+Dagogo-Jackauthor=S.+Timofeevskiauthor=H.+Hubbelingauthor=J.+F.+Gainorauthor=L.+A.+Ferrisauthor=A.+K.+Rileyauthor=K.+E.+Kattermannauthor=D.+Timoninaauthor=R.+S.+Heistauthor=A.+J.+Iafrateauthor=C.+H.+Benesauthor=J.+K.+Lennerzauthor=M.+Mino-Kenudsonauthor=J.+A.+Engelmanauthor=T.+W.+Johnsonauthor=A.+N.+Hataauthor=A.+T.+Shaw&title=Sequential+ALK+Inhibitors+can+Select+for+Lorlatinib-resistant+Compound+ALK+Mutations+in+ALK-positive+Lung+Cancer&doi=10.1158%2F2159-8290.CD-17-1256"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit110R"><div class="casContent"><span class="casTitleNuber">110</span><div class="casTitle"><span class="NLM_cas:atitle">Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung Cancer</span></div><div class="casAuthors">Yoda, Satoshi; Lin, Jessica J.; Lawrence, Michael S.; Burke, Benjamin J.; Friboulet, Luc; Langenbucher, Adam; Dardaei, Leila; Prutisto-Chang, Kylie; Dagogo-Jack, Ibiayi; Timofeevski, Sergei; Hubbeling, Harper; Gainor, Justin F.; Ferris, Lorin A.; Riley, Amanda K.; Kattermann, Krystina E.; Timonina, Daria; Heist, Rebecca S.; Iafrate, A. John; Benes, Cyril H.; Lennerz, Jochen K.; Mino-Kenudson, Mari; Engelman, Jeffrey A.; Johnson, Ted W.; Hata, Aaron N.; Shaw, Alice T.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">714-729</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The cornerstone of treatment for advanced ALK-pos. lung cancer is sequential therapy with increasingly potent and selective ALK inhibitors.  The third-generation ALK inhibitor lorlatinib has demonstrated clin. activity in patients who failed previous ALK inhibitors.  To define the spectrum of ALK mutations that confer lorlatinib resistance, we performed accelerated mutagenesis screening of Ba/F3 cells expressing EML4-ALK.  Under comparable conditions, N-ethyl-N-nitrosourea (ENU) mutagenesis generated numerous crizotinib-resistant but no lorlatinib-resistant clones harboring single ALK mutations.  In similar screens with EML4-ALK contg. single ALK resistance mutations, numerous lorlatinib-resistant clones emerged harboring compd. ALK mutations.  To det. the clin. relevance of these mutations, we analyzed repeat biopsies from lorlatinib-resistant patients.  Seven of 20 samples (35%) harbored compd. ALK mutations, including two identified in the ENU screen.  Whole-exome sequencing in three cases confirmed the stepwise accumulation of ALK mutations during sequential treatment.  These results suggest that sequential ALK inhibitors can foster the emergence of compd. ALK mutations, identification of which is crit. to informing drug design and developing effective therapeutic strategies.  Significance: Treatment with sequential first-, second-, and third-generation ALK inhibitors can select for compd. ALK mutations that confer high-level resistance to ALK-targeted therapies.  A more efficacious long-term strategy may be up-front treatment with a third-generation ALK inhibitor to prevent the emergence of on-target resistance.  Cancer Discov; 8(6); 714-29. ©2018 AACR.  This article is highlighted in the In This Issue feature, p.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYIrTj3mfqPLVg90H21EOLACvtfcHk0li-iEidSAL4xQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVKjs7nL&md5=f9ecf4202f089ed8eb20eceeca83be16</span></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-17-1256&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-17-1256%26sid%3Dliteratum%253Aachs%26aulast%3DYoda%26aufirst%3DS.%26aulast%3DLin%26aufirst%3DJ.%2BJ.%26aulast%3DLawrence%26aufirst%3DM.%2BS.%26aulast%3DBurke%26aufirst%3DB.%2BJ.%26aulast%3DFriboulet%26aufirst%3DL.%26aulast%3DLangenbucher%26aufirst%3DA.%26aulast%3DDardaei%26aufirst%3DL.%26aulast%3DPrutisto-Chang%26aufirst%3DK.%26aulast%3DDagogo-Jack%26aufirst%3DI.%26aulast%3DTimofeevski%26aufirst%3DS.%26aulast%3DHubbeling%26aufirst%3DH.%26aulast%3DGainor%26aufirst%3DJ.%2BF.%26aulast%3DFerris%26aufirst%3DL.%2BA.%26aulast%3DRiley%26aufirst%3DA.%2BK.%26aulast%3DKattermann%26aufirst%3DK.%2BE.%26aulast%3DTimonina%26aufirst%3DD.%26aulast%3DHeist%26aufirst%3DR.%2BS.%26aulast%3DIafrate%26aufirst%3DA.%2BJ.%26aulast%3DBenes%26aufirst%3DC.%2BH.%26aulast%3DLennerz%26aufirst%3DJ.%2BK.%26aulast%3DMino-Kenudson%26aufirst%3DM.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26aulast%3DJohnson%26aufirst%3DT.%2BW.%26aulast%3DHata%26aufirst%3DA.%2BN.%26aulast%3DShaw%26aufirst%3DA.%2BT.%26atitle%3DSequential%2520ALK%2520Inhibitors%2520can%2520Select%2520for%2520Lorlatinib-resistant%2520Compound%2520ALK%2520Mutations%2520in%2520ALK-positive%2520Lung%2520Cancer%26jtitle%3DCancer%2520Discovery%26date%3D2018%26volume%3D8%26spage%3D714%26epage%3D729%26doi%3D10.1158%2F2159-8290.CD-17-1256" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref111"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref111'); return false;" data-citation="" class="refNumLink">111</a></strong><div class="NLM_citation" id="cit111"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zou, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engstrom, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">West, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Appleman, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McTigue, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, Y.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brooun, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timofeevski, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonnell, S. R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Falk, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lappin, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Affolter, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nichols, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smeal, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charest, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fantin, V. R.</span></span> <span> </span><span class="NLM_article-title">PF-06463922 is a Potent and Selective Next-generation ROS1/ALK Inhibitor Capable of Blocking Crizotinib-resistant ROS1 Mutations</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>112</i></span>,  <span class="NLM_fpage">3493</span>– <span class="NLM_lpage">3498</span>, <span class="refDoi"> DOI: 10.1073/pnas.1420785112</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1073%2Fpnas.1420785112" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=25733882" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjs1Grur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=112&publication_year=2015&pages=3493-3498&author=H.+Y.+Zouauthor=Q.+Liauthor=L.+D.+Engstromauthor=M.+Westauthor=V.+Applemanauthor=K.+A.+Wongauthor=M.+McTigueauthor=Y.-L.+Dengauthor=W.+Liuauthor=A.+Broounauthor=S.+Timofeevskiauthor=S.+R.+P.+McDonnellauthor=P.+Jiangauthor=M.+D.+Falkauthor=P.+B.+Lappinauthor=T.+Affolterauthor=T.+Nicholsauthor=W.+Huauthor=J.+Lamauthor=T.+W.+Johnsonauthor=T.+Smealauthor=A.+Charestauthor=V.+R.+Fantin&title=PF-06463922+is+a+Potent+and+Selective+Next-generation+ROS1%2FALK+Inhibitor+Capable+of+Blocking+Crizotinib-resistant+ROS1+Mutations&doi=10.1073%2Fpnas.1420785112"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit111R"><div class="casContent"><span class="casTitleNuber">111</span><div class="casTitle"><span class="NLM_cas:atitle">PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations</span></div><div class="casAuthors">Zou, Helen Y.; Li, Qiuhua; Engstrom, Lars D.; West, Melissa; Appleman, Vicky; Wong, Katy A.; McTigue, Michele; Deng, Ya-Li; Liu, Wei; Brooun, Alexei; Timofeevski, Sergei; McDonnell, Scott R. P.; Jiang, Ping; Falk, Matthew D.; Lappin, Patrick B.; Affolter, Timothy; Nichols, Tim; Hu, Wenyue; Lam, Justine; Johnson, Ted W.; Smeal, Tod; Charest, Al; Fantin, Valeria R.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">112</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3493-3498</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Oncogenic c-ros oncogene 1 (ROS1) fusion kinases have been identified in a variety of human cancers and are attractive targets for cancer therapy.  The MET/ALK/ROS1 inhibitor crizotinib (Xalkori, PF-02341066) has demonstrated promising clin. activity in ROS1 fusion-pos. non-small cell lung cancer.  However, emerging clin. evidence has shown that patients can develop resistance by acquiring secondary point mutations in ROS1 kinase.  In this study the authors characterized the ROS1 activity of PF-06463922, a novel, orally available, CNS-penetrant, ATP-competitive small-mol. inhibitor of ALK/ROS1.  In vitro, PF-06463922 exhibited subnanomolar cellular potency against oncogenic ROS1 fusions and inhibited the crizotinib-refractory ROS1G2032R mutation and the ROS1G2026M gatekeeper mutation.  Compared with crizotinib and the second-generation ALK/ROS1 inhibitors ceritinib and alectinib, PF-06463922 showed significantly improved inhibitory activity against ROS1 kinase.  A crystal structure of the PF-06463922-ROS1 kinase complex revealed favorable interactions contributing to the high-affinity binding.  In vivo, PF-06463922 showed marked antitumor activity in tumor models expressing FIG-ROS1, CD74-ROS1, and the CD74-ROS1G2032R mutation.  Furthermore, PF-06463922 demonstrated antitumor activity in a genetically engineered mouse model of FIG-ROS1 glioblastoma.  Taken together, the authors' results indicate that PF-06463922 has potential for treating ROS1 fusion-pos. cancers, including those requiring agents with CNS-penetrating properties, as well as for overcoming crizotinib resistance driven by ROS1 mutation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5t2o5BKPhK7Vg90H21EOLACvtfcHk0li-iEidSAL4xQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjs1Grur8%253D&md5=8f549572dfac12c74b88705d57979c09</span></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1420785112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1420785112%26sid%3Dliteratum%253Aachs%26aulast%3DZou%26aufirst%3DH.%2BY.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DEngstrom%26aufirst%3DL.%2BD.%26aulast%3DWest%26aufirst%3DM.%26aulast%3DAppleman%26aufirst%3DV.%26aulast%3DWong%26aufirst%3DK.%2BA.%26aulast%3DMcTigue%26aufirst%3DM.%26aulast%3DDeng%26aufirst%3DY.-L.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DBrooun%26aufirst%3DA.%26aulast%3DTimofeevski%26aufirst%3DS.%26aulast%3DMcDonnell%26aufirst%3DS.%2BR.%2BP.%26aulast%3DJiang%26aufirst%3DP.%26aulast%3DFalk%26aufirst%3DM.%2BD.%26aulast%3DLappin%26aufirst%3DP.%2BB.%26aulast%3DAffolter%26aufirst%3DT.%26aulast%3DNichols%26aufirst%3DT.%26aulast%3DHu%26aufirst%3DW.%26aulast%3DLam%26aufirst%3DJ.%26aulast%3DJohnson%26aufirst%3DT.%2BW.%26aulast%3DSmeal%26aufirst%3DT.%26aulast%3DCharest%26aufirst%3DA.%26aulast%3DFantin%26aufirst%3DV.%2BR.%26atitle%3DPF-06463922%2520is%2520a%2520Potent%2520and%2520Selective%2520Next-generation%2520ROS1%252FALK%2520Inhibitor%2520Capable%2520of%2520Blocking%2520Crizotinib-resistant%2520ROS1%2520Mutations%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2015%26volume%3D112%26spage%3D3493%26epage%3D3498%26doi%3D10.1073%2Fpnas.1420785112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref112"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref112'); return false;" data-citation="" class="refNumLink">112</a></strong><div class="NLM_citation" id="cit112"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zou, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friboulet, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kodack, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engstrom, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">West, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsaparikos, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timofeevski, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katayama, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dinh, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamazaki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bezwada, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frias, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lifshits, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahmood, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gainor, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Affolter, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lappin, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gukasyan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jain, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fantin, V. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smeal, T.</span></span> <span> </span><span class="NLM_article-title">PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">70</span>– <span class="NLM_lpage">81</span>, <span class="refDoi"> DOI: 10.1016/j.ccell.2015.05.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1016%2Fj.ccell.2015.05.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=26144315" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFahsr7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2015&pages=70-81&author=H.+Y.+Zouauthor=L.+Fribouletauthor=D.+P.+Kodackauthor=L.+D.+Engstromauthor=Q.+Liauthor=M.+Westauthor=R.+W.+Tangauthor=H.+Wangauthor=K.+Tsaparikosauthor=J.+Wangauthor=S.+Timofeevskiauthor=R.+Katayamaauthor=D.+M.+Dinhauthor=H.+Lamauthor=J.+L.+Lamauthor=S.+Yamazakiauthor=W.+Huauthor=B.+Patelauthor=D.+Bezwadaauthor=R.+L.+Friasauthor=E.+Lifshitsauthor=S.+Mahmoodauthor=J.+F.+Gainorauthor=T.+Affolterauthor=P.+B.+Lappinauthor=H.+Gukasyanauthor=N.+Leeauthor=S.+Dengauthor=R.+K.+Jainauthor=T.+W.+Johnsonauthor=A.+T.+Shawauthor=V.+R.+Fantinauthor=T.+Smeal&title=PF-06463922%2C+an+ALK%2FROS1+Inhibitor%2C+Overcomes+Resistance+to+First+and+Second+Generation+ALK+Inhibitors+in+Preclinical+Models&doi=10.1016%2Fj.ccell.2015.05.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit112R"><div class="casContent"><span class="casTitleNuber">112</span><div class="casTitle"><span class="NLM_cas:atitle">PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models</span></div><div class="casAuthors">Zou, Helen Y.; Friboulet, Luc; Kodack, David P.; Engstrom, Lars D.; Li, Qiuhua; West, Melissa; Tang, Ruth W.; Wang, Hui; Tsaparikos, Konstantinos; Wang, Jinwei; Timofeevski, Sergei; Katayama, Ryohei; Dinh, Dac M.; Lam, Hieu; Lam, Justine L.; Yamazaki, Shinji; Hu, Wenyue; Patel, Bhushankumar; Bezwada, Divya; Frias, Rosa L.; Lifshits, Eugene; Mahmood, Sidra; Gainor, Justin F.; Affolter, Timothy; Lappin, Patrick B.; Gukasyan, Hovhannes; Lee, Nathan; Deng, Shibing; Jain, Rakesh K.; Johnson, Ted W.; Shaw, Alice T.; Fantin, Valeria R.; Smeal, Tod</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">70-81</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">We report the preclin. evaluation of PF-06463922, a potent and brain-penetrant ALK/ROS1 inhibitor.  Compared with other clin. available ALK inhibitors, PF-06463922 displayed superior potency against all known clin. acquired ALK mutations, including the highly resistant G1202R mutant.  Furthermore, PF-06463922 treatment led to regression of EML4-ALK-driven brain metastases, leading to prolonged mouse survival, in a superior manner.  Finally, PF-06463922 demonstrated high selectivity and safety margins in a variety of preclin. studies.  These results suggest that PF-06463922 will be highly effective for the treatment of patients with ALK-driven lung cancers, including those who relapsed on clin. available ALK inhibitors because of secondary ALK kinase domain mutations and/or brain metastases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3jseXrLwlSLVg90H21EOLACvtfcHk0li2-U9u-6WazA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFahsr7E&md5=5bd2b7be6086f607b33b2255ad350486</span></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1016%2Fj.ccell.2015.05.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccell.2015.05.010%26sid%3Dliteratum%253Aachs%26aulast%3DZou%26aufirst%3DH.%2BY.%26aulast%3DFriboulet%26aufirst%3DL.%26aulast%3DKodack%26aufirst%3DD.%2BP.%26aulast%3DEngstrom%26aufirst%3DL.%2BD.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DWest%26aufirst%3DM.%26aulast%3DTang%26aufirst%3DR.%2BW.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DTsaparikos%26aufirst%3DK.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DTimofeevski%26aufirst%3DS.%26aulast%3DKatayama%26aufirst%3DR.%26aulast%3DDinh%26aufirst%3DD.%2BM.%26aulast%3DLam%26aufirst%3DH.%26aulast%3DLam%26aufirst%3DJ.%2BL.%26aulast%3DYamazaki%26aufirst%3DS.%26aulast%3DHu%26aufirst%3DW.%26aulast%3DPatel%26aufirst%3DB.%26aulast%3DBezwada%26aufirst%3DD.%26aulast%3DFrias%26aufirst%3DR.%2BL.%26aulast%3DLifshits%26aufirst%3DE.%26aulast%3DMahmood%26aufirst%3DS.%26aulast%3DGainor%26aufirst%3DJ.%2BF.%26aulast%3DAffolter%26aufirst%3DT.%26aulast%3DLappin%26aufirst%3DP.%2BB.%26aulast%3DGukasyan%26aufirst%3DH.%26aulast%3DLee%26aufirst%3DN.%26aulast%3DDeng%26aufirst%3DS.%26aulast%3DJain%26aufirst%3DR.%2BK.%26aulast%3DJohnson%26aufirst%3DT.%2BW.%26aulast%3DShaw%26aufirst%3DA.%2BT.%26aulast%3DFantin%26aufirst%3DV.%2BR.%26aulast%3DSmeal%26aufirst%3DT.%26atitle%3DPF-06463922%252C%2520an%2520ALK%252FROS1%2520Inhibitor%252C%2520Overcomes%2520Resistance%2520to%2520First%2520and%2520Second%2520Generation%2520ALK%2520Inhibitors%2520in%2520Preclinical%2520Models%26jtitle%3DCancer%2520Cell%26date%3D2015%26volume%3D28%26spage%3D70%26epage%3D81%26doi%3D10.1016%2Fj.ccell.2015.05.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref113"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref113'); return false;" data-citation="" class="refNumLink">113</a></strong><div class="NLM_citation" id="cit113"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Russo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franchina, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ricciardi, G. R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferraro, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scimone, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bronte, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rolfo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adamo, V.</span></span> <span> </span><span class="NLM_article-title">Central Nervous System Involvement in ALK-rearranged NSCLC: Promising Strategies to Overcome Crizotinib Resistance</span>. <i>Expert Rev. Anticancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">615</span>– <span class="NLM_lpage">623</span>, <span class="refDoi"> DOI: 10.1080/14737140.2016.1182427</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1080%2F14737140.2016.1182427" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=27109446" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC28XnslGksLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2016&pages=615-623&author=A.+Russoauthor=T.+Franchinaauthor=G.+R.+R.+Ricciardiauthor=G.+Ferraroauthor=A.+Scimoneauthor=G.+Bronteauthor=A.+Russoauthor=C.+Rolfoauthor=V.+Adamo&title=Central+Nervous+System+Involvement+in+ALK-rearranged+NSCLC%3A+Promising+Strategies+to+Overcome+Crizotinib+Resistance&doi=10.1080%2F14737140.2016.1182427"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">Central nervous system involvement in ALK-rearranged NSCLC: promising strategies to overcome crizotinib resistance</span></div><div class="casAuthors">Russo, Alessandro; Franchina, Tindara; Ricciardi, Giuseppina Rosaria Rita; Ferraro, Giuseppa; Scimone, Antonino; Bronte, Giuseppe; Russo, Antonio; Rolfo, Christian; Adamo, Vincenzo</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Anticancer Therapy</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">615-623</span>CODEN:
                <span class="NLM_cas:coden">ERATBJ</span>;
        ISSN:<span class="NLM_cas:issn">1473-7140</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">ALK rearranged Non Small Cell Lung Cancers (NSCLCs) represent a distinct subgroup of patients with peculiar clinic-pathol. features.  These patients exhibit dramatic responses when treated with the ALK tyrosine kinase inhibitor Crizotinib, albeit Central Nervous System (CNS) activity is much less impressive than that obsd. against extracranial lesions.  CNS involvement has become increasingly obsd. in these patients, given their prolonged survival.  Several novel generation ALK inhibitors have been developing to increase CNS penetration and to provide more complete ALK inhibition..  The CNS activity of Crizotinib and novel generation ALK inhibitors will be summarized in this review, evaluating the strengths and weaknesses of the therapeutic strategies developed to date in this specific subgroup of NSCLCs with a look towards the future.  In the next few years, the results of ongoing comparative head-to-head trials will provide the definitive conclusions on the optimal treatment sequence in ALK-rearranged NSCLCs.  Moreover, ongoing clin. trials with novel-generation ALK inhibitors will produce more evidences on the best approach in the growing no. of ALK-pos. NSCLCs with CNS involvement.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3TX-jyciMtbVg90H21EOLACvtfcHk0li2-U9u-6WazA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XnslGksLk%253D&md5=7b45f0c41b30504cc526a1bc2a83f233</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1080%2F14737140.2016.1182427&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F14737140.2016.1182427%26sid%3Dliteratum%253Aachs%26aulast%3DRusso%26aufirst%3DA.%26aulast%3DFranchina%26aufirst%3DT.%26aulast%3DRicciardi%26aufirst%3DG.%2BR.%2BR.%26aulast%3DFerraro%26aufirst%3DG.%26aulast%3DScimone%26aufirst%3DA.%26aulast%3DBronte%26aufirst%3DG.%26aulast%3DRusso%26aufirst%3DA.%26aulast%3DRolfo%26aufirst%3DC.%26aulast%3DAdamo%26aufirst%3DV.%26atitle%3DCentral%2520Nervous%2520System%2520Involvement%2520in%2520ALK-rearranged%2520NSCLC%253A%2520Promising%2520Strategies%2520to%2520Overcome%2520Crizotinib%2520Resistance%26jtitle%3DExpert%2520Rev.%2520Anticancer%2520Ther.%26date%3D2016%26volume%3D16%26spage%3D615%26epage%3D623%26doi%3D10.1080%2F14737140.2016.1182427" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref114"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref114'); return false;" data-citation="" class="refNumLink">114</a></strong><div class="NLM_citation" id="cit114"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sparidans, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lebre, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beijnen, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schinkel, A. H.</span></span> <span> </span><span class="NLM_article-title">Oral Coadministration of Elacridar and Ritonavir Enhances Brain Accumulation and Oral Availability of the Novel ALK/ROS1 Inhibitor Lorlatinib</span>. <i>Eur. J. Pharm. Biopharm.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>136</i></span>,  <span class="NLM_fpage">120</span>– <span class="NLM_lpage">130</span>, <span class="refDoi"> DOI: 10.1016/j.ejpb.2019.01.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1016%2Fj.ejpb.2019.01.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=30660696" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhslGnu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=136&publication_year=2019&pages=120-130&author=W.+Liauthor=R.+W.+Sparidansauthor=Y.+Wangauthor=M.+C.+Lebreauthor=J.+H.+Beijnenauthor=A.+H.+Schinkel&title=Oral+Coadministration+of+Elacridar+and+Ritonavir+Enhances+Brain+Accumulation+and+Oral+Availability+of+the+Novel+ALK%2FROS1+Inhibitor+Lorlatinib&doi=10.1016%2Fj.ejpb.2019.01.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit114R"><div class="casContent"><span class="casTitleNuber">114</span><div class="casTitle"><span class="NLM_cas:atitle">Oral coadministration of elacridar and ritonavir enhances brain accumulation and oral availability of the novel ALK/ROS1 inhibitor lorlatinib</span></div><div class="casAuthors">Li, Wenlong; Sparidans, Rolf W.; Wang, Yaogeng; Lebre, Maria C.; Beijnen, Jos H.; Schinkel, Alfred H.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmaceutics and Biopharmaceutics</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">136</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">120-130</span>CODEN:
                <span class="NLM_cas:coden">EJPBEL</span>;
        ISSN:<span class="NLM_cas:issn">0939-6411</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Lorlatinib, a novel generation oral anaplastic lymphoma kinase (ALK) and ROS1 inhibitor with high membrane and blood-brain barrier permeability, recently received accelerated approval for treatment of ALK-rearranged non-small-cell lung cancer (NSCLC), and its further clin. development is ongoing.  We previously found that the efflux transporter P-glycoprotein (MDR1/ABCB1) restricts lorlatinib brain accumulation and that the drug-metabolizing enzyme cytochrome P 450-3A (CYP3A) limits its oral availability.  Using genetically modified mouse models, we investigated the impact of targeted pharmacol. inhibitors on lorlatinib pharmacokinetics and bioavailability.  Upon oral administration of lorlatinib, the plasma AUC0-8h in CYP3A4-humanized mice was ∼1.8-fold lower than in wild-type and Cyp3a-/- mice.  Oral coadministration of the CYP3A inhibitor ritonavir caused reversion to the AUC0-8h levels seen in wild-type and Cyp3a-/- mice, without altering the relative tissue distribution of lorlatinib.  Moreover, simultaneous pharmacol. inhibition of P-glycoprotein and CYP3A4 with oral elacridar and ritonavir in CYP3A4-humanized mice profoundly increased lorlatinib brain concns., but not its oral availability or other relative tissue distribution.  Oral lorlatinib pharmacokinetics was not significantly affected by absence of the multispecific Oatp1a/1b drug uptake transporters.  The abs. oral bioavailability of lorlatinib over 8 h in wild-type, Cyp3a-/-, and CYP3A4-humanized mice was 81.6%, 72.9%, and 58.5%, resp.  Lorlatinib thus has good oral bioavailability, which is markedly restricted by human CYP3A4 but not by mouse Cyp3a.  Pharmacol. inhibition of CYP3A4 reversed these effects, and simultaneous P-gp inhibition with elacridar boosted abs. brain levels of lorlatinib by 16-fold without obvious toxicity.  These insights may help to optimize the clin. application of lorlatinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzexELEtdHlrVg90H21EOLACvtfcHk0li2-U9u-6WazA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhslGnu78%253D&md5=2aa5b4e6260bb011036ac9cdb0193588</span></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1016%2Fj.ejpb.2019.01.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejpb.2019.01.016%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DW.%26aulast%3DSparidans%26aufirst%3DR.%2BW.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DLebre%26aufirst%3DM.%2BC.%26aulast%3DBeijnen%26aufirst%3DJ.%2BH.%26aulast%3DSchinkel%26aufirst%3DA.%2BH.%26atitle%3DOral%2520Coadministration%2520of%2520Elacridar%2520and%2520Ritonavir%2520Enhances%2520Brain%2520Accumulation%2520and%2520Oral%2520Availability%2520of%2520the%2520Novel%2520ALK%252FROS1%2520Inhibitor%2520Lorlatinib%26jtitle%3DEur.%2520J.%2520Pharm.%2520Biopharm.%26date%3D2019%26volume%3D136%26spage%3D120%26epage%3D130%26doi%3D10.1016%2Fj.ejpb.2019.01.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref115"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref115'); return false;" data-citation="" class="refNumLink">115</a></strong><div class="NLM_citation" id="cit115"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, A. T</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felip, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, T. M</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Besse, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Navarro, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Postel-Vinay, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gainor, J. F</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dietrich, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, L. P</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clancy, J. S</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martini, J.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abbattista, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solomon, B. J</span></span> <span> </span><span class="NLM_article-title">Lorlatinib in Non-small Cell Lung Cancer with ALK or ROS1 Rearrangement: an International, Multicentre, Open-label, Single-arm First-in-man Phase 1 Trial</span>. <i>Lancet Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">1590</span>– <span class="NLM_lpage">1599</span>, <span class="refDoi"> DOI: 10.1016/S1470-2045(17)30680-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1016%2FS1470-2045%2817%2930680-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=29074098" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhslSgu7vF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2017&pages=1590-1599&author=A.+T+Shawauthor=E.+Felipauthor=T.+M+Bauerauthor=B.+Besseauthor=A.+Navarroauthor=S.+Postel-Vinayauthor=J.+F+Gainorauthor=M.+Johnsonauthor=J.+Dietrichauthor=L.+P+Jamesauthor=J.+S+Clancyauthor=J.+Chenauthor=J.-F.+Martiniauthor=A.+Abbattistaauthor=B.+J+Solomon&title=Lorlatinib+in+Non-small+Cell+Lung+Cancer+with+ALK+or+ROS1+Rearrangement%3A+an+International%2C+Multicentre%2C+Open-label%2C+Single-arm+First-in-man+Phase+1+Trial&doi=10.1016%2FS1470-2045%2817%2930680-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit115R"><div class="casContent"><span class="casTitleNuber">115</span><div class="casTitle"><span class="NLM_cas:atitle">Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial</span></div><div class="casAuthors">Shaw, Alice T.; Felip, Enriqueta; Bauer, Todd M.; Besse, Benjamin; Navarro, Alejandro; Postel-Vinay, Sophie; Gainor, Justin F.; Johnson, Melissa; Dietrich, Jorg; James, Leonard P.; Clancy, Jill S.; Chen, Joseph; Martini, Jean-Francois; Abbattista, Antonello; Solomon, Benjamin J.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1590-1599</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Most patients with anaplastic lymphoma kinase (ALK)-rearranged or ROS proto-oncogene 1 (ROS1)-rearranged non-small-cell lung cancer (NSCLC) are sensitive to tyrosine kinase inhibitor (TKI) therapy, but resistance invariably develops, commonly within the CNS.  This study aimed to analyze the safety, efficacy, and pharmacokinetic properties of lorlatinib, a novel, highly potent, selective, and brain-penetrant ALK and ROS1 TKI with preclin. activity against most known resistance mutations, in patients with advanced ALK-pos. or ROS1-pos. NSCLC.  In this international multicentre, open-label, single-arm, first-in-man phase 1 dose-escalation study, eligible patients had advanced ALK-pos. or ROS1-pos. NSCLC and were older than 18 years, with an Eastern Cooperative Oncol. Group performance status of 0 or 1, and adequate end-organ function.  Lorlatinib was administered orally to patients at doses ranging from 10 mg to 200 mg once daily or 35 mg to 100 mg twice daily, with a min. of three patients receiving each dose.  For some patients, tumor biopsy was done before lorlatinib treatment to identify ALK resistance mutations.  Safety was assessed in patients who received at least one dose of lorlatinib; efficacy was assessed in the intention-to-treat population (patients who received at least one dose of study treatment and had either ALK or ROS1 rearrangement).  The primary endpoint was dose-limiting toxicities during cycle 1 according to investigator assessment; secondary endpoints included safety, pharmacokinetics, and overall response.  This study is ongoing and is registered with ClinicalTrials.gov, no. NCT01970865.  Between Jan 22, 2014, and July 10, 2015, 54 patients received at least one dose of lorlatinib, including 41 (77%) with ALK-pos. and 12 (23%) with ROS1-pos. NSCLC; one patient had unconfirmed ALK and ROS1 status. 28 (52%) patients had received two or more TKIs, and 39 (72%) patients had CNS metastases.  The most common treatment-related adverse events among the 54 patients were hypercholesterolemia (39 [72%] of 54 patients), hypertriglyceridemia (21 [39%] of 54 patients), peripheral neuropathy (21 [39%] of 54 patients), and peripheral edema (21 [39%] of 54 patients).  One dose-limiting toxicity occurred at 200 mg (the patient did not take at least 16 of 21 prescribed total daily doses in cycle 1 because of toxicities attributable to study drug, which were grade 2 neurocognitive adverse events comprising slowed speech and mentation and word-finding difficulty).  No max. tolerated dose was identified.  The recommended phase 2 dose was selected as 100 mg once daily.  For ALK-pos. patients, the proportion of patients who achieved an objective response was 19 (46%) of 41 patients (95% CI 31-63); for those who had received two or more TKIs, the proportion of patients with an objective response was 11 (42%) of 26 patients (23-63).  In ROS1-pos. patients, including seven crizotinib-pretreated patients, an objective response was achieved by six (50%) of 12 patients (95% CI 21-79).  In this phase 1, dose-escalation study, lorlatinib showed both systemic and intracranial activity in patients with advanced ALK-pos. or ROS1-pos. NSCLC, most of whom had CNS metastases and had previously had two or more TKI treatments fail.  Therefore, lorlatinib might be an effective therapeutic strategy for patients with ALK-pos. NSCLC who have become resistant to currently available TKIs, including second-generation ALK TKIs, and is being investigated in a phase 3 randomised controlled trial comparing lorlatinib to crizotinib (ClinicalTrials.gov, NCT03052608).Pfizer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpU5uB3o0yZkrVg90H21EOLACvtfcHk0ljQWhqrO_Hx0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhslSgu7vF&md5=aa28604c17c04fd005b70beda74ef2d6</span></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2817%2930680-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252817%252930680-0%26sid%3Dliteratum%253Aachs%26aulast%3DShaw%26aufirst%3DA.%2BT%26aulast%3DFelip%26aufirst%3DE.%26aulast%3DBauer%26aufirst%3DT.%2BM%26aulast%3DBesse%26aufirst%3DB.%26aulast%3DNavarro%26aufirst%3DA.%26aulast%3DPostel-Vinay%26aufirst%3DS.%26aulast%3DGainor%26aufirst%3DJ.%2BF%26aulast%3DJohnson%26aufirst%3DM.%26aulast%3DDietrich%26aufirst%3DJ.%26aulast%3DJames%26aufirst%3DL.%2BP%26aulast%3DClancy%26aufirst%3DJ.%2BS%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DMartini%26aufirst%3DJ.-F.%26aulast%3DAbbattista%26aufirst%3DA.%26aulast%3DSolomon%26aufirst%3DB.%2BJ%26atitle%3DLorlatinib%2520in%2520Non-small%2520Cell%2520Lung%2520Cancer%2520with%2520ALK%2520or%2520ROS1%2520Rearrangement%253A%2520an%2520International%252C%2520Multicentre%252C%2520Open-label%252C%2520Single-arm%2520First-in-man%2520Phase%25201%2520Trial%26jtitle%3DLancet%2520Oncol.%26date%3D2017%26volume%3D18%26spage%3D1590%26epage%3D1599%26doi%3D10.1016%2FS1470-2045%2817%2930680-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref116"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref116'); return false;" data-citation="" class="refNumLink">116</a></strong><div class="NLM_citation" id="cit116"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ou, S.-H. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felip, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Besse, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gadgeel, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camidge, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, C.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soo, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiari, R.</span></span> <span> </span><span class="NLM_article-title">Efficacy and Safety of Lorlatinib in Patients (pts) with ALK+ Non-small Cell Lung Cancer (NSCLC) with One or More Prior ALK Tyrosine Kinase Inhibitor (TKI): A Phase I/II Study</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>35</i></span> (<span class="NLM_issue">Suppl 15</span>),  <span class="NLM_fpage">9006</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1200%2FJCO.2017.35.15_suppl.9006" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2017&pages=9006&issue=Suppl+15&author=A.+T.+Shawauthor=S.-H.+I.+Ouauthor=E.+Felipauthor=T.+M.+Bauerauthor=B.+Besseauthor=S.+M.+Gadgeelauthor=D.+R.+Camidgeauthor=C.-C.+Linauthor=T.+Setoauthor=R.+A.+Sooauthor=R.+Chiari&title=Efficacy+and+Safety+of+Lorlatinib+in+Patients+%28pts%29+with+ALK%2B+Non-small+Cell+Lung+Cancer+%28NSCLC%29+with+One+or+More+Prior+ALK+Tyrosine+Kinase+Inhibitor+%28TKI%29%3A+A+Phase+I%2FII+Study"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.1200%2FJCO.2017.35.15_suppl.9006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2017.35.15_suppl.9006%26sid%3Dliteratum%253Aachs%26aulast%3DShaw%26aufirst%3DA.%2BT.%26aulast%3DOu%26aufirst%3DS.-H.%2BI.%26aulast%3DFelip%26aufirst%3DE.%26aulast%3DBauer%26aufirst%3DT.%2BM.%26aulast%3DBesse%26aufirst%3DB.%26aulast%3DGadgeel%26aufirst%3DS.%2BM.%26aulast%3DCamidge%26aufirst%3DD.%2BR.%26aulast%3DLin%26aufirst%3DC.-C.%26aulast%3DSeto%26aufirst%3DT.%26aulast%3DSoo%26aufirst%3DR.%2BA.%26aulast%3DChiari%26aufirst%3DR.%26atitle%3DEfficacy%2520and%2520Safety%2520of%2520Lorlatinib%2520in%2520Patients%2520%2528pts%2529%2520with%2520ALK%252B%2520Non-small%2520Cell%2520Lung%2520Cancer%2520%2528NSCLC%2529%2520with%2520One%2520or%2520More%2520Prior%2520ALK%2520Tyrosine%2520Kinase%2520Inhibitor%2520%2528TKI%2529%253A%2520A%2520Phase%2520I%252FII%2520Study%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2017%26volume%3D35%26issue%3DSuppl%252015%26spage%3D9006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref117"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref117'); return false;" data-citation="" class="refNumLink">117</a></strong><div class="NLM_citation" id="cit117"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Basit, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashraf, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Latif, M.</span></span> <span> </span><span class="NLM_article-title">First Macrocyclic 3rd-generation ALK Inhibitor for Treatment of ALK/ROS1 cancer: Clinical and Designing Strategy Update of Lorlatinib</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>134</i></span>,  <span class="NLM_fpage">348</span>– <span class="NLM_lpage">356</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2017.04.032</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1016%2Fj.ejmech.2017.04.032" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=28431340" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmtlKnt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=134&publication_year=2017&pages=348-356&author=S.+Basitauthor=Z.+Ashrafauthor=K.+Leeauthor=M.+Latif&title=First+Macrocyclic+3rd-generation+ALK+Inhibitor+for+Treatment+of+ALK%2FROS1+cancer%3A+Clinical+and+Designing+Strategy+Update+of+Lorlatinib&doi=10.1016%2Fj.ejmech.2017.04.032"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit117R"><div class="casContent"><span class="casTitleNuber">117</span><div class="casTitle"><span class="NLM_cas:atitle">First macrocyclic 3rd-generation ALK inhibitor for treatment of ALK/ROS1 cancer: Clinical and designing strategy update of lorlatinib</span></div><div class="casAuthors">Basit, Sulman; Ashraf, Zaman; Lee, Kwangho; Latif, Muhammad</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">134</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">348-356</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A review.  Non-small cell lung cancers (NSCLC) harboring anaplastic lymphoma kinase (ALK) gene rearrangements invariably develop resistance to 2nd-generation ALK inhibitors.  Lorlatinib (PF-06463922) is a 3rd-generation macrocyclic ALK-TKI that demonstrates many advantages over 2nd-generation ALK inhibitors.  Lorlatinib has demonstrated decent kinase selectivity, promising pharmacokinetic profile, selective brain-penetration and strong antiproliferative activity in several ALK/ROS1-driven tumor models.  The current review describes the activity spectrum, key events from discovery to clin. applications and the evidences that lorlatinib acts as an ALK/ROS1 inhibitor in clin. settings.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqgvg4dapRHrVg90H21EOLACvtfcHk0ljQWhqrO_Hx0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmtlKnt74%253D&md5=13f3886be0e0973a5627f33c6c50cf26</span></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2017.04.032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2017.04.032%26sid%3Dliteratum%253Aachs%26aulast%3DBasit%26aufirst%3DS.%26aulast%3DAshraf%26aufirst%3DZ.%26aulast%3DLee%26aufirst%3DK.%26aulast%3DLatif%26aufirst%3DM.%26atitle%3DFirst%2520Macrocyclic%25203rd-generation%2520ALK%2520Inhibitor%2520for%2520Treatment%2520of%2520ALK%252FROS1%2520cancer%253A%2520Clinical%2520and%2520Designing%2520Strategy%2520Update%2520of%2520Lorlatinib%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2017%26volume%3D134%26spage%3D348%26epage%3D356%26doi%3D10.1016%2Fj.ejmech.2017.04.032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref118"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref118'); return false;" data-citation="" class="refNumLink">118</a></strong><div class="NLM_citation" id="cit118"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Syed, Y. Y.</span></span> <span> </span><span class="NLM_article-title">Lorlatinib: First Global Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">93</span>– <span class="NLM_lpage">98</span>, <span class="refDoi"> DOI: 10.1007/s40265-018-1041-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1007%2Fs40265-018-1041-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=30604291" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC1MXnvFOqsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2019&pages=93-98&author=Y.+Y.+Syed&title=Lorlatinib%3A+First+Global+Approval&doi=10.1007%2Fs40265-018-1041-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit118R"><div class="casContent"><span class="casTitleNuber">118</span><div class="casTitle"><span class="NLM_cas:atitle">Lorlatinib: First Global Approval</span></div><div class="casAuthors">Syed, Yahiya Y.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">93-98</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  Lorlatinib is an oral small mol. inhibitor of anaplastic lymphoma kinase (ALK) and C-ros oncogene 1 (ROS1) kinase developed by Pfizer for the treatment of ALK-pos. non-small cell lung cancer (NSCLC).  Based on results from a phase I/II trial, lorlatinib received approval in Japan in Sept. 2018 and in the USA in Nov. 2018 for the treatment of ALK-pos. NSCLC.  This article summarizes the milestones in the development of lorlatinib leading to the first global approval for this indication.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqU4Wwiia48VbVg90H21EOLACvtfcHk0lgdjSENh4Zg2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXnvFOqsr4%253D&md5=f041ba0200e2d607bb2a014884455990</span></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.1007%2Fs40265-018-1041-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-018-1041-0%26sid%3Dliteratum%253Aachs%26aulast%3DSyed%26aufirst%3DY.%2BY.%26atitle%3DLorlatinib%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2019%26volume%3D79%26spage%3D93%26epage%3D98%26doi%3D10.1007%2Fs40265-018-1041-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref119"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref119'); return false;" data-citation="" class="refNumLink">119</a></strong><div class="NLM_citation" id="cit119"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friboulet, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leshchiner, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gainor, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergqvist, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brooun, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, Y.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dardaei, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frias, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schultz, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Logan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, L. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smeal, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timofeevski, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katayama, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iafrate, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McTigue, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Getz, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engelman, J. A.</span></span> <span> </span><span class="NLM_article-title">Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>374</i></span>,  <span class="NLM_fpage">54</span>– <span class="NLM_lpage">61</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1508887</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1056%2FNEJMoa1508887" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=26698910" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtlOlurzI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=374&publication_year=2016&pages=54-61&author=A.+T.+Shawauthor=L.+Fribouletauthor=I.+Leshchinerauthor=J.+F.+Gainorauthor=S.+Bergqvistauthor=A.+Broounauthor=B.+J.+Burkeauthor=Y.-L.+Dengauthor=W.+Liuauthor=L.+Dardaeiauthor=R.+L.+Friasauthor=K.+R.+Schultzauthor=J.+Loganauthor=L.+P.+Jamesauthor=T.+Smealauthor=S.+Timofeevskiauthor=R.+Katayamaauthor=A.+J.+Iafrateauthor=L.+Leauthor=M.+McTigueauthor=G.+Getzauthor=T.+W.+Johnsonauthor=J.+A.+Engelman&title=Resensitization+to+Crizotinib+by+the+Lorlatinib+ALK+Resistance+Mutation+L1198F&doi=10.1056%2FNEJMoa1508887"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit119R"><div class="casContent"><span class="casTitleNuber">119</span><div class="casTitle"><span class="NLM_cas:atitle">Resensitization to crizotinib by the lorlatinib ALK resistance mutation L1198F</span></div><div class="casAuthors">Shaw, Alice T.; Friboulet, Luc; Leshchiner, Ignaty; Gainor, Justin F.; Bergqvist, Simon; Brooun, Alexei; Burke, Benjamin J.; Deng, Ya-Li; Liu, Wei; Dardaei, Leila; Frias, Rosa L.; Schultz, Kate R.; Logan, Jennifer; James, Leonard P.; Smeal, Tod; Timofeevski, Sergei; Katayama, Ryohei; John, Iafrate A.; Le, Long; McTigue, Michele; Getz, Gad; Johnson, Ted W.; Engelman, Jeffrey A.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">374</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">54-61</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">In a patient who had metastatic anaplastic lymphoma kinase (ALK)-rearranged lung cancer, resistance to crizotinib developed because of a mutation in the ALK kinase domain.  This mutation is predicted to result in a substitution of cysteine by tyrosine at amino acid residue 1156 (C1156Y).  Her tumor did not respond to a second-generation ALK inhibitor, but it did respond to lorlatinib (PF-06463922), a third-generation inhibitor.  When her tumor relapsed, sequencing of the resistant tumor re- vealed an ALK L1198F mutation in addn. to the C1156Y mutation.  The L1198F substitution confers resistance to lorlatinib through steric interference with drug binding.  However, L1198F paradoxically enhances binding to crizotinib, negating the effect of C1156Y and resensitizing resistant cancers to crizotinib.  The patient received crizotinib again, and her cancer-related symptoms and liver failure re- solved.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphljr8b5kDw7Vg90H21EOLACvtfcHk0lgdjSENh4Zg2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtlOlurzI&md5=993f41fc3918a73d4ba69276556572d8</span></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1508887&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1508887%26sid%3Dliteratum%253Aachs%26aulast%3DShaw%26aufirst%3DA.%2BT.%26aulast%3DFriboulet%26aufirst%3DL.%26aulast%3DLeshchiner%26aufirst%3DI.%26aulast%3DGainor%26aufirst%3DJ.%2BF.%26aulast%3DBergqvist%26aufirst%3DS.%26aulast%3DBrooun%26aufirst%3DA.%26aulast%3DBurke%26aufirst%3DB.%2BJ.%26aulast%3DDeng%26aufirst%3DY.-L.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DDardaei%26aufirst%3DL.%26aulast%3DFrias%26aufirst%3DR.%2BL.%26aulast%3DSchultz%26aufirst%3DK.%2BR.%26aulast%3DLogan%26aufirst%3DJ.%26aulast%3DJames%26aufirst%3DL.%2BP.%26aulast%3DSmeal%26aufirst%3DT.%26aulast%3DTimofeevski%26aufirst%3DS.%26aulast%3DKatayama%26aufirst%3DR.%26aulast%3DIafrate%26aufirst%3DA.%2BJ.%26aulast%3DLe%26aufirst%3DL.%26aulast%3DMcTigue%26aufirst%3DM.%26aulast%3DGetz%26aufirst%3DG.%26aulast%3DJohnson%26aufirst%3DT.%2BW.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26atitle%3DResensitization%2520to%2520Crizotinib%2520by%2520the%2520Lorlatinib%2520ALK%2520Resistance%2520Mutation%2520L1198F%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2016%26volume%3D374%26spage%3D54%26epage%3D61%26doi%3D10.1056%2FNEJMoa1508887" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref120"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref120'); return false;" data-citation="" class="refNumLink">120</a></strong><div class="NLM_citation" id="cit120"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quail, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gingrich, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ott, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albom, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angeles, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aimone, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cristofani, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Machiorlatti, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abele, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ator, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dorsey, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inghirami, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruggeri, B. A.</span></span> <span> </span><span class="NLM_article-title">CEP-28122, a Highly Potent and Selective Orally Active Inhibitor of Anaplastic Lymphoma Kinase with Antitumor Activity in Experimental Models of Human Cancers</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">670</span>– <span class="NLM_lpage">679</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-11-0776</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1158%2F1535-7163.MCT-11-0776" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=22203728" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC38XjtlKisrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=670-679&author=M.+Chengauthor=M.+R.+Quailauthor=D.+E.+Gingrichauthor=G.+R.+Ottauthor=L.+Luauthor=W.+Wanauthor=M.+S.+Albomauthor=T.+S.+Angelesauthor=L.+D.+Aimoneauthor=F.+Cristofaniauthor=R.+Machiorlattiauthor=C.+Abeleauthor=M.+A.+Atorauthor=B.+D.+Dorseyauthor=G.+Inghiramiauthor=B.+A.+Ruggeri&title=CEP-28122%2C+a+Highly+Potent+and+Selective+Orally+Active+Inhibitor+of+Anaplastic+Lymphoma+Kinase+with+Antitumor+Activity+in+Experimental+Models+of+Human+Cancers&doi=10.1158%2F1535-7163.MCT-11-0776"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit120R"><div class="casContent"><span class="casTitleNuber">120</span><div class="casTitle"><span class="NLM_cas:atitle">CEP-28122, a Highly Potent and Selective Orally Active Inhibitor of Anaplastic Lymphoma Kinase with Antitumor Activity in Experimental Models of Human Cancers</span></div><div class="casAuthors">Cheng, Mangeng; Quail, Matthew R.; Gingrich, Diane E.; Ott, Gregory R.; Lu, Lihui; Wan, Weihua; Albom, Mark S.; Angeles, Thelma S.; Aimone, Lisa D.; Cristofani, Flavio; Machiorlatti, Rodolfo; Abele, Cristina; Ator, Mark A.; Dorsey, Bruce D.; Inghirami, Giorgio; Ruggeri, Bruce A.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">670-679</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Anaplastic lymphoma kinase (ALK) is constitutively activated in a no. of human cancer types due to chromosomal translocations, point mutations, and gene amplification and has emerged as an excellent mol. target for cancer therapy.  Here we report the identification and preclin. characterization of CEP-28122, a highly potent and selective orally active ALK inhibitor.  CEP-28122 is a potent inhibitor of recombinant ALK activity and cellular ALK tyrosine phosphorylation.  It induced concn.-dependent growth inhibition/cytotoxicity of ALK-pos. anaplastic large-cell lymphoma (ALCL), non-small cell lung cancer (NSCLC), and neuroblastoma cells, and displayed dose-dependent inhibition of ALK tyrosine phosphorylation in tumor xenografts in mice, with substantial target inhibition (>90%) for more than 12 h following single oral dosing at 30 mg/kg.  Dose-dependent antitumor activity was obsd. in ALK-pos. ALCL, NSCLC, and neuroblastoma tumor xenografts in mice administered CEP-28122 orally, with complete/near complete tumor regressions obsd. following treatment at doses of 30 mg/kg twice daily or higher.  Treatment of mice bearing Sup-M2 tumor xenografts for 4 wk and primary human ALCL tumor grafts for 2 wk at 55 or 100 mg/kg twice daily led to sustained tumor regression in all mice, with no tumor reemergence for more than 60 days postcessation of treatment.  Conversely, CEP-28122 displayed marginal antitumor activity against ALK-neg. human tumor xenografts under the same dosing regimens.  Administration of CEP-28122 was well tolerated in mice and rats.  In summary, CEP-28122 is a highly potent and selective orally active ALK inhibitor with a favorable pharmaceutical and pharmacokinetic profile and robust and selective pharmacol. efficacy against ALK-pos. human cancer cells and tumor xenograft models in mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWAF2Kawjc8rVg90H21EOLACvtfcHk0lgdjSENh4Zg2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XjtlKisrk%253D&md5=40001fb02de25d0f78bb11a41819651a</span></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-11-0776&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-11-0776%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DM.%26aulast%3DQuail%26aufirst%3DM.%2BR.%26aulast%3DGingrich%26aufirst%3DD.%2BE.%26aulast%3DOtt%26aufirst%3DG.%2BR.%26aulast%3DLu%26aufirst%3DL.%26aulast%3DWan%26aufirst%3DW.%26aulast%3DAlbom%26aufirst%3DM.%2BS.%26aulast%3DAngeles%26aufirst%3DT.%2BS.%26aulast%3DAimone%26aufirst%3DL.%2BD.%26aulast%3DCristofani%26aufirst%3DF.%26aulast%3DMachiorlatti%26aufirst%3DR.%26aulast%3DAbele%26aufirst%3DC.%26aulast%3DAtor%26aufirst%3DM.%2BA.%26aulast%3DDorsey%26aufirst%3DB.%2BD.%26aulast%3DInghirami%26aufirst%3DG.%26aulast%3DRuggeri%26aufirst%3DB.%2BA.%26atitle%3DCEP-28122%252C%2520a%2520Highly%2520Potent%2520and%2520Selective%2520Orally%2520Active%2520Inhibitor%2520of%2520Anaplastic%2520Lymphoma%2520Kinase%2520with%2520Antitumor%2520Activity%2520in%2520Experimental%2520Models%2520of%2520Human%2520Cancers%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2012%26volume%3D11%26spage%3D670%26epage%3D679%26doi%3D10.1158%2F1535-7163.MCT-11-0776" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref121"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref121'); return false;" data-citation="" class="refNumLink">121</a></strong><div class="NLM_citation" id="cit121"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, A.</span></span> <span> </span><span class="NLM_article-title">Novel 2, 4-diarylaminopyrimidine Analogues (DAAPalogues) Showing Potent c-Met/ALK Multikinase Inhibitory Activities</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">304</span>– <span class="NLM_lpage">308</span>, <span class="refDoi"> DOI: 10.1021/ml400373j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml400373j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFKmtr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=304-308&author=Z.+Liuauthor=J.+Aiauthor=X.+Pengauthor=Z.+Songauthor=K.+Wuauthor=J.+Zhangauthor=Q.+Yaoauthor=Y.+Chenauthor=Y.+Jiauthor=Y.+Yangauthor=M.+Gengauthor=A.+Zhang&title=Novel+2%2C+4-diarylaminopyrimidine+Analogues+%28DAAPalogues%29+Showing+Potent+c-Met%2FALK+Multikinase+Inhibitory+Activities&doi=10.1021%2Fml400373j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit121R"><div class="casContent"><span class="casTitleNuber">121</span><div class="casTitle"><span class="NLM_cas:atitle">Novel 2,4-Diarylaminopyrimidine Analogues (DAAPalogues) Showing Potent c-Met/ALK Multikinase Inhibitory Activities</span></div><div class="casAuthors">Liu, Zhiqing; Ai, Jing; Peng, Xia; Song, Zilan; Wu, Kui; Zhang, Jing; Yao, Qizheng; Chen, Yi; Ji, Yinchun; Yang, Yanhong; Geng, Meiyu; Zhang, Ao</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">304-308</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">By repurposing a typical dopamine D1/D5 receptor agonist motif, C1-substituted-N3-benzazepine or benzazecine, into the classical RTK inhibitor 2,4-diaminopyrimidine skeleton, a series of new 2,4-diarylaminopyrimidine analogs (DAAPalogues) were developed.  Two compds. were identified possessing high potency against both c-Met and ALK kinases.  Compd. (I) displayed appreciable antitumor efficacy at the dose of 1 mg/kg in the ALK-driven BF3/EML4-ALK xenograft mice model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgRNaImj02DLVg90H21EOLACvtfcHk0lhKmLp8EGgFrg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFKmtr4%253D&md5=86562545201476c05cce2e7143fa4cb7</span></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.1021%2Fml400373j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml400373j%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DAi%26aufirst%3DJ.%26aulast%3DPeng%26aufirst%3DX.%26aulast%3DSong%26aufirst%3DZ.%26aulast%3DWu%26aufirst%3DK.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DYao%26aufirst%3DQ.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DJi%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DGeng%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DA.%26atitle%3DNovel%25202%252C%25204-diarylaminopyrimidine%2520Analogues%2520%2528DAAPalogues%2529%2520Showing%2520Potent%2520c-Met%252FALK%2520Multikinase%2520Inhibitory%2520Activities%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D5%26spage%3D304%26epage%3D308%26doi%3D10.1021%2Fml400373j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref122"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref122'); return false;" data-citation="" class="refNumLink">122</a></strong><div class="NLM_citation" id="cit122"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Song, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, A.</span></span> <span> </span><span class="NLM_article-title">Discovery of Novel 2, 4-diarylaminopyrimidine Analogues (DAAPalogues) Showing Potent Inhibitory Activities against Both Wild-type and Mutant ALK Kinases</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">197</span>– <span class="NLM_lpage">211</span>, <span class="refDoi"> DOI: 10.1021/jm5005144</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm5005144" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC2cXnt1Cgu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=197-211&author=Z.+Songauthor=Y.+Yangauthor=Z.+Liuauthor=X.+Pengauthor=J.+Guoauthor=X.+Yangauthor=K.+Wuauthor=J.+Aiauthor=J.+Dingauthor=M.+Gengauthor=A.+Zhang&title=Discovery+of+Novel+2%2C+4-diarylaminopyrimidine+Analogues+%28DAAPalogues%29+Showing+Potent+Inhibitory+Activities+against+Both+Wild-type+and+Mutant+ALK+Kinases&doi=10.1021%2Fjm5005144"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit122R"><div class="casContent"><span class="casTitleNuber">122</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Novel 2,4-Diarylaminopyrimidine Analogues (DAAPalogues) Showing Potent Inhibitory Activities against Both Wild-type and Mutant ALK Kinases</span></div><div class="casAuthors">Song, Zilan; Yang, Yanhong; Liu, Zhiqing; Peng, Xia; Guo, Junfeng; Yang, Xinying; Wu, Kui; Ai, Jing; Ding, Jian; Geng, Meiyu; Zhang, Ao</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">197-211</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of new 2,4-diarylaminopyrimidine analogs (DAAPalogues) bearing a flexible amino acid side chain was developed, different from the majority of the literature reported ALK inhibitors that often possess a structurally constrained arylpiperazine fragment or its equiv. in the solvent-interaction region.  Extensive structural elaboration led to compd. I possessing IC50 values of 2.7 and 15.3 nM, resp., in the ALK wild-type and gate-keeper mutant L1196M enzymic assays.  This compd. not only showed high proliferative inhibition against ALK-addicted cells across different oncogenic forms but also effectively suppressed several ALK secondary mutant cells, including the gate-keeper L1196M and F1174L.  Significant antitumor efficacy was achieved in the ALK-driven SUP-M2 xenograft model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqM85-KYGRZZLVg90H21EOLACvtfcHk0lhKmLp8EGgFrg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXnt1Cgu7c%253D&md5=b82a016127ac916e365a2bcbace63f75</span></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.1021%2Fjm5005144&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm5005144%26sid%3Dliteratum%253Aachs%26aulast%3DSong%26aufirst%3DZ.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DPeng%26aufirst%3DX.%26aulast%3DGuo%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DWu%26aufirst%3DK.%26aulast%3DAi%26aufirst%3DJ.%26aulast%3DDing%26aufirst%3DJ.%26aulast%3DGeng%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DA.%26atitle%3DDiscovery%2520of%2520Novel%25202%252C%25204-diarylaminopyrimidine%2520Analogues%2520%2528DAAPalogues%2529%2520Showing%2520Potent%2520Inhibitory%2520Activities%2520against%2520Both%2520Wild-type%2520and%2520Mutant%2520ALK%2520Kinases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D197%26epage%3D211%26doi%3D10.1021%2Fjm5005144" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref123"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref123'); return false;" data-citation="" class="refNumLink">123</a></strong><div class="NLM_citation" id="cit123"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kuromitsu, S.</span>; <span class="NLM_string-name">Mori, M.</span>; <span class="NLM_string-name">Shimada, I.</span>; <span class="NLM_string-name">Kondoh, Y.</span>; <span class="NLM_string-name">Shindoh, N.</span>; <span class="NLM_string-name">Soga, T.</span>; <span class="NLM_string-name">Furutani, T.</span>; <span class="NLM_string-name">Konagai, S.</span>; <span class="NLM_string-name">Sakagami, H.</span>; <span class="NLM_string-name">Nakata, M.</span>; <span class="NLM_string-name">Ueno, Y.</span></span> <span> </span><span class="NLM_article-title">Anti-tumor Activity of ASP3026. A Novel and Selective ALK Inhibitor of Anaplastic Lymphoma Kinase (ALK)</span>. Presented at the  <i>Annual Meeting of the American Association for Cancer Res (AACR). Orlando, FL,</i> <span class="NLM_year">2011</span>; Abstract  <span class="NLM_fpage">2821</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&pages=2821&author=S.+Kuromitsu&author=M.+Mori&author=I.+Shimada&author=Y.+Kondoh&author=N.+Shindoh&author=T.+Soga&author=T.+Furutani&author=S.+Konagai&author=H.+Sakagami&author=M.+Nakata&author=Y.+Ueno&title=Anti-tumor+Activity+of+ASP3026.+A+Novel+and+Selective+ALK+Inhibitor+of+Anaplastic+Lymphoma+Kinase+%28ALK%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26sid%3Dliteratum%253Aachs%26aulast%3DKuromitsu%26aufirst%3DS.%26atitle%3DAnti-tumor%2520Activity%2520of%2520ASP3026.%2520A%2520Novel%2520and%2520Selective%2520ALK%2520Inhibitor%2520of%2520Anaplastic%2520Lymphoma%2520Kinase%2520%2528ALK%2529%26jtitle%3DAnnual%2520Meeting%2520of%2520the%2520American%2520Association%2520for%2520Cancer%2520Res%2520%2528AACR%2529.%2520Orlando%252C%2520FL%252C%26date%3D2011%26spage%3D2821" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref124"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref124'); return false;" data-citation="" class="refNumLink">124</a></strong><div class="NLM_citation" id="cit124"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reckamp, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Infante, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blumenschein, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wakelee, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gockerman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lovly, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dukart, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrow, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibbons, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horn, L.</span></span> <span> </span><span class="NLM_article-title">Phase I/II trial of X-396, a Novel Anaplastic Lymphoma Kinase (ALK) Inhibitor, in Patients with ALK+ Non-small Cell Lung Cancer (NSCLC)</span>. <i>J. Thorac. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">S36</span>– <span class="NLM_lpage">S37</span>, <span class="refDoi"> DOI: 10.1016/j.jtho.2015.12.062</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1016%2Fj.jtho.2015.12.062" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=S36-S37&author=K.+Reckampauthor=J.+Infanteauthor=G.+Blumenscheinauthor=H.+Wakeleeauthor=C.+Carterauthor=J.+Gockermanauthor=C.+Lovlyauthor=G.+Dukartauthor=K.+Harrowauthor=C.+Liangauthor=J.+Gibbonsauthor=L.+Horn&title=Phase+I%2FII+trial+of+X-396%2C+a+Novel+Anaplastic+Lymphoma+Kinase+%28ALK%29+Inhibitor%2C+in+Patients+with+ALK%2B+Non-small+Cell+Lung+Cancer+%28NSCLC%29&doi=10.1016%2Fj.jtho.2015.12.062"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.1016%2Fj.jtho.2015.12.062&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jtho.2015.12.062%26sid%3Dliteratum%253Aachs%26aulast%3DReckamp%26aufirst%3DK.%26aulast%3DInfante%26aufirst%3DJ.%26aulast%3DBlumenschein%26aufirst%3DG.%26aulast%3DWakelee%26aufirst%3DH.%26aulast%3DCarter%26aufirst%3DC.%26aulast%3DGockerman%26aufirst%3DJ.%26aulast%3DLovly%26aufirst%3DC.%26aulast%3DDukart%26aufirst%3DG.%26aulast%3DHarrow%26aufirst%3DK.%26aulast%3DLiang%26aufirst%3DC.%26aulast%3DGibbons%26aufirst%3DJ.%26aulast%3DHorn%26aufirst%3DL.%26atitle%3DPhase%2520I%252FII%2520trial%2520of%2520X-396%252C%2520a%2520Novel%2520Anaplastic%2520Lymphoma%2520Kinase%2520%2528ALK%2529%2520Inhibitor%252C%2520in%2520Patients%2520with%2520ALK%252B%2520Non-small%2520Cell%2520Lung%2520Cancer%2520%2528NSCLC%2529%26jtitle%3DJ.%2520Thorac.%2520Oncol.%26date%3D2016%26volume%3D11%26spage%3DS36%26epage%3DS37%26doi%3D10.1016%2Fj.jtho.2015.12.062" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref125"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref125'); return false;" data-citation="" class="refNumLink">125</a></strong><div class="NLM_citation" id="cit125"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sabbatini, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korenchuk, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowand, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leperi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atkins, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dumble, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kruger, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gontarek, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maksimchuk, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suravajjala, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lapierre, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shotwell, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chamberlain, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rabindran, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, R.</span></span> <span> </span><span class="NLM_article-title">GSK1838705A Inhibits the Insulin-like Growth Factor-1 Receptor and Anaplastic Lymphoma Kinase and Shows Antitumor Activity in Experimental Models of Human Cancers</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">2811</span>– <span class="NLM_lpage">2820</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-09-0423</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1158%2F1535-7163.MCT-09-0423" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=19825801" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1Cqur7N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2009&pages=2811-2820&author=P.+Sabbatiniauthor=S.+Korenchukauthor=J.+L.+Rowandauthor=A.+Groyauthor=Q.+Liuauthor=D.+Leperiauthor=C.+Atkinsauthor=M.+Dumbleauthor=J.+Yangauthor=K.+Andersonauthor=R.+G.+Krugerauthor=R.+R.+Gontarekauthor=K.+R.+Maksimchukauthor=S.+Suravajjalaauthor=R.+R.+Lapierreauthor=J.+B.+Shotwellauthor=J.+W.+Wilsonauthor=S.+D.+Chamberlainauthor=S.+K.+Rabindranauthor=R.+Kumar&title=GSK1838705A+Inhibits+the+Insulin-like+Growth+Factor-1+Receptor+and+Anaplastic+Lymphoma+Kinase+and+Shows+Antitumor+Activity+in+Experimental+Models+of+Human+Cancers&doi=10.1158%2F1535-7163.MCT-09-0423"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit125R"><div class="casContent"><span class="casTitleNuber">125</span><div class="casTitle"><span class="NLM_cas:atitle">GSK1838705A inhibits the insulin-like growth factor-1 receptor and anaplastic lymphoma kinase and shows antitumor activity in experimental models of human cancers</span></div><div class="casAuthors">Sabbatini, Peter; Korenchuk, Susan; Rowand, Jason L.; Groy, Arthur; Liu, Qi; Leperi, Dominic; Atkins, Charity; Dumble, Melissa; Yang, Jingsong; Anderson, Kelly; Kruger, Ryan G.; Gontarek, Richard R.; Maksimchuk, Kenneth R.; Suravajjala, Sapna; Lapierre, Russell R.; Shotwell, J. Brad; Wilson, Joseph W.; Chamberlain, Stanley D.; Rabindran, Sridhar K.; Kumar, Rakesh</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2811-2820</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The insulin-like growth factor-I receptor (IGF-IR) signaling pathway is activated in various tumors, and inhibition of IGF-IR kinase provides a therapeutic opportunity in these patients.  GSK1838705A is a small-mol. kinase inhibitor that inhibits IGF-IR and the insulin receptor with IC50s of 2.0 and 1.6 nmol/L, resp.  GSK1838705A blocks the in vitro proliferation of cell lines derived from solid and hematol. malignancies, including multiple myeloma and Ewing's sarcoma, and retards the growth of human tumor xenografts in vivo.  Despite the inhibitory effect of GSK1838705A on insulin receptor, minimal effects on glucose homeostasis were obsd. at efficacious doses.  GSK1838705A also inhibits the anaplastic lymphoma kinase (ALK), which drives the aberrant growth of anaplastic large-cell lymphomas, some neuroblastomas, and a subset of non-small cell lung cancers.  GSK1838705A inhibits ALK, with an IC50 of 0.5 nmol/L, and causes complete regression of ALK-dependent tumors in vivo at well-tolerated doses.  GSK1838705A is therefore a promising antitumor agent for therapeutic use in human cancers. [Mol Cancer Ther 2009;8(10):2811-20].</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqyQ0LEFOBer7Vg90H21EOLACvtfcHk0licKQ9v_E34GQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1Cqur7N&md5=42e56e8dd4920322b82bedd13721be5b</span></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-09-0423&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-09-0423%26sid%3Dliteratum%253Aachs%26aulast%3DSabbatini%26aufirst%3DP.%26aulast%3DKorenchuk%26aufirst%3DS.%26aulast%3DRowand%26aufirst%3DJ.%2BL.%26aulast%3DGroy%26aufirst%3DA.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DLeperi%26aufirst%3DD.%26aulast%3DAtkins%26aufirst%3DC.%26aulast%3DDumble%26aufirst%3DM.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DAnderson%26aufirst%3DK.%26aulast%3DKruger%26aufirst%3DR.%2BG.%26aulast%3DGontarek%26aufirst%3DR.%2BR.%26aulast%3DMaksimchuk%26aufirst%3DK.%2BR.%26aulast%3DSuravajjala%26aufirst%3DS.%26aulast%3DLapierre%26aufirst%3DR.%2BR.%26aulast%3DShotwell%26aufirst%3DJ.%2BB.%26aulast%3DWilson%26aufirst%3DJ.%2BW.%26aulast%3DChamberlain%26aufirst%3DS.%2BD.%26aulast%3DRabindran%26aufirst%3DS.%2BK.%26aulast%3DKumar%26aufirst%3DR.%26atitle%3DGSK1838705A%2520Inhibits%2520the%2520Insulin-like%2520Growth%2520Factor-1%2520Receptor%2520and%2520Anaplastic%2520Lymphoma%2520Kinase%2520and%2520Shows%2520Antitumor%2520Activity%2520in%2520Experimental%2520Models%2520of%2520Human%2520Cancers%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2009%26volume%3D8%26spage%3D2811%26epage%3D2820%26doi%3D10.1158%2F1535-7163.MCT-09-0423" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref126"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref126'); return false;" data-citation="" class="refNumLink">126</a></strong><div class="NLM_citation" id="cit126"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brooun, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bunker, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cook, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dack, K. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deal, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, Y.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dinh, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engstrom, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kania, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lingardo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McTigue, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmer, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, P. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sach, N. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smeal, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timofeevski, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsaparikos, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, M. P.</span></span> <span> </span><span class="NLM_article-title">Design of Potent and Selective Inhibitors to Overcome Clinical Anaplastic Lymphoma Kinase Mutations Resistant to Crizotinib</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">1170</span>– <span class="NLM_lpage">1187</span>, <span class="refDoi"> DOI: 10.1021/jm401805h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401805h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC2cXpsFaqsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=1170-1187&author=Q.+Huangauthor=T.+W.+Johnsonauthor=S.+Baileyauthor=A.+Broounauthor=K.+D.+Bunkerauthor=B.+J.+Burkeauthor=M.+R.+Collinsauthor=A.+S.+Cookauthor=J.+J.+Cuiauthor=K.+N.+Dackauthor=J.+G.+Dealauthor=Y.-L.+Dengauthor=D.+Dinhauthor=L.+D.+Engstromauthor=M.+Heauthor=J.+Hoffmanauthor=R.+L.+Hoffmanauthor=P.+S.+Johnsonauthor=R.+S.+Kaniaauthor=H.+Lamauthor=J.+L.+Lamauthor=P.+T.+Leauthor=Q.+Liauthor=L.+Lingardoauthor=W.+Liuauthor=M.+W.+Luauthor=M.+McTigueauthor=C.+L.+Palmerauthor=P.+F.+Richardsonauthor=N.+W.+Sachauthor=H.+Shenauthor=T.+Smealauthor=G.+L.+Smithauthor=A.+E.+Stewartauthor=S.+Timofeevskiauthor=K.+Tsaparikosauthor=H.+Wangauthor=H.+Zhuauthor=J.+Zhuauthor=H.+Y.+Zouauthor=M.+P.+Edwards&title=Design+of+Potent+and+Selective+Inhibitors+to+Overcome+Clinical+Anaplastic+Lymphoma+Kinase+Mutations+Resistant+to+Crizotinib&doi=10.1021%2Fjm401805h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit126R"><div class="casContent"><span class="casTitleNuber">126</span><div class="casTitle"><span class="NLM_cas:atitle">Design of Potent and Selective Inhibitors to Overcome Clinical Anaplastic Lymphoma Kinase Mutations Resistant to Crizotinib</span></div><div class="casAuthors">Huang, Qinhua; Johnson, Ted W.; Bailey, Simon; Brooun, Alexei; Bunker, Kevin D.; Burke, Benjamin J.; Collins, Michael R.; Cook, Andrew S.; Cui, J. Jean; Dack, Kevin N.; Deal, Judith G.; Deng, Ya-Li; Dinh, Dac; Engstrom, Lars D.; He, Mingying; Hoffman, Jacqui; Hoffman, Robert L.; Johnson, Patrick S.; Kania, Robert S.; Lam, Hieu; Lam, Justine L.; Le, Phuong T.; Li, Qiuhua; Lingardo, Laura; Liu, Wei; Lu, Melissa West; McTigue, Michele; Palmer, Cynthia L.; Richardson, Paul F.; Sach, Neal W.; Shen, Hong; Smeal, Tod; Smith, Graham L.; Stewart, Albert E.; Timofeevski, Sergei; Tsaparikos, Konstantinos; Wang, Hui; Zhu, Huichun; Zhu, Jinjiang; Zou, Helen Y.; Edwards, Martin P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1170-1187</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Crizotinib, an anaplastic lymphoma kinase (ALK) receptor tyrosine kinase inhibitor approved by the U.S.  Food and Drug Administration in 2011, is efficacious in ALK and ROS pos. patients.  Under pressure of crizotinib treatment, point mutations arise in the kinase domain of ALK, resulting in resistance and progressive disease.  The successful application of both structure-based and lipophilic-efficiency-focused drug design resulted in aminopyridine (I), which was potent across a broad panel of engineered ALK mutant cell lines and showed suitable preclin. pharmacokinetics and robust tumor growth inhibition in a crizotinib-resistant cell line (H3122-L1196M).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnhF6vRWLUrrVg90H21EOLACvtfcHk0licKQ9v_E34GQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXpsFaqsg%253D%253D&md5=c12e0400ac92eb3321fde81ee13a5e92</span></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=10.1021%2Fjm401805h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401805h%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DQ.%26aulast%3DJohnson%26aufirst%3DT.%2BW.%26aulast%3DBailey%26aufirst%3DS.%26aulast%3DBrooun%26aufirst%3DA.%26aulast%3DBunker%26aufirst%3DK.%2BD.%26aulast%3DBurke%26aufirst%3DB.%2BJ.%26aulast%3DCollins%26aufirst%3DM.%2BR.%26aulast%3DCook%26aufirst%3DA.%2BS.%26aulast%3DCui%26aufirst%3DJ.%2BJ.%26aulast%3DDack%26aufirst%3DK.%2BN.%26aulast%3DDeal%26aufirst%3DJ.%2BG.%26aulast%3DDeng%26aufirst%3DY.-L.%26aulast%3DDinh%26aufirst%3DD.%26aulast%3DEngstrom%26aufirst%3DL.%2BD.%26aulast%3DHe%26aufirst%3DM.%26aulast%3DHoffman%26aufirst%3DJ.%26aulast%3DHoffman%26aufirst%3DR.%2BL.%26aulast%3DJohnson%26aufirst%3DP.%2BS.%26aulast%3DKania%26aufirst%3DR.%2BS.%26aulast%3DLam%26aufirst%3DH.%26aulast%3DLam%26aufirst%3DJ.%2BL.%26aulast%3DLe%26aufirst%3DP.%2BT.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DLingardo%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DLu%26aufirst%3DM.%2BW.%26aulast%3DMcTigue%26aufirst%3DM.%26aulast%3DPalmer%26aufirst%3DC.%2BL.%26aulast%3DRichardson%26aufirst%3DP.%2BF.%26aulast%3DSach%26aufirst%3DN.%2BW.%26aulast%3DShen%26aufirst%3DH.%26aulast%3DSmeal%26aufirst%3DT.%26aulast%3DSmith%26aufirst%3DG.%2BL.%26aulast%3DStewart%26aufirst%3DA.%2BE.%26aulast%3DTimofeevski%26aufirst%3DS.%26aulast%3DTsaparikos%26aufirst%3DK.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DZhu%26aufirst%3DH.%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DZou%26aufirst%3DH.%2BY.%26aulast%3DEdwards%26aufirst%3DM.%2BP.%26atitle%3DDesign%2520of%2520Potent%2520and%2520Selective%2520Inhibitors%2520to%2520Overcome%2520Clinical%2520Anaplastic%2520Lymphoma%2520Kinase%2520Mutations%2520Resistant%2520to%2520Crizotinib%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D1170%26epage%3D1187%26doi%3D10.1021%2Fjm401805h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref127"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref127'); return false;" data-citation="" class="refNumLink">127</a></strong><div class="NLM_citation" id="cit127"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hatcher, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bahcall, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, H. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sim, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">George, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jänne, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span> <span> </span><span class="NLM_article-title">Discovery of Inhibitors that Overcome the G1202R Anaplastic Lymphoma Kinase Resistance Mutation</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">9296</span>– <span class="NLM_lpage">9308</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01136</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01136" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvVehs7vE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=9296-9308&author=J.+M.+Hatcherauthor=M.+Bahcallauthor=H.+G.+Choiauthor=Y.+Gaoauthor=T.+Simauthor=R.+Georgeauthor=P.+A.+J%C3%A4nneauthor=N.+S.+Gray&title=Discovery+of+Inhibitors+that+Overcome+the+G1202R+Anaplastic+Lymphoma+Kinase+Resistance+Mutation&doi=10.1021%2Facs.jmedchem.5b01136"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit127R"><div class="casContent"><span class="casTitleNuber">127</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Inhibitors That Overcome the G1202R Anaplastic Lymphoma Kinase Resistance Mutation</span></div><div class="casAuthors">Hatcher, John M.; Bahcall, Magda; Choi, Hwan Geun; Gao, Yang; Sim, Taebo; George, Rani; Janne, Pasi A.; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">9296-9308</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The treatment of patients with advanced nonsmall-cell lung cancer harboring chromosomal rearrangements of anaplastic lymphoma kinase (ALK) has been revolutionized by the development of crizotinib, a small-mol. inhibitor of ALK, ROS1, and MET.  However, resistance to crizotinib inevitably develops through a variety of mechanisms, leading to relapse both systemically and in the central nervous system (CNS).  This has motivated the development of "second-generation" ALK inhibitors, including alectinib and ceritinib, that overcome some of the mutations leading to resistance.  However, most of the reported ALK inhibitors do not show inhibition of the G1202R mutant, which is one of the most common mutations.  Herein, the authors report the development of a structural analog of alectinib I that is potent against the G1202R mutant as well as a variety of other frequently obsd. mutants.  In addn., I is capable of penetrating the CNS of mice following oral dosing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoI_JJeOYNwybVg90H21EOLACvtfcHk0liWfBf-8Fh8lA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvVehs7vE&md5=711b0353b771b54990264565c901a76f</span></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01136&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01136%26sid%3Dliteratum%253Aachs%26aulast%3DHatcher%26aufirst%3DJ.%2BM.%26aulast%3DBahcall%26aufirst%3DM.%26aulast%3DChoi%26aufirst%3DH.%2BG.%26aulast%3DGao%26aufirst%3DY.%26aulast%3DSim%26aufirst%3DT.%26aulast%3DGeorge%26aufirst%3DR.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DDiscovery%2520of%2520Inhibitors%2520that%2520Overcome%2520the%2520G1202R%2520Anaplastic%2520Lymphoma%2520Kinase%2520Resistance%2520Mutation%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D9296%26epage%3D9308%26doi%3D10.1021%2Facs.jmedchem.5b01136" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref128"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref128'); return false;" data-citation="" class="refNumLink">128</a></strong><div class="NLM_citation" id="cit128"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fushimi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujimori, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wakabayashi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hasui, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawakita, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imamura, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kato, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murakami, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishii, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kikko, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kasahara, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakatani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hiura, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyamoto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saikatendu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawson, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imoto, H.</span></span> <span> </span><span class="NLM_article-title">Discovery of Potent, Selective, and Brain-Penetrant 1 H-Pyrazol-5-yl-1H-pyrrolo [2, 3-b] pyridines as Anaplastic Lymphoma Kinase (ALK) Inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">4915</span>– <span class="NLM_lpage">4935</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01630</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01630" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC1MXnvFCgsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=4915-4935&author=M.+Fushimiauthor=I.+Fujimoriauthor=T.+Wakabayashiauthor=T.+Hasuiauthor=Y.+Kawakitaauthor=K.+Imamuraauthor=T.+Katoauthor=M.+Murakamiauthor=T.+Ishiiauthor=Y.+Kikkoauthor=M.+Kasaharaauthor=A.+Nakataniauthor=Y.+Hiuraauthor=M.+Miyamotoauthor=K.+Saikatenduauthor=H.+Zouauthor=S.+W.+Laneauthor=J.+D.+Lawsonauthor=H.+Imoto&title=Discovery+of+Potent%2C+Selective%2C+and+Brain-Penetrant+1+H-Pyrazol-5-yl-1H-pyrrolo+%5B2%2C+3-b%5D+pyridines+as+Anaplastic+Lymphoma+Kinase+%28ALK%29+Inhibitors&doi=10.1021%2Facs.jmedchem.8b01630"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit128R"><div class="casContent"><span class="casTitleNuber">128</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of potent, selective, and brain-penetrant 1H-pyrazol-5-yl-1H-pyrrolo[2,3-b]pyridines as anaplastic lymphoma kinase (ALK) inhibitors</span></div><div class="casAuthors">Fushimi, Makoto; Fujimori, Ikuo; Wakabayashi, Takeshi; Hasui, Tomoaki; Kawakita, Youichi; Imamura, Keisuke; Kato, Tomoko; Murakami, Morio; Ishii, Tsuyoshi; Kikko, Yorifumi; Kasahara, Maki; Nakatani, Atsushi; Hiura, Yuto; Miyamoto, Maki; Saikatendu, Kumar; Zou, Hua; Lane, Scott Weston; Lawson, J. David; Imoto, Hiroshi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4915-4935</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Anaplastic lymphoma kinase (ALK), a member of the receptor tyrosine kinase family, is predominantly expressed in the brain and implicated in neuronal development and cognition.  However, the detailed function of ALK in the central nervous system (CNS) is still unclear.  To elucidate the role of ALK in the CNS, it was necessary to discover a potent, selective, and brain-penetrant ALK inhibitor.  Scaffold hopping and lead optimization of N-(2,4-difluorobenzyl)-3-(1H-pyrazol-5-yl)imidazo[1,2-b]pyridazin-6-amine 1 guided by a cocrystal structure of compd. 1 bound to ALK resulted in the identification of (6-(1-(5-fluoropyridin-2-yl)ethoxy)-1-(5-methyl-1H-pyrazol-3-yl)-1H-pyrrolo[2,3-b]pyridin-3-yl)((2S)-2-methylmorpholin-4-yl)methanone 13 as a highly potent, selective, and brain-penetrable compd.  I.p. administration of compd. 13 significantly decreased the phosphorylated-ALK (p-ALK) levels in the hippocampus and prefrontal cortex in the mouse brain.  These results suggest that compd. 13 could serve as a useful chem. probe to elucidate the mechanism of ALK-mediated brain functions and the therapeutic potential of ALK inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq0WiOsZo1xFLVg90H21EOLACvtfcHk0liWfBf-8Fh8lA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXnvFCgsrg%253D&md5=8d3bac7f718930a6102cb7855af501cb</span></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01630&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01630%26sid%3Dliteratum%253Aachs%26aulast%3DFushimi%26aufirst%3DM.%26aulast%3DFujimori%26aufirst%3DI.%26aulast%3DWakabayashi%26aufirst%3DT.%26aulast%3DHasui%26aufirst%3DT.%26aulast%3DKawakita%26aufirst%3DY.%26aulast%3DImamura%26aufirst%3DK.%26aulast%3DKato%26aufirst%3DT.%26aulast%3DMurakami%26aufirst%3DM.%26aulast%3DIshii%26aufirst%3DT.%26aulast%3DKikko%26aufirst%3DY.%26aulast%3DKasahara%26aufirst%3DM.%26aulast%3DNakatani%26aufirst%3DA.%26aulast%3DHiura%26aufirst%3DY.%26aulast%3DMiyamoto%26aufirst%3DM.%26aulast%3DSaikatendu%26aufirst%3DK.%26aulast%3DZou%26aufirst%3DH.%26aulast%3DLane%26aufirst%3DS.%2BW.%26aulast%3DLawson%26aufirst%3DJ.%2BD.%26aulast%3DImoto%26aufirst%3DH.%26atitle%3DDiscovery%2520of%2520Potent%252C%2520Selective%252C%2520and%2520Brain-Penetrant%25201%2520H-Pyrazol-5-yl-1H-pyrrolo%2520%255B2%252C%25203-b%255D%2520pyridines%2520as%2520Anaplastic%2520Lymphoma%2520Kinase%2520%2528ALK%2529%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D4915%26epage%3D4935%26doi%3D10.1021%2Facs.jmedchem.8b01630" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref129"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref129'); return false;" data-citation="" class="refNumLink">129</a></strong><div class="NLM_citation" id="cit129"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Drilon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ou, S.-H. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, V. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, M.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camidge, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhai, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogers, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitten, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stopatschinskaja, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hyman, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doebele, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, A. T.</span></span> <span> </span><span class="NLM_article-title">Repotrectinib (TPX-0005) Is a Next-generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent-front Mutations</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1227</span>– <span class="NLM_lpage">1236</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-18-0484</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1158%2F2159-8290.CD-18-0484" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=30093503" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC1MXmt1ehtLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2018&pages=1227-1236&author=A.+Drilonauthor=S.-H.+I.+Ouauthor=B.+C.+Choauthor=D.-W.+Kimauthor=J.+Leeauthor=J.+J.+Linauthor=V.+W.+Zhuauthor=M.-J.+Ahnauthor=D.+R.+Camidgeauthor=J.+Nguyenauthor=D.+Zhaiauthor=W.+Dengauthor=Z.+Huangauthor=E.+Rogersauthor=J.+Liuauthor=J.+Whittenauthor=J.+K.+Limauthor=S.+Stopatschinskajaauthor=D.+M.+Hymanauthor=R.+C.+Doebeleauthor=J.+J.+Cuiauthor=A.+T.+Shaw&title=Repotrectinib+%28TPX-0005%29+Is+a+Next-generation+ROS1%2FTRK%2FALK+Inhibitor+That+Potently+Inhibits+ROS1%2FTRK%2FALK+Solvent-front+Mutations&doi=10.1158%2F2159-8290.CD-18-0484"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit129R"><div class="casContent"><span class="casTitleNuber">129</span><div class="casTitle"><span class="NLM_cas:atitle">Repotrectinib (TPX-0005) is a next-generation ROS1/TRK/ALK inhibitor that potently inhibits ROS1/TRK/ALK solvent-front mutations</span></div><div class="casAuthors">Drilon, Alexander; Ou, Sai-Hong Ignatius; Cho, Byoung Chul; Kim, Dong-Wan; Lee, Jeeyun; Lin, Jessica J.; Zhu, Viola W.; Ahn, Myung-Ju; Camidge, D. Ross; Nguyen, Judy; Zhai, Dayong; Deng, Wei; Huang, Zhongdong; Rogers, Evan; Liu, Juliet; Whitten, Jeff; Lim, John K.; Stopatschinskaja, Shanna; Hyman, David M.; Doebele, Robert C.; Cui, J. Jean; Shaw, Alice T.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1227-1236</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The use of tyrosine kinase inhibitors (TKI) with activity against ALK, ROS1, or TRKA-C can result in signifi cant clin. benefit in patients with diverse tumors harboring ALK, ROS1, or NTRK1-3 rearrangements; however, resistance invariably develops.  The emergence of on-target kinase domain mutations represents a major mechanism of acquired resistance.  Solvent-front substitutions such as ALKG1202R, ROS1G2032R or ROS1D2033N, TRKAG595R, and TRKCG623R are among the most recalcitrant of these mechanisms.  Repotrectinib (TPX-0005) is a rationally designed, low-mol.-wt., macrocyclic TKI that is selective and highly potent against ROS1, TRKA-C, and ALK.  Importantly, repotrectinib exhibits activity against a variety of solventfront substitutions in vitro and in vivo.  As clin. proof of concept, in an ongoing first-in-human phase I/II trial, repotrectinib achieved confirmed responses in patients with ROS1 or NTRK3 fusion- pos. cancers who had relapsed on earlier-generation TKIs due to ROS1 or TRKC solvent-front substitution-mediated resistance.  SIGNIFICANCE: Repotrectinib (TPX-0005), a next-generation ROS1, pan-TRK, and ALK TKI, overcomes resistance due to acquired solvent-front mutations involving ROS1, NTRK1-3, and ALK.  Repotrectinib may represent an effective therapeutic option for patients with ROS1-, NTRK1-3-, or ALK-rearranged malignancies who have progressed on earlier-generation TKIs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpNmuKNmAgWKLVg90H21EOLACvtfcHk0ljEzvyIcg9JuA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXmt1ehtLs%253D&md5=b5408bf045e049629557cb347ab61980</span></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-18-0484&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-18-0484%26sid%3Dliteratum%253Aachs%26aulast%3DDrilon%26aufirst%3DA.%26aulast%3DOu%26aufirst%3DS.-H.%2BI.%26aulast%3DCho%26aufirst%3DB.%2BC.%26aulast%3DKim%26aufirst%3DD.-W.%26aulast%3DLee%26aufirst%3DJ.%26aulast%3DLin%26aufirst%3DJ.%2BJ.%26aulast%3DZhu%26aufirst%3DV.%2BW.%26aulast%3DAhn%26aufirst%3DM.-J.%26aulast%3DCamidge%26aufirst%3DD.%2BR.%26aulast%3DNguyen%26aufirst%3DJ.%26aulast%3DZhai%26aufirst%3DD.%26aulast%3DDeng%26aufirst%3DW.%26aulast%3DHuang%26aufirst%3DZ.%26aulast%3DRogers%26aufirst%3DE.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DWhitten%26aufirst%3DJ.%26aulast%3DLim%26aufirst%3DJ.%2BK.%26aulast%3DStopatschinskaja%26aufirst%3DS.%26aulast%3DHyman%26aufirst%3DD.%2BM.%26aulast%3DDoebele%26aufirst%3DR.%2BC.%26aulast%3DCui%26aufirst%3DJ.%2BJ.%26aulast%3DShaw%26aufirst%3DA.%2BT.%26atitle%3DRepotrectinib%2520%2528TPX-0005%2529%2520Is%2520a%2520Next-generation%2520ROS1%252FTRK%252FALK%2520Inhibitor%2520That%2520Potently%2520Inhibits%2520ROS1%252FTRK%252FALK%2520Solvent-front%2520Mutations%26jtitle%3DCancer%2520Discovery%26date%3D2018%26volume%3D8%26spage%3D1227%26epage%3D1236%26doi%3D10.1158%2F2159-8290.CD-18-0484" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref130"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref130'); return false;" data-citation="" class="refNumLink">130</a></strong><div class="NLM_citation" id="cit130"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gingrich, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lisko, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curry, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quail, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albom, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angeles, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aimone, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haltiwanger, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wells-Knecht, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ott, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghose, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ator, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruggeri, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dorsey, B. D.</span></span> <span> </span><span class="NLM_article-title">Discovery of an Orally Efficacious Inhibitor of Anaplastic Lymphoma Kinase</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">4580</span>– <span class="NLM_lpage">4593</span>, <span class="refDoi"> DOI: 10.1021/jm201550q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm201550q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC38Xms1Sks7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=4580-4593&author=D.+E.+Gingrichauthor=J.+G.+Liskoauthor=M.+A.+Curryauthor=M.+Chengauthor=M.+Quailauthor=L.+Luauthor=W.+Wanauthor=M.+S.+Albomauthor=T.+S.+Angelesauthor=L.+D.+Aimoneauthor=R.+C.+Haltiwangerauthor=K.+Wells-Knechtauthor=G.+R.+Ottauthor=A.+K.+Ghoseauthor=M.+A.+Atorauthor=B.+Ruggeriauthor=B.+D.+Dorsey&title=Discovery+of+an+Orally+Efficacious+Inhibitor+of+Anaplastic+Lymphoma+Kinase&doi=10.1021%2Fjm201550q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit130R"><div class="casContent"><span class="casTitleNuber">130</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of an orally efficacious inhibitor of anaplastic lymphoma kinase</span></div><div class="casAuthors">Gingrich, Diane E.; Lisko, Joseph G.; Curry, Matthew A.; Cheng, Mangeng; Quail, Matthew; Lu, Lihui; Wan, Weihua; Albom, Mark S.; Angeles, Thelma S.; Aimone, Lisa D.; Haltiwanger, R. Curtis; Wells-Knecht, Kevin; Ott, Gregory R.; Ghose, Arup K.; Ator, Mark A.; Ruggeri, Bruce; Dorsey, Bruce D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4580-4593</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Anaplastic lymphoma kinase (ALK) is a promising therapeutic target for the treatment of cancer, supported by considerable favorable preclin. and clin. activities over the past several years and culminating in the recent FDA approval of the ALK inhibitor crizotinib.  Through a series of targeted modifications on an ALK inhibitor diaminopyrimidine scaffold, our research group has driven improvements in ALK potency, kinase selectivity, and overall pharmaceutical properties.  Optimization of this scaffold has led to the identification of a potent and efficacious inhibitor of ALK, I.  A striking feature of I over previously described ALK inhibitors is its >600-fold selectivity over insulin receptor (IR), a closely related kinase family member.  Most importantly, I exhibited dose proportional escalation in rat compared to compd. 3 which suffered dose limiting absorption preventing further advancement.  Compd. I exhibited significant in vivo antitumor efficacy when dosed orally in an ALK-pos. ALCL tumor xenograft model in SCID mice, warranting further assessment in advanced preclin. models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqX3rG4B6V3Y7Vg90H21EOLACvtfcHk0ljEzvyIcg9JuA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xms1Sks7s%253D&md5=f0592f6eb9d22a5b8e70ab5d3499f821</span></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=10.1021%2Fjm201550q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm201550q%26sid%3Dliteratum%253Aachs%26aulast%3DGingrich%26aufirst%3DD.%2BE.%26aulast%3DLisko%26aufirst%3DJ.%2BG.%26aulast%3DCurry%26aufirst%3DM.%2BA.%26aulast%3DCheng%26aufirst%3DM.%26aulast%3DQuail%26aufirst%3DM.%26aulast%3DLu%26aufirst%3DL.%26aulast%3DWan%26aufirst%3DW.%26aulast%3DAlbom%26aufirst%3DM.%2BS.%26aulast%3DAngeles%26aufirst%3DT.%2BS.%26aulast%3DAimone%26aufirst%3DL.%2BD.%26aulast%3DHaltiwanger%26aufirst%3DR.%2BC.%26aulast%3DWells-Knecht%26aufirst%3DK.%26aulast%3DOtt%26aufirst%3DG.%2BR.%26aulast%3DGhose%26aufirst%3DA.%2BK.%26aulast%3DAtor%26aufirst%3DM.%2BA.%26aulast%3DRuggeri%26aufirst%3DB.%26aulast%3DDorsey%26aufirst%3DB.%2BD.%26atitle%3DDiscovery%2520of%2520an%2520Orally%2520Efficacious%2520Inhibitor%2520of%2520Anaplastic%2520Lymphoma%2520Kinase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D4580%26epage%3D4593%26doi%3D10.1021%2Fjm201550q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref131"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref131'); return false;" data-citation="" class="refNumLink">131</a></strong><div class="NLM_citation" id="cit131"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Salem, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alsalahi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chervoneva, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aburto, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Addya, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ott, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruggeri, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cristofanilli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandez, S. V.</span></span> <span> </span><span class="NLM_article-title">The effects of CEP-37440, an Inhibitor of Focal Adhesion Kinase, in Vitro and in Vivo on Inflammatory Breast Cancer Cells</span>. <i>Breast Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">37</span>– <span class="NLM_lpage">52</span>, <span class="refDoi"> DOI: 10.1186/s13058-016-0694-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1186%2Fs13058-016-0694-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=27009091" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC2sXisVOhsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2016&pages=37-52&author=I.+Salemauthor=M.+Alsalahiauthor=I.+Chervonevaauthor=L.+D.+Aburtoauthor=S.+Addyaauthor=G.+R.+Ottauthor=B.+A.+Ruggeriauthor=M.+Cristofanilliauthor=S.+V.+Fernandez&title=The+effects+of+CEP-37440%2C+an+Inhibitor+of+Focal+Adhesion+Kinase%2C+in+Vitro+and+in+Vivo+on+Inflammatory+Breast+Cancer+Cells&doi=10.1186%2Fs13058-016-0694-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit131R"><div class="casContent"><span class="casTitleNuber">131</span><div class="casTitle"><span class="NLM_cas:atitle">The effects of CEP-37440, an inhibitor of focal adhesion kinase, in vitro and in vivo on inflammatory breast cancer cells</span></div><div class="casAuthors">Salem, Israa; Alsalahi, Manal; Chervoneva, Inna; Aburto, Lucy D.; Addya, Sankar; Ott, Gregory R.; Ruggeri, Bruce A.; Cristofanilli, Massimo; Fernandez, Sandra V.</div><div class="citationInfo"><span class="NLM_cas:title">Breast Cancer Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">37/1-37/15</span>CODEN:
                <span class="NLM_cas:coden">BRCRFS</span>;
        ISSN:<span class="NLM_cas:issn">1465-542X</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Inflammatory breast cancer (IBC) is an aggressive type of advanced breast cancer with a poor prognosis.  We recently found that focal adhesion kinase 1 (FAK1) is upregulated and phosphorylated (active) in IBC.  In this study, we investigated the effect of CEP-37440, a dual inhibitor of FAK1 and anaplastic lymphoma kinase (ALK), using human IBC cell lines and preclin. models of IBC.  Cell proliferation assays were performed in the presence of several concns. of CEP-37440 using IBC and triple-neg. breast cancer non-IBC cell lines.  In vitro, we studied the expression of total FAK1, phospho-FAK1 (Tyr 397), total ALK and phospho-ALK (Tyr 1604).  In vivo, we tested CEP-37440 using FC-IBC02, SUM149, and SUM190 IBC xenograft mouse models.  CEP-37440 at low concn. decreased the proliferation of the IBC cell lines FC-IBC02, SUM190, and KPL4, while not affecting the proliferation of normal breast epithelial cells.  At higher concn., CEP-37440 was also able to inhibit the proliferation of the IBC cell line MDA-IBC03 and the triple-neg. non-IBC cell lines MDA-MB-231 and MDA-MB-468; the IBC cell line SUM149 showed a slight response to the drug.  CEP-37440 decreased the cell proliferation of FC-IBC02, SUM190, and KPL4 by blocking the autophosphorylation kinase activity of FAK1 (Tyr 397).  None of the cells evaluated expressed ALK.  In vivo, after 7 wk of CEP-37440 treatment, the SUM190, FC-IBC02, and SUM149 breast tumor xenografts were smaller in mice treated with 55 mg/kg bid CEP-37440 compared to the controls; the tumor growth inhibition (TGI) was 79.7 %, 33 %, and 23 %, resp.  None of the FC-IBC02 breast xenografts mice treated with CEP-37440 developed brain metastasis while 20 % of the mice in the control group developed brain metastasis.  Expression array analyses in FC-IBC02 cells showed that CEP-37440 affects the expression of genes related to apoptosis, interferon signaling, and cytokines.  CEP-37440 is effective against some IBC cells that express phospho-FAK1 (Tyr 397), and its antiproliferative activity is related to its ability to decrease phospho-FAK1.  Our results suggest that combinational therapies could be more effective than using CEP-37440 as a single agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGouzKOMoopU8rVg90H21EOLACvtfcHk0ljEzvyIcg9JuA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXisVOhsL8%253D&md5=d69c00c3a502a33f80d58dcc04337596</span></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=10.1186%2Fs13058-016-0694-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13058-016-0694-4%26sid%3Dliteratum%253Aachs%26aulast%3DSalem%26aufirst%3DI.%26aulast%3DAlsalahi%26aufirst%3DM.%26aulast%3DChervoneva%26aufirst%3DI.%26aulast%3DAburto%26aufirst%3DL.%2BD.%26aulast%3DAddya%26aufirst%3DS.%26aulast%3DOtt%26aufirst%3DG.%2BR.%26aulast%3DRuggeri%26aufirst%3DB.%2BA.%26aulast%3DCristofanilli%26aufirst%3DM.%26aulast%3DFernandez%26aufirst%3DS.%2BV.%26atitle%3DThe%2520effects%2520of%2520CEP-37440%252C%2520an%2520Inhibitor%2520of%2520Focal%2520Adhesion%2520Kinase%252C%2520in%2520Vitro%2520and%2520in%2520Vivo%2520on%2520Inflammatory%2520Breast%2520Cancer%2520Cells%26jtitle%3DBreast%2520Cancer%2520Res.%26date%3D2016%26volume%3D18%26spage%3D37%26epage%3D52%26doi%3D10.1186%2Fs13058-016-0694-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref132"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref132'); return false;" data-citation="" class="refNumLink">132</a></strong><div class="NLM_citation" id="cit132"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Drew, L.</span>; <span class="NLM_string-name">Cheng, J.</span>; <span class="NLM_string-name">Engelman, J.</span>; <span class="NLM_string-name">Ferguson, D.</span>; <span class="NLM_string-name">Katayama, R.</span>; <span class="NLM_string-name">McDermott, B.</span>; <span class="NLM_string-name">Saeh, J.</span>; <span class="NLM_string-name">Shaw, A.</span>; <span class="NLM_string-name">Shen, M.</span>; <span class="NLM_string-name">Widzowski, D.</span>; <span class="NLM_string-name">Wu, A.</span></span> <span> </span><span class="NLM_article-title">AZD3463, a novel ALK/IGF1R inhibitor, Overcomes Multiple Mechanisms of Acquired Resistance to Crizotinib</span>. Presented at the  <i>104th Annual Meeting of the American Association for Cancer Research, Washington, DC,</i> <span class="NLM_year">2013</span>; Abstract  <span class="NLM_fpage">919</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&pages=919&author=L.+Drew&author=J.+Cheng&author=J.+Engelman&author=D.+Ferguson&author=R.+Katayama&author=B.+McDermott&author=J.+Saeh&author=A.+Shaw&author=M.+Shen&author=D.+Widzowski&author=A.+Wu&title=AZD3463%2C+a+novel+ALK%2FIGF1R+inhibitor%2C+Overcomes+Multiple+Mechanisms+of+Acquired+Resistance+to+Crizotinib"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26sid%3Dliteratum%253Aachs%26aulast%3DDrew%26aufirst%3DL.%26atitle%3DAZD3463%252C%2520a%2520novel%2520ALK%252FIGF1R%2520inhibitor%252C%2520Overcomes%2520Multiple%2520Mechanisms%2520of%2520Acquired%2520Resistance%2520to%2520Crizotinib%26jtitle%3D104th%2520Annual%2520Meeting%2520of%2520the%2520American%2520Association%2520for%2520Cancer%2520Research%252C%2520Washington%252C%2520DC%252C%26date%3D2013%26spage%3D919" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref133"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref133'); return false;" data-citation="" class="refNumLink">133</a></strong><div class="NLM_citation" id="cit133"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pang, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akiyama, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muscal, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span> <span> </span><span class="NLM_article-title">Novel ALK inhibitor AZD3463 Inhibits Neuroblastoma Growth by Overcoming Crizotinib Resistance and Inducing Apoptosis</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">19423</span>, <span class="refDoi"> DOI: 10.1038/srep19423</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1038%2Fsrep19423" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=26786851" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1ertrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2016&pages=19423&author=Y.+Wangauthor=L.+Wangauthor=S.+Guanauthor=W.+Caoauthor=H.+Wangauthor=Z.+Chenauthor=Y.+Zhaoauthor=Y.+Yuauthor=H.+Zhangauthor=J.+C.+Pangauthor=S.+L.+Huangauthor=Y.+Akiyamaauthor=Y.+Yangauthor=W.+Sunauthor=X.+Xuauthor=Y.+Shiauthor=H.+Zhangauthor=E.+S.+Kimauthor=J.+A.+Muscalauthor=F.+Luauthor=J.+Yang&title=Novel+ALK+inhibitor+AZD3463+Inhibits+Neuroblastoma+Growth+by+Overcoming+Crizotinib+Resistance+and+Inducing+Apoptosis&doi=10.1038%2Fsrep19423"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit133R"><div class="casContent"><span class="casTitleNuber">133</span><div class="casTitle"><span class="NLM_cas:atitle">Novel ALK inhibitor AZD3463 inhibits neuroblastoma growth by overcoming crizotinib resistance and inducing apoptosis</span></div><div class="casAuthors">Wang, Yongfeng; Wang, Long; Guan, Shan; Cao, Wenming; Wang, Hao; Chen, Zhenghu; Zhao, Yanling; Yu, Yang; Zhang, Huiyuan; Pang, Jonathan C.; Huang, Sophia L.; Akiyama, Yo; Yang, Yifan; Sun, Wenjing; Xu, Xin; Shi, Yan; Zhang, Hong; Kim, Eugene S.; Muscal, Jodi A.; Lu, Fengmin; Yang, Jianhua</div><div class="citationInfo"><span class="NLM_cas:title">Scientific Reports</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">19423</span>CODEN:
                <span class="NLM_cas:coden">SRCEC3</span>;
        ISSN:<span class="NLM_cas:issn">2045-2322</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">ALK receptor tyrosine kinase has been shown to be a therapeutic target in neuroblastoma.  Germline ALK activating mutations are responsible for the majority of hereditary neuroblastoma and somatic ALK activating mutations are also frequently obsd. in sporadic cases of advanced NB.  Crizotinib, a first-line therapy in the treatment of advanced non-small cell lung cancer (NSCLC) harboring ALK rearrangements, demonstrates striking efficacy against ALK-rearranged NB.  However, crizotinib fails to effectively inhibit the activity of ALK when activating mutations are present within its kinase domain, as with the F1174L mutation.  Here we show that a new ALK inhibitor AZD3463 effectively suppressed the proliferation of NB cell lines with wild type ALK (WT) as well as ALK activating mutations (F1174L and D1091N) by blocking the ALK-mediated PI3K/AKT/mTOR pathway and ultimately induced apoptosis and autophagy.  In addn., AZD3463 enhanced the cytotoxic effects of doxorubicin on NB cells.  AZD3463 also exhibited significant therapeutic efficacy on the growth of the NB tumors with WT and F1174L activating mutation ALK in orthotopic xenograft mouse models.  These results indicate that AZD3463 is a promising therapeutic agent in the treatment of NB.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxpTw1vcCp5LVg90H21EOLACvtfcHk0li2Cf0tXkna5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1ertrc%253D&md5=d0411dbc4fa257861c010195baaa17b7</span></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=10.1038%2Fsrep19423&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep19423%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DGuan%26aufirst%3DS.%26aulast%3DCao%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DYu%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DPang%26aufirst%3DJ.%2BC.%26aulast%3DHuang%26aufirst%3DS.%2BL.%26aulast%3DAkiyama%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DSun%26aufirst%3DW.%26aulast%3DXu%26aufirst%3DX.%26aulast%3DShi%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DKim%26aufirst%3DE.%2BS.%26aulast%3DMuscal%26aufirst%3DJ.%2BA.%26aulast%3DLu%26aufirst%3DF.%26aulast%3DYang%26aufirst%3DJ.%26atitle%3DNovel%2520ALK%2520inhibitor%2520AZD3463%2520Inhibits%2520Neuroblastoma%2520Growth%2520by%2520Overcoming%2520Crizotinib%2520Resistance%2520and%2520Inducing%2520Apoptosis%26jtitle%3DSci.%2520Rep.%26date%3D2016%26volume%3D6%26spage%3D19423%26doi%3D10.1038%2Fsrep19423" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref134"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref134'); return false;" data-citation="" class="refNumLink">134</a></strong><div class="NLM_citation" id="cit134"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shih, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Q.</span></span> <span> </span><span class="NLM_article-title">Design and Synthesis of Novel 3-sulfonylpyrazol-4-amino Pyrimidines as Potent Anaplastic Lymphoma Kinase (ALK) Inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">1910</span>– <span class="NLM_lpage">1918</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2016.03.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1016%2Fj.bmcl.2016.03.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=26979157" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC28XktFekt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=1910-1918&author=P.+Zhangauthor=J.+Dongauthor=B.+Zhongauthor=D.+Zhangauthor=H.+Yuanauthor=C.+Jinauthor=X.+Xuauthor=H.+Liauthor=Y.+Zhouauthor=Z.+Liangauthor=M.+Jiauthor=T.+Xuauthor=G.+Songauthor=L.+Zhangauthor=G.+Chenauthor=X.+Mengauthor=D.+Sunauthor=J.+Shihauthor=R.+Zhangauthor=G.+Houauthor=C.+Wangauthor=Y.+Jinauthor=Q.+Yang&title=Design+and+Synthesis+of+Novel+3-sulfonylpyrazol-4-amino+Pyrimidines+as+Potent+Anaplastic+Lymphoma+Kinase+%28ALK%29+Inhibitors&doi=10.1016%2Fj.bmcl.2016.03.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit134R"><div class="casContent"><span class="casTitleNuber">134</span><div class="casTitle"><span class="NLM_cas:atitle">Design and synthesis of novel 3-sulfonylpyrazol-4-amino pyrimidines as potent anaplastic lymphoma kinase (ALK) inhibitors</span></div><div class="casAuthors">Zhang, Peilong; Dong, Jiaqiang; Zhong, Boyu; Zhang, Deyi; Yuan, Hongbin; Jin, Can; Xu, Xiangyuan; Li, Hailong; Zhou, Yong; Liang, Zhi; Ji, Minghua; Xu, Tao; Song, Guowei; Zhang, Ling; Chen, Gang; Meng, Xuejing; Sun, Desheng; Shih, Joe; Zhang, Ruihao; Hou, Guojun; Wang, Chengcheng; Jin, Ying; Yang, Qiong</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1910-1918</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Anaplastic lymphoma kinase (ALK) is a highly attractive therapeutic target for the treatment of some non-small cell lung cancer patients.  This Letter describes the further SAR exploration on the novel 3-sulfonylpyrazol-4-amino pyrimidine scaffold.  This work identified a compd. I with very good in vitro/in vivo efficacies, good DMPK properties together with better hERG tolerability and it is currently being profiled for the evaluation as a potential pre-clin. candidate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxXkTKa-yf67Vg90H21EOLACvtfcHk0li2Cf0tXkna5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XktFekt7s%253D&md5=1484e714f7a8338805e8dd4b9cebf591</span></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2016.03.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2016.03.017%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DP.%26aulast%3DDong%26aufirst%3DJ.%26aulast%3DZhong%26aufirst%3DB.%26aulast%3DZhang%26aufirst%3DD.%26aulast%3DYuan%26aufirst%3DH.%26aulast%3DJin%26aufirst%3DC.%26aulast%3DXu%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DLiang%26aufirst%3DZ.%26aulast%3DJi%26aufirst%3DM.%26aulast%3DXu%26aufirst%3DT.%26aulast%3DSong%26aufirst%3DG.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DChen%26aufirst%3DG.%26aulast%3DMeng%26aufirst%3DX.%26aulast%3DSun%26aufirst%3DD.%26aulast%3DShih%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DR.%26aulast%3DHou%26aufirst%3DG.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DJin%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DQ.%26atitle%3DDesign%2520and%2520Synthesis%2520of%2520Novel%25203-sulfonylpyrazol-4-amino%2520Pyrimidines%2520as%2520Potent%2520Anaplastic%2520Lymphoma%2520Kinase%2520%2528ALK%2529%2520Inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D26%26spage%3D1910%26epage%3D1918%26doi%3D10.1016%2Fj.bmcl.2016.03.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref135"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref135'); return false;" data-citation="" class="refNumLink">135</a></strong><div class="NLM_citation" id="cit135"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Konagai, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mori, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimada, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kondoh, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shindou, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soga, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furutani, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakagami, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ueno, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaneko, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, R.</span></span> <span> </span><span class="NLM_article-title">Asp3026, A Selective ALK Inhibitor, Induces Tumor Regression Against Crizotinib Resistant Eml4-ALK-dependent Tumor Models In Mice</span>. <i>Ann. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">xi99</span>– <span class="NLM_lpage">xi131</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2012&pages=xi99-xi131&author=S.+Konagaiauthor=M.+Moriauthor=I.+Shimadaauthor=Y.+Kondohauthor=N.+Shindouauthor=T.+Sogaauthor=T.+Furutaniauthor=H.+Sakagamiauthor=Y.+Uenoauthor=N.+Kanekoauthor=R.+Tanaka&title=Asp3026%2C+A+Selective+ALK+Inhibitor%2C+Induces+Tumor+Regression+Against+Crizotinib+Resistant+Eml4-ALK-dependent+Tumor+Models+In+Mice"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKonagai%26aufirst%3DS.%26aulast%3DMori%26aufirst%3DM.%26aulast%3DShimada%26aufirst%3DI.%26aulast%3DKondoh%26aufirst%3DY.%26aulast%3DShindou%26aufirst%3DN.%26aulast%3DSoga%26aufirst%3DT.%26aulast%3DFurutani%26aufirst%3DT.%26aulast%3DSakagami%26aufirst%3DH.%26aulast%3DUeno%26aufirst%3DY.%26aulast%3DKaneko%26aufirst%3DN.%26aulast%3DTanaka%26aufirst%3DR.%26atitle%3DAsp3026%252C%2520A%2520Selective%2520ALK%2520Inhibitor%252C%2520Induces%2520Tumor%2520Regression%2520Against%2520Crizotinib%2520Resistant%2520Eml4-ALK-dependent%2520Tumor%2520Models%2520In%2520Mice%26jtitle%3DAnn.%2520Oncol.%26date%3D2012%26volume%3D23%26spage%3Dxi99%26epage%3Dxi131" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref136"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref136'); return false;" data-citation="" class="refNumLink">136</a></strong><div class="NLM_citation" id="cit136"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Simionato, F.</span>; <span class="NLM_string-name">Carbone, C.</span>; <span class="NLM_string-name">Tortora, G.</span>; <span class="NLM_string-name">Melisi, D.</span></span> <span> </span><span class="NLM_article-title">Resistance to ALK Inhibitors</span>.  <i>Resistance to Tyrosine Kinase Inhibitors</i>; <span class="NLM_publisher-name">Springer</span>: <span class="NLM_publisher-loc">Cham</span>, <span class="NLM_year">2016</span>,  <span class="NLM_fpage">147</span>– <span class="NLM_lpage">163</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1007%2F978-3-319-46091-8_5" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&pages=147-163&author=F.+Simionato&author=C.+Carbone&author=G.+Tortora&author=D.+Melisi&title=Resistance+to+Tyrosine+Kinase+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=10.1007%2F978-3-319-46091-8_5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1007%252F978-3-319-46091-8_5%26sid%3Dliteratum%253Aachs%26aulast%3DSimionato%26aufirst%3DF.%26atitle%3DResistance%2520to%2520ALK%2520Inhibitors%26btitle%3DResistance%2520to%2520Tyrosine%2520Kinase%2520Inhibitors%26pub%3DSpringer%26date%3D2016%26spage%3D147%26epage%3D163" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref137"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref137'); return false;" data-citation="" class="refNumLink">137</a></strong><div class="NLM_citation" id="cit137"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maitland, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ou, S.-H. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tolcher, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LoRusso, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bahceci, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ball, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuen, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pesco Koplowitz, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, T.</span></span> <span> </span><span class="NLM_article-title">Safety, Activity, and Pharmacokinetics of an Oral Anaplastic Lymphoma Kinase (ALK) Inhibitor, ASP3026, Observed in a “Fast Follower” Phase 1 Trial Design</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">2624</span>, <span class="refDoi"> DOI: 10.1200/jco.2014.32.15_suppl.2624</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1200%2Fjco.2014.32.15_suppl.2624" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2014&pages=2624&author=M.+L.+Maitlandauthor=S.-H.+I.+Ouauthor=A.+W.+Tolcherauthor=P.+LoRussoauthor=E.+Bahceciauthor=H.+A.+Ballauthor=J.+W.+Parkauthor=G.+Yuenauthor=L.+Pesco+Koplowitzauthor=T.+Li&title=Safety%2C+Activity%2C+and+Pharmacokinetics+of+an+Oral+Anaplastic+Lymphoma+Kinase+%28ALK%29+Inhibitor%2C+ASP3026%2C+Observed+in+a+%E2%80%9CFast+Follower%E2%80%9D+Phase+1+Trial+Design&doi=10.1200%2Fjco.2014.32.15_suppl.2624"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=10.1200%2Fjco.2014.32.15_suppl.2624&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252Fjco.2014.32.15_suppl.2624%26sid%3Dliteratum%253Aachs%26aulast%3DMaitland%26aufirst%3DM.%2BL.%26aulast%3DOu%26aufirst%3DS.-H.%2BI.%26aulast%3DTolcher%26aufirst%3DA.%2BW.%26aulast%3DLoRusso%26aufirst%3DP.%26aulast%3DBahceci%26aufirst%3DE.%26aulast%3DBall%26aufirst%3DH.%2BA.%26aulast%3DPark%26aufirst%3DJ.%2BW.%26aulast%3DYuen%26aufirst%3DG.%26aulast%3DPesco%2BKoplowitz%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DT.%26atitle%3DSafety%252C%2520Activity%252C%2520and%2520Pharmacokinetics%2520of%2520an%2520Oral%2520Anaplastic%2520Lymphoma%2520Kinase%2520%2528ALK%2529%2520Inhibitor%252C%2520ASP3026%252C%2520Observed%2520in%2520a%2520%25E2%2580%259CFast%2520Follower%25E2%2580%259D%2520Phase%25201%2520Trial%2520Design%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2014%26volume%3D32%26spage%3D2624%26doi%3D10.1200%2Fjco.2014.32.15_suppl.2624" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref138"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref138'); return false;" data-citation="" class="refNumLink">138</a></strong><div class="NLM_citation" id="cit138"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LoRusso, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maitland, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ou, S.-H. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bahceci, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ball, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuen, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tolcher, A.</span></span> <span> </span><span class="NLM_article-title">First-in-human, Open-label Dose-escalation and Dose-expansion Study of the Safety, Pharmacokinetics, and Antitumor Effects of an Oral ALK Inhibitor ASP3026 in Patients with Advanced Solid Tumors</span>. <i>J. Hematol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">23</span>, <span class="refDoi"> DOI: 10.1186/s13045-016-0254-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1186%2Fs13045-016-0254-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=26966027" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC2sXis1eisbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2016&pages=23&author=T.+Liauthor=P.+LoRussoauthor=M.+L.+Maitlandauthor=S.-H.+I.+Ouauthor=E.+Bahceciauthor=H.+A.+Ballauthor=J.+W.+Parkauthor=G.+Yuenauthor=A.+Tolcher&title=First-in-human%2C+Open-label+Dose-escalation+and+Dose-expansion+Study+of+the+Safety%2C+Pharmacokinetics%2C+and+Antitumor+Effects+of+an+Oral+ALK+Inhibitor+ASP3026+in+Patients+with+Advanced+Solid+Tumors&doi=10.1186%2Fs13045-016-0254-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit138R"><div class="casContent"><span class="casTitleNuber">138</span><div class="casTitle"><span class="NLM_cas:atitle">First-in-human, open-label dose-escalation and dose-expansion study of the safety, pharmacokinetics, and antitumor effects of an oral ALK inhibitor ASP3026 in patients with advanced solid tumors</span></div><div class="casAuthors">Li, Tianhong; Lo Russo, Patricia; Maitland, Michael L.; Ou, Sai-Hong Ignatius; Bahceci, Erkut; Ball, Howard A.; Park, Jung Wook; Yuen, Geoffrey; Tolcher, Anthony</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hematology & Oncology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">23/1-23/9</span>CODEN:
                <span class="NLM_cas:coden">JHOOAO</span>;
        ISSN:<span class="NLM_cas:issn">1756-8722</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: ASP3026 is a second-generation anaplastic lymphoma kinase (ALK) inhibitor that has potent in vitro activity against crizotinib-resistant ALK-pos. tumors.  This open-label, multicenter, first-in-human phase I study (NCT01284192) assessed the safety, pharmacokinetic profile, and antitumor activity of ASP3026.  Methods: Advanced solid tumor patients received oral ASP3026 in 3 + 3 dose-escalation cohorts at doses of 25-800 mg once daily in 28-day cycles.  The endpoints were to identify the max. tolerated dose (MTD), the recommended phase II dose (RP2D), and the pharmacokinetic profile of ASP3026.  A phase Ib expansion cohort enrolled patients with metastatic, crizotinib-resistant ALK-pos. solid tumors at the RP2D, and response was evaluated by RECIST 1.1.  Results: The dose-escalation cohort enrolled 33 patients, including three crizotinib-resistant, ALK-pos. patients, and the dose-expansion cohort enrolled another 13 crizotinib-resistant, ALK-pos. non-small cell lung cancer (NSCLC) patients.  ASP3026 demonstrated both linear pharmacokinetics and dose-proportional exposure for area under the plasma concn.-time curve and max. concn. obsd. with a median terminal half-life of 35 h, supporting the daily dosing.  Grade 3 rash and elevated transaminase concns. were dose-limiting toxicities obsd. at 800 mg; hence, 525 mg daily was the MTD and RP2D.  The most common treatment-related adverse events were nausea (38 %), fatigue (35 %), and vomiting (35 %).  Among the 16 patients with crizotinib-resistant ALK-pos. tumors (15 NSCLC, 1 neuroblastoma), eight patients achieved partial response (overall response rate 50 %; 95 % confidence interval 25-75 %) and seven patients (44 %) achieved stable disease.  Conclusions: ASP3026 was well tolerated and had therapeutic activity in patients with crizotinib-resistant ALKpos. advanced tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8s1yI8JbYIrVg90H21EOLACvtfcHk0ljkyywyTU-_-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXis1eisbc%253D&md5=ec3b634a66b3b310c8a0d6d83eeb9e62</span></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=10.1186%2Fs13045-016-0254-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13045-016-0254-5%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DT.%26aulast%3DLoRusso%26aufirst%3DP.%26aulast%3DMaitland%26aufirst%3DM.%2BL.%26aulast%3DOu%26aufirst%3DS.-H.%2BI.%26aulast%3DBahceci%26aufirst%3DE.%26aulast%3DBall%26aufirst%3DH.%2BA.%26aulast%3DPark%26aufirst%3DJ.%2BW.%26aulast%3DYuen%26aufirst%3DG.%26aulast%3DTolcher%26aufirst%3DA.%26atitle%3DFirst-in-human%252C%2520Open-label%2520Dose-escalation%2520and%2520Dose-expansion%2520Study%2520of%2520the%2520Safety%252C%2520Pharmacokinetics%252C%2520and%2520Antitumor%2520Effects%2520of%2520an%2520Oral%2520ALK%2520Inhibitor%2520ASP3026%2520in%2520Patients%2520with%2520Advanced%2520Solid%2520Tumors%26jtitle%3DJ.%2520Hematol.%2520Oncol.%26date%3D2016%26volume%3D9%26spage%3D23%26doi%3D10.1186%2Fs13045-016-0254-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref139"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref139'); return false;" data-citation="" class="refNumLink">139</a></strong><div class="NLM_citation" id="cit139"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Amatu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Somaschini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cerea, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bosotti, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valtorta, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buonandi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marrapese, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Veronese, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hornby, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Multani, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shoemaker, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lauricella, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giannetta, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maiolani, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanzulli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ardini, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galvani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isacchi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sartore-Bianchi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siena, S.</span></span> <span> </span><span class="NLM_article-title">Novel CAD-ALK Gene Rearrangement is Drugable by Entrectinib in Colorectal Cancer</span>. <i>Br. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>113</i></span>,  <span class="NLM_fpage">1730</span>– <span class="NLM_lpage">1734</span>, <span class="refDoi"> DOI: 10.1038/bjc.2015.401</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1038%2Fbjc.2015.401" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=26633560" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvF2ks7fL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2015&pages=1730-1734&author=A.+Amatuauthor=A.+Somaschiniauthor=G.+Cereaauthor=R.+Bosottiauthor=E.+Valtortaauthor=P.+Buonandiauthor=G.+Marrapeseauthor=S.+Veroneseauthor=D.+Luoauthor=Z.+Hornbyauthor=P.+Multaniauthor=D.+Murphyauthor=R.+Shoemakerauthor=C.+Lauricellaauthor=L.+Giannettaauthor=M.+Maiolaniauthor=A.+Vanzulliauthor=E.+Ardiniauthor=A.+Galvaniauthor=A.+Isacchiauthor=A.+Sartore-Bianchiauthor=S.+Siena&title=Novel+CAD-ALK+Gene+Rearrangement+is+Drugable+by+Entrectinib+in+Colorectal+Cancer&doi=10.1038%2Fbjc.2015.401"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit139R"><div class="casContent"><span class="casTitleNuber">139</span><div class="casTitle"><span class="NLM_cas:atitle">Novel CAD-ALK gene rearrangement is drugable by entrectinib in colorectal cancer</span></div><div class="casAuthors">Amatu, Alessio; Somaschini, Alessio; Cerea, Giulio; Bosotti, Roberta; Valtorta, Emanuele; Buonandi, Pasquale; Marrapese, Giovanna; Veronese, Silvio; Luo, David; Hornby, Zachary; Multani, Pratik; Murphy, Danielle; Shoemaker, Robert; Lauricella, Calogero; Giannetta, Laura; Maiolani, Martina; Vanzulli, Angelo; Ardini, Elena; Galvani, Arturo; Isacchi, Antonella; Sartore-Bianchi, Andrea; Siena, Salvatore</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">113</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1730-1734</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Background: Activated anaplastic lymphoma kinase (ALK) gene fusions are recurrent events in a small fraction of colorectal cancers (CRCs), although these events have not yet been exploited as in other malignancies.  Methods: We detected ALK protein expression by immunohistochem. and gene rearrangements by fluorescence in situ hybridization in the ALKA-372-001 phase I study of the pan-Trk, ROS1, and ALK inhibitor entrectinib.  One out of 487 CRCs showed ALK positivity with a peculiar pattern that prompted further characterization by targeted sequencing using anchored multiplex PCR.  Results: A novel ALK fusion with the carbamoyl-phosphate synthetase 2, aspartate transcarbamylase, and dihydroorotase (CAD) gene (CAD-ALK fusion gene) was identified.  It resulted from inversion within chromosome 2 and the fusion of exons 1-35 of CAD with exons 20-29 of ALK.  After failure of previous std. therapies, treatment of this patient with the ALK inhibitor entrectinib resulted in a durable objective tumor response.  Conclusions: We describe the novel CAD-ALK rearrangement as an oncogene and provide the first evidence of its drugability as a new mol. target in CRC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGretuldOSXUNLVg90H21EOLACvtfcHk0ljkyywyTU-_-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvF2ks7fL&md5=c542b6b8d0a856941275d14f82bd9000</span></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=10.1038%2Fbjc.2015.401&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbjc.2015.401%26sid%3Dliteratum%253Aachs%26aulast%3DAmatu%26aufirst%3DA.%26aulast%3DSomaschini%26aufirst%3DA.%26aulast%3DCerea%26aufirst%3DG.%26aulast%3DBosotti%26aufirst%3DR.%26aulast%3DValtorta%26aufirst%3DE.%26aulast%3DBuonandi%26aufirst%3DP.%26aulast%3DMarrapese%26aufirst%3DG.%26aulast%3DVeronese%26aufirst%3DS.%26aulast%3DLuo%26aufirst%3DD.%26aulast%3DHornby%26aufirst%3DZ.%26aulast%3DMultani%26aufirst%3DP.%26aulast%3DMurphy%26aufirst%3DD.%26aulast%3DShoemaker%26aufirst%3DR.%26aulast%3DLauricella%26aufirst%3DC.%26aulast%3DGiannetta%26aufirst%3DL.%26aulast%3DMaiolani%26aufirst%3DM.%26aulast%3DVanzulli%26aufirst%3DA.%26aulast%3DArdini%26aufirst%3DE.%26aulast%3DGalvani%26aufirst%3DA.%26aulast%3DIsacchi%26aufirst%3DA.%26aulast%3DSartore-Bianchi%26aufirst%3DA.%26aulast%3DSiena%26aufirst%3DS.%26atitle%3DNovel%2520CAD-ALK%2520Gene%2520Rearrangement%2520is%2520Drugable%2520by%2520Entrectinib%2520in%2520Colorectal%2520Cancer%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2015%26volume%3D113%26spage%3D1730%26epage%3D1734%26doi%3D10.1038%2Fbjc.2015.401" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref140"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref140'); return false;" data-citation="" class="refNumLink">140</a></strong><div class="NLM_citation" id="cit140"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De Braud, F. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pilla, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niger, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Damian, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bardazza, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinetti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pelosi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marrapese, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmeri, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cerea, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valtorta, E.</span></span> <span> </span><span class="NLM_article-title">Phase 1 Open Label, Dose Escalation Study of RXDX101, an Oral Pan-trk, ROS1, and ALK Inhibitor, in Patients with Advanced Solid Tumors with Relevant Molecular Alterations</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>32</i></span> (<span class="NLM_issue">Suppl 15</span>),  <span class="NLM_fpage">2502</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1200%2Fjco.2014.32.15_suppl.2502" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2014&pages=2502&issue=Suppl+15&author=F.+G.+De+Braudauthor=L.+Pillaauthor=M.+Nigerauthor=S.+Damianauthor=B.+Bardazzaauthor=A.+Martinettiauthor=G.+Pelosiauthor=G.+Marrapeseauthor=L.+Palmeriauthor=G.+Cereaauthor=E.+Valtorta&title=Phase+1+Open+Label%2C+Dose+Escalation+Study+of+RXDX101%2C+an+Oral+Pan-trk%2C+ROS1%2C+and+ALK+Inhibitor%2C+in+Patients+with+Advanced+Solid+Tumors+with+Relevant+Molecular+Alterations"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=10.1200%2Fjco.2014.32.15_suppl.2502&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252Fjco.2014.32.15_suppl.2502%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BBraud%26aufirst%3DF.%2BG.%26aulast%3DPilla%26aufirst%3DL.%26aulast%3DNiger%26aufirst%3DM.%26aulast%3DDamian%26aufirst%3DS.%26aulast%3DBardazza%26aufirst%3DB.%26aulast%3DMartinetti%26aufirst%3DA.%26aulast%3DPelosi%26aufirst%3DG.%26aulast%3DMarrapese%26aufirst%3DG.%26aulast%3DPalmeri%26aufirst%3DL.%26aulast%3DCerea%26aufirst%3DG.%26aulast%3DValtorta%26aufirst%3DE.%26atitle%3DPhase%25201%2520Open%2520Label%252C%2520Dose%2520Escalation%2520Study%2520of%2520RXDX101%252C%2520an%2520Oral%2520Pan-trk%252C%2520ROS1%252C%2520and%2520ALK%2520Inhibitor%252C%2520in%2520Patients%2520with%2520Advanced%2520Solid%2520Tumors%2520with%2520Relevant%2520Molecular%2520Alterations%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2014%26volume%3D32%26issue%3DSuppl%252015%26spage%3D2502" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref141"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref141'); return false;" data-citation="" class="refNumLink">141</a></strong><div class="NLM_citation" id="cit141"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Drilon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siena, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ou, S.-H. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farago, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wheler, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doebele, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giannetta, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cerea, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marrapese, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schirru, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amatu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bencardino, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmeri, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sartore-Bianchi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanzulli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cresta, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Damian, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duca, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ardini, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christiansen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kowalski, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chow-Maneval, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hornby, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Multani, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Braud, F. G.</span></span> <span> </span><span class="NLM_article-title">Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two phase I Trials (ALKA-372–001 and STARTRK-1)</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">400</span>– <span class="NLM_lpage">409</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-16-1237</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1158%2F2159-8290.CD-16-1237" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=28183697" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC2sXltlOqsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&pages=400-409&author=A.+Drilonauthor=S.+Sienaauthor=S.-H.+I.+Ouauthor=M.+Patelauthor=M.+J.+Ahnauthor=J.+Leeauthor=T.+M.+Bauerauthor=A.+F.+Faragoauthor=J.+J.+Whelerauthor=S.+V.+Liuauthor=R.+Doebeleauthor=L.+Giannettaauthor=G.+Cereaauthor=G.+Marrapeseauthor=M.+Schirruauthor=A.+Amatuauthor=K.+Bencardinoauthor=L.+Palmeriauthor=A.+Sartore-Bianchiauthor=A.+Vanzulliauthor=S.+Crestaauthor=S.+Damianauthor=M.+Ducaauthor=E.+Ardiniauthor=G.+Liauthor=J.+Christiansenauthor=K.+Kowalskiauthor=A.+D.+Johnsonauthor=R.+Patelauthor=D.+Luoauthor=E.+Chow-Manevalauthor=Z.+Hornbyauthor=P.+S.+Multaniauthor=A.+T.+Shawauthor=F.+G.+De+Braud&title=Safety+and+Antitumor+Activity+of+the+Multitargeted+Pan-TRK%2C+ROS1%2C+and+ALK+Inhibitor+Entrectinib%3A+Combined+Results+from+Two+phase+I+Trials+%28ALKA-372%E2%80%93001+and+STARTRK-1%29&doi=10.1158%2F2159-8290.CD-16-1237"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit141R"><div class="casContent"><span class="casTitleNuber">141</span><div class="casTitle"><span class="NLM_cas:atitle">Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1)</span></div><div class="casAuthors">Drilon, Alexander; Siena, Salvatore; Ou, Sai-Hong Ignatius; Patel, Manish; Ahn, Myung Ju; Lee, Jeeyun; Bauer, Todd M.; Farago, Anna F.; Wheler, Jennifer J.; Liu, Stephen V.; Doebele, Robert; Giannetta, Laura; Cerea, Giulio; Marrapese, Giovanna; Schirru, Michele; Amatu, Alessio; Bencardino, Katia; Palmeri, Laura; Sartore-Bianchi, Andrea; Vanzulli, Angelo; Cresta, Sara; Damian, Silvia; Duca, Matteo; Ardini, Elena; Li, Gang; Christiansen, Jason; Kowalski, Karey; Johnson, Ann D.; Patel, Rupal; Luo, David; Chow-Maneval, Edna; Hornby, Zachary; Multani, Pratik S.; Shaw, Alice T.; De Braud, Filippo G.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">400-409</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Entrectinib, a potent oral inhibitor of the tyrosine kinases TRKA/B/C, ROS1, and ALK, was evaluated in two phase I studies in patients with advanced or metastatic solid tumors, including patients with active central nervous system (CNS) disease.  Here, we summarize the overall safety and report the antitumor activity of entrectinib in a cohort of patients with tumors harboring NTRK1/2/3, ROS1, or ALK gene fusions, naive to prior TKI treatment targeting the specific gene, and who were treated at doses that achieved therapeutic exposures consistent with the recommended phase II dose.  Entrectinib was well tolerated, with predominantly Grades 1/2 adverse events that were reversible with dose modification.  Responses were obsd. in non-small cell lung cancer, colorectal cancer, mammary analog secretory carcinoma, melanoma, and renal cell carcinoma, as early as 4 wk after starting treatment and lasting as long as >2 years.  Notably, a complete CNS response was achieved in a patient with SQSTM1-NTRK1-rearranged lung cancer.  Significance: Gene fusions of NTRK1/2/3, ROS1, and ALK (encoding TRKA/B/C, ROS1, and ALK, resp.) lead to constitutive activation of oncogenic pathways.  Entrectinib was shown to be well tolerated and active against those gene fusions in solid tumors, including in patients with primary or secondary CNS disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGom-3oFgf_s-LVg90H21EOLACvtfcHk0ljbB1lH-GODqw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXltlOqsL8%253D&md5=2065abe157ef40489942215ec33482d0</span></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-16-1237&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-16-1237%26sid%3Dliteratum%253Aachs%26aulast%3DDrilon%26aufirst%3DA.%26aulast%3DSiena%26aufirst%3DS.%26aulast%3DOu%26aufirst%3DS.-H.%2BI.%26aulast%3DPatel%26aufirst%3DM.%26aulast%3DAhn%26aufirst%3DM.%2BJ.%26aulast%3DLee%26aufirst%3DJ.%26aulast%3DBauer%26aufirst%3DT.%2BM.%26aulast%3DFarago%26aufirst%3DA.%2BF.%26aulast%3DWheler%26aufirst%3DJ.%2BJ.%26aulast%3DLiu%26aufirst%3DS.%2BV.%26aulast%3DDoebele%26aufirst%3DR.%26aulast%3DGiannetta%26aufirst%3DL.%26aulast%3DCerea%26aufirst%3DG.%26aulast%3DMarrapese%26aufirst%3DG.%26aulast%3DSchirru%26aufirst%3DM.%26aulast%3DAmatu%26aufirst%3DA.%26aulast%3DBencardino%26aufirst%3DK.%26aulast%3DPalmeri%26aufirst%3DL.%26aulast%3DSartore-Bianchi%26aufirst%3DA.%26aulast%3DVanzulli%26aufirst%3DA.%26aulast%3DCresta%26aufirst%3DS.%26aulast%3DDamian%26aufirst%3DS.%26aulast%3DDuca%26aufirst%3DM.%26aulast%3DArdini%26aufirst%3DE.%26aulast%3DLi%26aufirst%3DG.%26aulast%3DChristiansen%26aufirst%3DJ.%26aulast%3DKowalski%26aufirst%3DK.%26aulast%3DJohnson%26aufirst%3DA.%2BD.%26aulast%3DPatel%26aufirst%3DR.%26aulast%3DLuo%26aufirst%3DD.%26aulast%3DChow-Maneval%26aufirst%3DE.%26aulast%3DHornby%26aufirst%3DZ.%26aulast%3DMultani%26aufirst%3DP.%2BS.%26aulast%3DShaw%26aufirst%3DA.%2BT.%26aulast%3DDe%2BBraud%26aufirst%3DF.%2BG.%26atitle%3DSafety%2520and%2520Antitumor%2520Activity%2520of%2520the%2520Multitargeted%2520Pan-TRK%252C%2520ROS1%252C%2520and%2520ALK%2520Inhibitor%2520Entrectinib%253A%2520Combined%2520Results%2520from%2520Two%2520phase%2520I%2520Trials%2520%2528ALKA-372%25E2%2580%2593001%2520and%2520STARTRK-1%2529%26jtitle%3DCancer%2520Discovery%26date%3D2017%26volume%3D7%26spage%3D400%26epage%3D409%26doi%3D10.1158%2F2159-8290.CD-16-1237" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref142"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref142'); return false;" data-citation="" class="refNumLink">142</a></strong><div class="NLM_citation" id="cit142"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Horn, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Infante, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reckamp, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blumenschein, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leal, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waqar, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gitlitz, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanborn, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whisenant, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neal, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gockerman, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dukart, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrow, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibbons, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holzhausen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lovly, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wakelee, H. A.</span></span> <span> </span><span class="NLM_article-title">Ensartinib (X-396) in ALK-Positive Non–small Cell Lung Cancer: Results from a First-in-human Phase I/II, Multicenter Study</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">2771</span>– <span class="NLM_lpage">2779</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-17-2398</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1158%2F1078-0432.CCR-17-2398" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=29563138" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtFeqsrbO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2018&pages=2771-2779&author=L.+Hornauthor=J.+R.+Infanteauthor=K.+L.+Reckampauthor=G.+R.+Blumenscheinauthor=T.+A.+Lealauthor=S.+N.+Waqarauthor=B.+J.+Gitlitzauthor=R.+E.+Sanbornauthor=J.+G.+Whisenantauthor=L.+Duauthor=J.+W.+Nealauthor=J.+P.+Gockermanauthor=G.+Dukartauthor=K.+Harrowauthor=C.+Liangauthor=J.+J.+Gibbonsauthor=A.+Holzhausenauthor=C.+M.+Lovlyauthor=H.+A.+Wakelee&title=Ensartinib+%28X-396%29+in+ALK-Positive+Non%E2%80%93small+Cell+Lung+Cancer%3A+Results+from+a+First-in-human+Phase+I%2FII%2C+Multicenter+Study&doi=10.1158%2F1078-0432.CCR-17-2398"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit142R"><div class="casContent"><span class="casTitleNuber">142</span><div class="casTitle"><span class="NLM_cas:atitle">Ensartinib (X-396) in ALK-Positive Non-Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study</span></div><div class="casAuthors">Horn, Leora; Infante, Jeffrey R.; Reckamp, Karen L.; Blumenschein, George R.; Leal, Ticiana A.; Waqar, Saiama N.; Gitlitz, Barbara J.; Sanborn, Rachel E.; Whisenant, Jennifer G.; Du, Liping; Neal, Joel W.; Gockerman, Jon P.; Dukart, Gary; Harrow, Kimberly; Liang, Chris; Gibbons, James J.; Holzhausen, Allison; Lovly, Christine M.; Wakelee, Heather A.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2771-2779</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Evaluate safety and det. the recommended phase II dose (RP2D) of ensartinib (X-396), a potent anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI), and evaluate preliminary pharmacokinetics and antitumor activity in a first-in-human, phase I/II clin. trial primarily in patients with non-small cell lung cancer (NSCLC).  Patients and Methods: In dose escalation, ensartinib was administered at doses of 25 to 250 mg once daily in patients with advanced solid tumors; in dose expansion, patients with advanced ALK-pos. NSCLC were administered 225 mg once daily.  Patients who had received prior ALK TKI(s) and patients with brain metastases were eligible.  Results: Thirty-seven patients enrolled in dose escalation, and 60 enrolled in dose expansion.  The most common treatment-related toxicities were rash (56%), nausea (36%), pruritus (28%), vomiting (26%), and fatigue (22%); 23% of patients experienced a treatment-related grade 3 to 4 toxicity (primarily rash and pruritus).  The max. tolerated dose was not reached, but the RP2D was chosen as 225 mg based on the frequency of rash obsd. at 250 mg without improvement in activity.  Among the ALK-pos. efficacy evaluable patients treated at ≥200 mg, the response rate (RR) was 60%, and median progression-free survival (PFS) was 9.2 mo.  RR in ALK TKI-naive patients was 80%, and median PFS was 26.2 mo.  In patients with prior crizotinib only, the RR was 69% and median PFS was 9.0 mo.  Responses were also obsd. in the central nervous system, with an intracranial RR of 64%.  Conclusions: Ensartinib was active and generally well tolerated in patients with ALK-pos. NSCLC.  Clin Cancer Res; 24(12); 2771-9. ©2018 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomgnuFLIl0jLVg90H21EOLACvtfcHk0li2g6D64USqsA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtFeqsrbO&md5=e14e00b46d6f389e524b9b902c581397</span></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-17-2398&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-17-2398%26sid%3Dliteratum%253Aachs%26aulast%3DHorn%26aufirst%3DL.%26aulast%3DInfante%26aufirst%3DJ.%2BR.%26aulast%3DReckamp%26aufirst%3DK.%2BL.%26aulast%3DBlumenschein%26aufirst%3DG.%2BR.%26aulast%3DLeal%26aufirst%3DT.%2BA.%26aulast%3DWaqar%26aufirst%3DS.%2BN.%26aulast%3DGitlitz%26aufirst%3DB.%2BJ.%26aulast%3DSanborn%26aufirst%3DR.%2BE.%26aulast%3DWhisenant%26aufirst%3DJ.%2BG.%26aulast%3DDu%26aufirst%3DL.%26aulast%3DNeal%26aufirst%3DJ.%2BW.%26aulast%3DGockerman%26aufirst%3DJ.%2BP.%26aulast%3DDukart%26aufirst%3DG.%26aulast%3DHarrow%26aufirst%3DK.%26aulast%3DLiang%26aufirst%3DC.%26aulast%3DGibbons%26aufirst%3DJ.%2BJ.%26aulast%3DHolzhausen%26aufirst%3DA.%26aulast%3DLovly%26aufirst%3DC.%2BM.%26aulast%3DWakelee%26aufirst%3DH.%2BA.%26atitle%3DEnsartinib%2520%2528X-396%2529%2520in%2520ALK-Positive%2520Non%25E2%2580%2593small%2520Cell%2520Lung%2520Cancer%253A%2520Results%2520from%2520a%2520First-in-human%2520Phase%2520I%252FII%252C%2520Multicenter%2520Study%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2018%26volume%3D24%26spage%3D2771%26epage%3D2779%26doi%3D10.1158%2F1078-0432.CCR-17-2398" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref143"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref143'); return false;" data-citation="" class="refNumLink">143</a></strong><div class="NLM_citation" id="cit143"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Horn, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reck, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrow, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oertel, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dukart, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mok, T.</span></span> <span> </span><span class="NLM_article-title">eXalt3: A Phase 3 Study of Ensartinib (X-396) in Anaplastic Lymphoma Kinase (ALK)-positive Non-small Cell Lung Cancer (NSCLC)</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">TPS8578</span>, <span class="refDoi"> DOI: 10.1200/JCO.2017.35.15_suppl.TPS8578</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1200%2FJCO.2017.35.15_suppl.TPS8578" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2017&pages=TPS8578&author=L.+Hornauthor=Y.-L.+Wuauthor=M.+Reckauthor=C.+Liangauthor=F.+Tanauthor=K.+Harrowauthor=V.+Oertelauthor=G.+Dukartauthor=T.+Mok&title=eXalt3%3A+A+Phase+3+Study+of+Ensartinib+%28X-396%29+in+Anaplastic+Lymphoma+Kinase+%28ALK%29-positive+Non-small+Cell+Lung+Cancer+%28NSCLC%29&doi=10.1200%2FJCO.2017.35.15_suppl.TPS8578"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=10.1200%2FJCO.2017.35.15_suppl.TPS8578&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2017.35.15_suppl.TPS8578%26sid%3Dliteratum%253Aachs%26aulast%3DHorn%26aufirst%3DL.%26aulast%3DWu%26aufirst%3DY.-L.%26aulast%3DReck%26aufirst%3DM.%26aulast%3DLiang%26aufirst%3DC.%26aulast%3DTan%26aufirst%3DF.%26aulast%3DHarrow%26aufirst%3DK.%26aulast%3DOertel%26aufirst%3DV.%26aulast%3DDukart%26aufirst%3DG.%26aulast%3DMok%26aufirst%3DT.%26atitle%3DeXalt3%253A%2520A%2520Phase%25203%2520Study%2520of%2520Ensartinib%2520%2528X-396%2529%2520in%2520Anaplastic%2520Lymphoma%2520Kinase%2520%2528ALK%2529-positive%2520Non-small%2520Cell%2520Lung%2520Cancer%2520%2528NSCLC%2529%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2017%26volume%3D35%26spage%3DTPS8578%26doi%3D10.1200%2FJCO.2017.35.15_suppl.TPS8578" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref144"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref144'); return false;" data-citation="" class="refNumLink">144</a></strong><div class="NLM_citation" id="cit144"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Weiss, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sachdev, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Infante, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mita, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Natale, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arkenau, H.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilcoxen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kansra, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laken, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brooks, D. G.</span></span> <span> </span><span class="NLM_article-title">Phase (Ph) 1/2 Study of TSR-011, a Potent Inhibitor of ALK and TRK, including Crizotinib-resistant ALK Mutations</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>32</i></span> (<span class="NLM_issue">Suppl 15</span>),  <span class="NLM_fpage">e19005</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1200%2Fjco.2014.32.15_suppl.e19005" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2014&pages=e19005&issue=Suppl+15&author=G.+J.+Weissauthor=J.+C.+Sachdevauthor=J.+R.+Infanteauthor=M.+M.+Mitaauthor=R.+B.+Nataleauthor=H.-T.+Arkenauauthor=K.+Wilcoxenauthor=V.+Kansraauthor=H.+Lakenauthor=L.+Hughesauthor=D.+G.+Brooks&title=Phase+%28Ph%29+1%2F2+Study+of+TSR-011%2C+a+Potent+Inhibitor+of+ALK+and+TRK%2C+including+Crizotinib-resistant+ALK+Mutations"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=10.1200%2Fjco.2014.32.15_suppl.e19005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252Fjco.2014.32.15_suppl.e19005%26sid%3Dliteratum%253Aachs%26aulast%3DWeiss%26aufirst%3DG.%2BJ.%26aulast%3DSachdev%26aufirst%3DJ.%2BC.%26aulast%3DInfante%26aufirst%3DJ.%2BR.%26aulast%3DMita%26aufirst%3DM.%2BM.%26aulast%3DNatale%26aufirst%3DR.%2BB.%26aulast%3DArkenau%26aufirst%3DH.-T.%26aulast%3DWilcoxen%26aufirst%3DK.%26aulast%3DKansra%26aufirst%3DV.%26aulast%3DLaken%26aufirst%3DH.%26aulast%3DHughes%26aufirst%3DL.%26aulast%3DBrooks%26aufirst%3DD.%2BG.%26atitle%3DPhase%2520%2528Ph%2529%25201%252F2%2520Study%2520of%2520TSR-011%252C%2520a%2520Potent%2520Inhibitor%2520of%2520ALK%2520and%2520TRK%252C%2520including%2520Crizotinib-resistant%2520ALK%2520Mutations%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2014%26volume%3D32%26issue%3DSuppl%252015%26spage%3De19005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref145"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref145'); return false;" data-citation="" class="refNumLink">145</a></strong><div class="NLM_citation" id="cit145"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Arkenau, H. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sachdev, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mita, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dziadziuszko, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Infante, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anthony, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voskoboynik, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castro, J.</span></span> <span> </span><span class="NLM_article-title">Phase (Ph) 1/2a Study of TSR-011, a Potent Inhibitor of ALK and TRK, in Advanced Solid Tumors Including Crizotinib-resistant ALK Positive Non-small Cell Lung Cancer</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>33</i></span> (<span class="NLM_issue">Suppl 15</span>),  <span class="NLM_fpage">8063</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1200%2Fjco.2015.33.15_suppl.8063" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2015&pages=8063&issue=Suppl+15&author=H.+T.+Arkenauauthor=J.+C.+Sachdevauthor=M.+M.+Mitaauthor=R.+Dziadziuszkoauthor=C.+C.+Linauthor=J.+C.+Yangauthor=J.+R.+Infanteauthor=S.+P.+Anthonyauthor=M.+Voskoboynikauthor=W.+C.+Suauthor=+Deauthor=J.+Castro&title=Phase+%28Ph%29+1%2F2a+Study+of+TSR-011%2C+a+Potent+Inhibitor+of+ALK+and+TRK%2C+in+Advanced+Solid+Tumors+Including+Crizotinib-resistant+ALK+Positive+Non-small+Cell+Lung+Cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=10.1200%2Fjco.2015.33.15_suppl.8063&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252Fjco.2015.33.15_suppl.8063%26sid%3Dliteratum%253Aachs%26aulast%3DArkenau%26aufirst%3DH.%2BT.%26aulast%3DSachdev%26aufirst%3DJ.%2BC.%26aulast%3DMita%26aufirst%3DM.%2BM.%26aulast%3DDziadziuszko%26aufirst%3DR.%26aulast%3DLin%26aufirst%3DC.%2BC.%26aulast%3DYang%26aufirst%3DJ.%2BC.%26aulast%3DInfante%26aufirst%3DJ.%2BR.%26aulast%3DAnthony%26aufirst%3DS.%2BP.%26aulast%3DVoskoboynik%26aufirst%3DM.%26aulast%3DSu%26aufirst%3DW.%2BC.%26aulast%3DDe%26aulast%3DCastro%26aufirst%3DJ.%26atitle%3DPhase%2520%2528Ph%2529%25201%252F2a%2520Study%2520of%2520TSR-011%252C%2520a%2520Potent%2520Inhibitor%2520of%2520ALK%2520and%2520TRK%252C%2520in%2520Advanced%2520Solid%2520Tumors%2520Including%2520Crizotinib-resistant%2520ALK%2520Positive%2520Non-small%2520Cell%2520Lung%2520Cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2015%26volume%3D33%26issue%3DSuppl%252015%26spage%3D8063" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref146"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref146'); return false;" data-citation="" class="refNumLink">146</a></strong><div class="NLM_citation" id="cit146"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Katayama, R.</span></span> <span> </span><span class="NLM_article-title">Therapeutic Strategies and Mechanisms of Drug Resistance in Anaplastic Lymphoma Kinase (ALK)-rearranged Lung Cancer</span>. <i>Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>177</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">8</span>, <span class="refDoi"> DOI: 10.1016/j.pharmthera.2017.02.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1016%2Fj.pharmthera.2017.02.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=28185914" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC2sXktVKjtLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=177&publication_year=2017&pages=1-8&author=R.+Katayama&title=Therapeutic+Strategies+and+Mechanisms+of+Drug+Resistance+in+Anaplastic+Lymphoma+Kinase+%28ALK%29-rearranged+Lung+Cancer&doi=10.1016%2Fj.pharmthera.2017.02.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit146R"><div class="casContent"><span class="casTitleNuber">146</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic strategies and mechanisms of drug resistance in anaplastic lymphoma kinase (ALK)-rearranged lung cancer</span></div><div class="casAuthors">Katayama, Ryohei</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">177</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1-8</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Anaplastic lymphoma kinase (ALK) gene encoding the receptor tyrosine kinase ALK is expressed as a fusion gene in a variety of carcinomas.  The expression of ALK is nearly undetectable in adults, and its activation is normally regulated by its ligands, FAM150A/B.  However, ALK gene rearrangements result in different ALK fusion proteins that are constitutively expressed via the active promoter of fusion partner genes.  ALK fusion proteins dimerize in a ligand-independent manner and lead to the dysregulation of cell proliferation via abnormal constitutive activation of ALK tyrosine kinase.  Many ALK tyrosine kinase inhibitors (TKIs) have been developed to date, three of which are currently in clin. use for the treatment of ALK-rearranged non-small cell lung cancer (NSCLC).  ALK TKIs often achieve marked tumor regression in NSCLC patients with ALK rearrangements; however, ALK TKI-resistant tumors inevitably emerge within a few years in most cases.  In this review, we summarize diverse ALK TKI resistance mechanisms identified in NSCLC with ALK rearrangements, and review potential therapeutic strategies to overcome ALK TKI resistance in these patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGofwQpPLFXGr7Vg90H21EOLACvtfcHk0lhBj0f_BAU0VA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXktVKjtLo%253D&md5=8f3cdccfa2e0f3b014c3cac8689cf8c7</span></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2017.02.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2017.02.015%26sid%3Dliteratum%253Aachs%26aulast%3DKatayama%26aufirst%3DR.%26atitle%3DTherapeutic%2520Strategies%2520and%2520Mechanisms%2520of%2520Drug%2520Resistance%2520in%2520Anaplastic%2520Lymphoma%2520Kinase%2520%2528ALK%2529-rearranged%2520Lung%2520Cancer%26jtitle%3DPharmacol.%2520Ther.%26date%3D2017%26volume%3D177%26spage%3D1%26epage%3D8%26doi%3D10.1016%2Fj.pharmthera.2017.02.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref147"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref147'); return false;" data-citation="" class="refNumLink">147</a></strong><div class="NLM_citation" id="cit147"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span> <span> </span><span class="NLM_article-title">Insight into Resistance Mechanism of Anaplastic Lymphoma Kinase to Alectinib and JH-VIII-157–02 Caused by G1202R Solvent front Mutation</span>. <i>Drug Des., Dev. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">1183</span>– <span class="NLM_lpage">1193</span>, <span class="refDoi"> DOI: 10.2147/DDDT.S147104</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.2147%2FDDDT.S147104" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=29785088" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtlCls7jJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2018&pages=1183-1193&author=H.+Wangauthor=Y.+Wangauthor=W.+Guoauthor=B.+Duauthor=X.+Huangauthor=R.+Wuauthor=B.+Yangauthor=X.+Linauthor=Y.+Wu&title=Insight+into+Resistance+Mechanism+of+Anaplastic+Lymphoma+Kinase+to+Alectinib+and+JH-VIII-157%E2%80%9302+Caused+by+G1202R+Solvent+front+Mutation&doi=10.2147%2FDDDT.S147104"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit147R"><div class="casContent"><span class="casTitleNuber">147</span><div class="casTitle"><span class="NLM_cas:atitle">Insight into resistance mechanism of anaplastic lymphoma kinase to alectinib and JH-VIII-157-02 caused by G1202R solvent front mutation</span></div><div class="casAuthors">Wang, Han; Wang, Yao; Guo, Wentao; Du, Bin; Huang, Xiaobing; Wu, Riping; Yang, Baoyu; Lin, Xiaoyan; Wu, Yilan</div><div class="citationInfo"><span class="NLM_cas:title">Drug Design, Development and Therapy</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1183-1193</span>CODEN:
                <span class="NLM_cas:coden">DDDTAQ</span>;
        ISSN:<span class="NLM_cas:issn">1177-8881</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">Background: Mutated anaplastic lymphoma kinase (ALK) drives the development of advanced non-small cell lung cancer (NSCLC).  Most reported small-mol. inhibitors targeting the ALK domain do not display good inhibition of the G1202R solvent front mutation.  The solvent front mutation was assumed to hinder drug binding.  However, a different fact could be uncovered by the simulations reported in this study through a structural analog of alectinib (JH-VIII-157-02), which demonstrated potent effects against the G1202R mutation.  Methods: Mol. docking, conventional mol. dynamics (MD) simulations, free energy calcns., and umbrella sampling (US) simulations were carried out to make clear the principles of the binding preferences of alectinib and JH-VIII-157-02 toward ALKWT and the ALK G1202R (ALKG1202R) mutation.  Results: JH-VIII-157-02 has similar binding affinities to both ALKWT and ALKG1202R whereas it has has a much lower binding affinity for alectinib to ALKG1202R.  Anal. of individual energy terms indicate the major variation involves the van der Waals and entropy terms.  Structural anal. reveals that the conformational change of the ATP-binding glycine-rich loop was primarily responsible for the alectinib resistance, not JH-VIII-157-02.  In addn., US simulations prove JH-VIII-157-02 has similar dissociative processes from both ALKWT and ALKG1202R, while alectinib is more easily dissocd. from ALKG1202R than from ALKWT, thus indicating lesser residence time.  Conclusion: Both the binding affinity and the drug residence time should be emphasized in rational drug design to overcome the G1202R solvent front mutation in ALK resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUg5P71nwEDrVg90H21EOLACvtfcHk0lhBj0f_BAU0VA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtlCls7jJ&md5=3fa915eddaf89a5383e0d3cc8621ffa8</span></div><a href="/servlet/linkout?suffix=cit147&amp;dbid=16384&amp;doi=10.2147%2FDDDT.S147104&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FDDDT.S147104%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DGuo%26aufirst%3DW.%26aulast%3DDu%26aufirst%3DB.%26aulast%3DHuang%26aufirst%3DX.%26aulast%3DWu%26aufirst%3DR.%26aulast%3DYang%26aufirst%3DB.%26aulast%3DLin%26aufirst%3DX.%26aulast%3DWu%26aufirst%3DY.%26atitle%3DInsight%2520into%2520Resistance%2520Mechanism%2520of%2520Anaplastic%2520Lymphoma%2520Kinase%2520to%2520Alectinib%2520and%2520JH-VIII-157%25E2%2580%259302%2520Caused%2520by%2520G1202R%2520Solvent%2520front%2520Mutation%26jtitle%3DDrug%2520Des.%252C%2520Dev.%2520Ther.%26date%3D2018%26volume%3D12%26spage%3D1183%26epage%3D1193%26doi%3D10.2147%2FDDDT.S147104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref148"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref148'); return false;" data-citation="" class="refNumLink">148</a></strong><div class="NLM_citation" id="cit148"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tai, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, C.</span></span> <span> </span><span class="NLM_article-title">GSK1838705A, an Insulin-like Growth Factor-1 Receptor/insulin Receptor Inhibitor, Induces Apoptosis and Reduces Viability of Docetaxel-resistant Prostate Cancer Cells Both in Vitro and in Vivo</span>. <i>OncoTargets Ther.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">753</span>– <span class="NLM_lpage">760</span>, <span class="refDoi"> DOI: 10.2147/OTT.S79105</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.2147%2FOTT.S79105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=25926740" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC28Xlt1agsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2015&pages=753-760&author=F.+Zhouauthor=X.+Chenauthor=S.+Fanauthor=S.+Taiauthor=C.+Jiangauthor=Y.+Zhangauthor=Z.+Haoauthor=J.+Zhouauthor=H.+Shiauthor=L.+Zhangauthor=C.+Liang&title=GSK1838705A%2C+an+Insulin-like+Growth+Factor-1+Receptor%2Finsulin+Receptor+Inhibitor%2C+Induces+Apoptosis+and+Reduces+Viability+of+Docetaxel-resistant+Prostate+Cancer+Cells+Both+in+Vitro+and+in+Vivo&doi=10.2147%2FOTT.S79105"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit148R"><div class="casContent"><span class="casTitleNuber">148</span><div class="casTitle"><span class="NLM_cas:atitle">GSK1838705A, an insulin-like growth factor-1 receptor/insulin receptor inhibitor, induces apoptosis and reduces viability of docetaxel-resistant prostate cancer cells both in vitro and in vivo</span></div><div class="casAuthors">Zhou, Fayou; Chen, Xianguo; Fan, Song; Tai, Sheng; Jiang, Changqin; Zhang, Yifei; Hao, Zongyao; Zhou, Jun; Shi, Haoqiang; Zhang, Li; Liang, Chaozhao</div><div class="citationInfo"><span class="NLM_cas:title">OncoTargets and Therapy</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">753-760</span>CODEN:
                <span class="NLM_cas:coden">OTNHAZ</span>;
        ISSN:<span class="NLM_cas:issn">1178-6930</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">Prostate cancer is the leading malignancy and the second most common cause of cancer-related death in men.  Despite high cure rates with surgery and/or radiation, 30%-40% of patients eventually develop advanced cancer.  Docetaxel is one of the most effective and well established chemotherapeutic agents for prostate cancer.  However, docetaxel resistance often develops within months.  Combination therapies have been proposed to improve the therapeutic efficacy of docetaxel in prostate cancer, and there is an urgent need to identify agents that are effective for treatment of the disease, esp. docetaxel-resistant prostate cancer.  In this work, we investigated the activity of GSK1838705A, a potent insulin-like growth factor-1 receptor (IGF1R)/insulin receptor (IR) inhibitor, in prostate cancer, esp. docetaxel-resistant prostate cancer.  We found that GSK1838705A could effectively reduce the viability of both docetaxel-sensitive and docetaxel-resistant prostate cancer cells.  GSK1838705A induced marked apoptosis in docetaxel-resistant cells, and also dramatically inhibited migration of these cells.  Further, GSK1838705A significantly inhibited phosphorylation of IGF1R/IR.  Importantly, GSK1838705A significantly suppressed docetaxel-resistant PC-3R tumor growth in vivo.  This is the first study of GSK1838705A in prostate cancer.  Our results indicate that GSK1838705A is a promising compd. for the treatment of prostate cancer, esp. for those who develop resistance to docetaxel, and might shed new light on treatment for prostate cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokJx0KUvPzN7Vg90H21EOLACvtfcHk0lhBj0f_BAU0VA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xlt1agsr8%253D&md5=0bfd916c092a7cda409984fb6692e167</span></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=10.2147%2FOTT.S79105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FOTT.S79105%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DF.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DFan%26aufirst%3DS.%26aulast%3DTai%26aufirst%3DS.%26aulast%3DJiang%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DHao%26aufirst%3DZ.%26aulast%3DZhou%26aufirst%3DJ.%26aulast%3DShi%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DLiang%26aufirst%3DC.%26atitle%3DGSK1838705A%252C%2520an%2520Insulin-like%2520Growth%2520Factor-1%2520Receptor%252Finsulin%2520Receptor%2520Inhibitor%252C%2520Induces%2520Apoptosis%2520and%2520Reduces%2520Viability%2520of%2520Docetaxel-resistant%2520Prostate%2520Cancer%2520Cells%2520Both%2520in%2520Vitro%2520and%2520in%2520Vivo%26jtitle%3DOncoTargets%2520Ther.%26date%3D2015%26volume%3D8%26spage%3D753%26epage%3D760%26doi%3D10.2147%2FOTT.S79105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref149"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref149'); return false;" data-citation="" class="refNumLink">149</a></strong><div class="NLM_citation" id="cit149"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hui, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pei, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, B.</span></span> <span> </span><span class="NLM_article-title">GSK1838705A, an IGF-1R inhibitor, Inhibits Glioma Cell Proliferation and Suppresses Tumor Growth in Vivo</span>. <i>Mol. Med. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">5641</span>– <span class="NLM_lpage">5646</span>, <span class="refDoi"> DOI: 10.3892/mmr.2015.4129</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.3892%2Fmmr.2015.4129" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=26238593" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFWns7fI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2015&pages=5641-5646&author=X.+Zhouauthor=F.+Shenauthor=P.+Maauthor=H.+Huiauthor=S.+Peiauthor=M.+Chenauthor=Z.+Wangauthor=W.+Zhouauthor=B.+Jin&title=GSK1838705A%2C+an+IGF-1R+inhibitor%2C+Inhibits+Glioma+Cell+Proliferation+and+Suppresses+Tumor+Growth+in+Vivo&doi=10.3892%2Fmmr.2015.4129"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit149R"><div class="casContent"><span class="casTitleNuber">149</span><div class="casTitle"><span class="NLM_cas:atitle">GSK1838705A, an IGF-1R inhibitor, inhibits glioma cell proliferation and suppresses tumor growth in vivo</span></div><div class="casAuthors">Zhou, Xiang; Shen, Fazheng; Ma, Pengju; Hui, Hongyan; Pei, Sujuan; Chen, Ming; Wang, Zhongwei; Zhou, Wenke; Jin, Baozhe</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Medicine Reports</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">4, Pt. B</span>),
    <span class="NLM_cas:pages">5641-5646</span>CODEN:
                <span class="NLM_cas:coden">MMROA5</span>;
        ISSN:<span class="NLM_cas:issn">1791-2997</span>.
    
            (<span class="NLM_cas:orgname">Spandidos Publications Ltd.</span>)
        </div><div class="casAbstract">Glioma is a type of primary malignant tumor of the central nervous system in humans.  At present, std. treatment involves surgical resection, followed by radiation therapy and chemotherapy.  However, the prognosis is poor and the long-term survival rate remains low.  An improved understanding of the mol. basis for glioma tumorigenesis is in urgently required.  The pro-survival effect of the insulin-like growth factor (IGF) signaling pathway has been implicated in progression of the glioma disease state.  GSK1838705A is a novel, small mol. kinase inhibitor of IGF-IR, which inhibits IGF signal transduction and downstream target activation.  Its anti-proliferative activity has been demonstrated in various tumor cell lines.  The present study investigated the potential use of GSK1838705A for the treatment of glioma.  Human U87MG glioma cells were used to examine the inhibitory activity of GSK1838705A in cell proliferation, migration and apoptosis.  The antitumor activity of GSK1838705A was assessed in a xenograft mouse model.  GSK1838705A inhibited the growth and induced the apoptosis of the U87MG glioma cells in a dose-dependent manner.  The GSK1838705A-treated cells exhibited reduced migratory activity in response to chemoattractants.  The present study further demonstrated the antitumor activity of GSK1838705A in vivo.  The administration of GSK1838705A significantly inhibited the growth of glioma tumors by inducing the apoptosis of tumor cells.  These results suggested that targeting IGF signaling with GSK1838705A may be a promising therapeutic strategy for the treatment of patients with glioma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpD5J-YhHjH3rVg90H21EOLACvtfcHk0lhBj0f_BAU0VA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFWns7fI&md5=171699df83385fbf417747bd6a013f26</span></div><a href="/servlet/linkout?suffix=cit149&amp;dbid=16384&amp;doi=10.3892%2Fmmr.2015.4129&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252Fmmr.2015.4129%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DX.%26aulast%3DShen%26aufirst%3DF.%26aulast%3DMa%26aufirst%3DP.%26aulast%3DHui%26aufirst%3DH.%26aulast%3DPei%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DJin%26aufirst%3DB.%26atitle%3DGSK1838705A%252C%2520an%2520IGF-1R%2520inhibitor%252C%2520Inhibits%2520Glioma%2520Cell%2520Proliferation%2520and%2520Suppresses%2520Tumor%2520Growth%2520in%2520Vivo%26jtitle%3DMol.%2520Med.%2520Rep.%26date%3D2015%26volume%3D12%26spage%3D5641%26epage%3D5646%26doi%3D10.3892%2Fmmr.2015.4129" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref150"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref150'); return false;" data-citation="" class="refNumLink">150</a></strong><div class="NLM_citation" id="cit150"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhai, D.</span>; <span class="NLM_string-name">Deng, W.</span>; <span class="NLM_string-name">Huang, Z.</span>; <span class="NLM_string-name">Rogers, E.</span>; <span class="NLM_string-name">Cui, J. J.</span></span> <span> </span><span class="NLM_article-title">The Novel, Rationally-designed, ALK/SRC Inhibitor TPX-0005 Overcomes Multiple Acquired Resistance Mechanisms to Current ALK Inhibitors</span>. Presented at the  <i>107th Annual Meeting of the American Association for Cancer Research (AACR), New Orleans, LA,</i> <span class="NLM_year">2016</span>; Abstract  <span class="NLM_fpage">2132</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&pages=2132&author=D.+Zhai&author=W.+Deng&author=Z.+Huang&author=E.+Rogers&author=J.+J.+Cui&title=The+Novel%2C+Rationally-designed%2C+ALK%2FSRC+Inhibitor+TPX-0005+Overcomes+Multiple+Acquired+Resistance+Mechanisms+to+Current+ALK+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit150&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26sid%3Dliteratum%253Aachs%26aulast%3DZhai%26aufirst%3DD.%26atitle%3DThe%2520Novel%252C%2520Rationally-designed%252C%2520ALK%252FSRC%2520Inhibitor%2520TPX-0005%2520Overcomes%2520Multiple%2520Acquired%2520Resistance%2520Mechanisms%2520to%2520Current%2520ALK%2520Inhibitors%26jtitle%3D107th%2520Annual%2520Meeting%2520of%2520the%2520American%2520Association%2520for%2520Cancer%2520Research%2520%2528AACR%2529%252C%2520New%2520Orleans%252C%2520LA%252C%26date%3D2016%26spage%3D2132" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref151"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref151'); return false;" data-citation="" class="refNumLink">151</a></strong><div class="NLM_citation" id="cit151"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Deng, W.</span>; <span class="NLM_string-name">Huang, J.</span>; <span class="NLM_string-name">Zhai, D.</span>; <span class="NLM_string-name">Rogers, E.</span>; <span class="NLM_string-name">Cui, J.</span></span> <span> </span><span class="NLM_article-title">Overcoming Acquired Drug Resistance by TPX-0005, an ALK, ROS1 and Pan-TRK Inhibitor</span>. Presented at the  <i>Annual Meeting of the American Association for Cancer Research (AACR), Washington, DC</i>, <span class="NLM_year">2017</span>; Abstract  <span class="NLM_fpage">3168</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&pages=3168&author=W.+Deng&author=J.+Huang&author=D.+Zhai&author=E.+Rogers&author=J.+Cui&title=Overcoming+Acquired+Drug+Resistance+by+TPX-0005%2C+an+ALK%2C+ROS1+and+Pan-TRK+Inhibitor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit151&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26sid%3Dliteratum%253Aachs%26aulast%3DDeng%26aufirst%3DW.%26atitle%3DOvercoming%2520Acquired%2520Drug%2520Resistance%2520by%2520TPX-0005%252C%2520an%2520ALK%252C%2520ROS1%2520and%2520Pan-TRK%2520Inhibitor%26jtitle%3DAnnual%2520Meeting%2520of%2520the%2520American%2520Association%2520for%2520Cancer%2520Research%2520%2528AACR%2529%252C%2520Washington%252C%2520DC%26date%3D2017%26spage%3D3168" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref152"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref152'); return false;" data-citation="" class="refNumLink">152</a></strong><div class="NLM_citation" id="cit152"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Epstein, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emkey, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whittington, D. A.</span></span> <span> </span><span class="NLM_article-title">The R1275Q Neuroblastoma Mutant and Certain ATP-competitive Inhibitors Stabilize Alternative Activation Loop Conformations of Anaplastic Lymphoma Kinase</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>287</i></span>,  <span class="NLM_fpage">37447</span>– <span class="NLM_lpage">37457</span>, <span class="refDoi"> DOI: 10.1074/jbc.M112.391425</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1074%2Fjbc.M112.391425" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=22932897" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFOqs73K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=287&publication_year=2012&pages=37447-37457&author=L.+F.+Epsteinauthor=H.+Chenauthor=R.+Emkeyauthor=D.+A.+Whittington&title=The+R1275Q+Neuroblastoma+Mutant+and+Certain+ATP-competitive+Inhibitors+Stabilize+Alternative+Activation+Loop+Conformations+of+Anaplastic+Lymphoma+Kinase&doi=10.1074%2Fjbc.M112.391425"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit152R"><div class="casContent"><span class="casTitleNuber">152</span><div class="casTitle"><span class="NLM_cas:atitle">The R1275Q Neuroblastoma Mutant and Certain ATP-competitive Inhibitors Stabilize Alternative Activation Loop Conformations of Anaplastic Lymphoma Kinase</span></div><div class="casAuthors">Epstein, Linda F.; Chen, Hao; Emkey, Renee; Whittington, Douglas A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">287</span>
        (<span class="NLM_cas:issue">44</span>),
    <span class="NLM_cas:pages">37447-37457</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase that, when genetically altered by mutation, amplification, chromosomal translocation or inversion, has been shown to play an oncogenic role in certain cancers.  Small mol. inhibitors targeting the kinase activity of ALK have proven to be effective therapies in certain ALK-driven malignancies and one such inhibitor, crizotinib, is now approved for the treatment of EML4-ALK-driven, non-small cell lung cancer.  In neuroblastoma, activating point mutations in the ALK kinase domain can drive disease progression, with the two most common mutations being F1174L and R1275Q.  We report here crystal structures of the ALK kinase domain contg. the F1174L and R1275Q mutations.  Also included are crystal structures of ALK in complex with novel small mol. ALK inhibitors, including a classic type II inhibitor, that stabilize previously unobserved conformations of the ALK activation loop.  Collectively, these structures illustrate a different series of activation loop conformations than has been obsd. in previous ALK crystal structures and provide insight into the activating nature of the R1275Q mutation.  The novel active site topologies presented here may also aid the structure-based drug design of a new generation of ALK inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0rQKncKYwgrVg90H21EOLACvtfcHk0lg00hAye47xBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFOqs73K&md5=ac3a068a4837dfb1d63d54826d2b4564</span></div><a href="/servlet/linkout?suffix=cit152&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M112.391425&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M112.391425%26sid%3Dliteratum%253Aachs%26aulast%3DEpstein%26aufirst%3DL.%2BF.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DEmkey%26aufirst%3DR.%26aulast%3DWhittington%26aufirst%3DD.%2BA.%26atitle%3DThe%2520R1275Q%2520Neuroblastoma%2520Mutant%2520and%2520Certain%2520ATP-competitive%2520Inhibitors%2520Stabilize%2520Alternative%2520Activation%2520Loop%2520Conformations%2520of%2520Anaplastic%2520Lymphoma%2520Kinase%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2012%26volume%3D287%26spage%3D37447%26epage%3D37457%26doi%3D10.1074%2Fjbc.M112.391425" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref153"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref153'); return false;" data-citation="" class="refNumLink">153</a></strong><div class="NLM_citation" id="cit153"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kong, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, T.</span></span> <span> </span><span class="NLM_article-title">Importance of Protein Flexibility in Ranking Inhibitor Affinities: Modeling the Binding Mechanisms of Piperidine Carboxamides as Type I1/2 ALK Inhibitors</span>. <i>Phys. Chem. Chem. Phys.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">6098</span>– <span class="NLM_lpage">6113</span>, <span class="refDoi"> DOI: 10.1039/C4CP05440G</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1039%2FC4CP05440G" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=25644934" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsFSmsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2015&pages=6098-6113&author=X.+Kongauthor=P.+Panauthor=D.+Liauthor=S.+Tianauthor=Y.+Liauthor=T.+Hou&title=Importance+of+Protein+Flexibility+in+Ranking+Inhibitor+Affinities%3A+Modeling+the+Binding+Mechanisms+of+Piperidine+Carboxamides+as+Type+I1%2F2+ALK+Inhibitors&doi=10.1039%2FC4CP05440G"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit153R"><div class="casContent"><span class="casTitleNuber">153</span><div class="casTitle"><span class="NLM_cas:atitle">Importance of protein flexibility in ranking inhibitor affinities: modeling the binding mechanisms of piperidine carboxamides as Type I1/2 ALK inhibitors</span></div><div class="casAuthors">Kong, Xiaotian; Pan, Peichen; Li, Dan; Tian, Sheng; Li, Youyong; Hou, Tingjun</div><div class="citationInfo"><span class="NLM_cas:title">Physical Chemistry Chemical Physics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">6098-6113</span>CODEN:
                <span class="NLM_cas:coden">PPCPFQ</span>;
        ISSN:<span class="NLM_cas:issn">1463-9076</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Anaplastic lymphoma kinase (ALK) has gained increased attention as an attractive therapeutic target for the treatment of various cancers, esp. non-small-cell lung cancer (NSCLC).  Recently, piperidine carboxamides were reported as Type I1/2 inhibitors of ALK, which occupy both the ATP binding site and the back ATP hydrophobic cavity in DFG-in conformation.  Due to the dynamic behavior of ALK in the binding of Type I1/2 inhibitors, the accurate predictions of the binding structures and relative binding potencies of these inhibitors are quite challenging.  In this study, different modeling techniques, including mol. docking, ensemble docking based on multiple receptor conformations, mol. dynamics simulations and free energy calcns., were utilized to explore the binding mechanisms of piperidine carboxamides.  Our predictions show that the conventional docking protocols are not sufficient to predict the relative binding potencies of the studied inhibitors with high accuracy, but incorporating protein flexibility before or after docking is quite effective to improve the prediction accuracy.  Notably, the binding free energies predicted by MM/GBSA or MM/PBSA based on the MD simulations for the docked poses give the highest correlation with the exptl. data, highlighting the importance of the inclusion of receptor flexibility for the accurate predictions of the binding potencies for Type I1/2 inhibitors of ALK.  Furthermore, the comprehensive anal. of several pairs of representative inhibitors demonstrates the importance of hydrophobic interactions in improving the binding affinities of the inhibitors with the hot-spot residues surrounding the binding pocket.  This work is expected to provide valuable clues for further rational design of novel and potent Type I1/2 ALK inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpHLqgO9iCaU7Vg90H21EOLACvtfcHk0liP_2vV6k-75Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsFSmsL8%253D&md5=4b9bcd6f5b434d8a8240a171ce9897a7</span></div><a href="/servlet/linkout?suffix=cit153&amp;dbid=16384&amp;doi=10.1039%2FC4CP05440G&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC4CP05440G%26sid%3Dliteratum%253Aachs%26aulast%3DKong%26aufirst%3DX.%26aulast%3DPan%26aufirst%3DP.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DTian%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DHou%26aufirst%3DT.%26atitle%3DImportance%2520of%2520Protein%2520Flexibility%2520in%2520Ranking%2520Inhibitor%2520Affinities%253A%2520Modeling%2520the%2520Binding%2520Mechanisms%2520of%2520Piperidine%2520Carboxamides%2520as%2520Type%2520I1%252F2%2520ALK%2520Inhibitors%26jtitle%3DPhys.%2520Chem.%2520Chem.%2520Phys.%26date%3D2015%26volume%3D17%26spage%3D6098%26epage%3D6113%26doi%3D10.1039%2FC4CP05440G" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref154"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref154'); return false;" data-citation="" class="refNumLink">154</a></strong><div class="NLM_citation" id="cit154"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kong, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, T.</span></span> <span> </span><span class="NLM_article-title">Importance of Protein Flexibility in Molecular Recognition: a Case Study on Type-I1/2 Inhibitors of ALK</span>. <i>Phys. Chem. Chem. Phys.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">4851</span>– <span class="NLM_lpage">4863</span>, <span class="refDoi"> DOI: 10.1039/C7CP08241J</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1039%2FC7CP08241J" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=29383359" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC1cXosF2ltg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2018&pages=4851-4863&author=X.+Kongauthor=H.+Sunauthor=P.+Panauthor=F.+Zhuauthor=S.+Changauthor=L.+Xuauthor=Y.+Liauthor=T.+Hou&title=Importance+of+Protein+Flexibility+in+Molecular+Recognition%3A+a+Case+Study+on+Type-I1%2F2+Inhibitors+of+ALK&doi=10.1039%2FC7CP08241J"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit154R"><div class="casContent"><span class="casTitleNuber">154</span><div class="casTitle"><span class="NLM_cas:atitle">Importance of protein flexibility in molecular recognition: a case study on Type-I1/2 inhibitors of ALK</span></div><div class="casAuthors">Kong, Xiaotian; Sun, Huiyong; Pan, Peichen; Zhu, Feng; Chang, Shan; Xu, Lei; Li, Youyong; Hou, Tingjun</div><div class="citationInfo"><span class="NLM_cas:title">Physical Chemistry Chemical Physics</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">4851-4863</span>CODEN:
                <span class="NLM_cas:coden">PPCPFQ</span>;
        ISSN:<span class="NLM_cas:issn">1463-9076</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Anaplastic lymphoma kinase (ALK) has been regarded as a promising target for the therapy of various cancers.  A large no. of ALK inhibitors with diverse scaffolds have been discovered, and most of them belong to Type-I inhibitors that only occupy the ATP-binding pocket.  Recently, we reported a series of novel and potent Type-I1/2 inhibitors of ALK with the 1-purine-3-piperidinecarboxamide scaffold, which can bind to both the ATP-binding site of ALK and the adjacent hydrophobic allosteric pocket.  In this study, the binding mechanisms of these Type-I1/2 ALK inhibitors were elucidated by multiple mol. modeling techniques.  The calcn. results demonstrate that the ensemble docking based on multiple protein structures and the MM/PB(GB)SA calcns. based on mol. dynamics (MD) simulations yield better predictions than conventional rigid receptor docking (Glide, Surflex-Dock, and Autodock Vina), highlighting the importance of incorporating receptor flexibility in the predictions of binding poses and binding affinities of Type-I1/2 ALK inhibitors.  Furthermore, the umbrella sampling (US) simulations and MM/GBSA binding free energy decompn. analyses indicate that Leu1122, Leu1198, Gly1202 and Glu1210 in the hinge region and Glu1197, Ile1171, Phe1174, Ile1179, His1247, Ile1268, Asp1270 and Phe1271 in the allosteric pocket of ALK are the key residues for detg. the relative binding strength of the studied inhibitors.  Besides, we found that the most potent inhibitor (001-017) tends to form stronger transient interactions with residues along the dissocn. channel due to the high electronegativity of its bulky 4-(trifluoromethoxy) phenylamine tail.  As a whole, both the stronger binding affinity and the higher energetic barrier (which may prolong the drug-target residence time) of 001-017 contribute to its excellent anti-proliferation activity against ALK-pos. cancer cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDYCtbvgqEXbVg90H21EOLACvtfcHk0liP_2vV6k-75Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXosF2ltg%253D%253D&md5=c9607c6402fdcdccf751ae34d5c8cea1</span></div><a href="/servlet/linkout?suffix=cit154&amp;dbid=16384&amp;doi=10.1039%2FC7CP08241J&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC7CP08241J%26sid%3Dliteratum%253Aachs%26aulast%3DKong%26aufirst%3DX.%26aulast%3DSun%26aufirst%3DH.%26aulast%3DPan%26aufirst%3DP.%26aulast%3DZhu%26aufirst%3DF.%26aulast%3DChang%26aufirst%3DS.%26aulast%3DXu%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DHou%26aufirst%3DT.%26atitle%3DImportance%2520of%2520Protein%2520Flexibility%2520in%2520Molecular%2520Recognition%253A%2520a%2520Case%2520Study%2520on%2520Type-I1%252F2%2520Inhibitors%2520of%2520ALK%26jtitle%3DPhys.%2520Chem.%2520Chem.%2520Phys.%26date%3D2018%26volume%3D20%26spage%3D4851%26epage%3D4863%26doi%3D10.1039%2FC7CP08241J" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref155"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref155'); return false;" data-citation="" class="refNumLink">155</a></strong><div class="NLM_citation" id="cit155"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wentsch, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walter, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bührmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayer-Wrangowski, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rauh, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaman, G. J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willemsen-Seegers, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buijsman, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henning, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dauch, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zender, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laufer, S.</span></span> <span> </span><span class="NLM_article-title">Optimized Target Residence Time: Type I1/2 Inhibitors for p38α MAP Kinase with Improved Binding Kinetics through Direct Interaction with the R-Spine</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">5363</span>– <span class="NLM_lpage">5367</span>, <span class="refDoi"> DOI: 10.1002/anie.201701185</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1002%2Fanie.201701185" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC2sXlvVCmu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2017&pages=5363-5367&author=H.+K.+Wentschauthor=N.+M.+Walterauthor=M.+B%C3%BChrmannauthor=S.+Mayer-Wrangowskiauthor=D.+Rauhauthor=G.+J.+R.+Zamanauthor=N.+Willemsen-Seegersauthor=R.+C.+Buijsmanauthor=M.+Henningauthor=D.+Dauchauthor=L.+Zenderauthor=S.+Laufer&title=Optimized+Target+Residence+Time%3A+Type+I1%2F2+Inhibitors+for+p38%CE%B1+MAP+Kinase+with+Improved+Binding+Kinetics+through+Direct+Interaction+with+the+R-Spine&doi=10.1002%2Fanie.201701185"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit155R"><div class="casContent"><span class="casTitleNuber">155</span><div class="casTitle"><span class="NLM_cas:atitle">Optimized Target Residence Time: Type I1/2 Inhibitors for p38α MAP Kinase with Improved Binding Kinetics through Direct Interaction with the R-Spine</span></div><div class="casAuthors">Wentsch, Heike K.; Walter, Niklas M.; Buehrmann, Mike; Mayer-Wrangowski, Svenja; Rauh, Daniel; Zaman, Guido J. R.; Willemsen-Seegers, Nicole; Buijsman, Rogier C.; Henning, Melanie; Dauch, Daniel; Zender, Lars; Laufer, Stefan</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">5363-5367</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Skepinone-L was recently reported to be a p38α MAP kinase inhibitor with high potency and excellent selectivity in vitro and in vivo.  However, this class of compds. still act as fully ATP-competitive Type I binders which, furthermore, suffer from short residence times at the enzyme.  We herein describe a further development with the first Type I1/2 binders for p38α MAP kinase.  Type I1/2 inhibitors interfere with the R-spine, inducing a glycine flip and occupying both hydrophobic regions I and II.  This design approach leads to prolonged target residence time, binding to both the active and inactive states of the kinase, excellent selectivity, excellent potency on the enzyme level, and low nanomolar activity in a human whole blood assay.  This promising binding mode is proven by X-ray crystallog.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoO3M43Sl8vibVg90H21EOLACvtfcHk0liP_2vV6k-75Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXlvVCmu70%253D&md5=c4a1f981eaf8a2146f758fe4e71ac8b5</span></div><a href="/servlet/linkout?suffix=cit155&amp;dbid=16384&amp;doi=10.1002%2Fanie.201701185&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201701185%26sid%3Dliteratum%253Aachs%26aulast%3DWentsch%26aufirst%3DH.%2BK.%26aulast%3DWalter%26aufirst%3DN.%2BM.%26aulast%3DB%25C3%25BChrmann%26aufirst%3DM.%26aulast%3DMayer-Wrangowski%26aufirst%3DS.%26aulast%3DRauh%26aufirst%3DD.%26aulast%3DZaman%26aufirst%3DG.%2BJ.%2BR.%26aulast%3DWillemsen-Seegers%26aufirst%3DN.%26aulast%3DBuijsman%26aufirst%3DR.%2BC.%26aulast%3DHenning%26aufirst%3DM.%26aulast%3DDauch%26aufirst%3DD.%26aulast%3DZender%26aufirst%3DL.%26aulast%3DLaufer%26aufirst%3DS.%26atitle%3DOptimized%2520Target%2520Residence%2520Time%253A%2520Type%2520I1%252F2%2520Inhibitors%2520for%2520p38%25CE%25B1%2520MAP%2520Kinase%2520with%2520Improved%2520Binding%2520Kinetics%2520through%2520Direct%2520Interaction%2520with%2520the%2520R-Spine%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2017%26volume%3D56%26spage%3D5363%26epage%3D5367%26doi%3D10.1002%2Fanie.201701185" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref156"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref156'); return false;" data-citation="" class="refNumLink">156</a></strong><div class="NLM_citation" id="cit156"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pargellis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Churchill, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cirillo, P. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilmore, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graham, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grob, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hickey, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moss, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pav, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Regan, J.</span></span> <span> </span><span class="NLM_article-title">Inhibition of p38 MAP Kinase by Utilizing a Novel Allosteric Binding Site</span>. <i>Nat. Struct. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">268</span>, <span class="refDoi"> DOI: 10.1038/nsb770</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1038%2Fnsb770" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=11896401" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BD38Xis1Kisbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2002&pages=268&author=C.+Pargellisauthor=L.+Tongauthor=L.+Churchillauthor=P.+F.+Cirilloauthor=T.+Gilmoreauthor=A.+G.+Grahamauthor=P.+M.+Grobauthor=E.+R.+Hickeyauthor=N.+Mossauthor=S.+Pavauthor=J.+Regan&title=Inhibition+of+p38+MAP+Kinase+by+Utilizing+a+Novel+Allosteric+Binding+Site&doi=10.1038%2Fnsb770"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit156R"><div class="casContent"><span class="casTitleNuber">156</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site</span></div><div class="casAuthors">Pargellis, Christopher; Tong, Liang; Churchill, Laurie; Cirillo, Pier F.; Gilmore, Thomas; Graham, Anne G.; Grob, Peter M.; Hickey, Eugene R.; Moss, Neil; Pav, Susan; Regan, John</div><div class="citationInfo"><span class="NLM_cas:title">Nature Structural Biology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">268-272</span>CODEN:
                <span class="NLM_cas:coden">NSBIEW</span>;
        ISSN:<span class="NLM_cas:issn">1072-8368</span>.
    
            (<span class="NLM_cas:orgname">Nature America Inc.</span>)
        </div><div class="casAbstract">The p38 MAP kinase plays a crucial role in regulating the prodn. of proinflammatory cytokines, such as tumor necrosis factor and interleukin-1.  Blocking this kinase may offer an effective therapy for treating many inflammatory diseases.  Here we report a new allosteric binding site for a diaryl urea class of highly potent and selective inhibitors against human p38 MAP kinase.  The formation of this binding site requires a large conformational change not obsd. previously for any of the protein Ser/Thr kinases.  This change is in the highly conserved Asp-Phe-Gly motif within the active site of the kinase.  Soln. studies demonstrate that this class of compds. has slow binding kinetics, consistent with the requirement for conformational change.  Improving interactions in this allosteric pocket, as well as establishing binding interactions in the ATP pocket, enhanced the affinity of the inhibitors by 12,000-fold.  One of the most potent compds. in this series, BIRB 796, has picomolar affinity for the kinase and low nanomolar inhibitory activity in cell culture.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqT8_QT7_pbYrVg90H21EOLACvtfcHk0ljWGstwr7oKXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xis1Kisbk%253D&md5=68850ecdbe08df4285ba38cfa2c93ea4</span></div><a href="/servlet/linkout?suffix=cit156&amp;dbid=16384&amp;doi=10.1038%2Fnsb770&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnsb770%26sid%3Dliteratum%253Aachs%26aulast%3DPargellis%26aufirst%3DC.%26aulast%3DTong%26aufirst%3DL.%26aulast%3DChurchill%26aufirst%3DL.%26aulast%3DCirillo%26aufirst%3DP.%2BF.%26aulast%3DGilmore%26aufirst%3DT.%26aulast%3DGraham%26aufirst%3DA.%2BG.%26aulast%3DGrob%26aufirst%3DP.%2BM.%26aulast%3DHickey%26aufirst%3DE.%2BR.%26aulast%3DMoss%26aufirst%3DN.%26aulast%3DPav%26aufirst%3DS.%26aulast%3DRegan%26aufirst%3DJ.%26atitle%3DInhibition%2520of%2520p38%2520MAP%2520Kinase%2520by%2520Utilizing%2520a%2520Novel%2520Allosteric%2520Binding%2520Site%26jtitle%3DNat.%2520Struct.%2520Biol.%26date%3D2002%26volume%3D9%26spage%3D268%26doi%3D10.1038%2Fnsb770" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref157"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref157'); return false;" data-citation="" class="refNumLink">157</a></strong><div class="NLM_citation" id="cit157"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Walter, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wentsch, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buhrmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doring, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayer-Wrangowski, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sievers-Engler, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willemsen-Seegers, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaman, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buijsman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lammerhofer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rauh, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laufer, S. A.</span></span> <span> </span><span class="NLM_article-title">Design, Synthesis, and Biological Evaluation of Novel Type I1/2 p38α MAP Kinase Inhibitors with Excellent Selectivity, High Potency, and Prolonged Target Residence Time by Interfering with the R-spine</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">8027</span>– <span class="NLM_lpage">8054</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00745</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00745" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlOksb3M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=8027-8054&author=N.+M.+Walterauthor=H.+K.+Wentschauthor=M.+Buhrmannauthor=S.+M.+Bauerauthor=E.+Doringauthor=S.+Mayer-Wrangowskiauthor=A.+Sievers-Englerauthor=N.+Willemsen-Seegersauthor=G.+Zamanauthor=R.+Buijsmanauthor=M.+Lammerhoferauthor=D.+Rauhauthor=S.+A.+Laufer&title=Design%2C+Synthesis%2C+and+Biological+Evaluation+of+Novel+Type+I1%2F2+p38%CE%B1+MAP+Kinase+Inhibitors+with+Excellent+Selectivity%2C+High+Potency%2C+and+Prolonged+Target+Residence+Time+by+Interfering+with+the+R-spine&doi=10.1021%2Facs.jmedchem.7b00745"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit157R"><div class="casContent"><span class="casTitleNuber">157</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, and Biological Evaluation of Novel Type I1/2 p38α MAP Kinase Inhibitors with Excellent Selectivity, High Potency, and Prolonged Target Residence Time by Interfering with the R-Spine</span></div><div class="casAuthors">Walter, Niklas M.; Wentsch, Heike K.; Buehrmann, Mike; Bauer, Silke M.; Doering, Eva; Mayer-Wrangowski, Svenja; Sievers-Engler, Adrian; Willemsen-Seegers, Nicole; Zaman, Guido; Buijsman, Rogier; Laemmerhofer, Michael; Rauh, Daniel; Laufer, Stefan A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">8027-8054</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We recently reported 1a (skepinone-L) as a type I p38α MAP kinase inhibitor with high potency and excellent selectivity in vitro and in vivo.  However, as a type I inhibitor, it is entirely ATP-competitive and shows just a moderate residence time.  Thus, the scope was to develop a new class of advanced compds. maintaining the structural binding features of skepinone-L scaffold like inducing a glycine flip at the hinge region and occupying both hydrophobic regions I and II.  Extending this scaffold with suitable residues resulted in an interference with the kinase's R-Spine.  By synthesizing 69 compds., we could significantly prolong the target residence time with one example to 3663 s, along with an excellent selectivity score of 0.006 and an outstanding potency of 1.0 nM.  This new binding mode was validated by cocrystn., showing all binding interactions typifying type I1/2 binding.  Moreover, microsomal studies showed convenient metabolic stability of the most potent, herein reported representatives.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpAGz7uVuEJALVg90H21EOLACvtfcHk0ljWGstwr7oKXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlOksb3M&md5=99afecb58a5cf1fff6d9a905eb9f3aca</span></div><a href="/servlet/linkout?suffix=cit157&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00745%26sid%3Dliteratum%253Aachs%26aulast%3DWalter%26aufirst%3DN.%2BM.%26aulast%3DWentsch%26aufirst%3DH.%2BK.%26aulast%3DBuhrmann%26aufirst%3DM.%26aulast%3DBauer%26aufirst%3DS.%2BM.%26aulast%3DDoring%26aufirst%3DE.%26aulast%3DMayer-Wrangowski%26aufirst%3DS.%26aulast%3DSievers-Engler%26aufirst%3DA.%26aulast%3DWillemsen-Seegers%26aufirst%3DN.%26aulast%3DZaman%26aufirst%3DG.%26aulast%3DBuijsman%26aufirst%3DR.%26aulast%3DLammerhofer%26aufirst%3DM.%26aulast%3DRauh%26aufirst%3DD.%26aulast%3DLaufer%26aufirst%3DS.%2BA.%26atitle%3DDesign%252C%2520Synthesis%252C%2520and%2520Biological%2520Evaluation%2520of%2520Novel%2520Type%2520I1%252F2%2520p38%25CE%25B1%2520MAP%2520Kinase%2520Inhibitors%2520with%2520Excellent%2520Selectivity%252C%2520High%2520Potency%252C%2520and%2520Prolonged%2520Target%2520Residence%2520Time%2520by%2520Interfering%2520with%2520the%2520R-spine%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D8027%26epage%3D8054%26doi%3D10.1021%2Facs.jmedchem.7b00745" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref158"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref158'); return false;" data-citation="" class="refNumLink">158</a></strong><div class="NLM_citation" id="cit158"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mei, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kevin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span> <span> </span><span class="NLM_article-title">Protein–ligand Interaction Fingerprints for Accurate Prediction of Dissociation Rates of p38 MAPK Type II Inhibitors</span>. <i>Integr. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">53</span>– <span class="NLM_lpage">60</span>, <span class="refDoi"> DOI: 10.1093/intbio/zyz004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1093%2Fintbio%2Fzyz004" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2019&pages=53-60&author=D.+Zhangauthor=S.+Huangauthor=H.+Meiauthor=M.+Kevinauthor=T.+Shiauthor=L.+Chen&title=Protein%E2%80%93ligand+Interaction+Fingerprints+for+Accurate+Prediction+of+Dissociation+Rates+of+p38+MAPK+Type+II+Inhibitors&doi=10.1093%2Fintbio%2Fzyz004"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit158&amp;dbid=16384&amp;doi=10.1093%2Fintbio%2Fzyz004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fintbio%252Fzyz004%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DD.%26aulast%3DHuang%26aufirst%3DS.%26aulast%3DMei%26aufirst%3DH.%26aulast%3DKevin%26aufirst%3DM.%26aulast%3DShi%26aufirst%3DT.%26aulast%3DChen%26aufirst%3DL.%26atitle%3DProtein%25E2%2580%2593ligand%2520Interaction%2520Fingerprints%2520for%2520Accurate%2520Prediction%2520of%2520Dissociation%2520Rates%2520of%2520p38%2520MAPK%2520Type%2520II%2520Inhibitors%26jtitle%3DIntegr.%2520Biol.%26date%3D2019%26volume%3D11%26spage%3D53%26epage%3D60%26doi%3D10.1093%2Fintbio%2Fzyz004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref159"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref159'); return false;" data-citation="" class="refNumLink">159</a></strong><div class="NLM_citation" id="cit159"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Blanc, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geney, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menet, C.</span></span> <span> </span><span class="NLM_article-title">Type II Kinase Inhibitors: an Opportunity in Cancer for Rational Design</span>. <i>Anti-Cancer Agents Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">731</span>– <span class="NLM_lpage">747</span>, <span class="refDoi"> DOI: 10.2174/1871520611313050008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.2174%2F1871520611313050008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=23094911" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC3sXpslyku78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2013&pages=731-747&author=J.+Blancauthor=R.+Geneyauthor=C.+Menet&title=Type+II+Kinase+Inhibitors%3A+an+Opportunity+in+Cancer+for+Rational+Design&doi=10.2174%2F1871520611313050008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit159R"><div class="casContent"><span class="casTitleNuber">159</span><div class="casTitle"><span class="NLM_cas:atitle">Type II kinase inhibitors: an opportunity in cancer for rational design</span></div><div class="casAuthors">Blanc, Javier; Geney, Raphael; Menet, Christel</div><div class="citationInfo"><span class="NLM_cas:title">Anti-Cancer Agents in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">731-747</span>CODEN:
                <span class="NLM_cas:coden">AAMCE4</span>;
        ISSN:<span class="NLM_cas:issn">1871-5206</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  With the advent of the Type II kinase inhibitor imatinib (Gleevec) for treatment against cancer, rational design of tailored mols. has brought a revolution in medicinal chem. for treating tumors caused by kinase malfunctioning.  Among different types of kinase inhibitors, the design of Type II inhibitors has been rationalized for maximizing the benefits and reducing drawbacks.  Here we highlight the development made in Type II inhibitors, discussing the advantages and disadvantages of these types of mols.  Furthermore, we present the strategies for designing druggable mols. that either selectively inhibit target kinases or overcome drug resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7md6eYN1yg7Vg90H21EOLACvtfcHk0ljCGEk9euDJSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXpslyku78%253D&md5=30e72045115f723f2b868381898c2218</span></div><a href="/servlet/linkout?suffix=cit159&amp;dbid=16384&amp;doi=10.2174%2F1871520611313050008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1871520611313050008%26sid%3Dliteratum%253Aachs%26aulast%3DBlanc%26aufirst%3DJ.%26aulast%3DGeney%26aufirst%3DR.%26aulast%3DMenet%26aufirst%3DC.%26atitle%3DType%2520II%2520Kinase%2520Inhibitors%253A%2520an%2520Opportunity%2520in%2520Cancer%2520for%2520Rational%2520Design%26jtitle%3DAnti-Cancer%2520Agents%2520Med.%2520Chem.%26date%3D2013%26volume%3D13%26spage%3D731%26epage%3D747%26doi%3D10.2174%2F1871520611313050008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref160"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref160'); return false;" data-citation="" class="refNumLink">160</a></strong><div class="NLM_citation" id="cit160"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Paiva, S.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crews, C. M.</span></span> <span> </span><span class="NLM_article-title">Targeted Protein Degradation: Elements of PROTAC Design</span>. <i>Curr. Opin. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">111</span>– <span class="NLM_lpage">119</span>, <span class="refDoi"> DOI: 10.1016/j.cbpa.2019.02.022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1016%2Fj.cbpa.2019.02.022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=31004963" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC1MXns1yrt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2019&pages=111-119&author=S.-L.+Paivaauthor=C.+M.+Crews&title=Targeted+Protein+Degradation%3A+Elements+of+PROTAC+Design&doi=10.1016%2Fj.cbpa.2019.02.022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit160R"><div class="casContent"><span class="casTitleNuber">160</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted protein degradation: elements of PROTAC design</span></div><div class="casAuthors">Paiva, Stacey-Lynn; Crews, Craig M.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Chemical Biology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">111-119</span>CODEN:
                <span class="NLM_cas:coden">COCBF4</span>;
        ISSN:<span class="NLM_cas:issn">1367-5931</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Targeted protein degrdn. using Proteolysis Targeting Chimeras (PROTACs) has emerged as a novel therapeutic modality in drug discovery.  PROTACs mediate the degrdn. of select proteins of interest (POIs) by hijacking the activity of E3 ubiquitin ligases for POI ubiquitination and subsequent degrdn. by the 26S proteasome.  This hijacking mechanism has been used to degrade various types of disease-relevant POIs.  In this review, we aim to highlight the recent advances in targeted protein degrdn. and describe the challenges that need to be addressed in order to efficiently develop potent PROTACs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGol6Nk0VkUdzLVg90H21EOLACvtfcHk0ljCGEk9euDJSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXns1yrt7s%253D&md5=5783311db47da378180c14d67526a398</span></div><a href="/servlet/linkout?suffix=cit160&amp;dbid=16384&amp;doi=10.1016%2Fj.cbpa.2019.02.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cbpa.2019.02.022%26sid%3Dliteratum%253Aachs%26aulast%3DPaiva%26aufirst%3DS.-L.%26aulast%3DCrews%26aufirst%3DC.%2BM.%26atitle%3DTargeted%2520Protein%2520Degradation%253A%2520Elements%2520of%2520PROTAC%2520Design%26jtitle%3DCurr.%2520Opin.%2520Chem.%2520Biol.%26date%3D2019%26volume%3D50%26spage%3D111%26epage%3D119%26doi%3D10.1016%2Fj.cbpa.2019.02.022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref161"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref161'); return false;" data-citation="" class="refNumLink">161</a></strong><div class="NLM_citation" id="cit161"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span> <span> </span><span class="NLM_article-title">The PROTAC Technology in Drug Development</span>. <i>Cell Biochem. Funct.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">21</span>– <span class="NLM_lpage">30</span>, <span class="refDoi"> DOI: 10.1002/cbf.3369</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1002%2Fcbf.3369" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=30604499" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhslygsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2019&pages=21-30&author=Y.+Zouauthor=D.+Maauthor=Y.+Wang&title=The+PROTAC+Technology+in+Drug+Development&doi=10.1002%2Fcbf.3369"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit161R"><div class="casContent"><span class="casTitleNuber">161</span><div class="casTitle"><span class="NLM_cas:atitle">The PROTAC technology in drug development</span></div><div class="casAuthors">Zou, Yutian; Ma, Danhui; Wang, Yinyin</div><div class="citationInfo"><span class="NLM_cas:title">Cell Biochemistry and Function</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">21-30</span>CODEN:
                <span class="NLM_cas:coden">CBFUDH</span>;
        ISSN:<span class="NLM_cas:issn">1099-0844</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Currently, a new technol. termed PROTAC, proteolysis targeting chimera, has been developed for inducing the protein degrdn. by a targeting mol.  This technol. takes advantage of a moiety of targeted protein and a moiety of recognizing E3 ubiquitin ligase and produces a hybrid mol. to specifically knock down a targeted protein.  During the first decade, three pedigreed groups worked on the development of this technol.  To date, this technol. has been extended by different groups, aiming to develop new drugs against different diseases including cancers.  This review summarizes the contributions of the groups for the development of PROTAC.  Significance of the study : This review summarized the development of the PROTAC technol. for readers and also presented the author's opinions on the application of the technol. in tumor therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprT1CUHOqrfbVg90H21EOLACvtfcHk0ljCGEk9euDJSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhslygsQ%253D%253D&md5=2a7417e2c385d01f7eaef52a72c7ea52</span></div><a href="/servlet/linkout?suffix=cit161&amp;dbid=16384&amp;doi=10.1002%2Fcbf.3369&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcbf.3369%26sid%3Dliteratum%253Aachs%26aulast%3DZou%26aufirst%3DY.%26aulast%3DMa%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DY.%26atitle%3DThe%2520PROTAC%2520Technology%2520in%2520Drug%2520Development%26jtitle%3DCell%2520Biochem.%2520Funct.%26date%3D2019%26volume%3D37%26spage%3D21%26epage%3D30%26doi%3D10.1002%2Fcbf.3369" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref162"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref162'); return false;" data-citation="" class="refNumLink">162</a></strong><div class="NLM_citation" id="cit162"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Choi, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamashita, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ueno, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takashima, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakajima, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yatabe, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takeuchi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamada, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haruta, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishikawa, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kimura, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitsudomi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanio, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mano, H.</span></span> <span> </span><span class="NLM_article-title">EML4-ALK Mutations in Lung Cancer that Confer Resistance to ALK Inhibitors</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>363</i></span>,  <span class="NLM_fpage">1734</span>– <span class="NLM_lpage">1739</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1007478</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1056%2FNEJMoa1007478" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=20979473" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlKitL%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=363&publication_year=2010&pages=1734-1739&author=Y.+L.+Choiauthor=M.+Sodaauthor=Y.+Yamashitaauthor=T.+Uenoauthor=J.+Takashimaauthor=T.+Nakajimaauthor=Y.+Yatabeauthor=K.+Takeuchiauthor=T.+Hamadaauthor=H.+Harutaauthor=Y.+Ishikawaauthor=H.+Kimuraauthor=T.+Mitsudomiauthor=Y.+Tanioauthor=H.+Mano&title=EML4-ALK+Mutations+in+Lung+Cancer+that+Confer+Resistance+to+ALK+Inhibitors&doi=10.1056%2FNEJMoa1007478"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit162R"><div class="casContent"><span class="casTitleNuber">162</span><div class="casTitle"><span class="NLM_cas:atitle">EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors</span></div><div class="casAuthors">Choi, Young Lim; Soda, Manabu; Yamashita, Yoshihiro; Ueno, Toshihide; Takashima, Junpei; Nakajima, Takahiro; Yatabe, Yasushi; Takeuchi, Kengo; Hamada, Toru; Haruta, Hidenori; Ishikawa, Yuichi; Kimura, Hideki; Mitsudomi, Tetsuya; Tanio, Yoshiro; Mano, Hiroyuki</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">363</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">1734-1739</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">The EML4 (echinoderm microtubule-assocd. protein-like 4)-ALK (anaplastic lymphoma kinase) fusion-type tyrosine kinase is an oncoprotein found in 4% to 5% of non-small-cell lung cancers, and clin. trials of specific inhibitors of ALK for the treatment of such tumors are currently under way.  Here, we report the discovery of two secondary mutations within the kinase domain of EML4-ALK in tumor cells isolated from a patient during the relapse phase of treatment with an ALK inhibitor.  Each mutation developed independently in subclones of the tumor and conferred marked resistance to two different ALK inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCIrEIBi5MjrVg90H21EOLACvtfcHk0ljCGEk9euDJSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlKitL%252FJ&md5=d903151706575c159b7abcdc8999281c</span></div><a href="/servlet/linkout?suffix=cit162&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1007478&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1007478%26sid%3Dliteratum%253Aachs%26aulast%3DChoi%26aufirst%3DY.%2BL.%26aulast%3DSoda%26aufirst%3DM.%26aulast%3DYamashita%26aufirst%3DY.%26aulast%3DUeno%26aufirst%3DT.%26aulast%3DTakashima%26aufirst%3DJ.%26aulast%3DNakajima%26aufirst%3DT.%26aulast%3DYatabe%26aufirst%3DY.%26aulast%3DTakeuchi%26aufirst%3DK.%26aulast%3DHamada%26aufirst%3DT.%26aulast%3DHaruta%26aufirst%3DH.%26aulast%3DIshikawa%26aufirst%3DY.%26aulast%3DKimura%26aufirst%3DH.%26aulast%3DMitsudomi%26aufirst%3DT.%26aulast%3DTanio%26aufirst%3DY.%26aulast%3DMano%26aufirst%3DH.%26atitle%3DEML4-ALK%2520Mutations%2520in%2520Lung%2520Cancer%2520that%2520Confer%2520Resistance%2520to%2520ALK%2520Inhibitors%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2010%26volume%3D363%26spage%3D1734%26epage%3D1739%26doi%3D10.1056%2FNEJMoa1007478" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref163"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref163'); return false;" data-citation="" class="refNumLink">163</a></strong><div class="NLM_citation" id="cit163"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nagasundaram, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson Alphonse, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samuel Gnana, P. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rajaretinam, R. K.</span></span> <span> </span><span class="NLM_article-title">Molecular Dynamics Validation of Crizotinib Resistance to ALK Mutations (L1196M and G1269A) and Identification of Specific Inhibitors</span>. <i>J. Cell. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>118</i></span>,  <span class="NLM_fpage">3462</span>– <span class="NLM_lpage">3471</span>, <span class="refDoi"> DOI: 10.1002/jcb.26004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1002%2Fjcb.26004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=28332225" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC2sXnvFKjs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=118&publication_year=2017&pages=3462-3471&author=N.+Nagasundaramauthor=C.+R.+Wilson+Alphonseauthor=P.+V.+Samuel+Gnanaauthor=R.+K.+Rajaretinam&title=Molecular+Dynamics+Validation+of+Crizotinib+Resistance+to+ALK+Mutations+%28L1196M+and+G1269A%29+and+Identification+of+Specific+Inhibitors&doi=10.1002%2Fjcb.26004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit163R"><div class="casContent"><span class="casTitleNuber">163</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Dynamics Validation of Crizotinib Resistance to ALK Mutations (L1196M and G1269A) and Identification of Specific Inhibitors</span></div><div class="casAuthors">Nagasundaram, Nagarajan; Wilson Alphonse, Carlton Ranjith; Samuel Gnana, Prakash Vincent; Rajaretinam, Rajesh Kannan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cellular Biochemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">118</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3462-3471</span>CODEN:
                <span class="NLM_cas:coden">JCEBD5</span>;
        ISSN:<span class="NLM_cas:issn">0730-2312</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Anaplastic lymphoma kinase (ALK) pos. non-small cell lung cancer (NSCLC) patients are mostly treated with ALK tyrosine kinase inhibitors (TKIs).  Crizotinib is the first generation ALK inhibitor practiced as a primary chemo to combat cancer cells followed by second generation inhibitor ceritinib which are effective against crizotinib resistant ALK mutations.  However, patients treated with these drugs invariably relapsed because of the development of new drug resistance mutations.  In this study we explored the crizotinib resistance in the presence of ALK mutations L1196M and G1269A through mol. dynamics simulation studies.  Further mutation specific inhibitors CID 71748211 and CID 71728095 were identified to potentially inhibit ALK with mutations L1196M and G1269A, resp.  This computational investigation in-sighted the mol. factors involved in crizotinib resistance which enhanced in the identification of new ALK drugs that brings individualized medicine to treat ALK pos. NSCLC patients with specific mutations.  J. Cell. Biochem. 9999: 1-10, 2017. © 2017 Wiley Periodicals, Inc.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrt7AC2ZGxDsbVg90H21EOLACvtfcHk0likV2PuA-4nNA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXnvFKjs7g%253D&md5=192a2d0f01038623006d2ed3a6939566</span></div><a href="/servlet/linkout?suffix=cit163&amp;dbid=16384&amp;doi=10.1002%2Fjcb.26004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcb.26004%26sid%3Dliteratum%253Aachs%26aulast%3DNagasundaram%26aufirst%3DN.%26aulast%3DWilson%2BAlphonse%26aufirst%3DC.%2BR.%26aulast%3DSamuel%2BGnana%26aufirst%3DP.%2BV.%26aulast%3DRajaretinam%26aufirst%3DR.%2BK.%26atitle%3DMolecular%2520Dynamics%2520Validation%2520of%2520Crizotinib%2520Resistance%2520to%2520ALK%2520Mutations%2520%2528L1196M%2520and%2520G1269A%2529%2520and%2520Identification%2520of%2520Specific%2520Inhibitors%26jtitle%3DJ.%2520Cell.%2520Biochem.%26date%3D2017%26volume%3D118%26spage%3D3462%26epage%3D3471%26doi%3D10.1002%2Fjcb.26004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref164"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref164'); return false;" data-citation="" class="refNumLink">164</a></strong><div class="NLM_citation" id="cit164"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Doebele, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pilling, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aisner, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kutateladze, T. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weickhardt, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kondo, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Linderman, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heasley, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franklin, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varella-Garcia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camidge, D. R.</span></span> <span> </span><span class="NLM_article-title">Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non–small Cell Lung Cancer</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">1472</span>– <span class="NLM_lpage">1482</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-11-2906</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1158%2F1078-0432.CCR-11-2906" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=22235099" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC38Xjt1Wksro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=1472-1482&author=R.+C.+Doebeleauthor=A.+B.+Pillingauthor=D.+L.+Aisnerauthor=T.+G.+Kutateladzeauthor=A.+T.+Leauthor=A.+J.+Weickhardtauthor=K.+L.+Kondoauthor=D.+J.+Lindermanauthor=L.+E.+Heasleyauthor=W.+A.+Franklinauthor=M.+Varella-Garciaauthor=D.+R.+Camidge&title=Mechanisms+of+Resistance+to+Crizotinib+in+Patients+with+ALK+Gene+Rearranged+Non%E2%80%93small+Cell+Lung+Cancer&doi=10.1158%2F1078-0432.CCR-11-2906"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit164R"><div class="casContent"><span class="casTitleNuber">164</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non-Small Cell Lung Cancer</span></div><div class="casAuthors">Doebele, Robert C.; Pilling, Amanda B.; Aisner, Dara L.; Kutateladze, Tatiana G.; Le, Anh T.; Weickhardt, Andrew J.; Kondo, Kimi L.; Linderman, Derek J.; Heasley, Lynn E.; Franklin, Wilbur A.; Varella-Garcia, Marileila; Camidge, D. Ross</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1472-1482</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Patients with anaplastic lymphoma kinase (ALK) gene rearrangements often manifest dramatic responses to crizotinib, a small-mol. ALK inhibitor.  Unfortunately, not every patient responds and acquired drug resistance inevitably develops in those who do respond.  This study aimed to define mol. mechanisms of resistance to crizotinib in patients with ALK+ non-small cell lung cancer (NSCLC).  We analyzed tissue obtained from 14 patients with ALK+ NSCLC showing evidence of radiol. progression while on crizotinib to define mechanisms of intrinsic and acquired resistance to crizotinib.  Eleven patients had material evaluable for mol. anal.  Four patients (36%) developed secondary mutations in the tyrosine kinase domain of ALK.  A novel mutation in the ALK domain, encoding a G1269A amino acid substitution that confers resistance to crizotinib in vitro, was identified in two of these cases.  Two patients, one with a resistance mutation, exhibited new onset ALK copy no. gain (CNG).  One patient showed outgrowth of epidermal growth factor receptor (EGFR) mutant NSCLC without evidence of a persistent ALK gene rearrangement.  Two patients exhibited a KRAS mutation, one of which occurred without evidence of a persisting ALK gene rearrangement.  One patient showed the emergence of an ALK gene fusion-neg. tumor compared with the baseline sample but with no identifiable alternate driver.  Two patients retained ALK positivity with no identifiable resistance mechanism.  Crizotinib resistance in ALK+ NSCLC occurs through somatic kinase domain mutations, ALK gene fusion CNG, and emergence of sep. oncogenic drivers.  Clin Cancer Res; 18(5); 1472-82.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGofhGQYtlS1w7Vg90H21EOLACvtfcHk0likV2PuA-4nNA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xjt1Wksro%253D&md5=575047615ef9e3d4af60d45605a747c5</span></div><a href="/servlet/linkout?suffix=cit164&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-11-2906&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-11-2906%26sid%3Dliteratum%253Aachs%26aulast%3DDoebele%26aufirst%3DR.%2BC.%26aulast%3DPilling%26aufirst%3DA.%2BB.%26aulast%3DAisner%26aufirst%3DD.%2BL.%26aulast%3DKutateladze%26aufirst%3DT.%2BG.%26aulast%3DLe%26aufirst%3DA.%2BT.%26aulast%3DWeickhardt%26aufirst%3DA.%2BJ.%26aulast%3DKondo%26aufirst%3DK.%2BL.%26aulast%3DLinderman%26aufirst%3DD.%2BJ.%26aulast%3DHeasley%26aufirst%3DL.%2BE.%26aulast%3DFranklin%26aufirst%3DW.%2BA.%26aulast%3DVarella-Garcia%26aufirst%3DM.%26aulast%3DCamidge%26aufirst%3DD.%2BR.%26atitle%3DMechanisms%2520of%2520Resistance%2520to%2520Crizotinib%2520in%2520Patients%2520with%2520ALK%2520Gene%2520Rearranged%2520Non%25E2%2580%2593small%2520Cell%2520Lung%2520Cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2012%26volume%3D18%26spage%3D1472%26epage%3D1482%26doi%3D10.1158%2F1078-0432.CCR-11-2906" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref165"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref165'); return false;" data-citation="" class="refNumLink">165</a></strong><div class="NLM_citation" id="cit165"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, F. Q.</span></span> <span> </span><span class="NLM_article-title">A molecular Dynamics Investigation on the Crizotinib Resistance Mechanism of C1156Y Mutation in ALK</span>. <i>Biochem. Biophys. Res. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>423</i></span>,  <span class="NLM_fpage">319</span>– <span class="NLM_lpage">324</span>, <span class="refDoi"> DOI: 10.1016/j.bbrc.2012.05.120</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1016%2Fj.bbrc.2012.05.120" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=22659414" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC38XovVGqtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=423&publication_year=2012&pages=319-324&author=H.+Y.+Sunauthor=F.+Q.+Ji&title=A+molecular+Dynamics+Investigation+on+the+Crizotinib+Resistance+Mechanism+of+C1156Y+Mutation+in+ALK&doi=10.1016%2Fj.bbrc.2012.05.120"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit165R"><div class="casContent"><span class="casTitleNuber">165</span><div class="casTitle"><span class="NLM_cas:atitle">A molecular dynamics investigation on the crizotinib resistance mechanism of C1156Y mutation in ALK</span></div><div class="casAuthors">Sun, Hui-Yong; Ji, Feng-Qin</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical and Biophysical Research Communications</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">423</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">319-324</span>CODEN:
                <span class="NLM_cas:coden">BBRCA9</span>;
        ISSN:<span class="NLM_cas:issn">0006-291X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Crizotinib is an anaplastic lymphoma kinase (ALK) inhibitor that has recently been approved in the US for the treatment of non-small cell lung carcinoma (NSCLC).  Despite its outstanding safety and efficacy, several resistant mutations against crizotinib have been detected in the treatment of NSCLC.  However, in contrast to the widely accepted mechanism of steric hindrance by mutations at the active site, the mechanism by which the C1156Y non-active site mutation confers resistance against crizotinib remains unclear.  In the present study, the resistance mechanism of C1156Y in ALK was investigated using mol. dynamics simulations.  The results suggest that despite the non-active site mutation, C1156Y causes the dislocation of crizotinib as well as the indirect conformational changes in the binding cavity, which results in a marked decrease in the van der Waals and electrostatic interactions between crizotinib and ALK.  The obtained results provide a detailed explanation of the resistance caused by C1156Y and may give a vital clue for the design of drugs to combat crizotinib resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGombudl3C-pNLVg90H21EOLACvtfcHk0likV2PuA-4nNA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XovVGqtL8%253D&md5=21c3026294682a348fa755d3beeaa987</span></div><a href="/servlet/linkout?suffix=cit165&amp;dbid=16384&amp;doi=10.1016%2Fj.bbrc.2012.05.120&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbrc.2012.05.120%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DH.%2BY.%26aulast%3DJi%26aufirst%3DF.%2BQ.%26atitle%3DA%2520molecular%2520Dynamics%2520Investigation%2520on%2520the%2520Crizotinib%2520Resistance%2520Mechanism%2520of%2520C1156Y%2520Mutation%2520in%2520ALK%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D2012%26volume%3D423%26spage%3D319%26epage%3D324%26doi%3D10.1016%2Fj.bbrc.2012.05.120" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref166"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref166'); return false;" data-citation="" class="refNumLink">166</a></strong><div class="NLM_citation" id="cit166"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramanathan, K.</span></span> <span> </span><span class="NLM_article-title">Exploring the Structural and Functional Impact of the ALK F1174L Mutation Using Bioinformatics Approach</span>. <i>J. Mol. Model.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">2324</span>, <span class="refDoi"> DOI: 10.1007/s00894-014-2324-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1007%2Fs00894-014-2324-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=24952065" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A280%3ADC%252BC2cfkvFeqtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2014&pages=2324&author=A.+Kumarauthor=K.+Ramanathan&title=Exploring+the+Structural+and+Functional+Impact+of+the+ALK+F1174L+Mutation+Using+Bioinformatics+Approach&doi=10.1007%2Fs00894-014-2324-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit166R"><div class="casContent"><span class="casTitleNuber">166</span><div class="casTitle"><span class="NLM_cas:atitle">Exploring the structural and functional impact of the ALK F1174L mutation using bioinformatics approach</span></div><div class="casAuthors">Kumar Anish; Ramanathan K</div><div class="citationInfo"><span class="NLM_cas:title">Journal of molecular modeling</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2324</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Crizotinib is the most effective and the only drug that has been approved for the treatment of anaplastic lymphoma kinase (ALK)-positive lung cancer.  Reports suggest that there is a development of an acquired resistance against crizotinib action due to the emergence of several mutations in the ALK gene and F1174L is one such mutation.  In this study, we used molecular docking and molecular dynamics (MD) approach to decipher the effect of F1174L mutation in drug-target binding.  Docking results suggest that crizotinib was found to adopt the most promising conformations to the native-type ALK by identifying the M1199 residue as a prospective partner for making a hydrogen bond as compared to the mutant-type ALK.  MD results showed that the average atom, especially atoms of the native-type ALK-crizotinib complex, movements were less, displayed less fluctuation, fast convergence of energy, and changes in geometry.  This shows the stable binding of crizotinib with the native-type ALK in comparison to the mutant-type ALK.  We believe that this study could be useful for the logical design of stronger, more selective, and more consistent ALK inhibitor against drug-resistant F1174L mutation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRxPVLsf2kt_LesJRIHUP1ofW6udTcc2eY8aqL3JXpylbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cfkvFeqtA%253D%253D&md5=dcadd6d1a230320bb32a90a462313410</span></div><a href="/servlet/linkout?suffix=cit166&amp;dbid=16384&amp;doi=10.1007%2Fs00894-014-2324-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00894-014-2324-3%26sid%3Dliteratum%253Aachs%26aulast%3DKumar%26aufirst%3DA.%26aulast%3DRamanathan%26aufirst%3DK.%26atitle%3DExploring%2520the%2520Structural%2520and%2520Functional%2520Impact%2520of%2520the%2520ALK%2520F1174L%2520Mutation%2520Using%2520Bioinformatics%2520Approach%26jtitle%3DJ.%2520Mol.%2520Model.%26date%3D2014%26volume%3D20%26spage%3D2324%26doi%3D10.1007%2Fs00894-014-2324-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref167"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref167'); return false;" data-citation="" class="refNumLink">167</a></strong><div class="NLM_citation" id="cit167"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Russo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Misale, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siravegna, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crisafulli, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lazzari, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corti, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rospo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novara, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mussolin, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartolini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cam, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shoemaker, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wild, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Nicolantonio, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bianchi, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siena, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bardelli, A.</span></span> <span> </span><span class="NLM_article-title">Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">36</span>– <span class="NLM_lpage">44</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-15-0940</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1158%2F2159-8290.CD-15-0940" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=26546295" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC28XptlCrsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2016&pages=36-44&author=M.+Russoauthor=S.+Misaleauthor=G.+Weiauthor=G.+Siravegnaauthor=G.+Crisafulliauthor=L.+Lazzariauthor=G.+Cortiauthor=G.+Rospoauthor=L.+Novaraauthor=B.+Mussolinauthor=A.+Bartoliniauthor=N.+Camauthor=R.+Patelauthor=S.+Yanauthor=R.+Shoemakerauthor=R.+Wildauthor=F.+Di+Nicolantonioauthor=A.+S.+Bianchiauthor=G.+Liauthor=S.+Sienaauthor=A.+Bardelli&title=Acquired+Resistance+to+the+TRK+Inhibitor+Entrectinib+in+Colorectal+Cancer&doi=10.1158%2F2159-8290.CD-15-0940"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit167R"><div class="casContent"><span class="casTitleNuber">167</span><div class="casTitle"><span class="NLM_cas:atitle">Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer</span></div><div class="casAuthors">Russo, Mariangela; Misale, Sandra; Wei, Ge; Siravegna, Giulia; Crisafulli, Giovanni; Lazzari, Luca; Corti, Giorgio; Rospo, Giuseppe; Novara, Luca; Mussolin, Benedetta; Bartolini, Alice; Cam, Nicholas; Patel, Roopal; Yan, Shunqi; Shoemaker, Robert; Wild, Robert; Di Nicolantonio, Federica; Bianchi, Andrea Sartore; Li, Gang; Siena, Salvatore; Bardelli, Alberto</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">36-44</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Entrectinib is a first-in-class pan-TRK kinase inhibitor currently undergoing clin. testing in colorectal cancer and other tumor types.  A patient with metastatic colorectal cancer harboring an LMNA-NTRK1 rearrangement displayed a remarkable response to treatment with entrectinib, which was followed by the emergence of resistance.  To characterize the mol. bases of the patient's relapse, circulating tumor DNA (ctDNA) was collected longitudinally during treatment, and a tissue biopsy, obtained before entrectinib treatment, was transplanted in mice (xenopatient), which then received the same entrectinib regimen until resistance developed.  Genetic profiling of ctDNA and xenopatient samples showed acquisition of two point mutations in the catalytic domain of NTRK1, p.G595R and p.G667C.  Biochem. and pharmacol. anal. in multiple preclin. models confirmed that either mutation renders the TRKA kinase insensitive to entrectinib.  These findings can be immediately exploited to design next-generation TRKA inhibitors.  Significance: We provide proof of principle that analyses of xenopatients (avatar) and liq. biopsies allow the identification of drug resistance mechanisms in parallel with clin. treatment of an individual patient.  We describe for the first time that p.G595R and p.G667C TRKA mutations drive acquired resistance to entrectinib in colorectal cancers carrying NTRK1 rearrangements.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1Unyh1xjaoLVg90H21EOLACvtfcHk0lidSFwXu_mDAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XptlCrsA%253D%253D&md5=5baa54a784e355b6afa50336b2708052</span></div><a href="/servlet/linkout?suffix=cit167&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-15-0940&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-15-0940%26sid%3Dliteratum%253Aachs%26aulast%3DRusso%26aufirst%3DM.%26aulast%3DMisale%26aufirst%3DS.%26aulast%3DWei%26aufirst%3DG.%26aulast%3DSiravegna%26aufirst%3DG.%26aulast%3DCrisafulli%26aufirst%3DG.%26aulast%3DLazzari%26aufirst%3DL.%26aulast%3DCorti%26aufirst%3DG.%26aulast%3DRospo%26aufirst%3DG.%26aulast%3DNovara%26aufirst%3DL.%26aulast%3DMussolin%26aufirst%3DB.%26aulast%3DBartolini%26aufirst%3DA.%26aulast%3DCam%26aufirst%3DN.%26aulast%3DPatel%26aufirst%3DR.%26aulast%3DYan%26aufirst%3DS.%26aulast%3DShoemaker%26aufirst%3DR.%26aulast%3DWild%26aufirst%3DR.%26aulast%3DDi%2BNicolantonio%26aufirst%3DF.%26aulast%3DBianchi%26aufirst%3DA.%2BS.%26aulast%3DLi%26aufirst%3DG.%26aulast%3DSiena%26aufirst%3DS.%26aulast%3DBardelli%26aufirst%3DA.%26atitle%3DAcquired%2520Resistance%2520to%2520the%2520TRK%2520Inhibitor%2520Entrectinib%2520in%2520Colorectal%2520Cancer%26jtitle%3DCancer%2520Discovery%26date%3D2016%26volume%3D6%26spage%3D36%26epage%3D44%26doi%3D10.1158%2F2159-8290.CD-15-0940" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref168"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref168'); return false;" data-citation="" class="refNumLink">168</a></strong><div class="NLM_citation" id="cit168"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, T.</span></span> <span> </span><span class="NLM_article-title">Insight into Crizotinib Resistance Mechanisms Caused by Three Mutations in ALK Tyrosine Kinase Using Free Energy Calculation Approaches</span>. <i>J. Chem. Inf. Model.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">2376</span>– <span class="NLM_lpage">2389</span>, <span class="refDoi"> DOI: 10.1021/ci400188q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ci400188q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1ymt7vI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2013&pages=2376-2389&author=H.+Sunauthor=Y.+Liauthor=D.+Liauthor=T.+Hou&title=Insight+into+Crizotinib+Resistance+Mechanisms+Caused+by+Three+Mutations+in+ALK+Tyrosine+Kinase+Using+Free+Energy+Calculation+Approaches&doi=10.1021%2Fci400188q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit168R"><div class="casContent"><span class="casTitleNuber">168</span><div class="casTitle"><span class="NLM_cas:atitle">Insight into Crizotinib Resistance Mechanisms Caused by Three Mutations in ALK Tyrosine Kinase using Free Energy Calculation Approaches</span></div><div class="casAuthors">Sun, Huiyong; Li, Youyong; Li, Dan; Hou, Tingjun</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2376-2389</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">As a safe and efficacious drug, crizotinib was approved by the U.S. Food and Drug Administration (FDA) in 2011 for the treatment of advanced fusion-type nonsmall-cell lung cancer.  Although high response ratio was detected from the patients treated with crizotinib, the cancer has eventually conferred resistance to crizotinib.  Several drug resistance mutations have been found in the anaplastic lymphoma kinase (ALK) tyrosine kinase domain as the target for crizotinib, but the drug resistance mechanisms remain unclear.  Therefore, in this study, the adaptive biasing force (ABF) method and two-end-state free energy calcn. approaches were employed to elucidate the resistance mechanisms of crizotinib induced by the mutations L1152R, G1202R, and S1206Y.  The ABF simulation results suggest that the reaction coordinates for the unbinding processes of crizotinib from the binding pockets of the mutated ALKs is different from that of the wild type ALK.  The potentials of mean force for the crizotinib unbinding and the binding free energies predicted by the two-end-state free energy calcns. are consistent with the exptl. data.  Our results indicate that the three mutations weaken the binding affinity of crizotinib obviously and lead to drug resistance.  The free energy decompn. anal. illustrates the importance of the loss of two important H-bonds in the L1152R and S1206Y mutants on drug resistance.  The entropy anal. shows that the entropy term plays a crit. role in the substantial change of the conformational entropies of G1202R and L1152R.  Our results reveal the mechanisms of drug resistance and provide vital clues for the development of new inhibitors to combat drug resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo3Vorb-VUQbrVg90H21EOLACvtfcHk0lidSFwXu_mDAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1ymt7vI&md5=d8bd7a807d1bc9b231eb6bd0367bed3a</span></div><a href="/servlet/linkout?suffix=cit168&amp;dbid=16384&amp;doi=10.1021%2Fci400188q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci400188q%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DHou%26aufirst%3DT.%26atitle%3DInsight%2520into%2520Crizotinib%2520Resistance%2520Mechanisms%2520Caused%2520by%2520Three%2520Mutations%2520in%2520ALK%2520Tyrosine%2520Kinase%2520Using%2520Free%2520Energy%2520Calculation%2520Approaches%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2013%26volume%3D53%26spage%3D2376%26epage%3D2389%26doi%3D10.1021%2Fci400188q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref169"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref169'); return false;" data-citation="" class="refNumLink">169</a></strong><div class="NLM_citation" id="cit169"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, T.</span></span> <span> </span><span class="NLM_article-title">P-loop Conformation Governed Crizotinib Resistance in G2032R-mutated ROS1 Tyrosine Kinase: Clues from Free Energy Landscape</span>. <i>PLoS Comput. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">e1003729</span>, <span class="refDoi"> DOI: 10.1371/journal.pcbi.1003729</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1371%2Fjournal.pcbi.1003729" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=25033171" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1amsbzI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2014&pages=e1003729&author=H.+Sunauthor=Y.+Liauthor=S.+Tianauthor=J.+Wangauthor=T.+Hou&title=P-loop+Conformation+Governed+Crizotinib+Resistance+in+G2032R-mutated+ROS1+Tyrosine+Kinase%3A+Clues+from+Free+Energy+Landscape&doi=10.1371%2Fjournal.pcbi.1003729"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit169R"><div class="casContent"><span class="casTitleNuber">169</span><div class="casTitle"><span class="NLM_cas:atitle">P-loop conformation governed crizotinib resistance in G2032R-mutated ROS1 tyrosine kinase: clues from free energy landscape</span></div><div class="casAuthors">Sun, Huiyong; Li, Youyong; Tian, Sheng; Wang, Junmei; Hou, Tingjun</div><div class="citationInfo"><span class="NLM_cas:title">PLoS Computational Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">e1003729/1-e1003729/13, 13 pp.</span>CODEN:
                <span class="NLM_cas:coden">PCBLBG</span>;
        ISSN:<span class="NLM_cas:issn">1553-7358</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Tyrosine kinases are regarded as excellent targets for chem. drug therapy of carcinomas.  However, under strong purifying selection, drug resistance usually occurs in the cancer cells within a short term.  Many cases of drug resistance have been found to be assocd. with secondary mutations in drug target, which lead to the attenuated drug-target interactions.  For example, recently, an acquired secondary mutation, G2032R, has been detected in the drug target, ROS1 tyrosine kinase, from a crizotinib-resistant patient, who responded poorly to crizotinib within a very short therapeutic term.  It was supposed that the mutation was located at the solvent front and might hinder the drug binding.  However, a different fact could be uncovered by the simulations reported in this study.  Here, free energy surfaces were characterized by the drug-target distance and the phosphate-binding loop (P-loop) conformational change of the crizotinib-ROS1 complex through advanced mol. dynamics techniques, and it was revealed that the more rigid P-loop region in the G2032R-mutated ROS1 was primarily responsible for the crizotinib resistance, which on one hand, impaired the binding of crizotinib directly, and on the other hand, shortened the residence time induced by the flattened free energy surface.  Therefore, both of the binding affinity and the drug residence time should be emphasized in rational drug design to overcome the kinase resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkA1c65wE9f7Vg90H21EOLACvtfcHk0lhWoqg7XbrmmA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1amsbzI&md5=6d1063a1e69ba81b2a77b4ae20f1ff74</span></div><a href="/servlet/linkout?suffix=cit169&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pcbi.1003729&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pcbi.1003729%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DTian%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DHou%26aufirst%3DT.%26atitle%3DP-loop%2520Conformation%2520Governed%2520Crizotinib%2520Resistance%2520in%2520G2032R-mutated%2520ROS1%2520Tyrosine%2520Kinase%253A%2520Clues%2520from%2520Free%2520Energy%2520Landscape%26jtitle%3DPLoS%2520Comput.%2520Biol.%26date%3D2014%26volume%3D10%26spage%3De1003729%26doi%3D10.1371%2Fjournal.pcbi.1003729" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref170"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref170'); return false;" data-citation="" class="refNumLink">170</a></strong><div class="NLM_citation" id="cit170"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Isozaki, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takigawa, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiura, K.</span></span> <span> </span><span class="NLM_article-title">Mechanisms of Acquired Resistance to ALK Inhibitors and the Rationale for Treating ALK-positive Lung Cancer</span>. <i>Cancers</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">763</span>– <span class="NLM_lpage">783</span>, <span class="refDoi"> DOI: 10.3390/cancers7020763</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.3390%2Fcancers7020763" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=25941796" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC1cXlsVKhsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2015&pages=763-783&author=H.+Isozakiauthor=N.+Takigawaauthor=K.+Kiura&title=Mechanisms+of+Acquired+Resistance+to+ALK+Inhibitors+and+the+Rationale+for+Treating+ALK-positive+Lung+Cancer&doi=10.3390%2Fcancers7020763"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit170R"><div class="casContent"><span class="casTitleNuber">170</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of acquired resistance to ALK inhibitors and the rationale for treating ALK-positive lung cancer</span></div><div class="casAuthors">Isozaki, Hideko; Takigawa, Nagio; Kiura, Katsuyuki</div><div class="citationInfo"><span class="NLM_cas:title">Cancers</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">763-783</span>CODEN:
                <span class="NLM_cas:coden">CANCCT</span>;
        ISSN:<span class="NLM_cas:issn">2072-6694</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">The discovery of an echinoderm microtubule-assocd. protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK) fusion gene led to improved clin. outcomes in patients with lung cancer after the development of the first ALK-targeting agent, crizotinib.  Some second-generation ALK tyrosine kinase inhibitors (TKIs), which might be more potent than crizotinib or effective on crizotinib-resistant patients, have been developed.  Although these ALK-TKIs show an excellent response initially, most patients eventually acquire resistance.  Therefore, careful consideration of the resistance mechanisms might lead to superior therapeutic strategies.  Here, we summarize the history of ALK-TKIs and their underlying resistance mechanisms in both the preclin. and clin. settings.  In addn., we discuss potential future treatment strategies in ALK-TKI-na.ovrddot.ive and -resistant patients with lung cancer harboring the EML4-ALK fusion gene.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFywf655AM27Vg90H21EOLACvtfcHk0lhWoqg7XbrmmA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXlsVKhsL4%253D&md5=7970f0ec14dc486b3920e6473f01a7c7</span></div><a href="/servlet/linkout?suffix=cit170&amp;dbid=16384&amp;doi=10.3390%2Fcancers7020763&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fcancers7020763%26sid%3Dliteratum%253Aachs%26aulast%3DIsozaki%26aufirst%3DH.%26aulast%3DTakigawa%26aufirst%3DN.%26aulast%3DKiura%26aufirst%3DK.%26atitle%3DMechanisms%2520of%2520Acquired%2520Resistance%2520to%2520ALK%2520Inhibitors%2520and%2520the%2520Rationale%2520for%2520Treating%2520ALK-positive%2520Lung%2520Cancer%26jtitle%3DCancers%26date%3D2015%26volume%3D7%26spage%3D763%26epage%3D783%26doi%3D10.3390%2Fcancers7020763" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref171"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref171'); return false;" data-citation="" class="refNumLink">171</a></strong><div class="NLM_citation" id="cit171"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gadgeel, S. M</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gandhi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riely, G. J</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiappori, A. A</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">West, H. L</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Azada, M. C</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morcos, P. N</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, R.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boisserie, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Laurenzio, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golding, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sato, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yokoyama, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ou, S.-H. I.</span></span> <span> </span><span class="NLM_article-title">Safety and Activity of Alectinib against Systemic Disease and Brain Metastases in Patients with Crizotinib-resistant ALK-rearranged Non-small-cell Lung Cancer (AF-002JG): Results from the Dose-finding Portion of a Phase 1/2 Study</span>. <i>Lancet Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">1119</span>– <span class="NLM_lpage">1128</span>, <span class="refDoi"> DOI: 10.1016/S1470-2045(14)70362-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1016%2FS1470-2045%2814%2970362-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=25153538" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVSmt77K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2014&pages=1119-1128&author=S.+M+Gadgeelauthor=L.+Gandhiauthor=G.+J+Rielyauthor=A.+A+Chiapporiauthor=H.+L+Westauthor=M.+C+Azadaauthor=P.+N+Morcosauthor=R.-M.+Leeauthor=L.+Garciaauthor=L.+Yuauthor=F.+Boisserieauthor=L.+Di+Laurenzioauthor=S.+Goldingauthor=J.+Satoauthor=S.+Yokoyamaauthor=T.+Tanakaauthor=S.-H.+I.+Ou&title=Safety+and+Activity+of+Alectinib+against+Systemic+Disease+and+Brain+Metastases+in+Patients+with+Crizotinib-resistant+ALK-rearranged+Non-small-cell+Lung+Cancer+%28AF-002JG%29%3A+Results+from+the+Dose-finding+Portion+of+a+Phase+1%2F2+Study&doi=10.1016%2FS1470-2045%2814%2970362-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit171R"><div class="casContent"><span class="casTitleNuber">171</span><div class="casTitle"><span class="NLM_cas:atitle">Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study</span></div><div class="casAuthors">Gadgeel, Shirish M.; Gandhi, Leena; Riely, Gregory J.; Chiappori, Alberto A.; West, Howard L.; Azada, Michele C.; Morcos, Peter N.; Lee, Ruey-Min; Garcia, Linta; Yu, Li; Boisserie, Frederic; Di Laurenzio, Laura; Golding, Sophie; Sato, Jotaro; Yokoyama, Shumpei; Tanaka, Tomohiro; Ou, Sai-Hong Ignatius</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1119-1128</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Patients with non-small-cell lung cancer (NSCLC) and ALK rearrangements generally have a progression-free survival of 8-11 mo while on treatment with the ALK inhibitor crizotinib.  However, resistance inevitably develops, with the brain a common site of progression.  More potent ALK inhibitors with consistently demonstrable CNS activity and good tolerability are needed urgently.  Alectinib is a novel, highly selective, and potent ALK inhibitor that has shown clin. activity in patients with crizotinib-naive ALK-rearranged NSCLC.  We did a phase 1/2 study of alectinib to establish the recommended phase 2 dose of the drug and examine its activity in patients resistant or intolerant to crizotinib.  We enrolled patients with ALK-rearranged NSCLC who progressed on or were intolerant to crizotinib.  We administered various oral doses of alectinib (300-900 mg twice a day) during the dose-escalation portion of the study (phase 1), to ascertain the recommended dose for phase 2.  We used Response Evaluation Criteria in Solid Tumors criteria (version 1.1) to investigate the activity of alectinib in all patients with a baseline scan and at least one post-treatment scan (CT or MRI), with central radiol. review of individuals with brain metastases.  We assessed safety in all patients who received at least one dose of alectinib.  Here, we present data for the phase 1 portion of the study, the primary objective of which was to establish the recommended phase 2 dose; phase 2 is ongoing.  This trial is registered at ClinicalTrials.gov, no. NCT01588028.47 patients were enrolled.  Alectinib was well tolerated, with the most common adverse events being fatigue (14 [30%]; all grade 1-2), myalgia (eight [17%]; all grade 1-2), and peripheral edema (seven [15%] grade 1-2, one [2%] grade 3).  Dose-limiting toxic effects were recorded in two patients in the cohort receiving alectinib 900 mg twice a day; one individual had grade 3 headache and the other had grade 3 neutropenia.  The most common grade 3-4 adverse events were increased levels of γ-glutamyl transpeptidase (two [4%]), a redn. in the no. of neutrophils (two [4%]), and hypophosphatemia (two [4%]).  Three patients reported four grade 4 serious adverse events that were deemed unrelated to alectinib: acute renal failure; pleural effusion and pericardial effusion; and brain metastasis.  At data cut-off (median follow-up 126 days [IQR 84-217]), 44 patients could be assessed for activity.  Investigator-assessed objective responses were noted in 24 (55%) patients, with a confirmed complete response in one (2%), a confirmed partial response in 14 (32%), and an unconfirmed partial response in nine (20%). 16 (36%) patients had stable disease; the remaining four (9%) had progressive disease.  Of 21 patients with CNS metastases at baseline, 11 (52%) had an objective response; six (29%) had a complete response (three unconfirmed) and five (24%) had a partial response (one unconfirmed); eight (38%) patients had stable disease and the remaining two (10%) had progressive disease.  Pharmacokinetic data indicated that mean exposure (AUC0-10) after multiple doses of alectinib (300-600 mg twice a day) was dose-dependent.  Alectinib was well tolerated, with promising antitumor activity in patients with ALK-rearranged NSCLC resistant to crizotinib, including those with CNS metastases.  On the basis of activity, tolerability, and pharmacokinetic data, we chose alectinib 600 mg twice a day as the recommended dose for phase 2.  Chugai Pharmaceuticals, F Hoffmann La-Roche.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGriCeVttS5axrVg90H21EOLACvtfcHk0lhWoqg7XbrmmA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVSmt77K&md5=aa56d295472ea5dcb29070a4e39d420a</span></div><a href="/servlet/linkout?suffix=cit171&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2814%2970362-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252814%252970362-6%26sid%3Dliteratum%253Aachs%26aulast%3DGadgeel%26aufirst%3DS.%2BM%26aulast%3DGandhi%26aufirst%3DL.%26aulast%3DRiely%26aufirst%3DG.%2BJ%26aulast%3DChiappori%26aufirst%3DA.%2BA%26aulast%3DWest%26aufirst%3DH.%2BL%26aulast%3DAzada%26aufirst%3DM.%2BC%26aulast%3DMorcos%26aufirst%3DP.%2BN%26aulast%3DLee%26aufirst%3DR.-M.%26aulast%3DGarcia%26aufirst%3DL.%26aulast%3DYu%26aufirst%3DL.%26aulast%3DBoisserie%26aufirst%3DF.%26aulast%3DDi%2BLaurenzio%26aufirst%3DL.%26aulast%3DGolding%26aufirst%3DS.%26aulast%3DSato%26aufirst%3DJ.%26aulast%3DYokoyama%26aufirst%3DS.%26aulast%3DTanaka%26aufirst%3DT.%26aulast%3DOu%26aufirst%3DS.-H.%2BI.%26atitle%3DSafety%2520and%2520Activity%2520of%2520Alectinib%2520against%2520Systemic%2520Disease%2520and%2520Brain%2520Metastases%2520in%2520Patients%2520with%2520Crizotinib-resistant%2520ALK-rearranged%2520Non-small-cell%2520Lung%2520Cancer%2520%2528AF-002JG%2529%253A%2520Results%2520from%2520the%2520Dose-finding%2520Portion%2520of%2520a%2520Phase%25201%252F2%2520Study%26jtitle%3DLancet%2520Oncol.%26date%3D2014%26volume%3D15%26spage%3D1119%26epage%3D1128%26doi%3D10.1016%2FS1470-2045%2814%2970362-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref172"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref172'); return false;" data-citation="" class="refNumLink">172</a></strong><div class="NLM_citation" id="cit172"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Courtin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smyth, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hearn, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saini, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, N. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyons, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallis, N. G.</span></span> <span> </span><span class="NLM_article-title">Emergence of Resistance to Tyrosine Kinase Inhibitors in Non-small-cell Lung Cancer can be Delayed by an upfront Combination with the HSP90 Inhibitor Onalespib</span>. <i>Br. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>115</i></span>,  <span class="NLM_fpage">1069</span>, <span class="refDoi"> DOI: 10.1038/bjc.2016.294</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1038%2Fbjc.2016.294" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=27673365" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslKns7%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2016&pages=1069&author=A.+Courtinauthor=T.+Smythauthor=K.+Hearnauthor=H.+K.+Sainiauthor=N.+T.+Thompsonauthor=J.+F.+Lyonsauthor=N.+G.+Wallis&title=Emergence+of+Resistance+to+Tyrosine+Kinase+Inhibitors+in+Non-small-cell+Lung+Cancer+can+be+Delayed+by+an+upfront+Combination+with+the+HSP90+Inhibitor+Onalespib&doi=10.1038%2Fbjc.2016.294"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit172R"><div class="casContent"><span class="casTitleNuber">172</span><div class="casTitle"><span class="NLM_cas:atitle">Emergence of resistance to tyrosine kinase inhibitors in non-small-cell lung cancer can be delayed by an upfront combination with the HSP90 inhibitor onalespib</span></div><div class="casAuthors">Courtin, Aurelie; Smyth, Tomoko; Hearn, Keisha; Saini, Harpreet K.; Thompson, Neil T.; Lyons, John F.; Wallis, Nicola G.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">115</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1069-1077</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Background: Tyrosine kinase inhibitors, such as crizotinib and erlotinib, are widely used to treat non-small-cell lung cancer, but after initial response, relapse is common because of the emergence of resistance through multiple mechanisms.  Here, we investigated whether a frontline combination with an HSP90 inhibitor could delay the emergence of resistance to these inhibitors in preclin. lung cancer models.  Methods: The HSP90 inhibitor, onalespib, was combined with either crizotinib or erlotinib in ALK- or EGFR-activated xenograft models resp. (H2228, HCC827).  Results: In both models, after initial response to the monotherapy kinase inhibitors, tumor relapse was obsd.  In contrast, tumor growth remained inhibited when treated with an onalespib/kinase inhibitor combination.  Anal. of H2228 tumors, which had relapsed on crizotinib monotherapy, identified a no. of clin. relevant crizotinib resistance mechanisms, suggesting that HSP90 inhibitor treatment was capable of suppressing multiple mechanisms of resistance.  Resistant cell lines, derived from these tumors, retained sensitivity to onalespib (proliferation and signalling pathways were inhibited), indicating that, despite their resistance to crizotinib, they were still sensitive to HSP90 inhibition.  Conclusions: Together, these preclin. data suggest that frontline combination with an HSP90 inhibitor may be a method for delaying the emergence of resistance to targeted therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1mncD8Op0sLVg90H21EOLACvtfcHk0lj3t8exDe8MxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslKns7%252FJ&md5=b008666833a5f4ada0635ef6dd195fbd</span></div><a href="/servlet/linkout?suffix=cit172&amp;dbid=16384&amp;doi=10.1038%2Fbjc.2016.294&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbjc.2016.294%26sid%3Dliteratum%253Aachs%26aulast%3DCourtin%26aufirst%3DA.%26aulast%3DSmyth%26aufirst%3DT.%26aulast%3DHearn%26aufirst%3DK.%26aulast%3DSaini%26aufirst%3DH.%2BK.%26aulast%3DThompson%26aufirst%3DN.%2BT.%26aulast%3DLyons%26aufirst%3DJ.%2BF.%26aulast%3DWallis%26aufirst%3DN.%2BG.%26atitle%3DEmergence%2520of%2520Resistance%2520to%2520Tyrosine%2520Kinase%2520Inhibitors%2520in%2520Non-small-cell%2520Lung%2520Cancer%2520can%2520be%2520Delayed%2520by%2520an%2520upfront%2520Combination%2520with%2520the%2520HSP90%2520Inhibitor%2520Onalespib%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2016%26volume%3D115%26spage%3D1069%26doi%3D10.1038%2Fbjc.2016.294" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref173"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref173'); return false;" data-citation="" class="refNumLink">173</a></strong><div class="NLM_citation" id="cit173"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gainor, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niederst, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lennerz, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dagogo-Jack, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sequist, L. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engelman, J. A.</span></span> <span> </span><span class="NLM_article-title">Dramatic Response to Combination Erlotinib and Crizotinib in a Patient with Advanced, EGFR-mutant Lung Cancer Harboring De Novo MET Amplification</span>. <i>J. Thorac. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">e83</span>– <span class="NLM_lpage">e85</span>, <span class="refDoi"> DOI: 10.1016/j.jtho.2016.02.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1016%2Fj.jtho.2016.02.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=26988570" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=e83-e85&author=J.+F.+Gainorauthor=M.+J.+Niederstauthor=J.+K.+Lennerzauthor=I.+Dagogo-Jackauthor=S.+Stevensauthor=A.+T.+Shawauthor=L.+V.+Sequistauthor=J.+A.+Engelman&title=Dramatic+Response+to+Combination+Erlotinib+and+Crizotinib+in+a+Patient+with+Advanced%2C+EGFR-mutant+Lung+Cancer+Harboring+De+Novo+MET+Amplification&doi=10.1016%2Fj.jtho.2016.02.021"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit173&amp;dbid=16384&amp;doi=10.1016%2Fj.jtho.2016.02.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jtho.2016.02.021%26sid%3Dliteratum%253Aachs%26aulast%3DGainor%26aufirst%3DJ.%2BF.%26aulast%3DNiederst%26aufirst%3DM.%2BJ.%26aulast%3DLennerz%26aufirst%3DJ.%2BK.%26aulast%3DDagogo-Jack%26aufirst%3DI.%26aulast%3DStevens%26aufirst%3DS.%26aulast%3DShaw%26aufirst%3DA.%2BT.%26aulast%3DSequist%26aufirst%3DL.%2BV.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26atitle%3DDramatic%2520Response%2520to%2520Combination%2520Erlotinib%2520and%2520Crizotinib%2520in%2520a%2520Patient%2520with%2520Advanced%252C%2520EGFR-mutant%2520Lung%2520Cancer%2520Harboring%2520De%2520Novo%2520MET%2520Amplification%26jtitle%3DJ.%2520Thorac.%2520Oncol.%26date%3D2016%26volume%3D11%26spage%3De83%26epage%3De85%26doi%3D10.1016%2Fj.jtho.2016.02.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref174"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref174'); return false;" data-citation="" class="refNumLink">174</a></strong><div class="NLM_citation" id="cit174"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Felip, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Braud, F. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maur, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loong, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vansteenkiste, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">John, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lolkema, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, R.</span></span> <span> </span><span class="NLM_article-title">Ceritinib plus Nivolumab (NIVO) in Patients (pts) with Anaplastic Lymphoma Kinase Positive (ALK+) Advanced Non-small Cell Lung Cancer (NSCLC)</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>35</i></span> (<span class="NLM_issue">Suppl 15</span>),  <span class="NLM_fpage">2502</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1200%2FJCO.2017.35.15_suppl.2502" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2017&pages=2502&issue=Suppl+15&author=E.+Felipauthor=F.+G.+De+Braudauthor=M.+Maurauthor=H.+H.+Loongauthor=A.+T.+Shawauthor=J.+F.+Vansteenkisteauthor=T.+Johnauthor=G.+Liuauthor=M.+P.+Lolkemaauthor=J.+W.+Scottauthor=R.+Yu&title=Ceritinib+plus+Nivolumab+%28NIVO%29+in+Patients+%28pts%29+with+Anaplastic+Lymphoma+Kinase+Positive+%28ALK%2B%29+Advanced+Non-small+Cell+Lung+Cancer+%28NSCLC%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit174&amp;dbid=16384&amp;doi=10.1200%2FJCO.2017.35.15_suppl.2502&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2017.35.15_suppl.2502%26sid%3Dliteratum%253Aachs%26aulast%3DFelip%26aufirst%3DE.%26aulast%3DDe%2BBraud%26aufirst%3DF.%2BG.%26aulast%3DMaur%26aufirst%3DM.%26aulast%3DLoong%26aufirst%3DH.%2BH.%26aulast%3DShaw%26aufirst%3DA.%2BT.%26aulast%3DVansteenkiste%26aufirst%3DJ.%2BF.%26aulast%3DJohn%26aufirst%3DT.%26aulast%3DLiu%26aufirst%3DG.%26aulast%3DLolkema%26aufirst%3DM.%2BP.%26aulast%3DScott%26aufirst%3DJ.%2BW.%26aulast%3DYu%26aufirst%3DR.%26atitle%3DCeritinib%2520plus%2520Nivolumab%2520%2528NIVO%2529%2520in%2520Patients%2520%2528pts%2529%2520with%2520Anaplastic%2520Lymphoma%2520Kinase%2520Positive%2520%2528ALK%252B%2529%2520Advanced%2520Non-small%2520Cell%2520Lung%2520Cancer%2520%2528NSCLC%2529%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2017%26volume%3D35%26issue%3DSuppl%252015%26spage%3D2502" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref175"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref175'); return false;" data-citation="" class="refNumLink">175</a></strong><div class="NLM_citation" id="cit175"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramalingam, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boyer, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carcereny Costa, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felip, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hida, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, B. G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. W.</span></span> <span> </span><span class="NLM_article-title">Avelumab (anti–PD-L1) in Combination with Crizotinib or Lorlatinib in Patients with Previously Treated Advanced NSCLC: Phase 1b Results from JAVELIN Lung 101</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">9008</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1200%2FJCO.2018.36.15_suppl.9008" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2018&pages=9008&author=A.+T.+Shawauthor=S.-H.+Leeauthor=S.+S.+Ramalingamauthor=T.+M.+Bauerauthor=M.+J.+Boyerauthor=E.+Carcereny+Costaauthor=E.+Felipauthor=J.+Y.+Hanauthor=T.+Hidaauthor=B.+G.+M.+Hughesauthor=S.+W.+Kim&title=Avelumab+%28anti%E2%80%93PD-L1%29+in+Combination+with+Crizotinib+or+Lorlatinib+in+Patients+with+Previously+Treated+Advanced+NSCLC%3A+Phase+1b+Results+from+JAVELIN+Lung+101"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit175&amp;dbid=16384&amp;doi=10.1200%2FJCO.2018.36.15_suppl.9008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2018.36.15_suppl.9008%26sid%3Dliteratum%253Aachs%26aulast%3DShaw%26aufirst%3DA.%2BT.%26aulast%3DLee%26aufirst%3DS.-H.%26aulast%3DRamalingam%26aufirst%3DS.%2BS.%26aulast%3DBauer%26aufirst%3DT.%2BM.%26aulast%3DBoyer%26aufirst%3DM.%2BJ.%26aulast%3DCarcereny%2BCosta%26aufirst%3DE.%26aulast%3DFelip%26aufirst%3DE.%26aulast%3DHan%26aufirst%3DJ.%2BY.%26aulast%3DHida%26aufirst%3DT.%26aulast%3DHughes%26aufirst%3DB.%2BG.%2BM.%26aulast%3DKim%26aufirst%3DS.%2BW.%26atitle%3DAvelumab%2520%2528anti%25E2%2580%2593PD-L1%2529%2520in%2520Combination%2520with%2520Crizotinib%2520or%2520Lorlatinib%2520in%2520Patients%2520with%2520Previously%2520Treated%2520Advanced%2520NSCLC%253A%2520Phase%25201b%2520Results%2520from%2520JAVELIN%2520Lung%2520101%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2018%26volume%3D36%26spage%3D9008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref176"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref176'); return false;" data-citation="" class="refNumLink">176</a></strong><div class="NLM_citation" id="cit176"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hellmann, M. D</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rizvi, N. A</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldman, J. W</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gettinger, S. N</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borghaei, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brahmer, J. R</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ready, N. E</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerber, D. E</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chow, L. Q</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Juergens, R. A</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shepherd, F. A</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laurie, S. A</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geese, W. J</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agrawal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, T. C</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antonia, S. J</span></span> <span> </span><span class="NLM_article-title">Nivolumab plus Ipilimumab as First-line Treatment for Advanced Non-small-cell Lung Cancer (CheckMate 012): Results of an Open-label, Phase 1, Multicohort Study</span>. <i>Lancet Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">31</span>– <span class="NLM_lpage">41</span>, <span class="refDoi"> DOI: 10.1016/S1470-2045(16)30624-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1016%2FS1470-2045%2816%2930624-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=27932067" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC28XitVSqs7zO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2017&pages=31-41&author=M.+D+Hellmannauthor=N.+A+Rizviauthor=J.+W+Goldmanauthor=S.+N+Gettingerauthor=H.+Borghaeiauthor=J.+R+Brahmerauthor=N.+E+Readyauthor=D.+E+Gerberauthor=L.+Q+Chowauthor=R.+A+Juergensauthor=F.+A+Shepherdauthor=S.+A+Laurieauthor=W.+J+Geeseauthor=S.+Agrawalauthor=T.+C+Youngauthor=X.+Liauthor=S.+J+Antonia&title=Nivolumab+plus+Ipilimumab+as+First-line+Treatment+for+Advanced+Non-small-cell+Lung+Cancer+%28CheckMate+012%29%3A+Results+of+an+Open-label%2C+Phase+1%2C+Multicohort+Study&doi=10.1016%2FS1470-2045%2816%2930624-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit176R"><div class="casContent"><span class="casTitleNuber">176</span><div class="casTitle"><span class="NLM_cas:atitle">Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study</span></div><div class="casAuthors">Hellmann, Matthew D.; Rizvi, Naiyer A.; Goldman, Jonathan W.; Gettinger, Scott N.; Borghaei, Hossein; Brahmer, Julie R.; Ready, Neal E.; Gerber, David E.; Chow, Laura Q.; Juergens, Rosalyn A.; Shepherd, Frances A.; Laurie, Scott A.; Geese, William J.; Agrawal, Shruti; Young, Tina C.; Li, Xuemei; Antonia, Scott J.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">31-41</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Nivolumab has shown improved survival in the treatment of advanced non-small-cell lung cancer (NSCLC) previously treated with chemotherapy.  We assessed the safety and activity of combination nivolumab plus ipilimumab as first-line therapy for NSCLC.  The open-label, phase 1, multicohort study (CheckMate 012) cohorts reported here were enrolled at eight US academic centers.  Eligible patients were aged 18 years or older with histol. or cytol. confirmed recurrent stage IIIb or stage IV, chemotherapy-naive NSCLC.  Patients were randomly assigned (1:1:1) by an interactive voice response system to receive nivolumab 1 mg/kg every 2 wk plus ipilimumab 1 mg/kg every 6 wk, nivolumab 3 mg/kg every 2 wk plus ipilimumab 1 mg/kg every 12 wk, or nivolumab 3 mg/kg every 2 wk plus ipilimumab 1 mg/kg every 6 wk until disease progression, unacceptable toxicities, or withdrawal of consent.  Data from the latter two cohorts, which were considered potentially suitable for further clin. development, are presented in this report; data from the other cohort (as well as several earlier cohorts) are described in the appendix.  The primary outcome was safety and tolerability, assessed in all treated patients.  This ongoing study is registered with ClinicalTrials.gov, no. NCT01454102.  Between May 15, 2014, and March 25, 2015, 78 patients were randomly assigned to receive nivolumab every 2 wk plus ipilimumab every 12 wk (n=38) or nivolumab every 2 wk plus ipilimumab every 6 wk (n=40).  One patient in the ipilimumab every-6-wk cohort was excluded before treatment; therefore 77 patients actually received treatment (38 in the ipilimumab every-12-wk cohort; 39 in the ipilimumab every-6-wk cohort).  At data cut-off on Jan 7, 2016, 29 (76%) patients in the ipilimumab every-12-wk cohort and 32 (82%) in the ipilimumab every-6-wk cohort had discontinued treatment.  Grade 3-4 treatment-related adverse events occurred in 14 (37%) patients in the ipilimumab every-12-wk cohort and 13 (33%) patients in the every-6-wk cohort; the most commonly reported grade 3 or 4 treatment-related adverse events were increased lipase (three [8%] and no patients), pneumonitis (two [5%] and one [3%] patients), adrenal insufficiency (one [3%] and two [5%] patients), and colitis (one [3%] and two [5%] patients).  Treatment-related serious adverse events were reported in 12 (32%) patients in the ipilimumab every-12-wk cohort and 11 (28%) patients in the every-6-wk cohort.  Treatment-related adverse events (any grade) prompted treatment discontinuation in four (11%) patients in the every-12-wk cohort and five (13%) patients in the every-6-wk cohort.  No treatment-related deaths occurred.  Confirmed objective responses were achieved in 18 (47% [95% CI 31-64]) patients in the ipilimumab every-12-wk cohort and 15 (38% [95% CI 23-55]) patients in the ipilimumab every-6-wk cohort; median duration of response was not reached in either cohort, with median follow-up times of 12·8 mo (IQR 9·3-15·5) in the ipilimumab every-12-wk cohort and 11·8 mo (6·7-15·9) in the ipilimumab every-6-wk cohort.  In patients with PD-L1 of 1% or greater, confirmed objective responses were achieved in 12 (57%) of 21 patients in the ipilimumab every-12-wk cohort and 13 (57%) of 23 patients in the ipilimumab every-6-wk cohort.  In NSCLC, first-line nivolumab plus ipilimumab had a tolerable safety profile and showed encouraging clin. activity characterized by a high response rate and durable response.  To our knowledge, the results of this study are the first suggestion of improved benefit compared with anti-PD-1 monotherapy in patients with NSCLC, supporting further assessment of this combination in a phase 3 study.Bristol-Myers Squibb.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAqE7VugWX-bVg90H21EOLACvtfcHk0lgthKDrttXFig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitVSqs7zO&md5=a5703524ec82e7f1dd55168404a61d2f</span></div><a href="/servlet/linkout?suffix=cit176&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2816%2930624-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252816%252930624-6%26sid%3Dliteratum%253Aachs%26aulast%3DHellmann%26aufirst%3DM.%2BD%26aulast%3DRizvi%26aufirst%3DN.%2BA%26aulast%3DGoldman%26aufirst%3DJ.%2BW%26aulast%3DGettinger%26aufirst%3DS.%2BN%26aulast%3DBorghaei%26aufirst%3DH.%26aulast%3DBrahmer%26aufirst%3DJ.%2BR%26aulast%3DReady%26aufirst%3DN.%2BE%26aulast%3DGerber%26aufirst%3DD.%2BE%26aulast%3DChow%26aufirst%3DL.%2BQ%26aulast%3DJuergens%26aufirst%3DR.%2BA%26aulast%3DShepherd%26aufirst%3DF.%2BA%26aulast%3DLaurie%26aufirst%3DS.%2BA%26aulast%3DGeese%26aufirst%3DW.%2BJ%26aulast%3DAgrawal%26aufirst%3DS.%26aulast%3DYoung%26aufirst%3DT.%2BC%26aulast%3DLi%26aufirst%3DX.%26aulast%3DAntonia%26aufirst%3DS.%2BJ%26atitle%3DNivolumab%2520plus%2520Ipilimumab%2520as%2520First-line%2520Treatment%2520for%2520Advanced%2520Non-small-cell%2520Lung%2520Cancer%2520%2528CheckMate%2520012%2529%253A%2520Results%2520of%2520an%2520Open-label%252C%2520Phase%25201%252C%2520Multicohort%2520Study%26jtitle%3DLancet%2520Oncol.%26date%3D2017%26volume%3D18%26spage%3D31%26epage%3D41%26doi%3D10.1016%2FS1470-2045%2816%2930624-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref177"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref177'); return false;" data-citation="" class="refNumLink">177</a></strong><div class="NLM_citation" id="cit177"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aggarwal, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borghaei, H.</span></span> <span> </span><span class="NLM_article-title">Treatment Paradigms for Advanced Non-small Cell Lung Cancer at Academic Medical Centers: Involvement in Clinical Trial Endpoint Design</span>. <i>Oncologist</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">700</span>– <span class="NLM_lpage">708</span>, <span class="refDoi"> DOI: 10.1634/theoncologist.2016-0345</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1634%2Ftheoncologist.2016-0345" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=28408617" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A280%3ADC%252BC1cvnslemsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2017&pages=700-708&author=C.+Aggarwalauthor=H.+Borghaei&title=Treatment+Paradigms+for+Advanced+Non-small+Cell+Lung+Cancer+at+Academic+Medical+Centers%3A+Involvement+in+Clinical+Trial+Endpoint+Design&doi=10.1634%2Ftheoncologist.2016-0345"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit177R"><div class="casContent"><span class="casTitleNuber">177</span><div class="casTitle"><span class="NLM_cas:atitle">Treatment Paradigms for Advanced Non-Small Cell Lung Cancer at Academic Medical Centers: Involvement in Clinical Trial Endpoint Design</span></div><div class="casAuthors">Aggarwal Charu; Borghaei Hossein</div><div class="citationInfo"><span class="NLM_cas:title">The oncologist</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">700-708</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Based on the positive results of various clinical trials, treatment options for non-small cell lung cancer (NSCLC) have expanded greatly over the last 25 years.  While regulatory approvals of chemotherapeutic agents for NSCLC have largely been based on improvements in overall survival, recent approvals of many targeted agents for NSCLC (afatinib, crizotinib, ceritinib, osimertinib) have been based on surrogate endpoints such as progression-free survival and objective response.  As such, selection of appropriate clinical endpoints for examining the efficacy of investigational agents for NSCLC is of vital importance in clinical trial design.  This review provides an overview of clinical trial endpoints previously utilized for approved agents for NSCLC and highlights the key efficacy results for these trials.  Trends for more recent approvals in NSCLC, including those for the immunotherapeutic agents nivolumab and pembrolizumab, are also discussed.  The results of a correlative analysis of endpoints from 18 clinical trials that supported approvals of investigational agents in clinical trials for NSCLC are also presented.  IMPLICATIONS FOR PRACTICE:  While improving survival remains the ultimate goal of oncology clinical trials, overall survival may not always be the most feasible or appropriate endpoint to assess patient response.  Recently, several investigational agents, both targeted agents and immunotherapies, have gained U.S.  Food and Drug Administration approval in non-small cell lung cancer based on alternate endpoints such as progression-free survival or response rate.  An understanding of the assessment of response and trial endpoint choice is important for future oncology clinical trial design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRvBm8Q8B105DdblLE_E9PWfW6udTcc2eYsMjuZAnEjmLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cvnslemsQ%253D%253D&md5=e3a79c668df131abd31ce667bc9f3ca1</span></div><a href="/servlet/linkout?suffix=cit177&amp;dbid=16384&amp;doi=10.1634%2Ftheoncologist.2016-0345&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1634%252Ftheoncologist.2016-0345%26sid%3Dliteratum%253Aachs%26aulast%3DAggarwal%26aufirst%3DC.%26aulast%3DBorghaei%26aufirst%3DH.%26atitle%3DTreatment%2520Paradigms%2520for%2520Advanced%2520Non-small%2520Cell%2520Lung%2520Cancer%2520at%2520Academic%2520Medical%2520Centers%253A%2520Involvement%2520in%2520Clinical%2520Trial%2520Endpoint%2520Design%26jtitle%3DOncologist%26date%3D2017%26volume%3D22%26spage%3D700%26epage%3D708%26doi%3D10.1634%2Ftheoncologist.2016-0345" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref178"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref178'); return false;" data-citation="" class="refNumLink">178</a></strong><div class="NLM_citation" id="cit178"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hainsworth, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waterhouse, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shih, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boccia, R. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Priego, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCleod, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kudrik, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitchell, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burris, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greco, F. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spigel, D. R.</span></span> <span> </span><span class="NLM_article-title">Phase II Trial of Preoperative Pemetrexed plus Carboplatin in Patients with Stage IB-III Nonsquamous Non-small Cell Lung Cancer (NSCLC)</span>. <i>Lung Cancer</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>118</i></span>,  <span class="NLM_fpage">6</span>– <span class="NLM_lpage">12</span>, <span class="refDoi"> DOI: 10.1016/j.lungcan.2018.01.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1016%2Fj.lungcan.2018.01.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=29572004" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A280%3ADC%252BC1Mnktl2jtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=118&publication_year=2018&pages=6-12&author=J.+D.+Hainsworthauthor=D.+M.+Waterhouseauthor=K.+C.+Shihauthor=R.+V.+Bocciaauthor=V.+M.+Priegoauthor=M.+J.+McCleodauthor=F.+J.+Kudrikauthor=R.+B.+Mitchellauthor=H.+A.+Burrisauthor=F.+A.+Grecoauthor=D.+R.+Spigel&title=Phase+II+Trial+of+Preoperative+Pemetrexed+plus+Carboplatin+in+Patients+with+Stage+IB-III+Nonsquamous+Non-small+Cell+Lung+Cancer+%28NSCLC%29&doi=10.1016%2Fj.lungcan.2018.01.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit178R"><div class="casContent"><span class="casTitleNuber">178</span><div class="casTitle"><span class="NLM_cas:atitle">Phase II trial of preoperative pemetrexed plus carboplatin in patients with stage IB-III nonsquamous non-small cell lung cancer (NSCLC)</span></div><div class="casAuthors">Hainsworth John D; Waterhouse David M; Shih Kent C; Burris Howard A 3rd; Greco F Anthony; Spigel David R; Boccia Ralph V; Priego Victor M; McCleod Michael J; Kudrik Fred J; Mitchell Reed Brian</div><div class="citationInfo"><span class="NLM_cas:title">Lung cancer (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">118</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">6-12</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">OBJECTIVES:  The combination of pemetrexed and carboplatin is a standard first-line treatment for patients with advanced NSCLC.  In this pilot phase II trial, we evaluated the feasibility of using pemetrexed and carboplatin as neoadjuvant therapy, prior to definitive surgical resection, for patients with localized NSCLC.  PATIENTS AND METHODS:  Patients with potentially resectable, previously untreated, clinical stage IB-III, nonsquamous NSCLC were eligible for this trial.  All patients received 4 cycles of pemetrexed (500 mg/m(2)) and carboplatin (AUC 6.0) administered at 21 day intervals.  Three to 6 weeks after completion of chemotherapy, definitive surgical resection was attempted.  The primary endpoint of this trial was the 3-year survival rate.  RESULTS:  Forty-six patients began protocol treatment, and 40 completed 4 courses of pemetrexed/carboplatin.  Surgical resection was performed in 27 patients (59%); all had pathologic partial responses.  The estimated 3-year survival rate for the entire group was 46%.  Toxicity of neoadjuvant therapy was consistent with toxicity previously reported with pemetrexed/carboplatin.  CONCLUSIONS:  Administration of 4 courses of pemetrexed/carboplatin was feasible.  The efficacy was similar to neoadjuvant regimens previously investigated.  A significant number of patients 19 of 46 (41%) in this trial did not have surgical resection after neoadjuvant therapy.  Further investigation of the role of neoadjuvant pemetrexed/carboplatin requires a larger, randomized clinical trial.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTDPd2sJyGpZoIRAdBLKY41fW6udTcc2eYsMjuZAnEjmLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1Mnktl2jtw%253D%253D&md5=3d999bdb991ca790a5931ef784913cb2</span></div><a href="/servlet/linkout?suffix=cit178&amp;dbid=16384&amp;doi=10.1016%2Fj.lungcan.2018.01.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.lungcan.2018.01.009%26sid%3Dliteratum%253Aachs%26aulast%3DHainsworth%26aufirst%3DJ.%2BD.%26aulast%3DWaterhouse%26aufirst%3DD.%2BM.%26aulast%3DShih%26aufirst%3DK.%2BC.%26aulast%3DBoccia%26aufirst%3DR.%2BV.%26aulast%3DPriego%26aufirst%3DV.%2BM.%26aulast%3DMcCleod%26aufirst%3DM.%2BJ.%26aulast%3DKudrik%26aufirst%3DF.%2BJ.%26aulast%3DMitchell%26aufirst%3DR.%2BB.%26aulast%3DBurris%26aufirst%3DH.%2BA.%26aulast%3DGreco%26aufirst%3DF.%2BA.%26aulast%3DSpigel%26aufirst%3DD.%2BR.%26atitle%3DPhase%2520II%2520Trial%2520of%2520Preoperative%2520Pemetrexed%2520plus%2520Carboplatin%2520in%2520Patients%2520with%2520Stage%2520IB-III%2520Nonsquamous%2520Non-small%2520Cell%2520Lung%2520Cancer%2520%2528NSCLC%2529%26jtitle%3DLung%2520Cancer%26date%3D2018%26volume%3D118%26spage%3D6%26epage%3D12%26doi%3D10.1016%2Fj.lungcan.2018.01.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67'],'ref68':['cit68'],'ref69':['cit69'],'ref70':['cit70'],'ref71':['cit71'],'ref72':['cit72'],'ref73':['cit73'],'ref74':['cit74'],'ref75':['cit75'],'ref76':['cit76'],'ref77':['cit77'],'ref78':['cit78'],'ref79':['cit79'],'ref80':['cit80'],'ref81':['cit81'],'ref82':['cit82'],'ref83':['cit83'],'ref84':['cit84'],'ref85':['cit85'],'ref86':['cit86'],'ref87':['cit87'],'ref88':['cit88'],'ref89':['cit89'],'ref90':['cit90'],'ref91':['cit91'],'ref92':['cit92'],'ref93':['cit93'],'ref94':['cit94'],'ref95':['cit95'],'ref96':['cit96'],'ref97':['cit97'],'ref98':['cit98'],'ref99':['cit99'],'ref100':['cit100'],'ref101':['cit101'],'ref102':['cit102'],'ref103':['cit103'],'ref104':['cit104'],'ref105':['cit105'],'ref106':['cit106'],'ref107':['cit107'],'ref108':['cit108'],'ref109':['cit109'],'ref110':['cit110'],'ref111':['cit111'],'ref112':['cit112'],'ref113':['cit113'],'ref114':['cit114'],'ref115':['cit115'],'ref116':['cit116'],'ref117':['cit117'],'ref118':['cit118'],'ref119':['cit119'],'ref120':['cit120'],'ref121':['cit121'],'ref122':['cit122'],'ref123':['cit123'],'ref124':['cit124'],'ref125':['cit125'],'ref126':['cit126'],'ref127':['cit127'],'ref128':['cit128'],'ref129':['cit129'],'ref130':['cit130'],'ref131':['cit131'],'ref132':['cit132'],'ref133':['cit133'],'ref134':['cit134'],'ref135':['cit135'],'ref136':['cit136'],'ref137':['cit137'],'ref138':['cit138'],'ref139':['cit139'],'ref140':['cit140'],'ref141':['cit141'],'ref142':['cit142'],'ref143':['cit143'],'ref144':['cit144'],'ref145':['cit145'],'ref146':['cit146'],'ref147':['cit147'],'ref148':['cit148'],'ref149':['cit149'],'ref150':['cit150'],'ref151':['cit151'],'ref152':['cit152'],'ref153':['cit153'],'ref154':['cit154'],'ref155':['cit155'],'ref156':['cit156'],'ref157':['cit157'],'ref158':['cit158'],'ref159':['cit159'],'ref160':['cit160'],'ref161':['cit161'],'ref162':['cit162'],'ref163':['cit163'],'ref164':['cit164'],'ref165':['cit165'],'ref166':['cit166'],'ref167':['cit167'],'ref168':['cit168'],'ref169':['cit169'],'ref170':['cit170'],'ref171':['cit171'],'ref172':['cit172'],'ref173':['cit173'],'ref174':['cit174'],'ref175':['cit175'],'ref176':['cit176'],'ref177':['cit177'],'ref178':['cit178']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 22 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Shaowen Xie, Yuan Sun, Yulin Liu, Xinnan Li, Xinuo Li, Wenyi Zhong, Feiyan Zhan, Jingjie Zhu, Hong Yao, Dong-Hua Yang, Zhe-Sheng Chen, Jinyi Xu, <span class="NLM_string-name hlFld-ContribAuthor">Shengtao Xu</span>. </span><span class="cited-content_cbyCitation_article-title">Development of Alectinib-Based PROTACs as Novel Potent Degraders of Anaplastic Lymphoma Kinase (ALK). </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (13)
                                     , 9120-9140. <a href="https://doi.org/10.1021/acs.jmedchem.1c00270" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00270</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00270&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.1c00270%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDevelopment%252Bof%252BAlectinib-Based%252BPROTACs%252Bas%252BNovel%252BPotent%252BDegraders%252Bof%252BAnaplastic%252BLymphoma%252BKinase%252B%252528ALK%252529%26aulast%3DXie%26aufirst%3DShaowen%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D11022021%26date%3D28062021%26volume%3D64%26issue%3D13%26spage%3D9120%26epage%3D9140" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Ikuo Fujimori, Takeshi Wakabayashi, Morio Murakami, Atsutoshi Okabe, Tsuyoshi Ishii, Aaron McGrath, Hua Zou, Kumar Singh Saikatendu, <span class="NLM_string-name hlFld-ContribAuthor">Hiroshi Imoto</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of Novel and Highly Selective Cyclopropane ALK Inhibitors through a Fragment-Assisted, Structure-Based Drug Design. </span><span class="cited-content_cbyCitation_journal-name">ACS Omega</span><span> <strong>2020,</strong> <em>5 </em>
                                    (49)
                                     , 31984-32001. <a href="https://doi.org/10.1021/acsomega.0c04900" title="DOI URL">https://doi.org/10.1021/acsomega.0c04900</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsomega.0c04900&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsomega.0c04900%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Omega%26atitle%3DDiscovery%252Bof%252BNovel%252Band%252BHighly%252BSelective%252BCyclopropane%252BALK%252BInhibitors%252Bthrough%252Ba%252BFragment-Assisted%25252C%252BStructure-Based%252BDrug%252BDesign%26aulast%3DFujimori%26aufirst%3DIkuo%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D07102020%26date%3D13112020%26date%3D30112020%26volume%3D5%26issue%3D49%26spage%3D31984%26epage%3D32001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Xiaoyun Lu, Jeff B. Smaill, <span class="NLM_string-name hlFld-ContribAuthor">Ke Ding</span>. </span><span class="cited-content_cbyCitation_article-title">Medicinal Chemistry Strategies for the Development of Kinase Inhibitors Targeting Point Mutations. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (19)
                                     , 10726-10741. <a href="https://doi.org/10.1021/acs.jmedchem.0c00507" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00507</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00507&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00507%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DMedicinal%252BChemistry%252BStrategies%252Bfor%252Bthe%252BDevelopment%252Bof%252BKinase%252BInhibitors%252BTargeting%252BPoint%252BMutations%26aulast%3DLu%26aufirst%3DXiaoyun%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D27032020%26date%3D02062020%26date%3D20052020%26volume%3D63%26issue%3D19%26spage%3D10726%26epage%3D10741" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lei  Zhong</span>, <span class="hlFld-ContribAuthor ">Yueshan  Li</span>, <span class="hlFld-ContribAuthor ">Liang  Xiong</span>, <span class="hlFld-ContribAuthor ">Wenjing  Wang</span>, <span class="hlFld-ContribAuthor ">Ming  Wu</span>, <span class="hlFld-ContribAuthor ">Ting  Yuan</span>, <span class="hlFld-ContribAuthor ">Wei  Yang</span>, <span class="hlFld-ContribAuthor ">Chenyu  Tian</span>, <span class="hlFld-ContribAuthor ">Zhuang  Miao</span>, <span class="hlFld-ContribAuthor ">Tianqi  Wang</span>, <span class="hlFld-ContribAuthor ">Shengyong  Yang</span>. </span><span class="cited-content_cbyCitation_article-title">Small molecules in targeted cancer therapy: advances, challenges, and future perspectives. </span><span class="cited-content_cbyCitation_journal-name">Signal Transduction and Targeted Therapy</span><span> <strong>2021,</strong> <em>6 </em>
                                    (1)
                                     <a href="https://doi.org/10.1038/s41392-021-00572-w" title="DOI URL">https://doi.org/10.1038/s41392-021-00572-w</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41392-021-00572-w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41392-021-00572-w%26sid%3Dliteratum%253Aachs%26jtitle%3DSignal%2520Transduction%2520and%2520Targeted%2520Therapy%26atitle%3DSmall%252Bmolecules%252Bin%252Btargeted%252Bcancer%252Btherapy%25253A%252Badvances%25252C%252Bchallenges%25252C%252Band%252Bfuture%252Bperspectives%26aulast%3DZhong%26aufirst%3DLei%26date%3D2021%26date%3D2021%26volume%3D6%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Tao  Pan</span>, <span class="hlFld-ContribAuthor ">Yanrong  Dan</span>, <span class="hlFld-ContribAuthor ">Dafeng  Guo</span>, <span class="hlFld-ContribAuthor ">Junhao  Jiang</span>, <span class="hlFld-ContribAuthor ">Dongzhi  Ran</span>, <span class="hlFld-ContribAuthor ">Lin  Zhang</span>, <span class="hlFld-ContribAuthor ">Binghua  Tian</span>, <span class="hlFld-ContribAuthor ">Jianyong  Yuan</span>, <span class="hlFld-ContribAuthor ">Yu  Yu</span>, <span class="hlFld-ContribAuthor ">Zongjie  Gan</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of 2,4-pyrimidinediamine derivatives as potent dual inhibitors of ALK and HDAC. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>224 </em>, 113672. <a href="https://doi.org/10.1016/j.ejmech.2021.113672" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113672</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113672&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113672%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252B2%25252C4-pyrimidinediamine%252Bderivatives%252Bas%252Bpotent%252Bdual%252Binhibitors%252Bof%252BALK%252Band%252BHDAC%26aulast%3DPan%26aufirst%3DTao%26date%3D2021%26volume%3D224%26spage%3D113672" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiaoxia  Liang</span>, <span class="hlFld-ContribAuthor ">Pan  Wu</span>, <span class="hlFld-ContribAuthor ">Qian  Yang</span>, <span class="hlFld-ContribAuthor ">Yunyu  Xie</span>, <span class="hlFld-ContribAuthor ">Changliang  He</span>, <span class="hlFld-ContribAuthor ">Lizi  Yin</span>, <span class="hlFld-ContribAuthor ">Zhongqiong  Yin</span>, <span class="hlFld-ContribAuthor ">Guizhou  Yue</span>, <span class="hlFld-ContribAuthor ">Yuanfeng  Zou</span>, <span class="hlFld-ContribAuthor ">Lixia  Li</span>, <span class="hlFld-ContribAuthor ">Xu  Song</span>, <span class="hlFld-ContribAuthor ">Cheng  Lv</span>, <span class="hlFld-ContribAuthor ">Wei  Zhang</span>, <span class="hlFld-ContribAuthor ">Bo  Jing</span>. </span><span class="cited-content_cbyCitation_article-title">An update of new small-molecule anticancer drugs approved from 2015 to 2020. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>220 </em>, 113473. <a href="https://doi.org/10.1016/j.ejmech.2021.113473" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113473</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113473&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113473%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DAn%252Bupdate%252Bof%252Bnew%252Bsmall-molecule%252Banticancer%252Bdrugs%252Bapproved%252Bfrom%252B2015%252Bto%252B2020%26aulast%3DLiang%26aufirst%3DXiaoxia%26date%3D2021%26volume%3D220%26spage%3D113473" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiao-Jing  Pang</span>, <span class="hlFld-ContribAuthor ">Xiu-Juan  Liu</span>, <span class="hlFld-ContribAuthor ">Yuan  Liu</span>, <span class="hlFld-ContribAuthor ">Wen-Bo  Liu</span>, <span class="hlFld-ContribAuthor ">Yin-Ru  Li</span>, <span class="hlFld-ContribAuthor ">Guang-Xi  Yu</span>, <span class="hlFld-ContribAuthor ">Xin-Yi  Tian</span>, <span class="hlFld-ContribAuthor ">Yan-Bing  Zhang</span>, <span class="hlFld-ContribAuthor ">Jian  Song</span>, <span class="hlFld-ContribAuthor ">Cheng-Yun  Jin</span>, <span class="hlFld-ContribAuthor ">Sai-Yang  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Drug Discovery Targeting Focal Adhesion Kinase (FAK) as a Promising Cancer Therapy. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2021,</strong> <em>26 </em>
                                    (14)
                                     , 4250. <a href="https://doi.org/10.3390/molecules26144250" title="DOI URL">https://doi.org/10.3390/molecules26144250</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules26144250&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules26144250%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DDrug%252BDiscovery%252BTargeting%252BFocal%252BAdhesion%252BKinase%252B%252528FAK%252529%252Bas%252Ba%252BPromising%252BCancer%252BTherapy%26aulast%3DPang%26aufirst%3DXiao-Jing%26date%3D2021%26date%3D2021%26volume%3D26%26issue%3D14%26spage%3D4250" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yubo  Wang</span>, <span class="hlFld-ContribAuthor ">Yuanyuan  Zhou</span>, <span class="hlFld-ContribAuthor ">Sheng  Cao</span>, <span class="hlFld-ContribAuthor ">Yue  Sun</span>, <span class="hlFld-ContribAuthor ">Zhiqiang  Dong</span>, <span class="hlFld-ContribAuthor ">Chen  Li</span>, <span class="hlFld-ContribAuthor ">Haoran  Wang</span>, <span class="hlFld-ContribAuthor ">Yuhong  Yao</span>, <span class="hlFld-ContribAuthor ">Haiyan  Yu</span>, <span class="hlFld-ContribAuthor ">Xiangyi  Song</span>, <span class="hlFld-ContribAuthor ">Ming  Li</span>, <span class="hlFld-ContribAuthor ">Jiefu  Wang</span>, <span class="hlFld-ContribAuthor ">Mingming  Wei</span>, <span class="hlFld-ContribAuthor ">Guang  Yang</span>, <span class="hlFld-ContribAuthor ">Cheng  Yang</span>. </span><span class="cited-content_cbyCitation_article-title">In vitro and in vivo degradation of programmed cell death ligand 1 (PD-L1) by a proteolysis targeting chimera (PROTAC). </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2021,</strong> <em>111 </em>, 104833. <a href="https://doi.org/10.1016/j.bioorg.2021.104833" title="DOI URL">https://doi.org/10.1016/j.bioorg.2021.104833</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2021.104833&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2021.104833%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DIn%252Bvitro%252Band%252Bin%252Bvivo%252Bdegradation%252Bof%252Bprogrammed%252Bcell%252Bdeath%252Bligand%252B1%252B%252528PD-L1%252529%252Bby%252Ba%252Bproteolysis%252Btargeting%252Bchimera%252B%252528PROTAC%252529%26aulast%3DWang%26aufirst%3DYubo%26date%3D2021%26volume%3D111%26spage%3D104833" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hossein  Mousavi</span>. </span><span class="cited-content_cbyCitation_article-title">A comprehensive survey upon diverse and prolific applications of chitosan-based catalytic systems in one-pot multi-component synthesis of heterocyclic rings. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Biological Macromolecules</span><span> <strong>2021,</strong> <em>57 </em><a href="https://doi.org/10.1016/j.ijbiomac.2021.06.123" title="DOI URL">https://doi.org/10.1016/j.ijbiomac.2021.06.123</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ijbiomac.2021.06.123&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ijbiomac.2021.06.123%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Biological%2520Macromolecules%26atitle%3DA%252Bcomprehensive%252Bsurvey%252Bupon%252Bdiverse%252Band%252Bprolific%252Bapplications%252Bof%252Bchitosan-based%252Bcatalytic%252Bsystems%252Bin%252Bone-pot%252Bmulti-component%252Bsynthesis%252Bof%252Bheterocyclic%252Brings%26aulast%3DMousavi%26aufirst%3DHossein%26date%3D2021%26volume%3D57" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Wenchao  Tian</span>, <span class="hlFld-ContribAuthor ">Xianxian  Liu</span>, <span class="hlFld-ContribAuthor ">Lulu  Wang</span>, <span class="hlFld-ContribAuthor ">Bufeng  Zheng</span>, <span class="hlFld-ContribAuthor ">Kun  Jiang</span>, <span class="hlFld-ContribAuthor ">Guoyong  Fu</span>, <span class="hlFld-ContribAuthor ">Wenyu  Feng</span>. </span><span class="cited-content_cbyCitation_article-title">Deciphering the selective binding mechanisms of anaplastic lymphoma kinase–derived neuroblastoma tumor neoepitopes to human leukocyte antigen. </span><span class="cited-content_cbyCitation_journal-name">Journal of Molecular Modeling</span><span> <strong>2021,</strong> <em>27 </em>
                                    (5)
                                     <a href="https://doi.org/10.1007/s00894-021-04754-9" title="DOI URL">https://doi.org/10.1007/s00894-021-04754-9</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s00894-021-04754-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs00894-021-04754-9%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Molecular%2520Modeling%26atitle%3DDeciphering%252Bthe%252Bselective%252Bbinding%252Bmechanisms%252Bof%252Banaplastic%252Blymphoma%252Bkinase%2525E2%252580%252593derived%252Bneuroblastoma%252Btumor%252Bneoepitopes%252Bto%252Bhuman%252Bleukocyte%252Bantigen%26aulast%3DTian%26aufirst%3DWenchao%26date%3D2021%26date%3D2021%26volume%3D27%26issue%3D5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ming  Qi</span>, <span class="hlFld-ContribAuthor ">Shufeng  Gao</span>, <span class="hlFld-ContribAuthor ">Sihui  Nie</span>, <span class="hlFld-ContribAuthor ">Ke  Wang</span>, <span class="hlFld-ContribAuthor ">Lingling  Guo</span>. </span><span class="cited-content_cbyCitation_article-title">Precise engineering of cetuximab encapsulated gadollium nanoassemblies:
              in vitro
              ultrasound diagnosis and
              in vivo
              thyroid cancer therapy. </span><span class="cited-content_cbyCitation_journal-name">Drug Delivery</span><span> <strong>2021,</strong> <em>28 </em>
                                    (1)
                                     , 569-579. <a href="https://doi.org/10.1080/10717544.2021.1889721" title="DOI URL">https://doi.org/10.1080/10717544.2021.1889721</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/10717544.2021.1889721&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F10717544.2021.1889721%26sid%3Dliteratum%253Aachs%26jtitle%3DDrug%2520Delivery%26atitle%3DPrecise%252Bengineering%252Bof%252Bcetuximab%252Bencapsulated%252Bgadollium%252Bnanoassemblies%25253A%252Bin%2525C2%2525A0vitro%252Bultrasound%252Bdiagnosis%252Band%252Bin%2525C2%2525A0vivo%252Bthyroid%252Bcancer%252Btherapy%26aulast%3DQi%26aufirst%3DMing%26date%3D2021%26date%3D2021%26volume%3D28%26issue%3D1%26spage%3D569%26epage%3D579" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Fu  He</span>, <span class="hlFld-ContribAuthor ">Kangjian  Song</span>, <span class="hlFld-ContribAuthor ">Ge  Guan</span>, <span class="hlFld-ContribAuthor ">Junyu  Huo</span>, <span class="hlFld-ContribAuthor ">Yang  Xin</span>, <span class="hlFld-ContribAuthor ">Tianxiang  Li</span>, <span class="hlFld-ContribAuthor ">Chao  Liu</span>, <span class="hlFld-ContribAuthor ">Qingwei  Zhu</span>, <span class="hlFld-ContribAuthor ">Ning  Fan</span>, <span class="hlFld-ContribAuthor ">Yuan  Guo</span>, <span class="hlFld-ContribAuthor ">Liqun  Wu</span>. </span><span class="cited-content_cbyCitation_article-title">The Phenomenon of Gene Rearrangement is Frequently Associated with TP53 Mutations and Poor Disease-Free Survival in Hepatocellular Carcinoma. </span><span class="cited-content_cbyCitation_journal-name">Pharmacogenomics and Personalized Medicine</span><span> <strong>2021,</strong> <em>Volume 14 </em>, 723-736. <a href="https://doi.org/10.2147/PGPM.S313848" title="DOI URL">https://doi.org/10.2147/PGPM.S313848</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2147/PGPM.S313848&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2147%2FPGPM.S313848%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmacogenomics%2520and%2520Personalized%2520Medicine%26atitle%3DThe%252BPhenomenon%252Bof%252BGene%252BRearrangement%252Bis%252BFrequently%252BAssociated%252Bwith%252BTP53%252BMutations%252Band%252BPoor%252BDisease-Free%252BSurvival%252Bin%252BHepatocellular%252BCarcinoma%26aulast%3DHe%26aufirst%3DFu%26date%3D2021%26date%3D2021%26volume%3DVolume%252014%26spage%3D723%26epage%3D736" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jianzhong  Chen</span>, <span class="hlFld-ContribAuthor ">Wei  Wang</span>, <span class="hlFld-ContribAuthor ">Haibo  Sun</span>, <span class="hlFld-ContribAuthor ">Laixue  Pang</span>, <span class="hlFld-ContribAuthor ">Baohua  Yin</span>. </span><span class="cited-content_cbyCitation_article-title">Mutation-mediated influences on binding of anaplastic lymphoma kinase to crizotinib decoded by multiple replica Gaussian accelerated molecular dynamics. </span><span class="cited-content_cbyCitation_journal-name">Journal of Computer-Aided Molecular Design</span><span> <strong>2020,</strong> <em>34 </em>
                                    (12)
                                     , 1289-1305. <a href="https://doi.org/10.1007/s10822-020-00355-5" title="DOI URL">https://doi.org/10.1007/s10822-020-00355-5</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s10822-020-00355-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs10822-020-00355-5%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Computer-Aided%2520Molecular%2520Design%26atitle%3DMutation-mediated%252Binfluences%252Bon%252Bbinding%252Bof%252Banaplastic%252Blymphoma%252Bkinase%252Bto%252Bcrizotinib%252Bdecoded%252Bby%252Bmultiple%252Breplica%252BGaussian%252Baccelerated%252Bmolecular%252Bdynamics%26aulast%3DChen%26aufirst%3DJianzhong%26date%3D2020%26date%3D2020%26volume%3D34%26issue%3D12%26spage%3D1289%26epage%3D1305" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Alberto  Ocaña</span>, <span class="hlFld-ContribAuthor ">Atanasio  Pandiella</span>. </span><span class="cited-content_cbyCitation_article-title">Proteolysis targeting chimeras (PROTACs) in cancer therapy. </span><span class="cited-content_cbyCitation_journal-name">Journal of Experimental & Clinical Cancer Research</span><span> <strong>2020,</strong> <em>39 </em>
                                    (1)
                                     <a href="https://doi.org/10.1186/s13046-020-01672-1" title="DOI URL">https://doi.org/10.1186/s13046-020-01672-1</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1186/s13046-020-01672-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1186%2Fs13046-020-01672-1%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Experimental%2520%2526%2520Clinical%2520Cancer%2520Research%26atitle%3DProteolysis%252Btargeting%252Bchimeras%252B%252528PROTACs%252529%252Bin%252Bcancer%252Btherapy%26aulast%3DOca%25C3%25B1a%26aufirst%3DAlberto%26date%3D2020%26date%3D2020%26volume%3D39%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yonghan  He</span>, <span class="hlFld-ContribAuthor ">Sajid  Khan</span>, <span class="hlFld-ContribAuthor ">Zhiguang  Huo</span>, <span class="hlFld-ContribAuthor ">Dongwen  Lv</span>, <span class="hlFld-ContribAuthor ">Xuan  Zhang</span>, <span class="hlFld-ContribAuthor ">Xingui  Liu</span>, <span class="hlFld-ContribAuthor ">Yaxia  Yuan</span>, <span class="hlFld-ContribAuthor ">Robert  Hromas</span>, <span class="hlFld-ContribAuthor ">Mingjiang  Xu</span>, <span class="hlFld-ContribAuthor ">Guangrong  Zheng</span>, <span class="hlFld-ContribAuthor ">Daohong  Zhou</span>. </span><span class="cited-content_cbyCitation_article-title">Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies. </span><span class="cited-content_cbyCitation_journal-name">Journal of Hematology & Oncology</span><span> <strong>2020,</strong> <em>13 </em>
                                    (1)
                                     <a href="https://doi.org/10.1186/s13045-020-00924-z" title="DOI URL">https://doi.org/10.1186/s13045-020-00924-z</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1186/s13045-020-00924-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1186%2Fs13045-020-00924-z%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Hematology%2520%2526%2520Oncology%26atitle%3DProteolysis%252Btargeting%252Bchimeras%252B%252528PROTACs%252529%252Bare%252Bemerging%252Btherapeutics%252Bfor%252Bhematologic%252Bmalignancies%26aulast%3DHe%26aufirst%3DYonghan%26date%3D2020%26date%3D2020%26volume%3D13%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">G.S.  Amitha</span>, <span class="hlFld-ContribAuthor ">Suni  Vasudevan</span>. </span><span class="cited-content_cbyCitation_article-title">DNA binding and cleavage studies of novel Betti base substituted quaternary Cu(II) and Zn(II) phthalocyanines. </span><span class="cited-content_cbyCitation_journal-name">Polyhedron</span><span> <strong>2020,</strong> <em>190 </em>, 114773. <a href="https://doi.org/10.1016/j.poly.2020.114773" title="DOI URL">https://doi.org/10.1016/j.poly.2020.114773</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.poly.2020.114773&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.poly.2020.114773%26sid%3Dliteratum%253Aachs%26jtitle%3DPolyhedron%26atitle%3DDNA%252Bbinding%252Band%252Bcleavage%252Bstudies%252Bof%252Bnovel%252BBetti%252Bbase%252Bsubstituted%252Bquaternary%252BCu%252528II%252529%252Band%252BZn%252528II%252529%252Bphthalocyanines%26aulast%3DAmitha%26aufirst%3DG.S.%26date%3D2020%26volume%3D190%26spage%3D114773" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Slimane  Toubal</span>, <span class="hlFld-ContribAuthor ">Catherine  Oiry</span>, <span class="hlFld-ContribAuthor ">Morgane  Bayle</span>, <span class="hlFld-ContribAuthor ">Gérard  Cros</span>, <span class="hlFld-ContribAuthor ">Jérémie  Neasta</span>. </span><span class="cited-content_cbyCitation_article-title">Urolithin C increases glucose‐induced ERK activation which contributes to insulin secretion. </span><span class="cited-content_cbyCitation_journal-name">Fundamental & Clinical Pharmacology</span><span> <strong>2020,</strong> <em>34 </em>
                                    (5)
                                     , 571-580. <a href="https://doi.org/10.1111/fcp.12551" title="DOI URL">https://doi.org/10.1111/fcp.12551</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/fcp.12551&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Ffcp.12551%26sid%3Dliteratum%253Aachs%26jtitle%3DFundamental%2520%2526%2520Clinical%2520Pharmacology%26atitle%3DUrolithin%252BC%252Bincreases%252Bglucose%2525E2%252580%252590induced%252BERK%252Bactivation%252Bwhich%252Bcontributes%252Bto%252Binsulin%252Bsecretion%26aulast%3DToubal%26aufirst%3DSlimane%26date%3D2020%26date%3D2020%26volume%3D34%26issue%3D5%26spage%3D571%26epage%3D580" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Juliana F.  Vilachã</span>, <span class="hlFld-ContribAuthor ">Sarah C.  Mitchel</span>, <span class="hlFld-ContribAuthor ">Muluembet Z.  Akele</span>, <span class="hlFld-ContribAuthor ">Stephen  Evans</span>, <span class="hlFld-ContribAuthor ">Matthew R.  Groves</span>. </span><span class="cited-content_cbyCitation_article-title">Making NSCLC Crystal Clear: How Kinase Structures Revolutionized Lung Cancer Treatment. </span><span class="cited-content_cbyCitation_journal-name">Crystals</span><span> <strong>2020,</strong> <em>10 </em>
                                    (9)
                                     , 725. <a href="https://doi.org/10.3390/cryst10090725" title="DOI URL">https://doi.org/10.3390/cryst10090725</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/cryst10090725&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fcryst10090725%26sid%3Dliteratum%253Aachs%26jtitle%3DCrystals%26atitle%3DMaking%252BNSCLC%252BCrystal%252BClear%25253A%252BHow%252BKinase%252BStructures%252BRevolutionized%252BLung%252BCancer%252BTreatment%26aulast%3DVilach%25C3%25A3%26aufirst%3DJuliana%2BF.%26date%3D2020%26date%3D2020%26volume%3D10%26issue%3D9%26spage%3D725" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kornelia  Czaja</span>, <span class="hlFld-ContribAuthor ">Jacek  Kujawski</span>, <span class="hlFld-ContribAuthor ">Paweł  Śliwa</span>, <span class="hlFld-ContribAuthor ">Rafał  Kurczab</span>, <span class="hlFld-ContribAuthor ">Radosław  Kujawski</span>, <span class="hlFld-ContribAuthor ">Anna  Stodolna</span>, <span class="hlFld-ContribAuthor ">Agnieszka  Myślińska</span>, <span class="hlFld-ContribAuthor ">Marek K.  Bernard</span>. </span><span class="cited-content_cbyCitation_article-title">Theoretical Investigations on Interactions of Arylsulphonyl Indazole Derivatives as Potential Ligands of VEGFR2 Kinase. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Molecular Sciences</span><span> <strong>2020,</strong> <em>21 </em>
                                    (13)
                                     , 4793. <a href="https://doi.org/10.3390/ijms21134793" title="DOI URL">https://doi.org/10.3390/ijms21134793</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ijms21134793&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fijms21134793%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Molecular%2520Sciences%26atitle%3DTheoretical%252BInvestigations%252Bon%252BInteractions%252Bof%252BArylsulphonyl%252BIndazole%252BDerivatives%252Bas%252BPotential%252BLigands%252Bof%252BVEGFR2%252BKinase%26aulast%3DCzaja%26aufirst%3DKornelia%26date%3D2020%26date%3D2020%26volume%3D21%26issue%3D13%26spage%3D4793" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Wei  Chen</span>, <span class="hlFld-ContribAuthor ">Dujia  Jin</span>, <span class="hlFld-ContribAuthor ">Yafei  Shi</span>, <span class="hlFld-ContribAuthor ">Yujun  Zhang</span>, <span class="hlFld-ContribAuthor ">Haiyan  Zhou</span>, <span class="hlFld-ContribAuthor ">Guohui  Li</span>. </span><span class="cited-content_cbyCitation_article-title">The underlying mechanisms of lorlatinib penetration across the blood
              ‐
              brain barrier and the distribution characteristics of lorlatinib in the brain. </span><span class="cited-content_cbyCitation_journal-name">Cancer Medicine</span><span> <strong>2020,</strong> <em>9 </em>
                                    (12)
                                     , 4350-4359. <a href="https://doi.org/10.1002/cam4.3061" title="DOI URL">https://doi.org/10.1002/cam4.3061</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cam4.3061&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcam4.3061%26sid%3Dliteratum%253Aachs%26jtitle%3DCancer%2520Medicine%26atitle%3DThe%252Bunderlying%252Bmechanisms%252Bof%252Blorlatinib%252Bpenetration%252Bacross%252Bthe%252Bblood%252B%2525E2%252580%252590%252Bbrain%252Bbarrier%252Band%252Bthe%252Bdistribution%252Bcharacteristics%252Bof%252Blorlatinib%252Bin%252Bthe%252Bbrain%26aulast%3DChen%26aufirst%3DWei%26date%3D2020%26date%3D2020%26volume%3D9%26issue%3D12%26spage%3D4350%26epage%3D4359" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Saumitra  Sengupta</span>, <span class="hlFld-ContribAuthor ">Goverdhan  Mehta</span>. </span><span class="cited-content_cbyCitation_article-title">Macrocyclization
              via
              C–H functionalization: a new paradigm in macrocycle synthesis. </span><span class="cited-content_cbyCitation_journal-name">Organic & Biomolecular Chemistry</span><span> <strong>2020,</strong> <em>18 </em>
                                    (10)
                                     , 1851-1876. <a href="https://doi.org/10.1039/C9OB02765C" title="DOI URL">https://doi.org/10.1039/C9OB02765C</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C9OB02765C&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC9OB02765C%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520%2526%2520Biomolecular%2520Chemistry%26atitle%3DMacrocyclization%252Bvia%252BC%2525E2%252580%252593H%252Bfunctionalization%25253A%252Ba%252Bnew%252Bparadigm%252Bin%252Bmacrocycle%252Bsynthesis%26aulast%3DSengupta%26aufirst%3DSaumitra%26date%3D2020%26date%3D2020%26volume%3D18%26issue%3D10%26spage%3D1851%26epage%3D1876" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiuyun  Sun</span>, <span class="hlFld-ContribAuthor ">Hongying  Gao</span>, <span class="hlFld-ContribAuthor ">Yiqing  Yang</span>, <span class="hlFld-ContribAuthor ">Ming  He</span>, <span class="hlFld-ContribAuthor ">Yue  Wu</span>, <span class="hlFld-ContribAuthor ">Yugang  Song</span>, <span class="hlFld-ContribAuthor ">Yan  Tong</span>, <span class="hlFld-ContribAuthor ">Yu  Rao</span>. </span><span class="cited-content_cbyCitation_article-title">PROTACs: great opportunities for academia and industry. </span><span class="cited-content_cbyCitation_journal-name">Signal Transduction and Targeted Therapy</span><span> <strong>2019,</strong> <em>4 </em>
                                    (1)
                                     <a href="https://doi.org/10.1038/s41392-019-0101-6" title="DOI URL">https://doi.org/10.1038/s41392-019-0101-6</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41392-019-0101-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41392-019-0101-6%26sid%3Dliteratum%253Aachs%26jtitle%3DSignal%2520Transduction%2520and%2520Targeted%2520Therapy%26atitle%3DPROTACs%25253A%252Bgreat%252Bopportunities%252Bfor%252Bacademia%252Band%252Bindustry%26aulast%3DSun%26aufirst%3DXiuyun%26date%3D2019%26date%3D2019%26volume%3D4%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00446/20191219/images/medium/jm9b00446_0028.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00446/20191219/images/large/jm9b00446_0028.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00446&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00446/20191219/images/medium/jm9b00446_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00446/20191219/images/large/jm9b00446_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Schematic summary of different categories of ALK alterations (gene amplification, mutations, and rearrangement) and corresponding cancers.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00446/20191219/images/large/jm9b00446_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00446&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00446/20191219/images/medium/jm9b00446_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00446/20191219/images/large/jm9b00446_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. (A) Overview of the native human anaplastic lymphoma kinase (ALK). The extracellular segment of ALK (residues 19–1038) contains an LDLa domain (453–471) sandwiched between the two MAM domains (264–427 and 480–626) along with a glycine-rich component (UniprotKB <a href="https://Q9UM73" class="ext-link">Q9UM73</a>). Architectures of (B) the anaplastic large cell lymphoma kinase (ALCL) NPM-ALK fusion protein, and (C) nonsmall cell lung cancer (NSCLC) EML4-ALK fusion protein (variant 1).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00446/20191219/images/large/jm9b00446_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00446&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00446/20191219/images/medium/jm9b00446_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00446/20191219/images/large/jm9b00446_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Mechanisms of acquired resistance to ALK inhibitor therapy in ALK-positive cancers, including acquired secondary mutations of ALK and/or fused ALK, gene amplification, bypass signaling pathway activation, and other mechanisms.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00446/20191219/images/large/jm9b00446_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00446&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00446/20191219/images/medium/jm9b00446_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00446/20191219/images/large/jm9b00446_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Representative ALK inhibitors in clinical and preclinical stages.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00446/20191219/images/large/jm9b00446_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00446&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00446/20191219/images/medium/jm9b00446_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00446/20191219/images/large/jm9b00446_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. (A) Crystal structure of the ALK domain (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4Z55">4Z55</a>), and (B) 2D diagram of the inferred interactions between the human ALK catalytic core residue, ATP, and a protein substrate.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00446/20191219/images/large/jm9b00446_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00446&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00446/20191219/images/medium/jm9b00446_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00446/20191219/images/large/jm9b00446_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. ALK signaling pathways and the important downstream targets of ALK. ALK, as a membrane receptor, receives and transfers extracellular signals by activating multiple intracellular signaling pathways. The PLC-γ/DAG/PKC and SRC/RAS/ERK1/2 pathways affect cell growth and proliferation, while the JAKs/STAT and PI3K/AKT/mTOR pathways regulate cell survival.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00446/20191219/images/large/jm9b00446_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00446&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00446/20191219/images/medium/jm9b00446_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00446/20191219/images/large/jm9b00446_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Discovery and design procedure of the dual c-Met/ALK inhibitor, Crizotinib, by combing SBDD strategy and medicinal chemistry. The procedure started from a moderate c-Met inhibitor (compound <b>13</b>, SU-11274) and optimized it to a potent inhibitor for c-Met (PHA-665752) and then generated compounds <b>15</b>, <b>16</b>, <b>17</b>, and Crizotinib after a series of optimizations.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00446/20191219/images/large/jm9b00446_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00446&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00446/20191219/images/medium/jm9b00446_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00446/20191219/images/large/jm9b00446_0008.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Binding modes of the selected representative ALK inhibitors: (A) Crizotinib (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2XP2">2XP2</a>), (B) Ceritinib (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4MKE">4MKE</a>), (C) Alectinib (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3AOX">3AOX</a>), (D) Brigatinib (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5J7H">5J7H</a>), (E) Entrectinib (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5FTO">5FTO</a>), and (F) Lorlatinib (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4CLI">4CLI</a>). The key residues involved in the interactions between ALK kinase and ALK inhibitors, such as Leu1122, Glu1167, Ile1171, Phe1174, Glu1197, Met1199, and Phe1271.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00446/20191219/images/large/jm9b00446_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00446&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00446/20191219/images/medium/jm9b00446_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00446/20191219/images/large/jm9b00446_0009.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. (A) Reported Crizotinib resistant mutations in the ALK kinase domain (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2XP2">2XP2</a>), and (B) the frequency (reported cases) of each mutation detected directly from the Crizotinib-resistant patients.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00446/20191219/images/large/jm9b00446_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00446&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00446/20191219/images/medium/jm9b00446_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00446/20191219/images/large/jm9b00446_0010.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Evolution of Ceritinib (<b>3</b>) from the initial hit TAE684 (<b>2</b>) due to its toxicity as a result of oxidative metabolism.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00446/20191219/images/large/jm9b00446_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00446&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00446/20191219/images/medium/jm9b00446_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00446/20191219/images/large/jm9b00446_0011.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Design strategy used from the initial hit <b>18</b> to the FDA-approved Alectinib (<b>4</b>) through a series of optimizations (compounds <b>19</b>–<b>21</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00446/20191219/images/large/jm9b00446_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00446&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig12" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00446/20191219/images/medium/jm9b00446_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00446/20191219/images/large/jm9b00446_0012.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Design and optimization strategy used to develop Brigatinib (<b>5</b>) and ALK-IN-1 (<b>27</b>) and key Brigatinib analogues during the discovery process (compounds <b>25</b>, <b>26</b>, and <b>28</b>–<b>32</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00446/20191219/images/large/jm9b00446_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00446&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig13" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00446/20191219/images/medium/jm9b00446_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00446/20191219/images/large/jm9b00446_0013.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. Macrocyclic ALK inhibitor TPX-0005 (<b>12</b>) and the design procedure of Loratinib (<b>11</b>) by the cyclization (compounds <b>33</b>–<b>35</b>) and optimization (compound <b>36</b>) of Crizotinib.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00446/20191219/images/large/jm9b00446_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00446&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig14" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00446/20191219/images/medium/jm9b00446_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00446/20191219/images/large/jm9b00446_0014.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. Development strategy for CEP-28122 (39) and CEP-37440. The combination of compound <b>37</b> and the 2,3,4,5-tetrahydro-1<i>H</i>-benzo[<i>d</i>]azepine fragment of the diaminopyrimidine analogue <b>38</b> yielded CEP-28122. The toxicity of CEP-28122 advanced the generation of CEP-37440 by optimizations (compounds <b>40</b> and <b>41</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00446/20191219/images/large/jm9b00446_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00446&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig15" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00446/20191219/images/medium/jm9b00446_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00446/20191219/images/large/jm9b00446_0015.jpeg" id="rightTab-gr15" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 15. Design of new 2,4-diarylaminopyrimidine analogues (DAAPalogues) by repurposing a typical dopamine D1/D5 (compounds <b>43</b> and <b>44</b>), which led to the generation of compounds <b>45</b> and <b>46</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00446/20191219/images/large/jm9b00446_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00446&amp;id=fig15"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig16" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 16</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00446/20191219/images/medium/jm9b00446_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00446/20191219/images/large/jm9b00446_0016.jpeg" id="rightTab-gr16" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 16. Development strategy for the new DAAPalogues with a flexible amino acid side chain by ring opening (compound <b>48</b>) and SBDD (compound <b>49</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00446/20191219/images/large/jm9b00446_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00446&amp;id=fig16"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig17" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Figure 17</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00446/20191219/images/medium/jm9b00446_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00446/20191219/images/large/jm9b00446_0017.jpeg" id="rightTab-gr17" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 17. Representative ALK inhibitors (compounds <b>50</b>–<b>54</b>) with the DAAPs scaffold by adopting a bioisosteric strategy.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00446/20191219/images/large/jm9b00446_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00446&amp;id=fig17"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig18" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Figure 18</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00446/20191219/images/medium/jm9b00446_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00446/20191219/images/large/jm9b00446_0018.jpeg" id="rightTab-gr18" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 18. Optimization of the substituent of ring A in hit <b>55</b> led to the discovery of Entrectinib (<b>9</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00446/20191219/images/large/jm9b00446_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00446&amp;id=fig18"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig19" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Figure 19</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00446/20191219/images/medium/jm9b00446_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00446/20191219/images/large/jm9b00446_0019.jpeg" id="rightTab-gr19" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 19. X-396 was generated by optimizing the side chain of Crizotinib.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00446/20191219/images/large/jm9b00446_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00446&amp;id=fig19"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig20" data-index="20" class="article__inlineFigure"><h2 class="fig-label">Figure 20</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00446/20191219/images/medium/jm9b00446_0020.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00446/20191219/images/large/jm9b00446_0020.jpeg" id="rightTab-gr20" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 20. Representative ALK inhibitors with the acyliminobenzimidazole scaffold. The optimizations of the HTS hit <b>56</b> led to the generation of the 3,5-difluoro analogues <b>59</b> (Belizatinib) and <b>61</b> with improved potency and selectivity toward ALK.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00446/20191219/images/large/jm9b00446_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00446&amp;id=fig20"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig21" data-index="21" class="article__inlineFigure"><h2 class="fig-label">Figure 21</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00446/20191219/images/medium/jm9b00446_0021.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00446/20191219/images/large/jm9b00446_0021.jpeg" id="rightTab-gr21" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 21. Optimization process (compound <b>62</b>) of Alectinib leading to the development of JH-VII-157-02 (<b>63</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00446/20191219/images/large/jm9b00446_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00446&amp;id=fig21"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig22" data-index="22" class="article__inlineFigure"><h2 class="fig-label">Figure 22</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00446/20191219/images/medium/jm9b00446_0022.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00446/20191219/images/large/jm9b00446_0022.jpeg" id="rightTab-gr22" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 22. Compound <b>65</b> was generated by the optimization of the 2,6-dichloro-3-fluorophenyl head and pyrazolopiperidine tail groups in Crizotinib (<b>1</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00446/20191219/images/large/jm9b00446_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00446&amp;id=fig22"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig23" data-index="23" class="article__inlineFigure"><h2 class="fig-label">Figure 23</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00446/20191219/images/medium/jm9b00446_0023.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00446/20191219/images/large/jm9b00446_0023.jpeg" id="rightTab-gr23" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 23. Discovery of a 1<i>H</i>-pyrazol-5-yl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine derivative <b>68</b> as a highly selective, potent, and brain-penetrant ALK inhibitor. The discovery process started from a HTS hit <b>66</b>, followed by scaffold hopping and SBDD-driven lead optimization.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00446/20191219/images/large/jm9b00446_0023.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00446&amp;id=fig23"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig24" data-index="24" class="article__inlineFigure"><h2 class="fig-label">Figure 24</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00446/20191219/images/medium/jm9b00446_0024.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00446/20191219/images/large/jm9b00446_0024.jpeg" id="rightTab-gr24" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 24. (A) Representative type-I1/2 ALK inhibitors with the piperidine carboxamide scaffold (compounds <b>69</b>–<b>72</b>), (B) cocrystal structure of compound <b>69</b> in complex with the ALK kinase, and (C) the pharmacophore modeling of compound <b>69</b> in the ALK kinase.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00446/20191219/images/large/jm9b00446_0024.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00446&amp;id=fig24"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig25" data-index="25" class="article__inlineFigure"><h2 class="fig-label">Figure 25</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00446/20191219/images/medium/jm9b00446_0025.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00446/20191219/images/large/jm9b00446_0025.jpeg" id="rightTab-gr25" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 25. (A) Representative type-I1/2 ALK inhibitors with the 1-purine-3-piperidinecarboxamide scaffold (compounds <b>73</b>–<b>77</b>), (B) cocrystal structure of compound <b>77</b> in complex with the ALK kinase, and (C) the pharmacophore modeling of compound <b>77</b> in the ALK kinase.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00446/20191219/images/large/jm9b00446_0025.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00446&amp;id=fig25"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig26" data-index="26" class="article__inlineFigure"><h2 class="fig-label">Figure 26</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00446/20191219/images/medium/jm9b00446_0026.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00446/20191219/images/large/jm9b00446_0026.jpeg" id="rightTab-gr26" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 26. (A) Transition from type-I (compound <b>78</b>) to type-II (compound <b>79</b>) ALK inhibitors, (B) cocrystal structure of compound <b>79</b> in complex with the ALK kinase, and (C) the pharmacophore modeling of compound <b>79</b> in the ALK kinase.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00446/20191219/images/large/jm9b00446_0026.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00446&amp;id=fig26"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig27" data-index="27" class="article__inlineFigure"><h2 class="fig-label">Figure 27</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00446/20191219/images/medium/jm9b00446_0027.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00446/20191219/images/large/jm9b00446_0027.jpeg" id="rightTab-gr27" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 27. Structures of the reported ALK PROTACs and the degradation process of ALK by PROTACs.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00446/20191219/images/large/jm9b00446_0027.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00446&amp;id=fig27"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i40">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_01305" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_01305" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 178 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morris, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirstein, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valentine, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dittmer, K. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shapiro, D. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saltman, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Look, A. T. J. S.</span></span> <span> </span><span class="NLM_article-title">Fusion of a Kinase Gene, ALK, to a Nucleolar Protein Gene, NPM, in Non-Hodgkin’s Lymphoma</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>263</i></span>,  <span class="NLM_fpage">1281</span>– <span class="NLM_lpage">1284</span>, <span class="refDoi"> DOI: 10.1126/science.8122112</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1126%2Fscience.8122112" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=8122112" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADyaK2cXis1aks7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=263&publication_year=1994&pages=1281-1284&author=S.+W.+Morrisauthor=M.+N.+Kirsteinauthor=M.+B.+Valentineauthor=K.+G.+Dittmerauthor=D.+N.+Shapiroauthor=D.+L.+Saltmanauthor=A.+T.+J.+S.+Look&title=Fusion+of+a+Kinase+Gene%2C+ALK%2C+to+a+Nucleolar+Protein+Gene%2C+NPM%2C+in+Non-Hodgkin%E2%80%99s+Lymphoma&doi=10.1126%2Fscience.8122112"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma</span></div><div class="casAuthors">Morris, Stephan, W.; Kirstein, Mark, N.; Valentine, Marcus B.; Dittmer, Kristopher G.; Shapiro, David N.; Saltman, David L.; Look, A. Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">263</span>
        (<span class="NLM_cas:issue">5151</span>),
    <span class="NLM_cas:pages">1281-4</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    </div><div class="casAbstract">The 2;5 chromosomal translocation occurs in most anaplastic large-cell non-Hodgkin's lymphomas arising from activated T lymphocytes.  This rearrangement was shown to fuse the NPM nucleolar phosphoprotein gene on chromosome 5q35 to a previously unidentified protein tyrosine kinase gene, ALK, on chromosome 2p23.  In the predicted hybrid protein, the amino terminus of nucleophosmin (NPM) is linked to the catalytic domain of anaplastic lymphoma kinase (ALK).  Expressed in the small intestine, testis, and brain but not in normal lymphoid cells, ALK shows greatest sequence similarity to the insulin receptor subfamily of kinases.  Unscheduled expression of the truncated ALK may contribute to malignant transformation in these lymphomas.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGox3KZnxLYaerVg90H21EOLACvtfcHk0lhWeckA3WwKyg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXis1aks7Y%253D&md5=219ee9615e613be456a05f8f1ded6066</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1126%2Fscience.8122112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.8122112%26sid%3Dliteratum%253Aachs%26aulast%3DMorris%26aufirst%3DS.%2BW.%26aulast%3DKirstein%26aufirst%3DM.%2BN.%26aulast%3DValentine%26aufirst%3DM.%2BB.%26aulast%3DDittmer%26aufirst%3DK.%2BG.%26aulast%3DShapiro%26aufirst%3DD.%2BN.%26aulast%3DSaltman%26aufirst%3DD.%2BL.%26aulast%3DLook%26aufirst%3DA.%2BT.%2BJ.%2BS.%26atitle%3DFusion%2520of%2520a%2520Kinase%2520Gene%252C%2520ALK%252C%2520to%2520a%2520Nucleolar%2520Protein%2520Gene%252C%2520NPM%252C%2520in%2520Non-Hodgkin%25E2%2580%2599s%2520Lymphoma%26jtitle%3DScience%26date%3D1994%26volume%3D263%26spage%3D1281%26epage%3D1284%26doi%3D10.1126%2Fscience.8122112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Iwahara, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujimoto, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cupples, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bucay, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arakawa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mori, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ratzkin, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, T. J. O.</span></span> <span> </span><span class="NLM_article-title">Molecular Characterization of ALK, a Receptor Tyrosine Kinase Expressed Specifically in the Nervous System</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">439</span>– <span class="NLM_lpage">449</span>, <span class="refDoi"> DOI: 10.1038/sj.onc.1200849</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1038%2Fsj.onc.1200849" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=9053841" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADyaK2sXht1ensbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=1997&pages=439-449&author=T.+Iwaharaauthor=J.+Fujimotoauthor=D.+Wenauthor=R.+Cupplesauthor=N.+Bucayauthor=T.+Arakawaauthor=S.+Moriauthor=B.+Ratzkinauthor=T.+J.+O.+Yamamoto&title=Molecular+Characterization+of+ALK%2C+a+Receptor+Tyrosine+Kinase+Expressed+Specifically+in+the+Nervous+System&doi=10.1038%2Fsj.onc.1200849"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system</span></div><div class="casAuthors">Iwahara, Toshinori; Fujimoto, Jiro; Wen, Duanzhi; Cupples, Rod; Bucay, Nathan; Arakawa, Tsutomu; Mori, Shigeo; Ratzkin, Barry; Yamamoto, Tadashi</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">439-449</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Stockton</span>)
        </div><div class="casAbstract">The 2;5 chromosomal translocation is frequently assocd. with anaplastic large cell lymphomas (ALCLs).  The translocation creates a fusion gene consisting of the alk (anaplastic lymphoma kinase) gene and the nucelophosmin (npm) gene: the 3' half of alk derived from chromosome 2 is fused to the 5' portion of npm from chromosome 5.  A recent study shows that the product of the npm-alk fusion gene is oncogenic.  To help understand how the npm-alk oncogene transform cells, it is important to investigate the normal biol. function of the alk gene product, ALK.  Here, we show mol. cloning of cDNAs for both the human and mouse ALK proteins.  The deduced amino acid sequences reveal that ALK is a novel receptor protein-tyrosine kinase having a putative transmembrane domain and an extracellular domain.  These sequences are absent in the product of the transforming npm-alk gene.  ALK shows the greatest sequence similarity to LTK (leukocyte tyrosine kinase) whose biol. function is presently unknown.  RNA blot hybridization anal. of various tissues reveals that the alk mRNA is dominantly detected in the brain and spinal cord.  Immunoblotting with anti-ALK antibody shows that ALK is highly expressed in the neonatal brain.  Furthermore, RNA in situ hybridization anal. shows that the alk mRNA is dominantly expressed in neurons in specific regions of the nervous system such as the thalamus, mid-brain, olfactory bulb, and ganglia of embryonic and neonatal mice.  These data suggest that ALK plays an important role(s) in the development of the brain and exerts its effects on specific neurons in the nervous system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-hGYy9uKgGbVg90H21EOLACvtfcHk0lhWeckA3WwKyg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXht1ensbs%253D&md5=7143e0a25247dd354bbf564cfd1702b6</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1200849&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1200849%26sid%3Dliteratum%253Aachs%26aulast%3DIwahara%26aufirst%3DT.%26aulast%3DFujimoto%26aufirst%3DJ.%26aulast%3DWen%26aufirst%3DD.%26aulast%3DCupples%26aufirst%3DR.%26aulast%3DBucay%26aufirst%3DN.%26aulast%3DArakawa%26aufirst%3DT.%26aulast%3DMori%26aufirst%3DS.%26aulast%3DRatzkin%26aufirst%3DB.%26aulast%3DYamamoto%26aufirst%3DT.%2BJ.%2BO.%26atitle%3DMolecular%2520Characterization%2520of%2520ALK%252C%2520a%2520Receptor%2520Tyrosine%2520Kinase%2520Expressed%2520Specifically%2520in%2520the%2520Nervous%2520System%26jtitle%3DOncogene%26date%3D1997%26volume%3D14%26spage%3D439%26epage%3D449%26doi%3D10.1038%2Fsj.onc.1200849" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cools, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wlodarska, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Somers, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mentens, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pedeutour, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maes, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Wolf-Peeters, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pauwels, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hagemeijer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marynen, P.</span></span> <span> </span><span class="NLM_article-title">Identification of Novel Fusion Partners of ALK, the Anaplastic Lymphoma Kinase, in Anaplastic Large-cell Lymphoma and Inflammatory Myofibroblastic Tumor</span>. <i>Genes, Chromosomes Cancer</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">354</span>– <span class="NLM_lpage">362</span>, <span class="refDoi"> DOI: 10.1002/gcc.10033</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1002%2Fgcc.10033" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=12112524" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BD38XlslyrtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2002&pages=354-362&author=J.+Coolsauthor=I.+Wlodarskaauthor=R.+Somersauthor=N.+Mentensauthor=F.+Pedeutourauthor=B.+Maesauthor=C.+De+Wolf-Peetersauthor=P.+Pauwelsauthor=A.+Hagemeijerauthor=P.+Marynen&title=Identification+of+Novel+Fusion+Partners+of+ALK%2C+the+Anaplastic+Lymphoma+Kinase%2C+in+Anaplastic+Large-cell+Lymphoma+and+Inflammatory+Myofibroblastic+Tumor&doi=10.1002%2Fgcc.10033"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of novel fusion partners of ALK, the anaplastic lymphoma kinase, in anaplastic large-cell lymphoma and inflammatory myofibroblastic tumor</span></div><div class="casAuthors">Cools, Jan; Wlodarska, Iwona; Somers, Riet; Mentens, Nicole; Pedeutour, Florence; Maes, Brigitte; De Wolf-Peeters, Christiane; Pauwels, Patrick; Hagemeijer, Anne; Marynen, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Genes, Chromosomes & Cancer</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">354-362</span>CODEN:
                <span class="NLM_cas:coden">GCCAES</span>;
        ISSN:<span class="NLM_cas:issn">1045-2257</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">ALK-pos. anaplastic large-cell lymphoma (ALCL) has been recognized as a distinct type of lymphoma in the heterogeneous group of T/Null-ALCL.  While most of the ALK-pos. ALCL (ALKomas) are characterized by the presence of the NPM-ALK fusion protein, the product of the t(2;5)(p23;q35), 10-20% of ALKomas contain variant ALK fusions, including ATIC-ALK, TFG-ALK, CLTC-ALK (previously designated CLTCL-ALK), TMP3-ALK, and MSN-ALK.  TMP3-ALK and TMP4-ALK fusions also have been detected in inflammatory myofibroblastic tumors (IMTs), making clear that aberrations of the ALK gene are not assocd. exclusively with the pathogenesis of ALK-pos. ALCL.  Here the authors report results of mol. studies on two lymphoma cases and one IMT case with variant rearrangements of ALK.  The authors' study led to the detection of the CLTC-ALK fusion in an ALCL case and to the identification of two novel fusion partners of ALK: ALO17 (KIAA 1618), a gene with unknown function, which was fused to ALK in an ALCL case with a t(2;17)(p23;q25), and CARS, encoding the cysteinyl-tRNA synthetase, which was fused to ALK in an IMT case with a t(2;11;2)(p23;p15;q31).  These results confirm the recurrent involvement of ALK in IMT and further demonstrate the diversity of ALK fusion partners, with the ability to homodimerize as a common characteristic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXRK_iZnUkNrVg90H21EOLACvtfcHk0lj-vJX5usLFjw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XlslyrtL8%253D&md5=5e15ec7d207444665354c7f08d2620fc</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1002%2Fgcc.10033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fgcc.10033%26sid%3Dliteratum%253Aachs%26aulast%3DCools%26aufirst%3DJ.%26aulast%3DWlodarska%26aufirst%3DI.%26aulast%3DSomers%26aufirst%3DR.%26aulast%3DMentens%26aufirst%3DN.%26aulast%3DPedeutour%26aufirst%3DF.%26aulast%3DMaes%26aufirst%3DB.%26aulast%3DDe%2BWolf-Peeters%26aufirst%3DC.%26aulast%3DPauwels%26aufirst%3DP.%26aulast%3DHagemeijer%26aufirst%3DA.%26aulast%3DMarynen%26aufirst%3DP.%26atitle%3DIdentification%2520of%2520Novel%2520Fusion%2520Partners%2520of%2520ALK%252C%2520the%2520Anaplastic%2520Lymphoma%2520Kinase%252C%2520in%2520Anaplastic%2520Large-cell%2520Lymphoma%2520and%2520Inflammatory%2520Myofibroblastic%2520Tumor%26jtitle%3DGenes%252C%2520Chromosomes%2520Cancer%26date%3D2002%26volume%3D34%26spage%3D354%26epage%3D362%26doi%3D10.1002%2Fgcc.10033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Carén, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abel, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kogner, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinsson, T. J. B. J.</span></span> <span> </span><span class="NLM_article-title">High Incidence of DNA Mutations and Gene Amplifications of the ALK Gene in Advanced Sporadic Neuroblastoma Tumours</span>. <i>Biochem. J.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>416</i></span>,  <span class="NLM_fpage">153</span>– <span class="NLM_lpage">159</span>, <span class="refDoi"> DOI: 10.1042/BJ20081834</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1042%2FBJ20081834" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=18990089" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtlGls7bO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=416&publication_year=2008&pages=153-159&author=H.+Car%C3%A9nauthor=F.+Abelauthor=P.+Kognerauthor=T.+J.+B.+J.+Martinsson&title=High+Incidence+of+DNA+Mutations+and+Gene+Amplifications+of+the+ALK+Gene+in+Advanced+Sporadic+Neuroblastoma+Tumours&doi=10.1042%2FBJ20081834"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">High incidence of DNA mutations and gene amplifications of the ALK gene in advanced sporadic neuroblastoma tumors</span></div><div class="casAuthors">Caren, Helena; Abel, Frida; Kogner, Per; Martinsson, Tommy</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Journal</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">416</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">153-159</span>CODEN:
                <span class="NLM_cas:coden">BIJOAK</span>;
        ISSN:<span class="NLM_cas:issn">0264-6021</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">ALK (anaplastic lymphoma kinase) is oncogenic in several tumors and has recently been identified as a predisposition gene for familial NB (neuroblastoma) harboring mutations in the TKD (tyrosine kinase domain).  We have analyzed a large set of sporadic human NB primary tumors of all clin. stages for chromosomal re-arrangements using a CGH (comparative genomic hybridization) array (n = 108) and mutations of the ALK gene (n = 90), and expression of ALK and related genes (n = 19).  ALK amplification or in-gene re-arrangements were found in 5% of NB tumors and mutations were found in 11%, including two novel not previously published mutations in the TKD, c.3733T > A and c.3735C > A.  DNA mutations in the TKD and gene amplifications were only found in advanced large primary tumors or metastatic tumors, and correlated with the expression levels of ALK and downstream genes as well as other unfavorable features, and poor outcome.  The results of the present study support that the ALK protein contributes to NB oncogenesis providing a highly interesting putative therapeutic target in a subset of unfavorable NB tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_-7KLmFXGrbVg90H21EOLACvtfcHk0lj-vJX5usLFjw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtlGls7bO&md5=b01f1d1181d189dd6db6c58590b8da9c</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1042%2FBJ20081834&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FBJ20081834%26sid%3Dliteratum%253Aachs%26aulast%3DCar%25C3%25A9n%26aufirst%3DH.%26aulast%3DAbel%26aufirst%3DF.%26aulast%3DKogner%26aufirst%3DP.%26aulast%3DMartinsson%26aufirst%3DT.%2BJ.%2BB.%2BJ.%26atitle%3DHigh%2520Incidence%2520of%2520DNA%2520Mutations%2520and%2520Gene%2520Amplifications%2520of%2520the%2520ALK%2520Gene%2520in%2520Advanced%2520Sporadic%2520Neuroblastoma%2520Tumours%26jtitle%3DBiochem.%2520J.%26date%3D2008%26volume%3D416%26spage%3D153%26epage%3D159%26doi%3D10.1042%2FBJ20081834" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Solomon, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varella-Garcia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camidge, D. R.</span></span> <span> </span><span class="NLM_article-title">ALK Gene Rearrangements: a New Therapeutic Target in a Molecularly Defined Subset of Non-small Cell Lung Cancer</span>. <i>J. Thorac. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">1450</span>– <span class="NLM_lpage">1454</span>, <span class="refDoi"> DOI: 10.1097/JTO.0b013e3181c4dedb</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1097%2FJTO.0b013e3181c4dedb" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=20009909" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A280%3ADC%252BD1MfisFGkuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2009&pages=1450-1454&author=B.+Solomonauthor=M.+Varella-Garciaauthor=D.+R.+Camidge&title=ALK+Gene+Rearrangements%3A+a+New+Therapeutic+Target+in+a+Molecularly+Defined+Subset+of+Non-small+Cell+Lung+Cancer&doi=10.1097%2FJTO.0b013e3181c4dedb"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">ALK gene rearrangements: a new therapeutic target in a molecularly defined subset of non-small cell lung cancer</span></div><div class="casAuthors">Solomon Benjamin; Varella-Garcia Marileila; Camidge D Ross</div><div class="citationInfo"><span class="NLM_cas:title">Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1450-4</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Transforming rearrangements of the ALK (anaplastic lymphoma kinase) gene have recently been described in non-small cell lung cancer (NSCLC).  The most common rearrangement arises from an inversion in the short arm of chromosome 2 that creates a fusion between the 5' portion of the EML4 (echinoderm microtubule-associated protein-like 4) gene and the 3' portion of the ALK gene.  At least seven ALK gene rearrangement variants have been described involving different EML4-ALK breakpoints or rarely other non-EML4 fusion partners.  ALK rearrangements may be readily identified in tumor tissue by reverse transcription-polymerase chain reaction or fluorescent in situ hybridization.  Although ALK gene rearrangements affect only about 4% of all lung cancers, they are more frequent in adenocarcinomas, in never or light smokers, and seem almost mutually exclusive with activating EGFR or KRAS mutations.  Promising results seen in patients with NSCLC containing fluorescent in situ hybridization-detected ALK rearrangements treated on a phase I study with PF02341066, an oral ALK inhibitor, indicate that ALK represents a new therapeutic target in this molecularly defined subset of NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcToajfqAoubLEEgZCMqtRBifW6udTcc2ebEN8EjOJ05hrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1MfisFGkuw%253D%253D&md5=f9cba2d2339e725ed625f629f66ba6a6</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1097%2FJTO.0b013e3181c4dedb&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FJTO.0b013e3181c4dedb%26sid%3Dliteratum%253Aachs%26aulast%3DSolomon%26aufirst%3DB.%26aulast%3DVarella-Garcia%26aufirst%3DM.%26aulast%3DCamidge%26aufirst%3DD.%2BR.%26atitle%3DALK%2520Gene%2520Rearrangements%253A%2520a%2520New%2520Therapeutic%2520Target%2520in%2520a%2520Molecularly%2520Defined%2520Subset%2520of%2520Non-small%2520Cell%2520Lung%2520Cancer%26jtitle%3DJ.%2520Thorac.%2520Oncol.%26date%3D2009%26volume%3D4%26spage%3D1450%26epage%3D1454%26doi%3D10.1097%2FJTO.0b013e3181c4dedb" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hallberg, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmer, R. H.</span></span> <span> </span><span class="NLM_article-title">Mechanistic Insight into ALK Receptor Tyrosine Kinase in Human Cancer Biology</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">685</span>– <span class="NLM_lpage">700</span>, <span class="refDoi"> DOI: 10.1038/nrc3580</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1038%2Fnrc3580" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=24060861" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsV2jtrbP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2013&pages=685-700&author=B.+Hallbergauthor=R.+H.+Palmer&title=Mechanistic+Insight+into+ALK+Receptor+Tyrosine+Kinase+in+Human+Cancer+Biology&doi=10.1038%2Fnrc3580"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology</span></div><div class="casAuthors">Hallberg, Bengt; Palmer, Ruth H.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">685-700</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The burgeoning field of anaplastic lymphoma kinase (ALK) in cancer encompasses many cancer types, from very rare cancers to the more prevalent non-small-cell lung cancer (NSCLC).  The common activation of ALK has led to the use of the ALK tyrosine kinase inhibitor (TKI) crizotinib in a range of patient populations and to the rapid development of second-generation drugs targeting ALK.  In this review, we discuss our current understanding of ALK function in human cancer and the implications for tumor treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrADI-N0ZBEr7Vg90H21EOLACvtfcHk0liZP-IkCvcESw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsV2jtrbP&md5=fab66b12114ca01348df4ca08d3b3e4e</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1038%2Fnrc3580&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc3580%26sid%3Dliteratum%253Aachs%26aulast%3DHallberg%26aufirst%3DB.%26aulast%3DPalmer%26aufirst%3DR.%2BH.%26atitle%3DMechanistic%2520Insight%2520into%2520ALK%2520Receptor%2520Tyrosine%2520Kinase%2520in%2520Human%2520Cancer%2520Biology%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2013%26volume%3D13%26spage%3D685%26epage%3D700%26doi%3D10.1038%2Fnrc3580" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Solomon, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ou, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Besse, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felip, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soo, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bearz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clancy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abbattista, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thurm, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peltz, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masters, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martini, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seto, T.</span></span> <span> </span><span class="NLM_article-title">Oa 05.06 Phase 2 Study of Lorlatinib in Patients with Advanced ALK+/ROS1+ Non-small-cell Lung Cancer</span>. <i>J. Thorac. Oncol..</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">S1756</span>, <span class="refDoi"> DOI: 10.1016/j.jtho.2017.09.351</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1016%2Fj.jtho.2017.09.351" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2017&pages=S1756&author=B.+Solomonauthor=A.+Shawauthor=S.+Ouauthor=B.+Besseauthor=E.+Felipauthor=T.+Bauerauthor=R.+Sooauthor=A.+Bearzauthor=C.+Linauthor=J.+Clancyauthor=A.+Abbattistaauthor=H.+Thurmauthor=G.+Peltzauthor=E.+Mastersauthor=J.+Martiniauthor=L.+Jamesauthor=T.+Seto&title=Oa+05.06+Phase+2+Study+of+Lorlatinib+in+Patients+with+Advanced+ALK%2B%2FROS1%2B+Non-small-cell+Lung+Cancer&doi=10.1016%2Fj.jtho.2017.09.351"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2Fj.jtho.2017.09.351&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jtho.2017.09.351%26sid%3Dliteratum%253Aachs%26aulast%3DSolomon%26aufirst%3DB.%26aulast%3DShaw%26aufirst%3DA.%26aulast%3DOu%26aufirst%3DS.%26aulast%3DBesse%26aufirst%3DB.%26aulast%3DFelip%26aufirst%3DE.%26aulast%3DBauer%26aufirst%3DT.%26aulast%3DSoo%26aufirst%3DR.%26aulast%3DBearz%26aufirst%3DA.%26aulast%3DLin%26aufirst%3DC.%26aulast%3DClancy%26aufirst%3DJ.%26aulast%3DAbbattista%26aufirst%3DA.%26aulast%3DThurm%26aufirst%3DH.%26aulast%3DPeltz%26aufirst%3DG.%26aulast%3DMasters%26aufirst%3DE.%26aulast%3DMartini%26aufirst%3DJ.%26aulast%3DJames%26aufirst%3DL.%26aulast%3DSeto%26aufirst%3DT.%26atitle%3DOa%252005.06%2520Phase%25202%2520Study%2520of%2520Lorlatinib%2520in%2520Patients%2520with%2520Advanced%2520ALK%252B%252FROS1%252B%2520Non-small-cell%2520Lung%2520Cancer%26jtitle%3DJ.%2520Thorac.%2520Oncol..%26date%3D2017%26volume%3D12%26spage%3DS1756%26doi%3D10.1016%2Fj.jtho.2017.09.351" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Debelenko, L. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arthur, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pack, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Helman, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schrump, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsokos, M.</span></span> <span> </span><span class="NLM_article-title">Identification of CARS-ALK Fusion in Primary and Metastatic Lesions of an Inflammatory Myofibroblastic Tumor</span>. <i>Lab. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>83</i></span>,  <span class="NLM_fpage">1255</span>– <span class="NLM_lpage">1265</span>, <span class="refDoi"> DOI: 10.1097/01.LAB.0000088856.49388.EA</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1097%2F01.LAB.0000088856.49388.EA" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=13679433" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BD3sXntFSlu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=83&publication_year=2003&pages=1255-1265&author=L.+V.+Debelenkoauthor=D.+C.+Arthurauthor=S.+D.+Packauthor=L.+J.+Helmanauthor=D.+S.+Schrumpauthor=M.+Tsokos&title=Identification+of+CARS-ALK+Fusion+in+Primary+and+Metastatic+Lesions+of+an+Inflammatory+Myofibroblastic+Tumor&doi=10.1097%2F01.LAB.0000088856.49388.EA"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of CARS-ALK Fusion in Primary and Metastatic Lesions of an Inflammatory Myofibroblastic Tumor</span></div><div class="casAuthors">Debelenko, Larisa V.; Arthur, Diane C.; Pack, Svetlana D.; Helman, Lee J.; Schrump, David S.; Tsokos, Maria</div><div class="citationInfo"><span class="NLM_cas:title">Laboratory Investigation</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">83</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1255-1265</span>CODEN:
                <span class="NLM_cas:coden">LAINAW</span>;
        ISSN:<span class="NLM_cas:issn">0023-6837</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Inflammatory myofibroblastic tumor (IMT) is a rare childhood neoplasm.  The natural history of this disease is poorly understood.  Recently chromosomal rearrangements involving the anaplastic lymphoma kinase (ALK) gene have been implicated in this tumor.  We have studied a case of ALK-pos. soft tissue IMT showing clin. and morphol. features of malignancy.  Interphase fluorescence in situ hybridization demonstrated ALK rearrangements in both primary and metastatic lesions.  Rapid amplification of cDNA ends (5'RACE) identified cysteinyl-tRNA synthetase (CARS) gene fused to ALK, which predicts an in-frame chimeric protein with the preserved functional catalytic domain of ALK at the C terminus.  Amplification and sequencing of tumor DNA confirmed the breakpoint at the genomic level.  Restriction anal. of DNA from primary soft tissue and recurrent lung tumors showed identical patterns, indicating the same clonal origin of both lesions.  Western blot anal. with C-terminus ALK antibody showed expression of an aberrantly sized chimeric protein of approx. 130 kd in tumor tissue.  This is the second case of IMT demonstrating CARS as the ALK fusion partner, which confirms the recurring involvement of ALK in IMT by a common genetic mechanism.  Moreover, identical clonality of sep. lesions involving different sites supports metastasis in IMT.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrllwxoK_YWV7Vg90H21EOLACvtfcHk0liZP-IkCvcESw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXntFSlu7o%253D&md5=4ac7cbe6b8cad0692c784c48fe62250b</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1097%2F01.LAB.0000088856.49388.EA&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F01.LAB.0000088856.49388.EA%26sid%3Dliteratum%253Aachs%26aulast%3DDebelenko%26aufirst%3DL.%2BV.%26aulast%3DArthur%26aufirst%3DD.%2BC.%26aulast%3DPack%26aufirst%3DS.%2BD.%26aulast%3DHelman%26aufirst%3DL.%2BJ.%26aulast%3DSchrump%26aufirst%3DD.%2BS.%26aulast%3DTsokos%26aufirst%3DM.%26atitle%3DIdentification%2520of%2520CARS-ALK%2520Fusion%2520in%2520Primary%2520and%2520Metastatic%2520Lesions%2520of%2520an%2520Inflammatory%2520Myofibroblastic%2520Tumor%26jtitle%3DLab.%2520Invest.%26date%3D2003%26volume%3D83%26spage%3D1255%26epage%3D1265%26doi%3D10.1097%2F01.LAB.0000088856.49388.EA" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gascoyne, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamant, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin-Subero, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lestou, V. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, N. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller-Hermelink, H.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seymour, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horsman, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Auvigne, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Espinos, E.</span></span> <span> </span><span class="NLM_article-title">ALK-positive Diffuse Large B-cell Lymphoma is Associated with Clathrin-ALK Rearrangements: report of 6 cases</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>102</i></span>,  <span class="NLM_fpage">2568</span>– <span class="NLM_lpage">2573</span>, <span class="refDoi"> DOI: 10.1182/blood-2003-03-0786</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1182%2Fblood-2003-03-0786" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=12763927" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BD3sXnslykurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2003&pages=2568-2573&author=R.+D.+Gascoyneauthor=L.+Lamantauthor=J.+I.+Martin-Suberoauthor=V.+S.+Lestouauthor=N.+L.+Harrisauthor=H.-K.+M%C3%BCller-Hermelinkauthor=J.+F.+Seymourauthor=L.+J.+Campbellauthor=D.+E.+Horsmanauthor=I.+Auvigneauthor=E.+Espinos&title=ALK-positive+Diffuse+Large+B-cell+Lymphoma+is+Associated+with+Clathrin-ALK+Rearrangements%3A+report+of+6+cases&doi=10.1182%2Fblood-2003-03-0786"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">ALK-positive diffuse large B-cell lymphoma is associated with clathrin-ALK rearrangements: Report of 6 cases</span></div><div class="casAuthors">Gascoyne, Randy D.; Lamant, Laurence; Martin-Subero, Jose I.; Lestou, Valia S.; Harris, Nancy Lee; Mueller-Hermelink, Hans-Konrad; Seymour, John F.; Campbell, Lynda J.; Horsman, Douglas E.; Auvigne, Isabelle; Espinos, Estelle; Siebert, Reiner; Delsol, Georges</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2568-2573</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Expression of ALK protein by lymphoid cells and the description of variant anaplastic lymphoma kinase (ALK) translocations have typically been restricted to cases of T-cell and null anaplastic large-cell lymphoma (ALCL).  All such cases result from a novel fusion created by the ALK gene on chromosome 2p23 and NPM on 5q35 or other variant translocation partners.  A rare variant of diffuse large B-cell lymphoma (DLBCL), originally described in 1997, was thought to overexpress full-length ALK in contrast to a chimeric protein characteristic of ALCL.  However, full-length ALK protein lacks tyrosine kinase activity and thus the mechanism of oncogenesis has remained elusive.  We describe 6 cases of ALK+ DLBCL characterized by a simple or complex t(2;17)(p23;q23) involving the clathrin gene (CLTC) at chromosome band 17q23 and the ALK gene at chromosome band 2p23.  All cases were studied using fluorescence in situ hybridization (FISH), complemented in one case with std. cytogenetic anal., multicolor karyotyping (M-FISH), and reverse transcriptase-polymerase chain reaction.  These results clearly demonstrate that most cases of ALK+ DLBCL share the same mechanism of deregulated ALK expression.  Moreover, these results demonstrate the presence of CLTC-ALK fusions in these tumors and extend the list of diseases assocd. with this genetic abnormality to include classical T-cell or null ALCL, ALK+ DLBCL, and inflammatory myofibroblastic tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3UcmsuahiXLVg90H21EOLACvtfcHk0liZP-IkCvcESw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXnslykurw%253D&md5=9eedc8c22c580dbadee982b4d3da35a8</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1182%2Fblood-2003-03-0786&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2003-03-0786%26sid%3Dliteratum%253Aachs%26aulast%3DGascoyne%26aufirst%3DR.%2BD.%26aulast%3DLamant%26aufirst%3DL.%26aulast%3DMartin-Subero%26aufirst%3DJ.%2BI.%26aulast%3DLestou%26aufirst%3DV.%2BS.%26aulast%3DHarris%26aufirst%3DN.%2BL.%26aulast%3DM%25C3%25BCller-Hermelink%26aufirst%3DH.-K.%26aulast%3DSeymour%26aufirst%3DJ.%2BF.%26aulast%3DCampbell%26aufirst%3DL.%2BJ.%26aulast%3DHorsman%26aufirst%3DD.%2BE.%26aulast%3DAuvigne%26aufirst%3DI.%26aulast%3DEspinos%26aufirst%3DE.%26atitle%3DALK-positive%2520Diffuse%2520Large%2520B-cell%2520Lymphoma%2520is%2520Associated%2520with%2520Clathrin-ALK%2520Rearrangements%253A%2520report%2520of%25206%2520cases%26jtitle%3DBlood%26date%3D2003%26volume%3D102%26spage%3D2568%26epage%3D2573%26doi%3D10.1182%2Fblood-2003-03-0786" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Soda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Enomoto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takada, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamashita, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishikawa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujiwara, S. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurashina, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hatanaka, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bando, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohno, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishikawa, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aburatani, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sohara, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugiyama, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Man, H.</span></span> <span> </span><span class="NLM_article-title">Identification of the Transforming EML4–ALK Fusion Gene in Non-small-cell Lung Cancer</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>448</i></span>,  <span class="NLM_fpage">561</span>– <span class="NLM_lpage">566</span>, <span class="refDoi"> DOI: 10.1038/nature05945</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1038%2Fnature05945" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=17625570" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BD2sXosVSrtrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=448&publication_year=2007&pages=561-566&author=M.+Sodaauthor=Y.+L.+Choiauthor=M.+Enomotoauthor=S.+Takadaauthor=Y.+Yamashitaauthor=S.+Ishikawaauthor=S.+I.+Fujiwaraauthor=H.+Watanabeauthor=K.+Kurashinaauthor=H.+Hatanakaauthor=M.+Bandoauthor=S.+Ohnoauthor=Y.+Ishikawaauthor=H.+Aburataniauthor=T.+Nikiauthor=Y.+Soharaauthor=Y.+Sugiyamaauthor=H.+Man&title=Identification+of+the+Transforming+EML4%E2%80%93ALK+Fusion+Gene+in+Non-small-cell+Lung+Cancer&doi=10.1038%2Fnature05945"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer</span></div><div class="casAuthors">Soda, Manabu; Choi, Young Lim; Enomoto, Munehiro; Takada, Shuji; Yamashita, Yoshihiro; Ishikawa, Shunpei; Fujiwara, Shin-ichiro; Watanabe, Hideki; Kurashina, Kentaro; Hatanaka, Hisashi; Bando, Masashi; Ohno, Shoji; Ishikawa, Yuichi; Aburatani, Hiroyuki; Niki, Toshiro; Sohara, Yasunori; Sugiyama, Yukihiko; Mano, Hiroyuki</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">448</span>
        (<span class="NLM_cas:issue">7153</span>),
    <span class="NLM_cas:pages">561-566</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Improvement in the clin. outcome of lung cancer is likely to be achieved by identification of the mol. events that underlie its pathogenesis.  Here we show that a small inversion within chromosome 2p results in the formation of a fusion gene comprising portions of the echinoderm microtubule-assocd. protein-like 4 (EML4) gene and the anaplastic lymphoma kinase (ALK) gene in non-small-cell lung cancer (NSCLC) cells.  Mouse 3T3 fibroblasts forced to express this human fusion tyrosine kinase generated transformed foci in culture and s.c. tumors in nude mice.  The EML4-ALK fusion transcript was detected in 6.7% (5 out of 75) of NSCLC patients examd.; these individuals were distinct from those harboring mutations in the epidermal growth factor receptor gene.  Our data demonstrate that a subset of NSCLC patients may express a transforming fusion kinase that is a promising candidate for a therapeutic target as well as for a diagnostic mol. marker in NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomhAXuLtrJ6rVg90H21EOLACvtfcHk0lh14o6guKDitQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXosVSrtrs%253D&md5=7f567e80814b9ccc87e5bceeebb467a7</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1038%2Fnature05945&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature05945%26sid%3Dliteratum%253Aachs%26aulast%3DSoda%26aufirst%3DM.%26aulast%3DChoi%26aufirst%3DY.%2BL.%26aulast%3DEnomoto%26aufirst%3DM.%26aulast%3DTakada%26aufirst%3DS.%26aulast%3DYamashita%26aufirst%3DY.%26aulast%3DIshikawa%26aufirst%3DS.%26aulast%3DFujiwara%26aufirst%3DS.%2BI.%26aulast%3DWatanabe%26aufirst%3DH.%26aulast%3DKurashina%26aufirst%3DK.%26aulast%3DHatanaka%26aufirst%3DH.%26aulast%3DBando%26aufirst%3DM.%26aulast%3DOhno%26aufirst%3DS.%26aulast%3DIshikawa%26aufirst%3DY.%26aulast%3DAburatani%26aufirst%3DH.%26aulast%3DNiki%26aufirst%3DT.%26aulast%3DSohara%26aufirst%3DY.%26aulast%3DSugiyama%26aufirst%3DY.%26aulast%3DMan%26aufirst%3DH.%26atitle%3DIdentification%2520of%2520the%2520Transforming%2520EML4%25E2%2580%2593ALK%2520Fusion%2520Gene%2520in%2520Non-small-cell%2520Lung%2520Cancer%26jtitle%3DNature%26date%3D2007%26volume%3D448%26spage%3D561%26epage%3D566%26doi%3D10.1038%2Fnature05945" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chiarle, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voena, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ambrogio, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piva, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inghirami, G.</span></span> <span> </span><span class="NLM_article-title">The Anaplastic Lymphoma Kinase in the Pathogenesis of Cancer</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">11</span>– <span class="NLM_lpage">23</span>, <span class="refDoi"> DOI: 10.1038/nrc2291</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1038%2Fnrc2291" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=18097461" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhsVKku73P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2008&pages=11-23&author=R.+Chiarleauthor=C.+Voenaauthor=C.+Ambrogioauthor=R.+Pivaauthor=G.+Inghirami&title=The+Anaplastic+Lymphoma+Kinase+in+the+Pathogenesis+of+Cancer&doi=10.1038%2Fnrc2291"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">The anaplastic lymphoma kinase in the pathogenesis of cancer</span></div><div class="casAuthors">Chiarle, Roberto; Voena, Claudia; Ambrogio, Chiara; Piva, Roberto; Inghirami, Giorgio</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">11-23</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The receptor tyrosine kinase anaplastic lymphoma kinase (ALK) was first identified as part of a chromosomal translocation assocd. with some anaplastic large cell lymphomas (ALCLs).  Now data are emerging that indicate that ALK might be a valid therapeutic target in ALCL and that it could also be involved in other cancers.  Tyrosine kinases are involved in the pathogenesis of most cancers.  However, few tyrosine kinases have been shown to have a well-defined pathogenetic role in lymphomas.  The anaplastic lymphoma kinase (ALK) is the oncogene of most anaplastic large cell lymphomas (ALCL), driving transformation through many mol. mechanisms.  In this review, we will analyze how translocations or deregulated expression of ALK contribute to oncogenesis and how recent genetic or pharmacol. tools, aimed at neutralizing its activity, can represent the basis for the design of powerful combination therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5HoaZPQUiUrVg90H21EOLACvtfcHk0lh14o6guKDitQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhsVKku73P&md5=a57d7ab61be51664ca9f5b804c3e2910</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1038%2Fnrc2291&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2291%26sid%3Dliteratum%253Aachs%26aulast%3DChiarle%26aufirst%3DR.%26aulast%3DVoena%26aufirst%3DC.%26aulast%3DAmbrogio%26aufirst%3DC.%26aulast%3DPiva%26aufirst%3DR.%26aulast%3DInghirami%26aufirst%3DG.%26atitle%3DThe%2520Anaplastic%2520Lymphoma%2520Kinase%2520in%2520the%2520Pathogenesis%2520of%2520Cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2008%26volume%3D8%26spage%3D11%26epage%3D23%26doi%3D10.1038%2Fnrc2291" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pillay, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Govender, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chetty, R.</span></span> <span> </span><span class="NLM_article-title">ALK Protein Expression in Rhabdomyosarcomas</span>. <i>Histopathol.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">461</span>– <span class="NLM_lpage">467</span>, <span class="refDoi"> DOI: 10.1046/j.1365-2559.2002.01534.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1046%2Fj.1365-2559.2002.01534.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=12405914" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A280%3ADC%252BD38nkslWqtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2002&pages=461-467&author=K.+Pillayauthor=D.+Govenderauthor=R.+Chetty&title=ALK+Protein+Expression+in+Rhabdomyosarcomas&doi=10.1046%2Fj.1365-2559.2002.01534.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">ALK protein expression in rhabdomyosarcomas</span></div><div class="casAuthors">Pillay K; Govender D; Chetty R</div><div class="citationInfo"><span class="NLM_cas:title">Histopathology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">461-7</span>
        ISSN:<span class="NLM_cas:issn">0309-0167</span>.
    </div><div class="casAbstract">AIMS:  The ALK p80 chimeric protein is thought to be up-regulated as a result of the t(2;5) as classically seen in anaplastic large cell lymphoma.  However, rhabdomyosarcomas (in particular, the alveolar subtype) have also been noted to show expression of this protein.  This study set out to examine ALK expression in a large number of rhabdomyosarcomas.  METHODS AND RESULTS:  Eighty-three cases of rhabdomyosarcomas and 16 cases of malignant mixed mullerian tumours with a rhabdomyosarcomatous component were retrieved from the archives of the Department of Anatomical Pathology for the period 1983-2001.  The sections were stained with polyclonal ALK antibody.  There were 52 male and 30 female patients.  In one case, the gender of the patient was not indicated.  The ages ranged from 1 week to 77 years.  The most common site was the head and neck region, followed by the pelvis and extremities.  Thirty-one cases were of the alveolar subtype while 40 cases were embryonal.  There were four mixed embryonal/alveolar, six pleomorphic and two unclassifiable rhabdomyosarcomas.  Fourteen of the 31 (45%) alveolar rhabdomyosarcomas stained positively for the ALK protein, while only six of the 40 embryonal (15%) cases showed positivity.  One case each of the mixed embryonal/alveolar, pleomorphic and unclassified cases was also immunopositive.  The rhabdomyosarcomatous component in the malignant mixed mullerian tumours was positive in four of the 16 cases.  CONCLUSION:  We conclude that a proportion of alveolar rhabdomyosarcomas (in particular) exhibit ALK protein expression.  However, ALK expression is not restricted to this subtype.  An extension of this study is to determine if this over-expression is as a result of the t(2;5) translocation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSUup51yhOB7-kdrW1FkXG-fW6udTcc2ebuRn-mFp988Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD38nkslWqtA%253D%253D&md5=1996dd2820ce0f74bbd8031cab29e1a9</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1046%2Fj.1365-2559.2002.01534.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1046%252Fj.1365-2559.2002.01534.x%26sid%3Dliteratum%253Aachs%26aulast%3DPillay%26aufirst%3DK.%26aulast%3DGovender%26aufirst%3DD.%26aulast%3DChetty%26aufirst%3DR.%26atitle%3DALK%2520Protein%2520Expression%2520in%2520Rhabdomyosarcomas%26jtitle%3DHistopathol.%26date%3D2002%26volume%3D41%26spage%3D461%26epage%3D467%26doi%3D10.1046%2Fj.1365-2559.2002.01534.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mosse, Y. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laudenslager, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Longo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cole, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Attiyeh, E. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laquaglia, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sennett, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lynch, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perri, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laureys, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Speleman, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hakonarson, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torkamani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schork, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brodeur, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tonini, G. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rappaport, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Devoto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maris, J. M.</span></span> <span> </span><span class="NLM_article-title">Identification of ALK as a Major Familial Neuroblastoma Predisposition Gene</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>455</i></span>,  <span class="NLM_fpage">930</span>– <span class="NLM_lpage">935</span>, <span class="refDoi"> DOI: 10.1038/nature07261</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1038%2Fnature07261" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=18724359" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht1Ggur%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=455&publication_year=2008&pages=930-935&author=Y.+P.+Mosseauthor=M.+Laudenslagerauthor=L.+Longoauthor=K.+A.+Coleauthor=A.+Woodauthor=E.+F.+Attiyehauthor=M.+J.+Laquagliaauthor=R.+Sennettauthor=J.+E.+Lynchauthor=P.+Perriauthor=G.+Laureysauthor=F.+Spelemanauthor=C.+Kimauthor=C.+Houauthor=H.+Hakonarsonauthor=A.+Torkamaniauthor=N.+J.+Schorkauthor=G.+M.+Brodeurauthor=G.+P.+Toniniauthor=E.+Rappaportauthor=M.+Devotoauthor=J.+M.+Maris&title=Identification+of+ALK+as+a+Major+Familial+Neuroblastoma+Predisposition+Gene&doi=10.1038%2Fnature07261"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of ALK as a major familial neuroblastoma predisposition gene</span></div><div class="casAuthors">Mosse, Yael P.; Laudenslager, Marci; Longo, Luca; Cole, Kristina A.; Wood, Andrew; Attiyeh, Edward F.; Laquaglia, Michael J.; Sennett, Rachel; Lynch, Jill E.; Perri, Patrizia; Laureys, Genevieve; Speleman, Frank; Kim, Cecilia; Hou, Cuiping; Hakonarson, Hakon; Torkamani, Ali; Schork, Nicholas J.; Brodeur, Garrett M.; Tonini, Gian P.; Rappaport, Eric; Devoto, Marcella; Maris, John M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">455</span>
        (<span class="NLM_cas:issue">7215</span>),
    <span class="NLM_cas:pages">930-935</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Neuroblastoma is a childhood cancer that can be inherited, but the genetic etiol. is largely unknown.  Here we show that germline mutations in the anaplastic lymphoma kinase (ALK) gene explain most hereditary neuroblastomas, and that activating mutations can also be somatically acquired.  We first identified a significant linkage signal at chromosome bands 2p23-24 using a whole-genome scan in neuroblastoma pedigrees.  Re-sequencing of regional candidate genes identified three sep. germline missense mutations in the tyrosine kinase domain of ALK that segregated with the disease in eight sep. families.  Re-sequencing in 194 high-risk neuroblastoma samples showed somatically acquired mutations in the tyrosine kinase domain in 12.4% of samples.  Nine of the ten mutations map to crit. regions of the kinase domain and were predicted, with high probability, to be oncogenic drivers.  Mutations resulted in constitutive phosphorylation, and targeted knockdown of ALK mRNA resulted in profound inhibition of growth in all cell lines harboring mutant or amplified ALK, as well as in two out of six wild-type cell lines for ALK.  Our results demonstrate that heritable mutations of ALK are the main cause of familial neuroblastoma, and that germline or acquired activation of this cell-surface kinase is a tractable therapeutic target for this lethal pediatric malignancy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMNOcIFf5xjbVg90H21EOLACvtfcHk0lhHK3XYj550AQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht1Ggur%252FP&md5=bb998ef8f6bfbd85f928263e13954ce4</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1038%2Fnature07261&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature07261%26sid%3Dliteratum%253Aachs%26aulast%3DMosse%26aufirst%3DY.%2BP.%26aulast%3DLaudenslager%26aufirst%3DM.%26aulast%3DLongo%26aufirst%3DL.%26aulast%3DCole%26aufirst%3DK.%2BA.%26aulast%3DWood%26aufirst%3DA.%26aulast%3DAttiyeh%26aufirst%3DE.%2BF.%26aulast%3DLaquaglia%26aufirst%3DM.%2BJ.%26aulast%3DSennett%26aufirst%3DR.%26aulast%3DLynch%26aufirst%3DJ.%2BE.%26aulast%3DPerri%26aufirst%3DP.%26aulast%3DLaureys%26aufirst%3DG.%26aulast%3DSpeleman%26aufirst%3DF.%26aulast%3DKim%26aufirst%3DC.%26aulast%3DHou%26aufirst%3DC.%26aulast%3DHakonarson%26aufirst%3DH.%26aulast%3DTorkamani%26aufirst%3DA.%26aulast%3DSchork%26aufirst%3DN.%2BJ.%26aulast%3DBrodeur%26aufirst%3DG.%2BM.%26aulast%3DTonini%26aufirst%3DG.%2BP.%26aulast%3DRappaport%26aufirst%3DE.%26aulast%3DDevoto%26aufirst%3DM.%26aulast%3DMaris%26aufirst%3DJ.%2BM.%26atitle%3DIdentification%2520of%2520ALK%2520as%2520a%2520Major%2520Familial%2520Neuroblastoma%2520Predisposition%2520Gene%26jtitle%3DNature%26date%3D2008%26volume%3D455%26spage%3D930%26epage%3D935%26doi%3D10.1038%2Fnature07261" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Murugan, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xing, M.</span></span> <span> </span><span class="NLM_article-title">Anaplastic Thyroid Cancers Harbor Novel Oncogenic Mutations of the ALK Gene</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">4403</span>– <span class="NLM_lpage">4411</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-10-4041</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1158%2F0008-5472.CAN-10-4041" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=21596819" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC3MXotlersb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2011&pages=4403-4411&author=A.+K.+Muruganauthor=M.+Xing&title=Anaplastic+Thyroid+Cancers+Harbor+Novel+Oncogenic+Mutations+of+the+ALK+Gene&doi=10.1158%2F0008-5472.CAN-10-4041"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Anaplastic Thyroid Cancers Harbor Novel Oncogenic Mutations of the ALK Gene</span></div><div class="casAuthors">Murugan, Avaniyapuram Kannan; Xing, Mingzhao</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">4403-4411</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Thyroid cancer is the most common endocrine cancer, and targeted approaches to treat it pose considerable interest.  In this study, the authors report the discovery of ALK gene mutations in thyroid cancer that may rationalize clin. evaluation of anaplastic lymphoma kinase (ALK) inhibitors in this setting.  In undifferentiated anaplastic thyroid cancer (ATC), the authors identified 2 novel point mutations, C3592T and G3602A, in exon 23 of the ALK gene, with a prevalence of 11.11%, but found no mutations in the matched normal tissues or in well-differentiated thyroid cancers.  These 2 mutations, resulting in L1198F and G1201E amino acid changes, resp., both reside within the ALK tyrosine kinase domain where they dramatically increased tyrosine kinase activities.  Similarly, these mutations heightened the ability of ALK to activate the phosphatidylinositol 3-kinase (PI3K)/Akt and mitogen-activated protein (MAP) kinase pathways in established mouse cells.  Further investigations showed that these 2 ALK mutants strongly promoted cell focus formation, anchorage-independent growth, and cell invasion.  Similar oncogenic properties were obsd. in the neuroblastoma-assocd. ALK mutants K1062M and F1174L but not in wild-type ALK.  Overall, the authors' results reveal 2 novel gain-of-function mutations of ALK in certain ATCs, and they suggest efforts to clin. evaluate the use of ALK kinase inhibitors to treat patients who harbor ATCs with these mutations.  Cancer Res; 71(13); 4403-11.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLyuBgJ52gn7Vg90H21EOLACvtfcHk0lhHK3XYj550AQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXotlersb4%253D&md5=0316be9945baab3a8d08b6c75e2cd90f</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-10-4041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-10-4041%26sid%3Dliteratum%253Aachs%26aulast%3DMurugan%26aufirst%3DA.%2BK.%26aulast%3DXing%26aufirst%3DM.%26atitle%3DAnaplastic%2520Thyroid%2520Cancers%2520Harbor%2520Novel%2520Oncogenic%2520Mutations%2520of%2520the%2520ALK%2520Gene%26jtitle%3DCancer%2520Res.%26date%3D2011%26volume%3D71%26spage%3D4403%26epage%3D4411%26doi%3D10.1158%2F0008-5472.CAN-10-4041" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ren, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, Z.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crosby, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haack, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, J.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beausoleil, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moritz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Innocenti, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rush, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, X.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, T.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Comb, M. J.</span></span> <span> </span><span class="NLM_article-title">Identification of Anaplastic Lymphoma Kinase as a Potential Therapeutic Target in Ovarian Cancer</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>72</i></span>,  <span class="NLM_fpage">3312</span>– <span class="NLM_lpage">3323</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-11-3931</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1158%2F0008-5472.CAN-11-3931" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=22570254" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC38XpsFKku7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2012&pages=3312-3323&author=H.+Renauthor=Z.-P.+Tanauthor=X.+Zhuauthor=K.+Crosbyauthor=H.+Haackauthor=J.-M.+Renauthor=S.+Beausoleilauthor=A.+Moritzauthor=G.+Innocentiauthor=J.+Rushauthor=Y.+Zhangauthor=X.-M.+Zhouauthor=T.-L.+Guauthor=Y.-F.+Yangauthor=M.+J.+Comb&title=Identification+of+Anaplastic+Lymphoma+Kinase+as+a+Potential+Therapeutic+Target+in+Ovarian+Cancer&doi=10.1158%2F0008-5472.CAN-11-3931"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of Anaplastic Lymphoma Kinase as a Potential Therapeutic Target in Ovarian Cancer</span></div><div class="casAuthors">Ren, Hong; Tan, Zhi-Ping; Zhu, Xin; Crosby, Katherine; Haack, Herbert; Ren, Jian-Min; Beausoleil, Sean; Moritz, Albrecht; Innocenti, Gregory; Rush, John; Zhang, Yi; Zhou, Xin-Min; Gu, Ting-Lei; Yang, Yi-Feng; Comb, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3312-3323</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Findings suggest the use of ALK kinase inhibitors now in clin. development as potential agents for treatment of some patients with serous ovarian carcinoma or stromal sarcoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoi924EZXGeJ7Vg90H21EOLACvtfcHk0lhHK3XYj550AQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XpsFKku7w%253D&md5=a263a135244b307b864c098769d10a7a</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-11-3931&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-11-3931%26sid%3Dliteratum%253Aachs%26aulast%3DRen%26aufirst%3DH.%26aulast%3DTan%26aufirst%3DZ.-P.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DCrosby%26aufirst%3DK.%26aulast%3DHaack%26aufirst%3DH.%26aulast%3DRen%26aufirst%3DJ.-M.%26aulast%3DBeausoleil%26aufirst%3DS.%26aulast%3DMoritz%26aufirst%3DA.%26aulast%3DInnocenti%26aufirst%3DG.%26aulast%3DRush%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DX.-M.%26aulast%3DGu%26aufirst%3DT.-L.%26aulast%3DYang%26aufirst%3DY.-F.%26aulast%3DComb%26aufirst%3DM.%2BJ.%26atitle%3DIdentification%2520of%2520Anaplastic%2520Lymphoma%2520Kinase%2520as%2520a%2520Potential%2520Therapeutic%2520Target%2520in%2520Ovarian%2520Cancer%26jtitle%3DCancer%2520Res.%26date%3D2012%26volume%3D72%26spage%3D3312%26epage%3D3323%26doi%3D10.1158%2F0008-5472.CAN-11-3931" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cui, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tran-Dube, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nambu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kung, P.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pairish, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Funk, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Botrous, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McTigue, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grodsky, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Padrique, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alton, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timofeevski, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamazaki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christensen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mroczkowski, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bender, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kania, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, M. P.</span></span> <span> </span><span class="NLM_article-title">Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective dual Inhibitor of Mesenchymal–Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">6342</span>– <span class="NLM_lpage">6363</span>, <span class="refDoi"> DOI: 10.1021/jm2007613</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm2007613" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtVegtLrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=6342-6363&author=J.+J.+Cuiauthor=M.+Tran-Dubeauthor=H.+Shenauthor=M.+Nambuauthor=P.-P.+Kungauthor=M.+Pairishauthor=L.+Jiaauthor=J.+Mengauthor=L.+Funkauthor=I.+Botrousauthor=M.+McTigueauthor=N.+Grodskyauthor=K.+Ryanauthor=E.+Padriqueauthor=G.+Altonauthor=S.+Timofeevskiauthor=S.+Yamazakiauthor=Q.+Liauthor=H.+Zouauthor=J.+Christensenauthor=B.+Mroczkowskiauthor=S.+Benderauthor=R.+S.+Kaniaauthor=M.+P.+Edwards&title=Structure+Based+Drug+Design+of+Crizotinib+%28PF-02341066%29%2C+a+Potent+and+Selective+dual+Inhibitor+of+Mesenchymal%E2%80%93Epithelial+Transition+Factor+%28c-MET%29+Kinase+and+Anaplastic+Lymphoma+Kinase+%28ALK%29&doi=10.1021%2Fjm2007613"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal-Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)</span></div><div class="casAuthors">Cui, J. Jean; Tran-Dube, Michelle; Shen, Hong; Nambu, Mitchell; Kung, Pei-Pei; Pairish, Mason; Jia, Lei; Meng, Jerry; Funk, Lee; Botrous, Iriny; McTigue, Michele; Grodsky, Neil; Ryan, Kevin; Padrique, Ellen; Alton, Gordon; Timofeevski, Sergei; Yamazaki, Shinji; Li, Qiuhua; Zou, Helen; Christensen, James; Mroczkowski, Barbara; Bender, Steve; Kania, Robert S.; Edwards, Martin P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">6342-6363</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Because of the crit. roles of aberrant signaling in cancer, both c-MET and ALK receptor tyrosine kinases are attractive oncol. targets for therapeutic intervention.  The cocrystal structure of 3 (PHA-665752), bound to c-MET kinase domain, revealed a novel ATP site environment, which served as the target to guide parallel, multiattribute drug design.  A novel 2-amino-5-aryl-3-benzyloxypyridine series was created to more effectively make the key interactions achieved with 3.  In the novel series, the 2-aminopyridine core allowed a 3-benzyloxy group to reach into the same pocket as the 2,6-dichlorophenyl group of 3 via a more direct vector and thus with a better ligand efficiency (LE).  Further optimization of the lead series generated the clin. candidate crizotinib (PF-02341066), which demonstrated potent in vitro and in vivo c-MET kinase and ALK inhibition, effective tumor growth inhibition, and good pharmaceutical properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHs_cKJ-U3t7Vg90H21EOLACvtfcHk0lhfuGs6lIhDZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtVegtLrN&md5=dbab4c1b3e7c76180dbad04be2b6a474</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Fjm2007613&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm2007613%26sid%3Dliteratum%253Aachs%26aulast%3DCui%26aufirst%3DJ.%2BJ.%26aulast%3DTran-Dube%26aufirst%3DM.%26aulast%3DShen%26aufirst%3DH.%26aulast%3DNambu%26aufirst%3DM.%26aulast%3DKung%26aufirst%3DP.-P.%26aulast%3DPairish%26aufirst%3DM.%26aulast%3DJia%26aufirst%3DL.%26aulast%3DMeng%26aufirst%3DJ.%26aulast%3DFunk%26aufirst%3DL.%26aulast%3DBotrous%26aufirst%3DI.%26aulast%3DMcTigue%26aufirst%3DM.%26aulast%3DGrodsky%26aufirst%3DN.%26aulast%3DRyan%26aufirst%3DK.%26aulast%3DPadrique%26aufirst%3DE.%26aulast%3DAlton%26aufirst%3DG.%26aulast%3DTimofeevski%26aufirst%3DS.%26aulast%3DYamazaki%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DZou%26aufirst%3DH.%26aulast%3DChristensen%26aufirst%3DJ.%26aulast%3DMroczkowski%26aufirst%3DB.%26aulast%3DBender%26aufirst%3DS.%26aulast%3DKania%26aufirst%3DR.%2BS.%26aulast%3DEdwards%26aufirst%3DM.%2BP.%26atitle%3DStructure%2520Based%2520Drug%2520Design%2520of%2520Crizotinib%2520%2528PF-02341066%2529%252C%2520a%2520Potent%2520and%2520Selective%2520dual%2520Inhibitor%2520of%2520Mesenchymal%25E2%2580%2593Epithelial%2520Transition%2520Factor%2520%2528c-MET%2529%2520Kinase%2520and%2520Anaplastic%2520Lymphoma%2520Kinase%2520%2528ALK%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D6342%26epage%3D6363%26doi%3D10.1021%2Fjm2007613" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Krause, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Etten, R. A.</span></span> <span> </span><span class="NLM_article-title">Tyrosine Kinases as Targets for Cancer Therapy</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>353</i></span>,  <span class="NLM_fpage">172</span>– <span class="NLM_lpage">187</span>, <span class="refDoi"> DOI: 10.1056/NEJMra044389</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1056%2FNEJMra044389" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=16014887" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BD2MXmtFClsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=353&publication_year=2005&pages=172-187&author=D.+S.+Krauseauthor=R.+A.+Van+Etten&title=Tyrosine+Kinases+as+Targets+for+Cancer+Therapy&doi=10.1056%2FNEJMra044389"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Tyrosine kinases as targets for cancer therapy</span></div><div class="casAuthors">Krause, Daniela S.; Van Etten, Richard A.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">353</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">172-187</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">A review discusses the mechanisms of aberrant tyrosine kinase signaling and strategies to inhibit TKs in cancer.  It also summarizes the status of TK-directed cancer therapies, and discusses challenges and prospects for the future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq89QOl9E0UMLVg90H21EOLACvtfcHk0lhfuGs6lIhDZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXmtFClsbs%253D&md5=0a98c8840a983300f6b0743673cf480c</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1056%2FNEJMra044389&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMra044389%26sid%3Dliteratum%253Aachs%26aulast%3DKrause%26aufirst%3DD.%2BS.%26aulast%3DVan%2BEtten%26aufirst%3DR.%2BA.%26atitle%3DTyrosine%2520Kinases%2520as%2520Targets%2520for%2520Cancer%2520Therapy%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2005%26volume%3D353%26spage%3D172%26epage%3D187%26doi%3D10.1056%2FNEJMra044389" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roskoski, R.,  Jr</span></span> <span> </span><span class="NLM_article-title">Anaplastic Lymphoma Kinase (ALK) Inhibitors in the Treatment of ALK-driven Lung Cancers</span>. <i>Pharmacol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>117</i></span>,  <span class="NLM_fpage">343</span>– <span class="NLM_lpage">356</span>, <span class="refDoi"> DOI: 10.1016/j.phrs.2017.01.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1016%2Fj.phrs.2017.01.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=28077299" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlaktbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=117&publication_year=2017&pages=343-356&author=R.+Roskoski&title=Anaplastic+Lymphoma+Kinase+%28ALK%29+Inhibitors+in+the+Treatment+of+ALK-driven+Lung+Cancers&doi=10.1016%2Fj.phrs.2017.01.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Anaplastic lymphoma kinase (ALK) inhibitors in the treatment of ALK-driven lung cancers</span></div><div class="casAuthors">Roskoski, Robert, Jr.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">117</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">343-356</span>CODEN:
                <span class="NLM_cas:coden">PHMREP</span>;
        ISSN:<span class="NLM_cas:issn">1043-6618</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Anaplastic lymphoma kinase is expressed in two-thirds of the anaplastic large-cell lymphomas as an NPM-ALK fusion protein.  Physiol. ALK is a receptor protein-tyrosine kinase within the insulin receptor superfamily of proteins that participates in nervous system development.  The EML4-ALK fusion protein and four other ALK-fusion proteins play a fundamental role in the development in about 5% of non-small cell lung cancers.  The amino-terminal portions of the ALK fusion proteins result in dimerization and subsequent activation of the ALK protein kinase domain that plays a key role in the pathogenesis of various tumors.  Downstream signaling from the ALK fusion protein leads to the activation of the Ras/Raf/MEK/ERK1/2 cell proliferation module and the JAK/STAT cell survival pathways.  Moreover, nearly two dozen ALK activating mutations are involved in the pathogenesis of childhood neuroblastomas.  The occurrence of oncogenic ALK-fusion proteins, particularly in non-small cell lung cancer, has fostered considerable interest in the development of ALK inhibitors.  Crizotinib was the first such inhibitor approved by the US Food and Drug Administration for the treatment of ALK-pos. non-small cell lung cancer in 2011.  The median time for the emergence of crizotinib drug resistance is 10.5 mo after the initiation of therapy.  Such resistance prompted the development of second-generation drugs including ceritinib and alectinib, which are approved for the treatment of non-small cell lung cancer.  Unlike the single gatekeeper mutation that occurs in drug-resistant epidermal growth factor receptor in lung cancer, nearly a dozen different mutations in the catalytic domain of ALK fusion proteins have been discovered that result in crizotinib resistance.  Crizotinib, ceritinib, and alectinib form a complex within the front cleft between the small and large lobes of an inactive ALK protein-kinase domain with a compact activation segment.  These drugs are classified as type I1/2 B inhibitors because they bind to an inactive enzyme and they do not extend past the gatekeeper into the back pocket of the drug binding site.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoq0rrYNRqutrVg90H21EOLACvtfcHk0lgt_9Rp56s3_w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlaktbo%253D&md5=49200353921714b975e564df79631578</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.phrs.2017.01.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.phrs.2017.01.007%26sid%3Dliteratum%253Aachs%26aulast%3DRoskoski%26aufirst%3DR.%26atitle%3DAnaplastic%2520Lymphoma%2520Kinase%2520%2528ALK%2529%2520Inhibitors%2520in%2520the%2520Treatment%2520of%2520ALK-driven%2520Lung%2520Cancers%26jtitle%3DPharmacol.%2520Res.%26date%3D2017%26volume%3D117%26spage%3D343%26epage%3D356%26doi%3D10.1016%2Fj.phrs.2017.01.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marsilje, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pei, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uno, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warmuth, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarkisova, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steffy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pferdekamper, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joseph, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuntland, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steensma, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chopiuk, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, W. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richmond, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groessl, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, Y.-Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phimister, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aycinena, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bursulaya, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karanewsky, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seidel, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michellys, P.-Y.</span></span> <span> </span><span class="NLM_article-title">Synthesis, Structure–activity Relationships, and in Vivo Efficacy of the Novel Potent and Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor 5-Chloro-N 2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl) phenyl)-N 4-(2-(isopropylsulfonyl) phenyl) Pyrimidine-2, 4-diamine (LDK378) Currently in Phase 1 and Phase 2 Clinical Trials</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">5675</span>– <span class="NLM_lpage">5690</span>, <span class="refDoi"> DOI: 10.1021/jm400402q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400402q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC3sXptVWjs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=5675-5690&author=T.+H.+Marsiljeauthor=W.+Peiauthor=B.+Chenauthor=W.+Luauthor=T.+Unoauthor=Y.+Jinauthor=T.+Jiangauthor=S.+Kimauthor=N.+Liauthor=M.+Warmuthauthor=Y.+Sarkisovaauthor=F.+Sunauthor=A.+Steffyauthor=A.+C.+Pferdekamperauthor=A.+G.+Liauthor=S.+B.+Josephauthor=Y.+Kimauthor=B.+Liuauthor=T.+Tuntlandauthor=X.+Cuiauthor=N.+S.+Grayauthor=R.+Steensmaauthor=Y.+Wanauthor=J.+Jiangauthor=G.+Chopiukauthor=J.+Liauthor=W.+P.+Gordonauthor=W.+Richmondauthor=K.+Johnsonauthor=J.+Changauthor=T.+Groesslauthor=Y.-Q.+Heauthor=A.+Phimisterauthor=A.+Aycinenaauthor=C.+C.+Leeauthor=B.+Bursulayaauthor=D.+S.+Karanewskyauthor=H.+M.+Seidelauthor=J.+L.+Harrisauthor=P.-Y.+Michellys&title=Synthesis%2C+Structure%E2%80%93activity+Relationships%2C+and+in+Vivo+Efficacy+of+the+Novel+Potent+and+Selective+Anaplastic+Lymphoma+Kinase+%28ALK%29+Inhibitor+5-Chloro-N+2-%282-isopropoxy-5-methyl-4-%28piperidin-4-yl%29+phenyl%29-N+4-%282-%28isopropylsulfonyl%29+phenyl%29+Pyrimidine-2%2C+4-diamine+%28LDK378%29+Currently+in+Phase+1+and+Phase+2+Clinical+Trials&doi=10.1021%2Fjm400402q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis, Structure-Activity Relationships, and in Vivo Efficacy of the Novel Potent and Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor 5-Chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) Currently in Phase 1 and Phase 2 Clinical Trials</span></div><div class="casAuthors">Marsilje, Thomas H.; Pei, Wei; Chen, Bei; Lu, Wenshuo; Uno, Tetsuo; Jin, Yunho; Jiang, Tao; Kim, Sungjoon; Li, Nanxin; Warmuth, Markus; Sarkisova, Yelena; Sun, Frank; Steffy, Auzon; Pferdekamper, AnneMarie C.; Li, Allen G.; Joseph, Sean B.; Kim, Young; Liu, Bo; Tuntland, Tove; Cui, Xiaoming; Gray, Nathanael S.; Steensma, Ruo; Wan, Yongqin; Jiang, Jiqing; Chopiuk, Greg; Li, Jie; Gordon, W. Perry; Richmond, Wendy; Johnson, Kevin; Chang, Jonathan; Groessl, Todd; He, You-Qun; Phimister, Andrew; Aycinena, Alex; Lee, Christian C.; Bursulaya, Badry; Karanewsky, Donald S.; Seidel, H. Martin; Harris, Jennifer L.; Michellys, Pierre-Yves</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">5675-5690</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The synthesis, preclin. profile, and in vivo efficacy in rat xenograft models of the novel and selective anaplastic lymphoma kinase inhibitor (I; LDK378) are described.  In this initial report, preliminary structure-activity relationships (SARs) are described as well as the rational design strategy employed to overcome the development deficiencies of the first generation ALK inhibitor (II; TAE684).  Compd. I is currently in phase 1 and phase 2 clin. trials with substantial antitumor activity being obsd. in ALK-pos. cancer patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZ-y7ZuX2XLLVg90H21EOLACvtfcHk0lgt_9Rp56s3_w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXptVWjs7g%253D&md5=4b8f66e4acb27efe814956d7d0016068</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Fjm400402q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400402q%26sid%3Dliteratum%253Aachs%26aulast%3DMarsilje%26aufirst%3DT.%2BH.%26aulast%3DPei%26aufirst%3DW.%26aulast%3DChen%26aufirst%3DB.%26aulast%3DLu%26aufirst%3DW.%26aulast%3DUno%26aufirst%3DT.%26aulast%3DJin%26aufirst%3DY.%26aulast%3DJiang%26aufirst%3DT.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DN.%26aulast%3DWarmuth%26aufirst%3DM.%26aulast%3DSarkisova%26aufirst%3DY.%26aulast%3DSun%26aufirst%3DF.%26aulast%3DSteffy%26aufirst%3DA.%26aulast%3DPferdekamper%26aufirst%3DA.%2BC.%26aulast%3DLi%26aufirst%3DA.%2BG.%26aulast%3DJoseph%26aufirst%3DS.%2BB.%26aulast%3DKim%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DB.%26aulast%3DTuntland%26aufirst%3DT.%26aulast%3DCui%26aufirst%3DX.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DSteensma%26aufirst%3DR.%26aulast%3DWan%26aufirst%3DY.%26aulast%3DJiang%26aufirst%3DJ.%26aulast%3DChopiuk%26aufirst%3DG.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DGordon%26aufirst%3DW.%2BP.%26aulast%3DRichmond%26aufirst%3DW.%26aulast%3DJohnson%26aufirst%3DK.%26aulast%3DChang%26aufirst%3DJ.%26aulast%3DGroessl%26aufirst%3DT.%26aulast%3DHe%26aufirst%3DY.-Q.%26aulast%3DPhimister%26aufirst%3DA.%26aulast%3DAycinena%26aufirst%3DA.%26aulast%3DLee%26aufirst%3DC.%2BC.%26aulast%3DBursulaya%26aufirst%3DB.%26aulast%3DKaranewsky%26aufirst%3DD.%2BS.%26aulast%3DSeidel%26aufirst%3DH.%2BM.%26aulast%3DHarris%26aufirst%3DJ.%2BL.%26aulast%3DMichellys%26aufirst%3DP.-Y.%26atitle%3DSynthesis%252C%2520Structure%25E2%2580%2593activity%2520Relationships%252C%2520and%2520in%2520Vivo%2520Efficacy%2520of%2520the%2520Novel%2520Potent%2520and%2520Selective%2520Anaplastic%2520Lymphoma%2520Kinase%2520%2528ALK%2529%2520Inhibitor%25205-Chloro-N%25202-%25282-isopropoxy-5-methyl-4-%2528piperidin-4-yl%2529%2520phenyl%2529-N%25204-%25282-%2528isopropylsulfonyl%2529%2520phenyl%2529%2520Pyrimidine-2%252C%25204-diamine%2520%2528LDK378%2529%2520Currently%2520in%2520Phase%25201%2520and%2520Phase%25202%2520Clinical%2520Trials%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D5675%26epage%3D5690%26doi%3D10.1021%2Fjm400402q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kinoshita, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobayashi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asoh, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furuichi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawada, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hara, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohwada, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hattori, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyagi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, W.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, M.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takanashi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsukaguchi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakamoto, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsukuda, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oikawa, N.</span></span> <span> </span><span class="NLM_article-title">9-substituted 6, 6-dimethyl-11-oxo-6, 11-dihydro-5 H-benzo [b] carbazoles as Highly Selective and Potent Anaplastic Lymphoma Kinase Inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">6286</span>– <span class="NLM_lpage">6294</span>, <span class="refDoi"> DOI: 10.1021/jm200652u</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm200652u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtVOns7vP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=6286-6294&author=K.+Kinoshitaauthor=T.+Kobayashiauthor=K.+Asohauthor=N.+Furuichiauthor=T.+Itoauthor=H.+Kawadaauthor=S.+Haraauthor=J.+Ohwadaauthor=K.+Hattoriauthor=T.+Miyagiauthor=W.-S.+Hongauthor=M.-J.+Parkauthor=K.+Takanashiauthor=T.+Tsukaguchiauthor=H.+Sakamotoauthor=T.+Tsukudaauthor=N.+Oikawa&title=9-substituted+6%2C+6-dimethyl-11-oxo-6%2C+11-dihydro-5+H-benzo+%5Bb%5D+carbazoles+as+Highly+Selective+and+Potent+Anaplastic+Lymphoma+Kinase+Inhibitors&doi=10.1021%2Fjm200652u"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">9-Substituted 6,6-Dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazoles as Highly Selective and Potent Anaplastic Lymphoma Kinase Inhibitors</span></div><div class="casAuthors">Kinoshita, Kazutomo; Kobayashi, Takamitsu; Asoh, Kohsuke; Furuichi, Noriyuki; Ito, Toshiya; Kawada, Hatsuo; Hara, Sousuke; Ohwada, Jun; Hattori, Kazuo; Miyagi, Takuho; Hong, Woo-Sang; Park, Min-Jeong; Takanashi, Kenji; Tsukaguchi, Toshiyuki; Sakamoto, Hiroshi; Tsukuda, Takuo; Oikawa, Nobuhiro</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">6286-6294</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">9-Substituted 6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazoles were discovered as highly selective and potent anaplastic lymphoma kinase (ALK) inhibitors by structure-based drug design.  The high target selectivity was achieved by introducing a substituent close to the E0 region of the ATP binding site, which has a unique amino acid sequence.  Among the identified inhibitors, compd. 13d (I) showed highly selective and potent inhibitory activity against ALK with an IC50 value of 2.9 nM and strong antiproliferative activity against KARPAS-299 with an IC50 value of 12.8 nM.  The compd. also displayed significant antitumor efficacy in an established ALK fusion gene-pos. anaplastic large-cell lymphoma (ALCL) xenograft model in mice without body wt. loss.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrfpJsdIdDvO7Vg90H21EOLACvtfcHk0lgt_9Rp56s3_w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtVOns7vP&md5=6293368243c840e12beefc8c8d6bb69a</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Fjm200652u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200652u%26sid%3Dliteratum%253Aachs%26aulast%3DKinoshita%26aufirst%3DK.%26aulast%3DKobayashi%26aufirst%3DT.%26aulast%3DAsoh%26aufirst%3DK.%26aulast%3DFuruichi%26aufirst%3DN.%26aulast%3DIto%26aufirst%3DT.%26aulast%3DKawada%26aufirst%3DH.%26aulast%3DHara%26aufirst%3DS.%26aulast%3DOhwada%26aufirst%3DJ.%26aulast%3DHattori%26aufirst%3DK.%26aulast%3DMiyagi%26aufirst%3DT.%26aulast%3DHong%26aufirst%3DW.-S.%26aulast%3DPark%26aufirst%3DM.-J.%26aulast%3DTakanashi%26aufirst%3DK.%26aulast%3DTsukaguchi%26aufirst%3DT.%26aulast%3DSakamoto%26aufirst%3DH.%26aulast%3DTsukuda%26aufirst%3DT.%26aulast%3DOikawa%26aufirst%3DN.%26atitle%3D9-substituted%25206%252C%25206-dimethyl-11-oxo-6%252C%252011-dihydro-5%2520H-benzo%2520%255Bb%255D%2520carbazoles%2520as%2520Highly%2520Selective%2520and%2520Potent%2520Anaplastic%2520Lymphoma%2520Kinase%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D6286%26epage%3D6294%26doi%3D10.1021%2Fjm200652u" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, W.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romero, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohlmann, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dwight, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dodd, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toms, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parillon, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anjum, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keats, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wardwell, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ning, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moran, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohemmad, Q. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jang, H. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clackson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narasimhan, N. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivera, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalgarno, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shakespeare, W. C.</span></span> <span> </span><span class="NLM_article-title">Discovery of Brigatinib (AP26113), a Phosphine Oxide-containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma Kinase</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">4948</span>– <span class="NLM_lpage">4964</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00306</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00306" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC28XntlCgur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=4948-4964&author=W.-S.+Huangauthor=S.+Liuauthor=D.+Zouauthor=M.+Thomasauthor=Y.+Wangauthor=T.+Zhouauthor=J.+Romeroauthor=A.+Kohlmannauthor=F.+Liauthor=J.+Qiauthor=L.+Caiauthor=T.+A.+Dwightauthor=Y.+Xuauthor=R.+Xuauthor=R.+Doddauthor=A.+Tomsauthor=L.+Parillonauthor=X.+Luauthor=R.+Anjumauthor=S.+Zhangauthor=F.+Wangauthor=J.+Keatsauthor=S.+D.+Wardwellauthor=Y.+Ningauthor=Q.+Xuauthor=L.+E.+Moranauthor=Q.+K.+Mohemmadauthor=H.+G.+Jangauthor=T.+Clacksonauthor=N.+I.+Narasimhanauthor=V.+M.+Riveraauthor=X.+Zhuauthor=D.+Dalgarnoauthor=W.+C.+Shakespeare&title=Discovery+of+Brigatinib+%28AP26113%29%2C+a+Phosphine+Oxide-containing%2C+Potent%2C+Orally+Active+Inhibitor+of+Anaplastic+Lymphoma+Kinase&doi=10.1021%2Facs.jmedchem.6b00306"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma Kinase</span></div><div class="casAuthors">Huang, Wei-Sheng; Liu, Shuangying; Zou, Dong; Thomas, Mathew; Wang, Yihan; Zhou, Tianjun; Romero, Jan; Kohlmann, Anna; Li, Feng; Qi, Jiwei; Cai, Lisi; Dwight, Timothy A.; Xu, Yongjin; Xu, Rongsong; Dodd, Rory; Toms, Angela; Parillon, Lois; Lu, Xiaohui; Anjum, Rana; Zhang, Sen; Wang, Frank; Keats, Jeffrey; Wardwell, Scott D.; Ning, Yaoyu; Xu, Qihong; Moran, Lauren E.; Mohemmad, Qurish K.; Jang, Hyun Gyung; Clackson, Tim; Narasimhan, Narayana I.; Rivera, Victor M.; Zhu, Xiaotian; Dalgarno, David; Shakespeare, William C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4948-4964</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In the treatment of echinoderm microtubule-assocd. protein-like 4 (EML4)-anaplastic lymphoma kinase pos. (ALK+) non-small-cell lung cancer (NSCLC), secondary mutations within the ALK kinase domain have emerged as a major resistance mechanism to both first- and second-generation ALK inhibitors.  This report describes the design and synthesis of a series of 2,4-diarylaminopyrimidine-based potent and selective ALK inhibitors culminating in identification of the investigational clin. candidate brigatinib.  A unique structural feature of brigatinib is a phosphine oxide, an overlooked but novel hydrogen-bond acceptor that drives potency and selectivity in addn. to favorable ADME properties.  Brigatinib displayed low nanomolar IC50s against native ALK and all tested clin. relevant ALK mutants in both enzyme-based biochem. and cell-based viability assays and demonstrated efficacy in multiple ALK+ xenografts in mice, including Karpas-299 (anaplastic large-cell lymphomas [ALCL]) and H3122 (NSCLC).  Brigatinib represents the most clin. advanced phosphine oxide-contg. drug candidate to date and is currently being evaluated in a global phase 2 registration trial.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5_iqprSA4QbVg90H21EOLACvtfcHk0li0gbXL32_m9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XntlCgur8%253D&md5=4cb93ff587579c97fda8aff0c7d43317</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00306%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DW.-S.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DZou%26aufirst%3DD.%26aulast%3DThomas%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DT.%26aulast%3DRomero%26aufirst%3DJ.%26aulast%3DKohlmann%26aufirst%3DA.%26aulast%3DLi%26aufirst%3DF.%26aulast%3DQi%26aufirst%3DJ.%26aulast%3DCai%26aufirst%3DL.%26aulast%3DDwight%26aufirst%3DT.%2BA.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DR.%26aulast%3DDodd%26aufirst%3DR.%26aulast%3DToms%26aufirst%3DA.%26aulast%3DParillon%26aufirst%3DL.%26aulast%3DLu%26aufirst%3DX.%26aulast%3DAnjum%26aufirst%3DR.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DKeats%26aufirst%3DJ.%26aulast%3DWardwell%26aufirst%3DS.%2BD.%26aulast%3DNing%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DQ.%26aulast%3DMoran%26aufirst%3DL.%2BE.%26aulast%3DMohemmad%26aufirst%3DQ.%2BK.%26aulast%3DJang%26aufirst%3DH.%2BG.%26aulast%3DClackson%26aufirst%3DT.%26aulast%3DNarasimhan%26aufirst%3DN.%2BI.%26aulast%3DRivera%26aufirst%3DV.%2BM.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DDalgarno%26aufirst%3DD.%26aulast%3DShakespeare%26aufirst%3DW.%2BC.%26atitle%3DDiscovery%2520of%2520Brigatinib%2520%2528AP26113%2529%252C%2520a%2520Phosphine%2520Oxide-containing%252C%2520Potent%252C%2520Orally%2520Active%2520Inhibitor%2520of%2520Anaplastic%2520Lymphoma%2520Kinase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D4948%26epage%3D4964%26doi%3D10.1021%2Facs.jmedchem.6b00306" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, P. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brooun, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deal, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, Y.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dinh, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engstrom, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kania, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kath, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lingardo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McTigue, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmer, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sach, N. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smeal, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timofeevski, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, M. P.</span></span> <span> </span><span class="NLM_article-title">Discovery of (10 R)-7-Amino-12-fluoro-2, 10, 16-trimethyl-15-oxo-10, 15, 16, 17-tetrahydro-2H-8, 4-(metheno) pyrazolo [4, 3-h][2, 5, 11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a Macrocyclic Inhibitor of Anaplastic Lymphoma Kinase (ALK) and c-ROS Oncogene 1 (ROS1) with Preclinical Brain Exposure and Broad-spectrum Potency against ALK-resistant mutations</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">4720</span>– <span class="NLM_lpage">4744</span>, <span class="refDoi"> DOI: 10.1021/jm500261q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500261q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC2cXnvVSgtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=4720-4744&author=T.+W.+Johnsonauthor=P.+F.+Richardsonauthor=S.+Baileyauthor=A.+Broounauthor=B.+J.+Burkeauthor=M.+R.+Collinsauthor=J.+J.+Cuiauthor=J.+G.+Dealauthor=Y.-L.+Dengauthor=D.+Dinhauthor=L.+D.+Engstromauthor=M.+Heauthor=J.+Hoffmanauthor=R.+L.+Hoffmanauthor=Q.+Huangauthor=R.+S.+Kaniaauthor=J.+C.+Kathauthor=H.+Lamauthor=J.+L.+Lamauthor=P.+T.+Leauthor=L.+Lingardoauthor=W.+Liuauthor=M.+McTigueauthor=C.+L.+Palmerauthor=N.+W.+Sachauthor=T.+Smealauthor=G.+L.+Smithauthor=A.+E.+Stewartauthor=S.+Timofeevskiauthor=H.+Zhuauthor=J.+Zhuauthor=H.+Y.+Zouauthor=M.+P.+Edwards&title=Discovery+of+%2810+R%29-7-Amino-12-fluoro-2%2C+10%2C+16-trimethyl-15-oxo-10%2C+15%2C+16%2C+17-tetrahydro-2H-8%2C+4-%28metheno%29+pyrazolo+%5B4%2C+3-h%5D%5B2%2C+5%2C+11%5D-benzoxadiazacyclotetradecine-3-carbonitrile+%28PF-06463922%29%2C+a+Macrocyclic+Inhibitor+of+Anaplastic+Lymphoma+Kinase+%28ALK%29+and+c-ROS+Oncogene+1+%28ROS1%29+with+Preclinical+Brain+Exposure+and+Broad-spectrum+Potency+against+ALK-resistant+mutations&doi=10.1021%2Fjm500261q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of (10R)-7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a Macrocyclic Inhibitor of Anaplastic Lymphoma Kinase (ALK) and c-ros Oncogene 1 (ROS1) with Preclinical Brain Exposure and Broad-Spectrum Potency against ALK-Resistant Mutations</span></div><div class="casAuthors">Johnson, Ted W.; Richardson, Paul F.; Bailey, Simon; Brooun, Alexei; Burke, Benjamin J.; Collins, Michael R.; Cui, J. Jean; Deal, Judith G.; Deng, Ya-Li; Dinh, Dac; Engstrom, Lars D.; He, Mingying; Hoffman, Jacqui; Hoffman, Robert L.; Huang, Qinhua; Kania, Robert S.; Kath, John C.; Lam, Hieu; Lam, Justine L.; Le, Phuong T.; Lingardo, Laura; Liu, Wei; McTigue, Michele; Palmer, Cynthia L.; Sach, Neal W.; Smeal, Tod; Smith, Graham L.; Stewart, Albert E.; Timofeevski, Sergei; Zhu, Huichun; Zhu, Jinjiang; Zou, Helen Y.; Edwards, Martin P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4720-4744</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Although crizotinib demonstrates robust efficacy in anaplastic lymphoma kinase (ALK)-pos. non-small-cell lung carcinoma patients, progression during treatment eventually develops.  Resistant patient samples revealed a variety of point mutations in the kinase domain of ALK, including the L1196M gatekeeper mutation.  In addn., some patients progress due to cancer metastasis in the brain.  Using structure-based drug design, lipophilic efficiency, and phys.-property-based optimization, highly potent macrocyclic ALK inhibitors were prepd. with good absorption, distribution, metab., and excretion (ADME), low propensity for p-glycoprotein 1-mediated efflux, and good passive permeability.  These structurally unusual macrocyclic inhibitors were potent against wild-type ALK and clin. reported ALK kinase domain mutations.  Significant synthetic challenges were overcome, utilizing novel transformations to enable the use of these macrocycles in drug discovery paradigms.  This work led to the discovery of 8k (PF-06463922), combining broad-spectrum potency, central nervous system ADME, and a high degree of kinase selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqXkb49ad31bVg90H21EOLACvtfcHk0lhZXpgK2RJtBA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXnvVSgtL4%253D&md5=db21844f8e9a2f9ca5953bca56ad7b1c</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Fjm500261q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500261q%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DT.%2BW.%26aulast%3DRichardson%26aufirst%3DP.%2BF.%26aulast%3DBailey%26aufirst%3DS.%26aulast%3DBrooun%26aufirst%3DA.%26aulast%3DBurke%26aufirst%3DB.%2BJ.%26aulast%3DCollins%26aufirst%3DM.%2BR.%26aulast%3DCui%26aufirst%3DJ.%2BJ.%26aulast%3DDeal%26aufirst%3DJ.%2BG.%26aulast%3DDeng%26aufirst%3DY.-L.%26aulast%3DDinh%26aufirst%3DD.%26aulast%3DEngstrom%26aufirst%3DL.%2BD.%26aulast%3DHe%26aufirst%3DM.%26aulast%3DHoffman%26aufirst%3DJ.%26aulast%3DHoffman%26aufirst%3DR.%2BL.%26aulast%3DHuang%26aufirst%3DQ.%26aulast%3DKania%26aufirst%3DR.%2BS.%26aulast%3DKath%26aufirst%3DJ.%2BC.%26aulast%3DLam%26aufirst%3DH.%26aulast%3DLam%26aufirst%3DJ.%2BL.%26aulast%3DLe%26aufirst%3DP.%2BT.%26aulast%3DLingardo%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DMcTigue%26aufirst%3DM.%26aulast%3DPalmer%26aufirst%3DC.%2BL.%26aulast%3DSach%26aufirst%3DN.%2BW.%26aulast%3DSmeal%26aufirst%3DT.%26aulast%3DSmith%26aufirst%3DG.%2BL.%26aulast%3DStewart%26aufirst%3DA.%2BE.%26aulast%3DTimofeevski%26aufirst%3DS.%26aulast%3DZhu%26aufirst%3DH.%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DZou%26aufirst%3DH.%2BY.%26aulast%3DEdwards%26aufirst%3DM.%2BP.%26atitle%3DDiscovery%2520of%2520%252810%2520R%2529-7-Amino-12-fluoro-2%252C%252010%252C%252016-trimethyl-15-oxo-10%252C%252015%252C%252016%252C%252017-tetrahydro-2H-8%252C%25204-%2528metheno%2529%2520pyrazolo%2520%255B4%252C%25203-h%255D%255B2%252C%25205%252C%252011%255D-benzoxadiazacyclotetradecine-3-carbonitrile%2520%2528PF-06463922%2529%252C%2520a%2520Macrocyclic%2520Inhibitor%2520of%2520Anaplastic%2520Lymphoma%2520Kinase%2520%2528ALK%2529%2520and%2520c-ROS%2520Oncogene%25201%2520%2528ROS1%2529%2520with%2520Preclinical%2520Brain%2520Exposure%2520and%2520Broad-spectrum%2520Potency%2520against%2520ALK-resistant%2520mutations%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D4720%26epage%3D4744%26doi%3D10.1021%2Fjm500261q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bode, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choquette, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potashman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romero, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stellwagen, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teffera, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whittington, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Epstein, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emkey, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, V. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saffran, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drew, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merkel, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szilvassy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brake, R. L.</span></span> <span> </span><span class="NLM_article-title">The Discovery and Optimization of a Novel Class of Potent, Selective, and Orally Bioavailable Anaplastic Lymphoma Kinase (ALK) Inhibitors with Potential Utility for the Treatment of Cancer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">6523</span>– <span class="NLM_lpage">6540</span>, <span class="refDoi"> DOI: 10.1021/jm3005866</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm3005866" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC38XptF2hsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=6523-6540&author=R.+T.+Lewisauthor=C.+M.+Bodeauthor=D.+M.+Choquetteauthor=M.+Potashmanauthor=K.+Romeroauthor=J.+C.+Stellwagenauthor=Y.+Tefferaauthor=E.+Mooreauthor=D.+A.+Whittingtonauthor=H.+Chenauthor=L.+F.+Epsteinauthor=R.+Emkeyauthor=P.+S.+Andrewsauthor=V.+L.+Yuauthor=D.+C.+Saffranauthor=M.+Xuauthor=A.+Drewauthor=P.+Merkelauthor=S.+Szilvassyauthor=R.+L.+Brake&title=The+Discovery+and+Optimization+of+a+Novel+Class+of+Potent%2C+Selective%2C+and+Orally+Bioavailable+Anaplastic+Lymphoma+Kinase+%28ALK%29+Inhibitors+with+Potential+Utility+for+the+Treatment+of+Cancer&doi=10.1021%2Fjm3005866"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">The Discovery and Optimization of a Novel Class of Potent, Selective, and Orally Bioavailable Anaplastic Lymphoma Kinase (ALK) Inhibitors with Potential Utility for the Treatment of Cancer</span></div><div class="casAuthors">Lewis, Richard T.; Bode, Christiane M.; Choquette, Deborah M.; Potashman, Michele; Romero, Karina; Stellwagen, John C.; Teffera, Yohannes; Moore, Earl; Whittington, Douglas A.; Chen, Hao; Epstein, Linda F.; Emkey, Renee; Andrews, Paul S.; Yu, Violeta L.; Saffran, Douglas C.; Xu, Man; Drew, Allison; Merkel, Patricia; Szilvassy, Steven; Brake, Rachael L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">6523-6540</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A class of 2-acyliminobenzimidazoles has been developed as potent and selective inhibitors of anaplastic lymphoma kinase (ALK).  Structure based design facilitated the rapid development of structure-activity relationships (SAR) and the optimization of kinase selectivity.  Introduction of an optimally placed polar substituent was key to solving issues of metabolic stability and led to the development of potent, selective, orally bioavailable ALK inhibitors.  Compd. I [Ar = 3,5-F2Ph] achieved substantial tumor regression in an NPM-ALK driven murine tumor xenograft model when dosed qd.  Compd. I [Ar = 3,5-F2Ph, 4-FPh] show favorable potency and PK characteristics in preclin. species indicative of suitability for further development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDAwmBMVhyL7Vg90H21EOLACvtfcHk0lhZXpgK2RJtBA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XptF2hsbo%253D&md5=a3c2f9e8dbf7d73319657e456bd45076</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Fjm3005866&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm3005866%26sid%3Dliteratum%253Aachs%26aulast%3DLewis%26aufirst%3DR.%2BT.%26aulast%3DBode%26aufirst%3DC.%2BM.%26aulast%3DChoquette%26aufirst%3DD.%2BM.%26aulast%3DPotashman%26aufirst%3DM.%26aulast%3DRomero%26aufirst%3DK.%26aulast%3DStellwagen%26aufirst%3DJ.%2BC.%26aulast%3DTeffera%26aufirst%3DY.%26aulast%3DMoore%26aufirst%3DE.%26aulast%3DWhittington%26aufirst%3DD.%2BA.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DEpstein%26aufirst%3DL.%2BF.%26aulast%3DEmkey%26aufirst%3DR.%26aulast%3DAndrews%26aufirst%3DP.%2BS.%26aulast%3DYu%26aufirst%3DV.%2BL.%26aulast%3DSaffran%26aufirst%3DD.%2BC.%26aulast%3DXu%26aufirst%3DM.%26aulast%3DDrew%26aufirst%3DA.%26aulast%3DMerkel%26aufirst%3DP.%26aulast%3DSzilvassy%26aufirst%3DS.%26aulast%3DBrake%26aufirst%3DR.%2BL.%26atitle%3DThe%2520Discovery%2520and%2520Optimization%2520of%2520a%2520Novel%2520Class%2520of%2520Potent%252C%2520Selective%252C%2520and%2520Orally%2520Bioavailable%2520Anaplastic%2520Lymphoma%2520Kinase%2520%2528ALK%2529%2520Inhibitors%2520with%2520Potential%2520Utility%2520for%2520the%2520Treatment%2520of%2520Cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D6523%26epage%3D6540%26doi%3D10.1021%2Fjm3005866" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ott, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Learn, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gingrich, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lisko, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curry, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mesaros, E. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghose, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quail, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dobrzanski, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albom, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angeles, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wells-Knecht, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aimone, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruckheimer, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandez, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ator, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruggeri, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dorsey, B. D.</span></span> <span> </span><span class="NLM_article-title">Discovery of Clinical Candidate CEP-37440, a Selective Inhibitor of Focal Adhesion Kinase (FAK) and Anaplastic Lymphoma Kinase (ALK)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">7478</span>– <span class="NLM_lpage">7496</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00487</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00487" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhtlaru77P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=7478-7496&author=G.+R.+Ottauthor=M.+Chengauthor=K.+S.+Learnauthor=J.+Wagnerauthor=D.+E.+Gingrichauthor=J.+G.+Liskoauthor=M.+Curryauthor=E.+F.+Mesarosauthor=A.+K.+Ghoseauthor=M.+R.+Quailauthor=W.+Wanauthor=L.+Luauthor=P.+Dobrzanskiauthor=M.+S.+Albomauthor=T.+S.+Angelesauthor=K.+Wells-Knechtauthor=Z.+Huangauthor=L.+D.+Aimoneauthor=E.+Bruckheimerauthor=N.+Andersonauthor=J.+Friedmanauthor=S.+V.+Fernandezauthor=M.+A.+Atorauthor=B.+A.+Ruggeriauthor=B.+D.+Dorsey&title=Discovery+of+Clinical+Candidate+CEP-37440%2C+a+Selective+Inhibitor+of+Focal+Adhesion+Kinase+%28FAK%29+and+Anaplastic+Lymphoma+Kinase+%28ALK%29&doi=10.1021%2Facs.jmedchem.6b00487"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Clinical Candidate CEP-37440, a Selective Inhibitor of Focal Adhesion Kinase (FAK) and Anaplastic Lymphoma Kinase (ALK)</span></div><div class="casAuthors">Ott, Gregory R.; Cheng, Mangeng; Learn, Keith S.; Wagner, Jason; Gingrich, Diane E.; Lisko, Joseph G.; Curry, Matthew; Mesaros, Eugen F.; Ghose, Arup K.; Quail, Matthew R.; Wan, Weihua; Lu, Lihui; Dobrzanski, Pawel; Albom, Mark S.; Angeles, Thelma S.; Wells-Knecht, Kevin; Huang, Zeqi; Aimone, Lisa D.; Bruckheimer, Elizabeth; Anderson, Nathan; Friedman, Jay; Fernandez, Sandra V.; Ator, Mark A.; Ruggeri, Bruce A.; Dorsey, Bruce D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">7478-7496</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Analogs structurally related to anaplastic lymphoma kinase (ALK) inhibitor (CEP-28122) were optimized for metabolic stability.  The results from this endeavor not only led to improved metabolic stability, pharmacokinetic parameters, and in vitro activity against clin. derived resistance mutations but also led to the incorporation of activity for focal adhesion kinase (FAK).  FAK activation, via amplification and/or overexpression, is characteristic of multiple invasive solid tumors and metastasis.  The discovery of the clin. stage, dual FAK/ALK inhibitor 27b (CEP-37440), including details surrounding SAR, in vitro/in vivo pharmacol., and pharmacokinetics, is reported herein.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9Ojryum63_LVg90H21EOLACvtfcHk0lhm9_ql5YC6PQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhtlaru77P&md5=3fcd1342d901b2379d0efbd118d3049f</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00487&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00487%26sid%3Dliteratum%253Aachs%26aulast%3DOtt%26aufirst%3DG.%2BR.%26aulast%3DCheng%26aufirst%3DM.%26aulast%3DLearn%26aufirst%3DK.%2BS.%26aulast%3DWagner%26aufirst%3DJ.%26aulast%3DGingrich%26aufirst%3DD.%2BE.%26aulast%3DLisko%26aufirst%3DJ.%2BG.%26aulast%3DCurry%26aufirst%3DM.%26aulast%3DMesaros%26aufirst%3DE.%2BF.%26aulast%3DGhose%26aufirst%3DA.%2BK.%26aulast%3DQuail%26aufirst%3DM.%2BR.%26aulast%3DWan%26aufirst%3DW.%26aulast%3DLu%26aufirst%3DL.%26aulast%3DDobrzanski%26aufirst%3DP.%26aulast%3DAlbom%26aufirst%3DM.%2BS.%26aulast%3DAngeles%26aufirst%3DT.%2BS.%26aulast%3DWells-Knecht%26aufirst%3DK.%26aulast%3DHuang%26aufirst%3DZ.%26aulast%3DAimone%26aufirst%3DL.%2BD.%26aulast%3DBruckheimer%26aufirst%3DE.%26aulast%3DAnderson%26aufirst%3DN.%26aulast%3DFriedman%26aufirst%3DJ.%26aulast%3DFernandez%26aufirst%3DS.%2BV.%26aulast%3DAtor%26aufirst%3DM.%2BA.%26aulast%3DRuggeri%26aufirst%3DB.%2BA.%26aulast%3DDorsey%26aufirst%3DB.%2BD.%26atitle%3DDiscovery%2520of%2520Clinical%2520Candidate%2520CEP-37440%252C%2520a%2520Selective%2520Inhibitor%2520of%2520Focal%2520Adhesion%2520Kinase%2520%2528FAK%2529%2520and%2520Anaplastic%2520Lymphoma%2520Kinase%2520%2528ALK%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D7478%26epage%3D7496%26doi%3D10.1021%2Facs.jmedchem.6b00487" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mori, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ueno, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konagai, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fushiki, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimada, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kondoh, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saito, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mori, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shindou, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soga, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakagami, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furutani, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doihara, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kudoh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuromitsu, S.</span></span> <span> </span><span class="NLM_article-title">The Selective Anaplastic Lymphoma Receptor Tyrosine Kinase Inhibitor ASP3026 Induces Tumor Regression and Prolongs Survival in Non-small Cell Lung Cancer Model Mice</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">329</span>– <span class="NLM_lpage">340</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-13-0395</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1158%2F1535-7163.MCT-13-0395" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=24419060" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFWmsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=329-340&author=M.+Moriauthor=Y.+Uenoauthor=S.+Konagaiauthor=H.+Fushikiauthor=I.+Shimadaauthor=Y.+Kondohauthor=R.+Saitoauthor=K.+Moriauthor=N.+Shindouauthor=T.+Sogaauthor=H.+Sakagamiauthor=T.+Furutaniauthor=H.+Doiharaauthor=M.+Kudohauthor=S.+Kuromitsu&title=The+Selective+Anaplastic+Lymphoma+Receptor+Tyrosine+Kinase+Inhibitor+ASP3026+Induces+Tumor+Regression+and+Prolongs+Survival+in+Non-small+Cell+Lung+Cancer+Model+Mice&doi=10.1158%2F1535-7163.MCT-13-0395"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">The Selective Anaplastic Lymphoma Receptor Tyrosine Kinase Inhibitor ASP3026 Induces Tumor Regression and Prolongs Survival in Non-Small Cell Lung Cancer Model Mice</span></div><div class="casAuthors">Mori, Masamichi; Ueno, Yoko; Konagai, Satoshi; Fushiki, Hiroshi; Shimada, Itsuro; Kondoh, Yutaka; Saito, Rika; Mori, Kenichi; Shindou, Nobuaki; Soga, Takatoshi; Sakagami, Hideki; Furutani, Takashi; Doihara, Hitoshi; Kudoh, Masafumi; Kuromitsu, Sadao</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">329-340</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Activation of anaplastic lymphoma receptor tyrosine kinase (ALK) is involved in the pathogenesis of several carcinomas, including non-small cell lung cancer (NSCLC).  Echinoderm microtubule-assocd. protein like 4 (EML4)-ALK, which is derived from the rearrangement of ALK and EML4 genes, has been validated as a therapeutic target in a subset of patients with NSCLC.  Here, we investigated the effects of ASP3026, a novel small-mol. ALK inhibitor, against ALK-driven NSCLC.  ASP3026 inhibited ALK activity in an ATP-competitive manner and had an inhibitory spectrum that differed from that of crizotinib, a dual ALK/MET inhibitor.  In mice xenografted with NCI-H2228 cells expressing EML4-ALK, orally administered ASP3026 was well absorbed in tumor tissues, reaching concns. >10-fold higher than those in plasma, and induced tumor regression with a wide therapeutic margin between efficacious and toxic doses.  In the same mouse model, ASP3026 enhanced the antitumor activities of paclitaxel and pemetrexed without affecting body wt.  ASP3026 also showed potent antitumor activities, including tumor shrinkage to a nondetectable level, in hEML4-ALK transgenic mice and prolonged survival in mice with intrapleural NCI-H2228 xenografts.  In an intrahepatic xenograft model using NCI-H2228 cells, ASP3026 induced continuous tumor regression, whereas mice treated with crizotinib showed tumor relapse after an initial response.  Finally, ASP3026 exhibited potent antitumor activity against cells expressing EML4-ALK with a mutation in the gatekeeper position (L1196M) that confers crizotinib resistance.  Taken together, these findings indicate that ASP3026 has potential efficacy for NSCLC and is expected to improve the therapeutic outcomes of patients with cancer with ALK abnormality.  Mol Cancer Ther; 13(2); 329-40. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpU-kqfwbUJrLVg90H21EOLACvtfcHk0lhm9_ql5YC6PQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFWmsb8%253D&md5=4d8de3814f3f8fa198f2d3acb5d3860a</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-13-0395&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-13-0395%26sid%3Dliteratum%253Aachs%26aulast%3DMori%26aufirst%3DM.%26aulast%3DUeno%26aufirst%3DY.%26aulast%3DKonagai%26aufirst%3DS.%26aulast%3DFushiki%26aufirst%3DH.%26aulast%3DShimada%26aufirst%3DI.%26aulast%3DKondoh%26aufirst%3DY.%26aulast%3DSaito%26aufirst%3DR.%26aulast%3DMori%26aufirst%3DK.%26aulast%3DShindou%26aufirst%3DN.%26aulast%3DSoga%26aufirst%3DT.%26aulast%3DSakagami%26aufirst%3DH.%26aulast%3DFurutani%26aufirst%3DT.%26aulast%3DDoihara%26aufirst%3DH.%26aulast%3DKudoh%26aufirst%3DM.%26aulast%3DKuromitsu%26aufirst%3DS.%26atitle%3DThe%2520Selective%2520Anaplastic%2520Lymphoma%2520Receptor%2520Tyrosine%2520Kinase%2520Inhibitor%2520ASP3026%2520Induces%2520Tumor%2520Regression%2520and%2520Prolongs%2520Survival%2520in%2520Non-small%2520Cell%2520Lung%2520Cancer%2520Model%2520Mice%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2014%26volume%3D13%26spage%3D329%26epage%3D340%26doi%3D10.1158%2F1535-7163.MCT-13-0395" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ardini, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menichincheri, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banfi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bosotti, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Ponti, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pulci, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballinari, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciomei, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Texido, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Degrassi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avanzi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amboldi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saccardo, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casero, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orsini, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bandiera, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mologni, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vernier, J.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felder, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donati, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isacchi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pesenti, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magnaghi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galvani, A.</span></span> <span> </span><span class="NLM_article-title">Entrectinib, a Pan-TRK, ROS1 and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">628</span>– <span class="NLM_lpage">639</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-15-0758</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1158%2F1535-7163.MCT-15-0758" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=26939704" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC28XlsVSqtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2016&pages=628-639&author=E.+Ardiniauthor=M.+Menichincheriauthor=P.+Banfiauthor=R.+Bosottiauthor=C.+De+Pontiauthor=R.+Pulciauthor=D.+Ballinariauthor=M.+Ciomeiauthor=G.+Texidoauthor=A.+Degrassiauthor=N.+Avanziauthor=N.+Amboldiauthor=M.+B.+Saccardoauthor=D.+Caseroauthor=P.+Orsiniauthor=T.+Bandieraauthor=L.+Mologniauthor=D.+Andersonauthor=G.+Weiauthor=J.+Harrisauthor=J.-M.+Vernierauthor=G.+Liauthor=E.+Felderauthor=D.+Donatiauthor=A.+Isacchiauthor=E.+Pesentiauthor=P.+Magnaghiauthor=A.+Galvani&title=Entrectinib%2C+a+Pan-TRK%2C+ROS1+and+ALK+Inhibitor+with+Activity+in+Multiple+Molecularly+Defined+Cancer+Indications&doi=10.1158%2F1535-7163.MCT-15-0758"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications</span></div><div class="casAuthors">Ardini, Elena; Menichincheri, Maria; Banfi, Patrizia; Bosotti, Roberta; De Ponti, Cristina; Pulci, Romana; Ballinari, Dario; Ciomei, Marina; Texido, Gemma; Degrassi, Anna; Avanzi, Nilla; Amboldi, Nadia; Saccardo, Maria Beatrice; Casero, Daniele; Orsini, Paolo; Bandiera, Tiziano; Mologni, Luca; Anderson, David; Wei, Ge; Harris, Jason; Vernier, Jean-Michel; Li, Gang; Felder, Eduard; Donati, Daniele; Isacchi, Antonella; Pesenti, Enrico; Magnaghi, Paola; Galvani, Arturo</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">628-639</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Activated ALK and ROS1 tyrosine kinases, resulting from chromosomal rearrangements, occur in a subset of non-small cell lung cancers (NSCLC) as well as other tumor types and their oncogenic relevance as actionable targets has been demonstrated by the efficacy of selective kinase inhibitors such as crizotinib, ceritinib, and alectinib.  More recently, low-frequency rearrangements of TRK kinases have been described in NSCLC, colorectal carcinoma, glioblastoma, and Spitzoid melanoma.  Entrectinib, whose discovery and preclin. characterization are reported herein, is a novel, potent inhibitor of ALK, ROS1, and, importantly, of TRK family kinases, which shows promise for therapy of tumors bearing oncogenic forms of these proteins.  Proliferation profiling against over 200 human tumor cell lines revealed that entrectinib is exquisitely potent in vitro against lines that are dependent on the drug's pharmacol. targets.  Oral administration of entrectinib to tumor-bearing mice induced regression in relevant human xenograft tumors, including the TRKA-dependent colorectal carcinoma KM12, ROS1-driven tumors, and several ALK-dependent models of different tissue origins, including a model of brain-localized lung cancer metastasis.  Entrectinib is currently showing great promise in phase I/II clin. trials, including the first documented objective responses to a TRK inhibitor in colorectal carcinoma and in NSCLC.  The drug is, thus, potentially suited to the therapy of several molecularly defined cancer settings, esp. that of TRK-dependent tumors, for which no approved drugs are currently available.  Mol Cancer Ther; 15(4); 628-39. ©2016 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOaNX-kFz2qbVg90H21EOLACvtfcHk0lhm9_ql5YC6PQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XlsVSqtL4%253D&md5=dd75115cb344f0e3a6d299781043d7d6</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-15-0758&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-15-0758%26sid%3Dliteratum%253Aachs%26aulast%3DArdini%26aufirst%3DE.%26aulast%3DMenichincheri%26aufirst%3DM.%26aulast%3DBanfi%26aufirst%3DP.%26aulast%3DBosotti%26aufirst%3DR.%26aulast%3DDe%2BPonti%26aufirst%3DC.%26aulast%3DPulci%26aufirst%3DR.%26aulast%3DBallinari%26aufirst%3DD.%26aulast%3DCiomei%26aufirst%3DM.%26aulast%3DTexido%26aufirst%3DG.%26aulast%3DDegrassi%26aufirst%3DA.%26aulast%3DAvanzi%26aufirst%3DN.%26aulast%3DAmboldi%26aufirst%3DN.%26aulast%3DSaccardo%26aufirst%3DM.%2BB.%26aulast%3DCasero%26aufirst%3DD.%26aulast%3DOrsini%26aufirst%3DP.%26aulast%3DBandiera%26aufirst%3DT.%26aulast%3DMologni%26aufirst%3DL.%26aulast%3DAnderson%26aufirst%3DD.%26aulast%3DWei%26aufirst%3DG.%26aulast%3DHarris%26aufirst%3DJ.%26aulast%3DVernier%26aufirst%3DJ.-M.%26aulast%3DLi%26aufirst%3DG.%26aulast%3DFelder%26aufirst%3DE.%26aulast%3DDonati%26aufirst%3DD.%26aulast%3DIsacchi%26aufirst%3DA.%26aulast%3DPesenti%26aufirst%3DE.%26aulast%3DMagnaghi%26aufirst%3DP.%26aulast%3DGalvani%26aufirst%3DA.%26atitle%3DEntrectinib%252C%2520a%2520Pan-TRK%252C%2520ROS1%2520and%2520ALK%2520Inhibitor%2520with%2520Activity%2520in%2520Multiple%2520Molecularly%2520Defined%2520Cancer%2520Indications%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2016%26volume%3D15%26spage%3D628%26epage%3D639%26doi%3D10.1158%2F1535-7163.MCT-15-0758" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Menichincheri, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ardini, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magnaghi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avanzi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banfi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bossi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buffa, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Canevari, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ceriani, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colombo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corti, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donati, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fasolini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felder, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiorelli, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiorentini, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galvani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isacchi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borgia, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marchionni, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nesi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orrenius, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panzeri, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pesenti, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rusconi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saccardo, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanotti, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perrone, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orsini, P.</span></span> <span> </span><span class="NLM_article-title">Discovery of Entrectinib: a New 3-aminoindazole as a Potent Anaplastic Lymphoma Kinase (ALK), c-ros Oncogene 1 Kinase (ROS1), and Pan-tropomyosin Receptor Kinases (Pan-TRKs) Inhibitor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">3392</span>– <span class="NLM_lpage">3408</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00064</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00064" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC28Xks1eitL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=3392-3408&author=M.+Menichincheriauthor=E.+Ardiniauthor=P.+Magnaghiauthor=N.+Avanziauthor=P.+Banfiauthor=R.+Bossiauthor=L.+Buffaauthor=G.+Canevariauthor=L.+Cerianiauthor=M.+Colomboauthor=L.+Cortiauthor=D.+Donatiauthor=M.+Fasoliniauthor=E.+Felderauthor=C.+Fiorelliauthor=F.+Fiorentiniauthor=A.+Galvaniauthor=A.+Isacchiauthor=A.+L.+Borgiaauthor=C.+Marchionniauthor=M.+Nesiauthor=C.+Orreniusauthor=A.+Panzeriauthor=E.+Pesentiauthor=L.+Rusconiauthor=M.+B.+Saccardoauthor=E.+Vanottiauthor=E.+Perroneauthor=P.+Orsini&title=Discovery+of+Entrectinib%3A+a+New+3-aminoindazole+as+a+Potent+Anaplastic+Lymphoma+Kinase+%28ALK%29%2C+c-ros+Oncogene+1+Kinase+%28ROS1%29%2C+and+Pan-tropomyosin+Receptor+Kinases+%28Pan-TRKs%29+Inhibitor&doi=10.1021%2Facs.jmedchem.6b00064"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Entrectinib: A New 3-Aminoindazole As a Potent Anaplastic Lymphoma Kinase (ALK), c-ros Oncogene 1 Kinase (ROS1), and Pan-Tropomyosin Receptor Kinases (Pan-TRKs) inhibitor</span></div><div class="casAuthors">Menichincheri, Maria; Ardini, Elena; Magnaghi, Paola; Avanzi, Nilla; Banfi, Patrizia; Bossi, Roberto; Buffa, Laura; Canevari, Giulia; Ceriani, Lucio; Colombo, Maristella; Corti, Luca; Donati, Daniele; Fasolini, Marina; Felder, Eduard; Fiorelli, Claudio; Fiorentini, Francesco; Galvani, Arturo; Isacchi, Antonella; Borgia, Andrea Lombardi; Marchionni, Chiara; Nesi, Marcella; Orrenius, Christian; Panzeri, Achille; Pesenti, Enrico; Rusconi, Luisa; Saccardo, Maria Beatrice; Vanotti, Ermes; Perrone, Ettore; Orsini, Paolo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3392-3408</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase responsible for the development of different tumor types.  Despite the remarkable clin. activity of crizotinib (Xalkori), the first ALK inhibitor approved in 2011, the emergence of resistance mutations and of brain metastases frequently causes relapse in patients.  Within the ALK drug discovery program, the authors identified compd. I, a novel 3-aminoindazole active on ALK in biochem. and in cellular assays.  Its optimization led to compd. II (entrectinib), a potent orally available ALK inhibitor active on ALK-dependent cell lines, efficiently penetrant the blood-brain barrier (BBB) in different animal species and highly efficacious in in vivo xenograft models.  Moreover, entrectinib resulted to be strictly potent on the closely related tyrosine kinases ROS1 and TRKs recently found constitutively activated in several tumor types.  Entrectinib is currently undergoing phase I/II clin. trial for the treatment of patients affected by ALK-, ROS1-, and TRK-pos. tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpU_xyLC5-GabVg90H21EOLACvtfcHk0lhQH5wOdeU60Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xks1eitL8%253D&md5=140217fba2ac81d71600f7344f2d8a3e</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00064%26sid%3Dliteratum%253Aachs%26aulast%3DMenichincheri%26aufirst%3DM.%26aulast%3DArdini%26aufirst%3DE.%26aulast%3DMagnaghi%26aufirst%3DP.%26aulast%3DAvanzi%26aufirst%3DN.%26aulast%3DBanfi%26aufirst%3DP.%26aulast%3DBossi%26aufirst%3DR.%26aulast%3DBuffa%26aufirst%3DL.%26aulast%3DCanevari%26aufirst%3DG.%26aulast%3DCeriani%26aufirst%3DL.%26aulast%3DColombo%26aufirst%3DM.%26aulast%3DCorti%26aufirst%3DL.%26aulast%3DDonati%26aufirst%3DD.%26aulast%3DFasolini%26aufirst%3DM.%26aulast%3DFelder%26aufirst%3DE.%26aulast%3DFiorelli%26aufirst%3DC.%26aulast%3DFiorentini%26aufirst%3DF.%26aulast%3DGalvani%26aufirst%3DA.%26aulast%3DIsacchi%26aufirst%3DA.%26aulast%3DBorgia%26aufirst%3DA.%2BL.%26aulast%3DMarchionni%26aufirst%3DC.%26aulast%3DNesi%26aufirst%3DM.%26aulast%3DOrrenius%26aufirst%3DC.%26aulast%3DPanzeri%26aufirst%3DA.%26aulast%3DPesenti%26aufirst%3DE.%26aulast%3DRusconi%26aufirst%3DL.%26aulast%3DSaccardo%26aufirst%3DM.%2BB.%26aulast%3DVanotti%26aufirst%3DE.%26aulast%3DPerrone%26aufirst%3DE.%26aulast%3DOrsini%26aufirst%3DP.%26atitle%3DDiscovery%2520of%2520Entrectinib%253A%2520a%2520New%25203-aminoindazole%2520as%2520a%2520Potent%2520Anaplastic%2520Lymphoma%2520Kinase%2520%2528ALK%2529%252C%2520c-ros%2520Oncogene%25201%2520Kinase%2520%2528ROS1%2529%252C%2520and%2520Pan-tropomyosin%2520Receptor%2520Kinases%2520%2528Pan-TRKs%2529%2520Inhibitor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D3392%26epage%3D3408%26doi%3D10.1021%2Facs.jmedchem.6b00064" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lovly, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heuckmann, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Stanchina, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pao, W.</span></span> <span> </span><span class="NLM_article-title">Insights into ALK-driven Cancers Revealed through Development of Novel ALK Tyrosine Kinase Inhibitors</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">4920</span>– <span class="NLM_lpage">4931</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-10-3879</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1158%2F0008-5472.CAN-10-3879" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=21613408" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC3MXovFartro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2011&pages=4920-4931&author=C.+M.+Lovlyauthor=J.+M.+Heuckmannauthor=E.+de+Stanchinaauthor=H.+Chenauthor=R.+K.+Thomasauthor=C.+Liangauthor=W.+Pao&title=Insights+into+ALK-driven+Cancers+Revealed+through+Development+of+Novel+ALK+Tyrosine+Kinase+Inhibitors&doi=10.1158%2F0008-5472.CAN-10-3879"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Insights into ALK-Driven Cancers Revealed through Development of Novel ALK Tyrosine Kinase Inhibitors</span></div><div class="casAuthors">Lovly, Christine M.; Heuckmann, Johannes M.; de Stanchina, Elisa; Chen, Heidi; Thomas, Roman K.; Liang, Chris; Pao, William</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">4920-4931</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Aberrant forms of the anaplastic lymphoma kinase (ALK) have been implicated in the pathogenesis of multiple human cancers, where ALK represents a rational therapeutic target in these settings.  In this study, we report the identification and biol. characterization of X-376 and X-396, two potent and highly specific ALK small mol. tyrosine kinase inhibitors (TKIs).  In Ambit kinome screens, cell growth inhibition studies, and surrogate kinase assays, X-376 and X-396 were more potent inhibitors of ALK but less potent inhibitors of MET compared to PF-02341066 (PF-1066), an ALK/MET dual TKI currently in clin. trials.  Both X-376 and X-396 displayed potent antitumor activity in vivo with favorable pharmacokinetic and toxicity profiles.  Similar levels of drug sensitivity were displayed by the three most common ALK fusion proteins in lung cancer (EML4-ALK variants E13;A20, E20;A20, and E6b;A20) as well as a KIF5B-ALK fusion protein.  Moreover, X-396 could potently inhibit ALK kinases engineered with two point mutations assocd. with acquired resistance to PF-1066, L1196M, and C1156Y, when engineered into an E13;A20 fusion variant.  Finally, X-396 displayed synergistic growth inhibitory activity when combined with the mTOR inhibitor rapamycin.  Our findings offer preclin. proof-of-concept for use of these novel agents to improve therapeutic outcomes of patients with mutant ALK-driven malignancies.  Cancer Res; 71(14); 4920-31.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmCEJra8njI7Vg90H21EOLACvtfcHk0lhQH5wOdeU60Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXovFartro%253D&md5=000cbd1295c9d9fa6a43027f08c31247</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-10-3879&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-10-3879%26sid%3Dliteratum%253Aachs%26aulast%3DLovly%26aufirst%3DC.%2BM.%26aulast%3DHeuckmann%26aufirst%3DJ.%2BM.%26aulast%3Dde%2BStanchina%26aufirst%3DE.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DThomas%26aufirst%3DR.%2BK.%26aulast%3DLiang%26aufirst%3DC.%26aulast%3DPao%26aufirst%3DW.%26atitle%3DInsights%2520into%2520ALK-driven%2520Cancers%2520Revealed%2520through%2520Development%2520of%2520Novel%2520ALK%2520Tyrosine%2520Kinase%2520Inhibitors%26jtitle%3DCancer%2520Res.%26date%3D2011%26volume%3D71%26spage%3D4920%26epage%3D4931%26doi%3D10.1158%2F0008-5472.CAN-10-3879" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cui, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhai, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogers, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitten, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span> <span> </span><span class="NLM_article-title">TPX-0005, a Novel ALK/ROS1/TRK inhibitor, Effectively Inhibited a Broad Spectrum of mMutations Including Solvent front ALK G1202R, ROS1 G2032R and TRKA G595R Mutants</span>. <i>Eur. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>69</i></span>,  <span class="NLM_fpage">S32</span>, <span class="refDoi"> DOI: 10.1016/S0959-8049(16)32675-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1016%2FS0959-8049%2816%2932675-2" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2016&pages=S32&author=J.+Cuiauthor=D.+Zhaiauthor=W.+Dengauthor=E.+Rogersauthor=Z.+Huangauthor=J.+Whittenauthor=Y.+Li&title=TPX-0005%2C+a+Novel+ALK%2FROS1%2FTRK+inhibitor%2C+Effectively+Inhibited+a+Broad+Spectrum+of+mMutations+Including+Solvent+front+ALK+G1202R%2C+ROS1+G2032R+and+TRKA+G595R+Mutants&doi=10.1016%2FS0959-8049%2816%2932675-2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1016%2FS0959-8049%2816%2932675-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0959-8049%252816%252932675-2%26sid%3Dliteratum%253Aachs%26aulast%3DCui%26aufirst%3DJ.%26aulast%3DZhai%26aufirst%3DD.%26aulast%3DDeng%26aufirst%3DW.%26aulast%3DRogers%26aufirst%3DE.%26aulast%3DHuang%26aufirst%3DZ.%26aulast%3DWhitten%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DY.%26atitle%3DTPX-0005%252C%2520a%2520Novel%2520ALK%252FROS1%252FTRK%2520inhibitor%252C%2520Effectively%2520Inhibited%2520a%2520Broad%2520Spectrum%2520of%2520mMutations%2520Including%2520Solvent%2520front%2520ALK%2520G1202R%252C%2520ROS1%2520G2032R%2520and%2520TRKA%2520G595R%2520Mutants%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D2016%26volume%3D69%26spage%3DS32%26doi%3D10.1016%2FS0959-8049%2816%2932675-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hatcher, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span> <span> </span><span class="NLM_article-title">Small Molecule Inhibitors of ALK</span>. <i>Top. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">435</span>– <span class="NLM_lpage">467</span>, <span class="refDoi"> DOI: 10.1007/7355_2017_18</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1007%2F7355_2017_18" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2017&pages=435-467&author=J.+M.+Hatcherauthor=N.+S.+Gray&title=Small+Molecule+Inhibitors+of+ALK&doi=10.1007%2F7355_2017_18"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1007%2F7355_2017_18&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F7355_2017_18%26sid%3Dliteratum%253Aachs%26aulast%3DHatcher%26aufirst%3DJ.%2BM.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DSmall%2520Molecule%2520Inhibitors%2520of%2520ALK%26jtitle%3DTop.%2520Med.%2520Chem.%26date%3D2017%26volume%3D28%26spage%3D435%26epage%3D467%26doi%3D10.1007%2F7355_2017_18" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Holla, V. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elamin, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Litzenburger, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khotskaya, Y. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shufean, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mendelsohn, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mills, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meric-Bernstam, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simon, G. R.</span></span> <span> </span><span class="NLM_article-title">ALK: a Tyrosine Kinase Target for Cancer Therapy</span>. <i>Cold Spring Harbor Mol. Case. Stud.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">a001115</span>, <span class="refDoi"> DOI: 10.1101/mcs.a001115</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1101%2Fmcs.a001115" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=28050598" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC1cXotlajtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2017&pages=a001115&author=V.+R.+Hollaauthor=Y.+Y.+Elaminauthor=A.+M.+Baileyauthor=A.+M.+Johnsonauthor=B.+C.+Litzenburgerauthor=Y.+B.+Khotskayaauthor=N.+S.+Sanchezauthor=J.+Zengauthor=M.+A.+Shufeanauthor=K.+R.+Shawauthor=J.+Mendelsohnauthor=G.+B.+Millsauthor=F.+Meric-Bernstamauthor=G.+R.+Simon&title=ALK%3A+a+Tyrosine+Kinase+Target+for+Cancer+Therapy&doi=10.1101%2Fmcs.a001115"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">ALK: a tyrosine kinase target for cancer therapy</span></div><div class="casAuthors">Holla, Vijaykumar R.; Elamin, Yasir Y.; Bailey, Ann Marie; Johnson, Amber M.; Litzenburger, Beate C.; Khotskaya, Yekaterina B.; Sanchez, Nora S.; Zeng, Jia; Abu Shufean, Md .; Shaw, Kenna R.; Mendelsohn, John; Mills, Gordon B.; Meric-Bernstam, Funda; Simon, George R.</div><div class="citationInfo"><span class="NLM_cas:title">Cold Spring Harbor Molecular Case Studies</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">a001115/1-a001115/21</span>CODEN:
                <span class="NLM_cas:coden">CSHMCJ</span>;
        ISSN:<span class="NLM_cas:issn">2373-2873</span>.
    
            (<span class="NLM_cas:orgname">Cold Spring Harbor Laboratory Press</span>)
        </div><div class="casAbstract">The anaplastic lymphoma kinase (ALK) gene plays an important physiol. role in the development of the brain and can be oncogenically altered in several malignancies, including non-small-cell lung cancer (NSCLC) and anaplastic large cell lymphomas (ALCL).  Most prevalent ALK alterations are chromosomal rearrangements resulting in fusion genes, as seen in ALCL and NSCLC.  In other tumors, ALK copy-no. gains and activating ALK mutations have been described.  Dramatic and often prolonged responses are seen in patients with ALK alterations when treated with ALK inhibitors.  Three of these-crizotinib, ceritinib, and alectinib-are now FDA approved for the treatment of metastatic NSCLC pos. for ALK fusions.  However, the emergence of resistance is universal.  Newer ALK inhibitors and other targeting strategies are being developed to counteract the newly emergent mechanism(s) of ALK inhibitor resistance.  This review outlines the recent developments in our understanding and treatment of tumors with ALK alterations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_NbgGW-_iP7Vg90H21EOLACvtfcHk0ljoUksw0Kac9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXotlajtbk%253D&md5=ab377ffa836af0e0a8380977c1c1cdb7</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1101%2Fmcs.a001115&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252Fmcs.a001115%26sid%3Dliteratum%253Aachs%26aulast%3DHolla%26aufirst%3DV.%2BR.%26aulast%3DElamin%26aufirst%3DY.%2BY.%26aulast%3DBailey%26aufirst%3DA.%2BM.%26aulast%3DJohnson%26aufirst%3DA.%2BM.%26aulast%3DLitzenburger%26aufirst%3DB.%2BC.%26aulast%3DKhotskaya%26aufirst%3DY.%2BB.%26aulast%3DSanchez%26aufirst%3DN.%2BS.%26aulast%3DZeng%26aufirst%3DJ.%26aulast%3DShufean%26aufirst%3DM.%2BA.%26aulast%3DShaw%26aufirst%3DK.%2BR.%26aulast%3DMendelsohn%26aufirst%3DJ.%26aulast%3DMills%26aufirst%3DG.%2BB.%26aulast%3DMeric-Bernstam%26aufirst%3DF.%26aulast%3DSimon%26aufirst%3DG.%2BR.%26atitle%3DALK%253A%2520a%2520Tyrosine%2520Kinase%2520Target%2520for%2520Cancer%2520Therapy%26jtitle%3DCold%2520Spring%2520Harbor%2520Mol.%2520Case.%2520Stud.%26date%3D2017%26volume%3D3%26spage%3Da001115%26doi%3D10.1101%2Fmcs.a001115" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Katayama, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lovly, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, A. T.</span></span> <span> </span><span class="NLM_article-title">Therapeutic Targeting of Anaplastic Lymphoma Kinase in Lung Cancer: a Paradigm for Precision Cancer Medicine</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">2227</span>– <span class="NLM_lpage">2235</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-14-2791</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1158%2F1078-0432.CCR-14-2791" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=25979929" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC2MXoslOktbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=2227-2235&author=R.+Katayamaauthor=C.+M.+Lovlyauthor=A.+T.+Shaw&title=Therapeutic+Targeting+of+Anaplastic+Lymphoma+Kinase+in+Lung+Cancer%3A+a+Paradigm+for+Precision+Cancer+Medicine&doi=10.1158%2F1078-0432.CCR-14-2791"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic Targeting of Anaplastic Lymphoma Kinase in Lung Cancer: A Paradigm for Precision Cancer Medicine</span></div><div class="casAuthors">Katayama, Ryohei; Lovly, Christine M.; Shaw, Alice T.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2227-2235</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  The anaplastic lymphoma kinase (ALK) receptor tyrosine kinase was initially discovered as a component of the fusion protein nucleophosmin (NPM)-ALK in anaplastic large-cell lymphoma (ALCL).  Genomic alterations in ALK, including rearrangements, point mutations, and genomic amplification, have now been identified in several malignancies, including lymphoma, non-small cell lung cancer (NSCLC), neuroblastoma, inflammatory myofibroblastic tumor, and others.  Importantly, ALK serves as a validated therapeutic target in these diseases.  Several ALK tyrosine kinase inhibitors (TKI), including crizotinib, ceritinib, and alectinib, have been developed, and some of them have already been approved for clin. use.  These ALK inhibitors have all shown remarkable clin. outcomes in ALK-rearranged NSCLC.  Unfortunately, as is the case for other kinase inhibitors in clin. use, sensitive tumors inevitably relapse due to acquired resistance.  This review focuses on the discovery, function, and therapeutic targeting of ALK, with a particular focus on ALK-rearranged NSCLC.  Clin Cancer Res; 21(10); 2227-35. cpr2015 AACR.  See all articles in this section, "Progress in Lung Cancer".</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr00cDhFZSKBrVg90H21EOLACvtfcHk0ljoUksw0Kac9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXoslOktbw%253D&md5=80994c4611159b7f7d007fd16e4f8472</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-14-2791&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-14-2791%26sid%3Dliteratum%253Aachs%26aulast%3DKatayama%26aufirst%3DR.%26aulast%3DLovly%26aufirst%3DC.%2BM.%26aulast%3DShaw%26aufirst%3DA.%2BT.%26atitle%3DTherapeutic%2520Targeting%2520of%2520Anaplastic%2520Lymphoma%2520Kinase%2520in%2520Lung%2520Cancer%253A%2520a%2520Paradigm%2520for%2520Precision%2520Cancer%2520Medicine%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2015%26volume%3D21%26spage%3D2227%26epage%3D2235%26doi%3D10.1158%2F1078-0432.CCR-14-2791" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bryan, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whittington, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doherty, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Falsey, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emkey, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brake, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, R. T.</span></span> <span> </span><span class="NLM_article-title">Rapid Development of Piperidine Carboxamides as Potent and Selective Anaplastic Lymphoma Kinase Inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">1698</span>– <span class="NLM_lpage">1705</span>, <span class="refDoi"> DOI: 10.1021/jm201565s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm201565s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVymsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=1698-1705&author=M.+C.+Bryanauthor=D.+A.+Whittingtonauthor=E.+M.+Dohertyauthor=J.+R.+Falseyauthor=A.+C.+Chengauthor=R.+Emkeyauthor=R.+L.+Brakeauthor=R.+T.+Lewis&title=Rapid+Development+of+Piperidine+Carboxamides+as+Potent+and+Selective+Anaplastic+Lymphoma+Kinase+Inhibitors&doi=10.1021%2Fjm201565s"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Rapid Development of Piperidine Carboxamides as Potent and Selective Anaplastic Lymphoma Kinase Inhibitors</span></div><div class="casAuthors">Bryan, Marian C.; Whittington, Douglas A.; Doherty, Elizabeth M.; Falsey, James R.; Cheng, Alan C.; Emkey, Renee; Brake, Rachael L.; Lewis, Richard T.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1698-1705</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Piperidine carboxamide I was identified as a novel inhibitor of anaplastic lymphoma kinase (ALK enzyme assay IC50 = 0.174 μM) during high throughput screening, with selectivity over the related kinase insulin-like growth factor-1 (IGF1R).  The X-ray cocrystal structure of 1 with the ALK kinase domain revealed an unusual DFG-shifted conformation, allowing access to an extended hydrophobic pocket.  Structure-activity relationship (SAR) studies were focused on the rapid parallel optimization of both the right- and left-hand side of the mol., culminating in mols. with improved potency and selectivity over IGF1R.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-7cIB41ZJN7Vg90H21EOLACvtfcHk0lhLySx5uP2U0Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVymsbs%253D&md5=04d47fd0f0a5b8b85c7add9787fe736e</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Fjm201565s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm201565s%26sid%3Dliteratum%253Aachs%26aulast%3DBryan%26aufirst%3DM.%2BC.%26aulast%3DWhittington%26aufirst%3DD.%2BA.%26aulast%3DDoherty%26aufirst%3DE.%2BM.%26aulast%3DFalsey%26aufirst%3DJ.%2BR.%26aulast%3DCheng%26aufirst%3DA.%2BC.%26aulast%3DEmkey%26aufirst%3DR.%26aulast%3DBrake%26aufirst%3DR.%2BL.%26aulast%3DLewis%26aufirst%3DR.%2BT.%26atitle%3DRapid%2520Development%2520of%2520Piperidine%2520Carboxamides%2520as%2520Potent%2520and%2520Selective%2520Anaplastic%2520Lymphoma%2520Kinase%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D1698%26epage%3D1705%26doi%3D10.1021%2Fjm201565s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tu, C.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, W.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, Y.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, C.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyu, P.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shih, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiaang, W. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, S. Y.</span></span> <span> </span><span class="NLM_article-title">Pyrazolylamine Derivatives Reveal the Conformational Switching between Type I and Type II Binding Modes of Anaplastic Lymphoma Kinase (ALK)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">3906</span>– <span class="NLM_lpage">3919</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00106</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00106" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC28Xlt1GjsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=3906-3919&author=C.-H.+Tuauthor=W.-H.+Linauthor=Y.-H.+Pengauthor=T.+Hsuauthor=J.-S.+Wuauthor=C.-Y.+Changauthor=C.-T.+Luauthor=P.-C.+Lyuauthor=C.+Shihauthor=W.+T.+Jiaangauthor=S.+Y.+Wu&title=Pyrazolylamine+Derivatives+Reveal+the+Conformational+Switching+between+Type+I+and+Type+II+Binding+Modes+of+Anaplastic+Lymphoma+Kinase+%28ALK%29&doi=10.1021%2Facs.jmedchem.6b00106"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Pyrazolylamine Derivatives Reveal the Conformational Switching between Type I and Type II Binding Modes of Anaplastic Lymphoma Kinase (ALK)</span></div><div class="casAuthors">Tu, Chih-Hsiang; Lin, Wen-Hsing; Peng, Yi-Hui; Hsu, Tsu; Wu, Jian-Sung; Chang, Chun-Yu; Lu, Cheng-Tai; Lyu, Ping-Chiang; Shih, Chuan; Jiaang, Weir-Torn; Wu, Su-Ying</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3906-3919</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Most anaplastic lymphoma kinase (ALK) inhibitors adopt a type I binding mode, but only limited type II ALK structural studies are available.  Herein, the authors present the structure of ALK in complex with N1-(3-4-[([5-(tert-butyl)-3-isoxazolyl]aminocarbonyl)amino]-3-methylphenyl-1H-5-pyrazolyl)-4-[(4-methylpiperazino)methyl]benzamide (5a), a novel ALK inhibitor adopting a type II binding mode.  It revealed binding of 5a resulted in the conformational change and reposition of the activation loop, αC-helix, and juxtamembrane domain, which are all important domains for the autoinhibition mechanism and downstream signal pathway regulation of ALK.  A structure-activity relationship study revealed that modifications to the structure of 5a led to significant differences in the ALK potency and altered the protein structure of ALK.  To the best of the authors' knowledge, this is the first structural biol. study to directly observe how changes in the structure of a small mol. can regulate the switch between the type I and type II binding modes and induce dramatic conformational changes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpX2IoqRzkgK7Vg90H21EOLACvtfcHk0lhLySx5uP2U0Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xlt1GjsLk%253D&md5=732cbe2ef77a84f50de49aeef838895d</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00106%26sid%3Dliteratum%253Aachs%26aulast%3DTu%26aufirst%3DC.-H.%26aulast%3DLin%26aufirst%3DW.-H.%26aulast%3DPeng%26aufirst%3DY.-H.%26aulast%3DHsu%26aufirst%3DT.%26aulast%3DWu%26aufirst%3DJ.-S.%26aulast%3DChang%26aufirst%3DC.-Y.%26aulast%3DLu%26aufirst%3DC.-T.%26aulast%3DLyu%26aufirst%3DP.-C.%26aulast%3DShih%26aufirst%3DC.%26aulast%3DJiaang%26aufirst%3DW.%2BT.%26aulast%3DWu%26aufirst%3DS.%2BY.%26atitle%3DPyrazolylamine%2520Derivatives%2520Reveal%2520the%2520Conformational%2520Switching%2520between%2520Type%2520I%2520and%2520Type%2520II%2520Binding%2520Modes%2520of%2520Anaplastic%2520Lymphoma%2520Kinase%2520%2528ALK%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D3906%26epage%3D3919%26doi%3D10.1021%2Facs.jmedchem.6b00106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, T.</span></span> <span> </span><span class="NLM_article-title">Combating Drug-Resistant Mutants of Anaplastic Lymphoma Kinase with Potent and Selective Type-I1/2 Inhibitors by Stabilizing Unique DFG-Shifted Loop Conformation</span>. <i>ACS Central Sci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">1208</span>– <span class="NLM_lpage">1220</span>, <span class="refDoi"> DOI: 10.1021/acscentsci.7b00419</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acscentsci.7b00419" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhslGgs77I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2017&pages=1208-1220&author=P.+Panauthor=H.+Yuauthor=Q.+Liuauthor=X.+Kongauthor=H.+Chenauthor=J.+Chenauthor=Q.+Liuauthor=D.+Liauthor=Y.+Kangauthor=H.+Sunauthor=W.+Zhouauthor=S.+Tianauthor=S.+Cuiauthor=F.+Zhuauthor=Y.+Liauthor=Y.+Huangauthor=T.+Hou&title=Combating+Drug-Resistant+Mutants+of+Anaplastic+Lymphoma+Kinase+with+Potent+and+Selective+Type-I1%2F2+Inhibitors+by+Stabilizing+Unique+DFG-Shifted+Loop+Conformation&doi=10.1021%2Facscentsci.7b00419"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Combating Drug-Resistant Mutants of Anaplastic Lymphoma Kinase with Potent and Selective Type-I1/2 Inhibitors by Stabilizing Unique DFG-Shifted Loop Conformation</span></div><div class="casAuthors">Pan, Peichen; Yu, Huidong; Liu, Qinglan; Kong, Xiaotian; Chen, Hu; Chen, Jiean; Liu, Qi; Li, Dan; Kang, Yu; Sun, Huiyong; Zhou, Wenfang; Tian, Sheng; Cui, Sunliang; Zhu, Feng; Li, Youyong; Huang, Yong; Hou, Tingjun</div><div class="citationInfo"><span class="NLM_cas:title">ACS Central Science</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1208-1220</span>CODEN:
                <span class="NLM_cas:coden">ACSCII</span>;
        ISSN:<span class="NLM_cas:issn">2374-7951</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Targeted inhibition of anaplastic lymphoma kinase (ALK) dramatically improved therapeutic outcomes in the treatment of ALK-pos. cancers, but unfortunately patients invariably progressed due to acquired resistance mutations in ALK.  Currently available drugs are all type-I inhibitors bound to the ATP-binding pocket and are most likely to be resistant in patients harboring genetic mutations surrounding the ATP pocket.  To overcome drug resistance, the authors rationally designed a novel kind of "bridge" inhibitor, which specially bind into an extended hydrophobic back pocket adjacent to the ATP-binding site of ALK.  The novel type-I1/2 inhibitors display excellent antiproliferation activity against ALK-pos. cancer cells and appear superior to two clin. used drugs, crizotinib and ceritinib.  Structural and mol. modeling analyses indicate that the inhibitor induces dramatic conformational transition and stabilizes unique DFG-shifted loop conformation, enabling persistent sensitivity to different genetic mutations in ALK.  These data highlight a rationale for further development of next-generation ALK inhibitors to combat drug resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUNJfWr_d0k7Vg90H21EOLACvtfcHk0lhLySx5uP2U0Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhslGgs77I&md5=9e0517648f375fe4fb7b9a3d622d5a8d</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1021%2Facscentsci.7b00419&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facscentsci.7b00419%26sid%3Dliteratum%253Aachs%26aulast%3DPan%26aufirst%3DP.%26aulast%3DYu%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DKong%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DKang%26aufirst%3DY.%26aulast%3DSun%26aufirst%3DH.%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DTian%26aufirst%3DS.%26aulast%3DCui%26aufirst%3DS.%26aulast%3DZhu%26aufirst%3DF.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DHou%26aufirst%3DT.%26atitle%3DCombating%2520Drug-Resistant%2520Mutants%2520of%2520Anaplastic%2520Lymphoma%2520Kinase%2520with%2520Potent%2520and%2520Selective%2520Type-I1%252F2%2520Inhibitors%2520by%2520Stabilizing%2520Unique%2520DFG-Shifted%2520Loop%2520Conformation%26jtitle%3DACS%2520Central%2520Sci.%26date%3D2017%26volume%3D3%26spage%3D1208%26epage%3D1220%26doi%3D10.1021%2Facscentsci.7b00419" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kang, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du Ha, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hwang, J. Y.</span></span> <span> </span><span class="NLM_article-title">Induced Protein Degradation of Anaplastic Lymphoma Kinase (ALK) by Proteolysis Targeting Chimera (PROTAC)</span>. <i>Biochem. Biophys. Res. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>505</i></span>,  <span class="NLM_fpage">542</span>– <span class="NLM_lpage">547</span>, <span class="refDoi"> DOI: 10.1016/j.bbrc.2018.09.169</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1016%2Fj.bbrc.2018.09.169" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=30274779" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvVejs7fE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=505&publication_year=2018&pages=542-547&author=C.+H.+Kangauthor=D.+H.+Leeauthor=C.+O.+Leeauthor=J.+Du+Haauthor=C.+H.+Parkauthor=J.+Y.+Hwang&title=Induced+Protein+Degradation+of+Anaplastic+Lymphoma+Kinase+%28ALK%29+by+Proteolysis+Targeting+Chimera+%28PROTAC%29&doi=10.1016%2Fj.bbrc.2018.09.169"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Induced protein degradation of anaplastic lymphoma kinase (ALK) by proteolysis targeting chimera (PROTAC)</span></div><div class="casAuthors">Kang, Chung Hyo; Lee, Dong Ho; Lee, Chong Ock; Du Ha, Jae; Park, Chi Hoon; Hwang, Jong Yeon</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical and Biophysical Research Communications</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">505</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">542-547</span>CODEN:
                <span class="NLM_cas:coden">BBRCA9</span>;
        ISSN:<span class="NLM_cas:issn">0006-291X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Recently, proteolysis targeting chimera (PROTAC) technol. is highlighted in drug discovery area as a new therapeutic approach.  PROTAC as a heterobifunctional mol. is comprised of two ligands, which recruit target protein and E3 ligase, resp.  To degrade the anaplastic lymphoma kinase (ALK) fusion protein, such as NPM-ALK or EML4-ALK, we generated several ALK-PROTAC mols. consisted of ceritinib, one of the ALK inhibitors, and ligand of von Hippel-Lindau (VHL) E3 ligase.  Among these mols., TD-004 effectively induced ALK degrdn. and inhibited the growth of ALK fusion pos. cell lines, SU-DHL-1 and H3122.  We also confirmed that TD-004 significantly reduced the tumor growth in H3122 xenograft model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8JUOZ5fYNW7Vg90H21EOLACvtfcHk0lg2gs_L1MeIcg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvVejs7fE&md5=cac9252fca98ebec4ad8e5aeed7b7550</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1016%2Fj.bbrc.2018.09.169&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbrc.2018.09.169%26sid%3Dliteratum%253Aachs%26aulast%3DKang%26aufirst%3DC.%2BH.%26aulast%3DLee%26aufirst%3DD.%2BH.%26aulast%3DLee%26aufirst%3DC.%2BO.%26aulast%3DDu%2BHa%26aufirst%3DJ.%26aulast%3DPark%26aufirst%3DC.%2BH.%26aulast%3DHwang%26aufirst%3DJ.%2BY.%26atitle%3DInduced%2520Protein%2520Degradation%2520of%2520Anaplastic%2520Lymphoma%2520Kinase%2520%2528ALK%2529%2520by%2520Proteolysis%2520Targeting%2520Chimera%2520%2528PROTAC%2529%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D2018%26volume%3D505%26spage%3D542%26epage%3D547%26doi%3D10.1016%2Fj.bbrc.2018.09.169" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Powell, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donovan, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nowak, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loehr, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bahcall, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janne, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">George, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span> <span> </span><span class="NLM_article-title">Chemically Induced Degradation of Anaplastic Lymphoma Kinase (ALK)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">4249</span>– <span class="NLM_lpage">4255</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01655</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01655" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC1cXns1OitrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=4249-4255&author=C.+E.+Powellauthor=Y.+Gaoauthor=L.+Tanauthor=K.+A.+Donovanauthor=R.+P.+Nowakauthor=A.+Loehrauthor=M.+Bahcallauthor=E.+S.+Fischerauthor=P.+A.+Janneauthor=R.+E.+Georgeauthor=N.+S.+Gray&title=Chemically+Induced+Degradation+of+Anaplastic+Lymphoma+Kinase+%28ALK%29&doi=10.1021%2Facs.jmedchem.7b01655"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Chemically Induced Degradation of Anaplastic Lymphoma Kinase (ALK)</span></div><div class="casAuthors">Powell, Chelsea E.; Gao, Yang; Tan, Li; Donovan, Katherine A.; Nowak, Radoslaw P.; Loehr, Amanda; Bahcall, Magda; Fischer, Eric S.; Janne, Pasi A.; George, Rani E.; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4249-4255</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We present the development of the first small mol. degraders that can induce anaplastic lymphoma kinase (ALK) degrdn., including in non-small-cell lung cancer (NSCLC), anaplastic large-cell lymphoma (ALCL), and neuroblastoma (NB) cell lines.  These degraders were developed through conjugation of known pyrimidine-based ALK inhibitors, TAE684 or LDK378, and the cereblon ligand pomalidomide.  We demonstrate that in some cell types degrader potency is compromised by expression of drug transporter ABCB1.  In addn., proteomic profiling demonstrated that these compds. also promote the degrdn. of addnl. kinases including PTK2 (FAK), Aurora A, FER, and RPS6KA1 (RSK1).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7mDH7Sj8EqbVg90H21EOLACvtfcHk0lg2gs_L1MeIcg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXns1OitrY%253D&md5=486db11b3fbc2283700f38b09cc39bd7</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01655&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01655%26sid%3Dliteratum%253Aachs%26aulast%3DPowell%26aufirst%3DC.%2BE.%26aulast%3DGao%26aufirst%3DY.%26aulast%3DTan%26aufirst%3DL.%26aulast%3DDonovan%26aufirst%3DK.%2BA.%26aulast%3DNowak%26aufirst%3DR.%2BP.%26aulast%3DLoehr%26aufirst%3DA.%26aulast%3DBahcall%26aufirst%3DM.%26aulast%3DFischer%26aufirst%3DE.%2BS.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26aulast%3DGeorge%26aufirst%3DR.%2BE.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DChemically%2520Induced%2520Degradation%2520of%2520Anaplastic%2520Lymphoma%2520Kinase%2520%2528ALK%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D4249%26epage%3D4255%26doi%3D10.1021%2Facs.jmedchem.7b01655" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, X.-R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, J.</span></span> <span> </span><span class="NLM_article-title">Proteolysis Targeting Chimeras (PROTACs) of Anaplastic Lymphoma Kinase (ALK)</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>151</i></span>,  <span class="NLM_fpage">304</span>– <span class="NLM_lpage">314</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2018.03.071</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1016%2Fj.ejmech.2018.03.071" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=29627725" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC1cXnt1ejs7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=151&publication_year=2018&pages=304-314&author=C.+Zhangauthor=X.-R.+Hanauthor=X.+Yangauthor=B.+Jiangauthor=J.+Liuauthor=Y.+Xiongauthor=J.+Jin&title=Proteolysis+Targeting+Chimeras+%28PROTACs%29+of+Anaplastic+Lymphoma+Kinase+%28ALK%29&doi=10.1016%2Fj.ejmech.2018.03.071"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Proteolysis Targeting Chimeras (PROTACs) of Anaplastic Lymphoma Kinase (ALK)</span></div><div class="casAuthors">Zhang, Chengwei; Han, Xiao-Ran; Yang, Xiaobao; Jiang, Biao; Liu, Jing; Xiong, Yue; Jin, Jian</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">151</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">304-314</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Anaplastic lymphoma kinase (ALK) activation has been assocd. with many types of human cancer.  Significant efforts have been devoted to the development of ALK inhibitors to antagonize the kinase activity of ALK.  Four ALK inhibitors have been approved by the FDA to date for treating patients with ALK-pos. nonsmall cell lung cancers (NSCLC).  However, drug resistance has been obsd. in the majority of patients treated with these inhibitors.  New therapeutic strategies (e.g., compds. with novel mechanisms of action) are needed to overcome the drug resistance issue.  The emerging PROTAC (Proteolysis Targeting Chimera) technol. has been successfully applied to selective degrdn. of multiple protein targets, but not ALK.  Since ALK protein levels are not important for viability in mammals, ALK PROTACs could lead to novel therapeutics with minimal toxicity.  Here the authors report the design, synthesis and biol. evaluation of novel PROTACs (degraders) of ALK.  MS4077 (I) and MS4078 (II) potently decreased cellular levels of oncogenic active ALK fusion proteins in a concn.- and time-dependent manner in SU-DHL-1 lymphoma and NCI-H2228 lung cancer cells.  The ALK protein degrdn. induced by compds. I and II was cereblon and proteasome dependent.  In addn., compds. I and II potently inhibited proliferation of SU-DHL-1 cells.  Furthermore, compd. II displayed good plasma exposure in a mouse pharmacokinetic study, thus is suitable for in vivo efficacy studies.  The authors also developed MS4748 and MS4740 , very close analogs of I and II resp., which are incapable to degrade the ALK fusion proteins, as neg. controls.  All 4 compds. are valuable chem. tools for investigating effects of ALK pharmacol. degrdn.  The study paved the way for developing the next generation of ALK PROTACs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPGM3aAZZ6h7Vg90H21EOLACvtfcHk0lg2gs_L1MeIcg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXnt1ejs7Y%253D&md5=804324b95034f38b46e45f89e18e55be</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.03.071&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.03.071%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DHan%26aufirst%3DX.-R.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DJiang%26aufirst%3DB.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DXiong%26aufirst%3DY.%26aulast%3DJin%26aufirst%3DJ.%26atitle%3DProteolysis%2520Targeting%2520Chimeras%2520%2528PROTACs%2529%2520of%2520Anaplastic%2520Lymphoma%2520Kinase%2520%2528ALK%2529%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D151%26spage%3D304%26epage%3D314%26doi%3D10.1016%2Fj.ejmech.2018.03.071" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bossi, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saccardo, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ardini, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menichincheri, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rusconi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magnaghi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orsini, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avanzi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borgia, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nesi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bandiera, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fogliatto, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertrand, J. A.</span></span> <span> </span><span class="NLM_article-title">Crystal Structures of Anaplastic Lymphoma Kinase in Complex with ATP Competitive Inhibitors</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">6813</span>– <span class="NLM_lpage">6825</span>, <span class="refDoi"> DOI: 10.1021/bi1005514</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi1005514" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpt1Clsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2010&pages=6813-6825&author=R.+T.+Bossiauthor=M.+B.+Saccardoauthor=E.+Ardiniauthor=M.+Menichincheriauthor=L.+Rusconiauthor=P.+Magnaghiauthor=P.+Orsiniauthor=N.+Avanziauthor=A.+L.+Borgiaauthor=M.+Nesiauthor=T.+Bandieraauthor=G.+Fogliattoauthor=J.+A.+Bertrand&title=Crystal+Structures+of+Anaplastic+Lymphoma+Kinase+in+Complex+with+ATP+Competitive+Inhibitors&doi=10.1021%2Fbi1005514"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal Structures of Anaplastic Lymphoma Kinase in Complex with ATP Competitive Inhibitors</span></div><div class="casAuthors">Bossi, Roberto T.; Saccardo, M. Beatrice; Ardini, Elena; Menichincheri, Maria; Rusconi, Luisa; Magnaghi, Paola; Orsini, Paolo; Avanzi, Nilla; Borgia, Andrea Lombardi; Nesi, Marcella; Bandiera, Tiziano; Fogliatto, Gianpaolo; Bertrand, Jay A.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">32</span>),
    <span class="NLM_cas:pages">6813-6825</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase involved in the development of several human cancers and, as a result, is a recognized target for the development of small-mol. inhibitors for the treatment of ALK-pos. malignancies.  Here, the crystal structures of the unphosphorylated human ALK kinase domain in complex with the ATP competitive ligands PHA-E429 and NVP-TAE684 are presented.  Anal. of these structures provides valuable information concerning the specific characteristics of the ALK active site as well as giving indications about how to obtain selective ALK inhibitors.  In addn., the ALK-KD-PHA-E429 structure led to the identification of a potential regulatory mechanism involving a link made between a short helical segment immediately following the DFG motif and an N-terminal two-stranded β-sheet.  Finally, mapping of the activating mutations assocd. with neuroblastoma onto the structures may explain the roles these residues have in the activation process.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2b8yuzTuAYbVg90H21EOLACvtfcHk0liPTd1dO-NagQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpt1Clsbs%253D&md5=e8e9e3fde63a196a15c874300c995342</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1021%2Fbi1005514&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi1005514%26sid%3Dliteratum%253Aachs%26aulast%3DBossi%26aufirst%3DR.%2BT.%26aulast%3DSaccardo%26aufirst%3DM.%2BB.%26aulast%3DArdini%26aufirst%3DE.%26aulast%3DMenichincheri%26aufirst%3DM.%26aulast%3DRusconi%26aufirst%3DL.%26aulast%3DMagnaghi%26aufirst%3DP.%26aulast%3DOrsini%26aufirst%3DP.%26aulast%3DAvanzi%26aufirst%3DN.%26aulast%3DBorgia%26aufirst%3DA.%2BL.%26aulast%3DNesi%26aufirst%3DM.%26aulast%3DBandiera%26aufirst%3DT.%26aulast%3DFogliatto%26aufirst%3DG.%26aulast%3DBertrand%26aufirst%3DJ.%2BA.%26atitle%3DCrystal%2520Structures%2520of%2520Anaplastic%2520Lymphoma%2520Kinase%2520in%2520Complex%2520with%2520ATP%2520Competitive%2520Inhibitors%26jtitle%3DBiochemistry%26date%3D2010%26volume%3D49%26spage%3D6813%26epage%3D6825%26doi%3D10.1021%2Fbi1005514" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ng, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ambing, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, M.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hua, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michellys, P.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lesley, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spraggon, G.</span></span> <span> </span><span class="NLM_article-title">Crystal Structure of the ALK (Anaplastic Lymphoma Kinase) Catalytic Domain</span>. <i>Biochem. J.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>430</i></span>,  <span class="NLM_fpage">425</span>– <span class="NLM_lpage">437</span>, <span class="refDoi"> DOI: 10.1042/BJ20100609</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1042%2FBJ20100609" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=20632993" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVyrtbzF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=430&publication_year=2010&pages=425-437&author=C.+C.+Leeauthor=Y.+Jiaauthor=N.+Liauthor=X.+Sunauthor=K.+Ngauthor=E.+Ambingauthor=M.-Y.+Gaoauthor=S.+Huaauthor=C.+Chenauthor=S.+Kimauthor=P.-Y.+Michellysauthor=S.+A.+Lesleyauthor=J.+L.+Harrisauthor=G.+Spraggon&title=Crystal+Structure+of+the+ALK+%28Anaplastic+Lymphoma+Kinase%29+Catalytic+Domain&doi=10.1042%2FBJ20100609"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structure of the ALK (anaplastic lymphoma kinase) catalytic domain</span></div><div class="casAuthors">Lee, Christian C.; Jia, Yong; Li, Nanxin; Sun, Xiuying; Ng, Kenneth; Ambing, Eileen; Gao, Mu-Yun; Hua, Su; Chen, Connie; Kim, Sungjoon; Michellys, Pierre-Yves; Lesley, Scott A.; Harris, Jennifer L.; Spraggon, Glen</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Journal</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">430</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">425-437</span>CODEN:
                <span class="NLM_cas:coden">BIJOAK</span>;
        ISSN:<span class="NLM_cas:issn">0264-6021</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">ALK (anaplastic lymphoma kinase) is an RTK (receptor tyrosine kinase) of the IRK (insulin receptor kinase) superfamily, which share an YXXXYY autophosphorylation motif within their A-loops (activation loops).  A common activation and regulatory mechanism is believed to exist for members of this superfamily typified by IRK and IGF1RK (insulin-like growth factor receptor kinase-1).  Chromosomal translocations involving ALK were first identified in anaplastic large-cell lymphoma, a subtype of non-Hodgkin's lymphoma, where aberrant fusion of the ALK kinase domain with the NPM (nucleophosmin) dimerization domain results in autophosphosphorylation and ligand-independent activation.  Activating mutations within the full-length ALK kinase domain, most commonly R1275Q and F1174L, which play a major role in neuroblastoma, were recently identified.  To provide a structural framework for understanding these mutations and to guide structure-assisted drug discovery efforts, the X-ray crystal structure of the unphosphorylated ALK catalytic domain was detd. in the apo, ADP-, and staurosporine-bound forms.  The structures reveal a partially inactive protein kinase conformation distinct from, and lacking, many of the neg. regulatory features obsd. in inactive IGF1RK/IRK structures in their unphosphorylated forms.  The A-loop adopts an inhibitory pose where a short proximal A-loop helix (αAL) packs against the αC helix and a novel N-terminal β-turn motif, whereas the distal portion obstructs part of the predicted peptide-binding region.  The structure helps explain the reported unique peptide substrate specificity and the importance of phosphorylation of the first A-loop Tyr1278 for kinase activity and NPM-ALK transforming potential.  A single amino acid difference in the ALK substrate peptide binding P-1 site (where the P-site is the phosphoacceptor site) was identified such that in conjunction with A-loop sequence variation including the RAS (Arg-Ala-Ser)-motif, rationalizes the difference in the A-loop tyrosine autophosphorylation preference between ALK and IGF1RK/IRK.  Enzymic anal. of recombinant R1275Q and F1174L ALK mutant catalytic domains confirms the enhanced activity and transforming potential of these mutants.  The transforming ability of the full-length ALK mutants in soft agar colony growth assays corroborates these findings.  The availability of a three-dimensional structure for ALK will facilitate future structure-function and rational drug design efforts targeting this receptor tyrosine kinase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWD8K_u619kbVg90H21EOLACvtfcHk0liPTd1dO-NagQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVyrtbzF&md5=e9e4f5bc0b22e3e2289eecfa10309c16</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1042%2FBJ20100609&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FBJ20100609%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DC.%2BC.%26aulast%3DJia%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DN.%26aulast%3DSun%26aufirst%3DX.%26aulast%3DNg%26aufirst%3DK.%26aulast%3DAmbing%26aufirst%3DE.%26aulast%3DGao%26aufirst%3DM.-Y.%26aulast%3DHua%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DMichellys%26aufirst%3DP.-Y.%26aulast%3DLesley%26aufirst%3DS.%2BA.%26aulast%3DHarris%26aufirst%3DJ.%2BL.%26aulast%3DSpraggon%26aufirst%3DG.%26atitle%3DCrystal%2520Structure%2520of%2520the%2520ALK%2520%2528Anaplastic%2520Lymphoma%2520Kinase%2529%2520Catalytic%2520Domain%26jtitle%3DBiochem.%2520J.%26date%3D2010%26volume%3D430%26spage%3D425%26epage%3D437%26doi%3D10.1042%2FBJ20100609" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hallberg, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmer, R. H.</span></span> <span> </span><span class="NLM_article-title">The Role of the ALK Receptor in Cancer Biology</span>. <i>Ann. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">iii4</span>– <span class="NLM_lpage">iii15</span>, <span class="refDoi"> DOI: 10.1093/annonc/mdw301</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1093%2Fannonc%2Fmdw301" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=27573755" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2016&pages=iii4-iii15&author=B.+Hallbergauthor=R.+H.+Palmer&title=The+Role+of+the+ALK+Receptor+in+Cancer+Biology&doi=10.1093%2Fannonc%2Fmdw301"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdw301&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdw301%26sid%3Dliteratum%253Aachs%26aulast%3DHallberg%26aufirst%3DB.%26aulast%3DPalmer%26aufirst%3DR.%2BH.%26atitle%3DThe%2520Role%2520of%2520the%2520ALK%2520Receptor%2520in%2520Cancer%2520Biology%26jtitle%3DAnn.%2520Oncol.%26date%3D2016%26volume%3D27%26spage%3Diii4%26epage%3Diii15%26doi%3D10.1093%2Fannonc%2Fmdw301" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tartari, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunby, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coluccia, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sottocornola, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cimbro, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scapozza, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donella-Deana, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinna, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gambacorti-Passerini, C.</span></span> <span> </span><span class="NLM_article-title">Characterization of Some Molecular Mechanisms Governing Autoactivation of the Catalytic Domain of the Anaplastic Lymphoma Kinase</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>283</i></span>,  <span class="NLM_fpage">3743</span>– <span class="NLM_lpage">3750</span>, <span class="refDoi"> DOI: 10.1074/jbc.M706067200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1074%2Fjbc.M706067200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=18070884" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhs1WgsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=283&publication_year=2008&pages=3743-3750&author=C.+J.+Tartariauthor=R.+H.+Gunbyauthor=A.+M.+Colucciaauthor=R.+Sottocornolaauthor=B.+Cimbroauthor=L.+Scapozzaauthor=A.+Donella-Deanaauthor=L.+A.+Pinnaauthor=C.+Gambacorti-Passerini&title=Characterization+of+Some+Molecular+Mechanisms+Governing+Autoactivation+of+the+Catalytic+Domain+of+the+Anaplastic+Lymphoma+Kinase&doi=10.1074%2Fjbc.M706067200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of Some Molecular Mechanisms Governing Autoactivation of the Catalytic Domain of the Anaplastic Lymphoma Kinase</span></div><div class="casAuthors">Tartari, Carmen J.; Gunby, Rosalind H.; Coluccia, Addolorata M. L.; Sottocornola, Roberta; Cimbro, Barbara; Scapozza, Leonardo; Donella-Deana, Arianna; Pinna, Lorenzo A.; Gambacorti-Passerini, Carlo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">283</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3743-3750</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">NPM/ALK is an oncogenic fusion protein expressed in ∼50% of anaplastic large cell lymphoma cases.  It derives from the t(2;5)(p23;q35) chromosomal translocation that fuses the catalytic domain of the tyrosine kinase, anaplastic lymphoma kinase (ALK), with the dimerization domain of the ubiquitously expressed nucleophosmin (NPM) protein.  Dimerization of the ALK kinase domain leads to its autophosphorylation and constitutive activation.  Activated NPM/ALK stimulates downstream survival and proliferation signaling pathways leading to malignant transformation.  Herein, we investigated the mol. mechanisms of autoactivation of the catalytic domain of ALK.  Because kinases are typically regulated by autophosphorylation of their activation loops, we systematically mutated (Tyr Phe) three potential autophosphorylation sites contained in the "YXXXYY" motif of the ALK activation loop, and detd. the effect of these mutations on the catalytic activity and biol. function of NPM/ALK.  We obsd. that mutation of both the second and third tyrosine residues (YFF mutant) did not affect the kinase activity or transforming ability of NPM/ALK.  In contrast, mutation of the first and second (FFY), first and third (FYF), or all three (FFF) tyrosine residues impaired both kinase activity and transforming ability of NPM/ALK.  Furthermore, a DFF mutant, in which the aspartic residue introduces a neg. charge similar to a phosphorylated tyrosine, possessed catalytic activity similar to the YFF mutant.  Together, our findings indicate that phosphorylation of the first tyrosine of the YXXXYY motif is necessary for the autoactivation of the ALK kinase domain and the transforming activity of NPM/ALK.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGop38yy8tqZ5LVg90H21EOLACvtfcHk0liuCbBtSsN8pQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhs1WgsL8%253D&md5=b6089571580540b97253db0b916e6ed3</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M706067200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M706067200%26sid%3Dliteratum%253Aachs%26aulast%3DTartari%26aufirst%3DC.%2BJ.%26aulast%3DGunby%26aufirst%3DR.%2BH.%26aulast%3DColuccia%26aufirst%3DA.%2BM.%26aulast%3DSottocornola%26aufirst%3DR.%26aulast%3DCimbro%26aufirst%3DB.%26aulast%3DScapozza%26aufirst%3DL.%26aulast%3DDonella-Deana%26aufirst%3DA.%26aulast%3DPinna%26aufirst%3DL.%2BA.%26aulast%3DGambacorti-Passerini%26aufirst%3DC.%26atitle%3DCharacterization%2520of%2520Some%2520Molecular%2520Mechanisms%2520Governing%2520Autoactivation%2520of%2520the%2520Catalytic%2520Domain%2520of%2520the%2520Anaplastic%2520Lymphoma%2520Kinase%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2008%26volume%3D283%26spage%3D3743%26epage%3D3750%26doi%3D10.1074%2Fjbc.M706067200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bai, R.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ouyang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miething, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morris, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peschel, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duyster, J.</span></span> <span> </span><span class="NLM_article-title">Nucleophosmin–anaplastic Lymphoma Kinase Associated with Anaplastic Large-cell Lymphoma Activates the Phosphatidylinositol 3-kinase/Akt antiapoptotic Signaling Pathway</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>96</i></span>,  <span class="NLM_fpage">4319</span>– <span class="NLM_lpage">4327</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1182%2Fblood.V96.13.4319" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=11110708" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BD3cXosl2htLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=2000&pages=4319-4327&author=R.-Y.+Baiauthor=T.+Ouyangauthor=C.+Miethingauthor=S.+W.+Morrisauthor=C.+Peschelauthor=J.+Duyster&title=Nucleophosmin%E2%80%93anaplastic+Lymphoma+Kinase+Associated+with+Anaplastic+Large-cell+Lymphoma+Activates+the+Phosphatidylinositol+3-kinase%2FAkt+antiapoptotic+Signaling+Pathway"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Nucleophosmin-anaplastic lymphoma kinase associated with anaplastic large-cell lymphoma activates the phosphatidylinositol 3-kinase/Akt antiapoptotic signaling pathway</span></div><div class="casAuthors">Bai, Ren-Yuan; Ouyang, Tao; Miething, Cornelius; Morris, Stephan W.; Peschel, Christian; Duyster, Justus</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">96</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">4319-4327</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">More than half of anaplastic large-cell lymphomas (ALCLs) have a chromosomal translocation t(2;5) that leads to the expression of a hybrid protein composed of the nucleolar phosphoprotein nucleophosmin (NPM) and the anaplastic lymphoma kinase (ALK) that exhibits an unregulated tyrosine kinase activity.  We have previously identified PLC-γ as a crucial downstream signaling mol. of NPM-ALK that contributes to its mitogenic potential.  Here, we show that NPM-ALK recruits the C-terminal SH2 domain of the phosphatidylinositol 3-kinase (PI 3-kinase) p85 subunit.  PI 3-kinase assays revealed that the kinase is activated by NPM-ALK in vivo, in turn activating PKB/Akt in NPM-ALK-expressing cells.  The use of 2 specific PI 3-kinase inhibitors, wortmannin and LY294002, demonstrated the requirement of PI 3-kinase for the growth of NPM-ALK-transformed cell lines, as well as a cell line established from a patient with ALCL.  Primary murine bone marrow retrovirally transduced with NPM-ALK showed a transformed phenotype that was reversible on treatment with PI 3-kinase inhibitors.  Flow cytometric anal. revealed that wortmannin-treated NPM-ALK-transformed cell lines underwent apoptosis.  Furthermore, apoptosis induced by overexpression of the proapoptotic mol. Bad could be partially blocked by the overexpression of NPM-ALK.  Thus, NPM-ALK activates the antiapoptotic PI 3-kinase/Akt pathway, which likely contributes to the mol. pathogenesis of ALCL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkqKB28Z-9f7Vg90H21EOLACvtfcHk0liuCbBtSsN8pQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXosl2htLg%253D&md5=cc7077b113a3ab10d76f9915aad6592d</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1182%2Fblood.V96.13.4319&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood.V96.13.4319%26sid%3Dliteratum%253Aachs%26aulast%3DBai%26aufirst%3DR.-Y.%26aulast%3DOuyang%26aufirst%3DT.%26aulast%3DMiething%26aufirst%3DC.%26aulast%3DMorris%26aufirst%3DS.%2BW.%26aulast%3DPeschel%26aufirst%3DC.%26aulast%3DDuyster%26aufirst%3DJ.%26atitle%3DNucleophosmin%25E2%2580%2593anaplastic%2520Lymphoma%2520Kinase%2520Associated%2520with%2520Anaplastic%2520Large-cell%2520Lymphoma%2520Activates%2520the%2520Phosphatidylinositol%25203-kinase%252FAkt%2520antiapoptotic%2520Signaling%2520Pathway%26jtitle%3DBlood%26date%3D2000%26volume%3D96%26spage%3D4319%26epage%3D4327" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ruchatz, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coluccia, A. M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stano, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marchesi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gambacorti-Passerini, C.</span></span> <span> </span><span class="NLM_article-title">Constitutive Activation of Jak2 Contributes to Proliferation and Resistance to Apoptosis in NPM/ALK-transformed Cells</span>. <i>Exp. Hematol.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">309</span>– <span class="NLM_lpage">315</span>, <span class="refDoi"> DOI: 10.1016/S0301-472X(03)00007-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1016%2FS0301-472X%2803%2900007-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=12691918" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BD3sXislChtrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2003&pages=309-315&author=H.+Ruchatzauthor=A.+M.+L.+Colucciaauthor=P.+Stanoauthor=E.+Marchesiauthor=C.+Gambacorti-Passerini&title=Constitutive+Activation+of+Jak2+Contributes+to+Proliferation+and+Resistance+to+Apoptosis+in+NPM%2FALK-transformed+Cells&doi=10.1016%2FS0301-472X%2803%2900007-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Constitutive activation of Jak2 contributes to proliferation and resistance to apoptosis in NPM/ALK-transformed cells</span></div><div class="casAuthors">Ruchatz, Holger; Coluccia, Addolorata Maria Luce; Stano, Paola; Marchesi, Edoardo; Gambacorti-Passerini, Carlo</div><div class="citationInfo"><span class="NLM_cas:title">Experimental Hematology (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">309-315</span>CODEN:
                <span class="NLM_cas:coden">EXHMA6</span>;
        ISSN:<span class="NLM_cas:issn">0301-472X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Inc.</span>)
        </div><div class="casAbstract">The t(2;5) translocation results in a 80-kDa oncogenic fusion protein consisting of NPM and the kinase domain of the tyrosine kinase ALK and is present in over half the cases of anaplastic large cell lymphoma (ALCL).  NPM/ALK exerts its transforming potential via activation of multiple signaling pathways promoting growth factor independence and protection from apoptosis.  Jak/Stat signaling is aberrantly activated in several human hematopoietic malignancies.  We investigated the role of Jak2 in the context of NPM/ALK-mediated oncogenesis.  Constitutive tyrosine phosphorylation of Jak2 was analyzed by Jak2 immunopptn. and subsequent anti-phosphotyrosine Western blotting.  NPM/ALK-transformed cells were treated with the Jak2 inhibitor AG490 or transfected with wild-type or dominant-neg. Jak2 expression constructs to measure [3H]-thymidine incorporation.  Apoptosis was assessed by flow cytometric anal. of annexin V-stained cells.  The effect of Jak2 on Stat5-dependent transcriptional activity was measured by β-casein promoter-dependent luciferase expression.  Jak2 was found to be constitutively tyrosine phosphorylated in ALCL cells and in NPM/ALK-transformed hematopoietic cells.  Also, NPM/ALK was present in immunoppts. of Jak2.  Inhibition of Jak2 led to a redn. of NPM/ALK-mediated proliferation and induced apoptosis.  Stat5-dependent transcriptional activity was inhibited by transfection of NPM/ALK-transformed cells with a dominant-neg. Jak2 expression construct or treatment with AG490.  Constitutive activation of Jak2 constitutes a pro-proliferative, anti-apoptotic signaling pathway in NPM/ALK-transformed hematopoietic cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9lWibjrvvMLVg90H21EOLACvtfcHk0liuCbBtSsN8pQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXislChtrg%253D&md5=4bd66278ccee9af218d0c2d133515e6a</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1016%2FS0301-472X%2803%2900007-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0301-472X%252803%252900007-9%26sid%3Dliteratum%253Aachs%26aulast%3DRuchatz%26aufirst%3DH.%26aulast%3DColuccia%26aufirst%3DA.%2BM.%2BL.%26aulast%3DStano%26aufirst%3DP.%26aulast%3DMarchesi%26aufirst%3DE.%26aulast%3DGambacorti-Passerini%26aufirst%3DC.%26atitle%3DConstitutive%2520Activation%2520of%2520Jak2%2520Contributes%2520to%2520Proliferation%2520and%2520Resistance%2520to%2520Apoptosis%2520in%2520NPM%252FALK-transformed%2520Cells%26jtitle%3DExp.%2520Hematol.%26date%3D2003%26volume%3D31%26spage%3D309%26epage%3D315%26doi%3D10.1016%2FS0301-472X%2803%2900007-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Berry, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luther, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhatnagar, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jamin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poon, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanda, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pei, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vetharoy, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hallsworth, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmad, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barker, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreau, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webber, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez-Atayde, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodig, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheung, N.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raynaud, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hallberg, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pearson, A. D.J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eccles, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chesler, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">George, R. E.</span></span> <span> </span><span class="NLM_article-title">The ALKF1174L Mutation Potentiates the Oncogenic Activity of MYCN in Neuroblastoma</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">117</span>– <span class="NLM_lpage">130</span>, <span class="refDoi"> DOI: 10.1016/j.ccr.2012.06.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1016%2Fj.ccr.2012.06.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=22789543" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVSltLzJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=117-130&author=T.+Berryauthor=W.+Lutherauthor=N.+Bhatnagarauthor=Y.+Jaminauthor=E.+Poonauthor=T.+Sandaauthor=D.+Peiauthor=B.+Sharmaauthor=W.+R.+Vetharoyauthor=A.+Hallsworthauthor=Z.+Ahmadauthor=K.+Barkerauthor=L.+Moreauauthor=H.+Webberauthor=W.+Wangauthor=Q.+Liuauthor=A.+Perez-Ataydeauthor=S.+Rodigauthor=N.-K.+Cheungauthor=F.+Raynaudauthor=B.+Hallbergauthor=S.+P.+Robinsonauthor=N.+S.+Grayauthor=A.+D.J.+Pearsonauthor=S.+A.+Ecclesauthor=L.+Cheslerauthor=R.+E.+George&title=The+ALKF1174L+Mutation+Potentiates+the+Oncogenic+Activity+of+MYCN+in+Neuroblastoma&doi=10.1016%2Fj.ccr.2012.06.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">The ALKF1174L Mutation Potentiates the Oncogenic Activity of MYCN in Neuroblastoma</span></div><div class="casAuthors">Berry, Teeara; Luther, William; Bhatnagar, Namrata; Jamin, Yann; Poon, Evon; Sanda, Takaomi; Pei, Desheng; Sharma, Bandana; Vetharoy, Winston R.; Hallsworth, Albert; Ahmad, Zai; Barker, Karen; Moreau, Lisa; Webber, Hannah; Wang, Wenchao; Liu, Qingsong; Perez-Atayde, Antonio; Rodig, Scott; Cheung, Nai-Kong; Raynaud, Florence; Hallberg, Bengt; Robinson, Simon P.; Gray, Nathanael S.; Pearson, Andrew D. J.; Eccles, Suzanne A.; Chesler, Louis; George, Rani E.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">117-130</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">The ALKF1174L mutation is assocd. with intrinsic and acquired resistance to crizotinib and cosegregates with MYCN in neuroblastoma.  In this study, we generated a mouse model overexpressing ALKF1174L in the neural crest.  Compared to ALKF1174L and MYCN alone, co-expression of these two oncogenes led to the development of neuroblastomas with earlier onset, higher penetrance, and enhanced lethality.  ALKF1174L/MYCN tumors exhibited increased MYCN dosage due to ALKF1174L-induced activation of the PI3K/AKT/mTOR and MAPK pathways, coupled with suppression of MYCN pro-apoptotic effects.  Combined treatment with the ATP-competitive mTOR inhibitor Torin2 overcame the resistance of ALKF1174L/MYCN tumors to crizotinib.  Our findings demonstrate a pathogenic role for ALKF1174L in neuroblastomas overexpressing MYCN and suggest a strategy for improving targeted therapy for ALK-pos. neuroblastoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQvwCqpbNJsbVg90H21EOLACvtfcHk0lhDG9h8iDClqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVSltLzJ&md5=17eaed93b440461999c4f8f099f57723</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2012.06.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2012.06.001%26sid%3Dliteratum%253Aachs%26aulast%3DBerry%26aufirst%3DT.%26aulast%3DLuther%26aufirst%3DW.%26aulast%3DBhatnagar%26aufirst%3DN.%26aulast%3DJamin%26aufirst%3DY.%26aulast%3DPoon%26aufirst%3DE.%26aulast%3DSanda%26aufirst%3DT.%26aulast%3DPei%26aufirst%3DD.%26aulast%3DSharma%26aufirst%3DB.%26aulast%3DVetharoy%26aufirst%3DW.%2BR.%26aulast%3DHallsworth%26aufirst%3DA.%26aulast%3DAhmad%26aufirst%3DZ.%26aulast%3DBarker%26aufirst%3DK.%26aulast%3DMoreau%26aufirst%3DL.%26aulast%3DWebber%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DPerez-Atayde%26aufirst%3DA.%26aulast%3DRodig%26aufirst%3DS.%26aulast%3DCheung%26aufirst%3DN.-K.%26aulast%3DRaynaud%26aufirst%3DF.%26aulast%3DHallberg%26aufirst%3DB.%26aulast%3DRobinson%26aufirst%3DS.%2BP.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DPearson%26aufirst%3DA.%2BD.J.%26aulast%3DEccles%26aufirst%3DS.%2BA.%26aulast%3DChesler%26aufirst%3DL.%26aulast%3DGeorge%26aufirst%3DR.%2BE.%26atitle%3DThe%2520ALKF1174L%2520Mutation%2520Potentiates%2520the%2520Oncogenic%2520Activity%2520of%2520MYCN%2520in%2520Neuroblastoma%26jtitle%3DCancer%2520Cell%26date%3D2012%26volume%3D22%26spage%3D117%26epage%3D130%26doi%3D10.1016%2Fj.ccr.2012.06.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schönherr, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruuth, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamaraj, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Combaret, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Djos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinsson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christensen, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmer, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hallberg, B.</span></span> <span> </span><span class="NLM_article-title">Anaplastic Lymphoma Kinase (ALK) Regulates Initiation of Transcription of MYCN in Neuroblastoma cells</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">5193</span>– <span class="NLM_lpage">5200</span>, <span class="refDoi"> DOI: 10.1038/onc.2012.12</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1038%2Fonc.2012.12" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=22286764" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A280%3ADC%252BC38vhsVGktg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2012&pages=5193-5200&author=C.+Sch%C3%B6nherrauthor=K.+Ruuthauthor=S.+Kamarajauthor=C.-L.+Wangauthor=H.-L.+Yangauthor=V.+Combaretauthor=A.+Djosauthor=T.+Martinssonauthor=J.+G.+Christensenauthor=R.+H.+Palmerauthor=B.+Hallberg&title=Anaplastic+Lymphoma+Kinase+%28ALK%29+Regulates+Initiation+of+Transcription+of+MYCN+in+Neuroblastoma+cells&doi=10.1038%2Fonc.2012.12"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Anaplastic Lymphoma Kinase (ALK) regulates initiation of transcription of MYCN in neuroblastoma cells</span></div><div class="casAuthors">Schonherr C; Ruuth K; Kamaraj S; Wang C-L; Yang H-L; Combaret V; Djos A; Martinsson T; Christensen J G; Palmer R H; Hallberg B</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">50</span>),
    <span class="NLM_cas:pages">5193-200</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Neuroblastoma is a neural crest-derived embryonal tumour of the postganglionic sympathetic nervous system and a disease with several different chromosomal gains and losses, which include MYCN-amplified neuroblastoma on chromosome 2, deletions of parts of the chromosomes 1p and 11q, gain of parts of 17q and triploidy.  Recently, activating mutations of the ALK (Anaplastic Lymphoma Kinase) RTK (Receptor Tyrosine Kinase) gene have been described in neuroblastoma.  A meta-analysis of neuroblastoma cases revealed that ALK mutations (49 of 709 cases) in relation to genomic subtype were most frequently observed in MYCN amplified tumours (8.9%), correlating with a poor clinical outcome.  MYCN proteins target proliferation and apoptotic pathways, and have an important role in the progression of neuroblastoma.  Here, we show that both wild-type and gain-of-function mutants in ALK are able to stimulate transcription at the MYCN promoter and initiate mRNA transcription of the MYCN gene in both neuronal and neuroblastoma cell lines.  Further, this stimulation of MYCN gene transcription and de novo MYCN protein expression is abrogated by specific ALK inhibitors, such as crizotinib (PF-2341066), NVP-TAE684, and by small interfering RNA to ALK resulting in a decrease in proliferation rate.  Finally, co-transfection of ALK gain-of-function mutations together with MYCN leads to an increase in transformation potential.  Taken together, our results indicate that ALK signalling regulates initiation of transcription of the MYCN gene providing a possible explanation for the poor clinical outcome observed when MYCN is amplified together with activated ALK.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQD76YHu5cthoqdXsLcGTEUfW6udTcc2eacA6K3brdkxrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38vhsVGktg%253D%253D&md5=e74e929dc9a43ba57fabd85e44e659d3</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1038%2Fonc.2012.12&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fonc.2012.12%26sid%3Dliteratum%253Aachs%26aulast%3DSch%25C3%25B6nherr%26aufirst%3DC.%26aulast%3DRuuth%26aufirst%3DK.%26aulast%3DKamaraj%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DC.-L.%26aulast%3DYang%26aufirst%3DH.-L.%26aulast%3DCombaret%26aufirst%3DV.%26aulast%3DDjos%26aufirst%3DA.%26aulast%3DMartinsson%26aufirst%3DT.%26aulast%3DChristensen%26aufirst%3DJ.%2BG.%26aulast%3DPalmer%26aufirst%3DR.%2BH.%26aulast%3DHallberg%26aufirst%3DB.%26atitle%3DAnaplastic%2520Lymphoma%2520Kinase%2520%2528ALK%2529%2520Regulates%2520Initiation%2520of%2520Transcription%2520of%2520MYCN%2520in%2520Neuroblastoma%2520cells%26jtitle%3DOncogene%26date%3D2012%26volume%3D31%26spage%3D5193%26epage%3D5200%26doi%3D10.1038%2Fonc.2012.12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez-Atayde, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kutok, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodig, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neuberg, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Helman, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">George, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanki, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Look, A. T.</span></span> <span> </span><span class="NLM_article-title">Activated ALK Collaborates with MYCN in Neuroblastoma Pathogenesis</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">362</span>– <span class="NLM_lpage">373</span>, <span class="refDoi"> DOI: 10.1016/j.ccr.2012.02.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1016%2Fj.ccr.2012.02.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=22439933" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC38Xkt1ymur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2012&pages=362-373&author=S.+Zhuauthor=J.-S.+Leeauthor=F.+Guoauthor=J.+Shinauthor=A.+R.+Perez-Ataydeauthor=J.+L.+Kutokauthor=S.+J.+Rodigauthor=D.+S.+Neubergauthor=D.+Helmanauthor=H.+Fengauthor=R.+A.+Stewartauthor=W.+Wangauthor=R.+E.+Georgeauthor=J.+P.+Kankiauthor=A.+T.+Look&title=Activated+ALK+Collaborates+with+MYCN+in+Neuroblastoma+Pathogenesis&doi=10.1016%2Fj.ccr.2012.02.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Activated ALK Collaborates with MYCN in Neuroblastoma Pathogenesis</span></div><div class="casAuthors">Zhu, Shizhen; Lee, Jeong-Soo; Guo, Feng; Shin, Jimann; Perez-Atayde, Antonio R.; Kutok, Jeffery L.; Rodig, Scott J.; Neuberg, Donna S.; Helman, Daniel; Feng, Hui; Stewart, Rodney A.; Wang, Wenchao; George, Rani E.; Kanki, John P.; Look, A. Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">362-373</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Amplification of the MYCN oncogene in childhood neuroblastoma is often accompanied by mutational activation of ALK (anaplastic lymphoma kinase), suggesting their pathogenic cooperation.  We generated a transgenic zebrafish model of neuroblastoma in which MYCN-induced tumors arise from a subpopulation of neuroblasts that migrate into the adrenal medulla analog following organogenesis.  Coexpression of activated ALK with MYCN in this model triples the disease penetrance and markedly accelerates tumor onset.  MYCN overexpression induces adrenal sympathetic neuroblast hyperplasia, blocks chromaffin cell differentiation, and ultimately triggers a developmentally-timed apoptotic response in the hyperplastic sympathoadrenal cells.  Coexpression of activated ALK with MYCN provides prosurvival signals that block this apoptotic response and allow continued expansion and oncogenic transformation of hyperplastic neuroblasts, thus promoting progression to neuroblastoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqsKEhBF_umXbVg90H21EOLACvtfcHk0lhDG9h8iDClqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xkt1ymur8%253D&md5=2ba0ffaa43656604d6269ff8a3e9052d</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2012.02.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2012.02.010%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DS.%26aulast%3DLee%26aufirst%3DJ.-S.%26aulast%3DGuo%26aufirst%3DF.%26aulast%3DShin%26aufirst%3DJ.%26aulast%3DPerez-Atayde%26aufirst%3DA.%2BR.%26aulast%3DKutok%26aufirst%3DJ.%2BL.%26aulast%3DRodig%26aufirst%3DS.%2BJ.%26aulast%3DNeuberg%26aufirst%3DD.%2BS.%26aulast%3DHelman%26aufirst%3DD.%26aulast%3DFeng%26aufirst%3DH.%26aulast%3DStewart%26aufirst%3DR.%2BA.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DGeorge%26aufirst%3DR.%2BE.%26aulast%3DKanki%26aufirst%3DJ.%2BP.%26aulast%3DLook%26aufirst%3DA.%2BT.%26atitle%3DActivated%2520ALK%2520Collaborates%2520with%2520MYCN%2520in%2520Neuroblastoma%2520Pathogenesis%26jtitle%3DCancer%2520Cell%26date%3D2012%26volume%3D21%26spage%3D362%26epage%3D373%26doi%3D10.1016%2Fj.ccr.2012.02.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Martelli, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sozzi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hernandez, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pettirossi, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Navarro, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conte, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gasparini, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perrone, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Modena, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pastorino, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carbone, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fabbri, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sidoni, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakamura, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gambacorta, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandez, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramirez, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, J. K.C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grigioni, W. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campo, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pileri, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Falini, B.</span></span> <span> </span><span class="NLM_article-title">EML4-ALK Rearrangement in Non-small Cell Lung Cancer and Non-tumor Lung Tissues</span>. <i>Am. J. Pathol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>174</i></span>,  <span class="NLM_fpage">661</span>– <span class="NLM_lpage">670</span>, <span class="refDoi"> DOI: 10.2353/ajpath.2009.080755</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.2353%2Fajpath.2009.080755" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=19147828" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BD1MXivVWntLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=174&publication_year=2009&pages=661-670&author=M.+P.+Martelliauthor=G.+Sozziauthor=L.+Hernandezauthor=V.+Pettirossiauthor=A.+Navarroauthor=D.+Conteauthor=P.+Gaspariniauthor=F.+Perroneauthor=P.+Modenaauthor=U.+Pastorinoauthor=A.+Carboneauthor=A.+Fabbriauthor=A.+Sidoniauthor=S.+Nakamuraauthor=M.+Gambacortaauthor=P.+L.+Fernandezauthor=J.+Ramirezauthor=J.+K.C.+Chanauthor=W.+F.+Grigioniauthor=E.+Campoauthor=S.+A.+Pileriauthor=B.+Falini&title=EML4-ALK+Rearrangement+in+Non-small+Cell+Lung+Cancer+and+Non-tumor+Lung+Tissues&doi=10.2353%2Fajpath.2009.080755"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">EML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissues</span></div><div class="casAuthors">Martelli, Maria Paola; Sozzi, Gabriella; Hernandez, Luis; Pettirossi, Valentina; Navarro, Alba; Conte, Davide; Gasparini, Patrizia; Perrone, Federica; Modena, Piergiorgio; Pastorino, Ugo; Carbone, Antonino; Fabbri, Alessandra; Sidoni, Angelo; Nakamura, Shigeo; Gambacorta, Marcello; Fernandez, Pedro Luis; Ramirez, Jose; Chan, John K. C.; Grigioni, Walter Franco; Campo, Elias; Pileri, Stefano A.; Falini, Brunangelo</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Pathology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">174</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">661-670</span>CODEN:
                <span class="NLM_cas:coden">AJPAA4</span>;
        ISSN:<span class="NLM_cas:issn">0002-9440</span>.
    
            (<span class="NLM_cas:orgname">American Society for Investigative Pathology</span>)
        </div><div class="casAbstract">A fusion gene, echinoderm microtubule assocd. protein like 4 - anaplastic lymphoma kinase (EML4-ALK), with transforming activity has recently been identified in a subset of non-small cell lung cancer (NSCLC), but its pathogenetic, diagnostic, and therapeutic roles remain unclear.  Both frequency and type of EML4-ALK transcripts were investigated by reverse transcription PCR in 120 frozen NSCLC specimens from Italy and Spain; non-neoplastic lung tissues taken far from the tumor were used as controls.  In cases carrying the fusion transcript, we detd. EML4-ALK gene and protein levels using fluorescence in situ hybridization, Western blotting, and immunopptn.  We also analyzed ALK protein levels in paraffin samples from 662 NSCLC specimens, including the 120 cases investigated in the mol. studies.  EML4-ALK transcripts (variants 1 and 3) were detected in 9 of 120 NSCLC samples but were not specific for NSCLC since they were also found in non-cancerous lung tissues taken far from the tumor.  Notably, no transcripts were detected in matching tumor samples from these patients.  Fluorescence in situ hybridization anal. of cases expressing EML4-ALK transcripts showed that only a minority of cells harbored the EML4-ALK gene.  None of these cases was found to express the EML4-ALK protein as examd. by immunohistochem., Western blotting, and immunopptn.  The EML4-ALK transcript cannot be regarded as a specific diagnostic tool for NSCLC.  Our results show therefore that the causal role and value of EML4-ALK as a therapeutic target remain to be defined.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYd62xRrWU0LVg90H21EOLACvtfcHk0lhnE_CG-VkWMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXivVWntLo%253D&md5=de2ae3f7a31558e1d6ad18c2c9b7dcc5</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.2353%2Fajpath.2009.080755&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2353%252Fajpath.2009.080755%26sid%3Dliteratum%253Aachs%26aulast%3DMartelli%26aufirst%3DM.%2BP.%26aulast%3DSozzi%26aufirst%3DG.%26aulast%3DHernandez%26aufirst%3DL.%26aulast%3DPettirossi%26aufirst%3DV.%26aulast%3DNavarro%26aufirst%3DA.%26aulast%3DConte%26aufirst%3DD.%26aulast%3DGasparini%26aufirst%3DP.%26aulast%3DPerrone%26aufirst%3DF.%26aulast%3DModena%26aufirst%3DP.%26aulast%3DPastorino%26aufirst%3DU.%26aulast%3DCarbone%26aufirst%3DA.%26aulast%3DFabbri%26aufirst%3DA.%26aulast%3DSidoni%26aufirst%3DA.%26aulast%3DNakamura%26aufirst%3DS.%26aulast%3DGambacorta%26aufirst%3DM.%26aulast%3DFernandez%26aufirst%3DP.%2BL.%26aulast%3DRamirez%26aufirst%3DJ.%26aulast%3DChan%26aufirst%3DJ.%2BK.C.%26aulast%3DGrigioni%26aufirst%3DW.%2BF.%26aulast%3DCampo%26aufirst%3DE.%26aulast%3DPileri%26aufirst%3DS.%2BA.%26aulast%3DFalini%26aufirst%3DB.%26atitle%3DEML4-ALK%2520Rearrangement%2520in%2520Non-small%2520Cell%2520Lung%2520Cancer%2520and%2520Non-tumor%2520Lung%2520Tissues%26jtitle%3DAm.%2520J.%2520Pathol.%26date%3D2009%26volume%3D174%26spage%3D661%26epage%3D670%26doi%3D10.2353%2Fajpath.2009.080755" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jin, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeon, H.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, H.-G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoo, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cha, S. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, T. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jheon, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, J. Y.</span></span> <span> </span><span class="NLM_article-title">EML4-ALK Fusion Gene in Korean Non-small Cell Lung Cancer</span>. <i>J. Korean Med. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">228</span>– <span class="NLM_lpage">230</span>, <span class="refDoi"> DOI: 10.3346/jkms.2012.27.2.228</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.3346%2Fjkms.2012.27.2.228" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=22323876" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC38Xks1Sis7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2012&pages=228-230&author=G.+Jinauthor=H.-S.+Jeonauthor=E.+B.+Leeauthor=H.-G.+Kangauthor=S.+S.+Yooauthor=S.+Y.+Leeauthor=J.+H.+Leeauthor=S.+I.+Chaauthor=T.+I.+Parkauthor=C.+H.+Kimauthor=S.+H.+Jheonauthor=J.+Y.+Park&title=EML4-ALK+Fusion+Gene+in+Korean+Non-small+Cell+Lung+Cancer&doi=10.3346%2Fjkms.2012.27.2.228"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">EML4-ALK fusion gene in Korean non-small cell lung cancer</span></div><div class="casAuthors">Jin, Guang; Jeon, Hyo-Sung; Lee, Eung Bae; Kang, Hyo-Gyoung; Yoo, Seung Soo; Lee, Shin Yup; Lee, Jae Hee; Cha, Sung Ick; Park, Tae In; Kim, Chang Ho; Jheon, Sang Hoon; Park, Jae Yong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Korean Medical Science</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">228-230</span>CODEN:
                <span class="NLM_cas:coden">JKMSEH</span>;
        ISSN:<span class="NLM_cas:issn">1011-8934</span>.
    
            (<span class="NLM_cas:orgname">Korean Academy of Medical Sciences</span>)
        </div><div class="casAbstract">A fusion gene between echinoderm microtubule-assocd. protein-like 4 (EML4) and the anaplastic lymphoma kinase (ALK) has been identified in non-small cell lung cancers (NSCLCs).  Although a few studies have evaluated EML4-ALK fusion genes in Korean NSCLCs, the prevalence of different EML4-ALK fusion variants has yet to be clearly assessed.  Herein, we have examd. the profiles of EML4-ALK fusion gene variants in Korean patients of NSCLCs.  EML4-ALK fusion genes have been detected in 10 (6.0%) of 167 patients of NSCLCs and in 9 (7.4%) of 121 patients of adenocarcinoma.  Of the 10 patients with fusion genes identified, 8 (80%) were E13;A20 (variant 1) and 2 (20%) were E6;A20, with an addnl. 33-bp sequence derived from intron 6 of EML4 (variant 3b).  These results indicate that the profiles of EML4-ALK fusion gene variants in Korean patients of NSCLC may differ from those in other ethnic populations.  Herein, we describe for the first time the profiles of EML4-ALK fusion variants of Korean patients with NSCLCs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkiLBeFQgaVLVg90H21EOLACvtfcHk0lhnE_CG-VkWMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xks1Sis7s%253D&md5=170cc1d4a768ed0f3aba204044bbc56a</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.3346%2Fjkms.2012.27.2.228&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3346%252Fjkms.2012.27.2.228%26sid%3Dliteratum%253Aachs%26aulast%3DJin%26aufirst%3DG.%26aulast%3DJeon%26aufirst%3DH.-S.%26aulast%3DLee%26aufirst%3DE.%2BB.%26aulast%3DKang%26aufirst%3DH.-G.%26aulast%3DYoo%26aufirst%3DS.%2BS.%26aulast%3DLee%26aufirst%3DS.%2BY.%26aulast%3DLee%26aufirst%3DJ.%2BH.%26aulast%3DCha%26aufirst%3DS.%2BI.%26aulast%3DPark%26aufirst%3DT.%2BI.%26aulast%3DKim%26aufirst%3DC.%2BH.%26aulast%3DJheon%26aufirst%3DS.%2BH.%26aulast%3DPark%26aufirst%3DJ.%2BY.%26atitle%3DEML4-ALK%2520Fusion%2520Gene%2520in%2520Korean%2520Non-small%2520Cell%2520Lung%2520Cancer%26jtitle%3DJ.%2520Korean%2520Med.%2520Sci.%26date%3D2012%26volume%3D27%26spage%3D228%26epage%3D230%26doi%3D10.3346%2Fjkms.2012.27.2.228" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Koivunen, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mermel, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zejnullahu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lifshits, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holmes, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, H. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richards, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugarbaker, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ducko, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindeman, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marcoux, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engelman, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyerson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janne, P. A.</span></span> <span> </span><span class="NLM_article-title">EML4-ALK Fusion Gene and Efficacy of an ALK Kinase Inhibitor in Lung Cancer</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">4275</span>– <span class="NLM_lpage">4283</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-08-0168</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1158%2F1078-0432.CCR-08-0168" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=18594010" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BD1cXnvFyks7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2008&pages=4275-4283&author=J.+P.+Koivunenauthor=C.+Mermelauthor=K.+Zejnullahuauthor=C.+Murphyauthor=E.+Lifshitsauthor=A.+J.+Holmesauthor=H.+G.+Choiauthor=J.+Kimauthor=D.+Chiangauthor=R.+Thomasauthor=J.+Leeauthor=W.+G.+Richardsauthor=D.+J.+Sugarbakerauthor=C.+Duckoauthor=N.+Lindemanauthor=J.+P.+Marcouxauthor=J.+A.+Engelmanauthor=N.+S.+Grayauthor=C.+Leeauthor=M.+Meyersonauthor=P.+A.+Janne&title=EML4-ALK+Fusion+Gene+and+Efficacy+of+an+ALK+Kinase+Inhibitor+in+Lung+Cancer&doi=10.1158%2F1078-0432.CCR-08-0168"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">EML4-ALK Fusion Gene and Efficacy of an ALK Kinase Inhibitor in Lung Cancer</span></div><div class="casAuthors">Koivunen, Jussi P.; Mermel, Craig; Zejnullahu, Kreshnik; Murphy, Carly; Lifshits, Eugene; Holmes, Alison J.; Choi, Hwan Geun; Kim, Jhingook; Chiang, Derek; Thomas, Roman; Lee, Jinseon; Richards, William G.; Sugarbaker, David J.; Ducko, Christopher; Lindeman, Neal; Marcoux, J. Paul; Engelman, Jeffrey A.; Gray, Nathanael S.; Lee, Charles; Meyerson, Matthew; Jaenne, Pasi A.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">4275-4283</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The EML4-ALK fusion gene has been detected in ∼7% of Japanese non-small cell lung cancers (NSCLC).  We detd. the frequency of EML4-ALK in Caucasian NSCLC and in NSCLC cell lines.  We also detd. whether TAE684, a specific ALK kinase inhibitor, would inhibit the growth of EML4-ALK-contg. cell lines in vitro and in vivo.  We screened 305 primary NSCLC [both U.S. (n = 138) and Korean (n = 167) patients] and 83 NSCLC cell lines using reverse transcription-PCR and by exon array analyses.  We evaluated the efficacy of TAE684 against NSCLC cell lines in vitro and in vivo.  We detected four different variants, including two novel variants, of EML4-ALK using reverse transcription-PCR in 8 of 305 tumors (3%) and 3 of 83 (3.6%) NSCLC cell lines.  All EML4-ALK-contg. tumors and cell lines were adenocarcinomas.  EML4-ALK was detected more frequently in NSCLC patients who were never or light (<10 pack-years) cigarette smokers compared with current/former smokers (6% vs. 1%; P = 0.049).  TAE684 inhibited the growth of one of three (H3122) EML4-ALK-contg. cell lines in vitro and in vivo, inhibited Akt phosphorylation, and caused apoptosis.  In another EML4-ALK cell line, DFCI032, TAE684 was ineffective due to coactivation of epidermal growth factor receptor and ERBB2.  The combination of TAE684 and CL-387,785 (epidermal growth factor receptor/ERBB2 kinase inhibitor) inhibited growth and Akt phosphorylation and led to apoptosis in the DFCI032 cell line.  EML4-ALK is found in the minority of NSCLC.  ALK kinase inhibitors alone or in combination may nevertheless be clin. effective treatments for NSCLC patients whose tumors contain EML4-ALK.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOXKywqERg6rVg90H21EOLACvtfcHk0li-fxgO--mM_Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXnvFyks7s%253D&md5=6e29703c783e6a29cf77e3c4b93fc15f</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-08-0168&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-08-0168%26sid%3Dliteratum%253Aachs%26aulast%3DKoivunen%26aufirst%3DJ.%2BP.%26aulast%3DMermel%26aufirst%3DC.%26aulast%3DZejnullahu%26aufirst%3DK.%26aulast%3DMurphy%26aufirst%3DC.%26aulast%3DLifshits%26aufirst%3DE.%26aulast%3DHolmes%26aufirst%3DA.%2BJ.%26aulast%3DChoi%26aufirst%3DH.%2BG.%26aulast%3DKim%26aufirst%3DJ.%26aulast%3DChiang%26aufirst%3DD.%26aulast%3DThomas%26aufirst%3DR.%26aulast%3DLee%26aufirst%3DJ.%26aulast%3DRichards%26aufirst%3DW.%2BG.%26aulast%3DSugarbaker%26aufirst%3DD.%2BJ.%26aulast%3DDucko%26aufirst%3DC.%26aulast%3DLindeman%26aufirst%3DN.%26aulast%3DMarcoux%26aufirst%3DJ.%2BP.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DLee%26aufirst%3DC.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26atitle%3DEML4-ALK%2520Fusion%2520Gene%2520and%2520Efficacy%2520of%2520an%2520ALK%2520Kinase%2520Inhibitor%2520in%2520Lung%2520Cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2008%26volume%3D14%26spage%3D4275%26epage%3D4283%26doi%3D10.1158%2F1078-0432.CCR-08-0168" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gainor, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varghese, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ou, S.-H. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kabraji, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Awad, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katayama, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pawlak, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mino-Kenudson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeap, B. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riely, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iafrate, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arcila, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ladanyi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engelman, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dias-Santagata, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, A. T.</span></span> <span> </span><span class="NLM_article-title">ALK Rearrangements are Mutually Exclusive with Mutations in EGFR or KRAS: an Analysis of 1,683 Patients with Non–small Cell Lung Cancer</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">4273</span>– <span class="NLM_lpage">4281</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-13-0318</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1158%2F1078-0432.CCR-13-0318" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=23729361" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1amt7zI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=4273-4281&author=J.+F.+Gainorauthor=A.+M.+Vargheseauthor=S.-H.+I.+Ouauthor=S.+Kabrajiauthor=M.+M.+Awadauthor=R.+Katayamaauthor=A.+Pawlakauthor=M.+Mino-Kenudsonauthor=B.+Y.+Yeapauthor=G.+J.+Rielyauthor=A.+J.+Iafrateauthor=M.+E.+Arcilaauthor=M.+Ladanyiauthor=J.+A.+Engelmanauthor=D.+Dias-Santagataauthor=A.+T.+Shaw&title=ALK+Rearrangements+are+Mutually+Exclusive+with+Mutations+in+EGFR+or+KRAS%3A+an+Analysis+of+1%2C683+Patients+with+Non%E2%80%93small+Cell+Lung+Cancer&doi=10.1158%2F1078-0432.CCR-13-0318"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">ALK Rearrangements Are Mutually Exclusive with Mutations in EGFR or KRAS: An Analysis of 1,683 Patients with Non-Small Cell Lung Cancer</span></div><div class="casAuthors">Gainor, Justin F.; Varghese, Anna M.; Ou, Sai-Hong Ignatius; Kabraji, Sheheryar; Awad, Mark M.; Katayama, Ryohei; Pawlak, Amanda; Mino-Kenudson, Mari; Yeap, Beow Y.; Riely, Gregory J.; Iafrate, A. John; Arcila, Maria E.; Ladanyi, Marc; Engelman, Jeffrey A.; Dias-Santagata, Dora; Shaw, Alice T.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4273-4281</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Anaplastic lymphoma kinase (ALK) gene rearrangements define a distinct mol. subset of non-small cell lung cancer (NSCLC).  Recently, several case reports and small series have reported that ALK rearrangements can overlap with other oncogenic drivers in NSCLC in crizotinib-naive and crizotinib-resistant cancers.  Exptl. Design: We reviewed clin. genotyping data from 1,683 patients with NSCLC and investigated the prevalence of concomitant EGFR or KRAS mutations among patients with ALK-pos. NSCLC.  We also examd. biopsy specimens from 34 patients with ALK-pos. NSCLC after the development of resistance to crizotinib.  Results: Screening identified 301 (17.8%) EGFR mutations, 465 (27.6%) KRAS mutations, and 75 (4.4%) ALK rearrangements.  EGFR mutations and ALK rearrangements were mutually exclusive.  Four patients with KRAS mutations were found to have abnormal ALK FISH patterns, most commonly involving isolated 5' green probes.  Sufficient tissue was available for confirmatory ALK immunohistochem. in 3 cases, all of which were neg. for ALK expression.  Among patients with ALK-pos. NSCLC who acquired resistance to crizotinib, repeat biopsy specimens were ALK FISH pos. in 29 of 29 (100%) cases.  Secondary mutations in the ALK kinase domain and ALK gene amplification were obsd. in 7 of 34 (20.6%) and 3 of 29 (10.3%) cases, resp.  No EGFR or KRAS mutations were identified among any of the 25 crizotinib-resistant, ALK-pos. patients with sufficient tissue for testing.  Conclusions: Functional ALK rearrangements were mutually exclusive with EGFR and KRAS mutations in a large Western patient population.  This lack of overlap was also obsd. in ALK-pos. cancers with acquired resistance to crizotinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnuDecyNaYQrVg90H21EOLACvtfcHk0li-fxgO--mM_Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1amt7zI&md5=6355f3f634ef5b7ba06a497d0bf71a1a</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-13-0318&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-13-0318%26sid%3Dliteratum%253Aachs%26aulast%3DGainor%26aufirst%3DJ.%2BF.%26aulast%3DVarghese%26aufirst%3DA.%2BM.%26aulast%3DOu%26aufirst%3DS.-H.%2BI.%26aulast%3DKabraji%26aufirst%3DS.%26aulast%3DAwad%26aufirst%3DM.%2BM.%26aulast%3DKatayama%26aufirst%3DR.%26aulast%3DPawlak%26aufirst%3DA.%26aulast%3DMino-Kenudson%26aufirst%3DM.%26aulast%3DYeap%26aufirst%3DB.%2BY.%26aulast%3DRiely%26aufirst%3DG.%2BJ.%26aulast%3DIafrate%26aufirst%3DA.%2BJ.%26aulast%3DArcila%26aufirst%3DM.%2BE.%26aulast%3DLadanyi%26aufirst%3DM.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26aulast%3DDias-Santagata%26aufirst%3DD.%26aulast%3DShaw%26aufirst%3DA.%2BT.%26atitle%3DALK%2520Rearrangements%2520are%2520Mutually%2520Exclusive%2520with%2520Mutations%2520in%2520EGFR%2520or%2520KRAS%253A%2520an%2520Analysis%2520of%25201%252C683%2520Patients%2520with%2520Non%25E2%2580%2593small%2520Cell%2520Lung%2520Cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2013%26volume%3D19%26spage%3D4273%26epage%3D4281%26doi%3D10.1158%2F1078-0432.CCR-13-0318" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Takeuchi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Togashi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hatano, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inamura, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takada, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ueno, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamashita, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Satoh, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okumura, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakagawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishikawa, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mano, H.</span></span> <span> </span><span class="NLM_article-title">KIF5B-ALK, a Novel Fusion Oncokinase Identified by an Immunohistochemistry-based Diagnostic System for ALK-positive Lung Cancer</span>. <i>Clin, Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">3143</span>– <span class="NLM_lpage">3149</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-08-3248</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1158%2F1078-0432.CCR-08-3248" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=19383809" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BD1MXltFOrtbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2009&pages=3143-3149&author=K.+Takeuchiauthor=Y.+L.+Choiauthor=Y.+Togashiauthor=M.+Sodaauthor=S.+Hatanoauthor=K.+Inamuraauthor=S.+Takadaauthor=T.+Uenoauthor=Y.+Yamashitaauthor=Y.+Satohauthor=S.+Okumuraauthor=K.+Nakagawaauthor=Y.+Ishikawaauthor=H.+Mano&title=KIF5B-ALK%2C+a+Novel+Fusion+Oncokinase+Identified+by+an+Immunohistochemistry-based+Diagnostic+System+for+ALK-positive+Lung+Cancer&doi=10.1158%2F1078-0432.CCR-08-3248"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">KIF5B-ALK, a Novel Fusion Oncokinase Identified by an Immunohistochemistry-based Diagnostic System for ALK-positive Lung Cancer</span></div><div class="casAuthors">Takeuchi, Kengo; Choi, Young Lim; Togashi, Yuki; Soda, Manabu; Hatano, Satoko; Inamura, Kentaro; Takada, Shuji; Ueno, Toshihide; Yamashita, Yoshihiro; Satoh, Yukitoshi; Okumura, Sakae; Nakagawa, Ken; Ishikawa, Yuichi; Mano, Hiroyuki</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3143-3149</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">EML4-ALK is a transforming fusion tyrosine kinase, several isoforms of which have been identified in lung cancer.  Immunohistochem. detection of EML4-ALK has proved difficult, however, likely as a result of low transcriptional activity conferred by the promoter-enhancer region of EML4.  The sensitivity of EML4-ALK detection by immunohistochem. should be increased adequately.  We developed an intercalated antibody-enhanced polymer (iAEP) method that incorporates an intercalating antibody between the primary antibody to ALK and the dextran polymer-based detection reagents.  Our iAEP method discriminated between tumors pos. or neg. for EML4-ALK in a test set of specimens.  Four tumors were also found to be pos. for ALK in an archive of lung adenocarcinoma (n = 130) and another 4 among fresh cases analyzed in a diagnostic lab.  These 8 tumors were found to include 1 with EML4-ALK variant 1, 1 with variant 2, 3 with variant 3, and 2 with previously unidentified variants (designated variants 6 and 7).  Inverse reverse transcription-PCR anal. revealed that the remaining tumor harbored a novel fusion in which intron 24 of KIF5B was ligated to intron 19 of ALK.  Multiplex reverse transcription-PCR anal. of addnl. archival tumor specimens identified another case of lung adenocarcinoma pos. for KIF5B-ALK.  The iAEP method should prove suitable for immunohistochem. screening of tumors pos. for ALK or ALK fusion proteins among pathol. archives.  Coupling of PCR-based detection to the iAEP method should further facilitate the rapid identification of novel ALK fusion genes such as KIF5B-ALK.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzRVhmhcxYtrVg90H21EOLACvtfcHk0li-fxgO--mM_Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXltFOrtbY%253D&md5=50abc7202077715519e1d41c024e4624</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-08-3248&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-08-3248%26sid%3Dliteratum%253Aachs%26aulast%3DTakeuchi%26aufirst%3DK.%26aulast%3DChoi%26aufirst%3DY.%2BL.%26aulast%3DTogashi%26aufirst%3DY.%26aulast%3DSoda%26aufirst%3DM.%26aulast%3DHatano%26aufirst%3DS.%26aulast%3DInamura%26aufirst%3DK.%26aulast%3DTakada%26aufirst%3DS.%26aulast%3DUeno%26aufirst%3DT.%26aulast%3DYamashita%26aufirst%3DY.%26aulast%3DSatoh%26aufirst%3DY.%26aulast%3DOkumura%26aufirst%3DS.%26aulast%3DNakagawa%26aufirst%3DK.%26aulast%3DIshikawa%26aufirst%3DY.%26aulast%3DMano%26aufirst%3DH.%26atitle%3DKIF5B-ALK%252C%2520a%2520Novel%2520Fusion%2520Oncokinase%2520Identified%2520by%2520an%2520Immunohistochemistry-based%2520Diagnostic%2520System%2520for%2520ALK-positive%2520Lung%2520Cancer%26jtitle%3DClin%252C%2520Cancer%2520Res.%26date%3D2009%26volume%3D15%26spage%3D3143%26epage%3D3149%26doi%3D10.1158%2F1078-0432.CCR-08-3248" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Takeuchi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Togashi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakata, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hatano, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asaka, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamanaka, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ninomiya, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uehara, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim Choi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Satoh, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okumura, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakagawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mano, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishikawa, Y.</span></span> <span> </span><span class="NLM_article-title">RET, ROS1 and ALK Fusions in Lung Cancer</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">378</span>– <span class="NLM_lpage">381</span>, <span class="refDoi"> DOI: 10.1038/nm.2658</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1038%2Fnm.2658" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=22327623" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC38XitFaks7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=378-381&author=K.+Takeuchiauthor=M.+Sodaauthor=Y.+Togashiauthor=R.+Suzukiauthor=S.+Sakataauthor=S.+Hatanoauthor=R.+Asakaauthor=W.+Hamanakaauthor=H.+Ninomiyaauthor=H.+Ueharaauthor=Y.+Lim+Choiauthor=Y.+Satohauthor=S.+Okumuraauthor=K.+Nakagawaauthor=H.+Manoauthor=Y.+Ishikawa&title=RET%2C+ROS1+and+ALK+Fusions+in+Lung+Cancer&doi=10.1038%2Fnm.2658"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">RET, ROS1 and ALK fusions in lung cancer</span></div><div class="casAuthors">Takeuchi, Kengo; Soda, Manabu; Togashi, Yuki; Suzuki, Ritsuro; Sakata, Seiji; Hatano, Satoko; Asaka, Reimi; Hamanaka, Wakako; Ninomiya, Hironori; Uehara, Hirofumi; Lim Choi, Young; Satoh, Yukitoshi; Okumura, Sakae; Nakagawa, Ken; Mano, Hiroyuki; Ishikawa, Yuichi</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">378-381</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Through an integrated mol.- and histopathol.-based screening system, we performed a screening for fusions of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1, receptor tyrosine kinase (ROS1) in 1,529 lung cancers and identified 44 ALK-fusion-pos. and 13 ROS1-fusion-pos. adenocarcinomas, including for unidentified fusion partners for ROS1.  In addn., we discovered previously unidentified kinase fusions that may be promising for mol.-targeted therapy, kinesin family member 5B (KIF5B)-ret proto-oncogene (RET) and coiled-coil domain contg. 6 (CCDC6)-RET, in 14 adenocarcinomas.  A multivariate anal. of 1,116 adenocarcinomas contg. these 71 kinase-fusion-pos. adenocarcinomas identified four independent factors that are indicators of poor prognosis: age ≥50 years, male sex, high pathol. stage and neg. kinase-fusion status.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhJr0BIAnHWLVg90H21EOLACvtfcHk0lgS9HA8QIi_Tw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XitFaks7s%253D&md5=986c7eba0992b29950756e129a395d60</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1038%2Fnm.2658&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.2658%26sid%3Dliteratum%253Aachs%26aulast%3DTakeuchi%26aufirst%3DK.%26aulast%3DSoda%26aufirst%3DM.%26aulast%3DTogashi%26aufirst%3DY.%26aulast%3DSuzuki%26aufirst%3DR.%26aulast%3DSakata%26aufirst%3DS.%26aulast%3DHatano%26aufirst%3DS.%26aulast%3DAsaka%26aufirst%3DR.%26aulast%3DHamanaka%26aufirst%3DW.%26aulast%3DNinomiya%26aufirst%3DH.%26aulast%3DUehara%26aufirst%3DH.%26aulast%3DLim%2BChoi%26aufirst%3DY.%26aulast%3DSatoh%26aufirst%3DY.%26aulast%3DOkumura%26aufirst%3DS.%26aulast%3DNakagawa%26aufirst%3DK.%26aulast%3DMano%26aufirst%3DH.%26aulast%3DIshikawa%26aufirst%3DY.%26atitle%3DRET%252C%2520ROS1%2520and%2520ALK%2520Fusions%2520in%2520Lung%2520Cancer%26jtitle%3DNat.%2520Med.%26date%3D2012%26volume%3D18%26spage%3D378%26epage%3D381%26doi%3D10.1038%2Fnm.2658" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">van
der Krogt, J.-A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bempt, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferreiro, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mentens, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobs, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pluys, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doms, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geerdens, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uyttebroeck, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pierre, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michaux, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Devos, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vandenberghe, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tousseyn, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cools, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wlodarska, I.</span></span> <span> </span><span class="NLM_article-title">ALK-positive Anaplastic Large Cell Lymphoma with the Variant RNF213-, ATIC-and TPM3-ALK Fusions is Characterized by Copy Number Gain of the Rearranged ALK gene</span>. <i>Haematologica</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>102</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">1605</span>– <span class="NLM_lpage">1616</span>, <span class="refDoi"> DOI: 10.3324/haematol.2016.146571</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.3324%2Fhaematol.2016.146571" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=28659337" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitV2jsrfI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2017&pages=1605-1616&issue=9&author=J.-A.+van%0Ader+Krogtauthor=M.+V.+Bemptauthor=J.+F.+Ferreiroauthor=N.+Mentensauthor=K.+Jacobsauthor=U.+Pluysauthor=K.+Domsauthor=E.+Geerdensauthor=A.+Uyttebroeckauthor=P.+Pierreauthor=L.+Michauxauthor=T.+Devosauthor=P.+Vandenbergheauthor=T.+Tousseynauthor=J.+Coolsauthor=I.+Wlodarska&title=ALK-positive+Anaplastic+Large+Cell+Lymphoma+with+the+Variant+RNF213-%2C+ATIC-and+TPM3-ALK+Fusions+is+Characterized+by+Copy+Number+Gain+of+the+Rearranged+ALK+gene&doi=10.3324%2Fhaematol.2016.146571"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Anaplastic lymphoma kinase-positive anaplastic large cell lymphoma with the variant RNF213-, ATIC- and TPM3-ALK fusions is characterized by copy number gain of the rearranged ALK gene</span></div><div class="casAuthors">van der Krogt, Jo-Anne; Bempt, Marlies Vanden; Ferreiro, Julio Finalet; Mentens, Nicole; Jacobs, Kris; Pluys, Ursula; Doms, Kathleen; Geerdens, Ellen; Uyttebroeck, Anne; Pierre, Pascal; Michaux, Lucienne; Devos, Timothy; Vandenberghe, Peter; Tousseyn, Thomas; Cools, Jan; Wlodarska, Iwona</div><div class="citationInfo"><span class="NLM_cas:title">Haematologica</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1605-1616</span>CODEN:
                <span class="NLM_cas:coden">HAEMAX</span>;
        ISSN:<span class="NLM_cas:issn">1592-8721</span>.
    
            (<span class="NLM_cas:orgname">Ferrata Storti Foundation</span>)
        </div><div class="casAbstract">Anaplastic lymphoma kinase (ALK)-pos. anaplastic large cell lymphoma is characterized by 2p23/ALK aberrations, including the classic t(2;5)(p23;q35)/NPM1-ALK rearrangement present in ∼80% of cases and several variant t(2p23/ALK) occurring in the remaining cases.  The ALK fusion partners play a key role in the constitutive activation of the chimeric protein and its subcellular localization.  Using various mol. technologies, we have characterized ALK fusions in eight recently diagnosed anaplastic large cell lymphoma cases with cytoplasmic- only ALK expression.  The identified partner genes included EEF1G (one case), RNF213/ALO17 (one case), ATIC (four cases) and TPM3 (two cases).  Notably, all cases showed copy no. gain of the rearranged ALK gene, which is never obsd. in NPM1-ALK-pos. lymphomas.  We hypothesized that this could be due to lower expression levels and/or lower oncogenic potential of the variant ALK fusions.  Indeed, all partner genes, except EEF1G, showed lower expression in normal and malignant T cells, in comparison with NPM1.  In addn., we investigated the transformation potential of endogenous Npm1-Alk and Atic-Alk fusions generated by clustered regularly interspaced short palindromic repeats/Cas9 genome editing in Ba/F3 cells.  We found that Npm1-Alk has a stronger transformation potential than Atic-Alk, and we obsd. a subclonal gain of Atic-Alk after a longer culture period, which was not obsd. for Npm1-Alk.  Taken together, our data illustrate that lymphomas driven by the variant ATIC-ALK fusion (and likely by RNF213- ALK and TPM3-ALK), but not the classic NPM1-ALK, require an increased dosage of the ALK hybrid gene to compensate for the relatively low and insufficient expression and signaling properties of the chimeric gene.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopa0QUpQo5y7Vg90H21EOLACvtfcHk0lgS9HA8QIi_Tw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitV2jsrfI&md5=69b0f94368167ddaad61fa7e0b617c09</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.3324%2Fhaematol.2016.146571&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3324%252Fhaematol.2016.146571%26sid%3Dliteratum%253Aachs%26aulast%3Dvan%2Bder%2BKrogt%26aufirst%3DJ.-A.%26aulast%3DBempt%26aufirst%3DM.%2BV.%26aulast%3DFerreiro%26aufirst%3DJ.%2BF.%26aulast%3DMentens%26aufirst%3DN.%26aulast%3DJacobs%26aufirst%3DK.%26aulast%3DPluys%26aufirst%3DU.%26aulast%3DDoms%26aufirst%3DK.%26aulast%3DGeerdens%26aufirst%3DE.%26aulast%3DUyttebroeck%26aufirst%3DA.%26aulast%3DPierre%26aufirst%3DP.%26aulast%3DMichaux%26aufirst%3DL.%26aulast%3DDevos%26aufirst%3DT.%26aulast%3DVandenberghe%26aufirst%3DP.%26aulast%3DTousseyn%26aufirst%3DT.%26aulast%3DCools%26aufirst%3DJ.%26aulast%3DWlodarska%26aufirst%3DI.%26atitle%3DALK-positive%2520Anaplastic%2520Large%2520Cell%2520Lymphoma%2520with%2520the%2520Variant%2520RNF213-%252C%2520ATIC-and%2520TPM3-ALK%2520Fusions%2520is%2520Characterized%2520by%2520Copy%2520Number%2520Gain%2520of%2520the%2520Rearranged%2520ALK%2520gene%26jtitle%3DHaematologica%26date%3D2017%26volume%3D102%26issue%3D9%26spage%3D1605%26epage%3D1616%26doi%3D10.3324%2Fhaematol.2016.146571" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kovach, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katzman, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salloum, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ettinghausen, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madeb, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koniaris, L. G.</span></span> <span> </span><span class="NLM_article-title">Inflammatory Myofibroblastic Tumors</span>. <i>J. Surg. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>94</i></span>,  <span class="NLM_fpage">385</span>– <span class="NLM_lpage">391</span>, <span class="refDoi"> DOI: 10.1002/jso.20516</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1002%2Fjso.20516" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=16967468" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A280%3ADC%252BD28rlsVygtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=2006&pages=385-391&author=S.+J.+Kovachauthor=A.+C.+Fischerauthor=P.+J.+Katzmanauthor=R.+M.+Salloumauthor=S.+E.+Ettinghausenauthor=R.+Madebauthor=L.+G.+Koniaris&title=Inflammatory+Myofibroblastic+Tumors&doi=10.1002%2Fjso.20516"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Inflammatory myofibroblastic tumors</span></div><div class="casAuthors">Kovach Stephen J; Fischer Anne C; Katzman Philip J; Salloum Rabih M; Ettinghausen Stephen E; Madeb Ralph; Koniaris Leonidas G</div><div class="citationInfo"><span class="NLM_cas:title">Journal of surgical oncology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">94</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">385-91</span>
        ISSN:<span class="NLM_cas:issn">0022-4790</span>.
    </div><div class="casAbstract">INTRODUCTION:  Inflammatory myofibroblastic tumors (IMT) while uncommon may arise within numerous organs.  Historically, the literature regarding IMT has been confined to small one organ case series, with few reviews encompassing multiple anatomic sites, and little data regarding adjuvant treatment.  METHODS:  A review of patients with IMT treated at two large academic medical centers over a 15-year period was undertaken.  Patient demographics, pathologic diagnoses, and pertinent clinical data were obtained.  RESULTS:  Forty-four cases of pathologically confirmed IMT were identified.  Tumor locations included multiple anatomic sites.  Therapies included complete resection, incomplete resection, observation, or chemotherapy, and/or radiation.  Five patients underwent adjuvant chemotherapy and/or radiation therapy following surgery (14%) for local aggressiveness of the tumor, invasion, positive margins, or location of tumor that was not amenable to surgical resection.  A second, concomitant, histologically distinct, neoplasm was identified in five cases.  Of the patients who underwent treatment three local recurrences were noted (8%) and occurred in patients with partial resection without adjuvant chemo- or radiotherapy.  CONCLUSIONS:  Inflammatory myofibroblastic tumors may be a locally aggressive and destructive neoplasm.  Tumor recurrence is unusual following complete surgical resection or organ-preserving combined modality therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTNcHU--PsRpzAyhZbj3lKdfW6udTcc2ebLwmPCp4TNKLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD28rlsVygtA%253D%253D&md5=de1262010b27e35365b3f666b26d3a37</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1002%2Fjso.20516&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjso.20516%26sid%3Dliteratum%253Aachs%26aulast%3DKovach%26aufirst%3DS.%2BJ.%26aulast%3DFischer%26aufirst%3DA.%2BC.%26aulast%3DKatzman%26aufirst%3DP.%2BJ.%26aulast%3DSalloum%26aufirst%3DR.%2BM.%26aulast%3DEttinghausen%26aufirst%3DS.%2BE.%26aulast%3DMadeb%26aufirst%3DR.%26aulast%3DKoniaris%26aufirst%3DL.%2BG.%26atitle%3DInflammatory%2520Myofibroblastic%2520Tumors%26jtitle%3DJ.%2520Surg.%2520Oncol.%26date%3D2006%26volume%3D94%26spage%3D385%26epage%3D391%26doi%3D10.1002%2Fjso.20516" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hawkins, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dvorak, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henkle, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellingham, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perlman, E. J.</span></span> <span> </span><span class="NLM_article-title">Recurrent Involvement of 2p23 in Inflammatory Myofibroblastic Tumors</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">2776</span>– <span class="NLM_lpage">2780</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10383129" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADyaK1MXktVOktbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=1999&pages=2776-2780&author=C.+A.+Griffinauthor=A.+L.+Hawkinsauthor=C.+Dvorakauthor=C.+Henkleauthor=T.+Ellinghamauthor=E.+J.+Perlman&title=Recurrent+Involvement+of+2p23+in+Inflammatory+Myofibroblastic+Tumors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Recurrent involvement of 2p23 in inflammatory myofibroblastic tumors</span></div><div class="casAuthors">Griffin, Constance A.; Hawkins, Anita L.; Dvorak, Cecily; Henkle, Carol; Ellingham, Tara; Perlman, Elizabeth J.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2776-2780</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">AACR Subscription Office</span>)
        </div><div class="casAbstract">Inflammatory myofibroblastic tumor (IMT) is a relatively rare soft tissue tumor.  The reactive vs. neoplastic pathogenesis of this tumor is unresolved.  We found clonal chromosome aberrations involving 2p23 upon metaphase anal. of two IMTs.  Fluorescence in situ hybridization with a probe flanking the ALK gene at 2p23 demonstrated rearrangement of the probe in both of these cases and in a third case, and immunohistochem. revealed ALK expression in all three cases.  A 2p22-24 involvement has been reported previously in four addnl. cases of IMT.  We suggest that chromosomal rearrangements involving 2p23 near or within ALK are recurrent alterations in IMT and that ALK may have a novel role outside its previously recognized realm of lymphoid neoplasms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocvXV2ukz3crVg90H21EOLACvtfcHk0lhv3Ql8VqK6DQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXktVOktbk%253D&md5=8054eeaaf0cb85ee85afff461797c84c</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGriffin%26aufirst%3DC.%2BA.%26aulast%3DHawkins%26aufirst%3DA.%2BL.%26aulast%3DDvorak%26aufirst%3DC.%26aulast%3DHenkle%26aufirst%3DC.%26aulast%3DEllingham%26aufirst%3DT.%26aulast%3DPerlman%26aufirst%3DE.%2BJ.%26atitle%3DRecurrent%2520Involvement%2520of%25202p23%2520in%2520Inflammatory%2520Myofibroblastic%2520Tumors%26jtitle%3DCancer%2520Res.%26date%3D1999%26volume%3D59%26spage%3D2776%26epage%3D2780" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lovly, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lipson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otto, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brennan, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borinstein, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stephens, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, V. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coffin, C. M.</span></span> <span> </span><span class="NLM_article-title">Inflammatory Myofibroblastic Tumors Harbor Multiple Potentially Actionable Kinase Fusions</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">889</span>– <span class="NLM_lpage">895</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-14-0377</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1158%2F2159-8290.CD-14-0377" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=24875859" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtlSrtbzP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2014&pages=889-895&author=C.+M.+Lovlyauthor=A.+Guptaauthor=D.+Lipsonauthor=G.+Ottoauthor=T.+Brennanauthor=C.+T.+Chungauthor=S.+C.+Borinsteinauthor=J.+S.+Rossauthor=P.+J.+Stephensauthor=V.+A.+Millerauthor=C.+M.+Coffin&title=Inflammatory+Myofibroblastic+Tumors+Harbor+Multiple+Potentially+Actionable+Kinase+Fusions&doi=10.1158%2F2159-8290.CD-14-0377"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Inflammatory Myofibroblastic Tumors Harbor Multiple Potentially Actionable Kinase Fusions</span></div><div class="casAuthors">Lovly, Christine M.; Gupta, Abha; Lipson, Doron; Otto, Geoff; Brennan, Tina; Chung, Catherine T.; Borinstein, Scott C.; Ross, Jeffrey S.; Stephens, Philip J.; Miller, Vincent A.; Coffin, Cheryl M.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">889-895</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Inflammatory myofibroblastic tumor (IMT) is a neoplasm that typically occurs in 1 children.  The genetic landscape of this tumor is incompletely understood and therapeutic options are limited.  Although 50% of IMTs harbor anaplastic lymphoma kinase (ALK) rearrangements, no therapeutic targets have been identified in ALK-neg. tumors.  We report for the first time 1 that IMTs harbor other actionable targets, including ROS1 and PDGFRβ fusions.  We detail the case of an 8-yr-old boy with treatment-refractory ALK-neg. IMT.  Mol. tumor profiling revealed a ROS1 fusion, and he had a dramatic response to the ROS1 inhibitor crizotinib.  This case prompted assessment of a larger series of IMTs.  Next-generation sequencing revealed that 85% of cases evaluated harbored kinase fusions involving ALK1R0S1, or PDGFRp.  Our study represents the most comprehensive genetic anal. of IMTs to date and also provides a rationale for routine mol. profiling of these tumors to detect therapeutically actionable kinase fusions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr63dmuwBRGZLVg90H21EOLACvtfcHk0lhv3Ql8VqK6DQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtlSrtbzP&md5=a61b1ddd3f6eac36782b33601d1beb3a</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-14-0377&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-14-0377%26sid%3Dliteratum%253Aachs%26aulast%3DLovly%26aufirst%3DC.%2BM.%26aulast%3DGupta%26aufirst%3DA.%26aulast%3DLipson%26aufirst%3DD.%26aulast%3DOtto%26aufirst%3DG.%26aulast%3DBrennan%26aufirst%3DT.%26aulast%3DChung%26aufirst%3DC.%2BT.%26aulast%3DBorinstein%26aufirst%3DS.%2BC.%26aulast%3DRoss%26aufirst%3DJ.%2BS.%26aulast%3DStephens%26aufirst%3DP.%2BJ.%26aulast%3DMiller%26aufirst%3DV.%2BA.%26aulast%3DCoffin%26aufirst%3DC.%2BM.%26atitle%3DInflammatory%2520Myofibroblastic%2520Tumors%2520Harbor%2520Multiple%2520Potentially%2520Actionable%2520Kinase%2520Fusions%26jtitle%3DCancer%2520Discovery%26date%3D2014%26volume%3D4%26spage%3D889%26epage%3D895%26doi%3D10.1158%2F2159-8290.CD-14-0377" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lenz, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staudt, L. M.</span></span> <span> </span><span class="NLM_article-title">Aggressive lymphomas</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>362</i></span>,  <span class="NLM_fpage">1417</span>– <span class="NLM_lpage">1429</span>, <span class="refDoi"> DOI: 10.1056/NEJMra0807082</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1056%2FNEJMra0807082" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=20393178" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC3cXkslajtbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=362&publication_year=2010&pages=1417-1429&author=G.+Lenzauthor=L.+M.+Staudt&title=Aggressive+lymphomas&doi=10.1056%2FNEJMra0807082"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Aggressive lymphomas</span></div><div class="casAuthors">Lenz, Georg; Staudt, Louis M.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">362</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">1417-1429</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">A review.  Given the emergence of many new therapeutic agents that affect essential regulatory pathways in lymphomas, the challenge is to identify rational combinations that kill lymphoma cells synergistically.  This effort requires both preclin. evaluation and the development of clin.-trial strategies that include mol. profiling.  Gene expression profiling could be used to det. the lymphoma subtype and to est. the risk assocd. with std. therapy.  Cancer gene resequencing could be used to identify tumors that are likely to be dependent on a particular signaling pathway and to det. which step in the pathway to inhibit.  Finally, the activity of the targeted pathways before and during therapy could be used to assess the efficacy of the treatment.  We expect that this "divide-and-conquer" approach will provide increasingly effective and nontoxic therapies for patients with lymphomas.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpAtbs8gSY6hrVg90H21EOLACvtfcHk0lgfVBP102LjhQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXkslajtbY%253D&md5=005333ef8156a770b418a07aae2f19d8</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1056%2FNEJMra0807082&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMra0807082%26sid%3Dliteratum%253Aachs%26aulast%3DLenz%26aufirst%3DG.%26aulast%3DStaudt%26aufirst%3DL.%2BM.%26atitle%3DAggressive%2520lymphomas%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2010%26volume%3D362%26spage%3D1417%26epage%3D1429%26doi%3D10.1056%2FNEJMra0807082" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chikatsu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kojima, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzukawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shinagawa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagasawa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ozawa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamashita, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mori, N.</span></span> <span> </span><span class="NLM_article-title">ALK+, CD30–, CD20– large B-cell Lymphoma Containing Anaplastic Lymphoma Kinase (ALK) Fused to Clathrin Heavy Chain Gene (CLTC)</span>. <i>Mod. Pathol.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">828</span>– <span class="NLM_lpage">832</span>, <span class="refDoi"> DOI: 10.1097/01.MP.0000081729.40230.1F</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1097%2F01.MP.0000081729.40230.1F" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=12920229" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A280%3ADC%252BD3szotl2gtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2003&pages=828-832&author=N.+Chikatsuauthor=H.+Kojimaauthor=K.+Suzukawaauthor=A.+Shinagawaauthor=T.+Nagasawaauthor=H.+Ozawaauthor=Y.+Yamashitaauthor=N.+Mori&title=ALK%2B%2C+CD30%E2%80%93%2C+CD20%E2%80%93+large+B-cell+Lymphoma+Containing+Anaplastic+Lymphoma+Kinase+%28ALK%29+Fused+to+Clathrin+Heavy+Chain+Gene+%28CLTC%29&doi=10.1097%2F01.MP.0000081729.40230.1F"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">ALK+, CD30-, CD20- large B-cell lymphoma containing anaplastic lymphoma kinase (ALK) fused to clathrin heavy chain gene (CLTC)</span></div><div class="casAuthors">Chikatsu Norio; Kojima Hiroshi; Suzukawa Kazumi; Shinagawa Atsushi; Nagasawa Toshiro; Ozawa Hiroaki; Yamashita Yoriko; Mori Naoyoshi</div><div class="citationInfo"><span class="NLM_cas:title">Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">828-32</span>
        ISSN:<span class="NLM_cas:issn">0893-3952</span>.
    </div><div class="casAbstract">Pathological features and genomic basis of a rare case of ALK(+), CD30(-), CD20(-) large B-cell lymphoma were analyzed.  A 36-year-old Japanese female was admitted because of lumbago and constitutional symptoms.  Physical examination and laboratory tests showed anemia (hemoglobin, 7.5 g/dL), mild hepatosplenomegaly, and immunoglobin G (IgG) lambda-type monoclonal gammopathy (IgG, 2782 mg/dL).  The lymphoma spread exclusively in extranodal sites such as bone marrow, liver, spleen, ovary, and muscle.  Biopsy specimens obtained from the ovary showed monomorphic proliferation of large immunoblastic cells with basophilic cytoplasm, round-shaped nuclei with a high nuclear to cytoplasmic ratio, and prominent single nucleolus.  Immunostaining with anti-anaplastic lymphoma kinase (ALK) antibody, ALK1, showed finely granular cytoplasmic staining pattern.  These cells were also positive for epithelial membrane antigen, CD4, CD19, CD38, CD138, cytoplasmic IgG, and lambda chain, but negative for CD30 (Ber-H2), CD56, CD57, and other T- and B-cell markers.  Southern blot analyses revealed that Ig heavy and lambda light chain genes, but not T-cell receptor (TCR) beta gene, were clonally rearranged.  Chromosomal analyses by conventional G-banding, spectral karyotyping, and fluorescence in situ hybridization showed complex abnormality involving 2p23, and chromosome 2 was translocated to chromosome 17.  As 2;17 translocation resulting in the fusion of clathrin heavy chain (CLTC) gene with ALK was previously reported in inflammatory myofibroblastic tumor, we performed reverse transcriptase-polymerase chain reaction and demonstrated that the lymphoma cells contained CLTC-ALK fusion transcript.  Under the diagnosis of ALK(+), CD30(-), CD20(-) large B-cell lymphoma, she was treated with conventional combination chemotherapies.  However, the lymphoma was primarily chemotherapy resistant, and the patient died 11 months after admission.  We consider that this case confirms the existence of ALK(+), CD30(-), CD20(-) large B-cell lymphomas proposed by Delsol et al. (16) and further provides relevant information regarding their clinicopathological features and cytogenetics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRjvhATsCXEtwaK-_ZudimnfW6udTcc2eb1Hk8X5JhDc7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3szotl2gtQ%253D%253D&md5=79464c7972c0383f24b2a4c287aa10e3</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1097%2F01.MP.0000081729.40230.1F&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F01.MP.0000081729.40230.1F%26sid%3Dliteratum%253Aachs%26aulast%3DChikatsu%26aufirst%3DN.%26aulast%3DKojima%26aufirst%3DH.%26aulast%3DSuzukawa%26aufirst%3DK.%26aulast%3DShinagawa%26aufirst%3DA.%26aulast%3DNagasawa%26aufirst%3DT.%26aulast%3DOzawa%26aufirst%3DH.%26aulast%3DYamashita%26aufirst%3DY.%26aulast%3DMori%26aufirst%3DN.%26atitle%3DALK%252B%252C%2520CD30%25E2%2580%2593%252C%2520CD20%25E2%2580%2593%2520large%2520B-cell%2520Lymphoma%2520Containing%2520Anaplastic%2520Lymphoma%2520Kinase%2520%2528ALK%2529%2520Fused%2520to%2520Clathrin%2520Heavy%2520Chain%2520Gene%2520%2528CLTC%2529%26jtitle%3DMod.%2520Pathol.%26date%3D2003%26volume%3D16%26spage%3D828%26epage%3D832%26doi%3D10.1097%2F01.MP.0000081729.40230.1F" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Van
Roosbroeck, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cools, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dierickx, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vandenberghe, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stul, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delabie, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Wolf-Peeters, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marynen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wlodarska, I.</span></span> <span> </span><span class="NLM_article-title">ALK-positive Large B-cell Lymphomas with Cryptic SEC31A-ALK and NPM1-ALK Fusions</span>. <i>Haematologica</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>95</i></span>,  <span class="NLM_fpage">509</span>– <span class="NLM_lpage">513</span>, <span class="refDoi"> DOI: 10.3324/haematol.2009.014761</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.3324%2Fhaematol.2009.014761" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=20207848" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht12msLvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=2010&pages=509-513&author=K.+Van%0ARoosbroeckauthor=J.+Coolsauthor=D.+Dierickxauthor=J.+Thomasauthor=P.+Vandenbergheauthor=M.+Stulauthor=J.+Delabieauthor=C.+De+Wolf-Peetersauthor=P.+Marynenauthor=I.+Wlodarska&title=ALK-positive+Large+B-cell+Lymphomas+with+Cryptic+SEC31A-ALK+and+NPM1-ALK+Fusions&doi=10.3324%2Fhaematol.2009.014761"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">ALK-positive large B-cell lymphomas with cryptic SEC31A-ALK and NPM1-ALK fusions</span></div><div class="casAuthors">Van Roosbroeck, Katrien; Cools, Jan; Dierickx, Daan; Thomas, Jose; Vandenberghe, Peter; Stul, Michel; Delabie, Jan; De Wolf-Peeters, Chris; Marynen, Peter; Wlodarska, Iwona</div><div class="citationInfo"><span class="NLM_cas:title">Haematologica</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">95</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">509-513</span>CODEN:
                <span class="NLM_cas:coden">HAEMAX</span>;
        ISSN:<span class="NLM_cas:issn">0390-6078</span>.
    
            (<span class="NLM_cas:orgname">Ferrata Storti Foundation</span>)
        </div><div class="casAbstract">We report 2 ALK-pos. large B-cell lymphoma cases showing granular cytoplasmic and cytoplasmic/nuclear ALK immunostaining in which cryptic ALK rearrangements were identified by fluorescent in situ hybridization and mol. anal.  In the first case, the ALK-involving t(2;3)(p23;q27) masked the cryptic SEC31A-ALK fusion generated by an insertion of the 5' end of SEC31A (4q21) upstream of the 3' end of ALK.  This rearrangement was assocd. with loss of the 5' end of ALK and duplication of SEC31A-ALK on der(20).  In the second case with complex rearrangements of both chromosomes 2, a submicroscopic NPM1-ALK fusion created by insertion of the 3' end of ALK into the NPM1 locus was evidenced.  Further studies of SEC31A-ALK showed that this variant fusion transforms IL3-dependent Ba/F3 cells to growth factor independence, and that the ALK inhibitor TAE-684 reduces cell proliferation and kinase activity of SEC31A-ALK and its downstream effectors ERK1/2, AKT, STAT3 and STAT5.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfOGiY_6QU4LVg90H21EOLACvtfcHk0lgfVBP102LjhQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht12msLvN&md5=f9a7c32c4b6cc160d6866fe58ca0bb57</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.3324%2Fhaematol.2009.014761&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3324%252Fhaematol.2009.014761%26sid%3Dliteratum%253Aachs%26aulast%3DVan%2BRoosbroeck%26aufirst%3DK.%26aulast%3DCools%26aufirst%3DJ.%26aulast%3DDierickx%26aufirst%3DD.%26aulast%3DThomas%26aufirst%3DJ.%26aulast%3DVandenberghe%26aufirst%3DP.%26aulast%3DStul%26aufirst%3DM.%26aulast%3DDelabie%26aufirst%3DJ.%26aulast%3DDe%2BWolf-Peeters%26aufirst%3DC.%26aulast%3DMarynen%26aufirst%3DP.%26aulast%3DWlodarska%26aufirst%3DI.%26atitle%3DALK-positive%2520Large%2520B-cell%2520Lymphomas%2520with%2520Cryptic%2520SEC31A-ALK%2520and%2520NPM1-ALK%2520Fusions%26jtitle%3DHaematologica%26date%3D2010%26volume%3D95%26spage%3D509%26epage%3D513%26doi%3D10.3324%2Fhaematol.2009.014761" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Takeuchi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Togashi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ota, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sekiguchi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hatano, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asaka, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noguchi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mano, H.</span></span> <span> </span><span class="NLM_article-title">Identification of a Novel Fusion, SQSTM1-ALK, in ALK-positive Large B-cell Lymphoma</span>. <i>Haematologica</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>96</i></span>,  <span class="NLM_fpage">464</span>– <span class="NLM_lpage">467</span>, <span class="refDoi"> DOI: 10.3324/haematol.2010.033514</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.3324%2Fhaematol.2010.033514" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=21134980" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1WnsLfO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=2011&pages=464-467&author=K.+Takeuchiauthor=M.+Sodaauthor=Y.+Togashiauthor=Y.+Otaauthor=Y.+Sekiguchiauthor=S.+Hatanoauthor=R.+Asakaauthor=M.+Noguchiauthor=H.+Mano&title=Identification+of+a+Novel+Fusion%2C+SQSTM1-ALK%2C+in+ALK-positive+Large+B-cell+Lymphoma&doi=10.3324%2Fhaematol.2010.033514"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of a novel fusion, SQSTM1-ALK, in ALK-positive large B-cell lymphoma</span></div><div class="casAuthors">Takeuchi, Kengo; Soda, Manabu; Togashi, Yuki; Ota, Yasunori; Sekiguchi, Yasunobu; Hatano, Satoko; Asaka, Reimi; Noguchi, Masaaki; Mano, Hiroyuki</div><div class="citationInfo"><span class="NLM_cas:title">Haematologica</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">96</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">464-467</span>CODEN:
                <span class="NLM_cas:coden">HAEMAX</span>;
        ISSN:<span class="NLM_cas:issn">0390-6078</span>.
    
            (<span class="NLM_cas:orgname">Ferrata Storti Foundation</span>)
        </div><div class="casAbstract">ALK-pos. large B-cell lymphoma is a rare subtype of lymphoma, and most cases follow an aggressive clin. course with a poor prognosis.  We examd. an ALK-pos. large B-cell lymphoma case showing an anti-ALK immunohistochem. pattern distinct from those of 2 known ALK fusions, CLTC-ALK and NPM-ALK, for the presence of a novel ALK fusion; this led to the identification of SQSTM1-ALK.  SQSTM1 is an ubiquitin binding protein that is assocd. with oxidative stress, cell signaling, and autophagy.  We showed transforming activities of SQSTM1-ALK with a focus formation assay and an in vivo tumorigenicity assay using 3T3 fibroblasts infected with a recombinant retrovirus encoding SQSTM1-ALK.  ALK-inhibitor therapies are promising for treating ALK-pos. large B-cell lymphoma, esp. for refractory cases.  SQSTM1-ALK may be a rare fusion, but our data provide novel biol. insights and serve as a key for the accurate diagnosis of this rare lymphoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpJvBjSH8V87Vg90H21EOLACvtfcHk0ljpj-Nv6kFJcQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1WnsLfO&md5=0d760599f0a3559f50a962a1d5aad22c</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.3324%2Fhaematol.2010.033514&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3324%252Fhaematol.2010.033514%26sid%3Dliteratum%253Aachs%26aulast%3DTakeuchi%26aufirst%3DK.%26aulast%3DSoda%26aufirst%3DM.%26aulast%3DTogashi%26aufirst%3DY.%26aulast%3DOta%26aufirst%3DY.%26aulast%3DSekiguchi%26aufirst%3DY.%26aulast%3DHatano%26aufirst%3DS.%26aulast%3DAsaka%26aufirst%3DR.%26aulast%3DNoguchi%26aufirst%3DM.%26aulast%3DMano%26aufirst%3DH.%26atitle%3DIdentification%2520of%2520a%2520Novel%2520Fusion%252C%2520SQSTM1-ALK%252C%2520in%2520ALK-positive%2520Large%2520B-cell%2520Lymphoma%26jtitle%3DHaematologica%26date%3D2011%26volume%3D96%26spage%3D464%26epage%3D467%26doi%3D10.3324%2Fhaematol.2010.033514" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ouyang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span> <span> </span><span class="NLM_article-title">Promising Response of Anaplastic Lymphoma Kinase-positive Large B-cell Lymphoma to Crizotinib Salvage Treatment: Case Report and Review of Literature</span>. <i>Int. J. Clin. Exp. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">6977</span>– <span class="NLM_lpage">6985</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=26221234" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVWgtLzN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2015&pages=6977-6985&author=J.+Liauthor=J.+Ouyangauthor=R.+Zhouauthor=B.+Chenauthor=Y.+Xu&title=Promising+Response+of+Anaplastic+Lymphoma+Kinase-positive+Large+B-cell+Lymphoma+to+Crizotinib+Salvage+Treatment%3A+Case+Report+and+Review+of+Literature"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Promising response of anaplastic lymphoma kinase-positive large B-cell lymphoma to crizotinib salvage treatment: case report and review of literature</span></div><div class="casAuthors">Li, Jian; Ouyang, Jian; Zhou, Rongfu; Chen, Bing; Xu, Yong</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Clinical and Experimental Medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">6977-6985</span>CODEN:
                <span class="NLM_cas:coden">IJCEFA</span>;
        ISSN:<span class="NLM_cas:issn">1940-5901</span>.
    
            (<span class="NLM_cas:orgname">e-Century Publishing Corp.</span>)
        </div><div class="casAbstract">Anaplastic lymphoma kinase (ALK)-pos. diffuse large B-cell lymphoma (ALK + DLBCL) is a rare and poorly characterized subtype of lymphoma.  Reports suggest that this type of tumor responds poorly to std. regimens for non-Hodgkin's lymphoma, with rituximab playing no therapeutic role due to the absence of CD20 expression.  In view of the expression of ALK in this disease, it is plausible that the ALK inhibitor crizotinib may be an effective treatment.  We report a case of a 21-yr-old male ALK + DLBCL patient.  He initially received five cycles of CHOP-21 (vincristine, pirarubicin, cyclophosphamide and prednisone) and achieved a partial remission (PR) but soon deteriorated.  He was subsequently treated with five courses of the salvage chemotherapy regimen ICE (ifosfamide, carboplatin and etoposide) and achieved PR again.  He refused to accept an autologous stem-cell transplantation, after which the disease progressed rapidly.  We administered two courses of an alternative salvage chemotherapy regimen contg. GEMOX and dexamethasone with the addn. of the ALK inhibitor crizotinib.  His symptoms alleviated for a short time but soon worsened and the patient died of massive progressive disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrD7dTikl9df7Vg90H21EOLACvtfcHk0ljpj-Nv6kFJcQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVWgtLzN&md5=6814dafe3466a245e0be2f7d1ca6bb9f</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DOuyang%26aufirst%3DJ.%26aulast%3DZhou%26aufirst%3DR.%26aulast%3DChen%26aufirst%3DB.%26aulast%3DXu%26aufirst%3DY.%26atitle%3DPromising%2520Response%2520of%2520Anaplastic%2520Lymphoma%2520Kinase-positive%2520Large%2520B-cell%2520Lymphoma%2520to%2520Crizotinib%2520Salvage%2520Treatment%253A%2520Case%2520Report%2520and%2520Review%2520of%2520Literature%26jtitle%3DInt.%2520J.%2520Clin.%2520Exp.%2520Med.%26date%3D2015%26volume%3D8%26spage%3D6977%26epage%3D6985" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Philip, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Specialities, M.</span></span> <span> </span><span class="NLM_article-title">ALK Positive DLBCL-A Report of Two Cases and Review of Literature</span>. <i>Univ. J. Med. Med. Special.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">2455</span>– <span class="NLM_lpage">2460</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2016&pages=2455-2460&author=A.+Philipauthor=M.+Specialities&title=ALK+Positive+DLBCL-A+Report+of+Two+Cases+and+Review+of+Literature"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPhilip%26aufirst%3DA.%26aulast%3DSpecialities%26aufirst%3DM.%26atitle%3DALK%2520Positive%2520DLBCL-A%2520Report%2520of%2520Two%2520Cases%2520and%2520Review%2520of%2520Literature%26jtitle%3DUniv.%2520J.%2520Med.%2520Med.%2520Special.%26date%3D2016%26volume%3D2%26spage%3D2455%26epage%3D2460" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Röttgers, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gombert, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teigler-Schlegel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Busch, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gamerdinger, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slany, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harbott, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borkhardt, A.</span></span> <span> </span><span class="NLM_article-title">ALK Fusion Genes in Children with Atypical Myeloproliferative Leukemia</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">1197</span>– <span class="NLM_lpage">1200</span>, <span class="refDoi"> DOI: 10.1038/leu.2010.18</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1038%2Fleu.2010.18" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=20428197" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A280%3ADC%252BC3cvotlGqsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2010&pages=1197-1200&author=S.+R%C3%B6ttgersauthor=M.+Gombertauthor=A.+Teigler-Schlegelauthor=K.+Buschauthor=U.+Gamerdingerauthor=R.+Slanyauthor=J.+Harbottauthor=A.+Borkhardt&title=ALK+Fusion+Genes+in+Children+with+Atypical+Myeloproliferative+Leukemia&doi=10.1038%2Fleu.2010.18"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">ALK fusion genes in children with atypical myeloproliferative leukemia</span></div><div class="casAuthors">Rottgers S; Gombert M; Teigler-Schlegel A; Busch K; Gamerdinger U; Slany R; Harbott J; Borkhardt A</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1197-200</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRTs975Eq7vfLP3FVUi_gf8fW6udTcc2eb_FazZLGdGgLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3cvotlGqsA%253D%253D&md5=f80cacdded9c4f6b1b9ffebc639f204e</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1038%2Fleu.2010.18&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2010.18%26sid%3Dliteratum%253Aachs%26aulast%3DR%25C3%25B6ttgers%26aufirst%3DS.%26aulast%3DGombert%26aufirst%3DM.%26aulast%3DTeigler-Schlegel%26aufirst%3DA.%26aulast%3DBusch%26aufirst%3DK.%26aulast%3DGamerdinger%26aufirst%3DU.%26aulast%3DSlany%26aufirst%3DR.%26aulast%3DHarbott%26aufirst%3DJ.%26aulast%3DBorkhardt%26aufirst%3DA.%26atitle%3DALK%2520Fusion%2520Genes%2520in%2520Children%2520with%2520Atypical%2520Myeloproliferative%2520Leukemia%26jtitle%3DLeukemia%26date%3D2010%26volume%3D24%26spage%3D1197%26epage%3D1200%26doi%3D10.1038%2Fleu.2010.18" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shinmura, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kageyama, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bunai, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamo, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takamochi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanahashi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niwa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogawa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugimura, H.</span></span> <span> </span><span class="NLM_article-title">EML4-ALK Fusion Transcripts, but no NPM-, TPM3-, CLTC-, ATIC-, or TFG-ALK Fusion Transcripts, in Non-small Cell Lung Carcinomas</span>. <i>Lung Cancer</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">163</span>– <span class="NLM_lpage">169</span>, <span class="refDoi"> DOI: 10.1016/j.lungcan.2007.12.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1016%2Fj.lungcan.2007.12.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=18242762" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A280%3ADC%252BD1cvns1ShtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2008&pages=163-169&author=K.+Shinmuraauthor=S.+Kageyamaauthor=H.+Taoauthor=T.+Bunaiauthor=M.+Suzukiauthor=T.+Kamoauthor=K.+Takamochiauthor=K.+Suzukiauthor=M.+Tanahashiauthor=H.+Niwaauthor=H.+Ogawaauthor=H.+Sugimura&title=EML4-ALK+Fusion+Transcripts%2C+but+no+NPM-%2C+TPM3-%2C+CLTC-%2C+ATIC-%2C+or+TFG-ALK+Fusion+Transcripts%2C+in+Non-small+Cell+Lung+Carcinomas&doi=10.1016%2Fj.lungcan.2007.12.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">EML4-ALK fusion transcripts, but no NPM-, TPM3-, CLTC-, ATIC-, or TFG-ALK fusion transcripts, in non-small cell lung carcinomas</span></div><div class="casAuthors">Shinmura Kazuya; Kageyama Shinji; Tao Hong; Bunai Tomoyasu; Suzuki Masaya; Kamo Takaharu; Takamochi Kazuya; Suzuki Kazuya; Tanahashi Masayuki; Niwa Hiroshi; Ogawa Hiroshi; Sugimura Haruhiko</div><div class="citationInfo"><span class="NLM_cas:title">Lung cancer (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">163-9</span>
        ISSN:<span class="NLM_cas:issn">0169-5002</span>.
    </div><div class="casAbstract">EML4-ALK gene fusions have recently been discovered in a subset of human lung carcinomas, and fusions of the ALK tyrosine kinase gene with the NPM, TPM3, CLTC, ATIC, and TFG genes have been found in hematological malignancies.  To elucidate the role of fusions between ALK and other genes in pulmonary carcinogenesis, we examined 77 non-small cell lung carcinomas (NSCLCs) for EML4-, NPM-, TPM3-, CLTC-, ATIC-, and TFG-ALK fusion transcripts by RT-PCR and subsequent sequencing analysis.  Although no expression of NPM-, TPM3-, CLTC-, ATIC-, or TFG-ALK fusion transcripts were detected in any of the cases, expression of EML4-ALK fusion transcripts was detected in two (2.6%) of the 77 NSCLCs.  In one of the two NSCLCs there was fusion between exon 13 of EML4 and exon 20 of ALK, i.e., variant 1, and in the other there was fusion between exon 20 of EML4 and exon 20 of ALK, i.e., variant 2.  Both patients had a history of smoking, and histologically the carcinomas were adenocarcinoma.  No somatic mutations were detected in the mutation cluster regions of the EGFR, K-RAS, and PIK3CA genes in these two carcinomas, however, a Pro177Ser mutation of the p53 gene was detected in the carcinoma that contained the variant 1 EML4-ALK fusion transcripts.  In situ PCR of a paraffin block section showed that the carcinoma with expression of the variant 1 actually contained an EML4-ALK fusion gene.  These results suggested that the EML4-ALK fusion gene product is involved in the carcinogenesis of a subset of NSCLCs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ7jmhu7h4ah3O4gDb7JggCfW6udTcc2eY6Tp7QBB4g67ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1cvns1ShtQ%253D%253D&md5=22dc66a7d0dc1d7451e55a22fb4675bd</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1016%2Fj.lungcan.2007.12.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.lungcan.2007.12.013%26sid%3Dliteratum%253Aachs%26aulast%3DShinmura%26aufirst%3DK.%26aulast%3DKageyama%26aufirst%3DS.%26aulast%3DTao%26aufirst%3DH.%26aulast%3DBunai%26aufirst%3DT.%26aulast%3DSuzuki%26aufirst%3DM.%26aulast%3DKamo%26aufirst%3DT.%26aulast%3DTakamochi%26aufirst%3DK.%26aulast%3DSuzuki%26aufirst%3DK.%26aulast%3DTanahashi%26aufirst%3DM.%26aulast%3DNiwa%26aufirst%3DH.%26aulast%3DOgawa%26aufirst%3DH.%26aulast%3DSugimura%26aufirst%3DH.%26atitle%3DEML4-ALK%2520Fusion%2520Transcripts%252C%2520but%2520no%2520NPM-%252C%2520TPM3-%252C%2520CLTC-%252C%2520ATIC-%252C%2520or%2520TFG-ALK%2520Fusion%2520Transcripts%252C%2520in%2520Non-small%2520Cell%2520Lung%2520Carcinomas%26jtitle%3DLung%2520Cancer%26date%3D2008%26volume%3D61%26spage%3D163%26epage%3D169%26doi%3D10.1016%2Fj.lungcan.2007.12.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Debelenko, L. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raimondi, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daw, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shivakumar, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bridge, J. A.</span></span> <span> </span><span class="NLM_article-title">Renal Cell Carcinoma with Novel VCL–ALK Fusion: New Representative of ALK-associated Tumor Spectrum</span>. <i>Mod. Pathol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">430</span>– <span class="NLM_lpage">442</span>, <span class="refDoi"> DOI: 10.1038/modpathol.2010.213</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1038%2Fmodpathol.2010.213" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=21076462" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC3MXisFartLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2011&pages=430-442&author=L.+V.+Debelenkoauthor=S.+C.+Raimondiauthor=N.+Dawauthor=B.+R.+Shivakumarauthor=D.+Huangauthor=M.+Nelsonauthor=J.+A.+Bridge&title=Renal+Cell+Carcinoma+with+Novel+VCL%E2%80%93ALK+Fusion%3A+New+Representative+of+ALK-associated+Tumor+Spectrum&doi=10.1038%2Fmodpathol.2010.213"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Renal cell carcinoma with novel VCL-ALK fusion: new representative of ALK-associated tumor spectrum</span></div><div class="casAuthors">Debelenko, Larisa V.; Raimondi, Susana C.; Daw, Najat; Shivakumar, Bangalore R.; Huang, Dali; Nelson, Marilu; Bridge, Julia A.</div><div class="citationInfo"><span class="NLM_cas:title">Modern Pathology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">430-442</span>CODEN:
                <span class="NLM_cas:coden">MODPEO</span>;
        ISSN:<span class="NLM_cas:issn">0893-3952</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Renal cell carcinoma represents a model for contemporary classification of solid tumors; however, unusual and unclassifiable cases exist and are not rare in children and young adults.  The anaplastic lymphoma kinase (ALK) gene has recently been implicated in subsets of pulmonary, esophageal, breast, and colon cancers.  These findings strengthen the importance of mol. classification of carcinomas across different organ sites, esp. considering the evolving targeted anticancer therapies with ALK inhibitors.  In the current study of six pediatric renal cell carcinomas, two cases exhibited structural karyotypic abnormalities involving the ALK locus on chromosomal band 2p23.  Fluorescence in situ hybridization (FISH) studies were pos. for an ALK rearrangement in one case, and subsequent 5' rapid amplification of cDNA ends anal. of this tumor revealed that the 3' portion of the ALK transcript encoding for the kinase domain was fused in frame to the 5' portion of vinculin.  The new fusion gene is predicted to have an open reading frame of 4122 bp encoding for a 1374-aa oncoprotein; its expression was shown by immunoblotting with anti-VCL and anti-ALK antibodies in tumor tissue lysates.  Immunohistochem. with the same antibodies demonstrated cytoplasmic and subplasmalemmal localization of the oncoprotein detd. by its N-terminal VCL portion.  FISH with a custom-designed VCL-ALK dual-fusion probe set confirmed the presence of the fusion in neoplastic cells and demonstrated the potential clin. utility of this approach for detecting VCL-ALK in routinely processed tissue.  The five remaining pediatric renal cell carcinomas did not show ALK rearrangement by FISH or ALK expression by immunohistochem.  The data identify the kidney as a new organ site for ALK-assocd. carcinomas and VCL as a novel ALK fusion partner.  The results should prompt further studies to advance the mol. classification of renal cell carcinoma and help to select patients who would benefit from appropriate targeted therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGph2N9DB-4oJ7Vg90H21EOLACvtfcHk0lg_VqcJSe2RZg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXisFartLY%253D&md5=9b228dba96ec3e98598c82963d851002</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1038%2Fmodpathol.2010.213&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fmodpathol.2010.213%26sid%3Dliteratum%253Aachs%26aulast%3DDebelenko%26aufirst%3DL.%2BV.%26aulast%3DRaimondi%26aufirst%3DS.%2BC.%26aulast%3DDaw%26aufirst%3DN.%26aulast%3DShivakumar%26aufirst%3DB.%2BR.%26aulast%3DHuang%26aufirst%3DD.%26aulast%3DNelson%26aufirst%3DM.%26aulast%3DBridge%26aufirst%3DJ.%2BA.%26atitle%3DRenal%2520Cell%2520Carcinoma%2520with%2520Novel%2520VCL%25E2%2580%2593ALK%2520Fusion%253A%2520New%2520Representative%2520of%2520ALK-associated%2520Tumor%2520Spectrum%26jtitle%3DMod.%2520Pathol.%26date%3D2011%26volume%3D24%26spage%3D430%26epage%3D442%26doi%3D10.1038%2Fmodpathol.2010.213" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thorner, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shago, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marrano, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaikh, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Somers, G. R.</span></span> <span> </span><span class="NLM_article-title">TFE3-positive Renal Cell Carcinomas are not always Xp11 Translocation Carcinomas: Report of a Case with a TPM3-ALK Translocation</span>. <i>Pathol., Res. Pract.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>212</i></span>,  <span class="NLM_fpage">937</span>– <span class="NLM_lpage">942</span>, <span class="refDoi"> DOI: 10.1016/j.prp.2016.07.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1016%2Fj.prp.2016.07.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=27450657" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1aitrjE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=212&publication_year=2016&pages=937-942&author=P.+S.+Thornerauthor=M.+Shagoauthor=P.+Marranoauthor=F.+Shaikhauthor=G.+R.+Somers&title=TFE3-positive+Renal+Cell+Carcinomas+are+not+always+Xp11+Translocation+Carcinomas%3A+Report+of+a+Case+with+a+TPM3-ALK+Translocation&doi=10.1016%2Fj.prp.2016.07.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">TFE3-positive renal cell carcinomas are not always Xp11 translocation carcinomas: Report of a case with a TPM3-ALK translocation</span></div><div class="casAuthors">Thorner, Paul Scott; Shago, Mary; Marrano, Paula; Shaikh, Furqan; Somers, Gino R.</div><div class="citationInfo"><span class="NLM_cas:title">Pathology, Research and Practice</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">212</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">937-942</span>CODEN:
                <span class="NLM_cas:coden">PARPDS</span>;
        ISSN:<span class="NLM_cas:issn">0344-0338</span>.
    
            (<span class="NLM_cas:orgname">Elsevier GmbH</span>)
        </div><div class="casAbstract">Translocation-assocd. renal cell carcinoma (RCC) is a distinct subtype of RCC with gene rearrangements of the TFE3 or TFEB loci.  The TFE3 gene is located at Xp11 and can fuse to a no. of translocation partners, resulting in high nuclear expression of TFE3 protein.  TFE3 immunostaining is often used as a surrogate marker for a TFE3 translocation.  We report a case of an RCC that expressed TFE3 but showed only gain of TFE3 rather than a translocation.  Moreover, this case had a t(1;2) translocation fusing ALK and TMP3, identical to that seen in inflammatory myofibroblastic tumor.  There was resulting overexpression of ALK protein in a cytoplasmic and membranous pattern.  The patient was not treated with chemotherapy but following regional nodal recurrence, an ALK inhibitor was added and the patient remains alive one year later.  There are only rare reports of RCC with an ALK-TMP3 fusion, and these tumors can express TFE3 on some unknown basis not related to a TFE3 translocation.  Any RCC pos. for TFE3 and lacking a translocation should be tested for ALK expression and translocation.  Recognition of this subtype of RCC will allow ALK inhibitor therapy to be added, in the hope of improving patient outcome.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrdVKPjHxvuf7Vg90H21EOLACvtfcHk0lg_VqcJSe2RZg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1aitrjE&md5=94e5a2ef64c27431a3d1e5373a4a5116</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1016%2Fj.prp.2016.07.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.prp.2016.07.004%26sid%3Dliteratum%253Aachs%26aulast%3DThorner%26aufirst%3DP.%2BS.%26aulast%3DShago%26aufirst%3DM.%26aulast%3DMarrano%26aufirst%3DP.%26aulast%3DShaikh%26aufirst%3DF.%26aulast%3DSomers%26aufirst%3DG.%2BR.%26atitle%3DTFE3-positive%2520Renal%2520Cell%2520Carcinomas%2520are%2520not%2520always%2520Xp11%2520Translocation%2520Carcinomas%253A%2520Report%2520of%2520a%2520Case%2520with%2520a%2520TPM3-ALK%2520Translocation%26jtitle%3DPathol.%252C%2520Res.%2520Pract.%26date%3D2016%26volume%3D212%26spage%3D937%26epage%3D942%26doi%3D10.1016%2Fj.prp.2016.07.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pietrantonio, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maggi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Bartolomeo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Facciorusso, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perrone, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Testi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iacovelli, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miceli, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bossi, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leone, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milione, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pelosi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Braud, F.</span></span> <span> </span><span class="NLM_article-title">Gain of ALK Gene Copy Number may Predict Lack of Benefit from Anti-EGFR Treatment in Patients with Advanced Colorectal Cancer and RAS-RAF-PI3KCA Wild-type Status</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">e92147</span>, <span class="refDoi"> DOI: 10.1371/journal.pone.0092147</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1371%2Fjournal.pone.0092147" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=24691006" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1aqtr3K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=e92147&issue=4&author=F.+Pietrantonioauthor=C.+Maggiauthor=M.+Di+Bartolomeoauthor=M.+G.+Facciorussoauthor=F.+Perroneauthor=A.+Testiauthor=R.+Iacovelliauthor=R.+Miceliauthor=I.+Bossiauthor=G.+Leoneauthor=M.+Milioneauthor=G.+Pelosiauthor=F.+de+Braud&title=Gain+of+ALK+Gene+Copy+Number+may+Predict+Lack+of+Benefit+from+Anti-EGFR+Treatment+in+Patients+with+Advanced+Colorectal+Cancer+and+RAS-RAF-PI3KCA+Wild-type+Status&doi=10.1371%2Fjournal.pone.0092147"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Gain of ALK gene copy number may predict lack of benefit from anti-EGFR treatment in patients with advanced colorectal cancer and RAS-RAF-PI3KCA wild-type status</span></div><div class="casAuthors">Pietrantonio, Filippo; Maggi, Claudia; Di Bartolomeo, Maria; Facciorusso, Maria Grazia; Perrone, Federica; Testi, Adele; Iacovelli, Roberto; Miceli, Rosalba; Bossi, Ilaria; Leone, Giorgia; Milione, Massimo; Pelosi, Giuseppe; de Braud, Filippo</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">e92147/1-e92147/6, 6 pp.</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Introduction: Although cetuximab and panitumumab show an increased efficacy for patients with KRAS-NRAS-BRAF and PI3KCA wild-type metastatic colorectal cancer, primary resistance occurs in a relevant subset of molecularly enriched populations.  Patients and Methods: We evaluated the outcome of 68 patients with advanced colorectal cancer and RAS, BRAF and PI3KCA status according to ALK gene status (disomic vs. gain of ALK gene copy no. - defined as mean of 3 to 5 fusion signals in ≥10% of cells).  All consecutive patients received cetuximab and irinotecan or panitumumab alone for chemorefractory disease.  Results: No ALK translocations or amplifications were detected.  ALK gene copy no. gain was found in 25 (37%) tumors.  Response rate was significantly higher in patients with disomic ALK as compared to those with gain of gene copy no. (70% vs. 32%; p = 0.0048).  Similarly, progression-free survival was significantly different when comparing the two groups (6.7 vs. 5.3 mo; p = 0.045).  A trend was obsd. also for overall survival (18.5 vs. 15.6 mo; p = 0.885).  Conclusion: Gain of ALK gene copy no. might represent a neg. prognostic factor in mCRC and may have a role in resistance to anti-EGFR therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1XkXZJKSCNLVg90H21EOLACvtfcHk0lh0otiXqVQ2hQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1aqtr3K&md5=4ad6f527567c2fabec7fbda64dcd1b84</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0092147&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0092147%26sid%3Dliteratum%253Aachs%26aulast%3DPietrantonio%26aufirst%3DF.%26aulast%3DMaggi%26aufirst%3DC.%26aulast%3DDi%2BBartolomeo%26aufirst%3DM.%26aulast%3DFacciorusso%26aufirst%3DM.%2BG.%26aulast%3DPerrone%26aufirst%3DF.%26aulast%3DTesti%26aufirst%3DA.%26aulast%3DIacovelli%26aufirst%3DR.%26aulast%3DMiceli%26aufirst%3DR.%26aulast%3DBossi%26aufirst%3DI.%26aulast%3DLeone%26aufirst%3DG.%26aulast%3DMilione%26aufirst%3DM.%26aulast%3DPelosi%26aufirst%3DG.%26aulast%3Dde%2BBraud%26aufirst%3DF.%26atitle%3DGain%2520of%2520ALK%2520Gene%2520Copy%2520Number%2520may%2520Predict%2520Lack%2520of%2520Benefit%2520from%2520Anti-EGFR%2520Treatment%2520in%2520Patients%2520with%2520Advanced%2520Colorectal%2520Cancer%2520and%2520RAS-RAF-PI3KCA%2520Wild-type%2520Status%26jtitle%3DPLoS%2520One%26date%3D2014%26volume%3D9%26issue%3D4%26spage%3De92147%26doi%3D10.1371%2Fjournal.pone.0092147" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref69"><div class="reference"><strong class="refLabel"><a href="#ref69" class="rightTabRefNumLink">69</a></strong><div class="NLM_citation" id="rightTab-cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lin, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soriano, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivers, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pandita, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Modrusan, Z.</span></span> <span> </span><span class="NLM_article-title">Exon Array Profiling Detects EML4-ALK Fusion in Breast, Colorectal, and Non–small Cell Lung Cancers</span>. <i>Mol. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">1466</span>– <span class="NLM_lpage">1476</span>, <span class="refDoi"> DOI: 10.1158/1541-7786.MCR-08-0522</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1158%2F1541-7786.MCR-08-0522" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=19737969" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtFCjtbvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2009&pages=1466-1476&author=E.+Linauthor=L.+Liauthor=Y.+Guanauthor=R.+Sorianoauthor=C.+S.+Riversauthor=S.+Mohanauthor=A.+Panditaauthor=J.+Tangauthor=Z.+Modrusan&title=Exon+Array+Profiling+Detects+EML4-ALK+Fusion+in+Breast%2C+Colorectal%2C+and+Non%E2%80%93small+Cell+Lung+Cancers&doi=10.1158%2F1541-7786.MCR-08-0522"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Exon Array Profiling Detects EML4-ALK Fusion in Breast, Colorectal, and Non-Small Cell Lung Cancers</span></div><div class="casAuthors">Lin, Eva; Li, Li; Guan, Yinghui; Soriano, Robert; Rivers, Celina Sanchez; Mohan, Sankar; Pandita, Ajay; Tang, Jerry; Modrusan, Zora</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1466-1476</span>CODEN:
                <span class="NLM_cas:coden">MCROC5</span>;
        ISSN:<span class="NLM_cas:issn">1541-7786</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The echinoderm microtubule-assocd. protein-like 4-anaplastic lymphoma kinase (EML4-ALK) fusion gene has been identified as an oncogene in a subset of non-small cell lung cancers (NSCLC).  We used profiling of cancer genomes on an exon array to develop a novel computational method for the global search of gene rearrangements.  This approach led to the detection of EML4-ALK fusion in breast and colorectal carcinomas in addn. to NSCLC.  Screening of a large collection of patient tumor samples showed the presence of EML4-ALK fusion in 2.4% of breast (5 of 209), 2.4% of colorectal (2 of 83), and in 11.3% of NSCLC (12 of 106).  Besides previously known EML4-ALK variants 1 (E13; A20) and 2 (E20; A20), a novel variant E21; A20 was found in colorectal carcinoma.  The presence of an EML-ALK rearrangement was verified by identifying genomic fusion points in tumor samples representative of breast, colon, and NSCLC.  EML4-ALK translocation was also confirmed by fluorescence in situ hybridization assay, which revealed its substantial heterogeneity in both primary tumors and tumor-derived cell lines.  To elucidate the functional significance of EML4-ALK, we examd. the growth of cell lines harboring the fusion following EML4 and ALK silencing by small interfering RNA.  Significant growth inhibition was obsd. in some but not all cell lines, suggesting their variable dependence on ALK-mediated cell survival signaling.  Collectively, these findings show the recurrence of EML4-ALK fusion in multiple solid tumors and further substantiate its role in tumorigenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpeB-bLrMJbCbVg90H21EOLACvtfcHk0lh0otiXqVQ2hQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtFCjtbvN&md5=4723927a63f9621cc3714ec080b37ae8</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1158%2F1541-7786.MCR-08-0522&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1541-7786.MCR-08-0522%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DE.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DGuan%26aufirst%3DY.%26aulast%3DSoriano%26aufirst%3DR.%26aulast%3DRivers%26aufirst%3DC.%2BS.%26aulast%3DMohan%26aufirst%3DS.%26aulast%3DPandita%26aufirst%3DA.%26aulast%3DTang%26aufirst%3DJ.%26aulast%3DModrusan%26aufirst%3DZ.%26atitle%3DExon%2520Array%2520Profiling%2520Detects%2520EML4-ALK%2520Fusion%2520in%2520Breast%252C%2520Colorectal%252C%2520and%2520Non%25E2%2580%2593small%2520Cell%2520Lung%2520Cancers%26jtitle%3DMol.%2520Cancer%2520Res.%26date%3D2009%26volume%3D7%26spage%3D1466%26epage%3D1476%26doi%3D10.1158%2F1541-7786.MCR-08-0522" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref70"><div class="reference"><strong class="refLabel"><a href="#ref70" class="rightTabRefNumLink">70</a></strong><div class="NLM_citation" id="rightTab-cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Demeure, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aziz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenberg, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gurley, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bussey, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carpten, J. D.</span></span> <span> </span><span class="NLM_article-title">Whole-genome Sequencing of an Aggressive BRAF Wild-type Papillary Thyroid Cancer Identified EML4–ALK Translocation as a Therapeutic Target</span>. <i>World J. Surg.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">1296</span>– <span class="NLM_lpage">1305</span>, <span class="refDoi"> DOI: 10.1007/s00268-014-2485-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1007%2Fs00268-014-2485-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=24633422" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A280%3ADC%252BC2crktFyhsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2014&pages=1296-1305&author=M.+J.+Demeureauthor=M.+Azizauthor=R.+Rosenbergauthor=S.+D.+Gurleyauthor=K.+J.+Busseyauthor=J.+D.+Carpten&title=Whole-genome+Sequencing+of+an+Aggressive+BRAF+Wild-type+Papillary+Thyroid+Cancer+Identified+EML4%E2%80%93ALK+Translocation+as+a+Therapeutic+Target&doi=10.1007%2Fs00268-014-2485-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Whole-genome sequencing of an aggressive BRAF wild-type papillary thyroid cancer identified EML4-ALK translocation as a therapeutic target</span></div><div class="casAuthors">Demeure Michael J; Aziz Meraj; Rosenberg Richard; Gurley Steven D; Bussey Kimberly J; Carpten John D</div><div class="citationInfo"><span class="NLM_cas:title">World journal of surgery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1296-305</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Recent advances in the treatment of cancer have focused on targeting genomic aberrations with selective therapeutic agents.  In radioiodine resistant aggressive papillary thyroid cancers, there remain few effective therapeutic options.  A 62-year-old man who underwent multiple operations for papillary thyroid cancer and whose metastases progressed despite standard treatments provided tumor tissue.  METHODS:  We analyzed tumor and whole blood DNA by whole genome sequencing, achieving 80× or greater coverage over 94 % of the exome and 90 % of the genome.  We determined somatic mutations and structural alterations.  RESULTS:  We found a total of 57 somatic mutations in 55 genes of the cancer genome.  There was notably a lack of mutations in NRAS and BRAF, and no RET/PTC rearrangement.  There was a mutation in the TRAPP oncogene and a loss of heterozygosity of the p16, p18, and RB1 tumor suppressor genes.  The oncogenic driver for this tumor is a translocation involving the genes for anaplastic lymphoma receptor tyrosine kinase (ALK) and echinoderm microtubule associated protein like 4 (EML4).  The EML4-ALK translocation has been reported in approximately 5 % of lung cancers, as well as in pediatric neuroblastoma, and is a therapeutic target for crizotinib.  CONCLUSIONS:  This is the first report of the whole genomic sequencing of a papillary thyroid cancer in which we identified an EML4-ALK translocation of a TRAPP oncogene mutation.  These findings suggest that this tumor has a more distinct oncogenesis than BRAF mutant papillary thyroid cancer.  Whole genome sequencing can elucidate an oncogenic context and expose potential therapeutic vulnerabilities in rare cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRIV4GB44ay0I2y4bB4mnvYfW6udTcc2eaUcVWOPWffsrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2crktFyhsg%253D%253D&md5=706f7ff0576d59301ba6af47e1853dbd</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1007%2Fs00268-014-2485-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00268-014-2485-3%26sid%3Dliteratum%253Aachs%26aulast%3DDemeure%26aufirst%3DM.%2BJ.%26aulast%3DAziz%26aufirst%3DM.%26aulast%3DRosenberg%26aufirst%3DR.%26aulast%3DGurley%26aufirst%3DS.%2BD.%26aulast%3DBussey%26aufirst%3DK.%2BJ.%26aulast%3DCarpten%26aufirst%3DJ.%2BD.%26atitle%3DWhole-genome%2520Sequencing%2520of%2520an%2520Aggressive%2520BRAF%2520Wild-type%2520Papillary%2520Thyroid%2520Cancer%2520Identified%2520EML4%25E2%2580%2593ALK%2520Translocation%2520as%2520a%2520Therapeutic%2520Target%26jtitle%3DWorld%2520J.%2520Surg.%26date%3D2014%26volume%3D38%26spage%3D1296%26epage%3D1305%26doi%3D10.1007%2Fs00268-014-2485-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref71"><div class="reference"><strong class="refLabel"><a href="#ref71" class="rightTabRefNumLink">71</a></strong><div class="NLM_citation" id="rightTab-cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barila, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evdokimova, V. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trivedi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panebianco, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gandhi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carty, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodak, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dacic, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Y. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nikiforova, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferris, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altschuler, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nikiforov, Y. E.</span></span> <span> </span><span class="NLM_article-title">Identification of the Transforming STRN-ALK Fusion as a Potential Therapeutic Target in the Aggressive Forms of Thyroid Cancer</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>111</i></span>,  <span class="NLM_fpage">4233</span>– <span class="NLM_lpage">4238</span>, <span class="refDoi"> DOI: 10.1073/pnas.1321937111</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1073%2Fpnas.1321937111" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=24613930" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjtlyntr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2014&pages=4233-4238&author=L.+M.+Kellyauthor=G.+Barilaauthor=P.+Liuauthor=V.+N.+Evdokimovaauthor=S.+Trivediauthor=F.+Panebiancoauthor=M.+Gandhiauthor=S.+E.+Cartyauthor=S.+P.+Hodakauthor=J.+Luoauthor=S.+Dacicauthor=Y.+P.+Yuauthor=M.+N.+Nikiforovaauthor=R.+L.+Ferrisauthor=D.+L.+Altschulerauthor=Y.+E.+Nikiforov&title=Identification+of+the+Transforming+STRN-ALK+Fusion+as+a+Potential+Therapeutic+Target+in+the+Aggressive+Forms+of+Thyroid+Cancer&doi=10.1073%2Fpnas.1321937111"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of the transforming STRN-ALK fusion as a potential therapeutic target in the aggressive forms of thyroid cancer</span></div><div class="casAuthors">Kelly, Lindsey M.; Barila, Guillermo; Liu, Pengyuan; Evdokimova, Viktoria N.; Trivedi, Sumita; Panebianco, Federica; Gandhi, Manoj; Carty, Sally E.; Hodak, Steven P.; Luo, Jianhua; Dacic, Sanja; Yu, Yan P.; Nikiforova, Marina N.; Ferris, Robert L.; Altschuler, Daniel L.; Nikiforov, Yuri E.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4233-4238</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Thyroid cancer is a common endocrine malignancy that encompasses well-differentiated as well as dedifferentiated cancer types.  The latter tumors have high mortality and lack effective therapies.  Using a paired-end RNA-sequencing approach, we report the discovery of rearrangements involving the anaplastic lymphoma kinase (ALK) gene in thyroid cancer.  The most common of these involves a fusion between ALK and the striatin (STRN) gene, which is the result of a complex rearrangement involving the short arm of chromosome 2.  STRN-ALK leads to constitutive activation of ALK kinase via dimerization mediated by the coiled-coil domain of STRN and to a kinase-dependent, TSH-independent proliferation of thyroid cells.  Moreover, expression of STRN-ALK transforms cells in vitro and induces tumor formation in nude mice.  The kinase activity of STRN-ALK and the ALK-induced cell growth can be blocked by the ALK inhibitors crizotinib and TAE684.  In addn. to well-differentiated papillary cancer, STRN-ALK was found with a higher prevalence in poorly differentiated and anaplastic thyroid cancers, and it did not overlap with other known driver mutations in these tumors.  Our data demonstrate that STRN-ALK fusion occurs in a subset of patients with highly aggressive types of thyroid cancer and provide initial evidence suggesting that it may represent a therapeutic target for these patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvFujoadOIy7Vg90H21EOLACvtfcHk0lh0pThFQZJtHg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjtlyntr8%253D&md5=f2698ba003f5fcf98b05f82122c94f15</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1321937111&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1321937111%26sid%3Dliteratum%253Aachs%26aulast%3DKelly%26aufirst%3DL.%2BM.%26aulast%3DBarila%26aufirst%3DG.%26aulast%3DLiu%26aufirst%3DP.%26aulast%3DEvdokimova%26aufirst%3DV.%2BN.%26aulast%3DTrivedi%26aufirst%3DS.%26aulast%3DPanebianco%26aufirst%3DF.%26aulast%3DGandhi%26aufirst%3DM.%26aulast%3DCarty%26aufirst%3DS.%2BE.%26aulast%3DHodak%26aufirst%3DS.%2BP.%26aulast%3DLuo%26aufirst%3DJ.%26aulast%3DDacic%26aufirst%3DS.%26aulast%3DYu%26aufirst%3DY.%2BP.%26aulast%3DNikiforova%26aufirst%3DM.%2BN.%26aulast%3DFerris%26aufirst%3DR.%2BL.%26aulast%3DAltschuler%26aufirst%3DD.%2BL.%26aulast%3DNikiforov%26aufirst%3DY.%2BE.%26atitle%3DIdentification%2520of%2520the%2520Transforming%2520STRN-ALK%2520Fusion%2520as%2520a%2520Potential%2520Therapeutic%2520Target%2520in%2520the%2520Aggressive%2520Forms%2520of%2520Thyroid%2520Cancer%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2014%26volume%3D111%26spage%3D4233%26epage%3D4238%26doi%3D10.1073%2Fpnas.1321937111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref72"><div class="reference"><strong class="refLabel"><a href="#ref72" class="rightTabRefNumLink">72</a></strong><div class="NLM_citation" id="rightTab-cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ji, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oh, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yun, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, W.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, H.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, M.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, J.-M.</span></span> <span> </span><span class="NLM_article-title">Identification of Driving ALK Fusion Genes and Genomic Landscape of Medullary Thyroid Cancer</span>. <i>PLoS Genet.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">e1005467</span>, <span class="refDoi"> DOI: 10.1371/journal.pgen.1005467</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1371%2Fjournal.pgen.1005467" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=26295973" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC28Xls1Wisbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2015&pages=e1005467&author=J.+H.+Jiauthor=Y.+L.+Ohauthor=M.+Hongauthor=J.+W.+Yunauthor=H.-W.+Leeauthor=D.+Kimauthor=Y.+Jiauthor=D.-H.+Kimauthor=W.-Y.+Parkauthor=H.-T.+Shinauthor=K.-M.+Kimauthor=M.-J.+Ahnauthor=K.+Parkauthor=J.-M.+Sun&title=Identification+of+Driving+ALK+Fusion+Genes+and+Genomic+Landscape+of+Medullary+Thyroid+Cancer&doi=10.1371%2Fjournal.pgen.1005467"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of Driving ALK fusion genes and genomic landscape of medullary thyroid cancer</span></div><div class="casAuthors">Ho, Ji Jun; Oh, Young Lyun; Hong, Mineui; Yun, Jae Won; Lee, Hyun-Woo; Kim, Deok-Geun; Ji, Yongick; Kim, Duk-Hwan; Park, Woong-Yang; Shin, Hyun-Tae; Kim, Kyoung-Mee; Ahn, Myung-Ju; Park, Keunchil; Sun, Jong-Mu</div><div class="citationInfo"><span class="NLM_cas:title">PLoS Genetics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">e1005467/1-e1005467/12</span>CODEN:
                <span class="NLM_cas:coden">PGLEB5</span>;
        ISSN:<span class="NLM_cas:issn">1553-7404</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">The genetic landscape of medullary thyroid cancer (MTC) is not yet fully understood, although some oncogenic mutations have been identified.  To explore genetic profiles of MTCs, formalin-fixed, paraffin-embedded tumor tissues from MTC patients were assayed on the Ion AmpliSeq Cancer Panel v2.  Eighty-four sporadic MTC samples and 36 paired normal thyroid tissues were successfully sequenced.  We discovered 101 hotspot mutations in 18 genes in the 84 MTC tissue samples.  The most common mutation was in the ret proto-oncogene, which occurred in 47 cases followed by mutations in genes encoding Harvey rat sarcoma viral oncogene homolog (N = 14), serine/threonine kinase 11 (N = 11), v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog (N = 6), mutL homolog 1 (N = 4), Kiesten rat sarcoma viral oncogene homolog (N = 3) and MET protooncogene (N = 3).  We also evaluated anaplastic lymphoma kinase (ALK) rearrangement by immunohistochem. and break-apart fluorescence in situ hybridization (FISH).  Two of 98 screened cases were pos. for ALK FISH.  To identify the genomic breakpoint and 5' fusion partner of ALK, customized targeted cancer panel sequencing was performed using DNA from tumor samples of the two patients.  Glutamine: fructose-6-phosphate transaminase 1 (GFPT1)-ALK and echinoderm microtubule-assocd. protein-like 4 (EML4)-ALK fusions were identified.  Addnl. PCR anal., followed by Sanger sequencing, confirmed the GFPT1 ALK fusion, indicating that the fusion is a result of intra-chromosomal translocation or deletion.  Notably, a metastatic MTC case harboring the EML4-ALK fusion showed a dramatic response to an ALK inhibitor, crizotinib.  In conclusion, we found several genetic mutations in MTC and are the first to identify ALK fusions in MTC.  Our results suggest that the EML4-ALK fusion in MTC may be a potential driver mutation and a valid target of ALK inhibitors.  Furthermore, the GFPT1-ALK fusion may be a potential candidate for mol. target therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXTAvKjl0oerVg90H21EOLACvtfcHk0lh0pThFQZJtHg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xls1Wisbw%253D&md5=89569abca7307a746aab80ef3823ee21</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pgen.1005467&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pgen.1005467%26sid%3Dliteratum%253Aachs%26aulast%3DJi%26aufirst%3DJ.%2BH.%26aulast%3DOh%26aufirst%3DY.%2BL.%26aulast%3DHong%26aufirst%3DM.%26aulast%3DYun%26aufirst%3DJ.%2BW.%26aulast%3DLee%26aufirst%3DH.-W.%26aulast%3DKim%26aufirst%3DD.%26aulast%3DJi%26aufirst%3DY.%26aulast%3DKim%26aufirst%3DD.-H.%26aulast%3DPark%26aufirst%3DW.-Y.%26aulast%3DShin%26aufirst%3DH.-T.%26aulast%3DKim%26aufirst%3DK.-M.%26aulast%3DAhn%26aufirst%3DM.-J.%26aulast%3DPark%26aufirst%3DK.%26aulast%3DSun%26aufirst%3DJ.-M.%26atitle%3DIdentification%2520of%2520Driving%2520ALK%2520Fusion%2520Genes%2520and%2520Genomic%2520Landscape%2520of%2520Medullary%2520Thyroid%2520Cancer%26jtitle%3DPLoS%2520Genet.%26date%3D2015%26volume%3D11%26spage%3De1005467%26doi%3D10.1371%2Fjournal.pgen.1005467" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref73"><div class="reference"><strong class="refLabel"><a href="#ref73" class="rightTabRefNumLink">73</a></strong><div class="NLM_citation" id="rightTab-cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Busam, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kutzner, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cerroni, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiesner, T.</span></span> <span> </span><span class="NLM_article-title">Clinical and Pathologic Findings of Spitz Nevi and Atypical Spitz Tumors with ALK Fusions</span>. <i>Am. J. Surg. Pathol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">925</span>– <span class="NLM_lpage">933</span>, <span class="refDoi"> DOI: 10.1097/PAS.0000000000000187</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1097%2FPAS.0000000000000187" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=24698967" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A280%3ADC%252BC2cngsFGlsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2014&pages=925-933&author=K.+J.+Busamauthor=H.+Kutznerauthor=L.+Cerroniauthor=T.+Wiesner&title=Clinical+and+Pathologic+Findings+of+Spitz+Nevi+and+Atypical+Spitz+Tumors+with+ALK+Fusions&doi=10.1097%2FPAS.0000000000000187"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical and pathologic findings of Spitz nevi and atypical Spitz tumors with ALK fusions</span></div><div class="casAuthors">Busam Klaus J; Kutzner Heinz; Cerroni Lorenzo; Wiesner Thomas</div><div class="citationInfo"><span class="NLM_cas:title">The American journal of surgical pathology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">925-33</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Spitz tumors represent a group of melanocytic neoplasms that typically affect young individuals.  Microscopically, the lesions are composed of cytologically distinct spindle and epithelioid melanocytes, with a range in the architectural display or the cells, their nuclear features, and secondary epidermal or stromal changes.  Recently, kinase fusions have been documented in a subset of Spitz tumors, but there is limited information on the clinical and pathologic features associated with those lesions.  Here, we report a series of 17 patients (9 male, 8 female) with spitzoid neoplasms showing ALK fusions (5 Spitz nevi and 12 atypical Spitz tumors).  The patients' ages ranged from 2 years to 35 years (mean=17 y; median=16 y).  Most lesions were located on the lower extremities and presented clinically as polypoid nodules.  All tumors were compound melanocytic proliferations with a predominant intradermal growth.  Tumor thickness ranged from 1.1 to 6 mm (mean=2.9 mm; median=2.5 mm).  The most characteristic histopathologic feature of the tumors (seen in all but 2 lesions) was a plexiform dermal growth of intersecting fascicles of fusiform melanocytes.  All but 2 tumors were amelanotic.  All tumors were strongly immunoreactive for ALK.  The ALK rearrangements were confirmed in all cases by fluorescence in situ hybridization (FISH), and the fusion partner was determined by quantitative polymerase chain reaction as TPM3 (tropomyosin 3) in 11 cases and DCTN1 (dynactin 1) in 6 cases.  None of the 8 tumors that were analyzed by FISH for copy number changes of 6p, 6q, 9p, or 11q met criteria for melanoma.  Two patients underwent a sentinel lymph node biopsy, and in both cases melanocyte nests were found in the subcapsular sinus of the node.  Array comparative genomic hybridization of these 2 tumors revealed no chromosomal gains or losses.  In conclusion, our study revealed that Spitz nevi/tumors with ALK rearrangement show a characteristic plexiform morphology and that ALK immunohistochemistry and FISH enable the accurate identification of this morphologic and genetic distinct subset of spitzoid neoplasms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSyswsOXNcjAiXXDYhVZBdlfW6udTcc2eZ3Ik1ME3hE3bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cngsFGlsw%253D%253D&md5=a01efaff0c91475ecc621cbcad020a61</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1097%2FPAS.0000000000000187&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FPAS.0000000000000187%26sid%3Dliteratum%253Aachs%26aulast%3DBusam%26aufirst%3DK.%2BJ.%26aulast%3DKutzner%26aufirst%3DH.%26aulast%3DCerroni%26aufirst%3DL.%26aulast%3DWiesner%26aufirst%3DT.%26atitle%3DClinical%2520and%2520Pathologic%2520Findings%2520of%2520Spitz%2520Nevi%2520and%2520Atypical%2520Spitz%2520Tumors%2520with%2520ALK%2520Fusions%26jtitle%3DAm.%2520J.%2520Surg.%2520Pathol.%26date%3D2014%26volume%3D38%26spage%3D925%26epage%3D933%26doi%3D10.1097%2FPAS.0000000000000187" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref74"><div class="reference"><strong class="refLabel"><a href="#ref74" class="rightTabRefNumLink">74</a></strong><div class="NLM_citation" id="rightTab-cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ouchi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyachi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuma, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuchiya, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iehara, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konishi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yanagisawa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hosoi, H.</span></span> <span> </span><span class="NLM_article-title">FN1: a Novel Fusion Partner of ALK in an Inflammatory Myofibroblastic Tumor</span>. <i>Pediatr. Blood Cancer</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">909</span>– <span class="NLM_lpage">911</span>, <span class="refDoi"> DOI: 10.1002/pbc.25424</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1002%2Fpbc.25424" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=25682942" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A280%3ADC%252BC2Mrls1Glug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2015&pages=909-911&author=K.+Ouchiauthor=M.+Miyachiauthor=Y.+Tsumaauthor=K.+Tsuchiyaauthor=T.+Ieharaauthor=E.+Konishiauthor=A.+Yanagisawaauthor=H.+Hosoi&title=FN1%3A+a+Novel+Fusion+Partner+of+ALK+in+an+Inflammatory+Myofibroblastic+Tumor&doi=10.1002%2Fpbc.25424"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">FN1: a novel fusion partner of ALK in an inflammatory myofibroblastic tumor</span></div><div class="casAuthors">Ouchi Kazutaka; Miyachi Mitsuru; Tsuma Yusuke; Tsuchiya Kunihiko; Iehara Tomoko; Konishi Eiichi; Yanagisawa Akio; Hosoi Hajime</div><div class="citationInfo"><span class="NLM_cas:title">Pediatric blood & cancer</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">909-11</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Inflammatory myofibroblastic tumors (IMTs) are rare tumors characterized as low-to-intermediate grade sarcomas.  Rearrangements of the anaplastic lymphoma kinase (ALK) gene have been reported in IMT.  Here, we describe a novel fusion gene in an IMT tumor specimen.  A 12-year-old male was admitted to our hospital with a bladder tumor.  We identified the fibronectin 1 gene (FN1) as a fusion partner of ALK using 5'RACE.  This novel fusion, FN1-ALK, resulted in ALK overexpression in the IMT.  This finding should clarify the causes of IMT and facilitate development of novel therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRjaaAYd2aD2OWhZTslLrfffW6udTcc2ea7i-4FxOi1XLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2Mrls1Glug%253D%253D&md5=41480048a531d203fbb98429634242b2</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1002%2Fpbc.25424&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpbc.25424%26sid%3Dliteratum%253Aachs%26aulast%3DOuchi%26aufirst%3DK.%26aulast%3DMiyachi%26aufirst%3DM.%26aulast%3DTsuma%26aufirst%3DY.%26aulast%3DTsuchiya%26aufirst%3DK.%26aulast%3DIehara%26aufirst%3DT.%26aulast%3DKonishi%26aufirst%3DE.%26aulast%3DYanagisawa%26aufirst%3DA.%26aulast%3DHosoi%26aufirst%3DH.%26atitle%3DFN1%253A%2520a%2520Novel%2520Fusion%2520Partner%2520of%2520ALK%2520in%2520an%2520Inflammatory%2520Myofibroblastic%2520Tumor%26jtitle%3DPediatr.%2520Blood%2520Cancer%26date%3D2015%26volume%3D62%26spage%3D909%26epage%3D911%26doi%3D10.1002%2Fpbc.25424" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref75"><div class="reference"><strong class="refLabel"><a href="#ref75" class="rightTabRefNumLink">75</a></strong><div class="NLM_citation" id="rightTab-cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tucker, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chand, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Danielson, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruuth, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El Wakil, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witek, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jamin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Umapathy, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smeal, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinsson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chesler, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmer, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hallberg, B.</span></span> <span> </span><span class="NLM_article-title">The ALK Inhibitor PF-06463922 is Effective as a Single Agent in Neuroblastoma Driven by Expression of ALK and MYCN</span>. <i>Dis. Models &amp; Mech.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">941</span>– <span class="NLM_lpage">952</span>, <span class="refDoi"> DOI: 10.1242/dmm.024448</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1242%2Fdmm.024448" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=27483357" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2016&pages=941-952&author=J.+Guanauthor=E.+R.+Tuckerauthor=H.+Wanauthor=D.+Chandauthor=L.+S.+Danielsonauthor=K.+Ruuthauthor=A.+El+Wakilauthor=B.+Witekauthor=Y.+Jaminauthor=G.+Umapathyauthor=S.+P.+Robinsonauthor=T.+W.+Johnsonauthor=T.+Smealauthor=T.+Martinssonauthor=L.+Cheslerauthor=R.+H.+Palmerauthor=B.+Hallberg&title=The+ALK+Inhibitor+PF-06463922+is+Effective+as+a+Single+Agent+in+Neuroblastoma+Driven+by+Expression+of+ALK+and+MYCN&doi=10.1242%2Fdmm.024448"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1242%2Fdmm.024448&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1242%252Fdmm.024448%26sid%3Dliteratum%253Aachs%26aulast%3DGuan%26aufirst%3DJ.%26aulast%3DTucker%26aufirst%3DE.%2BR.%26aulast%3DWan%26aufirst%3DH.%26aulast%3DChand%26aufirst%3DD.%26aulast%3DDanielson%26aufirst%3DL.%2BS.%26aulast%3DRuuth%26aufirst%3DK.%26aulast%3DEl%2BWakil%26aufirst%3DA.%26aulast%3DWitek%26aufirst%3DB.%26aulast%3DJamin%26aufirst%3DY.%26aulast%3DUmapathy%26aufirst%3DG.%26aulast%3DRobinson%26aufirst%3DS.%2BP.%26aulast%3DJohnson%26aufirst%3DT.%2BW.%26aulast%3DSmeal%26aufirst%3DT.%26aulast%3DMartinsson%26aufirst%3DT.%26aulast%3DChesler%26aufirst%3DL.%26aulast%3DPalmer%26aufirst%3DR.%2BH.%26aulast%3DHallberg%26aufirst%3DB.%26atitle%3DThe%2520ALK%2520Inhibitor%2520PF-06463922%2520is%2520Effective%2520as%2520a%2520Single%2520Agent%2520in%2520Neuroblastoma%2520Driven%2520by%2520Expression%2520of%2520ALK%2520and%2520MYCN%26jtitle%3DDis.%2520Models%2520%2526amp%253B%2520Mech.%26date%3D2016%26volume%3D9%26spage%3D941%26epage%3D952%26doi%3D10.1242%2Fdmm.024448" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref76"><div class="reference"><strong class="refLabel"><a href="#ref76" class="rightTabRefNumLink">76</a></strong><div class="NLM_citation" id="rightTab-cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chand, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamazaki, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruuth, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schonherr, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinsson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kogner, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Attiyeh, E. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maris, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morozova, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marra, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohira, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakagawara, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sandstrom, P.-E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmer, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hallberg, B.</span></span> <span> </span><span class="NLM_article-title">Cell Culture and Drosophila Model Systems Define Three Classes of Anaplastic Lymphoma Kinase Mutations in Neuroblastoma</span>. <i>Dis. Models &amp; Mech.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">373</span>– <span class="NLM_lpage">382</span>, <span class="refDoi"> DOI: 10.1242/dmm.010348</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1242%2Fdmm.010348" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=23104988" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2013&pages=373-382&author=D.+Chandauthor=Y.+Yamazakiauthor=K.+Ruuthauthor=C.+Schonherrauthor=T.+Martinssonauthor=P.+Kognerauthor=E.+F.+Attiyehauthor=J.+Marisauthor=O.+Morozovaauthor=M.+A.+Marraauthor=M.+Ohiraauthor=A.+Nakagawaraauthor=P.-E.+Sandstromauthor=R.+H.+Palmerauthor=B.+Hallberg&title=Cell+Culture+and+Drosophila+Model+Systems+Define+Three+Classes+of+Anaplastic+Lymphoma+Kinase+Mutations+in+Neuroblastoma&doi=10.1242%2Fdmm.010348"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1242%2Fdmm.010348&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1242%252Fdmm.010348%26sid%3Dliteratum%253Aachs%26aulast%3DChand%26aufirst%3DD.%26aulast%3DYamazaki%26aufirst%3DY.%26aulast%3DRuuth%26aufirst%3DK.%26aulast%3DSchonherr%26aufirst%3DC.%26aulast%3DMartinsson%26aufirst%3DT.%26aulast%3DKogner%26aufirst%3DP.%26aulast%3DAttiyeh%26aufirst%3DE.%2BF.%26aulast%3DMaris%26aufirst%3DJ.%26aulast%3DMorozova%26aufirst%3DO.%26aulast%3DMarra%26aufirst%3DM.%2BA.%26aulast%3DOhira%26aufirst%3DM.%26aulast%3DNakagawara%26aufirst%3DA.%26aulast%3DSandstrom%26aufirst%3DP.-E.%26aulast%3DPalmer%26aufirst%3DR.%2BH.%26aulast%3DHallberg%26aufirst%3DB.%26atitle%3DCell%2520Culture%2520and%2520Drosophila%2520Model%2520Systems%2520Define%2520Three%2520Classes%2520of%2520Anaplastic%2520Lymphoma%2520Kinase%2520Mutations%2520in%2520Neuroblastoma%26jtitle%3DDis.%2520Models%2520%2526amp%253B%2520Mech.%26date%3D2013%26volume%3D6%26spage%3D373%26epage%3D382%26doi%3D10.1242%2Fdmm.010348" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref77"><div class="reference"><strong class="refLabel"><a href="#ref77" class="rightTabRefNumLink">77</a></strong><div class="NLM_citation" id="rightTab-cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Janoueix-Lerosey, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lequin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brugieres, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ribeiro, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Pontual, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Combaret, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raynal, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puisieux, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schleiermacher, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pierron, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valteau-Couanet, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frebourg, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyonnet, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amiel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delattre, O.</span></span> <span> </span><span class="NLM_article-title">Somatic and Germline Activating Mutations of the ALK Kinase Receptor in Neuroblastoma</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>455</i></span>,  <span class="NLM_fpage">967</span>, <span class="refDoi"> DOI: 10.1038/nature07398</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1038%2Fnature07398" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=18923523" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht1GgurrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=455&publication_year=2008&pages=967&author=I.+Janoueix-Leroseyauthor=D.+Lequinauthor=L.+Brugieresauthor=A.+Ribeiroauthor=L.+de+Pontualauthor=V.+Combaretauthor=V.+Raynalauthor=A.+Puisieuxauthor=G.+Schleiermacherauthor=G.+Pierronauthor=D.+Valteau-Couanetauthor=T.+Frebourgauthor=J.+Michonauthor=S.+Lyonnetauthor=J.+Amielauthor=O.+Delattre&title=Somatic+and+Germline+Activating+Mutations+of+the+ALK+Kinase+Receptor+in+Neuroblastoma&doi=10.1038%2Fnature07398"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma</span></div><div class="casAuthors">Janoueix-Lerosey, Isabelle; Lequin, Delphine; Brugieres, Laurence; Ribeiro, Agnes; de Pontual, Loic; Combaret, Valerie; Raynal, Virginie; Puisieux, Alain; Schleiermacher, Gudrun; Pierron, Gaelle; Valteau-Couanet, Dominique; Frebourg, Thierry; Michon, Jean; Lyonnet, Stanislas; Amiel, Jeanne; Delattre, Olivier</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">455</span>
        (<span class="NLM_cas:issue">7215</span>),
    <span class="NLM_cas:pages">967-970</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Neuroblastoma, a tumor derived from the peripheral sympathetic nervous system, is one of the most frequent solid tumors in childhood.  It usually occurs sporadically but familial cases are obsd., with a subset of cases occurring in assocn. with congenital malformations of the neural crest being linked to germline mutations of the PHOX2B gene.  Here the authors conducted genome-wide comparative genomic hybridization anal. on a large series of neuroblastomas.  Copy no. increase at the locus encoding the anaplastic lymphoma kinase (ALK) tyrosine kinase receptor was obsd. recurrently.  One particularly informative case presented a high-level gene amplification that was strictly limited to ALK, indicating that this gene may contribute on its own to neuroblastoma development.  Through subsequent direct sequencing of cell lines and primary tumor DNAs the authors identified somatic mutations of the ALK kinase domain that mainly clustered in two hotspots.  Germline mutations were obsd. in two neuroblastoma families, indicating that ALK is a neuroblastoma predisposition gene.  Mutated ALK proteins were overexpressed, hyperphosphorylated and showed constitutive kinase activity.  The knockdown of ALK expression in ALK-mutated cells, but also in cell lines overexpressing a wild-type ALK, led to a marked decrease of cell proliferation.  Altogether, these data identify ALK as a crit. player in neuroblastoma development that may hence represent a very attractive therapeutic target in this disease that is still frequently fatal with current treatments.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrr_O_BMCZk7rVg90H21EOLACvtfcHk0ljDjSWdQpQwqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht1GgurrI&md5=7321fe0dc6408f9b5b3c53b8d83478ce</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1038%2Fnature07398&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature07398%26sid%3Dliteratum%253Aachs%26aulast%3DJanoueix-Lerosey%26aufirst%3DI.%26aulast%3DLequin%26aufirst%3DD.%26aulast%3DBrugieres%26aufirst%3DL.%26aulast%3DRibeiro%26aufirst%3DA.%26aulast%3Dde%2BPontual%26aufirst%3DL.%26aulast%3DCombaret%26aufirst%3DV.%26aulast%3DRaynal%26aufirst%3DV.%26aulast%3DPuisieux%26aufirst%3DA.%26aulast%3DSchleiermacher%26aufirst%3DG.%26aulast%3DPierron%26aufirst%3DG.%26aulast%3DValteau-Couanet%26aufirst%3DD.%26aulast%3DFrebourg%26aufirst%3DT.%26aulast%3DMichon%26aufirst%3DJ.%26aulast%3DLyonnet%26aufirst%3DS.%26aulast%3DAmiel%26aufirst%3DJ.%26aulast%3DDelattre%26aufirst%3DO.%26atitle%3DSomatic%2520and%2520Germline%2520Activating%2520Mutations%2520of%2520the%2520ALK%2520Kinase%2520Receptor%2520in%2520Neuroblastoma%26jtitle%3DNature%26date%3D2008%26volume%3D455%26spage%3D967%26doi%3D10.1038%2Fnature07398" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref78"><div class="reference"><strong class="refLabel"><a href="#ref78" class="rightTabRefNumLink">78</a></strong><div class="NLM_citation" id="rightTab-cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Javanmardi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fransson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Djos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sjöberg, R.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nilsson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Truvé, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kogner, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinsson, T.</span></span> <span> </span><span class="NLM_article-title">Low Frequency ALK Hotspots Mutations in Neuroblastoma Tumours Detected by Ultra-deep Sequencing: Implications for ALK Inhibitor Treatment</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">2199</span>, <span class="refDoi"> DOI: 10.1038/s41598-018-37240-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1038%2Fs41598-018-37240-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=30778092" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A280%3ADC%252BB3cfkvVKjsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2019&pages=2199&author=N.+Javanmardiauthor=S.+Franssonauthor=A.+Djosauthor=R.-M.+Sj%C3%B6bergauthor=S.+Nilssonauthor=K.+Truv%C3%A9author=P.+Kognerauthor=T.+Martinsson&title=Low+Frequency+ALK+Hotspots+Mutations+in+Neuroblastoma+Tumours+Detected+by+Ultra-deep+Sequencing%3A+Implications+for+ALK+Inhibitor+Treatment&doi=10.1038%2Fs41598-018-37240-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Low Frequency ALK Hotspots Mutations In Neuroblastoma Tumours Detected By Ultra-deep Sequencing: Implications For ALK Inhibitor Treatment</span></div><div class="casAuthors">Javanmardi Niloufar; Fransson Susanne; Djos Anna; Sjoberg Rose-Marie; Nilsson Staffan; Martinsson Tommy; Truve Katarina; Kogner Per</div><div class="citationInfo"><span class="NLM_cas:title">Scientific reports</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">2199</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The ALK tyrosine kinase receptor is oncogenically activated in neuroblastoma.  Whereas numerous ALK fusion genes have been reported in different malignancies, in neuroblastoma ALK is mainly activated through point mutations.  Three hotspot residues (F1174, F1245, and R1275) account for 85% of mutant ALK seen in neuroblastoma.  In a cohort of 105 Swedish neuroblastoma cases of all stages, these hotspot regions were re-sequenced (>5000X).  ALK mutations were detected in 16 of 105 patients (range of variant allele fraction: 2.7-60%).  Mutations at the F1174 and F1245 hotspot were observed in eleven and three cases respectively.  ALK mutations were also detected at the I1171 and L1240 codons in one tumor each.  No mutations were detected at R1275.  Sanger sequencing could confirm ALK status for all mutated samples with variant allele fraction above 15%.  Four of the samples with subclonal ALK mutation fraction below this would have gone undetected relying on Sanger sequencing only.  No distinct mutation spectrum in relation to neuroblastoma tumours genomic subtypes could be detected although there was a paucity of ALK mutations among 11q-deleted tumors.  As ALK mutations status opens up an excellent opportunity for application of small molecule inhibitors targeting ALK, early and sensitive detection of ALK alterations is clinically important considering its potential role in tumour progression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQXJxcEA9wkeY3yKPtYViAGfW6udTcc2eb5BIRW6urIKLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cfkvVKjsw%253D%253D&md5=8afd0c50192683e770638326e3042e64</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1038%2Fs41598-018-37240-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41598-018-37240-z%26sid%3Dliteratum%253Aachs%26aulast%3DJavanmardi%26aufirst%3DN.%26aulast%3DFransson%26aufirst%3DS.%26aulast%3DDjos%26aufirst%3DA.%26aulast%3DSj%25C3%25B6berg%26aufirst%3DR.-M.%26aulast%3DNilsson%26aufirst%3DS.%26aulast%3DTruv%25C3%25A9%26aufirst%3DK.%26aulast%3DKogner%26aufirst%3DP.%26aulast%3DMartinsson%26aufirst%3DT.%26atitle%3DLow%2520Frequency%2520ALK%2520Hotspots%2520Mutations%2520in%2520Neuroblastoma%2520Tumours%2520Detected%2520by%2520Ultra-deep%2520Sequencing%253A%2520Implications%2520for%2520ALK%2520Inhibitor%2520Treatment%26jtitle%3DSci.%2520Rep.%26date%3D2019%26volume%3D9%26spage%3D2199%26doi%3D10.1038%2Fs41598-018-37240-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref79"><div class="reference"><strong class="refLabel"><a href="#ref79" class="rightTabRefNumLink">79</a></strong><div class="NLM_citation" id="rightTab-cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Karachaliou, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santarpia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez Cao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teixido, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sosa, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berenguer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez Capote, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altavilla, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosell, R.</span></span> <span> </span><span class="NLM_article-title">Anaplastic lymphoma Kinase Inhibitors in Phase I and Phase II Clinical Trials for Non-small Cell Lung Cancer</span>. <i>Expert Opin. Invest. Drugs</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">713</span>– <span class="NLM_lpage">722</span>, <span class="refDoi"> DOI: 10.1080/13543784.2017.1324572</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1080%2F13543784.2017.1324572" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=28463570" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC2sXot1Shu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2017&pages=713-722&author=N.+Karachaliouauthor=M.+Santarpiaauthor=M.+Gonzalez+Caoauthor=C.+Teixidoauthor=A.+E.+Sosaauthor=J.+Berenguerauthor=A.+Rodriguez+Capoteauthor=G.+Altavillaauthor=R.+Rosell&title=Anaplastic+lymphoma+Kinase+Inhibitors+in+Phase+I+and+Phase+II+Clinical+Trials+for+Non-small+Cell+Lung+Cancer&doi=10.1080%2F13543784.2017.1324572"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">Anaplastic lymphoma kinase inhibitors in phase I and phase II clinical trials for non-small cell lung cancer</span></div><div class="casAuthors">Karachaliou, Niki; Santarpia, Mariacarmela; Gonzalez Cao, Maria; Teixido, Cristina; Sosa, Aaron E.; Berenguer, Jordi; Rodriguez Capote, Alejandra; Altavilla, Giuseppe; Rosell, Rafael</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Investigational Drugs</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">713-722</span>CODEN:
                <span class="NLM_cas:coden">EOIDER</span>;
        ISSN:<span class="NLM_cas:issn">1354-3784</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Crizotinib is a first-in-class ALK tyrosine kinase inhibitor (TKI), which has proven its superiority over std. platinum-based chemotherapy for the first-line therapy of ALK-rearranged non-small cell lung cancer (NSCLC) patients.  The development of acquired resistance to crizotinib represents an ongoing challenge with the central nervous system being one of the most common sites of relapse.  Ceritinib and alectinib are approved second-generation ALK TKIs.  Several novel ALK inhibitors, more potent and with different selectivity compared to crizotinib, are currently in development.  This review will focus on new ALK inhibitors, currently in phase 1 or 2 clin. studies.  We will also comment on the mechanisms of resistance to ALK inhibition and the strategies to delay or overcome resistance.  The therapeutic management of ALK-rearranged NSCLC has been greatly improved.  Next-generation ALK inhibitors have shown differential potency against ALK rearrangements and ALK resistance mutations.  The mol. profile of the tumor at the time of disease progression to crizotinib is crucial for the sequencing of novel ALK TKIs.  Ongoing clin. studies will address key issues, including the optimal therapeutic algorithm and whether combinational approaches are more effective than single ALK inhibition for the outcome of ALK-rearranged NSCLC patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFDGNGYI_s2rVg90H21EOLACvtfcHk0ljDjSWdQpQwqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXot1Shu7k%253D&md5=ebf670719201fd89280b1ae88c162dd5</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1080%2F13543784.2017.1324572&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F13543784.2017.1324572%26sid%3Dliteratum%253Aachs%26aulast%3DKarachaliou%26aufirst%3DN.%26aulast%3DSantarpia%26aufirst%3DM.%26aulast%3DGonzalez%2BCao%26aufirst%3DM.%26aulast%3DTeixido%26aufirst%3DC.%26aulast%3DSosa%26aufirst%3DA.%2BE.%26aulast%3DBerenguer%26aufirst%3DJ.%26aulast%3DRodriguez%2BCapote%26aufirst%3DA.%26aulast%3DAltavilla%26aufirst%3DG.%26aulast%3DRosell%26aufirst%3DR.%26atitle%3DAnaplastic%2520lymphoma%2520Kinase%2520Inhibitors%2520in%2520Phase%2520I%2520and%2520Phase%2520II%2520Clinical%2520Trials%2520for%2520Non-small%2520Cell%2520Lung%2520Cancer%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2017%26volume%3D26%26spage%3D713%26epage%3D722%26doi%3D10.1080%2F13543784.2017.1324572" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref80"><div class="reference"><strong class="refLabel"><a href="#ref80" class="rightTabRefNumLink">80</a></strong><div class="NLM_citation" id="rightTab-cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Christensen, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arango, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonnell, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamazaki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alton, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mroczkowski, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Los, G.</span></span> <span> </span><span class="NLM_article-title">Cytoreductive Antitumor Activity of PF-2341066, a Novel Inhibitor of Anaplastic Lymphoma Kinase and c-Met, in Experimental Models of Anaplastic Large-cell Lymphoma</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">3314</span>– <span class="NLM_lpage">3322</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-07-0365</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1158%2F1535-7163.MCT-07-0365" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=18089725" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhsVCjsrrL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=3314-3322&author=J.+G.+Christensenauthor=H.+Y.+Zouauthor=M.+E.+Arangoauthor=Q.+Liauthor=J.+H.+Leeauthor=S.+R.+McDonnellauthor=S.+Yamazakiauthor=G.+R.+Altonauthor=B.+Mroczkowskiauthor=G.+Los&title=Cytoreductive+Antitumor+Activity+of+PF-2341066%2C+a+Novel+Inhibitor+of+Anaplastic+Lymphoma+Kinase+and+c-Met%2C+in+Experimental+Models+of+Anaplastic+Large-cell+Lymphoma&doi=10.1158%2F1535-7163.MCT-07-0365"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma</span></div><div class="casAuthors">Christensen, James G.; Zou, Helen Y.; Arango, Maria E.; Li, Qiuhua; Lee, Joseph H.; McDonnell, Scott R.; Yamazaki, Shinji; Alton, Gordon R.; Mroczkowski, Barbara; Los, Gerrit</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">12, Pt. 1</span>),
    <span class="NLM_cas:pages">3314-3322</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A t(2;5) chromosomal translocation resulting in expression of an oncogenic kinase fusion protein known as nucleophosmin-anaplastic lymphoma kinase (NPM-ALK) has been implicated in the pathogenesis of anaplastic large-cell lymphoma (ALCL).  PF-2341066 was recently identified as a p.o. bioavailable, small-mol. inhibitor of the catalytic activity of c-Met kinase and the NPM-ALK fusion protein.  PF-2341066 also potently inhibited NPM-ALK phosphorylation in Karpas299 or SU-DHL-1 ALCL cells (mean IC50 value, 24 nmol/L).  In biochem. and cellular screens, PF-2341066 was shown to be selective for c-Met and ALK at pharmacol. relevant concns. across a panel of >120 diverse kinases.  PF-2341066 potently inhibited cell proliferation, which was assocd. with G1-S-phase cell cycle arrest and induction of apoptosis in ALK-pos. ALCL cells (IC50 values, ∼30 nmol/L) but not ALK-neg. lymphoma cells.  The induction of apoptosis was confirmed using terminal deoxyribonucleotide transferase-mediated nick-end labeling and Annexin V staining (IC50 values, 25-50 nmol/L).  P.o. administration of PF-2341066 to severe combined immunodeficient-Beige mice bearing Karpas299 ALCL tumor xenografts resulted in dose-dependent antitumor efficacy with complete regression of all tumors at the 100 mg/kg/d dose within 15 days of initial compd. administration.  A strong correlation was obsd. between antitumor response and inhibition of NPM-ALK phosphorylation and induction of apoptosis in tumor tissue.  In addn., inhibition of key NPM-ALK signaling mediators, including phospholipase C-γ, signal transducers and activators of transcription 3, extracellular signal-regulated kinases, and Akt by PF-2341066 were obsd. at concns. or dose levels, which correlated with inhibition of NPM-ALK phosphorylation and function.  Collectively, these data illustrate the potential clin. utility of inhibitors of NPM-ALK in treatment of patients with ALK-pos. ALCL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGptqY0tUwGnurVg90H21EOLACvtfcHk0lgNq8TSw0DWpQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhsVCjsrrL&md5=04fbbaf43ca527408bde8cabcd38e1fd</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-07-0365&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-07-0365%26sid%3Dliteratum%253Aachs%26aulast%3DChristensen%26aufirst%3DJ.%2BG.%26aulast%3DZou%26aufirst%3DH.%2BY.%26aulast%3DArango%26aufirst%3DM.%2BE.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DLee%26aufirst%3DJ.%2BH.%26aulast%3DMcDonnell%26aufirst%3DS.%2BR.%26aulast%3DYamazaki%26aufirst%3DS.%26aulast%3DAlton%26aufirst%3DG.%2BR.%26aulast%3DMroczkowski%26aufirst%3DB.%26aulast%3DLos%26aufirst%3DG.%26atitle%3DCytoreductive%2520Antitumor%2520Activity%2520of%2520PF-2341066%252C%2520a%2520Novel%2520Inhibitor%2520of%2520Anaplastic%2520Lymphoma%2520Kinase%2520and%2520c-Met%252C%2520in%2520Experimental%2520Models%2520of%2520Anaplastic%2520Large-cell%2520Lymphoma%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2007%26volume%3D6%26spage%3D3314%26epage%3D3322%26doi%3D10.1158%2F1535-7163.MCT-07-0365" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref81"><div class="reference"><strong class="refLabel"><a href="#ref81" class="rightTabRefNumLink">81</a></strong><div class="NLM_citation" id="rightTab-cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Camidge, D R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bang, Y.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwak, E. L</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iafrate, A J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varella-Garcia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fox, S. B</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riely, G. J</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solomon, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ou, S.-H. I</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salgia, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fidias, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engelman, J. A</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gandhi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janne, P. A</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costa, D. B</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shapiro, G. I</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LoRusso, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruffner, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stephenson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilner, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, J. W</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, A. T</span></span> <span> </span><span class="NLM_article-title">Activity and Safety of Crizotinib in Patients with ALK-positive Non-small Cell Lung Cancer: Updated Results from a Phase 1 Study</span>. <i>Lancet Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">1011</span>– <span class="NLM_lpage">1019</span>, <span class="refDoi"> DOI: 10.1016/S1470-2045(12)70344-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1016%2FS1470-2045%2812%2970344-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=22954507" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsVCjsb3E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2012&pages=1011-1019&author=D+R.+Camidgeauthor=Y.-J.+Bangauthor=E.+L+Kwakauthor=A+J.+Iafrateauthor=M.+Varella-Garciaauthor=S.+B+Foxauthor=G.+J+Rielyauthor=B.+Solomonauthor=S.-H.+I+Ouauthor=D.-W.+Kimauthor=R.+Salgiaauthor=P.+Fidiasauthor=J.+A+Engelmanauthor=L.+Gandhiauthor=P.+A+Janneauthor=D.+B+Costaauthor=G.+I+Shapiroauthor=P.+LoRussoauthor=K.+Ruffnerauthor=P.+Stephensonauthor=Y.+Tangauthor=K.+Wilnerauthor=J.+W+Clarkauthor=A.+T+Shaw&title=Activity+and+Safety+of+Crizotinib+in+Patients+with+ALK-positive+Non-small+Cell+Lung+Cancer%3A+Updated+Results+from+a+Phase+1+Study&doi=10.1016%2FS1470-2045%2812%2970344-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study</span></div><div class="casAuthors">Camidge, D. Ross; Bang, Yung-Jue; Kwak, Eunice L.; Iafrate, A. John; Varella-Garcia, Marileila; Fox, Stephen B.; Riely, Gregory J.; Solomon, Benjamin; Ou, Sai-Hong I.; Kim, Dong-Wan; Salgia, Ravi; Fidias, Panagiotis; Engelman, Jeffrey A.; Gandhi, Leena; Jaenne, Pasi A.; Costa, Daniel B.; Shapiro, Geoffrey I.; LoRusso, Patricia; Ruffner, Katherine; Stephenson, Patricia; Tang, Yiyun; Wilner, Keith; Clark, Jeffrey W.; Shaw, Alice T.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1011-1019</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Summary: Background: ALK fusion genes occur in a subset of non-small-cell lung cancers (NSCLCs).  We assessed the tolerability and activity of crizotinib in patients with NSCLC who were prospectively identified to have an ALK fusion within the first-in-man phase 1 crizotinib study.  Methods: In this phase 1 study, patients with ALK-pos. stage III or IV NSCLC received oral crizotinib 250 mg twice daily in 28-day cycles.  Endpoints included tumor responses, duration of response, time to tumor response, progression-free survival (PFS), overall survival at 6 and 12 mo, and detn. of the safety and tolerability and characterization of the plasma pharmacokinetic profile of crizotinib after oral administration.  Responses were analyzed in evaluable patients and PFS and safety were analyzed in all patients.  This study is registered with ClinicalTrials.gov, no. NCT00585195.  Findings: Between Aug 27, 2008, and June 1, 2011, 149 ALK-pos. patients were enrolled, 143 of whom were included in the response-evaluable population. 87 of 143 patients had an objective response (60·8%, 95% CI 52·3-68·9), including three complete responses and 84 partial responses.  Median time to first documented objective response was 7·9 wk (range 2·1-39·6) and median duration of response was 49·1 wk (95% CI 39·3-75·4).  The response rate seemed to be largely independent of age, sex, performance status, or line of treatment.  Median PFS was 9·7 mo (95% CI 7·7-12·8).  Median overall survival data are not yet mature, but estd. overall survival at 6 and 12 mo was 87·9% (95% CI 81·3-92·3) and 74·8% (66·4-81·5), resp. 39 patients continued to receive crizotinib for more than 2 wk after progression because of perceived ongoing clin. benefit from the drug (12 for at least 6 mo from the time of their initial investigator-defined disease progression).  Overall, 144 (97%) of 149 patients experienced treatment-related adverse events, which were mostly grade 1 or 2.  The most common adverse events were visual effects, nausea, diarrhoea, constipation, vomiting, and peripheral edema.  The most common treatment-related grade 3 or 4 adverse events were neutropenia (n=9), raised alanine aminotransferase (n=6), hypophosphatemia (n=6), and lymphopenia (n=6).  Interpretation: Crizotinib is well tolerated with rapid, durable responses in patients with ALK-pos. NSCLC.  There seems to be potential for ongoing benefit after initial disease progression in this population, but a more formal definition of ongoing benefit in this context is needed.  Funding: Pfizer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNr3aI1rrjmbVg90H21EOLACvtfcHk0lgNq8TSw0DWpQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsVCjsb3E&md5=bd3aec44b197ee2f4c9d49ea540a672f</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2812%2970344-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252812%252970344-3%26sid%3Dliteratum%253Aachs%26aulast%3DCamidge%26aufirst%3DD%2BR.%26aulast%3DBang%26aufirst%3DY.-J.%26aulast%3DKwak%26aufirst%3DE.%2BL%26aulast%3DIafrate%26aufirst%3DA%2BJ.%26aulast%3DVarella-Garcia%26aufirst%3DM.%26aulast%3DFox%26aufirst%3DS.%2BB%26aulast%3DRiely%26aufirst%3DG.%2BJ%26aulast%3DSolomon%26aufirst%3DB.%26aulast%3DOu%26aufirst%3DS.-H.%2BI%26aulast%3DKim%26aufirst%3DD.-W.%26aulast%3DSalgia%26aufirst%3DR.%26aulast%3DFidias%26aufirst%3DP.%26aulast%3DEngelman%26aufirst%3DJ.%2BA%26aulast%3DGandhi%26aufirst%3DL.%26aulast%3DJanne%26aufirst%3DP.%2BA%26aulast%3DCosta%26aufirst%3DD.%2BB%26aulast%3DShapiro%26aufirst%3DG.%2BI%26aulast%3DLoRusso%26aufirst%3DP.%26aulast%3DRuffner%26aufirst%3DK.%26aulast%3DStephenson%26aufirst%3DP.%26aulast%3DTang%26aufirst%3DY.%26aulast%3DWilner%26aufirst%3DK.%26aulast%3DClark%26aufirst%3DJ.%2BW%26aulast%3DShaw%26aufirst%3DA.%2BT%26atitle%3DActivity%2520and%2520Safety%2520of%2520Crizotinib%2520in%2520Patients%2520with%2520ALK-positive%2520Non-small%2520Cell%2520Lung%2520Cancer%253A%2520Updated%2520Results%2520from%2520a%2520Phase%25201%2520Study%26jtitle%3DLancet%2520Oncol.%26date%3D2012%26volume%3D13%26spage%3D1011%26epage%3D1019%26doi%3D10.1016%2FS1470-2045%2812%2970344-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref82"><div class="reference"><strong class="refLabel"><a href="#ref82" class="rightTabRefNumLink">82</a></strong><div class="NLM_citation" id="rightTab-cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakagawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crino, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, M.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Pas, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Besse, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solomon, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blackhall, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O'Byrne, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moro-Sibilot, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camidge, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mok, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirsh, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riely, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iyer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tassell, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilner, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janne, P. A.</span></span> <span> </span><span class="NLM_article-title">Crizotinib versus Chemotherapy in Advanced ALK-positive Lung Cancer</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>368</i></span>,  <span class="NLM_fpage">2385</span>– <span class="NLM_lpage">2394</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1214886</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1056%2FNEJMoa1214886" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=23724913" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtVSnu7%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=368&publication_year=2013&pages=2385-2394&author=A.+T.+Shawauthor=D.-W.+Kimauthor=K.+Nakagawaauthor=T.+Setoauthor=L.+Crinoauthor=M.-J.+Ahnauthor=T.+De+Pasauthor=B.+Besseauthor=B.+J.+Solomonauthor=F.+Blackhallauthor=Y.-L.+Wuauthor=M.+Thomasauthor=K.+J.+O%27Byrneauthor=D.+Moro-Sibilotauthor=D.+R.+Camidgeauthor=T.+Mokauthor=V.+Hirshauthor=G.+J.+Rielyauthor=S.+Iyerauthor=V.+Tassellauthor=A.+Polliauthor=K.+D.+Wilnerauthor=P.+A.+Janne&title=Crizotinib+versus+Chemotherapy+in+Advanced+ALK-positive+Lung+Cancer&doi=10.1056%2FNEJMoa1214886"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">Crizotinib versus chemotherapy in advanced ALK-positive lung cancer</span></div><div class="casAuthors">Shaw, Alice T.; Kim, Dong-Wan; Nakagawa, Kazuhiko; Seto, Takashi; Crino, Lucio; Ahn, Myung-Ju; De Pas, Tommaso; Besse, Benjamin; Solomon, Benjamin J.; Blackhall, Fiona; Wu, Yi-Long; Thomas, Michael; O'Byrne, Kenneth J.; Moro-Sibilot, Denis; Camidge, D. Ross; Mok, Tony; Hirsh, Vera; Riely, Gregory J.; Iyer, Shrividya; Tassell, Vanessa; Polli, Anna; Wilner, Keith D.; Janne, Pasi A.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">368</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">2385-2394</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">In single-group studies, chromosomal rearrangements of the anaplastic lymphoma kinase gene (ALK) have been assocd. with marked clin. responses to crizotinib, an oral tyrosine kinase inhibitor targeting ALK.  Whether crizotinib is superior to std. chemotherapy with respect to efficacy is unknown.  We conducted a phase 3, open-label trial comparing crizotinib with chemotherapy in 347 patients with locally advanced or metastatic ALK-pos. lung cancer who had received one prior platinum-based regimen.  Patients were randomly assigned to receive oral treatment with crizotinib (250 mg) twice daily or i.v. chemotherapy with either pemetrexed (500 mg per square meter of body-surface area) or docetaxel (75 mg per square meter) every 3 wk.  Patients in the chemotherapy group who had disease progression were permitted to cross over to crizotinib as part of a sep. study.  The primary end point was progression-free survival.  The median progression-free survival was 7.7 mo in the crizotinib group and 3.0 mo in the chemotherapy group (hazard ratio for progression or death with crizotinib, 0.49; 95% confidence interval [CI], 0.37 to 0.64; P<0.001).  The response rates were 65% (95% CI, 58 to 72) with crizotinib, as compared with 20% (95% CI, 14 to 26) with chemotherapy (P<0.001).  An interim anal. of overall survival showed no significant improvement with crizotinib as compared with chemotherapy (hazard ratio for death in the crizotinib group, 1.02; 95% CI, 0.68 to 1.54; P = 0.54).  Common adverse events assocd. with crizotinib were visual disorder, gastrointestinal side effects, and elevated liver aminotransferase levels, whereas common adverse events with chemotherapy were fatigue, alopecia, and dyspnea.  Patients reported greater redns. in symptoms of lung cancer and greater improvement in global quality of life with crizotinib than with chemotherapy.  Crizotinib is superior to std. chemotherapy in patients with previously treated, advanced non-small-cell lung cancer with ALK rearrangement.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrk62MsVCiljLVg90H21EOLACvtfcHk0lgNq8TSw0DWpQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtVSnu7%252FM&md5=8c6f1a73472f87fa9a19ceac6fdbb132</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1214886&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1214886%26sid%3Dliteratum%253Aachs%26aulast%3DShaw%26aufirst%3DA.%2BT.%26aulast%3DKim%26aufirst%3DD.-W.%26aulast%3DNakagawa%26aufirst%3DK.%26aulast%3DSeto%26aufirst%3DT.%26aulast%3DCrino%26aufirst%3DL.%26aulast%3DAhn%26aufirst%3DM.-J.%26aulast%3DDe%2BPas%26aufirst%3DT.%26aulast%3DBesse%26aufirst%3DB.%26aulast%3DSolomon%26aufirst%3DB.%2BJ.%26aulast%3DBlackhall%26aufirst%3DF.%26aulast%3DWu%26aufirst%3DY.-L.%26aulast%3DThomas%26aufirst%3DM.%26aulast%3DO%2527Byrne%26aufirst%3DK.%2BJ.%26aulast%3DMoro-Sibilot%26aufirst%3DD.%26aulast%3DCamidge%26aufirst%3DD.%2BR.%26aulast%3DMok%26aufirst%3DT.%26aulast%3DHirsh%26aufirst%3DV.%26aulast%3DRiely%26aufirst%3DG.%2BJ.%26aulast%3DIyer%26aufirst%3DS.%26aulast%3DTassell%26aufirst%3DV.%26aulast%3DPolli%26aufirst%3DA.%26aulast%3DWilner%26aufirst%3DK.%2BD.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26atitle%3DCrizotinib%2520versus%2520Chemotherapy%2520in%2520Advanced%2520ALK-positive%2520Lung%2520Cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2013%26volume%3D368%26spage%3D2385%26epage%3D2394%26doi%3D10.1056%2FNEJMoa1214886" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref83"><div class="reference"><strong class="refLabel"><a href="#ref83" class="rightTabRefNumLink">83</a></strong><div class="NLM_citation" id="rightTab-cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yoneda, K. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scranton, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cadogan, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tassell, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nadanaciva, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilner, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stollenwerk, N. S.</span></span> <span> </span><span class="NLM_article-title">Interstitial Lung Disease Associated with Crizotinib in Patients with Advanced Non–small Cell Lung Cancer: Independent Review of Four PROFILE Trials</span>. <i>Clin. Lung Cancer</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">472</span>– <span class="NLM_lpage">479</span>, <span class="refDoi"> DOI: 10.1016/j.cllc.2017.03.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1016%2Fj.cllc.2017.03.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=28373069" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC2sXltVWqs70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2017&pages=472-479&author=K.+Y.+Yonedaauthor=J.+R.+Scrantonauthor=M.+A.+Cadoganauthor=V.+Tassellauthor=S.+Nadanacivaauthor=K.+D.+Wilnerauthor=N.+S.+Stollenwerk&title=Interstitial+Lung+Disease+Associated+with+Crizotinib+in+Patients+with+Advanced+Non%E2%80%93small+Cell+Lung+Cancer%3A+Independent+Review+of+Four+PROFILE+Trials&doi=10.1016%2Fj.cllc.2017.03.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Interstitial Lung Disease Associated With Crizotinib in Patients With Advanced Non-Small Cell Lung Cancer: Independent Review of Four PROFILE Trials</span></div><div class="casAuthors">Yoneda, Ken Y.; Scranton, Judith R.; Cadogan, Michael A.; Tassell, Vanessa; Nadanaciva, Sashi; Wilner, Keith D.; Stollenwerk, Nicholas S.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Lung Cancer</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">472-479</span>CODEN:
                <span class="NLM_cas:coden">CLCLCA</span>;
        ISSN:<span class="NLM_cas:issn">1525-7304</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Interstitial lung disease (ILD) is a rare, but potentially serious, side effect assocd. with crizotinib, a tyrosine kinase inhibitor for anaplastic lymphoma kinase-pos. (ALK+) advanced non-small cell lung cancer.  Our objective was to det. the incidence and nature of ILD assocd. with crizotinib in 4 PROFILE trials (ClinicalTrials.gov identifiers, NCT00585195, NCT00932451, NCT00932893, and NCT01154140).Grade ≥ 3 respiratory adverse events (AEs) and serious AEs (SAEs) and any grade AEs/SAEs reported as pneumonitis, ILD, or radiation pneumonitis in trials PROFILE 1001, PROFILE 1005, PROFILE 1007, and PROFILE 1014 were evaluated by an expert independent review committee that included a pulmonologist, medical oncologist, and radiologist.  Events were designated as disease progression, de novo ILD possibly or probably related to crizotinib, exacerbation or recurrence of pre-existing ILD, concurrent illness, other toxicity not thought to be related to ILD, or inconclusive.The independent review committee evaluated 446 events (in 368 of 1669 patients who had received crizotinib therapy).  They classified these events as follows: progressive disease, 77; de novo ILD, 20; pre-existing ILD, 3; concurrent illness, 9; other toxicities, 310; and inconclusive, 27.  The incidence of de novo ILD was 1.2% overall, 1.3% in whites, and 1.2% overall in Asians, but greater at 3.7% in Japanese patients.  The median onset of ILD from the initiation of crizotinib therapy was 23 days (range, 3-763 days).  The mortality rate due to ILD was 50%.  Survival was improved if crizotinib was discontinued on presentation of ILD (9 of 14 patients) compared with discontinued later or continued (1 of 6 patients).ILD assocd. with crizotinib, although rare, can occur at any time and requires close monitoring.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMBcvulNV2H7Vg90H21EOLACvtfcHk0lgXaqUyzbE2kw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXltVWqs70%253D&md5=2d20be1a1b9d34bb53530139a5894543</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1016%2Fj.cllc.2017.03.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cllc.2017.03.004%26sid%3Dliteratum%253Aachs%26aulast%3DYoneda%26aufirst%3DK.%2BY.%26aulast%3DScranton%26aufirst%3DJ.%2BR.%26aulast%3DCadogan%26aufirst%3DM.%2BA.%26aulast%3DTassell%26aufirst%3DV.%26aulast%3DNadanaciva%26aufirst%3DS.%26aulast%3DWilner%26aufirst%3DK.%2BD.%26aulast%3DStollenwerk%26aufirst%3DN.%2BS.%26atitle%3DInterstitial%2520Lung%2520Disease%2520Associated%2520with%2520Crizotinib%2520in%2520Patients%2520with%2520Advanced%2520Non%25E2%2580%2593small%2520Cell%2520Lung%2520Cancer%253A%2520Independent%2520Review%2520of%2520Four%2520PROFILE%2520Trials%26jtitle%3DClin.%2520Lung%2520Cancer%26date%3D2017%26volume%3D18%26spage%3D472%26epage%3D479%26doi%3D10.1016%2Fj.cllc.2017.03.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref84"><div class="reference"><strong class="refLabel"><a href="#ref84" class="rightTabRefNumLink">84</a></strong><div class="NLM_citation" id="rightTab-cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wood, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laudenslager, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haglund, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Attiyeh, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pawel, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Courtright, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plegaria, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christensen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maris, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mosse, Y.</span></span> <span> </span><span class="NLM_article-title">Inhibition of ALK Mutated Neuroblastomas by the Selective Inhibitor PF-02341066</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>27</i></span> (<span class="NLM_issue">Suppl 15</span>),  <span class="NLM_fpage">10008b</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2009&pages=10008b&issue=Suppl+15&author=A.+Woodauthor=M.+Laudenslagerauthor=E.+Haglundauthor=E.+Attiyehauthor=B.+Pawelauthor=J.+Courtrightauthor=J.+Plegariaauthor=J.+Christensenauthor=J.+Marisauthor=Y.+Mosse&title=Inhibition+of+ALK+Mutated+Neuroblastomas+by+the+Selective+Inhibitor+PF-02341066"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWood%26aufirst%3DA.%26aulast%3DLaudenslager%26aufirst%3DM.%26aulast%3DHaglund%26aufirst%3DE.%26aulast%3DAttiyeh%26aufirst%3DE.%26aulast%3DPawel%26aufirst%3DB.%26aulast%3DCourtright%26aufirst%3DJ.%26aulast%3DPlegaria%26aufirst%3DJ.%26aulast%3DChristensen%26aufirst%3DJ.%26aulast%3DMaris%26aufirst%3DJ.%26aulast%3DMosse%26aufirst%3DY.%26atitle%3DInhibition%2520of%2520ALK%2520Mutated%2520Neuroblastomas%2520by%2520the%2520Selective%2520Inhibitor%2520PF-02341066%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2009%26volume%3D27%26issue%3DSuppl%252015%26spage%3D10008b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref85"><div class="reference"><strong class="refLabel"><a href="#ref85" class="rightTabRefNumLink">85</a></strong><div class="NLM_citation" id="rightTab-cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mossé, Y. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voss, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rolland, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minard, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fox, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adamson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilner, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blaney, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weigel, B. J.</span></span> <span> </span><span class="NLM_article-title">Targeting ALK with Crizotinib in Pediatric Anaplastic Large Cell Lymphoma and Inflammatory Myofibroblastic Tumor: A Children’s Oncology Group Study</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">3215</span>– <span class="NLM_lpage">3221</span>, <span class="refDoi"> DOI: 10.1200/JCO.2017.73.4830</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1200%2FJCO.2017.73.4830" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=28787259" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitVemu7vM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2017&pages=3215-3221&author=Y.+P.+Moss%C3%A9author=S.+D.+Vossauthor=M.+S.+Limauthor=D.+Rollandauthor=C.+G.+Minardauthor=E.+Foxauthor=P.+Adamsonauthor=K.+Wilnerauthor=S.+M.+Blaneyauthor=B.+J.+Weigel&title=Targeting+ALK+with+Crizotinib+in+Pediatric+Anaplastic+Large+Cell+Lymphoma+and+Inflammatory+Myofibroblastic+Tumor%3A+A+Children%E2%80%99s+Oncology+Group+Study&doi=10.1200%2FJCO.2017.73.4830"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting ALK with crizotinib in pediatric anaplastic large cell lymphoma and inflammatory myofibroblastic tumor: a children's oncology group study</span></div><div class="casAuthors">Mosse, Yael P.; Voss, Stephan D.; Lim, Megan S.; Rolland, Delphine; Minard, Charles G.; Fox, Elizabeth; Adamson, Peter; Wilner, Keith; Blaney, Susan M.; Weigel, Brenda J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">28</span>),
    <span class="NLM_cas:pages">3215-3221</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">1527-7755</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose Fusions involving the ALK gene are the predominant genetic lesion underlying pediatric anaplastic large cell lymphomas (ALCL) and inflammatory myofibroblastic tumors (IMTs).  We assessed the activity of the ALK inhibitor crizotinib in patients who had no known curative treatment options at diagnosis or with relapsed/recurrent disease.  Methods In this study, 26 patients with relapsed/refractory ALK-pos. ALCL and 14 patients with metastatic or inoperable ALK-pos. IMT received crizotinib orally twice daily.  Study objectives were measurement of efficacy and safety.  Correlative studies evaluated the serial detection of NPM-ALK fusion transcripts in patients with ALCL.  Results The overall response rates for patients with ALCL treated at doses of 165 (ALCL165) and 280 (ALCL280) mg/m2 were 83% and 90%, resp.  The overall response rate for patients with IMT (treated at 100, 165, and 280 mg/m2/dose) was 86%.  A complete response was obsd. in 83% (five of six) of ALCL165, 80% (16 of 20) of ALCL280, and 36% (five of 14) of patients with IMT.  Partial response rates were 0% (none of six), 10% (two of 20), and 50% (seven of 14), resp.  The median duration of therapy was 2.79, 0.4, and 1.63 years, resp., with 12 patients ceasing protocol therapy to proceed to transplantation.  The most common drug-related adverse event was decrease in neutrophil count in 33% and 70% of the ALCL165 and ALCL280 groups, resp., and in 43% of patients with IMT.  Levels of NPM-ALK decreased during therapy in most patients with ALCL.  Conclusion The robust and sustained clin. responses to crizotinib therapy in patients with relapsed ALCL and metastatic or unresectable IMT highlight the importance of the ALK pathway in these diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGTozo3kOHTrVg90H21EOLACvtfcHk0lgXaqUyzbE2kw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitVemu7vM&md5=82b4c6382025c935271554cfe71189bd</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1200%2FJCO.2017.73.4830&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2017.73.4830%26sid%3Dliteratum%253Aachs%26aulast%3DMoss%25C3%25A9%26aufirst%3DY.%2BP.%26aulast%3DVoss%26aufirst%3DS.%2BD.%26aulast%3DLim%26aufirst%3DM.%2BS.%26aulast%3DRolland%26aufirst%3DD.%26aulast%3DMinard%26aufirst%3DC.%2BG.%26aulast%3DFox%26aufirst%3DE.%26aulast%3DAdamson%26aufirst%3DP.%26aulast%3DWilner%26aufirst%3DK.%26aulast%3DBlaney%26aufirst%3DS.%2BM.%26aulast%3DWeigel%26aufirst%3DB.%2BJ.%26atitle%3DTargeting%2520ALK%2520with%2520Crizotinib%2520in%2520Pediatric%2520Anaplastic%2520Large%2520Cell%2520Lymphoma%2520and%2520Inflammatory%2520Myofibroblastic%2520Tumor%253A%2520A%2520Children%25E2%2580%2599s%2520Oncology%2520Group%2520Study%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2017%26volume%3D35%26spage%3D3215%26epage%3D3221%26doi%3D10.1200%2FJCO.2017.73.4830" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref86"><div class="reference"><strong class="refLabel"><a href="#ref86" class="rightTabRefNumLink">86</a></strong><div class="NLM_citation" id="rightTab-cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sullivan, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Planchard, D.</span></span> <span> </span><span class="NLM_article-title">ALK Inhibitors in Non-small Cell Lung Cancer: the Latest Evidence and Developments</span>. <i>Ther. Adv. Med. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">32</span>– <span class="NLM_lpage">47</span>, <span class="refDoi"> DOI: 10.1177/1758834015617355</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1177%2F1758834015617355" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=26753004" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVSns7jE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2016&pages=32-47&author=I.+Sullivanauthor=D.+Planchard&title=ALK+Inhibitors+in+Non-small+Cell+Lung+Cancer%3A+the+Latest+Evidence+and+Developments&doi=10.1177%2F1758834015617355"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">ALK inhibitors in non-small cell lung cancer: the latest evidence and developments</span></div><div class="casAuthors">Sullivan, Ivana; Planchard, David</div><div class="citationInfo"><span class="NLM_cas:title">Therapeutic Advances in Medical Oncology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">32-47</span>CODEN:
                <span class="NLM_cas:coden">TAMOB8</span>;
        ISSN:<span class="NLM_cas:issn">1758-8340</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications Ltd.</span>)
        </div><div class="casAbstract">The treatment of patients with advanced non-small cell lung cancer (NSCLC) harbouring chromosomal rearrangements of ALK (anaplastic lymphoma kinase) was revolutionized by crizotinib, a small mol. inhibitor of ALK, ROS1 and MET.  Unfortunately, the disease progressed within the first 12 mo in most of the patients because of the development of crizotinib resistance in the majority of patients and the emergence of acquired resistance mutations in most of them.  Many of them had been reported even before its approval leading to the rapid development of second-generation ALK inhibitors for crizotinibresistant NSCLC.  In the last few years, novel potent ALK inhibitors with promising results and a good toxicity profile have become available: ceritinib (LDK378), alectinib (RG7853/ AF-802/RO5424802/CH5424802), brigatinib (AP26113), entrectinib (RXDX-101, NMS-E628), PF-06463922, ASP3026, TSR-011, X-376/X-396 and CEP-28122/CEP-37440.  Moreover, HSP90 (90 kDa heat shock protein) inhibitors have demonstrated clin. activity in patients with ALK+ NSCLC.  This review focuses on the mol. and clin. properties of this new generation of ALK inhibitors under development in the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDmT62DyyrILVg90H21EOLACvtfcHk0liv9pbNtjb_Lg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVSns7jE&md5=9266542af3ea2ad9aadde47361105372</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1177%2F1758834015617355&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1758834015617355%26sid%3Dliteratum%253Aachs%26aulast%3DSullivan%26aufirst%3DI.%26aulast%3DPlanchard%26aufirst%3DD.%26atitle%3DALK%2520Inhibitors%2520in%2520Non-small%2520Cell%2520Lung%2520Cancer%253A%2520the%2520Latest%2520Evidence%2520and%2520Developments%26jtitle%3DTher.%2520Adv.%2520Med.%2520Oncol.%26date%3D2016%26volume%3D8%26spage%3D32%26epage%3D47%26doi%3D10.1177%2F1758834015617355" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref87"><div class="reference"><strong class="refLabel"><a href="#ref87" class="rightTabRefNumLink">87</a></strong><div class="NLM_citation" id="rightTab-cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gainor, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sherman, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willoughby, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Logan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kennedy, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brastianos, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chi, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, A. T.</span></span> <span> </span><span class="NLM_article-title">Alectinib Salvages CNS Relapses in ALK-positive Lung Cancer Patients Previously Treated with Crizotinib and Ceritinib</span>. <i>J. Thorac. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">232</span>– <span class="NLM_lpage">236</span>, <span class="refDoi"> DOI: 10.1097/JTO.0000000000000455</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1097%2FJTO.0000000000000455" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=25526238" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvVentLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=232-236&author=J.+F.+Gainorauthor=C.+A.+Shermanauthor=K.+Willoughbyauthor=J.+Loganauthor=E.+Kennedyauthor=P.+K.+Brastianosauthor=A.+S.+Chiauthor=A.+T.+Shaw&title=Alectinib+Salvages+CNS+Relapses+in+ALK-positive+Lung+Cancer+Patients+Previously+Treated+with+Crizotinib+and+Ceritinib&doi=10.1097%2FJTO.0000000000000455"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">Alectinib Salvages CNS Relapses in ALK-Positive Lung Cancer Patients Previously Treated with Crizotinib and Ceritinib</span></div><div class="casAuthors">Gainor, Justin F.; Sherman, Carol A.; Willoughby, Kathryn; Logan, Jennifer; Kennedy, Elizabeth; Brastianos, Priscilla K.; Chi, Andrew S.; Shaw, Alice T.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Thoracic Oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">232-236</span>CODEN:
                <span class="NLM_cas:coden">JTOOB7</span>;
        ISSN:<span class="NLM_cas:issn">1556-0864</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Background: Leptomeningeal metastases (LM) are an increasingly frequent and devastating complication of anaplastic lymphoma kinase (ALK)-rearranged non-small-cell lung cancer (NSCLC).  Currently, the optimal management of LM in ALK-pos. patients remains poorly understood as these patients have been routinely excluded from clin. trials.  Methods: We describe four ALK-pos. patients with LM who were treated with the next-generation ALK inhibitor alectinib through single-patient, compassionate use protocols at two institutions.  All patients had previously been treated with both FDA-approved ALK inhibitors-crizotinib and ceritinib.  Patients received alectinib at a starting dose of 600 mg twice daily.  Results: Four ALK-pos. NSCLC patients with symptomatic leptomeningeal disease were identified.  Three of four patients experienced significant clin. and radiog. improvements in LM upon treatment with alectinib.  A fourth patient had stable intracranial disease for 4 mo before eventual systemic disease progression.  Overall, alectinib was well tolerated.  One patient required dose redn. due to grade 2 hyperbilirubinemia.  Conclusions: Alectinib is active in ALK-rearranged NSCLC patients with LM, including in patients previously treated with crizotinib and ceritinib.  Addnl. prospective studies of alectinib in ALK-pos. patients with LM are warranted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmmZ6TOOMXVrVg90H21EOLACvtfcHk0liv9pbNtjb_Lg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvVentLY%253D&md5=02a74597e914c4472f8d4d7edc128ba1</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1097%2FJTO.0000000000000455&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FJTO.0000000000000455%26sid%3Dliteratum%253Aachs%26aulast%3DGainor%26aufirst%3DJ.%2BF.%26aulast%3DSherman%26aufirst%3DC.%2BA.%26aulast%3DWilloughby%26aufirst%3DK.%26aulast%3DLogan%26aufirst%3DJ.%26aulast%3DKennedy%26aufirst%3DE.%26aulast%3DBrastianos%26aufirst%3DP.%2BK.%26aulast%3DChi%26aufirst%3DA.%2BS.%26aulast%3DShaw%26aufirst%3DA.%2BT.%26atitle%3DAlectinib%2520Salvages%2520CNS%2520Relapses%2520in%2520ALK-positive%2520Lung%2520Cancer%2520Patients%2520Previously%2520Treated%2520with%2520Crizotinib%2520and%2520Ceritinib%26jtitle%3DJ.%2520Thorac.%2520Oncol.%26date%3D2015%26volume%3D10%26spage%3D232%26epage%3D236%26doi%3D10.1097%2FJTO.0000000000000455" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref88"><div class="reference"><strong class="refLabel"><a href="#ref88" class="rightTabRefNumLink">88</a></strong><div class="NLM_citation" id="rightTab-cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Deeks, E. D.</span></span> <span> </span><span class="NLM_article-title">Ceritinib: a Review in ALK-positive Advanced NSCLC</span>. <i>Target. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">693</span>– <span class="NLM_lpage">700</span>, <span class="refDoi"> DOI: 10.1007/s11523-016-0460-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1007%2Fs11523-016-0460-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=27699584" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A280%3ADC%252BC2svmsVCruw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=693-700&author=E.+D.+Deeks&title=Ceritinib%3A+a+Review+in+ALK-positive+Advanced+NSCLC&doi=10.1007%2Fs11523-016-0460-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">Ceritinib: a Review in ALK-Positive Advanced NSCLC</span></div><div class="casAuthors">Deeks Emma D</div><div class="citationInfo"><span class="NLM_cas:title">Targeted oncology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">693-700</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Ceritinib (Zykadia®) is an oral, selective inhibitor of the anaplastic lymphoma kinase (ALK), a receptor tyrosine kinase which, after genetic rearrangement, acts as an oncogenic driver in a proportion of non-small cell lung cancers (NSCLCs).  The drug is approved in several countries worldwide for the treatment of patients with ALK-positive, advanced NSCLC who have previously received the first-generation ALK inhibitor crizotinib (indication details may vary by country).  Approval was based on its clinical benefit in this setting in the phase I and II trials known as ASCEND-1 and -2.  Across these noncomparative studies, 36-56 % of patients achieved a response with ceritinib (at the recommended dosage of 750 mg once daily) and the responses were durable, lasting up to a median of 10 months.  Patients survived free from progression for a median of up to 7 months and had a median overall survival of up to 17 months.  Moreover, efficacy outcomes in patients with brain metastases were generally consistent with those of the overall study populations.  Ceritinib has an acceptable tolerability profile, with gastrointestinal issues, fatigue and liver test abnormalities being the most common adverse reactions.  Thus, ceritinib is a valuable treatment option for patients with ALK-positive advanced NSCLC who have already received crizotinib therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRKOyGNG4eqHGmbXvSEQle5fW6udTcc2ebmH6g_w7aj87ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2svmsVCruw%253D%253D&md5=27514a024616dc2b02e8fbcd5c7bbd70</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1007%2Fs11523-016-0460-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11523-016-0460-7%26sid%3Dliteratum%253Aachs%26aulast%3DDeeks%26aufirst%3DE.%2BD.%26atitle%3DCeritinib%253A%2520a%2520Review%2520in%2520ALK-positive%2520Advanced%2520NSCLC%26jtitle%3DTarget.%2520Oncol.%26date%3D2016%26volume%3D11%26spage%3D693%26epage%3D700%26doi%3D10.1007%2Fs11523-016-0460-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref89"><div class="reference"><strong class="refLabel"><a href="#ref89" class="rightTabRefNumLink">89</a></strong><div class="NLM_citation" id="rightTab-cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Galkin, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melnick, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hood, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xia, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steensma, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chopiuk, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schultz, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warmuth, M.</span></span> <span> </span><span class="NLM_article-title">Identification of NVP-TAE684, a Potent, Selective, and Efficacious Inhibitor of NPM-ALK</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>104</i></span>,  <span class="NLM_fpage">270</span>– <span class="NLM_lpage">275</span>, <span class="refDoi"> DOI: 10.1073/pnas.0609412103</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1073%2Fpnas.0609412103" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=17185414" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjt12jsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2007&pages=270-275&author=A.+V.+Galkinauthor=J.+S.+Melnickauthor=S.+Kimauthor=T.+L.+Hoodauthor=N.+Liauthor=L.+Liauthor=G.+Xiaauthor=R.+Steensmaauthor=G.+Chopiukauthor=J.+Jiangauthor=Y.+Wanauthor=P.+Dingauthor=Y.+Liuauthor=F.+Sunauthor=P.+G.+Schultzauthor=N.+S.+Grayauthor=M.+Warmuth&title=Identification+of+NVP-TAE684%2C+a+Potent%2C+Selective%2C+and+Efficacious+Inhibitor+of+NPM-ALK&doi=10.1073%2Fpnas.0609412103"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK</span></div><div class="casAuthors">Galkin, Anna V.; Melnick, Jonathon S.; Kim, Sunjoon; Hood, Tami L.; Li, Nanxin; Li, Lintong; Xia, Gang; Steensma, Ruo; Chopiuk, Greg; Wan, Yongqin; Ding, Peter; Liu, Yi; Sun, Fangxian; Schultz, Peter G.; Gray, Nathanael S.; Warmuth, Markus</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">104</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">270-275</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Constitutive overexpression and activation of NPM-ALK fusion protein [t(2:5)(p23;q35)] is a key oncogenic event that drives the survival and proliferation of anaplastic large cell lymphomas (ALCLs).  We have identified a highly potent and selective small-mol. ALK inhibitor, NVP-TAE684, which blocked the growth of ALCL-derived and ALK-dependent cell lines with IC50 values between 2 and 10 nM.  NVP-TAE684 treatment resulted in a rapid and sustained inhibition of phosphorylation of NPM-ALK and its downstream effectors and subsequent induction of apoptosis and cell cycle arrest.  In vivo, NVP-TAE684 suppressed lymphomagenesis in two independent models of ALK-pos. ALCL and induced regression of established Karpas-299 lymphomas.  NVP-TAE684 also induced down-regulation of CD30 expression, suggesting that CD30 may be used as a biomarker of therapeutic NPM-ALK kinase activity inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLbZwqZzPX-bVg90H21EOLACvtfcHk0lgcaeuObAXnew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjt12jsQ%253D%253D&md5=4a3441ee637a67dc496c80730bd0e184</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0609412103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0609412103%26sid%3Dliteratum%253Aachs%26aulast%3DGalkin%26aufirst%3DA.%2BV.%26aulast%3DMelnick%26aufirst%3DJ.%2BS.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DHood%26aufirst%3DT.%2BL.%26aulast%3DLi%26aufirst%3DN.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DXia%26aufirst%3DG.%26aulast%3DSteensma%26aufirst%3DR.%26aulast%3DChopiuk%26aufirst%3DG.%26aulast%3DJiang%26aufirst%3DJ.%26aulast%3DWan%26aufirst%3DY.%26aulast%3DDing%26aufirst%3DP.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DSun%26aufirst%3DF.%26aulast%3DSchultz%26aufirst%3DP.%2BG.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DWarmuth%26aufirst%3DM.%26atitle%3DIdentification%2520of%2520NVP-TAE684%252C%2520a%2520Potent%252C%2520Selective%252C%2520and%2520Efficacious%2520Inhibitor%2520of%2520NPM-ALK%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2007%26volume%3D104%26spage%3D270%26epage%3D275%26doi%3D10.1073%2Fpnas.0609412103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref90"><div class="reference"><strong class="refLabel"><a href="#ref90" class="rightTabRefNumLink">90</a></strong><div class="NLM_citation" id="rightTab-cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Khozin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blumenthal, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brower, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fox, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Helms, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leong, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al Hakim, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boyd, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keegan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Justice, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pazdur, R.</span></span> <span> </span><span class="NLM_article-title">FDA Approval: Ceritinib for the Treatment of Metastatic Anaplastic Lymphoma Kinase–positive Non–small Cell Lung Cancer</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">2436</span>– <span class="NLM_lpage">2439</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-14-3157</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1158%2F1078-0432.CCR-14-3157" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=25754348" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC2MXps1aktLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=2436-2439&author=S.+Khozinauthor=G.+M.+Blumenthalauthor=L.+Zhangauthor=S.+Tangauthor=M.+Browerauthor=E.+Foxauthor=W.+Helmsauthor=R.+Leongauthor=P.+Songauthor=Y.+Panauthor=Q.+Liuauthor=P.+Zhaoauthor=H.+Zhaoauthor=D.+Luauthor=Z.+Tangauthor=A.+Al+Hakimauthor=K.+Boydauthor=P.+Keeganauthor=R.+Justiceauthor=R.+Pazdur&title=FDA+Approval%3A+Ceritinib+for+the+Treatment+of+Metastatic+Anaplastic+Lymphoma+Kinase%E2%80%93positive+Non%E2%80%93small+Cell+Lung+Cancer&doi=10.1158%2F1078-0432.CCR-14-3157"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">FDA Approval: Ceritinib for the Treatment of Metastatic Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer</span></div><div class="casAuthors">Khozin, Sean; Blumenthal, Gideon M.; Zhang, Lijun; Tang, Shenghui; Brower, Margaret; Fox, Emily; Helms, Whitney; Leong, Ruby; Song, Pengfei; Pan, Yuzhuo; Liu, Qi; Zhao, Ping; Zhao, Hong; Lu, Donghao; Tang, Zhe; Al Hakim, Ali; Boyd, Karen; Keegan, Patricia; Justice, Robert; Pazdur, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2436-2439</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">On Apr. 29, 2014, the FDA granted accelerated approval to ceritinib (ZYKADIA; Novartis Pharmaceuticals Corporation), a breakthrough therapy-designated drug, for the treatment of patients with anaplastic lymphoma kinase (ALK)-pos., metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib.  The approval was based on a single-arm multicenter trial enrolling 163 patients with metastatic ALK-pos. NSCLC who had disease progression on (91%) or intolerance to crizotinib.  Patients received ceritinib at a starting dose of 750 mg orally once daily.  The objective response rate (ORR) by a blinded independent review committee was 44% (95% CI, 36-52), and the median duration of response (DOR) was 7.1 mo.  The ORR by investigator assessment was similar.  Safety was evaluated in 255 patients.  The most common adverse reactions and lab. abnormalities included diarrhea (86%), nausea (80%), increased alanine transaminase (80%), increased aspartate transaminase (75%), vomiting (60%), increased glucose (49%), and increased lipase (28%).  Although 74% of patients required at least one dose redn. or interruption due to adverse reactions, the discontinuation rate due to adverse reactions was low (10%).  With this safety profile, the benefit-risk anal. was considered favorable because of the clin. meaningful ORR and DOR.  Clin Cancer Res; 21(11); 2436-9. ©2015 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoopHbie8F3MLVg90H21EOLACvtfcHk0lgcaeuObAXnew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXps1aktLY%253D&md5=0b83c696c11bdc5281cdae60a8b0bf50</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-14-3157&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-14-3157%26sid%3Dliteratum%253Aachs%26aulast%3DKhozin%26aufirst%3DS.%26aulast%3DBlumenthal%26aufirst%3DG.%2BM.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DTang%26aufirst%3DS.%26aulast%3DBrower%26aufirst%3DM.%26aulast%3DFox%26aufirst%3DE.%26aulast%3DHelms%26aufirst%3DW.%26aulast%3DLeong%26aufirst%3DR.%26aulast%3DSong%26aufirst%3DP.%26aulast%3DPan%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DZhao%26aufirst%3DP.%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DLu%26aufirst%3DD.%26aulast%3DTang%26aufirst%3DZ.%26aulast%3DAl%2BHakim%26aufirst%3DA.%26aulast%3DBoyd%26aufirst%3DK.%26aulast%3DKeegan%26aufirst%3DP.%26aulast%3DJustice%26aufirst%3DR.%26aulast%3DPazdur%26aufirst%3DR.%26atitle%3DFDA%2520Approval%253A%2520Ceritinib%2520for%2520the%2520Treatment%2520of%2520Metastatic%2520Anaplastic%2520Lymphoma%2520Kinase%25E2%2580%2593positive%2520Non%25E2%2580%2593small%2520Cell%2520Lung%2520Cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2015%26volume%3D21%26spage%3D2436%26epage%3D2439%26doi%3D10.1158%2F1078-0432.CCR-14-3157" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref91"><div class="reference"><strong class="refLabel"><a href="#ref91" class="rightTabRefNumLink">91</a></strong><div class="NLM_citation" id="rightTab-cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dhillon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, M.</span></span> <span> </span><span class="NLM_article-title">Ceritinib: First Global Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>74</i></span>,  <span class="NLM_fpage">1285</span>– <span class="NLM_lpage">1291</span>, <span class="refDoi"> DOI: 10.1007/s40265-014-0251-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1007%2Fs40265-014-0251-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=24980964" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVOisbbK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2014&pages=1285-1291&author=S.+Dhillonauthor=M.+Clark&title=Ceritinib%3A+First+Global+Approval&doi=10.1007%2Fs40265-014-0251-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">Ceritinib: First Global Approval</span></div><div class="casAuthors">Dhillon, Sohita; Clark, Madeleine</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1285-1291</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  Ceritinib is an oral anaplastic lymphoma kinase (ALK) inhibitor developed by Novartis for the treatment of tumors characterised by genetic abnormalities in ALK.  ALK is a member of the insulin receptor family of tyrosine kinases that can become oncogenic when fused to other proteins.  Ceritinib has been approved in the US under 'Breakthrough Therapy' designation for the second-line treatment of ALK-pos. non-small cell lung cancer (NSCLC).  Regulatory submissions have also been made in the EU and other countries.  Phase III development is ongoing worldwide to evaluate ceritinib both as a first- and second-line therapy for ALK-pos. NSCLC.  This article summarizes the milestones in the development of ceritinib leading to this first approval for the treatment of patients with ALK-pos. metastatic NSCLC who have progressed on or are intolerant to crizotinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGot1rTUW_DPL7Vg90H21EOLACvtfcHk0lhZGD70R_ZOug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVOisbbK&md5=ec44e05bf8556567826c3eb7f5dbd5dc</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1007%2Fs40265-014-0251-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-014-0251-3%26sid%3Dliteratum%253Aachs%26aulast%3DDhillon%26aufirst%3DS.%26aulast%3DClark%26aufirst%3DM.%26atitle%3DCeritinib%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2014%26volume%3D74%26spage%3D1285%26epage%3D1291%26doi%3D10.1007%2Fs40265-014-0251-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref92"><div class="reference"><strong class="refLabel"><a href="#ref92" class="rightTabRefNumLink">92</a></strong><div class="NLM_citation" id="rightTab-cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Felip, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orlov, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, C.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, C.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishio, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cobo Dols, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKeage, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, W.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mok, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scagliotti, G. V.</span></span> <span> </span><span class="NLM_article-title">ASCEND-3: A Single-arm, Open-label, Multicenter Phase II Study of Ceritinib in ALKi-naïve Adult Patients (pts) with ALK-rearranged (ALK+) Non-small Cell Lung Cancer (NSCLC)</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>33</i></span> (<span class="NLM_issue">Suppl 15</span>),  <span class="NLM_fpage">8060</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1200%2Fjco.2015.33.15_suppl.8060" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2015&pages=8060&issue=Suppl+15&author=E.+Felipauthor=S.+Orlovauthor=K.+Parkauthor=C.-J.+Yuauthor=C.-M.+Tsaiauthor=M.+Nishioauthor=M.+Cobo+Dolsauthor=M.+J.+McKeageauthor=W.-C.+Suauthor=T.+Mokauthor=G.+V.+Scagliotti&title=ASCEND-3%3A+A+Single-arm%2C+Open-label%2C+Multicenter+Phase+II+Study+of+Ceritinib+in+ALKi-na%C3%AFve+Adult+Patients+%28pts%29+with+ALK-rearranged+%28ALK%2B%29+Non-small+Cell+Lung+Cancer+%28NSCLC%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1200%2Fjco.2015.33.15_suppl.8060&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252Fjco.2015.33.15_suppl.8060%26sid%3Dliteratum%253Aachs%26aulast%3DFelip%26aufirst%3DE.%26aulast%3DOrlov%26aufirst%3DS.%26aulast%3DPark%26aufirst%3DK.%26aulast%3DYu%26aufirst%3DC.-J.%26aulast%3DTsai%26aufirst%3DC.-M.%26aulast%3DNishio%26aufirst%3DM.%26aulast%3DCobo%2BDols%26aufirst%3DM.%26aulast%3DMcKeage%26aufirst%3DM.%2BJ.%26aulast%3DSu%26aufirst%3DW.-C.%26aulast%3DMok%26aufirst%3DT.%26aulast%3DScagliotti%26aufirst%3DG.%2BV.%26atitle%3DASCEND-3%253A%2520A%2520Single-arm%252C%2520Open-label%252C%2520Multicenter%2520Phase%2520II%2520Study%2520of%2520Ceritinib%2520in%2520ALKi-na%25C3%25AFve%2520Adult%2520Patients%2520%2528pts%2529%2520with%2520ALK-rearranged%2520%2528ALK%252B%2529%2520Non-small%2520Cell%2520Lung%2520Cancer%2520%2528NSCLC%2529%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2015%26volume%3D33%26issue%3DSuppl%252015%26spage%3D8060" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref93"><div class="reference"><strong class="refLabel"><a href="#ref93" class="rightTabRefNumLink">93</a></strong><div class="NLM_citation" id="rightTab-cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, A. T</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crino, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gridelli, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiura, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novello, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bearz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gautschi, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mok, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishio, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scagliotti, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spigel, D. R</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deudon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pantano, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urban, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Massacesi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viraswami-Appanna, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felip, E.</span></span> <span> </span><span class="NLM_article-title">Ceritinib versus Chemotherapy in Patients with ALK-rearranged Non-small-cell Lung Cancer Previously Given Chemotherapy and Crizotinib (ASCEND-5): a Randomised, Controlled, Open-label, Phase 3 Trial</span>. <i>Lancet Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">874</span>– <span class="NLM_lpage">886</span>, <span class="refDoi"> DOI: 10.1016/S1470-2045(17)30339-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1016%2FS1470-2045%2817%2930339-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=28602779" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC2sXpvVWhsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2017&pages=874-886&author=A.+T+Shawauthor=T.+M.+Kimauthor=L.+Crinoauthor=C.+Gridelliauthor=K.+Kiuraauthor=G.+Liuauthor=S.+Novelloauthor=A.+Bearzauthor=O.+Gautschiauthor=T.+Mokauthor=M.+Nishioauthor=G.+Scagliottiauthor=D.+R+Spigelauthor=S.+Deudonauthor=C.+Zhengauthor=S.+Pantanoauthor=P.+Urbanauthor=C.+Massacesiauthor=K.+Viraswami-Appannaauthor=E.+Felip&title=Ceritinib+versus+Chemotherapy+in+Patients+with+ALK-rearranged+Non-small-cell+Lung+Cancer+Previously+Given+Chemotherapy+and+Crizotinib+%28ASCEND-5%29%3A+a+Randomised%2C+Controlled%2C+Open-label%2C+Phase+3+Trial&doi=10.1016%2FS1470-2045%2817%2930339-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial</span></div><div class="casAuthors">Shaw, Alice T.; Kim, Tae Min; Crino, Lucio; Gridelli, Cesare; Kiura, Katsuyuki; Liu, Geoffrey; Novello, Silvia; Bearz, Alessandra; Gautschi, Oliver; Mok, Tony; Nishio, Makoto; Scagliotti, Giorgio; Spigel, David R.; Deudon, Stephanie; Zheng, Cheng; Pantano, Serafino; Urban, Patrick; Massacesi, Cristian; Viraswami-Appanna, Kalyanee; Felip, Enriqueta</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">874-886</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Ceritinib is a next-generation anaplastic lymphoma kinase (ALK) inhibitor, which has shown robust anti-tumor efficacy, along with intracranial activity, in patients with ALK-rearranged non-small-cell lung cancer.  In phase 1 and 2 studies, ceritinib has been shown to be highly active in both ALK inhibitor-naive and ALK inhibitor-pretreated patients who had progressed after chemotherapy (mostly multiple lines).  In this study, we compared the efficacy and safety of ceritinib vs. single-agent chemotherapy in patients with advanced ALK-rearranged non-small-cell lung cancer who had previously progressed following crizotinib and platinum-based doublet chemotherapy.  In this randomized, controlled, open-label, phase 3 trial, we recruited patients aged at least 18 years with ALK-rearranged stage IIIB or IV non-small-cell lung cancer (with at least one measurable lesion) who had received previous chemotherapy (one or two lines, including a platinum doublet) and crizotinib and had subsequent disease progression, from 99 centers across 20 countries.  Other inclusion criteria were a WHO performance status of 0-2, adequate organ function and lab. test results, a life expectancy of at least 12 wk, and having recovered from previous anticancer treatment-related toxicities.  We randomly allocated patients (1:1; with blocking [block size of four]; stratified by WHO performance status [0 vs 1-2] and presence or absence of brain metastases) to oral ceritinib 750 mg per day fasted (in 21 day treatment cycles) or chemotherapy (i.v. pemetrexed 500 mg/m2 or docetaxel 75 mg/m2 [investigator choice], every 21 days).  Patients who discontinued chemotherapy because of progressive disease could cross over to the ceritinib group.  The primary endpoint was progression-free survival, assessed by a masked independent review committee using Response Evaluation Criteria in Solid Tumors 1.1 in the intention-to-treat population, assessed every 6 wk until month 18 and every 9 wk thereafter.  This trial is registered with ClinicalTrials.gov, no. NCT01828112, and is ongoing but no longer recruiting patients.  Between June 28, 2013, and Nov 2, 2015, we randomly allocated 231 patients; 115 (50%) to ceritinib and 116 (50%) to chemotherapy (40 [34%] to pemetrexed, 73 [63%] to docetaxel, and three [3%] discontinued before receiving treatment).  Median follow-up was 16·5 mo (IQR 11·5-21·4).  Ceritinib showed a significant improvement in median progression-free survival compared with chemotherapy (5·4 mo [95% CI 4·1-6·9] for ceritinib vs 1·6 mo [1·4-2·8] for chemotherapy; hazard ratio 0·49 [0·36-0·67]; p<0·0001).  Serious adverse events were reported in 49 (43%) of 115 patients in the ceritinib group and 36 (32%) of 113 in the chemotherapy group.  Treatment-related serious adverse events were similar between groups (13 [11%] in the ceritinib group vs 12 [11%] in the chemotherapy group).  The most frequent grade 3-4 adverse events in the ceritinib group were increased alanine aminotransferase concn. (24 [21%] of 115 vs two [2%] of 113 in the chemotherapy group), increased γ glutamyltransferase concn. (24 [21%] vs one [1%]), and increased aspartate aminotransferase concn. (16 [14%] vs one [1%] in the chemotherapy group).  Six (5%) of 115 patients in the ceritinib group discontinued because of adverse events compared with eight (7%) of 116 in the chemotherapy group. 15 (13%) of 115 patients in the ceritinib group and five (4%) of 113 in the chemotherapy group died during the treatment period (from the day of the first dose of study treatment to 30 days after the final dose). 13 (87%) of the 15 patients who died in the ceritinib group died because of disease progression and two (13%) died because of an adverse event (one [7%] cerebrovascular accident and one [7%] respiratory failure); neither of these deaths were considered by the investigator to be treatment related.  The five (4%) deaths in the chemotherapy group were all due to disease progression.  These findings show that patients derive significant clin. benefit from a more potent ALK inhibitor after failure of crizotinib, and establish ceritinib as a more efficacious treatment option compared with chemotherapy in this patient population.  Novartis Pharmaceuticals Corporation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpMT91wojAiELVg90H21EOLACvtfcHk0lhZGD70R_ZOug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXpvVWhsLc%253D&md5=b75ab3a89c51975715ba614a1780d433</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2817%2930339-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252817%252930339-X%26sid%3Dliteratum%253Aachs%26aulast%3DShaw%26aufirst%3DA.%2BT%26aulast%3DKim%26aufirst%3DT.%2BM.%26aulast%3DCrino%26aufirst%3DL.%26aulast%3DGridelli%26aufirst%3DC.%26aulast%3DKiura%26aufirst%3DK.%26aulast%3DLiu%26aufirst%3DG.%26aulast%3DNovello%26aufirst%3DS.%26aulast%3DBearz%26aufirst%3DA.%26aulast%3DGautschi%26aufirst%3DO.%26aulast%3DMok%26aufirst%3DT.%26aulast%3DNishio%26aufirst%3DM.%26aulast%3DScagliotti%26aufirst%3DG.%26aulast%3DSpigel%26aufirst%3DD.%2BR%26aulast%3DDeudon%26aufirst%3DS.%26aulast%3DZheng%26aufirst%3DC.%26aulast%3DPantano%26aufirst%3DS.%26aulast%3DUrban%26aufirst%3DP.%26aulast%3DMassacesi%26aufirst%3DC.%26aulast%3DViraswami-Appanna%26aufirst%3DK.%26aulast%3DFelip%26aufirst%3DE.%26atitle%3DCeritinib%2520versus%2520Chemotherapy%2520in%2520Patients%2520with%2520ALK-rearranged%2520Non-small-cell%2520Lung%2520Cancer%2520Previously%2520Given%2520Chemotherapy%2520and%2520Crizotinib%2520%2528ASCEND-5%2529%253A%2520a%2520Randomised%252C%2520Controlled%252C%2520Open-label%252C%2520Phase%25203%2520Trial%26jtitle%3DLancet%2520Oncol.%26date%3D2017%26volume%3D18%26spage%3D874%26epage%3D886%26doi%3D10.1016%2FS1470-2045%2817%2930339-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref94"><div class="reference"><strong class="refLabel"><a href="#ref94" class="rightTabRefNumLink">94</a></strong><div class="NLM_citation" id="rightTab-cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Soria, J.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, D. S W</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiari, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paz-Ares, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolf, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geater, S. L</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orlov, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortinovis, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, C.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hochmair, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortot, A. B</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, C.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moro-Sibilot, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campelo, R. G</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCulloch, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dugan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pantano, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Branle, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Massacesi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Castro, G.</span></span> <span> </span><span class="NLM_article-title">First-line Ceritinib versus Platinum-based Chemotherapy in Advanced ALK-rearranged Non-small Cell Lung Cancer (ASCEND-4): a Randomised, Open-label, Phase 3 Study</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>389</i></span>,  <span class="NLM_fpage">917</span>– <span class="NLM_lpage">929</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(17)30123-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1016%2FS0140-6736%2817%2930123-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=28126333" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFGku7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=389&publication_year=2017&pages=917-929&author=J.-C.+Soriaauthor=D.+S+W+Tanauthor=R.+Chiariauthor=Y.-L.+Wuauthor=L.+Paz-Aresauthor=J.+Wolfauthor=S.+L+Geaterauthor=S.+Orlovauthor=D.+Cortinovisauthor=C.-J.+Yuauthor=M.+Hochmairauthor=A.+B+Cortotauthor=C.-M.+Tsaiauthor=D.+Moro-Sibilotauthor=R.+G+Campeloauthor=T.+McCullochauthor=P.+Senauthor=M.+Duganauthor=S.+Pantanoauthor=F.+Branleauthor=C.+Massacesiauthor=G.+de+Castro&title=First-line+Ceritinib+versus+Platinum-based+Chemotherapy+in+Advanced+ALK-rearranged+Non-small+Cell+Lung+Cancer+%28ASCEND-4%29%3A+a+Randomised%2C+Open-label%2C+Phase+3+Study&doi=10.1016%2FS0140-6736%2817%2930123-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study</span></div><div class="casAuthors">Soria, Jean-Charles; Tan, Daniel S. W.; Chiari, Rita; Wu, Yi-Long; Paz-Ares, Luis; Wolf, Juergen; Geater, Sarayut L.; Orlov, Sergey; Cortinovis, Diego; Yu, Chong-Jen; Hochmair, Maximillian; Cortot, Alexis B.; Tsai, Chun-Ming; Moro-Sibilot, Denis; Campelo, Rosario G.; McCulloch, Tracey; Sen, Paramita; Dugan, Margaret; Pantano, Serafino; Branle, Fabrice; Massacesi, Cristian; de Castro, Gilberto, Jr.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">389</span>
        (<span class="NLM_cas:issue">10072</span>),
    <span class="NLM_cas:pages">917-929</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The efficacy of ceritinib in patients with untreated anaplastic lymphoma kinase (ALK)-rearranged non-small-cell lung cancer (NSCLC) is not known.  We assessed the efficacy and safety of ceritinib vs. platinum-based chemotherapy in these patients.  This randomised, open-label, phase 3 study in untreated patients with stage IIIB/IV ALK-rearranged non-squamous NSCLC was done in 134 centers across 28 countries.  Eligible patients were assigned via interactive response technol. to oral ceritinib 750 mg/day or platinum-based chemotherapy ([cisplatin 75 mg/m2 or carboplatin AUC 5-6 plus pemetrexed 500 mg/m2] every 3 wk for four cycles followed by maintenance pemetrexed); randomization was stratified by World Health Organization performance status (0 vs 1-2), previous neoadjuvant or adjuvant chemotherapy, and presence of brain metastases as per investigator's assessment at screening.  Investigators and patients were not masked to treatment assignment.  The primary endpoint was blinded independent review committee assessed progression-free survival, based on all randomly assigned patients (the full anal. set).  Efficacy analyses were done based on the full anal. set.  All safety analyses were done based on the safety set, which included all patients who received at least one dose of study drug.  This trial is registered with ClinicalTrials.gov, no. NCT01828099.  Between Aug 19, 2013, and May 11, 2015, 376 patients were randomly assigned to ceritinib (n=189) or chemotherapy (n=187).  Median progression-free survival (as assessed by blinded independent review committee) was 16·6 mo (95% CI 12·6-27·2) in the ceritinib group and 8·1 mo (5·8-11·1) in the chemotherapy group (hazard ratio 0·55 [95% CI 0·42-0·73]; p<0·00001).  The most common adverse events were diarrhoea (in 160 [85%] of 189 patients), nausea (130 [69%]), vomiting (125 [66%]), and an increase in alanine aminotransferase (114 [60%]) in the ceritinib group and nausea (in 97 [55%] of 175 patients), vomiting (63 [36%]), and anemia (62 [35%]) in the chemotherapy group.  First-line ceritinib showed a statistically significant and clin. meaningful improvement in progression-free survival vs. chemotherapy in patients with advanced ALK-rearranged NSCLC.  Novartis Pharmaceuticals Corporation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdGKYa204H9rVg90H21EOLACvtfcHk0lhVLHe1BA7LSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFGku7Y%253D&md5=a51029d59399ff42f840ffc1b2b5caf7</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2817%2930123-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252817%252930123-X%26sid%3Dliteratum%253Aachs%26aulast%3DSoria%26aufirst%3DJ.-C.%26aulast%3DTan%26aufirst%3DD.%2BS%2BW%26aulast%3DChiari%26aufirst%3DR.%26aulast%3DWu%26aufirst%3DY.-L.%26aulast%3DPaz-Ares%26aufirst%3DL.%26aulast%3DWolf%26aufirst%3DJ.%26aulast%3DGeater%26aufirst%3DS.%2BL%26aulast%3DOrlov%26aufirst%3DS.%26aulast%3DCortinovis%26aufirst%3DD.%26aulast%3DYu%26aufirst%3DC.-J.%26aulast%3DHochmair%26aufirst%3DM.%26aulast%3DCortot%26aufirst%3DA.%2BB%26aulast%3DTsai%26aufirst%3DC.-M.%26aulast%3DMoro-Sibilot%26aufirst%3DD.%26aulast%3DCampelo%26aufirst%3DR.%2BG%26aulast%3DMcCulloch%26aufirst%3DT.%26aulast%3DSen%26aufirst%3DP.%26aulast%3DDugan%26aufirst%3DM.%26aulast%3DPantano%26aufirst%3DS.%26aulast%3DBranle%26aufirst%3DF.%26aulast%3DMassacesi%26aufirst%3DC.%26aulast%3Dde%2BCastro%26aufirst%3DG.%26atitle%3DFirst-line%2520Ceritinib%2520versus%2520Platinum-based%2520Chemotherapy%2520in%2520Advanced%2520ALK-rearranged%2520Non-small%2520Cell%2520Lung%2520Cancer%2520%2528ASCEND-4%2529%253A%2520a%2520Randomised%252C%2520Open-label%252C%2520Phase%25203%2520Study%26jtitle%3DLancet%26date%3D2017%26volume%3D389%26spage%3D917%26epage%3D929%26doi%3D10.1016%2FS0140-6736%2817%2930123-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref95"><div class="reference"><strong class="refLabel"><a href="#ref95" class="rightTabRefNumLink">95</a></strong><div class="NLM_citation" id="rightTab-cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sakamoto, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsukaguchi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hiroshima, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kodama, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobayashi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukami, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oikawa, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsukuda, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishii, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aoki, Y.</span></span> <span> </span><span class="NLM_article-title">CH5424802, a Selective ALK Inhibitor Capable of Blocking the Resistant Gatekeeper Mutant</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">679</span>– <span class="NLM_lpage">690</span>, <span class="refDoi"> DOI: 10.1016/j.ccr.2011.04.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1016%2Fj.ccr.2011.04.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=21575866" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmtFGlsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2011&pages=679-690&author=H.+Sakamotoauthor=T.+Tsukaguchiauthor=S.+Hiroshimaauthor=T.+Kodamaauthor=T.+Kobayashiauthor=T.+A.+Fukamiauthor=N.+Oikawaauthor=T.+Tsukudaauthor=N.+Ishiiauthor=Y.+Aoki&title=CH5424802%2C+a+Selective+ALK+Inhibitor+Capable+of+Blocking+the+Resistant+Gatekeeper+Mutant&doi=10.1016%2Fj.ccr.2011.04.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">CH5424802, a Selective ALK Inhibitor Capable of Blocking the Resistant Gatekeeper Mutant</span></div><div class="casAuthors">Sakamoto, Hiroshi; Tsukaguchi, Toshiyuki; Hiroshima, Sayuri; Kodama, Tatsushi; Kobayashi, Takamitsu; Fukami, Takaaki A.; Oikawa, Nobuhiro; Tsukuda, Takuo; Ishii, Nobuya; Aoki, Yuko</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">679-690</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Anaplastic lymphoma kinase (ALK) is a tyrosine kinase that is constitutively activated in certain cancers, following gene alterations such as chromosomal translocation, amplification, or point mutation.  Here, the authors identified CH5424802, a potent, selective, and orally available ALK inhibitor with a unique chem. scaffold, showing preferential antitumor activity against cancers with gene alterations of ALK, such as non-small cell lung cancer (NSCLC) cells expressing EML4-ALK fusion and anaplastic large-cell lymphoma (ALCL) cells expressing NPM-ALK fusion in vitro and in vivo.  CH5424802 inhibited ALK L1196M, which corresponds to the gatekeeper mutation conferring common resistance to kinase inhibitors, and blocked EML4-ALK L1196M-driven cell growth.  The authors' results support the potential for clin. evaluation of CH5424802 for the treatment of patients with ALK-driven tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrk3zvzF9p67Vg90H21EOLACvtfcHk0lhVLHe1BA7LSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmtFGlsL8%253D&md5=cae32f3a3647926ba835293b68e776f8</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2011.04.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2011.04.004%26sid%3Dliteratum%253Aachs%26aulast%3DSakamoto%26aufirst%3DH.%26aulast%3DTsukaguchi%26aufirst%3DT.%26aulast%3DHiroshima%26aufirst%3DS.%26aulast%3DKodama%26aufirst%3DT.%26aulast%3DKobayashi%26aufirst%3DT.%26aulast%3DFukami%26aufirst%3DT.%2BA.%26aulast%3DOikawa%26aufirst%3DN.%26aulast%3DTsukuda%26aufirst%3DT.%26aulast%3DIshii%26aufirst%3DN.%26aulast%3DAoki%26aufirst%3DY.%26atitle%3DCH5424802%252C%2520a%2520Selective%2520ALK%2520Inhibitor%2520Capable%2520of%2520Blocking%2520the%2520Resistant%2520Gatekeeper%2520Mutant%26jtitle%3DCancer%2520Cell%26date%3D2011%26volume%3D19%26spage%3D679%26epage%3D690%26doi%3D10.1016%2Fj.ccr.2011.04.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref96"><div class="reference"><strong class="refLabel"><a href="#ref96" class="rightTabRefNumLink">96</a></strong><div class="NLM_citation" id="rightTab-cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McKeage, K.</span></span> <span> </span><span class="NLM_article-title">Alectinib: a Review of its Use in Advanced ALK-rearranged Non-small Cell Lung Cancer</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>75</i></span>,  <span class="NLM_fpage">75</span>– <span class="NLM_lpage">82</span>, <span class="refDoi"> DOI: 10.1007/s40265-014-0329-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1007%2Fs40265-014-0329-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=25428710" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvF2hu73P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2015&pages=75-82&author=K.+McKeage&title=Alectinib%3A+a+Review+of+its+Use+in+Advanced+ALK-rearranged+Non-small+Cell+Lung+Cancer&doi=10.1007%2Fs40265-014-0329-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">Alectinib: A Review of Its Use in Advanced ALK-Rearranged Non-Small Cell Lung Cancer</span></div><div class="casAuthors">McKeage, Kate</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">75-82</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  Alectinib (Alecensa) is a second-generation, orally active, potent and highly selective inhibitor of anaplastic lymphoma kinase (ALK).  Alectinib is approved for the treatment of ALK fusion-gene pos., unresectable, advanced or recurrent non-small cell lung cancer (NSCLC) in Japan, where it has been given orphan drug designation.  Approval was based on a phase 1-2 study in ALK inhibitor-naive patients with ALK-rearranged advanced NSCLC who received twice-daily alectinib 300 mg.  In the phase 2 portion, 93.5 % of patients achieved an objective response.  Treatment response was rapid, with a partial response achieved in two-thirds of patients within 3 wk (cycle 1).  Patient follow-up is ongoing, and after approx. 2 years, 19.6 % of patients had achieved a complete response, and the 2-yr progression-free survival rate is 76 %.  During treatment with alectinib (median follow-up approx. 8 mo), there was no progression of CNS lesions among patients with known CNS metastases at baseline (although prior radiation therapy may have confounded results).  In preclin. models, alectinib was active against most ALK fusion-gene mutations related to crizotinib resistance, and preliminary results from clin. trials indicate efficacy in crizotinib-refractory NSCLC.  Alectinib was generally well tolerated in clin. trials, and there were no treatment-related grade 4 adverse events or deaths.  The most common grade 3 treatment-related adverse events were decreased neutrophil counts and increased creatinine phosphokinase.  While more data are needed to confirm the efficacy of alectinib and to evaluate its activity in crizotinib-resistant disease, the drug provides a very promising option for the treatment of ALK-rearranged advanced NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq38gxDn8-OqbVg90H21EOLACvtfcHk0lhVLHe1BA7LSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvF2hu73P&md5=17517e7ce95efd8be1b5c5300b404c8a</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1007%2Fs40265-014-0329-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-014-0329-y%26sid%3Dliteratum%253Aachs%26aulast%3DMcKeage%26aufirst%3DK.%26atitle%3DAlectinib%253A%2520a%2520Review%2520of%2520its%2520Use%2520in%2520Advanced%2520ALK-rearranged%2520Non-small%2520Cell%2520Lung%2520Cancer%26jtitle%3DDrugs%26date%3D2015%26volume%3D75%26spage%3D75%26epage%3D82%26doi%3D10.1007%2Fs40265-014-0329-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref97"><div class="reference"><strong class="refLabel"><a href="#ref97" class="rightTabRefNumLink">97</a></strong><div class="NLM_citation" id="rightTab-cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Song, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, A.</span></span> <span> </span><span class="NLM_article-title">Alectinib: a Novel Second Generation Anaplastic Lymphoma Kinase (ALK) Inhibitor for Overcoming Clinically-acquired Resistance</span>. <i>Acta Pharm. Sin. B</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">34</span>– <span class="NLM_lpage">37</span>, <span class="refDoi"> DOI: 10.1016/j.apsb.2014.12.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1016%2Fj.apsb.2014.12.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=26579422" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A280%3ADC%252BC28rgtlOnsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2015&pages=34-37&author=Z.+Songauthor=M.+Wangauthor=A.+Zhang&title=Alectinib%3A+a+Novel+Second+Generation+Anaplastic+Lymphoma+Kinase+%28ALK%29+Inhibitor+for+Overcoming+Clinically-acquired+Resistance&doi=10.1016%2Fj.apsb.2014.12.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">Alectinib: a novel second generation anaplastic lymphoma kinase (ALK) inhibitor for overcoming clinically-acquired resistance</span></div><div class="casAuthors">Song Zilan; Wang Meining; Zhang Ao</div><div class="citationInfo"><span class="NLM_cas:title">Acta pharmaceutica Sinica. B</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">34-7</span>
        ISSN:<span class="NLM_cas:issn">2211-3835</span>.
    </div><div class="casAbstract">The development of inhibitors for the tyrosine anaplastic lymphoma kinase (ALK) has advanced rapidly, driven by biology and medicinal chemistry.  The first generation ALK inhibitor crizotinib was granted US FDA approval with only four years of preclinical and clinical testing.  Although this drug offers significant clinical benefit to the ALK-positive patients, resistance has been developed through a variety of mechanisms.  In addition to ceritinib, alectinib is another second-generation ALK inhibitor launched in 2014 in Japan.  This drug has a unique chemical structure bearing a 5H-benzo[b]carbazol-11(6H)-one structural scaffold with an IC50 value of 1.9 nmol/L, and is highly potent against ALK bearing the gatekeeper mutation L1196M with an IC50 of 1.56 nmol/L.  In the clinic, alectinib is highly efficacious in treatment of ALK-positive non-small cell lung cancer (NSCLC), and retains potency to combat crizotinib-resistant ALK mutations L1196M, F1174L, R1275Q and C1156Y.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ-qtzzXrDFl0loaUqgkFHkfW6udTcc2eaRjKben8VdB7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28rgtlOnsQ%253D%253D&md5=897904214b032d104d09280ebe1b95ca</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1016%2Fj.apsb.2014.12.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.apsb.2014.12.007%26sid%3Dliteratum%253Aachs%26aulast%3DSong%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DA.%26atitle%3DAlectinib%253A%2520a%2520Novel%2520Second%2520Generation%2520Anaplastic%2520Lymphoma%2520Kinase%2520%2528ALK%2529%2520Inhibitor%2520for%2520Overcoming%2520Clinically-acquired%2520Resistance%26jtitle%3DActa%2520Pharm.%2520Sin.%2520B%26date%3D2015%26volume%3D5%26spage%3D34%26epage%3D37%26doi%3D10.1016%2Fj.apsb.2014.12.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref98"><div class="reference"><strong class="refLabel"><a href="#ref98" class="rightTabRefNumLink">98</a></strong><div class="NLM_citation" id="rightTab-cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kodama, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hasegawa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takanashi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakurai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kondoh, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakamoto, H.</span></span> <span> </span><span class="NLM_article-title">Antitumor Activity of the Selective ALK Inhibitor Alectinib in Models of Intracranial Metastases</span>. <i>Cancer Chemother. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>74</i></span>,  <span class="NLM_fpage">1023</span>– <span class="NLM_lpage">1028</span>, <span class="refDoi"> DOI: 10.1007/s00280-014-2578-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1007%2Fs00280-014-2578-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=25205428" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFeju7%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2014&pages=1023-1028&author=T.+Kodamaauthor=M.+Hasegawaauthor=K.+Takanashiauthor=Y.+Sakuraiauthor=O.+Kondohauthor=H.+Sakamoto&title=Antitumor+Activity+of+the+Selective+ALK+Inhibitor+Alectinib+in+Models+of+Intracranial+Metastases&doi=10.1007%2Fs00280-014-2578-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">Antitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastases</span></div><div class="casAuthors">Kodama, Tatsushi; Hasegawa, Masami; Takanashi, Kenji; Sakurai, Yuji; Kondoh, Osamu; Sakamoto, Hiroshi</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Chemotherapy and Pharmacology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1023-1028</span>CODEN:
                <span class="NLM_cas:coden">CCPHDZ</span>;
        ISSN:<span class="NLM_cas:issn">0344-5704</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Purpose: The clin. efficacy of the anaplastic lymphoma kinase (ALK) inhibitor crizotinib has been demonstrated in ALK fusion-pos. non-small cell lung cancer (NSCLC); however, brain metastases are frequent sites of initial failure in patients due to poor penetration of the central nervous system by crizotinib.  Here, we examd. the efficacy of a selective ALK inhibitor alectinib/CH5424802 in preclin. models of intracranial tumors.  Methods: We established intracranial tumor implantation mouse models of EML4-ALK-pos. NSCLC NCI-H2228 and examd. the antitumor activity of alectinib in this model.  Plasma distribution and brain distribution of alectinib were examd. by quant. whole-body autoradiog. administrating a single oral dose of 14C-labeled alectinib to rats.  The drug permeability of alectinib was evaluated in Caco-2 cell.  Results: Alectinib resulted in regression of NCI-H2228 tumor in mouse brain and provided a survival benefit.  In a pharmacokinetic study using rats, alectinib showed a high brain-to-plasma ratio, and in an in vitro drug permeability study using Caco-2 cells, alectinib was not transported by P-glycoprotein efflux transporter that is a key factor in blood-brain barrier penetration.  Conclusions: We established intracranial tumor implantation models of EML4-ALK-pos. NSCLC.  Alectinib showed potent efficacy against intracranial EML4-ALK-pos. tumor.  These results demonstrated that alectinib might provide therapeutic opportunities for crizotinib-treated patients with brain metastases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCY4brINPNC7Vg90H21EOLACvtfcHk0lgNIAgrJzEuBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFeju7%252FK&md5=19b3fa282fb58bf492714d39207edac6</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1007%2Fs00280-014-2578-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00280-014-2578-6%26sid%3Dliteratum%253Aachs%26aulast%3DKodama%26aufirst%3DT.%26aulast%3DHasegawa%26aufirst%3DM.%26aulast%3DTakanashi%26aufirst%3DK.%26aulast%3DSakurai%26aufirst%3DY.%26aulast%3DKondoh%26aufirst%3DO.%26aulast%3DSakamoto%26aufirst%3DH.%26atitle%3DAntitumor%2520Activity%2520of%2520the%2520Selective%2520ALK%2520Inhibitor%2520Alectinib%2520in%2520Models%2520of%2520Intracranial%2520Metastases%26jtitle%3DCancer%2520Chemother.%2520Pharmacol.%26date%3D2014%26volume%3D74%26spage%3D1023%26epage%3D1028%26doi%3D10.1007%2Fs00280-014-2578-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref99"><div class="reference"><strong class="refLabel"><a href="#ref99" class="rightTabRefNumLink">99</a></strong><div class="NLM_citation" id="rightTab-cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ou, S.-H. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Petris, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Govindan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J. C.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lena, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moro-Sibilot, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bearz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramirez, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mekhail, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spira, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bordogna, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balas, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morcos, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monnet, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeaiter, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D.-W.</span></span> <span> </span><span class="NLM_article-title">Alectinib in Crizotinib-refractory ALK-rearranged Non-small Cell Lung Cancer: a Phase II Global Study</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">661</span>– <span class="NLM_lpage">668</span>, <span class="refDoi"> DOI: 10.1200/JCO.2015.63.9443</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1200%2FJCO.2015.63.9443" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=26598747" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC28Xpt1Oqsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2016&pages=661-668&author=S.-H.+I.+Ouauthor=J.+S.+Ahnauthor=L.+De+Petrisauthor=R.+Govindanauthor=J.+C.-H.+Yangauthor=B.+Hughesauthor=H.+Lenaauthor=D.+Moro-Sibilotauthor=A.+Bearzauthor=S.+V.+Ramirezauthor=T.+Mekhailauthor=A.+Spiraauthor=W.+Bordognaauthor=B.+Balasauthor=P.+N.+Morcosauthor=A.+Monnetauthor=A.+Zeaiterauthor=D.-W.+Kim&title=Alectinib+in+Crizotinib-refractory+ALK-rearranged+Non-small+Cell+Lung+Cancer%3A+a+Phase+II+Global+Study&doi=10.1200%2FJCO.2015.63.9443"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">Alectinib in crizotinib-refractory ALK-rearranged non-small-cell lung cancer: a phase II global study</span></div><div class="casAuthors">Ou, Sai-Hong Ignatius; Ahn, Jin Seok; De Petris, Luigi; Govindan, Ramaswamy; Yang, James Chih-Hsin; Hughes, Brett; Lena, Herve; Moro-Sibilot, Denis; Bearz, Alessandra; Ramirez, Santiago Viteri; Mekhail, Tarek; Spira, Alexander; Bordogna, Walter; Balas, Bogdana; Morcos, Peter N.; Monnet, Annabelle; Zeaiter, Ali; Kim, Dong-Wan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">661-668</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose Crizotinib confers improved progression-free survival compared with chemotherapy in anaplastic lymphoma kinase (ALK)-rearranged non-small-cell lung cancer (NSCLC), but progression invariably occurs.  We investigated the efficacy and safety of alectinib, a potent and selective ALK inhibitor with excellent CNS penetration, in patients with crizotinib-refractory ALK-pos. NSCLC.  Patients and Methods Alectinib 600 mg was administered orally twice daily.  The primary end point was objective response rate (ORR) by central independent review committee (IRC).  Results Of the 138 patients treated, 84 patients (61%) had CNS metastases at baseline, and 122 were response evaluable (RE) by IRC.  ORR by IRC was 50% (95% CI, 41% to 59%), and the median duration of response (DOR) was 11.2 mo (95% CI, 9.6 mo to not reached).  In 96 patients (79%) previously treated with chemotherapy, the ORR was 45% (95% CI, 35% to 55%).  Median IRC-assessed progression-free survival for all 138 patients was 8.9 mo (95% CI, 5.6 to 11.3 mo).  CNS disease control rate was 83% (95% CI, 74% to 91%), and the median CNS DOR was 10.3 mo (95% CI, 7.6 to 11.2 mo).  CNS ORR in 35 patients with baseline measurable CNS lesions was 57% (95% CI, 39% to 74%).  Of the 23 patients with baseline CNS metastases (measurable or nonmeasurable) and no prior radiation, 10 (43%) had a complete CNS response.  At 12 mo, the cumulative CNS progression rate (24.8%) was lower than the cumulative non-CNS progression rate (33.2%) for all patients.  Common adverse events were constipation (33%), fatigue (26%), and peripheral edema (25%); most were grade 1 to 2.  Conclusion Alectinib is highly active and well tolerated in patients with advanced, crizotinib-refractory ALK-pos. NSCLC, including those with CNS metastases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxXslEhXXl2bVg90H21EOLACvtfcHk0lgNIAgrJzEuBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xpt1Oqsb8%253D&md5=d5ff375edc945f1a930564e3fb2a42aa</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1200%2FJCO.2015.63.9443&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2015.63.9443%26sid%3Dliteratum%253Aachs%26aulast%3DOu%26aufirst%3DS.-H.%2BI.%26aulast%3DAhn%26aufirst%3DJ.%2BS.%26aulast%3DDe%2BPetris%26aufirst%3DL.%26aulast%3DGovindan%26aufirst%3DR.%26aulast%3DYang%26aufirst%3DJ.%2BC.-H.%26aulast%3DHughes%26aufirst%3DB.%26aulast%3DLena%26aufirst%3DH.%26aulast%3DMoro-Sibilot%26aufirst%3DD.%26aulast%3DBearz%26aufirst%3DA.%26aulast%3DRamirez%26aufirst%3DS.%2BV.%26aulast%3DMekhail%26aufirst%3DT.%26aulast%3DSpira%26aufirst%3DA.%26aulast%3DBordogna%26aufirst%3DW.%26aulast%3DBalas%26aufirst%3DB.%26aulast%3DMorcos%26aufirst%3DP.%2BN.%26aulast%3DMonnet%26aufirst%3DA.%26aulast%3DZeaiter%26aufirst%3DA.%26aulast%3DKim%26aufirst%3DD.-W.%26atitle%3DAlectinib%2520in%2520Crizotinib-refractory%2520ALK-rearranged%2520Non-small%2520Cell%2520Lung%2520Cancer%253A%2520a%2520Phase%2520II%2520Global%2520Study%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2016%26volume%3D34%26spage%3D661%26epage%3D668%26doi%3D10.1200%2FJCO.2015.63.9443" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref100"><div class="reference"><strong class="refLabel"><a href="#ref100" class="rightTabRefNumLink">100</a></strong><div class="NLM_citation" id="rightTab-cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, A. T</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gandhi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gadgeel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riely, G. J</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cetnar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">West, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camidge, D R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Socinski, M. A</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiappori, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mekhail, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chao, B. H</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borghaei, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gold, K. A</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeaiter, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bordogna, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balas, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puig, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henschel, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ou, S.-H. I.</span></span> <span> </span><span class="NLM_article-title">Alectinib in ALK-positive, Crizotinib-resistant, Non-small cell Lung Cancer: a Single-group, Multicentre, Phase 2 Trial</span>. <i>Lancet Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">234</span>– <span class="NLM_lpage">242</span>, <span class="refDoi"> DOI: 10.1016/S1470-2045(15)00488-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1016%2FS1470-2045%2815%2900488-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=26708155" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitVGrtLzL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2016&pages=234-242&author=A.+T+Shawauthor=L.+Gandhiauthor=S.+Gadgeelauthor=G.+J+Rielyauthor=J.+Cetnarauthor=H.+Westauthor=D+R.+Camidgeauthor=M.+A+Socinskiauthor=A.+Chiapporiauthor=T.+Mekhailauthor=B.+H+Chaoauthor=H.+Borghaeiauthor=K.+A+Goldauthor=A.+Zeaiterauthor=W.+Bordognaauthor=B.+Balasauthor=O.+Puigauthor=V.+Henschelauthor=S.-H.+I.+Ou&title=Alectinib+in+ALK-positive%2C+Crizotinib-resistant%2C+Non-small+cell+Lung+Cancer%3A+a+Single-group%2C+Multicentre%2C+Phase+2+Trial&doi=10.1016%2FS1470-2045%2815%2900488-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial</span></div><div class="casAuthors">Shaw, Alice T.; Gandhi, Leena; Gadgeel, Shirish; Riely, Gregory J.; Cetnar, Jeremy; West, Howard; Camidge, D. Ross; Socinski, Mark A.; Chiappori, Alberto; Mekhail, Tarek; Chao, Bo H.; Borghaei, Hossein; Gold, Kathryn A.; Zeaiter, Ali; Bordogna, Walter; Balas, Bogdana; Puig, Oscar; Henschel, Volkmar; Ou, Sai-Hong Ignatius</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">234-242</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Alectinib-a highly selective, CNS-active, ALK inhibitor-showed promising clin. activity in crizotinib-naive and crizotinib-resistant patients with ALK-rearranged (ALK-pos.) non-small-cell lung cancer (NSCLC).  We aimed to assess the safety and efficacy of alectinib in patients with ALK-pos. NSCLC who progressed on previous crizotinib.  We did a phase 2 study at 27 centers in the USA and Canada.  We enrolled patients aged 18 years or older with stage IIIB-IV, ALK-pos. NSCLC who had progressed after crizotinib.  Patients were treated with oral alectinib 600 mg twice daily until progression, death, or withdrawal.  The primary endpoint was the proportion of patients achieving an objective response by an independent review committee using Response Evaluation Criteria in Solid Tumors, version 1.1.  Response endpoints were assessed in the response-evaluable population (ie, patients with measurable disease at baseline who received at least one dose of study drug), and efficacy and safety analyses were done in the intention-to-treat population (all enrolled patients).  This study is registered with ClinicalTrials.gov, no. NCT01871805.  The study is ongoing and patients are still receiving treatment.  Between Sept 4, 2013, and Aug 4, 2014, 87 patients were enrolled into the study (intention-to-treat population).  At the time of the primary anal. (median follow-up 4·8 mo [IQR 3·3-7·1]), 33 of 69 patients with measurable disease at baseline had a confirmed partial response; thus, the proportion of patients achieving an objective response by the independent review committee was 48% (95% CI 36-60).  Adverse events were predominantly grade 1 or 2, most commonly constipation (31 [36%]), fatigue (29 [33%]), myalgia (21 [24%]), and peripheral edema (20 [23%]).  The most common grade 3 and 4 adverse events were changes in lab. values, including increased blood creatine phosphokinase (seven [8%]), increased alanine aminotransferase (five [6%]), and increased aspartate aminotransferase (four [5%]).  Two patients died: one had a hemorrhage (judged related to study treatment), and one had disease progression and a history of stroke (judged unrelated to treatment).  Alectinib showed clin. activity and was well tolerated in patients with ALK-pos. NSCLC who had progressed on crizotinib.  Therefore, alectinib could be a suitable treatment for patients with ALK-pos. disease who have progressed on crizotinib.F Hoffmann-La Roche.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoG8mULfydoWbVg90H21EOLACvtfcHk0ljvyC9C6yzg1A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitVGrtLzL&md5=5d1fb42c02d26aa8b99c29442a36e2ed</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2815%2900488-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252815%252900488-X%26sid%3Dliteratum%253Aachs%26aulast%3DShaw%26aufirst%3DA.%2BT%26aulast%3DGandhi%26aufirst%3DL.%26aulast%3DGadgeel%26aufirst%3DS.%26aulast%3DRiely%26aufirst%3DG.%2BJ%26aulast%3DCetnar%26aufirst%3DJ.%26aulast%3DWest%26aufirst%3DH.%26aulast%3DCamidge%26aufirst%3DD%2BR.%26aulast%3DSocinski%26aufirst%3DM.%2BA%26aulast%3DChiappori%26aufirst%3DA.%26aulast%3DMekhail%26aufirst%3DT.%26aulast%3DChao%26aufirst%3DB.%2BH%26aulast%3DBorghaei%26aufirst%3DH.%26aulast%3DGold%26aufirst%3DK.%2BA%26aulast%3DZeaiter%26aufirst%3DA.%26aulast%3DBordogna%26aufirst%3DW.%26aulast%3DBalas%26aufirst%3DB.%26aulast%3DPuig%26aufirst%3DO.%26aulast%3DHenschel%26aufirst%3DV.%26aulast%3DOu%26aufirst%3DS.-H.%2BI.%26atitle%3DAlectinib%2520in%2520ALK-positive%252C%2520Crizotinib-resistant%252C%2520Non-small%2520cell%2520Lung%2520Cancer%253A%2520a%2520Single-group%252C%2520Multicentre%252C%2520Phase%25202%2520Trial%26jtitle%3DLancet%2520Oncol.%26date%3D2016%26volume%3D17%26spage%3D234%26epage%3D242%26doi%3D10.1016%2FS1470-2045%2815%2900488-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref101"><div class="reference"><strong class="refLabel"><a href="#ref101" class="rightTabRefNumLink">101</a></strong><div class="NLM_citation" id="rightTab-cit101"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hida, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nokihara, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kondo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Azuma, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takiguchi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishio, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshioka, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imamura, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hotta, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goto, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Satouchi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozuki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shukuya, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakagawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitsudomi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asakawa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asabe, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamura, T.</span></span> <span> </span><span class="NLM_article-title">Alectinib versus Crizotinib in Patients with ALK-positive Non-small-cell Lung Cancer (J-ALEX): an Open-label, Randomised Phase 3 trial</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>390</i></span>,  <span class="NLM_fpage">29</span>– <span class="NLM_lpage">39</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(17)30565-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1016%2FS0140-6736%2817%2930565-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=28501140" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC2sXns1yhsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=390&publication_year=2017&pages=29-39&author=T.+Hidaauthor=H.+Nokiharaauthor=M.+Kondoauthor=Y.+H.+Kimauthor=K.+Azumaauthor=T.+Setoauthor=Y.+Takiguchiauthor=M.+Nishioauthor=H.+Yoshiokaauthor=F.+Imamuraauthor=K.+Hottaauthor=S.+Watanabeauthor=K.+Gotoauthor=M.+Satouchiauthor=T.+Kozukiauthor=T.+Shukuyaauthor=K.+Nakagawaauthor=T.+Mitsudomiauthor=N.+Yamamotoauthor=T.+Asakawaauthor=R.+Asabeauthor=T.+Tanakaauthor=T.+Tamura&title=Alectinib+versus+Crizotinib+in+Patients+with+ALK-positive+Non-small-cell+Lung+Cancer+%28J-ALEX%29%3A+an+Open-label%2C+Randomised+Phase+3+trial&doi=10.1016%2FS0140-6736%2817%2930565-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial</span></div><div class="casAuthors">Hida, Toyoaki; Nokihara, Hiroshi; Kondo, Masashi; Kim, Young Hak; Azuma, Koichi; Seto, Takashi; Takiguchi, Yuichi; Nishio, Makoto; Yoshioka, Hiroshige; Imamura, Fumio; Hotta, Katsuyuki; Watanabe, Satoshi; Goto, Koichi; Satouchi, Miyako; Kozuki, Toshiyuki; Shukuya, Takehito; Nakagawa, Kazuhiko; Mitsudomi, Tetsuya; Yamamoto, Nobuyuki; Asakawa, Takashi; Asabe, Ryoichi; Tanaka, Tomohiro; Tamura, Tomohide</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">390</span>
        (<span class="NLM_cas:issue">10089</span>),
    <span class="NLM_cas:pages">29-39</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Alectinib, a potent, highly selective, CNS-active inhibitor of anaplastic lymphoma kinase (ALK), showed promising efficacy and tolerability in the single-arm phase 1/2 AF-001JP trial in Japanese patients with ALK-pos. non-small-cell lung cancer.  Given those promising results, we did a phase 3 trial to directly compare the efficacy and safety of alectinib and crizotinib.  J-ALEX was a randomized, open-label, phase 3 trial that recruited ALK inhibitor-naive Japanese patients with ALK-pos. non-small-cell lung cancer, who were chemotherapy-naive or had received one previous chemotherapy regimen, from 41 study sites in Japan.  Patients were randomly assigned (1:1) via an interactive web response system using a permuted-block method stratified by Eastern Cooperative Oncol. Group performance status, treatment line, and disease stage to receive oral alectinib 300 mg twice daily or crizotinib 250 mg twice daily until progressive disease, unacceptable toxicity, death, or withdrawal.  The primary endpoint was progression-free survival assessed by an independent review facility.  The efficacy anal. was done in the intention-to-treat population, and safety analyses were done in all patients who received at least one dose of the study drug.  The study is ongoing and patient recruitment is closed.  This study is registered with the Japan Pharmaceutical Information Center (no. JapicCTI-132316).  Between Nov 18, 2013, and Aug 4, 2015, 207 patients were recruited and assigned to the alectinib (n=103) or crizotinib (n=104) groups.  At data cutoff for the second interim anal., 24 patients in the alectinib group had discontinued treatment compared with 61 in the crizotinib group, mostly due to lack of efficacy or adverse events.  At the second interim anal. (data cutoff date Dec 3, 2015), an independent data monitoring committee detd. that the primary endpoint of the study had been met (hazard ratio 0·34 [99·7% CI 0·17-0·71], stratified log-rank p<0·0001) and recommended an immediate release of the data.  Median progression-free survival had not yet been reached with alectinib (95% CI 20·3-not estd.) and was 10·2 mo (8·2-12·0) with crizotinib.  Grade 3 or 4 adverse events occurred at a greater frequency with crizotinib (54 [52%] of 104) than alectinib (27 [26%] of 103).  Dose interruptions due to adverse events were also more prevalent with crizotinib (77 [74%] of 104) than with alectinib (30 [29%] of 103), and more patients receiving crizotinib (21 [20%]) than alectinib (nine [9%]) discontinued the study drug because of an adverse event.  No adverse events with a fatal outcome occurred in either treatment group.  These results provide the first head-to-head comparison of alectinib and crizotinib and have the potential to change the std. of care for the first-line treatment of ALK-pos. non-small-cell lung cancer.  The dose of alectinib (300 mg twice daily) used in this study is lower than the approved dose in countries other than Japan; however, this limitation is being addressed in the ongoing ALEX study.Chugai Pharmaceutical Co, Ltd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoyh_vdatHGGrVg90H21EOLACvtfcHk0ljvyC9C6yzg1A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXns1yhsb8%253D&md5=aabae96d2acd1e4f9e4a5a1041fe04c6</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2817%2930565-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252817%252930565-2%26sid%3Dliteratum%253Aachs%26aulast%3DHida%26aufirst%3DT.%26aulast%3DNokihara%26aufirst%3DH.%26aulast%3DKondo%26aufirst%3DM.%26aulast%3DKim%26aufirst%3DY.%2BH.%26aulast%3DAzuma%26aufirst%3DK.%26aulast%3DSeto%26aufirst%3DT.%26aulast%3DTakiguchi%26aufirst%3DY.%26aulast%3DNishio%26aufirst%3DM.%26aulast%3DYoshioka%26aufirst%3DH.%26aulast%3DImamura%26aufirst%3DF.%26aulast%3DHotta%26aufirst%3DK.%26aulast%3DWatanabe%26aufirst%3DS.%26aulast%3DGoto%26aufirst%3DK.%26aulast%3DSatouchi%26aufirst%3DM.%26aulast%3DKozuki%26aufirst%3DT.%26aulast%3DShukuya%26aufirst%3DT.%26aulast%3DNakagawa%26aufirst%3DK.%26aulast%3DMitsudomi%26aufirst%3DT.%26aulast%3DYamamoto%26aufirst%3DN.%26aulast%3DAsakawa%26aufirst%3DT.%26aulast%3DAsabe%26aufirst%3DR.%26aulast%3DTanaka%26aufirst%3DT.%26aulast%3DTamura%26aufirst%3DT.%26atitle%3DAlectinib%2520versus%2520Crizotinib%2520in%2520Patients%2520with%2520ALK-positive%2520Non-small-cell%2520Lung%2520Cancer%2520%2528J-ALEX%2529%253A%2520an%2520Open-label%252C%2520Randomised%2520Phase%25203%2520trial%26jtitle%3DLancet%26date%3D2017%26volume%3D390%26spage%3D29%26epage%3D39%26doi%3D10.1016%2FS0140-6736%2817%2930565-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref102"><div class="reference"><strong class="refLabel"><a href="#ref102" class="rightTabRefNumLink">102</a></strong><div class="NLM_citation" id="rightTab-cit102"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J. C.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ou, S.-H. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Petris, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gadgeel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gandhi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barlesi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Govindan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dingemans, A.-M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crino, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lena, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Popat, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dansin, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golding, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bordogna, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balas, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morcos, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeaiter, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, A. T.</span></span> <span> </span><span class="NLM_article-title">Pooled Systemic Efficacy and Safety Data from the Pivotal Phase II Studies (NP28673 and NP28761) of Alectinib in ALK-positive Non-small Cell Lung Cancer</span>. <i>J. Thorac. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">1552</span>– <span class="NLM_lpage">1560</span>, <span class="refDoi"> DOI: 10.1016/j.jtho.2017.06.070</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1016%2Fj.jtho.2017.06.070" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=28689043" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A280%3ADC%252BC1cjlslSnug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2017&pages=1552-1560&author=J.+C.-H.+Yangauthor=S.-H.+I.+Ouauthor=L.+De+Petrisauthor=S.+Gadgeelauthor=L.+Gandhiauthor=D.-W.+Kimauthor=F.+Barlesiauthor=R.+Govindanauthor=A.-M.+C.+Dingemansauthor=L.+Crinoauthor=H.+Lenaauthor=S.+Popatauthor=J.+S.+Ahnauthor=E.+Dansinauthor=S.+Goldingauthor=W.+Bordognaauthor=B.+Balasauthor=P.+N.+Morcosauthor=A.+Zeaiterauthor=A.+T.+Shaw&title=Pooled+Systemic+Efficacy+and+Safety+Data+from+the+Pivotal+Phase+II+Studies+%28NP28673+and+NP28761%29+of+Alectinib+in+ALK-positive+Non-small+Cell+Lung+Cancer&doi=10.1016%2Fj.jtho.2017.06.070"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit102R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">Pooled Systemic Efficacy and Safety Data from the Pivotal Phase II Studies (NP28673 and NP28761) of Alectinib in ALK-positive Non-Small Cell Lung Cancer</span></div><div class="casAuthors">Yang James Chih-Hsin; Ou Sai-Hong Ignatius; De Petris Luigi; Gadgeel Shirish; Gandhi Leena; Kim Dong-Wan; Barlesi Fabrice; Govindan Ramaswamy; Dingemans Anne-Marie C; Crino Lucio; Lena Herve; Popat Sanjay; Ahn Jin Seok; Dansin Eric; Golding Sophie; Bordogna Walter; Balas Bogdana; Zeaiter Ali; Morcos Peter N; Shaw Alice T</div><div class="citationInfo"><span class="NLM_cas:title">Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1552-1560</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">INTRODUCTION:  Alectinib demonstrated clinical efficacy and an acceptable safety profile in two phase II studies (NP28761 and NP28673).  Here we report the pooled efficacy and safety data after 15 and 18 months more follow-up than in the respective primary analyses.  METHODS:  Enrolled patients had ALK receptor tyrosine kinase gene (ALK)-positive NSCLC and had progressed while taking, or could not tolerate, crizotinib.  Patients received oral alectinib, 600 mg twice daily.  The primary end point in both studies was objective response rate assessed by an independent review committee (IRC) using the Response Evaluation Criteria in Solid Tumors, version 1.1.  Secondary end points included disease control rate, duration of response, progression-free survival, overall survival, and safety.  RESULTS:  The pooled data set included 225 patients (n = 138 in NP28673 and n = 87 in NP28761).  The response-evaluable population included 189 patients (84% [n = 122 in NP28673 and n = 67 in NP28761]).  In the response-evaluable population, objective response rate as assessed by the IRC was 51.3% (95% confidence interval [CI]: 44.0-58.6 [all PRs]), the disease control rate was 78.8% (95% CI: 72.3-84.4), and the median duration of response was 14.9 months (95% CI: 11.1-20.4) after 58% of events.  Median progression-free survival as assessed by the IRC was 8.3 months (95% CI: 7.0-11.3) and median overall survival was 26.0 months (95% CI: 21.4-not estimable).  Grade 3 or higher adverse events (AEs) occurred in 40% of patients, 6% of patients had treatment withdrawn on account of AEs, and 33% had AEs leading to dose interruptions/modification.  CONCLUSIONS:  This pooled data analysis confirmed the robust systemic efficacy of alectinib in ALK-positive NSCLC with a durable response rate.  Alectinib also had an acceptable safety profile with a longer duration of follow-up.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSKYNXogQ0TxJHZzFRCXxVKfW6udTcc2eZF7GIyXksw17ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cjlslSnug%253D%253D&md5=6e811162d59e5c66ce21ceef64479b02</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1016%2Fj.jtho.2017.06.070&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jtho.2017.06.070%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DJ.%2BC.-H.%26aulast%3DOu%26aufirst%3DS.-H.%2BI.%26aulast%3DDe%2BPetris%26aufirst%3DL.%26aulast%3DGadgeel%26aufirst%3DS.%26aulast%3DGandhi%26aufirst%3DL.%26aulast%3DKim%26aufirst%3DD.-W.%26aulast%3DBarlesi%26aufirst%3DF.%26aulast%3DGovindan%26aufirst%3DR.%26aulast%3DDingemans%26aufirst%3DA.-M.%2BC.%26aulast%3DCrino%26aufirst%3DL.%26aulast%3DLena%26aufirst%3DH.%26aulast%3DPopat%26aufirst%3DS.%26aulast%3DAhn%26aufirst%3DJ.%2BS.%26aulast%3DDansin%26aufirst%3DE.%26aulast%3DGolding%26aufirst%3DS.%26aulast%3DBordogna%26aufirst%3DW.%26aulast%3DBalas%26aufirst%3DB.%26aulast%3DMorcos%26aufirst%3DP.%2BN.%26aulast%3DZeaiter%26aufirst%3DA.%26aulast%3DShaw%26aufirst%3DA.%2BT.%26atitle%3DPooled%2520Systemic%2520Efficacy%2520and%2520Safety%2520Data%2520from%2520the%2520Pivotal%2520Phase%2520II%2520Studies%2520%2528NP28673%2520and%2520NP28761%2529%2520of%2520Alectinib%2520in%2520ALK-positive%2520Non-small%2520Cell%2520Lung%2520Cancer%26jtitle%3DJ.%2520Thorac.%2520Oncol.%26date%3D2017%26volume%3D12%26spage%3D1552%26epage%3D1560%26doi%3D10.1016%2Fj.jtho.2017.06.070" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref103"><div class="reference"><strong class="refLabel"><a href="#ref103" class="rightTabRefNumLink">103</a></strong><div class="NLM_citation" id="rightTab-cit103"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riely, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, A. T.</span></span> <span> </span><span class="NLM_article-title">Targeting ALK: Precision Medicine Takes on Drug Resistance</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">137</span>– <span class="NLM_lpage">155</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-16-1123</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1158%2F2159-8290.CD-16-1123" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=28122866" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC2sXitVCjs7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&pages=137-155&author=J.+J.+Linauthor=G.+J.+Rielyauthor=A.+T.+Shaw&title=Targeting+ALK%3A+Precision+Medicine+Takes+on+Drug+Resistance&doi=10.1158%2F2159-8290.CD-16-1123"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting ALK: Precision Medicine Takes on Drug Resistance</span></div><div class="casAuthors">Lin, Jessica J.; Riely, Gregory J.; Shaw, Alice T.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">137-155</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Anaplastic lymphoma kinase (ALK) is a validated mol. target in several ALK-rearranged malignancies, including non-small cell lung cancer.  However, the clin. benefit of targeting ALK using tyrosine kinase inhibitors (TKI) is almost universally limited by the emergence of drug resistance.  Diverse mechanisms of resistance to ALK TKIs have now been discovered, and these basic mechanisms are informing the development of novel therapeutic strategies to overcome resistance in the clinic.  In this review, we summarize the current successes and challenges of targeting ALK.  Significance: Effective long-term treatment of ALK-rearranged cancers requires a mechanistic understanding of resistance to ALK TKIs so that rational therapies can be selected to combat resistance.  This review underscores the importance of serial biopsies in capturing the dynamic therapeutic vulnerabilities within a patient's tumor and offers a perspective into the complexity of on-target and off-target ALK TKI resistance mechanisms.  Therapeutic strategies that can successfully overcome, and potentially prevent, these resistance mechanisms will have the greatest impact on patient outcome.  Cancer Discov; 7(2); 137-55. ©2017 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLmMz7s4fYu7Vg90H21EOLACvtfcHk0lj3tElfJGWl4w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXitVCjs7c%253D&md5=6f7d5358d13c75b215b0d1e6ce8ac8ff</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-16-1123&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-16-1123%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DJ.%2BJ.%26aulast%3DRiely%26aufirst%3DG.%2BJ.%26aulast%3DShaw%26aufirst%3DA.%2BT.%26atitle%3DTargeting%2520ALK%253A%2520Precision%2520Medicine%2520Takes%2520on%2520Drug%2520Resistance%26jtitle%3DCancer%2520Discovery%26date%3D2017%26volume%3D7%26spage%3D137%26epage%3D155%26doi%3D10.1158%2F2159-8290.CD-16-1123" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref104"><div class="reference"><strong class="refLabel"><a href="#ref104" class="rightTabRefNumLink">104</a></strong><div class="NLM_citation" id="rightTab-cit104"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Qian, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liebman, M.</span></span> <span> </span><span class="NLM_article-title">Drug Resistance in ALK-positive Non-small Cell Lung Cancer Patients</span>. <i>Semin. Cell Dev. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">150</span>– <span class="NLM_lpage">157</span>, <span class="refDoi"> DOI: 10.1016/j.semcdb.2016.09.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1016%2Fj.semcdb.2016.09.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=27693505" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhs1Cgu7%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2017&pages=150-157&author=M.+Qianauthor=B.+Zhuauthor=X.+Wangauthor=M.+Liebman&title=Drug+Resistance+in+ALK-positive+Non-small+Cell+Lung+Cancer+Patients&doi=10.1016%2Fj.semcdb.2016.09.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit104R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">Drug resistance in ALK-positive Non-small cell lung cancer patients</span></div><div class="casAuthors">Qian, Mengjia; Zhu, Bijun; Wang, Xiangdong; Liebman, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Seminars in Cell & Developmental Biology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">150-157</span>CODEN:
                <span class="NLM_cas:coden">SCDBFX</span>;
        ISSN:<span class="NLM_cas:issn">1084-9521</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Patients are diagnosed as anaplastic lymphoma kinase (ALK) pos., i.e. exhibiting the ALK rearrangement, and comprise 3-7% of non-small-cell lung cancer (NSCLC) cases.  Three generations of ALK inhibitors have been developed and used in targeted therapy, although there are still improving spaces of drug resistance at the initiation of each treatment.  The current review discusses the pathophysiol. of ALK-pos. NSCLC and the role of three generations of ALK target inhibitors including crizotinib, ceritinib, alectinib and lorlatinib, as well as the mechanisms of the secondary resistance.  We mainly focused on the point mutations that are the most important resistance-producing mechanism and most common form caused by each inhibitor.  In addn., we examine the three-dimensional structure of ALK to understand the functional impact of these mutations and analyze the underlying mol. mechanisms of the resistance to each generation of ALK inhibitor to benefit the selection decision of the most rational therapy and improve therapeutic effects to the disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOXTnzPNyv8rVg90H21EOLACvtfcHk0lj3tElfJGWl4w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhs1Cgu7%252FN&md5=6e8f364568b5fa51ea521b30a2d654f6</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1016%2Fj.semcdb.2016.09.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.semcdb.2016.09.016%26sid%3Dliteratum%253Aachs%26aulast%3DQian%26aufirst%3DM.%26aulast%3DZhu%26aufirst%3DB.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DLiebman%26aufirst%3DM.%26atitle%3DDrug%2520Resistance%2520in%2520ALK-positive%2520Non-small%2520Cell%2520Lung%2520Cancer%2520Patients%26jtitle%3DSemin.%2520Cell%2520Dev.%2520Biol.%26date%3D2017%26volume%3D64%26spage%3D150%26epage%3D157%26doi%3D10.1016%2Fj.semcdb.2016.09.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref105"><div class="reference"><strong class="refLabel"><a href="#ref105" class="rightTabRefNumLink">105</a></strong><div class="NLM_citation" id="rightTab-cit105"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tiseo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, M.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reckamp, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansen, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huber, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">West, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groen, H. J.M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hochmair, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leighl, N. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gettinger, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langer, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paz-Ares Rodriguez, L. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smit, E. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reichmann, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haluska, F. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kerstein, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camidge, D. R.</span></span> <span> </span><span class="NLM_article-title">Brigatinib in Patients with Crizotinib-refractory Anaplastic Lymphoma Kinase-positive Non-small-cell Lung Cancer: a Randomized, Multicenter Phase II Trial</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">2490</span>– <span class="NLM_lpage">2498</span>, <span class="refDoi"> DOI: 10.1200/JCO.2016.71.5904</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1200%2FJCO.2016.71.5904" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=28475456" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitVSqsbfK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2017&pages=2490-2498&author=D.-W.+Kimauthor=M.+Tiseoauthor=M.-J.+Ahnauthor=K.+L.+Reckampauthor=K.+H.+Hansenauthor=S.-W.+Kimauthor=R.+M.+Huberauthor=H.+L.+Westauthor=H.+J.M.+Groenauthor=M.+J.+Hochmairauthor=N.+B.+Leighlauthor=S.+N.+Gettingerauthor=C.+J.+Langerauthor=L.+G.+Paz-Ares+Rodriguezauthor=E.+F.+Smitauthor=E.+S.+Kimauthor=W.+Reichmannauthor=F.+G.+Haluskaauthor=D.+Kersteinauthor=D.+R.+Camidge&title=Brigatinib+in+Patients+with+Crizotinib-refractory+Anaplastic+Lymphoma+Kinase-positive+Non-small-cell+Lung+Cancer%3A+a+Randomized%2C+Multicenter+Phase+II+Trial&doi=10.1200%2FJCO.2016.71.5904"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit105R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">Brigatinib in patients with crizotinib-refractory anaplastic lymphoma kinase-positive non-small-cell lung cancer: a randomized, multicenter phase II trial</span></div><div class="casAuthors">Kim, Dong-Wan; Tiseo, Marcello; Ahn, Myung-Ju; Reckamp, Karen L.; Hansen, Karin Holmskov; Kim, Sang-We; Huber, Rudolf M.; West, Howard L.; Groen, Harry J. M.; Hochmair, Maximilian J.; Leighl, Natasha B.; Gettinger, Scott N.; Langer, Corey J.; Rodr'iguez, Luis G. Paz-Ares; Smit, Egbert F.; Kim, Edward S.; Reichmann, William; Haluska, Frank G.; Kerstein, David; Camidge, D. Ross</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">2490-2500</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">1527-7755</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: Most crizotinib-treated patients with anaplastic lymphoma kinase gene (ALK)-rearranged non-smallcell lung cancer (ALK-pos. NSCLC) eventually experience disease progression.  We evaluated two regimens of brigatinib, an investigational next-generation ALK inhibitor, in crizotinib-refractory ALK-pos. NSCLC.  Patients and Methods Patients were stratified by brain metastases and best response to crizotinib.  They were randomly assigned (1:1) to oral brigatinib 90 mg once daily (arm A) or 180 mg once daily with a 7-day lead-in at 90 mg (180 mg once daily [with lead-in]; arm B).  Investigator-assessed confirmed objective response rate (ORR) was the primary end point.  Results Of 222 patients enrolled (arm A: n = 112, 109 treated; arm B: n = 110, 110 treated), 154 (69%) had baseline brain metastases and 164 of 222 (74%) had received prior chemotherapy.  With 8.0-mo median follow-up, investigator-assessed confirmed ORR was 45% (97.5% CI, 34% to 56%) in arm A and 54% (97.5% CI, 43% to 65%) in arm B.  Investigator-assessed median progression-free survival was 9.2 mo (95% CI, 7.4 to 15.6) and 12.9 mo (95% CI, 11.1 to not reached) in arms A and B, resp.  Independent review committee-assessed intracranial ORR in patients with measurable brain metastases at baseline was 42% (11 of 26 patients) in arm A and 67% (12 of 18 patients) in arm B.  Common treatment-emergent adverse events were nausea (arm A/B, 33%/ 40%), diarrhea (arm A/B, 19%/38%), headache (arm A/B, 28%/27%), and cough (arm A/B, 18%/ 34%), and were mainly grades 1 to 2.  A subset of pulmonary adverse events with early onset (median onset: day 2) occurred in 14 of 219 treated patients (all grades, 6%; grade $ 3, 3%); none occurred after escalation to 180 mg in arm B.  Seven of 14 patients were successfully retreated with brigatinib.  Conclusion Brigatinib yielded substantial whole-body and intracranial responses as well as robust progressionfree survival; 180 mg (with lead-in) showed consistently better efficacy than 90 mg, with acceptable safety.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4RtdJwkNkyLVg90H21EOLACvtfcHk0lgrcJttmPKrgQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitVSqsbfK&md5=efe68d35d297c3d9e70023f887c23a2c</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1200%2FJCO.2016.71.5904&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2016.71.5904%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DD.-W.%26aulast%3DTiseo%26aufirst%3DM.%26aulast%3DAhn%26aufirst%3DM.-J.%26aulast%3DReckamp%26aufirst%3DK.%2BL.%26aulast%3DHansen%26aufirst%3DK.%2BH.%26aulast%3DKim%26aufirst%3DS.-W.%26aulast%3DHuber%26aufirst%3DR.%2BM.%26aulast%3DWest%26aufirst%3DH.%2BL.%26aulast%3DGroen%26aufirst%3DH.%2BJ.M.%26aulast%3DHochmair%26aufirst%3DM.%2BJ.%26aulast%3DLeighl%26aufirst%3DN.%2BB.%26aulast%3DGettinger%26aufirst%3DS.%2BN.%26aulast%3DLanger%26aufirst%3DC.%2BJ.%26aulast%3DPaz-Ares%2BRodriguez%26aufirst%3DL.%2BG.%26aulast%3DSmit%26aufirst%3DE.%2BF.%26aulast%3DKim%26aufirst%3DE.%2BS.%26aulast%3DReichmann%26aufirst%3DW.%26aulast%3DHaluska%26aufirst%3DF.%2BG.%26aulast%3DKerstein%26aufirst%3DD.%26aulast%3DCamidge%26aufirst%3DD.%2BR.%26atitle%3DBrigatinib%2520in%2520Patients%2520with%2520Crizotinib-refractory%2520Anaplastic%2520Lymphoma%2520Kinase-positive%2520Non-small-cell%2520Lung%2520Cancer%253A%2520a%2520Randomized%252C%2520Multicenter%2520Phase%2520II%2520Trial%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2017%26volume%3D35%26spage%3D2490%26epage%3D2498%26doi%3D10.1200%2FJCO.2016.71.5904" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref106"><div class="reference"><strong class="refLabel"><a href="#ref106" class="rightTabRefNumLink">106</a></strong><div class="NLM_citation" id="rightTab-cit106"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Markham, A.</span></span> <span> </span><span class="NLM_article-title">Brigatinib: First Global Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>77</i></span>,  <span class="NLM_fpage">1131</span>– <span class="NLM_lpage">1135</span>, <span class="refDoi"> DOI: 10.1007/s40265-017-0776-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1007%2Fs40265-017-0776-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=28597393" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtVOjsrzL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2017&pages=1131-1135&author=A.+Markham&title=Brigatinib%3A+First+Global+Approval&doi=10.1007%2Fs40265-017-0776-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">Brigatinib: First Global Approval</span></div><div class="casAuthors">Markham, Anthony</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1131-1135</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Brigatinib (ALUNBRIG) is a small mol. antineoplastic anaplastic lymphoma kinase (ALK) inhibitor being developed by ARIAD Pharmaceuticals (a wholly-owned subsidiary of Takeda Pharmaceutical Company).  In Apr. 2017 brigatinib received accelerated approval in the USA for the treatment of patients with ALK-pos. metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib.  The development of resistance to crizotinib is a therapeutic challenge that has led to the development of second-generation ALK-inhibitors such as brigatinib, which have activity against treatment-resistant ALK mutants.  This article summarizes the milestones in the development of brigatinib leading to this first global approval for the treatment of patients with ALK-pos. metastatic NSCLC who have progressed on or are intolerant to crizotinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmmCYwTukZCLVg90H21EOLACvtfcHk0lgrcJttmPKrgQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtVOjsrzL&md5=c03f9d61e8e8fd4187d47ee207452f31</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1007%2Fs40265-017-0776-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-017-0776-3%26sid%3Dliteratum%253Aachs%26aulast%3DMarkham%26aufirst%3DA.%26atitle%3DBrigatinib%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2017%26volume%3D77%26spage%3D1131%26epage%3D1135%26doi%3D10.1007%2Fs40265-017-0776-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref107"><div class="reference"><strong class="refLabel"><a href="#ref107" class="rightTabRefNumLink">107</a></strong><div class="NLM_citation" id="rightTab-cit107"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Friboulet, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katayama, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gainor, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crystal, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michellys, P.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Awad, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yanagitani, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pferdekamper, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kasibhatla, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hua, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNamara, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahmood, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lockerman, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujita, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishio, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engelman, J. A.</span></span> <span> </span><span class="NLM_article-title">The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non–small Cell Lung Cancer</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">662</span>– <span class="NLM_lpage">673</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-13-0846</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1158%2F2159-8290.CD-13-0846" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=24675041" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC2cXpsVGgs78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2014&pages=662-673&author=L.+Fribouletauthor=N.+Liauthor=R.+Katayamaauthor=C.+C.+Leeauthor=J.+F.+Gainorauthor=A.+S.+Crystalauthor=P.-Y.+Michellysauthor=M.+M.+Awadauthor=N.+Yanagitaniauthor=S.+Kimauthor=A.+C.+Pferdekamperauthor=J.+Liauthor=S.+Kasibhatlaauthor=F.+Sunauthor=X.+Sunauthor=S.+Huaauthor=P.+McNamaraauthor=S.+Mahmoodauthor=E.+L.+Lockermanauthor=N.+Fujitaauthor=M.+Nishioauthor=J.+L.+Harrisauthor=A.+T.+Shawauthor=J.+A.+Engelman&title=The+ALK+Inhibitor+Ceritinib+Overcomes+Crizotinib+Resistance+in+Non%E2%80%93small+Cell+Lung+Cancer&doi=10.1158%2F2159-8290.CD-13-0846"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit107R"><div class="casContent"><span class="casTitleNuber">107</span><div class="casTitle"><span class="NLM_cas:atitle">The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non-Small Cell Lung Cancer</span></div><div class="casAuthors">Friboulet, Luc; Li, Nanxin; Katayama, Ryohei; Lee, Christian C.; Gainor, Justin F.; Crystal, Adam S.; Michellys, Pierre-Yves; Awad, Mark M.; Yanagitani, Noriko; Kim, Sungjoon; Pferdekamper, AnneMarie C.; Li, Jie; Kasibhatla, Shailaja; Sun, Frank; Sun, Xiuying; Hua, Su; McNamara, Peter; Mahmood, Sidra; Lockerman, Elizabeth L.; Fujita, Naoya; Nishio, Makoto; Harris, Jennifer L.; Shaw, Alice T.; Engelman, Jeffrey A.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">662-673</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Non-small cell lung cancers (NSCLC) harboring anaplastic lymphoma kinase (ALK) gene rearrangements invariably develop resistance to the ALK tyrosine kinase inhibitor (TKI) crizotinib.  Herein, we report the first preclin. evaluation of the next-generation ALK TKI, ceritinib (LDKB78), in the setting of crizotinib resistance.  An interrogation of in vitro and in vivo models of acquired resistance to crizotinib, including cell lines established from biopsies of patients with crizotinib-resistant NSCLC, revealed that ceritinib potently overcomes crizotinib-resistant mutations.  In particular, ceritinib effectively inhibits ALK harboring L1196M, G1269A, 11171T1 and S1206Y mutations, and a cocrystal structure of ceritinib bound to ALK provides structural bases for this increased potency.  However, we obsd. that ceritinib did not overcome two crizotinib-resistant ALK mutations, G1202R and F1174C, and one of these mutations was identified in 5 of 11 biopsies from patients with acquired resistance to ceritinib.  Altogether, our results demonstrate that ceritinib can overcome crizotinib resistance, consistent with clin. data showing marked efficacy of ceritinib in patients with crizotinib-resistant disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrRf8PgZpJ60bVg90H21EOLACvtfcHk0lgrcJttmPKrgQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXpsVGgs78%253D&md5=f60c45d0debfa6e86ff10c758c95da8d</span></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-13-0846&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-13-0846%26sid%3Dliteratum%253Aachs%26aulast%3DFriboulet%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DN.%26aulast%3DKatayama%26aufirst%3DR.%26aulast%3DLee%26aufirst%3DC.%2BC.%26aulast%3DGainor%26aufirst%3DJ.%2BF.%26aulast%3DCrystal%26aufirst%3DA.%2BS.%26aulast%3DMichellys%26aufirst%3DP.-Y.%26aulast%3DAwad%26aufirst%3DM.%2BM.%26aulast%3DYanagitani%26aufirst%3DN.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DPferdekamper%26aufirst%3DA.%2BC.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DKasibhatla%26aufirst%3DS.%26aulast%3DSun%26aufirst%3DF.%26aulast%3DSun%26aufirst%3DX.%26aulast%3DHua%26aufirst%3DS.%26aulast%3DMcNamara%26aufirst%3DP.%26aulast%3DMahmood%26aufirst%3DS.%26aulast%3DLockerman%26aufirst%3DE.%2BL.%26aulast%3DFujita%26aufirst%3DN.%26aulast%3DNishio%26aufirst%3DM.%26aulast%3DHarris%26aufirst%3DJ.%2BL.%26aulast%3DShaw%26aufirst%3DA.%2BT.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26atitle%3DThe%2520ALK%2520Inhibitor%2520Ceritinib%2520Overcomes%2520Crizotinib%2520Resistance%2520in%2520Non%25E2%2580%2593small%2520Cell%2520Lung%2520Cancer%26jtitle%3DCancer%2520Discovery%26date%3D2014%26volume%3D4%26spage%3D662%26epage%3D673%26doi%3D10.1158%2F2159-8290.CD-13-0846" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref108"><div class="reference"><strong class="refLabel"><a href="#ref108" class="rightTabRefNumLink">108</a></strong><div class="NLM_citation" id="rightTab-cit108"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, C.</span></span> <span> </span><span class="NLM_article-title">Ceritinib (LDK378): A Potent Alternative to Crizotinib for ALK-rearranged Non–small-cell Lung Cancer</span>. <i>Clin. Lung Cancer</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">86</span>– <span class="NLM_lpage">91</span>, <span class="refDoi"> DOI: 10.1016/j.cllc.2014.09.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1016%2Fj.cllc.2014.09.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=25458559" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVGksrzE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2015&pages=86-91&author=S.+Liauthor=X.+Qiauthor=Y.+Huangauthor=D.+Liuauthor=F.+Zhouauthor=C.+Zhou&title=Ceritinib+%28LDK378%29%3A+A+Potent+Alternative+to+Crizotinib+for+ALK-rearranged+Non%E2%80%93small-cell+Lung+Cancer&doi=10.1016%2Fj.cllc.2014.09.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit108R"><div class="casContent"><span class="casTitleNuber">108</span><div class="casTitle"><span class="NLM_cas:atitle">Ceritinib (LDK378): A Potent Alternative to Crizotinib for ALK-Rearranged Non-Small-Cell Lung Cancer</span></div><div class="casAuthors">Li, Sen; Qi, Xiaolong; Huang, Yufeng; Liu, Dingfeng; Zhou, Fangyu; Zhou, Caicun</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Lung Cancer</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">86-91</span>CODEN:
                <span class="NLM_cas:coden">CLCLCA</span>;
        ISSN:<span class="NLM_cas:issn">1525-7304</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  The success in identifying the chromosomal rearrangements involving the anaplastic lymphoma kinase (ALK) as an oncogenic driver has thoroughly changed the treatment of non-small-cell lung cancer.  In the past decade, targeted drugs have emerged as an efficient personalized strategy for ALK-rearranged non-small-cell lung cancer.  The accelerated approval of potent ALK inhibitors, such as crizotinib and more recently ceritinib (LDK378), based on the well designed phase I/II trials has been a landmark success in clin. cancer research and contributes a new era of oncogenic targeted therapy characterized by elegant clin. trial design.  In this review, the authors aim to present the current knowledge on acquired resistance of crizotinib known as a first-in-class ALK inhibitor and potential solns. to improve the cost-effectiveness, and to review the difference between ceritinib and crizotinib; preclin. data and results of the elegant early clin. trial of ceritinib which promoted its accelerated approval, pharmacokinetics, safety profile, and tolerability, the updated results (eg, efficacy on brain metastases), and robust design of ongoing phase II/III trials, and future directions of ceritinib to be a potent alternative to crizotinib for ALK-rearranged non-small-cell lung cancer are also presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGorcQKb4SrB8bVg90H21EOLACvtfcHk0lg4VGuKrYA49Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVGksrzE&md5=aa7cc0221ecea1ce5dc9bb3b87a77c67</span></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1016%2Fj.cllc.2014.09.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cllc.2014.09.011%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DS.%26aulast%3DQi%26aufirst%3DX.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DD.%26aulast%3DZhou%26aufirst%3DF.%26aulast%3DZhou%26aufirst%3DC.%26atitle%3DCeritinib%2520%2528LDK378%2529%253A%2520A%2520Potent%2520Alternative%2520to%2520Crizotinib%2520for%2520ALK-rearranged%2520Non%25E2%2580%2593small-cell%2520Lung%2520Cancer%26jtitle%3DClin.%2520Lung%2520Cancer%26date%3D2015%26volume%3D16%26spage%3D86%26epage%3D91%26doi%3D10.1016%2Fj.cllc.2014.09.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref109"><div class="reference"><strong class="refLabel"><a href="#ref109" class="rightTabRefNumLink">109</a></strong><div class="NLM_citation" id="rightTab-cit109"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gainor, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dardaei, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friboulet, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leshchiner, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katayama, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dagogo-Jack, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gadgeel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schultz, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chin, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parks, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiCecca, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lockerman, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huynh, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Logan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ritterhouse, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le, L. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muniappan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Digumarthy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Channick, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keyes, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Getz, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dias-Santagata, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heist, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lennerz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sequist, L. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benes, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iafrate, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mino-Kenudson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engelman, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, A. T.</span></span> <span> </span><span class="NLM_article-title">Molecular Mechanisms of Resistance to First-and Second-generation ALK Inhibitors in ALK-rearranged Lung Cancer</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">1118</span>– <span class="NLM_lpage">1133</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-16-0596</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1158%2F2159-8290.CD-16-0596" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=27432227" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhs1OhurrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2016&pages=1118-1133&author=J.+F.+Gainorauthor=L.+Dardaeiauthor=S.+Yodaauthor=L.+Fribouletauthor=I.+Leshchinerauthor=R.+Katayamaauthor=I.+Dagogo-Jackauthor=S.+Gadgeelauthor=K.+Schultzauthor=M.+Singhauthor=E.+Chinauthor=M.+Parksauthor=D.+Leeauthor=R.+H.+DiCeccaauthor=E.+Lockermanauthor=T.+Huynhauthor=J.+Loganauthor=L.+L.+Ritterhouseauthor=L.+P.+Leauthor=A.+Muniappanauthor=S.+Digumarthyauthor=C.+Channickauthor=C.+Keyesauthor=G.+Getzauthor=D.+Dias-Santagataauthor=R.+S.+Heistauthor=J.+Lennerzauthor=L.+V.+Sequistauthor=C.+H.+Benesauthor=A.+J.+Iafrateauthor=M.+Mino-Kenudsonauthor=J.+A.+Engelmanauthor=A.+T.+Shaw&title=Molecular+Mechanisms+of+Resistance+to+First-and+Second-generation+ALK+Inhibitors+in+ALK-rearranged+Lung+Cancer&doi=10.1158%2F2159-8290.CD-16-0596"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit109R"><div class="casContent"><span class="casTitleNuber">109</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer</span></div><div class="casAuthors">Gainor, Justin F.; Dardaei, Leila; Yoda, Satoshi; Friboulet, Luc; Leshchiner, Ignaty; Katayama, Ryohei; Dagogo-Jack, Ibiayi; Gadgeel, Shirish; Schultz, Katherine; Singh, Manrose; Chin, Emily; Parks, Melissa; Lee, Dana; DiCecca, Richard H.; Lockerman, Elizabeth; Huynh, Tiffany; Logan, Jennifer; Ritterhouse, Lauren L.; Le, Long P.; Muniappan, Ashok; Digumarthy, Subba; Channick, Colleen; Keyes, Colleen; Getz, Gad; Dias-Santagata, Dora; Heist, Rebecca S.; Lennerz, Jochen; Sequist, Lecia V.; Benes, Cyril H.; Iafrate, A. John; Mino-Kenudson, Mari; Engelman, Jeffrey A.; Shaw, Alice T.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1118-1133</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Advanced, anaplastic lymphoma kinase (ALK)-pos. lung cancer is currently treated with the first-generation ALK inhibitor crizotinib followed by more potent, second-generation ALK inhibitors (e.g., ceritinib and alectinib) upon progression.  Second-generation inhibitors are generally effective even in the absence of crizotinib-resistant ALK mutations, likely reflecting incomplete inhibition of ALK by crizotinib in many cases.  Herein, we analyzed 103 repeat biopsies from ALK-pos. patients progressing on various ALK inhibitors.  We find that each ALK inhibitor is assocd. with a distinct spectrum of ALK resistance mutations and that the frequency of one mutation, ALKG1202R, increases significantly after treatment with second-generation agents.  To investigate strategies to overcome resistance to second-generation ALK inhibitors, we examine the activity of the third-generation ALK inhibitor lorlatinib in a series of ceritinib-resistant, patient-derived cell lines, and observe that the presence of ALK resistance mutations is highly predictive for sensitivity to lorlatinib, whereas those cell lines without ALK mutations are resistant.  Significance: Secondary ALK mutations are a common resistance mechanism to second-generation ALK inhibitors and predict for sensitivity to the third-generation ALK inhibitor lorlatinib.  These findings highlight the importance of repeat biopsies and genotyping following disease progression on targeted therapies, particularly second-generation ALK inhibitors.  Cancer Discov; 6(10); 1118-33. ©2016 AACR.  See related commentary by Qiao and Lovly, p. 1084.  This article is highlighted in the In This Issue feature, p.  1069.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqg_wNC_RoH0LVg90H21EOLACvtfcHk0lg4VGuKrYA49Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhs1OhurrJ&md5=e68f42dbce3f4f4de0c6d9c64f6b7b82</span></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-16-0596&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-16-0596%26sid%3Dliteratum%253Aachs%26aulast%3DGainor%26aufirst%3DJ.%2BF.%26aulast%3DDardaei%26aufirst%3DL.%26aulast%3DYoda%26aufirst%3DS.%26aulast%3DFriboulet%26aufirst%3DL.%26aulast%3DLeshchiner%26aufirst%3DI.%26aulast%3DKatayama%26aufirst%3DR.%26aulast%3DDagogo-Jack%26aufirst%3DI.%26aulast%3DGadgeel%26aufirst%3DS.%26aulast%3DSchultz%26aufirst%3DK.%26aulast%3DSingh%26aufirst%3DM.%26aulast%3DChin%26aufirst%3DE.%26aulast%3DParks%26aufirst%3DM.%26aulast%3DLee%26aufirst%3DD.%26aulast%3DDiCecca%26aufirst%3DR.%2BH.%26aulast%3DLockerman%26aufirst%3DE.%26aulast%3DHuynh%26aufirst%3DT.%26aulast%3DLogan%26aufirst%3DJ.%26aulast%3DRitterhouse%26aufirst%3DL.%2BL.%26aulast%3DLe%26aufirst%3DL.%2BP.%26aulast%3DMuniappan%26aufirst%3DA.%26aulast%3DDigumarthy%26aufirst%3DS.%26aulast%3DChannick%26aufirst%3DC.%26aulast%3DKeyes%26aufirst%3DC.%26aulast%3DGetz%26aufirst%3DG.%26aulast%3DDias-Santagata%26aufirst%3DD.%26aulast%3DHeist%26aufirst%3DR.%2BS.%26aulast%3DLennerz%26aufirst%3DJ.%26aulast%3DSequist%26aufirst%3DL.%2BV.%26aulast%3DBenes%26aufirst%3DC.%2BH.%26aulast%3DIafrate%26aufirst%3DA.%2BJ.%26aulast%3DMino-Kenudson%26aufirst%3DM.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26aulast%3DShaw%26aufirst%3DA.%2BT.%26atitle%3DMolecular%2520Mechanisms%2520of%2520Resistance%2520to%2520First-and%2520Second-generation%2520ALK%2520Inhibitors%2520in%2520ALK-rearranged%2520Lung%2520Cancer%26jtitle%3DCancer%2520Discovery%26date%3D2016%26volume%3D6%26spage%3D1118%26epage%3D1133%26doi%3D10.1158%2F2159-8290.CD-16-0596" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref110"><div class="reference"><strong class="refLabel"><a href="#ref110" class="rightTabRefNumLink">110</a></strong><div class="NLM_citation" id="rightTab-cit110"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yoda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawrence, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friboulet, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langenbucher, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dardaei, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prutisto-Chang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dagogo-Jack, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timofeevski, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hubbeling, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gainor, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferris, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riley, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kattermann, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timonina, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heist, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iafrate, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benes, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lennerz, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mino-Kenudson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engelman, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hata, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, A. T.</span></span> <span> </span><span class="NLM_article-title">Sequential ALK Inhibitors can Select for Lorlatinib-resistant Compound ALK Mutations in ALK-positive Lung Cancer</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">714</span>– <span class="NLM_lpage">729</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-17-1256</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1158%2F2159-8290.CD-17-1256" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=29650534" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVKjs7nL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2018&pages=714-729&author=S.+Yodaauthor=J.+J.+Linauthor=M.+S.+Lawrenceauthor=B.+J.+Burkeauthor=L.+Fribouletauthor=A.+Langenbucherauthor=L.+Dardaeiauthor=K.+Prutisto-Changauthor=I.+Dagogo-Jackauthor=S.+Timofeevskiauthor=H.+Hubbelingauthor=J.+F.+Gainorauthor=L.+A.+Ferrisauthor=A.+K.+Rileyauthor=K.+E.+Kattermannauthor=D.+Timoninaauthor=R.+S.+Heistauthor=A.+J.+Iafrateauthor=C.+H.+Benesauthor=J.+K.+Lennerzauthor=M.+Mino-Kenudsonauthor=J.+A.+Engelmanauthor=T.+W.+Johnsonauthor=A.+N.+Hataauthor=A.+T.+Shaw&title=Sequential+ALK+Inhibitors+can+Select+for+Lorlatinib-resistant+Compound+ALK+Mutations+in+ALK-positive+Lung+Cancer&doi=10.1158%2F2159-8290.CD-17-1256"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit110R"><div class="casContent"><span class="casTitleNuber">110</span><div class="casTitle"><span class="NLM_cas:atitle">Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung Cancer</span></div><div class="casAuthors">Yoda, Satoshi; Lin, Jessica J.; Lawrence, Michael S.; Burke, Benjamin J.; Friboulet, Luc; Langenbucher, Adam; Dardaei, Leila; Prutisto-Chang, Kylie; Dagogo-Jack, Ibiayi; Timofeevski, Sergei; Hubbeling, Harper; Gainor, Justin F.; Ferris, Lorin A.; Riley, Amanda K.; Kattermann, Krystina E.; Timonina, Daria; Heist, Rebecca S.; Iafrate, A. John; Benes, Cyril H.; Lennerz, Jochen K.; Mino-Kenudson, Mari; Engelman, Jeffrey A.; Johnson, Ted W.; Hata, Aaron N.; Shaw, Alice T.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">714-729</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The cornerstone of treatment for advanced ALK-pos. lung cancer is sequential therapy with increasingly potent and selective ALK inhibitors.  The third-generation ALK inhibitor lorlatinib has demonstrated clin. activity in patients who failed previous ALK inhibitors.  To define the spectrum of ALK mutations that confer lorlatinib resistance, we performed accelerated mutagenesis screening of Ba/F3 cells expressing EML4-ALK.  Under comparable conditions, N-ethyl-N-nitrosourea (ENU) mutagenesis generated numerous crizotinib-resistant but no lorlatinib-resistant clones harboring single ALK mutations.  In similar screens with EML4-ALK contg. single ALK resistance mutations, numerous lorlatinib-resistant clones emerged harboring compd. ALK mutations.  To det. the clin. relevance of these mutations, we analyzed repeat biopsies from lorlatinib-resistant patients.  Seven of 20 samples (35%) harbored compd. ALK mutations, including two identified in the ENU screen.  Whole-exome sequencing in three cases confirmed the stepwise accumulation of ALK mutations during sequential treatment.  These results suggest that sequential ALK inhibitors can foster the emergence of compd. ALK mutations, identification of which is crit. to informing drug design and developing effective therapeutic strategies.  Significance: Treatment with sequential first-, second-, and third-generation ALK inhibitors can select for compd. ALK mutations that confer high-level resistance to ALK-targeted therapies.  A more efficacious long-term strategy may be up-front treatment with a third-generation ALK inhibitor to prevent the emergence of on-target resistance.  Cancer Discov; 8(6); 714-29. ©2018 AACR.  This article is highlighted in the In This Issue feature, p.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYIrTj3mfqPLVg90H21EOLACvtfcHk0ljnqBbZQJhcWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVKjs7nL&md5=f9ecf4202f089ed8eb20eceeca83be16</span></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-17-1256&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-17-1256%26sid%3Dliteratum%253Aachs%26aulast%3DYoda%26aufirst%3DS.%26aulast%3DLin%26aufirst%3DJ.%2BJ.%26aulast%3DLawrence%26aufirst%3DM.%2BS.%26aulast%3DBurke%26aufirst%3DB.%2BJ.%26aulast%3DFriboulet%26aufirst%3DL.%26aulast%3DLangenbucher%26aufirst%3DA.%26aulast%3DDardaei%26aufirst%3DL.%26aulast%3DPrutisto-Chang%26aufirst%3DK.%26aulast%3DDagogo-Jack%26aufirst%3DI.%26aulast%3DTimofeevski%26aufirst%3DS.%26aulast%3DHubbeling%26aufirst%3DH.%26aulast%3DGainor%26aufirst%3DJ.%2BF.%26aulast%3DFerris%26aufirst%3DL.%2BA.%26aulast%3DRiley%26aufirst%3DA.%2BK.%26aulast%3DKattermann%26aufirst%3DK.%2BE.%26aulast%3DTimonina%26aufirst%3DD.%26aulast%3DHeist%26aufirst%3DR.%2BS.%26aulast%3DIafrate%26aufirst%3DA.%2BJ.%26aulast%3DBenes%26aufirst%3DC.%2BH.%26aulast%3DLennerz%26aufirst%3DJ.%2BK.%26aulast%3DMino-Kenudson%26aufirst%3DM.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26aulast%3DJohnson%26aufirst%3DT.%2BW.%26aulast%3DHata%26aufirst%3DA.%2BN.%26aulast%3DShaw%26aufirst%3DA.%2BT.%26atitle%3DSequential%2520ALK%2520Inhibitors%2520can%2520Select%2520for%2520Lorlatinib-resistant%2520Compound%2520ALK%2520Mutations%2520in%2520ALK-positive%2520Lung%2520Cancer%26jtitle%3DCancer%2520Discovery%26date%3D2018%26volume%3D8%26spage%3D714%26epage%3D729%26doi%3D10.1158%2F2159-8290.CD-17-1256" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref111"><div class="reference"><strong class="refLabel"><a href="#ref111" class="rightTabRefNumLink">111</a></strong><div class="NLM_citation" id="rightTab-cit111"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zou, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engstrom, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">West, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Appleman, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McTigue, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, Y.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brooun, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timofeevski, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonnell, S. R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Falk, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lappin, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Affolter, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nichols, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smeal, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charest, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fantin, V. R.</span></span> <span> </span><span class="NLM_article-title">PF-06463922 is a Potent and Selective Next-generation ROS1/ALK Inhibitor Capable of Blocking Crizotinib-resistant ROS1 Mutations</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>112</i></span>,  <span class="NLM_fpage">3493</span>– <span class="NLM_lpage">3498</span>, <span class="refDoi"> DOI: 10.1073/pnas.1420785112</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1073%2Fpnas.1420785112" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=25733882" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjs1Grur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=112&publication_year=2015&pages=3493-3498&author=H.+Y.+Zouauthor=Q.+Liauthor=L.+D.+Engstromauthor=M.+Westauthor=V.+Applemanauthor=K.+A.+Wongauthor=M.+McTigueauthor=Y.-L.+Dengauthor=W.+Liuauthor=A.+Broounauthor=S.+Timofeevskiauthor=S.+R.+P.+McDonnellauthor=P.+Jiangauthor=M.+D.+Falkauthor=P.+B.+Lappinauthor=T.+Affolterauthor=T.+Nicholsauthor=W.+Huauthor=J.+Lamauthor=T.+W.+Johnsonauthor=T.+Smealauthor=A.+Charestauthor=V.+R.+Fantin&title=PF-06463922+is+a+Potent+and+Selective+Next-generation+ROS1%2FALK+Inhibitor+Capable+of+Blocking+Crizotinib-resistant+ROS1+Mutations&doi=10.1073%2Fpnas.1420785112"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit111R"><div class="casContent"><span class="casTitleNuber">111</span><div class="casTitle"><span class="NLM_cas:atitle">PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations</span></div><div class="casAuthors">Zou, Helen Y.; Li, Qiuhua; Engstrom, Lars D.; West, Melissa; Appleman, Vicky; Wong, Katy A.; McTigue, Michele; Deng, Ya-Li; Liu, Wei; Brooun, Alexei; Timofeevski, Sergei; McDonnell, Scott R. P.; Jiang, Ping; Falk, Matthew D.; Lappin, Patrick B.; Affolter, Timothy; Nichols, Tim; Hu, Wenyue; Lam, Justine; Johnson, Ted W.; Smeal, Tod; Charest, Al; Fantin, Valeria R.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">112</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3493-3498</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Oncogenic c-ros oncogene 1 (ROS1) fusion kinases have been identified in a variety of human cancers and are attractive targets for cancer therapy.  The MET/ALK/ROS1 inhibitor crizotinib (Xalkori, PF-02341066) has demonstrated promising clin. activity in ROS1 fusion-pos. non-small cell lung cancer.  However, emerging clin. evidence has shown that patients can develop resistance by acquiring secondary point mutations in ROS1 kinase.  In this study the authors characterized the ROS1 activity of PF-06463922, a novel, orally available, CNS-penetrant, ATP-competitive small-mol. inhibitor of ALK/ROS1.  In vitro, PF-06463922 exhibited subnanomolar cellular potency against oncogenic ROS1 fusions and inhibited the crizotinib-refractory ROS1G2032R mutation and the ROS1G2026M gatekeeper mutation.  Compared with crizotinib and the second-generation ALK/ROS1 inhibitors ceritinib and alectinib, PF-06463922 showed significantly improved inhibitory activity against ROS1 kinase.  A crystal structure of the PF-06463922-ROS1 kinase complex revealed favorable interactions contributing to the high-affinity binding.  In vivo, PF-06463922 showed marked antitumor activity in tumor models expressing FIG-ROS1, CD74-ROS1, and the CD74-ROS1G2032R mutation.  Furthermore, PF-06463922 demonstrated antitumor activity in a genetically engineered mouse model of FIG-ROS1 glioblastoma.  Taken together, the authors' results indicate that PF-06463922 has potential for treating ROS1 fusion-pos. cancers, including those requiring agents with CNS-penetrating properties, as well as for overcoming crizotinib resistance driven by ROS1 mutation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5t2o5BKPhK7Vg90H21EOLACvtfcHk0ljnqBbZQJhcWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjs1Grur8%253D&md5=8f549572dfac12c74b88705d57979c09</span></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1420785112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1420785112%26sid%3Dliteratum%253Aachs%26aulast%3DZou%26aufirst%3DH.%2BY.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DEngstrom%26aufirst%3DL.%2BD.%26aulast%3DWest%26aufirst%3DM.%26aulast%3DAppleman%26aufirst%3DV.%26aulast%3DWong%26aufirst%3DK.%2BA.%26aulast%3DMcTigue%26aufirst%3DM.%26aulast%3DDeng%26aufirst%3DY.-L.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DBrooun%26aufirst%3DA.%26aulast%3DTimofeevski%26aufirst%3DS.%26aulast%3DMcDonnell%26aufirst%3DS.%2BR.%2BP.%26aulast%3DJiang%26aufirst%3DP.%26aulast%3DFalk%26aufirst%3DM.%2BD.%26aulast%3DLappin%26aufirst%3DP.%2BB.%26aulast%3DAffolter%26aufirst%3DT.%26aulast%3DNichols%26aufirst%3DT.%26aulast%3DHu%26aufirst%3DW.%26aulast%3DLam%26aufirst%3DJ.%26aulast%3DJohnson%26aufirst%3DT.%2BW.%26aulast%3DSmeal%26aufirst%3DT.%26aulast%3DCharest%26aufirst%3DA.%26aulast%3DFantin%26aufirst%3DV.%2BR.%26atitle%3DPF-06463922%2520is%2520a%2520Potent%2520and%2520Selective%2520Next-generation%2520ROS1%252FALK%2520Inhibitor%2520Capable%2520of%2520Blocking%2520Crizotinib-resistant%2520ROS1%2520Mutations%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2015%26volume%3D112%26spage%3D3493%26epage%3D3498%26doi%3D10.1073%2Fpnas.1420785112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref112"><div class="reference"><strong class="refLabel"><a href="#ref112" class="rightTabRefNumLink">112</a></strong><div class="NLM_citation" id="rightTab-cit112"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zou, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friboulet, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kodack, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engstrom, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">West, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsaparikos, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timofeevski, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katayama, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dinh, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamazaki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bezwada, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frias, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lifshits, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahmood, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gainor, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Affolter, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lappin, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gukasyan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jain, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fantin, V. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smeal, T.</span></span> <span> </span><span class="NLM_article-title">PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">70</span>– <span class="NLM_lpage">81</span>, <span class="refDoi"> DOI: 10.1016/j.ccell.2015.05.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1016%2Fj.ccell.2015.05.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=26144315" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFahsr7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2015&pages=70-81&author=H.+Y.+Zouauthor=L.+Fribouletauthor=D.+P.+Kodackauthor=L.+D.+Engstromauthor=Q.+Liauthor=M.+Westauthor=R.+W.+Tangauthor=H.+Wangauthor=K.+Tsaparikosauthor=J.+Wangauthor=S.+Timofeevskiauthor=R.+Katayamaauthor=D.+M.+Dinhauthor=H.+Lamauthor=J.+L.+Lamauthor=S.+Yamazakiauthor=W.+Huauthor=B.+Patelauthor=D.+Bezwadaauthor=R.+L.+Friasauthor=E.+Lifshitsauthor=S.+Mahmoodauthor=J.+F.+Gainorauthor=T.+Affolterauthor=P.+B.+Lappinauthor=H.+Gukasyanauthor=N.+Leeauthor=S.+Dengauthor=R.+K.+Jainauthor=T.+W.+Johnsonauthor=A.+T.+Shawauthor=V.+R.+Fantinauthor=T.+Smeal&title=PF-06463922%2C+an+ALK%2FROS1+Inhibitor%2C+Overcomes+Resistance+to+First+and+Second+Generation+ALK+Inhibitors+in+Preclinical+Models&doi=10.1016%2Fj.ccell.2015.05.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit112R"><div class="casContent"><span class="casTitleNuber">112</span><div class="casTitle"><span class="NLM_cas:atitle">PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models</span></div><div class="casAuthors">Zou, Helen Y.; Friboulet, Luc; Kodack, David P.; Engstrom, Lars D.; Li, Qiuhua; West, Melissa; Tang, Ruth W.; Wang, Hui; Tsaparikos, Konstantinos; Wang, Jinwei; Timofeevski, Sergei; Katayama, Ryohei; Dinh, Dac M.; Lam, Hieu; Lam, Justine L.; Yamazaki, Shinji; Hu, Wenyue; Patel, Bhushankumar; Bezwada, Divya; Frias, Rosa L.; Lifshits, Eugene; Mahmood, Sidra; Gainor, Justin F.; Affolter, Timothy; Lappin, Patrick B.; Gukasyan, Hovhannes; Lee, Nathan; Deng, Shibing; Jain, Rakesh K.; Johnson, Ted W.; Shaw, Alice T.; Fantin, Valeria R.; Smeal, Tod</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">70-81</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">We report the preclin. evaluation of PF-06463922, a potent and brain-penetrant ALK/ROS1 inhibitor.  Compared with other clin. available ALK inhibitors, PF-06463922 displayed superior potency against all known clin. acquired ALK mutations, including the highly resistant G1202R mutant.  Furthermore, PF-06463922 treatment led to regression of EML4-ALK-driven brain metastases, leading to prolonged mouse survival, in a superior manner.  Finally, PF-06463922 demonstrated high selectivity and safety margins in a variety of preclin. studies.  These results suggest that PF-06463922 will be highly effective for the treatment of patients with ALK-driven lung cancers, including those who relapsed on clin. available ALK inhibitors because of secondary ALK kinase domain mutations and/or brain metastases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3jseXrLwlSLVg90H21EOLACvtfcHk0liQz6K1msJrmg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFahsr7E&md5=5bd2b7be6086f607b33b2255ad350486</span></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1016%2Fj.ccell.2015.05.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccell.2015.05.010%26sid%3Dliteratum%253Aachs%26aulast%3DZou%26aufirst%3DH.%2BY.%26aulast%3DFriboulet%26aufirst%3DL.%26aulast%3DKodack%26aufirst%3DD.%2BP.%26aulast%3DEngstrom%26aufirst%3DL.%2BD.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DWest%26aufirst%3DM.%26aulast%3DTang%26aufirst%3DR.%2BW.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DTsaparikos%26aufirst%3DK.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DTimofeevski%26aufirst%3DS.%26aulast%3DKatayama%26aufirst%3DR.%26aulast%3DDinh%26aufirst%3DD.%2BM.%26aulast%3DLam%26aufirst%3DH.%26aulast%3DLam%26aufirst%3DJ.%2BL.%26aulast%3DYamazaki%26aufirst%3DS.%26aulast%3DHu%26aufirst%3DW.%26aulast%3DPatel%26aufirst%3DB.%26aulast%3DBezwada%26aufirst%3DD.%26aulast%3DFrias%26aufirst%3DR.%2BL.%26aulast%3DLifshits%26aufirst%3DE.%26aulast%3DMahmood%26aufirst%3DS.%26aulast%3DGainor%26aufirst%3DJ.%2BF.%26aulast%3DAffolter%26aufirst%3DT.%26aulast%3DLappin%26aufirst%3DP.%2BB.%26aulast%3DGukasyan%26aufirst%3DH.%26aulast%3DLee%26aufirst%3DN.%26aulast%3DDeng%26aufirst%3DS.%26aulast%3DJain%26aufirst%3DR.%2BK.%26aulast%3DJohnson%26aufirst%3DT.%2BW.%26aulast%3DShaw%26aufirst%3DA.%2BT.%26aulast%3DFantin%26aufirst%3DV.%2BR.%26aulast%3DSmeal%26aufirst%3DT.%26atitle%3DPF-06463922%252C%2520an%2520ALK%252FROS1%2520Inhibitor%252C%2520Overcomes%2520Resistance%2520to%2520First%2520and%2520Second%2520Generation%2520ALK%2520Inhibitors%2520in%2520Preclinical%2520Models%26jtitle%3DCancer%2520Cell%26date%3D2015%26volume%3D28%26spage%3D70%26epage%3D81%26doi%3D10.1016%2Fj.ccell.2015.05.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref113"><div class="reference"><strong class="refLabel"><a href="#ref113" class="rightTabRefNumLink">113</a></strong><div class="NLM_citation" id="rightTab-cit113"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Russo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franchina, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ricciardi, G. R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferraro, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scimone, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bronte, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rolfo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adamo, V.</span></span> <span> </span><span class="NLM_article-title">Central Nervous System Involvement in ALK-rearranged NSCLC: Promising Strategies to Overcome Crizotinib Resistance</span>. <i>Expert Rev. Anticancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">615</span>– <span class="NLM_lpage">623</span>, <span class="refDoi"> DOI: 10.1080/14737140.2016.1182427</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1080%2F14737140.2016.1182427" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=27109446" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC28XnslGksLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2016&pages=615-623&author=A.+Russoauthor=T.+Franchinaauthor=G.+R.+R.+Ricciardiauthor=G.+Ferraroauthor=A.+Scimoneauthor=G.+Bronteauthor=A.+Russoauthor=C.+Rolfoauthor=V.+Adamo&title=Central+Nervous+System+Involvement+in+ALK-rearranged+NSCLC%3A+Promising+Strategies+to+Overcome+Crizotinib+Resistance&doi=10.1080%2F14737140.2016.1182427"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">Central nervous system involvement in ALK-rearranged NSCLC: promising strategies to overcome crizotinib resistance</span></div><div class="casAuthors">Russo, Alessandro; Franchina, Tindara; Ricciardi, Giuseppina Rosaria Rita; Ferraro, Giuseppa; Scimone, Antonino; Bronte, Giuseppe; Russo, Antonio; Rolfo, Christian; Adamo, Vincenzo</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Anticancer Therapy</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">615-623</span>CODEN:
                <span class="NLM_cas:coden">ERATBJ</span>;
        ISSN:<span class="NLM_cas:issn">1473-7140</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">ALK rearranged Non Small Cell Lung Cancers (NSCLCs) represent a distinct subgroup of patients with peculiar clinic-pathol. features.  These patients exhibit dramatic responses when treated with the ALK tyrosine kinase inhibitor Crizotinib, albeit Central Nervous System (CNS) activity is much less impressive than that obsd. against extracranial lesions.  CNS involvement has become increasingly obsd. in these patients, given their prolonged survival.  Several novel generation ALK inhibitors have been developing to increase CNS penetration and to provide more complete ALK inhibition..  The CNS activity of Crizotinib and novel generation ALK inhibitors will be summarized in this review, evaluating the strengths and weaknesses of the therapeutic strategies developed to date in this specific subgroup of NSCLCs with a look towards the future.  In the next few years, the results of ongoing comparative head-to-head trials will provide the definitive conclusions on the optimal treatment sequence in ALK-rearranged NSCLCs.  Moreover, ongoing clin. trials with novel-generation ALK inhibitors will produce more evidences on the best approach in the growing no. of ALK-pos. NSCLCs with CNS involvement.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3TX-jyciMtbVg90H21EOLACvtfcHk0liQz6K1msJrmg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XnslGksLk%253D&md5=7b45f0c41b30504cc526a1bc2a83f233</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1080%2F14737140.2016.1182427&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F14737140.2016.1182427%26sid%3Dliteratum%253Aachs%26aulast%3DRusso%26aufirst%3DA.%26aulast%3DFranchina%26aufirst%3DT.%26aulast%3DRicciardi%26aufirst%3DG.%2BR.%2BR.%26aulast%3DFerraro%26aufirst%3DG.%26aulast%3DScimone%26aufirst%3DA.%26aulast%3DBronte%26aufirst%3DG.%26aulast%3DRusso%26aufirst%3DA.%26aulast%3DRolfo%26aufirst%3DC.%26aulast%3DAdamo%26aufirst%3DV.%26atitle%3DCentral%2520Nervous%2520System%2520Involvement%2520in%2520ALK-rearranged%2520NSCLC%253A%2520Promising%2520Strategies%2520to%2520Overcome%2520Crizotinib%2520Resistance%26jtitle%3DExpert%2520Rev.%2520Anticancer%2520Ther.%26date%3D2016%26volume%3D16%26spage%3D615%26epage%3D623%26doi%3D10.1080%2F14737140.2016.1182427" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref114"><div class="reference"><strong class="refLabel"><a href="#ref114" class="rightTabRefNumLink">114</a></strong><div class="NLM_citation" id="rightTab-cit114"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sparidans, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lebre, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beijnen, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schinkel, A. H.</span></span> <span> </span><span class="NLM_article-title">Oral Coadministration of Elacridar and Ritonavir Enhances Brain Accumulation and Oral Availability of the Novel ALK/ROS1 Inhibitor Lorlatinib</span>. <i>Eur. J. Pharm. Biopharm.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>136</i></span>,  <span class="NLM_fpage">120</span>– <span class="NLM_lpage">130</span>, <span class="refDoi"> DOI: 10.1016/j.ejpb.2019.01.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1016%2Fj.ejpb.2019.01.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=30660696" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhslGnu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=136&publication_year=2019&pages=120-130&author=W.+Liauthor=R.+W.+Sparidansauthor=Y.+Wangauthor=M.+C.+Lebreauthor=J.+H.+Beijnenauthor=A.+H.+Schinkel&title=Oral+Coadministration+of+Elacridar+and+Ritonavir+Enhances+Brain+Accumulation+and+Oral+Availability+of+the+Novel+ALK%2FROS1+Inhibitor+Lorlatinib&doi=10.1016%2Fj.ejpb.2019.01.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit114R"><div class="casContent"><span class="casTitleNuber">114</span><div class="casTitle"><span class="NLM_cas:atitle">Oral coadministration of elacridar and ritonavir enhances brain accumulation and oral availability of the novel ALK/ROS1 inhibitor lorlatinib</span></div><div class="casAuthors">Li, Wenlong; Sparidans, Rolf W.; Wang, Yaogeng; Lebre, Maria C.; Beijnen, Jos H.; Schinkel, Alfred H.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmaceutics and Biopharmaceutics</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">136</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">120-130</span>CODEN:
                <span class="NLM_cas:coden">EJPBEL</span>;
        ISSN:<span class="NLM_cas:issn">0939-6411</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Lorlatinib, a novel generation oral anaplastic lymphoma kinase (ALK) and ROS1 inhibitor with high membrane and blood-brain barrier permeability, recently received accelerated approval for treatment of ALK-rearranged non-small-cell lung cancer (NSCLC), and its further clin. development is ongoing.  We previously found that the efflux transporter P-glycoprotein (MDR1/ABCB1) restricts lorlatinib brain accumulation and that the drug-metabolizing enzyme cytochrome P 450-3A (CYP3A) limits its oral availability.  Using genetically modified mouse models, we investigated the impact of targeted pharmacol. inhibitors on lorlatinib pharmacokinetics and bioavailability.  Upon oral administration of lorlatinib, the plasma AUC0-8h in CYP3A4-humanized mice was ∼1.8-fold lower than in wild-type and Cyp3a-/- mice.  Oral coadministration of the CYP3A inhibitor ritonavir caused reversion to the AUC0-8h levels seen in wild-type and Cyp3a-/- mice, without altering the relative tissue distribution of lorlatinib.  Moreover, simultaneous pharmacol. inhibition of P-glycoprotein and CYP3A4 with oral elacridar and ritonavir in CYP3A4-humanized mice profoundly increased lorlatinib brain concns., but not its oral availability or other relative tissue distribution.  Oral lorlatinib pharmacokinetics was not significantly affected by absence of the multispecific Oatp1a/1b drug uptake transporters.  The abs. oral bioavailability of lorlatinib over 8 h in wild-type, Cyp3a-/-, and CYP3A4-humanized mice was 81.6%, 72.9%, and 58.5%, resp.  Lorlatinib thus has good oral bioavailability, which is markedly restricted by human CYP3A4 but not by mouse Cyp3a.  Pharmacol. inhibition of CYP3A4 reversed these effects, and simultaneous P-gp inhibition with elacridar boosted abs. brain levels of lorlatinib by 16-fold without obvious toxicity.  These insights may help to optimize the clin. application of lorlatinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzexELEtdHlrVg90H21EOLACvtfcHk0liQz6K1msJrmg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhslGnu78%253D&md5=2aa5b4e6260bb011036ac9cdb0193588</span></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1016%2Fj.ejpb.2019.01.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejpb.2019.01.016%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DW.%26aulast%3DSparidans%26aufirst%3DR.%2BW.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DLebre%26aufirst%3DM.%2BC.%26aulast%3DBeijnen%26aufirst%3DJ.%2BH.%26aulast%3DSchinkel%26aufirst%3DA.%2BH.%26atitle%3DOral%2520Coadministration%2520of%2520Elacridar%2520and%2520Ritonavir%2520Enhances%2520Brain%2520Accumulation%2520and%2520Oral%2520Availability%2520of%2520the%2520Novel%2520ALK%252FROS1%2520Inhibitor%2520Lorlatinib%26jtitle%3DEur.%2520J.%2520Pharm.%2520Biopharm.%26date%3D2019%26volume%3D136%26spage%3D120%26epage%3D130%26doi%3D10.1016%2Fj.ejpb.2019.01.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref115"><div class="reference"><strong class="refLabel"><a href="#ref115" class="rightTabRefNumLink">115</a></strong><div class="NLM_citation" id="rightTab-cit115"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, A. T</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felip, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, T. M</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Besse, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Navarro, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Postel-Vinay, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gainor, J. F</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dietrich, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, L. P</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clancy, J. S</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martini, J.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abbattista, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solomon, B. J</span></span> <span> </span><span class="NLM_article-title">Lorlatinib in Non-small Cell Lung Cancer with ALK or ROS1 Rearrangement: an International, Multicentre, Open-label, Single-arm First-in-man Phase 1 Trial</span>. <i>Lancet Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">1590</span>– <span class="NLM_lpage">1599</span>, <span class="refDoi"> DOI: 10.1016/S1470-2045(17)30680-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1016%2FS1470-2045%2817%2930680-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=29074098" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhslSgu7vF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2017&pages=1590-1599&author=A.+T+Shawauthor=E.+Felipauthor=T.+M+Bauerauthor=B.+Besseauthor=A.+Navarroauthor=S.+Postel-Vinayauthor=J.+F+Gainorauthor=M.+Johnsonauthor=J.+Dietrichauthor=L.+P+Jamesauthor=J.+S+Clancyauthor=J.+Chenauthor=J.-F.+Martiniauthor=A.+Abbattistaauthor=B.+J+Solomon&title=Lorlatinib+in+Non-small+Cell+Lung+Cancer+with+ALK+or+ROS1+Rearrangement%3A+an+International%2C+Multicentre%2C+Open-label%2C+Single-arm+First-in-man+Phase+1+Trial&doi=10.1016%2FS1470-2045%2817%2930680-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit115R"><div class="casContent"><span class="casTitleNuber">115</span><div class="casTitle"><span class="NLM_cas:atitle">Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial</span></div><div class="casAuthors">Shaw, Alice T.; Felip, Enriqueta; Bauer, Todd M.; Besse, Benjamin; Navarro, Alejandro; Postel-Vinay, Sophie; Gainor, Justin F.; Johnson, Melissa; Dietrich, Jorg; James, Leonard P.; Clancy, Jill S.; Chen, Joseph; Martini, Jean-Francois; Abbattista, Antonello; Solomon, Benjamin J.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1590-1599</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Most patients with anaplastic lymphoma kinase (ALK)-rearranged or ROS proto-oncogene 1 (ROS1)-rearranged non-small-cell lung cancer (NSCLC) are sensitive to tyrosine kinase inhibitor (TKI) therapy, but resistance invariably develops, commonly within the CNS.  This study aimed to analyze the safety, efficacy, and pharmacokinetic properties of lorlatinib, a novel, highly potent, selective, and brain-penetrant ALK and ROS1 TKI with preclin. activity against most known resistance mutations, in patients with advanced ALK-pos. or ROS1-pos. NSCLC.  In this international multicentre, open-label, single-arm, first-in-man phase 1 dose-escalation study, eligible patients had advanced ALK-pos. or ROS1-pos. NSCLC and were older than 18 years, with an Eastern Cooperative Oncol. Group performance status of 0 or 1, and adequate end-organ function.  Lorlatinib was administered orally to patients at doses ranging from 10 mg to 200 mg once daily or 35 mg to 100 mg twice daily, with a min. of three patients receiving each dose.  For some patients, tumor biopsy was done before lorlatinib treatment to identify ALK resistance mutations.  Safety was assessed in patients who received at least one dose of lorlatinib; efficacy was assessed in the intention-to-treat population (patients who received at least one dose of study treatment and had either ALK or ROS1 rearrangement).  The primary endpoint was dose-limiting toxicities during cycle 1 according to investigator assessment; secondary endpoints included safety, pharmacokinetics, and overall response.  This study is ongoing and is registered with ClinicalTrials.gov, no. NCT01970865.  Between Jan 22, 2014, and July 10, 2015, 54 patients received at least one dose of lorlatinib, including 41 (77%) with ALK-pos. and 12 (23%) with ROS1-pos. NSCLC; one patient had unconfirmed ALK and ROS1 status. 28 (52%) patients had received two or more TKIs, and 39 (72%) patients had CNS metastases.  The most common treatment-related adverse events among the 54 patients were hypercholesterolemia (39 [72%] of 54 patients), hypertriglyceridemia (21 [39%] of 54 patients), peripheral neuropathy (21 [39%] of 54 patients), and peripheral edema (21 [39%] of 54 patients).  One dose-limiting toxicity occurred at 200 mg (the patient did not take at least 16 of 21 prescribed total daily doses in cycle 1 because of toxicities attributable to study drug, which were grade 2 neurocognitive adverse events comprising slowed speech and mentation and word-finding difficulty).  No max. tolerated dose was identified.  The recommended phase 2 dose was selected as 100 mg once daily.  For ALK-pos. patients, the proportion of patients who achieved an objective response was 19 (46%) of 41 patients (95% CI 31-63); for those who had received two or more TKIs, the proportion of patients with an objective response was 11 (42%) of 26 patients (23-63).  In ROS1-pos. patients, including seven crizotinib-pretreated patients, an objective response was achieved by six (50%) of 12 patients (95% CI 21-79).  In this phase 1, dose-escalation study, lorlatinib showed both systemic and intracranial activity in patients with advanced ALK-pos. or ROS1-pos. NSCLC, most of whom had CNS metastases and had previously had two or more TKI treatments fail.  Therefore, lorlatinib might be an effective therapeutic strategy for patients with ALK-pos. NSCLC who have become resistant to currently available TKIs, including second-generation ALK TKIs, and is being investigated in a phase 3 randomised controlled trial comparing lorlatinib to crizotinib (ClinicalTrials.gov, NCT03052608).Pfizer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpU5uB3o0yZkrVg90H21EOLACvtfcHk0liGeS8dOKEvKg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhslSgu7vF&md5=aa28604c17c04fd005b70beda74ef2d6</span></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2817%2930680-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252817%252930680-0%26sid%3Dliteratum%253Aachs%26aulast%3DShaw%26aufirst%3DA.%2BT%26aulast%3DFelip%26aufirst%3DE.%26aulast%3DBauer%26aufirst%3DT.%2BM%26aulast%3DBesse%26aufirst%3DB.%26aulast%3DNavarro%26aufirst%3DA.%26aulast%3DPostel-Vinay%26aufirst%3DS.%26aulast%3DGainor%26aufirst%3DJ.%2BF%26aulast%3DJohnson%26aufirst%3DM.%26aulast%3DDietrich%26aufirst%3DJ.%26aulast%3DJames%26aufirst%3DL.%2BP%26aulast%3DClancy%26aufirst%3DJ.%2BS%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DMartini%26aufirst%3DJ.-F.%26aulast%3DAbbattista%26aufirst%3DA.%26aulast%3DSolomon%26aufirst%3DB.%2BJ%26atitle%3DLorlatinib%2520in%2520Non-small%2520Cell%2520Lung%2520Cancer%2520with%2520ALK%2520or%2520ROS1%2520Rearrangement%253A%2520an%2520International%252C%2520Multicentre%252C%2520Open-label%252C%2520Single-arm%2520First-in-man%2520Phase%25201%2520Trial%26jtitle%3DLancet%2520Oncol.%26date%3D2017%26volume%3D18%26spage%3D1590%26epage%3D1599%26doi%3D10.1016%2FS1470-2045%2817%2930680-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref116"><div class="reference"><strong class="refLabel"><a href="#ref116" class="rightTabRefNumLink">116</a></strong><div class="NLM_citation" id="rightTab-cit116"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ou, S.-H. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felip, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Besse, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gadgeel, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camidge, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, C.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soo, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiari, R.</span></span> <span> </span><span class="NLM_article-title">Efficacy and Safety of Lorlatinib in Patients (pts) with ALK+ Non-small Cell Lung Cancer (NSCLC) with One or More Prior ALK Tyrosine Kinase Inhibitor (TKI): A Phase I/II Study</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>35</i></span> (<span class="NLM_issue">Suppl 15</span>),  <span class="NLM_fpage">9006</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1200%2FJCO.2017.35.15_suppl.9006" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2017&pages=9006&issue=Suppl+15&author=A.+T.+Shawauthor=S.-H.+I.+Ouauthor=E.+Felipauthor=T.+M.+Bauerauthor=B.+Besseauthor=S.+M.+Gadgeelauthor=D.+R.+Camidgeauthor=C.-C.+Linauthor=T.+Setoauthor=R.+A.+Sooauthor=R.+Chiari&title=Efficacy+and+Safety+of+Lorlatinib+in+Patients+%28pts%29+with+ALK%2B+Non-small+Cell+Lung+Cancer+%28NSCLC%29+with+One+or+More+Prior+ALK+Tyrosine+Kinase+Inhibitor+%28TKI%29%3A+A+Phase+I%2FII+Study"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.1200%2FJCO.2017.35.15_suppl.9006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2017.35.15_suppl.9006%26sid%3Dliteratum%253Aachs%26aulast%3DShaw%26aufirst%3DA.%2BT.%26aulast%3DOu%26aufirst%3DS.-H.%2BI.%26aulast%3DFelip%26aufirst%3DE.%26aulast%3DBauer%26aufirst%3DT.%2BM.%26aulast%3DBesse%26aufirst%3DB.%26aulast%3DGadgeel%26aufirst%3DS.%2BM.%26aulast%3DCamidge%26aufirst%3DD.%2BR.%26aulast%3DLin%26aufirst%3DC.-C.%26aulast%3DSeto%26aufirst%3DT.%26aulast%3DSoo%26aufirst%3DR.%2BA.%26aulast%3DChiari%26aufirst%3DR.%26atitle%3DEfficacy%2520and%2520Safety%2520of%2520Lorlatinib%2520in%2520Patients%2520%2528pts%2529%2520with%2520ALK%252B%2520Non-small%2520Cell%2520Lung%2520Cancer%2520%2528NSCLC%2529%2520with%2520One%2520or%2520More%2520Prior%2520ALK%2520Tyrosine%2520Kinase%2520Inhibitor%2520%2528TKI%2529%253A%2520A%2520Phase%2520I%252FII%2520Study%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2017%26volume%3D35%26issue%3DSuppl%252015%26spage%3D9006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref117"><div class="reference"><strong class="refLabel"><a href="#ref117" class="rightTabRefNumLink">117</a></strong><div class="NLM_citation" id="rightTab-cit117"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Basit, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashraf, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Latif, M.</span></span> <span> </span><span class="NLM_article-title">First Macrocyclic 3rd-generation ALK Inhibitor for Treatment of ALK/ROS1 cancer: Clinical and Designing Strategy Update of Lorlatinib</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>134</i></span>,  <span class="NLM_fpage">348</span>– <span class="NLM_lpage">356</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2017.04.032</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1016%2Fj.ejmech.2017.04.032" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=28431340" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmtlKnt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=134&publication_year=2017&pages=348-356&author=S.+Basitauthor=Z.+Ashrafauthor=K.+Leeauthor=M.+Latif&title=First+Macrocyclic+3rd-generation+ALK+Inhibitor+for+Treatment+of+ALK%2FROS1+cancer%3A+Clinical+and+Designing+Strategy+Update+of+Lorlatinib&doi=10.1016%2Fj.ejmech.2017.04.032"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit117R"><div class="casContent"><span class="casTitleNuber">117</span><div class="casTitle"><span class="NLM_cas:atitle">First macrocyclic 3rd-generation ALK inhibitor for treatment of ALK/ROS1 cancer: Clinical and designing strategy update of lorlatinib</span></div><div class="casAuthors">Basit, Sulman; Ashraf, Zaman; Lee, Kwangho; Latif, Muhammad</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">134</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">348-356</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A review.  Non-small cell lung cancers (NSCLC) harboring anaplastic lymphoma kinase (ALK) gene rearrangements invariably develop resistance to 2nd-generation ALK inhibitors.  Lorlatinib (PF-06463922) is a 3rd-generation macrocyclic ALK-TKI that demonstrates many advantages over 2nd-generation ALK inhibitors.  Lorlatinib has demonstrated decent kinase selectivity, promising pharmacokinetic profile, selective brain-penetration and strong antiproliferative activity in several ALK/ROS1-driven tumor models.  The current review describes the activity spectrum, key events from discovery to clin. applications and the evidences that lorlatinib acts as an ALK/ROS1 inhibitor in clin. settings.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqgvg4dapRHrVg90H21EOLACvtfcHk0liGeS8dOKEvKg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmtlKnt74%253D&md5=13f3886be0e0973a5627f33c6c50cf26</span></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2017.04.032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2017.04.032%26sid%3Dliteratum%253Aachs%26aulast%3DBasit%26aufirst%3DS.%26aulast%3DAshraf%26aufirst%3DZ.%26aulast%3DLee%26aufirst%3DK.%26aulast%3DLatif%26aufirst%3DM.%26atitle%3DFirst%2520Macrocyclic%25203rd-generation%2520ALK%2520Inhibitor%2520for%2520Treatment%2520of%2520ALK%252FROS1%2520cancer%253A%2520Clinical%2520and%2520Designing%2520Strategy%2520Update%2520of%2520Lorlatinib%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2017%26volume%3D134%26spage%3D348%26epage%3D356%26doi%3D10.1016%2Fj.ejmech.2017.04.032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref118"><div class="reference"><strong class="refLabel"><a href="#ref118" class="rightTabRefNumLink">118</a></strong><div class="NLM_citation" id="rightTab-cit118"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Syed, Y. Y.</span></span> <span> </span><span class="NLM_article-title">Lorlatinib: First Global Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">93</span>– <span class="NLM_lpage">98</span>, <span class="refDoi"> DOI: 10.1007/s40265-018-1041-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1007%2Fs40265-018-1041-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=30604291" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC1MXnvFOqsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2019&pages=93-98&author=Y.+Y.+Syed&title=Lorlatinib%3A+First+Global+Approval&doi=10.1007%2Fs40265-018-1041-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit118R"><div class="casContent"><span class="casTitleNuber">118</span><div class="casTitle"><span class="NLM_cas:atitle">Lorlatinib: First Global Approval</span></div><div class="casAuthors">Syed, Yahiya Y.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">93-98</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  Lorlatinib is an oral small mol. inhibitor of anaplastic lymphoma kinase (ALK) and C-ros oncogene 1 (ROS1) kinase developed by Pfizer for the treatment of ALK-pos. non-small cell lung cancer (NSCLC).  Based on results from a phase I/II trial, lorlatinib received approval in Japan in Sept. 2018 and in the USA in Nov. 2018 for the treatment of ALK-pos. NSCLC.  This article summarizes the milestones in the development of lorlatinib leading to the first global approval for this indication.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqU4Wwiia48VbVg90H21EOLACvtfcHk0ljNUy7lGELO9A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXnvFOqsr4%253D&md5=f041ba0200e2d607bb2a014884455990</span></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.1007%2Fs40265-018-1041-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-018-1041-0%26sid%3Dliteratum%253Aachs%26aulast%3DSyed%26aufirst%3DY.%2BY.%26atitle%3DLorlatinib%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2019%26volume%3D79%26spage%3D93%26epage%3D98%26doi%3D10.1007%2Fs40265-018-1041-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref119"><div class="reference"><strong class="refLabel"><a href="#ref119" class="rightTabRefNumLink">119</a></strong><div class="NLM_citation" id="rightTab-cit119"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friboulet, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leshchiner, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gainor, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergqvist, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brooun, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, Y.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dardaei, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frias, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schultz, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Logan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, L. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smeal, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timofeevski, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katayama, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iafrate, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McTigue, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Getz, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engelman, J. A.</span></span> <span> </span><span class="NLM_article-title">Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>374</i></span>,  <span class="NLM_fpage">54</span>– <span class="NLM_lpage">61</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1508887</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1056%2FNEJMoa1508887" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=26698910" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtlOlurzI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=374&publication_year=2016&pages=54-61&author=A.+T.+Shawauthor=L.+Fribouletauthor=I.+Leshchinerauthor=J.+F.+Gainorauthor=S.+Bergqvistauthor=A.+Broounauthor=B.+J.+Burkeauthor=Y.-L.+Dengauthor=W.+Liuauthor=L.+Dardaeiauthor=R.+L.+Friasauthor=K.+R.+Schultzauthor=J.+Loganauthor=L.+P.+Jamesauthor=T.+Smealauthor=S.+Timofeevskiauthor=R.+Katayamaauthor=A.+J.+Iafrateauthor=L.+Leauthor=M.+McTigueauthor=G.+Getzauthor=T.+W.+Johnsonauthor=J.+A.+Engelman&title=Resensitization+to+Crizotinib+by+the+Lorlatinib+ALK+Resistance+Mutation+L1198F&doi=10.1056%2FNEJMoa1508887"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit119R"><div class="casContent"><span class="casTitleNuber">119</span><div class="casTitle"><span class="NLM_cas:atitle">Resensitization to crizotinib by the lorlatinib ALK resistance mutation L1198F</span></div><div class="casAuthors">Shaw, Alice T.; Friboulet, Luc; Leshchiner, Ignaty; Gainor, Justin F.; Bergqvist, Simon; Brooun, Alexei; Burke, Benjamin J.; Deng, Ya-Li; Liu, Wei; Dardaei, Leila; Frias, Rosa L.; Schultz, Kate R.; Logan, Jennifer; James, Leonard P.; Smeal, Tod; Timofeevski, Sergei; Katayama, Ryohei; John, Iafrate A.; Le, Long; McTigue, Michele; Getz, Gad; Johnson, Ted W.; Engelman, Jeffrey A.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">374</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">54-61</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">In a patient who had metastatic anaplastic lymphoma kinase (ALK)-rearranged lung cancer, resistance to crizotinib developed because of a mutation in the ALK kinase domain.  This mutation is predicted to result in a substitution of cysteine by tyrosine at amino acid residue 1156 (C1156Y).  Her tumor did not respond to a second-generation ALK inhibitor, but it did respond to lorlatinib (PF-06463922), a third-generation inhibitor.  When her tumor relapsed, sequencing of the resistant tumor re- vealed an ALK L1198F mutation in addn. to the C1156Y mutation.  The L1198F substitution confers resistance to lorlatinib through steric interference with drug binding.  However, L1198F paradoxically enhances binding to crizotinib, negating the effect of C1156Y and resensitizing resistant cancers to crizotinib.  The patient received crizotinib again, and her cancer-related symptoms and liver failure re- solved.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphljr8b5kDw7Vg90H21EOLACvtfcHk0ljNUy7lGELO9A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtlOlurzI&md5=993f41fc3918a73d4ba69276556572d8</span></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1508887&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1508887%26sid%3Dliteratum%253Aachs%26aulast%3DShaw%26aufirst%3DA.%2BT.%26aulast%3DFriboulet%26aufirst%3DL.%26aulast%3DLeshchiner%26aufirst%3DI.%26aulast%3DGainor%26aufirst%3DJ.%2BF.%26aulast%3DBergqvist%26aufirst%3DS.%26aulast%3DBrooun%26aufirst%3DA.%26aulast%3DBurke%26aufirst%3DB.%2BJ.%26aulast%3DDeng%26aufirst%3DY.-L.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DDardaei%26aufirst%3DL.%26aulast%3DFrias%26aufirst%3DR.%2BL.%26aulast%3DSchultz%26aufirst%3DK.%2BR.%26aulast%3DLogan%26aufirst%3DJ.%26aulast%3DJames%26aufirst%3DL.%2BP.%26aulast%3DSmeal%26aufirst%3DT.%26aulast%3DTimofeevski%26aufirst%3DS.%26aulast%3DKatayama%26aufirst%3DR.%26aulast%3DIafrate%26aufirst%3DA.%2BJ.%26aulast%3DLe%26aufirst%3DL.%26aulast%3DMcTigue%26aufirst%3DM.%26aulast%3DGetz%26aufirst%3DG.%26aulast%3DJohnson%26aufirst%3DT.%2BW.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26atitle%3DResensitization%2520to%2520Crizotinib%2520by%2520the%2520Lorlatinib%2520ALK%2520Resistance%2520Mutation%2520L1198F%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2016%26volume%3D374%26spage%3D54%26epage%3D61%26doi%3D10.1056%2FNEJMoa1508887" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref120"><div class="reference"><strong class="refLabel"><a href="#ref120" class="rightTabRefNumLink">120</a></strong><div class="NLM_citation" id="rightTab-cit120"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quail, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gingrich, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ott, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albom, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angeles, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aimone, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cristofani, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Machiorlatti, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abele, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ator, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dorsey, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inghirami, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruggeri, B. A.</span></span> <span> </span><span class="NLM_article-title">CEP-28122, a Highly Potent and Selective Orally Active Inhibitor of Anaplastic Lymphoma Kinase with Antitumor Activity in Experimental Models of Human Cancers</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">670</span>– <span class="NLM_lpage">679</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-11-0776</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1158%2F1535-7163.MCT-11-0776" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=22203728" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC38XjtlKisrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=670-679&author=M.+Chengauthor=M.+R.+Quailauthor=D.+E.+Gingrichauthor=G.+R.+Ottauthor=L.+Luauthor=W.+Wanauthor=M.+S.+Albomauthor=T.+S.+Angelesauthor=L.+D.+Aimoneauthor=F.+Cristofaniauthor=R.+Machiorlattiauthor=C.+Abeleauthor=M.+A.+Atorauthor=B.+D.+Dorseyauthor=G.+Inghiramiauthor=B.+A.+Ruggeri&title=CEP-28122%2C+a+Highly+Potent+and+Selective+Orally+Active+Inhibitor+of+Anaplastic+Lymphoma+Kinase+with+Antitumor+Activity+in+Experimental+Models+of+Human+Cancers&doi=10.1158%2F1535-7163.MCT-11-0776"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit120R"><div class="casContent"><span class="casTitleNuber">120</span><div class="casTitle"><span class="NLM_cas:atitle">CEP-28122, a Highly Potent and Selective Orally Active Inhibitor of Anaplastic Lymphoma Kinase with Antitumor Activity in Experimental Models of Human Cancers</span></div><div class="casAuthors">Cheng, Mangeng; Quail, Matthew R.; Gingrich, Diane E.; Ott, Gregory R.; Lu, Lihui; Wan, Weihua; Albom, Mark S.; Angeles, Thelma S.; Aimone, Lisa D.; Cristofani, Flavio; Machiorlatti, Rodolfo; Abele, Cristina; Ator, Mark A.; Dorsey, Bruce D.; Inghirami, Giorgio; Ruggeri, Bruce A.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">670-679</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Anaplastic lymphoma kinase (ALK) is constitutively activated in a no. of human cancer types due to chromosomal translocations, point mutations, and gene amplification and has emerged as an excellent mol. target for cancer therapy.  Here we report the identification and preclin. characterization of CEP-28122, a highly potent and selective orally active ALK inhibitor.  CEP-28122 is a potent inhibitor of recombinant ALK activity and cellular ALK tyrosine phosphorylation.  It induced concn.-dependent growth inhibition/cytotoxicity of ALK-pos. anaplastic large-cell lymphoma (ALCL), non-small cell lung cancer (NSCLC), and neuroblastoma cells, and displayed dose-dependent inhibition of ALK tyrosine phosphorylation in tumor xenografts in mice, with substantial target inhibition (>90%) for more than 12 h following single oral dosing at 30 mg/kg.  Dose-dependent antitumor activity was obsd. in ALK-pos. ALCL, NSCLC, and neuroblastoma tumor xenografts in mice administered CEP-28122 orally, with complete/near complete tumor regressions obsd. following treatment at doses of 30 mg/kg twice daily or higher.  Treatment of mice bearing Sup-M2 tumor xenografts for 4 wk and primary human ALCL tumor grafts for 2 wk at 55 or 100 mg/kg twice daily led to sustained tumor regression in all mice, with no tumor reemergence for more than 60 days postcessation of treatment.  Conversely, CEP-28122 displayed marginal antitumor activity against ALK-neg. human tumor xenografts under the same dosing regimens.  Administration of CEP-28122 was well tolerated in mice and rats.  In summary, CEP-28122 is a highly potent and selective orally active ALK inhibitor with a favorable pharmaceutical and pharmacokinetic profile and robust and selective pharmacol. efficacy against ALK-pos. human cancer cells and tumor xenograft models in mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWAF2Kawjc8rVg90H21EOLACvtfcHk0ljNUy7lGELO9A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XjtlKisrk%253D&md5=40001fb02de25d0f78bb11a41819651a</span></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-11-0776&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-11-0776%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DM.%26aulast%3DQuail%26aufirst%3DM.%2BR.%26aulast%3DGingrich%26aufirst%3DD.%2BE.%26aulast%3DOtt%26aufirst%3DG.%2BR.%26aulast%3DLu%26aufirst%3DL.%26aulast%3DWan%26aufirst%3DW.%26aulast%3DAlbom%26aufirst%3DM.%2BS.%26aulast%3DAngeles%26aufirst%3DT.%2BS.%26aulast%3DAimone%26aufirst%3DL.%2BD.%26aulast%3DCristofani%26aufirst%3DF.%26aulast%3DMachiorlatti%26aufirst%3DR.%26aulast%3DAbele%26aufirst%3DC.%26aulast%3DAtor%26aufirst%3DM.%2BA.%26aulast%3DDorsey%26aufirst%3DB.%2BD.%26aulast%3DInghirami%26aufirst%3DG.%26aulast%3DRuggeri%26aufirst%3DB.%2BA.%26atitle%3DCEP-28122%252C%2520a%2520Highly%2520Potent%2520and%2520Selective%2520Orally%2520Active%2520Inhibitor%2520of%2520Anaplastic%2520Lymphoma%2520Kinase%2520with%2520Antitumor%2520Activity%2520in%2520Experimental%2520Models%2520of%2520Human%2520Cancers%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2012%26volume%3D11%26spage%3D670%26epage%3D679%26doi%3D10.1158%2F1535-7163.MCT-11-0776" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref121"><div class="reference"><strong class="refLabel"><a href="#ref121" class="rightTabRefNumLink">121</a></strong><div class="NLM_citation" id="rightTab-cit121"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, A.</span></span> <span> </span><span class="NLM_article-title">Novel 2, 4-diarylaminopyrimidine Analogues (DAAPalogues) Showing Potent c-Met/ALK Multikinase Inhibitory Activities</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">304</span>– <span class="NLM_lpage">308</span>, <span class="refDoi"> DOI: 10.1021/ml400373j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml400373j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFKmtr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=304-308&author=Z.+Liuauthor=J.+Aiauthor=X.+Pengauthor=Z.+Songauthor=K.+Wuauthor=J.+Zhangauthor=Q.+Yaoauthor=Y.+Chenauthor=Y.+Jiauthor=Y.+Yangauthor=M.+Gengauthor=A.+Zhang&title=Novel+2%2C+4-diarylaminopyrimidine+Analogues+%28DAAPalogues%29+Showing+Potent+c-Met%2FALK+Multikinase+Inhibitory+Activities&doi=10.1021%2Fml400373j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit121R"><div class="casContent"><span class="casTitleNuber">121</span><div class="casTitle"><span class="NLM_cas:atitle">Novel 2,4-Diarylaminopyrimidine Analogues (DAAPalogues) Showing Potent c-Met/ALK Multikinase Inhibitory Activities</span></div><div class="casAuthors">Liu, Zhiqing; Ai, Jing; Peng, Xia; Song, Zilan; Wu, Kui; Zhang, Jing; Yao, Qizheng; Chen, Yi; Ji, Yinchun; Yang, Yanhong; Geng, Meiyu; Zhang, Ao</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">304-308</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">By repurposing a typical dopamine D1/D5 receptor agonist motif, C1-substituted-N3-benzazepine or benzazecine, into the classical RTK inhibitor 2,4-diaminopyrimidine skeleton, a series of new 2,4-diarylaminopyrimidine analogs (DAAPalogues) were developed.  Two compds. were identified possessing high potency against both c-Met and ALK kinases.  Compd. (I) displayed appreciable antitumor efficacy at the dose of 1 mg/kg in the ALK-driven BF3/EML4-ALK xenograft mice model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgRNaImj02DLVg90H21EOLACvtfcHk0lh4EV6Xl1Xe0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFKmtr4%253D&md5=86562545201476c05cce2e7143fa4cb7</span></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.1021%2Fml400373j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml400373j%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DAi%26aufirst%3DJ.%26aulast%3DPeng%26aufirst%3DX.%26aulast%3DSong%26aufirst%3DZ.%26aulast%3DWu%26aufirst%3DK.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DYao%26aufirst%3DQ.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DJi%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DGeng%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DA.%26atitle%3DNovel%25202%252C%25204-diarylaminopyrimidine%2520Analogues%2520%2528DAAPalogues%2529%2520Showing%2520Potent%2520c-Met%252FALK%2520Multikinase%2520Inhibitory%2520Activities%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D5%26spage%3D304%26epage%3D308%26doi%3D10.1021%2Fml400373j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref122"><div class="reference"><strong class="refLabel"><a href="#ref122" class="rightTabRefNumLink">122</a></strong><div class="NLM_citation" id="rightTab-cit122"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Song, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, A.</span></span> <span> </span><span class="NLM_article-title">Discovery of Novel 2, 4-diarylaminopyrimidine Analogues (DAAPalogues) Showing Potent Inhibitory Activities against Both Wild-type and Mutant ALK Kinases</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">197</span>– <span class="NLM_lpage">211</span>, <span class="refDoi"> DOI: 10.1021/jm5005144</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm5005144" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC2cXnt1Cgu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=197-211&author=Z.+Songauthor=Y.+Yangauthor=Z.+Liuauthor=X.+Pengauthor=J.+Guoauthor=X.+Yangauthor=K.+Wuauthor=J.+Aiauthor=J.+Dingauthor=M.+Gengauthor=A.+Zhang&title=Discovery+of+Novel+2%2C+4-diarylaminopyrimidine+Analogues+%28DAAPalogues%29+Showing+Potent+Inhibitory+Activities+against+Both+Wild-type+and+Mutant+ALK+Kinases&doi=10.1021%2Fjm5005144"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit122R"><div class="casContent"><span class="casTitleNuber">122</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Novel 2,4-Diarylaminopyrimidine Analogues (DAAPalogues) Showing Potent Inhibitory Activities against Both Wild-type and Mutant ALK Kinases</span></div><div class="casAuthors">Song, Zilan; Yang, Yanhong; Liu, Zhiqing; Peng, Xia; Guo, Junfeng; Yang, Xinying; Wu, Kui; Ai, Jing; Ding, Jian; Geng, Meiyu; Zhang, Ao</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">197-211</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of new 2,4-diarylaminopyrimidine analogs (DAAPalogues) bearing a flexible amino acid side chain was developed, different from the majority of the literature reported ALK inhibitors that often possess a structurally constrained arylpiperazine fragment or its equiv. in the solvent-interaction region.  Extensive structural elaboration led to compd. I possessing IC50 values of 2.7 and 15.3 nM, resp., in the ALK wild-type and gate-keeper mutant L1196M enzymic assays.  This compd. not only showed high proliferative inhibition against ALK-addicted cells across different oncogenic forms but also effectively suppressed several ALK secondary mutant cells, including the gate-keeper L1196M and F1174L.  Significant antitumor efficacy was achieved in the ALK-driven SUP-M2 xenograft model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqM85-KYGRZZLVg90H21EOLACvtfcHk0lhN7DkQpOJm5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXnt1Cgu7c%253D&md5=b82a016127ac916e365a2bcbace63f75</span></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.1021%2Fjm5005144&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm5005144%26sid%3Dliteratum%253Aachs%26aulast%3DSong%26aufirst%3DZ.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DPeng%26aufirst%3DX.%26aulast%3DGuo%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DWu%26aufirst%3DK.%26aulast%3DAi%26aufirst%3DJ.%26aulast%3DDing%26aufirst%3DJ.%26aulast%3DGeng%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DA.%26atitle%3DDiscovery%2520of%2520Novel%25202%252C%25204-diarylaminopyrimidine%2520Analogues%2520%2528DAAPalogues%2529%2520Showing%2520Potent%2520Inhibitory%2520Activities%2520against%2520Both%2520Wild-type%2520and%2520Mutant%2520ALK%2520Kinases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D197%26epage%3D211%26doi%3D10.1021%2Fjm5005144" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref123"><div class="reference"><strong class="refLabel"><a href="#ref123" class="rightTabRefNumLink">123</a></strong><div class="NLM_citation" id="rightTab-cit123"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kuromitsu, S.</span>; <span class="NLM_string-name">Mori, M.</span>; <span class="NLM_string-name">Shimada, I.</span>; <span class="NLM_string-name">Kondoh, Y.</span>; <span class="NLM_string-name">Shindoh, N.</span>; <span class="NLM_string-name">Soga, T.</span>; <span class="NLM_string-name">Furutani, T.</span>; <span class="NLM_string-name">Konagai, S.</span>; <span class="NLM_string-name">Sakagami, H.</span>; <span class="NLM_string-name">Nakata, M.</span>; <span class="NLM_string-name">Ueno, Y.</span></span> <span> </span><span class="NLM_article-title">Anti-tumor Activity of ASP3026. A Novel and Selective ALK Inhibitor of Anaplastic Lymphoma Kinase (ALK)</span>. Presented at the  <i>Annual Meeting of the American Association for Cancer Res (AACR). Orlando, FL,</i> <span class="NLM_year">2011</span>; Abstract  <span class="NLM_fpage">2821</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&pages=2821&author=S.+Kuromitsu&author=M.+Mori&author=I.+Shimada&author=Y.+Kondoh&author=N.+Shindoh&author=T.+Soga&author=T.+Furutani&author=S.+Konagai&author=H.+Sakagami&author=M.+Nakata&author=Y.+Ueno&title=Anti-tumor+Activity+of+ASP3026.+A+Novel+and+Selective+ALK+Inhibitor+of+Anaplastic+Lymphoma+Kinase+%28ALK%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26sid%3Dliteratum%253Aachs%26aulast%3DKuromitsu%26aufirst%3DS.%26atitle%3DAnti-tumor%2520Activity%2520of%2520ASP3026.%2520A%2520Novel%2520and%2520Selective%2520ALK%2520Inhibitor%2520of%2520Anaplastic%2520Lymphoma%2520Kinase%2520%2528ALK%2529%26jtitle%3DAnnual%2520Meeting%2520of%2520the%2520American%2520Association%2520for%2520Cancer%2520Res%2520%2528AACR%2529.%2520Orlando%252C%2520FL%252C%26date%3D2011%26spage%3D2821" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref124"><div class="reference"><strong class="refLabel"><a href="#ref124" class="rightTabRefNumLink">124</a></strong><div class="NLM_citation" id="rightTab-cit124"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reckamp, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Infante, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blumenschein, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wakelee, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gockerman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lovly, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dukart, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrow, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibbons, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horn, L.</span></span> <span> </span><span class="NLM_article-title">Phase I/II trial of X-396, a Novel Anaplastic Lymphoma Kinase (ALK) Inhibitor, in Patients with ALK+ Non-small Cell Lung Cancer (NSCLC)</span>. <i>J. Thorac. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">S36</span>– <span class="NLM_lpage">S37</span>, <span class="refDoi"> DOI: 10.1016/j.jtho.2015.12.062</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1016%2Fj.jtho.2015.12.062" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=S36-S37&author=K.+Reckampauthor=J.+Infanteauthor=G.+Blumenscheinauthor=H.+Wakeleeauthor=C.+Carterauthor=J.+Gockermanauthor=C.+Lovlyauthor=G.+Dukartauthor=K.+Harrowauthor=C.+Liangauthor=J.+Gibbonsauthor=L.+Horn&title=Phase+I%2FII+trial+of+X-396%2C+a+Novel+Anaplastic+Lymphoma+Kinase+%28ALK%29+Inhibitor%2C+in+Patients+with+ALK%2B+Non-small+Cell+Lung+Cancer+%28NSCLC%29&doi=10.1016%2Fj.jtho.2015.12.062"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.1016%2Fj.jtho.2015.12.062&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jtho.2015.12.062%26sid%3Dliteratum%253Aachs%26aulast%3DReckamp%26aufirst%3DK.%26aulast%3DInfante%26aufirst%3DJ.%26aulast%3DBlumenschein%26aufirst%3DG.%26aulast%3DWakelee%26aufirst%3DH.%26aulast%3DCarter%26aufirst%3DC.%26aulast%3DGockerman%26aufirst%3DJ.%26aulast%3DLovly%26aufirst%3DC.%26aulast%3DDukart%26aufirst%3DG.%26aulast%3DHarrow%26aufirst%3DK.%26aulast%3DLiang%26aufirst%3DC.%26aulast%3DGibbons%26aufirst%3DJ.%26aulast%3DHorn%26aufirst%3DL.%26atitle%3DPhase%2520I%252FII%2520trial%2520of%2520X-396%252C%2520a%2520Novel%2520Anaplastic%2520Lymphoma%2520Kinase%2520%2528ALK%2529%2520Inhibitor%252C%2520in%2520Patients%2520with%2520ALK%252B%2520Non-small%2520Cell%2520Lung%2520Cancer%2520%2528NSCLC%2529%26jtitle%3DJ.%2520Thorac.%2520Oncol.%26date%3D2016%26volume%3D11%26spage%3DS36%26epage%3DS37%26doi%3D10.1016%2Fj.jtho.2015.12.062" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref125"><div class="reference"><strong class="refLabel"><a href="#ref125" class="rightTabRefNumLink">125</a></strong><div class="NLM_citation" id="rightTab-cit125"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sabbatini, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korenchuk, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowand, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leperi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atkins, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dumble, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kruger, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gontarek, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maksimchuk, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suravajjala, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lapierre, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shotwell, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chamberlain, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rabindran, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, R.</span></span> <span> </span><span class="NLM_article-title">GSK1838705A Inhibits the Insulin-like Growth Factor-1 Receptor and Anaplastic Lymphoma Kinase and Shows Antitumor Activity in Experimental Models of Human Cancers</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">2811</span>– <span class="NLM_lpage">2820</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-09-0423</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1158%2F1535-7163.MCT-09-0423" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=19825801" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1Cqur7N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2009&pages=2811-2820&author=P.+Sabbatiniauthor=S.+Korenchukauthor=J.+L.+Rowandauthor=A.+Groyauthor=Q.+Liuauthor=D.+Leperiauthor=C.+Atkinsauthor=M.+Dumbleauthor=J.+Yangauthor=K.+Andersonauthor=R.+G.+Krugerauthor=R.+R.+Gontarekauthor=K.+R.+Maksimchukauthor=S.+Suravajjalaauthor=R.+R.+Lapierreauthor=J.+B.+Shotwellauthor=J.+W.+Wilsonauthor=S.+D.+Chamberlainauthor=S.+K.+Rabindranauthor=R.+Kumar&title=GSK1838705A+Inhibits+the+Insulin-like+Growth+Factor-1+Receptor+and+Anaplastic+Lymphoma+Kinase+and+Shows+Antitumor+Activity+in+Experimental+Models+of+Human+Cancers&doi=10.1158%2F1535-7163.MCT-09-0423"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit125R"><div class="casContent"><span class="casTitleNuber">125</span><div class="casTitle"><span class="NLM_cas:atitle">GSK1838705A inhibits the insulin-like growth factor-1 receptor and anaplastic lymphoma kinase and shows antitumor activity in experimental models of human cancers</span></div><div class="casAuthors">Sabbatini, Peter; Korenchuk, Susan; Rowand, Jason L.; Groy, Arthur; Liu, Qi; Leperi, Dominic; Atkins, Charity; Dumble, Melissa; Yang, Jingsong; Anderson, Kelly; Kruger, Ryan G.; Gontarek, Richard R.; Maksimchuk, Kenneth R.; Suravajjala, Sapna; Lapierre, Russell R.; Shotwell, J. Brad; Wilson, Joseph W.; Chamberlain, Stanley D.; Rabindran, Sridhar K.; Kumar, Rakesh</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2811-2820</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The insulin-like growth factor-I receptor (IGF-IR) signaling pathway is activated in various tumors, and inhibition of IGF-IR kinase provides a therapeutic opportunity in these patients.  GSK1838705A is a small-mol. kinase inhibitor that inhibits IGF-IR and the insulin receptor with IC50s of 2.0 and 1.6 nmol/L, resp.  GSK1838705A blocks the in vitro proliferation of cell lines derived from solid and hematol. malignancies, including multiple myeloma and Ewing's sarcoma, and retards the growth of human tumor xenografts in vivo.  Despite the inhibitory effect of GSK1838705A on insulin receptor, minimal effects on glucose homeostasis were obsd. at efficacious doses.  GSK1838705A also inhibits the anaplastic lymphoma kinase (ALK), which drives the aberrant growth of anaplastic large-cell lymphomas, some neuroblastomas, and a subset of non-small cell lung cancers.  GSK1838705A inhibits ALK, with an IC50 of 0.5 nmol/L, and causes complete regression of ALK-dependent tumors in vivo at well-tolerated doses.  GSK1838705A is therefore a promising antitumor agent for therapeutic use in human cancers. [Mol Cancer Ther 2009;8(10):2811-20].</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqyQ0LEFOBer7Vg90H21EOLACvtfcHk0lgYu-fOgiSSfQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1Cqur7N&md5=42e56e8dd4920322b82bedd13721be5b</span></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-09-0423&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-09-0423%26sid%3Dliteratum%253Aachs%26aulast%3DSabbatini%26aufirst%3DP.%26aulast%3DKorenchuk%26aufirst%3DS.%26aulast%3DRowand%26aufirst%3DJ.%2BL.%26aulast%3DGroy%26aufirst%3DA.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DLeperi%26aufirst%3DD.%26aulast%3DAtkins%26aufirst%3DC.%26aulast%3DDumble%26aufirst%3DM.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DAnderson%26aufirst%3DK.%26aulast%3DKruger%26aufirst%3DR.%2BG.%26aulast%3DGontarek%26aufirst%3DR.%2BR.%26aulast%3DMaksimchuk%26aufirst%3DK.%2BR.%26aulast%3DSuravajjala%26aufirst%3DS.%26aulast%3DLapierre%26aufirst%3DR.%2BR.%26aulast%3DShotwell%26aufirst%3DJ.%2BB.%26aulast%3DWilson%26aufirst%3DJ.%2BW.%26aulast%3DChamberlain%26aufirst%3DS.%2BD.%26aulast%3DRabindran%26aufirst%3DS.%2BK.%26aulast%3DKumar%26aufirst%3DR.%26atitle%3DGSK1838705A%2520Inhibits%2520the%2520Insulin-like%2520Growth%2520Factor-1%2520Receptor%2520and%2520Anaplastic%2520Lymphoma%2520Kinase%2520and%2520Shows%2520Antitumor%2520Activity%2520in%2520Experimental%2520Models%2520of%2520Human%2520Cancers%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2009%26volume%3D8%26spage%3D2811%26epage%3D2820%26doi%3D10.1158%2F1535-7163.MCT-09-0423" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref126"><div class="reference"><strong class="refLabel"><a href="#ref126" class="rightTabRefNumLink">126</a></strong><div class="NLM_citation" id="rightTab-cit126"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brooun, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bunker, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cook, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dack, K. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deal, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, Y.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dinh, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engstrom, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kania, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lingardo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McTigue, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmer, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, P. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sach, N. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smeal, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timofeevski, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsaparikos, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, M. P.</span></span> <span> </span><span class="NLM_article-title">Design of Potent and Selective Inhibitors to Overcome Clinical Anaplastic Lymphoma Kinase Mutations Resistant to Crizotinib</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">1170</span>– <span class="NLM_lpage">1187</span>, <span class="refDoi"> DOI: 10.1021/jm401805h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401805h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC2cXpsFaqsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=1170-1187&author=Q.+Huangauthor=T.+W.+Johnsonauthor=S.+Baileyauthor=A.+Broounauthor=K.+D.+Bunkerauthor=B.+J.+Burkeauthor=M.+R.+Collinsauthor=A.+S.+Cookauthor=J.+J.+Cuiauthor=K.+N.+Dackauthor=J.+G.+Dealauthor=Y.-L.+Dengauthor=D.+Dinhauthor=L.+D.+Engstromauthor=M.+Heauthor=J.+Hoffmanauthor=R.+L.+Hoffmanauthor=P.+S.+Johnsonauthor=R.+S.+Kaniaauthor=H.+Lamauthor=J.+L.+Lamauthor=P.+T.+Leauthor=Q.+Liauthor=L.+Lingardoauthor=W.+Liuauthor=M.+W.+Luauthor=M.+McTigueauthor=C.+L.+Palmerauthor=P.+F.+Richardsonauthor=N.+W.+Sachauthor=H.+Shenauthor=T.+Smealauthor=G.+L.+Smithauthor=A.+E.+Stewartauthor=S.+Timofeevskiauthor=K.+Tsaparikosauthor=H.+Wangauthor=H.+Zhuauthor=J.+Zhuauthor=H.+Y.+Zouauthor=M.+P.+Edwards&title=Design+of+Potent+and+Selective+Inhibitors+to+Overcome+Clinical+Anaplastic+Lymphoma+Kinase+Mutations+Resistant+to+Crizotinib&doi=10.1021%2Fjm401805h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit126R"><div class="casContent"><span class="casTitleNuber">126</span><div class="casTitle"><span class="NLM_cas:atitle">Design of Potent and Selective Inhibitors to Overcome Clinical Anaplastic Lymphoma Kinase Mutations Resistant to Crizotinib</span></div><div class="casAuthors">Huang, Qinhua; Johnson, Ted W.; Bailey, Simon; Brooun, Alexei; Bunker, Kevin D.; Burke, Benjamin J.; Collins, Michael R.; Cook, Andrew S.; Cui, J. Jean; Dack, Kevin N.; Deal, Judith G.; Deng, Ya-Li; Dinh, Dac; Engstrom, Lars D.; He, Mingying; Hoffman, Jacqui; Hoffman, Robert L.; Johnson, Patrick S.; Kania, Robert S.; Lam, Hieu; Lam, Justine L.; Le, Phuong T.; Li, Qiuhua; Lingardo, Laura; Liu, Wei; Lu, Melissa West; McTigue, Michele; Palmer, Cynthia L.; Richardson, Paul F.; Sach, Neal W.; Shen, Hong; Smeal, Tod; Smith, Graham L.; Stewart, Albert E.; Timofeevski, Sergei; Tsaparikos, Konstantinos; Wang, Hui; Zhu, Huichun; Zhu, Jinjiang; Zou, Helen Y.; Edwards, Martin P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1170-1187</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Crizotinib, an anaplastic lymphoma kinase (ALK) receptor tyrosine kinase inhibitor approved by the U.S.  Food and Drug Administration in 2011, is efficacious in ALK and ROS pos. patients.  Under pressure of crizotinib treatment, point mutations arise in the kinase domain of ALK, resulting in resistance and progressive disease.  The successful application of both structure-based and lipophilic-efficiency-focused drug design resulted in aminopyridine (I), which was potent across a broad panel of engineered ALK mutant cell lines and showed suitable preclin. pharmacokinetics and robust tumor growth inhibition in a crizotinib-resistant cell line (H3122-L1196M).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnhF6vRWLUrrVg90H21EOLACvtfcHk0lgYu-fOgiSSfQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXpsFaqsg%253D%253D&md5=c12e0400ac92eb3321fde81ee13a5e92</span></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=10.1021%2Fjm401805h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401805h%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DQ.%26aulast%3DJohnson%26aufirst%3DT.%2BW.%26aulast%3DBailey%26aufirst%3DS.%26aulast%3DBrooun%26aufirst%3DA.%26aulast%3DBunker%26aufirst%3DK.%2BD.%26aulast%3DBurke%26aufirst%3DB.%2BJ.%26aulast%3DCollins%26aufirst%3DM.%2BR.%26aulast%3DCook%26aufirst%3DA.%2BS.%26aulast%3DCui%26aufirst%3DJ.%2BJ.%26aulast%3DDack%26aufirst%3DK.%2BN.%26aulast%3DDeal%26aufirst%3DJ.%2BG.%26aulast%3DDeng%26aufirst%3DY.-L.%26aulast%3DDinh%26aufirst%3DD.%26aulast%3DEngstrom%26aufirst%3DL.%2BD.%26aulast%3DHe%26aufirst%3DM.%26aulast%3DHoffman%26aufirst%3DJ.%26aulast%3DHoffman%26aufirst%3DR.%2BL.%26aulast%3DJohnson%26aufirst%3DP.%2BS.%26aulast%3DKania%26aufirst%3DR.%2BS.%26aulast%3DLam%26aufirst%3DH.%26aulast%3DLam%26aufirst%3DJ.%2BL.%26aulast%3DLe%26aufirst%3DP.%2BT.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DLingardo%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DLu%26aufirst%3DM.%2BW.%26aulast%3DMcTigue%26aufirst%3DM.%26aulast%3DPalmer%26aufirst%3DC.%2BL.%26aulast%3DRichardson%26aufirst%3DP.%2BF.%26aulast%3DSach%26aufirst%3DN.%2BW.%26aulast%3DShen%26aufirst%3DH.%26aulast%3DSmeal%26aufirst%3DT.%26aulast%3DSmith%26aufirst%3DG.%2BL.%26aulast%3DStewart%26aufirst%3DA.%2BE.%26aulast%3DTimofeevski%26aufirst%3DS.%26aulast%3DTsaparikos%26aufirst%3DK.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DZhu%26aufirst%3DH.%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DZou%26aufirst%3DH.%2BY.%26aulast%3DEdwards%26aufirst%3DM.%2BP.%26atitle%3DDesign%2520of%2520Potent%2520and%2520Selective%2520Inhibitors%2520to%2520Overcome%2520Clinical%2520Anaplastic%2520Lymphoma%2520Kinase%2520Mutations%2520Resistant%2520to%2520Crizotinib%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D1170%26epage%3D1187%26doi%3D10.1021%2Fjm401805h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref127"><div class="reference"><strong class="refLabel"><a href="#ref127" class="rightTabRefNumLink">127</a></strong><div class="NLM_citation" id="rightTab-cit127"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hatcher, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bahcall, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, H. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sim, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">George, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jänne, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span> <span> </span><span class="NLM_article-title">Discovery of Inhibitors that Overcome the G1202R Anaplastic Lymphoma Kinase Resistance Mutation</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">9296</span>– <span class="NLM_lpage">9308</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01136</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01136" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvVehs7vE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=9296-9308&author=J.+M.+Hatcherauthor=M.+Bahcallauthor=H.+G.+Choiauthor=Y.+Gaoauthor=T.+Simauthor=R.+Georgeauthor=P.+A.+J%C3%A4nneauthor=N.+S.+Gray&title=Discovery+of+Inhibitors+that+Overcome+the+G1202R+Anaplastic+Lymphoma+Kinase+Resistance+Mutation&doi=10.1021%2Facs.jmedchem.5b01136"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit127R"><div class="casContent"><span class="casTitleNuber">127</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Inhibitors That Overcome the G1202R Anaplastic Lymphoma Kinase Resistance Mutation</span></div><div class="casAuthors">Hatcher, John M.; Bahcall, Magda; Choi, Hwan Geun; Gao, Yang; Sim, Taebo; George, Rani; Janne, Pasi A.; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">9296-9308</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The treatment of patients with advanced nonsmall-cell lung cancer harboring chromosomal rearrangements of anaplastic lymphoma kinase (ALK) has been revolutionized by the development of crizotinib, a small-mol. inhibitor of ALK, ROS1, and MET.  However, resistance to crizotinib inevitably develops through a variety of mechanisms, leading to relapse both systemically and in the central nervous system (CNS).  This has motivated the development of "second-generation" ALK inhibitors, including alectinib and ceritinib, that overcome some of the mutations leading to resistance.  However, most of the reported ALK inhibitors do not show inhibition of the G1202R mutant, which is one of the most common mutations.  Herein, the authors report the development of a structural analog of alectinib I that is potent against the G1202R mutant as well as a variety of other frequently obsd. mutants.  In addn., I is capable of penetrating the CNS of mice following oral dosing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoI_JJeOYNwybVg90H21EOLACvtfcHk0lik9TEbYsiHEw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvVehs7vE&md5=711b0353b771b54990264565c901a76f</span></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01136&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01136%26sid%3Dliteratum%253Aachs%26aulast%3DHatcher%26aufirst%3DJ.%2BM.%26aulast%3DBahcall%26aufirst%3DM.%26aulast%3DChoi%26aufirst%3DH.%2BG.%26aulast%3DGao%26aufirst%3DY.%26aulast%3DSim%26aufirst%3DT.%26aulast%3DGeorge%26aufirst%3DR.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DDiscovery%2520of%2520Inhibitors%2520that%2520Overcome%2520the%2520G1202R%2520Anaplastic%2520Lymphoma%2520Kinase%2520Resistance%2520Mutation%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D9296%26epage%3D9308%26doi%3D10.1021%2Facs.jmedchem.5b01136" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref128"><div class="reference"><strong class="refLabel"><a href="#ref128" class="rightTabRefNumLink">128</a></strong><div class="NLM_citation" id="rightTab-cit128"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fushimi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujimori, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wakabayashi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hasui, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawakita, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imamura, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kato, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murakami, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishii, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kikko, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kasahara, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakatani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hiura, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyamoto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saikatendu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawson, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imoto, H.</span></span> <span> </span><span class="NLM_article-title">Discovery of Potent, Selective, and Brain-Penetrant 1 H-Pyrazol-5-yl-1H-pyrrolo [2, 3-b] pyridines as Anaplastic Lymphoma Kinase (ALK) Inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">4915</span>– <span class="NLM_lpage">4935</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01630</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01630" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC1MXnvFCgsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=4915-4935&author=M.+Fushimiauthor=I.+Fujimoriauthor=T.+Wakabayashiauthor=T.+Hasuiauthor=Y.+Kawakitaauthor=K.+Imamuraauthor=T.+Katoauthor=M.+Murakamiauthor=T.+Ishiiauthor=Y.+Kikkoauthor=M.+Kasaharaauthor=A.+Nakataniauthor=Y.+Hiuraauthor=M.+Miyamotoauthor=K.+Saikatenduauthor=H.+Zouauthor=S.+W.+Laneauthor=J.+D.+Lawsonauthor=H.+Imoto&title=Discovery+of+Potent%2C+Selective%2C+and+Brain-Penetrant+1+H-Pyrazol-5-yl-1H-pyrrolo+%5B2%2C+3-b%5D+pyridines+as+Anaplastic+Lymphoma+Kinase+%28ALK%29+Inhibitors&doi=10.1021%2Facs.jmedchem.8b01630"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit128R"><div class="casContent"><span class="casTitleNuber">128</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of potent, selective, and brain-penetrant 1H-pyrazol-5-yl-1H-pyrrolo[2,3-b]pyridines as anaplastic lymphoma kinase (ALK) inhibitors</span></div><div class="casAuthors">Fushimi, Makoto; Fujimori, Ikuo; Wakabayashi, Takeshi; Hasui, Tomoaki; Kawakita, Youichi; Imamura, Keisuke; Kato, Tomoko; Murakami, Morio; Ishii, Tsuyoshi; Kikko, Yorifumi; Kasahara, Maki; Nakatani, Atsushi; Hiura, Yuto; Miyamoto, Maki; Saikatendu, Kumar; Zou, Hua; Lane, Scott Weston; Lawson, J. David; Imoto, Hiroshi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4915-4935</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Anaplastic lymphoma kinase (ALK), a member of the receptor tyrosine kinase family, is predominantly expressed in the brain and implicated in neuronal development and cognition.  However, the detailed function of ALK in the central nervous system (CNS) is still unclear.  To elucidate the role of ALK in the CNS, it was necessary to discover a potent, selective, and brain-penetrant ALK inhibitor.  Scaffold hopping and lead optimization of N-(2,4-difluorobenzyl)-3-(1H-pyrazol-5-yl)imidazo[1,2-b]pyridazin-6-amine 1 guided by a cocrystal structure of compd. 1 bound to ALK resulted in the identification of (6-(1-(5-fluoropyridin-2-yl)ethoxy)-1-(5-methyl-1H-pyrazol-3-yl)-1H-pyrrolo[2,3-b]pyridin-3-yl)((2S)-2-methylmorpholin-4-yl)methanone 13 as a highly potent, selective, and brain-penetrable compd.  I.p. administration of compd. 13 significantly decreased the phosphorylated-ALK (p-ALK) levels in the hippocampus and prefrontal cortex in the mouse brain.  These results suggest that compd. 13 could serve as a useful chem. probe to elucidate the mechanism of ALK-mediated brain functions and the therapeutic potential of ALK inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq0WiOsZo1xFLVg90H21EOLACvtfcHk0lik9TEbYsiHEw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXnvFCgsrg%253D&md5=8d3bac7f718930a6102cb7855af501cb</span></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01630&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01630%26sid%3Dliteratum%253Aachs%26aulast%3DFushimi%26aufirst%3DM.%26aulast%3DFujimori%26aufirst%3DI.%26aulast%3DWakabayashi%26aufirst%3DT.%26aulast%3DHasui%26aufirst%3DT.%26aulast%3DKawakita%26aufirst%3DY.%26aulast%3DImamura%26aufirst%3DK.%26aulast%3DKato%26aufirst%3DT.%26aulast%3DMurakami%26aufirst%3DM.%26aulast%3DIshii%26aufirst%3DT.%26aulast%3DKikko%26aufirst%3DY.%26aulast%3DKasahara%26aufirst%3DM.%26aulast%3DNakatani%26aufirst%3DA.%26aulast%3DHiura%26aufirst%3DY.%26aulast%3DMiyamoto%26aufirst%3DM.%26aulast%3DSaikatendu%26aufirst%3DK.%26aulast%3DZou%26aufirst%3DH.%26aulast%3DLane%26aufirst%3DS.%2BW.%26aulast%3DLawson%26aufirst%3DJ.%2BD.%26aulast%3DImoto%26aufirst%3DH.%26atitle%3DDiscovery%2520of%2520Potent%252C%2520Selective%252C%2520and%2520Brain-Penetrant%25201%2520H-Pyrazol-5-yl-1H-pyrrolo%2520%255B2%252C%25203-b%255D%2520pyridines%2520as%2520Anaplastic%2520Lymphoma%2520Kinase%2520%2528ALK%2529%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D4915%26epage%3D4935%26doi%3D10.1021%2Facs.jmedchem.8b01630" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref129"><div class="reference"><strong class="refLabel"><a href="#ref129" class="rightTabRefNumLink">129</a></strong><div class="NLM_citation" id="rightTab-cit129"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Drilon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ou, S.-H. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, V. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, M.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camidge, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhai, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogers, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitten, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stopatschinskaja, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hyman, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doebele, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, A. T.</span></span> <span> </span><span class="NLM_article-title">Repotrectinib (TPX-0005) Is a Next-generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent-front Mutations</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1227</span>– <span class="NLM_lpage">1236</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-18-0484</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1158%2F2159-8290.CD-18-0484" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=30093503" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC1MXmt1ehtLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2018&pages=1227-1236&author=A.+Drilonauthor=S.-H.+I.+Ouauthor=B.+C.+Choauthor=D.-W.+Kimauthor=J.+Leeauthor=J.+J.+Linauthor=V.+W.+Zhuauthor=M.-J.+Ahnauthor=D.+R.+Camidgeauthor=J.+Nguyenauthor=D.+Zhaiauthor=W.+Dengauthor=Z.+Huangauthor=E.+Rogersauthor=J.+Liuauthor=J.+Whittenauthor=J.+K.+Limauthor=S.+Stopatschinskajaauthor=D.+M.+Hymanauthor=R.+C.+Doebeleauthor=J.+J.+Cuiauthor=A.+T.+Shaw&title=Repotrectinib+%28TPX-0005%29+Is+a+Next-generation+ROS1%2FTRK%2FALK+Inhibitor+That+Potently+Inhibits+ROS1%2FTRK%2FALK+Solvent-front+Mutations&doi=10.1158%2F2159-8290.CD-18-0484"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit129R"><div class="casContent"><span class="casTitleNuber">129</span><div class="casTitle"><span class="NLM_cas:atitle">Repotrectinib (TPX-0005) is a next-generation ROS1/TRK/ALK inhibitor that potently inhibits ROS1/TRK/ALK solvent-front mutations</span></div><div class="casAuthors">Drilon, Alexander; Ou, Sai-Hong Ignatius; Cho, Byoung Chul; Kim, Dong-Wan; Lee, Jeeyun; Lin, Jessica J.; Zhu, Viola W.; Ahn, Myung-Ju; Camidge, D. Ross; Nguyen, Judy; Zhai, Dayong; Deng, Wei; Huang, Zhongdong; Rogers, Evan; Liu, Juliet; Whitten, Jeff; Lim, John K.; Stopatschinskaja, Shanna; Hyman, David M.; Doebele, Robert C.; Cui, J. Jean; Shaw, Alice T.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1227-1236</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The use of tyrosine kinase inhibitors (TKI) with activity against ALK, ROS1, or TRKA-C can result in signifi cant clin. benefit in patients with diverse tumors harboring ALK, ROS1, or NTRK1-3 rearrangements; however, resistance invariably develops.  The emergence of on-target kinase domain mutations represents a major mechanism of acquired resistance.  Solvent-front substitutions such as ALKG1202R, ROS1G2032R or ROS1D2033N, TRKAG595R, and TRKCG623R are among the most recalcitrant of these mechanisms.  Repotrectinib (TPX-0005) is a rationally designed, low-mol.-wt., macrocyclic TKI that is selective and highly potent against ROS1, TRKA-C, and ALK.  Importantly, repotrectinib exhibits activity against a variety of solventfront substitutions in vitro and in vivo.  As clin. proof of concept, in an ongoing first-in-human phase I/II trial, repotrectinib achieved confirmed responses in patients with ROS1 or NTRK3 fusion- pos. cancers who had relapsed on earlier-generation TKIs due to ROS1 or TRKC solvent-front substitution-mediated resistance.  SIGNIFICANCE: Repotrectinib (TPX-0005), a next-generation ROS1, pan-TRK, and ALK TKI, overcomes resistance due to acquired solvent-front mutations involving ROS1, NTRK1-3, and ALK.  Repotrectinib may represent an effective therapeutic option for patients with ROS1-, NTRK1-3-, or ALK-rearranged malignancies who have progressed on earlier-generation TKIs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpNmuKNmAgWKLVg90H21EOLACvtfcHk0lhDQr2zboxaQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXmt1ehtLs%253D&md5=b5408bf045e049629557cb347ab61980</span></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-18-0484&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-18-0484%26sid%3Dliteratum%253Aachs%26aulast%3DDrilon%26aufirst%3DA.%26aulast%3DOu%26aufirst%3DS.-H.%2BI.%26aulast%3DCho%26aufirst%3DB.%2BC.%26aulast%3DKim%26aufirst%3DD.-W.%26aulast%3DLee%26aufirst%3DJ.%26aulast%3DLin%26aufirst%3DJ.%2BJ.%26aulast%3DZhu%26aufirst%3DV.%2BW.%26aulast%3DAhn%26aufirst%3DM.-J.%26aulast%3DCamidge%26aufirst%3DD.%2BR.%26aulast%3DNguyen%26aufirst%3DJ.%26aulast%3DZhai%26aufirst%3DD.%26aulast%3DDeng%26aufirst%3DW.%26aulast%3DHuang%26aufirst%3DZ.%26aulast%3DRogers%26aufirst%3DE.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DWhitten%26aufirst%3DJ.%26aulast%3DLim%26aufirst%3DJ.%2BK.%26aulast%3DStopatschinskaja%26aufirst%3DS.%26aulast%3DHyman%26aufirst%3DD.%2BM.%26aulast%3DDoebele%26aufirst%3DR.%2BC.%26aulast%3DCui%26aufirst%3DJ.%2BJ.%26aulast%3DShaw%26aufirst%3DA.%2BT.%26atitle%3DRepotrectinib%2520%2528TPX-0005%2529%2520Is%2520a%2520Next-generation%2520ROS1%252FTRK%252FALK%2520Inhibitor%2520That%2520Potently%2520Inhibits%2520ROS1%252FTRK%252FALK%2520Solvent-front%2520Mutations%26jtitle%3DCancer%2520Discovery%26date%3D2018%26volume%3D8%26spage%3D1227%26epage%3D1236%26doi%3D10.1158%2F2159-8290.CD-18-0484" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref130"><div class="reference"><strong class="refLabel"><a href="#ref130" class="rightTabRefNumLink">130</a></strong><div class="NLM_citation" id="rightTab-cit130"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gingrich, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lisko, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curry, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quail, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albom, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angeles, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aimone, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haltiwanger, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wells-Knecht, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ott, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghose, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ator, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruggeri, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dorsey, B. D.</span></span> <span> </span><span class="NLM_article-title">Discovery of an Orally Efficacious Inhibitor of Anaplastic Lymphoma Kinase</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">4580</span>– <span class="NLM_lpage">4593</span>, <span class="refDoi"> DOI: 10.1021/jm201550q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm201550q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC38Xms1Sks7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=4580-4593&author=D.+E.+Gingrichauthor=J.+G.+Liskoauthor=M.+A.+Curryauthor=M.+Chengauthor=M.+Quailauthor=L.+Luauthor=W.+Wanauthor=M.+S.+Albomauthor=T.+S.+Angelesauthor=L.+D.+Aimoneauthor=R.+C.+Haltiwangerauthor=K.+Wells-Knechtauthor=G.+R.+Ottauthor=A.+K.+Ghoseauthor=M.+A.+Atorauthor=B.+Ruggeriauthor=B.+D.+Dorsey&title=Discovery+of+an+Orally+Efficacious+Inhibitor+of+Anaplastic+Lymphoma+Kinase&doi=10.1021%2Fjm201550q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit130R"><div class="casContent"><span class="casTitleNuber">130</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of an orally efficacious inhibitor of anaplastic lymphoma kinase</span></div><div class="casAuthors">Gingrich, Diane E.; Lisko, Joseph G.; Curry, Matthew A.; Cheng, Mangeng; Quail, Matthew; Lu, Lihui; Wan, Weihua; Albom, Mark S.; Angeles, Thelma S.; Aimone, Lisa D.; Haltiwanger, R. Curtis; Wells-Knecht, Kevin; Ott, Gregory R.; Ghose, Arup K.; Ator, Mark A.; Ruggeri, Bruce; Dorsey, Bruce D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4580-4593</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Anaplastic lymphoma kinase (ALK) is a promising therapeutic target for the treatment of cancer, supported by considerable favorable preclin. and clin. activities over the past several years and culminating in the recent FDA approval of the ALK inhibitor crizotinib.  Through a series of targeted modifications on an ALK inhibitor diaminopyrimidine scaffold, our research group has driven improvements in ALK potency, kinase selectivity, and overall pharmaceutical properties.  Optimization of this scaffold has led to the identification of a potent and efficacious inhibitor of ALK, I.  A striking feature of I over previously described ALK inhibitors is its >600-fold selectivity over insulin receptor (IR), a closely related kinase family member.  Most importantly, I exhibited dose proportional escalation in rat compared to compd. 3 which suffered dose limiting absorption preventing further advancement.  Compd. I exhibited significant in vivo antitumor efficacy when dosed orally in an ALK-pos. ALCL tumor xenograft model in SCID mice, warranting further assessment in advanced preclin. models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqX3rG4B6V3Y7Vg90H21EOLACvtfcHk0lhDQr2zboxaQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xms1Sks7s%253D&md5=f0592f6eb9d22a5b8e70ab5d3499f821</span></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=10.1021%2Fjm201550q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm201550q%26sid%3Dliteratum%253Aachs%26aulast%3DGingrich%26aufirst%3DD.%2BE.%26aulast%3DLisko%26aufirst%3DJ.%2BG.%26aulast%3DCurry%26aufirst%3DM.%2BA.%26aulast%3DCheng%26aufirst%3DM.%26aulast%3DQuail%26aufirst%3DM.%26aulast%3DLu%26aufirst%3DL.%26aulast%3DWan%26aufirst%3DW.%26aulast%3DAlbom%26aufirst%3DM.%2BS.%26aulast%3DAngeles%26aufirst%3DT.%2BS.%26aulast%3DAimone%26aufirst%3DL.%2BD.%26aulast%3DHaltiwanger%26aufirst%3DR.%2BC.%26aulast%3DWells-Knecht%26aufirst%3DK.%26aulast%3DOtt%26aufirst%3DG.%2BR.%26aulast%3DGhose%26aufirst%3DA.%2BK.%26aulast%3DAtor%26aufirst%3DM.%2BA.%26aulast%3DRuggeri%26aufirst%3DB.%26aulast%3DDorsey%26aufirst%3DB.%2BD.%26atitle%3DDiscovery%2520of%2520an%2520Orally%2520Efficacious%2520Inhibitor%2520of%2520Anaplastic%2520Lymphoma%2520Kinase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D4580%26epage%3D4593%26doi%3D10.1021%2Fjm201550q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref131"><div class="reference"><strong class="refLabel"><a href="#ref131" class="rightTabRefNumLink">131</a></strong><div class="NLM_citation" id="rightTab-cit131"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Salem, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alsalahi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chervoneva, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aburto, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Addya, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ott, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruggeri, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cristofanilli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandez, S. V.</span></span> <span> </span><span class="NLM_article-title">The effects of CEP-37440, an Inhibitor of Focal Adhesion Kinase, in Vitro and in Vivo on Inflammatory Breast Cancer Cells</span>. <i>Breast Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">37</span>– <span class="NLM_lpage">52</span>, <span class="refDoi"> DOI: 10.1186/s13058-016-0694-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1186%2Fs13058-016-0694-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=27009091" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC2sXisVOhsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2016&pages=37-52&author=I.+Salemauthor=M.+Alsalahiauthor=I.+Chervonevaauthor=L.+D.+Aburtoauthor=S.+Addyaauthor=G.+R.+Ottauthor=B.+A.+Ruggeriauthor=M.+Cristofanilliauthor=S.+V.+Fernandez&title=The+effects+of+CEP-37440%2C+an+Inhibitor+of+Focal+Adhesion+Kinase%2C+in+Vitro+and+in+Vivo+on+Inflammatory+Breast+Cancer+Cells&doi=10.1186%2Fs13058-016-0694-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit131R"><div class="casContent"><span class="casTitleNuber">131</span><div class="casTitle"><span class="NLM_cas:atitle">The effects of CEP-37440, an inhibitor of focal adhesion kinase, in vitro and in vivo on inflammatory breast cancer cells</span></div><div class="casAuthors">Salem, Israa; Alsalahi, Manal; Chervoneva, Inna; Aburto, Lucy D.; Addya, Sankar; Ott, Gregory R.; Ruggeri, Bruce A.; Cristofanilli, Massimo; Fernandez, Sandra V.</div><div class="citationInfo"><span class="NLM_cas:title">Breast Cancer Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">37/1-37/15</span>CODEN:
                <span class="NLM_cas:coden">BRCRFS</span>;
        ISSN:<span class="NLM_cas:issn">1465-542X</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Inflammatory breast cancer (IBC) is an aggressive type of advanced breast cancer with a poor prognosis.  We recently found that focal adhesion kinase 1 (FAK1) is upregulated and phosphorylated (active) in IBC.  In this study, we investigated the effect of CEP-37440, a dual inhibitor of FAK1 and anaplastic lymphoma kinase (ALK), using human IBC cell lines and preclin. models of IBC.  Cell proliferation assays were performed in the presence of several concns. of CEP-37440 using IBC and triple-neg. breast cancer non-IBC cell lines.  In vitro, we studied the expression of total FAK1, phospho-FAK1 (Tyr 397), total ALK and phospho-ALK (Tyr 1604).  In vivo, we tested CEP-37440 using FC-IBC02, SUM149, and SUM190 IBC xenograft mouse models.  CEP-37440 at low concn. decreased the proliferation of the IBC cell lines FC-IBC02, SUM190, and KPL4, while not affecting the proliferation of normal breast epithelial cells.  At higher concn., CEP-37440 was also able to inhibit the proliferation of the IBC cell line MDA-IBC03 and the triple-neg. non-IBC cell lines MDA-MB-231 and MDA-MB-468; the IBC cell line SUM149 showed a slight response to the drug.  CEP-37440 decreased the cell proliferation of FC-IBC02, SUM190, and KPL4 by blocking the autophosphorylation kinase activity of FAK1 (Tyr 397).  None of the cells evaluated expressed ALK.  In vivo, after 7 wk of CEP-37440 treatment, the SUM190, FC-IBC02, and SUM149 breast tumor xenografts were smaller in mice treated with 55 mg/kg bid CEP-37440 compared to the controls; the tumor growth inhibition (TGI) was 79.7 %, 33 %, and 23 %, resp.  None of the FC-IBC02 breast xenografts mice treated with CEP-37440 developed brain metastasis while 20 % of the mice in the control group developed brain metastasis.  Expression array analyses in FC-IBC02 cells showed that CEP-37440 affects the expression of genes related to apoptosis, interferon signaling, and cytokines.  CEP-37440 is effective against some IBC cells that express phospho-FAK1 (Tyr 397), and its antiproliferative activity is related to its ability to decrease phospho-FAK1.  Our results suggest that combinational therapies could be more effective than using CEP-37440 as a single agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGouzKOMoopU8rVg90H21EOLACvtfcHk0lhDQr2zboxaQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXisVOhsL8%253D&md5=d69c00c3a502a33f80d58dcc04337596</span></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=10.1186%2Fs13058-016-0694-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13058-016-0694-4%26sid%3Dliteratum%253Aachs%26aulast%3DSalem%26aufirst%3DI.%26aulast%3DAlsalahi%26aufirst%3DM.%26aulast%3DChervoneva%26aufirst%3DI.%26aulast%3DAburto%26aufirst%3DL.%2BD.%26aulast%3DAddya%26aufirst%3DS.%26aulast%3DOtt%26aufirst%3DG.%2BR.%26aulast%3DRuggeri%26aufirst%3DB.%2BA.%26aulast%3DCristofanilli%26aufirst%3DM.%26aulast%3DFernandez%26aufirst%3DS.%2BV.%26atitle%3DThe%2520effects%2520of%2520CEP-37440%252C%2520an%2520Inhibitor%2520of%2520Focal%2520Adhesion%2520Kinase%252C%2520in%2520Vitro%2520and%2520in%2520Vivo%2520on%2520Inflammatory%2520Breast%2520Cancer%2520Cells%26jtitle%3DBreast%2520Cancer%2520Res.%26date%3D2016%26volume%3D18%26spage%3D37%26epage%3D52%26doi%3D10.1186%2Fs13058-016-0694-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref132"><div class="reference"><strong class="refLabel"><a href="#ref132" class="rightTabRefNumLink">132</a></strong><div class="NLM_citation" id="rightTab-cit132"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Drew, L.</span>; <span class="NLM_string-name">Cheng, J.</span>; <span class="NLM_string-name">Engelman, J.</span>; <span class="NLM_string-name">Ferguson, D.</span>; <span class="NLM_string-name">Katayama, R.</span>; <span class="NLM_string-name">McDermott, B.</span>; <span class="NLM_string-name">Saeh, J.</span>; <span class="NLM_string-name">Shaw, A.</span>; <span class="NLM_string-name">Shen, M.</span>; <span class="NLM_string-name">Widzowski, D.</span>; <span class="NLM_string-name">Wu, A.</span></span> <span> </span><span class="NLM_article-title">AZD3463, a novel ALK/IGF1R inhibitor, Overcomes Multiple Mechanisms of Acquired Resistance to Crizotinib</span>. Presented at the  <i>104th Annual Meeting of the American Association for Cancer Research, Washington, DC,</i> <span class="NLM_year">2013</span>; Abstract  <span class="NLM_fpage">919</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&pages=919&author=L.+Drew&author=J.+Cheng&author=J.+Engelman&author=D.+Ferguson&author=R.+Katayama&author=B.+McDermott&author=J.+Saeh&author=A.+Shaw&author=M.+Shen&author=D.+Widzowski&author=A.+Wu&title=AZD3463%2C+a+novel+ALK%2FIGF1R+inhibitor%2C+Overcomes+Multiple+Mechanisms+of+Acquired+Resistance+to+Crizotinib"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26sid%3Dliteratum%253Aachs%26aulast%3DDrew%26aufirst%3DL.%26atitle%3DAZD3463%252C%2520a%2520novel%2520ALK%252FIGF1R%2520inhibitor%252C%2520Overcomes%2520Multiple%2520Mechanisms%2520of%2520Acquired%2520Resistance%2520to%2520Crizotinib%26jtitle%3D104th%2520Annual%2520Meeting%2520of%2520the%2520American%2520Association%2520for%2520Cancer%2520Research%252C%2520Washington%252C%2520DC%252C%26date%3D2013%26spage%3D919" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref133"><div class="reference"><strong class="refLabel"><a href="#ref133" class="rightTabRefNumLink">133</a></strong><div class="NLM_citation" id="rightTab-cit133"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pang, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akiyama, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muscal, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span> <span> </span><span class="NLM_article-title">Novel ALK inhibitor AZD3463 Inhibits Neuroblastoma Growth by Overcoming Crizotinib Resistance and Inducing Apoptosis</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">19423</span>, <span class="refDoi"> DOI: 10.1038/srep19423</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1038%2Fsrep19423" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=26786851" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1ertrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2016&pages=19423&author=Y.+Wangauthor=L.+Wangauthor=S.+Guanauthor=W.+Caoauthor=H.+Wangauthor=Z.+Chenauthor=Y.+Zhaoauthor=Y.+Yuauthor=H.+Zhangauthor=J.+C.+Pangauthor=S.+L.+Huangauthor=Y.+Akiyamaauthor=Y.+Yangauthor=W.+Sunauthor=X.+Xuauthor=Y.+Shiauthor=H.+Zhangauthor=E.+S.+Kimauthor=J.+A.+Muscalauthor=F.+Luauthor=J.+Yang&title=Novel+ALK+inhibitor+AZD3463+Inhibits+Neuroblastoma+Growth+by+Overcoming+Crizotinib+Resistance+and+Inducing+Apoptosis&doi=10.1038%2Fsrep19423"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit133R"><div class="casContent"><span class="casTitleNuber">133</span><div class="casTitle"><span class="NLM_cas:atitle">Novel ALK inhibitor AZD3463 inhibits neuroblastoma growth by overcoming crizotinib resistance and inducing apoptosis</span></div><div class="casAuthors">Wang, Yongfeng; Wang, Long; Guan, Shan; Cao, Wenming; Wang, Hao; Chen, Zhenghu; Zhao, Yanling; Yu, Yang; Zhang, Huiyuan; Pang, Jonathan C.; Huang, Sophia L.; Akiyama, Yo; Yang, Yifan; Sun, Wenjing; Xu, Xin; Shi, Yan; Zhang, Hong; Kim, Eugene S.; Muscal, Jodi A.; Lu, Fengmin; Yang, Jianhua</div><div class="citationInfo"><span class="NLM_cas:title">Scientific Reports</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">19423</span>CODEN:
                <span class="NLM_cas:coden">SRCEC3</span>;
        ISSN:<span class="NLM_cas:issn">2045-2322</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">ALK receptor tyrosine kinase has been shown to be a therapeutic target in neuroblastoma.  Germline ALK activating mutations are responsible for the majority of hereditary neuroblastoma and somatic ALK activating mutations are also frequently obsd. in sporadic cases of advanced NB.  Crizotinib, a first-line therapy in the treatment of advanced non-small cell lung cancer (NSCLC) harboring ALK rearrangements, demonstrates striking efficacy against ALK-rearranged NB.  However, crizotinib fails to effectively inhibit the activity of ALK when activating mutations are present within its kinase domain, as with the F1174L mutation.  Here we show that a new ALK inhibitor AZD3463 effectively suppressed the proliferation of NB cell lines with wild type ALK (WT) as well as ALK activating mutations (F1174L and D1091N) by blocking the ALK-mediated PI3K/AKT/mTOR pathway and ultimately induced apoptosis and autophagy.  In addn., AZD3463 enhanced the cytotoxic effects of doxorubicin on NB cells.  AZD3463 also exhibited significant therapeutic efficacy on the growth of the NB tumors with WT and F1174L activating mutation ALK in orthotopic xenograft mouse models.  These results indicate that AZD3463 is a promising therapeutic agent in the treatment of NB.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxpTw1vcCp5LVg90H21EOLACvtfcHk0li1N2XyERrBUw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1ertrc%253D&md5=d0411dbc4fa257861c010195baaa17b7</span></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=10.1038%2Fsrep19423&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep19423%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DGuan%26aufirst%3DS.%26aulast%3DCao%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DYu%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DPang%26aufirst%3DJ.%2BC.%26aulast%3DHuang%26aufirst%3DS.%2BL.%26aulast%3DAkiyama%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DSun%26aufirst%3DW.%26aulast%3DXu%26aufirst%3DX.%26aulast%3DShi%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DKim%26aufirst%3DE.%2BS.%26aulast%3DMuscal%26aufirst%3DJ.%2BA.%26aulast%3DLu%26aufirst%3DF.%26aulast%3DYang%26aufirst%3DJ.%26atitle%3DNovel%2520ALK%2520inhibitor%2520AZD3463%2520Inhibits%2520Neuroblastoma%2520Growth%2520by%2520Overcoming%2520Crizotinib%2520Resistance%2520and%2520Inducing%2520Apoptosis%26jtitle%3DSci.%2520Rep.%26date%3D2016%26volume%3D6%26spage%3D19423%26doi%3D10.1038%2Fsrep19423" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref134"><div class="reference"><strong class="refLabel"><a href="#ref134" class="rightTabRefNumLink">134</a></strong><div class="NLM_citation" id="rightTab-cit134"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shih, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Q.</span></span> <span> </span><span class="NLM_article-title">Design and Synthesis of Novel 3-sulfonylpyrazol-4-amino Pyrimidines as Potent Anaplastic Lymphoma Kinase (ALK) Inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">1910</span>– <span class="NLM_lpage">1918</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2016.03.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1016%2Fj.bmcl.2016.03.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=26979157" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC28XktFekt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=1910-1918&author=P.+Zhangauthor=J.+Dongauthor=B.+Zhongauthor=D.+Zhangauthor=H.+Yuanauthor=C.+Jinauthor=X.+Xuauthor=H.+Liauthor=Y.+Zhouauthor=Z.+Liangauthor=M.+Jiauthor=T.+Xuauthor=G.+Songauthor=L.+Zhangauthor=G.+Chenauthor=X.+Mengauthor=D.+Sunauthor=J.+Shihauthor=R.+Zhangauthor=G.+Houauthor=C.+Wangauthor=Y.+Jinauthor=Q.+Yang&title=Design+and+Synthesis+of+Novel+3-sulfonylpyrazol-4-amino+Pyrimidines+as+Potent+Anaplastic+Lymphoma+Kinase+%28ALK%29+Inhibitors&doi=10.1016%2Fj.bmcl.2016.03.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit134R"><div class="casContent"><span class="casTitleNuber">134</span><div class="casTitle"><span class="NLM_cas:atitle">Design and synthesis of novel 3-sulfonylpyrazol-4-amino pyrimidines as potent anaplastic lymphoma kinase (ALK) inhibitors</span></div><div class="casAuthors">Zhang, Peilong; Dong, Jiaqiang; Zhong, Boyu; Zhang, Deyi; Yuan, Hongbin; Jin, Can; Xu, Xiangyuan; Li, Hailong; Zhou, Yong; Liang, Zhi; Ji, Minghua; Xu, Tao; Song, Guowei; Zhang, Ling; Chen, Gang; Meng, Xuejing; Sun, Desheng; Shih, Joe; Zhang, Ruihao; Hou, Guojun; Wang, Chengcheng; Jin, Ying; Yang, Qiong</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1910-1918</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Anaplastic lymphoma kinase (ALK) is a highly attractive therapeutic target for the treatment of some non-small cell lung cancer patients.  This Letter describes the further SAR exploration on the novel 3-sulfonylpyrazol-4-amino pyrimidine scaffold.  This work identified a compd. I with very good in vitro/in vivo efficacies, good DMPK properties together with better hERG tolerability and it is currently being profiled for the evaluation as a potential pre-clin. candidate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxXkTKa-yf67Vg90H21EOLACvtfcHk0li1N2XyERrBUw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XktFekt7s%253D&md5=1484e714f7a8338805e8dd4b9cebf591</span></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2016.03.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2016.03.017%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DP.%26aulast%3DDong%26aufirst%3DJ.%26aulast%3DZhong%26aufirst%3DB.%26aulast%3DZhang%26aufirst%3DD.%26aulast%3DYuan%26aufirst%3DH.%26aulast%3DJin%26aufirst%3DC.%26aulast%3DXu%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DLiang%26aufirst%3DZ.%26aulast%3DJi%26aufirst%3DM.%26aulast%3DXu%26aufirst%3DT.%26aulast%3DSong%26aufirst%3DG.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DChen%26aufirst%3DG.%26aulast%3DMeng%26aufirst%3DX.%26aulast%3DSun%26aufirst%3DD.%26aulast%3DShih%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DR.%26aulast%3DHou%26aufirst%3DG.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DJin%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DQ.%26atitle%3DDesign%2520and%2520Synthesis%2520of%2520Novel%25203-sulfonylpyrazol-4-amino%2520Pyrimidines%2520as%2520Potent%2520Anaplastic%2520Lymphoma%2520Kinase%2520%2528ALK%2529%2520Inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D26%26spage%3D1910%26epage%3D1918%26doi%3D10.1016%2Fj.bmcl.2016.03.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref135"><div class="reference"><strong class="refLabel"><a href="#ref135" class="rightTabRefNumLink">135</a></strong><div class="NLM_citation" id="rightTab-cit135"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Konagai, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mori, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimada, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kondoh, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shindou, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soga, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furutani, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakagami, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ueno, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaneko, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, R.</span></span> <span> </span><span class="NLM_article-title">Asp3026, A Selective ALK Inhibitor, Induces Tumor Regression Against Crizotinib Resistant Eml4-ALK-dependent Tumor Models In Mice</span>. <i>Ann. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">xi99</span>– <span class="NLM_lpage">xi131</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2012&pages=xi99-xi131&author=S.+Konagaiauthor=M.+Moriauthor=I.+Shimadaauthor=Y.+Kondohauthor=N.+Shindouauthor=T.+Sogaauthor=T.+Furutaniauthor=H.+Sakagamiauthor=Y.+Uenoauthor=N.+Kanekoauthor=R.+Tanaka&title=Asp3026%2C+A+Selective+ALK+Inhibitor%2C+Induces+Tumor+Regression+Against+Crizotinib+Resistant+Eml4-ALK-dependent+Tumor+Models+In+Mice"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKonagai%26aufirst%3DS.%26aulast%3DMori%26aufirst%3DM.%26aulast%3DShimada%26aufirst%3DI.%26aulast%3DKondoh%26aufirst%3DY.%26aulast%3DShindou%26aufirst%3DN.%26aulast%3DSoga%26aufirst%3DT.%26aulast%3DFurutani%26aufirst%3DT.%26aulast%3DSakagami%26aufirst%3DH.%26aulast%3DUeno%26aufirst%3DY.%26aulast%3DKaneko%26aufirst%3DN.%26aulast%3DTanaka%26aufirst%3DR.%26atitle%3DAsp3026%252C%2520A%2520Selective%2520ALK%2520Inhibitor%252C%2520Induces%2520Tumor%2520Regression%2520Against%2520Crizotinib%2520Resistant%2520Eml4-ALK-dependent%2520Tumor%2520Models%2520In%2520Mice%26jtitle%3DAnn.%2520Oncol.%26date%3D2012%26volume%3D23%26spage%3Dxi99%26epage%3Dxi131" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref136"><div class="reference"><strong class="refLabel"><a href="#ref136" class="rightTabRefNumLink">136</a></strong><div class="NLM_citation" id="rightTab-cit136"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Simionato, F.</span>; <span class="NLM_string-name">Carbone, C.</span>; <span class="NLM_string-name">Tortora, G.</span>; <span class="NLM_string-name">Melisi, D.</span></span> <span> </span><span class="NLM_article-title">Resistance to ALK Inhibitors</span>.  <i>Resistance to Tyrosine Kinase Inhibitors</i>; <span class="NLM_publisher-name">Springer</span>: <span class="NLM_publisher-loc">Cham</span>, <span class="NLM_year">2016</span>,  <span class="NLM_fpage">147</span>– <span class="NLM_lpage">163</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1007%2F978-3-319-46091-8_5" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&pages=147-163&author=F.+Simionato&author=C.+Carbone&author=G.+Tortora&author=D.+Melisi&title=Resistance+to+Tyrosine+Kinase+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=10.1007%2F978-3-319-46091-8_5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1007%252F978-3-319-46091-8_5%26sid%3Dliteratum%253Aachs%26aulast%3DSimionato%26aufirst%3DF.%26atitle%3DResistance%2520to%2520ALK%2520Inhibitors%26btitle%3DResistance%2520to%2520Tyrosine%2520Kinase%2520Inhibitors%26pub%3DSpringer%26date%3D2016%26spage%3D147%26epage%3D163" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref137"><div class="reference"><strong class="refLabel"><a href="#ref137" class="rightTabRefNumLink">137</a></strong><div class="NLM_citation" id="rightTab-cit137"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maitland, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ou, S.-H. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tolcher, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LoRusso, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bahceci, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ball, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuen, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pesco Koplowitz, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, T.</span></span> <span> </span><span class="NLM_article-title">Safety, Activity, and Pharmacokinetics of an Oral Anaplastic Lymphoma Kinase (ALK) Inhibitor, ASP3026, Observed in a “Fast Follower” Phase 1 Trial Design</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">2624</span>, <span class="refDoi"> DOI: 10.1200/jco.2014.32.15_suppl.2624</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1200%2Fjco.2014.32.15_suppl.2624" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2014&pages=2624&author=M.+L.+Maitlandauthor=S.-H.+I.+Ouauthor=A.+W.+Tolcherauthor=P.+LoRussoauthor=E.+Bahceciauthor=H.+A.+Ballauthor=J.+W.+Parkauthor=G.+Yuenauthor=L.+Pesco+Koplowitzauthor=T.+Li&title=Safety%2C+Activity%2C+and+Pharmacokinetics+of+an+Oral+Anaplastic+Lymphoma+Kinase+%28ALK%29+Inhibitor%2C+ASP3026%2C+Observed+in+a+%E2%80%9CFast+Follower%E2%80%9D+Phase+1+Trial+Design&doi=10.1200%2Fjco.2014.32.15_suppl.2624"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=10.1200%2Fjco.2014.32.15_suppl.2624&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252Fjco.2014.32.15_suppl.2624%26sid%3Dliteratum%253Aachs%26aulast%3DMaitland%26aufirst%3DM.%2BL.%26aulast%3DOu%26aufirst%3DS.-H.%2BI.%26aulast%3DTolcher%26aufirst%3DA.%2BW.%26aulast%3DLoRusso%26aufirst%3DP.%26aulast%3DBahceci%26aufirst%3DE.%26aulast%3DBall%26aufirst%3DH.%2BA.%26aulast%3DPark%26aufirst%3DJ.%2BW.%26aulast%3DYuen%26aufirst%3DG.%26aulast%3DPesco%2BKoplowitz%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DT.%26atitle%3DSafety%252C%2520Activity%252C%2520and%2520Pharmacokinetics%2520of%2520an%2520Oral%2520Anaplastic%2520Lymphoma%2520Kinase%2520%2528ALK%2529%2520Inhibitor%252C%2520ASP3026%252C%2520Observed%2520in%2520a%2520%25E2%2580%259CFast%2520Follower%25E2%2580%259D%2520Phase%25201%2520Trial%2520Design%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2014%26volume%3D32%26spage%3D2624%26doi%3D10.1200%2Fjco.2014.32.15_suppl.2624" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref138"><div class="reference"><strong class="refLabel"><a href="#ref138" class="rightTabRefNumLink">138</a></strong><div class="NLM_citation" id="rightTab-cit138"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LoRusso, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maitland, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ou, S.-H. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bahceci, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ball, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuen, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tolcher, A.</span></span> <span> </span><span class="NLM_article-title">First-in-human, Open-label Dose-escalation and Dose-expansion Study of the Safety, Pharmacokinetics, and Antitumor Effects of an Oral ALK Inhibitor ASP3026 in Patients with Advanced Solid Tumors</span>. <i>J. Hematol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">23</span>, <span class="refDoi"> DOI: 10.1186/s13045-016-0254-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1186%2Fs13045-016-0254-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=26966027" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC2sXis1eisbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2016&pages=23&author=T.+Liauthor=P.+LoRussoauthor=M.+L.+Maitlandauthor=S.-H.+I.+Ouauthor=E.+Bahceciauthor=H.+A.+Ballauthor=J.+W.+Parkauthor=G.+Yuenauthor=A.+Tolcher&title=First-in-human%2C+Open-label+Dose-escalation+and+Dose-expansion+Study+of+the+Safety%2C+Pharmacokinetics%2C+and+Antitumor+Effects+of+an+Oral+ALK+Inhibitor+ASP3026+in+Patients+with+Advanced+Solid+Tumors&doi=10.1186%2Fs13045-016-0254-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit138R"><div class="casContent"><span class="casTitleNuber">138</span><div class="casTitle"><span class="NLM_cas:atitle">First-in-human, open-label dose-escalation and dose-expansion study of the safety, pharmacokinetics, and antitumor effects of an oral ALK inhibitor ASP3026 in patients with advanced solid tumors</span></div><div class="casAuthors">Li, Tianhong; Lo Russo, Patricia; Maitland, Michael L.; Ou, Sai-Hong Ignatius; Bahceci, Erkut; Ball, Howard A.; Park, Jung Wook; Yuen, Geoffrey; Tolcher, Anthony</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hematology & Oncology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">23/1-23/9</span>CODEN:
                <span class="NLM_cas:coden">JHOOAO</span>;
        ISSN:<span class="NLM_cas:issn">1756-8722</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: ASP3026 is a second-generation anaplastic lymphoma kinase (ALK) inhibitor that has potent in vitro activity against crizotinib-resistant ALK-pos. tumors.  This open-label, multicenter, first-in-human phase I study (NCT01284192) assessed the safety, pharmacokinetic profile, and antitumor activity of ASP3026.  Methods: Advanced solid tumor patients received oral ASP3026 in 3 + 3 dose-escalation cohorts at doses of 25-800 mg once daily in 28-day cycles.  The endpoints were to identify the max. tolerated dose (MTD), the recommended phase II dose (RP2D), and the pharmacokinetic profile of ASP3026.  A phase Ib expansion cohort enrolled patients with metastatic, crizotinib-resistant ALK-pos. solid tumors at the RP2D, and response was evaluated by RECIST 1.1.  Results: The dose-escalation cohort enrolled 33 patients, including three crizotinib-resistant, ALK-pos. patients, and the dose-expansion cohort enrolled another 13 crizotinib-resistant, ALK-pos. non-small cell lung cancer (NSCLC) patients.  ASP3026 demonstrated both linear pharmacokinetics and dose-proportional exposure for area under the plasma concn.-time curve and max. concn. obsd. with a median terminal half-life of 35 h, supporting the daily dosing.  Grade 3 rash and elevated transaminase concns. were dose-limiting toxicities obsd. at 800 mg; hence, 525 mg daily was the MTD and RP2D.  The most common treatment-related adverse events were nausea (38 %), fatigue (35 %), and vomiting (35 %).  Among the 16 patients with crizotinib-resistant ALK-pos. tumors (15 NSCLC, 1 neuroblastoma), eight patients achieved partial response (overall response rate 50 %; 95 % confidence interval 25-75 %) and seven patients (44 %) achieved stable disease.  Conclusions: ASP3026 was well tolerated and had therapeutic activity in patients with crizotinib-resistant ALKpos. advanced tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8s1yI8JbYIrVg90H21EOLACvtfcHk0liuTP9ifj2Uyw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXis1eisbc%253D&md5=ec3b634a66b3b310c8a0d6d83eeb9e62</span></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=10.1186%2Fs13045-016-0254-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13045-016-0254-5%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DT.%26aulast%3DLoRusso%26aufirst%3DP.%26aulast%3DMaitland%26aufirst%3DM.%2BL.%26aulast%3DOu%26aufirst%3DS.-H.%2BI.%26aulast%3DBahceci%26aufirst%3DE.%26aulast%3DBall%26aufirst%3DH.%2BA.%26aulast%3DPark%26aufirst%3DJ.%2BW.%26aulast%3DYuen%26aufirst%3DG.%26aulast%3DTolcher%26aufirst%3DA.%26atitle%3DFirst-in-human%252C%2520Open-label%2520Dose-escalation%2520and%2520Dose-expansion%2520Study%2520of%2520the%2520Safety%252C%2520Pharmacokinetics%252C%2520and%2520Antitumor%2520Effects%2520of%2520an%2520Oral%2520ALK%2520Inhibitor%2520ASP3026%2520in%2520Patients%2520with%2520Advanced%2520Solid%2520Tumors%26jtitle%3DJ.%2520Hematol.%2520Oncol.%26date%3D2016%26volume%3D9%26spage%3D23%26doi%3D10.1186%2Fs13045-016-0254-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref139"><div class="reference"><strong class="refLabel"><a href="#ref139" class="rightTabRefNumLink">139</a></strong><div class="NLM_citation" id="rightTab-cit139"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Amatu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Somaschini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cerea, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bosotti, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valtorta, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buonandi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marrapese, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Veronese, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hornby, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Multani, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shoemaker, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lauricella, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giannetta, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maiolani, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanzulli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ardini, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galvani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isacchi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sartore-Bianchi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siena, S.</span></span> <span> </span><span class="NLM_article-title">Novel CAD-ALK Gene Rearrangement is Drugable by Entrectinib in Colorectal Cancer</span>. <i>Br. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>113</i></span>,  <span class="NLM_fpage">1730</span>– <span class="NLM_lpage">1734</span>, <span class="refDoi"> DOI: 10.1038/bjc.2015.401</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1038%2Fbjc.2015.401" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=26633560" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvF2ks7fL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2015&pages=1730-1734&author=A.+Amatuauthor=A.+Somaschiniauthor=G.+Cereaauthor=R.+Bosottiauthor=E.+Valtortaauthor=P.+Buonandiauthor=G.+Marrapeseauthor=S.+Veroneseauthor=D.+Luoauthor=Z.+Hornbyauthor=P.+Multaniauthor=D.+Murphyauthor=R.+Shoemakerauthor=C.+Lauricellaauthor=L.+Giannettaauthor=M.+Maiolaniauthor=A.+Vanzulliauthor=E.+Ardiniauthor=A.+Galvaniauthor=A.+Isacchiauthor=A.+Sartore-Bianchiauthor=S.+Siena&title=Novel+CAD-ALK+Gene+Rearrangement+is+Drugable+by+Entrectinib+in+Colorectal+Cancer&doi=10.1038%2Fbjc.2015.401"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit139R"><div class="casContent"><span class="casTitleNuber">139</span><div class="casTitle"><span class="NLM_cas:atitle">Novel CAD-ALK gene rearrangement is drugable by entrectinib in colorectal cancer</span></div><div class="casAuthors">Amatu, Alessio; Somaschini, Alessio; Cerea, Giulio; Bosotti, Roberta; Valtorta, Emanuele; Buonandi, Pasquale; Marrapese, Giovanna; Veronese, Silvio; Luo, David; Hornby, Zachary; Multani, Pratik; Murphy, Danielle; Shoemaker, Robert; Lauricella, Calogero; Giannetta, Laura; Maiolani, Martina; Vanzulli, Angelo; Ardini, Elena; Galvani, Arturo; Isacchi, Antonella; Sartore-Bianchi, Andrea; Siena, Salvatore</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">113</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1730-1734</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Background: Activated anaplastic lymphoma kinase (ALK) gene fusions are recurrent events in a small fraction of colorectal cancers (CRCs), although these events have not yet been exploited as in other malignancies.  Methods: We detected ALK protein expression by immunohistochem. and gene rearrangements by fluorescence in situ hybridization in the ALKA-372-001 phase I study of the pan-Trk, ROS1, and ALK inhibitor entrectinib.  One out of 487 CRCs showed ALK positivity with a peculiar pattern that prompted further characterization by targeted sequencing using anchored multiplex PCR.  Results: A novel ALK fusion with the carbamoyl-phosphate synthetase 2, aspartate transcarbamylase, and dihydroorotase (CAD) gene (CAD-ALK fusion gene) was identified.  It resulted from inversion within chromosome 2 and the fusion of exons 1-35 of CAD with exons 20-29 of ALK.  After failure of previous std. therapies, treatment of this patient with the ALK inhibitor entrectinib resulted in a durable objective tumor response.  Conclusions: We describe the novel CAD-ALK rearrangement as an oncogene and provide the first evidence of its drugability as a new mol. target in CRC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGretuldOSXUNLVg90H21EOLACvtfcHk0liDmOUD3DIXdw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvF2ks7fL&md5=c542b6b8d0a856941275d14f82bd9000</span></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=10.1038%2Fbjc.2015.401&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbjc.2015.401%26sid%3Dliteratum%253Aachs%26aulast%3DAmatu%26aufirst%3DA.%26aulast%3DSomaschini%26aufirst%3DA.%26aulast%3DCerea%26aufirst%3DG.%26aulast%3DBosotti%26aufirst%3DR.%26aulast%3DValtorta%26aufirst%3DE.%26aulast%3DBuonandi%26aufirst%3DP.%26aulast%3DMarrapese%26aufirst%3DG.%26aulast%3DVeronese%26aufirst%3DS.%26aulast%3DLuo%26aufirst%3DD.%26aulast%3DHornby%26aufirst%3DZ.%26aulast%3DMultani%26aufirst%3DP.%26aulast%3DMurphy%26aufirst%3DD.%26aulast%3DShoemaker%26aufirst%3DR.%26aulast%3DLauricella%26aufirst%3DC.%26aulast%3DGiannetta%26aufirst%3DL.%26aulast%3DMaiolani%26aufirst%3DM.%26aulast%3DVanzulli%26aufirst%3DA.%26aulast%3DArdini%26aufirst%3DE.%26aulast%3DGalvani%26aufirst%3DA.%26aulast%3DIsacchi%26aufirst%3DA.%26aulast%3DSartore-Bianchi%26aufirst%3DA.%26aulast%3DSiena%26aufirst%3DS.%26atitle%3DNovel%2520CAD-ALK%2520Gene%2520Rearrangement%2520is%2520Drugable%2520by%2520Entrectinib%2520in%2520Colorectal%2520Cancer%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2015%26volume%3D113%26spage%3D1730%26epage%3D1734%26doi%3D10.1038%2Fbjc.2015.401" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref140"><div class="reference"><strong class="refLabel"><a href="#ref140" class="rightTabRefNumLink">140</a></strong><div class="NLM_citation" id="rightTab-cit140"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De Braud, F. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pilla, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niger, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Damian, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bardazza, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinetti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pelosi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marrapese, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmeri, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cerea, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valtorta, E.</span></span> <span> </span><span class="NLM_article-title">Phase 1 Open Label, Dose Escalation Study of RXDX101, an Oral Pan-trk, ROS1, and ALK Inhibitor, in Patients with Advanced Solid Tumors with Relevant Molecular Alterations</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>32</i></span> (<span class="NLM_issue">Suppl 15</span>),  <span class="NLM_fpage">2502</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1200%2Fjco.2014.32.15_suppl.2502" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2014&pages=2502&issue=Suppl+15&author=F.+G.+De+Braudauthor=L.+Pillaauthor=M.+Nigerauthor=S.+Damianauthor=B.+Bardazzaauthor=A.+Martinettiauthor=G.+Pelosiauthor=G.+Marrapeseauthor=L.+Palmeriauthor=G.+Cereaauthor=E.+Valtorta&title=Phase+1+Open+Label%2C+Dose+Escalation+Study+of+RXDX101%2C+an+Oral+Pan-trk%2C+ROS1%2C+and+ALK+Inhibitor%2C+in+Patients+with+Advanced+Solid+Tumors+with+Relevant+Molecular+Alterations"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=10.1200%2Fjco.2014.32.15_suppl.2502&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252Fjco.2014.32.15_suppl.2502%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BBraud%26aufirst%3DF.%2BG.%26aulast%3DPilla%26aufirst%3DL.%26aulast%3DNiger%26aufirst%3DM.%26aulast%3DDamian%26aufirst%3DS.%26aulast%3DBardazza%26aufirst%3DB.%26aulast%3DMartinetti%26aufirst%3DA.%26aulast%3DPelosi%26aufirst%3DG.%26aulast%3DMarrapese%26aufirst%3DG.%26aulast%3DPalmeri%26aufirst%3DL.%26aulast%3DCerea%26aufirst%3DG.%26aulast%3DValtorta%26aufirst%3DE.%26atitle%3DPhase%25201%2520Open%2520Label%252C%2520Dose%2520Escalation%2520Study%2520of%2520RXDX101%252C%2520an%2520Oral%2520Pan-trk%252C%2520ROS1%252C%2520and%2520ALK%2520Inhibitor%252C%2520in%2520Patients%2520with%2520Advanced%2520Solid%2520Tumors%2520with%2520Relevant%2520Molecular%2520Alterations%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2014%26volume%3D32%26issue%3DSuppl%252015%26spage%3D2502" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref141"><div class="reference"><strong class="refLabel"><a href="#ref141" class="rightTabRefNumLink">141</a></strong><div class="NLM_citation" id="rightTab-cit141"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Drilon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siena, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ou, S.-H. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farago, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wheler, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doebele, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giannetta, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cerea, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marrapese, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schirru, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amatu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bencardino, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmeri, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sartore-Bianchi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanzulli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cresta, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Damian, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duca, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ardini, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christiansen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kowalski, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chow-Maneval, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hornby, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Multani, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Braud, F. G.</span></span> <span> </span><span class="NLM_article-title">Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two phase I Trials (ALKA-372–001 and STARTRK-1)</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">400</span>– <span class="NLM_lpage">409</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-16-1237</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1158%2F2159-8290.CD-16-1237" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=28183697" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC2sXltlOqsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&pages=400-409&author=A.+Drilonauthor=S.+Sienaauthor=S.-H.+I.+Ouauthor=M.+Patelauthor=M.+J.+Ahnauthor=J.+Leeauthor=T.+M.+Bauerauthor=A.+F.+Faragoauthor=J.+J.+Whelerauthor=S.+V.+Liuauthor=R.+Doebeleauthor=L.+Giannettaauthor=G.+Cereaauthor=G.+Marrapeseauthor=M.+Schirruauthor=A.+Amatuauthor=K.+Bencardinoauthor=L.+Palmeriauthor=A.+Sartore-Bianchiauthor=A.+Vanzulliauthor=S.+Crestaauthor=S.+Damianauthor=M.+Ducaauthor=E.+Ardiniauthor=G.+Liauthor=J.+Christiansenauthor=K.+Kowalskiauthor=A.+D.+Johnsonauthor=R.+Patelauthor=D.+Luoauthor=E.+Chow-Manevalauthor=Z.+Hornbyauthor=P.+S.+Multaniauthor=A.+T.+Shawauthor=F.+G.+De+Braud&title=Safety+and+Antitumor+Activity+of+the+Multitargeted+Pan-TRK%2C+ROS1%2C+and+ALK+Inhibitor+Entrectinib%3A+Combined+Results+from+Two+phase+I+Trials+%28ALKA-372%E2%80%93001+and+STARTRK-1%29&doi=10.1158%2F2159-8290.CD-16-1237"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit141R"><div class="casContent"><span class="casTitleNuber">141</span><div class="casTitle"><span class="NLM_cas:atitle">Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1)</span></div><div class="casAuthors">Drilon, Alexander; Siena, Salvatore; Ou, Sai-Hong Ignatius; Patel, Manish; Ahn, Myung Ju; Lee, Jeeyun; Bauer, Todd M.; Farago, Anna F.; Wheler, Jennifer J.; Liu, Stephen V.; Doebele, Robert; Giannetta, Laura; Cerea, Giulio; Marrapese, Giovanna; Schirru, Michele; Amatu, Alessio; Bencardino, Katia; Palmeri, Laura; Sartore-Bianchi, Andrea; Vanzulli, Angelo; Cresta, Sara; Damian, Silvia; Duca, Matteo; Ardini, Elena; Li, Gang; Christiansen, Jason; Kowalski, Karey; Johnson, Ann D.; Patel, Rupal; Luo, David; Chow-Maneval, Edna; Hornby, Zachary; Multani, Pratik S.; Shaw, Alice T.; De Braud, Filippo G.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">400-409</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Entrectinib, a potent oral inhibitor of the tyrosine kinases TRKA/B/C, ROS1, and ALK, was evaluated in two phase I studies in patients with advanced or metastatic solid tumors, including patients with active central nervous system (CNS) disease.  Here, we summarize the overall safety and report the antitumor activity of entrectinib in a cohort of patients with tumors harboring NTRK1/2/3, ROS1, or ALK gene fusions, naive to prior TKI treatment targeting the specific gene, and who were treated at doses that achieved therapeutic exposures consistent with the recommended phase II dose.  Entrectinib was well tolerated, with predominantly Grades 1/2 adverse events that were reversible with dose modification.  Responses were obsd. in non-small cell lung cancer, colorectal cancer, mammary analog secretory carcinoma, melanoma, and renal cell carcinoma, as early as 4 wk after starting treatment and lasting as long as >2 years.  Notably, a complete CNS response was achieved in a patient with SQSTM1-NTRK1-rearranged lung cancer.  Significance: Gene fusions of NTRK1/2/3, ROS1, and ALK (encoding TRKA/B/C, ROS1, and ALK, resp.) lead to constitutive activation of oncogenic pathways.  Entrectinib was shown to be well tolerated and active against those gene fusions in solid tumors, including in patients with primary or secondary CNS disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGom-3oFgf_s-LVg90H21EOLACvtfcHk0liDmOUD3DIXdw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXltlOqsL8%253D&md5=2065abe157ef40489942215ec33482d0</span></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-16-1237&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-16-1237%26sid%3Dliteratum%253Aachs%26aulast%3DDrilon%26aufirst%3DA.%26aulast%3DSiena%26aufirst%3DS.%26aulast%3DOu%26aufirst%3DS.-H.%2BI.%26aulast%3DPatel%26aufirst%3DM.%26aulast%3DAhn%26aufirst%3DM.%2BJ.%26aulast%3DLee%26aufirst%3DJ.%26aulast%3DBauer%26aufirst%3DT.%2BM.%26aulast%3DFarago%26aufirst%3DA.%2BF.%26aulast%3DWheler%26aufirst%3DJ.%2BJ.%26aulast%3DLiu%26aufirst%3DS.%2BV.%26aulast%3DDoebele%26aufirst%3DR.%26aulast%3DGiannetta%26aufirst%3DL.%26aulast%3DCerea%26aufirst%3DG.%26aulast%3DMarrapese%26aufirst%3DG.%26aulast%3DSchirru%26aufirst%3DM.%26aulast%3DAmatu%26aufirst%3DA.%26aulast%3DBencardino%26aufirst%3DK.%26aulast%3DPalmeri%26aufirst%3DL.%26aulast%3DSartore-Bianchi%26aufirst%3DA.%26aulast%3DVanzulli%26aufirst%3DA.%26aulast%3DCresta%26aufirst%3DS.%26aulast%3DDamian%26aufirst%3DS.%26aulast%3DDuca%26aufirst%3DM.%26aulast%3DArdini%26aufirst%3DE.%26aulast%3DLi%26aufirst%3DG.%26aulast%3DChristiansen%26aufirst%3DJ.%26aulast%3DKowalski%26aufirst%3DK.%26aulast%3DJohnson%26aufirst%3DA.%2BD.%26aulast%3DPatel%26aufirst%3DR.%26aulast%3DLuo%26aufirst%3DD.%26aulast%3DChow-Maneval%26aufirst%3DE.%26aulast%3DHornby%26aufirst%3DZ.%26aulast%3DMultani%26aufirst%3DP.%2BS.%26aulast%3DShaw%26aufirst%3DA.%2BT.%26aulast%3DDe%2BBraud%26aufirst%3DF.%2BG.%26atitle%3DSafety%2520and%2520Antitumor%2520Activity%2520of%2520the%2520Multitargeted%2520Pan-TRK%252C%2520ROS1%252C%2520and%2520ALK%2520Inhibitor%2520Entrectinib%253A%2520Combined%2520Results%2520from%2520Two%2520phase%2520I%2520Trials%2520%2528ALKA-372%25E2%2580%2593001%2520and%2520STARTRK-1%2529%26jtitle%3DCancer%2520Discovery%26date%3D2017%26volume%3D7%26spage%3D400%26epage%3D409%26doi%3D10.1158%2F2159-8290.CD-16-1237" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref142"><div class="reference"><strong class="refLabel"><a href="#ref142" class="rightTabRefNumLink">142</a></strong><div class="NLM_citation" id="rightTab-cit142"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Horn, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Infante, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reckamp, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blumenschein, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leal, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waqar, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gitlitz, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanborn, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whisenant, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neal, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gockerman, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dukart, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrow, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibbons, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holzhausen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lovly, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wakelee, H. A.</span></span> <span> </span><span class="NLM_article-title">Ensartinib (X-396) in ALK-Positive Non–small Cell Lung Cancer: Results from a First-in-human Phase I/II, Multicenter Study</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">2771</span>– <span class="NLM_lpage">2779</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-17-2398</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1158%2F1078-0432.CCR-17-2398" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=29563138" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtFeqsrbO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2018&pages=2771-2779&author=L.+Hornauthor=J.+R.+Infanteauthor=K.+L.+Reckampauthor=G.+R.+Blumenscheinauthor=T.+A.+Lealauthor=S.+N.+Waqarauthor=B.+J.+Gitlitzauthor=R.+E.+Sanbornauthor=J.+G.+Whisenantauthor=L.+Duauthor=J.+W.+Nealauthor=J.+P.+Gockermanauthor=G.+Dukartauthor=K.+Harrowauthor=C.+Liangauthor=J.+J.+Gibbonsauthor=A.+Holzhausenauthor=C.+M.+Lovlyauthor=H.+A.+Wakelee&title=Ensartinib+%28X-396%29+in+ALK-Positive+Non%E2%80%93small+Cell+Lung+Cancer%3A+Results+from+a+First-in-human+Phase+I%2FII%2C+Multicenter+Study&doi=10.1158%2F1078-0432.CCR-17-2398"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit142R"><div class="casContent"><span class="casTitleNuber">142</span><div class="casTitle"><span class="NLM_cas:atitle">Ensartinib (X-396) in ALK-Positive Non-Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study</span></div><div class="casAuthors">Horn, Leora; Infante, Jeffrey R.; Reckamp, Karen L.; Blumenschein, George R.; Leal, Ticiana A.; Waqar, Saiama N.; Gitlitz, Barbara J.; Sanborn, Rachel E.; Whisenant, Jennifer G.; Du, Liping; Neal, Joel W.; Gockerman, Jon P.; Dukart, Gary; Harrow, Kimberly; Liang, Chris; Gibbons, James J.; Holzhausen, Allison; Lovly, Christine M.; Wakelee, Heather A.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2771-2779</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Evaluate safety and det. the recommended phase II dose (RP2D) of ensartinib (X-396), a potent anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI), and evaluate preliminary pharmacokinetics and antitumor activity in a first-in-human, phase I/II clin. trial primarily in patients with non-small cell lung cancer (NSCLC).  Patients and Methods: In dose escalation, ensartinib was administered at doses of 25 to 250 mg once daily in patients with advanced solid tumors; in dose expansion, patients with advanced ALK-pos. NSCLC were administered 225 mg once daily.  Patients who had received prior ALK TKI(s) and patients with brain metastases were eligible.  Results: Thirty-seven patients enrolled in dose escalation, and 60 enrolled in dose expansion.  The most common treatment-related toxicities were rash (56%), nausea (36%), pruritus (28%), vomiting (26%), and fatigue (22%); 23% of patients experienced a treatment-related grade 3 to 4 toxicity (primarily rash and pruritus).  The max. tolerated dose was not reached, but the RP2D was chosen as 225 mg based on the frequency of rash obsd. at 250 mg without improvement in activity.  Among the ALK-pos. efficacy evaluable patients treated at ≥200 mg, the response rate (RR) was 60%, and median progression-free survival (PFS) was 9.2 mo.  RR in ALK TKI-naive patients was 80%, and median PFS was 26.2 mo.  In patients with prior crizotinib only, the RR was 69% and median PFS was 9.0 mo.  Responses were also obsd. in the central nervous system, with an intracranial RR of 64%.  Conclusions: Ensartinib was active and generally well tolerated in patients with ALK-pos. NSCLC.  Clin Cancer Res; 24(12); 2771-9. ©2018 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomgnuFLIl0jLVg90H21EOLACvtfcHk0lipnA7MpFsEFQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtFeqsrbO&md5=e14e00b46d6f389e524b9b902c581397</span></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-17-2398&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-17-2398%26sid%3Dliteratum%253Aachs%26aulast%3DHorn%26aufirst%3DL.%26aulast%3DInfante%26aufirst%3DJ.%2BR.%26aulast%3DReckamp%26aufirst%3DK.%2BL.%26aulast%3DBlumenschein%26aufirst%3DG.%2BR.%26aulast%3DLeal%26aufirst%3DT.%2BA.%26aulast%3DWaqar%26aufirst%3DS.%2BN.%26aulast%3DGitlitz%26aufirst%3DB.%2BJ.%26aulast%3DSanborn%26aufirst%3DR.%2BE.%26aulast%3DWhisenant%26aufirst%3DJ.%2BG.%26aulast%3DDu%26aufirst%3DL.%26aulast%3DNeal%26aufirst%3DJ.%2BW.%26aulast%3DGockerman%26aufirst%3DJ.%2BP.%26aulast%3DDukart%26aufirst%3DG.%26aulast%3DHarrow%26aufirst%3DK.%26aulast%3DLiang%26aufirst%3DC.%26aulast%3DGibbons%26aufirst%3DJ.%2BJ.%26aulast%3DHolzhausen%26aufirst%3DA.%26aulast%3DLovly%26aufirst%3DC.%2BM.%26aulast%3DWakelee%26aufirst%3DH.%2BA.%26atitle%3DEnsartinib%2520%2528X-396%2529%2520in%2520ALK-Positive%2520Non%25E2%2580%2593small%2520Cell%2520Lung%2520Cancer%253A%2520Results%2520from%2520a%2520First-in-human%2520Phase%2520I%252FII%252C%2520Multicenter%2520Study%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2018%26volume%3D24%26spage%3D2771%26epage%3D2779%26doi%3D10.1158%2F1078-0432.CCR-17-2398" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref143"><div class="reference"><strong class="refLabel"><a href="#ref143" class="rightTabRefNumLink">143</a></strong><div class="NLM_citation" id="rightTab-cit143"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Horn, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reck, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrow, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oertel, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dukart, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mok, T.</span></span> <span> </span><span class="NLM_article-title">eXalt3: A Phase 3 Study of Ensartinib (X-396) in Anaplastic Lymphoma Kinase (ALK)-positive Non-small Cell Lung Cancer (NSCLC)</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">TPS8578</span>, <span class="refDoi"> DOI: 10.1200/JCO.2017.35.15_suppl.TPS8578</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1200%2FJCO.2017.35.15_suppl.TPS8578" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2017&pages=TPS8578&author=L.+Hornauthor=Y.-L.+Wuauthor=M.+Reckauthor=C.+Liangauthor=F.+Tanauthor=K.+Harrowauthor=V.+Oertelauthor=G.+Dukartauthor=T.+Mok&title=eXalt3%3A+A+Phase+3+Study+of+Ensartinib+%28X-396%29+in+Anaplastic+Lymphoma+Kinase+%28ALK%29-positive+Non-small+Cell+Lung+Cancer+%28NSCLC%29&doi=10.1200%2FJCO.2017.35.15_suppl.TPS8578"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=10.1200%2FJCO.2017.35.15_suppl.TPS8578&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2017.35.15_suppl.TPS8578%26sid%3Dliteratum%253Aachs%26aulast%3DHorn%26aufirst%3DL.%26aulast%3DWu%26aufirst%3DY.-L.%26aulast%3DReck%26aufirst%3DM.%26aulast%3DLiang%26aufirst%3DC.%26aulast%3DTan%26aufirst%3DF.%26aulast%3DHarrow%26aufirst%3DK.%26aulast%3DOertel%26aufirst%3DV.%26aulast%3DDukart%26aufirst%3DG.%26aulast%3DMok%26aufirst%3DT.%26atitle%3DeXalt3%253A%2520A%2520Phase%25203%2520Study%2520of%2520Ensartinib%2520%2528X-396%2529%2520in%2520Anaplastic%2520Lymphoma%2520Kinase%2520%2528ALK%2529-positive%2520Non-small%2520Cell%2520Lung%2520Cancer%2520%2528NSCLC%2529%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2017%26volume%3D35%26spage%3DTPS8578%26doi%3D10.1200%2FJCO.2017.35.15_suppl.TPS8578" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref144"><div class="reference"><strong class="refLabel"><a href="#ref144" class="rightTabRefNumLink">144</a></strong><div class="NLM_citation" id="rightTab-cit144"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Weiss, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sachdev, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Infante, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mita, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Natale, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arkenau, H.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilcoxen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kansra, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laken, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brooks, D. G.</span></span> <span> </span><span class="NLM_article-title">Phase (Ph) 1/2 Study of TSR-011, a Potent Inhibitor of ALK and TRK, including Crizotinib-resistant ALK Mutations</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>32</i></span> (<span class="NLM_issue">Suppl 15</span>),  <span class="NLM_fpage">e19005</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1200%2Fjco.2014.32.15_suppl.e19005" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2014&pages=e19005&issue=Suppl+15&author=G.+J.+Weissauthor=J.+C.+Sachdevauthor=J.+R.+Infanteauthor=M.+M.+Mitaauthor=R.+B.+Nataleauthor=H.-T.+Arkenauauthor=K.+Wilcoxenauthor=V.+Kansraauthor=H.+Lakenauthor=L.+Hughesauthor=D.+G.+Brooks&title=Phase+%28Ph%29+1%2F2+Study+of+TSR-011%2C+a+Potent+Inhibitor+of+ALK+and+TRK%2C+including+Crizotinib-resistant+ALK+Mutations"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=10.1200%2Fjco.2014.32.15_suppl.e19005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252Fjco.2014.32.15_suppl.e19005%26sid%3Dliteratum%253Aachs%26aulast%3DWeiss%26aufirst%3DG.%2BJ.%26aulast%3DSachdev%26aufirst%3DJ.%2BC.%26aulast%3DInfante%26aufirst%3DJ.%2BR.%26aulast%3DMita%26aufirst%3DM.%2BM.%26aulast%3DNatale%26aufirst%3DR.%2BB.%26aulast%3DArkenau%26aufirst%3DH.-T.%26aulast%3DWilcoxen%26aufirst%3DK.%26aulast%3DKansra%26aufirst%3DV.%26aulast%3DLaken%26aufirst%3DH.%26aulast%3DHughes%26aufirst%3DL.%26aulast%3DBrooks%26aufirst%3DD.%2BG.%26atitle%3DPhase%2520%2528Ph%2529%25201%252F2%2520Study%2520of%2520TSR-011%252C%2520a%2520Potent%2520Inhibitor%2520of%2520ALK%2520and%2520TRK%252C%2520including%2520Crizotinib-resistant%2520ALK%2520Mutations%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2014%26volume%3D32%26issue%3DSuppl%252015%26spage%3De19005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref145"><div class="reference"><strong class="refLabel"><a href="#ref145" class="rightTabRefNumLink">145</a></strong><div class="NLM_citation" id="rightTab-cit145"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Arkenau, H. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sachdev, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mita, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dziadziuszko, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Infante, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anthony, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voskoboynik, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castro, J.</span></span> <span> </span><span class="NLM_article-title">Phase (Ph) 1/2a Study of TSR-011, a Potent Inhibitor of ALK and TRK, in Advanced Solid Tumors Including Crizotinib-resistant ALK Positive Non-small Cell Lung Cancer</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>33</i></span> (<span class="NLM_issue">Suppl 15</span>),  <span class="NLM_fpage">8063</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1200%2Fjco.2015.33.15_suppl.8063" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2015&pages=8063&issue=Suppl+15&author=H.+T.+Arkenauauthor=J.+C.+Sachdevauthor=M.+M.+Mitaauthor=R.+Dziadziuszkoauthor=C.+C.+Linauthor=J.+C.+Yangauthor=J.+R.+Infanteauthor=S.+P.+Anthonyauthor=M.+Voskoboynikauthor=W.+C.+Suauthor=+Deauthor=J.+Castro&title=Phase+%28Ph%29+1%2F2a+Study+of+TSR-011%2C+a+Potent+Inhibitor+of+ALK+and+TRK%2C+in+Advanced+Solid+Tumors+Including+Crizotinib-resistant+ALK+Positive+Non-small+Cell+Lung+Cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=10.1200%2Fjco.2015.33.15_suppl.8063&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252Fjco.2015.33.15_suppl.8063%26sid%3Dliteratum%253Aachs%26aulast%3DArkenau%26aufirst%3DH.%2BT.%26aulast%3DSachdev%26aufirst%3DJ.%2BC.%26aulast%3DMita%26aufirst%3DM.%2BM.%26aulast%3DDziadziuszko%26aufirst%3DR.%26aulast%3DLin%26aufirst%3DC.%2BC.%26aulast%3DYang%26aufirst%3DJ.%2BC.%26aulast%3DInfante%26aufirst%3DJ.%2BR.%26aulast%3DAnthony%26aufirst%3DS.%2BP.%26aulast%3DVoskoboynik%26aufirst%3DM.%26aulast%3DSu%26aufirst%3DW.%2BC.%26aulast%3DDe%26aulast%3DCastro%26aufirst%3DJ.%26atitle%3DPhase%2520%2528Ph%2529%25201%252F2a%2520Study%2520of%2520TSR-011%252C%2520a%2520Potent%2520Inhibitor%2520of%2520ALK%2520and%2520TRK%252C%2520in%2520Advanced%2520Solid%2520Tumors%2520Including%2520Crizotinib-resistant%2520ALK%2520Positive%2520Non-small%2520Cell%2520Lung%2520Cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2015%26volume%3D33%26issue%3DSuppl%252015%26spage%3D8063" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref146"><div class="reference"><strong class="refLabel"><a href="#ref146" class="rightTabRefNumLink">146</a></strong><div class="NLM_citation" id="rightTab-cit146"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Katayama, R.</span></span> <span> </span><span class="NLM_article-title">Therapeutic Strategies and Mechanisms of Drug Resistance in Anaplastic Lymphoma Kinase (ALK)-rearranged Lung Cancer</span>. <i>Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>177</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">8</span>, <span class="refDoi"> DOI: 10.1016/j.pharmthera.2017.02.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1016%2Fj.pharmthera.2017.02.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=28185914" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC2sXktVKjtLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=177&publication_year=2017&pages=1-8&author=R.+Katayama&title=Therapeutic+Strategies+and+Mechanisms+of+Drug+Resistance+in+Anaplastic+Lymphoma+Kinase+%28ALK%29-rearranged+Lung+Cancer&doi=10.1016%2Fj.pharmthera.2017.02.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit146R"><div class="casContent"><span class="casTitleNuber">146</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic strategies and mechanisms of drug resistance in anaplastic lymphoma kinase (ALK)-rearranged lung cancer</span></div><div class="casAuthors">Katayama, Ryohei</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">177</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1-8</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Anaplastic lymphoma kinase (ALK) gene encoding the receptor tyrosine kinase ALK is expressed as a fusion gene in a variety of carcinomas.  The expression of ALK is nearly undetectable in adults, and its activation is normally regulated by its ligands, FAM150A/B.  However, ALK gene rearrangements result in different ALK fusion proteins that are constitutively expressed via the active promoter of fusion partner genes.  ALK fusion proteins dimerize in a ligand-independent manner and lead to the dysregulation of cell proliferation via abnormal constitutive activation of ALK tyrosine kinase.  Many ALK tyrosine kinase inhibitors (TKIs) have been developed to date, three of which are currently in clin. use for the treatment of ALK-rearranged non-small cell lung cancer (NSCLC).  ALK TKIs often achieve marked tumor regression in NSCLC patients with ALK rearrangements; however, ALK TKI-resistant tumors inevitably emerge within a few years in most cases.  In this review, we summarize diverse ALK TKI resistance mechanisms identified in NSCLC with ALK rearrangements, and review potential therapeutic strategies to overcome ALK TKI resistance in these patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGofwQpPLFXGr7Vg90H21EOLACvtfcHk0ljHY4LuNtksaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXktVKjtLo%253D&md5=8f3cdccfa2e0f3b014c3cac8689cf8c7</span></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2017.02.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2017.02.015%26sid%3Dliteratum%253Aachs%26aulast%3DKatayama%26aufirst%3DR.%26atitle%3DTherapeutic%2520Strategies%2520and%2520Mechanisms%2520of%2520Drug%2520Resistance%2520in%2520Anaplastic%2520Lymphoma%2520Kinase%2520%2528ALK%2529-rearranged%2520Lung%2520Cancer%26jtitle%3DPharmacol.%2520Ther.%26date%3D2017%26volume%3D177%26spage%3D1%26epage%3D8%26doi%3D10.1016%2Fj.pharmthera.2017.02.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref147"><div class="reference"><strong class="refLabel"><a href="#ref147" class="rightTabRefNumLink">147</a></strong><div class="NLM_citation" id="rightTab-cit147"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span> <span> </span><span class="NLM_article-title">Insight into Resistance Mechanism of Anaplastic Lymphoma Kinase to Alectinib and JH-VIII-157–02 Caused by G1202R Solvent front Mutation</span>. <i>Drug Des., Dev. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">1183</span>– <span class="NLM_lpage">1193</span>, <span class="refDoi"> DOI: 10.2147/DDDT.S147104</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.2147%2FDDDT.S147104" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=29785088" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtlCls7jJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2018&pages=1183-1193&author=H.+Wangauthor=Y.+Wangauthor=W.+Guoauthor=B.+Duauthor=X.+Huangauthor=R.+Wuauthor=B.+Yangauthor=X.+Linauthor=Y.+Wu&title=Insight+into+Resistance+Mechanism+of+Anaplastic+Lymphoma+Kinase+to+Alectinib+and+JH-VIII-157%E2%80%9302+Caused+by+G1202R+Solvent+front+Mutation&doi=10.2147%2FDDDT.S147104"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit147R"><div class="casContent"><span class="casTitleNuber">147</span><div class="casTitle"><span class="NLM_cas:atitle">Insight into resistance mechanism of anaplastic lymphoma kinase to alectinib and JH-VIII-157-02 caused by G1202R solvent front mutation</span></div><div class="casAuthors">Wang, Han; Wang, Yao; Guo, Wentao; Du, Bin; Huang, Xiaobing; Wu, Riping; Yang, Baoyu; Lin, Xiaoyan; Wu, Yilan</div><div class="citationInfo"><span class="NLM_cas:title">Drug Design, Development and Therapy</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1183-1193</span>CODEN:
                <span class="NLM_cas:coden">DDDTAQ</span>;
        ISSN:<span class="NLM_cas:issn">1177-8881</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">Background: Mutated anaplastic lymphoma kinase (ALK) drives the development of advanced non-small cell lung cancer (NSCLC).  Most reported small-mol. inhibitors targeting the ALK domain do not display good inhibition of the G1202R solvent front mutation.  The solvent front mutation was assumed to hinder drug binding.  However, a different fact could be uncovered by the simulations reported in this study through a structural analog of alectinib (JH-VIII-157-02), which demonstrated potent effects against the G1202R mutation.  Methods: Mol. docking, conventional mol. dynamics (MD) simulations, free energy calcns., and umbrella sampling (US) simulations were carried out to make clear the principles of the binding preferences of alectinib and JH-VIII-157-02 toward ALKWT and the ALK G1202R (ALKG1202R) mutation.  Results: JH-VIII-157-02 has similar binding affinities to both ALKWT and ALKG1202R whereas it has has a much lower binding affinity for alectinib to ALKG1202R.  Anal. of individual energy terms indicate the major variation involves the van der Waals and entropy terms.  Structural anal. reveals that the conformational change of the ATP-binding glycine-rich loop was primarily responsible for the alectinib resistance, not JH-VIII-157-02.  In addn., US simulations prove JH-VIII-157-02 has similar dissociative processes from both ALKWT and ALKG1202R, while alectinib is more easily dissocd. from ALKG1202R than from ALKWT, thus indicating lesser residence time.  Conclusion: Both the binding affinity and the drug residence time should be emphasized in rational drug design to overcome the G1202R solvent front mutation in ALK resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUg5P71nwEDrVg90H21EOLACvtfcHk0ljHY4LuNtksaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtlCls7jJ&md5=3fa915eddaf89a5383e0d3cc8621ffa8</span></div><a href="/servlet/linkout?suffix=cit147&amp;dbid=16384&amp;doi=10.2147%2FDDDT.S147104&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FDDDT.S147104%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DGuo%26aufirst%3DW.%26aulast%3DDu%26aufirst%3DB.%26aulast%3DHuang%26aufirst%3DX.%26aulast%3DWu%26aufirst%3DR.%26aulast%3DYang%26aufirst%3DB.%26aulast%3DLin%26aufirst%3DX.%26aulast%3DWu%26aufirst%3DY.%26atitle%3DInsight%2520into%2520Resistance%2520Mechanism%2520of%2520Anaplastic%2520Lymphoma%2520Kinase%2520to%2520Alectinib%2520and%2520JH-VIII-157%25E2%2580%259302%2520Caused%2520by%2520G1202R%2520Solvent%2520front%2520Mutation%26jtitle%3DDrug%2520Des.%252C%2520Dev.%2520Ther.%26date%3D2018%26volume%3D12%26spage%3D1183%26epage%3D1193%26doi%3D10.2147%2FDDDT.S147104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref148"><div class="reference"><strong class="refLabel"><a href="#ref148" class="rightTabRefNumLink">148</a></strong><div class="NLM_citation" id="rightTab-cit148"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tai, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, C.</span></span> <span> </span><span class="NLM_article-title">GSK1838705A, an Insulin-like Growth Factor-1 Receptor/insulin Receptor Inhibitor, Induces Apoptosis and Reduces Viability of Docetaxel-resistant Prostate Cancer Cells Both in Vitro and in Vivo</span>. <i>OncoTargets Ther.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">753</span>– <span class="NLM_lpage">760</span>, <span class="refDoi"> DOI: 10.2147/OTT.S79105</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.2147%2FOTT.S79105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=25926740" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC28Xlt1agsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2015&pages=753-760&author=F.+Zhouauthor=X.+Chenauthor=S.+Fanauthor=S.+Taiauthor=C.+Jiangauthor=Y.+Zhangauthor=Z.+Haoauthor=J.+Zhouauthor=H.+Shiauthor=L.+Zhangauthor=C.+Liang&title=GSK1838705A%2C+an+Insulin-like+Growth+Factor-1+Receptor%2Finsulin+Receptor+Inhibitor%2C+Induces+Apoptosis+and+Reduces+Viability+of+Docetaxel-resistant+Prostate+Cancer+Cells+Both+in+Vitro+and+in+Vivo&doi=10.2147%2FOTT.S79105"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit148R"><div class="casContent"><span class="casTitleNuber">148</span><div class="casTitle"><span class="NLM_cas:atitle">GSK1838705A, an insulin-like growth factor-1 receptor/insulin receptor inhibitor, induces apoptosis and reduces viability of docetaxel-resistant prostate cancer cells both in vitro and in vivo</span></div><div class="casAuthors">Zhou, Fayou; Chen, Xianguo; Fan, Song; Tai, Sheng; Jiang, Changqin; Zhang, Yifei; Hao, Zongyao; Zhou, Jun; Shi, Haoqiang; Zhang, Li; Liang, Chaozhao</div><div class="citationInfo"><span class="NLM_cas:title">OncoTargets and Therapy</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">753-760</span>CODEN:
                <span class="NLM_cas:coden">OTNHAZ</span>;
        ISSN:<span class="NLM_cas:issn">1178-6930</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">Prostate cancer is the leading malignancy and the second most common cause of cancer-related death in men.  Despite high cure rates with surgery and/or radiation, 30%-40% of patients eventually develop advanced cancer.  Docetaxel is one of the most effective and well established chemotherapeutic agents for prostate cancer.  However, docetaxel resistance often develops within months.  Combination therapies have been proposed to improve the therapeutic efficacy of docetaxel in prostate cancer, and there is an urgent need to identify agents that are effective for treatment of the disease, esp. docetaxel-resistant prostate cancer.  In this work, we investigated the activity of GSK1838705A, a potent insulin-like growth factor-1 receptor (IGF1R)/insulin receptor (IR) inhibitor, in prostate cancer, esp. docetaxel-resistant prostate cancer.  We found that GSK1838705A could effectively reduce the viability of both docetaxel-sensitive and docetaxel-resistant prostate cancer cells.  GSK1838705A induced marked apoptosis in docetaxel-resistant cells, and also dramatically inhibited migration of these cells.  Further, GSK1838705A significantly inhibited phosphorylation of IGF1R/IR.  Importantly, GSK1838705A significantly suppressed docetaxel-resistant PC-3R tumor growth in vivo.  This is the first study of GSK1838705A in prostate cancer.  Our results indicate that GSK1838705A is a promising compd. for the treatment of prostate cancer, esp. for those who develop resistance to docetaxel, and might shed new light on treatment for prostate cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokJx0KUvPzN7Vg90H21EOLACvtfcHk0ljHY4LuNtksaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xlt1agsr8%253D&md5=0bfd916c092a7cda409984fb6692e167</span></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=10.2147%2FOTT.S79105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FOTT.S79105%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DF.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DFan%26aufirst%3DS.%26aulast%3DTai%26aufirst%3DS.%26aulast%3DJiang%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DHao%26aufirst%3DZ.%26aulast%3DZhou%26aufirst%3DJ.%26aulast%3DShi%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DLiang%26aufirst%3DC.%26atitle%3DGSK1838705A%252C%2520an%2520Insulin-like%2520Growth%2520Factor-1%2520Receptor%252Finsulin%2520Receptor%2520Inhibitor%252C%2520Induces%2520Apoptosis%2520and%2520Reduces%2520Viability%2520of%2520Docetaxel-resistant%2520Prostate%2520Cancer%2520Cells%2520Both%2520in%2520Vitro%2520and%2520in%2520Vivo%26jtitle%3DOncoTargets%2520Ther.%26date%3D2015%26volume%3D8%26spage%3D753%26epage%3D760%26doi%3D10.2147%2FOTT.S79105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref149"><div class="reference"><strong class="refLabel"><a href="#ref149" class="rightTabRefNumLink">149</a></strong><div class="NLM_citation" id="rightTab-cit149"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hui, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pei, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, B.</span></span> <span> </span><span class="NLM_article-title">GSK1838705A, an IGF-1R inhibitor, Inhibits Glioma Cell Proliferation and Suppresses Tumor Growth in Vivo</span>. <i>Mol. Med. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">5641</span>– <span class="NLM_lpage">5646</span>, <span class="refDoi"> DOI: 10.3892/mmr.2015.4129</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.3892%2Fmmr.2015.4129" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=26238593" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFWns7fI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2015&pages=5641-5646&author=X.+Zhouauthor=F.+Shenauthor=P.+Maauthor=H.+Huiauthor=S.+Peiauthor=M.+Chenauthor=Z.+Wangauthor=W.+Zhouauthor=B.+Jin&title=GSK1838705A%2C+an+IGF-1R+inhibitor%2C+Inhibits+Glioma+Cell+Proliferation+and+Suppresses+Tumor+Growth+in+Vivo&doi=10.3892%2Fmmr.2015.4129"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit149R"><div class="casContent"><span class="casTitleNuber">149</span><div class="casTitle"><span class="NLM_cas:atitle">GSK1838705A, an IGF-1R inhibitor, inhibits glioma cell proliferation and suppresses tumor growth in vivo</span></div><div class="casAuthors">Zhou, Xiang; Shen, Fazheng; Ma, Pengju; Hui, Hongyan; Pei, Sujuan; Chen, Ming; Wang, Zhongwei; Zhou, Wenke; Jin, Baozhe</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Medicine Reports</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">4, Pt. B</span>),
    <span class="NLM_cas:pages">5641-5646</span>CODEN:
                <span class="NLM_cas:coden">MMROA5</span>;
        ISSN:<span class="NLM_cas:issn">1791-2997</span>.
    
            (<span class="NLM_cas:orgname">Spandidos Publications Ltd.</span>)
        </div><div class="casAbstract">Glioma is a type of primary malignant tumor of the central nervous system in humans.  At present, std. treatment involves surgical resection, followed by radiation therapy and chemotherapy.  However, the prognosis is poor and the long-term survival rate remains low.  An improved understanding of the mol. basis for glioma tumorigenesis is in urgently required.  The pro-survival effect of the insulin-like growth factor (IGF) signaling pathway has been implicated in progression of the glioma disease state.  GSK1838705A is a novel, small mol. kinase inhibitor of IGF-IR, which inhibits IGF signal transduction and downstream target activation.  Its anti-proliferative activity has been demonstrated in various tumor cell lines.  The present study investigated the potential use of GSK1838705A for the treatment of glioma.  Human U87MG glioma cells were used to examine the inhibitory activity of GSK1838705A in cell proliferation, migration and apoptosis.  The antitumor activity of GSK1838705A was assessed in a xenograft mouse model.  GSK1838705A inhibited the growth and induced the apoptosis of the U87MG glioma cells in a dose-dependent manner.  The GSK1838705A-treated cells exhibited reduced migratory activity in response to chemoattractants.  The present study further demonstrated the antitumor activity of GSK1838705A in vivo.  The administration of GSK1838705A significantly inhibited the growth of glioma tumors by inducing the apoptosis of tumor cells.  These results suggested that targeting IGF signaling with GSK1838705A may be a promising therapeutic strategy for the treatment of patients with glioma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpD5J-YhHjH3rVg90H21EOLACvtfcHk0li70Lrzv6ngBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFWns7fI&md5=171699df83385fbf417747bd6a013f26</span></div><a href="/servlet/linkout?suffix=cit149&amp;dbid=16384&amp;doi=10.3892%2Fmmr.2015.4129&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252Fmmr.2015.4129%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DX.%26aulast%3DShen%26aufirst%3DF.%26aulast%3DMa%26aufirst%3DP.%26aulast%3DHui%26aufirst%3DH.%26aulast%3DPei%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DJin%26aufirst%3DB.%26atitle%3DGSK1838705A%252C%2520an%2520IGF-1R%2520inhibitor%252C%2520Inhibits%2520Glioma%2520Cell%2520Proliferation%2520and%2520Suppresses%2520Tumor%2520Growth%2520in%2520Vivo%26jtitle%3DMol.%2520Med.%2520Rep.%26date%3D2015%26volume%3D12%26spage%3D5641%26epage%3D5646%26doi%3D10.3892%2Fmmr.2015.4129" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref150"><div class="reference"><strong class="refLabel"><a href="#ref150" class="rightTabRefNumLink">150</a></strong><div class="NLM_citation" id="rightTab-cit150"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhai, D.</span>; <span class="NLM_string-name">Deng, W.</span>; <span class="NLM_string-name">Huang, Z.</span>; <span class="NLM_string-name">Rogers, E.</span>; <span class="NLM_string-name">Cui, J. J.</span></span> <span> </span><span class="NLM_article-title">The Novel, Rationally-designed, ALK/SRC Inhibitor TPX-0005 Overcomes Multiple Acquired Resistance Mechanisms to Current ALK Inhibitors</span>. Presented at the  <i>107th Annual Meeting of the American Association for Cancer Research (AACR), New Orleans, LA,</i> <span class="NLM_year">2016</span>; Abstract  <span class="NLM_fpage">2132</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&pages=2132&author=D.+Zhai&author=W.+Deng&author=Z.+Huang&author=E.+Rogers&author=J.+J.+Cui&title=The+Novel%2C+Rationally-designed%2C+ALK%2FSRC+Inhibitor+TPX-0005+Overcomes+Multiple+Acquired+Resistance+Mechanisms+to+Current+ALK+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit150&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26sid%3Dliteratum%253Aachs%26aulast%3DZhai%26aufirst%3DD.%26atitle%3DThe%2520Novel%252C%2520Rationally-designed%252C%2520ALK%252FSRC%2520Inhibitor%2520TPX-0005%2520Overcomes%2520Multiple%2520Acquired%2520Resistance%2520Mechanisms%2520to%2520Current%2520ALK%2520Inhibitors%26jtitle%3D107th%2520Annual%2520Meeting%2520of%2520the%2520American%2520Association%2520for%2520Cancer%2520Research%2520%2528AACR%2529%252C%2520New%2520Orleans%252C%2520LA%252C%26date%3D2016%26spage%3D2132" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref151"><div class="reference"><strong class="refLabel"><a href="#ref151" class="rightTabRefNumLink">151</a></strong><div class="NLM_citation" id="rightTab-cit151"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Deng, W.</span>; <span class="NLM_string-name">Huang, J.</span>; <span class="NLM_string-name">Zhai, D.</span>; <span class="NLM_string-name">Rogers, E.</span>; <span class="NLM_string-name">Cui, J.</span></span> <span> </span><span class="NLM_article-title">Overcoming Acquired Drug Resistance by TPX-0005, an ALK, ROS1 and Pan-TRK Inhibitor</span>. Presented at the  <i>Annual Meeting of the American Association for Cancer Research (AACR), Washington, DC</i>, <span class="NLM_year">2017</span>; Abstract  <span class="NLM_fpage">3168</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&pages=3168&author=W.+Deng&author=J.+Huang&author=D.+Zhai&author=E.+Rogers&author=J.+Cui&title=Overcoming+Acquired+Drug+Resistance+by+TPX-0005%2C+an+ALK%2C+ROS1+and+Pan-TRK+Inhibitor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit151&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26sid%3Dliteratum%253Aachs%26aulast%3DDeng%26aufirst%3DW.%26atitle%3DOvercoming%2520Acquired%2520Drug%2520Resistance%2520by%2520TPX-0005%252C%2520an%2520ALK%252C%2520ROS1%2520and%2520Pan-TRK%2520Inhibitor%26jtitle%3DAnnual%2520Meeting%2520of%2520the%2520American%2520Association%2520for%2520Cancer%2520Research%2520%2528AACR%2529%252C%2520Washington%252C%2520DC%26date%3D2017%26spage%3D3168" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref152"><div class="reference"><strong class="refLabel"><a href="#ref152" class="rightTabRefNumLink">152</a></strong><div class="NLM_citation" id="rightTab-cit152"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Epstein, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emkey, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whittington, D. A.</span></span> <span> </span><span class="NLM_article-title">The R1275Q Neuroblastoma Mutant and Certain ATP-competitive Inhibitors Stabilize Alternative Activation Loop Conformations of Anaplastic Lymphoma Kinase</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>287</i></span>,  <span class="NLM_fpage">37447</span>– <span class="NLM_lpage">37457</span>, <span class="refDoi"> DOI: 10.1074/jbc.M112.391425</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1074%2Fjbc.M112.391425" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=22932897" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFOqs73K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=287&publication_year=2012&pages=37447-37457&author=L.+F.+Epsteinauthor=H.+Chenauthor=R.+Emkeyauthor=D.+A.+Whittington&title=The+R1275Q+Neuroblastoma+Mutant+and+Certain+ATP-competitive+Inhibitors+Stabilize+Alternative+Activation+Loop+Conformations+of+Anaplastic+Lymphoma+Kinase&doi=10.1074%2Fjbc.M112.391425"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit152R"><div class="casContent"><span class="casTitleNuber">152</span><div class="casTitle"><span class="NLM_cas:atitle">The R1275Q Neuroblastoma Mutant and Certain ATP-competitive Inhibitors Stabilize Alternative Activation Loop Conformations of Anaplastic Lymphoma Kinase</span></div><div class="casAuthors">Epstein, Linda F.; Chen, Hao; Emkey, Renee; Whittington, Douglas A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">287</span>
        (<span class="NLM_cas:issue">44</span>),
    <span class="NLM_cas:pages">37447-37457</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase that, when genetically altered by mutation, amplification, chromosomal translocation or inversion, has been shown to play an oncogenic role in certain cancers.  Small mol. inhibitors targeting the kinase activity of ALK have proven to be effective therapies in certain ALK-driven malignancies and one such inhibitor, crizotinib, is now approved for the treatment of EML4-ALK-driven, non-small cell lung cancer.  In neuroblastoma, activating point mutations in the ALK kinase domain can drive disease progression, with the two most common mutations being F1174L and R1275Q.  We report here crystal structures of the ALK kinase domain contg. the F1174L and R1275Q mutations.  Also included are crystal structures of ALK in complex with novel small mol. ALK inhibitors, including a classic type II inhibitor, that stabilize previously unobserved conformations of the ALK activation loop.  Collectively, these structures illustrate a different series of activation loop conformations than has been obsd. in previous ALK crystal structures and provide insight into the activating nature of the R1275Q mutation.  The novel active site topologies presented here may also aid the structure-based drug design of a new generation of ALK inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0rQKncKYwgrVg90H21EOLACvtfcHk0li70Lrzv6ngBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFOqs73K&md5=ac3a068a4837dfb1d63d54826d2b4564</span></div><a href="/servlet/linkout?suffix=cit152&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M112.391425&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M112.391425%26sid%3Dliteratum%253Aachs%26aulast%3DEpstein%26aufirst%3DL.%2BF.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DEmkey%26aufirst%3DR.%26aulast%3DWhittington%26aufirst%3DD.%2BA.%26atitle%3DThe%2520R1275Q%2520Neuroblastoma%2520Mutant%2520and%2520Certain%2520ATP-competitive%2520Inhibitors%2520Stabilize%2520Alternative%2520Activation%2520Loop%2520Conformations%2520of%2520Anaplastic%2520Lymphoma%2520Kinase%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2012%26volume%3D287%26spage%3D37447%26epage%3D37457%26doi%3D10.1074%2Fjbc.M112.391425" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref153"><div class="reference"><strong class="refLabel"><a href="#ref153" class="rightTabRefNumLink">153</a></strong><div class="NLM_citation" id="rightTab-cit153"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kong, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, T.</span></span> <span> </span><span class="NLM_article-title">Importance of Protein Flexibility in Ranking Inhibitor Affinities: Modeling the Binding Mechanisms of Piperidine Carboxamides as Type I1/2 ALK Inhibitors</span>. <i>Phys. Chem. Chem. Phys.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">6098</span>– <span class="NLM_lpage">6113</span>, <span class="refDoi"> DOI: 10.1039/C4CP05440G</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1039%2FC4CP05440G" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=25644934" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsFSmsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2015&pages=6098-6113&author=X.+Kongauthor=P.+Panauthor=D.+Liauthor=S.+Tianauthor=Y.+Liauthor=T.+Hou&title=Importance+of+Protein+Flexibility+in+Ranking+Inhibitor+Affinities%3A+Modeling+the+Binding+Mechanisms+of+Piperidine+Carboxamides+as+Type+I1%2F2+ALK+Inhibitors&doi=10.1039%2FC4CP05440G"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit153R"><div class="casContent"><span class="casTitleNuber">153</span><div class="casTitle"><span class="NLM_cas:atitle">Importance of protein flexibility in ranking inhibitor affinities: modeling the binding mechanisms of piperidine carboxamides as Type I1/2 ALK inhibitors</span></div><div class="casAuthors">Kong, Xiaotian; Pan, Peichen; Li, Dan; Tian, Sheng; Li, Youyong; Hou, Tingjun</div><div class="citationInfo"><span class="NLM_cas:title">Physical Chemistry Chemical Physics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">6098-6113</span>CODEN:
                <span class="NLM_cas:coden">PPCPFQ</span>;
        ISSN:<span class="NLM_cas:issn">1463-9076</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Anaplastic lymphoma kinase (ALK) has gained increased attention as an attractive therapeutic target for the treatment of various cancers, esp. non-small-cell lung cancer (NSCLC).  Recently, piperidine carboxamides were reported as Type I1/2 inhibitors of ALK, which occupy both the ATP binding site and the back ATP hydrophobic cavity in DFG-in conformation.  Due to the dynamic behavior of ALK in the binding of Type I1/2 inhibitors, the accurate predictions of the binding structures and relative binding potencies of these inhibitors are quite challenging.  In this study, different modeling techniques, including mol. docking, ensemble docking based on multiple receptor conformations, mol. dynamics simulations and free energy calcns., were utilized to explore the binding mechanisms of piperidine carboxamides.  Our predictions show that the conventional docking protocols are not sufficient to predict the relative binding potencies of the studied inhibitors with high accuracy, but incorporating protein flexibility before or after docking is quite effective to improve the prediction accuracy.  Notably, the binding free energies predicted by MM/GBSA or MM/PBSA based on the MD simulations for the docked poses give the highest correlation with the exptl. data, highlighting the importance of the inclusion of receptor flexibility for the accurate predictions of the binding potencies for Type I1/2 inhibitors of ALK.  Furthermore, the comprehensive anal. of several pairs of representative inhibitors demonstrates the importance of hydrophobic interactions in improving the binding affinities of the inhibitors with the hot-spot residues surrounding the binding pocket.  This work is expected to provide valuable clues for further rational design of novel and potent Type I1/2 ALK inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpHLqgO9iCaU7Vg90H21EOLACvtfcHk0litfUaXLZD9ug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsFSmsL8%253D&md5=4b9bcd6f5b434d8a8240a171ce9897a7</span></div><a href="/servlet/linkout?suffix=cit153&amp;dbid=16384&amp;doi=10.1039%2FC4CP05440G&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC4CP05440G%26sid%3Dliteratum%253Aachs%26aulast%3DKong%26aufirst%3DX.%26aulast%3DPan%26aufirst%3DP.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DTian%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DHou%26aufirst%3DT.%26atitle%3DImportance%2520of%2520Protein%2520Flexibility%2520in%2520Ranking%2520Inhibitor%2520Affinities%253A%2520Modeling%2520the%2520Binding%2520Mechanisms%2520of%2520Piperidine%2520Carboxamides%2520as%2520Type%2520I1%252F2%2520ALK%2520Inhibitors%26jtitle%3DPhys.%2520Chem.%2520Chem.%2520Phys.%26date%3D2015%26volume%3D17%26spage%3D6098%26epage%3D6113%26doi%3D10.1039%2FC4CP05440G" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref154"><div class="reference"><strong class="refLabel"><a href="#ref154" class="rightTabRefNumLink">154</a></strong><div class="NLM_citation" id="rightTab-cit154"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kong, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, T.</span></span> <span> </span><span class="NLM_article-title">Importance of Protein Flexibility in Molecular Recognition: a Case Study on Type-I1/2 Inhibitors of ALK</span>. <i>Phys. Chem. Chem. Phys.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">4851</span>– <span class="NLM_lpage">4863</span>, <span class="refDoi"> DOI: 10.1039/C7CP08241J</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1039%2FC7CP08241J" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=29383359" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC1cXosF2ltg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2018&pages=4851-4863&author=X.+Kongauthor=H.+Sunauthor=P.+Panauthor=F.+Zhuauthor=S.+Changauthor=L.+Xuauthor=Y.+Liauthor=T.+Hou&title=Importance+of+Protein+Flexibility+in+Molecular+Recognition%3A+a+Case+Study+on+Type-I1%2F2+Inhibitors+of+ALK&doi=10.1039%2FC7CP08241J"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit154R"><div class="casContent"><span class="casTitleNuber">154</span><div class="casTitle"><span class="NLM_cas:atitle">Importance of protein flexibility in molecular recognition: a case study on Type-I1/2 inhibitors of ALK</span></div><div class="casAuthors">Kong, Xiaotian; Sun, Huiyong; Pan, Peichen; Zhu, Feng; Chang, Shan; Xu, Lei; Li, Youyong; Hou, Tingjun</div><div class="citationInfo"><span class="NLM_cas:title">Physical Chemistry Chemical Physics</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">4851-4863</span>CODEN:
                <span class="NLM_cas:coden">PPCPFQ</span>;
        ISSN:<span class="NLM_cas:issn">1463-9076</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Anaplastic lymphoma kinase (ALK) has been regarded as a promising target for the therapy of various cancers.  A large no. of ALK inhibitors with diverse scaffolds have been discovered, and most of them belong to Type-I inhibitors that only occupy the ATP-binding pocket.  Recently, we reported a series of novel and potent Type-I1/2 inhibitors of ALK with the 1-purine-3-piperidinecarboxamide scaffold, which can bind to both the ATP-binding site of ALK and the adjacent hydrophobic allosteric pocket.  In this study, the binding mechanisms of these Type-I1/2 ALK inhibitors were elucidated by multiple mol. modeling techniques.  The calcn. results demonstrate that the ensemble docking based on multiple protein structures and the MM/PB(GB)SA calcns. based on mol. dynamics (MD) simulations yield better predictions than conventional rigid receptor docking (Glide, Surflex-Dock, and Autodock Vina), highlighting the importance of incorporating receptor flexibility in the predictions of binding poses and binding affinities of Type-I1/2 ALK inhibitors.  Furthermore, the umbrella sampling (US) simulations and MM/GBSA binding free energy decompn. analyses indicate that Leu1122, Leu1198, Gly1202 and Glu1210 in the hinge region and Glu1197, Ile1171, Phe1174, Ile1179, His1247, Ile1268, Asp1270 and Phe1271 in the allosteric pocket of ALK are the key residues for detg. the relative binding strength of the studied inhibitors.  Besides, we found that the most potent inhibitor (001-017) tends to form stronger transient interactions with residues along the dissocn. channel due to the high electronegativity of its bulky 4-(trifluoromethoxy) phenylamine tail.  As a whole, both the stronger binding affinity and the higher energetic barrier (which may prolong the drug-target residence time) of 001-017 contribute to its excellent anti-proliferation activity against ALK-pos. cancer cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDYCtbvgqEXbVg90H21EOLACvtfcHk0litfUaXLZD9ug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXosF2ltg%253D%253D&md5=c9607c6402fdcdccf751ae34d5c8cea1</span></div><a href="/servlet/linkout?suffix=cit154&amp;dbid=16384&amp;doi=10.1039%2FC7CP08241J&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC7CP08241J%26sid%3Dliteratum%253Aachs%26aulast%3DKong%26aufirst%3DX.%26aulast%3DSun%26aufirst%3DH.%26aulast%3DPan%26aufirst%3DP.%26aulast%3DZhu%26aufirst%3DF.%26aulast%3DChang%26aufirst%3DS.%26aulast%3DXu%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DHou%26aufirst%3DT.%26atitle%3DImportance%2520of%2520Protein%2520Flexibility%2520in%2520Molecular%2520Recognition%253A%2520a%2520Case%2520Study%2520on%2520Type-I1%252F2%2520Inhibitors%2520of%2520ALK%26jtitle%3DPhys.%2520Chem.%2520Chem.%2520Phys.%26date%3D2018%26volume%3D20%26spage%3D4851%26epage%3D4863%26doi%3D10.1039%2FC7CP08241J" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref155"><div class="reference"><strong class="refLabel"><a href="#ref155" class="rightTabRefNumLink">155</a></strong><div class="NLM_citation" id="rightTab-cit155"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wentsch, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walter, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bührmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayer-Wrangowski, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rauh, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaman, G. J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willemsen-Seegers, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buijsman, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henning, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dauch, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zender, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laufer, S.</span></span> <span> </span><span class="NLM_article-title">Optimized Target Residence Time: Type I1/2 Inhibitors for p38α MAP Kinase with Improved Binding Kinetics through Direct Interaction with the R-Spine</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">5363</span>– <span class="NLM_lpage">5367</span>, <span class="refDoi"> DOI: 10.1002/anie.201701185</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1002%2Fanie.201701185" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC2sXlvVCmu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2017&pages=5363-5367&author=H.+K.+Wentschauthor=N.+M.+Walterauthor=M.+B%C3%BChrmannauthor=S.+Mayer-Wrangowskiauthor=D.+Rauhauthor=G.+J.+R.+Zamanauthor=N.+Willemsen-Seegersauthor=R.+C.+Buijsmanauthor=M.+Henningauthor=D.+Dauchauthor=L.+Zenderauthor=S.+Laufer&title=Optimized+Target+Residence+Time%3A+Type+I1%2F2+Inhibitors+for+p38%CE%B1+MAP+Kinase+with+Improved+Binding+Kinetics+through+Direct+Interaction+with+the+R-Spine&doi=10.1002%2Fanie.201701185"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit155R"><div class="casContent"><span class="casTitleNuber">155</span><div class="casTitle"><span class="NLM_cas:atitle">Optimized Target Residence Time: Type I1/2 Inhibitors for p38α MAP Kinase with Improved Binding Kinetics through Direct Interaction with the R-Spine</span></div><div class="casAuthors">Wentsch, Heike K.; Walter, Niklas M.; Buehrmann, Mike; Mayer-Wrangowski, Svenja; Rauh, Daniel; Zaman, Guido J. R.; Willemsen-Seegers, Nicole; Buijsman, Rogier C.; Henning, Melanie; Dauch, Daniel; Zender, Lars; Laufer, Stefan</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">5363-5367</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Skepinone-L was recently reported to be a p38α MAP kinase inhibitor with high potency and excellent selectivity in vitro and in vivo.  However, this class of compds. still act as fully ATP-competitive Type I binders which, furthermore, suffer from short residence times at the enzyme.  We herein describe a further development with the first Type I1/2 binders for p38α MAP kinase.  Type I1/2 inhibitors interfere with the R-spine, inducing a glycine flip and occupying both hydrophobic regions I and II.  This design approach leads to prolonged target residence time, binding to both the active and inactive states of the kinase, excellent selectivity, excellent potency on the enzyme level, and low nanomolar activity in a human whole blood assay.  This promising binding mode is proven by X-ray crystallog.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoO3M43Sl8vibVg90H21EOLACvtfcHk0litfUaXLZD9ug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXlvVCmu70%253D&md5=c4a1f981eaf8a2146f758fe4e71ac8b5</span></div><a href="/servlet/linkout?suffix=cit155&amp;dbid=16384&amp;doi=10.1002%2Fanie.201701185&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201701185%26sid%3Dliteratum%253Aachs%26aulast%3DWentsch%26aufirst%3DH.%2BK.%26aulast%3DWalter%26aufirst%3DN.%2BM.%26aulast%3DB%25C3%25BChrmann%26aufirst%3DM.%26aulast%3DMayer-Wrangowski%26aufirst%3DS.%26aulast%3DRauh%26aufirst%3DD.%26aulast%3DZaman%26aufirst%3DG.%2BJ.%2BR.%26aulast%3DWillemsen-Seegers%26aufirst%3DN.%26aulast%3DBuijsman%26aufirst%3DR.%2BC.%26aulast%3DHenning%26aufirst%3DM.%26aulast%3DDauch%26aufirst%3DD.%26aulast%3DZender%26aufirst%3DL.%26aulast%3DLaufer%26aufirst%3DS.%26atitle%3DOptimized%2520Target%2520Residence%2520Time%253A%2520Type%2520I1%252F2%2520Inhibitors%2520for%2520p38%25CE%25B1%2520MAP%2520Kinase%2520with%2520Improved%2520Binding%2520Kinetics%2520through%2520Direct%2520Interaction%2520with%2520the%2520R-Spine%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2017%26volume%3D56%26spage%3D5363%26epage%3D5367%26doi%3D10.1002%2Fanie.201701185" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref156"><div class="reference"><strong class="refLabel"><a href="#ref156" class="rightTabRefNumLink">156</a></strong><div class="NLM_citation" id="rightTab-cit156"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pargellis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Churchill, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cirillo, P. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilmore, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graham, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grob, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hickey, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moss, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pav, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Regan, J.</span></span> <span> </span><span class="NLM_article-title">Inhibition of p38 MAP Kinase by Utilizing a Novel Allosteric Binding Site</span>. <i>Nat. Struct. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">268</span>, <span class="refDoi"> DOI: 10.1038/nsb770</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1038%2Fnsb770" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=11896401" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BD38Xis1Kisbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2002&pages=268&author=C.+Pargellisauthor=L.+Tongauthor=L.+Churchillauthor=P.+F.+Cirilloauthor=T.+Gilmoreauthor=A.+G.+Grahamauthor=P.+M.+Grobauthor=E.+R.+Hickeyauthor=N.+Mossauthor=S.+Pavauthor=J.+Regan&title=Inhibition+of+p38+MAP+Kinase+by+Utilizing+a+Novel+Allosteric+Binding+Site&doi=10.1038%2Fnsb770"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit156R"><div class="casContent"><span class="casTitleNuber">156</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site</span></div><div class="casAuthors">Pargellis, Christopher; Tong, Liang; Churchill, Laurie; Cirillo, Pier F.; Gilmore, Thomas; Graham, Anne G.; Grob, Peter M.; Hickey, Eugene R.; Moss, Neil; Pav, Susan; Regan, John</div><div class="citationInfo"><span class="NLM_cas:title">Nature Structural Biology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">268-272</span>CODEN:
                <span class="NLM_cas:coden">NSBIEW</span>;
        ISSN:<span class="NLM_cas:issn">1072-8368</span>.
    
            (<span class="NLM_cas:orgname">Nature America Inc.</span>)
        </div><div class="casAbstract">The p38 MAP kinase plays a crucial role in regulating the prodn. of proinflammatory cytokines, such as tumor necrosis factor and interleukin-1.  Blocking this kinase may offer an effective therapy for treating many inflammatory diseases.  Here we report a new allosteric binding site for a diaryl urea class of highly potent and selective inhibitors against human p38 MAP kinase.  The formation of this binding site requires a large conformational change not obsd. previously for any of the protein Ser/Thr kinases.  This change is in the highly conserved Asp-Phe-Gly motif within the active site of the kinase.  Soln. studies demonstrate that this class of compds. has slow binding kinetics, consistent with the requirement for conformational change.  Improving interactions in this allosteric pocket, as well as establishing binding interactions in the ATP pocket, enhanced the affinity of the inhibitors by 12,000-fold.  One of the most potent compds. in this series, BIRB 796, has picomolar affinity for the kinase and low nanomolar inhibitory activity in cell culture.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqT8_QT7_pbYrVg90H21EOLACvtfcHk0lhM9uJnnsI6jQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xis1Kisbk%253D&md5=68850ecdbe08df4285ba38cfa2c93ea4</span></div><a href="/servlet/linkout?suffix=cit156&amp;dbid=16384&amp;doi=10.1038%2Fnsb770&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnsb770%26sid%3Dliteratum%253Aachs%26aulast%3DPargellis%26aufirst%3DC.%26aulast%3DTong%26aufirst%3DL.%26aulast%3DChurchill%26aufirst%3DL.%26aulast%3DCirillo%26aufirst%3DP.%2BF.%26aulast%3DGilmore%26aufirst%3DT.%26aulast%3DGraham%26aufirst%3DA.%2BG.%26aulast%3DGrob%26aufirst%3DP.%2BM.%26aulast%3DHickey%26aufirst%3DE.%2BR.%26aulast%3DMoss%26aufirst%3DN.%26aulast%3DPav%26aufirst%3DS.%26aulast%3DRegan%26aufirst%3DJ.%26atitle%3DInhibition%2520of%2520p38%2520MAP%2520Kinase%2520by%2520Utilizing%2520a%2520Novel%2520Allosteric%2520Binding%2520Site%26jtitle%3DNat.%2520Struct.%2520Biol.%26date%3D2002%26volume%3D9%26spage%3D268%26doi%3D10.1038%2Fnsb770" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref157"><div class="reference"><strong class="refLabel"><a href="#ref157" class="rightTabRefNumLink">157</a></strong><div class="NLM_citation" id="rightTab-cit157"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Walter, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wentsch, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buhrmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doring, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayer-Wrangowski, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sievers-Engler, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willemsen-Seegers, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaman, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buijsman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lammerhofer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rauh, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laufer, S. A.</span></span> <span> </span><span class="NLM_article-title">Design, Synthesis, and Biological Evaluation of Novel Type I1/2 p38α MAP Kinase Inhibitors with Excellent Selectivity, High Potency, and Prolonged Target Residence Time by Interfering with the R-spine</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">8027</span>– <span class="NLM_lpage">8054</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00745</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00745" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlOksb3M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=8027-8054&author=N.+M.+Walterauthor=H.+K.+Wentschauthor=M.+Buhrmannauthor=S.+M.+Bauerauthor=E.+Doringauthor=S.+Mayer-Wrangowskiauthor=A.+Sievers-Englerauthor=N.+Willemsen-Seegersauthor=G.+Zamanauthor=R.+Buijsmanauthor=M.+Lammerhoferauthor=D.+Rauhauthor=S.+A.+Laufer&title=Design%2C+Synthesis%2C+and+Biological+Evaluation+of+Novel+Type+I1%2F2+p38%CE%B1+MAP+Kinase+Inhibitors+with+Excellent+Selectivity%2C+High+Potency%2C+and+Prolonged+Target+Residence+Time+by+Interfering+with+the+R-spine&doi=10.1021%2Facs.jmedchem.7b00745"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit157R"><div class="casContent"><span class="casTitleNuber">157</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, and Biological Evaluation of Novel Type I1/2 p38α MAP Kinase Inhibitors with Excellent Selectivity, High Potency, and Prolonged Target Residence Time by Interfering with the R-Spine</span></div><div class="casAuthors">Walter, Niklas M.; Wentsch, Heike K.; Buehrmann, Mike; Bauer, Silke M.; Doering, Eva; Mayer-Wrangowski, Svenja; Sievers-Engler, Adrian; Willemsen-Seegers, Nicole; Zaman, Guido; Buijsman, Rogier; Laemmerhofer, Michael; Rauh, Daniel; Laufer, Stefan A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">8027-8054</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We recently reported 1a (skepinone-L) as a type I p38α MAP kinase inhibitor with high potency and excellent selectivity in vitro and in vivo.  However, as a type I inhibitor, it is entirely ATP-competitive and shows just a moderate residence time.  Thus, the scope was to develop a new class of advanced compds. maintaining the structural binding features of skepinone-L scaffold like inducing a glycine flip at the hinge region and occupying both hydrophobic regions I and II.  Extending this scaffold with suitable residues resulted in an interference with the kinase's R-Spine.  By synthesizing 69 compds., we could significantly prolong the target residence time with one example to 3663 s, along with an excellent selectivity score of 0.006 and an outstanding potency of 1.0 nM.  This new binding mode was validated by cocrystn., showing all binding interactions typifying type I1/2 binding.  Moreover, microsomal studies showed convenient metabolic stability of the most potent, herein reported representatives.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpAGz7uVuEJALVg90H21EOLACvtfcHk0lhM9uJnnsI6jQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlOksb3M&md5=99afecb58a5cf1fff6d9a905eb9f3aca</span></div><a href="/servlet/linkout?suffix=cit157&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00745%26sid%3Dliteratum%253Aachs%26aulast%3DWalter%26aufirst%3DN.%2BM.%26aulast%3DWentsch%26aufirst%3DH.%2BK.%26aulast%3DBuhrmann%26aufirst%3DM.%26aulast%3DBauer%26aufirst%3DS.%2BM.%26aulast%3DDoring%26aufirst%3DE.%26aulast%3DMayer-Wrangowski%26aufirst%3DS.%26aulast%3DSievers-Engler%26aufirst%3DA.%26aulast%3DWillemsen-Seegers%26aufirst%3DN.%26aulast%3DZaman%26aufirst%3DG.%26aulast%3DBuijsman%26aufirst%3DR.%26aulast%3DLammerhofer%26aufirst%3DM.%26aulast%3DRauh%26aufirst%3DD.%26aulast%3DLaufer%26aufirst%3DS.%2BA.%26atitle%3DDesign%252C%2520Synthesis%252C%2520and%2520Biological%2520Evaluation%2520of%2520Novel%2520Type%2520I1%252F2%2520p38%25CE%25B1%2520MAP%2520Kinase%2520Inhibitors%2520with%2520Excellent%2520Selectivity%252C%2520High%2520Potency%252C%2520and%2520Prolonged%2520Target%2520Residence%2520Time%2520by%2520Interfering%2520with%2520the%2520R-spine%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D8027%26epage%3D8054%26doi%3D10.1021%2Facs.jmedchem.7b00745" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref158"><div class="reference"><strong class="refLabel"><a href="#ref158" class="rightTabRefNumLink">158</a></strong><div class="NLM_citation" id="rightTab-cit158"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mei, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kevin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span> <span> </span><span class="NLM_article-title">Protein–ligand Interaction Fingerprints for Accurate Prediction of Dissociation Rates of p38 MAPK Type II Inhibitors</span>. <i>Integr. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">53</span>– <span class="NLM_lpage">60</span>, <span class="refDoi"> DOI: 10.1093/intbio/zyz004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1093%2Fintbio%2Fzyz004" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2019&pages=53-60&author=D.+Zhangauthor=S.+Huangauthor=H.+Meiauthor=M.+Kevinauthor=T.+Shiauthor=L.+Chen&title=Protein%E2%80%93ligand+Interaction+Fingerprints+for+Accurate+Prediction+of+Dissociation+Rates+of+p38+MAPK+Type+II+Inhibitors&doi=10.1093%2Fintbio%2Fzyz004"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit158&amp;dbid=16384&amp;doi=10.1093%2Fintbio%2Fzyz004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fintbio%252Fzyz004%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DD.%26aulast%3DHuang%26aufirst%3DS.%26aulast%3DMei%26aufirst%3DH.%26aulast%3DKevin%26aufirst%3DM.%26aulast%3DShi%26aufirst%3DT.%26aulast%3DChen%26aufirst%3DL.%26atitle%3DProtein%25E2%2580%2593ligand%2520Interaction%2520Fingerprints%2520for%2520Accurate%2520Prediction%2520of%2520Dissociation%2520Rates%2520of%2520p38%2520MAPK%2520Type%2520II%2520Inhibitors%26jtitle%3DIntegr.%2520Biol.%26date%3D2019%26volume%3D11%26spage%3D53%26epage%3D60%26doi%3D10.1093%2Fintbio%2Fzyz004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref159"><div class="reference"><strong class="refLabel"><a href="#ref159" class="rightTabRefNumLink">159</a></strong><div class="NLM_citation" id="rightTab-cit159"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Blanc, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geney, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menet, C.</span></span> <span> </span><span class="NLM_article-title">Type II Kinase Inhibitors: an Opportunity in Cancer for Rational Design</span>. <i>Anti-Cancer Agents Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">731</span>– <span class="NLM_lpage">747</span>, <span class="refDoi"> DOI: 10.2174/1871520611313050008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.2174%2F1871520611313050008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=23094911" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC3sXpslyku78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2013&pages=731-747&author=J.+Blancauthor=R.+Geneyauthor=C.+Menet&title=Type+II+Kinase+Inhibitors%3A+an+Opportunity+in+Cancer+for+Rational+Design&doi=10.2174%2F1871520611313050008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit159R"><div class="casContent"><span class="casTitleNuber">159</span><div class="casTitle"><span class="NLM_cas:atitle">Type II kinase inhibitors: an opportunity in cancer for rational design</span></div><div class="casAuthors">Blanc, Javier; Geney, Raphael; Menet, Christel</div><div class="citationInfo"><span class="NLM_cas:title">Anti-Cancer Agents in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">731-747</span>CODEN:
                <span class="NLM_cas:coden">AAMCE4</span>;
        ISSN:<span class="NLM_cas:issn">1871-5206</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  With the advent of the Type II kinase inhibitor imatinib (Gleevec) for treatment against cancer, rational design of tailored mols. has brought a revolution in medicinal chem. for treating tumors caused by kinase malfunctioning.  Among different types of kinase inhibitors, the design of Type II inhibitors has been rationalized for maximizing the benefits and reducing drawbacks.  Here we highlight the development made in Type II inhibitors, discussing the advantages and disadvantages of these types of mols.  Furthermore, we present the strategies for designing druggable mols. that either selectively inhibit target kinases or overcome drug resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7md6eYN1yg7Vg90H21EOLACvtfcHk0lhM9uJnnsI6jQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXpslyku78%253D&md5=30e72045115f723f2b868381898c2218</span></div><a href="/servlet/linkout?suffix=cit159&amp;dbid=16384&amp;doi=10.2174%2F1871520611313050008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1871520611313050008%26sid%3Dliteratum%253Aachs%26aulast%3DBlanc%26aufirst%3DJ.%26aulast%3DGeney%26aufirst%3DR.%26aulast%3DMenet%26aufirst%3DC.%26atitle%3DType%2520II%2520Kinase%2520Inhibitors%253A%2520an%2520Opportunity%2520in%2520Cancer%2520for%2520Rational%2520Design%26jtitle%3DAnti-Cancer%2520Agents%2520Med.%2520Chem.%26date%3D2013%26volume%3D13%26spage%3D731%26epage%3D747%26doi%3D10.2174%2F1871520611313050008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref160"><div class="reference"><strong class="refLabel"><a href="#ref160" class="rightTabRefNumLink">160</a></strong><div class="NLM_citation" id="rightTab-cit160"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Paiva, S.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crews, C. M.</span></span> <span> </span><span class="NLM_article-title">Targeted Protein Degradation: Elements of PROTAC Design</span>. <i>Curr. Opin. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">111</span>– <span class="NLM_lpage">119</span>, <span class="refDoi"> DOI: 10.1016/j.cbpa.2019.02.022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1016%2Fj.cbpa.2019.02.022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=31004963" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC1MXns1yrt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2019&pages=111-119&author=S.-L.+Paivaauthor=C.+M.+Crews&title=Targeted+Protein+Degradation%3A+Elements+of+PROTAC+Design&doi=10.1016%2Fj.cbpa.2019.02.022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit160R"><div class="casContent"><span class="casTitleNuber">160</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted protein degradation: elements of PROTAC design</span></div><div class="casAuthors">Paiva, Stacey-Lynn; Crews, Craig M.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Chemical Biology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">111-119</span>CODEN:
                <span class="NLM_cas:coden">COCBF4</span>;
        ISSN:<span class="NLM_cas:issn">1367-5931</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Targeted protein degrdn. using Proteolysis Targeting Chimeras (PROTACs) has emerged as a novel therapeutic modality in drug discovery.  PROTACs mediate the degrdn. of select proteins of interest (POIs) by hijacking the activity of E3 ubiquitin ligases for POI ubiquitination and subsequent degrdn. by the 26S proteasome.  This hijacking mechanism has been used to degrade various types of disease-relevant POIs.  In this review, we aim to highlight the recent advances in targeted protein degrdn. and describe the challenges that need to be addressed in order to efficiently develop potent PROTACs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGol6Nk0VkUdzLVg90H21EOLACvtfcHk0lgGgufiBnxKng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXns1yrt7s%253D&md5=5783311db47da378180c14d67526a398</span></div><a href="/servlet/linkout?suffix=cit160&amp;dbid=16384&amp;doi=10.1016%2Fj.cbpa.2019.02.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cbpa.2019.02.022%26sid%3Dliteratum%253Aachs%26aulast%3DPaiva%26aufirst%3DS.-L.%26aulast%3DCrews%26aufirst%3DC.%2BM.%26atitle%3DTargeted%2520Protein%2520Degradation%253A%2520Elements%2520of%2520PROTAC%2520Design%26jtitle%3DCurr.%2520Opin.%2520Chem.%2520Biol.%26date%3D2019%26volume%3D50%26spage%3D111%26epage%3D119%26doi%3D10.1016%2Fj.cbpa.2019.02.022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref161"><div class="reference"><strong class="refLabel"><a href="#ref161" class="rightTabRefNumLink">161</a></strong><div class="NLM_citation" id="rightTab-cit161"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span> <span> </span><span class="NLM_article-title">The PROTAC Technology in Drug Development</span>. <i>Cell Biochem. Funct.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">21</span>– <span class="NLM_lpage">30</span>, <span class="refDoi"> DOI: 10.1002/cbf.3369</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1002%2Fcbf.3369" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=30604499" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhslygsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2019&pages=21-30&author=Y.+Zouauthor=D.+Maauthor=Y.+Wang&title=The+PROTAC+Technology+in+Drug+Development&doi=10.1002%2Fcbf.3369"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit161R"><div class="casContent"><span class="casTitleNuber">161</span><div class="casTitle"><span class="NLM_cas:atitle">The PROTAC technology in drug development</span></div><div class="casAuthors">Zou, Yutian; Ma, Danhui; Wang, Yinyin</div><div class="citationInfo"><span class="NLM_cas:title">Cell Biochemistry and Function</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">21-30</span>CODEN:
                <span class="NLM_cas:coden">CBFUDH</span>;
        ISSN:<span class="NLM_cas:issn">1099-0844</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Currently, a new technol. termed PROTAC, proteolysis targeting chimera, has been developed for inducing the protein degrdn. by a targeting mol.  This technol. takes advantage of a moiety of targeted protein and a moiety of recognizing E3 ubiquitin ligase and produces a hybrid mol. to specifically knock down a targeted protein.  During the first decade, three pedigreed groups worked on the development of this technol.  To date, this technol. has been extended by different groups, aiming to develop new drugs against different diseases including cancers.  This review summarizes the contributions of the groups for the development of PROTAC.  Significance of the study : This review summarized the development of the PROTAC technol. for readers and also presented the author's opinions on the application of the technol. in tumor therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprT1CUHOqrfbVg90H21EOLACvtfcHk0lgGgufiBnxKng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhslygsQ%253D%253D&md5=2a7417e2c385d01f7eaef52a72c7ea52</span></div><a href="/servlet/linkout?suffix=cit161&amp;dbid=16384&amp;doi=10.1002%2Fcbf.3369&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcbf.3369%26sid%3Dliteratum%253Aachs%26aulast%3DZou%26aufirst%3DY.%26aulast%3DMa%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DY.%26atitle%3DThe%2520PROTAC%2520Technology%2520in%2520Drug%2520Development%26jtitle%3DCell%2520Biochem.%2520Funct.%26date%3D2019%26volume%3D37%26spage%3D21%26epage%3D30%26doi%3D10.1002%2Fcbf.3369" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref162"><div class="reference"><strong class="refLabel"><a href="#ref162" class="rightTabRefNumLink">162</a></strong><div class="NLM_citation" id="rightTab-cit162"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Choi, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamashita, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ueno, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takashima, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakajima, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yatabe, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takeuchi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamada, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haruta, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishikawa, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kimura, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitsudomi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanio, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mano, H.</span></span> <span> </span><span class="NLM_article-title">EML4-ALK Mutations in Lung Cancer that Confer Resistance to ALK Inhibitors</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>363</i></span>,  <span class="NLM_fpage">1734</span>– <span class="NLM_lpage">1739</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1007478</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1056%2FNEJMoa1007478" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=20979473" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlKitL%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=363&publication_year=2010&pages=1734-1739&author=Y.+L.+Choiauthor=M.+Sodaauthor=Y.+Yamashitaauthor=T.+Uenoauthor=J.+Takashimaauthor=T.+Nakajimaauthor=Y.+Yatabeauthor=K.+Takeuchiauthor=T.+Hamadaauthor=H.+Harutaauthor=Y.+Ishikawaauthor=H.+Kimuraauthor=T.+Mitsudomiauthor=Y.+Tanioauthor=H.+Mano&title=EML4-ALK+Mutations+in+Lung+Cancer+that+Confer+Resistance+to+ALK+Inhibitors&doi=10.1056%2FNEJMoa1007478"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit162R"><div class="casContent"><span class="casTitleNuber">162</span><div class="casTitle"><span class="NLM_cas:atitle">EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors</span></div><div class="casAuthors">Choi, Young Lim; Soda, Manabu; Yamashita, Yoshihiro; Ueno, Toshihide; Takashima, Junpei; Nakajima, Takahiro; Yatabe, Yasushi; Takeuchi, Kengo; Hamada, Toru; Haruta, Hidenori; Ishikawa, Yuichi; Kimura, Hideki; Mitsudomi, Tetsuya; Tanio, Yoshiro; Mano, Hiroyuki</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">363</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">1734-1739</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">The EML4 (echinoderm microtubule-assocd. protein-like 4)-ALK (anaplastic lymphoma kinase) fusion-type tyrosine kinase is an oncoprotein found in 4% to 5% of non-small-cell lung cancers, and clin. trials of specific inhibitors of ALK for the treatment of such tumors are currently under way.  Here, we report the discovery of two secondary mutations within the kinase domain of EML4-ALK in tumor cells isolated from a patient during the relapse phase of treatment with an ALK inhibitor.  Each mutation developed independently in subclones of the tumor and conferred marked resistance to two different ALK inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCIrEIBi5MjrVg90H21EOLACvtfcHk0lgGgufiBnxKng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlKitL%252FJ&md5=d903151706575c159b7abcdc8999281c</span></div><a href="/servlet/linkout?suffix=cit162&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1007478&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1007478%26sid%3Dliteratum%253Aachs%26aulast%3DChoi%26aufirst%3DY.%2BL.%26aulast%3DSoda%26aufirst%3DM.%26aulast%3DYamashita%26aufirst%3DY.%26aulast%3DUeno%26aufirst%3DT.%26aulast%3DTakashima%26aufirst%3DJ.%26aulast%3DNakajima%26aufirst%3DT.%26aulast%3DYatabe%26aufirst%3DY.%26aulast%3DTakeuchi%26aufirst%3DK.%26aulast%3DHamada%26aufirst%3DT.%26aulast%3DHaruta%26aufirst%3DH.%26aulast%3DIshikawa%26aufirst%3DY.%26aulast%3DKimura%26aufirst%3DH.%26aulast%3DMitsudomi%26aufirst%3DT.%26aulast%3DTanio%26aufirst%3DY.%26aulast%3DMano%26aufirst%3DH.%26atitle%3DEML4-ALK%2520Mutations%2520in%2520Lung%2520Cancer%2520that%2520Confer%2520Resistance%2520to%2520ALK%2520Inhibitors%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2010%26volume%3D363%26spage%3D1734%26epage%3D1739%26doi%3D10.1056%2FNEJMoa1007478" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref163"><div class="reference"><strong class="refLabel"><a href="#ref163" class="rightTabRefNumLink">163</a></strong><div class="NLM_citation" id="rightTab-cit163"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nagasundaram, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson Alphonse, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samuel Gnana, P. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rajaretinam, R. K.</span></span> <span> </span><span class="NLM_article-title">Molecular Dynamics Validation of Crizotinib Resistance to ALK Mutations (L1196M and G1269A) and Identification of Specific Inhibitors</span>. <i>J. Cell. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>118</i></span>,  <span class="NLM_fpage">3462</span>– <span class="NLM_lpage">3471</span>, <span class="refDoi"> DOI: 10.1002/jcb.26004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1002%2Fjcb.26004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=28332225" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC2sXnvFKjs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=118&publication_year=2017&pages=3462-3471&author=N.+Nagasundaramauthor=C.+R.+Wilson+Alphonseauthor=P.+V.+Samuel+Gnanaauthor=R.+K.+Rajaretinam&title=Molecular+Dynamics+Validation+of+Crizotinib+Resistance+to+ALK+Mutations+%28L1196M+and+G1269A%29+and+Identification+of+Specific+Inhibitors&doi=10.1002%2Fjcb.26004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit163R"><div class="casContent"><span class="casTitleNuber">163</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Dynamics Validation of Crizotinib Resistance to ALK Mutations (L1196M and G1269A) and Identification of Specific Inhibitors</span></div><div class="casAuthors">Nagasundaram, Nagarajan; Wilson Alphonse, Carlton Ranjith; Samuel Gnana, Prakash Vincent; Rajaretinam, Rajesh Kannan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cellular Biochemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">118</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3462-3471</span>CODEN:
                <span class="NLM_cas:coden">JCEBD5</span>;
        ISSN:<span class="NLM_cas:issn">0730-2312</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Anaplastic lymphoma kinase (ALK) pos. non-small cell lung cancer (NSCLC) patients are mostly treated with ALK tyrosine kinase inhibitors (TKIs).  Crizotinib is the first generation ALK inhibitor practiced as a primary chemo to combat cancer cells followed by second generation inhibitor ceritinib which are effective against crizotinib resistant ALK mutations.  However, patients treated with these drugs invariably relapsed because of the development of new drug resistance mutations.  In this study we explored the crizotinib resistance in the presence of ALK mutations L1196M and G1269A through mol. dynamics simulation studies.  Further mutation specific inhibitors CID 71748211 and CID 71728095 were identified to potentially inhibit ALK with mutations L1196M and G1269A, resp.  This computational investigation in-sighted the mol. factors involved in crizotinib resistance which enhanced in the identification of new ALK drugs that brings individualized medicine to treat ALK pos. NSCLC patients with specific mutations.  J. Cell. Biochem. 9999: 1-10, 2017. © 2017 Wiley Periodicals, Inc.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrt7AC2ZGxDsbVg90H21EOLACvtfcHk0lhknztklfo9wg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXnvFKjs7g%253D&md5=192a2d0f01038623006d2ed3a6939566</span></div><a href="/servlet/linkout?suffix=cit163&amp;dbid=16384&amp;doi=10.1002%2Fjcb.26004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcb.26004%26sid%3Dliteratum%253Aachs%26aulast%3DNagasundaram%26aufirst%3DN.%26aulast%3DWilson%2BAlphonse%26aufirst%3DC.%2BR.%26aulast%3DSamuel%2BGnana%26aufirst%3DP.%2BV.%26aulast%3DRajaretinam%26aufirst%3DR.%2BK.%26atitle%3DMolecular%2520Dynamics%2520Validation%2520of%2520Crizotinib%2520Resistance%2520to%2520ALK%2520Mutations%2520%2528L1196M%2520and%2520G1269A%2529%2520and%2520Identification%2520of%2520Specific%2520Inhibitors%26jtitle%3DJ.%2520Cell.%2520Biochem.%26date%3D2017%26volume%3D118%26spage%3D3462%26epage%3D3471%26doi%3D10.1002%2Fjcb.26004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref164"><div class="reference"><strong class="refLabel"><a href="#ref164" class="rightTabRefNumLink">164</a></strong><div class="NLM_citation" id="rightTab-cit164"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Doebele, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pilling, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aisner, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kutateladze, T. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weickhardt, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kondo, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Linderman, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heasley, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franklin, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varella-Garcia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camidge, D. R.</span></span> <span> </span><span class="NLM_article-title">Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non–small Cell Lung Cancer</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">1472</span>– <span class="NLM_lpage">1482</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-11-2906</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1158%2F1078-0432.CCR-11-2906" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=22235099" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC38Xjt1Wksro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=1472-1482&author=R.+C.+Doebeleauthor=A.+B.+Pillingauthor=D.+L.+Aisnerauthor=T.+G.+Kutateladzeauthor=A.+T.+Leauthor=A.+J.+Weickhardtauthor=K.+L.+Kondoauthor=D.+J.+Lindermanauthor=L.+E.+Heasleyauthor=W.+A.+Franklinauthor=M.+Varella-Garciaauthor=D.+R.+Camidge&title=Mechanisms+of+Resistance+to+Crizotinib+in+Patients+with+ALK+Gene+Rearranged+Non%E2%80%93small+Cell+Lung+Cancer&doi=10.1158%2F1078-0432.CCR-11-2906"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit164R"><div class="casContent"><span class="casTitleNuber">164</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non-Small Cell Lung Cancer</span></div><div class="casAuthors">Doebele, Robert C.; Pilling, Amanda B.; Aisner, Dara L.; Kutateladze, Tatiana G.; Le, Anh T.; Weickhardt, Andrew J.; Kondo, Kimi L.; Linderman, Derek J.; Heasley, Lynn E.; Franklin, Wilbur A.; Varella-Garcia, Marileila; Camidge, D. Ross</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1472-1482</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Patients with anaplastic lymphoma kinase (ALK) gene rearrangements often manifest dramatic responses to crizotinib, a small-mol. ALK inhibitor.  Unfortunately, not every patient responds and acquired drug resistance inevitably develops in those who do respond.  This study aimed to define mol. mechanisms of resistance to crizotinib in patients with ALK+ non-small cell lung cancer (NSCLC).  We analyzed tissue obtained from 14 patients with ALK+ NSCLC showing evidence of radiol. progression while on crizotinib to define mechanisms of intrinsic and acquired resistance to crizotinib.  Eleven patients had material evaluable for mol. anal.  Four patients (36%) developed secondary mutations in the tyrosine kinase domain of ALK.  A novel mutation in the ALK domain, encoding a G1269A amino acid substitution that confers resistance to crizotinib in vitro, was identified in two of these cases.  Two patients, one with a resistance mutation, exhibited new onset ALK copy no. gain (CNG).  One patient showed outgrowth of epidermal growth factor receptor (EGFR) mutant NSCLC without evidence of a persistent ALK gene rearrangement.  Two patients exhibited a KRAS mutation, one of which occurred without evidence of a persisting ALK gene rearrangement.  One patient showed the emergence of an ALK gene fusion-neg. tumor compared with the baseline sample but with no identifiable alternate driver.  Two patients retained ALK positivity with no identifiable resistance mechanism.  Crizotinib resistance in ALK+ NSCLC occurs through somatic kinase domain mutations, ALK gene fusion CNG, and emergence of sep. oncogenic drivers.  Clin Cancer Res; 18(5); 1472-82.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGofhGQYtlS1w7Vg90H21EOLACvtfcHk0lhknztklfo9wg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xjt1Wksro%253D&md5=575047615ef9e3d4af60d45605a747c5</span></div><a href="/servlet/linkout?suffix=cit164&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-11-2906&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-11-2906%26sid%3Dliteratum%253Aachs%26aulast%3DDoebele%26aufirst%3DR.%2BC.%26aulast%3DPilling%26aufirst%3DA.%2BB.%26aulast%3DAisner%26aufirst%3DD.%2BL.%26aulast%3DKutateladze%26aufirst%3DT.%2BG.%26aulast%3DLe%26aufirst%3DA.%2BT.%26aulast%3DWeickhardt%26aufirst%3DA.%2BJ.%26aulast%3DKondo%26aufirst%3DK.%2BL.%26aulast%3DLinderman%26aufirst%3DD.%2BJ.%26aulast%3DHeasley%26aufirst%3DL.%2BE.%26aulast%3DFranklin%26aufirst%3DW.%2BA.%26aulast%3DVarella-Garcia%26aufirst%3DM.%26aulast%3DCamidge%26aufirst%3DD.%2BR.%26atitle%3DMechanisms%2520of%2520Resistance%2520to%2520Crizotinib%2520in%2520Patients%2520with%2520ALK%2520Gene%2520Rearranged%2520Non%25E2%2580%2593small%2520Cell%2520Lung%2520Cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2012%26volume%3D18%26spage%3D1472%26epage%3D1482%26doi%3D10.1158%2F1078-0432.CCR-11-2906" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref165"><div class="reference"><strong class="refLabel"><a href="#ref165" class="rightTabRefNumLink">165</a></strong><div class="NLM_citation" id="rightTab-cit165"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, F. Q.</span></span> <span> </span><span class="NLM_article-title">A molecular Dynamics Investigation on the Crizotinib Resistance Mechanism of C1156Y Mutation in ALK</span>. <i>Biochem. Biophys. Res. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>423</i></span>,  <span class="NLM_fpage">319</span>– <span class="NLM_lpage">324</span>, <span class="refDoi"> DOI: 10.1016/j.bbrc.2012.05.120</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1016%2Fj.bbrc.2012.05.120" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=22659414" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC38XovVGqtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=423&publication_year=2012&pages=319-324&author=H.+Y.+Sunauthor=F.+Q.+Ji&title=A+molecular+Dynamics+Investigation+on+the+Crizotinib+Resistance+Mechanism+of+C1156Y+Mutation+in+ALK&doi=10.1016%2Fj.bbrc.2012.05.120"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit165R"><div class="casContent"><span class="casTitleNuber">165</span><div class="casTitle"><span class="NLM_cas:atitle">A molecular dynamics investigation on the crizotinib resistance mechanism of C1156Y mutation in ALK</span></div><div class="casAuthors">Sun, Hui-Yong; Ji, Feng-Qin</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical and Biophysical Research Communications</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">423</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">319-324</span>CODEN:
                <span class="NLM_cas:coden">BBRCA9</span>;
        ISSN:<span class="NLM_cas:issn">0006-291X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Crizotinib is an anaplastic lymphoma kinase (ALK) inhibitor that has recently been approved in the US for the treatment of non-small cell lung carcinoma (NSCLC).  Despite its outstanding safety and efficacy, several resistant mutations against crizotinib have been detected in the treatment of NSCLC.  However, in contrast to the widely accepted mechanism of steric hindrance by mutations at the active site, the mechanism by which the C1156Y non-active site mutation confers resistance against crizotinib remains unclear.  In the present study, the resistance mechanism of C1156Y in ALK was investigated using mol. dynamics simulations.  The results suggest that despite the non-active site mutation, C1156Y causes the dislocation of crizotinib as well as the indirect conformational changes in the binding cavity, which results in a marked decrease in the van der Waals and electrostatic interactions between crizotinib and ALK.  The obtained results provide a detailed explanation of the resistance caused by C1156Y and may give a vital clue for the design of drugs to combat crizotinib resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGombudl3C-pNLVg90H21EOLACvtfcHk0lhknztklfo9wg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XovVGqtL8%253D&md5=21c3026294682a348fa755d3beeaa987</span></div><a href="/servlet/linkout?suffix=cit165&amp;dbid=16384&amp;doi=10.1016%2Fj.bbrc.2012.05.120&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbrc.2012.05.120%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DH.%2BY.%26aulast%3DJi%26aufirst%3DF.%2BQ.%26atitle%3DA%2520molecular%2520Dynamics%2520Investigation%2520on%2520the%2520Crizotinib%2520Resistance%2520Mechanism%2520of%2520C1156Y%2520Mutation%2520in%2520ALK%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D2012%26volume%3D423%26spage%3D319%26epage%3D324%26doi%3D10.1016%2Fj.bbrc.2012.05.120" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref166"><div class="reference"><strong class="refLabel"><a href="#ref166" class="rightTabRefNumLink">166</a></strong><div class="NLM_citation" id="rightTab-cit166"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramanathan, K.</span></span> <span> </span><span class="NLM_article-title">Exploring the Structural and Functional Impact of the ALK F1174L Mutation Using Bioinformatics Approach</span>. <i>J. Mol. Model.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">2324</span>, <span class="refDoi"> DOI: 10.1007/s00894-014-2324-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1007%2Fs00894-014-2324-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=24952065" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A280%3ADC%252BC2cfkvFeqtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2014&pages=2324&author=A.+Kumarauthor=K.+Ramanathan&title=Exploring+the+Structural+and+Functional+Impact+of+the+ALK+F1174L+Mutation+Using+Bioinformatics+Approach&doi=10.1007%2Fs00894-014-2324-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit166R"><div class="casContent"><span class="casTitleNuber">166</span><div class="casTitle"><span class="NLM_cas:atitle">Exploring the structural and functional impact of the ALK F1174L mutation using bioinformatics approach</span></div><div class="casAuthors">Kumar Anish; Ramanathan K</div><div class="citationInfo"><span class="NLM_cas:title">Journal of molecular modeling</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2324</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Crizotinib is the most effective and the only drug that has been approved for the treatment of anaplastic lymphoma kinase (ALK)-positive lung cancer.  Reports suggest that there is a development of an acquired resistance against crizotinib action due to the emergence of several mutations in the ALK gene and F1174L is one such mutation.  In this study, we used molecular docking and molecular dynamics (MD) approach to decipher the effect of F1174L mutation in drug-target binding.  Docking results suggest that crizotinib was found to adopt the most promising conformations to the native-type ALK by identifying the M1199 residue as a prospective partner for making a hydrogen bond as compared to the mutant-type ALK.  MD results showed that the average atom, especially atoms of the native-type ALK-crizotinib complex, movements were less, displayed less fluctuation, fast convergence of energy, and changes in geometry.  This shows the stable binding of crizotinib with the native-type ALK in comparison to the mutant-type ALK.  We believe that this study could be useful for the logical design of stronger, more selective, and more consistent ALK inhibitor against drug-resistant F1174L mutation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRxPVLsf2kt_LesJRIHUP1ofW6udTcc2eafQvpxGycgT7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cfkvFeqtA%253D%253D&md5=dcadd6d1a230320bb32a90a462313410</span></div><a href="/servlet/linkout?suffix=cit166&amp;dbid=16384&amp;doi=10.1007%2Fs00894-014-2324-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00894-014-2324-3%26sid%3Dliteratum%253Aachs%26aulast%3DKumar%26aufirst%3DA.%26aulast%3DRamanathan%26aufirst%3DK.%26atitle%3DExploring%2520the%2520Structural%2520and%2520Functional%2520Impact%2520of%2520the%2520ALK%2520F1174L%2520Mutation%2520Using%2520Bioinformatics%2520Approach%26jtitle%3DJ.%2520Mol.%2520Model.%26date%3D2014%26volume%3D20%26spage%3D2324%26doi%3D10.1007%2Fs00894-014-2324-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref167"><div class="reference"><strong class="refLabel"><a href="#ref167" class="rightTabRefNumLink">167</a></strong><div class="NLM_citation" id="rightTab-cit167"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Russo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Misale, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siravegna, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crisafulli, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lazzari, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corti, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rospo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novara, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mussolin, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartolini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cam, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shoemaker, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wild, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Nicolantonio, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bianchi, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siena, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bardelli, A.</span></span> <span> </span><span class="NLM_article-title">Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">36</span>– <span class="NLM_lpage">44</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-15-0940</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1158%2F2159-8290.CD-15-0940" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=26546295" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC28XptlCrsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2016&pages=36-44&author=M.+Russoauthor=S.+Misaleauthor=G.+Weiauthor=G.+Siravegnaauthor=G.+Crisafulliauthor=L.+Lazzariauthor=G.+Cortiauthor=G.+Rospoauthor=L.+Novaraauthor=B.+Mussolinauthor=A.+Bartoliniauthor=N.+Camauthor=R.+Patelauthor=S.+Yanauthor=R.+Shoemakerauthor=R.+Wildauthor=F.+Di+Nicolantonioauthor=A.+S.+Bianchiauthor=G.+Liauthor=S.+Sienaauthor=A.+Bardelli&title=Acquired+Resistance+to+the+TRK+Inhibitor+Entrectinib+in+Colorectal+Cancer&doi=10.1158%2F2159-8290.CD-15-0940"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit167R"><div class="casContent"><span class="casTitleNuber">167</span><div class="casTitle"><span class="NLM_cas:atitle">Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer</span></div><div class="casAuthors">Russo, Mariangela; Misale, Sandra; Wei, Ge; Siravegna, Giulia; Crisafulli, Giovanni; Lazzari, Luca; Corti, Giorgio; Rospo, Giuseppe; Novara, Luca; Mussolin, Benedetta; Bartolini, Alice; Cam, Nicholas; Patel, Roopal; Yan, Shunqi; Shoemaker, Robert; Wild, Robert; Di Nicolantonio, Federica; Bianchi, Andrea Sartore; Li, Gang; Siena, Salvatore; Bardelli, Alberto</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">36-44</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Entrectinib is a first-in-class pan-TRK kinase inhibitor currently undergoing clin. testing in colorectal cancer and other tumor types.  A patient with metastatic colorectal cancer harboring an LMNA-NTRK1 rearrangement displayed a remarkable response to treatment with entrectinib, which was followed by the emergence of resistance.  To characterize the mol. bases of the patient's relapse, circulating tumor DNA (ctDNA) was collected longitudinally during treatment, and a tissue biopsy, obtained before entrectinib treatment, was transplanted in mice (xenopatient), which then received the same entrectinib regimen until resistance developed.  Genetic profiling of ctDNA and xenopatient samples showed acquisition of two point mutations in the catalytic domain of NTRK1, p.G595R and p.G667C.  Biochem. and pharmacol. anal. in multiple preclin. models confirmed that either mutation renders the TRKA kinase insensitive to entrectinib.  These findings can be immediately exploited to design next-generation TRKA inhibitors.  Significance: We provide proof of principle that analyses of xenopatients (avatar) and liq. biopsies allow the identification of drug resistance mechanisms in parallel with clin. treatment of an individual patient.  We describe for the first time that p.G595R and p.G667C TRKA mutations drive acquired resistance to entrectinib in colorectal cancers carrying NTRK1 rearrangements.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1Unyh1xjaoLVg90H21EOLACvtfcHk0ljY00fJpbLwgQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XptlCrsA%253D%253D&md5=5baa54a784e355b6afa50336b2708052</span></div><a href="/servlet/linkout?suffix=cit167&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-15-0940&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-15-0940%26sid%3Dliteratum%253Aachs%26aulast%3DRusso%26aufirst%3DM.%26aulast%3DMisale%26aufirst%3DS.%26aulast%3DWei%26aufirst%3DG.%26aulast%3DSiravegna%26aufirst%3DG.%26aulast%3DCrisafulli%26aufirst%3DG.%26aulast%3DLazzari%26aufirst%3DL.%26aulast%3DCorti%26aufirst%3DG.%26aulast%3DRospo%26aufirst%3DG.%26aulast%3DNovara%26aufirst%3DL.%26aulast%3DMussolin%26aufirst%3DB.%26aulast%3DBartolini%26aufirst%3DA.%26aulast%3DCam%26aufirst%3DN.%26aulast%3DPatel%26aufirst%3DR.%26aulast%3DYan%26aufirst%3DS.%26aulast%3DShoemaker%26aufirst%3DR.%26aulast%3DWild%26aufirst%3DR.%26aulast%3DDi%2BNicolantonio%26aufirst%3DF.%26aulast%3DBianchi%26aufirst%3DA.%2BS.%26aulast%3DLi%26aufirst%3DG.%26aulast%3DSiena%26aufirst%3DS.%26aulast%3DBardelli%26aufirst%3DA.%26atitle%3DAcquired%2520Resistance%2520to%2520the%2520TRK%2520Inhibitor%2520Entrectinib%2520in%2520Colorectal%2520Cancer%26jtitle%3DCancer%2520Discovery%26date%3D2016%26volume%3D6%26spage%3D36%26epage%3D44%26doi%3D10.1158%2F2159-8290.CD-15-0940" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref168"><div class="reference"><strong class="refLabel"><a href="#ref168" class="rightTabRefNumLink">168</a></strong><div class="NLM_citation" id="rightTab-cit168"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, T.</span></span> <span> </span><span class="NLM_article-title">Insight into Crizotinib Resistance Mechanisms Caused by Three Mutations in ALK Tyrosine Kinase Using Free Energy Calculation Approaches</span>. <i>J. Chem. Inf. Model.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">2376</span>– <span class="NLM_lpage">2389</span>, <span class="refDoi"> DOI: 10.1021/ci400188q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ci400188q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1ymt7vI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2013&pages=2376-2389&author=H.+Sunauthor=Y.+Liauthor=D.+Liauthor=T.+Hou&title=Insight+into+Crizotinib+Resistance+Mechanisms+Caused+by+Three+Mutations+in+ALK+Tyrosine+Kinase+Using+Free+Energy+Calculation+Approaches&doi=10.1021%2Fci400188q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit168R"><div class="casContent"><span class="casTitleNuber">168</span><div class="casTitle"><span class="NLM_cas:atitle">Insight into Crizotinib Resistance Mechanisms Caused by Three Mutations in ALK Tyrosine Kinase using Free Energy Calculation Approaches</span></div><div class="casAuthors">Sun, Huiyong; Li, Youyong; Li, Dan; Hou, Tingjun</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2376-2389</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">As a safe and efficacious drug, crizotinib was approved by the U.S. Food and Drug Administration (FDA) in 2011 for the treatment of advanced fusion-type nonsmall-cell lung cancer.  Although high response ratio was detected from the patients treated with crizotinib, the cancer has eventually conferred resistance to crizotinib.  Several drug resistance mutations have been found in the anaplastic lymphoma kinase (ALK) tyrosine kinase domain as the target for crizotinib, but the drug resistance mechanisms remain unclear.  Therefore, in this study, the adaptive biasing force (ABF) method and two-end-state free energy calcn. approaches were employed to elucidate the resistance mechanisms of crizotinib induced by the mutations L1152R, G1202R, and S1206Y.  The ABF simulation results suggest that the reaction coordinates for the unbinding processes of crizotinib from the binding pockets of the mutated ALKs is different from that of the wild type ALK.  The potentials of mean force for the crizotinib unbinding and the binding free energies predicted by the two-end-state free energy calcns. are consistent with the exptl. data.  Our results indicate that the three mutations weaken the binding affinity of crizotinib obviously and lead to drug resistance.  The free energy decompn. anal. illustrates the importance of the loss of two important H-bonds in the L1152R and S1206Y mutants on drug resistance.  The entropy anal. shows that the entropy term plays a crit. role in the substantial change of the conformational entropies of G1202R and L1152R.  Our results reveal the mechanisms of drug resistance and provide vital clues for the development of new inhibitors to combat drug resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo3Vorb-VUQbrVg90H21EOLACvtfcHk0ljY00fJpbLwgQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1ymt7vI&md5=d8bd7a807d1bc9b231eb6bd0367bed3a</span></div><a href="/servlet/linkout?suffix=cit168&amp;dbid=16384&amp;doi=10.1021%2Fci400188q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci400188q%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DHou%26aufirst%3DT.%26atitle%3DInsight%2520into%2520Crizotinib%2520Resistance%2520Mechanisms%2520Caused%2520by%2520Three%2520Mutations%2520in%2520ALK%2520Tyrosine%2520Kinase%2520Using%2520Free%2520Energy%2520Calculation%2520Approaches%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2013%26volume%3D53%26spage%3D2376%26epage%3D2389%26doi%3D10.1021%2Fci400188q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref169"><div class="reference"><strong class="refLabel"><a href="#ref169" class="rightTabRefNumLink">169</a></strong><div class="NLM_citation" id="rightTab-cit169"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, T.</span></span> <span> </span><span class="NLM_article-title">P-loop Conformation Governed Crizotinib Resistance in G2032R-mutated ROS1 Tyrosine Kinase: Clues from Free Energy Landscape</span>. <i>PLoS Comput. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">e1003729</span>, <span class="refDoi"> DOI: 10.1371/journal.pcbi.1003729</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1371%2Fjournal.pcbi.1003729" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=25033171" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1amsbzI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2014&pages=e1003729&author=H.+Sunauthor=Y.+Liauthor=S.+Tianauthor=J.+Wangauthor=T.+Hou&title=P-loop+Conformation+Governed+Crizotinib+Resistance+in+G2032R-mutated+ROS1+Tyrosine+Kinase%3A+Clues+from+Free+Energy+Landscape&doi=10.1371%2Fjournal.pcbi.1003729"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit169R"><div class="casContent"><span class="casTitleNuber">169</span><div class="casTitle"><span class="NLM_cas:atitle">P-loop conformation governed crizotinib resistance in G2032R-mutated ROS1 tyrosine kinase: clues from free energy landscape</span></div><div class="casAuthors">Sun, Huiyong; Li, Youyong; Tian, Sheng; Wang, Junmei; Hou, Tingjun</div><div class="citationInfo"><span class="NLM_cas:title">PLoS Computational Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">e1003729/1-e1003729/13, 13 pp.</span>CODEN:
                <span class="NLM_cas:coden">PCBLBG</span>;
        ISSN:<span class="NLM_cas:issn">1553-7358</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Tyrosine kinases are regarded as excellent targets for chem. drug therapy of carcinomas.  However, under strong purifying selection, drug resistance usually occurs in the cancer cells within a short term.  Many cases of drug resistance have been found to be assocd. with secondary mutations in drug target, which lead to the attenuated drug-target interactions.  For example, recently, an acquired secondary mutation, G2032R, has been detected in the drug target, ROS1 tyrosine kinase, from a crizotinib-resistant patient, who responded poorly to crizotinib within a very short therapeutic term.  It was supposed that the mutation was located at the solvent front and might hinder the drug binding.  However, a different fact could be uncovered by the simulations reported in this study.  Here, free energy surfaces were characterized by the drug-target distance and the phosphate-binding loop (P-loop) conformational change of the crizotinib-ROS1 complex through advanced mol. dynamics techniques, and it was revealed that the more rigid P-loop region in the G2032R-mutated ROS1 was primarily responsible for the crizotinib resistance, which on one hand, impaired the binding of crizotinib directly, and on the other hand, shortened the residence time induced by the flattened free energy surface.  Therefore, both of the binding affinity and the drug residence time should be emphasized in rational drug design to overcome the kinase resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkA1c65wE9f7Vg90H21EOLACvtfcHk0liocMm-TPsWPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1amsbzI&md5=6d1063a1e69ba81b2a77b4ae20f1ff74</span></div><a href="/servlet/linkout?suffix=cit169&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pcbi.1003729&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pcbi.1003729%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DTian%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DHou%26aufirst%3DT.%26atitle%3DP-loop%2520Conformation%2520Governed%2520Crizotinib%2520Resistance%2520in%2520G2032R-mutated%2520ROS1%2520Tyrosine%2520Kinase%253A%2520Clues%2520from%2520Free%2520Energy%2520Landscape%26jtitle%3DPLoS%2520Comput.%2520Biol.%26date%3D2014%26volume%3D10%26spage%3De1003729%26doi%3D10.1371%2Fjournal.pcbi.1003729" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref170"><div class="reference"><strong class="refLabel"><a href="#ref170" class="rightTabRefNumLink">170</a></strong><div class="NLM_citation" id="rightTab-cit170"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Isozaki, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takigawa, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiura, K.</span></span> <span> </span><span class="NLM_article-title">Mechanisms of Acquired Resistance to ALK Inhibitors and the Rationale for Treating ALK-positive Lung Cancer</span>. <i>Cancers</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">763</span>– <span class="NLM_lpage">783</span>, <span class="refDoi"> DOI: 10.3390/cancers7020763</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.3390%2Fcancers7020763" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=25941796" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC1cXlsVKhsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2015&pages=763-783&author=H.+Isozakiauthor=N.+Takigawaauthor=K.+Kiura&title=Mechanisms+of+Acquired+Resistance+to+ALK+Inhibitors+and+the+Rationale+for+Treating+ALK-positive+Lung+Cancer&doi=10.3390%2Fcancers7020763"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit170R"><div class="casContent"><span class="casTitleNuber">170</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of acquired resistance to ALK inhibitors and the rationale for treating ALK-positive lung cancer</span></div><div class="casAuthors">Isozaki, Hideko; Takigawa, Nagio; Kiura, Katsuyuki</div><div class="citationInfo"><span class="NLM_cas:title">Cancers</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">763-783</span>CODEN:
                <span class="NLM_cas:coden">CANCCT</span>;
        ISSN:<span class="NLM_cas:issn">2072-6694</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">The discovery of an echinoderm microtubule-assocd. protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK) fusion gene led to improved clin. outcomes in patients with lung cancer after the development of the first ALK-targeting agent, crizotinib.  Some second-generation ALK tyrosine kinase inhibitors (TKIs), which might be more potent than crizotinib or effective on crizotinib-resistant patients, have been developed.  Although these ALK-TKIs show an excellent response initially, most patients eventually acquire resistance.  Therefore, careful consideration of the resistance mechanisms might lead to superior therapeutic strategies.  Here, we summarize the history of ALK-TKIs and their underlying resistance mechanisms in both the preclin. and clin. settings.  In addn., we discuss potential future treatment strategies in ALK-TKI-na.ovrddot.ive and -resistant patients with lung cancer harboring the EML4-ALK fusion gene.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFywf655AM27Vg90H21EOLACvtfcHk0liocMm-TPsWPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXlsVKhsL4%253D&md5=7970f0ec14dc486b3920e6473f01a7c7</span></div><a href="/servlet/linkout?suffix=cit170&amp;dbid=16384&amp;doi=10.3390%2Fcancers7020763&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fcancers7020763%26sid%3Dliteratum%253Aachs%26aulast%3DIsozaki%26aufirst%3DH.%26aulast%3DTakigawa%26aufirst%3DN.%26aulast%3DKiura%26aufirst%3DK.%26atitle%3DMechanisms%2520of%2520Acquired%2520Resistance%2520to%2520ALK%2520Inhibitors%2520and%2520the%2520Rationale%2520for%2520Treating%2520ALK-positive%2520Lung%2520Cancer%26jtitle%3DCancers%26date%3D2015%26volume%3D7%26spage%3D763%26epage%3D783%26doi%3D10.3390%2Fcancers7020763" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref171"><div class="reference"><strong class="refLabel"><a href="#ref171" class="rightTabRefNumLink">171</a></strong><div class="NLM_citation" id="rightTab-cit171"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gadgeel, S. M</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gandhi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riely, G. J</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiappori, A. A</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">West, H. L</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Azada, M. C</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morcos, P. N</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, R.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boisserie, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Laurenzio, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golding, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sato, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yokoyama, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ou, S.-H. I.</span></span> <span> </span><span class="NLM_article-title">Safety and Activity of Alectinib against Systemic Disease and Brain Metastases in Patients with Crizotinib-resistant ALK-rearranged Non-small-cell Lung Cancer (AF-002JG): Results from the Dose-finding Portion of a Phase 1/2 Study</span>. <i>Lancet Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">1119</span>– <span class="NLM_lpage">1128</span>, <span class="refDoi"> DOI: 10.1016/S1470-2045(14)70362-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1016%2FS1470-2045%2814%2970362-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=25153538" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVSmt77K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2014&pages=1119-1128&author=S.+M+Gadgeelauthor=L.+Gandhiauthor=G.+J+Rielyauthor=A.+A+Chiapporiauthor=H.+L+Westauthor=M.+C+Azadaauthor=P.+N+Morcosauthor=R.-M.+Leeauthor=L.+Garciaauthor=L.+Yuauthor=F.+Boisserieauthor=L.+Di+Laurenzioauthor=S.+Goldingauthor=J.+Satoauthor=S.+Yokoyamaauthor=T.+Tanakaauthor=S.-H.+I.+Ou&title=Safety+and+Activity+of+Alectinib+against+Systemic+Disease+and+Brain+Metastases+in+Patients+with+Crizotinib-resistant+ALK-rearranged+Non-small-cell+Lung+Cancer+%28AF-002JG%29%3A+Results+from+the+Dose-finding+Portion+of+a+Phase+1%2F2+Study&doi=10.1016%2FS1470-2045%2814%2970362-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit171R"><div class="casContent"><span class="casTitleNuber">171</span><div class="casTitle"><span class="NLM_cas:atitle">Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study</span></div><div class="casAuthors">Gadgeel, Shirish M.; Gandhi, Leena; Riely, Gregory J.; Chiappori, Alberto A.; West, Howard L.; Azada, Michele C.; Morcos, Peter N.; Lee, Ruey-Min; Garcia, Linta; Yu, Li; Boisserie, Frederic; Di Laurenzio, Laura; Golding, Sophie; Sato, Jotaro; Yokoyama, Shumpei; Tanaka, Tomohiro; Ou, Sai-Hong Ignatius</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1119-1128</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Patients with non-small-cell lung cancer (NSCLC) and ALK rearrangements generally have a progression-free survival of 8-11 mo while on treatment with the ALK inhibitor crizotinib.  However, resistance inevitably develops, with the brain a common site of progression.  More potent ALK inhibitors with consistently demonstrable CNS activity and good tolerability are needed urgently.  Alectinib is a novel, highly selective, and potent ALK inhibitor that has shown clin. activity in patients with crizotinib-naive ALK-rearranged NSCLC.  We did a phase 1/2 study of alectinib to establish the recommended phase 2 dose of the drug and examine its activity in patients resistant or intolerant to crizotinib.  We enrolled patients with ALK-rearranged NSCLC who progressed on or were intolerant to crizotinib.  We administered various oral doses of alectinib (300-900 mg twice a day) during the dose-escalation portion of the study (phase 1), to ascertain the recommended dose for phase 2.  We used Response Evaluation Criteria in Solid Tumors criteria (version 1.1) to investigate the activity of alectinib in all patients with a baseline scan and at least one post-treatment scan (CT or MRI), with central radiol. review of individuals with brain metastases.  We assessed safety in all patients who received at least one dose of alectinib.  Here, we present data for the phase 1 portion of the study, the primary objective of which was to establish the recommended phase 2 dose; phase 2 is ongoing.  This trial is registered at ClinicalTrials.gov, no. NCT01588028.47 patients were enrolled.  Alectinib was well tolerated, with the most common adverse events being fatigue (14 [30%]; all grade 1-2), myalgia (eight [17%]; all grade 1-2), and peripheral edema (seven [15%] grade 1-2, one [2%] grade 3).  Dose-limiting toxic effects were recorded in two patients in the cohort receiving alectinib 900 mg twice a day; one individual had grade 3 headache and the other had grade 3 neutropenia.  The most common grade 3-4 adverse events were increased levels of γ-glutamyl transpeptidase (two [4%]), a redn. in the no. of neutrophils (two [4%]), and hypophosphatemia (two [4%]).  Three patients reported four grade 4 serious adverse events that were deemed unrelated to alectinib: acute renal failure; pleural effusion and pericardial effusion; and brain metastasis.  At data cut-off (median follow-up 126 days [IQR 84-217]), 44 patients could be assessed for activity.  Investigator-assessed objective responses were noted in 24 (55%) patients, with a confirmed complete response in one (2%), a confirmed partial response in 14 (32%), and an unconfirmed partial response in nine (20%). 16 (36%) patients had stable disease; the remaining four (9%) had progressive disease.  Of 21 patients with CNS metastases at baseline, 11 (52%) had an objective response; six (29%) had a complete response (three unconfirmed) and five (24%) had a partial response (one unconfirmed); eight (38%) patients had stable disease and the remaining two (10%) had progressive disease.  Pharmacokinetic data indicated that mean exposure (AUC0-10) after multiple doses of alectinib (300-600 mg twice a day) was dose-dependent.  Alectinib was well tolerated, with promising antitumor activity in patients with ALK-rearranged NSCLC resistant to crizotinib, including those with CNS metastases.  On the basis of activity, tolerability, and pharmacokinetic data, we chose alectinib 600 mg twice a day as the recommended dose for phase 2.  Chugai Pharmaceuticals, F Hoffmann La-Roche.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGriCeVttS5axrVg90H21EOLACvtfcHk0liocMm-TPsWPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVSmt77K&md5=aa56d295472ea5dcb29070a4e39d420a</span></div><a href="/servlet/linkout?suffix=cit171&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2814%2970362-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252814%252970362-6%26sid%3Dliteratum%253Aachs%26aulast%3DGadgeel%26aufirst%3DS.%2BM%26aulast%3DGandhi%26aufirst%3DL.%26aulast%3DRiely%26aufirst%3DG.%2BJ%26aulast%3DChiappori%26aufirst%3DA.%2BA%26aulast%3DWest%26aufirst%3DH.%2BL%26aulast%3DAzada%26aufirst%3DM.%2BC%26aulast%3DMorcos%26aufirst%3DP.%2BN%26aulast%3DLee%26aufirst%3DR.-M.%26aulast%3DGarcia%26aufirst%3DL.%26aulast%3DYu%26aufirst%3DL.%26aulast%3DBoisserie%26aufirst%3DF.%26aulast%3DDi%2BLaurenzio%26aufirst%3DL.%26aulast%3DGolding%26aufirst%3DS.%26aulast%3DSato%26aufirst%3DJ.%26aulast%3DYokoyama%26aufirst%3DS.%26aulast%3DTanaka%26aufirst%3DT.%26aulast%3DOu%26aufirst%3DS.-H.%2BI.%26atitle%3DSafety%2520and%2520Activity%2520of%2520Alectinib%2520against%2520Systemic%2520Disease%2520and%2520Brain%2520Metastases%2520in%2520Patients%2520with%2520Crizotinib-resistant%2520ALK-rearranged%2520Non-small-cell%2520Lung%2520Cancer%2520%2528AF-002JG%2529%253A%2520Results%2520from%2520the%2520Dose-finding%2520Portion%2520of%2520a%2520Phase%25201%252F2%2520Study%26jtitle%3DLancet%2520Oncol.%26date%3D2014%26volume%3D15%26spage%3D1119%26epage%3D1128%26doi%3D10.1016%2FS1470-2045%2814%2970362-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref172"><div class="reference"><strong class="refLabel"><a href="#ref172" class="rightTabRefNumLink">172</a></strong><div class="NLM_citation" id="rightTab-cit172"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Courtin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smyth, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hearn, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saini, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, N. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyons, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallis, N. G.</span></span> <span> </span><span class="NLM_article-title">Emergence of Resistance to Tyrosine Kinase Inhibitors in Non-small-cell Lung Cancer can be Delayed by an upfront Combination with the HSP90 Inhibitor Onalespib</span>. <i>Br. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>115</i></span>,  <span class="NLM_fpage">1069</span>, <span class="refDoi"> DOI: 10.1038/bjc.2016.294</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1038%2Fbjc.2016.294" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=27673365" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslKns7%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2016&pages=1069&author=A.+Courtinauthor=T.+Smythauthor=K.+Hearnauthor=H.+K.+Sainiauthor=N.+T.+Thompsonauthor=J.+F.+Lyonsauthor=N.+G.+Wallis&title=Emergence+of+Resistance+to+Tyrosine+Kinase+Inhibitors+in+Non-small-cell+Lung+Cancer+can+be+Delayed+by+an+upfront+Combination+with+the+HSP90+Inhibitor+Onalespib&doi=10.1038%2Fbjc.2016.294"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit172R"><div class="casContent"><span class="casTitleNuber">172</span><div class="casTitle"><span class="NLM_cas:atitle">Emergence of resistance to tyrosine kinase inhibitors in non-small-cell lung cancer can be delayed by an upfront combination with the HSP90 inhibitor onalespib</span></div><div class="casAuthors">Courtin, Aurelie; Smyth, Tomoko; Hearn, Keisha; Saini, Harpreet K.; Thompson, Neil T.; Lyons, John F.; Wallis, Nicola G.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">115</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1069-1077</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Background: Tyrosine kinase inhibitors, such as crizotinib and erlotinib, are widely used to treat non-small-cell lung cancer, but after initial response, relapse is common because of the emergence of resistance through multiple mechanisms.  Here, we investigated whether a frontline combination with an HSP90 inhibitor could delay the emergence of resistance to these inhibitors in preclin. lung cancer models.  Methods: The HSP90 inhibitor, onalespib, was combined with either crizotinib or erlotinib in ALK- or EGFR-activated xenograft models resp. (H2228, HCC827).  Results: In both models, after initial response to the monotherapy kinase inhibitors, tumor relapse was obsd.  In contrast, tumor growth remained inhibited when treated with an onalespib/kinase inhibitor combination.  Anal. of H2228 tumors, which had relapsed on crizotinib monotherapy, identified a no. of clin. relevant crizotinib resistance mechanisms, suggesting that HSP90 inhibitor treatment was capable of suppressing multiple mechanisms of resistance.  Resistant cell lines, derived from these tumors, retained sensitivity to onalespib (proliferation and signalling pathways were inhibited), indicating that, despite their resistance to crizotinib, they were still sensitive to HSP90 inhibition.  Conclusions: Together, these preclin. data suggest that frontline combination with an HSP90 inhibitor may be a method for delaying the emergence of resistance to targeted therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1mncD8Op0sLVg90H21EOLACvtfcHk0lj1ZSfausCElQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslKns7%252FJ&md5=b008666833a5f4ada0635ef6dd195fbd</span></div><a href="/servlet/linkout?suffix=cit172&amp;dbid=16384&amp;doi=10.1038%2Fbjc.2016.294&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbjc.2016.294%26sid%3Dliteratum%253Aachs%26aulast%3DCourtin%26aufirst%3DA.%26aulast%3DSmyth%26aufirst%3DT.%26aulast%3DHearn%26aufirst%3DK.%26aulast%3DSaini%26aufirst%3DH.%2BK.%26aulast%3DThompson%26aufirst%3DN.%2BT.%26aulast%3DLyons%26aufirst%3DJ.%2BF.%26aulast%3DWallis%26aufirst%3DN.%2BG.%26atitle%3DEmergence%2520of%2520Resistance%2520to%2520Tyrosine%2520Kinase%2520Inhibitors%2520in%2520Non-small-cell%2520Lung%2520Cancer%2520can%2520be%2520Delayed%2520by%2520an%2520upfront%2520Combination%2520with%2520the%2520HSP90%2520Inhibitor%2520Onalespib%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2016%26volume%3D115%26spage%3D1069%26doi%3D10.1038%2Fbjc.2016.294" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref173"><div class="reference"><strong class="refLabel"><a href="#ref173" class="rightTabRefNumLink">173</a></strong><div class="NLM_citation" id="rightTab-cit173"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gainor, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niederst, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lennerz, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dagogo-Jack, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sequist, L. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engelman, J. A.</span></span> <span> </span><span class="NLM_article-title">Dramatic Response to Combination Erlotinib and Crizotinib in a Patient with Advanced, EGFR-mutant Lung Cancer Harboring De Novo MET Amplification</span>. <i>J. Thorac. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">e83</span>– <span class="NLM_lpage">e85</span>, <span class="refDoi"> DOI: 10.1016/j.jtho.2016.02.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1016%2Fj.jtho.2016.02.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=26988570" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=e83-e85&author=J.+F.+Gainorauthor=M.+J.+Niederstauthor=J.+K.+Lennerzauthor=I.+Dagogo-Jackauthor=S.+Stevensauthor=A.+T.+Shawauthor=L.+V.+Sequistauthor=J.+A.+Engelman&title=Dramatic+Response+to+Combination+Erlotinib+and+Crizotinib+in+a+Patient+with+Advanced%2C+EGFR-mutant+Lung+Cancer+Harboring+De+Novo+MET+Amplification&doi=10.1016%2Fj.jtho.2016.02.021"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit173&amp;dbid=16384&amp;doi=10.1016%2Fj.jtho.2016.02.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jtho.2016.02.021%26sid%3Dliteratum%253Aachs%26aulast%3DGainor%26aufirst%3DJ.%2BF.%26aulast%3DNiederst%26aufirst%3DM.%2BJ.%26aulast%3DLennerz%26aufirst%3DJ.%2BK.%26aulast%3DDagogo-Jack%26aufirst%3DI.%26aulast%3DStevens%26aufirst%3DS.%26aulast%3DShaw%26aufirst%3DA.%2BT.%26aulast%3DSequist%26aufirst%3DL.%2BV.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26atitle%3DDramatic%2520Response%2520to%2520Combination%2520Erlotinib%2520and%2520Crizotinib%2520in%2520a%2520Patient%2520with%2520Advanced%252C%2520EGFR-mutant%2520Lung%2520Cancer%2520Harboring%2520De%2520Novo%2520MET%2520Amplification%26jtitle%3DJ.%2520Thorac.%2520Oncol.%26date%3D2016%26volume%3D11%26spage%3De83%26epage%3De85%26doi%3D10.1016%2Fj.jtho.2016.02.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref174"><div class="reference"><strong class="refLabel"><a href="#ref174" class="rightTabRefNumLink">174</a></strong><div class="NLM_citation" id="rightTab-cit174"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Felip, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Braud, F. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maur, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loong, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vansteenkiste, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">John, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lolkema, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, R.</span></span> <span> </span><span class="NLM_article-title">Ceritinib plus Nivolumab (NIVO) in Patients (pts) with Anaplastic Lymphoma Kinase Positive (ALK+) Advanced Non-small Cell Lung Cancer (NSCLC)</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>35</i></span> (<span class="NLM_issue">Suppl 15</span>),  <span class="NLM_fpage">2502</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1200%2FJCO.2017.35.15_suppl.2502" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2017&pages=2502&issue=Suppl+15&author=E.+Felipauthor=F.+G.+De+Braudauthor=M.+Maurauthor=H.+H.+Loongauthor=A.+T.+Shawauthor=J.+F.+Vansteenkisteauthor=T.+Johnauthor=G.+Liuauthor=M.+P.+Lolkemaauthor=J.+W.+Scottauthor=R.+Yu&title=Ceritinib+plus+Nivolumab+%28NIVO%29+in+Patients+%28pts%29+with+Anaplastic+Lymphoma+Kinase+Positive+%28ALK%2B%29+Advanced+Non-small+Cell+Lung+Cancer+%28NSCLC%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit174&amp;dbid=16384&amp;doi=10.1200%2FJCO.2017.35.15_suppl.2502&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2017.35.15_suppl.2502%26sid%3Dliteratum%253Aachs%26aulast%3DFelip%26aufirst%3DE.%26aulast%3DDe%2BBraud%26aufirst%3DF.%2BG.%26aulast%3DMaur%26aufirst%3DM.%26aulast%3DLoong%26aufirst%3DH.%2BH.%26aulast%3DShaw%26aufirst%3DA.%2BT.%26aulast%3DVansteenkiste%26aufirst%3DJ.%2BF.%26aulast%3DJohn%26aufirst%3DT.%26aulast%3DLiu%26aufirst%3DG.%26aulast%3DLolkema%26aufirst%3DM.%2BP.%26aulast%3DScott%26aufirst%3DJ.%2BW.%26aulast%3DYu%26aufirst%3DR.%26atitle%3DCeritinib%2520plus%2520Nivolumab%2520%2528NIVO%2529%2520in%2520Patients%2520%2528pts%2529%2520with%2520Anaplastic%2520Lymphoma%2520Kinase%2520Positive%2520%2528ALK%252B%2529%2520Advanced%2520Non-small%2520Cell%2520Lung%2520Cancer%2520%2528NSCLC%2529%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2017%26volume%3D35%26issue%3DSuppl%252015%26spage%3D2502" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref175"><div class="reference"><strong class="refLabel"><a href="#ref175" class="rightTabRefNumLink">175</a></strong><div class="NLM_citation" id="rightTab-cit175"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramalingam, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boyer, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carcereny Costa, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felip, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hida, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, B. G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. W.</span></span> <span> </span><span class="NLM_article-title">Avelumab (anti–PD-L1) in Combination with Crizotinib or Lorlatinib in Patients with Previously Treated Advanced NSCLC: Phase 1b Results from JAVELIN Lung 101</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">9008</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1200%2FJCO.2018.36.15_suppl.9008" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2018&pages=9008&author=A.+T.+Shawauthor=S.-H.+Leeauthor=S.+S.+Ramalingamauthor=T.+M.+Bauerauthor=M.+J.+Boyerauthor=E.+Carcereny+Costaauthor=E.+Felipauthor=J.+Y.+Hanauthor=T.+Hidaauthor=B.+G.+M.+Hughesauthor=S.+W.+Kim&title=Avelumab+%28anti%E2%80%93PD-L1%29+in+Combination+with+Crizotinib+or+Lorlatinib+in+Patients+with+Previously+Treated+Advanced+NSCLC%3A+Phase+1b+Results+from+JAVELIN+Lung+101"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit175&amp;dbid=16384&amp;doi=10.1200%2FJCO.2018.36.15_suppl.9008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2018.36.15_suppl.9008%26sid%3Dliteratum%253Aachs%26aulast%3DShaw%26aufirst%3DA.%2BT.%26aulast%3DLee%26aufirst%3DS.-H.%26aulast%3DRamalingam%26aufirst%3DS.%2BS.%26aulast%3DBauer%26aufirst%3DT.%2BM.%26aulast%3DBoyer%26aufirst%3DM.%2BJ.%26aulast%3DCarcereny%2BCosta%26aufirst%3DE.%26aulast%3DFelip%26aufirst%3DE.%26aulast%3DHan%26aufirst%3DJ.%2BY.%26aulast%3DHida%26aufirst%3DT.%26aulast%3DHughes%26aufirst%3DB.%2BG.%2BM.%26aulast%3DKim%26aufirst%3DS.%2BW.%26atitle%3DAvelumab%2520%2528anti%25E2%2580%2593PD-L1%2529%2520in%2520Combination%2520with%2520Crizotinib%2520or%2520Lorlatinib%2520in%2520Patients%2520with%2520Previously%2520Treated%2520Advanced%2520NSCLC%253A%2520Phase%25201b%2520Results%2520from%2520JAVELIN%2520Lung%2520101%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2018%26volume%3D36%26spage%3D9008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref176"><div class="reference"><strong class="refLabel"><a href="#ref176" class="rightTabRefNumLink">176</a></strong><div class="NLM_citation" id="rightTab-cit176"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hellmann, M. D</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rizvi, N. A</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldman, J. W</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gettinger, S. N</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borghaei, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brahmer, J. R</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ready, N. E</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerber, D. E</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chow, L. Q</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Juergens, R. A</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shepherd, F. A</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laurie, S. A</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geese, W. J</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agrawal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, T. C</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antonia, S. J</span></span> <span> </span><span class="NLM_article-title">Nivolumab plus Ipilimumab as First-line Treatment for Advanced Non-small-cell Lung Cancer (CheckMate 012): Results of an Open-label, Phase 1, Multicohort Study</span>. <i>Lancet Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">31</span>– <span class="NLM_lpage">41</span>, <span class="refDoi"> DOI: 10.1016/S1470-2045(16)30624-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1016%2FS1470-2045%2816%2930624-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=27932067" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A528%3ADC%252BC28XitVSqs7zO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2017&pages=31-41&author=M.+D+Hellmannauthor=N.+A+Rizviauthor=J.+W+Goldmanauthor=S.+N+Gettingerauthor=H.+Borghaeiauthor=J.+R+Brahmerauthor=N.+E+Readyauthor=D.+E+Gerberauthor=L.+Q+Chowauthor=R.+A+Juergensauthor=F.+A+Shepherdauthor=S.+A+Laurieauthor=W.+J+Geeseauthor=S.+Agrawalauthor=T.+C+Youngauthor=X.+Liauthor=S.+J+Antonia&title=Nivolumab+plus+Ipilimumab+as+First-line+Treatment+for+Advanced+Non-small-cell+Lung+Cancer+%28CheckMate+012%29%3A+Results+of+an+Open-label%2C+Phase+1%2C+Multicohort+Study&doi=10.1016%2FS1470-2045%2816%2930624-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit176R"><div class="casContent"><span class="casTitleNuber">176</span><div class="casTitle"><span class="NLM_cas:atitle">Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study</span></div><div class="casAuthors">Hellmann, Matthew D.; Rizvi, Naiyer A.; Goldman, Jonathan W.; Gettinger, Scott N.; Borghaei, Hossein; Brahmer, Julie R.; Ready, Neal E.; Gerber, David E.; Chow, Laura Q.; Juergens, Rosalyn A.; Shepherd, Frances A.; Laurie, Scott A.; Geese, William J.; Agrawal, Shruti; Young, Tina C.; Li, Xuemei; Antonia, Scott J.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">31-41</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Nivolumab has shown improved survival in the treatment of advanced non-small-cell lung cancer (NSCLC) previously treated with chemotherapy.  We assessed the safety and activity of combination nivolumab plus ipilimumab as first-line therapy for NSCLC.  The open-label, phase 1, multicohort study (CheckMate 012) cohorts reported here were enrolled at eight US academic centers.  Eligible patients were aged 18 years or older with histol. or cytol. confirmed recurrent stage IIIb or stage IV, chemotherapy-naive NSCLC.  Patients were randomly assigned (1:1:1) by an interactive voice response system to receive nivolumab 1 mg/kg every 2 wk plus ipilimumab 1 mg/kg every 6 wk, nivolumab 3 mg/kg every 2 wk plus ipilimumab 1 mg/kg every 12 wk, or nivolumab 3 mg/kg every 2 wk plus ipilimumab 1 mg/kg every 6 wk until disease progression, unacceptable toxicities, or withdrawal of consent.  Data from the latter two cohorts, which were considered potentially suitable for further clin. development, are presented in this report; data from the other cohort (as well as several earlier cohorts) are described in the appendix.  The primary outcome was safety and tolerability, assessed in all treated patients.  This ongoing study is registered with ClinicalTrials.gov, no. NCT01454102.  Between May 15, 2014, and March 25, 2015, 78 patients were randomly assigned to receive nivolumab every 2 wk plus ipilimumab every 12 wk (n=38) or nivolumab every 2 wk plus ipilimumab every 6 wk (n=40).  One patient in the ipilimumab every-6-wk cohort was excluded before treatment; therefore 77 patients actually received treatment (38 in the ipilimumab every-12-wk cohort; 39 in the ipilimumab every-6-wk cohort).  At data cut-off on Jan 7, 2016, 29 (76%) patients in the ipilimumab every-12-wk cohort and 32 (82%) in the ipilimumab every-6-wk cohort had discontinued treatment.  Grade 3-4 treatment-related adverse events occurred in 14 (37%) patients in the ipilimumab every-12-wk cohort and 13 (33%) patients in the every-6-wk cohort; the most commonly reported grade 3 or 4 treatment-related adverse events were increased lipase (three [8%] and no patients), pneumonitis (two [5%] and one [3%] patients), adrenal insufficiency (one [3%] and two [5%] patients), and colitis (one [3%] and two [5%] patients).  Treatment-related serious adverse events were reported in 12 (32%) patients in the ipilimumab every-12-wk cohort and 11 (28%) patients in the every-6-wk cohort.  Treatment-related adverse events (any grade) prompted treatment discontinuation in four (11%) patients in the every-12-wk cohort and five (13%) patients in the every-6-wk cohort.  No treatment-related deaths occurred.  Confirmed objective responses were achieved in 18 (47% [95% CI 31-64]) patients in the ipilimumab every-12-wk cohort and 15 (38% [95% CI 23-55]) patients in the ipilimumab every-6-wk cohort; median duration of response was not reached in either cohort, with median follow-up times of 12·8 mo (IQR 9·3-15·5) in the ipilimumab every-12-wk cohort and 11·8 mo (6·7-15·9) in the ipilimumab every-6-wk cohort.  In patients with PD-L1 of 1% or greater, confirmed objective responses were achieved in 12 (57%) of 21 patients in the ipilimumab every-12-wk cohort and 13 (57%) of 23 patients in the ipilimumab every-6-wk cohort.  In NSCLC, first-line nivolumab plus ipilimumab had a tolerable safety profile and showed encouraging clin. activity characterized by a high response rate and durable response.  To our knowledge, the results of this study are the first suggestion of improved benefit compared with anti-PD-1 monotherapy in patients with NSCLC, supporting further assessment of this combination in a phase 3 study.Bristol-Myers Squibb.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAqE7VugWX-bVg90H21EOLACvtfcHk0lhB4VpzFgkUcw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitVSqs7zO&md5=a5703524ec82e7f1dd55168404a61d2f</span></div><a href="/servlet/linkout?suffix=cit176&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2816%2930624-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252816%252930624-6%26sid%3Dliteratum%253Aachs%26aulast%3DHellmann%26aufirst%3DM.%2BD%26aulast%3DRizvi%26aufirst%3DN.%2BA%26aulast%3DGoldman%26aufirst%3DJ.%2BW%26aulast%3DGettinger%26aufirst%3DS.%2BN%26aulast%3DBorghaei%26aufirst%3DH.%26aulast%3DBrahmer%26aufirst%3DJ.%2BR%26aulast%3DReady%26aufirst%3DN.%2BE%26aulast%3DGerber%26aufirst%3DD.%2BE%26aulast%3DChow%26aufirst%3DL.%2BQ%26aulast%3DJuergens%26aufirst%3DR.%2BA%26aulast%3DShepherd%26aufirst%3DF.%2BA%26aulast%3DLaurie%26aufirst%3DS.%2BA%26aulast%3DGeese%26aufirst%3DW.%2BJ%26aulast%3DAgrawal%26aufirst%3DS.%26aulast%3DYoung%26aufirst%3DT.%2BC%26aulast%3DLi%26aufirst%3DX.%26aulast%3DAntonia%26aufirst%3DS.%2BJ%26atitle%3DNivolumab%2520plus%2520Ipilimumab%2520as%2520First-line%2520Treatment%2520for%2520Advanced%2520Non-small-cell%2520Lung%2520Cancer%2520%2528CheckMate%2520012%2529%253A%2520Results%2520of%2520an%2520Open-label%252C%2520Phase%25201%252C%2520Multicohort%2520Study%26jtitle%3DLancet%2520Oncol.%26date%3D2017%26volume%3D18%26spage%3D31%26epage%3D41%26doi%3D10.1016%2FS1470-2045%2816%2930624-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref177"><div class="reference"><strong class="refLabel"><a href="#ref177" class="rightTabRefNumLink">177</a></strong><div class="NLM_citation" id="rightTab-cit177"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aggarwal, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borghaei, H.</span></span> <span> </span><span class="NLM_article-title">Treatment Paradigms for Advanced Non-small Cell Lung Cancer at Academic Medical Centers: Involvement in Clinical Trial Endpoint Design</span>. <i>Oncologist</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">700</span>– <span class="NLM_lpage">708</span>, <span class="refDoi"> DOI: 10.1634/theoncologist.2016-0345</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1634%2Ftheoncologist.2016-0345" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=28408617" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A280%3ADC%252BC1cvnslemsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2017&pages=700-708&author=C.+Aggarwalauthor=H.+Borghaei&title=Treatment+Paradigms+for+Advanced+Non-small+Cell+Lung+Cancer+at+Academic+Medical+Centers%3A+Involvement+in+Clinical+Trial+Endpoint+Design&doi=10.1634%2Ftheoncologist.2016-0345"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit177R"><div class="casContent"><span class="casTitleNuber">177</span><div class="casTitle"><span class="NLM_cas:atitle">Treatment Paradigms for Advanced Non-Small Cell Lung Cancer at Academic Medical Centers: Involvement in Clinical Trial Endpoint Design</span></div><div class="casAuthors">Aggarwal Charu; Borghaei Hossein</div><div class="citationInfo"><span class="NLM_cas:title">The oncologist</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">700-708</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Based on the positive results of various clinical trials, treatment options for non-small cell lung cancer (NSCLC) have expanded greatly over the last 25 years.  While regulatory approvals of chemotherapeutic agents for NSCLC have largely been based on improvements in overall survival, recent approvals of many targeted agents for NSCLC (afatinib, crizotinib, ceritinib, osimertinib) have been based on surrogate endpoints such as progression-free survival and objective response.  As such, selection of appropriate clinical endpoints for examining the efficacy of investigational agents for NSCLC is of vital importance in clinical trial design.  This review provides an overview of clinical trial endpoints previously utilized for approved agents for NSCLC and highlights the key efficacy results for these trials.  Trends for more recent approvals in NSCLC, including those for the immunotherapeutic agents nivolumab and pembrolizumab, are also discussed.  The results of a correlative analysis of endpoints from 18 clinical trials that supported approvals of investigational agents in clinical trials for NSCLC are also presented.  IMPLICATIONS FOR PRACTICE:  While improving survival remains the ultimate goal of oncology clinical trials, overall survival may not always be the most feasible or appropriate endpoint to assess patient response.  Recently, several investigational agents, both targeted agents and immunotherapies, have gained U.S.  Food and Drug Administration approval in non-small cell lung cancer based on alternate endpoints such as progression-free survival or response rate.  An understanding of the assessment of response and trial endpoint choice is important for future oncology clinical trial design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRvBm8Q8B105DdblLE_E9PWfW6udTcc2eakDclvXUrOerntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cvnslemsQ%253D%253D&md5=e3a79c668df131abd31ce667bc9f3ca1</span></div><a href="/servlet/linkout?suffix=cit177&amp;dbid=16384&amp;doi=10.1634%2Ftheoncologist.2016-0345&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1634%252Ftheoncologist.2016-0345%26sid%3Dliteratum%253Aachs%26aulast%3DAggarwal%26aufirst%3DC.%26aulast%3DBorghaei%26aufirst%3DH.%26atitle%3DTreatment%2520Paradigms%2520for%2520Advanced%2520Non-small%2520Cell%2520Lung%2520Cancer%2520at%2520Academic%2520Medical%2520Centers%253A%2520Involvement%2520in%2520Clinical%2520Trial%2520Endpoint%2520Design%26jtitle%3DOncologist%26date%3D2017%26volume%3D22%26spage%3D700%26epage%3D708%26doi%3D10.1634%2Ftheoncologist.2016-0345" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref178"><div class="reference"><strong class="refLabel"><a href="#ref178" class="rightTabRefNumLink">178</a></strong><div class="NLM_citation" id="rightTab-cit178"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hainsworth, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waterhouse, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shih, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boccia, R. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Priego, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCleod, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kudrik, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitchell, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burris, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greco, F. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spigel, D. R.</span></span> <span> </span><span class="NLM_article-title">Phase II Trial of Preoperative Pemetrexed plus Carboplatin in Patients with Stage IB-III Nonsquamous Non-small Cell Lung Cancer (NSCLC)</span>. <i>Lung Cancer</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>118</i></span>,  <span class="NLM_fpage">6</span>– <span class="NLM_lpage">12</span>, <span class="refDoi"> DOI: 10.1016/j.lungcan.2018.01.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=10.1016%2Fj.lungcan.2018.01.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=29572004" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;key=1%3ACAS%3A280%3ADC%252BC1Mnktl2jtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=118&publication_year=2018&pages=6-12&author=J.+D.+Hainsworthauthor=D.+M.+Waterhouseauthor=K.+C.+Shihauthor=R.+V.+Bocciaauthor=V.+M.+Priegoauthor=M.+J.+McCleodauthor=F.+J.+Kudrikauthor=R.+B.+Mitchellauthor=H.+A.+Burrisauthor=F.+A.+Grecoauthor=D.+R.+Spigel&title=Phase+II+Trial+of+Preoperative+Pemetrexed+plus+Carboplatin+in+Patients+with+Stage+IB-III+Nonsquamous+Non-small+Cell+Lung+Cancer+%28NSCLC%29&doi=10.1016%2Fj.lungcan.2018.01.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit178R"><div class="casContent"><span class="casTitleNuber">178</span><div class="casTitle"><span class="NLM_cas:atitle">Phase II trial of preoperative pemetrexed plus carboplatin in patients with stage IB-III nonsquamous non-small cell lung cancer (NSCLC)</span></div><div class="casAuthors">Hainsworth John D; Waterhouse David M; Shih Kent C; Burris Howard A 3rd; Greco F Anthony; Spigel David R; Boccia Ralph V; Priego Victor M; McCleod Michael J; Kudrik Fred J; Mitchell Reed Brian</div><div class="citationInfo"><span class="NLM_cas:title">Lung cancer (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">118</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">6-12</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">OBJECTIVES:  The combination of pemetrexed and carboplatin is a standard first-line treatment for patients with advanced NSCLC.  In this pilot phase II trial, we evaluated the feasibility of using pemetrexed and carboplatin as neoadjuvant therapy, prior to definitive surgical resection, for patients with localized NSCLC.  PATIENTS AND METHODS:  Patients with potentially resectable, previously untreated, clinical stage IB-III, nonsquamous NSCLC were eligible for this trial.  All patients received 4 cycles of pemetrexed (500 mg/m(2)) and carboplatin (AUC 6.0) administered at 21 day intervals.  Three to 6 weeks after completion of chemotherapy, definitive surgical resection was attempted.  The primary endpoint of this trial was the 3-year survival rate.  RESULTS:  Forty-six patients began protocol treatment, and 40 completed 4 courses of pemetrexed/carboplatin.  Surgical resection was performed in 27 patients (59%); all had pathologic partial responses.  The estimated 3-year survival rate for the entire group was 46%.  Toxicity of neoadjuvant therapy was consistent with toxicity previously reported with pemetrexed/carboplatin.  CONCLUSIONS:  Administration of 4 courses of pemetrexed/carboplatin was feasible.  The efficacy was similar to neoadjuvant regimens previously investigated.  A significant number of patients 19 of 46 (41%) in this trial did not have surgical resection after neoadjuvant therapy.  Further investigation of the role of neoadjuvant pemetrexed/carboplatin requires a larger, randomized clinical trial.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTDPd2sJyGpZoIRAdBLKY41fW6udTcc2eakDclvXUrOerntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1Mnktl2jtw%253D%253D&md5=3d999bdb991ca790a5931ef784913cb2</span></div><a href="/servlet/linkout?suffix=cit178&amp;dbid=16384&amp;doi=10.1016%2Fj.lungcan.2018.01.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.lungcan.2018.01.009%26sid%3Dliteratum%253Aachs%26aulast%3DHainsworth%26aufirst%3DJ.%2BD.%26aulast%3DWaterhouse%26aufirst%3DD.%2BM.%26aulast%3DShih%26aufirst%3DK.%2BC.%26aulast%3DBoccia%26aufirst%3DR.%2BV.%26aulast%3DPriego%26aufirst%3DV.%2BM.%26aulast%3DMcCleod%26aufirst%3DM.%2BJ.%26aulast%3DKudrik%26aufirst%3DF.%2BJ.%26aulast%3DMitchell%26aufirst%3DR.%2BB.%26aulast%3DBurris%26aufirst%3DH.%2BA.%26aulast%3DGreco%26aufirst%3DF.%2BA.%26aulast%3DSpigel%26aufirst%3DD.%2BR.%26atitle%3DPhase%2520II%2520Trial%2520of%2520Preoperative%2520Pemetrexed%2520plus%2520Carboplatin%2520in%2520Patients%2520with%2520Stage%2520IB-III%2520Nonsquamous%2520Non-small%2520Cell%2520Lung%2520Cancer%2520%2528NSCLC%2529%26jtitle%3DLung%2520Cancer%26date%3D2018%26volume%3D118%26spage%3D6%26epage%3D12%26doi%3D10.1016%2Fj.lungcan.2018.01.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4Z55" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4Z55','PDB','4Z55'); return false;">PDB: 4Z55</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2XP2" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2XP2','PDB','2XP2'); return false;">PDB: 2XP2</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4MKE" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4MKE','PDB','4MKE'); return false;">PDB: 4MKE</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3AOX" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3AOX','PDB','3AOX'); return false;">PDB: 3AOX</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5J7H" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5J7H','PDB','5J7H'); return false;">PDB: 5J7H</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5FTO" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5FTO','PDB','5FTO'); return false;">PDB: 5FTO</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4CLI" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4CLI','PDB','4CLI'); return false;">PDB: 4CLI</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4CDE" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4CDE','PDB','4CDE'); return false;">PDB: 4CDE</a></li></ul></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.9b00446%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2019.62.issue-24%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.9b00446" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                5MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"677a9f423d7d3cb8","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
